NCT Number,Title,Acronym,Status,Study Results,Conditions,Interventions,Outcome Measures,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,Funded Bys,Study Type,Study Designs,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents,URL
NCT03942471,Mindfulness for Adolescents With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus,Behavioral: Mindfulness Based Stress Reduction,Change in Mindful Attention Awareness Measurements after Mindfulness Training|Change in Diabetes Quality of Life: DQOL-Y Measurements after Mindfulness Training|Change in HbA1c Measurements after Mindfulness Training,Duquesne University,All,"12 Years to 19 Years   (Child, Adult)",Not Applicable,65,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10/14/2015,14-Oct-15,1-Oct-18,5-Jan-19,8-May-19,null,8-May-19,,"""Informed Consent Form: Parental Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03942471/ICF_000.pdf|""Informed Consent Form: Consent Form Amended"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03942471/ICF_001.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03942471/Prot_002.pdf",https://ClinicalTrials.gov/show/NCT03942471
NCT03920397,Mesenchymal Stem Cells in Patients With Type 1 Diabetes Mellitus,,Enrolling by invitation,No Results Available,Type 1 Diabetes Mellitus,Biological: Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation,Pancreatic β-cell function after an adipose tissue-derived stem/stromal cells infusion|Glycemic control after an adipose tissue-derived stem/stromal cells|Oral cholecalciferol 2000UI/day supplementation,Universidade Federal do Rio de Janeiro,All,"16 Years to 35 Years   (Child, Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Nutro_MesenchymalStemCells_DM1,1-Mar-15,1-Mar-20,1-Dec-25,18-Apr-19,null,23-Apr-19,"Clementino Fraga Filho University Hospital of Rio de Janeiro, Rio de Janeiro, Brazil",,https://ClinicalTrials.gov/show/NCT03920397
NCT03916601,"Comparison of Exposure and Activity of SAR341402 Mix 70/30 to NovoLog Mix 70/30, NovoMix 30 and SAR341402 Rapid-acting Solution in Patients With Type 1 Diabetes Mellitus",,Completed,No Results Available,Type 1 Diabetes,Drug: SAR341402|Drug: Insulin Aspart,"(Cohort 1) Assessment of PK parameter: Maximum insulin concentration (INS-Cmax)|(Cohort 1) Assessment of PK parameter: Area under the insulin concentration time curve (INS-AUClast)|(Cohort 2) Assessment of PK parameters: Area under the insulin concentration time curve from 0 to 4 hours post administration (INS-AUC0-4H)|(Cohort 2) Area under the insulin concentration time curve from 4 to 12 hours post administration (INS-AUC4-12H)|(Cohort 2) Assessment of PK parameter: Maximum insulin concentration (INS-Cmax)|Assessment of PK parameter: Area under the insulin concentration time curve from 0 to infinity (INS-AUC)|Assessment of PK parameter: Area under the insulin concentration time curve for fractional periods post administration (INS-AUC0-4H, INS-AUC0-24H, INS-AUC4-24H)|Assessment of PK parameter: Time to INS-Cmax|Assessment of PK parameter: Half-life (t1/2)|Assessment of PD parameter: GIR versus time curve from 0 to 24 hours post administration (GIR-AUC0-24H)|Assessment of PD parameter: Maximum smoothed body weight standardized glucose infusion rate (GIRmax)|Assessment of PD parameter: Time to GIRmax (GIR-tmax)|Assessment of PK parameter: Time to Cmax (INS-tmax)|Assessment of PD parameter: The area under the body weight standardized glucose infusion rate (GIR) versus time curve from 0 to 4 hours post administration (GIR-AUC0-4H)|Assessment of PD parameter: The area under the body weight standardized glucose infusion rate (GIR) versus time curve from 4 to 12 hours post administration (GIR-AUC4-12H)",Sanofi,All,18 Years to 64 Years   (Adult),Phase 1,52,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PDY15084|2017-002482-22|U1111-1197-7984,13-Dec-17,22-Mar-18,22-Mar-18,16-Apr-19,null,16-Apr-19,"Investigational Site Number 2760001, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT03916601
NCT03911843,Omega-3 and Vitamin D Supplements in Childhood T1D,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: omega-3 supplementation|Drug: Vitamin D supplementation,Change from Baseline Plasma glucose levels to 12 months|Change from Baseline HbA1c% to 12 months|Change from Baseline vitamin D to 12 months|Change from Baseline Fatty acids to 12 months|Change from Baseline C-peptide to 12 months|Change from Baseline IDAA1c to 12 months,Azienda Ospedaliero Universitaria Maggiore della Carita|University of Eastern Piedmont,All,"1 Year to 18 Years   (Child, Adult)",Phase 2|Phase 3,64,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,AOU Novara,1-Jan-17,31-Dec-18,31-Dec-18,11-Apr-19,null,11-Apr-19,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03911843/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03911843/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03911843/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT03911843
NCT03906383,Changes in the Diameter of Retinal Vessels After Remote Ischemic Conditioning in Patients With Type 1 Diabetes,,Completed,No Results Available,"Retinal Ischemia|Diabetes Complications|Ischemia|Diabetes Mellitus, Type 1",Other: Remote Ischemic Conditioning,Diameter change of retinal vessels,University of Aarhus,All,20 Years to 31 Years   (Adult),Not Applicable,21,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,RIK_RVA Diabetes,21-Nov-17,16-Oct-18,16-Oct-18,8-Apr-19,null,16-Apr-19,"University of Aarhus, Aarhus C, Danmark, Denmark",,https://ClinicalTrials.gov/show/NCT03906383
NCT03879642,Reducing Hypoglycemia Fear in Parents of Young Children With Type 1 Diabetes,,Completed,No Results Available,Parents,Behavioral: REDCHiP,Hypoglycemia Fear Survey|Child hemoglobin A1c,University of Kansas Medical Center|Children's Mercy Hospital Kansas City,All,1 Year to 6 Years   (Child),Not Applicable,43,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,R21HD081502,1-Oct-15,1-Oct-18,Mar-19,19-Mar-19,null,19-Mar-19,,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT03879642/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03879642
NCT03829800,"Formulas for Diabetes With Sucromalt & Isomaltulose on Glycemic Index, Hormones & Subjective Appetite in Type 2 Diabetes",,Completed,No Results Available,"Diabetes Mellitus, Type 2",Dietary Supplement: Ensure® Abbott Nutrition|Dietary Supplement: Glucerna® Abbott Nutrition|Dietary Supplement: Diasip® Nutricia Advanced|Dietary Supplement: Glicolab®,Change from baseline Glycemia at 180 minutes|Change from baseline Insulin at 180 minutes|Glycemic Index (GI)|Glycemic Load (GL)|Change from baseline GLP-1 at 180 minutes|Change from baseline GIP at 180 minutes|Change from baseline Hunger at 180 minutes|Change from baseline Fullness at 180 minutes|Change from baseline Desire to eat at 180 minutes|Change from baseline Prospective food consumption at 180 minutes|Change from baseline Subjective appetite at 180 minutes|Age|Weight|Height|Body Mass Index|Hip Circumference|Total Cholesterol|HDL-C|LDL-C|Triacylglycerides|HbA1c,Universidad del Zulia,All,51 Years to 63 Years   (Adult),Not Applicable,23,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Basic Science",1001092016,1-Sep-16,1-Sep-17,15-Nov-18,4-Feb-19,null,4-Feb-19,,,https://ClinicalTrials.gov/show/NCT03829800
NCT03825562,Acceptance and Value Based Methods in Increasing Wellbeing of Adolescents With Type 1 Diabetes,,Recruiting,No Results Available,Diabetes,"Behavioral: acceptance and commitment therapy, ACT",Glycemic control|Quality of life assessed by KINDL-r Questionnaire|Diabetes Related Psychological flexibility assessed by DAAS|Depressive symptoms assessed by RBDI|Psychological flexibility assessed by CAMM,Central Finland Hospital District|University of Jyvaskyla|Finnish Diabetes Association,All,12 Years to 16 Years   (Child),Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Dnro 7U/2015,Oct-15,May-19,Dec-19,31-Jan-19,null,3-May-19,"Iina Alho, Jyväskylä, Finland",,https://ClinicalTrials.gov/show/NCT03825562
NCT03763474,Euglyca Application in Children and Adolescents With Type 1 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Combination Product: Euglyca application,Level of glycosylated hemoglobin in the 2 groups|Change from Baseline glycosylated hemoglobin at 3 months in the 2 groups|Change from 3 months glycosylated hemoglobin at 6 months in the 2 groups|Change from 6 months glycosylated hemoglobin at 12 months in the 2 groups|Percentage of Normoglycemias in the 2 groups|Diabetes Treatment Satisfaction Questionnaire (DTSQ) score in the 2 groups,Aristotle University Of Thessaloniki,All,"6 Years to 18 Years   (Child, Adult)",Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,Euglyca application,1-Apr-17,1-Sep-18,1-Sep-18,4-Dec-18,null,4-Dec-18,"Endocrine Unit of 3rd Department of Pediatrics of Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT03763474/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03763474
NCT03722225,CHO-loading Before and High Intermittent CHO-intake During Physical Exercise in T1D,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Other: Carbohydrate loading and high intermittent carbohydrate intake during physical exercise,"The percentage of the glucose values spent in target range, defined as 72-180 mg/dl.","Örebro University, Sweden",All,18 Years to 50 Years   (Adult),Not Applicable,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,Dnr:2012/159,20-Jan-16,18-Mar-16,25-Mar-16,26-Oct-18,null,26-Oct-18,,,https://ClinicalTrials.gov/show/NCT03722225
NCT03699189,"ANAIS, a Spanish Version of the DAFNE Programme",ANAIS,Completed,No Results Available,"Diabetes Mellitus, Type 1",Behavioral: Immediate ANAIS,HbA1c|Lipids|Weight|Hypoglycemic events|Treatment satisfaction|Self-defined objectives|The quality of life,Rosa María Sánchez Hernández|Ana M. Wägner|Dácil Alvarado-Martel|Yaiza López-Plasencia|Armando Carrillo-Domínguez|Julia Rodríguez-Cordero|Francisco J Nóvoa-Mogollón|Angelines Jiménez-Rodríguez|Hospital Universitario Insular Gran Canaria,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,ANAIS,Nov-11,Feb-15,Feb-15,8-Oct-18,null,8-Oct-18,,,https://ClinicalTrials.gov/show/NCT03699189
NCT03680482,To Compare the Effects of Non-nutritive Sweeteners Intake in Subjects With T2DM,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Other: Intervention ingest a 48 mg of sucralose|Other: Intervention ingest a 96 mg of stevia,glycemic response in blood|Insulin response in blood,University of Chile|Sociedad Chilena de Nutrición,All,30 Years to 55 Years   (Adult),Not Applicable,17,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Screening,SUE,11-Jan-16,8-Aug-16,31-Aug-17,21-Sep-18,null,28-Feb-19,,,https://ClinicalTrials.gov/show/NCT03680482
NCT03671161,Flash Glucose Measure System and Continuous Subcutaneous Insulin Infusion Therapy in Poorly Controlled Diabetes Type 1 Patients,FREESTYLE,Completed,No Results Available,"Glucose Metabolism Disorders (Including Diabetes Mellitus)|Diabetes Mellitus, Type 1",Device: Insulin Pump and flash glucose monitoring,Change in HbA1c ≥1%|Number of severe hypoglycemia episodes|Number of ketoacidosis episodes|Any positive change in DTSQ scale (ΔDTSQM6-DTSQM0>0) (Diabetes Treatment Satisfaction Questionnaire)|Any positive change in HFS scale (Hypoglycemia Fear Scale)|Number of Hypoglycemia episodes|Frequency of hypoglycemia episodes|Frequency of severe hypoglycemia episodes|Frequency of ketoacidosis episodes|Any changes in Weight,Groupe Hospitalier Pitie-Salpetriere,All,18 Years to 55 Years   (Adult),Not Applicable,19,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment,CIC1421-18-15,1-Jan-16,1-Jul-17,1-Jul-17,14-Sep-18,null,24-Sep-18,"Groupe Hospitalier Pitié-Salpêtrière, Paris, France",,https://ClinicalTrials.gov/show/NCT03671161
NCT03662334,A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20),HALO-117-406,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Rapid Acting insulin with pre-treatment of rHuPH20|Device: Sham injection,"Part 1: Area Under the Curve (AUC) of Glucose Infusion Rate (GIR) From 0-6 Hours|Part 2: Time to Reduction in Plasma Glucose by 80 Milligrams Per Deciliter (mg/dL) Following CSII Bolus|Part 3: Time to Achieve Plasma Glucose >90 mg/dL After Release of Hypoglycemic CSII Clamp|Part 1: Time-action Profile, Assessed by GIR in Euglycemic Participants|Part 1: Mean Maximum Concentration (Cmax)|Part 1: Time to Achieve Maximum Concentration (Tmax)|Part 1: Early Time to 50% Maximum Serum Insulin Concentration (t50%) Max|Part 1: Time to 50% of Total AUC (AUC0-last)|Part 1: Fractional and Absolute AUC0-1hr|Part 1: Fractional and Absolute AUC2hr-end|Part 1: Area Under the Curve From Time Zero to the Last Measureable Concentration (AUC0-last)|Part 1: Mean Residence Time (MRT)|Part 2: Plasma Glucose Concentration Over Time|Part 2: Insulin Analog Serum Concentration as a Function of Time Following Bolus Insulin Infusion|Part 3: Plasma Glucose Concentration Over Time|Part 3: Insulin Analog Serum Concentration as a Function of Time Following Termination of Insulin Infusion",Halozyme Therapeutics,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,14,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",HALO-117-406,3-Oct-13,27-Feb-14,27-Feb-14,7-Sep-18,1-Feb-19,1-Feb-19,"Profil Institute for Clinical Research, Chula Vista, California, United States",,https://ClinicalTrials.gov/show/NCT03662334
NCT03659461,"Glucagon-like Peptide-1 Levels, Insulin Resistance and Insulin Sensitivity Index in Type 2 Diabetes Mellitus",GLP-1,Recruiting,No Results Available,Type 2 Diabetes Mellitus|PreDiabetes,Drug: Sitagliptin,change in blood glucose load response to sitagliptin|change in blood insulin response to sitagliptin,National University of Malaysia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",UKM-22,1-Oct-17,Jan-20,Jan-20,6-Sep-18,null,6-Sep-18,"Hospital Sultan Ismail, Johor Bahru, Johor, Malaysia",,https://ClinicalTrials.gov/show/NCT03659461
NCT03660293,Prediction and Prevention of Asymptomatic Cardiovascular Insult in Type 1 Diabetic Children: Comparative Effectiveness of Cardioprotective Drugs,,Recruiting,No Results Available,"Diabetes Mellitus, Type 1",Drug: Atorvastatin|Drug: Captopril|Drug: L-carnitine,"The cardiac changes induced by Simvastatin, captopril and L-Carnitine in type 1 diabetic children and adolescents.|The role of Troponin I levels as a cardiac marker for detection of asymptomatic cardiovascular insult in diabetic children.|The role of recent echocardiographic parameters for early detection of silent myocardial dysfunction|Identification of risk factors for developing diabetic cardiac insult.",Tanta University,All,"3 Years to 18 Years   (Child, Adult)",Not Applicable,150,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention",31499/04/17,1-Apr-17,Apr-19,Apr-19,6-Sep-18,null,6-Sep-18,"Faculty of Medicine- Tanta University, Tanta, Gharbia, Egypt",,https://ClinicalTrials.gov/show/NCT03660293
NCT03598738,The Effect of Esomeprazole on Type 2 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Esomeprazole 40mg,HbA1c change,Baskent University Ankara Hospital,All,"47 Years to 72 Years   (Adult, Older Adult)",Not Applicable,32,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KA12/242,1-Dec-15,1-Dec-17,1-Dec-17,25-Jul-18,null,26-Jul-18,,,https://ClinicalTrials.gov/show/NCT03598738
NCT03594240,Vitamin B Complex and Diabetic Nephropathy in Type 1 Diabetes,,Completed,No Results Available,Plasma Homocysteine|HbA1c Level,Drug: Vitamin B complex tablets (Neurorubine TM -Forte Lactab TM)|Dietary Supplement: Placebo,Change in plasma homocysteine|Change in HbA1c level,Ain Shams University,All,"12 Years to 18 Years   (Child, Adult)",Phase 3,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Ain Shams Pediatrics 2082016,1-Mar-17,1-Mar-18,2-Apr-18,20-Jul-18,null,20-Jul-18,"Nancy Elbarbary, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT03594240
NCT03594565,"The Use of Topical Nasal Steroids for Skin Reactions to Continuous Glucose Monitoring System, Among Children and Youth With Type 1 Diabetes Mellitus: Case Series",,Completed,No Results Available,T1DM|Hypersensitivity,Drug: Fluticasone Propionate,Difference in skin irritation before and after regular application of nsFP according to the modified Draize scale.|Change in BMI SDS|Change in height SDS 6 months after nsFP use|Change in mean glucose 6 months after nsFP use|Change in glycated hemoglobin 6 months after nsFP use,Assaf-Harofeh Medical Center,All,"1 Year to 20 Years   (Child, Adult)",Early Phase 1,13,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,0277-16-ASF,Mar-16,Jun-17,Jun-18,20-Jul-18,null,20-Jul-18,,,https://ClinicalTrials.gov/show/NCT03594565
NCT03582878,Sirolimus vs Mycophenolate With Tacrolimus in Simultaneous Pancreas and Kidney Transplantation,,Recruiting,No Results Available,"Diabetes Mellitus, Type 1",Drug: Sirolimus Oral Product|Drug: Mycophenolate Mofetil,Pancreas graft survival|Recipient survival|Wound healing time|Kidney graft survival,Institute for Clinical and Experimental Medicine,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,240,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SiroMMFStudy 1,1-Jan-04,1-Jan-19,1-Jan-20,11-Jul-18,null,11-Jul-18,"Institute for Clinical and Experimental Medicine, Prague, Czechia",,https://ClinicalTrials.gov/show/NCT03582878
NCT03583268,Determining the Appropriate Intensity of Exercise to Prevent Post-exercise Hypoglycemia in Persons Living With T1D,,Completed,No Results Available,Type 1 Diabetes,Other: Exercise,Percent time spent </= 3.9 mmol/L as measured by continuous glucose monitor|Mean absolute glucose change (MAG-mmol/L/h) as measured by continuous glucose monitor|Continuous overall net glycemic action (CONGA-mmol/L) as measured by continuous glucose monitor,University of Manitoba|The Lawson Foundation,All,"15 Years to 35 Years   (Child, Adult)",Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,B2014:095,May-13,Mar-16,Mar-16,11-Jul-18,null,11-Jul-18,"Children's Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada",,https://ClinicalTrials.gov/show/NCT03583268
NCT03554590,"DM1, Effects of Carbo-Counting on Glycemic Control",,Recruiting,No Results Available,Type 1 Diabetes Mellitus,Behavioral: carbohydrate counting|Behavioral: insulin therapy according to standard care,glycemic control|anthropometric parameters: BMI|anthropometric parameters: WAIST AND HIP CIRCUMFERENCE|anthropometric parameters: BIOIMPEDENTIOMETRIC PARAMETERS|dietary lifestyle|glucose variability: mean and standard deviation of self monitoring blood glucose (SMBG)|glucose variability: incidence of hypoglycaemia,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DM1cc,Dec-16,Dec-18,Jan-20,13-Jun-18,null,13-Jun-18,"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy",,https://ClinicalTrials.gov/show/NCT03554590
NCT03544684,Fasted Exercise in People With Type 1 Diabetes,,Completed,No Results Available,Type1diabetes,Behavioral: Effects of the type of exercise on blood glucose concentrations,24 hour glycaemic profile,Liverpool John Moores University,All,18 Years to 55 Years   (Adult),Not Applicable,14,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,T1D_PARTA,9-Mar-15,10-Oct-17,10-Oct-17,4-Jun-18,null,11-Jun-18,"Liverpool John Moores University, Liverpool, Merseyside, United Kingdom",,https://ClinicalTrials.gov/show/NCT03544684
NCT03545802,Home-HIT and Type 1 Diabetes,,Completed,No Results Available,Type1diabetes,Behavioral: Home-HIT,change in maximal aerobic capacity|adherence and compliance over the course of the training programme|change in insulin sensitivity|change in glycaemic control,Liverpool John Moores University,All,18 Years to 55 Years   (Adult),Not Applicable,11,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,Home-HIT_T1D,20-May-17,13-Feb-18,13-Feb-18,4-Jun-18,null,4-Jun-18,"Liverpool John Moores University, Liverpool, Merseyside, United Kingdom",,https://ClinicalTrials.gov/show/NCT03545802
NCT03545841,HIT in People With Type 1 Diabetes,,Completed,No Results Available,Type1diabetes,Other: HIT|Other: MICT,Maximal aerobic capacity|Vascular stiffness,Liverpool John Moores University,null,"Child, Adult, Older Adult",Not Applicable,14,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,T1D_PARTB,9-Mar-15,10-Oct-17,10-Oct-17,4-Jun-18,null,4-Jun-18,"Liverpool John Moores University, Liverpool, Merseyside, United Kingdom",,https://ClinicalTrials.gov/show/NCT03545841
NCT03534193,Effectiveness of Using Educational Modules Via Bedside Tablet in Newly Diagnosed Type 1 Diabetes,,Recruiting,No Results Available,Type 1 Diabetes Mellitus,Other: Molly Center Diabetes Care Guide (Paper-based)|Other: Tablet based interactive diabetes education modules,Effectiveness of tablet education in newly diagnosed type 1 diabetes|Improved subject compliance with glucose monitoring,Hackensack Meridian Health|Verizon Foundation,All,"up to 21 Years   (Child, Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,PRO 2016-0713,17-Apr-17,Apr-20,Jun-20,23-May-18,null,23-May-18,"Joseph M. Sanzari Children's Hospital, Hackensack, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT03534193
NCT03526289,GIP/GLP-1 Co-Activity in Subjects With Overweight and Type 2 Diabetes: Lowering of Food Intake,GASOLIN II,Completed,No Results Available,Type 2 Diabetes Mellitus|Overweight and Obesity,Biological: GIP1-42 infusion|Other: Saline,food intake|Appetite|satiety|prospective food consumption|fullness|Thirst|Nausea|Energy expenditure|gastric emptying|gallbladder emptying|glucagon responses|Insulin responses|C-peptide responses|gut hormone responses|bone turnover markers,"University Hospital, Gentofte, Copenhagen|Zealand Pharma",Male,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,22,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",H-16031728,8-Nov-17,24-Oct-18,24-Oct-18,16-May-18,null,5-Dec-18,"Center for diabetes research, Hellerup, Denmark",,https://ClinicalTrials.gov/show/NCT03526289
NCT03513874,Metformin Plus Insulin on Non-obese Autoimmune Diabetes,,Recruiting,No Results Available,Type 1 Diabetes Mellitus|Autoimmune Diabetes,Drug: Metformin|Drug: Insulin,Mean amplitude of glycemic excursions (MAGE)|Change in C-peptide|Change in HbA1c|Change in daily insulin dose|Change in body mass index (BMI)|Change in lipid profiles|Adverse effects,Second Xiangya Hospital of Central South University,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,15,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MET201801,1-Aug-17,31-Dec-18,1-Mar-19,2-May-18,null,16-Oct-18,"Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China",,https://ClinicalTrials.gov/show/NCT03513874
NCT03506711,Isometric Handgrip Exercise -MRI in Children and Adolescents,,Recruiting,No Results Available,Type 1 Diabetes Mellitus|Coronary Artery Disease,Diagnostic Test: Isometric Handgrip Exercise during magnetic resonance imaging,Change in coronary cross sectional area (mm2),University of Lausanne Hospitals,All,"8 Years to 18 Years   (Child, Adult)",Not Applicable,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,CER-VD 213/15,1-Feb-16,30-Dec-18,30-Dec-19,24-Apr-18,null,24-Apr-18,"Pediatric Endocrinology, Diabetology and Obesity Unit, Service of Pediatrics, Lausanne University Hospital, Lausanne, Vaud, Switzerland",,https://ClinicalTrials.gov/show/NCT03506711
NCT03484741,Mesenchymal Stem Cell Therapy for Type 1 Diabetes Mellitus Patients,,Recruiting,No Results Available,Type 1 Diabetes Mellitus,Biological: MSC and PRP,Fasting blood glucose|Hemoglobin A1c (HbA1c) level|Adverse events|Insulin dose|C-peptide|Blood insulin level,Van Hanh General Hospital|University of Science Ho Chi Minh City,All,18 Years to 45 Years   (Adult),Phase 1|Phase 2,15,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DIME 1001,1-Apr-17,Nov-18,Nov-18,2-Apr-18,null,4-Apr-18,"Van Hanh Geral Hospital, Ho Chi Minh City, Ho Chi Minh, Vietnam",,https://ClinicalTrials.gov/show/NCT03484741
NCT03481374,Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes Mellitus.,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Diagnostic Test: autonomic function testing,VO2 max,Hasselt University|Jessa Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,79,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,CVDIABMEL-1,1-Jul-16,31-Mar-17,31-Mar-17,29-Mar-18,null,17-Apr-18,"Jessa Ziekenhuis, Hasselt, Belgium",,https://ClinicalTrials.gov/show/NCT03481374
NCT03478202,GOLO Open-Label Pilot 1,,Completed,No Results Available,"Diabetes Mellitus, Type II",Dietary Supplement: GOLO RELEASE,Change from baseline in weight|Change from baseline in waist circumference|Change from baseline in hip circumference|Change from baseline in Body Mass Index (BMI)|Change from baseline in Hemoglobin A1C|Change from baseline in fasting Insulin level,Golo,All,"18 Years to 69 Years   (Adult, Older Adult)",Not Applicable,27,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,GOLO1701,1-Aug-17,23-Dec-17,23-Dec-17,27-Mar-18,null,27-Mar-18,"Buynak Clinical Research, Valparaiso, Indiana, United States",,https://ClinicalTrials.gov/show/NCT03478202
NCT03473704,Telematic Program for the Treatment of Depression in Type 1 Diabetes,,Recruiting,No Results Available,Type 1 Diabetes Mellitus|Depression,Behavioral: Treatment group (TG)|Behavioral: Control group (CG),Depression|Depression symptoms|Fear of Hypoglycemia|Distress|Quality of Life|Anxiety|Coping|Personality|Adherence|Glycemic control|Hypoglycemia|Hyperglycemia|Ketone|Blood glucose self-tests|Complications of diabetes|Another disease,Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud|University of Malaga,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,WEB_TDDI1 STUDY,19-Jan-17,1-Oct-20,1-Oct-20,22-Mar-18,null,22-Mar-18,"University of Malaga, Málaga, Spain",,https://ClinicalTrials.gov/show/NCT03473704
NCT03463564,Insulin Pump vs Multiple Daily Injections of Insulin and Glyco-metabolic Control in Type 1 Diabetic Patients,METRO,Recruiting,No Results Available,Type 1 Diabetes Mellitus,Device: Insulin pump|Drug: Insulin injections,HbA1c change|Change in mean amplitude glucose excursions (MAGE|Change in coefficient of variation (CV)|Change in standard deviation (SD) of mean glucose levels|Change in glucose variability|Occurrence of hypoglycemic events|Change in weight|Change in lipid profile|Total daily insulin doses/Kg|Diabetes treatment satisfaction,"University of Campania ""Luigi Vanvitelli""",All,18 Years to 30 Years   (Adult),Phase 4,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,24012014-33,Jan-16,Dec-26,Dec-26,13-Mar-18,null,15-Mar-18,"Unit of Diabetes, Naples, Italy",,https://ClinicalTrials.gov/show/NCT03463564
NCT03455816,"Clinical Study to Evaluate the Bio-Psychosocial Impact of Mobile App for Diabetes Type 1 (""SOCIAL DIABETES"")",,Recruiting,No Results Available,"Diabetes Mellitus, Type 1",Device: Social Diabetes App|Device: Usual clinical monitoring group (Control group),glycosylated hemoglobin|Quality of life assessment: Diabetes Quality of Life (DQoL) questionnaire.|Mean blood glucose|Standard deviation|Number of mild hypoglycaemia|Number of severe hypoglycaemia|Number of hyperglycemia|Episodes of ketosis|Episodes of ketoacidosis|Number of hospital admissions for glycemic decompensation|Fear of hypoglycemia: Questionnaire FH-15|Diabetes treatment satisfaction questionnaire ( DTSQ)|Diabetes distress scale. DDS|Scale of adherence to treatment in patients with diabetes type 1,Soledad Ruiz de Adana|Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,148,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Social Diabetes,7-Jul-17,Jun-18,Dec-18,7-Mar-18,null,13-Mar-18,"Regional University Hospital of Málaga, Málaga, Spain",,https://ClinicalTrials.gov/show/NCT03455816
NCT03452605,The Effect of Cocoa Flavanol on the BOLD Response and Cognitive Function in Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus,Dietary Supplement: cocoa flavanol supplementation,cognitive function|BOLD fmri response,Vrije Universiteit Brussel,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,22,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",T1DCFMRI,20-Nov-15,15-Mar-17,15-Mar-17,2-Mar-18,null,2-Mar-18,,,https://ClinicalTrials.gov/show/NCT03452605
NCT03451201,High-Intensity Exercise and Endothelial Function in Type 1 Diabetes(HIIT-T1D),HIIT-T1D,Completed,No Results Available,Type 1 Diabetes Mellitus|Endothelial Dysfunction,Behavioral: High Intensity Interval Training|Behavioral: Moderate Continuous Exercise Training|Other: Non-exercise,Endothelial Dependent Mediated Vascular Dilation|Peak oxygen consumption|Endothelial independent vascular dilation,Hospital de Clinicas de Porto Alegre,All,18 Years to 40 Years   (Adult),Not Applicable,36,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,150564,Jan-15,Jan-16,Jan-17,1-Mar-18,null,5-Mar-18,"Serviço de Endocrinologia e Metabologia do HCPA, Porto Alegre, RS, Brazil",,https://ClinicalTrials.gov/show/NCT03451201
NCT03444142,Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Drug: Exenatide LAR|Drug: Dulaglutide,"Heart rate: nighttime, daytime and 24-h|Systolic blood pressure, daytime, night and 24 h|Diastolic blood pressure, daytime, night and 24 h|Blood pressure|Categories: dipper o non dipper|Fasting glucose levels|Central and peripheral blood pressure|Pulse wave velocity|Cardio-ankle Vascular Index (CAVI)|Glycosylated hemoglobin|Body Weight|Body Mass Index|Total cholesterol|Triglycerides levels|High density lipoprotein (c-HDL) levels|Alanine aminotransferase (ALT) levels|Aspartate aminotransferase (AST) levels|Creatinine levels|Uric acid levels|Waist Circumference",University of Guadalajara,All,31 Years to 60 Years   (Adult),Phase 4,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Exenatida LAR Dulaglutida-with,17-Nov-17,30-May-19,30-May-19,23-Feb-18,null,17-Apr-19,"Instituto de terapeutica Experimental y Clinica. Centro universitario de Ciencias de la Salud. Universidad de Guadalajara, Guadalajara, Jalisco, Mexico",,https://ClinicalTrials.gov/show/NCT03444142
NCT03428295,Dose Safety Hybrid Closed Loop and Fully Automated Closed Loop Artificial Pancreas Device in CRC,,Suspended,No Results Available,"Glucose, Low Blood|Glucose, High Blood",Device: Dose Safety AP system,Percentage of time in hypoglycemic range|Percentage of time in severe hyperglycemic range,Dose Safety Inc.|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Benaroya Research Institute,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,20,Industry|NIH|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APS4|2R44DK104317-03,22-Jun-17,31-Aug-19,31-Aug-19,9-Feb-18,null,12-Feb-19,"Dose Safety, Redmond, Washington, United States",,https://ClinicalTrials.gov/show/NCT03428295
NCT03422965,Perifoveal Vascular Network Assessed by OCT-Angiography in Type I Diabetes Mellitus,,Recruiting,No Results Available,"Retinal Vascular|Retinal Disease|Retinal Ischemia|Retinal Ischaemia Due to Type 1 Diabetes Mellitus|Diabetes Mellitus|Diabetic Retinopathy|Diabetes Mellitus, Type 1|Vessels; Retina, Tortuous",Diagnostic Test: Optical Coherence Tomography Angiography|Diagnostic Test: Blood test|Diagnostic Test: Urine test,Perifoveal vessel density|Parafoveal vessel density|Total Avascular Area|Foveal Avascular Zone,Hospital Clinic of Barcelona|Fundació La Marató de TV3,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,1000,Other,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic",OCTAMaratoTV3ICOF,8-May-17,8-May-19,31-Dec-20,6-Feb-18,null,7-Feb-18,"Institut Clinic de Oftalmologia (ICOF), Hospital Clínic de Barcelona, Barcelona, Spain|Diabetes Unit, Institut Clinic de Malalties Digestives i Métaboliques (ICMDM), Hospital Clínic de Barcelona, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT03422965
NCT03411460,Satisfaction of Hospitalized Diabetic Patients Using a Continuous Glucose Monitoring System,GLUCO FLASH,Terminated,No Results Available,Insulin-Dependent Diabetes,Device: FreeStyle Libre™ system|Procedure: Finger prick,Satisfaction of patient-determined hospital care at discharge in the two groups|Patient satisfaction concerning treatment for their diabetes|Patient quality of sleep|Satisfaction of nursing staff concerning care of patient|Time taken by nurse to measure circulating glucose level|Time necessary to achieve satisfactory equilibrium using insulin pump|Number of glucose readings above 2g/l and below 0.80g/l over the hospital stay|Number of hypoglycmic events with the corresponding glucose level,Centre Hospitalier Universitaire de Nīmes,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,LOCAL/2016/MR-01,19-Apr-17,23-Aug-17,23-Aug-17,26-Jan-18,null,26-Jan-18,"CHU Nimes, Nîmes, France",,https://ClinicalTrials.gov/show/NCT03411460
NCT03406585,Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes,,Recruiting,No Results Available,Type1 Diabetes Mellitus,Drug: ProTrans: Allogeneic transplantation with WJMSCs|Drug: Placebos,"Safety; measured through set safety parameters|Efficacy; comparison of the intervention versus placebo at day 372 versus start of treatment|Number of patients insulin independent (ADA criteria) at days 187 and 372|Number of patients with daily insulin needs <0.25U/kg at days 187 and 372|Insulin requirement/kg BW at days 187 and 372|HbA1c at days 187 and 372.|Glucose variability at day 372|Delta change of levels of fasting C-peptide at day 372|Numbers of patients with peak C-peptide >0.20 nmol/l, in response to the MMTT, at day 372",NextCell Pharma Ab,All,18 Years to 40 Years   (Adult),Phase 1|Phase 2,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ProTrans-T1D|2017-002766-50,28-Nov-17,1-Jun-20,1-Jun-20,23-Jan-18,null,30-Jan-18,"Karolinska Trial Alliance, Fas 1 enheten, Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT03406585
NCT03400501,Reducing the Risk of Metabolic Decompensation in Diabetic Adolescents by Supervised School Administration of Insulin,,Recruiting,No Results Available,Type 1 Diabetes Mellitus,Drug: Insulin Degludec|Drug: Insulin Glargine,Lower beta hydroxybutyrate levels|Control of HbA1c levels|Measure of beta hydroxybutyrate levels between the 2 groups.,Yale University,All,"8 Years to 18 Years   (Child, Adult)",Early Phase 1,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2000020909,1-Oct-17,Aug-19,Feb-20,17-Jan-18,null,27-Jun-18,"Yale University, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03400501
NCT03392441,Insulin Deprivation on Brain Structure and Function in Humans With Type 1 Diabetes,,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 1|Diabetes|Diabetes Complications",Other: Insulin Deprivation in Type 1 Diabetic Patients,Change in Structural MRI,Mayo Clinic,All,"14 Years to 45 Years   (Child, Adult)",Not Applicable,48,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,17-005244,30-Nov-17,21-Jul-18,30-Jun-19,8-Jan-18,null,16-Aug-18,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03392441
NCT03392961,Effect of Dosing Time and Meal on IN-105 (Insulin Tregopil) PK and PD,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: IN-105 (Insulin Tregopil)|Other: Placebo comparator,Area under the plasma concentration-time curve (AUC0-last) will be assessed (Cohort 1)|The maximum observed plasma drug concentration (Cmax) will be assessed (Cohort 1)|Glucose AUC0-t will be assessed (Cohort 1)|Glucose concentration (Cmin) will be assessed (Cohort 1)|Glucose concentration (Tmin) will be assessed (Cohort 1)|Area under the plasma concentration-time curve (AUC0-last) will be assessed (Cohort 2)|The maximum observed plasma drug concentration (Cmax) will be assessed. (Cohort 2)|Glucose AUC0-t will be assessed (Cohort 2)|Glucose concentration (Cmin) will be assessed (Cohort 2)|Glucose concentration (Tmin) will be assessed (Cohort 2)|Area under the plasma concentration-time curve (AUC0-last) will be assessed (Cohort 3)|The maximum observed plasma drug concentration (Cmax) will be assessed (Cohort 3)|Glucose AUC0-t will be assessed (Cohort 3)|Glucose concentration (Cmin) will be assessed. (Cohort 3)|Glucose concentration (Tmin) will be assessed. (Cohort 3)|Number of Participants With Adverse Events as a Measure of Safety and Tolerability,Biocon Limited,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,51,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IN-105-DM-01-G-14,27-Mar-14,1-Jul-14,1-Jul-14,8-Jan-18,null,23-Jan-18,,,https://ClinicalTrials.gov/show/NCT03392961
NCT03390231,Stem Cell Educator Therapy in Diabetes,,Recruiting,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Combination Product: Stem Cell Educator therapy,Changes of inflammation-related markers in diabetic patients after Stem Cell Educator therapy|Change in insulin resistance|Metabolic control in HbA1C levels|Metabolic control in blood glucose levels|Metabolic control in fasting C-peptide levels,Tianhe Stem Cell Biotechnologies Inc.|Chinese PLA General Hospital,All,20 Years to 60 Years   (Adult),Phase 2,100,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,S2017-059-01,27-Nov-17,30-Dec-20,31-Dec-20,4-Jan-18,null,5-Feb-19,"Department of Endocrinology, Chinese PLA General Hospital, Beijing, China",,https://ClinicalTrials.gov/show/NCT03390231
NCT03380988,Fiber-enriched Buckwheat Pasta and Glucose Variability in Patients With Type 1 Diabetes and Celiac Disease,,Completed,No Results Available,Type 2 Diabetes Mellitus|Celiac Disease,Other: Acute test meal with fiber-enriched buckwheat pasta|Other: Acute test meal with corn pasta,Postprandial glucose response,Federico II University,All,20 Years to 50 Years   (Adult),Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,175/15,Nov-15,Dec-16,Feb-17,21-Dec-17,null,21-Dec-17,"Department of Clinical Medicine and Surgery, Naples, Italy",,https://ClinicalTrials.gov/show/NCT03380988
NCT03378635,A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects,,Completed,No Results Available,"Hypoglycemia|Diabetes Mellitus, Type 1",Drug: Dasiglucagon|Drug: GlucaGen|Drug: Placebo,Time to plasma glucose recovery|Plasma glucose recovery|Plasma glucose changes drom baseline|Time to target|Pharmacodynamics - Area under the effect curve|Pharmacokinetics - Area under the plasma concentration curve|Pharmacokinetics - Maximum plasma concentration|Pharmacokinetics - Time to maximum plasma concentration|Safety - Adverse events|Safety - Biochemistry laboratory parameters|Safety - Hematology laboratory parameters|Safety - Blood pressure|Safety - Pulse|Safety - Physical Examination|Safety - Electrocardiogram|Safety - Injection site reactions|Safety - Glucose for rescue|Immunogenicity - Occurence of anti-drug antibodies,Zealand Pharma,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,166,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ZP4207-16137,7-Dec-17,27-Apr-18,25-May-18,20-Dec-17,null,7-May-19,"ProSciento, Chula Vista, California, United States|Clinical Research Center, Medizinische Universität Graz, Graz, Austria|LMC Diabetes & Manna Research, Toronto, Canada|Profil, Mainz, Germany|Profil, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT03378635
NCT03377699,"Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes",EXPECT,Recruiting,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: Insulin degludec|Drug: Insulin Aspart|Drug: Insulin detemir,"Last planned glycosylated haemoglobin (HbA1c) prior to delivery|HbA1c below or equal to 6.0% (42 mmol/mol) from last planned HbA1c prior to delivery (yes/no)|Last planned average post-prandial glucose prior to delivery. Average of three main meals.|Last planned fasting plasma glucose prior to delivery|Number of hypoglycaemic episodes|Development of sight-threatening retinopathy defined as proliferative retinopathy or maculopathy (yes/no)|Number of adverse events|Pre-eclampsia defined as new-onset hypertension occurring from gestational week 20 to delivery and simultaneous proteinuria or presence of eclampsia, HELLP syndrome, or other severe organ involvement (yes/no)|Birth weight (kg)|Pre-term delivery (delivery before 37 completed gestational weeks) (yes/no)|Presence of major abnormalities (classified according to EUROCAT) (yes/no)|Live born infants (yes/no)|Number of adverse events in the infant|Neonatal hypoglycaemic episodes defined as plasma glucose below or equal to 1.7 mmol/L (31 mg/dL) or below or equal to 2.5 mmol/L (45 mg/dl) (yes/no)|HbA1c below or equal to 6.5% (48 mmol/mol) from last planned HbA1c prior to delivery (yes/no)|Mode of delivery, e.g. vaginal, operative vaginal, planned caesarean section or unplanned caesarean section, induced or spontaneous delivery|Change in body weight|Early foetal death (delivery before 20 completed GWs) (yes/no)|Perinatal mortality (death of foetus/infant ) (yes/no)|Neonatal mortality (death of infant) (yes/no)",Novo Nordisk A/S,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,300,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN1250-4300|U1111-1191-3018|2017-000048-17,22-Nov-17,15-Oct-21,15-Oct-21,19-Dec-17,null,15-May-19,"Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Córdoba, Argentina|Novo Nordisk Investigational Site, Mendoza, Argentina|Novo Nordisk Investigational Site, Salta, Argentina|Novo Nordisk Investigational Site, Blacktown, New South Wales, Australia|Novo Nordisk Investigational Site, Campbelltown, New South Wales, Australia|Novo Nordisk Investigational Site, St Leonards, New South Wales, Australia|Novo Nordisk Investigational Site, Ipswich, Queensland, Australia|Novo Nordisk Investigational Site, Elizabeth Vale, South Australia, Australia|Novo Nordisk Investigational Site, Box Hill, Victoria, Australia|Novo Nordisk Investigational Site, Parkville, Victoria, Australia|Novo Nordisk Investigational Site, Graz, Austria|Novo Nordisk Investigational Site, Innsbruck, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Goiânia, Goias, Brazil|Novo Nordisk Investigational Site, Curitiba, Parana, Brazil|Novo Nordisk Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Ribeirao Preto, Brazil|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Vancouver, British Columbia, Canada|Novo Nordisk Investigational Site, Halifax, Nova Scotia, Canada|Novo Nordisk Investigational Site, Cambridge, Ontario, Canada|Novo Nordisk Investigational Site, London, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, St John's, Canada|Novo Nordisk Investigational Site, Aarhus N, Denmark|Novo Nordisk Investigational Site, København ø, Denmark|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Larissa, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Dublin 2, Ireland|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Galway, Ireland|Novo Nordisk Investigational Site, Petach Tikva, Israel|Novo Nordisk Investigational Site, Rehovot, Israel|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Padova, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Sant'Andrea Delle Fratte (PG), Italy|Novo Nordisk Investigational Site, Torino, Italy|Novo Nordisk Investigational Site, Ekaterinburg, Russian Federation|Novo Nordisk Investigational Site, Kirov, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Tomsk, Russian Federation|Novo Nordisk Investigational Site, Ulianovsk, Russian Federation|Novo Nordisk Investigational Site, Yoshkar-Ola, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Bath, United Kingdom|Novo Nordisk Investigational Site, Cambridge, United Kingdom|Novo Nordisk Investigational Site, High Wycombe, United Kingdom|Novo Nordisk Investigational Site, Leeds, United Kingdom|Novo Nordisk Investigational Site, Middlesbrough, United Kingdom|Novo Nordisk Investigational Site, Norwich, United Kingdom|Novo Nordisk Investigational Site, Nottingham, United Kingdom|Novo Nordisk Investigational Site, Oxford, United Kingdom|Novo Nordisk Investigational Site, Truro, United Kingdom",,https://ClinicalTrials.gov/show/NCT03377699
NCT03378271,Accuracy and Treatment Experience of Two Glucose Monitoring Systems Tested in Patients With Type 1 Diabetes and Renal Impairment,,Recruiting,No Results Available,Diabetes Mellitus Complication|Renal Impairment,Device: Simultanious CGM/FGM,"Accuracy of CGM and FGM|The evaluation of the accuracy of the 2 glucose monitoring systems during each studied time interval (day 1-3 and day 4-6)|The evaluation of the accuracy of the 2 glucose monitoring systems for various glucose intervals (hypo, normo- and hyperglycaemia)|The evaluation of the accuracy of the 2 glucose monitoring systems during dialysis and not in dialysis|The evaluation of patients preferences and experience of the two glucose monitoring systems.",Vastra Gotaland Region,All,"18 Years to 79 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CGM renal impairment,5-May-16,30-Dec-19,31-Dec-20,19-Dec-17,null,26-Nov-18,"NU-Hospital Group, Uddevalla, Sweden",,https://ClinicalTrials.gov/show/NCT03378271
NCT03376789,Mylan Insulin Glargine Study,,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 1",Drug: MYL-1501D,Change in HbA1c,Mylan Inc.|Mylan GmbH,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,202,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MYL-1501D-3004,29-Nov-17,Oct-18,Dec-18,18-Dec-17,null,27-Jun-18,"Valley Research, Fresno, California, United States",,https://ClinicalTrials.gov/show/NCT03376789
NCT03374462,Type 1 Diabetes Telemedicine,,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 1",Behavioral: Telemedicine Intervention,Improvement in A1C Levels|Increased visit frequency|Impact on high-cost health care utilization|Feasibility of home-based telemedicine|Acceptability of home-based telemedicine,"University of California, Davis",All,1 Year to 17 Years   (Child),Not Applicable,59,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,1125857,27-Nov-17,1-Apr-19,31-Oct-19,15-Dec-17,null,28-May-18,"University of California-Davis, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT03374462
NCT03371082,Gan & Lee Insulin Glargine Target Type (1) Evaluating Research,GLITTER 1,Recruiting,No Results Available,"Diabetes Mellitus, Type 1",Biological: Gan & Lee Insulin Glargine Injection|Biological: Lantus®,Immunogenicity,"Gan and Lee Pharmaceuticals, USA",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,550,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GL-GLAT1-3001,20-Oct-17,1-Oct-19,31-Jan-20,13-Dec-17,null,10-Jul-18,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Valley Research, Fresno, California, United States|The Rose Salter Medical Research Foundation, Newport Beach, California, United States|California Medical Research Association, Northridge, California, United States|Metabolic Institute of America, Tarzana, California, United States|CMR of Greater New Haven, LLC, Hamden, Connecticut, United States|Meridien Research, Bradenton, Florida, United States|The Center for Diabetes and Endocrine Care, Fort Lauderdale, Florida, United States|Homestead Associates in Research, Homestead, Florida, United States|Central Florida Endocrine and Diabetes Consultants - Maitland, Maitland, Florida, United States|Biotech Pharmaceutical Group, LLC, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Miami Dade Medical Research Institute, LLC, Miami, Florida, United States|Suncoast Clinical Research, Inc., New Port Richey, Florida, United States|Peninsula Research, Ormond Beach, Florida, United States|Oviedo Medical Research, LLC, Oviedo, Florida, United States|Metabolic Research Institute, Inc., West Palm Beach, Florida, United States|River Birch Research Alliance, LLC, Blue Ridge, Georgia, United States|iResearch Atlanta, Decatur, Georgia, United States|Sestron Clinical Research, Marietta, Georgia, United States|Endocrine Research Solutions, Inc., Roswell, Georgia, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|Advanced Clinical Research - Idaho, Boise, Idaho, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States|Midwest CRC, Crystal Lake, Illinois, United States|Iowa Diabetes and Endocrinology Research Center, Des Moines, Iowa, United States|Kentucky Diabetes Endocrinology Center, Lexington, Kentucky, United States|Palm Research Center, Inc., Las Vegas, Nevada, United States|Physicians East, PA, Greenville, North Carolina, United States|Lillestol Research LLC, Fargo, North Dakota, United States|Endocrinology Associates, Inc., Columbus, Ohio, United States|Aventiv Research, Inc., Columbus, Ohio, United States|PriMed Clinical Research, Dayton, Ohio, United States|University Diabetes & Endocrine Consultants, Chattanooga, Tennessee, United States|ClinSearch - Clinical Research Specialists, Chattanooga, Tennessee, United States|New Phase Research & Development, Knoxville, Tennessee, United States|Texas Diabetes & Endocrinology - Central Austin, Austin, Texas, United States|Texas Diabetes & Endocrinology - South Austin, Austin, Texas, United States|Research Institute of Dallas, Dallas, Texas, United States|Texas Diabetes & Endocrinology, Round Rock, Texas, United States|Clinical Trials of Texas, San Antonio, Texas, United States|Northeast Clinical Research of San Antonio, Schertz, Texas, United States|Radiant Research, Murray, Utah, United States|Advanced Research Institute, Ogden, Utah, United States|Wasatch Clinical Research, LLC, Salt Lake City, Utah, United States|Burke Internal Medicine, Burke, Virginia, United States|Stonesifer Clinical Research, Federal Way, Washington, United States|Rainier Clinical Research Center, Inc., Renton, Washington, United States|MultiCare Institute for Research & Innovation, Tacoma, Washington, United States|Diabetologie Ceské Budejovice s.r.o, Ceské Budejovice, Jihocesky KRAJ, Czechia|Krajská zdravotní, a.s., Masarykova nemocnice v Ústí nad Labem, Ústí Nad Labem, Severoceský KRAJ, Czechia|Diahaza s.r.o., Holešov, Czechia|Diabetologická ambulance, Hradec Králové, Czechia|Diabetologie MUDr. Tomáš Edelsberger, Krnov, Czechia|PreventaMed, Olomouc, Czechia|Genom, Ostrava, Czechia|Studienzentrum Aschaffenburg, Aschaffenburg, Bayern, Germany|Diabetes-falkensee.de - Zentrum für Klinische Studien, Falkensee, Brandenburg, Germany|Diabeteszentrum DO, Dortmund, Nordrhein-westfalen, Germany|Diabetes Schwerpunktpraxis, Gemeinschaftspraxis Alain Barakat und Helene Willems, Duisburg, Nordrhein-westfalen, Germany|Diabetologische Schwerpunktpraxis Pirna, Pirna, Sachsen, Germany|RED-Institut GmbH, Oldenburg, Schleswig-holstein, Germany|Lausmed Egeszsegugyi es Szolgaltato Kft., Baja, Bacs-kiskun, Hungary|CRU Hungary Egészségügyi és Szolgáltató Kft., Miskolc, Borsod-abauj-zemplen, Hungary|Markhot Ferenc Oktatókórház és Rendelointézet, Eger, Heves, Hungary|Zala County Hospital, Zalaegerszeg, Zala, Hungary|Betegapolo-Irgalmasrend Budai Irgalmasrendi Kórház, Diabetológiai Ambulancia, Budapest, Hungary|Synexus Magyarország, Budapest, Hungary|Semmelweis Egyetem II. Sz. Belgyógyászati Klinika, Budapest, Hungary|KO-MED Centra Kliniczne Lublin, Lublin, Lubelskie, Poland|Centrum Medyczne Pratia Kraków, Kraków, Malopolskie, Poland|NZOZ Medyczne Centrum Diabetologiczno-Endokrynologiczno-Metaboliczne ""Diab-Endo-Met"", Kraków, Malopolskie, Poland|Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji w Warszawie, Warszawa, Mazowieckie, Poland|Centrum Badan Klinicznych PI-House, Gdansk, Pomorskie, Poland|Praktyka Lekarska Ewa Krzyzagórska, Poznań, Wielkopolskie, Poland|Niepubliczny Zaklad Opieki Zdrowotnej Gdanska Poradnia Cukrzycowa Sp. z o.o., Gdansk, Poland|IDIBGI-Hospital General Dr. Josep Trueta, Girona, Gerona, Spain|Complejo Hospitalario Universitario La Coruña, A Coruna, LA Coruna, Spain|Complejo Hospitalario Universitario de Ferrol, Ferrol, LA Coruna, Spain|Centro de Especialidades San Jose Obrero. Hospital Universitario Virgen de la Victoria, Málaga, Malaga, Spain|Hospital Universitario Ramón Y Cajal, Madrid, Spain|Nuevas Tecnologías en Diabetes y Endocrinología, Sevilla, Spain|Hospital Universitario Nuestra Señora de Valme, Sevilla, Spain|Consorci Hospital General Universitari de València, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT03371082
NCT03368937,A Pilot Test of t:Slim X2 With Control-IQ Technology,,Completed,Has Results,Type1 Diabetes Mellitus,Device: Tandem t:slim X2 with Control-IQ Technology,System Suitability,"University of Virginia|Tandem Diabetes Care, Inc.|DexCom, Inc.|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",All,"18 Years to 74 Years   (Adult, Older Adult)",Not Applicable,5,Other|Industry|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,20251|UC4DK108483,8-Dec-17,11-Dec-17,11-Dec-17,11-Dec-17,27-Feb-19,27-Feb-19,"University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03368937/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03368937/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03368937
NCT03369067,Artificial Pancreas and Remote Monitoring During a T1DM Youth Ski Camp,,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: Tandem t:slim X2 with Control-IQ Technology + Dexcom G6|Device: Dexcom CGM G5|Device: Continuous Subcutaneous Insulin Infusion,Percent time spent in glycemic zone (70-180mg/dl),"University of Virginia|Tandem Diabetes Care, Inc.|DexCom, Inc.|University of Virginia Strategic Investment Fund",All,"6 Years to 18 Years   (Child, Adult)",Not Applicable,55,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,20335,18-Dec-17,15-Apr-18,15-Apr-18,11-Dec-17,null,14-Aug-18,"Stanford University, Stanford, California, United States|Barbara Davis Center, University of Colorado, Aurora, Colorado, United States|University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT03369067
NCT03366337,A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX,PHOENIX,"Active, not recruiting",No Results Available,IgA Nephropathy|CKD Associated With Type 1 Diabetes|Focal Segmental Glomerulosclerosis|Autosomal Dominant Polycystic Kidney,Drug: Bardoxolone methyl capsules,Increase in eGFR from baseline|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,"Reata Pharmaceuticals, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,103,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,402-C-1702,26-Dec-17,Jul-19,Aug-19,8-Dec-17,null,14-Mar-19,"University of Alabama Birmingham, Birmingham, Alabama, United States|Phoenician Centers for Research & Innovation (PCRI), Phoenix, Arizona, United States|University of California Los Angeles, Los Angeles, California, United States|Denver Nephrology, Denver, Colorado, United States|Gulfcoast Endocrine and Diabetes Center, Clearwater, Florida, United States|South Florida Research Institute, Lauderdale Lakes, Florida, United States|Coastal Nephrology Associates, Port Charlotte, Florida, United States|Kidney Care Augusta, Augusta, Georgia, United States|Boise Kidney & Hypertension, PLLC, Caldwell, Idaho, United States|Boise Kidney & Hypertension, PLLC, Meridian, Idaho, United States|Research By Design, Evergreen Park, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Four Rivers Clinical Research, Inc, Paducah, Kentucky, United States|Northwest Louisiana Nephrology, Shreveport, Louisiana, United States|Tufts Medical Center - Division of Nephrology Tufts Medical Center, Boston, Massachusetts, United States|Clinical Research Consultants, LLC, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Jacobi Medical Center, Bronx, New York, United States|Columbia University Medical Center - Nephrology, New York, New York, United States|Physician's East Endocrine Research, Greenville, North Carolina, United States|Remington-Davis Clinical Research, Columbus, Ohio, United States|Northeast Clinical Research Center, LLC, Bethlehem, Pennsylvania, United States|The Warren Alpert School of Brown University, Providence, Rhode Island, United States|Nephrology Associates, Chattanooga, Tennessee, United States|Research Management, Inc., Austin, Texas, United States|Renal Disease Research Intitute, Dallas, Texas, United States|Renal Associates, PA, San Antonio, Texas, United States|Advanced Clinical Research, West Jordan, Utah, United States|Mendez Center for Clinical Research LLC, Fairfax Station, Virginia, United States|Larry Stonesifer, M.D., Federal Way, Washington, United States",,https://ClinicalTrials.gov/show/NCT03366337
NCT03367390,A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM),,Completed,No Results Available,Type1 Diabetes Mellitus,Device: AID System|Drug: Insulin Lispro,Number of Participants Who Show a Decrease or Suspension of Basal Insulin Delivery in Response to Hypoglycemia Challenges|Number of Participants Who Show an Increase of Basal Insulin Delivery in Response to the Hyperglycemia Challenge|Number of Participants Who Show a Resumption of Auto Mode Following Restored Continuous Glucose Monitoring (CGM) Connectivity,Eli Lilly and Company,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,30,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,16679|F3Z-MC-IOQS,8-Nov-17,9-Feb-18,9-Feb-18,8-Dec-17,null,15-Mar-18,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT03367390
NCT03365349,Two Narrative Medicine Interventions in Type 1 Diabetes,,Completed,No Results Available,Type1diabetes,"Other: participating in a session of ""living theatre""|Other: writing workshop",Change from baseline IPQR (Illness Perception Questionnaire) score at 3 months|comparison of the two groups concerning answers to qualitative interviews at T 3 months after the intervention,Assistance Publique - Hôpitaux de Paris,All,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,87,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,TDV,1-Feb-12,28-Feb-13,1-Aug-13,7-Dec-17,null,7-Dec-17,,,https://ClinicalTrials.gov/show/NCT03365349
NCT03363100,Diabetes Coaching Program for Medicare Advantage Members With Type 2 Diabetes - Impact on A1c,,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 2",Behavioral: Digital health Partnership program,A1c,Evidation Health|Humana Co.Ltd.,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,624,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,EH-006,5-Dec-17,Jan-19,Jan-19,6-Dec-17,null,25-Jul-18,"Evidation Health, San Mateo, California, United States",,https://ClinicalTrials.gov/show/NCT03363100
NCT03361098,DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2,DECREASE,Recruiting,No Results Available,Type 2 Diabetes Mellitus|Obesity,Drug: Dapagliflozin 10mg|Drug: Exenatide|Other: placebo exenatide|Other: placebo dapagliflozin,Differences in neuronal activity in the central reward and satiety circuits in response to food-related stimuli by BOLD fMRI signal|Feeding behaviour; ad libitum lunch buffet|Self-reported hunger|Difference in resting energy expenditure measured by indirect calorimetry measurements|Change in bodyweight (kg) and body mass index (kg/m2)|Difference in bodycomposition measured by bio electrical impedance analysis and waist and hip circumference measurements (cm)|Difference in resting brain activity by fMRI resting state measurements|Effect on cardiovascular autonomic balance by cardiovascular reflex test with finger plethysmography (Nexfin)|Arterial stiffness: Pulse Wave analysis|Renal measurements collecting 24 hour urine|Laboratory parameters,VU University Medical Center|AstraZeneca,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,64,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DC2017DECREASE01,18-Sep-17,31-Jan-20,31-Jan-20,4-Dec-17,null,4-Dec-17,"VU Medical Center, Amsterdam, Noord-Holland, Netherlands",,https://ClinicalTrials.gov/show/NCT03361098
NCT03358394,Mindfulness-based Arabic Guided Self-help for Parents of Children With Type 1 Diabetes,,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 1",Behavioral: A human-interventional study,Generalized Anxiety Disorder Scale (GAD-7)|The Patient Health Questionnaire (PHQ-9).|Mindfulness,SHAHAH ALTAMMAR|University of Sheffield,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,Reference Number 016511,26-Oct-17,26-Feb-18,16-May-18,30-Nov-17,null,6-Dec-17,"Shahah Altammar, Kuwait, Kuwait",,https://ClinicalTrials.gov/show/NCT03358394
NCT03356457,Development of Agents to Diminish the Risk of Hypoglycemia-induced Brain Injury in Type 1 Diabetes,,Recruiting,No Results Available,Hyperglycaemia (Diabetic),Drug: Dichloroacetate|Drug: Placebo oral capsule,• Measurement of hormone changes during hypoglycemia|cognitive function,Yale University,All,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,24,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2000020041,30-Nov-17,30-Nov-20,30-Nov-20,29-Nov-17,null,10-Jan-19,"Yale New Haven Hospital, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03356457
NCT03353376,Group Versus Individual Care in Diabetes Clinic,,Completed,No Results Available,Diabetes Mellitus|Group Meetings,Behavioral: group care with Empowerment model,change in in Hba1c levels|change in scores of diabetes specific questionnaire|change in BMI in kg/m2|change in non HDL Cholesterol,Rabin Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,JSMG-01,13-Sep-10,2-Jan-14,2-Jan-14,27-Nov-17,null,27-Nov-17,,,https://ClinicalTrials.gov/show/NCT03353376
NCT03353792,Using an Artificial Pancreas System in Older Adult Type 1 Diabetes Mellitus Patients,T1DM AP,Recruiting,No Results Available,Type1 Diabetes Mellitus,Device: CL/AP system|Device: usual diabetic care,brain alternate fuel uptake|change of cognitive function,Yale University,All,"50 Years to 75 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2000020059,1-Nov-17,Jan-22,Nov-22,27-Nov-17,null,10-Jan-19,"Yale New Haven Hospital, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03353792
NCT03354286,Supporting Parents of Young Children With Type 1 Diabetes in Closed-Loop System,,"Active, not recruiting",No Results Available,Type 1 Diabetes Mellitus,"Behavioral: Developmental & Technological Demands|Behavioral: Distress Reduction|Behavioral: Nutrition, Set Point, & C:I Ratio|Behavioral: Hypoglycemia management|Behavioral: Minimal Intervention",Time spent in blood glucose range|Hemoglobin A1c|Problem Areas in Diabetes|Parent Diabetes Distress Scale|Patient Health Questionnaire 8|State-Trait Anxiety Inventory|Pittsburgh Sleep Quality Index|Hypoglycemic Fear Survey - Parents|Hypoglycemia Confidence Questionnaire|Pediatric Quality of Life Inventory|Glucose Monitoring System Satisfaction Survey|General and diabetes-specific technology use|Diabetes management behaviors|Health care utilization,"Stanford University|University of Colorado, Denver|Indiana University|Yale University|University of South Florida",All,2 Years to 6 Years   (Child),Not Applicable,26,Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,43167,7-Nov-17,30-Apr-19,30-Apr-20,27-Nov-17,null,4-Apr-19,"Stanford University School of Medicine, Palo Alto, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03354286/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03354286
NCT03350191,A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: SAR425899|Drug: [68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer)|Drug: [68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer),Glucagon receptor occupancy|GLP-1 receptor occupancy|Adverse events|Pharmacokinetics|Change in fasting plasma glucose (FPG)|Change in ketone bodies|Change lipid biomarkers|Change in volume of distribution (Vt) in the liver|Change in Vt in the pancreas|Average standard uptake values (SUVs) of PET tracers in the liver and pancreas,Sanofi|Antaros Medical AB,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,13,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,PDY15264|2017-001789-23,20-Dec-17,7-Jun-18,7-Jun-18,22-Nov-17,null,11-Oct-18,"Investigational Site Number 7520001, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT03350191
NCT03345004,GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes,,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus|Autoimmune Diseases|Metabolic Disease|Glucose Metabolism Disorders|Immune System Diseases|Endocrine System Diseases|Juvenile Diabetes|Insulin Dependent Diabetes|Autoimmune Diabetes|Vitamin D|Physiological Effects of Drugs",Biological: GAD-alum|Dietary Supplement: Vitamin D|Biological: Placebo for Diamyd (GAD-alum)|Dietary Supplement: Placebo for Vitamin D,Change in stimulated C-peptide during a MMTT|Stimulated maximum C-peptide above 0.2 nmol/L|Stimulated C-peptide above 0.2 nmol/L at 90 min|• Change in maximum C-peptide|C-peptide levels during a MMTT|• Change in Fasting C-peptide|Change in HbA1c|Change in insulin consumption|Change in IDAA1c|Proportion of patients with IDAA1c ≤ 9|Change in glycemic variability/fluctuations|Number of hypoglycemias|Number of patients having at least 1 severe hypoglycemic event|Change in Rate of hypoglycemic events|Injection site reactions|Adverse Events|Laboratory analysis of safety parameters|Urine analysis|Physical examination|GAD65A titer|Vital signs|Total serum Immunoglobulin E|Concentrations of serum autoantibodies|Concentrations of serum autoantibodies isotypes|Cytokine secretion patterns of PBMCs|Number of PMBCs secreting specific cytokines|Proliferation of PBMCs|Flow cytometric analysis of PBMC subsets|Exploratory immunological characterization|Change in Quality of Life|Quality adjusted life years,Diamyd Medical AB,All,"12 Years to 24 Years   (Child, Adult)",Phase 2,109,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DIAGNODE-2 (D/P2/17/6)|2017-001861-25,20-Dec-17,Aug-20,Aug-20,17-Nov-17,null,9-May-19,"Diabetes Centre, Institute of Clinical and Experimental Medicine, Praha, Czechia|Department of Paediatrics, University Hospital Motol, Praha, Czechia|Diabeter Rotterdam, Rotterdam, Netherlands|Adult and Pediatrics Endocrinology and Diabetology, Hospital Universitario Cruces, Barakaldo, Spain|Adult Endocrinology and Diabetology, Hospital vall D' Hebrón, Barcelona, Spain|Pediatrics Endocrinology and Diabetology, Hospital Vall D'Hebrón, Barcelona, Spain|Adult Endocrinology and Diabetology, Hospital Ramón y Cajal, Madrid, Spain|Adult Endocrinology and Diabetology, Hospital Carlos Haya, Málaga, Spain|Pediatrics Endocrinology and Diabetology, Hospital Materno-Ifantil, Málaga, Spain|Adult Endocrinology and Diabetology, Hospital Macarena, Sevilla, Spain|Pediatrics Endocrinology and Diabetology, Hospital Virgen del Rocío, Sevilla, Spain|Adult and Pediatrics Endocrinology and Diabetology, Hospital Miguel Servet, Zaragoza, Spain|Barn- och Ungdomskliniken, Universitetssjukhuset, Linköping, Sweden|Endokrinmedicinska kliniken. Universitetssjukhuset, Linköping, Sweden|Barn-och Ungdomsmedicinmottagningen and Endokrinmottagningen, Skånes Universitetssjukhus, Malmö, Sweden|Barn- och ungdomskliniken, Uddevalla Sjukhus, Uddevalla, Sweden|Diabetesmottagningen, Uddevalla Sjukhus, Uddevalla, Sweden|Barnmottagningen, Norrlands Universitetssjukhus, Umeå, Sweden",,https://ClinicalTrials.gov/show/NCT03345004
NCT03341013,A Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: MEDI0382 Formulation 2|Drug: MEDI0382 Formulation 3,"Area under the drug concentration curve|Maximum observed plasma concentration of MEDI0382|Area under the plasma drug concentration versus time curve from zero to infinity and to last observation|Time to maximum observed plasma drug concentration|Terminal phase elimination half-life|Apparent clearance|Adverse Events|12 lead electrocardiogram including RR, PR, QRS, QT, and QTc intervals|Anti-drug antibody titer|Vital signs (temperature)|Anti-drug antibody incidence|Clinical laboratory assessments (hematology)|Vital signs (systolic and diastolic blood pressure)|Vital signs (pulse rate and respiratory rate)|Clinical laboratory assessments (serum chemistry)|Clinical laboratory assessments (urinalysis)",MedImmune LLC,All,18 Years to 45 Years   (Adult),Phase 1,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,D5670C00003,30-Nov-17,29-Jan-18,29-Jan-18,14-Nov-17,null,14-Feb-18,"Research Site, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT03341013
NCT03341299,A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 1 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Biological: LY900014|Biological: Insulin Lispro,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC) for Each Treatment Arm|Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Curve for Each Treatment Arm,Eli Lilly and Company,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,36,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",16641|I8B-MC-ITRV|2017-001500-30,13-Nov-17,3-Apr-18,3-Apr-18,14-Nov-17,null,17-Apr-18,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany",,https://ClinicalTrials.gov/show/NCT03341299
NCT03339453,A Study of Glucagon Nasal Powder in Participants With Type 1 Diabetes Mellitus,,Completed,No Results Available,"Hypoglycemia|Diabetes Mellitus, Type 1",Drug: Glucagon Nasal Powder|Drug: Glucagon Hydrochloride Solution,Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia|Pharmacodynamics (PD): Change from Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM|Pharmacodynamics (PD): Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM|Pharmacokinetics (PK): Change from Baseline in Area Under the Concentration Versus Time Curve (AUC) of Glucagon Nasal Powder and Glucagon Hydrochloride IM|Pharmacokinetics (PK): Change from Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM|Pharmacokinetics (PK): Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM,Eli Lilly and Company,All,18 Years to 64 Years   (Adult),Phase 1,70,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,16547|I8R-MC-IGBI|2017-000249-33,10-Nov-17,17-Dec-17,13-Jan-18,13-Nov-17,null,29-Jan-18,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany",,https://ClinicalTrials.gov/show/NCT03339453
NCT03333525,Does Protein and Fat Content of Meal Increase Glucose Concentrations,,Completed,No Results Available,Type 1 Diabetes Mellitus,Other: Calculation of insulin dosages for different meals,Change Postprandial Glucose Concentrations|Postprandial insulin need,TC Erciyes University|Hacettepe University,All,"16 Years to 18 Years   (Child, Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013/173|KEPAN|ESPEN Travel Grant (36 th),10-Sep-13,20-Feb-14,20-Feb-14,7-Nov-17,null,7-Nov-17,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT03333525/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03333525
NCT03333642,Surgery Treatment of Type 2 Diabetes Mellitus Patients With Grade 1 Obesity and Overweight,,Recruiting,No Results Available,Diabetes Mellitus|Obesity|Overweight,Procedure: Duodenal Ileal Interposition with Sleeve Gastrectomy,Remission of type 2 Diabetes at 24 months|Control of type 2 diabetes,Hospital Federal de Bonsucesso,All,"20 Years to 65 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,67955917.2.0000.5253,27-Nov-17,Jul-19,Jul-21,7-Nov-17,null,5-Mar-18,"Hospital Federal de Bonsucesso, Rio de Janeiro, Brazil",,https://ClinicalTrials.gov/show/NCT03333642
NCT03335371,Evaluation of TTP399 in Patients With Type 1 Diabetes,SimpliciT1,Recruiting,No Results Available,"Diabetes Mellitus, Type 1",Drug: TTP399|Drug: Placebo Oral Tablet,"Change in HbA1c from baseline at 12 weeks|Adverse Events|Time in target glycemic range (70-180 mg/dL)|Time in hyperglycemic range (Level 1 > 180 mg/dL, Level 2 (>250 mg/dL)|Time in hypoglycemic range (Level 1 < 70 mg/dL, Level 2 < 54 mg/dL)|Change from baseline in total daily insulin dose|Change from baseline of meal time bolus insulin",vTv Therapeutics|Juvenile Diabetes Research Foundation,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,126,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TTP399-203|JDRF#2-IND-2018-500,25-Oct-17,Dec-19,Dec-19,7-Nov-17,null,15-May-19,"Site 05, Escondido, California, United States|Site 13, Aurora, Colorado, United States|Site 06, Atlanta, Georgia, United States|Site 10, West Des Moines, Iowa, United States|Site 16, Asheville, North Carolina, United States|Site 01, Chapel Hill, North Carolina, United States|Site 03, Durham, North Carolina, United States|Site 04, Morehead City, North Carolina, United States|Site 12, Wilmington, North Carolina, United States|Site 02, Winston-Salem, North Carolina, United States|Site 11, Norman, Oklahoma, United States|Site 07, Greer, South Carolina, United States|Site 08, Dallas, Texas, United States|Site 14, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT03335371
NCT03332472,Telemedicine on Metabolic Control in Type 1 Diabetes Mellitus Andalusian Patients (PLATEDIAN),PLATEDIAN,Completed,No Results Available,Telemedicine,Other: Telemedicine group|Other: Conventional group,HbA1c|Total daily dose of insulin|Total daily dose of insulin by weight|Number of mild hypoglycaemia|Number of severe hypoglycemia|Number of hyperglycemia greater than 250 mg / dl / week|Number of episodes of ketosis number of episodes of ketoacidosis|Number of hospital admissions due to glycemic decompensations|Fear of hypoglycemia: FH-15 scale|Quality of life|Stress: DDS questionnaire|Time invested in the care of each patient|Number of telephone calls|Number of face-to-face visits|Analytics performed in the center|Analytic done in domestic scope with glucometer|Cost of hypoglycaemic treatment (insulin)|Costs and consumption of health resources|Costs associated with the time spent going to the patient's hospital and family members|Costs associated with days lost due to complications.|Mean blood glucose|Standard deviation,"Sociedad Andaluza de Endocrinología, Diabetes y Nutrición",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,334,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PLATEDIAN,Dec-13,Nov-14,Dec-16,6-Nov-17,null,6-Nov-17,"Hospital Regional Universitario de Málaga. Unidad de Diabetes, Málaga, Spain",,https://ClinicalTrials.gov/show/NCT03332472
NCT03332836,Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus,,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Biological: HM12460A,Number of participants with adverse events|Cmax of HM12460A|AUC of HM12460A,Hanmi Pharmaceutical Company Limited,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,48,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HM-INS-102,25-Oct-17,30-Jun-19,30-Jun-19,6-Nov-17,null,6-Nov-17,"Hanmi Investigative Site, Chula Vista, California, United States",,https://ClinicalTrials.gov/show/NCT03332836
NCT03332849,Multiple Ascending Dose Study of HM12470 in Type 1 and Type 2 Diabetes Mellitus,,"Active, not recruiting",No Results Available,Type1 Diabetes Mellitus|Type2 Diabetes Mellitus,Biological: HM12470,Number of participants with adverse events|Cmax of HM12470|AUC of HM12470,Hanmi Pharmaceutical Company Limited,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,60,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HM-INS115-103,28-Jul-15,30-Apr-18,30-Apr-18,6-Nov-17,null,6-Nov-17,"Hanmi Investigative Site, Chula Vista, California, United States",,https://ClinicalTrials.gov/show/NCT03332849
NCT03328845,Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study),INEOX,Recruiting,No Results Available,Type 1 Diabetes Mellitus,Drug: Toujeo SoloStar|Drug: Tresiba|Drug: Humalog Kwikpen|Drug: NovoRapid|Drug: Apidra,Oxidative stress markers with the new slow insulin analogues|HbA1c|Mean blood glucose|Standard deviation|Number of mild hypoglycemia|Number of severe hypoglycemia|Number of hyperglycemia|Episodes of ketosis|Number os hospital admissions|Quality of life questionnaire in diabetes (DQOL)|Scale of adherence to treatment in patients with diabetes type 1 (DM1)|Diabetes distress scale. DDS|Fear of hypoglycemia: Questionnaire FH-15|Diabetes treatment satisfaction questionnaire (DTSQ).,Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FIM-EOX-2016-01,Jan-17,Jun-18,Dec-19,1-Nov-17,null,1-Nov-17,"Regional University Hospital of Málaga, Málaga, Spain",,https://ClinicalTrials.gov/show/NCT03328845
NCT03328975,An Evaluation of Blood Glucose Levels and Insulin Requirement After Subacromial Corticosteroid Injection in Insulin Dependent Diabetics,,Withdrawn,No Results Available,Shoulder Injury|Insulin-dependent Diabetics,Drug: Dexamethasone|Other: Placebo,Can diabetic patients maintain their blood glucose in a normal range after receiving a corticosteroid injection?,University of Pittsburgh,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PRO17070506,1-Nov-17,1-Nov-21,1-Nov-22,1-Nov-17,null,1-Nov-17,,,https://ClinicalTrials.gov/show/NCT03328975
NCT03324438,Home Telemedicine to Optimize Health Outcomes in High-Risk Youth With Type 1 Diabetes,,Recruiting,No Results Available,Type 1 Diabetes Mellitus,Behavioral: Home Telehealth T1D C2oYoT1-HR|Behavioral: Personalized Behavioral Health|Behavioral: Personalized Adherence Feedback,Glycemic control (A1C): Change from baseline and every 12 weeks up to 72 weeks (18 mo)|Hyperglycemia - Change from baseline and every 12 weeks up to 72 weeks (18 mo)|Pediatric Diabetes Quality of Life Scale - Change from baseline and every 12 weeks up to 72 weeks (18 mo)|Adherence - Change from baseline and every 12 weeks up to 72 weeks (18 mo)|Psychosocial Measures - Change from baseline and every 24 weeks up to 72 weeks (18 mo)|Biological Markers of T1D Complications - Change from baseline and every 24 weeks up to 72 weeks (18 mo),"University of Colorado, Denver",All,10 Years to 17 Years   (Child),Not Applicable,110,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17-0004,1-Nov-17,30-Nov-20,31-Dec-20,27-Oct-17,null,31-May-18,"Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT03324438
NCT03320031,A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy,,Recruiting,No Results Available,Type 2 Diabetes Mellitus|Peritoneal Dialysis,Drug: Linagliptin|Drug: Humalog Mix 75/25,glucose variability|HbA1c|FPG|insulin dosage|body weight|hypoglycemia,Yanbing Li|Sun Yat-sen University,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,232,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2017187,3-Jun-17,Dec-19,Dec-19,24-Oct-17,null,24-Oct-17,"endocrinology department of the first affiliated hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT03320031
NCT03312478,Association of Type 1 Diabetes Mellitus in Offsprings With Positive Parental History of Diabetes,SHINE,Completed,No Results Available,Type 1 Diabetes,Drug: Blood draw for insulin auto-anti body tests*,Odds of Type 1 Diabetes Mellitus child having a diabetic parent|Characterization of this population by gender|Characterization of this population by age|Characterization of this population by socio-economic profile|Means of HbA1c in Type 1 diabetes mellitus (T1DM) patients|Standard deviation of HbA1c in T1DM patients|Distribution of prescribed therapies by type of insulin to T1DM patients|Means of fasting blood glucose (FBG) in T1DM patients|Standard deviation of FBG in T1DM patients|Duration of diabetes in parent|Mean duration of diabetes in parent|Characterization of family history of diabetes|Characterization of frequency of consultation|Characterization of diabetes education,Sanofi,All,"2 Years to 20 Years   (Child, Adult)",Phase 4,375,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LANTUL08473|U1111-1200-1995,13-Oct-17,19-Aug-18,19-Aug-18,17-Oct-17,null,22-Aug-18,"National Institute of Child Health, Karachi, Sind, Pakistan",,https://ClinicalTrials.gov/show/NCT03312478
NCT03310944,Comparison of Sotagliflozin Prototype Tablets With Reference Tablet in Healthy Subjects,,Completed,No Results Available,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Drug: sotagliflozin (SAR439954),Assessment of Pharmacokinetic (PK) Parameter: AUC|Assessment of PK Parameter: Area under the concentration-time curve from 0 to last quantifiable concentration (AUClast)|Assessment of PK Parameter: Maximum plasma concentration (Cmax)|Assessment of PK Parameter: Tmax|Assessment of PK Parameter: Time to reach AUClast (Tlast)|Assessment of PK Parameter: Terminal elimination half-life (t1/2)|Assessment of PK Parameter: Tlast|Assessment of PK Parameter: t1/2|Assessment of PK Parameter: Cmax|Assessment of PK Parameter: AUC|Assessment of PK Parameter: AUClast|Adverse Events,Sanofi,All,18 Years to 55 Years   (Adult),Phase 1,12,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,BDR14994|2017‐002104‐27|U1111-1195-6292,18-Oct-17,8-Dec-17,8-Dec-17,16-Oct-17,null,14-Dec-17,"Investigational Site Number 276001, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT03310944
NCT03307850,Impact of Non-glucose Signals on Glycemic Control in Patients With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus,Other: Observation During Exercise and Stress,"Impact of Stress and Exercise on CGM Glucose Levels, determining how these factors affect time within target glucose range 70-180 mg/dl|CGM Glucose Levels 70-180 mg/dl|CGM Glucose Levels less than 70 mg/dl|CGM Glucose Levels greater than 180 mg/dl",Sansum Diabetes Research Institute|Mayo Clinic|Harvard University,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,JDRFSignals1,1-Nov-17,31-Aug-18,31-Aug-18,12-Oct-17,null,5-Sep-18,"Sansum Diabetes Research Institute, Santa Barbara, California, United States|Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03307850
NCT03305367,Dose-response Effect of Pine Nut Oil as a Dual FFA1 and FFA4 Agonist on Glucose Tolerance in Healthy Humans.,,Completed,No Results Available,Type 2 Diabetes Mellitus,Dietary Supplement: Hydrolyzed pine nut oil,Blood glucose|Insulin and C-peptide|Incretins|ghrelin|appetite|Gastrointestinal tolerability,Odense University Hospital|University of Southern Denmark,All,"40 Years to 70 Years   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,PINO3,6-Feb-17,23-Aug-17,23-Aug-17,9-Oct-17,null,13-Dec-18,"Department of Endocrinology, Odense, Denmark",,https://ClinicalTrials.gov/show/NCT03305367
NCT03300934,Adolescence and Diabetes:Can an Automated Closed Loop System Improve Control ?,SPIDIMAN2,Completed,No Results Available,Type1 Diabetes Mellitus,Device: closed loop glucose control system,"Time spent in glucose target (%) (3.9 - 10 mmol/l)|Time spent below glucose target (%) (<3.0mmol/l and < 2,5 mmol/l)|Time spent above glucose target (%) (> 10 mmol/l)|Severe hypoglycaemic events|Severe Diabetes ketoacidosis|Use of the automated closed loop system (% time)|Use of the CGM during closed loop|Quality of life perception in adolescents|Family Responsibility perception|User experience after the 4 week treatment",Centre Hospitalier du Luxembourg|University of Cambridge|Luxembourg Institute of Health,All,"12 Years to 18 Years   (Child, Adult)",Not Applicable,16,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Spidiman,1-Jul-17,19-Jul-18,19-Jul-18,4-Oct-17,null,31-Jul-18,"Clinique des Enfants CHluxembourg, Luxembourg, Luxembourg",,https://ClinicalTrials.gov/show/NCT03300934
NCT03298542,"A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes",,Recruiting,No Results Available,Pre-Symptomatic Type 1 Diabetes,Drug: Golimumab|Drug: Placebo,Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Percentage of Participants With Treatment-Emergent Infections|Percentage of Participants With Study Treatment Injection Site Reactions|Number of Participants With Treatment Related AEs and SAEs Reported From Week 52 to Week 78|Serum Concentration of Golimumab|Incidence of Antibodies to Golimumab,"Janssen Research & Development, LLC",All,"6 Years to 21 Years   (Child, Adult)",Phase 1,15,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CR108354|2017-000225-12|CNTO148DML1001,16-Oct-17,21-Feb-21,21-Feb-21,2-Oct-17,null,10-May-19,"UC Denver-Colorado Barbara Davis Center, University of Colorado SOM Pediatric Endocrinology, Aurora, Colorado, United States|Emory-Children's Pediatric Research Center, Atlanta, Georgia, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Oulu University Hosp. - Oulu, Oulu, Finland|Tampere University Hospital, Tampere, Finland|Turku University Hospital, Turku, Finland|Linkoping University Hospital, Linkoping, Sweden|Lund University Hospital/Skåne, Lund/Malmo, Sweden",,https://ClinicalTrials.gov/show/NCT03298542
NCT03296800,"Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects",,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Bexagliflozin|Drug: Probenecid|Drug: Rifampin|Drug: Verapamil,Cmax (Maximum observed plasma concentration)|Tmax (Time of maximum observed plasma concentration)|T1/2 (Apparent terminal elimination half-life)|AUC0-inf (Area under the plasma concentration-time curve from Time 0 to infinity)|Urinary Glucose Excretion 0-24 hr|Urinary Glucose Excretion 24-48 hr|Safety as measured by adverse events,Theracos,All,18 Years to 55 Years   (Adult),Phase 1,48,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,THR-1442-C-454,27-Sep-17,6-Dec-17,6-Dec-17,28-Sep-17,null,8-Jan-18,"Covance Clinical Research Unit, Daytona Beach, Florida, United States",,https://ClinicalTrials.gov/show/NCT03296800
NCT03286816,The Effect of Intravenous Lactate on Brain Lactate Concentrations During Hypoglycemia,,Completed,No Results Available,Type 1 Diabetes Mellitus With Hypoglycemia,Drug: SodiumChloride|Drug: Sodium Lactate,"the effect of intravenous lactate administration, compared to placebo, on brain lactate concentrations during euglycemia and hypoglycemia in patients with T1DM and normal awareness of hypoglycemia|the effect of exogenous lactate on brain lactate concentrations during euglycemia and hypoglycemia between T1DM patients with normal awareness of hypoglycemia and T1DM patients with impaired awareness of hypoglycemia|The changes in counterregulatory hormone and to hypoglycemia in response to lactate infusion, compared to placebo, in patients with normal awareness of hypoglycemia|The changes in and symptoms to hypoglycemia in response to lactate infusion, compared to placebo, in patients with normal awareness of hypoglycemia|The changes in brain pH in response to intravenous lactate administration, compared to placebo|Changes in immune cell composition capacity in response to hypoglycemia compared to euglycemia and in response to lactate infusion compared to placebo|Changes in immune cell cytokine production capacity in response to hypoglycemia compared to euglycemia and in response to lactate infusion compared to placebo",Radboud University|Dutch Diabetes Research Foundation|European Foundation for the Study of Diabetes,All,18 Years to 50 Years   (Adult),Not Applicable,19,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,Lac_iv,Nov-16,May-17,Aug-17,19-Sep-17,null,19-Sep-17,"Radboud umc, Nijmegen, Netherlands",,https://ClinicalTrials.gov/show/NCT03286816
NCT03283566,Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT,,Recruiting,No Results Available,Chronic Pancreatitis|Insulin Dependent Diabetes,Drug: Hydroxychloroquine|Drug: Placebo,Quotient of stimulated C-peptide/glucose level normalized for IEQ/Kg infused in response to MMTT|C-peptide AUC in response to MMTT|Ratio of C-peptide AUC to glucose AUC in response to MMTT,The Cleveland Clinic|Allegheny Singer Research Institute|Stanford University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,10,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",17-912,3-Oct-17,3-Oct-19,3-Oct-19,14-Sep-17,null,16-Nov-18,"Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03283566
NCT03272269,Study of IMCY-0098 in Patients With Recent Onset Type 1 Diabetes,,"Active, not recruiting",No Results Available,Type 1 Diabetes Mellitus,Drug: IMCY-0098|Other: Placebo,Incidence of all adverse events reported for subjects|Assessment of residual beta cell function and markers of metabolic control,Imcyse SA,All,18 Years to 30 Years   (Adult),Phase 1,41,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",IMCY-T1D-001,23-Aug-17,Apr-19,Apr-19,5-Sep-17,null,3-Dec-18,"Hôpital Erasme, Brussels, Belgium|UZ Brussel, Brussels, Belgium|UZ Gent, Gent, Belgium|Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark|CHU de Nantes, Hôpital Laennec, Nantes, France|GWT-TUD GmbH, Dresden, Germany|Klaipeda University Hospital, Klaipėda, Lithuania|University Hospital Santaros Klinikos, Vilnius, Lithuania|Clinical Trial Center, CTC, Göteborg, Sweden|ProbarE Stockholm, Stockholm, Sweden|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|Cardiff University, Cardiff, United Kingdom|Royal Devon and Exeter NHS Trust, Exeter, United Kingdom|Guy's and St. Thomas NHS Trust, London, United Kingdom|St. Bartholomew's Hospital (Barts Health NHS Trust), London, United Kingdom|Newcastle University, Newcastle upon Tyne, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT03272269
NCT03260868,Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy),,Terminated,No Results Available,Type 1 Diabetes Mellitus,Drug: Insulin glargine (HOE901)|Drug: Glulisine|Drug: Aspart|Drug: Lispro,Change in HbA1c|Was it Worth It (WIWI) Questionnaire scores|Work Productivity and Impairment-study participation (WPAI-SP)|Overall Study Experience-Participation (OSEP) Part 1|Overall Study Experience-Participation (OSEP) Part 2|Diabetes Treatment Satisfaction Questionnaire scores|Hypoglycemia Fear Survey-II (HFS-II)|Diabetes Distress Scale (DDS)|HbA1c|Fasting Plasma Glucose (FPG)|7-point Self-monitored plasma glucose (SMPG) profile|Overall Study Experience-Sites (OSES) scores,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 4,15,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSC15146|U1111-1190-7531,22-Sep-17,22-Nov-18,22-Nov-18,24-Aug-17,null,13-Mar-19,"Investigational Site Number 8400002, West Des Moines, Iowa, United States|Investigational Site Number 8400004, Houston, Texas, United States|Investigational Site Number 8400003, Bridgeport, West Virginia, United States|Investigational Site Number 1240001, Barrie, Canada|Investigational Site Number 1240003, Oakville, Canada|Investigational Site Number 1240002, Thornhill, Canada",,https://ClinicalTrials.gov/show/NCT03260868
NCT03258086,Vitamin D in Diabetic Children,,Completed,No Results Available,Vitamin D Deficiency,Diagnostic Test: blood sample test,Assessment of vitamin D level (ng/ml),Assiut University,All,5 Years to 15 Years   (Child),Not Applicable,80,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,17100043,1-Nov-16,Aug-17,Sep-17,23-Aug-17,null,9-Jan-18,"Women Health Hospital - Assiut university, Assiut, Egypt",,https://ClinicalTrials.gov/show/NCT03258086
NCT03258268,Easy Diabetes Treatment Study 1,EASY-1,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Device: Standard of Care with EASY DSS|Other: Standard of Care without EASY DSS,HbA1c|Fasting plasma glucose|Achieving treatment target|Hypoglycemia,Läkarexpressen AB|Region Skane|Lund University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,484,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",EASY-1,7-Aug-17,7-Sep-18,7-Oct-18,23-Aug-17,null,23-Aug-17,"Region Skåne, Skåne, Sweden",,https://ClinicalTrials.gov/show/NCT03258268
NCT03258840,"EPA Supplementation on Vascular Inflammation, and Gene Expression of PON2 in Patients With Type II Diabetes Mellitus",,Completed,No Results Available,Diabetes Mellitus Type II,Dietary Supplement: EPA Supplement|Dietary Supplement: EPA Placebo,HbA1c|PON2 gene expression|Systolic blood pressure|Diastolic blood pressure|serum paraoxonase-1(PON-1) activity|PON1/HDL-c Ratio|serum paraoxonase lactonase (PON-HCTLase) activity|HDL-c|FBS|HDL2-c|HDL3-c|Serum apo B|Serum apo A-I|apo B/apo A-I Ratio|Serum methionine|Serum malondialdehyde (MDA)|Serum homocysteine (Hcy)|Serum sE-Selectin|sVCAM-1|Serum cysteine|Serum Lpa,Tehran University of Medical Sciences,All,35 Years to 50 Years   (Adult),Not Applicable,36,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",15202,Jan-13,Apr-13,Aug-14,23-Aug-17,null,23-Aug-17,"Tehran University of Medical Sciences (TUMS), School of Nutritional Sciences and Dietetics, Department of Cellular and Molecular Nutrition, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT03258840
NCT03255902,Family Routines - Healthy Families,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Behavioral: Parenting classes,Bedtime blood glucose level and morning fasting glucose level|Change in HbA1c,William Beaumont Hospitals|University of Michigan,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,8,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2016-154,24-May-16,1-Mar-17,1-Mar-17,21-Aug-17,null,21-Aug-17,,,https://ClinicalTrials.gov/show/NCT03255902
NCT03251846,Pediatrics Owning Performance Study,POPS!,Recruiting,No Results Available,"Diabetes Mellitus, Type 1",Device: Pops! One personalized mobile platform,HbA1c|Testing frequency|quality of life|Average blood glucose|Blood glucose variability|Hypoglycemia,Children's Hospitals and Clinics of Minnesota|Pops! Diabetes Care,All,"10 Years to 25 Years   (Child, Adult)",Not Applicable,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1704-059,17-Jul-17,Jul-18,Jul-18,16-Aug-17,null,17-Aug-17,"Children's Hospitals and Clinics of Minnesota, Saint Paul, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03251846
NCT03246828,Glucagon in MODY (Maturity Onset Diabetes of the Young),,Recruiting,No Results Available,MODY1|MODY3,Other: Omission of gliclazide,Change in plasma glucagon from baseline (0min)|Change in plasma c-peptide from baseline (0min)|Change in plasma non-esterified fatty acids (NEFA) from baseline (0min)|Continuous glucose monitor recordings,University of Oxford|Oxford University Hospitals NHS Trust,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12538,3-Jul-17,Aug-18,Aug-18,11-Aug-17,null,3-May-18,"Clinical Research Unit, OCDEM, Churchill Hospital, Oxford, Oxfordshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT03246828
NCT03242005,The PSIQS Study - User Experience With Pro-Set,,Withdrawn,No Results Available,"Diabetes Mellitus, Type 1",Device: MiniMed® Pro-set®|Device: MiniMed® Quick-set®,Compare Pro-set® vs. Quick-set® for non-inferiority for set insertion failures (set removal) due to either occlusion alerts or hyperglycemia|Compare Pro-set® vs. Quick-set® for set removals due to hyperglycemia; > 400mg/dl.|Compare Pro-set® vs. Quick- set® for set removals due to set failure; hyperglycemia >250mg/dl.|Compare Pro-set® vs. Quick- set® for set removals at less than 60 hours post insertion.|Compare Pro-set® vs. Quick- set® for duration of wear,"Becton, Dickinson and Company",All,"13 Years to 70 Years   (Child, Adult, Older Adult)",Not Applicable,0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,DBC-17SCARL23,Sep-17,Dec-17,Feb-18,8-Aug-17,null,14-Sep-17,,,https://ClinicalTrials.gov/show/NCT03242005
NCT03242018,"A Study to Evaluate Safety and Effects of Sotagliflozin Dose 1 and Dose 2 on Glucose Control in Patients With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control",SOTA-CKD4,"Active, not recruiting",No Results Available,Type 2 Diabetes Mellitus-Chronic Kidney Disease Stage 4,Drug: Placebo|Drug: Sotagliflozin (SAR439954),Change in HbA1c|Change in Fasting Plasma Glucose (FPG)|Change in Systolic Blood Pressure (SBP) for patients with SBP ≥130 mmHg|Change in SBP|Change in body weight|Change in urinary albumin-to-creatinine ratio (UACR)|Patients with HbA1c less than 6.5%|Patients with HbA1c less than 7.0%|Adverse events,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,276,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFC15166|2016-004906-32|U1111-1190-7589,17-Aug-17,Dec-19,Dec-19,8-Aug-17,null,6-May-19,"Investigational Site Number 8405033, Guntersville, Alabama, United States|Investigational Site Number 8405005, Phoenix, Arizona, United States|Investigational Site Number 8405007, Little Rock, Arkansas, United States|Investigational Site Number 8405015, Chula Vista, California, United States|Investigational Site Number 8405032, La Jolla, California, United States|Investigational Site Number 8405003, Norco, California, United States|Investigational Site Number 8405013, Northridge, California, United States|Investigational Site Number 8405018, San Dimas, California, United States|Investigational Site Number 8405001, DeLand, Florida, United States|Investigational Site Number 8405043, Miami, Florida, United States|Investigational Site Number 8405006, Ocoee, Florida, United States|Investigational Site Number 8405025, Ormond Beach, Florida, United States|Investigational Site Number 8405039, Lawrenceville, Georgia, United States|Investigational Site Number 8405041, Arlington Heights, Illinois, United States|Investigational Site Number 8405030, Sellersburg, Indiana, United States|Investigational Site Number 8405019, Lake Charles, Louisiana, United States|Investigational Site Number 8405034, Flint, Michigan, United States|Investigational Site Number 8405012, Norfolk, Nebraska, United States|Investigational Site Number 8405035, Albany, New York, United States|Investigational Site Number 8405014, Bronx, New York, United States|Investigational Site Number 8405027, Laurelton, New York, United States|Investigational Site Number 8405037, New Bern, North Carolina, United States|Investigational Site Number 8405038, Winston-Salem, North Carolina, United States|Investigational Site Number 8405009, Dayton, Ohio, United States|Investigational Site Number 8405004, Beaumont, Texas, United States|Investigational Site Number 8405036, Dallas, Texas, United States|Investigational Site Number 8405020, Houston, Texas, United States|Investigational Site Number 8405026, Houston, Texas, United States|Investigational Site Number 8405047, Hurst, Texas, United States|Investigational Site Number 8405031, San Antonio, Texas, United States|Investigational Site Number 8405016, San Antonio, Texas, United States|Investigational Site Number 8405008, Layton, Utah, United States|Investigational Site Number 8405040, Winchester, Virginia, United States|Investigational Site Number 0325001, Buenos Aires, Argentina|Investigational Site Number 0325003, Launs Este, Argentina|Investigational Site Number 0325004, Mar Del Plata, Argentina|Investigational Site Number 0765003, Belém, Brazil|Investigational Site Number 0765001, Fortaleza, Brazil|Investigational Site Number 0765004, Rio De Janeiro, Brazil|Investigational Site Number 0765002, Sao Paulo, Brazil|Investigational Site Number 1705004, Barranquilla, Colombia|Investigational Site Number 1705005, Bogota, Colombia|Investigational Site Number 1705002, Manizales, Colombia|Investigational Site Number 1705001, Zipaquira, Colombia|Investigational Site Number 2765001, Frankfurt Am Main, Germany|Investigational Site Number 2765003, Hannover, Germany|Investigational Site Number 2765004, Münster, Germany|Investigational Site Number 3485005, Baja, Hungary|Investigational Site Number 3485007, Debrecen, Hungary|Investigational Site Number 3485003, Nyregyhza, Hungary|Investigational Site Number 3485004, Pécs, Hungary|Investigational Site Number 3765002, Ashkelon, Israel|Investigational Site Number 3765001, Haifa, Israel|Investigational Site Number 3765007, Kfar-Saba, Israel|Investigational Site Number 3765005, Ramat Gan, Israel|Investigational Site Number 3765004, Rehovot, Israel|Investigational Site Number 3765003, Tel Aviv, Israel|Investigational Site Number 3765006, Zefat, Israel|Investigational Site Number 3805003, Catania, Italy|Investigational Site Number 3805005, Milano, Italy|Investigational Site Number 3805006, Napoli, Italy|Investigational Site Number 3805002, Napoli, Italy|Investigational Site Number 3805001, Pavia, Italy|Investigational Site Number 3805004, Roma, Italy|Investigational Site Number 4845007, Guadalajara Jalisco, Mexico|Investigational Site Number 4845001, Guadalajara, Mexico|Investigational Site Number 4845004, Guadalajara, Mexico|Investigational Site Number 4845008, Merida, Yucatan, Mexico|Investigational Site Number 4845006, Monterrey, N.L, Mexico|Investigational Site Number 4845003, Morelia, Mexico|Investigational Site Number 4845002, Queretaro, Mexico|Investigational Site Number 4845005, Xalapa, Mexico|Investigational Site Number 6165003, Krakow, Poland|Investigational Site Number 6165002, Lodz, Poland|Investigational Site Number 6165004, Oswiecim, Poland|Investigational Site Number 6165005, Pu?Awy, Poland|Investigational Site Number 6165001, Rzeszow, Poland|Investigational Site Number 6425005, Bacau, Romania|Investigational Site Number 6425002, Bucure?Ti, Romania|Investigational Site Number 6425003, Bucure?Ti, Romania|Investigational Site Number 6425007, Hunedoara, Romania|Investigational Site Number 6425004, Ia?I, Romania|Investigational Site Number 6425001, Targu-Mures, Romania|Investigational Site Number 6435004, Chelyabinsk, Russian Federation|Investigational Site Number 6435005, Kemerovo, Russian Federation|Investigational Site Number 6435003, Krasnodar, Russian Federation|Investigational Site Number 6435006, Novosibirsk, Russian Federation|Investigational Site Number 6435001, Saint-Petersburg, Russian Federation|Investigational Site Number 7105003, Cape Town, South Africa|Investigational Site Number 7105004, Cape Town, South Africa|Investigational Site Number 7105001, Johannesburg, South Africa|Investigational Site Number 7105002, Pretoria, South Africa|Investigational Site Number 7245005, Barcelona, Spain|Investigational Site Number 7245007, Barcelona, Spain|Investigational Site Number 7245003, Ferrol, Spain|Investigational Site Number 7245009, Granada, Spain|Investigational Site Number 7245006, Madrid Madrid, Spain|Investigational Site Number 7245004, Málaga Málaga, Spain|Investigational Site Number 7245001, Sevilla Sevilla, Spain|Investigational Site Number 7245002, Zaragoza, Spain|Investigational Site Number 8045004, Chernivtsi, Ukraine|Investigational Site Number 8045006, Kiev, Ukraine|Investigational Site Number 8045007, Kyiv, Ukraine|Investigational Site Number 8045003, Kyiv, Ukraine|Investigational Site Number 8045001, Kyiv, Ukraine|Investigational Site Number 8045002, Zaporizhzhia, Ukraine",,https://ClinicalTrials.gov/show/NCT03242018
NCT03240432,Wireless Innovation for Seniors With Diabetes Mellitus,WISDM,"Active, not recruiting",No Results Available,Type 1 Diabetes Mellitus,Device: Dexcom CGM,Time spent with glucose level <70 mg/dL|Change in HbA1c|Change in QOL: Preferring Hypoglycemia Scale|Change in QOL: Blood glucose Monitoring Satisfaction Questionnaire|Change in QOL: Hypoglycemia Fear Survey|Change in QOL: Diabetes Distress Questionnaire|Change in QOL: PROMIS Measures for QOL|Change in QOL: NIH Cognitive Toolbox|Change in QOL: NIH Emotions Toolbox|Time spent with glucose level <60 mg/dL|Time spent with glucose level <54 mg/dL,Jaeb Center for Health Research|The Leona M. and Harry B. Helmsley Charitable Trust|Juvenile Diabetes Research Foundation,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,WISDM,26-Sep-17,Oct-19,Oct-19,7-Aug-17,null,4-Jun-18,"University of Southern California, Beverly Hills, California, United States|Scripps Whittier Diabetes Institute, La Jolla, California, United States|University of Colorado - Barbara Davis Center, Aurora, Colorado, United States|University of Miami, Miami, Florida, United States|Florida Hospital Diabetes Institute, Orlando, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa, United States|University of Massachusetts, Worcester, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|International Diabetes Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University - Naomi Berrie Diabetes Center, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Washington Diabetes Care Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT03240432
NCT03241212,Adolescent Self-Care and Knowledge Education in Diabetes--Improved by Texting,ASKED-IT,"Active, not recruiting",No Results Available,Type 1 Diabetes Mellitus,Behavioral: Texting,"Change in knowledge about type 1 diabetes|Change in diabetes self-care practices|Change in Hemoglobin A1c|Change in blood glucose testing frequency|Change in percent of blood glucoses high, in range and low|Percent of text messages responded to in the study.","University of Colorado, Denver",All,"15 Years to 21 Years   (Child, Adult)",Not Applicable,148,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,17-1135,12-Sep-17,Dec-19,Dec-19,7-Aug-17,null,4-Jan-19,"Barbara Davis Center, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT03241212
NCT03241706,Liver Glycogen and Hypoglycemia in Humans,,Not yet recruiting,No Results Available,Hypoglycemia; Iatrogenic,Drug: Fructose|Drug: Saline|Drug: Somatostatin|Drug: Insulin|Drug: Glucagon|Drug: Dextrose solution,Epinephrine|Glucagon|Glucose Infusion Rate|Liver Glycogen|Hepatic Glucose Production|Peripheral Glucose Uptake,Jason Winnick|University of Cincinnati,All,21 Years to 40 Years   (Adult),Phase 1,40,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,2016-7982,1-Sep-17,31-May-21,31-May-22,7-Aug-17,null,7-Aug-17,,,https://ClinicalTrials.gov/show/NCT03241706
NCT03239119,The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus,,Not yet recruiting,No Results Available,Type2 Diabetes Mellitus,Biological: rE-4 5 mcg|Biological: rE-4 10 mcg|Biological: Placebo 5 mcg|Biological: Placebo 10 mcg,Change in HbA1c from Baseline to Week 30|The number of subjects achieving HbA1c target values of < 7% and ≤ 6.5% by Week 30|Change in body weight from Baseline to each intermediate visit and Week 30|Change in FPG from Baseline to each intermediate visit and Week 30|Change in 7-SMBG from Baseline to Week 16，Week 24 and Week 30,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,456,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",rE-4201706/PRO,30-Nov-17,30-Dec-18,15-Jan-19,3-Aug-17,null,3-Aug-17,,,https://ClinicalTrials.gov/show/NCT03239119
NCT03235219,"A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus",,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: JNJ-64565111|Drug: Placebo,"Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Maximum Observed Serum Concentration (Cmax)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Area Under Concentration-Time Curve From Time Zero to the Last Quantifiable Time (AUC [0-last])|Average Concentration Over the Dosing Interval Tau (T) at Steady State (Caverage,ss)|Minimum Observed Serum Concentration (Cmin)|Accumulation Ratio|Area Under Curve over the dosing interval AUC (0-T)|Apparent Terminal Elimination Half-life (t1/2term)|Apparent Clearance (CL/F)|Apparent Volume of Distribution (V/F)|Terminal Rate Constant (Kel)|Number of Participants With Anti-JNJ-64565111 Antibodies as Measure of Immunogenicity|Change From Baseline in Body Weight|Change From Baseline in Fasting Plasma Glucose (FPG)|Change From Baseline in Hemoglobin A1c (HbA1c)|Change From Baseline in Fasting Lipids|Change From Baseline for 24-hour Mean Plasma Glucose|Change From Baseline in C-peptide Area Under the Curve (AUC) Calculated From a 6-Hour Mixed Meal Tolerance Test (MMTT)|Change From Baseline in Total and/or Incremental Plasma Glucose Area Under the Curve (AUC) Calculated From a 6-Hour Mixed Meal Tolerance Test (MMTT)|Change From Baseline in Insulin Area Under the Curve (AUC) Calculated From a 6-Hour Mixed Meal Tolerance Test (MMTT)|Change From Baseline in Glucagon Area Under the Curve (AUC) Calculated From a 6-Hour Mixed Meal Tolerance Test (MMTT)|Change From Baseline in 24-hour Blood Pressure|Change From Baseline in 24-hour Heart Rate|Change From Baseline in Body Mass Index (BMI)|Change From Baseline Insulin Secretion as Assessed by the Insulinogenic Index|Change from Baseline in Insulin Secretion as Assessed by Homeostasis Model Assessment of Beta Cell Function (HOMA-%B)|Change From Baseline in Insulin Sensitivity as Assessed by Matsuda Index|Change From Baseline in Insulin Sensitivity as Assessed by Homeostasis Model Assessment for Insulin Sensitivity (HOMA-%S)","Janssen Research & Development, LLC",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,39,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CR108339|64565111EDI1002,1-Aug-17,19-Feb-18,19-Feb-18,1-Aug-17,null,12-Apr-18,"ProSciento, Inc., Chula Vista, California, United States|Advanced Pharma CR, LLC, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT03235219
NCT03230266,Root Cause Determination of Catheter Obstructions,CATS,"Active, not recruiting",No Results Available,Type1diabetes,Procedure: Collection of intra-peritoneal catheters for insulin infusion,"Collection of catheters for intra-peritoneal insulin infusion from implanted pumps presenting obstructions or not : collection of biological and device samples (blood, catheters, insulin)|Associated conditions related to the patient and to infused insulin","University Hospital, Montpellier|Juvenile Diabetes Research Foundation",All,"21 Years to 75 Years   (Adult, Older Adult)",Not Applicable,140,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,9802,17-May-17,17-Dec-18,17-Dec-18,26-Jul-17,null,26-Jul-17,"Montpellier University Hospital, Montpellier, France",,https://ClinicalTrials.gov/show/NCT03230266
NCT03228732,The Effects of Fluoxetine and/or DHEA,,Recruiting,No Results Available,Type 1 Diabetes Mellitus,Drug: Placebo Oral Tablet|Drug: Fluoxetine|Drug: DHEA|Drug: Fluoxetine and DHEA,Change in the level of catecholamines in plasma,University of Maryland,All,18 Years to 50 Years   (Adult),Early Phase 1,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",HP-00075896,19-Dec-17,10-Dec-20,10-Dec-20,25-Jul-17,null,31-Jan-19,"University of Maryland, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03228732
NCT03228004,Type 1 Diabetes Data Acquisition and Transfer Adherence Study,T1D-DATA,Completed,No Results Available,Type 1 Diabetes Mellitus,Behavioral: Glooko MeterSync,Improved glycemic control|Frequency of data upload,University of Florida,All,2 Years to 17 Years   (Child),Phase 1,53,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB201700818,26-Jul-17,24-Apr-18,8-Apr-19,24-Jul-17,null,12-Apr-19,"University of Florida, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT03228004
NCT03220425,Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Insulin detemir|Drug: NPH insulin,The change in the level of glycosylated haemoglobin(HbA1c),Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,752,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),NN304-1335,1-Feb-01,12-Nov-01,12-Nov-01,18-Jul-17,null,18-Jul-17,"Novo Nordisk Investigational Site, Broadmeadow, New South Wales, Australia|Novo Nordisk Investigational Site, Ashford, Australia|Novo Nordisk Investigational Site, Box Hill, Australia|Novo Nordisk Investigational Site, Clayton, Australia|Novo Nordisk Investigational Site, Garran, Australia|Novo Nordisk Investigational Site, Ringwood, Australia|Novo Nordisk Investigational Site, Stones Corner, Australia|Novo Nordisk Investigational Site, Woodville, Australia|Novo Nordisk Investigational Site, Bornem, Belgium|Novo Nordisk Investigational Site, Edegem, Belgium|Novo Nordisk Investigational Site, Gent, Belgium|Novo Nordisk Investigational Site, Leuven, Belgium|Novo Nordisk Investigational Site, Luxembourg, Belgium|Novo Nordisk Investigational Site, Fredericia, Denmark|Novo Nordisk Investigational Site, Frederiksberg, Denmark|Novo Nordisk Investigational Site, Hvidovre, Denmark|Novo Nordisk Investigational Site, København, Denmark|Novo Nordisk Investigational Site, Middelfart, Denmark|Novo Nordisk Investigational Site, Odense, Denmark|Novo Nordisk Investigational Site, Vejle, Denmark|Novo Nordisk Investigational Site, Århus C, Denmark|Novo Nordisk Investigational Site, Espoo, Finland|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Joensuu, Finland|Novo Nordisk Investigational Site, Kemi, Finland|Novo Nordisk Investigational Site, Vantaa, Finland|Novo Nordisk Investigational Site, ANGERS cedex 09, France|Novo Nordisk Investigational Site, Avignon, France|Novo Nordisk Investigational Site, Bondy, France|Novo Nordisk Investigational Site, Corbeil Essonnes, France|Novo Nordisk Investigational Site, LA ROCHELLE cedex, France|Novo Nordisk Investigational Site, Le Creusot, France|Novo Nordisk Investigational Site, MONTPELLIER cedex 5, France|Novo Nordisk Investigational Site, Narbonne, France|Novo Nordisk Investigational Site, NEVERS cedex, France|Novo Nordisk Investigational Site, Paris Cedex 10, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Poitiers, France|Novo Nordisk Investigational Site, Rennes, France|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Amersfoort, Netherlands|Novo Nordisk Investigational Site, Apeldoorn, Netherlands|Novo Nordisk Investigational Site, Brunssum, Netherlands|Novo Nordisk Investigational Site, Den Haag, Netherlands|Novo Nordisk Investigational Site, Eindhoven, Netherlands|Novo Nordisk Investigational Site, Haarlem, Netherlands|Novo Nordisk Investigational Site, Hengelo, Netherlands|Novo Nordisk Investigational Site, Utrecht, Netherlands|Novo Nordisk Investigational Site, Bergen, Norway|Novo Nordisk Investigational Site, Jessheim, Norway|Novo Nordisk Investigational Site, Kongsvinger, Norway|Novo Nordisk Investigational Site, Oslo, Norway|Novo Nordisk Investigational Site, Oslo, Norway|Novo Nordisk Investigational Site, Sarpsborg, Norway|Novo Nordisk Investigational Site, Stavanger, Norway|Novo Nordisk Investigational Site, Stord, Norway|Novo Nordisk Investigational Site, Trondheim, Norway|Novo Nordisk Investigational Site, Falun, Sweden|Novo Nordisk Investigational Site, Helsingborg, Sweden|Novo Nordisk Investigational Site, Karlstad, Sweden|Novo Nordisk Investigational Site, Lund, Sweden|Novo Nordisk Investigational Site, Skövde, Sweden|Novo Nordisk Investigational Site, Stockholm, Sweden|Novo Nordisk Investigational Site, Umeå, Sweden|Novo Nordisk Investigational Site, Uppsala, Sweden|Novo Nordisk Investigational Site, Värnamo, Sweden|Novo Nordisk Investigational Site, Örebro, Sweden|Novo Nordisk Investigational Site, Abergavenny, United Kingdom|Novo Nordisk Investigational Site, Blackburn, United Kingdom|Novo Nordisk Investigational Site, Bolton, United Kingdom|Novo Nordisk Investigational Site, Bristol, United Kingdom|Novo Nordisk Investigational Site, Cosham, United Kingdom|Novo Nordisk Investigational Site, Derby, United Kingdom|Novo Nordisk Investigational Site, Gillingham, United Kingdom|Novo Nordisk Investigational Site, Glasgow, United Kingdom|Novo Nordisk Investigational Site, Glasgow, United Kingdom|Novo Nordisk Investigational Site, Guildford, United Kingdom|Novo Nordisk Investigational Site, Kettering, United Kingdom|Novo Nordisk Investigational Site, Livingstone, United Kingdom|Novo Nordisk Investigational Site, Llantrisant, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Newcastle, United Kingdom|Novo Nordisk Investigational Site, Northampton, United Kingdom|Novo Nordisk Investigational Site, Norwich, United Kingdom|Novo Nordisk Investigational Site, Nottingham, United Kingdom|Novo Nordisk Investigational Site, Oxford, United Kingdom|Novo Nordisk Investigational Site, Sheffield, United Kingdom|Novo Nordisk Investigational Site, Sidcup, United Kingdom|Novo Nordisk Investigational Site, Stevenage, United Kingdom|Novo Nordisk Investigational Site, Taunton, United Kingdom|Novo Nordisk Investigational Site, York, United Kingdom",,https://ClinicalTrials.gov/show/NCT03220425
NCT03216226,A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus,,Completed,No Results Available,"Hypoglycemia|Diabetes Mellitus, Type 1",Drug: dasiglucagon|Drug: GlucaGen,Overall ADA incidence|Treatment-induced ADA|Treatment-boosted ADA|Characterization of ADA response - incidence of neutralizing activity|Characterization of ADA response - titer of neutralizing activity|Characterization of ADA response - cross-reactivity|Characterization of ADA response - timing|Characterization of ADA response - duration|Safety - Adverse Events|Safety - Laboratory parameters|Safety - Vital Signs|Safety - Physical Examination|Safety - Electrocardiogram|Pharmacokinetics - Area under the plasma concentration curve|Pharmacokinetics - Maximum plasma concentration|Pharmacokinetics - Time to maximum plasma concentration|Pharmacodynamics - Area under the effect curve|Pharmacodynamics - Change from baseline plasma glucose|Pharmacodynamics - Time to maximum plasma glucose concentration,Zealand Pharma|SynteractHCR,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,112,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ZP4207-16136,28-Jun-17,14-Feb-18,14-Feb-18,13-Jul-17,null,2-Apr-19,"Compass Research, Orlando, Florida, United States|Advanced Clinical Research, Meridian, Idaho, United States|CRC - Clinical Research Center, Medizinische Universität Graz, Graz, Austria|LMC Manna Research, Barrie, Canada|LMC Calgary, Calgary, Canada|LMC Diabetes & Manna Research, Toronto, Canada|Diabeteszentrum Hamburg West, Gemeinschaftspraxis für Innere Medizin, Hamburg, Germany",,https://ClinicalTrials.gov/show/NCT03216226
NCT03217175,Efficacy of Glucagon In the Prevention of Hypoglycemia During Mild Exercise,,Suspended,No Results Available,Type 1 Diabetes Mellitus,Device: Bihormonal Bionic Pancreas|Device: Insulin Only Bionic Pancreas|Drug: Glucagon|Drug: Placebo,Number of subjects with plasma glucose < 60 mg/dl|Duration of plasma glucose < 60 mg/dl|Nadir plasma glucose|Area over the curve and < 60 mg/dl|Time from exercise start to plasma glucose < 60 mg/dl,Massachusetts General Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2017P001409,18-Aug-17,Dec-18,Dec-18,13-Jul-17,null,19-Apr-18,"MGH Diabetes Research Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03217175
NCT03215498,"A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes",,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: Insulin aspart,"Continuous subcutaneous infusion related area under the insulin aspart curve, baseline corrected and based on concentrations from 0 to 30 min|Continuous subcutaneous infusion related time from bolus to 50% of max insulin aspart concentration|Continuous subcutaneous infusion related time from bolus to max insulin aspart concentration|Continuous subcutaneous infusion related area under the insulin aspart curve, baseline corrected and based on concentrations from 0 to 15 min.|Continuous subcutaneous infusion related area under the insulin aspart curve, baseline corrected and based on concentrations from 0 to 1 hour|Continuous subcutaneous infusion related area under the insulin aspart curve, baseline corrected and based on concentrations from 0 to 1,5 hour|Continuous subcutaneous infusion related area under the insulin aspart curve, baseline corrected and based on concentrations from 0 to 2 hours|Continuous subcutaneous infusion related area under the insulin aspart curve, baseline corrected and based on concentrations from 0 to first time the curve is back to baseline|Continuous subcutaneous infusion related area under the insulin aspart curve, baseline corrected and based on concentrations from 2 hours to first time the curve is back to baseline|Continuous subcutaneous infusion related time from bolus to late 50% of max insulin aspart concentration|Continuous subcutaneous infusion related time from bolus to max baseline corrected insulin aspart concentration|Continuous subcutaneous infusion related time from bolus administration to 50% of max baseline corrected Glucose Infusion Rate|Continuous subcutaneous infusion related time from bolus administration to max of baseline corrected Glucose Infusion Rate|Continuous subcutaneous infusion related area under the glucose infusion rate curve, baseline corrected and based on concentrations from 0 to 30 min|Continuous subcutaneous infusion related area under the glucose infusion rate curve, baseline corrected and based on concentrations from 0 to 1 hour|Continuous subcutaneous infusion related area under the glucose infusion rate curve, baseline corrected and based on concentrations from 0 to 1,5 hour|Continuous subcutaneous infusion related area under the glucose infusion rate curve, baseline corrected and based on concentrations from 0 to 2 hours|Continuous subcutaneous infusion related area under the glucose infusion rate curve, baseline corrected and based on concentrations from 0 to first time the curve is back to baseline|Continuous subcutaneous infusion related area under the glucose infusion rate curve, baseline corrected and based on concentrations from 2 hours to first time the curve is back to baseline|Area under the glucose infusion rate curve based on concentrations from -2 to 0 hours|Area under the glucose infusion rate curve based on concentrations from 12 to 14 hours|Continuous subcutaneous infusion related max of baseline corrected Glucose Infusion Rate|Continuous subcutaneous infusion related time from bolus to late 50% of max baseline corrected glucose infusion rate|Number of adverse events ( AEs)|Number of hypoglycaemic episodes",Novo Nordisk A/S,All,18 Years to 64 Years   (Adult),Phase 1,58,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NN1218-4349|2016-004306-34|U1111-1189-1545,3-Jul-17,20-Nov-17,20-Nov-17,12-Jul-17,null,29-Mar-19,"Novo Nordisk Investigational Site, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT03215498
NCT03215914,Hybrid Closed Loop Insulin Delivery System in Hypoglycemia,Aim2,Recruiting,No Results Available,Type1diabetes|Hypoglycemia Unawareness|Nocturnal Hypoglycemia|Hypoglycemia Night|Hypoglycemia,Device: MiniMed 670G system,Endogenous Glucose Production,University of Pennsylvania|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"25 Years to 70 Years   (Adult, Older Adult)",Not Applicable,18,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,827557|2R01DK091331,1-Aug-17,31-Dec-21,31-Dec-22,12-Jul-17,null,11-Sep-18,"Clinical and Translational Research Center, Hospital of University of Pennsylvania, Philadelphia, Pennsylvania, United States|Rodebaugh Diabetes Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pennsylvania - Institute for Diabetes, Obesity and Metabolism, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03215914
NCT03212950,Closed-Loop With Faster Aspart in Young Adults With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Fast-CL|Drug: Regular-CL,Time within range 3.9 - 10 mmol/l (70 - 180 mg/dl),"University of Ljubljana, Faculty of Medicine",All,18 Years to 25 Years   (Adult),Not Applicable,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PD-FAST-01,10-Jul-17,1-Nov-17,1-Nov-17,11-Jul-17,null,6-Nov-17,"UMC-University Children's Hospital, Ljubljana, Slovenia",,https://ClinicalTrials.gov/show/NCT03212950
NCT03214107,Carbohydrate-based Strategies to Prevent Exercise-induced Hypoglycemia,,Recruiting,No Results Available,Type 1 Diabetes Mellitus,Other: Exercise|Other: Snack,Percentage of time of capillary glucose levels spent between 4-10 mmol/L|Percentage of time of sensor glucose levels spent between 4-10 mmol/L|Percentage of time of glucose levels spent below 4 mmol/L|Decrease in glucose levels|Increase in glucose level|Number of participants with an exercise-induced hypoglycemia below 4 mmol/L|Number of participants with an exercise-induced hypoglycemia below 3.5 mmol/L|Number of participants requiring an oral treatment for hypoglycemia|Total number of hypoglycemia episodes requiring treatment|Percentage of time of glucose levels spent above 10 mmol/L|Mean time (minutes) to the first hypoglycemic event|Mean glucose levels|Standard deviation of glucose levels|Percentage of time of glucose levels between 4 and 10 mmol/L|Number of participants requiring treatment for hypoglycemia|Number of hypoglycemic episodes requiring treatment,Institut de Recherches Cliniques de Montreal,All,"14 Years and older   (Child, Adult, Older Adult)",Not Applicable,37,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SNACK-1,3-Aug-17,Dec-18,Dec-18,11-Jul-17,null,13-Mar-18,"Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT03214107
NCT03214367,A Study of LY900014 in Participants With Type 1 Diabetes,PRONTO-T1D,"Active, not recruiting",No Results Available,Type 1 Diabetes Mellitus,Drug: LY900014|Drug: Insulin Lispro|Drug: Insulin Glargine|Drug: Insulin Degludec,"Change from Baseline in Hemoglobin A1c (HbA1c)|1-hour Postprandial Glucose (PPG) Excursion during Mixed-Meal Tolerance Test (MMTT)|2-hour PPG Excursion during MMTT|Rate of Severe Hypoglycemia|Rate of Documented Symptomatic Hypoglycemia|Change From Baseline in 1,5-Anhydroglucitol (1,5-AG)|Change from Baseline in 10-Point Self-Monitoring Blood Glucose (SMBG) Values|Change from Baseline in Insulin Dose|Change from Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ) Regimen Inconvenience Domain Score|Change from Baseline in ITSQ Lifestyle Flexibility Domain Score|Proportion of Participants with HbA1c <7%|Change from Baseline in HbA1c",Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1199,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",16313|I8B-MC-ITRM|2015-005356-99,17-Jul-17,6-Sep-18,5-Sep-19,11-Jul-17,null,4-Dec-18,"Internal Medicine Center LLC, Mobile, Alabama, United States|AMCR Institute INC, Escondido, California, United States|Iderc, P.L.C., West Des Moines, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Manhattan Medical Research, New York, New York, United States|Physicians East, Greenville, North Carolina, United States|Diabetes & Endocrinology Consultants PC, Morehead City, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Your Diabetes Endocrine Nutrition Group PC, Mentor, Ohio, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Partners in Nephrology & Endocrinology, Pittsburgh, Pennsylvania, United States|Sudir Bansal M.D. Inc., Warwick, Rhode Island, United States|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Caba, Argentina|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Caba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ciudad Autonoma de Buenos Aire, Argentina|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Ciudad Autonoma de Buenos Aire, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Córdoba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Córdoba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mar del Plata, Argentina|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Box Hill, Australia|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Geelong, Australia|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Merewether, Australia|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Oaklands Park, Australia|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Graz, Austria|Universitätsklinikum Graz, Graz, Austria|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Wien, Austria|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Bad Mergentheim, Germany|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Falkensee, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Hessen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Magdeburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mayen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Münster, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oldenburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rheine, Germany|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Saterland, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ampelókipoi, Greece|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Lárisa, Greece|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Thessaloníki, Greece|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Thessaloníki, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Thessaloníki, Greece|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Thérmi, Greece|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Ahmedabad, India|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Hyderabad, India|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Hyderabad, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyderabad, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indore, India|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Pune, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Secunderabad, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Visakhapatnam, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ravenna, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Siena, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amagasaki, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Kamakura, Japan|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kumamoto, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Miyazaki, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Naka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sapporo, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Sapporo, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Sasebo, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Shinjuku, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ōita, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ōsaka, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Ōsaka, Japan|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zapopan, Mexico|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Auckland, New Zealand|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Christchurch, New Zealand|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wellington, New Zealand|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdańsk, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kraków, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ruda Śląska, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szczecin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szczecin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warszawa, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wrocław, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Łódź, Poland|Centro de Endocrinologia del Este, Yabucoa, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bacău, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Braşov, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucuresti, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lasi, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oradea, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ploieşti, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ploieşti, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Satu Mare, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Timişoara, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Târgu-Mureş, Romania|Arkhangelsk the first city clinical hospital, Arkhangel'sk, Russian Federation|Medical Center ""Mir Zdorovja"", Kursk, Russian Federation|Endocrinological Research Center of the Ministry of Health, Moscow, Russian Federation|First Moscow State Medical University, Moscow, Russian Federation|City Clinical Hospital # 52, Moscow, Russian Federation|City Hospital of Saint Martyr Elizabeth, Saint Petersburg, Russian Federation|Saratov Regional Clinical Hospital, Saratov, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Košice, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malacky, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nové Mesto nad Váhom, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rožňava, Slovakia|Corporacion Sanitaria Parc Tauli - Endo, Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Málaga, Spain|Nuevas Tecnologias en Diabetes y Endocrinologia, Sevilla, Spain|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Sevilla, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Teruel, Spain|Hospital de la Ribera - Endo, Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Göteborg, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Linköping, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lund, Sweden|Karolinska Universitetssjukhuset Huddinge - Endokrinmottagning C2-84, Stockholm, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chang-hua, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yongkang, Taiwan",,https://ClinicalTrials.gov/show/NCT03214367
NCT03211858,Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine,GEMELLI 1,Completed,No Results Available,Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus,Drug: SAR341402|Drug: insulin aspart|Drug: insulin glargine (HOE901),"Change in glycated hemoglobin (HbA1c)|Change in HbA1c|Patients with HbA1c <7%|Change in Fasting Plasma Glucose (FPG)|Change in mean 24-hour plasma glucose concentration|Change in Postprandial Plasma Glucose (PPG)|Change in 7-point self-monitored plasma glucose (SMPG)|Hypoglycemic patients|Hypoglycemic events|Anti-SAR341402/NovoLog/NovoRapid antibody status|Treatment-induced, treatment-boosted and treatment-emergent AIAs",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,597,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EFC15081|2017-000091-28|U1111-1191-5775,2-Aug-17,16-Jul-18,12-Jan-19,7-Jul-17,null,18-Feb-19,"Investigational Site Number 8400040, Little Rock, Arkansas, United States|Investigational Site Number 8400012, Concord, California, United States|Investigational Site Number 8400002, Escondido, California, United States|Investigational Site Number 8400030, Fresno, California, United States|Investigational Site Number 8400004, Greenbrae, California, United States|Investigational Site Number 8400014, La Jolla, California, United States|Investigational Site Number 8400043, Los Angeles, California, United States|Investigational Site Number 8400036, Pomona, California, United States|Investigational Site Number 8400011, Santa Barbara, California, United States|Investigational Site Number 8400013, Ventura, California, United States|Investigational Site Number 8400037, Aurora, Colorado, United States|Investigational Site Number 8400018, Englewood, Colorado, United States|Investigational Site Number 8400031, New Port Richey, Florida, United States|Investigational Site Number 8400027, Ocoee, Florida, United States|Investigational Site Number 8400007, Atlanta, Georgia, United States|Investigational Site Number 8400022, Columbus, Georgia, United States|Investigational Site Number 8400032, Roswell, Georgia, United States|Investigational Site Number 8400038, Arlington Heights, Illinois, United States|Investigational Site Number 8400005, Des Moines, Iowa, United States|Investigational Site Number 8400041, Metairie, Louisiana, United States|Investigational Site Number 8400015, Rockville, Maryland, United States|Investigational Site Number 8400042, Waltham, Massachusetts, United States|Investigational Site Number 8400019, Flint, Michigan, United States|Investigational Site Number 8400003, Omaha, Nebraska, United States|Investigational Site Number 8400024, Henderson, Nevada, United States|Investigational Site Number 8400028, New York, New York, United States|Investigational Site Number 8400025, Morehead City, North Carolina, United States|Investigational Site Number 8400010, Wilmington, North Carolina, United States|Investigational Site Number 8400023, Fargo, North Dakota, United States|Investigational Site Number 8400029, Bend, Oregon, United States|Investigational Site Number 8400033, Chattanooga, Tennessee, United States|Investigational Site Number 8400044, Austin, Texas, United States|Investigational Site Number 8400009, Dallas, Texas, United States|Investigational Site Number 8400035, Dallas, Texas, United States|Investigational Site Number 8400021, Dallas, Texas, United States|Investigational Site Number 8400017, Houston, Texas, United States|Investigational Site Number 8400001, Houston, Texas, United States|Investigational Site Number 8400020, Houston, Texas, United States|Investigational Site Number 8400016, Mesquite, Texas, United States|Investigational Site Number 8400034, Salt Lake City, Utah, United States|Investigational Site Number 8400008, Renton, Washington, United States|Investigational Site Number 8400039, Bridgeport, West Virginia, United States|Investigational Site Number 2460006, Jyväskylä, Finland|Investigational Site Number 2460002, Kuopio, Finland|Investigational Site Number 2460004, Pori, Finland|Investigational Site Number 2460003, Seinäjoki, Finland|Investigational Site Number 2760001, Berlin, Germany|Investigational Site Number 2760006, Essen, Germany|Investigational Site Number 2760004, Heidelberg, Germany|Investigational Site Number 2760005, Oldenburg In Holstein, Germany|Investigational Site Number 2760002, Pirna, Germany|Investigational Site Number 3480012, Balatonfüred, Hungary|Investigational Site Number 3480011, Budapest, Hungary|Investigational Site Number 3480008, Budapest, Hungary|Investigational Site Number 3480001, Budapest, Hungary|Investigational Site Number 3480005, Budapest, Hungary|Investigational Site Number 3480004, Budapest, Hungary|Investigational Site Number 3480007, Debrecen, Hungary|Investigational Site Number 3480003, Nagykanizsa, Hungary|Investigational Site Number 3480010, Nyíregyháza, Hungary|Investigational Site Number 3480009, Szentendre, Hungary|Investigational Site Number 3920009, Fukuyama-Shi, Japan|Investigational Site Number 3920008, Higashiosaka-Shi, Japan|Investigational Site Number 3920007, Kashiwara-Shi, Japan|Investigational Site Number 3920001, Koriyama-Shi, Japan|Investigational Site Number 3920005, Kumamoto-Shi, Japan|Investigational Site Number 3920003, Mito-Shi, Japan|Investigational Site Number 3920010, Osaka-Shi, Japan|Investigational Site Number 3920002, Sagamihara-Shi, Japan|Investigational Site Number 3920004, Shinjuku-Ku, Japan|Investigational Site Number 3920006, Ushiku-Shi, Japan|Investigational Site Number 6160004, Bialystok, Poland|Investigational Site Number 6160003, Krakow, Poland|Investigational Site Number 6160005, Krakow, Poland|Investigational Site Number 6160007, Lublin, Poland|Investigational Site Number 6160006, Nowy Sacz, Poland|Investigational Site Number 6160001, Poznan, Poland|Investigational Site Number 6160002, Warszawa, Poland|Investigational Site Number 6430002, Samara, Russian Federation|Investigational Site Number 6430003, Saratov, Russian Federation|Investigational Site Number 6430001, St. Petersburg, Russian Federation|Investigational Site Number 6430004, Tomsk, Russian Federation",,https://ClinicalTrials.gov/show/NCT03211858
NCT03202732,DiabetesFlex - Patient Involvement and Patient-reported Outcome Measures in Type 1 Diabetes,,Recruiting,No Results Available,Type1 Diabetes Mellitus,Other: DiabetesFlex,"HbA1c|General health will be assessed by items from the SF-36 questionnaire|Health literacy will be assessed by The Health Literacy Questionnaire (sub scale 6 and 9)|Well-being will be assessed by the WHO-5 Well-being Index|Patient Activated Measure (PAM)|""Generic questions concerning patient involvement"" is validate by ""DEFACTUM""|The problem Areas In Diabetes Scale (PAID)|Blood pressure|Urine albumine/creatinine ratio|Number and type consultations|Mortality",Annesofie Lunde Jensen|Aarhus University Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,400,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,DiabetesFlex2017,9-Oct-17,20-Feb-20,1-Feb-21,29-Jun-17,null,12-Feb-19,"Aahurs University Hospital, Aarhus, Denmark",,https://ClinicalTrials.gov/show/NCT03202732
NCT03202875,A Study to Compare Pharmacokinetics (PK) and Pharmacodynamics (PD) of SAR341402 to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes,Drug: SAR341402|Drug: Insulin Aspart,Assessment of PK parameters: maximum plasma concentration (Cmax)|Assessment of PK parameters: Area under the concentration versus time curve (AUC)|Assessment of PK parameter: AUC from dosing to last concentration (AUClast)|Assessment of PD parameters: Area under the body weight standardized glucose infusion rate (GIR)|Assessment of PK: Fractional area under the concentration versus time curve|Assessment of PK: Time to 20 % of INS-AUC|Assessment of PK: time to reach INS-Cmax (INS-tmax)|Assessment of PK: time to reach INS-t1/2z (INS-t1/2z)|Assessment of PD: Fractional area under the body weight standardized GIR versus time curve|Assessment of PD: Time to 20 % of total GIR-AUC0-12h|Assessment of PD: Maximum smoothed body weight standardized GIR (GIRmax)|Assessment of PD: Time to GIRmax (GIR-tmax)|Number of adverse events (AEs),Sanofi,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,30,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PDY12695|2012-002355-42|U1111-1127-2950,14-Nov-12,28-Dec-12,28-Dec-12,29-Jun-17,null,29-Jun-17,"Investigational Site 276001, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT03202875
NCT03199638,Exercise Snacks and Glutamine to Improve Glucose Control in Adolescents With Type 1 Diabetes,,Recruiting,No Results Available,"Diabetes Mellitus, Type 1|Autoimmune Diseases|Diabetes Mellitus|Endocrine System Diseases|Glucose Metabolism Disorders|Immune System Diseases|Metabolic Diseases",Drug: Glutamine vs. Placebo|Other: Exercise,"Changes in HbA1C|Changes in MAGE|Changes in % BG at target (70-180), below target (<70), above target (>180)|Changes in ISS|Changes in total insulin dosing (units/kg/day)",Nemours Children's Clinic,All,"13 Years to 19 Years   (Child, Adult)",Not Applicable,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Nemours IRB #790908,Apr-16,Jun-17,Jun-17,27-Jun-17,null,27-Jun-17,"Nemours Children's Clinic, Jacksonville, Florida, United States|Nemours Children's Clinic, Jacksonville, Florida, United States",,https://ClinicalTrials.gov/show/NCT03199638
NCT03199716,Parent Mentors to Improve Adherence to Type I Diabetes Care Regimen in Adolescents,,Recruiting,No Results Available,"Diabetes Mellitus, Type 1",Other: Parent mentors,Daily frequency of blood glucose monitoring (BGM)|HbA1c levels,"University of California, Davis|Children's Miracle Network",All,10 Years to 15 Years   (Child),Not Applicable,66,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,615897,Sep-14,May-27,May-27,27-Jun-17,null,28-Jun-18,"UC Davis Pediatrics Endocrinology, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT03199716
NCT03197324,Bexagliflozin Drug/Drug Interaction Study With Digoxin,,Completed,No Results Available,Type2 Diabetes Mellitus,Drug: Bexagliflozin|Drug: Digoxin,Digoxin Cmax (Maximum observed plasma concentration)|Digoxin Tmax (Time of maximum observed plasma concentration)|Digoxin T1/2 (Apparent terminal elimination half-life)|AUC0-inf (Area under the plasma concentration-time curve from Time 0 to infinity)|Safety as measured by adverse events,Theracos,All,18 Years to 55 Years   (Adult),Phase 1,20,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,THR-1442-C-443,24-Jul-17,17-Sep-17,17-Sep-17,23-Jun-17,null,25-Sep-17,"Covance CRU, Daytona Beach, Florida, United States",,https://ClinicalTrials.gov/show/NCT03197324
NCT03195140,Diabetes Pump With Predictive Low Glucose Suspend Pivotal Trial,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: Predictive Low Glucose Suspend,Sensor Glucose Values|Hypoglycemia <60 mg/dL|Hypoglycemia <50 mg/dL|Hypoglycemia AUC <70 mg/dL|Hypoglycemia index|Hypoglycemic events|Glucose Control|Hyperglycemia >250 mg/dL|Hyperglycemia >180 mg/dL|Hyperglycemia AUC >180 mg/dL|Hyperglycemia index,"Tandem Diabetes Care, Inc.|Jaeb Center for Health Research",All,"6 Years and older   (Child, Adult, Older Adult)",Not Applicable,107,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,G170105,11-Aug-17,6-Feb-18,6-Feb-18,22-Jun-17,null,8-Feb-18,"Stanford University, Palo Alto, California, United States|William Sansum Diabetes Center, Santa Barbara, California, United States|Barbara Davis Center, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03195140
NCT03195257,Glucose-Dependent Insulinotropic Polypeptide - Effects on Markers of Bone Turnover in Patients With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus,Other: GIP|Other: GLP-1|Other: Saline,C-terminal telopeptide of type I collagen (CTX).|Parathyroid hormone (PTH)|N-terminal propeptide of type 1 procollagen (P1NP).,"Mikkel Christensen|University Hospital, Gentofte, Copenhagen",Male,18 Years to 50 Years   (Adult),Not Applicable,10,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",GIP-T1DM-BTM,17-Nov-12,1-Dec-16,1-Dec-16,22-Jun-17,null,23-Jun-17,,,https://ClinicalTrials.gov/show/NCT03195257
NCT03191396,Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes,SUSTAIN 10,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 2",Drug: Semaglutide|Drug: Liraglutide,"Change in HbA1c|Change in body weight (kg)|Change in fasting plasma glucose (FPG)|Change in self-measured plasma glucose (SMPG), 7 point profile: Mean 7-point profile|Change in self-measured plasma glucose (SMPG), 7 point profile: Mean post prandial increment (over all meals)|Change in fasting blood lipids: total cholesterol|Change in fasting blood lipids: low-density lipoprotein (LDL)-cholesterol|Change in fasting blood lipids: high-density lipoprotein (HDL)-cholesterol|Change in fasting blood lipids: triglycerides|Change in Body Mass Index (BMI)|Change in waist circumference|Change in systolic blood pressure|Change in diastolic blood pressure|Change in body weight (%)|Subjects who achieve HbA1c below 7.0% (53 mmol/mol), American Diabetes Association (ADA) target|Subjects who achieve HbA1c below or equal to 6.5% (48 mmol/mol), American Association of Clinical Endocrinologists (AACE) target|Subjects who achieve weight loss above or equal to 3%|Subjects who achieve weight loss above or equal to 5%|Subjects who achieve weight loss above or equal to 10%|Subjects who achieve HbA1c below 7.0% (53 mmol/mol) without severe or blood glucose confirmed symptomatic hypoglycaemia episodes and no weight gain|Subjects who achieve HbA1c reduction above or equal to 1%|Subjects who achieve HbA1c reduction above or equal to 1% and weight loss above or equal to 3%|Subjects who achieve HbA1c reduction above or equal to 1% and weight loss above or equal to 5%|Subjects who achieve HbA1c reduction above or equal to 1% and weight loss above or equal to 10%|Change in SF-36v2TM Short Form health survey. Total summary scores (physical component and mental component) and scores from the 8 domains|Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ). Treatment satisfaction summary score (sum of 6 of 8 items) and the 8 items separately upportive secondary safety endpoints|Number of treatment-emergent adverse events|Number of treatment-emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes|Treatment-emergent severe or blood glucose confirmed symptomatic hypoglycaemia episodes",Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,577,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN9535-4339|2016-004965-22|U1111-1190-5868,27-Jun-17,9-Jul-18,13-Aug-18,19-Jun-17,null,29-Nov-18,"Novo Nordisk Investigational Site, Burgas, Bulgaria|Novo Nordisk Investigational Site, Dupnitsa, Bulgaria|Novo Nordisk Investigational Site, Lukovit, Bulgaria|Novo Nordisk Investigational Site, Madan, Bulgaria|Novo Nordisk Investigational Site, Petrich, Bulgaria|Novo Nordisk Investigational Site, Ruse, Bulgaria|Novo Nordisk Investigational Site, Sliven, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Vratsa, Bulgaria|Novo Nordisk Investigational Site, Brno, Czechia|Novo Nordisk Investigational Site, Brno, Czechia|Novo Nordisk Investigational Site, Nachod, Czechia|Novo Nordisk Investigational Site, Praha 10, Czechia|Novo Nordisk Investigational Site, Praha 4, Czechia|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Jyväskylä, Finland|Novo Nordisk Investigational Site, Kuusamo, Finland|Novo Nordisk Investigational Site, Lahti, Finland|Novo Nordisk Investigational Site, Oulu, Finland|Novo Nordisk Investigational Site, Rauma, Finland|Novo Nordisk Investigational Site, Turku, Finland|Novo Nordisk Investigational Site, Varkaus, Finland|Novo Nordisk Investigational Site, Béziers, France|Novo Nordisk Investigational Site, Dambach-la-ville, France|Novo Nordisk Investigational Site, DIJON cedex, France|Novo Nordisk Investigational Site, LA ROCHELLE cedex, France|Novo Nordisk Investigational Site, Le Coudray, France|Novo Nordisk Investigational Site, Le Creusot, France|Novo Nordisk Investigational Site, Nantes, France|Novo Nordisk Investigational Site, Obernai, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, PERPIGNAN cedex, France|Novo Nordisk Investigational Site, Schiltigheim, France|Novo Nordisk Investigational Site, Strasbourg, France|Novo Nordisk Investigational Site, Vandoeuvre Les Nancy, France|Novo Nordisk Investigational Site, Venissieux, France|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Stuttgart, Germany|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Nagykanizsa, Hungary|Novo Nordisk Investigational Site, Pécs, Hungary|Novo Nordisk Investigational Site, Siófok, Hungary|Novo Nordisk Investigational Site, Szolnok, Hungary|Novo Nordisk Investigational Site, Tatabánya, Hungary|Novo Nordisk Investigational Site, Zalaegerszeg, Hungary|Novo Nordisk Investigational Site, Bergamo, Italy|Novo Nordisk Investigational Site, Como, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Pavia, Italy|Novo Nordisk Investigational Site, Rome, Italy|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Szczecin, Poland|Novo Nordisk Investigational Site, Celje, Slovenia|Novo Nordisk Investigational Site, Jesenice, Slovenia|Novo Nordisk Investigational Site, Koper, Slovenia|Novo Nordisk Investigational Site, Ljubljana, Slovenia|Novo Nordisk Investigational Site, Alcorcón, Spain|Novo Nordisk Investigational Site, Almería, Spain|Novo Nordisk Investigational Site, La Roca del Vallés, Spain|Novo Nordisk Investigational Site, Palma de Mallorca, Spain|Novo Nordisk Investigational Site, Valladolid, Spain|Novo Nordisk Investigational Site, Vic (Barcelona), Spain|Novo Nordisk Investigational Site, Kristianstad, Sweden|Novo Nordisk Investigational Site, Lund, Sweden|Novo Nordisk Investigational Site, Stockholm, Sweden|Novo Nordisk Investigational Site, Stockholm, Sweden|Novo Nordisk Investigational Site, Ängelholm, Sweden|Novo Nordisk Investigational Site, Örebro, Sweden|Novo Nordisk Investigational Site, Blackpool, United Kingdom|Novo Nordisk Investigational Site, Bristol, United Kingdom|Novo Nordisk Investigational Site, Coventry, United Kingdom|Novo Nordisk Investigational Site, Crewe, United Kingdom|Novo Nordisk Investigational Site, Faringdon, United Kingdom|Novo Nordisk Investigational Site, Hinckley, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Northwood, United Kingdom|Novo Nordisk Investigational Site, Norwich, United Kingdom|Novo Nordisk Investigational Site, Nuneaton, United Kingdom|Novo Nordisk Investigational Site, Rhyl, United Kingdom|Novo Nordisk Investigational Site, Rotherham, United Kingdom|Novo Nordisk Investigational Site, Sidcup, United Kingdom|Novo Nordisk Investigational Site, Southampton, United Kingdom|Novo Nordisk Investigational Site, St Helens, United Kingdom|Novo Nordisk Investigational Site, Truro, United Kingdom|Novo Nordisk Investigational Site, Watford, United Kingdom",,https://ClinicalTrials.gov/show/NCT03191396
NCT03188757,The Influence of Acute Hyperglycaemia on Brain in T1D,,Completed,No Results Available,Hyperglycemia|Type 1 Diabetes Mellitus,Other: hyperglycaemic clamp,prolonged reaction time,"University of Ljubljana, Faculty of Medicine",All,"12 Years to 20 Years   (Child, Adult)",Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,Hyperglycemia-01,13-Jul-17,30-Mar-18,30-Mar-18,15-Jun-17,null,9-May-18,"Medical Faculty - University of Ljubljana, Ljubljana, Slovenia",,https://ClinicalTrials.gov/show/NCT03188757
NCT03186300,Patient Empowerment Through Predictive Personalised Decision Support (PEPPER),PEPPER,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: PEPPER system,"Change in the percentage of time spent in hypoglycaemia (glucose level below 3, 9 mmol/L or 70 mg/dl)|Number of incidence of low glucose alarms|Number of incidence of high glucose alarms|Number of incidence of carbohydrate adviser|Number of incidence of low glucose suspend|Number of incidence of fault detection alarm|Change in the percentage of time in glucose target range (glucose levels 3.9-10 mmol/l or 70 - 180 mg/dl)|Change in the percentage of time in hyperglycaemia (glucose level above 10 mmol/l or 180 mg/dl)|Change in the number of episodes of post-prandial hypoglycaemia (glucose level below 3,9 mmol/L or 70 mg/dl) within 4 hours|Change in the number of episodes of post-prandial hypoglycaemia (glucose level below 3,9 mmol/L or 70 mg/dl) within 6 hours|Change in the post-prandial glucose level at 120 minutes (mg/dl)|Change in the post-prandial glucose level at 120 minutes (mmol/l)|Change in the post-prandial area under the curve (AUC) of glucose level at 4 hours (min x mg/dl)|Change in the post-prandial area under the curve (AUC) of glucose level at 4 hours (min x mmol/l)|Change in glycaemic risk measured with low blood glucose index (LBGI)|Change in glycaemic risk measured with high blood glucose index (HBGI)|Change in glycaemic variability measured with mean amplitude of glycaemic excursions (MAGE) (mg/dl)|Change in glycaemic variability measured with mean amplitude of glycaemic excursions (MAGE) (mmol/l)|Change in glycaemic variability measured with continuous overall net glycemic action at 2 hours (CONGA-2) (mg/dl)|Change in glycaemic variability measured with continuous overall net glycemic action at 2 hours (CONGA-2) (mmol/l)|Measurement of satisfaction of diabetes treatment using Diabetes Treatment Satisfaction Questionnaire (DTSQ)|Measurement of quality of life in patients with diabetes mellitus using Diabetes Quality of Life (DQOL) questionnaire.|Measurement of diabetes related problems by using Problem Areas in Diabetes (PAID) questionnaire|Evaluation of usability and the treatment satisfaction of PEPPER system by using non-validated questionnaires.",Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta|Imperial College London|Oxford Brookes University|University of Girona|Cellnovo Limited|Romsoft SRL,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,599/16/EC|689810,1-Sep-17,12-Dec-18,12-Dec-18,14-Jun-17,null,5-Mar-19,"Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain",,https://ClinicalTrials.gov/show/NCT03186300
NCT03182231,GLP1-imaging Before and After Bariatric Surgery,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Bariatric Surgery Candidate",Radiation: 68Ga-NODAGA-exendin-4 PET/CT,Pancreatic uptake of 68Ga-NODAGA-exendin-4|T2D outcome|Beta cell function,Radboud University|Rijnstate Hospital,Female,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,12,Other,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,NL51980.091.15,7-Oct-16,1-May-19,1-Dec-19,9-Jun-17,null,10-Aug-18,"Rijnstate hospital, Arnhem, Netherlands|Radboudumc, Nijmegen, Netherlands",,https://ClinicalTrials.gov/show/NCT03182231
NCT03182426,Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM),,Recruiting,No Results Available,"Diabetes Mellitus, Type 1",Drug: Plerixafor|Drug: Alemtuzumab|Drug: Anakinra|Drug: Etanercept|Drug: Liraglutide,"Change of 2-hour mixed meal stimulated C-peptide AUC|Rate of Serious Adverse Event/Medical Event of Special Interest|""Responder"" status|Exogenous insulin usage|Proportion of subjects with HbA1c ≤6.5%|Proportion of subjects with HbA1c ≤7.0%|Proportion of subjects free from severe hypoglycaemia|Proportion of subjects progressing to complete beta cell loss|Autoantibodies associated with T1DM|T1DM T-cell autoreactivity|T-cell phenotyping",University of Alberta|Alberta Innovates Health Solutions,All,18 Years to 45 Years   (Adult),Phase 1|Phase 2,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00053082,15-Aug-17,30-Aug-22,31-Dec-22,9-Jun-17,null,24-Jul-18,"University of Alberta, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT03182426
NCT03182842,FreeStyle Libre FGM During Summer Camp for Children With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus|Hypoglycemia|Hyperglycemia,Device: FreeStyle Libre FGM|Device: SMBG - Blinded Sensor,Time within 3.9 and 10 mmol/l,"University of Ljubljana, Faculty of Medicine",All,6 Years to 15 Years   (Child),Not Applicable,45,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",Free-Summer-01,17-Jun-17,1-Jul-17,1-Jul-17,9-Jun-17,null,5-Jul-17,"Medical Faculty - University of Ljubljana, Ljubljana, Slovenia",,https://ClinicalTrials.gov/show/NCT03182842
NCT03179280,Effect of Dual-wave Insulin Bolus on Postprandial Glycaemia,,Completed,No Results Available,Type1 Diabetes,Drug: insulin,post-prandial euglycaemia (PPG),Aristotle University Of Thessaloniki,All,"11 Years to 20 Years   (Child, Adult)",Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Dual-wave insulin,Mar-11,May-11,May-11,7-Jun-17,null,7-Jun-17,"Unit of Pediatric Endocrinology, Diabetes and Metabolism-4th Department of Pediatrics, Medical School of Aristotle University of Thessaloniki, Thessaloniki, Greece",,https://ClinicalTrials.gov/show/NCT03179280
NCT03179332,"A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone® Insulin Lispro, Fiasp® and NovoRapid® Delivered by an Insulin Pump",,Completed,No Results Available,Type1 Diabetes Mellitus,Drug: BioChaperone® insulin lispro|Drug: Fiasp®|Drug: Novorapid®,AUCGIR(0-60min)|AUCins(0-30min)|AUCins(0-60min)|AUCins(0-600min)|Cmax insulin|Tmax insulin|TmaxGIR|GIRmax|Adverse Events|Clinical safety laboratory,Adocia,All,18 Years to 64 Years   (Adult),Phase 1,43,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CT032-ADO02,20-Jun-17,27-Sep-17,27-Sep-17,7-Jun-17,null,12-Dec-17,"Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT03179332
NCT03179423,Clinical Trial Assessing the GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years,RAINBOW-T1D,"Active, not recruiting",No Results Available,Diabetes Mellitus Type 1,Drug: GNbAC1|Drug: Placebo,Safety and tolerability of GNbAC1 in patients with recent onset type 1 diabetes: Serious Adverse Events (SAE) and Adverse Events (AE),GeNeuro Australia PTY Ltd|Southern Star Research Pty Ltd.,All,18 Years to 55 Years   (Adult),Phase 2,60,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GNC-301,14-Jun-17,1-Sep-18,1-Apr-19,7-Jun-17,null,6-Mar-19,"Macquarie University Hospital, Macquarie University, New South Wales, Australia|AIM Centre, Merewether, New South Wales, Australia|Northern Sydney Local Health District - Royal North Shore Hospital, St Leonards, New South Wales, Australia|Ipswich Research Centre, Ipswich, Queensland, Australia|Mater Misericordiae Ltd and Mater Medical Research Institute Limited, South Brisbane, Queensland, Australia|Gold Coast Hospital and Health Service, Southport, Queensland, Australia|Southern Adelaide Local Health Network - Repatriation General Hospital, Adelaide, South Australia, Australia|Northern Adelaide Local Health Network Incorporated, operating as Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia|Eastern Health, Box Hill, Victoria, Australia|St Vincent's Hospital (Melbourne) Limited, Fitzroy, Victoria, Australia|Barwon Health - University of Geelong, Geelong, Victoria, Australia|Heidelberg Repatriation Hospital, Heidelberg, Victoria, Australia|Keogh Institute of Medical Research, Nedlands, Western Australia, Australia",,https://ClinicalTrials.gov/show/NCT03179423
NCT03177096,Impact of the Continuous Measurement of Blood Glucose on Insulin Pump on Child Quality of Life With Type 1 Diabetes,IM-CAPT,"Active, not recruiting",No Results Available,Type1diabetes,Behavioral: Peds QL questionnaire and diabetes modulate|Behavioral: WHO-5 questionnaire|Behavioral: Felt questionnaire,Evolution of Peds QL questionnaire results|Evolution of WHO-5 and felt questionnaire,Groupe Hospitalier de la Region de Mulhouse et Sud Alsace,All,2 Years to 13 Years   (Child),Not Applicable,14,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,GHR 866|2016-A01264-47,20-Sep-16,12-Jul-17,May-18,6-Jun-17,null,23-May-18,"GHRMSA, Mulhouse, France",,https://ClinicalTrials.gov/show/NCT03177096
NCT03175315,Evaluation of a Treatment and Education Program for Diabetic Patients Who Use Flash Glucose Monitoring,FLASH,Completed,No Results Available,Diabetes Mellitus,Behavioral: Treatment and education program for patients with diabetes who use flash glucose monitoring (FLASH),"Changes in Glycemic Control Measured by A1c|Changes in ""time-in-range""|Changes in hypoglycemic episodes|Changes in the duration of hypoglycemic episodes|Changes in hyperglycemic episodes|Changes in the duration of hyperglycemic episodes|Hypoglycaemia Awareness|Diabetes Empowerment|Diabetes Distress|Problem Areas in Diabetes|Depressive symptoms",Norbert Hermanns|Abbott Diabetes Care|Forschungsinstitut der Diabetes Akademie Mergentheim,All,"16 Years to 75 Years   (Child, Adult, Older Adult)",Not Applicable,216,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NH052017,2-May-17,9-Mar-18,9-Mar-18,5-Jun-17,null,3-Aug-18,"Diabetes und Stoffwechselpraxis Wetter, Wetter, Germany",,https://ClinicalTrials.gov/show/NCT03175315
NCT03176524,"A Trial to Investigate the Safety and the Pharmacokinetic, Pharmacodynamic Characteristics of Two BioChaperone® Glucagon Formulations Compared to Marketed GlucaGen® in Subjects With T1DM",,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: BioChaperone® glucagon formulation 1|Drug: BioChaperone® glucagon formulation 2|Drug: GlucaGen® HypoKit®,Clinical safety laboratory|Physical examination|ECG parameters|Vital signs|Adverse events and serious adverse events|Assessments of local tolerability at injection site|AUCPK 0-30min|AUC PK 0-4h|ΔAUCPG 0-30min|ΔAUCPG 0-4h|ΔPG 30min|Percentage of patients achieving a plasma glucose increase of ≥20 mg/dL from baseline within 30 minutes after treatment|Time to plasma glucose increase of ≥20 mg/dL from baseline,Adocia,All,18 Years to 64 Years   (Adult),Phase 1,27,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BC13-CT028,6-Jun-17,4-Sep-17,4-Sep-17,5-Jun-17,null,12-Dec-17,"Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT03176524
NCT03174288,The Impact of Fitness and Mineralocorticoid Receptor Blockade on Vascular Dysfunction in Adults With Type 1 Diabetes,EJB048,Recruiting,No Results Available,Type 1 Diabetes,Other: Exercise|Drug: Spironolactone,Augmentation Index-Change from baseline|Flow Mediated Dilation-Change from baseline|Pulse Wave Velocity-Change from baseline|Post Ischemic Flow Velocity-Change from baseline|Insulin Sensitivity-Change from baseline|Microvascular Blood Volume-Change from baseline,University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,18 Years to 50 Years   (Adult),Not Applicable,60,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18237|5R01DK101944-03,Aug-15,Dec-21,Dec-21,2-Jun-17,null,2-Jun-17,"University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT03174288
NCT03174522,The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM,,Recruiting,No Results Available,"Peripheral Arterial Disease (PAD)|Diabetes Mellitus (DM)|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Cardiovascular Disease|Critical Limb Ischemia (CLI)",Drug: REX-001|Drug: Placebo,Complete healing of all ischemic ulcers on the index leg.,Rexgenero Limited|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,78,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",REX-001-004_CLI 5,25-Apr-17,31-Oct-20,31-Oct-21,2-Jun-17,null,31-Aug-18,"First site: Hospital Reina Sofía de Córdoba, Cordoba, Córdoba, Spain",,https://ClinicalTrials.gov/show/NCT03174522
NCT03170544,Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001),,Completed,No Results Available,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,"Drug: MK-1092, 4.0 nmol/kg|Drug: MK-1092, 8.0 nmol/kg|Drug: MK-1092, 16 nmol/kg|Drug: MK-1092, 32 nmol/kg|Drug: MK-1092, 64 nmol/kg|Drug: Glargine 3.0 nmol/kg|Drug: Lispro 1.2 nmol/kg|Drug: Placebo to glargine|Drug: Placebo to MK-1092|Other: Dextrose|Biological: Insulin",Percentage of Participants Who Experienced an Adverse Event (AE)|Percentage of Participants Who Discontinued the Study Due to an AE|Maximal Glucose Infusion Rate (GIRmax) in Adult Participants with T1DM|GIRmax in Healthy Adult Participants|Time-Weighted Average GIR (TWA[GIR])|Maximal Plasma Drug Concentration (Cmax) Parts 1 and 3|Total Amount of Plasma Drug Concentration (AUC0-inf.) Parts 1 and 3|Rate of Plasma Drug Removal (CL/F) Parts 1 and 3|Time to Reach Maximum Plasma Drug Concentration (Tmax) Parts 1 and 3|Time to Reach a 50% Decrease In Plasma Drug Concentration (t1/2) Parts 1 and 3|GIRmax in Adult Participants with T2DM|Maximal Plasma Drug Concentration (Cmax) Part 4|Total Amount of Plasma Drug Concentration (AUC0-inf.) Part 4|Rate of Plasma Drug Removal (CL/F) Part 4|Time to Reach Maximum Plasma Drug Concentration (Tmax) Part 4,Merck Sharp & Dohme Corp.,All,18 Years to 60 Years   (Adult),Phase 1,69,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1092-001|MK-1092-001,16-Aug-17,8-Nov-18,8-Nov-18,31-May-17,null,12-Feb-19,"ProSciento Inc. ( Site 0001), Chula Vista, California, United States",,https://ClinicalTrials.gov/show/NCT03170544
NCT03167411,Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection,,Completed,No Results Available,Type2 Diabetes Mellitus,Drug: Bexagliflozin|Drug: Exenatide Injection,Cmax (Maximum observed plasma concentration)|Tmax (Time of maximum observed plasma concentration)|T1/2 (Apparent terminal elimination half-life)|AUC0-inf (Area under the plasma concentration-time curve from Time 0 to infinity)|Urinary Glucose Excretion 0-12 hr|Urinary Glucose Excretion 12-24 hr|Urinary Glucose Excretion 24-36 hr|Urinary Glucose Excretion 36-48 hr|Safety as measured by adverse events,Theracos,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,THR-1442-C-458,20-Jun-17,29-Jun-17,29-Jun-17,30-May-17,null,22-Aug-17,"Clinical Research Site, Evansville, Indiana, United States",,https://ClinicalTrials.gov/show/NCT03167411
NCT03168633,Lifestyle Advises Sent Via Email in Attempt of Improving A1C in DM2 Patients,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: web-based DM2 information pages,HbA1C values of patients after 6 months|percentage of messages opened and read,Rambam Health Care Campus,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,0456-14-RMB CTIL,Jul-15,30-Jan-17,30-Jan-17,30-May-17,null,30-May-17,,,https://ClinicalTrials.gov/show/NCT03168633
NCT03168867,Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms),3Ms,Recruiting,No Results Available,Type 1 Diabetes Mellitus,Behavioral: The 3Ms Intervention,Metabolic Control|Regimen Adherence (objective)|Diabetes Management (self-reported)|Parental Monitoring of Diabetes Care (self-reported)|Diabetes- Specific Family Functioning (self-reported)|Adolescent Depression (self-reported)|Executive Functioning (self-reported)|Cost Analysis (self-reported)|Diabetes Emotional Distress (self-reported)|Household Chaos (self-reported),Wayne State University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,10 Years to 15 Years   (Child),Not Applicable,212,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",015117B3E|R01DK110075|1R01DK110075-01A1,25-Sep-17,Aug-21,Mar-22,30-May-17,null,7-Sep-18,"Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Children's Hospital University of Illinois, Chicago, Illinois, United States|La Rabida Children's Hospital, Chicago, Illinois, United States|Children's Hospital of Michigan, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT03168867
NCT03170089,Oral Health Awareness and Oral Hygiene in Insulin Dependent Diabetes Mellitus,,Unknown status,No Results Available,Health Attitude|Diabetes type1,Behavioral: Oral Health Educational Program,Patient awareness|Oral hygiene,Cairo University,All,6 Years to 8 Years   (Child),Not Applicable,44,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,S.Haikal,30-Jun-17,30-Oct-17,30-Dec-17,30-May-17,null,30-May-17,,,https://ClinicalTrials.gov/show/NCT03170089
NCT03165786,A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes,FREE,Completed,No Results Available,Type1diabetes,Behavioral: FREE,Hypoglycemia Fear Scale Score (HFS_2)|Diabetes Self-Management Questionnaire Scale Score (DSMQ)|Glycemic control|Glycemic variability,University of Illinois at Chicago,All,18 Years to 30 Years   (Adult),Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,2016-0206,26-Oct-16,16-Jan-18,16-Jan-18,24-May-17,null,28-Mar-19,"University of Illinois at Chicago, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT03165786
NCT03166124,A Study of LY900014 in Elderly and Younger Adult Participants With Type 1 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: LY900014|Drug: Insulin Lispro,Pharmacokinetics: Area Under the Plasma Concentration Curve (AUC) of Insulin Lispro for Each Treatment Arm|Total Amount of Glucose Infused (Gtot) Over Duration of Clamp for Each Treatment Arm,Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 1,84,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",16637|I8B-MC-ITRR,24-May-17,18-Nov-17,18-Nov-17,24-May-17,null,27-Dec-17,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany",,https://ClinicalTrials.gov/show/NCT03166124
NCT03163511,"A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness",,Recruiting,No Results Available,Type 1 Diabetes Mellitus With Hypoglycemia,Combination Product: VC-02 Combination Product,Incidence of all adverse events reported for Cohort 1 subjects|Change in C-peptide for Cohort 2 subjects,ViaCyte|California Institute for Regenerative Medicine (CIRM),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,55,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other,VC02-101,6-Jul-17,Jun-19,Dec-20,23-May-17,null,8-Jan-19,"University of California San Diego, San Diego, California, United States|Johns Hopkins University, Baltimore, Maryland, United States|University of Minnesota, Minneapolis, Minnesota, United States|Ohio State University, Columbus, Ohio, United States|University of Alberta, Edmonton, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT03163511
NCT03161964,Propranolol in Treating Hypoglycemia Unawareness,,Recruiting,No Results Available,Type 1 Diabetes Mellitus,"Drug: Propranolol 80 Mg Oral Capsule, Extended Release|Drug: Placebo oral capsule",Ratio of self-reported hypoglycemic episodes to total hypoglycemic episodes determined by continuous glucose monitoring (CGM)|Gold questionnaire score for hypoglycemia awareness|Clarke questionnaire score for hypoglycemia awareness|Pederson-Bjergaard questionnaire score for hypoglycemia awareness|Nadir glucose level|Nadir glucose level in categories|Hypoglycemia Duration|Blood Glucose Area Under the Curve (AUC)|Duration of Hypoglycemia Onset-to-Diagnosis|Duration of Hypoglycemia Onset-to-Treatment|Duration of Hypoglycemia Diagnosis-to-Recovery|Duration of Hypoglycemia Treatment-to-Recovery|Total Hypoglycemia Episodes|Total Severe Hypoglycemia Episodes|Fear of Hypoglycemia Score|Mean Blood Glucose,"Yu Kuei (Alex) Lin, MD|University of Utah",All,21 Years to 59 Years   (Adult),Phase 2,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB #101995,19-Oct-17,31-Jul-19,31-Jul-19,22-May-17,null,11-Jul-18,"University of Utah, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT03161964
NCT03162237,Safety and Efficacy Study of Islets Xenotransplantation,,Enrolling by invitation,No Results Available,Type 1 Diabetes,Other: Porcine islets|Other: Autologous Treg,Blood glucose|Porcine C-peptide|Hemoglobin A1c|AST|ALT|Scr|BUN|Ultrasonic examination for liver|MRI for liver|Virus detection|Immune cells detection|Cytokine detection,"Wei Wang,MD|Hunan Xeno-life Science Ltd|Central South University",All,18 Years to 40 Years   (Adult),Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CellTransplant&GeneTherapy2013,Jul-13,Dec-18,Dec-20,22-May-17,null,22-May-17,"Cell Transplantation and Gene Therapy Institute, Changsha, Hunan, China",,https://ClinicalTrials.gov/show/NCT03162237
NCT03162926,A Safety and Tolerability Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes Mellitus,Combination Product: VC-02 Combination Product (aka PEC-Direct),Incidence of all adverse events reported for subjects,ViaCyte,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,3,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VC02-102,5-Jul-17,15-Feb-18,15-Feb-18,22-May-17,null,18-Oct-18,"University of Alberta, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT03162926
NCT03158415,Parents of Young Adults With Type 1 Diabetes: An Exploratory Study,,Completed,No Results Available,Type1diabetes|Parents,Behavioral: T1DToolkit.org mobile diabetes education,Lived experience|Diabetes Distress,University of Florida|University of South Florida,All,"21 Years to 99 Years   (Adult, Older Adult)",Not Applicable,22,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,IRB201700810|13177,1-May-17,18-Jul-17,18-Jul-17,18-May-17,null,27-Feb-19,"University of Florida, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT03158415
NCT03156361,21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus,,Completed,No Results Available,Type1 Diabetes Mellitus,Drug: HDV insulin lispro 100 UNIT/mL|Drug: Insulin Lispro 100 Units/mL,Glucose area under the curve|total units Insulin,Diasome Pharmaceuticals|Integrium,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DP 01-2017-02,18-May-17,15-Jan-18,15-Mar-18,17-May-17,null,31-Jul-18,"Atlanta Diabetes Association, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT03156361
NCT03155594,CGM to Aid Transition From Inpatient to Outpatient,,Unknown status,No Results Available,Diabete Mellitus,Device: Freestyle Libre,Changes in care|Accuracy of device,Methodist Medical Center of Illinois,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1023056-2,9-May-17,15-Jul-17,1-Aug-17,16-May-17,null,16-May-17,"Methodist Medica Center of Illinois, Peoria, Illinois, United States",,https://ClinicalTrials.gov/show/NCT03155594
NCT03154060,Evaluation of the Accuracy and Precision of Flash Glucose Monitoring Sensors in Different Sites,OUT OF SIGHT,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: Abbott FreeStyle Libre Flash Glucose Monitoring sensors,Mean Absolute Relative Difference|Precision Absolute Relative Deviation,Universitaire Ziekenhuizen Leuven|Onze Lieve Vrouwziekenhuis Aalst,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,23,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,OOS-60146,19-May-17,4-Aug-17,4-Aug-17,15-May-17,null,7-Aug-17,"Onze-Lieve-Vrouwziekenhuis Aalst, Aalst, Belgium|UZ Leuven, Leuven, Belgium",,https://ClinicalTrials.gov/show/NCT03154060
NCT03149770,"Naloxone, Hypoglycemia and Exercise",,Recruiting,No Results Available,"Diabetes Mellitus, Type 1",Drug: Naloxone|Drug: Placebo,Change in Symptom Score|Change in Epinephrine Levels,University of Minnesota - Clinical and Translational Science Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Study00000026,18-Sep-17,Dec-20,Dec-20,11-May-17,null,11-Oct-18,"University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03149770
NCT03147274,Group Education Curriculum for Older Teens With Type 1 Diabetes,SMART T1D,Completed,No Results Available,Type 1 Diabetes Mellitus,Behavioral: Intervention,Change from baseline self-care adherence at 12 months|Change from baseline transition readiness at 12 months|Change from baseline hemoglobin A1c at 12 months,Boston Children’s Hospital,All,"15 Years to 18 Years   (Child, Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,IRB-P00023671,3-May-17,21-Feb-19,21-Feb-19,10-May-17,null,17-Apr-19,"Boston Children's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03147274
NCT03144869,Physical Activity Monitoring Paediatric Type 1 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Behavioral: physical activity monitor and feedback,Recruitment|Adherence|Retention|Data completion|Occurrence of adverse events|Acceptability|Demographics|Clinical information|Parental self-efficacy for diabetes management|Parental fear of hypoglycaemia,Sheffield Hallam University|Sheffield Children's Hospital NHS Foundation Trust,All,7 Years to 11 Years   (Child),Not Applicable,13,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,CA16015,1-Sep-17,1-Aug-18,1-Aug-18,9-May-17,null,6-Sep-18,"Sheffield Children's Hospital NHS Foundation Trust, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT03144869
NCT03143816,Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study—STAT Study,STAT,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 1",Drug: Technosphere insulin,"Improved time in range (70-180 mg/dl) with TI on CGM|Better post-prandial glucose excursion (1-4 hours after meals) with TI|Less glucose variability (GV) (standard deviation and/or coefficient variation)|The area under the curve calculation (AUC) in the PPBG and PPGE,|Change in HbA1c in one-month treatment|above the target time (>180 mg/dl) on CGM|hypoglycemia frequency (below the target <70, <60, <50 mg/dl) on CGM",University of Colorado Denver School of Medicine Barbara Davis Center|Atlanta Diabetes Associates|University of Southern California|Rainier Clinical Research Center|Mannkind Corporation,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,60,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STAT,30-Sep-17,15-Dec-17,31-Dec-17,8-May-17,null,9-Nov-17,"Barbara Davis Center, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT03143816
NCT03139864,Comparison of the Use of Energy Substrates and Hormonal Regulation of Blood Sugar During Exercise of Increasing Intensity Between Children With Type 1 Diabetes and Non-diabetic Control Children.,DIABSPORT,Recruiting,No Results Available,Type 1 Diabetes,Procedure: controlled physical activity,Comparison of substrate utilization between infants with type 1 diabetes and infants without type 1 diabetes during exercise|hormonal regulation of blood glucose|lipoxmax : the intensity for wich lipid oxydation is maximum will be carried out by indirect calorimetry|Comparison between infants during 10 days before and 4 days after exercise of blood glucose modification,"University Hospital, Clermont-Ferrand",All,6 Years to 12 Years   (Child),Not Applicable,48,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,CHU-0292|2016-A01837-44,4-Apr-17,May-19,Dec-19,4-May-17,null,4-Feb-19,"CHU Clermont-Ferrand, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT03139864
NCT03130101,Insulin Management for Exercise in Patients With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes|Hypoglycemia|Physical Activity,Other: Change in their basal insulin rate,Time in interstitial glucose target range (CGM analysis),York University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,17,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,e2017 - 073,3-Apr-17,1-Feb-18,1-Feb-18,26-Apr-17,null,15-Jan-19,"York University, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03130101
NCT03117998,"Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus",,Recruiting,No Results Available,Type1 Diabetes Mellitus,Biological: REMD-477|Biological: Placebo Comparator,Daily Insulin Use|Glucose after Mixed Meal Tolerance Test (MMTT)|Continuous Glucose Monitoring (CGM)|Seven-Point Glucose Profile|Product of the ratio of average glucose and insulin|Adverse Events|Hypoglycemic Events|HbA1c at Week 13|HbA1c Reduction of ≥ 0.4%|C-peptide after MMTT and Arginine Challenge|Glucagon after MMTT|GLP-1 after MMTT|Immunogenicity|Peak Serum Concentration|Area under the serum concentration|Half-life of REMD-477,"REMD Biotherapeutics, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,150,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R477-202,17-Aug-17,31-Dec-19,28-Feb-20,18-Apr-17,null,1-May-19,"Altman Clinical and Translational Research Institute, San Diego, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|University of Colorado, Denver/Barbara Davis Center for Diabetes, Aurora, Colorado, United States|Atlanta Diabetes Assoicates, Atlanta, Georgia, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Dallas Diabetes Research Center, Dallas, Texas, United States|Rainer Clinical Research Center, Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT03117998
NCT03112343,Information and Communication Technology Based Centralized Clinical Trial Monitoring System for Insulin Dose Adjustment,ICT,Completed,No Results Available,Diabetes Mellitus|Insulin Hypoglycemia|Insulin-dependent Diabetes Mellitus,Device: Algorithm-based feedback messages|Device: Personal Health Record,"the proportion of patients who reach his/her optimal insulin dose within 12 weeks of enrolling in the study without severe hypoglycemia or unscheduled clinic visits.|the proportion of patients who reach HbA1c <7% without severe hypoglycemia (unrecoverable hypoglycemia without the help of others) at Week 24|the proportion of patients who reach HbA1c <7% without severe hypoglycemia (unrecoverable hypoglycemia without the help of others) at Week 12|mean fasting blood glucose values for three consecutive days prior to Week 12 and Week 24|levels of HbA1c at Week 12 and Week 24|lipid profile at Week 12 and Week 24|the proportion of patients having hypoglycemia (total, asymptomatic, daytime, nighttime, severe hypoglycemia, and coma/convulsions) at Week 12 and Week 24|the number of steps during Week 1-12 and Week 13-24|recorded exchange unit by food group|daily insulin dose|blood pressure|body weight|lean body mass|fat mass|Satisfaction evaluation by questionnaire for ICT-based centralized clinical trial monitoring|Satisfaction evaluation by DTSQ|the number of telephone counselling by diabetes educators|the number of self-monitoring blood glucose measurements","Samsung Medical Center|Ministry of Trade, Industry & Energy, Republic of Korea|Korea Evaluation Institute of Industrial Technology|Daegu Metropolitan City, Korea|ICT Clinical Trial Coordination Center",All,"18 Years to 69 Years   (Adult, Older Adult)",Not Applicable,112,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2016-08-006-001,26-Sep-17,30-Sep-18,30-Dec-18,13-Apr-17,null,5-Apr-19,"Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03112343
NCT03111238,The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM,,Recruiting,No Results Available,"Peripheral Arterial Disease (PAD)|Diabetes Mellitus (DM)|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Cardiovascular Disease|Critical Limb Ischemia (CLI)",Drug: REX-001|Drug: Placebo,Complete relief of ischemic rest pain without developing ischemic lesions on the index leg.,Rexgenero Limited|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,60,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",REX-001-004_CLI 4,5-Apr-17,Oct-19,Oct-20,12-Apr-17,null,28-Mar-19,"First site: Hospital Reina Sofía de Córdoba, Cordoba, Córdoba, Spain",,https://ClinicalTrials.gov/show/NCT03111238
NCT03111433,Efficacy of Coenzyme q10 in Pediatrics With Type 1 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Dietary Supplement: Coenzyme Q10|Drug: Insulin,change in soluble interacellular adhesion molecule level,Ain Shams University,All,"8 Years to 18 Years   (Child, Adult)",Phase 2,49,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PHCL136,19-Mar-17,20-Jan-18,20-Jan-18,12-Apr-17,null,3-Apr-18,"Ainshams university pediatric's hospital, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT03111433
NCT03107208,Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes,,Recruiting,No Results Available,Diabetic Ketoacidosis|Type 1 Diabetes Mellitus,Drug: Glargine|Device: Continuous Glucose Monitor (Abbott FreeStyle Libre Pro),Rate of Rebound Hyperglycemia|Rate of Recurrent Ketogenesis|Risk of Hypoglycemia between those given early administration of glargine versus those given standard-of-care management.|Evaluation of CGM and POC glucose monitoring during DKA treatment in children.,"University of Colorado, Denver",All,"6 Years to 18 Years   (Child, Adult)",Phase 4,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16-1965,21-Jul-17,May-19,Jul-19,11-Apr-17,null,18-Jul-18,"Children's Hospital Colorado, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT03107208
NCT03104829,DSME or DSME + MI in T1DM on Glycemic Control,,Unknown status,No Results Available,Diabetes Mellitus,Behavioral: Motivational interviewing|Drug: DSME participants in this arm will receive standard care for diabetes (DSME) at the beginning of the study and 3 months later,HbA1C|Pre and post test scores for Diabetic knowledge|Diabetic self-care behavior score,Mahidol University,All,"10 Years to 18 Years   (Child, Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SI-DSME-MI-01,Oct-16,Oct-18,Oct-18,7-Apr-17,null,7-Apr-17,"Ornsuda Lertbannaphong, Bangkok Noi, Bangkok, Thailand",,https://ClinicalTrials.gov/show/NCT03104829
NCT03102892,Antimicrobial Photodynamic Therapy on Periodontal Treatment and Salivary Status of Type 1 Diabetes Mellitus Patients,,Recruiting,No Results Available,"Diabetes Mellitus, Type 1|Periodontal Diseases|Periodontal Pocket",Procedure: Scaling root planing|Procedure: Antimicrobial photodynamic therapy,Periodontal disease (gingivitis and periodontitis) measured by a periodontal probe and classified according to severity|Salivary glucose - collection of stimulated saliva in 10 minutes and measured with a colorimetric kit|Salivary pH and buffering Capacity - collection of stimulated saliva in 10 minutes and measurement of acidity with a pHmeter|Capillary glycemia measured by a glucometer,University of Sao Paulo,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",BauruSchoolDentistryPDTDM1,10-Mar-17,10-Oct-18,10-Dec-18,6-Apr-17,null,3-May-18,"Bauru School of Dentistry, Bauru, Sao Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT03102892
NCT03103867,"QUality of Control and slEep in Children With diabeteS, Using New Technology",QUEST,Completed,No Results Available,"Diabetes Mellitus, Type 1","Device: CGM augmented pump with PLGS ,|Device: Insulin pump with CGM",Time in glucose target|time below glucose target|Time above glucose target|Sleep quantity in patients and caregivers|perception of quality of sleep and quality of life in patients and caregivers|hypoglycaemia fear in patients and caregivers,Centre Hospitalier du Luxembourg,All,6 Years to 14 Years   (Child),Not Applicable,32,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QUEST,23-Feb-17,4-May-18,15-Jul-18,6-Apr-17,null,3-Aug-18,"Clinique des Enfants CHluxembourg, Luxembourg, Luxembourg",,https://ClinicalTrials.gov/show/NCT03103867
NCT03101865,The Artificial Pancreas in Very Young Children With T1D - Pilot (KidsAP01),,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: FlorenceM,Time in target (3.9 to 10.0mmol/l) (70 to 180 mg/dl)|Time spent below target glucose (3.9mmol/l)(70mg/dl)|Time spent above target glucose (10.0mmol/l) (180mg/dl)|Average glucose|Standard deviation of glucose levels|Coefficient of variation of glucose levels|Time with glucose levels < 3.5mmol/l (63 mg/dl)|Time with glucose levels <2.8mmol/l (50mg/dl)|Time with glucose levels in significant hyperglycaemia|Total daily insulin dose|Daily basal insulin dose|Daily bolus insulin dose|AUC of glucose below 3.5mmol/l (63mg/dl),University of Cambridge|European Commission|Medtronic|Cambridge University Hospitals NHS Foundation Trust|The Leeds Teaching Hospitals NHS Trust|University of Luxembourg|University of Leipzig|Medical University of Graz|Medical University Innsbruck|Medical University of Vienna|Jaeb Center for Health Research,All,1 Year to 7 Years   (Child),Not Applicable,24,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,KidsAP01,8-Aug-17,11-May-18,11-May-18,5-Apr-17,null,5-Jun-18,"Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria|Department of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria|Deptartment of Pediatrics, Medical University of Vienna, Vienna, Austria|Division for Paediatric Diabetology, University of Leipzig, Leipzig, Germany|Clinique Pédiatrique de Luxembourg, Luxembourg, Luxembourg|University of Cambridge, Cambridge, United Kingdom|St James's University Hospital, Leeds, United Kingdom",,https://ClinicalTrials.gov/show/NCT03101865
NCT03102476,Environmental Effects Type 1 Diabetes Mellitus,,Completed,No Results Available,Type1diabetes,Drug: Humalog,"Area under the glucose infusion rate curve from 0 hours until the end of clamp.|Onset of action, time from trial product administration until the blood glucose concentration has decreased at least 0.3 mmol/L (5 mg/dL) from the baseline|Area under the glucose infusion rate curve from 0 hours until 2 hours|Area under the glucose infusion rate curve from 0 hours until 4 hours|Area under the glucose infusion rate curve from 0 hours until 6 hours|Area under the glucose infusion rate curve from 4 hours until 6 hours|Maximum glucose infusion rate|Time to maximum glucose infusion rate curve",University of Hull,Male,18 Years to 55 Years   (Adult),Not Applicable,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,Version: 3.0 (02-07-2014),Jun-16,2-Feb-18,2-Feb-18,5-Apr-17,null,31-Oct-18,"Hull and East Yorkshire NHS Trust, Hull, United Kingdom",,https://ClinicalTrials.gov/show/NCT03102476
NCT03096392,Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: HDV insulin lispro 100 UNT/ML|Drug: Insulin Lispro 100 UNT/ML,"The amount of time, in minutes, glucose levels are within range (70-180 mg/dL)|The number of events that blood glucose is equal to or less than 70 mg/dL|The number of events blood glucose is less than 54 mg/dL|Postprandial glucose levels in mg/dL following test meal challenge|HbA1c levels in percentage (%) at beginning of trial compared to HbA1c levels at the end of the study|Self-Monitoring Blood Glucose (SMBG) results in mg/dL before and after every meal|Total doses of insulin used (in number of units of insulin injected) during the study",Diasome Pharmaceuticals|Integrium,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,46,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DP 01-2017-01,18-Apr-17,15-Nov-17,18-Mar-18,30-Mar-17,null,31-Jul-18,"Barbara Davis Center for Diabetes, University of Colorado, Aurora, Colorado, United States|Baptist Diabetes Associates, Miami, Florida, United States|Lucas Research, Inc., Morehead City, North Carolina, United States|Texas Diabetes and Endocrinology, Austin, Texas, United States|Texas Diabetes and Endocrinology, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT03096392
NCT03095651,Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002),,Completed,Has Results,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Biological: MK-5160 16 nmol/kg|Biological: MK-5160 32 nmol/kg|Biological: MK-5160 64 nmol/kg|Biological: Glargine 0.4 U/kg|Biological: Placebo to Glargine|Biological: Placebo to MK-5160|Drug: Dextrose|Biological: Glargine 0.6 U/kg,Number of Participants Experiencing an Adverse Event (AE)|Number of Participants Discontinuing Study Drug Due to an AE|Maximal Glucose Infusion Rate|Maximum Plasma Concentration (Cmax) of MK-5160|Maximum Plasma Concentration (Cmax) of Glargine|Day 12 to Day 1 Accumulation Ratio of Cmax|Steady State Plasma Concentration (Css) of MK-5160|Steady State Plasma Concentration (Css) of Glargine|Plasma Concentration/Time (AUC0-24) of MK-5160|Plasma Concentration/Time (AUC0-24) of Glargine|Day 12 to Day 1 Accumulation Ratio of AUC0-24.|Plasma Clearance|Time to Maximum Plasma Concentration|Apparent Terminal Half-life,Merck Sharp & Dohme Corp.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,33,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",5160-002|MK-5160-002,12-Apr-17,30-Jan-18,30-Jan-18,29-Mar-17,1-Apr-19,1-Apr-19,"ProSciento Inc. ( Site 0001), Chula Vista, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT03095651/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03095651
NCT03092882,Digital Self-Management Program for Medicare Advantage Members With Type 2 Diabetes- Impact on A1c,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: Diabetes Self-Management Program,Change from Baseline in A1c at 6 months,Evidation Health|Humana Co.Ltd.,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,607,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,EH-004,3-Mar-17,28-Feb-18,28-Feb-18,28-Mar-17,null,17-Jul-18,"Evidation Health, San Mateo, California, United States",,https://ClinicalTrials.gov/show/NCT03092882
NCT03093636,Efficacy of inControl Advice: A Decision Support System (DSS) for Diabetes,DSS,Completed,No Results Available,Type1 Diabetes Mellitus,Device: Continuous Glucose Monitor (CGM)+Decision Support System (DSS)|Other: Continuous Glucose Monitor (CGM) alone,Increased % time within target range,"Stacey Anderson|TypeZero Technologies, Inc.|Novo Nordisk A/S|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|DexCom, Inc.|University of Virginia",All,"15 Years to 100 Years   (Child, Adult, Older Adult)",Not Applicable,111,Other|Industry|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,19634|DP3DK101055|U1111-1191-3911,17-Apr-17,19-Mar-19,19-Mar-19,28-Mar-17,null,28-Mar-19,"Stanford University, Stanford, California, United States|Icahn School of Medicine at Mt. Sinai, New York, New York, United States|University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT03093636
NCT03091673,Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Glucagon,Change in Plasma Glucose|Time for Plasma Glucose to Increase by ≥25 mg/dL|Plasma Glucagon Area Under the Curve|Plasma Glucagon Cmax|Plasma Glucagon Tmax,Xeris Pharmaceuticals|The EMMES Corporation,All,2 Years to 17 Years   (Child),Phase 3,31,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,XSGP-302,27-Mar-17,7-Sep-17,27-Sep-17,27-Mar-17,16-Nov-18,11-Dec-18,"Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Women & Children's Hospital of Buffalo, Buffalo, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT03091673/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT03091673/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03091673
NCT03092310,Feasibility Evaluation of an Artificial Pancreas With Glucose Prediction Trust Index,,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: Artificial Pancreas Device,"Percent time within the target glucose range of 70-180 mg/dl overall as assessed by continuous glucose monitoring (CGM).|Assessment of the trust index predictions vs. standard eMPC glucose predictions.|Frequency of hypoglycemia during closed-loop use.|Frequency of hyperglycemia during closed-loop use.|Percent time within the target glucose range of 70-140 mg/dl during closed-loop use.|Percent time glucose is within range 70-150 mg/dl postprandial within 5 hours following meals, during closed-loop use.|Standard Deviation and Coefficient of Variation of glucose values|Markers of hypo- and hyperglycemia|Insulin Doses Given|Number of treatments given for hypoglycemia (defined as carbohydrates given for treatment of a documented or suspected low blood sugar), during the 48 hours of closed-loop use.|Number of alerts given by the HMS to prevent hypoglycemia|Failure analysis of the devices/connectivity issues that may occur (# disconnects and device restarts).",Sansum Diabetes Research Institute|Harvard University,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00020556,20-Mar-17,20-Dec-17,20-Dec-17,27-Mar-17,null,12-Jul-18,"William Sansum Diabetes Center, Santa Barbara, California, United States",,https://ClinicalTrials.gov/show/NCT03092310
NCT03089632,The Effect of Gluten-free Diet in Type 1 Diabetics With Dyspepsia Symptoms,,Recruiting,No Results Available,"Diabetes Mellitus, Type 1|Gastroparesis|Dyspepsia|Gluten Sensitivity",Other: Gluten-free diet,Changes in upper gastrointestinal symptoms assessed by the Leeds short-form questionnaire (SF-LDQ)|Changes in upper gastrointestinal symptoms assessed by the Gastroparesis Cardinal Symptoms Index (GCSI)|Changes in gastric emptying determined by gastric scintigraphy.|Changes in gastro-duodenal motility assessed by videofluoroscopy|Changes in glycemic control assessed by continuous glucose monitoring,McMaster University,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DM1 and GFD_01,15-Dec-17,1-Jun-18,30-Jun-18,24-Mar-17,null,20-Dec-17,"McMaster Health Sciences Centre, Hamilton, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03089632
NCT03090451,Exercise Physiology Study,,Completed,No Results Available,Type 1 Diabetes Mellitus|Hypoglycemia,Behavioral: Aerobic Exercise,Non-insulin mediated glucose uptake (NIMGU)|Insulin mediated glucose uptake (IMGU)|Mean glucose level|Time spent in severe hypoglycemia|Time spent in hypoglycemia|Time spent in hyperglycemia,Oregon Health and Science University,All,18 Years to 45 Years   (Adult),Not Applicable,26,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,16761,1-May-17,14-Dec-18,14-Dec-18,24-Mar-17,null,13-Mar-19,"Oregon Health & Science University, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT03090451
NCT03084900,Patient-Centered Decision Support to Improve Diabetes Management in Pre-Teens and Adolescents With Type 1 Diabetes,CHICAT1,Recruiting,No Results Available,Diabetes Mellitus,Other: Arm 1,HbA1c value|Hypoglycemia|DKA,Indiana University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"12 Years and older   (Child, Adult, Older Adult)",Not Applicable,255,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,1612394802|1DP3DK113183-01,27-Jul-17,31-Mar-21,31-Mar-21,21-Mar-17,null,19-Feb-19,"Riley Hospital for Children, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT03084900
NCT03085771,Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes,DESIRED,Recruiting,No Results Available,"Diabetes Mellitus, Type 1",Drug: desferal|Drug: Isotonic saline,Endothelial precursor cell account (EPC),Karolinska University Hospital,All,18 Years to 55 Years   (Adult),Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2016/1925-31,1-Jan-17,12-Dec-20,12-Dec-22,21-Mar-17,null,9-Aug-18,"Karolinska University Hospital, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT03085771
NCT03083899,The Diabetes Patient Takes Responsibility,DiaTast,Recruiting,No Results Available,"Diabetes Mellitus, Type 1|Patient Reported Outcome|Health Care Economics and Organizations",Other: Out-patient clinic on demand|Other: Scheduled out-patient clinic,Patient reported outcome|Clinical diabetes variables 1|Health Care Economy|Clinical diabetes variables 2|Clinical diabetes variables 3|Diabetes Dependent quality of Life,Hospital of South West Jutland,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,500,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,Diatast,1-Mar-17,30-Sep-19,30-Nov-19,20-Mar-17,null,21-Sep-17,"Hospital of South West Jutland, Esbjerg, Denmark",,https://ClinicalTrials.gov/show/NCT03083899
NCT03081676,The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea,HNF1A-Clamp,Completed,No Results Available,"Maturity-Onset Diabetes of the Young, Type 3",Drug: Glimepiride 1Mg Tablet|Drug: Glucagon-like Peptide-1|Drug: Glucose-Dependent Insulinotropic Polypeptide|Drug: Placebo Oral Tablet|Drug: Placebo infusion,Insulin secretion|Glucagon secretion|Maximal insulin secretion|Maximal glucagon secretion|DPP-4 activity|Amount glucose used to maintain the glucose clamp,"University Hospital, Gentofte, Copenhagen",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",H-16038140,8-Mar-17,1-Jun-18,1-Jun-18,16-Mar-17,null,11-Oct-18,"Center for Diabetes Research, Gentofte Hospital, Hellerup, Denmark",,https://ClinicalTrials.gov/show/NCT03081676
NCT03079921,Adrenergic System in Islet Transplantation,Aim 1 Islets,Recruiting,No Results Available,Type1diabetes|Hypoglycemia|Hypoglycemia Unawareness,Drug: Phentolamine|Drug: Propranolol|Drug: Placebo,C-PEPTIDE suppression during hyperinsulinemia euglycemia.|GLUCAGON activation during hyperinsulinemia hypoglycemia.|EPINEPHRINE during hyperinsulinemia hypoglycemia.|Rates of ENDOGENOUS GLUCOSE PRODUCTION during hyperinsulinemia hypoglycemia.|AUTONOMIC SYMPTOMS during hyperinsulinemia,University of Pennsylvania|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"21 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,45,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",826386|2R01DK091331-06,20-Jan-17,Dec-19,Dec-20,15-Mar-17,null,24-Aug-18,"University of Pennsylvania - Institute for Diabetes, Obesity and Metabolism, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03079921
NCT03078491,Technological Advances in Glucose Management in Older Adults,TANGO,Recruiting,No Results Available,Type 1 Diabetes Mellitus|Older Adults|Hypoglycemia,Other: eCGM (enhanced CGM),Change in duration of hypoglycemia|Fasting and bedtime CGM glucose values per day|Severe biochemical hypoglycemia|Severe clinical hypoglycemia|Hemoglobin A1C|Cost-effectiveness and cost-utility|Barriers and facilitators of CGM use,Joslin Diabetes Center|Beth Israel Deaconess Medical Center|Boston Children’s Hospital|RTI International,All,65 Years and older   (Older Adult),Not Applicable,168,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CHS #2016-29,30-Mar-17,31-Jul-21,1-Jan-22,13-Mar-17,null,17-Aug-18,"Joslin Diabetes Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03078491
NCT03073577,Islet Transplantation Using PKX-001,,"Active, not recruiting",No Results Available,Type 1 Diabetes Mellitus,Drug: Antiaging Glycopeptide,Adverse event morbidity|Serious adverse event morbidity|Number of participants with insulin independence|Islet yield|Engraftment index|Islet viability|Glucose stimulated insulin release|Oxygen consumption ratio|Insulin requirement|Beta-2 score,University of Alberta|ProtoKinetix Inc.,All,"18 Years to 68 Years   (Adult, Older Adult)",Phase 1,6,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00067564,16-Feb-17,Sep-20,Jan-21,8-Mar-17,null,27-Mar-19,"University of Alberta, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT03073577
NCT03072407,"MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM",,Completed,No Results Available,Type2 Diabetes Mellitus,Biological: PB-119 injection|Biological: PB-119 injection placebo,"the number of AEs and the finding from the physical examination, the abnormal lab results|PB-119 blood plasma concentration|PB-119 antibody|Insulin sensitivity (SI)|Beta-cell Responsivity Index|Disposition Index","PegBio Co., Ltd.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,CSP-PB119-US01-01,24-Nov-15,2-Nov-16,15-Nov-16,7-Mar-17,null,20-Apr-18,"Clinical Pharmacology of Miami, Inc., Miami, Florida, United States|Frontage Clinical Services. Inc., Hackensack, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT03072407
NCT03068273,Managing Type 1 and High Risk Type 2 Diabetes in the Hospital Setting: Glucose as a Vital Sign (Pilot),Pilot Hosp CGM,Unknown status,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Device: Real-time CGM data,Target range (70-180 mg/dL): % days at target (type 1 diabetes)|Target range (70-180 mg/dL): % days at target (type 2 diabetes)|CGM patient acceptability questionnaire - patient-reported outcome|Hypoglycemia (<70 mg/dL): rate comparison (type 1 diabetes)|Hypoglycemia (<70 mg/dL): rate comparison (type 2 diabetes)|Hyperglycemia (>180 mg/dL): rate comparison (type 1 diabetes)|Hyperglycemia (>180 mg/dL): rate comparison (type 2 diabetes),Scripps Whittier Diabetes Institute,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,56,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,15-6878,May-15,31-Dec-17,31-Dec-17,1-Mar-17,null,1-Mar-17,"Scripps Whittier Diabetes Institute, La Jolla, California, United States",,https://ClinicalTrials.gov/show/NCT03068273
NCT03066089,Clinical Evaluation of Fenfuro (Fenugreek Seed Extract) in Type-2 Diabetic Subjects: an add-on Study,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Fenfuro,"Change in Fasting Blood Sugar|Change in Postprandial sugar|Change in HbA1c levels|SGPT,SGOT,ALP,Creatinine,TLC,DLC & Hb",Chemical Resources,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,104,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,CR-FEN/PREDIA/02/15,14-Dec-15,Oct-17,Oct-17,28-Feb-17,null,31-Jan-18,"Gian Sagar Medical College & Hospital, Rajpura, Punjab, India",,https://ClinicalTrials.gov/show/NCT03066089
NCT03064906,Insulet Artificial Pancreas Evaluating Meal Performance and Moderate Exercise (IDE2),IDE2,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: Insulet AP (artificial pancreas) System,Percentage of time in hypoglycemic range (defined as < 70 mg/dL)|Percentage of time in hyperglycemic range(defined as ≥ 250 mg/dL)|Mean glucose|Percentage of time < 50 mg/dL|Percentage of time < 60 mg/dL|Percentage of time > 180 mg/dL|Percentage of time ≥ 300 mg/dL|Percentage of time between 70-180 mg/dL|Percentage of time between 70-140 mg/dL|Standard deviation|Coefficient of variation|Meal challenge-12 hour PPG dinner|Meal challenge-4 hour PPG breakfast|Meal challenge-4 hour PPG lunch|Exercise challenge-immediate and delayed glucose response|Effect of changing setpoints,Insulet Corporation,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,24,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,IDE2,18-Mar-17,7-Apr-17,7-Apr-17,27-Feb-17,null,12-Jun-18,"Stanford University, Palo Alto, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|University of Colorado Denver, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT03064906
NCT03063229,Energy Balance Following Islet Transplantation,EBFIT,"Active, not recruiting",No Results Available,Type 1 Diabetes,Device: Accelerometer|Other: Anthropomentry|Procedure: Blood tests|Device: BODPOD|Procedure: MRI (Magnetic Resonance Imaging)|Other: Food Diary|Device: CGMS (Continuous Glucose Monitoring System)|Other: Questionnaire and Hypo Score|Procedure: Mixed Meal Tolerance Test (MMTT)|Procedure: Indirect Calorimetry|Drug: Doubly Labelled Water|Drug: Hepatic Mitochondrial Oxidation breath test,"Body composition|Total energy intake|The activity component of energy expenditure using accelerometry.|Resting Energy Expenditure (REE)|Hepatic fat oxidation using Sodium 13C octanoate.|Liver fat, abdominal subcutaneous and visceral fat using MRI scans.|BODPOD|Hypoglycaemia scores.|Post-Prandial Thermogenesis (PPT)|Total metabolic Rate (TMR)",University of Edinburgh|NHS Lothian,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,REC 16/SS0031 R&D: 2016/0118,Jun-16,Sep-18,Sep-19,24-Feb-17,null,3-May-18,"Royal Infirmary Edinburgh, Edinburgh, Midlothian, United Kingdom",,https://ClinicalTrials.gov/show/NCT03063229
NCT03057470,Optimal Insulin Correction Factor in Post- High Intensity Exercise Hyperglycemia in Adults With Type 1 Diabetes (FIT),FIT,Unknown status,No Results Available,"Diabetes Mellitus, Type 1",Drug: 50% bolus insulin correction|Drug: 100% bolus insulin correction|Drug: 150% bolus insulin correction|Other: 0% bolus insulin correction,"Reduction In Plasma Glucose (YSI)|Investigate Glycemic Response of a 0%, 50%, 100% and 150% Bolus Insulin Correction of Post-exercise Hyperglycemia Compared to no Bolus Insulin Correction",LMC Diabetes & Endocrinology Ltd.|Sanofi,All,18 Years to 55 Years   (Adult),Phase 4,18,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FIT,May-16,Mar-17,Mar-17,20-Feb-17,null,20-Feb-17,"LMC Bayview, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03057470
NCT03056456,A Study of LY900014 Administered by an Insulin Pump in Type 1 Diabetes Participants,,Completed,No Results Available,Type1 Diabetes Mellitus,Drug: LY900014|Drug: Insulin Lispro,Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Insulin Lispro|Pharmacodynamics (PD): Area Under the Baseline Subtracted Concentration Versus Time Curve (AUC) of Glucose,Eli Lilly and Company,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,30,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",16727|I8B-MC-ITSC|2016-004093-18,23-Feb-17,19-Jun-17,19-Jun-17,17-Feb-17,null,29-Jun-17,"For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Neuss, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany",,https://ClinicalTrials.gov/show/NCT03056456
NCT03048227,Can Continuous Glucose Measurements Help Diabetic Patients Treated With an Implantated Pump?,CGMIP,Not yet recruiting,No Results Available,Type1diabetes,Device: Continuous Glucose Measurement (CGM),"Time spent with glucose|HbA1c|Time spent in hypoglycaemia|Time spent in hyperglycemia|Time spent in glucose range|Glucose mean and standard deviation|Low Blood Glucose Index (LBGI)|High Blood Glucose Index (HBGI)|Glucose Variability|Number of symptomatique hypoglycaemia, severe et non severe|Number of pump programmation|Percentage of sensor use|Score of Quality of Life questionnaire (IDSRQ)","University Hospital, Montpellier",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,28,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,UF9773,1-Mar-17,1-Dec-19,31-Dec-19,9-Feb-17,null,9-Feb-17,"Chu de Nancy, Nancy, Vandoeuvre-les-nancy, France|CHU de Bordeaux, Bordeaux, France|CH Sud Francilien, Corbeil-essonnes, France|CHU de Dijon, Dijon, France|CHRU de Lille, Lille, France|AP - Hôpitaux de Marseille, Marseille, France|UHMontpellier, Montpellier, France|AP - Hôpitaux de Paris, Paris, France|CHRU de Strasbourg, Strasbourg, France|Chu de Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT03048227
NCT03046927,Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes,PCR,Recruiting,No Results Available,Type 1 Diabetes,Drug: Ergocalciferol|Other: Placebo,Residual beta-cell function (RBCF)|Glycemic control (HbA1c)|Glucagon-like peptide-1 (GLP-1)|Differences in the duration of PCR in subjects with high-risk SNPs receiving vitamin D vs. placebo|Vitamin D Binding Protein (VDBP)|Duration of Partial Clinical Remission (PCR),"Benjamin U. Nwosu|University of Massachusetts, Worcester|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",All,"10 Years to 21 Years   (Child, Adult)",Phase 2|Phase 3,40,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",H00010550|1R21DK113353,19-Oct-17,31-Jul-20,31-Jul-20,8-Feb-17,null,21-Jun-18,"University of Massachusetts Medical School, Worcester, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03046927
NCT03047200,Pancreatic Islet Cell Transplantation After Kidney Transplantation - A Novel Approach to Immunosupression,,Withdrawn,No Results Available,Islet Cell Transplantation|Type 1 Diabetes,Biological: Islet cell transplantation,Restoration of sustained euglycemia without exogenous insulin or with reduced insulin dosage in patients who underwent pancreatic islet cell after kidney transplantation|To assess incidence of hypoglycemic episodes|To monitor insulin requirements in patients who did not achieve insulin independence|To assess total islet mass needed to achieve sustained euglycemia with or without exogenous insulin.,Baylor Research Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,008-189,Jul-08,Jan-17,Jan-17,8-Feb-17,null,15-Feb-17,"Baylor University Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT03047200
NCT03039933,Intervention to Reduce Fear of Hypoglycemia and Optimize Type 1 Diabetes Outcomes,,Recruiting,No Results Available,Type1diabetes|Fear of Hypoglycemia,Behavioral: Fear of Hypoglycemia|Other: Treatment As Usual,Decrease in scores on the Hypoglycemia Fear Survey,"University of Colorado, Denver|University of Virginia",All,10 Years to 17 Years   (Child),Not Applicable,88,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16-0645,Aug-16,Jul-19,Jul-19,1-Feb-17,null,31-May-18,"University of Colorado, Denver, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT03039933
NCT03037190,Preservation of Residual Beta Cell Mass and Prevention of Celiac Disease in Children With Recent Onset Type 1 Diabetes,Diabglut,Recruiting,No Results Available,"Diabetes Mellitus, Type 1|Remission|Celiac Disease in Children",Other: withdrawal of gluten from the diet,Preservation of beta cells function|Prevention of Celiac DIsease,Lund University,All,"3 Years to 18 Years   (Child, Adult)",Not Applicable,160,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,LUDU,Dec-15,Dec-20,Dec-20,31-Jan-17,null,23-Aug-18,"Skanes University Hospital, Lund, Region Skane, Sweden",,https://ClinicalTrials.gov/show/NCT03037190
NCT03034226,Comparison Between Hypoglycemic Counter Regulatory Responses in Type 1 Diabetics vs Control Subjects,,"Active, not recruiting",No Results Available,"Hypoglycemia|Diabetes Mellitus, Type 1",Other: Glucose clamp technique,Insulin sensitivity|Hormonal counter regulatory response to hypoglycemia|Symptoms during hypoglycemia,University of Aarhus,Male,20 Years to 50 Years   (Adult),Not Applicable,18,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,Project 1-10-72-304-16,23-Feb-17,1-Feb-18,Oct-19,27-Jan-17,null,21-Mar-18,"Department of Clinical Medicine, Aarhus, Denmark",,https://ClinicalTrials.gov/show/NCT03034226
NCT03032354,Probiotics in Newly Recognized Type 1 Diabetes,,Unknown status,No Results Available,"Diabetes Mellitus, Type 1","Drug: Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12|Other: Placebo, (Placebo group)","Area under the curve (AUC) during fasting and at 30,60,90,120 min following the start of the meal|Insulin requirement (U / kg body mass )|HbA1c|Weight in kilograms|Number of participants with abnormal laboratory values and/or adverse events that are related to treatment ( eg.abdominal pain, diarrhea , constipation , vomiting,flatulence)|Occurrence of other autoimmune diseases|Height in meters|BMI in kg/m2|BMI score|severe hypoglycemia|ketoacidosis|Fasting c- peptide concentrations in ng/ml",Medical University of Warsaw,All,8 Years to 17 Years   (Child),Phase 4,96,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AgaLidka,15-Jul-17,Dec-18,Dec-18,26-Jan-17,null,11-Jul-17,,,https://ClinicalTrials.gov/show/NCT03032354
NCT03029351,GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes,1981 GLP,Not yet recruiting,No Results Available,Type2 Diabetes|Kidney Diseases,Drug: Exenatide Extended Release for Inj Susp 2 MG|Drug: Placebos,change from baseline in albuminuria levels|change in albuminuria category (micro or macro)|change in creatinine clearance|change in Cystatin C|change in TGFβ|change in type I and IV collagen|Change in CTGF|change in fibronectin levels|change in the expression of SMAD3|change in SMAD4|change in NQO-1|change in GST-1P|change in HO-1|Change in Nrf-2/keap-1,University at Buffalo|AstraZeneca,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 4,90,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1981 GLP,Feb-17,Feb-20,Feb-20,24-Jan-17,null,25-Jan-17,,,https://ClinicalTrials.gov/show/NCT03029351
NCT03028220,Impact on Hypoglycaemia Awareness of Real Time CGM and Intermittent Continuous Glucose Data,I HART-CGM,Completed,Has Results,Type 1 Diabetes Mellitus With Hypoglycemia|Impaired Awareness of Hypoglycemia|Type1diabetes,Device: Dexcom G5 Continuous Glucose Monitor|Device: Abbott Freestyle Libre,"% Time Spent in Hypoglycaemia (<3.3mmol/L, 60mg/dL)|% Time Spent in Hypoglycaemia (<2.8mmol/L, 50mg/dL)|% Time Spent in Hypoglycaemia (<3.9mmol/L, 70mg/dL)|% Time Spent in Euglycaemia (3.9-7.8mmol/L, 70-140mg/dL)|% Time Spent in Euglycaemia (3.9-10mmol/L, 70-180mg/dL)|% Time Spent in Hyperglycaemia (>10mmol/L, 180mg/dL)|% Time Spent in Hyperglycaemia (>15mmol/L, 270mg/dL)|Hypoglycemia|Severe Hypoglycaemia|Glucose Variability Measured by CV|Glucose Variability Measured by MAGE|Glucose Variability Measured by CONGA",Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15HH2875,Jan-16,Feb-17,Aug-17,23-Jan-17,15-Apr-19,15-Apr-19,,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT03028220/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03028220
NCT03022058,Evaluation of the EarEEG System for Detection of Hypoglycaemia-induced Changes in the EEG in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: Ear-EEG system,Presence of significant qEEG hypoglycaemia indicators when comparing normo- and hypoglycaemic EEG as measured by the EarEEG systems for subjects where hypoglycaemia-induced changes have been observed in the scalp EEG (visit 4),Odense University Hospital|University of Aarhus|T&W Engineering A/S|UNEEG Medical A/S,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,12,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,56205,22-Jun-17,16-Nov-17,16-Nov-17,16-Jan-17,null,11-Apr-18,"Diabetes Research Center, Odense, Denmark",,https://ClinicalTrials.gov/show/NCT03022058
NCT03020069,Use of Continuous Glucose Monitoring System With Intensive Feedback in Adolescents With Poorly Controlled Type 1 Diabetes,,Enrolling by invitation,No Results Available,Type 1 Diabetes,Device: CGMS Device|Other: No Device,"Quality of life (Peds QL 3.2, Diabetes module)|Measures of the level of glycemic control by HbA1c|Measures of the level of glycemic control average glucose tests results on the patient's glucose meter",New York University School of Medicine,All,"13 Years to 19 Years   (Child, Adult)",Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,16-01011,Nov-15,Nov-19,Nov-20,13-Jan-17,null,12-Dec-18,"New York University Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03020069
NCT03018444,The Effect of HMG-CoA Reductase Inhibition on Postprandial GLP-1 Secretion,,Completed,No Results Available,"Diabetes Mellitus, Type 2|Hydroxymethylglutaryl-CoA Reductase Inhibitors",Drug: Atorvastatin|Other: Placebo,Postprandial GLP-1 secretion|Postprandial Bile Acid Composition|Postprandial total plasma Bile Acid|Postprandial Glucose Tolerance|Postprandial plasma lipid response|Postprandial GIP secretion|Enteric hormones known to influence glucose metabolism|Gallbladder emptying|Faecal content of bile acid|Gut microbiota composition|Gastric emptying|Resting Energy Expenditure,"University Hospital, Gentofte, Copenhagen",Male,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",H-16034243,Oct-16,Jan-17,Jan-17,12-Jan-17,null,3-Mar-17,"University Hospital, Gentofte, Copenhagen, Hellerup, Region Hovedstaden, Denmark",,https://ClinicalTrials.gov/show/NCT03018444
NCT03018665,A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese,,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2",Drug: Exenatide|Drug: BIAsp30|Drug: Metformin,Rate of Inducing Diabetes Remission|Change of Rate of Maintaining Diabetes Remission|Time of Maintaining Diabetes Remission|Change of Blood Pressure|Change of Heart Rate|Change of Weight|Change of Waistline|Change of Glycosylated Hemoglobin|Change of Pancreatic Beta-cell Function|Change of Insulin Resistance Index|The Incidence of Hypoglycemia|The Incidence of Diabetic Retinopathy|The Incidence of Diabetic Nephropathy,First Hospital of Jilin University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,JLUEND001,Feb-17,Dec-21,null,12-Jan-17,null,12-Jan-17,"First Hospital of Jilin University, Changchun, Jilin, China",,https://ClinicalTrials.gov/show/NCT03018665
NCT03017287,Safety and Efficacy of the GlucoMe APP in Patients With Uncontrolled Diabetes Treated With MDI,,Unknown status,No Results Available,"Diabetes Mellitus, Type 1 or 2",Device: GlucoMe App,Hypoglycemic and Hyperglycemic Events|Correlation between GlucoMe and HCT recommendations|Target HbA1C/glucose achievement,GlucoMe,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,40,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Clin-002-00,Jan-17,May-17,Aug-17,11-Jan-17,null,11-Jan-17,"Diabitic Unit of the Wolfson Medical Center, Holon, Israel",,https://ClinicalTrials.gov/show/NCT03017287
NCT03017352,Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic Cases,MAG1C,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 1",Drug: Exenatide|Drug: Placebos,Change in HbA1c|adverse events (including hypoglycaemic episodes)|changes in insulin dosage|changes in body weight|changes in BMI|changes in body composition|changes in fasting plasma glucose|changes in post prandial plasma glucose|changes in fasting plasma levels of C-peptide|Quality of life self reported|Treatment satisfaction|dietary patterns|HDL (High Density Lipoprotein)|LDL (Low Density Lipoprotein)|VLDL (Very Low Density Lipoprotein)|total cholesterol|triglycerides|proBNP (Pro-Brain Natriuretic Peptide)|hsCRP (High-Sensitivity C-Reactive Protein),"Filip Krag Knop|Steno Diabetes Center Copenhagen|University Hospital, Gentofte, Copenhagen",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,108,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Eudract-nr.: 2016-001365-92,Dec-16,Jul-19,Jul-19,11-Jan-17,null,13-Mar-19,"Steno Diabetes Center Copenhagen, Gentofte, Capital Region, Denmark",,https://ClinicalTrials.gov/show/NCT03017352
NCT03010683,"Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus",,Unknown status,No Results Available,Type 2 Diabetes Mellitus|Coronary Artery Disease,Drug: Liraglutide|Drug: Metformin,"Differences in pulse wave velocity at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R.|Differences in augmentation index at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R.|Differences in coronary flow reserve at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R.|Differences in endothelial glycocalyx thickness at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R.|Endothelial glycocalyx and pulse wave velocity.|Endothelial glycocalyx and coronary flow reserve.",University of Athens,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,GLP1-DM-ATTIKON,Nov-15,Jun-17,Dec-17,5-Jan-17,null,9-Jan-17,"''Attikon'' University General Hospital, Haidari, Athens, Attiki, Greece",,https://ClinicalTrials.gov/show/NCT03010683
NCT03011008,Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus,,Recruiting,No Results Available,Type 1 Diabetes Mellitus|Autoimmune Diabetes,Drug: Liraglutide|Drug: Insulin,Mean amplitude of glycemic excursions (MAGE)|Change in HbA1C|Change in C-peptide|Change in insulin dose|Hyperglycemic and hypoglycemic events|Life quality evaluation,Second Xiangya Hospital of Central South University,All,"18 Years and older   (Adult, Older Adult)",Phase 4,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2,Jan-17,Dec-20,Jun-21,5-Jan-17,null,17-Oct-18,"Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China",,https://ClinicalTrials.gov/show/NCT03011008
NCT03011021,Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes,,Recruiting,No Results Available,Type1 Diabetes Mellitus|Autoimmune Diabetes,Drug: Liraglutide|Biological: UCB-Treg|Drug: Insulin,Adverse effects|Change in HbA1C|Change in C-peptide|Change in insulin dose|Hypoglycaemic events|Change in titer of autoantibodies|Change in immune cells diversities and quantities.|Change in autoimmune-related cytokines|Life quality evaluation,Second Xiangya Hospital of Central South University,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1,Jan-17,Jan-19,Nov-19,5-Jan-17,null,17-Apr-18,"Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China",,https://ClinicalTrials.gov/show/NCT03011021
NCT03003806,Evaluation of the Dreamed Advisor Pro for Automated Insulin Pump Setting Adjustments in Children and Adolescents With Type 1 Diabetes- The Advice4U Pro Study,Advice4U,Recruiting,No Results Available,Type1 Diabetes Mellitus,Device: DreaMed Advisor Pro|Other: Medical guided recommendation,Percentage of glucose readings within range of 70-180 mg/dl (3.9 to 10 mmol/l).|Percentage of glucose readings below 54 mg/dl (3.3 mmol/l)|HbA1c|Percentage of glucose readings below 70 mg/dl (3.9 mmol/L)|Percentage of readings below 50 mg/dl (2.8 mmol/L)|Percentage of readings above 180 mg/dl (10.0 mmol/L)|Percentage of readings above 240 mg/dl (13.3 mmol/L)|Area above the curve of glucose glucose level of 180 mg/dl|Area under the curve of glucose level of 70 mg/dl|Mean sensor blood glucose|Glucose variability measured by Standard Deviation|Number of recommendations for changes in settings per patient|Number of recommendations for changes in settings per iteration|Number of physician override Advisor recommendations|Number of patients overrides of recommendation|Estimated time duration needed for the physician to give its recommendations|Device satisfaction questionaire|Diabetes treatment satisfaction questionnaire,Rabin Medical Center|DreaMed|The Leona M. and Harry B. Helmsley Charitable Trust,All,"10 Years to 21 Years   (Child, Adult)",Not Applicable,112,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RMC072016ctil,2-Oct-17,Jun-19,Jun-19,28-Dec-16,null,21-Jun-18,"Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|University of Florida College of Medicine, Gainesville, Florida, United States|Joslin Diabetes Center, One Joslin Place, Boston, Massachusetts, United States|Diabetes -Zentrum fuer kinder und jugendliche, Hannover, Germany|Schnider children's medical center, Petach-Tikva, Israel|University Children's Hospital, Ljubljana, Slovenia",,https://ClinicalTrials.gov/show/NCT03003806
NCT02994277,Artificial Pancreas in Latin America,,Completed,No Results Available,Diabetes,Device: 1° Phase: UVa algorithm 2° Phase: ITBA/UNLP algorithm,System connectivity|Technical fail rate|Percentage of time in glycaemia between 70-180 mg/dl|Percentage of time in glycaemia between 181-250 mg/dl|Percentage of time in hypoglycaemia defined as <70 mg/dl|Percentage of time in hyperglycaemia defined as >180 mg/dl|Number of all hypoglycaemic events (syntomatic and non syntomatic)|Comparison of glycaemic profiles during the trial with glycaemic profiles in the days before the trial|Meal composition's effect in the efficacy of the system to control glycaemia,Hospital Italiano de Buenos Aires|Instituto Tecnológico de Buenos Aires|Universidad Nacional de La Plata|Universidad Nacional de Quilmes|University of Virginia|Fundación Nuria/Cellex,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,5,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2680,Nov-16,6-Jul-17,7-Jul-17,15-Dec-16,null,9-Nov-17,,,https://ClinicalTrials.gov/show/NCT02994277
NCT02987556,Diabeloop WP7 : Crossover Evaluation of the Safety and the Efficacy of Artificial Pancreas Diabeloop (WP7),WP7,Completed,No Results Available,"Closed Loop|Diabetes Mellitus, Type 1",Device: Continuous Glucose Monitoring|Device: External Insulin Pump|Other: telemdecine|Device: The Diabeloop Software (Model predictive control),"Percentage of time spent in the tight glycemic control area 70-180 mg/dl continuously measured for 12 weeks|Percentage of time spent in the glycemic range 70-180 mg/dl, 80-140 mg/dl and in blood glucose >180 mg/dL during nights and during 24 hours for 12 weeks|Measurement of HbA1c at the onset and at the end of each period of treatment|Average blood glucose levels throughout the full period|Calculated risks of hypo- and hyperglycemia (LBGI, HBGI) throughout the full period during 12 weeks|Total supplies of insulin during tests|Number of hyper-glycemic events defined by American Diabetes Association (ADA) : severe hyperglycemia > 360 mg/dl (20 mmol/l) measured by CGM or significant ketose (acetonemia > 3 mmol/l)|Number of hypoglycemic events, defined by any threshold crossing 60 mg/dl ( 3,33 mmol/l); 70 mg/dl (3,9 mmol/l) and < 54 mg/dl (3 mmol/l) measured by the CGM|Measuring the oral carbohydrates intake during the last week of each period of treatment|Number of technical problems causing interruptions of the closed loop|Percentage of time spent in good-working mode during the closed loop period|For the use and the acceptance, a satisfaction survey will be done on the daily management of diabetes, the modification of daily life with the system dan the fear of hypoglycemia|Percentage of time spent in blood glucose <70 mg/dl continuously measured for 12 weeks",Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,71,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2016-A01198-43,30-Mar-17,28-Aug-18,28-Aug-18,9-Dec-16,null,1-Feb-19,"Centre Hospitalier Universitaire Jean Minjoz, Besancon, France|Centre Hospitalier Universitaire, Caen, France|Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France|Centre Hospitalier Universitaire, Grenoble, France|Centre Hospitalier Universitaire, Lyon, France|Centre Hospitalier Universitaire, Marseille, France|Centre Hospitalier Universitaire, Montpellier, France|Centre Hospitalier Universitaire, Nancy, France|Centre Hospitalier Universitaire, Nantes, France|Centre Hospitalier Universitaire, Reims, France|Centre Hospitalier Universitaire, Strasbourg, France|Centre Hospitalier Universitaire, Toulouse, France",,https://ClinicalTrials.gov/show/NCT02987556
NCT02987738,Pilot Study to Explore the Efficacy of DAPAglifozin as add-on to Closed-loop Control in Patients With Type 1 Diabetes,DapaDream,Completed,No Results Available,Type1diabetes,Drug: Dapagliflozin|Drug: Placebo Oral Tablet,Time in Range 70-180%|urinary glucose excretion|postprandial insulin need|ß-hydroxybutyrate|Reduction of Insulin dose,Kinderkrankenhaus auf der Bult|AstraZeneca|Alcedis GmbH,All,"12 Years to 21 Years   (Child, Adult)",Phase 1,30,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",ESR-15-11453,9-Feb-17,19-Dec-17,19-Dec-17,9-Dec-16,null,28-Feb-18,"Kinder - und Jugendkrankenhaus AUF DER BULT, Hannover, Germany",,https://ClinicalTrials.gov/show/NCT02987738
NCT02984514,Brown Adipose Tissue in Type 1 Diabetes,,Completed,No Results Available,Type1diabetes,Radiation: Positron emission tomography with tracer 18F-deoxy glucose,Activity of brown adipose tissue in correlation to exogenous insulin needs using the tracer 18F-deoxy glucose in positron emission tomography measurements|Glucose uptake in muscle in correlation to exogenous insulin needs; assessment using the tracer 18F deoxy glucose in positron emission tomography measurements.,Per-Ola Carlsson|Uppsala University Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,11,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,Dnr 2015/191,Oct-15,Jan-18,Jun-18,7-Dec-16,null,11-Oct-18,"Uppsala University Hospital, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT02984514
NCT02984709,Check It! 2.0: Positive Psychology Intervention for Adolescents With Type 1 Diabetes,,Completed,Has Results,Type1diabetes,Behavioral: Positive Psychology Intervention|Behavioral: Education,Glycemic Control (A1C)|Positive Affect|Frequency of Blood Glucose Monitoring|Diabetes Family Conflict Scale|Diabetes-Specific Quality of Life|Primary Control Coping|Secondary Control Coping|Disengagement Coping|Self Care Inventory,Vanderbilt University|Vanderbilt University Medical Center,All,13 Years to 17 Years   (Child),Not Applicable,48,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,161732,Oct-16,24-Feb-17,10-Aug-17,7-Dec-16,24-Apr-19,24-Apr-19,"Vanderbilt University Medical Center, Nashville, Tennessee, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02984709/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02984709/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02984709
NCT02985866,The International Diabetes Closed Loop (iDCL) Trial: Protocol 1,iDCL,Recruiting,No Results Available,Type1 Diabetes Mellitus,Device: Artificial Pancreas|Other: Sensor Augmented Therapy,"Comparing differences between baseline and 3 months post randomization periods, the first co-primary is superiority in CGM-measured time below 70 mg/dL and the second co-primary is non-inferiority in CGM-measured time above 180 mg/dL.","Stacey Anderson|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Jaeb Center for Health Research|TypeZero Technologies, Inc.|DexCom, Inc.|Roche Diagnostic Ltd.|Ascensia Diabetes Care|University of Virginia",All,"14 Years and older   (Child, Adult, Older Adult)",Not Applicable,126,Other|NIH|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,iDCL|UC4DK108483,27-Oct-17,1-Jun-18,1-Jun-18,7-Dec-16,null,31-Oct-17,"William Sansum Diabetes Center, Santa Barbara, California, United States|Stanford University, Stanford, California, United States|Barbara Davis Center, University of Colorado, Aurora, Colorado, United States|Harvard University (Joslin Diabetes Center), Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02985866
NCT02980627,iOmit: Reducing Intentional Insulin Misuse in Type 1 Diabetes,iOmit,"Active, not recruiting",No Results Available,Type 1 Diabetes Mellitus|Eating Disorders,Behavioral: Therapy with Mobile App Enhancement,Metabolic Control (Change in HbA1c)|Mobile Technology Engagement (Frequency of Use)|Adequate Insulin Dosing (Frequency)|Medical Utilization: Total Number of Primary Care Visits|Medical Utilization: Total Number of Emergency Department Care Visits|Participant Engagement in Treatment as evidenced by attendance/treatment completion|Improvement in Metabolic Control; CGM Continuous Glucose Monitoring|Decrease in Diabetes-Specific Eating Disorder symptomatology|Decrease in Overall Eating Disorder symptomatology,Duke University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,18 Years to 55 Years   (Adult),Not Applicable,27,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00068040|1R21DK106603-01A1,Mar-16,May-19,May-19,2-Dec-16,null,29-Apr-19,"Duke University Health System, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02980627
NCT02981069,"Effect of GLP-1 Receptor Agonist, Exenatide on Glucosuria Induced Elevation in ENDOGENOUS GLUCOSE PRODUCTION (EGP)",,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Drug: Dapagliflozin|Drug: Exenatide|Drug: Placebo,Change in Endogenous Glucose Production (EGP) for Dapagliflozin only|Change in EGP for Dapagliflozin plus exenatide (Byetta)|Change in EGP for Dapagliflozin plus exenatide (Bydureon)|Change in EGP for Exenatide (Byetta) vs dapagliflozin/exenatide|Change in EGP for dapagliflozin vs placebo|Change in EGP for exenatide (byetta) vs placebo|Change in EGP for dapagliflozin/exenatide vs placebo,The University of Texas Health Science Center at San Antonio|AstraZeneca,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,80,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HSC20160597H,15-Dec-17,31-Mar-20,31-Mar-21,2-Dec-16,null,7-Feb-19,"University of Texas Health Science Center, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT02981069
NCT02974309,Family Routines Enhancing Adolescent Diabetes by Optimizing Management,FREADOM,Recruiting,No Results Available,Type 1 Diabetes,Behavioral: Sleep Extension|Behavioral: Routine,HbA1c|Glucose Levels via continuous glucose monitor|Sleep Duration,University of Arizona,All,10 Years to 17 Years   (Child),Not Applicable,175,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",RDK110528A,1-Jun-17,Jun-21,Jun-21,28-Nov-16,null,11-Sep-17,"Angel Wing Clinic for Diabetes, Tucson, Arizona, United States",,https://ClinicalTrials.gov/show/NCT02974309
NCT02970357,Evaluation of the Impact of a Therapeutic Education Program for Children With Type 1 Diabetes,PROGETE,Completed,No Results Available,"Diabetes Mellitus, Type I|Program Evaluation|Therapeutic Education|Children",Other: DIAPASON Questionnaire|Behavioral: WHO-5,The DIAPASON questionnaire|Evolution of glycated hemoglobin|Occurrence of severe hypoglycemic events|Occurrence of ketoacidosis events|Need for care indicators|Behavioral indicators|Psychological indicators,Groupe Hospitalier de la Region de Mulhouse et Sud Alsace,All,"10 Years to 20 Years   (Child, Adult)",Not Applicable,68,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,805|2015-A017101-48,Jan-16,29-Nov-16,6-Feb-17,22-Nov-16,null,1-Aug-17,"GHRMSA, Mulhouse, France",,https://ClinicalTrials.gov/show/NCT02970357
NCT02970656,A Pilot Study of Biomarkers of Stress in Youth Who Use Teens.Connect,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Behavioral: Teens.Connect,Glycosylated Hemoglobin (HbA1c)|Perceived Stress Scale|Adolescent Stress Questionnaire (ASQ)|Responses to Stress Questionnaire for Diabetes (RSQ)|Stress Biomarkers|Awakening and sleep time|Genotype & DNA Methylation|DNA Methylation,Yale University|Miller Foundation,All,11 Years to 14 Years   (Child),Not Applicable,29,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1503015414,8-Feb-17,28-Feb-19,28-Feb-19,22-Nov-16,null,2-Apr-19,"Yale School of Nursing, West Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02970656
NCT02971202,"Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)",,Recruiting,No Results Available,"Type 1 Diabetes Mellitus|Maturity-Onset Diabetes of the Young, Type 2|MODY2|Insulin Resistance","Drug: Hyperinsulinemic, euglycemic clamp|Drug: 20% dextrose",Whole-body glucose utilization (Rd)|Hepatic insulin sensitivity|Adipose tissue insulin sensitivity,Vanderbilt University|Vanderbilt University Medical Center,All,"13 Years to 51 Years   (Child, Adult)",Phase 1,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,161504,Dec-16,Dec-18,Jun-19,22-Nov-16,null,1-Aug-18,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT02971202
NCT02971228,Feasibility Trial Testing the Bionic Pancreas With ZP4207,dasiglucagon,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Insulin Lispro|Drug: ZP4207 (dasiglucagon)|Drug: Glucagon|Device: iPhone-based bionic pancreas|Device: iLet-based bionic pancreas,"Safety and Tolerability as measured by adverse events, local tolerability of infusion site reactions, and clinical laboratory parameters|Glycemic Regulation|Average percent glucagon dose amounts calculated by the bionic pancreas control algorithm that are successfully delivered by the pump.|Average percent insulin dose amounts calculated by the bionic pancreas control algorithm that are successfully delivered by the pump.|Average percent insulin dose amounts successfully issued to the pump by the bionic pancreas control algorithm that are successfully delivered by the pump.|Average percent glucagon dose amounts successfully issued to the pump by the bionic pancreas control algorithm that a successfully delivered by the pump.|Average percent of 5 minute steps during which the bionic pancreas is functioning nominally in all respects based on real-time continuous glucose monitoring (CGM) data (new CGM glucose reading captured, dose calculated, dose issued to pumps)|Average percent of 5 minute steps during which the bionic pancreas is functioning nominally with or without a new CGM glucose reading captured (dose calculated, dose issued to pumps).|CGM reliability index, calculated as percent of possible values actually recorded by CGM|CGM Mean Absolute Relative Difference versus time-stamped blood glucose (BG) values from meter download|List of technical faults associated with the BP including cause and resolution|Diabetes treatment satisfaction questionnaire - status|Diabetes treatment satisfaction questionnaire - change|T1-Diabetes distress scale|Problem areas in diabetes survey|Hypoglycemia fear survey|Impact of daily diabetes demands|Bionic pancreas user opinion survey","Zealand Pharma|Massachusetts General Hospital|Beta Bionics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,10,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ZP4207-16051,Nov-16,24-May-17,7-Jun-17,22-Nov-16,null,27-Jun-18,"MGH Diabetes Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02971228
NCT02969863,The Monitoring Study,,Completed,Has Results,Type1diabetes,Device: Bihormonal Bionic Pancreas|Device: Insulin Only Bionic Pancreas|Other: Monitored for Hypoglycemia|Other: Not Monitored for Hypoglycemia,Percentage of Time Spent With Dexcom CGMG < 60 mg/dl,Massachusetts General Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,27,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2016P002450,1-Apr-17,1-Jun-17,28-Dec-17,21-Nov-16,30-Jul-18,30-Jul-18,"MGH Diabetes Research Center, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT02969863/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02969863
NCT02962492,An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes,,Unknown status,No Results Available,Evaluate Ketogenic Stress,Drug: Exenatide/Exenatide extended release|Drug: Dapagliflozin|Drug: Placebo,"change in beta-hydroxybutyrate in the plasma samples from baseline|change in acetoacetic acid in the plasma samples from baseline|change in urinary ketone bodies changes after 12 weeks of dapagliflozin and Bydureon or combination of both treatments compared to baseline|change in basal plasma glucagon after 12 weeks of dapagliflozin and Bydureon or combination of both treatments compared to baseline|change in FFA ( free fatty acids) after 12 weeks of dapagliflozin and Bydureon or combination of both treatments compared to baseline|changes in AUC0hr-6hr of ketone bodies (plasma and urine), FFA and glucagon between dapagliflozin, exenatide, combination of both and placebo from baseline|Changes in lipolysis mediator (HSL) in plasma and expression of HSL and SGLT-2 in adipose tissue and MNC will be compared to baseline",University at Buffalo|AstraZeneca,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,80,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",1973,Nov-16,Oct-18,Oct-18,11-Nov-16,null,16-Nov-16,"ECMC Ambulatory Center, 3rd Floor, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT02962492
NCT02956044,"Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin",,Completed,No Results Available,Type2 Diabetes Mellitus,Drug: Bexagliflozin|Drug: Metformin|Drug: Glimepiride|Drug: Sitagliptin,Cmax (Maximum observed plasma concentration)|Tmax (Time of maximum observed plasma concentration)|T1/2 (Apparent terminal elimination half-life)|AUC0-inf (Area under the plasma concentration-time curve from Time 0 to infinity)|Urinary Glucose Excretion 0-12 hr|Urinary Glucose Excretion 12-24 hr|Urinary Glucose Excretion 24-36 hr|Urinary Glucose Excretion 36-48 hr|Safety as measured by adverse events,Theracos,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,54,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,THR-1442-C-453,Nov-16,Mar-17,Mar-17,4-Nov-16,null,20-Sep-17,"Clinical Research Site, Evansville, Indiana, United States",,https://ClinicalTrials.gov/show/NCT02956044
NCT02940873,Hypoglycaemia Awareness Restoration Programme,HARPdoc,Recruiting,No Results Available,Type 1 Diabetes Mellitus|Hypoglycemia,Behavioral: HARPdoc courses|Behavioral: BGAT courses,Difference in severe hypoglycaemia between study arms|Difference in rate of moderate hypoglycaemia between study arms|The impact on hypoglycaemia without sacrificing diabetes control as reflected by the HbA1c|Changes in HbA1c > 0.3% and % participants with HbA1c <7%. between study arms|Difference in the Gold score between study arms|Difference in awareness of hypoglycaemia by modified Clarke score between study arms|Changes in cognitions around hypoglycaemia using the Attitudes to Awareness between study arms|Changes in cognitions using the Hypoglycaemia Fear Survey between study arms|Changes in cognitions around hypoglycaemia using the Hyperglycaemia Avoidance between study arms|Change in psychological health - anxiety and depression using HADS|Change in psychological health - problems related to diabetes (PAID)|Quality of Life - general,King's College London|Juvenile Diabetes Research Foundation|King's College Hospital NHS Trust|Guy's and St Thomas' NHS Foundation Trust|Sheffield Teaching Hospitals NHS Foundation Trust|Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust|Joslin Diabetes Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,96,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,4-SRA-2017-266-M-N,9-Mar-17,Jul-21,Dec-21,21-Oct-16,null,1-Mar-19,"Joslin Diabetes Center, Boston, Massachusetts, United States|Royal Bournemouth Hospital, Bournemouth, United Kingdom|King's College Hospital NHS Foundation Trust and Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT02940873
NCT02939768,Impact of Different Types of Exercise Training on Biochemical Markers of Insulin-dependent Patients,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Other: High-intensity interval training (HIIT)|Other: Strength training (ST)|Other: ST combined with HIIT (ST+HIIT),Glycated haemoglobin (HbA1c)|Tumor necrosis factor alpha (TNF-α)|Mitochondrial superoxide dismutase (MnSOD) activity,Federal University of Rio Grande do Sul,All,18 Years to 40 Years   (Adult),Not Applicable,28,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,53935916.9.0000.5347,Aug-16,Nov-17,Nov-17,20-Oct-16,null,8-Nov-17,"Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande Do Sul, Brazil",,https://ClinicalTrials.gov/show/NCT02939768
NCT02940418,Use of Stem Cells in Diabetes Mellitus Type 1,,Recruiting,No Results Available,Diabetes Mellitus Type 1,Biological: Adipose mesenchymal cells with bone marrow mononuclear cells,Safety of using allogenic ASC assessed by any adverse events,Sophia Al-Adwan|University of Jordan,All,18 Years to 35 Years   (Adult),Phase 1,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,T1DM.UJCTC,19-Feb-17,Aug-19,Nov-19,20-Oct-16,null,6-Jun-18,"Cell Therapy Center, Amman, Jordan",,https://ClinicalTrials.gov/show/NCT02940418
NCT02938572,"A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus",,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: NNC0143-0406|Drug: Insulin Aspart,The ratio of suppression of endogenous glucose production relative to total glucose lowering effect|Number of treatment emergent adverse events,Novo Nordisk A/S,All,18 Years to 55 Years   (Adult),Phase 1,47,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1406-4218|2014-005340-18|U1111-1164-6715,19-Oct-16,17-Jun-17,4-Jul-17,19-Oct-16,null,26-Feb-18,"Novo Nordisk Investigational Site, Graz, Austria",,https://ClinicalTrials.gov/show/NCT02938572
NCT02936843,Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy,TINSAL-T1DN,Recruiting,No Results Available,Type 1 Diabetes|Peripheral Neuropathy,Drug: Salsalate|Drug: PLACEBO,Change in Intra-epidermal nerve fiber density (IENFD),University of Michigan,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,70,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HUM00103828,Oct-16,Dec-21,Jun-23,18-Oct-16,null,25-Jan-19,"University of Michigan Health System, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02936843
NCT02932826,Safety Study and Therapeutic Effects of Umbilical Cord Blood Treg on Autoimmune Diabetes,,Recruiting,No Results Available,"Diabetes Mellitus, Type 1",Biological: Umbilical Cord Blood Regulatory T cells Therapy|Drug: Insulin,Number of Participants with Adverse events as a Measure of Safety and Tolerability|C-peptide|Insulin requirement|Blood glucose|HbA1c|Autoimmune Status,Second Xiangya Hospital of Central South University,All,"6 Years to 60 Years   (Child, Adult)",Phase 1|Phase 2,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015CX009,Oct-16,Nov-18,Nov-20,13-Oct-16,null,17-Oct-17,"Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China",,https://ClinicalTrials.gov/show/NCT02932826
NCT02928250,Role of Carnosine as an Adjuvant Therapy for Diabetic Nephropathy in Pediatrics With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes|Oxidative Stress|Carnosine|Diabetic Nephropathy,Dietary Supplement: Carnosine|Dietary Supplement: Placebo,"effect on on urinary albumin excretion (UAE)|effect on alpha 1 microglobulin(A1M))|total antioxidant capacity (TAC), malondialdhyde (MDA).",Ain Shams University,All,"5 Years to 18 Years   (Child, Adult)",Not Applicable,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,Ain Shams University 1361,Aug-15,May-16,null,10-Oct-16,null,10-Oct-16,,,https://ClinicalTrials.gov/show/NCT02928250
NCT02928016,Effectiveness of Carbohydrate Counting Method With Mixed Meals,,Completed,No Results Available,Type 1 Diabetes,Other: Mixed meal 1|Other: Mixed meal 2|Other: Mixed meal 3|Other: Mixed meal 4|Other: Mixed meal 5|Other: Mixed meal 6,Capillary blood glucose,Agricultural University of Athens|Harokopio University,All,18 Years to 55 Years   (Adult),Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,HRBD 11th Session 6/4/2014 NHA,Sep-14,Apr-15,Jun-16,7-Oct-16,null,11-Oct-16,,,https://ClinicalTrials.gov/show/NCT02928016
NCT02925676,Evaluation of the Hypoglycaemia Alarm Device Hyposafe H02,,Recruiting,No Results Available,"Diabetes Mellitus, Type 1",Device: hyposafe H02,sensitivity|Positive predictive value|Number of adverse events|overall sensitivity|overall positive predictive value|sensitivity during insulin-induced hypoglycaemia|positive predictive value for insulin-induced hypoglycaemia|Change in EEG quality (power in alpha frequency band) over time|Change in impedance (kOhm) over time|Device complaints|Mean glucose level at the time of a hypoglycaemia alarm|Number of adverse device effects|Feasibility of using hyposafe H02 on a daily basis based on diary|Development in discomfort over time based on questionnaires|Link strength between the implant and the external device (Volt)|User satisfaction based on questionnaire|Mean number of hours of use per hyposafe H02 device|Percentage of correct key press in response to hypoglycaemia alarm|Alarm fatigue based on interview|User experience in an everyday context based on interview,UNEEG Medical A/S,All,"18 Years to 70 Years   (Adult, Older Adult)",Early Phase 1,20,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,Pilot 2 Diabetes,Sep-16,Dec-18,Dec-18,6-Oct-16,null,18-Oct-17,"Odense University Hospital, Odense, Denmark",,https://ClinicalTrials.gov/show/NCT02925676
NCT02925299,Day and Night Closed-loop in Young People With Type 1 Diabetes,DAN05,Recruiting,No Results Available,"Diabetes Mellitus|Diabetes Mellitus, Type 1|Glucose Metabolism Disorders|Endocrine System Diseases|Autoimmune Diseases",Device: FlorenceM|Device: Insulin pump therapy,"The primary outcome is the centralised measurement of glycated haemoglobin (HbA1c) at 6 months.|Time spent in the target glucose range (3.9 to 10mmol/l) (70 to 180mg/dl)|Time spent below target glucose (3.9mmol/l)(70mg/dl)|Time spent above target glucose (10.0 mmol/l) (180 mg/dl)|Mean and standard deviation or percentiles sensor glucose|Coefficient of variation of glucose levels|Time with glucose levels < 3.5 mmol/l (63 mg/dl)|Time with glucose levels <3.0 mmol/l (54 mg/dl)|Time with glucose levels in significant hyperglycaemia (glucose levels > 16.7 mmol/l) (300mg/dl)|Changes in total basal and bolus insulin dose|AUC of glucose below 3.5mmol/l (63mg/dl)|AUC glucose above 10.0mmol/L (180mg/dL)|HbA1c <7.0%, HbA1c <7.5%, Relative reduction ≥10% from baseline. o Absolute reduction ≥0.5% from baseline o Absolute reduction ≥1% from baseline o Absolute reduction ≥1% from baseline or HbA1c <7.0%",Jaeb Center for Health Research|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Cambridge University Hospitals NHS Foundation Trust|University of Colorado Denver School of Medicine Barbara Davis Center|Indiana University|The Leeds Teaching Hospitals NHS Trust|Stanford University|Yale University,All,"6 Years to 18 Years   (Child, Adult)",Not Applicable,130,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAN05|1UC4DK108520-01,12-May-17,Oct-19,Oct-19,5-Oct-16,null,3-Jan-19,"Stanford University, Palo Alto, California, United States|University of Colorado Denver School of Medicine Barbara Davis Center, Aurora, Colorado, United States|Yale University, Hartford, Connecticut, United States|Indiana University, Indianapolis, Indiana, United States|University of Cambridge, Cambridge, Cambridgeshire County, United Kingdom|Nottingham Children's Hospital, Nottingham, England, United Kingdom|Southampton Children's Hospital, Southampton, England, United Kingdom|The Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT02925299
NCT02923323,"Cross-sectional, Case Control Study of Neurocognitive Performance During Hyperglycemia , and Brain Tissue Integrity in Youth With Type 1 Diabetes and in Healthy",T1DM,Unknown status,No Results Available,"Diabetes Mellitus, Type 1","Device: MRI including DTI , EEG, CGMS|Behavioral: Neurocognitive tests",Association between interstitial glucose concentration and EEG power|Association between interstitial glucose concentration and neurocognitive functions,"Assaf-Harofeh Medical Center|Bar-Ilan University, Israel|Hadassah Medical Organization",All,"12 Years to 18 Years   (Child, Adult)",Not Applicable,90,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,97/14,Mar-16,Oct-16,Oct-17,4-Oct-16,null,4-Oct-16,"Assaf Haroffeh Medical center, Zerifin, Israel",,https://ClinicalTrials.gov/show/NCT02923323
NCT02916251,ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon,,Completed,No Results Available,Diabetes Mellitus Type 1,Drug: ZP4207(dasiglucagon) glucagon analogue|Drug: Glucagon (Native glucagon),"PK endpoint for ZP4207(dasiglucagon) and baseline adjusted glucagon: AUC 0-240 min|PK endpoint for ZP4207(dasiglucagon) and baseline adjusted glucagon: Cmax|PK endpoint for ZP4207(dasiglucagon) and baseline adjusted glucagon: tmax|PD endpoint: Plasma glucose profiles above baseline: AUE 0-240 min|PD endpoint: Plasma glucose profiles above baseline: CEmax|PD endpoint: Plasma glucose profiles above baseline: tmax|PK endpoints for ZP4207(dasiglucagon) and baseline adjusted glucagon: MRT|PK endpoints for ZP4207(dasiglucagon) and baseline adjusted glucagon: Vz/f,|PK endpoints for ZP4207(dasiglucagon) and baseline adjusted glucagon: λz|PK endpoints for ZP4207(dasiglucagon) and baseline adjusted glucagon: t½,|PK endpoints for ZP4207(dasiglucagon) and baseline adjusted glucagon: CL/f|PK endpoints for ZP4207(dasiglucagon) and baseline adjusted glucagon: AUC 0-30min|PK endpoints for ZP4207(dasiglucagon) and baseline adjusted glucagon: AUC 0-inf|Insulin concentrations before and after dosing with ZP4207(dasiglucagon) or glucagon:|PD endpoints for ZP4207(dasiglucagon) and baseline adjusted glucagon: AUE 0-30min|PD endpoints for ZP4207(dasiglucagon) and baseline adjusted glucagon: CE 30min|PD endpoints for ZP4207(dasiglucagon) and baseline adjusted glucagon: t50%CE, early|PD endpoints for ZP4207(dasiglucagon) and baseline adjusted glucagon: t10%CE, late|PD endpoints: Percentage of patients achieving a plasma glucose increase of ≥20 mg/dL within 30 minutes after treatment|PD endpoints: Time to plasma glucose increase of ≥20 mg/dL|PD endpoints: Percentage of patients achieving a plasma glucose concentration ≥70 mg/dL within 30 minutes after treatment (insulin-induced hypoglycemia)|PD endpoints: Time to plasma glucose concentration of ≥70 mg/dL (insulin-induced hypoglycemia)|Safety endpoints: Number of participants with adverse events|Safety endpoints: Local tolerability of injection site|Safety endpoints: Laboratory safety parameters|Safety endpoints: Physical examination|Safety endpoints: Vital signs|Safety endpoints: ECGs|Safety endpoints: Antidrug antibodies incidences",Zealand Pharma,All,18 Years to 64 Years   (Adult),Phase 2,38,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ZP4207-16098,1-Dec-16,5-Apr-17,5-Apr-17,27-Sep-16,null,21-Apr-17,"Profil Institut für Stoffwechselforschung GmbH, Neuss, North Rhine-Westphalia, Germany",,https://ClinicalTrials.gov/show/NCT02916251
NCT02916680,Pancreatic Islet Transplantation in the Anterior Chamber of the Human Eye - a Pilot Study,,Recruiting,No Results Available,Type 1 Diabetes Mellitus,Procedure: Pancreatic islet transplantation in the anterior chamber,Absence of ophthalmic complications|Change in insulin production|Change in insulin requirements|Change in HbA1c|Change in fasting glucose|Change in total number of hypoglycemic events,"University Hospital, Basel, Switzerland",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,4,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Eye ITPL,Mar-16,Apr-20,Apr-20,27-Sep-16,null,9-May-19,"University Hospital Basel, Basel, Switzerland",,https://ClinicalTrials.gov/show/NCT02916680
NCT02914496,ACT Stress Management in Type 1 Diabetes,,Enrolling by invitation,No Results Available,Type 1 Diabetes,Behavioral: Acceptance and Commitment Therapy (ACT),"HbA1c|Manchester Short Assessment of Quality of life|Depression Anxiety stress scales|The Hypoglycemia Fear Survey emotions, depression, anxiety, fear of hypoglycemia, general and diabetes related distress.|The Problem Areas in Diabetes (Swe-PAID-20) Scale|Acceptance and action diabetes questionnaire|The Summary of Self-Care Activities",Karolinska Institutet,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,EPN Stockhom 2016/14-31/1,Oct-16,Sep-18,Oct-21,26-Sep-16,null,21-Aug-18,"Ersta sjukhus, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT02914496
NCT02914886,Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS),LAS,Enrolling by invitation,No Results Available,Type 1 Diabetes|Lipoatrophy,Drug: Apidra|Drug: current insulin,Relative thickness as assessed by MRI|Relative thickness as assessed by USG|indicator dermatoses of Diabetes mellitus and associated autoimmune disorders of the skin|Number of new lipoatrophic areas|Glycemic control|Insulin requirements|Laboratory findings|Side effects,Kinderkrankenhaus auf der Bult|Sanofi,All,"6 Years to 40 Years   (Child, Adult)",Phase 4,24,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IIT-14652,Sep-16,Aug-19,Oct-19,26-Sep-16,null,8-Aug-18,,,https://ClinicalTrials.gov/show/NCT02914886
NCT02912455,CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes,,Terminated,No Results Available,"Diabetes Mellitus, Type 2|Obesity",Drug: canagliflozin|Drug: Placebo (for canagliflozin),The change in Hemoglobin A1c from randomization following the 6 month administration of canagliflozin vs. placebo in patients with type 2 diabetes post-bariatric surgery|Percent of subjects with normal Hemoglobin A1c (≤6.5%) after 6 month administration of canagliflozin vs. placebo in patients with type 2 diabetes post-bariatric surgery|The change in fasting glucose from randomization following the 6 month administration of canagliflozin vs. placebo in patients with type 2 diabetes post-bariatric surgery.|The change in body weight from randomization following the 6 month administration of canagliflozin vs. placebo in patients with type 2 diabetes post-bariatric surgery.|The change in total cholesterol from randomization following the 6 month administration of canagliflozin vs. placebo in patients with type 2 diabetes post-bariatric surgery.|The change in diastolic and systolic blood pressure from randomization following the 6 month administration of canagliflozin vs. placebo in patients with type 2 diabetes post-bariatric surgery|The change in adiponectin levels from randomization following the 6 month administration of canagliflozin vs. placebo in patients with type 2 diabetes post-bariatric surgery.|The change in leptin levels from randomization following the 6 month administration of canagliflozin vs. placebo in patients with type 2 diabetes post-bariatric surgery.|The change in C-reactive protein levels from randomization following the 6 month administration of canagliflozin vs. placebo in patients with type 2 diabetes post-bariatric surgery.|The number of symptomatic hypoglycemia episodes from randomization following the 6 month administration of canagliflozin vs. placebo in patients with type 2 diabetes post-bariatric surgery.|The change in DXA scan results from randomization following the 6 month administration of canagliflozin vs. placebo in patients with type 2 diabetes post-bariatric surgery.,"The Cleveland Clinic|Janssen Scientific Affairs, LLC",All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 4,16,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",16-574,5-Jan-17,19-Jul-18,19-Jul-18,23-Sep-16,null,5-Mar-19,"Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02912455
NCT02912728,Strategies to Enhance New CGM Use in Early Childhood (SENCE),SENCE,"Active, not recruiting",No Results Available,Type 1 Diabetes Mellitus,Behavioral: CGM + Family Behavioral Intervention|Device: Standard CGM,Time in glucose range 70-180|HbA1c at 6-months|% HbA1c <7.0%|% HbA1c <7.5%|% with relative reduction in HbA1c >=10%|% with absolute reduction in HbA1c >=0.5%|% with absolute reduction in HbA1c >=1%|% with absolute reduction in HbA1c >=1% or HbA1c <7.0%|Mean glucose|Glucose variability measured by coefficient of variation|% time >180 mg/dl|% time >250 mg/dl|% time >300 mg/dl|Area under the curve 180 mg/dl|High blood glucose index (HBGI)|% time <54 mg/dl|% time <60 mg/dl|% time <70 mg/dl|Area over the curve 70 mg/dl|Low blood glucose index (LBGI)|Hypoglycemic events (using <54 mg/dl)|WHO-5 Well Being Index|Hypoglycemia Fear Survey Total Score|Hypoglycemia Fear Survey Worry Subscale|Diabetes Technology Questionnaire|Problem Areas in Diabetes - Parent (PAID-PR)|Diabetes Family Impact Survey|Satisfaction Questionnaire,Jaeb Center for Health Research|The Leona M. and Harry B. Helmsley Charitable Trust|Indiana University School of Medicine,All,2 Years to 7 Years   (Child),Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,T1DX SENCE,30-Jan-17,Dec-18,Dec-19,23-Sep-16,null,6-Sep-18,"Indiana, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT02912728
NCT02910518,"A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus",,Completed,No Results Available,Type1 Diabetes Mellitus,Drug: Insulin glulisine (U300)|Drug: Insulin glulisine|Drug: Insulin aspart|Drug: NPH insulin|Drug: Glucagon|Drug: Glucose|Drug: Heparin,Assessment of PK parameter: maximum observed insulin concentration|Assessment of PK parameter: area under the concentration time curve|Assessment of PK parameter: time to reach Cmax (INS-tmax)|Assessment of PK parameter: terminal half-life (INS-t1/2z)|Assessment of PD parameter: area under the body weight standardized glucose infusion rate (GIR) versus time curve from 0 to 10 hours (GIR-AUC0-10)|Assessment of PD parameter: maximum smoothed body weight standardized GIR (GIRmax)|Assessment of PD parameter: time to GIRmax (GIR-tmax)|Duration of blood glucose control under clamp conditions - time|Number of patients with treatment emergent adverse events,Sanofi,All,18 Years to 64 Years   (Adult),Phase 1,44,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BEQ13941|2016-001498-34|U1111-1183-8636,17-Feb-17,3-May-17,3-May-17,22-Sep-16,null,12-Jun-17,"Investigational Site Number 276001, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT02910518
NCT02909829,Safety and Efficacy of Artificial Pancreas With and Without a Meal Detection Module on Glycemic Control in Adolescents With Type 1 Diabetes After a Missed Bolus,,Recruiting,No Results Available,"Diabetes Mellitus, Type 1",Device: Closed Loop Delivery|Device: Closed Loop Delivery with Meal Detection Module|Device: Conventional Pump Therapy,AUCinc: The incremental area under the curve (as compared to pre-meal glucose value) of the postprandial glucose excursions for the lunch meal.|AUCinc: The incremental area under the curve (as compared to pre-meal glucose value) of the postprandial glucose excursions: a. >10.0 mmol/L; b. >13.9 mmol/L; c. >16.7 mmol/L|Percentage of postprandial time of sensor glucose measurements spent: a. <3.9 mmol/L; b. between 3.9 and 7.8 mmol/L; c. between 3.9 and 10.0 mmol/L; d. >10.0 mmol/L; e. >13.9 mmol/L; f. >16.7 mmol/L.|Mean sensor glucose concentration.|Total insulin delivery|Glucose concentration as measured by CGM at 2 hours (120 min) post-meal.|Incremental glucose concentration as measured by CGM at 2 hours (120 min) post-meal.|Incremental postprandial peak of glucose concentration as measured by CGM.|Number of hyperglycemic events > 18.0mmol/L.|1. Glucose concentration as measured by CGM at 5 hours (300 min) post-meal. Glucose concentration as measured by CGM at 5 hours (300 min) post-meal,McGill University,All,"12 Years to 18 Years   (Child, Adult)",Not Applicable,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Missed Bolus 9h,31-Oct-17,Sep-19,Sep-19,21-Sep-16,null,8-Jan-19,"McGill University Health Centre, Montréal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02909829
NCT02906891,A Pilot Study of Nocturnal Hypoglycemia Prevention in Type 1 Diabetes Using the Vigilant Diabetes Management Companion,,Terminated,No Results Available,"Hypoglycemia|Diabetes Mellitus, Type 1",Device: Vigilant Diabetes Management Application,"Reduction in the aggregate rate of nocturnal biochemical severe hypoglycemia in the Vigilant period versus the Baseline period as measured by meter or logged blood glucose values (mg/dL).|Reduction in the aggregate rate of nocturnal hypoglycemia in the Vigilant period versus the Baseline period as measured by meter or logged blood glucose values (mg/dL).|An aggregate (total study population) reduction in the rate of mild hypoglycemia (biochemical and logged) as measured by home blood glucose values <70 mg/dL at 3 months, compared to the monthly rate of hypoglycemia in the Baseline period.|An aggregate reduction in the rate of biochemical severe hypoglycemia as measured by home blood glucose values <40 mg/dL, during months 1-3, compared to the monthly rate of biochemical severe hypoglycemia in the Baseline period.|An aggregate reduction in average HbA1will be measured at baseline using DCA 2000 or equivalent NGSP- certified point-of-care method or local laboratory at 3 months, compared to HbA1c levels obtained at study initiation.|An aggregate reduction in the survey self-reported rate of use of; 1) Glucagon 2) Emergency medical services for hypoglycemia, and 3) Hospital, urgent care or clinic visits for hypoglycemia or associated with hypoglycemia care visits.|An aggregate reduction in the mean glycemic variability, as measured by monthly ADRR (Average Daily Risk Range), calculated based on downloaded meter download data|An aggregate (total study population) reduction in the LBGI and HBGI, as measured by percent of readings in and out of range calculated based on downloaded blood glucose meter download data.|Reduction in reported fear of hypoglycemia as compared to baseline Fear of Hypoglycemia Fear Survey. The Hypoglycemia Fear Survey II (HSF II) will be used.|Improvement in self-reported lost work productivity as a result of hypoglycemia. Individuals will complete a questionnaire about lost work days as a result of hypoglycemia at baseline and at 3 months.|Improvement in self-reported psychosocial self-efficacy as compared to baseline measured using the Diabetes Empowerment Scale Short Form (DES-SF).","InSpark Technologies, Inc.|East Carolina University",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,13,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,VG2NOCHPUS1,May-16,Dec-16,Dec-16,20-Sep-16,null,3-Mar-17,"East Carolina University, Greenville, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02906891
NCT02907346,A Reinforcement Approach to Increase Use of CGM,,Recruiting,No Results Available,Type 1 Diabetes,Device: CGM,Change in the Proportion of days participants wear the CGM|Change in the number of weeks participants wear the CGM on at least 5 days|Change in A1c,Yale University,All,"13 Years to 26 Years   (Child, Adult)",Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1603017504,Sep-16,Jun-18,Dec-18,20-Sep-16,null,9-Jan-18,"Yale University School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02907346
NCT02908087,Incretin-based Therapy in Early Diagnosed Type 1 Diabetes,,Enrolling by invitation,No Results Available,Type 1 Diabetes,Drug: Victoza® (liraglutide)|Drug: Placebo,"Serum C-peptide AUC|Safety: Serum and urine amylase, serum lipase, serum calcitonin levels will be monitored|Number of hypoglycemia episodes|Frequency of gastrointestinal side effects|Insulin dose",University of Oulu|Oulu University Hospital|Tampere University Hospital|Turku University Hospital|Skane University Hospital,All,"10 Years to 30 Years   (Child, Adult)",Phase 2,10,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LiraT1D10-30|2014-004760-37|3-SRA-2014-301-M-R|U1111-1177-0661,Mar-16,Jul-18,Jul-18,20-Sep-16,null,26-Oct-17,"University of Oulu and Oulu University Hospital, Dept of Children and Adolescents, Oulu, Finland|University of Tampere and Tampere University Hospital, Tampere, Finland|University of Turku and Turku University Hospital, Turku, Finland|Lund University and Skåne University Hospital, Malmö, Sweden",,https://ClinicalTrials.gov/show/NCT02908087
NCT02903615,Optimising Health in Type 1 Diabetes,,Recruiting,No Results Available,Diabetes Mellitus,Other: Novel diet|Other: Standard diet,Glucose control|Inflammation|Gut microbiome|C-peptide|postprandial glucose excursion|Follow-up of glycemic control and insulin secretion,Garvan Institute of Medical Research,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16/053,Sep-16,Nov-19,Dec-19,16-Sep-16,null,23-Mar-18,"professor Katherine Samaras, Sydney, New South Wales, Australia|Garvan Institute to Medical Research, Sydney, Australia",,https://ClinicalTrials.gov/show/NCT02903615
NCT02897219,A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: ipragliflozin|Drug: Placebo|Other: Insulin Therapy,Change from baseline in HbA1c|Change from baseline in Fasting plasma glucose|Change from baseline in self-monitored blood glucose level|Change from baseline in leptin|Change from baseline in glycoalbumin|Change from baseline in adiponectin|Change from baseline in glucagon|Change from baseline in number of units of insulin administered concomitantly|Change from baseline in body weight|Change from baseline in waist circumference|Safety assessed by incidence of adverse events|Safety assessed by sitting blood pressure|Safety assessed by sitting pulse rate|Safety assessed by standard 12-lead electrocardiogram|Safety assessed by laboratory tests: Hematology|Safety assessed by laboratory tests: Biochemistry|Safety assessed by laboratory tests: Urinalysis,Astellas Pharma Inc,All,"20 Years and older   (Adult, Older Adult)",Phase 3,175,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1941-CL-6002,29-Aug-16,22-Jul-17,15-Mar-18,13-Sep-16,null,6-Mar-19,"Site JP00005, Aichi, Japan|Site JP00028, Aichi, Japan|Site JP00003, Chiba, Japan|Site JP00013, Chiba, Japan|Site JP00035, Chiba, Japan|Site JP00022, Fukuoka, Japan|Site JP00023, Fukuoka, Japan|Site JP00031, Fukuoka, Japan|Site JP00002, Gunma, Japan|Site JP00011, Gunma, Japan|Site JP00006, Hiroshima, Japan|Site JP00033, Hokkaido, Japan|Site JP00034, Hokkaido, Japan|Site JP00021, Hyogo, Japan|Site JP00009, Ibaraki, Japan|Site JP00010, Ibaraki, Japan|Site JP00004, Kanagawa, Japan|Site JP00015, Kanagawa, Japan|Site JP00016, Kanagawa, Japan|Site JP00019, Mie, Japan|Site JP00008, Nagasaki, Japan|Site JP00024, Nagasaki, Japan|Site JP00025, Nagasaki, Japan|Site JP00032, Nagasaki, Japan|Site JP00026, Niigata, Japan|Site JP00020, Osaka, Japan|Site JP00029, Osaka, Japan|Site JP00036, Osaka, Japan|Site JP00012, Saitama, Japan|Site JP00017, Shizuoka, Japan|Site JP00018, Shizuoka, Japan|Site JP00001, Tochigi, Japan|Site JP00030, Tokushima, Japan|Site JP00014, Tokyo, Japan|Site JP00027, Toyama, Japan|Site JP00007, Yamaguchi, Japan",,https://ClinicalTrials.gov/show/NCT02897219
NCT02897557,Insulet Artificial Pancreas Early Feasibility Study,,Completed,No Results Available,Type 1 Diabetes,Device: Insulet Artificial Pancreas (AP) System,Percentage of time in hypoglycemic range (defined as <70 mg/dL)|Percentage of time in severe hyperglycemic range (defined as >/=250 mg/dL)|Mean glucose|Percentage of time < 50 mg/dL|Percentage of time < 60 mg/dL|Percentage of time > 180 mg/dL|Percentage of time >/= 300 mg/dL|Percentage of time in the broad euglycemic range (defined as 70-180) mg/dL)|Percentage of time in the tight euglycemic range (defined as 70-140) mg/dL)|Standard deviation and coefficient of variation of CGM values,Insulet Corporation,All,"6 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,59,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AP-IDE #1 and 1a,Sep-16,Feb-17,Mar-17,13-Sep-16,null,26-Apr-17,"Stanford University, Palo Alto, California, United States|William Sansum Diabetes Center, Santa Barbara, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|University of Colorado Denver, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT02897557
NCT02898506,Incretin-based Therapy in Late Preclinical Type 1 Diabetes,,Enrolling by invitation,No Results Available,Type 1 Diabetes,Drug: Victoza®|Drug: Placebo,"FPIR|Safety: serum and urine amylase, serum lipase, serum calcitonin, hypoglycemia|Tolerability|Serum C-peptide AUC",University of Oulu|Oulu University Hospital|Tampere University Hospital|Turku University Hospital|Skane University Hospital,All,"10 Years to 30 Years   (Child, Adult)",Phase 2,82,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",LiraAABDG10-30|2014-004761-25|U1111-1177-0704|3-SRA-2014-301-M-R,Mar-16,Jul-19,Jul-19,13-Sep-16,null,26-Oct-17,"University of Oulu and Oulu University Hospital, Dept of Children and Adolescents, Oulu, Finland|University of Tampere and Tampere University Hospital, Tampere, Finland|University of Turku and Turku University Hospital, Turku, Finland|Lund University and Skåne University Hospital, Malmö, Sweden",,https://ClinicalTrials.gov/show/NCT02898506
NCT02892604,Study the Feasibility of Permanent Use of inControl for the Treatment of Type 1 Diabetes,IDCLTraining,Unknown status,No Results Available,Type 1 Diabetes,Device: insulin pump to inControl AP platform,Percent time of active insulin closed-loop delivery|Percent time with blood glucose in target range,"University Hospital, Montpellier|MEDBIOMED, Montpellier, France|Jaeb Center for Health Research|University of Virginia",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,5,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9722,Nov-16,Jun-17,Jul-17,8-Sep-16,null,29-Nov-16,"UHMontpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT02892604
NCT02893306,MSC Administration for the Management of Type 1 Diabetic Patients,DMT1-MSC,Unknown status,No Results Available,Type 1 Diabetes Mellitus,Biological: MSCs,Changes in insulin pancreatic reserve|Changes in insulin requirement,Universidad del Desarrollo|Clinica Alemana de Santiago,All,"18 Years and older   (Adult, Older Adult)",Phase 2,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DMT1-MSC,Mar-12,Mar-17,Mar-17,8-Sep-16,null,8-Sep-16,"Clinica Alemana de Santiago, Santiago, Region Metropolitana, Chile",,https://ClinicalTrials.gov/show/NCT02893306
NCT02888691,Low Carbohydrate Diet vs. High Carbohydrate Diet in Type 1 Diabetes,HiLo12,Completed,No Results Available,Type 1 Diabetes,Other: Low carbohydrate diet|Other: High carbohydrate diet,Time in euglycemia|Mean glucose|Standard deviation of glucose|Coefficient of variation of glucose|Mean amplitude of glycemic excursions|Time in hypoglycemia|Time in hyperglycemia|Change in A1c|AUC low|AUC high|Post breakfast glucose excursion|Severe hypoglycemia|Total daily dose|Total daily basal insulin 24 hour|Total nightime basal insulin|Total daytime basal insulin|Total daily bolus insulin|Blood glucose readings|Carbohydrate servings|Body composition|Weight|Hip circumference|Waist circumference|Systolic blood pressure|Diastolic blood pressure|Heart rate|Diabetes treatment satisfaction|Hypoglycemia fear|Cholesterol|HDL|LDL|Triglycerides|Free fatty acids|Sodium|Potassium|Creatinine|Urate|Albumin|Hemoglobin|Leucocytes|Thrombocytes|Iron|Transferrin|Ferritin|Folate|Vitamin B-12|Magnesium|Zinc|U-alb-crea ratio|Supar|CRP|IL-1|IL-6|IL-8|TNF-alpha,Hvidovre University Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,14,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HiLo12,Aug-16,Nov-17,Nov-17,5-Sep-16,null,23-Feb-18,"Hvidovre University Hospital, Hvidovre, Denmark",,https://ClinicalTrials.gov/show/NCT02888691
NCT02882737,"The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus",,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Glucagon before exercise|Drug: Glucagon after exercise|Drug: Glucagon after resting,"The primary endpoint is peak plasma glucose achieved within 2 hours after the 200 μg subcutaneous glucagon injection. In the primary analysis, the investigators will compare the peak plasma glucose after exercise and after resting.|The time-to-peak value after glucagon injection.|Duration of the glucagon effect; equal to the time point from glucagon injection to when plasma glucose is below baseline.|The glycaemic effect, calculated as the total area under the curve (tAUC) after each glucagon injection.|Changes in plasma ketone bodies after each glucagon injection.|Changes in plasma lactic acid after each glucagon injection|Changes in plasma glucagon after each glucagon injection|Changes in serum free fatty acid (FFA) after each glucagon injection|Changes in serum triglycerides after each glucagon injection|Number of events of hypoglycemia (plasma glucose ≤3.9 mmol/l) in the three study days.|Number of re-events of hypoglycemia (plasma glucose ≤3.9 mmol/l) 30 minutes after first event in the three study groups.|Number of rebound hyperglycemia (plasma glucose ≥10.0 mmol/l).|Mean absolute difference (MARD) in the two CGM sites during the four days after the study day using the daily 8 prespecified plasma glucose measurements by Bayer Contour Link as the reference value.|Mean absolute relative difference (MARD) during the study visits between the two sensor sites with the YSI 2300 STAT PLUS as the reference value.|MARD during the hypoglycemia range (≤3.9 mmol/l) of the study visits between the two sensor sites (CGMarm vs. CGMabdomen) with the YSI 2300 STAT PLUS as the reference value.|MARD during the euglycemia range (>3.9 mmol/l and < 10.0 mmol/l) of the study visits between the two sensor sites (CGMarm vs. CGMabdomen) with the YSI 2300 STAT PLUS as the reference.|MARD during the hyperglycemia range (≥10.0 mmol/l) of the study visits for the two Dexcom G4 sensor sites (CGMarm vs. CGMabdomen) with the YSI 2300 STAT PLUS as the reference value|MARD for the two sensor sites (CGMarm and CGMabdomen) from day 1- 7 with the Bayer Contour Link as the reference value.|The rate-of change (ROC) of the two sensors.|The rate-of change (ROC) of plasma glucose measured by the YSI 2300 STAT PLUS.|The Precision Absolute Relative Difference (=CGM readings of one system will be subtracted from CGM readings of the other system, and this difference will be divided by the average of the CGM readings of the abdominal sensors.)|The sensors' sensitivity and specificity to detect a hypoglycemic event.|The point accuracy of both sensors with the Clarke error grid analysis|The pressure induced sensor attenuation (PISA) by using a recent fault detection algorithm that can detect non-physiologic anomalous low sensor readings.|The fused data from the two sensors.",Hvidovre University Hospital|Technical University of Denmark,All,18 Years to 64 Years   (Adult),Not Applicable,14,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,16016762,Sep-16,11-Jul-17,11-Jul-17,30-Aug-16,null,24-Jul-17,"Isabelle Steineck, Hvidovre, Denmark",,https://ClinicalTrials.gov/show/NCT02882737
NCT02883829,Effects of Web-Based Health Information on Risk Behavior for Youth With Type 1 Diabetes in College,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Behavioral: Peer-Based Web-Based Health Information|Behavioral: Provider-Based Web-Based Health Information,"Changes in attitudes, beliefs, and intentions about alcohol",Boston Children’s Hospital,All,"17 Years to 25 Years   (Child, Adult)",Not Applicable,138,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,IRB-P00023029,4-Apr-17,10-May-17,10-May-17,30-Aug-16,null,17-Nov-17,"Boston Children's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02883829
NCT02881528,Autoimmune Diabetes Accelerator Prevention Trial,adAPT,Withdrawn,No Results Available,Prediabetic State,Drug: Metformin Hydrochloride|Drug: Placebo,"Between group difference in reduction of Homeostatic Model Assessment (HOMAR) of Insulin Resistance (IR, mass units).|Between group difference in reduction in beta cell demand as measured by serum glucose (mmol/L) and C-peptide (ng/mL)|Feasibility of a randomized controlled trial in children who are at high risk of T1D as measured by recruitment rates (%)|Feasibility of a randomized controlled trial in children who are at high risk of T1D as measured by attrition rates (%)",University of Exeter|University of Dundee|University of Bristol,All,5 Years to 16 Years   (Child),Phase 4,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",15/135763|2015-000748-41|15/ES/0075,30-Mar-16,30-Jun-17,22-Dec-17,29-Aug-16,null,16-Oct-18,"NHS Ayrshire & Arran, Kilmarnock, Ayrshire, United Kingdom|NHS Grampian, Aberdeen, Grampian, United Kingdom|NHS Lanarkshire, Wishaw, Lanarkshire, United Kingdom|NHS Tayside, Dundee, Tayside, United Kingdom|NHS Greater Glasgow & Clyde, Glasgow, United Kingdom",,https://ClinicalTrials.gov/show/NCT02881528
NCT02882477,Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy,,Unknown status,No Results Available,Diabetes Mellitus|Iron Metabolism Disorders|Gastroduodenal Ulcer|Optic Atrophy|Sensorineural Hearing Loss|Platelet Dysfunction,Drug: Deferiprone|Drug: Acetylcysteine|Drug: Sitagliptin and Metformin,Insulin levels in blood in response to Glucose Challenge - Oral Glucose tolerance test (OGTT ) and Intra venous glucose tolerance test (IVGTT)|Platelet aggregation to Adenosine diphosphate (ADP) and Collagen - blood test for Platelet function test|Nerve conduction velocity in VEP|HBA1C level|daily glucose level measurement in the blood using Glucometer two to 5 times daily|C-Peptide levels in blood in response to Glucose Challenge - Oral Glucose tolerance test ( OGTT ) and Intra venous glucose tolerance test IVGTT,Hadassah Medical Organization,All,"3 Years and older   (Child, Adult, Older Adult)",Phase 2|Phase 3,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0003-16-HMO,Dec-16,May-18,Dec-18,29-Aug-16,null,29-Aug-16,"Hadassah medical center, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT02882477
NCT02881060,The Late Effects of Ethanol Intake on the Glucose Response to Subcutaneous Glucagon in Type 1 Diabetes,ALCO1,Completed,No Results Available,"Hypoglycemia|Diabetes Mellitus, Type 1",Dietary Supplement: Alcohol|Dietary Supplement: Placebo,"Increase in plasma glucose|Peak plasma glucose|Total AUC(0-120)|PI-AUC(0-120)|Tmax|Time above 4.0mM|Time above baseline|Rescue rates|Hyperglycemia rates|Changes in plasma ketone bodies, measured as area under the curve|Changes in plasma ketone bodies, measured as incremental peak|Changes in plasma glucagon, measured as area under the curve|Changes in plasma glucagon, measured as incremental peak|Changes in insulin, measured as area under the curve|Changes in insulin, measured as incremental peak|Changes in growth hormones, measured as area under the curve|Changes in growth hormones, measured as incremental peak|Changes in serum corticole, measured as area under the curve|Changes in serum corticole, measured as incremental peak|Changes in plasma ethanol, measured as area under the curve|Changes in plasma ethanol, measured as incremental peak|Changes in free fatty acids, measured as area under the curve|Changes in free fatty acids, measured as incremental peak|Changes in triglycerides, measured as area under the curve|Changes in triglycerides, measured as incremental peak|Average in blood pressure|Average heart rate|Intensity of hypoglycemia|Cognitive impairment|Side effects|Incidence of vomiting|Meal induced glucose excursion|Meal induced hormonal changes|Nocturnal changes in plasma glucose|Nocturnal changes in corticol|Nocturnal changes in growth hormone|Nocturnal changes in ketones|Nocturnal changes in ethanol|Nocturnal changes in glucagon|Difference between the first second glucagon injection and between both study visits in peak change plasma glucose|Difference between glucagon injections on both study visits in positive incremental area under the glucose curve from 0-120 minutes|Difference between glucagon injections on both study visits in total area under the glucose curve from 0-120 minutes|Difference between glucagon injections on both study visits in time-to-peak glucose value|Difference between glucagon injections on both study visits in duration of glucose above 4.0 mmol/l after first and second glucagon injection|Difference between glucagon injections on both study visits in duration of glucose above baseline after first and second glucagon injection|Difference in glucose sensor data on study night with alcohol vs. study night without alcohol - Mean absolute relative difference (MARD) values of glucose sensors compared with YSI from 7 PM- 8 AM.|Difference in glucose sensor data on study night with alcohol vs. study night without alcohol - Precision absolute relative difference (PARD) 120 min before and 120 after each glucagon injection.|Difference in glucose sensor data on study night with alcohol vs. study night without alcohol - MARD values between glucose sensors 0-120 minutes after each glucagon injection.|Difference in glucose sensor data within 2 days after study night with alcohol vs. study night without alcohol - Time in range (glucose sensor value =4.0-10.0mmol/l)|Difference in glucose sensor data within 2 days after study night with alcohol vs. study night without alcohol - Time in hypoglycaemia (glucose sensor value < 4.0 mmol/l)|Difference in glucose sensor data within 2 days after study night with alcohol vs. study night without alcohol - Time in hyperglycaemia (glucose sensor value >10.0mmol/l)|Difference in glucose sensor data within 2 days after study night with alcohol vs. study night without alcohol - Number of hypoglycaemia episodes (glucose sensor value < 4.0 mmol/l)|Difference in glucose sensor data between the study period with and without alcohol - Clarke- Error Grid analysis for both sensors compared with YSI during study visit|Difference in glucose sensor data between the study period with and without alcohol - PARD values from day 1-7|Difference in glucose sensor data between the study period with and without alcohol - PARD values <4.0 mmol/L from day 1-7|Difference in glucose sensor data between the study period with and without alcohol - PARD values 4.0-10.0 mmol/L from day 1-7|Difference in glucose sensor data between the study period with and without alcohol PARD values >10.0 mmol/L from day 1-7|Difference in glucose sensor data between the study period with and without alcohol - Number of hypoglycaemia episodes (glucose sensor value < 4.0 mmol/l)",Hvidovre University Hospital|Danish Diabetes Academy|University of Copenhagen,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",H-16027080,Aug-16,26-Jan-17,26-Jan-17,26-Aug-16,null,24-Jul-17,"Hvidovre University Hospital, Hvidovre, Denmark",,https://ClinicalTrials.gov/show/NCT02881060
NCT02879409,HbA1c Variability in Type II Diabetes,,Recruiting,No Results Available,Diabetes Mellitus Type 2,Drug: Metformin|Drug: Gliclazide|Drug: Sitagliptin|Drug: Liraglutide|Drug: Pioglitazone|Drug: Dapagliflozin|Drug: human insulin,"Determination of the variability of HbA1c (by measurement of standard deviation of HbA1c) between the 2 diabetes treatment thresholds|Association of the variability of HbA1c (by measurement of standard deviation of HbA1c) to microvascular changes in heart rate variability, corneal nerve fiber density, albumin/creatinine ratio and estimated glomerular filtration rate.|Association of the variability of HbA1c (by measurement of standard deviation of HbA1c) to oxidative stress markers measured by urinary isoprostanes and inflammation measured by highly sensitive C-reactive protein.|Comparison of HbA1c (percent) for each subject at baseline and following sample storage of 2 years to assess HbA1c measurement stability.",Weill Cornell Medical College in Qatar|Hamad Medical Corporation|Sidra Medical and Research Center|University of Hull,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,150,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,14-00058|NPRP: 8-315-3-065|15103/15,Nov-16,Apr-19,Aug-19,25-Aug-16,null,2-Jun-17,"Hamad Medical Corporation, Doha, Qatar",,https://ClinicalTrials.gov/show/NCT02879409
NCT02877680,Strengths-Based Behavioral mHealth App for Parents of Adolescents With Type 1 Diabetes-Pilot Study,T1DoingWell,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 1",Behavioral: T1Doing Well,Feasibility of Study Design|Acceptability (survey)|Acceptability (interview)|Glycemic control|Adherence (objective)|Adherence (self-report)|Diabetes strengths|Diabetes-related family conflict|Diabetes burden/distress|Health-related quality of life,"Baylor College of Medicine|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Feinberg School of Medicine, Northwestern University|United States Department of Agriculture (USDA)",All,12 Years to 17 Years   (Child),Not Applicable,82,Other|NIH|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-37311|1R21DK107951,31-Jul-17,Jun-19,Jun-19,24-Aug-16,null,16-Jan-19,"Texas Children's Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02877680
NCT02877771,Tandem Predictive Low Glucose Suspend Inpatient Feasibility Study,,Completed,No Results Available,Diabetes Mellitus|Type 1 Diabetes|Insulin Pump,Device: t:slim insulin pump with predictive low glucose suspend,Suspension of Insulin Delivery|Restoration of insulin delivery|Agreement between algorithm-recommended pump action,"Tandem Diabetes Care, Inc.|Jaeb Center for Health Research",All,"18 Years and older   (Adult, Older Adult)",Phase 1,10,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),10300,Aug-16,Aug-16,Aug-16,24-Aug-16,null,1-Sep-16,"Stanford University, Palo Alto, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT02877771
NCT02871089,Closed Loop From Onset in Type 1 Diabetes,CLOuD,Recruiting,No Results Available,Diabetes Mellitus|Type 1 Diabetes,Device: FlorenceM|Other: Multiple Daily Injections,Area under the meal stimulated C-peptide curve (AUC) during a mixed meal tolerance test (MMTT)|Mean stimulated C-peptide AUC during a mixed meal tolerance test|HbA1c Levels|Percentage of patients in each group with HbA1c <7.5% (58mmol/mol)|Percentage of time spent with sensor glucose readings in the target range (3.9 to 10mmol/l)|Mean sensor glucose level|Standard deviation of sensor glucose levels|Coefficient of variation of sensor levels|Percentage of time with sensor glucose levels <3.5 mmol/l and <2.8 mmol/l|Percentage of time spent below target glucose (3.9mmol/l)|AUC of sensor glucose below 3.5mmol/l|Time spent with sensor glucose above target (10.0 mmol/l)|Time with sensor glucose levels in significant hyperglycaemia (glucose levels > 16.7 mmol/l)|Insulin Requirements|Weight|Blood pressure|Lipid profile,University of Cambridge|Cambridge University Hospitals NHS Foundation Trust|Alder Hey Children's NHS Foundation Trust|Nottingham University Hospitals NHS Trust|Oxford University Hospitals NHS Trust|University Hospital Southampton NHS Foundation Trust|Jaeb Center for Health Research|The Leeds Teaching Hospitals NHS Trust|University of Edinburgh,All,10 Years to 16 Years   (Child),Phase 2,96,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,CLOuD,Jan-17,Oct-20,Oct-21,18-Aug-16,null,5-Jun-18,"Southampton Children's Hospital, Southampton, Hampshire, United Kingdom|Nottingham Children's Hospital, Nottingham, Nottinghamshire, United Kingdom|John Radcliffe Hospital, Oxford, Oxfordshire, United Kingdom|Alder Hey Children's NHS Foundation Trust, Liverpool, West Derby, United Kingdom|St James's University Hospital, Leeds, West Yorkshire, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|Royal Hospital for Sick Children, Edinburgh, United Kingdom",,https://ClinicalTrials.gov/show/NCT02871089
NCT02871180,Late Night Snack and Insulin Glargine,,Completed,No Results Available,Type 1 Diabetes|Hypoglycemia,Dietary Supplement: Late night snack|Other: No late night snack,Hypoglycemia|Blood glucose profile,Diabeteszentrum Bad Lauterberg im Harz,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,Late night snack & Lantus,Mar-03,Aug-16,null,18-Aug-16,null,18-Aug-16,"Diabeteszentrum Bad Lauterberg, Bad Lauterberg, Niedersachsen, Germany",,https://ClinicalTrials.gov/show/NCT02871180
NCT02867436,The Effect of Gluten-free Diet on New Onset Type 1 Diabetes (T1D),,Recruiting,No Results Available,Type 1 Diabetes,Other: Gluten-free diet,"Change in C-peptide area under the curve measured by mixed-meal tolerance test (MMTT) between group on GFD and standard gluten-containing diet.|Changes in mean HbA1c at 6 and 12 months relative to baseline at month 1.|Changes in mean insulin dose at 6 and 12 months relative to baseline at month 1.|Changes in immunological parameters (FoxP3 Tregs, Th1 and Th17 counts) at 6 and 12 months relative to baseline at month 1.|Differences in fecal microbiome between children on normal diet and children on gluten-free diet over the first year of diabetes duration;","University Hospital, Motol|Faculty Hospital Kralovske Vinohrady|Czech Academy of Sciences",All,"4 Years to 19 Years   (Child, Adult)",Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,16-27994A,Mar-16,Dec-19,Dec-19,16-Aug-16,null,16-Aug-16,"University Hospital Královské Vinohrady, Prague, Czech Republic|University Hospital Motol, Prague, Czech Republic",,https://ClinicalTrials.gov/show/NCT02867436
NCT02866435,Identifying the Brain Substrates of Hypoglycemia Unawareness in Type 1 Diabetes,,Recruiting,No Results Available,Hypoglycemia,Drug: Insulin|Drug: Glucose|Drug: Potassium phosphate,"Change from baseline (i.e., normal glucose levels) functional connectivity, measured as a dimensionless correlation coefficient of MRI signals among brain areas, at hypoglycemia|Change from baseline (i.e., normal glucose levels) cerebral blood flow, measured in ml/min/100g, at hypoglycemia",University of Minnesota - Clinical and Translational Science Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science",25007,Nov-16,Sep-19,Dec-19,15-Aug-16,null,11-Oct-18,"University of Minnesota, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02866435
NCT02862730,Four Way Crossover Closed Loop With Exercise Detection,,Completed,Has Results,Type 1 Diabetes,Device: Artificial Pancreas Controller in Dual Hormone Mode|Device: Subject's insulin pump|Device: Artificial Pancreas Controller in Single Hormone Mode|Device: Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode,Percent of Time With Sensed Glucose < 3.9 mmol/L|Percent of Time With Sensed Glucose Between 3.9-10 mmol/L|Mean Sensed Glucose|Number of Carbohydrate Treatments|Percent of Time With Sensed Glucose < 3.0 mmol/L|Percent of Time With Sensed Glucose > 10 mmol/L|Number of Events With Capillary Blood Glucose < 3.9 mmol/L|Number of Events With Capillary Blood Glucose < 3.0 mmol/L|Mean Amount of Insulin Delivered|Mean Amount of Glucagon Delivered,Oregon Health and Science University,All,21 Years to 45 Years   (Adult),Not Applicable,25,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15590,Oct-16,Aug-17,31-Jan-18,11-Aug-16,17-May-18,14-Sep-18,"Oregon Health and Science University, Portland, Oregon, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT02862730/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02862730
NCT02862860,Search for a Link Between the Different Variables for Glycaemia and Oxidative Stress or Impaired HDL Function,Holter Gly,Unknown status,No Results Available,Type-1 Diabetes,Biological: blood sample|Biological: urine sample|Device: installation of Holter,Average blood glucose|Time hypoglycemia|Time hyperglycemia|Amplitude of glycemic variations,Centre Hospitalier Universitaire Dijon,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),Duvillard Hors AOI 2011,May-12,May-17,null,11-Aug-16,null,11-Aug-16,"CHU Dijon Bourgogne, Dijon, France",,https://ClinicalTrials.gov/show/NCT02862860
NCT02861157,Mobile Technology & Online Tools to Track Adherence in Chronic Illness Patients,OMMS,Completed,No Results Available,"Diabetes Mellitus, Type 1",Behavioral: Planet T1D,Knowledge of Type 1 Diabetes Disease|Diabetes Management Questionnaire (DMQ)|Perceived Treatment Benefits|STARx Transition Readiness Questionnaire|Diabetes Self-Efficacy scale|Self-Management: Self-Efficacy for Managing Chronic Disease Scale|Self-Management: Partners in Health Scale|Quality of Life,3-C Institute for Social Development,All,12 Years to 17 Years   (Child),Phase 2,200,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2R44DP003101 Diabetes|2R44DP003101,1-Jul-15,12-Sep-16,12-Sep-16,10-Aug-16,null,30-Jan-17,"3-C Institute for Social Development, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02861157
NCT02859779,Needs Assessment of Mediterranean Adolescents With Type 1 Diabetes About Therapeutic Education Sessions,BADET,Unknown status,No Results Available,Type 1 Diabetes in Adolescence,Behavioral: education programs,Needs and expectations of adolescents with type 1 diabetes for skills to be developed during the educational sessions|Needs and expectations of parents of adolescents with type 1 diabetes for skills to be developed during the educational sessions,Assistance Publique Hopitaux De Marseille,All,11 Years to 16 Years   (Child),Not Applicable,200,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,2015-36,25-Nov-16,Jun-18,Dec-18,9-Aug-16,null,12-Jun-17,"Hôpital de la Timone Assistance Publique Hôpitaux de Marseille, Marseille, France",,https://ClinicalTrials.gov/show/NCT02859779
NCT02859818,"Description of the Evolution of a Cohort of Adolescents With Type 1 Diabetes Following Their Participation in Therapeutic Education Program Based on Social Cognitive Theory: Socio-cognitive Profile, Physiological Behaviour of Therapeutic Adherence and Quality of Life",ETPACAP,Not yet recruiting,No Results Available,Type 1 Pediatric Diabetes,Other: therapeutic education program,"Self-efficacy evaluated with the 10 items-SEDM|Adherence will be evaluated using 'the Diabetes Self-Management Profile ""tool (DSMP)|Quality of life will be assessed using the KIDSCREEN-27|Glycemic control: glycated hemoglobin (HbA1c)|Outcome expectations, socio-structural factors and personal goals",Assistance Publique Hopitaux De Marseille,All,11 Years to 17 Years   (Child),Not Applicable,168,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),RCAPHM15_0120,Dec-16,Dec-19,May-20,9-Aug-16,null,9-Aug-16,"Assistance Publique Hôpitaux de Marseille, Marseille, France",,https://ClinicalTrials.gov/show/NCT02859818
NCT02855307,Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Other: 60-minute exercise|Device: Insulin pump|Device: Dexcom G4 Platinum glucose sensor|Drug: Insulin|Other: Single-hormone closed-loop strategy,Percentage of time of plasma glucose levels spent below 3.9 mmol/L|Relative decrease in glucose levels during exercise compared to pre-breakfast levels|Number of patients experiencing exercise-induced hypoglycemia requiring treatment|Decremental area under the curve from the start of the exercise|Percentage of time of plasma glucose levels spent below 3.3 mmol/L|Percentage of time of plasma glucose levels spent below 2.8 mmol/L|Percentage of time of plasma glucose levels spent between 3.9 and 7.8 mmol/L|Percentage of time of plasma glucose levels spent above 10 mmol/L|Percentage of time of plasma glucose levels spent above 13.9 mmol/L|Percentage of time of plasma glucose levels spent above 16.7 mmol/L|Mean plasma glucose levels|Standard deviation of glucose levels|Coefficient of variation of glucose levels|Mean time (minutes) to the first hypoglycemic event,Institut de Recherches Cliniques de Montreal,All,"18 Years and older   (Adult, Older Adult)",Phase 2,37,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,CLASS-16,Sep-16,Dec-18,Dec-18,4-Aug-16,null,11-Feb-19,"Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02855307
NCT02854696,Health Economic Analysis of Islet Cell Transplantation for the Stabilization of the Severe Forms of Type 1 Diabetes,STABILOT,Recruiting,No Results Available,Type 1 Diabetes,Procedure: Islet graft|Drug: best medical care,Incremental cost- utility ratio at 1 year|Cost-effectiveness ratio at 1 year|Assessment of individual medical benefit of quality of life|Assessment of individual medical benefit in terms of metabolic efficacy|Assessment and comparison of individual medical benefit in terms of complications of islet cell transplantation between the two groups|Assessment and comparison of clinical benefit for patients with brittle type 1 diabetes with impairment of vital prognosis before and after islet cell transplantation|Assessment and comparison of costs for patients with brittle type 1 diabetes with impairment of vital prognosis before and after islet cell transplantation|Assessment of total cost of islet cell transplantation,"University Hospital, Grenoble",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,38RC14.453,Jul-16,Mar-23,Dec-23,3-Aug-16,null,17-Mar-17,"University Hospital of Besançon, Besancon, France|university hospital of Clermont Ferrand, Clermont Ferrand, France|Grenoble University Hospital, Grenoble, France|University hospital of Lille, Lille, France|University Hospital of Lyon, Lyon, France|University Hospital of Montpellier, Montpellier, France|University hospital of Nancy, Nancy, France|university hospital of Nantes, Nantes, France|APHP, Paris, France|University hospital of Strasbourg, Strasbourg, France|University Hospital of Geneva, Geneva, Switzerland",,https://ClinicalTrials.gov/show/NCT02854696
NCT02849288,Bigfoot Biomedical Clinical Research Center (CRC) Trial,,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: Bigfoot Biomedical Type 1 Diabetes Management System (T1DMS),Evaluate performance of the algorithm/ system commanded delivery of insulin in response to glucose trends from the CGM. in an effort to avoid hypoglycemia and hyperglycemia.|Assessment of safety outcomes and serious adverse events and device related adverse effects.|Measures of glycemic control|System functionality as evidenced by the availability of CGM data,"Bigfoot Biomedical Inc.|Jaeb Center for Health Research|Profil Institute for Clinical Research, Inc.",All,"7 Years and older   (Child, Adult, Older Adult)",Phase 1,20,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TST-10025,Jul-16,Dec-16,Dec-16,29-Jul-16,null,19-Dec-16,"William Sansum Diabetes Research Institute, Santa Barbara, California, United States|Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT02849288
NCT02848261,Remote Monitoring of Diabetes in Young Children With Type 1 Diabetes,,Recruiting,No Results Available,Type 1 Diabetes Mellitus,Behavioral: Developmental Demands|Behavioral: Distress Reduction|Behavioral: Remote Monitoring|Behavioral: Fear of Hypoglycemia|Behavioral: No intervention,Time spent in blood glucose range|Pediatric Quality of Life Inventory|A1c|Problem Areas in Diabetes|Diabetes Distress Scale|Patient Health Questionnaire 9|State-Trait Anxiety Inventory|Pittsburgh Sleep Quality Index|Hypoglycemic Fear Survey|Hypoglycemic Confidence Questionnaire|Glucose Monitoring System Satisfaction Survey|General and diabetes-specific technology use,"Stanford University|University of Colorado, Denver|Indiana University",All,2 Years to 6 Years   (Child),Not Applicable,90,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,37360,15-Aug-16,Aug-19,Aug-19,28-Jul-16,null,9-May-18,"Stanford University, Stanford, California, United States|University of Colorado, Aurora, Colorado, United States|Indiana University, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT02848261
NCT02846545,A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes,T1GER,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 1",Biological: Golimumab|Biological: Placebo,C-peptide Area Under the Curve (AUC) Calculated From a 4 Hour Mixed Meal Tolerance Test (MMTT) at Week 52|Change From Baseline in Insulin use in Units per Kilogram Body Weight per day|Change From Baseline in Glycosylated Haemoglobin (HbA1c)|Hypoglycemic Event Rates|C-peptide Area Under the Curve (AUC) Calculated From a 4 Hour Mixed Meal Tolerance Test (MMTT) Over Time|Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Percentage of Participants With Severe Infections Through Weeks 52 and 104|Percentage of Participants With Study Agent Injection Site Reactions Through Week 52,"Janssen Research & Development, LLC",All,"6 Years to 21 Years   (Child, Adult)",Phase 2,84,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CR108187|CNTO148DML2001,26-Aug-16,25-May-19,25-May-20,27-Jul-16,null,22-Apr-19,"Little Rock, Arkansas, United States|Newport Beach, California, United States|Sacramento, California, United States|San Diego, California, United States|San Francisco, California, United States|Walnut Creek, California, United States|Aurora, Colorado, United States|New Haven, Connecticut, United States|Doral, Florida, United States|Gainesville, Florida, United States|Atlanta, Georgia, United States|Columbus, Georgia, United States|Boise, Idaho, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Lexington, Kentucky, United States|Louisville, Kentucky, United States|Baton Rouge, Louisiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Worcester, Massachusetts, United States|Morristown, New Jersey, United States|Bronx, New York, United States|Buffalo, New York, United States|Mentor, Ohio, United States|Philadelphai, Pennsylvania, United States|Sioux Falls, South Dakota, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Schertz, Texas, United States|Webster, Texas, United States|Seattle, Washington, United States|Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT02846545
NCT02843503,Factors in Accuracy Studies Influencing Measured CGM Performance.,FACT-CGM,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: Arterialized-venous reference (YSI)|Device: Venous reference measurement (YSI)|Device: Capillary reference (SMBG),Mean Absolute Relative Difference (MARD)|Accuracy of sensors (MARD) per hypoglycemic range|Accuracy (MARD) of sensors per hyperglycemic range|Glucose content (mg/dL) of venous reference samples.|Glucose content (mg/dL) of venous-arterialized reference samples.|Glucose content (mg/dL) of capillary reference samples.,"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|DexCom, Inc.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,21,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NL57491.018.16,Jul-16,Jan-17,Jan-17,26-Jul-16,null,24-Jan-17,"Academic Medical Center, Amsterdam, Noord-Holland, Netherlands",,https://ClinicalTrials.gov/show/NCT02843503
NCT02843724,Integrative Care for Type 2 Diabetes,,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2",Other: Naturopathic Care|Other: Usual (Conventional) Care,"Clinically meaningful reduction of HbA1c above and beyond that of control arm|Incidence of metabolic syndrome|Weight (as part of BMI)|Height (as part of BMI)|Waist circumference (as part of metabolic syndrome)|Fasting blood glucose|Glycated hemoglobin (HbA1c)|Blood pressure (BP)|Total cholesterol (TC) (blood)|High-density lipoprotein (HDL-C) (blood)|Low-density lipoprotein (LDL-C) (blood)|Triglycerides (TG))(blood)|High-sensitivity C-reactive protein (hs-CRP)|Incidence of smoking|Incidence of obesity|Incidence of depression (PHQ-9)|Impact on stress, anxiety, quality of life|Impact on anxiety|DES|SF-12|Compliance/adherence with treatment prescriptions including changes in lifestyle, diet, exercise, and nutraceutical supplementation|Compliance/adherence with pharmaceutical prescriptions using a medication adherence questionnaire|Adverse Events",The Canadian College of Naturopathic Medicine,All,"21 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,148,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CanadianCNN,Jul-16,Dec-18,Jul-19,26-Jul-16,null,26-Jul-16,"Wise Elephant Family Health Team, Brampton, Ontario, Canada|The Canadian College of Naturopathic Medicine, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02843724
NCT02844517,International Diabetes Closed Loop (iDCL) Trial: Research Site Training Protocol,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: Artificial Pancreas,The primary outcome is a qualitative assessment of the system's suitability for use in a large-scale in-home clinical trial based on the results of the Technology Acceptance questionnaire and feedback from clinical staff.,"University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Jaeb Center for Health Research|TypeZero Technologies, LLC|Tandem Diabetes Care, Inc.|DexCom, Inc.|Roche Diagnostic Ltd.",All,"14 Years to 74 Years   (Child, Adult, Older Adult)",Not Applicable,43,Other|NIH|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,19068|UC4DK108483,Nov-16,Oct-17,Oct-17,26-Jul-16,null,7-May-18,"William Sansum Diabetes Center, Santa Barbara, California, United States|Stanford University, Stanford, California, United States|Barbara Davis Center, University of Colorado, Aurora, Colorado, United States|Harvard University (Joslin Diabetes Center), Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Mt. Sinai, New York, New York, United States|University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States|University of Montpellier, Montpellier, France|University of Padova, Padova, Italy|Academic Medical Center, Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT02844517
NCT02845024,The Effect of Non-surgical Periodontal Therapy Plus Doxycycline on HbA1c in Patients With Type 2 Diabetes Mellitus,,Completed,No Results Available,Diabetes Mellitus With Periodontal Disease,Drug: Doxycycline Group|Drug: placebo Group,Periodontal pocket depth|glycated hemoglobin (HbA1c),"Islamic Azad University, Tehran",All,35 Years to 60 Years   (Adult),Not Applicable,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",515,Sep-14,Dec-15,Jul-16,26-Jul-16,null,4-Oct-16,,,https://ClinicalTrials.gov/show/NCT02845024
NCT02839031,Cognitive-Behavioral Therapy (CBT) in Children With Diabetes,DI-CO,Recruiting,No Results Available,"Diabetes Mellitus, Type 1","Behavioral: ""CBT"" (Cognitive-Behavioral Therapy)|Behavioral: Control (telephonic support without CBT content)",Glycated hemoglobin (HbA1c) level,"University Hospital, Montpellier",All,"6 Years to 18 Years   (Child, Adult)",Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,UF 9369,Mar-15,Oct-18,Oct-18,20-Jul-16,null,8-May-18,"Montpellier University Hospital, Montpellier, France",,https://ClinicalTrials.gov/show/NCT02839031
NCT02836873,Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Bexagliflozin|Drug: Placebo,Change in HbA1c at 24 weeks|Change in body weight at 24 weeks in subjects with baseline body mass index (BMI) ≥ 25 kg/m|Change in systolic blood pressure (SBP) at 24 weeks in subjects with baseline SBP ≥ 130 mmHg|Change in HbA1c at 24 weeks in subjects with eGFR 45 to 59 mL/min/1.73 m2 at week 24|Change in HbA1c at 24 weeks in subjects with eGFR 30 to 44 mL/min/1.73 m2 at week 24,Theracos,All,"20 Years and older   (Adult, Older Adult)",Phase 3,312,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",THR-1442-C-448,23-Sep-16,11-Jan-18,11-Jan-18,19-Jul-16,null,20-Dec-18,"Research Site, Fresno, California, United States|Research Site, La Palma, California, United States|Research Site, Lincoln, California, United States|Research Site, Riverside, California, United States|Research Site, Sacramento, California, United States|Research Site, San Dimas, California, United States|Research Site, Monument, Colorado, United States|Research Site, Norwalk, Connecticut, United States|Research Site, Hollywood, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Paducah, Kentucky, United States|Research Site, Auburn, Maine, United States|Research Site, Rockport, Maine, United States|Research Site, Nashua, New Hampshire, United States|Research Site, Bronx, New York, United States|Research Site, Stow, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Austin, Texas, United States|Research Site, Austin, Texas, United States|Research Site, North Richland Hills, Texas, United States|Research Site, Round Rock, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Dijon, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Pierre Benite, France|Research Site, Poitiers, France|Research Site, Venissieux, France|Research Site, Atsugi-shi, Kanagawa, Japan|Research Site, Kamakura-shi, Kanagawa, Japan|Research Site, Kawasaki-shi, Kanagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Kawagoe-shi, Saitama, Japan|Research Site, Kawaguchi-shi, Saitama, Japan|Research site, Sayama-shi, SAitama, Japan|Research Site, Hachioji-shi, Tokyo, Japan|Research Site, Hachioji-shi, Tokyo, Japan|Research Site, Minato-ku, Tokyo, Japan|Research Site, Ota-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Toshima-ku, Toyko, Japan|Research Site, Alcala de Henares, Spain|Research Site, Alicante, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Malaga, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT02836873
NCT02837094,Enhanced Epidermal Antigen Specific Immunotherapy Trial -1,EE-ASI-1,"Active, not recruiting",No Results Available,Type 1 Diabetes,Drug: C19-A3 GNP,To examine the risk of C19A3 GNP administration in terms of general safety and induction of hypersensitivity.|To study the feasibility of delivering C19A3 GNP via microneedles to humans.|To study the immune responses to C19A3 GNP generated in blood.|To study the immune responses to C19A3 GNP generated in the draining (axillary) lymph node.,Cardiff University,All,"16 Years to 40 Years   (Child, Adult)",Phase 1,8,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,SPON1455-15,29-Sep-16,31-Jan-20,31-Jan-20,19-Jul-16,null,16-May-19,"Cardiff and Vale University Health Board, Cardiff, United Kingdom",,https://ClinicalTrials.gov/show/NCT02837094
NCT02835183,Evaluation of iDECIDE: A Smartphone App for Insulin Dosing Accounting for Alcohol and Exercise,,Unknown status,No Results Available,Type 1 Diabetes,Device: iDECIDE|Device: Insulin pump,Compare mean postprandial glucose level|Hypoglycemia events|Hyperglycemia events,Arizona State University|Mayo Clinic,All,18 Years to 60 Years   (Adult),Phase 1,30,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,iDECIDEEvaluation,Jan-17,Oct-17,Oct-17,15-Jul-16,null,15-Jul-16,,,https://ClinicalTrials.gov/show/NCT02835183
NCT02829177,Microalbuminuria and Allopurinol in Type 1 Diabetes,MIKAL,Completed,No Results Available,Type 1 Diabetes|Diabetic Nephropathy,Drug: Allopurinol|Drug: Placebo,Improved Albuminuria,Peter Rossing|Steno Diabetes Center Copenhagen,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",3004,Sep-14,10-Aug-16,20-Sep-17,12-Jul-16,null,10-Sep-18,"Steno Diabetes Center, Gentofte, Denmark",,https://ClinicalTrials.gov/show/NCT02829177
NCT02829268,A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome,,Recruiting,No Results Available,Wolfram Syndrome|Diabetes Mellitus|Optic Nerve Atrophy|Ataxia,Drug: dantrolene sodium,Number of participants with treatment-related adverse events as assessed by liver function tests|Changes in C-peptide levels in participants assessed by the ELISA assay|Changes in Visual Functioning in participants assessed by Visual Functioning Questionnaire-25.|Changes in best-corrected visual acuity in participants measured by Snellen optotype|Changes in Neurological Functions in participants assessed by the Wolfram Unified Rating Scale (WURS),Washington University School of Medicine|National Institutes of Health (NIH),All,"5 Years to 60 Years   (Child, Adult)",Phase 1|Phase 2,50,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,201607006,Jan-17,Dec-20,Mar-21,12-Jul-16,null,14-May-19,"Washington University School of Medicine, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT02829268
NCT02827669,One Drop Experts Program for Type 2 Diabetes Self-Management: Impact on A1c,,Completed,No Results Available,Type 2 Diabetes Mellitus,Behavioral: One Drop Experts Program|Behavioral: One Drop Experts Program + Apple Watch,HbA1c,Evidation Health|One Drop,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,297,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,EH-001,Jun-16,Feb-17,Feb-17,11-Jul-16,null,22-Mar-17,"Evidation Health, San Mateo, California, United States",,https://ClinicalTrials.gov/show/NCT02827669
NCT02827890,CKD-396 Drug-drug Interaction Study(B) (CKD-396 DDI(B) P1),,Completed,No Results Available,Diabetes Mellitus Type 2,Drug: Januvia Tab. 100mg|Drug: Januvia Tab. 100mg + Duvie Tab. 0.5mg,"AUCτ of Sitagliptin|Css,max of Sitagliptin|Css,min of Sitagliptin|Css,av of Sitagliptin|Tss,max of Sitagliptin|t1/2 of Sitagliptin|CLss/F of Sitagliptin|Vdss/F of Sitagliptin|fluctuation[(Css,max-Css,min)/Css,av] of Sitagliptin|swing[(Css,max-Css,min)/Css,min] of Sitagliptin",Chong Kun Dang Pharmaceutical,Male,"19 Years and older   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,165DDI16003,Apr-16,Apr-16,May-16,11-Jul-16,null,9-Aug-17,"Chonbuk National University Hospital, Jeonju-si, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02827890
NCT02824874,CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1),,Completed,No Results Available,"Diabetes Mellitus, Type II",Drug: Duvie Tab. 0.5mg|Drug: Duvie Tab. 0.5mg + Januvia Tab. 100mg,"AUCτ of Lobeglitazone|Css,max of Lobeglitazone|Css,min of Lobeglitazone|Css,av of Lobeglitazone|Tss,max of Lobeglitazone|t1/2 of Lobeglitazone|CLss/F of Lobeglitazone|Vdss/F of Lobeglitazone|fluctuation[(Css,max-Css,min)/Css,av] of Lobeglitazone|swing[(Css,max-Css,min)/Css,min] of Lobeglitazone",Chong Kun Dang Pharmaceutical,Male,"19 Years and older   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,165DDI16002,Apr-16,Apr-16,May-16,7-Jul-16,null,11-Jul-16,"Chonbuk National University Hospital, Jeonju-si, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02824874
NCT02825251,Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes,Onset® 5,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart,"Change in Glycosylated Haemoglobin (HbA1c)|Change From Baseline in 1-hour PPG Increment|Change From Baseline in 1,5-anhydroglucitol|Change From Baseline in Time Spent in Low IG (≤3.9 mmol/L [70 mg/dL]) During CGM|Change From Baseline in Fasting Plasma Glucose (FPG)|Percentage of Subjects Reaching HbA1c <7.0% (53 mmol/Mol)|Percentage of Subjects Reaching HbA1c <7.0% (53 mmol/Mol) Without Severe Hypoglycaemic Episodes|Change From Baseline in 30-min, 1-hour, 2-hour, 3-hour and 4-hour PPG (Meal Test)|Change From Baseline in 30-min, 2-hour, 3-hour and 4-hour PPG Increment (Meal Test)|Change From Baseline in Mean of the 7-7-9 Point Self-measured Plasma Glucose (SMPG) Profile|Change From Baseline of the 7-7-9 Point SMPG Profile: PPG (Mean, Breakfast, Lunch and Main Evening Meal)|Change From Baseline of the 7-7-9 Point SMPG Profile: PPG Increment (Mean, Breakfast, Lunch and Main Evening Meal)|Change From Baseline of the 7-7-9 Point SMPG Profile: Pre-prandial Plasma Glucose (PG) (Mean, Pre-breakfast, Pre-lunch, Pre-main Evening Meal)|Change From Baseline of the 7-7-9 Point SMPG Profile: Fluctuation in 7-7-9 Point Profile|Change From Baseline of the 7-7-9 Point SMPG Profile: in Nocturnal SMPG Measurements|Percentage of Subjects Reaching Overall PPG (1 Hour) ≤7.8 mmol/L [140 mg/dL]|Percentage of Subjects Reaching Overall PPG (1 Hour) ≤7.8 mmol/L [140 mg/dL] Without Severe Hypoglycaemia|Change From Baseline in Lipids-lipoproteins Profile (Total Cholesterol, High Density Lipoproteins, Low Density Lipoproteins)|Insulin Dose in Units/Day: Total Basal|Insulin Dose in Units/Day: Total Bolus|Insulin Dose in Units/Day: Total Daily Insulin Dose|Insulin Dose in Units/Day: Individual Meal Insulin Dose|Insulin Dose in Units/kg/Day: Total Basal|Insulin Dose in Units/kg/Day: Total Bolus|Insulin Dose in Units/kg/Day: Total Daily Insulin Dose|Insulin Dose in Units/kg/Day: Individual Meal Insulin Dose|Insulin Delivery Pump Parameter: Insulin Carbohydrate Ratio|Insulin Delivery Pump Parameter: Glucose Sensitivity Factor|Insulin Delivery Pump Parameter: Active Insulin Time|Change From Baseline in Mean IG Increment (0-30 Min, 0-1 Hour and 0-2 Hours After Start of Meal) (Mean, Breakfast, Lunch and Main Evening Meal)|Change From Baseline in Mean Time to the IG Peak After Start of Meal (Mean, Breakfast, Lunch and Main Evening Meal)|Change From Baseline in Mean IG Peak After Start of Meal (Mean, Breakfast, Lunch and Main Evening Meal)|Percentage of Time Spent With IG ≤2.5, 3.0, 3.5, 3.9 mmol/L [45, 54, 63, 70 mg/dL]) and IG >10.0, 12.0, 13.9 mmol/L [180, 216, 250 mg/dL])|Incidence of Episodes With IG ≤2.5, 3.0, 3.5, 3.9 mmol/L [45, 54, 63, 70 mg/dL]) and IG >10.0, 12.0, 13.9 mmol/L [180, 216, 250 mg/dL])|Change From Baseline in Mean of the IG Profile|Percentage of Time Spent Within IG Target Range 4.0-7.8 mmol/L (71-140 mg/dL) and 4.0-10 mmol/L (71-180 mg/dL)|Variation in the IG Profile|Area Under the Curve (AUC3.9-IG) for IG ≤3.9 mmol/L [70 mg/dL]|Change From Baseline in AUCIG,0-15min|Change From Baseline in AUCIG,0-30min|Change From Baseline in AUCIG,0-1h|Change From Baseline in AUCIG,0-2h|Change From Baseline in AUCIG,0-4h|Change From Baseline in Time to the IG Peak After Start of Meal|Change From Baseline in IG Peak After Start of Meal|Number of Treatment Emergent Adverse Events (AEs)|Number of Treatment Emergent Infusion Site Reactions|Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association (ADA) and Novo Nordisk (NN) Definition: Overall|Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Daytime Hypoglycaemic Episodes (06:00-00:00 - Inclusive)|Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Nocturnal Hypoglycaemic Episodes (00:01-05:59 - Inclusive)|Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 1 Hour After Start of the Meal|Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes During First 2 Hours After Start of the Meal|Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes During First 4 Hours After Start of the Meal|Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes Occurring Between 2 to 4 Hours After Start of the Meal|Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes Occurring Between 1 Hour to 2 Hours After Start of the Meal|Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes Occurring Between 2 to 3 Hours After Start of the Meal|Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes Occurring Between 3 to 4 Hours After Start of the Meal|Number of Unexplained Episodes of Hyperglycaemia (Confirmed by SMPG)|Change From Baseline in Physical Examination: Respiratory System|Change From Baseline in Physical Examination: Cardiovascular System|Change From Baseline in Physical Examination: Central and Peripheral Nervous System|Change From Baseline in Physical Examination: Gastrointestinal System, Including the Mouth|Change From Baseline in Physical Examination: Musculoskeletal System|Change From Baseline in Physical Examination: Skin|Change From Baseline in Physical Examination: Head, Ears, Eyes, Nose, Throat and Neck|Change From Baseline in Vital Sign: Blood Pressure|Change From Baseline in Vital Sign: Pulse|Change From Screening in Electrocardiogram (ECG)|Change From Screening in Fundus Photography/Fundoscopy|Change From Baseline in Haematology: Haemoglobin|Change From Baseline in Haematology: Haematocrit|Change From Baseline in Haematology: Erythrocytes|Change From Baseline in Haematology: Thrombocytes|Change From Baseline in Haematology: Leucocytes|Change From Baseline in Biochemistry: Total Protein|Change From Baseline in Biochemistry: Creatinine|Change From Baseline in Biochemistry: Alanine Aminotransferase (ALT)|Change From Baseline in Biochemistry: Aspartate Aminotransferase (AST)|Change From Baseline in Biochemistry: Alkaline Phosphatase (ALP)|Change From Baseline in Biochemistry: Sodium|Change From Baseline in Biochemistry: Potassium|Change From Baseline in Biochemistry: Albumin|Change From Baseline in Biochemistry: Total Bilirubin|Change From Baseline in Urinalysis: Albumin/Creatine Ratio|Change From Baseline in Urinalysis: Erythrocytes|Change From Baseline in Urinalysis: Protein|Change From Baseline in Urinalysis: Ketones|Change From Baseline in Body Weight|Change From Baseline in Body Mass Index (BMI)|Number of Change-of-infusion-sets Per Week|Number of Subjects With at Least One Non-routine Change-of-infusion-sets Categorised by Reasons for Change-of-infusion-sets",Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,472,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1218-3854|2010-024054-11|U1111-1118-2480|NL54555.018.16,6-Jul-16,20-Jun-17,21-Jul-17,7-Jul-16,24-Jul-18,3-Jan-19,"Novo Nordisk Investigational Site, Encino, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Roseville, California, United States|Novo Nordisk Investigational Site, San Mateo, California, United States|Novo Nordisk Investigational Site, San Ramon, California, United States|Novo Nordisk Investigational Site, Santa Barbara, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Newark, Delaware, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Arlington Heights, Illinois, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Rockville, Maryland, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, Asheville, North Carolina, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Amarillo, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Mesquite, Texas, United States|Novo Nordisk Investigational Site, Federal Way, Washington, United States|Novo Nordisk Investigational Site, Renton, Washington, United States|Novo Nordisk Investigational Site, Arlon, Belgium|Novo Nordisk Investigational Site, Bonheiden, Belgium|Novo Nordisk Investigational Site, Brussels, Belgium|Novo Nordisk Investigational Site, Edegem, Belgium|Novo Nordisk Investigational Site, Leuven, Belgium|Novo Nordisk Investigational Site, Sint-Niklaas, Belgium|Novo Nordisk Investigational Site, Wilrijk, Belgium|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Barrie, Ontario, Canada|Novo Nordisk Investigational Site, Concord, Ontario, Canada|Novo Nordisk Investigational Site, London, Ontario, Canada|Novo Nordisk Investigational Site, Oakville, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Caen, France|Novo Nordisk Investigational Site, LA ROCHELLE cedex, France|Novo Nordisk Investigational Site, Le Creusot, France|Novo Nordisk Investigational Site, MONTPELLIER cedex 5, France|Novo Nordisk Investigational Site, Narbonne, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Saint Herblain, France|Novo Nordisk Investigational Site, Strasbourg, France|Novo Nordisk Investigational Site, TOULOUSE cedex, France|Novo Nordisk Investigational Site, Venissieux, France|Novo Nordisk Investigational Site, Bad Mergentheim, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Friedrichsthal, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Ludwigshafen, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Neuwied, Germany|Novo Nordisk Investigational Site, Rehlingen-Siersburg, Germany|Novo Nordisk Investigational Site, Rostock, Germany|Novo Nordisk Investigational Site, Amsterdam, Netherlands|Novo Nordisk Investigational Site, Apeldoorn, Netherlands|Novo Nordisk Investigational Site, Eindhoven, Netherlands|Novo Nordisk Investigational Site, Hoofddorp, Netherlands|Novo Nordisk Investigational Site, Hoogeveen, Netherlands|Novo Nordisk Investigational Site, Leiden, Netherlands|Novo Nordisk Investigational Site, Nijmegen, Netherlands|Novo Nordisk Investigational Site, Rotterdam, Netherlands|Novo Nordisk Investigational Site, Utrecht, Netherlands|Novo Nordisk Investigational Site, Venlo, Netherlands|Novo Nordisk Investigational Site, Cheboksary, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, St. Petersburg, Russian Federation|Novo Nordisk Investigational Site, Ljubljana, Slovenia|Novo Nordisk Investigational Site, Novo mesto, Slovenia|Novo Nordisk Investigational Site, Cambridge, United Kingdom|Novo Nordisk Investigational Site, Guildford, United Kingdom|Novo Nordisk Investigational Site, Harrogate, North Yorkshire, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Manchester, United Kingdom|Novo Nordisk Investigational Site, St Helens, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02825251/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02825251/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02825251
NCT02824510,Evaluation of Glycemic Changes During Exercise in Children With Type 1 Diabetes,TREAD-DIAB,Unknown status,No Results Available,Type 1 Diabetes,"Other: Algorithmic changes in insulin therapy.|Other: Treadmill exercises|Drug: Insulin aspart, glargine and detemir",Subcutaneous glucose evolution,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,All,"7 Years to 18 Years   (Child, Adult)",Not Applicable,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013/18NOV/510,Aug-14,Sep-16,null,6-Jul-16,null,7-Jul-16,"Pediatric Endocrinology, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT02824510
NCT02820558,Neuropeptide Therapy of Recent Onset Type 1 Diabetes,,Unknown status,No Results Available,"Diabetes Mellitus, Type 1",Drug: Substance P,Stage A Safety: Side effects reported for entire cohort|C-Peptide Levels (small cohort)|C-Peptide Levels (large cohort),Vanilloid Genetics Inc.,All,"10 Years to 18 Years   (Child, Adult)",Phase 1,12,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VanilloidGenetics-001-13,May-16,Sep-17,Sep-17,1-Jul-16,null,1-Jul-16,"Hospital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02820558
NCT02821026,Omental Islet Transplant,,"Active, not recruiting",No Results Available,Type 1 Diabetes,Procedure: Omental Islet transplant|Drug: Anti-Thymocyte Globulin|Drug: Mycophenolate mofetil|Drug: Tacrolimus|Drug: Etanercept|Drug: Sirolimus,"The incidence of Serious Adverse Events|The proportion of subjects with HbA1c ≤ 6.5% at 1 year AND free of severe hypoglycemic events from Day 28 to Day 365, inclusive, after the islet transplant|The percent reduction in insulin requirements at Day 75±7 after islet transplant|The percent reduction in insulin requirements at Day 365±14 after islet transplant|The percent reduction in insulin requirements at Day 730±14 after islet transplant|Change from baseline in HbA1c at Day 75±7 after islet transplant|Change from baseline in HbA1c at Day 365±14 after islet transplant|Change from baseline in HbA1c at Day 730±14 after islet transplant|Change from baseline in Mean Amplitude of Glycemic Excursions at Day 75±7 after islet transplant|Change from baseline in Mean Amplitude of Glycemic Excursions at Day 365±14 after islet transplant|Change from baseline in Mean Amplitude of Glycemic Excursions at Day 730±14 after islet transplant|Change from baseline in Lability Index at Day 75±7 after islet transplant|Change from baseline in Lability Index at Day 365±14 after islet transplant|Change from baseline in Lability Index at Day 730±14 after islet transplant|Change from baseline in Ryan hypoglycemia severity score at Day 75±7 after islet transplant|Change from baseline in Ryan hypoglycemia severity score at Day 365±14 after islet transplant|Change from baseline in Ryan hypoglycemia severity score at Day 730±14 after islet transplant|Change from baseline in Clarke score at Day 75±7 after islet transplant|Change from baseline in Clarke score at Day 365±14 after islet transplant|Change from baseline in Clarke score at Day 730±14 after islet transplant|Change from baseline in number of severe hypoglycemic episodes at Day 75±7 after islet transplant|Change from baseline in number of severe hypoglycemic episodes at Day 365±14 after islet transplant|Change from baseline in number of severe hypoglycemic episodes at Day 730±14 after islet transplant|Change from baseline in basal (fasting) and 90- min glucose and c-peptide derived from the mixed-meal tolerance test at Day 75±7 after islet transplant|Change from baseline in basal (fasting) and 90- min glucose and c-peptide derived from the mixed-meal tolerance test at Day 365±14 after islet transplant|Change from baseline in basal (fasting) and 90- min glucose and c-peptide derived from the mixed-meal tolerance test at Day 730±14 after islet transplant|Change from baseline in beta-score at Day 75±7 after islet transplant|Change from baseline in beta-score at Day 365±14 after islet transplant|Change from baseline in beta-score at Day 730±14 after islet transplant|Change from baseline in C-peptide creatinine ratio at Day 75±7 after islet transplant|Change from baseline in C-peptide creatinine ratio at Day 365±14 after islet transplant|Change from baseline in C-peptide creatinine ratio at Day 730±14 after islet transplant|Change from baseline in acute insulin response to glucose at Day 75±7 after islet transplant|Change from baseline in acute insulin response to glucose at Day 365±14 after islet transplant|Change from baseline in acute insulin response to glucose at Day 730±14 after islet transplant|Change from baseline in insulin sensitivity at Day 75±7 after islet transplant|Change from baseline in insulin sensitivity at Day 365±14 after islet transplant|Change from baseline in insulin sensitivity at Day 730±14 after islet transplant|Change from baseline in disposition index derived from the insulin-modified frequently-sampled intravenous glucose tolerance (FSIGT) test at Day 75±7 after islet transplant|Change from baseline in disposition index derived from the insulin-modified frequently-sampled intravenous glucose tolerance (FSIGT) test at Day 365±14 after islet transplant|Change from baseline in disposition index derived from the insulin-modified frequently-sampled intravenous glucose tolerance (FSIGT) test at Day 730±14 after islet transplant|Change from baseline in glucose variability and hypoglycemia duration derived from the continuous glucose monitoring system® (CGMS) at Day 75±7 after islet transplant|Change from baseline in glucose variability and hypoglycemia duration derived from the continuous glucose monitoring system® (CGMS) at Day 365±14 after islet transplant|Change from baseline in glucose variability and hypoglycemia duration derived from the continuous glucose monitoring system® (CGMS) at Day 730±14 after islet transplant|Change from baseline in diabetes distress scores measured by Diabetes Distress scale at Day 75±7 after islet transplant|Change from baseline in diabetes distress scores measured by Diabetes Distress scale at Day 365±14 after islet transplant|Change from baseline in diabetes distress scores measured by Diabetes Distress scale at Day 730±14 after islet transplant|Change from baseline in health status measured by EQ-5D at Day 75±7 after islet transplant|Change from baseline in health status measured by EQ-5D at Day 365± 14 after islet transplant|Change from baseline in health status measured by EQ-5D at Day 730± 14 after islet transplant|Change from baseline in the score measured by Hypoglycemia Fear Survey-HFS at Day 75±7 after islet transplant|Change from baseline in the score measured by Hypoglycemia Fear Survey-HFS at Day 365±14after islet transplant|Change from baseline in the score measured by Hypoglycemia Fear Survey-HFS at Day 730±14 after islet transplant|Change from baseline in health scores obtained through SF-36v2 health survey at Day 75±7 after islet transplant|Change from baseline in health scores obtained through SF-36v2 health survey at Day 365±14 after islet transplant|Change from baseline in health scores obtained through SF-36v2 health survey at Day 730±14 after islet transplant|Incidence of AEs associated with conventional immunosuppression|Renal function (serum creatinine and GFR)|Lipid profiles (triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol)|The incidence of AEs related to the islet transplant procedure|The incidence of immune sensitization defined by presence of anti-HLA antibodies absent prior to transplantation|The incidence of discontinuation of immunosuppression",University of Alberta,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,4,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00058260,May-16,Jan-20,Sep-20,1-Jul-16,null,16-Apr-19,"Clinical Islet Transplant Program, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT02821026
NCT02821585,Impact of a Nutritional Intervention on Type1 Diabetes Adult With Metabolic Syndrome,MEDIT,Completed,No Results Available,Type 1 Diabetes|Metabolic Syndrome,Behavioral: Nutritional Counseling,Change in Waist Circumference|Mediterranean Diet Score|Body Mass Index (BMI)|Percentage of body fat|Insulin Sensitivity|Systolic and diastolic Blood pressure|Lipid profile|Glycemic variability,Institut de Recherches Cliniques de Montreal,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,29,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MEDIT-1,Jan-16,Apr-18,Apr-18,1-Jul-16,null,31-Jan-19,"Institut de recherches cliniques de Montréal, Montréal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02821585
NCT02820298,Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Bexagliflozin,Pharmacokinetics of Bexagliflozin - Cmax|Pharmacokinetics of Bexagliflozin - Tmax|Pharmacokinetics of Bexagliflozin - AUC0-t|Pharmacokinetics of Bexagliflozin - AUC0-∞|Safety of Bexagliflozin|Pharmacodynamics of Bexagliflozin,Theracos,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,25,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,THR-1442-C-481,Jun-16,Aug-16,Aug-16,30-Jun-16,null,22-Aug-17,"Denver Clinical Research Unit, Lakewood, Colorado, United States",,https://ClinicalTrials.gov/show/NCT02820298
NCT02814838,"A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes",,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Insulin-Dependent",Drug: Ladarixin|Drug: Placebo,AUC of C-peptide|Insulin requirement|HbA1c|Cumulative severe hypoglycaemic events|Adverse Events|Serious Adverse Events|Vital signs,Dompé Farmaceutici S.p.A,All,18 Years to 45 Years   (Adult),Phase 2,72,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MEX0114|2014-003968-20,Aug-16,Apr-19,Sep-19,28-Jun-16,null,13-Jun-18,"Universitair Ziekenhuis Brussel Diabetes Clinic, Brussels, Belgium|Universitair Ziekenhuis Leuven Campus Gasthuisberg Endocrinology, Leuven, Belgium|Med. Klinik und Poliklinik 3, Universitätsklinikum Giessen und Marburg GmbH, Giessen, Germany|Zentrum für Diabetes und Gefäßerkrankungen, Münster, Germany|Università Aldo Moro-Ospedale Policlinico, Bari, Italy|Presidio Policlinico di Monserrato, Cagliari, Italy|Internal Medicine - Diabetes & Endocrinology Unit, San Raffaele Hospital Milan, Milan, Italy|Unità Operativa Complessa di Endocrinologia e Dialettologia. Università Campus Bio-Medico di Roma, Rome, Italy",,https://ClinicalTrials.gov/show/NCT02814838
NCT02816099,Influence of Glycaemic Balance on the Ability of Apolipoprotein C1 to Inhibit Cholesteryl Ester Transfer Protein in Type-1 Diabetes Patients,ApoC1,Unknown status,No Results Available,diabète de Type 1,Biological: Prise de sang,Comparaison of linear correlation coefficients between plasma concentrations of apoC1 and CETP activity,Centre Hospitalier Universitaire Dijon,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,240,Other,Interventional,Intervention Model: Parallel Assignment|Masking: None (Open Label),BOUILLET AOI 2015,Nov-14,Mar-17,null,28-Jun-16,null,28-Jun-16,"CHU de Besançon, Besancon, France|CHU Dijon Bourgogne, Dijon, France",,https://ClinicalTrials.gov/show/NCT02816099
NCT02813421,Continue Glucose Monitoring Before Insulin Pump,,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: CGM Informed,Percentage time within target blood glucose (range: 70-180 mg/dL)|Percentage of time within target blood glucose (range: 70-180 mg/dL)|Mean Blood Glucose (mg/dL)|Blood Glucose Standard Deviation (mg/dL)|Total daily insulin dose (units)|Percentage basal insulin (%)|Total number of insulin dose adjustments|Total number of phone calls to clinic hotline|Number of insulin dose adjustments made per phone call|Episodes of hyperglycemia|Episodes of hypoglycemia|Hemoglobin A1c (%)|Patient/Parent Satisfaction|Nursing/physician Satisfaction,Children's Hospital Los Angeles,All,"2 Years to 24 Years   (Child, Adult)",Not Applicable,11,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,CHLA-15-00535,Mar-16,1-May-17,1-May-17,27-Jun-16,null,9-May-17,"Children's Hospital Los Angeles, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT02813421
NCT02814123,Effect of Basal-Bolus Closed-Loop Co-Administration of Insulin and Pramlintide on Improving the Glycemic Control in Type 1 Diabetes,,Recruiting,No Results Available,"Diabetes Mellitus, Type 1",Other: 24-hour inpatient intervention,"Percentage of time of plasma glucose levels spent in target range. Target range is defined to be between 3.9 and 10.0 mmol/L of fast-acting insulin-plus-pramlintide closed-loop delivery vs. fast-acting insulin-alone closed-loop delivery.|Percentage of time of plasma glucose levels spent in target range. Target range is defined to be between 3.9 and 10.0 mmol/L of regular insulin-plus-pramlintide closed-loop delivery vs. fast-acting insulin-alone closed-loop delivery.|Percentage of time of plasma glucose levels spent in target range, comparing fast-acting insulin-plus-pramlintide closed-loop delivery vs. regular insulin-plus-pramlintide closed-loop delivery.|Percentage of time (8:00-8:00) of plasma glucose levels spent: a. 3.9-7.8 mmol/L; b. 3.9-10 mmol/L; c. <3.9 mmol/L; d. <3.3 mmol/L; e. <2.8 mmol/L; f. >7.8 mmol/L; g. >10 mmol/L; h. >13.9 mmol/L; i. >16.7 mmol/L|Percentage of overnight time (23:00-8:00) of plasma glucose levels: a. 3.9-7.8 mmol/L; b. 3.9-10 mmol/L; c. <3.9 mmol/L; d. <3.3 mmol/L; e. <2.8 mmol/L; f. >7.8 mmol/L; g. >10 mmol/L; h. >13.9 mmol/L; i. >16.7 mmol/L|Standard deviation of glucose levels as a measure of glucose variability.|Total insulin delivery.|Total pramlintide delivery.|Mean plasma glucose level during: a. the overall study period; b. overnight period.|Mean plasma insulin concentration.|Mean plasma glucagon concentration.|Mean plasma amylin concentration.|Number of subjects experiencing hypoglycemia requiring oral treatment during: a. the overall study period; b. the night.|Gastrointestinal symptoms during the treatment optimization (i.e., the minimum 10 days prior to the 24-hour closed-loop visits) and during the 24-hour closed-loop visits.",McGill University,All,"18 Years and older   (Adult, Older Adult)",Phase 2,28,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MAP-1,13-Jan-17,30-Jun-18,30-Jun-18,27-Jun-16,null,8-Jan-18,"McGill University Health Centre, Montréal, Quebec, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT02814123/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT02814123/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02814123
NCT02812498,Teleconsultation in Type 1 Diabetes Mellitus,TELEDIAB,Completed,No Results Available,Type 1 Diabetes Mellitus,Other: Teleconsultation|Other: Standard,"glycosylated hemoglobin HbA1c|HbA1c glycosylated hemoglobin|Patient satisfactory assessment by a questionnaire on their perception of advantages (diabetes management, comfort and convenience) and limits (technical problems, poor interaction with physicians) of the service|Cost analysis by patient estimation through a questionnaire of the overall cost and time saved thanks to the service",Niguarda Hospital,All,"5 Years to 50 Years   (Child, Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,535-B-102014,Jan-15,Jul-18,Sep-18,24-Jun-16,null,15-Mar-19,"AO Ospedale Civile Legnano Legnano, Legnano, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy",,https://ClinicalTrials.gov/show/NCT02812498
NCT02806960,A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes,,Terminated,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Drug: LY900018,Pharmacokinetics (PK): Area Under the Curve from Time Zero to the Last Quantifiable Concentration (AUC[0-t]) of LY900018|PK: Area Under the Curve Extrapolated to Infinity (AUC[0-inf]) of LY900018|PK: Time to Maximum Concentration (Tmax) of LY900018|PK: Maximum Concentration (Cmax) of LY900018|Pharmacodynamics (PD): Area Under the Effect Concentration Time Curve (AUEC₀₋₁.₅) of Blood Glucose (BG)|PD: Tmax of BG|PD: Cmax of BG,Eli Lilly and Company|Locemia Solutions ULC,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,12,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science,16493|I8R-MC-IGBH|AMG110|AMG-P4-459,Jun-14,Jun-14,Jul-14,21-Jun-16,null,18-Oct-16,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mount-Royal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02806960
NCT02806973,A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Drug: LY900018,"Pharmacokinetics (PK): Area Under the Curve from Time Zero to the Last Quantifiable Concentration (AUC[0-t]) of LY900018 Quantifiable Concentration (AUC[0-t]) of LY900018|PK: Area Under the Curve Extrapolated to Infinity (AUC[0-inf]) of LY900018|PK: Time to Maximum Concentration (Tmax) of LY900018|PK: Maximum Concentration (Cmax) of LY900018|Pharmacodynamics (PD): Area Under the Effect Concentration Time Curve (AUEC₀₋₁.₅, ₀₋₃) of Blood Glucose (BG)|PD: Tmax of BG|PD: Cmax of BG",Eli Lilly and Company|Locemia Solutions ULC,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,32,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science,16428|I8R-MC-IGBG|AMG112|AGL-P5-310,Jan-15,Apr-15,Apr-15,21-Jun-16,null,21-Jun-16,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mount-Royal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02806973
NCT02807155,Let's Empower and Prepare Young Adults With Type 1 Diabetes,LEAP,Completed,No Results Available,Type 1 Diabetes Mellitus,Behavioral: Transition Empowerment Program|Behavioral: Transition Empowerment Program + Diabetes Wellness Council|Behavioral: Online Transition Empowement Program Access,Number of Routine Diabetes Clinic Visits|Hemoglobin A1C|Incidence of Hypoglycemia|Health Care Utilization|Diabetes Empowerment Scale- Short Form|Diabetes Knowledge Test- Adapted|Perceived Stress Scale- Adapted|Patient Health Questionnaire-9|Satisfaction with Life Scale|Arizona Integrative Outcomes Scale,University of Southern California|The Leona M. and Harry B. Helmsley Charitable Trust,All,19 Years to 25 Years   (Adult),Not Applicable,104,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2010PG-T1D011,Oct-09,Jul-13,null,21-Jun-16,null,21-Jun-16,"University of Southern California, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT02807155
NCT02803892,Monotherapy With Rapamycin in Long-standing Type 1 Diabetes,MONORAPA,Recruiting,No Results Available,"Diabetes Mellitus, Type 1",Drug: rapamycin|Drug: Vildagliptin|Drug: Placebo 1|Drug: Placebo 2,Change from Baseline C-peptide response in the MMTT|Change from Baseline C-peptide after the MMTT|Change from Baseline insulin requirement|Change from Baseline fasting C-peptide|Change from Baseline HbA1c|Adverse Events (AEs) related to the immunosuppression|Adverse Events (AEs) and Serious Adverse Events (SAEs),Piemonti Lorenzo|Italian Diabetes Foundation|Ospedale San Raffaele,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",DRI-2/2014 MONORAPA,May-16,Dec-18,Mar-19,17-Jun-16,null,8-Feb-18,"IRCCS San Raffaele Scientific Institute, Milan, Italy",,https://ClinicalTrials.gov/show/NCT02803892
NCT02803905,Islet Transplant Alone in OMENtum,ITA-OMEN,Recruiting,No Results Available,"Islets of Langerhans Transplantation|Diabetes Mellitus, Type 1",Biological: Biological: Islet transplantation,A1c </= 6.5% and no severe hypoglycemia|Insulin requirements|Insulin secretion|Glucose control|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,Piemonti Lorenzo|Ospedale San Raffaele,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,12,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ITA OMEN,Apr-16,Mar-20,Dec-20,17-Jun-16,null,8-Feb-18,"IRCCS San Raffaele Scientific Institute, Milan, Italy",,https://ClinicalTrials.gov/show/NCT02803905
NCT02804165,Gene-virus Interactions Implicated in Type 1 Diabetes,GENEVIR,Withdrawn,No Results Available,Type 1 Diabetes,Genetic: Enterovirus vaccination,"Identification of gene-enterovirus interaction effect on T1D onset|""Precipitating"" effect of enterovirus infection on T1D.",Hospices Civils de Lyon,All,"1 Year to 60 Years   (Child, Adult)",Not Applicable,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2013-836,Jan-17,Jul-22,Jul-22,17-Jun-16,null,10-May-18,"Hospices Civils de Lyon, Lyon, France",,https://ClinicalTrials.gov/show/NCT02804165
NCT02801942,Immune Profile in Subjects With New Onset Type 1 Diabetes,,Completed,Has Results,"Diabetes Mellitus, Type 1",Procedure: Inguinal lymph node fine needle aspirate biopsy|Procedure: Inguinal lymph node core biopsy|Procedure: Peripheral blood collection|Other: Pre- and post-biopsy questionnaire,"Percentage of Leukocyte Subsets Including B Lymphocytes, Classical B Lymphocytes, Double Negative B Lymphocytes, Naive B Lymphocytes, Plasmablast and Transitional B Lymphocytes in Blood|Percentage of Leukocyte Subsets Including B Lymphocytes, Classical B Lymphocytes, Double Negative B Lymphocytes, Naive B Lymphocytes, Plasmablast and Transitional B Lymphocytes in iLN|Percentage of Leukocyte Subsets Including B-cells, Clusters of Differentiation 56 Positive (CD56+) CD16+ , CD56bright Natural Killer (NK) Cells, CD56lo CD16+, CD56lo CD16 Negative (CD56lo CD16-), Dendritic Cells, NK Cells in Blood|Percentage of Leukocyte Subsets Including B-cells, CD56+ CD16+, CD56bright NK Cells, CD56lo CD16+, CD56lo CD16-, Dendritic Cells, NK Cells in iLN|Percentage of Leukocyte Subsets Including CD56+CD16+, CD56bright NK Cells, CD56lo CD16+ and CD56lo CD16- in Blood|Percentage of Leukocyte Subsets Including CD56+CD16+, CD56bright NK Cells CD56lo CD16+ and CD56lo CD16- in iLN|Percentage of Leukocyte Subsets Including Myeloid Dendritic Cells and Plasmacytoid Dendritic Cells in Blood|Percentage of Leukocyte Subsets Including Myeloid Dendritic Cells and Plasmacytoid Dendritic Cells in iLN|Percentage of Leukocyte Subsets Including CD14+ CD16+ Monocytes, CD14+ Monocytes, and CD16+ Monocytes in Blood|Percentage of Leukocyte Subsets Including CD14+ CD16+ Monocytes, CD14+ Monocytes and CD16+ Monocytes in iLN|Percentage of Leukocyte Subsets Including CD45RA+ Effector Memory CD8, Central Memory CD8, Effector Memory CD8, Naive CD8 and Stem Cell Memory-like CD8 Cells in Blood|Percentage of Leukocyte Subsets Including CD45RA+ Effector Memory CD8, Central Memory CD8, Effector Memory CD8, Naive CD8 and Stem Cell Memory-like CD8 Cells in iLN|Percentage of Leukocyte Subsets Including Programmed Death 1 (PD-1)+ Inducible Costimulator (ICOS)+ Follicular Helper T (TFH) Cell-like Regulatory (Reg) T Cells in Blood|Percentage of Leukocyte Subsets Including PD-1+ ICOS+ TFH Cell-like Reg T Cells in iLN|Percentage of Leukocyte Subsets Including PD-1+ ICOS+ TFH Cells in Blood|Percentage of Leukocyte Subsets Including PD-1+ ICOS+ TFH Cells in iLN|Percentage of Leukocyte Subsets Including Central Memory Conventional (Conv) T Cells, Effector Memory Conv T Cells, Naive Conv T Cells and Stem Cell Memory-like Conv T Cells in Blood|Percentage of Leukocyte Subsets Including Central Memory Conv T Cells, Effector Memory Conv T Cells, Naive Conv T Cells and Stem Cell Memory-like Conv T Cells in iLN|Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, Type 17 T Helper (TH17) Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 T Cells, TH1 TH2 Cells, TH2 Cells, and TH22 Cells in Blood|Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, Type 17 T Helper (TH17) Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 T Cells, TH1 TH2 Cells, TH2 Cells, and TH22 Cells in iLN|Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 Cells, TH1 TH2 Cells, TH17 Cells, TH2 Cells and TH22 Cells-like Reg T Cells in Blood|Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 Cells, TH1 TH2 Cells, TH17 Cells, TH2 Cells and TH22 Cells-like Reg T Cells in iLN|Percentage of Leukocyte Subsets Including Reg T Cells in Blood|Percentage of Leukocyte Subsets Including Reg T Cells in iLN|Percentage of Leukocyte Subsets Including CD69+ CD8 and Antigen Ki67 (Ki67)+ CD8 in Blood|Percentage of Leukocyte Subsets Including CD69+ CD8 and Antigen Ki67 (Ki67)+ CD8 in iLN|Percentage of Leukocyte Subsets Including CD15s+ Reg T Cells, CD69+ Reg T Cells, Helios+ Reg T Cells, Ki67+ T Reg Cells, Memory Reg T Cells and Resting Reg T Cells in Blood|Percentage of Leukocyte Subsets Including CD15s+ Reg T Cells, CD69+ Reg T Cells, Helios+ Reg T Cells, Ki67+ T Reg Cells, Memory Reg T Cells and Resting Reg T Cells in iLN|Percentage of Leukocyte Subsets Including CD15s+ Conv T Cells, CD69+ Conv T Cells, Helios+ Conv T Cells and Ki67+ Conv T Cells in Blood|Percentage of Leukocyte Subsets Including CD15s+ Conv T Cells, CD69+ Conv T Cells, Helios+ Conv T Cells and Ki67+ Conv T Cells in iLN|Percentage of Leukocyte Subsets Including CD15s+ Memory Conv T Cells, CD69+ Memory Conv T Cells, Helios+ Memory Conv T Cells and Ki67+ Memory Conv T Cells in Blood|Percentage of Leukocyte Subsets Including CD15s+ Memory Conv T Cells, CD69+ Memory Conv T Cells, Helios+ Memory Conv T Cells and Ki67+ Memory Conv T Cells in iLN|Percentage of Leukocyte Subsets Including B Lymphocytes, Classical B Lymphocytes, Double Negative B Lymphocytes, Naive B Lymphocytes, Plasmablast and Transitional B Lymphocytes in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including B-cells, CD56+ CD16+, CD56bright NK Cells, CD56lo CD16+, CD56lo CD16, Dendritic Cells, NK Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including CD56+CD16+, CD56br NK Cells CD56lo CD16+ and CD56lo CD16- in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including Myeloid Dendritic Cells and Plasmacytoid Dendritic Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including CD14+ CD16+ Monocytes, CD14+ Monocytes and CD16+ Monocytes in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including CD45RA+ Effector Memory CD8, Central Memory CD8, Effector Memory CD8, Naive CD8 and Stem Cell Memory-like CD8 in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including PD-1+ ICOS+ TFH Cell-like Reg T Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including PD-1+ ICOS+ TFH Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including Central Memory Conv T Cells, Effector Memory Conv T Cells, Naive Conv T Cells and Stem Cell Memory-like Conv T Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, TH17 Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 T Cells, TH1 TH2 Cells, TH2 Cells, and TH22 Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 Cells, TH1 TH2 Cells, TH17 Cells, TH2 Cells and TH22 Cells-like Reg T Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including Reg T Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including CD69+ CD8 and Antigen Ki67 (Ki67)+ CD8 in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including CD15s+ Reg T Cells, CD69+ Reg T Cells, Helios+ Reg T Cells, Ki67+ T Reg Cells, Memory Reg T Cells and Resting Reg T Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including CD15s+ Conv T Cells, CD69+ Conv T Cells, Helios+ Conv T Cells and Ki67+ Conv T Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including CD15s+ Memory Conv T Cells, CD69+ Memory Conv T Cells, Helios+ Memory Conv T Cells and Ki67+ Memory Conv T Cells in iLN Core Biopsies and iLN FNA|Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs|Number of Participants Undergoing Procedure Under Local Anesthetics|Number of Participants Undergoing iLN Biopsy Under Local Anesthetics|Number of Participants With Different Reasons for Participating in the Study|Number of Participants With Extreme Anxiety Towards the Lymph Node Biopsy|Number of Participants Looking Forward to Undergo the Procedure|Number of Participants With Aspects Better Explained About the Lymph Node Biopsy Procedure|Number of Participants Who Considered to Undergo Lymph Node Biopsy Procedure Another Time|Number of Participants Who Were Encouraged to be Included in Study for iLN Biopsy|Number of Participants Who Appreciated Receiving Study Feedback",GlaxoSmithKline,All,18 Years to 40 Years   (Adult),Not Applicable,22,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,203158,25-Jul-16,21-Dec-17,21-Dec-17,16-Jun-16,27-Feb-19,27-Feb-19,"GSK Investigational Site, Cambridge, United Kingdom|GSK Investigational Site, Cardiff, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02801942/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02801942/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02801942
NCT02798250,Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation - Part 2,,Completed,No Results Available,Type 1 Diabetes,Other: Dual-hormone closed-loop|Drug: Insulin|Drug: Glucagon|Device: Dexcom G4 Platinum glucose sensor|Device: Accu Chek Combo insulin pump,Percentage of time below 4.0 mmol/L|Mean glucose|Percentage of time of glucose concentrations between 4.0 and 8.0 mmol/L|Percentage of time of glucose concentrations between 4.0 and 10.0 mmol/L|Percentage of time of glucose concentrations below 3.1 mmol/L|Area under the curve of glucose values below 4.0 mmol/L|Area under the curve of glucose values below 3.1 mmol/L|Number of patients with at least one hypoglycemic event with or without symptoms|Total number of hypoglycemic event below 3.1 mmol/L|Total carbohydrate intake for hypoglycemia correction|Total insulin delivery|Total glucagon delivery,Institut de Recherches Cliniques de Montreal,All,"18 Years and older   (Adult, Older Adult)",Phase 2,11,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,CLASS-Safety study - Part 2,Jun-16,Mar-17,Mar-17,14-Jun-16,null,26-Apr-17,"Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02798250
NCT02796950,The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion,,Completed,No Results Available,Diabetes Mellitus Type 2,Drug: Acipimox,Levels of GLP-1 in plasma|Lipolytic activity in adipose tissue by measuring FFA (free fatty acid) levels|Insulin sensitivity by measuring blood glucose after an OGTT,University of Aarhus,Male,20 Years to 50 Years   (Adult),Not Applicable,8,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,GLP-1-16-02-261-16,Jun-16,20-Jan-17,20-Jan-17,13-Jun-16,null,8-May-18,"University Hospital of Aarhus, Aarhus, Denmark",,https://ClinicalTrials.gov/show/NCT02796950
NCT02797730,Study of Impact of Art Therapy Sessions Given to Family Caregivers of Children With Type 1 Diabetes,EDUCARTPED,Completed,No Results Available,Quality of Life,Behavioral: art-therapy sessions,PedsQL Family Impact score to assess Family Quality of Life|Anxiety score of caregivers|self esteem score of caregivers|quality of life score|satisfaction score,Poitiers University Hospital,All,18 Years to 60 Years   (Adult),Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,EDUCARTPED,May-16,Aug-16,Aug-16,13-Jun-16,null,12-Oct-16,"La rochelle, La rochelle, France|NIORT, Niort, France|POITIERS, Poitiers, France",,https://ClinicalTrials.gov/show/NCT02797730
NCT02793427,Patient With Any Pathology (According to the Appreciation of the Investigator) Which Could Disturb the Participation in the Study,AGEDIA,"Active, not recruiting",No Results Available,Type 1 Diabetes in Children,Biological: blood sample collection,Serum AGEs,CHU de Reims,All,"1 Year to 18 Years   (Child, Adult)",Not Applicable,160,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,PA10007,Feb-11,Jun-19,null,8-Jun-16,null,9-Jun-16,"Chu Reims, Reims, France",,https://ClinicalTrials.gov/show/NCT02793427
NCT02794155,Study of HDV Insulin Versus Insulin in Type 1 Diabetes Subjects (ISLE-1),ISLE-1,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: HDV Insulin Lispro|Drug: Insulin LISPRO,"Change in HbA1c|Change in fasting blood glucose glucose levels|Hypoglycemia occurrences by category: Severe, Documented Symptomatic, and Asymptomatic Hypoglycemia|Number of Patients with Adverse Events|Change in total insulin usage|Change in Body Weight|Mean Mixed Meal Tolerance Test",Diasome Pharmaceuticals|Integrium,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,157,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DP 01-2015-01,Jun-16,28-Apr-18,15-Jun-18,8-Jun-16,null,31-Jul-18,"Hope & Wellness Clinical Trials, Inc., Corona, California, United States|National Research Institute, Los Angeles, California, United States|California Medical Research Associates Inc., Northridge, California, United States|Bay Area Clinical Research, San Carlos, California, United States|Mills-Peninsula Health Services, San Mateo, California, United States|Orange County Research Center, Tustin, California, United States|Creekside Endocrine Associates, PC, Denver, Colorado, United States|Advanced Pharma CR, LLC, Miami, Florida, United States|Ormond Medical Arts Pharmaceutical Research Center, Ormond Beach, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Endocrine Research Solutions, Inc., Roswell, Georgia, United States|Rocky Mountain Diabetes & Osteoporosis Center, PA, Idaho Falls, Idaho, United States|Associates in Endocrinology, Elgin, Illinois, United States|University of Massachusetts Memorial Hospital, Worcester, Massachusetts, United States|Desert Endocrinology Clinical Research Center, Henderson, Nevada, United States|SUNY Upstate Medical University, Syracuse, New York, United States|LION Research, Norman, Oklahoma, United States|Endocrine and Psychiatry Center, Houston, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Rainier Clinical Research Center, Inc., Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT02794155
NCT02790645,Telemedicine Program in Type 1 Diabetes and CSII,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Other: Group 2a. Telemedicine program|Other: Group 1a. Control|Other: Group 1b.Telemedicine program|Other: Group 2b. Control,Assessment of clinical and metabolic parameters (glycosylated hemoglobin-HbA1c- and glycemic variability-SD-).|Assessment of inflammatory markers (hs-CRP).|Assessment of inflammatory markers (IL-6).|Assessment of inflammatory markers (TNF-α).|Assessment of inflammatory markers (MCP-1).|Assessment of redox markers (CAT).|Assessment of redox markers (TBARS).|Assessment of redox markers (oxidized LDL).|Assessment of quality of life with the DQOL|Assessment of depression with the BDI-II|Assessment of anxiety with the STAI|Assessment of distress related to diabetes with the DDS|Assessment of treatment satisfaction with the DTSQ|Assessment of fear of hypoglycemia with the FH-15|Assessment of cost-effectiveness with a structured interview designed by our research group of direct and indirect costs.,"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud|Ministerio de Economía y Competitividad, Spain|Andaluz Health Service|Roche Pharma AG",All,"16 Years to 85 Years   (Child, Adult, Older Adult)",Not Applicable,51,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CSII TELEMEDICINE PROGRAM,Sep-12,Apr-16,19-Sep-16,6-Jun-16,null,13-Jul-17,,,https://ClinicalTrials.gov/show/NCT02790645
NCT02790892,Creative Arts Diabetes Initiative for Youth/Young Adults Transitioning to Adult Care,CADI,Completed,No Results Available,"Coping Behavior|Emotional Distress|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Behavioral: Art therapy - pre and post test measures,Decrease diabetes related distress|Increase social support|Increase emotional,University of Manitoba,All,"15 Years to 24 Years   (Child, Adult)",Not Applicable,12,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,HS19577 (H2016:119),Apr-16,21-Jan-19,21-Jan-19,6-Jun-16,null,23-Jan-19,"University of Manitoba, Winnipeg, Manitoba, Canada",,https://ClinicalTrials.gov/show/NCT02790892
NCT02791035,"Correlation Between Change of HbA1c, Urinary Glucose Excretion and Other Factors in Patients Treated With Ipragliflozin",,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Oral administration of Ipragliflozin,"Correlation between change of HbA1c and urinary glucose excretion|Correlation between reduction in HbA1c and various parameters (HOMA-IR, HOMA-ß, insulinogenic index)|Correlation between increase in urinary glucose excretion and various parameters (HOMA-IR, HOMA-ß, insulinogenic index)|Change of HbA1c|Chang e of fasting glucose|Change of waist circumference|Percentage of subjects achieving the target HbA1c(<6.5%)","Asan Medical Center|Severance Hospital|Samsung Medical Center|Kyung Hee University Hospital at Gangdong|Astellas Pharma Korea, Inc.",All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 4,100,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,AMC 2016-0100,Jun-16,Mar-17,Mar-17,6-Jun-16,null,5-Jul-17,"Asan Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02791035
NCT02786953,Sleep Promotion to Improve Diabetes Management in Adolescents With T1D,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Behavioral: Sleep Promotion,Sleep Quality|Glycemic Control (HbA1c)|Sleep Duration|Quality of Life (PedsQL)|Adherence (Self Care Inventory),Vanderbilt University Medical Center,All,13 Years to 17 Years   (Child),Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,151271,19-Oct-17,23-Oct-18,5-Feb-19,1-Jun-16,null,5-Apr-19,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT02786953
NCT02787551,"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period",LixiLan-G,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: insulin glargine/lixisenatide fixed ratio combination|Drug: liraglutide|Drug: exenatide|Drug: exenatide extended-release|Drug: albiglutide|Drug: dulaglutide|Drug: metformin|Drug: pioglitazone|Drug: SGLT2 inhibitor,Change from baseline in HbA1c|Percentage of participants reaching HbA1c targets|Change from baseline in fasting plasma glucose (FPG)|Change from baseline in 7-point self-monitored plasma glucose (SMPG) profiles|Change from baseline in 2-hour postprandial glucose (PPG) during standardized meal test|Change from baseline in blood glucose excursion during standardized meal test|Change from baseline in body weight|Percentage of participants with symptomatic hypoglycemia|Number of adverse events|Percentage of patients requiring rescue therapy,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,515,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EFC13794|2014-004850-32|U1111-1168-4639,6-Jul-16,25-May-18,17-Nov-18,1-Jun-16,null,6-Mar-19,"Investigational Site Number 8400064, Birmingham, Alabama, United States|Investigational Site Number 8400073, Fountain Hills, Arizona, United States|Investigational Site Number 8400047, Phoenix, Arizona, United States|Investigational Site Number 8400103, Bakersfield, California, United States|Investigational Site Number 8400137, Fresno, California, United States|Investigational Site Number 8400043, Huntington Park, California, United States|Investigational Site Number 8400124, Lamont, California, United States|Investigational Site Number 8400027, Lancaster, California, United States|Investigational Site Number 8400098, Los Angeles, California, United States|Investigational Site Number 8400013, Los Angeles, California, United States|Investigational Site Number 8400042, Mission Hills, California, United States|Investigational Site Number 8400006, Northridge, California, United States|Investigational Site Number 8400021, Orange, California, United States|Investigational Site Number 8400126, Rialto, California, United States|Investigational Site Number 8400094, Santa Ana, California, United States|Investigational Site Number 8400009, Ventura, California, United States|Investigational Site Number 8400071, Denver, Colorado, United States|Investigational Site Number 8400036, Denver, Colorado, United States|Investigational Site Number 8400114, Jacksonville, Florida, United States|Investigational Site Number 8400133, Miami, Florida, United States|Investigational Site Number 8400058, Port Charlotte, Florida, United States|Investigational Site Number 8400084, Tampa, Florida, United States|Investigational Site Number 8400112, West Palm Beach, Florida, United States|Investigational Site Number 8400045, Lawrenceville, Georgia, United States|Investigational Site Number 8400096, Snellville, Georgia, United States|Investigational Site Number 8400023, Springfield, Illinois, United States|Investigational Site Number 8400049, Avon, Indiana, United States|Investigational Site Number 8400053, Avon, Indiana, United States|Investigational Site Number 8400085, Avon, Indiana, United States|Investigational Site Number 8400120, Avon, Indiana, United States|Investigational Site Number 8400041, Evansville, Indiana, United States|Investigational Site Number 8400038, Indianapolis, Indiana, United States|Investigational Site Number 8400130, Council Bluffs, Iowa, United States|Investigational Site Number 8400034, Lexington, Kentucky, United States|Investigational Site Number 8400091, Lexington, Kentucky, United States|Investigational Site Number 8400078, Marrero, Louisiana, United States|Investigational Site Number 8400032, Metairie, Louisiana, United States|Investigational Site Number 8400088, New Orleans, Louisiana, United States|Investigational Site Number 8400033, Baltimore, Maryland, United States|Investigational Site Number 8400051, Jefferson City, Missouri, United States|Investigational Site Number 8400083, Papillion, Nebraska, United States|Investigational Site Number 8400044, Henderson, Nevada, United States|Investigational Site Number 8400079, Albany, New York, United States|Investigational Site Number 8400061, New York, New York, United States|Investigational Site Number 8400123, North Massapequa, New York, United States|Investigational Site Number 8400095, Staten Island, New York, United States|Investigational Site Number 8400067, West Seneca, New York, United States|Investigational Site Number 8400111, Yonkers, New York, United States|Investigational Site Number 8400020, Morehead City, North Carolina, United States|Investigational Site Number 8400065, Wilmington, North Carolina, United States|Investigational Site Number 8400018, Fargo, North Dakota, United States|Investigational Site Number 8400019, Columbus, Ohio, United States|Investigational Site Number 8400056, Dayton, Ohio, United States|Investigational Site Number 8400125, Mentor, Ohio, United States|Investigational Site Number 8400099, Oklahoma City, Oklahoma, United States|Investigational Site Number 8400129, Scottdale, Pennsylvania, United States|Investigational Site Number 8400076, Smithfield, Pennsylvania, United States|Investigational Site Number 8400104, Warwick, Rhode Island, United States|Investigational Site Number 8400090, Columbia, South Carolina, United States|Investigational Site Number 8400139, Austin, Texas, United States|Investigational Site Number 8400001, Dallas, Texas, United States|Investigational Site Number 8400118, Edinburg, Texas, United States|Investigational Site Number 8400008, Houston, Texas, United States|Investigational Site Number 8400109, Houston, Texas, United States|Investigational Site Number 8400063, Houston, Texas, United States|Investigational Site Number 8400106, Houston, Texas, United States|Investigational Site Number 8400014, North Richland Hills, Texas, United States|Investigational Site Number 8400089, San Antonio, Texas, United States|Investigational Site Number 8400135, Schertz, Texas, United States|Investigational Site Number 8400075, Shavano Park, Texas, United States|Investigational Site Number 8400107, Sugar Land, Texas, United States|Investigational Site Number 8400054, Orem, Utah, United States|Investigational Site Number 8400025, Salt Lake City, Utah, United States|Investigational Site Number 8400092, Weber City, Virginia, United States|Investigational Site Number 1240003, Burlington, Canada|Investigational Site Number 1240006, Corunna, Canada|Investigational Site Number 1240002, Red Deer, Canada|Investigational Site Number 1240001, Vancouver, Canada|Investigational Site Number 2330002, Pärnu, Estonia|Investigational Site Number 2330003, Tallinn, Estonia|Investigational Site Number 2330001, Tallinn, Estonia|Investigational Site Number 2330004, Viljandimaa, Estonia|Investigational Site Number 2760001, Dresden, Germany|Investigational Site Number 2760003, Oldenburg In Holstein, Germany|Investigational Site Number 3760001, Haifa, Israel|Investigational Site Number 3760002, Haifa, Israel|Investigational Site Number 3760005, Jerusalem, Israel|Investigational Site Number 3760006, Jerusalem, Israel|Investigational Site Number 3760004, Tel Aviv, Israel|Investigational Site Number 3800008, Bergamo, Italy|Investigational Site Number 3800002, Bologna, Italy|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800006, Milano, Italy|Investigational Site Number 3800005, Napoli, Italy|Investigational Site Number 3800004, Roma, Italy|Investigational Site Number 3800003, Roma, Italy|Investigational Site Number 6420004, Bacau, Romania|Investigational Site Number 6420006, Brasov, Romania|Investigational Site Number 6420001, Bucuresti, Romania|Investigational Site Number 6420008, Buzau, Romania|Investigational Site Number 6420003, Cluj Napoca, Romania|Investigational Site Number 6420002, Oradea, Romania|Investigational Site Number 6420009, Targoviste, Romania|Investigational Site Number 6420005, Timisoara, Romania|Investigational Site Number 6420007, Târgu Mureș Judetul. Mures, Romania|Investigational Site Number 7030006, Bratislava, Slovakia|Investigational Site Number 7030009, Lubochna, Slovakia|Investigational Site Number 7030002, Lucenec, Slovakia|Investigational Site Number 7030005, Malacky, Slovakia|Investigational Site Number 7030007, Presov, Slovakia|Investigational Site Number 7030001, Roznava, Slovakia|Investigational Site Number 7030008, Sabinov, Slovakia|Investigational Site Number 7030004, Trencin, Slovakia|Investigational Site Number 7030003, Zilina, Slovakia|Investigational Site Number 7240012, Alzira, Spain|Investigational Site Number 7240005, Barcelona, Spain|Investigational Site Number 7240002, Ferrol, Spain|Investigational Site Number 7240008, Málaga, Spain|Investigational Site Number 7240011, Pozuelo De Alarcón, Spain|Investigational Site Number 7240003, Quart De Poblet, Spain|Investigational Site Number 7240006, Sabadell, Spain|Investigational Site Number 7240007, Sevilla, Spain|Investigational Site Number 7240009, sEVILLA, Spain|Investigational Site Number 7240004, Sevilla, Spain",,https://ClinicalTrials.gov/show/NCT02787551
NCT02784236,INTEGRATED IMPACT ASSESSMENT a Telemedicine Program in the Care of Patients With Diabetes Mellitus Type 1 Intensive Treatment With Multiple Daily Injections.,,Completed,No Results Available,Metabolic Impact,Device: telemedicine,To analyze the metabolic impact measured through HbA1c of a telemedicine program by MenaDiab® online platform in the care of patients with DM1.,Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,121,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,STUDY TC MENARINI,Apr-14,Mar-16,Sep-16,27-May-16,null,6-Feb-17,"FIMABIS, Malaga, Spain",,https://ClinicalTrials.gov/show/NCT02784236
NCT02777073,Effects of Single Doses of Liraglutide and Dapagliflozin on Hyperglycemia and Ketogenesis in Type 1 Diabetes,1974,Completed,No Results Available,Type 1 Diabetes,Drug: Farxiga|Drug: Victoza|Drug: Placebo,difference in ketone bodies formation after single dose of liraglutide and dapagliflozin|effect of liraglutide and dapagliflozin on glucagon concentrations|effect of liraglutide and dapagliflozin on Free Fatty Acid|effect of liraglutide and dapagliflozin on C-Reactive Protein|effect of liraglutide and dapagliflozin on IL-6 and IL1-b,University at Buffalo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,2,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1974,Mar-16,Dec-16,Dec-16,19-May-16,null,9-Feb-17,"ECMC Ambulatory Center, 3rd Floor, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT02777073
NCT02776007,"Patients Perceptions of Using the ""Libre"" System Compared With Conventional SMBG in Adolescents With Type 1 Diabetes The Libre Sat Trial",,"Active, not recruiting",No Results Available,Type 1 Diabetes,Device: Libre Flash CGMS|Device: Self-Measurement Blood Glucose,Diabetes Treatment satisfaction questionnaire|Libre-user evaluation questionnaire|Glycemic control measured by HbA1c,Rabin Medical Center|Abbott,All,12 Years to 17 Years   (Child),Not Applicable,60,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RMC023516Ctil,Jul-16,Dec-18,Mar-19,18-May-16,null,15-May-18,"Schneider Children's Medical Center, Petach-Tikva, Israel",,https://ClinicalTrials.gov/show/NCT02776007
NCT02776696,Comparison of Two Closed-Loop Strategies for Glucose Control in Type 1 Diabetes The DREMED Trail- 2,,Recruiting,No Results Available,Type 1 Diabetes,Device: Advanced Hybrid Closed Loop System|Device: Hybrid Closed Loop System,Percentage of glucose sensor readings within 70 to 180 mg/dl|Area Under the Curve of glucose sensor readings below 70 mg/dl|Percentage of glucose sensor readings below 70 mg/dl|Area Under the Curve of glucose sensor readings above 180 mg/dl|Percentage of glucose sensor readings above 180 mg/dl|Average of glucose sensor readings|Standard Deviation of glucose sensor readings|Time in glucose range of 70-180 mg/dl during day time (6am-12am)|Time in glucose range of 70-180 mg/dl during night time (12am-6am)|Area Under the Curve of glucose sensor readings above 250 mg/dL|Area Under the Curve of glucose sensor readings above 300 mg/dL|Percentage of glucose sensor readings above 250 mg/dL|Percentage of glucose sensor readings above 300 mg/dL|Area Under the Curve of glucose sensor readings below 50 mg/dL|Area Under the Curve of glucose sensor readings below 60 mg/dL|Percentage of glucose sensor readings below 50 mg/dL|Percentage of glucose sensor readings below 60 mg/dL|Percentage of time in Closed Loop|Sensor mean absolute relative difference (MARD)|Total insulin dose|Serious Adverse Events (SAE)|Serious Adverse Device Events (SADE)|Unanticipated Adverse Device Effects (UADE)|Incidence of Severe Hypoglycemia|Incidence of Diabetic Ketoacidosis (DKA)|Closed-loop acceptance questionnaire,Rabin Medical Center,All,"10 Years to 40 Years   (Child, Adult)",Not Applicable,180,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,rmc082315ctil,Jun-16,Dec-18,Mar-19,18-May-16,null,19-Sep-18,"Schneider Children's Medical Center, Petach-Tikva, Israel",,https://ClinicalTrials.gov/show/NCT02776696
NCT02774876,Closed-loop Control of Postprandial Glucose Levels After Meals With Different Macronutrients Content in Adults With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Device: Patient's insulin pump|Drug: Insulin|Device: Dexcom G4 Platinum glucose sensor|Other: Single-hormone closed-loop,Area under the curve of sensor glucose levels|Mean sensor glucose levels|Peak glucose excursion|Time to peak glucose|Percentage of time of sensor glucose concentrations between 3.9 and 7.8 mmol/L|Percentage of time of sensor glucose concentrations between 3.9 and 10 mmol/L|Percentage of time of sensor glucose concentrations above 10 mmol/L|Percentage of time of sensor glucose concentrations above 13.9 mmol/L|Total insulin delivery|Standard deviation of glucose levels|Coefficient of variation of glucose levels,Institut de Recherches Cliniques de Montreal,All,"18 Years and older   (Adult, Older Adult)",Phase 2,15,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLASS-Macro,Jun-16,Sep-17,Sep-17,17-May-16,null,30-Oct-17,"Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02774876
NCT02772783,"Dietary Glycemic Index, Brain Function and Food Intake in Patients With Type 1 Diabetes Mellitus",,Completed,No Results Available,"Diabetes Mellitus, Type 1",Other: high GI meal|Other: low GI meal|Drug: euglycemic insulin clamp|Drug: primed-variable insulin infusion,"Nucleus Accumbens blood flow (right and left)|Nucleus Accumbens blood flow|blood flow in other brain areas involved in intake regulation|functional connectivity of Nucleus Accumbens, Hypothalamus and other brain areas involved in intake regulation",Boston Children’s Hospital|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital,Male,18 Years to 45 Years   (Adult),Not Applicable,15,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",IRB-P00022176|IRB- 2016P000079,Jul-16,May-18,May-18,16-May-16,null,8-May-18,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02772783
NCT02772887,Nutraceutical Citrulline in Pregnancy,,Recruiting,No Results Available,Type 2 Diabetes,Dietary Supplement: L-Citrulline|Other: Placebo,Blood pressure|Placental growth factor (PlGF),University of Pittsburgh,Female,"14 Years to 40 Years   (Child, Adult)",Not Applicable,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",PRO15090627,Aug-16,Dec-19,Dec-20,16-May-16,null,5-Jun-18,"Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02772887
NCT02773875,"Fault Detection, Zone MPC and DiAs System in T1D",ZoneMPC,Unknown status,No Results Available,Type 1 Diabetes,Device: Artificial pancreas system (Algorithm + CGM + pump),Amount of time sensor glucose levels are >250 mg/dl|Effectiveness of sensor fault detection algorithm as defined by % of sensor failures caught by the system|Mean sensor glucose values|Percent of time in range between 70-180 mg/dl,"Rensselaer Polytechnic Institute|Stanford University|University of Colorado, Denver|Harvard University|University of California, San Diego|University of California, Santa Barbara",All,18 Years to 55 Years   (Adult),Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IDE G150122,May-16,Nov-16,Dec-16,16-May-16,null,16-May-16,,,https://ClinicalTrials.gov/show/NCT02773875
NCT02772679,T1DM Immunotherapy Using Polyclonal Tregs + IL-2,TILT,"Active, not recruiting",No Results Available,Type 1 Diabetes Mellitus,Biological: PolyTregs+IL-2,"Adverse events|Survival of Tregs|C-peptide response|Insulin use|HbA1c levels|Severe hypoglycemic events|Proportion of subjects who achieve at least a 13-week reduction in insulin dose to < 0.5 units/kg in each treatment arm|Analysis of the effects of IL-2 on Treg kinetics and phenotype|Levels of unmethylated insulin DNA (assay of beta cell death)|Analysis of autoantibodies, enumeration and phenotypes islet antigen tetramer+ CD8, intracellular cytokine staining of T cells, serum proteomics, cytokines, and Treg phenotyping and functional assays|Analysis of general immune response as assessed by, for example, viral tetramer+ CD8 cells and effects of Treg infusions on peripheral blood cells measured by flow cytometry including T cell subsets, B cells and other innate cell subsets","Jeffrey Bluestone|Yale University|University of California, San Francisco",All,18 Years to 45 Years   (Adult),Phase 1,16,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16-19632,Aug-16,Jul-21,Dec-21,13-May-16,null,7-May-19,"University of California, San Francisco Medical Center, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02772679
NCT02769884,MMPPC Outpatient Clinical Protocol 2016,MMPPC,Completed,No Results Available,Type 1 Diabetes,Device: MMPPC algorithm artificial pancreas,Mean CGM glucose value|CGM percent time < 60 mg/dl|CGM percent time < 50 mg/dl|CGM percent time < 70 mg/dl|% 70-140 mg/dl|% 70-180 mg/dl|% CGM >180 mg/dl|% CGM >250 mg/dl|number of SMBG <70 mg/dl|number of SMBG <60 mg/dl|number of SMBG <50 mg/dl|Grams of carbs for hypoglycemia|Total daily dose of insulin|% time CGM used|% time in closed loop|% of subjects with mean CGM <169 (eHbA1C < 7.5%),"Rensselaer Polytechnic Institute|Stanford University|University of Colorado, Denver|Mount Sinai Hospital, New York",All,"15 Years to 55 Years   (Child, Adult)",Phase 2,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MMPPC- outpatient-2016,Jul-16,Dec-16,Dec-16,12-May-16,null,30-Jan-18,,,https://ClinicalTrials.gov/show/NCT02769884
NCT02768987,Bright 1 Bodies Weight Management Program,B1B,Completed,No Results Available,"Diabetes Mellitus, Type 1",Behavioral: Bright 1 Bodies,"Change from baseline body mass index (BMI) over 24 weeks|Change from baseline in daily physical activity energy expenditure over 24 weeks|Change from baseline in Progressive Aerobic Cardiovascular Endurance Run score over 24 weeks|Change from baseline in blood pressure over 24 weeks|Change from baseline daily insulin usage over 24 weeks|Change from baseline lipid profile over 12 weeks|Change from baseline adipocytokines over 12 weeks|Change from baseline inflammatory factors including C-reactive protein, interleukin-6, fibrinogen, and plasminogen activator inhibitor-1 over 12 weeks|Change from baseline micro RNA expression over 12 weeks|Change from baseline pediatric quality of life questionnaire score over 24 weeks|Change from baseline diabetes self-care inventory score over 24 weeks|Change from baseline hypoglycemia fear survey score over 24 weeks|Change from baseline psychosocial determinants of physical activity behavior questionnaire score over 24 weeks|Change from baseline self-perception profile for adolescents questionnaire social acceptance subscale score over 24 weeks|Change from baseline in handgrip strength over 24 weeks|Change from baseline in sit-and-reach test over 24 weeks|Change from baseline in push-up test over 24 weeks",Yale University|University of the West of Scotland|Texas A&M University,All,"11 Years to 19 Years   (Child, Adult)",Not Applicable,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,1605017843,Jul-16,31-Oct-17,8-Nov-17,11-May-16,null,30-May-18,"Yale Children's Diabetes Program, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02768987
NCT02767596,Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog,,Terminated,No Results Available,Diabetes Mellitus Type 2,Drug: Lixisenatide|Drug: Basal insulins,Change in hemoglobin A1c|Change in body weight,Laniado Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 4,2,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LIX001,12-Jul-16,Feb-17,21-Feb-17,10-May-16,null,7-Apr-17,"Bildirici Diabetes Center, Laniado Hospital, Netanya, Israel",,https://ClinicalTrials.gov/show/NCT02767596
NCT02765347,The Effects of Metformin on Glycemic Control and Insulin Sensitivity in Adolescents With T1DM,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Metformin|Drug: Insulin,HbA1c,"Third Affiliated Hospital, Sun Yat-Sen University",All,"12 Years and older   (Child, Adult, Older Adult)",Phase 4,30,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2016-T1DM,Jun-16,Jan-18,Jan-18,6-May-16,null,12-Apr-18,"The Third Affliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT02765347
NCT02763423,Allogeneic Umbilical Cord Mesenchymal Stem Cell Transplantation for Type 1 Diabetes With Diabetic Ketoacidosis,UCMSCDKA,Recruiting,No Results Available,"Ketoacidosis, Diabetic",Procedure: umbilical cord mesenchymal stem cell,Changes from baseline exogenous insulin dose at different time points post treatment|C-peptide level|HbA1c level|titres of islet antigen antibodies,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,All,"12 Years to 35 Years   (Child, Adult)",Phase 2,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NJGYNFM-SC-02,Jan-09,Dec-19,Dec-19,5-May-16,null,5-May-16,"The affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT02763423
NCT02760303,Reducing Stress in Adolescents and Young Adults With Type 1 Diabetes to Improve Diabetes Care,T1D,Completed,No Results Available,Type 1 Diabetes,Behavioral: Cognitive Behavioral Therapy|Behavioral: Mindfulness Based Stress Reduction|Behavioral: Diabetes Support and Education,Metabolic Control|Regimen Adherence (objective)|Regimen Adherence (daily diary)|Regimen Adherence (self-reported)|Psychological Stress (general)|Psychological Stress (diabetes-related)|Psychological Stress (attitudes)|Diabetes Quality of Life,Wayne State University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"16 Years to 20 Years   (Child, Adult)",Not Applicable,60,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",066115B3E|R01DK059067,Sep-15,Oct-16,May-17,3-May-16,null,2-Jun-17,"Wayne State University School of Medicine, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02760303
NCT02758483,Glucose Variability in Patients With Type 1 Diabetes With a Sucrose-added Diet,,Completed,No Results Available,Type 1 Diabetes Mellitus,Other: Control diet|Other: Test Diet,"Compare the intraday and interday glucose variability effect of sucrose-free with a sucrose-free diet for patients with type 1 diabetes.|Evaluate the intraday glycemic variability effect of foods containing different macronutrients quantity, through CONGA index.|Compare the intraday glycemic variability effect of sucrose-free diet and sucrose-added diet, through MAGE index, in patients with type 1 diabetes|Compare the interday glycemic variability effect of sucrose-free diet and sucrose-added diet, through MODD index, in patients with type 1 diabetes",Universidade Federal do Rio de Janeiro,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,UFRJNutrology,23-Mar-17,31-Jul-17,1-Jan-18,2-May-16,null,28-Sep-18,"Clementino Fraga Filho University Hospital of Rio de Janeiro, Rio de Janeiro, Brazil",,https://ClinicalTrials.gov/show/NCT02758483
NCT02755064,Relationship Between Gastric Emptying and Glycemic Variability in Type 1 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Erythromycin lactobionate|Drug: Placebo IV|Drug: [13C]-Spirulina|Drug: Erythromycin Ethylsuccinate Suspension|Drug: Placebo Suspension,Relationship between gastric emptying and glycemia|Number of subjects with delayed gastric emptying,Adil Bharucha|Mayo Clinic,All,"Child, Adult, Older Adult",Phase 1,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,08-008620|UL1TR000135,Jun-10,Nov-13,Nov-13,28-Apr-16,null,28-Apr-16,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02755064
NCT02752880,The Efficacy and Safety of Chinese Herbal Medicine YH1 as Add-On Medication in Poorly Controlled Type 2 Diabetes Patients,,Completed,No Results Available,Type 2 Diabetes,Drug: YH1|Drug: placebo,change in HbA1c,Chang Gung Memorial Hospital,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,46,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","104-7934A3,105-7009C,106-0917C",Jun-16,Feb-18,Feb-18,27-Apr-16,null,20-Mar-18,"Taoyuan, Taiwan",,https://ClinicalTrials.gov/show/NCT02752880
NCT02750267,Closed-Loop Control in Young Children 5-8 Years Old Using DiAs Platform,,Completed,Has Results,"Diabetes Mellitus, Type 1",Device: Diabetes Assistant (DiAs) with Closed-Loop,"Percent of Sensor Glucose Readings Between 70-180 mg/dL|Percent of Time Sensor Glucose Readings Are <70 mg/dL|Percent of Time Sensor Glucose Readings Are >150 mg/dL|Percent of Time Sensor Glucose Readings Are >180 mg/dL|Percent of Time Sensor Glucose Readings Are >250 mg/dL|Percent of Time Sensor Glucose Readings Are >400 mg/dL|Distribution of Sensor and Meter Glucose Values (Maximum, Minimum, Median, Interquartile Range, Mean, Standard Deviation)|Distribution of Sensor and Meter Glucose Values (Maximum)|Distribution of Sensor and Meter Glucose Values (Minimum)|Distribution of Sensor and Meter Glucose Values (Median/Interquartile Range)|Mean BG (as Measured by CGM)|Hypoglycemia Area Under the Curve <60|Hypoglycemia Area Under the Curve <70 mg/dL|Hyperglycemia Area Under the Curve >180|Hyperglycemia Area Under the Curve >250 mg/dL|Incidence of Hypoglycemia Per Subject, Defined by Handheld Meter Glucose <70 mg/dL|End of Night Blood Glucose","University of Virginia|DexCom, Inc.",All,5 Years to 9 Years   (Child),Not Applicable,12,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18888,May-16,May-16,May-16,25-Apr-16,23-Jun-17,24-Jul-17,"University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02750267
NCT02747680,Cerebral Responses to Insulin Induced Hypoglycemia,1018,Recruiting,No Results Available,Type 1 Diabetes|Healthy|Hypoglycemia Unawareness,Other: hypoglycemia (low blood sugar) in MRI,Brain activation during euglycemia (normal blood sugar) using functional MRI|Brain activation during hypoglycemia (low blood sugar) using functional MRI,University of Minnesota - Clinical and Translational Science Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,0301M40641,Jan-03,Dec-19,Dec-19,22-Apr-16,null,13-Mar-19,"University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02747680
NCT02748018,Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home,,Recruiting,No Results Available,Type 1 Diabetes,Device: 670G Insulin Pump|Device: Subject's Current Diabetes Therapy,CSII Cohort: change of A1C (∆A1C) for subjects with baseline A1c > 8%|CSII Cohort: Time in Hypoglycemic Range for subjects with baseline A1c ≤ 8%|MDI Cohort: change of A1C (∆A1C) for subjects with baseline A1c > 8%|MDI Cohort: Time in Hypoglycemic Range for subjects with baseline A1c ≤ 8%|SAP Cohort: change of A1C (∆A1C) for subjects with baseline A1c > 8%|SAP Cohort: Time in Hypoglycemic Range for subjects with baseline A1c ≤ 8%|CSII Cohort: Time in Hypoglycemic Range for subjects with baseline A1c > 8%|CSII Cohort: Change in A1C (∆A1C) for subjects with baseline A1c ≤ 8%|CSII Cohort: Time in Hypoglycemic Range during Night for all subjects|CSII Cohort: Time in Target Range 70mg/dL (3.9mmol/L) - 180 mg/dL (10.0mmol/L) during Night for all subjects|CSII Cohort: Time in Target Range 70mg/dL (3.9mmol/L) - 180 mg/dL (10.0mmol/L) during Day and Night for all subjects|CSII Cohort: Time in Hypoglycemic Range during Day and Night for all subjects|CSII Cohort: Change in A1C for all subjects|MDI Cohort: Time in Hypoglycemic Range for subjects with baseline A1c > 8%|MDI Cohort: Change in A1C (∆A1C) for subjects with baseline A1c ≤ 8%|MDI Cohort: Time in Hypoglycemic Range during Night for all subjects|MDI Cohort: Time in Target Range 70mg/dL (3.9mmol/L) - 180 mg/dL (10.0mmol/L) during Night for all subjects|MDI Cohort: Time in Target Range 70mg/dL (3.9mmol/L) - 180 mg/dL (10.0mmol/L) during Day and Night for all subjects|MDI Cohort: Time in Hypoglycemic Range during Day and Night for all subjects|MDI Cohort: Change in A1C for all subjects|SAP Cohort: Time in Hypoglycemic Range for subjects with baseline A1c > 8%|SAP Cohort: Change in A1C (∆A1C) for subjects with baseline A1c ≤ 8%|SAP Cohort: Time in Hypoglycemic Range during Night for all subjects|SAP Cohort: Time in Target Range 70mg/dL (3.9mmol/L) - 180 mg/dL (10.0mmol/L) during Night for all subjects|SAP Cohort: Time in Target Range 70mg/dL (3.9mmol/L) - 180 mg/dL (10.0mmol/L) during Day and Night for all subjects|SAP Cohort: Time in Hypoglycemic Range during Day and Night for all subjects|SAP Cohort: Change in A1C for all subjects,Medtronic Diabetes,All,"2 Years to 80 Years   (Child, Adult, Older Adult)",Not Applicable,1500,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CEP 304,25-May-17,Aug-21,Dec-21,22-Apr-16,null,9-May-19,"Scripps Health System, La Jolla, California, United States|Stanford University, Palo Alto, California, United States|Sansum Diabetes Research Institute, Santa Barbara, California, United States|SoCal Diabetes, Torrance, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Barbara Davis Center, Aurora, Colorado, United States|Barbara Davis Center, Aurora, Colorado, United States|Yale School of Medicine, New Haven, Connecticut, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Endocrine Research Solutions, Roswell, Georgia, United States|Rocky Mountain Diabetes, Idaho Falls, Idaho, United States|IDERC, Des Moines, Iowa, United States|University of Michigan, Ann Arbor, Michigan, United States|Grunberger Diabetes Institute, Bloomfield Hills, Michigan, United States|Initernational Diabetes Center, Minneapolis, Minnesota, United States|International Diabetes Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University St. Louis, Saint Louis, Missouri, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Sanford Health, Sioux Falls, South Dakota, United States|Texas Diabetes & Endocrinology, Austin, Texas, United States|Texas Children's Hospital / Baylor University, Houston, Texas, United States|Rainier Clinical Research, Renton, Washington, United States|University of Washington, Seattle, Washington, United States|Westminster Endocrine & Diabetes Research Society, New Westminster, British Columbia, Canada|Diabeteszentrum für Kinder und Jugendliche, Kinder- und Jugendkrankenhaus Auf der Bult, Hannover, Germany|A.S.S.T. Spedali Civili, Brescia, Italy|Dept Internal Medicine, Örebro University Hospital, Örebro, Sweden|Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, United Kingdom",,https://ClinicalTrials.gov/show/NCT02748018
NCT02746627,Check It! Positive Psychology Intervention to Improve Adherence in Adolescents With T1D,,Completed,Has Results,Type 1 Diabetes Mellitus,Behavioral: Positive Affect|Behavioral: Education,Glycemic Control (HbA1c)|Frequency of Blood Glucose Monitoring|Diabetes-Related Quality of Life|Family Conflict|Positive Affect|Coping,Vanderbilt University Medical Center,All,13 Years to 17 Years   (Child),Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,131384,Jan-14,Feb-16,Feb-16,21-Apr-16,11-Feb-19,13-Mar-19,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT02746627
NCT02745808,Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes,,Recruiting,No Results Available,Erectile Dysfunction|Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Biological: HUC-MSCs|Biological: Injectable Collagen Scaffold + HUC-MSCs,Safety and Tolerability assessed by Adverse Events|Improvement in IIEF-5 (International Index of Erectile Function)|Improvement in penile colour Doppler ultrasonography,Chinese Academy of Sciences|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,Male,"20 Years to 65 Years   (Adult, Older Adult)",Phase 1,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,CAS-XDA-DEF/IGDB,Sep-15,Dec-20,Dec-20,20-Apr-16,null,25-Jan-19,"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT02745808
NCT02739906,A Trial to Investigate Post Prandial Blood Glucose Control With Fast-acting Human Insulin HinsBet® Compared to Insulin Lispro (Humalog®) and Regular Human Insulin (Huminsulin® Normal) After Ingestion of a Standardized Meal in Subjects With T1DM,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: BioChaperone Human Insulin (HinsBet®)|Drug: Insulin Lispro (Humalog®)|Drug: Regular human insulin (Huminsulin® Normal),"BG1h|ΔBG1h|AUCBG,0-1h|ΔAUCBG,0-1h|AUCIns,0-1h|Adverse Events|Local tolerability (Number of injection site reactions)",Adocia,All,18 Years to 64 Years   (Adult),Phase 1|Phase 2,36,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",BC3-CT021,Apr-16,Aug-16,Aug-16,15-Apr-16,null,18-Aug-16,"Profil Mainz GmbH & Co.KG, Mainz, Germany|Profil GmbH, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT02739906
NCT02737722,Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus,,"Active, not recruiting",No Results Available,Diabetic Foot Infections,Drug: Bisphosphocin Nu-3|Drug: Placebo,Number of subjects with treatment related Adverse Event as graded according to Common Terminology Criteria for Adverse Events v4.0 (CTCAE)|Microbiological activity of Bisphosphocin Nu-3 as measured by wound assessments.|Microbiological activity of Bisphosphocin Nu-3 as measured by presence of pathologenic bacteria.,Lakewood-Amedex Inc,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",LAI2014-1,Apr-16,Aug-17,Nov-17,14-Apr-16,null,5-Sep-17,"Center for Clinical Research, Inc., San Francisco, California, United States|Journey Research, Inc., Oldsmar, Florida, United States|Clinical Research Solutions, Franklin, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT02737722
NCT02738151,Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist,BRIGHT,Completed,Has Results,"Diabetes Mellitus, Type 2","Drug: Insulin glargine, 300U/mL|Drug: Insulin degludec, 100 U/mL|Drug: Non-insulin anti-diabetic treatment","Change From Baseline in HbA1c to Week 24|Change From Baseline in HbA1c to Week 12|Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 and Week 24|Change From Baseline in Fasting Self-Monitoring Plasma Glucose (SMPG) to Week 12 and Week 24|Change From Baseline in 8 Point SMPG Profile to Week 12 and Week 24 Per Time Point|Change From Baseline in 4-point SMPG Profile to Week 12 and Week 24 Per Time Point|Change From Baseline in 24-hour Average 8-point SMPG Profile to Week 12 and Week 24|Change From Baseline in Variability of Fasting SMPG to Week 12 and Week 24|Change From Baseline in Variability of 24-Hour 8-Point SMPG Profiles at Week 12 and Week 24|Percentage of Participants Reaching Target HbA1c of < 7% and =<6.5% at Week 12 and Week 24|Percentage of Participants Reaching Target HbA1c <7% and =<6.5% at Week 12 and Week 24 Without Severe and/or Confirmed Hypoglycemia (70 mg/dL) Event|Percentage of Participants With Sulphonylurea or Meglitinide Dose Reduction/ Discontinuation Due to Hypoglycemia During 24 Weeks Treatment Period|Percentage of Participants Requiring a Rescue Therapy During 24 Weeks Treatment Period|Change From Baseline in Basal Insulin Dose (U/kg Body Weight) to Week 12 and Week 24|Percentage of Participants With At Least One Hypoglycemic Events (Any, Severe and/or Confirmed Hypoglycemia: Any Time of the Day) by Study Period|Percentage of Participants With At Least One Hypoglycemic Events (Any, Severe and/or Confirmed Hypoglycemia: Nocturnal) by Study Period|Hypoglycemia (Any, Severe and/or Confirmed Hypoglycemia: Any Time of the Day) Event Rate Per Participant Year During Study Period|Hypoglycemia (Any, Severe and/or Confirmed Hypoglycemia: Nocturnal ) Event Rate Per Participant Year During Study Period",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 4,929,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LPS14584|2015-005101-36|U1111-1177-6327,19-May-16,15-Aug-17,15-Aug-17,14-Apr-16,14-Sep-18,14-Sep-18,"Investigational Site Number 840038, Sheffield, Alabama, United States|Investigational Site Number 840066, Phoenix, Arizona, United States|Investigational Site Number 840051, Anaheim, California, United States|Investigational Site Number 840081, Chino, California, United States|Investigational Site Number 840016, Huntington Park, California, United States|Investigational Site Number 840002, La Jolla, California, United States|Investigational Site Number 840091, Los Angeles, California, United States|Investigational Site Number 840058, Northridge, California, United States|Investigational Site Number 840021, Palm Springs, California, United States|Investigational Site Number 840087, Santa Ana, California, United States|Investigational Site Number 840030, Torrance, California, United States|Investigational Site Number 840065, Van Nuys, California, United States|Investigational Site Number 840075, Bradenton, Florida, United States|Investigational Site Number 840076, New Port Richey, Florida, United States|Investigational Site Number 840026, Ocoee, Florida, United States|Investigational Site Number 840052, Palm Harbor, Florida, United States|Investigational Site Number 840080, Palm Harbor, Florida, United States|Investigational Site Number 840018, Port Charlotte, Florida, United States|Investigational Site Number 840071, Lawrenceville, Georgia, United States|Investigational Site Number 840085, Roswell, Georgia, United States|Investigational Site Number 840072, Statesboro, Georgia, United States|Investigational Site Number 840039, Stockbridge, Georgia, United States|Investigational Site Number 840036, Arlington Heights, Illinois, United States|Investigational Site Number 840010, Chicago, Illinois, United States|Investigational Site Number 840005, Avon, Indiana, United States|Investigational Site Number 840063, Council Bluffs, Iowa, United States|Investigational Site Number 840098, Des Moines, Iowa, United States|Investigational Site Number 840101, Des Moines, Iowa, United States|Investigational Site Number 840096, West Des Moines, Iowa, United States|Investigational Site Number 840061, Paris, Kentucky, United States|Investigational Site Number 840011, Hyattsville, Maryland, United States|Investigational Site Number 840001, Rockville, Maryland, United States|Investigational Site Number 840041, Flint, Michigan, United States|Investigational Site Number 840057, Flint, Michigan, United States|Investigational Site Number 840033, Troy, Michigan, United States|Investigational Site Number 840084, Olive Branch, Mississippi, United States|Investigational Site Number 840048, Chesterfield, Missouri, United States|Investigational Site Number 840023, Las Vegas, Nevada, United States|Investigational Site Number 840045, Las Vegas, Nevada, United States|Investigational Site Number 840031, Linden, New Jersey, United States|Investigational Site Number 840060, Hickory, North Carolina, United States|Investigational Site Number 840064, Morganton, North Carolina, United States|Investigational Site Number 840043, Wilmington, North Carolina, United States|Investigational Site Number 840082, Winston-Salem, North Carolina, United States|Investigational Site Number 840025, Oklahoma City, Oklahoma, United States|Investigational Site Number 840022, Oklahoma City, Oklahoma, United States|Investigational Site Number 840029, Beaver, Pennsylvania, United States|Investigational Site Number 840056, Downingtown, Pennsylvania, United States|Investigational Site Number 840093, Anderson, South Carolina, United States|Investigational Site Number 840097, Greenville, South Carolina, United States|Investigational Site Number 840070, Greer, South Carolina, United States|Investigational Site Number 840044, North Myrtle Beach, South Carolina, United States|Investigational Site Number 840069, Simpsonville, South Carolina, United States|Investigational Site Number 840079, Bristol, Tennessee, United States|Investigational Site Number 840006, Chattanooga, Tennessee, United States|Investigational Site Number 840088, Knoxville, Tennessee, United States|Investigational Site Number 840077, New Tazewell, Tennessee, United States|Investigational Site Number 840007, Dallas, Texas, United States|Investigational Site Number 840086, Dallas, Texas, United States|Investigational Site Number 840027, Houston, Texas, United States|Investigational Site Number 840004, Houston, Texas, United States|Investigational Site Number 840040, Houston, Texas, United States|Investigational Site Number 840046, Houston, Texas, United States|Investigational Site Number 840054, Hurst, Texas, United States|Investigational Site Number 840017, Mesquite, Texas, United States|Investigational Site Number 840008, Missouri City, Texas, United States|Investigational Site Number 840094, San Antonio, Texas, United States|Investigational Site Number 840009, Sugar Land, Texas, United States|Investigational Site Number 840053, Waco, Texas, United States|Investigational Site Number 840095, Ogden, Utah, United States|Investigational Site Number 840032, Salt Lake City, Utah, United States|Investigational Site Number 840024, Norfolk, Virginia, United States|Investigational Site Number 840020, Richmond, Virginia, United States|Investigational Site Number 840012, Renton, Washington, United States|Investigational Site Number 100001, Sofia, Bulgaria|Investigational Site Number 100002, Sofia, Bulgaria|Investigational Site Number 100003, Sofia, Bulgaria|Investigational Site Number 191001, Rijeka, Croatia|Investigational Site Number 191002, Rijeka, Croatia|Investigational Site Number 191003, Zagreb, Croatia|Investigational Site Number 203009, Hlucin, Czechia|Investigational Site Number 203006, Jilove u Prahy, Czechia|Investigational Site Number 203005, Liberec, Czechia|Investigational Site Number 203001, Pardubice, Czechia|Investigational Site Number 203007, Praha 1, Czechia|Investigational Site Number 203008, Praha 2, Czechia|Investigational Site Number 203002, Praha 8, Czechia|Investigational Site Number 203004, Vsetin, Czechia|Investigational Site Number 208003, Aarhus, Denmark|Investigational Site Number 208002, Hillerød, Denmark|Investigational Site Number 208001, København NV., Denmark|Investigational Site Number 208004, Odense, Denmark|Investigational Site Number 250002, La Roche Sur Yon, France|Investigational Site Number 250003, La Rochelle Cedex 1, France|Investigational Site Number 250001, Nantes cedex 01, France|Investigational Site Number 250006, Nimes, France|Investigational Site Number 250005, POITIERS Cedex, France|Investigational Site Number 250007, Venissieux, France|Investigational Site Number 300005, Alexandroupolis, Greece|Investigational Site Number 300001, Athens, Greece|Investigational Site Number 300002, Athens, Greece|Investigational Site Number 300003, Athens, Greece|Investigational Site Number 348004, Budapest, Hungary|Investigational Site Number 348002, Budapest, Hungary|Investigational Site Number 348001, Budapest, Hungary|Investigational Site Number 348003, Gyöngyös, Hungary|Investigational Site Number 376001, Haifa, Israel|Investigational Site Number 376004, Haifa, Israel|Investigational Site Number 376008, Haifa, Israel|Investigational Site Number 376009, Kfar Saba, Israel|Investigational Site Number 376002, Petach tikva, Israel|Investigational Site Number 376006, Tel Aviv, Israel|Investigational Site Number 376003, Tel Hashomer, Israel|Investigational Site Number 376007, Tel-Aviv, Israel|Investigational Site Number 380007, Bari, Italy|Investigational Site Number 380009, Catanzaro, Italy|Investigational Site Number 380010, Chieti, Italy|Investigational Site Number 380014, Milano, Italy|Investigational Site Number 380002, Moncalieri, Italy|Investigational Site Number 380011, Napoli, Italy|Investigational Site Number 380008, Roma, Italy|Investigational Site Number 380015, Roma, Italy|Investigational Site Number 380016, Roma, Italy|Investigational Site Number 380013, Sesto San Giovanni, Italy|Investigational Site Number 380005, Torino, Italy|Investigational Site Number 380012, Verona, Italy|Investigational Site Number 642007, Brasov, Romania|Investigational Site Number 642008, Brasov, Romania|Investigational Site Number 642001, Bucharest, Romania|Investigational Site Number 642013, Bucharest, Romania|Investigational Site Number 642015, Bucuresti, Romania|Investigational Site Number 642003, Cluj-Napoca, Romania|Investigational Site Number 642009, Constanta, Romania|Investigational Site Number 642014, Iasi, Romania|Investigational Site Number 642005, Oradea, Romania|Investigational Site Number 642012, Oradea, Romania|Investigational Site Number 642010, Targu-Mures, Romania|Investigational Site Number 642004, Targu-Mures, Romania|Investigational Site Number 642006, Targu-Mures, Romania|Investigational Site Number 688001, Belgrade, Serbia|Investigational Site Number 688002, Nis, Serbia|Investigational Site Number 688003, Nis, Serbia|Investigational Site Number 703006, Kosice, Slovakia|Investigational Site Number 703002, Lubochna, Slovakia|Investigational Site Number 703001, Moldava nad Bodvou, Slovakia|Investigational Site Number 703003, Sabinov, Slovakia|Investigational Site Number 703005, Trebisov, Slovakia|Investigational Site Number 752102, Lund, Sweden|Investigational Site Number 752101, Skövde, Sweden|Investigational Site Number 756003, Olten, Switzerland|Investigational Site Number 756001, St. Gallen, Switzerland|Investigational Site Number 826001, Chertsey, United Kingdom|Investigational Site Number 826005, Gillingham, United Kingdom|Investigational Site Number 826008, Lincoln, United Kingdom|Investigational Site Number 826002, London, United Kingdom|Investigational Site Number 826009, Manchester, United Kingdom|Investigational Site Number 826006, Margate, United Kingdom|Investigational Site Number 826004, Swansea, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02738151/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02738151/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02738151
NCT02735837,The Effect of Topical Doxycycline Gel on HbA1c in Patients With Type 2 Diabetes Mellitus(DM) ®,,Completed,No Results Available,Diabetes Mellitus With Periodontal Disease,Drug: Doxycycline Group|Drug: placebo topical gel,Periodontal pocket|glycated hemoglobin (HbA1c),"Amirhossein Farahmand|Islamic Azad University, Tehran",All,"Child, Adult, Older Adult",Phase 2|Phase 3,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",560,Jan-15,Mar-16,Apr-16,13-Apr-16,null,4-Oct-16,,,https://ClinicalTrials.gov/show/NCT02735837
NCT02733991,Study of MiniMed™ 640G Insulin Pump With SmartGuard™ in Prevention of Low Glucose Events in Adults With Type 1 Diabetes,SMILE,Completed,No Results Available,Type 1 Diabetes,Device: MiniMed™640G and Suspend before low|Device: MiniMed™640G,Mean number of sensor glucose hypoglycaemic events below or equal to 55 mg/dL per patient/week.|Mean time spent of sensor glucose values below or equal 40 mg/dL.|Mean time spent of sensor glucose values below or equal 55 mg/dL.|Mean time spent of sensor glucose values below or equal 70 mg/dL.|Mean AUC of sensor glucose values below or equal 70 mg/dL.|Mean AUC of sensor glucose values below or equal 55 mg/dL.|Mean AUC of sensor glucose values below or equal 40 mg/dL.|Mean time spent of sensor glucose values within range and including 70-140 mg/dL.|Mean time spent of sensor glucose values within range and including 70-180 mg/dL.|Mean amplitude of glycaemic excursions.|Mean HbA1c change from baseline to 6 months.,Medtronic Diabetes,All,"24 Years to 75 Years   (Adult, Older Adult)",Not Applicable,169,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CEP311,Dec-16,Oct-18,Oct-18,12-Apr-16,null,26-Mar-19,"CHU de Besançon, Besançon, France|CHU Grenoble, Grenoble, France|APHM - La Conception, Marseille, France|CHU Montpellier - Hôpital Lapeyronie, Montpellier, France|Ospedale Papa Giovanni XXIII, Bergamo, Italy|Ospedale S. Raffaele, Milan, Italy|Ospedale S. Gionanni di Dio, Olbia, Italy|Groene Hart Ziekenhuis, Gouda, Netherlands|Maasstad Ziekenhuis, Rotterdam, Netherlands|UMC Utrecht, Utrecht, Netherlands|Isala, Zwolle, Netherlands|Harrogate District Hospital, Harrogate, N. Yorkshire, United Kingdom|King's College London, London, United Kingdom|Manchester Diabetes Center, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT02733991
NCT02734667,Initiation of Continuous Glucose Monitoring at Diagnosis of Type 1 Diabetes,,"Active, not recruiting",No Results Available,Type 1 Diabetes Mellitus,Device: CGM at diagnosis of T1D,Pediatric Quality of Life Inventory|Time spent in blood glucose range|Problem Areas in Diabetes|Diabetes Distress Scale|Patient Health Questionnaire 9|State-Trait Anxiety Inventory|Pittsburgh Sleep Quality Index|Hypoglycemic Fear Survey|Hypoglycemic Confidence Questionnaire|Glucose Monitoring System Satisfaction Survey|General and diabetes-specific technology use|Center for Epidemiologic Studies Depression Measure|Child Health Utility 9D|A1c|C-peptide,"Korey Hood|University of Colorado, Denver|Stanford University",All,2 Years to 17 Years   (Child),Not Applicable,64,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,35990,Feb-16,Mar-20,Mar-21,12-Apr-16,null,4-Apr-19,"Stanford University, Stanford, California, United States|University of Colorado, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT02734667
NCT02734745,Accuracy of Freestyle Libre,,Unknown status,No Results Available,Diabetes Type 1,Device: flash glucose monitoring,accuracy of freestyle Libre flash monitoring|Evaluate the accuracy of the Free Style Libre for each day of use and during normoglycaemia ( between 70 and 180 mg / dl )|Evaluate the accuracy of the Free Style Libre for each day of use and during hypoglicaemia ( < 70 mg / dl )|Evaluate the accuracy of the Free Style Libre for each day of use and during hyperglicemia ( >180 mg / dl ),University of Padova,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,48,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,3724/AO/16,1-Apr-16,1-Dec-17,1-Dec-17,12-Apr-16,null,4-Oct-17,"University of Padova, Padova, Italy",,https://ClinicalTrials.gov/show/NCT02734745
NCT02735031,Exenatide and Impaired Hypoglycaemic Awareness in Type 1 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Hypoglycemia",Drug: Exenatide|Drug: Placebo,Symptom score in response to insulin-induced hypoglycaemia|Adrenaline response to insulin-induced hypoglycaemia|Glucagon response to insulin-induced hypoglycaemia|Time until glycaemic recovery from hypoglycaemia|Maximal glucose excursion post-hypoglycaemia|Time until glucose peak post-hypoglycaemia|Area under the glucose concentration curve post-hypoglycaemia|Hunger score post-hypoglycaemia|Carbohydrate requirement after recovery from hypoglycaemia|Number of severe hypoglycaemic events during follow-up|Number of nocturnal hypoglycaemic events during follow-up|Number of any hypoglycaemic events during follow-up|Number of hypoglycaemic events measured by glucose sensor monitoring|Time spent under hypoglycaemic conditions measured by glucose sensor monitoring|Glucose variability as measured by glucose sensor monitoring,Radboud University|AstraZeneca,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2|Phase 3,10,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ESR-15-10862,21-Feb-17,28-Mar-18,9-Apr-18,12-Apr-16,null,12-Apr-18,"Radboud university medical centre, Nijmegen, Netherlands",,https://ClinicalTrials.gov/show/NCT02735031
NCT02735044,Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus,EDITION JUNIOR,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: insulin glargine (U300)|Drug: insulin glargine|Drug: fast-acting insulin analogue,Change from baseline in HbA1c|Percentage of patients with HbA1c values of <7.5% without any episode of severe and/or documented (SMPG <54 mg/dL; 3.0 mmol/L) symptomatic hypoglycemia during the last 3 months of the main 6-month randomized period|Change from baseline in Fasting Plasma Glucose (FPG)|Percentage of patients with FPG of ≤130 mg/dL (7.2 mmol/L) without any episode of severe and/or documented (SMPG <54 mg/dL; 3.0 mmol/L) symptomatic hypoglycemia during the last 3 months of the main 6-month randomized period|Change from baseline in 24-hour mean plasma glucose based on 8-point self-monitored plasma glucose (SMPG) profiles|Change from baseline in variability of 24-hour mean plasma glucose based on 8-point SMPG profiles|Number (%) of patients with hypoglycemia|Number (%) of patients with hyperglycemia with ketosis|Number (%) of patients with adverse events,Sanofi,All,6 Years to 17 Years   (Child),Phase 3,463,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EFC13957|2015-002084-42|U1111-1168-4546,14-Apr-16,31-May-18,20-Dec-18,12-Apr-16,null,10-Jan-19,"Investigational Site Number 8400008, Tucson, Arizona, United States|Investigational Site Number 8400037, Atlanta, Georgia, United States|Investigational Site Number 8400032, Indianapolis, Indiana, United States|Investigational Site Number 8400015, Buffalo, New York, United States|Investigational Site Number 8400016, Chapel Hill, North Carolina, United States|Investigational Site Number 8400035, Morehead City, North Carolina, United States|Investigational Site Number 8400038, Oklahoma City, Oklahoma, United States|Investigational Site Number 8400030, Philadelphia, Pennsylvania, United States|Investigational Site Number 8400010, Rapid City, South Dakota, United States|Investigational Site Number 8400005, Dallas, Texas, United States|Investigational Site Number 8400021, Dallas, Texas, United States|Investigational Site Number 8400029, Lufkin, Texas, United States|Investigational Site Number 8400034, Seattle, Washington, United States|Investigational Site Number 0320003, Caba, Argentina|Investigational Site Number 0320001, Caba, Argentina|Investigational Site Number 0320004, Capital Federal, Argentina|Investigational Site Number 0320002, Capital Federal, Argentina|Investigational Site Number 0320006, Mendoza, Argentina|Investigational Site Number 0320005, Salta, Argentina|Investigational Site Number 0320007, San Miguel De Tucuman, Argentina|Investigational Site Number 0760005, Curitiba, Brazil|Investigational Site Number 0760006, Fortaleza, Brazil|Investigational Site Number 0760004, Fortaleza, Brazil|Investigational Site Number 0760003, Porto Alegre, Brazil|Investigational Site Number 0760001, Sao Paulo, Brazil|Investigational Site Number 0760002, Sao Paulo, Brazil|Investigational Site Number 1000001, Plovdiv, Bulgaria|Investigational Site Number 1000005, Sofia, Bulgaria|Investigational Site Number 1000004, Varna, Bulgaria|Investigational Site Number 1240003, Halifax, Canada|Investigational Site Number 1240002, Montreal, Canada|Investigational Site Number 1240005, Montreal, Canada|Investigational Site Number 1240006, Sherbrooke, Canada|Investigational Site Number 1520002, Santiago, Chile|Investigational Site Number 1520004, Santiago, Chile|Investigational Site Number 1520006, Santiago, Chile|Investigational Site Number 1520007, Temuco, Chile|Investigational Site Number 1520003, Viña Del Mar, Chile|Investigational Site Number 2030003, Hradec Kralove, Czechia|Investigational Site Number 2030005, Ostrava - Poruba, Czechia|Investigational Site Number 2030001, Praha 5 - Motol, Czechia|Investigational Site Number 2080001, Herlev, Denmark|Investigational Site Number 2500003, Montpellier, France|Investigational Site Number 2500002, Toulouse, France|Investigational Site Number 2760002, Hannover, Germany|Investigational Site Number 2760001, Heidelberg, Germany|Investigational Site Number 2760004, Leipzig, Germany|Investigational Site Number 2760003, Münster, Germany|Investigational Site Number 3480001, Budapest, Hungary|Investigational Site Number 3480004, Budapest, Hungary|Investigational Site Number 3480003, Budapest, Hungary|Investigational Site Number 3480005, Gyula, Hungary|Investigational Site Number 3480002, Miskolc, Hungary|Investigational Site Number 3480006, Pécs, Hungary|Investigational Site Number 3480007, Székesfehérvár, Hungary|Investigational Site Number 3760003, Beer Sheva, Israel|Investigational Site Number 3760001, Haifa, Israel|Investigational Site Number 3760006, Holon, Israel|Investigational Site Number 3760002, Petach Tikva, Israel|Investigational Site Number 3800001, Firenze, Italy|Investigational Site Number 3800005, Roma, Italy|Investigational Site Number 3800004, Torino, Italy|Investigational Site Number 3800006, Varese, Italy|Investigational Site Number 3800003, Verona, Italy|Investigational Site Number 3920006, Chiyoda-Ku, Japan|Investigational Site Number 3920002, Fukuoka-Shi, Japan|Investigational Site Number 3920003, Hiroshima-Shi, Japan|Investigational Site Number 3920007, Kobe-Shi, Japan|Investigational Site Number 3920005, Osaka-Shi, Japan|Investigational Site Number 3920004, Shinjuku-Ku, Japan|Investigational Site Number 4280002, Daugavpils, Latvia|Investigational Site Number 4280001, Rīga, Latvia|Investigational Site Number 8070001, Skopje, Macedonia, The Former Yugoslav Republic of|Investigational Site Number 4840003, Durango, Mexico|Investigational Site Number 4840001, Monterrey, Mexico|Investigational Site Number 4840004, México, Mexico|Investigational Site Number 4840002, Puebla, Mexico|Investigational Site Number 4840005, Veracruz, Mexico|Investigational Site Number 6160005, Bielsko-Biala, Poland|Investigational Site Number 6160001, Gdansk, Poland|Investigational Site Number 6160006, Szczecin, Poland|Investigational Site Number 6160007, Warszawa, Poland|Investigational Site Number 6160004, Warszawa, Poland|Investigational Site Number 6160003, Warszawa, Poland|Investigational Site Number 6420005, Bucharest, Romania|Investigational Site Number 6420007, Constanta, Romania|Investigational Site Number 6420004, Craiova, Romania|Investigational Site Number 6420006, Sibiu, Romania|Investigational Site Number 6420003, Timisoara, Romania|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430004, Smolensk, Russian Federation|Investigational Site Number 6430002, St-Petersburg, Russian Federation|Investigational Site Number 6430003, Ufa, Russian Federation|Investigational Site Number 6880002, Belgrade, Serbia|Investigational Site Number 6880003, Belgrade, Serbia|Investigational Site Number 6880004, Nis, Serbia|Investigational Site Number 7240005, Barcelona, Spain|Investigational Site Number 7240002, Barcelona, Spain|Investigational Site Number 7240003, Esplugues De Llobregat, Spain|Investigational Site Number 7240004, Sabadell, Spain|Investigational Site Number 7240006, Santa Cruz De Tenerife, Spain|Investigational Site Number 7240001, Vitoria, Spain|Investigational Site Number 7520002, Stockholm, Sweden|Investigational Site Number 8260005, Doncaster, United Kingdom|Investigational Site Number 8260001, Ipswich, United Kingdom|Investigational Site Number 8260004, Kettering, United Kingdom|Investigational Site Number 8260002, Salisbury, United Kingdom",,https://ClinicalTrials.gov/show/NCT02735044
NCT02730949,D-chiro-Inositol in Overweight Type 1 Diabetes Patients,,Completed,No Results Available,Type 1 Diabetes,Dietary Supplement: D-chiro-inositol|Dietary Supplement: Folic Acid,efficacy of DCI oral supplementation on metabolic control|BMI kg/m2|Insulin Requirement (I.R.) IU/kg,Campus Bio-Medico University,All,"17 Years to 50 Years   (Child, Adult)",Phase 3,26,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16/14PARComETCBM,Mar-14,May-15,Dec-15,7-Apr-16,null,7-Apr-16,"University Campus Bio Medico, Rome, Italy",,https://ClinicalTrials.gov/show/NCT02730949
NCT02727231,Closing the Loop in Adults With Type 1 Diabetes and HbA1C<7.5% Under Free Living Conditions,,Completed,No Results Available,Type 1 Diabetes,Device: Florence D2A or similar closed loop glucose control system|Device: CSII with CGM,Time spent in the target glucose range (3.9 to 10.0 mmol/l) based on subcutaneous glucose monitoring|Continuous subcutaneous glucose monitoring (CGM) based outcome|Continuous subcutaneous glucose monitoring (CGM) based outcome during overnight period between 24:00 and 06:00|Continuous subcutaneous glucose monitoring (CGM) based outcome during day period between 06:00 to 24:00|Insulin dose|Adverse Events|Utility Evaluation,University of Cambridge|Medical University of Graz,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,29,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AP@home04 phase2,Mar-16,Oct-16,Oct-16,4-Apr-16,null,11-Oct-16,"Medical University of Graz, Graz, Austria|Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital, Cambridge, Cambridgeshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT02727231
NCT02725502,Incretin Axis in Type 1 Diabetes Mellitus,,Unknown status,No Results Available,Type 1 Diabetes Mellitus,Drug: Linagliptin|Drug: Placebo,Effect of Linagliptin on HbA1c in T1DM patients|Effect of Linagliptin on glycemic variability in T1DM patients|Effect of Linagliptin on insulin requirement in T1DM patients|Effect of linagliptin on GLP1 level during mixed meal test in T1DM patients|Effect of linagliptin on glucagon level during mixed meal test in T1DM patients,Postgraduate Institute of Medical Education and Research,All,"15 Years to 30 Years   (Child, Adult)",Not Applicable,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Type 1 Diabetes Mellitus,Jul-13,Apr-16,May-16,1-Apr-16,null,1-Apr-16,"Department of Endocrinology, PGIMER, Chandigarh, India",,https://ClinicalTrials.gov/show/NCT02725502
NCT02721888,Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism,LIRA-NAFLD/LIP,Unknown status,No Results Available,Type 2 Diabetes,Drug: Liraglutide|Drug: MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)|Biological: Blood sample|Other: Kinetic substudy (10 patients),"Effect of liraglutide on fatty liver content evaluated by proton-spectroscopy (1H-spectroscopy and lipoprotein kinetics, in patients with type 2 diabetes|Effects of liraglutide on Very Low Density Lipoprotein 1 (VLDL1) apolipoprotein B (apoB) production rate|Effects of liraglutide on Very Low Density Lipoprotein 2 (VLDL2) apolipoprotein B (apoB) production rate|Effects of liraglutide on Intermediate Density Lipoprotein (IDL) apolipoprotein B (apoB) production rate|Effects of liraglutide on Low Density Lipoprotein (LDL) apolipoprotein B (apoB) production rate|Effects of liraglutide on High Density Lipoprotein (HDL) apolipoprotein A1 (apoA1) production rate|Effects of liraglutide on Very Low Density Lipoprotein 1 (VLDL1) apolipoprotein B (apoB) fractional catabolic rate|Effects of liraglutide on Very Low Density Lipoprotein 2 (VLDL2) apolipoprotein B (apoB) fractional catabolic rate|Effects of liraglutide on Intermediate Density Lipoprotein (IDL) apolipoprotein B (apoB) fractional catabolic rate|Effects of liraglutide on Low Density Lipoprotein (LDL) apolipoprotein B (apoB) fractional catabolic rate|Effects of liraglutide on High Density Lipoprotein (HDL) apolipoprotein A1 (apoA1) fractional catabolic rate|Modification of body weight|Modification of subcutaneous fat by Magnetic Resonance Imaging (MRI)|Modification of visceral fat by Magnetic Resonance Imaging (MRI)",Centre Hospitalier Universitaire Dijon,All,"18 Years and older   (Adult, Older Adult)",Phase 4,120,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VERGES NOVO 2012,Jul-12,Mar-16,null,29-Mar-16,null,29-Mar-16,"CHU de Dijon, Dijon, France",,https://ClinicalTrials.gov/show/NCT02721888
NCT02718950,"Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans",i-LAB,Unknown status,No Results Available,Obesity|Type 2 Diabetes Mellitus,Drug: Liraglutide 3.0 mg,Evaluate the effect of liraglutide administration on brown adipose tissue (BAT) activation in humans|Evaluate the effect of liraglutide administration on hypothalamic activation in humans|Evaluate the effect of liraglutide administration on non-shivering thermogenesis in humans|Evaluate the effect of liraglutide administration on body weight in humans|Evaluate the effect of liraglutide administration on metabolic basal rate in humans|Evaluate the effect of liraglutide administration on body composition in humans,"University of Campinas, Brazil",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,i-LAB|U1111-1178-4180,Jun-16,Mar-17,Apr-17,24-Mar-16,null,24-Mar-16,,,https://ClinicalTrials.gov/show/NCT02718950
NCT02716519,Use of Santyl Within an Accountable Care Organization,,Withdrawn,No Results Available,"Pressure Ulcer|Foot Ulcer, Diabetic",Biological: Santyl|Other: Standard Care,"Target Ulcer Complications|The incidence of increase in ulcer size by more than 25% between treatment groups during the assessment period|The incidence of cellulitis between treatment groups during the assessment period|The incidence of ulcer infections between treatment groups during the assessment period|The incidence of osteomyelitis between treatment groups during the assessment period|The incidence of requirement for surgical intervention between treatment groups during the assessment period|Percentage change in ulcer area from baseline to the end of treatment period|Study discontinuations (target ulcer related)|Hospital readmission for target ulcer treatment|Emergency department visits for target ulcer treatment|During the acute phase, daily time at bedside for target ulcer treatment|During the acute phase, daily wound care products (including dressings) for target ulcer treatment|During the acute phase, daily antibiotics and analgesics used for target ulcer treatment|During the acute phase, daily lab tests for target ulcer treatment|During the acute phase, daily surgical procedures for target ulcer treatment|During the post-acute phase, weekly clinician time at bedside for target ulcer treatment|During the post-acute phase, weekly patient and caregiver time for target ulcer treatment|During the post-acute phase, weekly wound care products (including dressings) for target ulcer treatment|During the post-acute phase, weekly antibiotics and analgesics used for target ulcer treatment|During the post-acute phase, weekly lab tests for target ulcer treatment|During the post-acute phase, weekly surgical procedures for target ulcer treatment","Smith & Nephew, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 4,0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,017-101-09-037,Aug-16,Dec-18,Dec-18,23-Mar-16,null,15-Mar-17,"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02716519
NCT02714972,"Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents",PHM3,Completed,No Results Available,Type 1 Diabetes|Hypoglycemia|Hyperglycemia|Artificial Pancreas,Device: Hyperglycemia Minimization Algorithm,"Comparison of percent time in range overnight between the two treatment arms|Mean overnight sensor glucose|Glucose standard deviation and coefficient of variation|Percent of sensor measurements below 50 mg/dl (2.8 mmol/L)|Percent of sensor measurements below 60 mg/dl (3.3 mmol/L)|Percent of sensor measurements below 70 mg/dl (3.9 mmol/L)|Area under the curve 70 mg/dl (3.9 mmol/L)|Low blood glucose index|Percent of sensor measurements above 180 mg/dl (10.0 mmol/L)|Percent of sensor measurements above 250 mg/dl (13.9 mmol/L)|Percent of sensor measurements above 300 mg/dl (16.7 mmol/L)|Area under the curve 180 mg/dl (10.0 mmol/L)|High blood glucose index|Percent of sensor measurements between 70 mg/dl (3.9 mmol/L)|Percent of sensor measurements between 140 mg/dl (7.8 mmol/L)|Percentage of nights with events of sensor glucose below 50 mg/dl (2.8 mmol/L), 60 mg/dl (3.3 mmol/L), and 70 mg/dl (3.9 mmol/L) continuously for more than 0, 10, 25, 30, 60, and 120 minutes|Percentage of nights with events of sensor glucose below 50 mg/dl (2.8 mmol/L), 60 mg/dl (3.3 mmol/L), and 70 mg/dl (3.9 mmol/L) cumulatively for more than 30, 60, 120, and 180 minutes|Percentage of nights with events of sensor glucose above 180 mg/dl (10.0 mmol/L), 250 mg/dl (13.9 mmol/L), and 300 mg/dl (16.7 mmol/L) continuously for more than 0, 30, 60, and 120 minutes|Percentage of nights with events of sensor glucose above 180 mg/dl (10.0 mmol/L), 250 mg/dl (13.9 mmol/L), and 300 mg/dl (16.7 mmol/L) cumulatively for more than 60, 120, and 180 minutes|Mean morning blood glucose (subject-level data) and percent of morning with blood glucose below 50 mg/dl (2.8 mmol/L), 60 mg/dl (3.3 mmol/L), 70 mg/dl (3.9 mmol/L) (night-level data)|Mean morning blood glucose (subject-level data) and percent of morning with blood glucose between 70 mg/dl (3.9 mmol/L) and 180 mg/dl (10.0 mmol/L) (night-level data)|Mean morning blood glucose (subject-level data) and percent of morning with blood glucose above 180 mg/dl (10.0 mmol/L), 250 mg/dl (13.9 mmol/L), and 300 mg/dl (16.7 mmol/L) (night-level data)|Amount of total (manual, automatic, combined) and insulin boluses",Jaeb Center for Health Research|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,6 Years to 14 Years   (Child),Phase 2,35,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",PHM3,May-16,Mar-17,May-17,22-Mar-16,null,10-May-17,"Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT02714972
NCT02715193,"Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus",,Completed,No Results Available,Type 1 Diabetes Mellitus|Diabetes,Biological: REMD-477|Biological: Placebo Comparator,"Number of treatment emergent adverse events per subject, including changes in vital signs, physical and neurological examinations, laboratory safety tests and ECGs|Changes from baseline in 24-hour insulin requirements on Day 1 relative to the two 24 hour periods post-treatment on Days 3 and 4, between the REMD-477 and placebo treated subjects, needed to maintain targeted glycemic control.|Immunogenicity: Incidence of REMD-477 neutralizing and non-neutralizing antibodies|Changes from baseline over time of AST.|Changes from baseline over time of ALT.|Changes from baseline over time of ALP.|Changes from baseline over time of total bilirubin.|Changes from baseline over time of amylase|Changes from baseline over time of lipase","REMD Biotherapeutics, Inc.",All,18 Years to 60 Years   (Adult),Phase 1,21,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R477-101,Mar-16,Jan-17,Jan-17,22-Mar-16,null,7-Feb-17,"San Diego, California, United States|St. Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT02715193
NCT02713841,Pharmacologic Response and Safety of Inhaled Insulin in Type 1 Diabetes,Samba-01,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: inhaled human insulin (INH)|Drug: sc insulin lispro (LIS),"Area under the insulin human / insulin lispro concentration-time curve from 0 to 8 hours (AUCINS,0-8h)|Bioavailability",Dance Biopharm Inc.,All,18 Years to 64 Years   (Adult),Phase 1|Phase 2,12,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),Samba-01,May-13,Jul-13,Jul-13,21-Mar-16,null,21-Mar-16,,,https://ClinicalTrials.gov/show/NCT02713841
NCT02705053,At Home Study of a Zone-Model Predictive Control (MPC) Controller and a Health Monitoring System (HMS) With the Diabetes Assistant (DiAs) System and Run-to-Run Adaptation,,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: CGM and Insulin Pump|Device: Closed-Loop Control System,"Change in Hemoglobin A1c (HbA1c) (%) from baseline (week 2) to end of week 15 (end of study), with A1c measured at weeks 7 and 11 as well for repeated measures.|Time within the target range for glucose 70-180 mg/dl overall|Time within the tight target range for glucose 80-140 mg/dl overnight|Time within the target range for glucose 70-150 mg/dl postprandial within 5 hours following meals|Markers of hypo- and hyperglycemia|Insulin Doses Given|Treatments for hypoglycemia|Number of alerts given by the HMS to prevent hypoglycemia|Outside interventions needed.|Failure analysis of the devices/connectivity issues that may occur (# disconnects and device restarts).|Time with glucose ≤ 70 mg/dL, overall","Sansum Diabetes Research Institute|Harvard University|University of California, Santa Barbara|Mayo Clinic|University of Virginia|University of Padova",All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 3,32,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,G150063_2,Feb-16,Aug-16,Aug-16,10-Mar-16,null,14-Oct-16,"William Sansum Diabetes Center, Santa Barbara, California, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02705053
NCT02703324,A Study of LY900014 Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: LY900014|Drug: Insulin Lispro,Pharmacokinetics: Area under the Concentration Curve (AUC) of Insulin Lispro|Pharmacodynamics: Area under the Concentration Curve (AUC) of Glucose Following a Meal,Eli Lilly and Company,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,28,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",16070|I8B-FW-ITRF|2015‐004705‐16,Mar-16,Aug-16,Aug-16,9-Mar-16,null,29-Aug-16,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany",,https://ClinicalTrials.gov/show/NCT02703324
NCT02703350,A Study of LY900014 in Participants With Type 1 Diabetes on Insulin Injection Therapy,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: LY900014|Drug: Insulin Lispro,Pharmacokinetics:Area under the Concentration Curve (AUC) of Insulin Lispro (Part A)|Pharmacokinetics:Area under the Concentration Curve (AUC) of Insulin Lispro (Part B)|Pharmacodynamics:Area under the Concentration Curve (AUC) of Glucose Following a Meal (Part A)|Pharmacodynamics:Area under the Concentration Curve (AUC) of Glucose Following a Meal (Part B),Eli Lilly and Company,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",16068|I8B-FW-ITRG|2015‐004737‐27,Mar-16,Jul-16,Jul-16,9-Mar-16,null,29-Jul-16,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Mainz, Germany",,https://ClinicalTrials.gov/show/NCT02703350
NCT02701257,"The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas",,Terminated,No Results Available,Diabetes Mellitus Type 1,Device: iPhone bionic pancreas|Device: iLet bionic pancreas|Drug: Xeris Xerisol glucagon|Drug: Lilly glucagon|Device: iLet infusion set|Device: Contact Detach infusion set,"Average percent dose amounts calculated by the bionic pancreas control algorithm that are successfully delivered by the pump (aggregate of both insulin and glucagon doses)|Average percent dose amounts calculated by the bionic pancreas control algorithm that are successfully delivered by the pump (glucagon doses).|Insulin area under the curve in the 3.5 hours following the insulin bolus|Average continuous glucose monitor (CGM) glucose|Percentage of time in each of the following ranges: < 50 mg/dl, < 60 mg/dl, <70 mg/dl, 70-120 mg/dl, 70-180 mg/dl, >180 mg/dl, >250 mg/dl|Percentage of subjects with mean CGM glucose < 154 mg/dl|Number of severe hypoglycemic events (subject unable to self-treat, requiring the assistance of another person)|Average percent insulin dose amounts calculated by the bionic pancreas control algorithm that are successfully delivered by the pump.|Average percent glucagon dose amounts calculated by the bionic pancreas control algorithm that are successfully delivered by the pump.|Average percent insulin dose amounts successfully issued to the pump by the bionic pancreas control algorithm that are successfully delivered by the pump.|Average percent glucagon dose amounts successfully issued to the pump by the bionic pancreas control algorithm that a successfully delivered by the pump.|Average percent of 5 minute steps during which the bionic pancreas is functioning nominally in all respects based on real-time CGM data (new CGM glucose reading captured, dose calculated, dose issued to pumps|Average percent of 5 minute steps during which the bionic pancreas is functioning nominally with or without a new CGM glucose reading captured (dose calculated, dose issued to pumps).|CGM reliability index, calculated as percent of possible values actually recorded by CGM.|Glucagon total delivery per kg of body mass.|Insulin total delivery per kg of body mass.|Number of episodes of symptomatic hypoglycemia.|Total grams of carbohydrate taken for hypoglycemia.|Difference in mean nausea from VAS during the study|Difference in Infusion site pain from VAS|Difference in local erythema and edema according to the Draize scale|Number of unscheduled infusion set replacements.|Number of unscheduled CGM sensor changes.|Insulin area under the curve during the initial 90 minute fasted period|Mean insulin levels during the initial 90 minute fasted period|Difference between insulin levels at baseline and at 90 minutes|Tmax after the insulin dose|T 1/2 max after the insulin dose|C max after the insulin dose|AUC in the first 30 minutes after the insulin dose|AUC in the first 60 minutes after the insulin dose|AUC in the first 90 minutes after the insulin dose|Terminal half life after the insulin dose|Difference between the fasted PG value and the PG value at 90 minutes|Difference in the PG prior to the meal and peak post-prandial glucose|PG AUC in the 3.5 hours following the meal",Massachusetts General Hospital|Boston University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015P002773,Mar-16,May-18,May-18,8-Mar-16,null,10-May-18,"MGH Diabetes Research Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02701257
NCT02702011,Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: empagliflozin medium dose|Drug: empagliflozin low dose|Drug: empagliflozin high dose|Drug: placebo,Change From Baseline in 24 Hour UGE on Day 7,Boehringer Ingelheim|Eli Lilly and Company,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 2,48,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,1245.113,20-Mar-16,5-Sep-16,3-Oct-16,8-Mar-16,2-Apr-18,2-Apr-18,"Souseikai Hakata Clinic, Fukuoka, Fukuoka, Japan|Nishikumamoto Hospital, Kumamoto, Kumamoto, Japan|Shinjuku Research Park Clinic, Tokyo, Shinjyuku-ku, Japan|SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan",,https://ClinicalTrials.gov/show/NCT02702011
NCT02700048,Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia,,"Active, not recruiting",No Results Available,Hypoglycemia Unawareness|Type 1 Diabetes,Drug: intra-nasal naloxone|Drug: Intra-nasal saline,within person difference in peak epinephrine during hypoglycemia|naloxone pharmacokinetics,University of Minnesota - Clinical and Translational Science Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,18,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,CTSI # 22405,Jun-16,Nov-19,Dec-19,7-Mar-16,null,12-Oct-18,"Clinical and Translational Science Institute, University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02700048
NCT02693938,Blood Glucose Variability and Insulin Action During Menstrual Cycle in Females With Type 1 Diabetes,,Recruiting,No Results Available,Type 1 Diabetes,Device: Follicular Euglycemic clamp|Device: Luteal Euglycemic clamp,The change in area under the glucose infusion rate (AUCGIR) during different phases of menstrual cycle|Glucose Infusion Rate,Yale University|The Leona M. and Harry B. Helmsley Charitable Trust,Female,"12 Years to 35 Years   (Child, Adult)",Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,1509016531,Jan-16,Jan-19,Jan-20,29-Feb-16,null,21-Aug-18,"Yale University School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02693938
NCT02692547,Feasibility Study to Evaluate the Hybrid-Logic Closed Loop System in Type 1 Diabetes,DREAMED,Withdrawn,No Results Available,Type 1 Diabetes,Device: Hybrid-logic closed loop system,Descriptive endpoints,Medtronic Diabetes,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CEP312,Feb-16,Feb-16,Feb-16,26-Feb-16,null,19-Jan-18,,,https://ClinicalTrials.gov/show/NCT02692547
NCT02691247,Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study),,"Active, not recruiting",No Results Available,Diabetes Mellitus,Biological: CLBS03 Low Dose|Biological: CLBS03 High Dose|Biological: Placebo,Mixed Meal Tolerance Test (MMTT)-stimulated C-peptide area under the curve (AUC)|MMTT-stimulated C-peptide AUC|Change in hemoglobin A1c (HbA1c)|Change in insulin usage|Proportion of subjects with adverse events,"Caladrius Biosciences, Inc.|Sanford Health|California Institute for Regenerative Medicine (CIRM)",All,8 Years to 17 Years   (Child),Phase 2,113,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CLBS03-P01,Feb-16,Mar-19,Mar-20,25-Feb-16,null,10-May-19,"Rady Children's Hospital, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Barbara Davis Center for Diabetes, Aurora, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Diabetes Research Institute, Miami, Florida, United States|Indiana University, Indianapolis, Indiana, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Children's Mercy Kansas City, Kansas City, Missouri, United States|Sanford Research, Fargo, North Dakota, United States|Oregon Health Science University, Portland, Oregon, United States|Sanford Research, Sioux Falls, South Dakota, United States|Vanderbilt Eskind Diabetes Clinic, Nashville, Tennessee, United States|Baylor College of Medicine / Texas Children's Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02691247
NCT02691481,Diabetes-Specific Nutritional Formulas Versus Oatmeal,,Completed,No Results Available,Type 2 Diabetes Mellitus|Obesity,Dietary Supplement: Oatmeal breakfast|Dietary Supplement: Glucerna formula|Dietary Supplement: Ultra Glucose Control formula,Glucose area under the curve 0-240 minutes,Joslin Diabetes Center,All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,25,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),2014-01,May-14,Sep-14,Oct-14,25-Feb-16,null,25-Feb-16,,,https://ClinicalTrials.gov/show/NCT02691481
NCT02689479,11C-5-HTP PET in Clinical Islet Transplantation,,Completed,No Results Available,Type 1 Diabetes,Procedure: Positron-Emission Tomography|Biological: 11C-5-HTP|Procedure: Magnetic Resonance Imaging|Procedure: Mixed-Meal Tolerance Test (MMTT)|Procedure: Continuous Glucose Monitoring System® (CGMS)|Procedure: Glomerular Filtration Rate Testing|Procedure: Blood draw,The relationship between β cell mass calculated from the 11C-5-HTP PET scans and the MMTT C-peptide at 90 minutes|The relationship between βcell mass calculated from the 11C-5-HTP PET and the β-score computed at the time of the PET scan|The relationship between βcell mass calculated from the 11C-5-HTP PET and CPGCR computed at the time of the PET scan|The relationship between βcell mass calculated from the 11C-5-HTP PET and number of islets transplanted (Total IEQ)|The distribution of islets in the liver|The distribution of fat accumulation in the liver|The relationship between distribution patterns in the liver and MMTT C-peptide at 90 minutes computed at the time of the PET scan|The relationship with PET and peak C-peptide|The relationship with PET and C-peptide AUC|The distribution of islets in the liver related to distribution of fat accumulation in the liver as measured by MRI|The incidence and severity of adverse events related to the PET investigation including allergic reactions,National Institute of Allergy and Infectious Diseases (NIAID),All,"Child, Adult, Older Adult",Not Applicable,8,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,DAIT CIT-09,May-13,Sep-14,Sep-14,24-Feb-16,null,24-Feb-16,"Karolinska University Hospital, Stockholm, Sweden|Uppsala University, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT02689479
NCT02688218,Exercise Detection Study,,"Active, not recruiting",No Results Available,Type 1 Diabetes,Behavioral: Aerobic Exercise|Behavioral: Resistance Exercise,Mean change in sensor glucose in subjects with type 1 diabetes,Oregon Health and Science University,All,21 Years to 45 Years   (Adult),Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,15452,Feb-16,Jun-18,Sep-18,23-Feb-16,null,20-Sep-17,"Oregon Health and Science University, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT02688218
NCT02688933,A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus,,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: HOE901-U300 (Insulin Glargine 300 U/ml)|Drug: Lantus (Insulin Glargine 100 U/ml)|Drug: Mandated back ground therapy,Percentage of Time of Mean Glucose Concentration Within the Target Range of 70-180 mg/dL as Obtained From CGM|Percentage of Participants With Documented Symptomatic Nocturnal Hypoglycemia|Documented Symptomatic Nocturnal Hypoglycemia Event Rate Per Participant-Year|Mean Change From Baseline in Glucose Level During Last 4 Hours of CGM Data Collection Prior to the Next Day Basal Insulin Injection During Week 15 and/or Week 16|Percentage of Time Glucose Concentrations Within the Target Range of 70 to 140 mg/dL During Last 4 Hours of CGM Data Collection Prior to Next Day Basal Insulin Injection|Coefficient of Variation (CV%) in Mean CGM Glucose,Sanofi,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,638,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LPS14587|U1111-1176-0936,5-May-16,19-Jun-17,19-Jun-17,23-Feb-16,20-Aug-18,20-Aug-18,"Investigational Site Number 840-151, Little Rock, Arkansas, United States|Investigational Site Number 840-071, Concord, California, United States|Investigational Site Number 840-149, Escondido, California, United States|Investigational Site Number 840-004, Fresno, California, United States|Investigational Site Number 840-110, Greenbrae, California, United States|Investigational Site Number 840-124, La Jolla, California, United States|Investigational Site Number 840-030, La Mesa, California, United States|Investigational Site Number 840-044, Los Angeles, California, United States|Investigational Site Number 840-022, Los Angeles, California, United States|Investigational Site Number 840-129, Los Gatos, California, United States|Investigational Site Number 840-024, Northridge, California, United States|Investigational Site Number 840-069, Pomona, California, United States|Investigational Site Number 840-090, Pomona, California, United States|Investigational Site Number 840-132, Rolling Hills Estates, California, United States|Investigational Site Number 840-130, San Jose, California, United States|Investigational Site Number 840-055, San Ramon, California, United States|Investigational Site Number 840-028, Santa Barbara, California, United States|Investigational Site Number 840-063, Tarzana, California, United States|Investigational Site Number 840-138, Tustin, California, United States|Investigational Site Number 840-016, Ventura, California, United States|Investigational Site Number 840-039, Denver, Colorado, United States|Investigational Site Number 840-021, Denver, Colorado, United States|Investigational Site Number 840-070, Denver, Colorado, United States|Investigational Site Number 840-046, Englewood, Colorado, United States|Investigational Site Number 840-072, Coral Gables, Florida, United States|Investigational Site Number 840-133, Hialeah, Florida, United States|Investigational Site Number 840-137, Maitland, Florida, United States|Investigational Site Number 840-049, Miami, Florida, United States|Investigational Site Number 840-076, Miami, Florida, United States|Investigational Site Number 840-023, New Port Richey, Florida, United States|Investigational Site Number 840-053, Ocoee, Florida, United States|Investigational Site Number 840-112, Ormond Beach, Florida, United States|Investigational Site Number 840-018, Palm Harbor, Florida, United States|Investigational Site Number 840-047, Port Charlotte, Florida, United States|Investigational Site Number 840-114, Tampa, Florida, United States|Investigational Site Number 840-036, West Palm Beach, Florida, United States|Investigational Site Number 840-001, Atlanta, Georgia, United States|Investigational Site Number 840-064, Columbus, Georgia, United States|Investigational Site Number 840-012, Lawrenceville, Georgia, United States|Investigational Site Number 840-008, Roswell, Georgia, United States|Investigational Site Number 840-014, Stockbridge, Georgia, United States|Investigational Site Number 840-060, Idaho Falls, Idaho, United States|Investigational Site Number 840-125, Arlington Heights, Illinois, United States|Investigational Site Number 840-011, Chicago, Illinois, United States|Investigational Site Number 840-134, Crystal Lake, Illinois, United States|Investigational Site Number 840-002, West Des Moines, Iowa, United States|Investigational Site Number 840-073, Wichita, Kansas, United States|Investigational Site Number 840-062, Covington, Kentucky, United States|Investigational Site Number 840-042, Lexington, Kentucky, United States|Investigational Site Number 840-009, Metairie, Louisiana, United States|Investigational Site Number 840-032, New Orleans, Louisiana, United States|Investigational Site Number 840-054, Hyattsville, Maryland, United States|Investigational Site Number 840-006, Rockville, Maryland, United States|Investigational Site Number 840-157, Framingham, Massachusetts, United States|Investigational Site Number 840-122, Waltham, Massachusetts, United States|Investigational Site Number 840-037, Flint, Michigan, United States|Investigational Site Number 840-067, Billings, Montana, United States|Investigational Site Number 840-094, Lincoln, Nebraska, United States|Investigational Site Number 840-033, Omaha, Nebraska, United States|Investigational Site Number 840-142, Omaha, Nebraska, United States|Investigational Site Number 840-040, Henderson, Nevada, United States|Investigational Site Number 840-017, Las Vegas, Nevada, United States|Investigational Site Number 840-102, New York, New York, United States|Investigational Site Number 840-108, New York, New York, United States|Investigational Site Number 840-109, Staten Island, New York, United States|Investigational Site Number 840-045, Greenville, North Carolina, United States|Investigational Site Number 840-010, Morehead City, North Carolina, United States|Investigational Site Number 840-080, Morehead City, North Carolina, United States|Investigational Site Number 840-051, Fargo, North Dakota, United States|Investigational Site Number 840-123, Columbus, Ohio, United States|Investigational Site Number 840-104, Mentor, Ohio, United States|Investigational Site Number 840-079, Norman, Oklahoma, United States|Investigational Site Number 840-162, Bend, Oregon, United States|Investigational Site Number 840-096, Portland, Oregon, United States|Investigational Site Number 840-058, Chattanooga, Tennessee, United States|Investigational Site Number 840-003, Dallas, Texas, United States|Investigational Site Number 840-019, Dallas, Texas, United States|Investigational Site Number 840-075, Dallas, Texas, United States|Investigational Site Number 840-005, Dallas, Texas, United States|Investigational Site Number 840-013, Dallas, Texas, United States|Investigational Site Number 840-153, El Paso, Texas, United States|Investigational Site Number 840-026, Fort Worth, Texas, United States|Investigational Site Number 840-081, Houston, Texas, United States|Investigational Site Number 840-160, Houston, Texas, United States|Investigational Site Number 840-156, Houston, Texas, United States|Investigational Site Number 840-152, Houston, Texas, United States|Investigational Site Number 840-031, Houston, Texas, United States|Investigational Site Number 840-140, Lufkin, Texas, United States|Investigational Site Number 840-029, Mesquite, Texas, United States|Investigational Site Number 840-048, North Richland Hills, Texas, United States|Investigational Site Number 840-150, Pearland, Texas, United States|Investigational Site Number 840-083, Murray, Utah, United States|Investigational Site Number 840-101, Ogden, Utah, United States|Investigational Site Number 840-097, Salt Lake City, Utah, United States|Investigational Site Number 840-143, Bennington, Vermont, United States|Investigational Site Number 840-056, Burlington, Vermont, United States|Investigational Site Number 840-015, Renton, Washington, United States|Investigational Site Number 840-074, Spokane, Washington, United States|Investigational Site Number 840-139, Bridgeport, West Virginia, United States|Investigational Site Number 840-111, Manati, Puerto Rico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02688933/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02688933/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02688933
NCT02687256,Evaluation of Extended Infusion Set Wear Using Medtronic Extended Wear Sof-set Infusion Set,,Completed,No Results Available,Type 1 Diabetes,Device: Extended Wear infusion set|Device: Standard Infusion set|Drug: Heparin,Time to an infusion set failure due to an occlusion|signs of infection at insulin infusion site,Stanford University|Medtronic,All,18 Years to 55 Years   (Adult),Phase 1,24,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",IRB 36142,Mar-16,Nov-17,Nov-17,22-Feb-16,null,5-Jun-18,"Stanford University, Palo Alto, California, United States",,https://ClinicalTrials.gov/show/NCT02687256
NCT02687893,Effect of Hypoglycemia on Sleep,,Completed,No Results Available,Hypoglycemia,Behavioral: Aerobic Exercise|Behavioral: Resistance Exercise,Mean duration of time with sensed glucose less than 70 mg/dl post-exercise|Mean duration with sensed glucose between 70 - 180 mg/dl post-exercise|Mean duration with capillary blood glucose between 70 - 180 mg/dl|Mean wake up after sleep onset duration post-exercise|Mean amplitude of glucose excursions|Mean duration of total sleep time|Mean time subject in bed|Mean time for sleep onset|Mean time of sleep efficiency|Mean number of wake bouts|Mean wake bout time|Mean number of sleep bouts|Mean sleep bout time|Mean number of carbohydrate treatments to treat hypoglycemia|Mean daily carbohydrate intake|Mean daily insulin intake|Mean of total duration of activity by the subject|Mean duration of time with sensed glucose < 50 mg/dl|Mean duration of time with capillary blood glucose < 50 mg/dl|Mean duration of time with capillary blood glucose < 70 mg/dl|Mean duration of time with sensed glucose > 180 mg/dl|Mean duration of time with capillary blood glucose > 180 mg/dl,Oregon Health and Science University,All,21 Years to 45 Years   (Adult),Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15228,Feb-16,Sep-16,18-Jul-18,22-Feb-16,null,10-Apr-19,"Oregon Health and Science University, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT02687893
NCT02686177,Effect of GLP-1 on Angiogenesis,ANGIOSAFE 1,Recruiting,No Results Available,Type 2 Diabetes,Drug: Liraglutide|Drug: Metformin or sulfonylurea,Difference of ANGPTL4 concentration at 4 weeks of treatment from baseline in Liraglutide and control group|Difference of ANGPT2 concentration at 4 weeks of treatment from baseline in Liraglutide and control group|Difference of endothelial circulating progenitor cells (CD34+KDR+) concentration at 4 weeks of treatment from baseline in Liraglutide and control group|Difference of AngiomiR-126 expression at 4 weeks of treatment from baseline in Liraglutide and control group|Difference of Circulating soluble adhesion molecules as endothelial activation markers: ICAM-1 and VCAM-1 concentration at 4 weeks of treatment from baseline (Liraglutide versus control group),Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",Phase 4,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P140710|2015-002930-35,18-May-16,18-Jun-19,18-Jun-19,19-Feb-16,null,29-Aug-17,"Nutrition department, pole ENDO - Assistance Publique Hôpitaux Marseille, Marseille, France",,https://ClinicalTrials.gov/show/NCT02686177
NCT02685449,Insulin Requirement for Pure-protein Meal in Children With Type 1 Diabetes on Insulin Pumps.,,Unknown status,No Results Available,Diabetes type1,Drug: Insulin glulisine|Drug: Insulin aspart|Drug: Insulin lispro,Postprandial glycemia|Hypoglycemia episodes|Glucose Area Under the Curve (AUC)|Mean amplitude of glycemic excursion|The difference between the maximum and baseline glucose level,Medical University of Warsaw,All,"10 Years to 18 Years   (Child, Adult)",Phase 4,70,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Białko_5h,Feb-16,Feb-18,Aug-18,18-Feb-16,null,29-Jul-16,"Medical University, Warsaw, Poland",,https://ClinicalTrials.gov/show/NCT02685449
NCT02682940,T1 Diabetes Hypoglycemia Prevention Pilot,,Terminated,No Results Available,"Diabetes Mellitus, Type 1|Hypoglycemia",Device: Vigilant Diabetes Management Application,"Aggregate reduction in the rate of mild hypoglycemia (biochemical and logged) as measured by meter or logged home blood glucose values <56 mg/dL at 3 months, compared to the monthly rate of hypoglycemia in the baseline period.|An aggregate reduction in the rate of biochemical severe hypoglycemia as measured by meter or logged home blood glucose values <40 mg/dL, at 3 months, compared to the monthly rate in the baseline period|An aggregate (total study population) reduction in the LBGI and HBGI, as measured by percent of readings in and out of range calculated based on downloaded blood glucose meter download data.|An aggregate reduction in average HbA1will be measured at baseline using DCA 2000 or equivalent NGSP-certified point-of-care method or local laboratory at 3 months, compared to HbA1c levels obtained at study initiation.|An aggregate reduction in the survey self-reported rate of use of; 1) Glucagon 2) Emergency medical services for hypoglycemia, and 3) Hospital, urgent care or clinic visits for hypoglycemia or associated with hypoglycemia care visits.|An aggregate reduction in the mean glycemic variability, as measured by monthly ADRR (Average Daily Risk Range), calculated based on downloaded meter download data|Reduction in reported fear of hypoglycemia as compared to baseline Fear of Hypoglycemia Fear Survey. The Hypoglycemia Fear Survey II (HSF II) will be used.|Improvement in self-reported lost work productivity as a result of hypoglycemia. Individuals will complete a questionnaire about lost work days as a result of hypoglycemia at baseline and at 3 months.|Improvement in self-reported psychosocial self-efficacy as compared to baseline measured using the Diabetes Empowerment Scale Short Form (DES-SF).","InSpark Technologies, Inc.|Atlanta Diabetes Associates",All,"11 Years to 74 Years   (Child, Adult, Older Adult)",Not Applicable,4,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VG2HT1US1,May-16,Dec-16,Dec-16,17-Feb-16,null,3-Mar-17,"Atlanta Diabetes Associates, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT02682940
NCT02682680,Randomized Trial Comparing Colesevelam vs. Ezetimibe,GOAL-RCT,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Colesevelam|Drug: Ezetimibe,"Proportion of subjects who achieve target HbA1c and LDL cholesterol|Proportion of subjects who achieve the primary outcome measure in the sub-group of subjects on sodium/glucose cotransporter 2 inhibitor (SGLT2i) therapy|Absolute change in LDL cholesterol|Absolute change in non-high-density lipoprotein (HDL) cholesterol|Absolute change in fasting plasma glucose (FPG)|Absolute change in HbA1c|Absolute change in LDL cholesterol in sub-group of subjects on SGLT2i therapy|Absolute change in HDL cholesterol in sub-group of subjects on SGLT2i therapy|Absolute change in FPG in sub-group of subjects on SGLT2i therapy|Absolute change in HbA1c in sub-group of subjects on SGLT2i therapy|Proportion of subjects achieving a composite target of glycemic control, LDL cholesterol control and blood pressure control|Proportion of subjects achieving a composite target of glycemic control with no hypoglycemia and no weight gain|Proportion of subjects with ≥ 0.3% reduction in HbA1c and ≥ 10% reduction in LDL cholesterol from baseline|Proportion of subjects with ≥ 0.5% reduction in HbA1c and ≥ 15% reduction in LDL cholesterol|Absolute change in high-sensitivity C-reactive protein (hs-CRP) levels from baseline|Absolute change in triglyceride levels from baseline|Proportion of subjects achieving target HbA1c and LDL cholesterol in the sub-group of subjects on non-insulin therapies|Absolute change in FPG in the sub-group of subjects on non-insulin therapies|Absolute change in HbA1c in the sub-group of subjects on non-insulin therapies|Absolute change in LDL cholesterol in the sub-group of subjects on non-insulin therapies|Absolute change in non-HDL cholesterol in the sub-group of subjects on non-insulin therapies|Rate of non-severe and severe hypoglycemia|Absolute change in alanine aminotransferase (ALT)|Absolute change in creatine kinase (CK)","LMC Diabetes & Endocrinology Ltd.|Bausch Health Americas, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 4,200,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GOAL RCT,11-Jan-16,25-May-17,25-May-17,15-Feb-16,null,20-Mar-19,"LMC Calgary, Calgary, Alberta, Canada|LMC Barrie, Barrie, Ontario, Canada|LMC Brampton, Brampton, Ontario, Canada|LMC Etobicoke, Etobicoke, Ontario, Canada|LMC Markham, Markham, Ontario, Canada|LMC Oakville, Oakville, Ontario, Canada|LMC Thornhill, Thornhill, Ontario, Canada|Manna Toronto, Toronto, Ontario, Canada|LMC Bayview, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02682680
NCT02680054,Fat and Protein Study,,Terminated,No Results Available,Type 1 Diabetes,"Drug: Insulin, Asp(B28)-",Mean post-prandial glucose excursion for 8 hours following the test meal|Peak glucose level following test meal|Peak glucose excursion from baseline following test meal|Time of peak glucose level following test meal|Rate of blood glucose excursion from baseline to peak|Mean post-prandial glucose excursion for 5 and 12 hours following the test meal|Various areas under curve of glucose level following test meal|Time from baseline BG at which BG returns to baseline level,Oxford University Hospitals NHS Trust,All,"6 Years to 18 Years   (Child, Adult)",Phase 4,38,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,114185|2015-003666-85,Feb-16,31-Aug-18,31-Aug-18,11-Feb-16,null,25-Apr-19,"Royal Berkshire Hospital, Reading, Berkshire, United Kingdom|Oxford Children's Hospital, John Radcliffe Hospital, Oxford, Oxon, United Kingdom",,https://ClinicalTrials.gov/show/NCT02680054
NCT02679287,Project Nightlight: Efficacy and System Acceptance of Dinner/Night vs. 24hr Closed Loop Control,,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 1",Device: CLC,"Time <70 mg/dl by CGM and Hemoglobin A1c|Time between 70-180 mg/dL by CGM|Time >180 mg/dL by CGM|Mean glucose by CGM (overall, 7am and bedtime)|Low Blood Glucose Index (LBGI)|High Blood Glucose Index (HBGI)","University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Roche Diagnostic Ltd.|TypeZero Technologies, LLC|Tandem Diabetes Care, Inc.|DexCom, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,76,Other|NIH|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18617|R01DK085623,Feb-16,Apr-19,Apr-19,10-Feb-16,null,19-Oct-18,"University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02679287
NCT02677454,Evaluation of a Flash Glucose Monitoring System in Ambulatory Patients With Type 1 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus",Device: Flash Glucose Monitor,Mean Absolute Relative Difference (MARD)|Mean absolute Difference (MAD)|Pearson Correlation Coefficient|Mean absolute relative difference (MARD)|Mean absolute difference MAD|Pearson Correlation|Mean absolute difference (MAD)|questionnaire,Vastra Gotaland Region,All,"18 Years to 74 Years   (Adult, Older Adult)",Not Applicable,56,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Libre,Jun-15,Dec-15,Apr-16,9-Feb-16,null,15-Nov-16,"NU-Hospital Group, Uddevalla, Sweden",,https://ClinicalTrials.gov/show/NCT02677454
NCT02676609,Impact of Food Carbohydrate and Insulin Dose Computing by on Smart Phone on Glucose Control in Patients With Diabetes,GLUCAL,Completed,No Results Available,Type 1 Diabetes,Device: Automated carbohydrate and meal insulin dose computing,2-hour postmeal blood glucose values between 80 and 180 mg/dl|Mean 2-hour postmeal blood glucose level,"University Hospital, Montpellier|Université Montpellier",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,UF 9665,Feb-16,Jun-16,Aug-16,8-Feb-16,null,29-Nov-16,"Hôpital Lapeyronie, Montpellier, Hérault, France",,https://ClinicalTrials.gov/show/NCT02676609
NCT02674828,Physical Activity and Glycemic Control in Adolescents,,"Active, not recruiting",No Results Available,Type 1 Diabetes,Behavioral: Reinforcement for meeting targeted physical activity goals|Other: Standard of Care,"proportion of days participants walked the recommended number of steps|proportion of days in the month participants walked 10,000 or more steps|number of consecutive weeks step goal met|Body Mass Index|Waist Circumference|Systolic Blood Pressure|Diastolic Blood Pressure|Six Minute Walk Test|Sit to Stand Test|Harvard Step Test|Physical Activity Questionnaire|Habitual Total Weekend Activity Score|Habitual Total Weekday Activity Score",Yale University|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"13 Years to 24 Years   (Child, Adult)",Not Applicable,12,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1509016461|DP3DK097705,1-Feb-16,1-Jan-18,Jan-19,5-Feb-16,null,27-Jun-18,"Yale University School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02674828
NCT02673138,Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion,,Completed,Has Results,Type 1 Diabetes,Drug: canagliflozin|Other: basal interruption without canagliflozin,Differences in Plasma Glucose Levels Following the Interruption of Basal Subcutaneous Infusion of Insulin|Differences in BHB (Beta-hydroxybutyrate) Levels Following Interruption of Basal|Differences in Free Fatty Acid Levels Following Interruption of Basal Subcutaneous Insulin Infusion|Differences in Glucagon Levels Following the Interruption of the Basal Subcutaneous Insulin Infusion,Yale University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,18 Years to 45 Years   (Adult),Not Applicable,10,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1508016333|1K12DK094714-01,Jan-16,Jan-17,Jul-17,3-Feb-16,29-Nov-18,29-Nov-18,"Yale University School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02673138
NCT02670915,Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes,onset®7,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart|Drug: insulin degludec,"Change in the Percentage of HbA1c|Change in 8-point SMPG Profile: Mean PPG Over All Three Meals|Change in 8-point SMPG Profile: PPG Increment Over All Three Meals|Change in 8-point SMPG Profile: Individual Meal (Breakfast, Lunch and Main Evening Meal) PPG|Change in 8-point SMPG Profile: Individual Meal (Breakfast, Lunch and Main Evening Meal) PPG Increment|Change in 8-point SMPG Profile: Mean of the 8-point Profile|Fluctuation in the 8-point SMPG Profile|Change in FPG|Change in 1,5-anhydroglucitol|Percentage of Subjects Reaching HbA1c Target (HbA1c Less Than 7.5 %) According to ISPAD Guidelines|Percentage of Subjects Reaching HbA1c Target (HbA1c Less Than 7.5 %) According to ISPAD Guidelines, Without Severe Hypoglycaemia|Insulin Dose (Units/Day): Total Basal|Insulin Dose (Units/Day): Total Bolus|Insulin Dose (Units/Day): Individual Meal Insulin Dose|Insulin Dose (Units/kg/Day): Total Basal|Insulin Dose (Units/kg/Day): Total Bolus|Insulin Dose (Units/kg/Day): Individual Meal Insulin Dose|Change of Time Spent in Low Interstitial Glucose (IG) (IG <=3.9 mmol/L [70 mg/dL])|Incidence of Episodes With IG <=2.5, 3.0, 3.9 mmol/L (45, 54, 70 mg/dL) and IG >10.0, 12.0 mmol/L (180, 216 mg/dL)|Percentage of Time Spent With IG <=2.5, 3.0, 3.9 mmol/L (45, 54, 70 mg/dL) and IG >10.0, 12.0 mmol/L (180, 216 mg/dL)|Percentage of Time Spent Within IG Target 4.0-10.0 mmol/L (71-180 mg/dL) Both Included|Change in Mean IG Increment (0-1 Hours and 0-2 Hours After Start of the Meal)|Change in Mean IG Peak After Start of Meal|Change in Mean Time to the IG Peak After Meal|Change in 30-minute PPG|Change in 30-minute PPG Increment|Change in 1-hour PPG|Change in 1-hour PPG Increment|Change in 2-hour PPG|Change in 2-hour PPG Increment|Change in AUCIG,0-15min|Change in AUCIG,0-30min|Change in AUCIG,0-1h|Change in AUCIG,0-2h|Change in AUCIG,0-4h|Change in Time to the IG Peak After Start of Meal|Change in IG Peak After Start of Meal|Number of Treatment Emergent Hypoglycaemic Episodes According to American Diabetes Association (ADA)/ISPAD Classification: Total|Number of Treatment Emergent Hypoglycaemic Episodes According to ADA/ISPAD Classification: Daytime|Number of Treatment Emergent Hypoglycaemic Episodes According to ADA/ISPAD Classification: Nocturnal (23:00-7:00, Both Included)|Number of Treatment Emergent Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification: Total|Number of Treatment Emergent Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification: Daytime|Number of Treatment Emergent Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification: Nocturnal (23:00-7:00, Both Included)|Number of Treatment Emergent Meal Related (From Start of Meal Until 1 Hour After Start of Meal) Hypoglycaemic Episodes According to ADA/ISPAD Classification|Number of Treatment Emergent Meal Related (From Start of Meal Until 2 Hours After Start of Meal) Hypoglycaemic Episodes According to ADA/ISPAD Classification|Number of Treatment Emergent Meal Related (From Start of Meal Until 4 Hours After Start of Meal) Hypoglycaemic Episodes According to ADA/ISPAD Classification|Number of Treatment Emergent Meal Related (From 2-4 Hours After Start of Meal) Hypoglycaemic Episodes According to ADA/ISPAD Classification|Number of Treatment Emergent Meal Related (From Start of Meal Until 1 Hour After Start of Meal) Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification|Number of Treatment Emergent Meal Related (From Start of Meal Until 2 Hours After Start of Meal) Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification|Number of Treatment Emergent Meal Related (From Start of Meal Until 4 Hours After Start of Meal) Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification|Number of Treatment Emergent Meal Related (From 2-4 Hours After Start of Meal) Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification|Number of Treatment Emergent Adverse Events (AEs)|Number of Treatment Emergent Injection Site Reactions|Change in Physical Examination|Change in Vital Sign: Blood Pressure|Change in Vital Sign: Pulse|Change in Body Weight|Change in Height|Change in Body Mass Index|Change in SD Score of Body Weight|Change in SD Score of Body Mass Index|Change in Haematology: Haemoglobin|Change in Haematology: Haematocrit|Change in Haematology: Erythrocytes|Change in Haematology: Thrombocytes|Change in Haematology: Leukocytes|Change in Biochemistry: Creatinine|Change in Biochemistry: Alanine Aminotransferase (ALT)|Change in Biochemistry: Aspartate Aminotransferase (AST)|Change in Biochemistry: Alkaline Phosphatase (AP)|Change in Biochemistry: Sodium|Change in Biochemistry: Potassium|Change in Biochemistry: Albumin|Change in Biochemistry: Total Bilirubin|Change in Lipid Profile: Total Cholesterol|Change in Lipid Profile: High Density Lipoproteins (HDL)|Change in Lipid Profile: Low Density Lipoproteins (LDL)|Change in Anti-insulin Aspart Antibody Development: Specific|Change in Anti-insulin Aspart Antibody Development: Cross-reacting With Human Insulin|Change in Anti-insulin Aspart Antibody Development: Total",Novo Nordisk A/S,All,1 Year to 17 Years   (Child),Phase 3,834,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1218-4101|2014-002568-33|U1111-1158-1170|JapicCTI-163248,4-May-16,5-Feb-18,3-Mar-18,2-Feb-16,4-Apr-19,18-Apr-19,"Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Long Beach, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Sacramento, California, United States|Novo Nordisk Investigational Site, Ventura, California, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, Gainesville, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Tallahassee, Florida, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Boise, Idaho, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Springfield, Illinois, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Neptune, New Jersey, United States|Novo Nordisk Investigational Site, Buffalo, New York, United States|Novo Nordisk Investigational Site, Mineola, New York, United States|Novo Nordisk Investigational Site, Raleigh, North Carolina, United States|Novo Nordisk Investigational Site, Fargo, North Dakota, United States|Novo Nordisk Investigational Site, Columbus, Ohio, United States|Novo Nordisk Investigational Site, Tulsa, Oklahoma, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Sioux Falls, South Dakota, United States|Novo Nordisk Investigational Site, Amarillo, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Salt Lake City, Utah, United States|Novo Nordisk Investigational Site, Pleven, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Varna, Bulgaria|Novo Nordisk Investigational Site, Hradec Kralove, Czechia|Novo Nordisk Investigational Site, Opava, Czechia|Novo Nordisk Investigational Site, Ostrava - Poruba, Czechia|Novo Nordisk Investigational Site, Pardubice, Czechia|Novo Nordisk Investigational Site, Praha, Czechia|Novo Nordisk Investigational Site, Usti nad Labem, Czechia|Novo Nordisk Investigational Site, Tallinn, Estonia|Novo Nordisk Investigational Site, Tartu, Estonia|Novo Nordisk Investigational Site, Espoo, Finland|Novo Nordisk Investigational Site, OYS, Finland|Novo Nordisk Investigational Site, Seinäjoki, Finland|Novo Nordisk Investigational Site, Bochum, Germany|Novo Nordisk Investigational Site, Freiburg, Germany|Novo Nordisk Investigational Site, Hannover, Germany|Novo Nordisk Investigational Site, Ludwigshafen, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Neuwied, Germany|Novo Nordisk Investigational Site, Oldenburg, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Ahmedabad, Gujarat, India|Novo Nordisk Investigational Site, Kochi, Kerala, India|Novo Nordisk Investigational Site, Indore, Madhya Pradesh, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Kolkata, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, Beer Sheva, Israel|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Holon, Israel|Novo Nordisk Investigational Site, Petah Tikva, Israel|Novo Nordisk Investigational Site, Tel Aviv, Israel|Novo Nordisk Investigational Site, Zerifin, Israel|Novo Nordisk Investigational Site, Ancona, Italy|Novo Nordisk Investigational Site, Catanzaro, Italy|Novo Nordisk Investigational Site, Chieti, Italy|Novo Nordisk Investigational Site, Napoli, Italy|Novo Nordisk Investigational Site, Verona, Italy|Novo Nordisk Investigational Site, Amagasaki-shi, Hyogo, Japan|Novo Nordisk Investigational Site, Chuo-shi, Yamanashi, Japan|Novo Nordisk Investigational Site, Fukuoka, Japan|Novo Nordisk Investigational Site, Hiroshima-shi, Hiroshima, Japan|Novo Nordisk Investigational Site, Iruma-gun, Saitama, Japan|Novo Nordisk Investigational Site, Kitakyushu,Fukuoka, Japan|Novo Nordisk Investigational Site, Kitakyushu-shi, Fukuoka, Japan|Novo Nordisk Investigational Site, Kobe-shi, Hyogo, Japan|Novo Nordisk Investigational Site, Kobe-shi, Hyogo, Japan|Novo Nordisk Investigational Site, Kochi-shi, Kochi, Japan|Novo Nordisk Investigational Site, Kofu, Yamanashi, Japan|Novo Nordisk Investigational Site, Kumamoto-shi, Kumamoto, Japan|Novo Nordisk Investigational Site, Kure-shi, Hiroshima, Japan|Novo Nordisk Investigational Site, Kyoto, Japan|Novo Nordisk Investigational Site, Maebashi-shi, Gunma, Japan|Novo Nordisk Investigational Site, Matsumoto-shi, Nagano,, Japan|Novo Nordisk Investigational Site, Matsuyama-shi, Ehime, Japan|Novo Nordisk Investigational Site, Musashino-shi, Tokyo, Japan|Novo Nordisk Investigational Site, Niigata-shi, Niigata, Japan|Novo Nordisk Investigational Site, Niigata-shi, Niigata, Japan|Novo Nordisk Investigational Site, Okayama Kita-ku, Okayama, Japan|Novo Nordisk Investigational Site, Okayama-shi, Okayama, Japan|Novo Nordisk Investigational Site, Okayama-shi, Okayama, Japan|Novo Nordisk Investigational Site, Osaka-shi, Osaka, Japan|Novo Nordisk Investigational Site, Ota-shi, Gunma, Japan|Novo Nordisk Investigational Site, Otsu-shi, Shiga, Japan|Novo Nordisk Investigational Site, Saga-shi, Saga, Japan|Novo Nordisk Investigational Site, Sendai-shi, Miyagi, Japan|Novo Nordisk Investigational Site, Suzaka-shi ,Nagano, Japan|Novo Nordisk Investigational Site, Tochigi, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tsu-shi, Mie, Japan|Novo Nordisk Investigational Site, Yokohama-shi, Kanagawa, Japan|Novo Nordisk Investigational Site, Yokosuka-shi, Kanagawa, Japan|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Kaunas, Lithuania|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Wroclaw, Poland|Novo Nordisk Investigational Site, San Juan, Puerto Rico|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Rostov-on-Don, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Samara, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Tomsk, Russian Federation|Novo Nordisk Investigational Site, Ufa, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Nis, Serbia|Novo Nordisk Investigational Site, Novi Sad, Serbia|Novo Nordisk Investigational Site, Adana, Turkey|Novo Nordisk Investigational Site, Antalya, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, İzmir, Turkey|Novo Nordisk Investigational Site, Izmir, Turkey|Novo Nordisk Investigational Site, Samsun, Turkey|Novo Nordisk Investigational Site, Dnipro, Ukraine|Novo Nordisk Investigational Site, Ivano-Frankivsk, Ukraine|Novo Nordisk Investigational Site, Kharkiv, Ukraine|Novo Nordisk Investigational Site, Kharkiv, Ukraine|Novo Nordisk Investigational Site, Kiev, Ukraine|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Lviv, Ukraine|Novo Nordisk Investigational Site, Vinnytsia, Ukraine|Novo Nordisk Investigational Site, Zaporizhzhia, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02670915/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02670915/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02670915
NCT02671968,Real-Time Continuous Glucose Monitoring (RT-CGM) in Patients With Type 1 Diabetes at High Risk for Low Glucose Values Using Multiple Daily Injections (MDI) in Germany (HYPODE-STUDY),,Completed,No Results Available,Diabetes,Device: Continuous Glucose Monitoring System,"Change in the total number of low glucose events (<55 mg/dl), between baseline and outcome phase (week 22-26) in CGM group and control group (change = subtracting number of follow up events from number of baseline events","Science Consulting in Diabetes|DexCom, Inc. a Delaware corporation, USA|Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Germany",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,141,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment,IDT-1510-SI / HypoDE,Feb-16,14-Jul-17,24-Oct-17,2-Feb-16,null,12-Mar-18,"Gemeinschaftspraxis Dres. Klausmann, Aschaffenburg, Germany|m&i-Fachklinik Bad Heilbrunn, Bad Heilbrunn, Germany|Forschungsinstitut Diabetes-Akademie Bad Mergentheim (FIDAM), Bad Mergentheim, Germany|Diabetologische Schwerpunktpraxis, Bergheim, Germany|Medicover Berlin-Mitte, Berlin, Germany|Diabetologikum Duisburg, Duisburg, Germany|Diabetes Praxis Essen, Essen, Germany|Diabetologische Schwerpunktpraxis mit Fußambulanz, Essen, Germany|Zentrum für Diabetologie Bergedorf, Hamburg, Germany|Gemeinschaftspraxis Dres. Kaltheuner, Leverkusen, Germany|Diabetes Schwerpunkt Praxis Zentrum für Hormone und Stoffwechsel, Marktredwitz, Germany|Schwerpunktpraxis für Diabetes und Ernährungsmedizin, Münster, Germany",,https://ClinicalTrials.gov/show/NCT02671968
NCT02667769,Comparison of Two Protocols on the Implementation of a Fasting Day in Type 1 Diabetes,,Unknown status,No Results Available,Fasting,Other: Fasting day,Plasma glucose day- and night profiles,Diabeteszentrum Bad Lauterberg im Harz,All,"Child, Adult, Older Adult",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),DZBL-2014-2,Aug-14,Jun-16,null,29-Jan-16,null,16-Aug-16,"Diabeteszentrum Bad Lauterberg, Bad Lauterberg, Niedersachsen, Germany",,https://ClinicalTrials.gov/show/NCT02667769
NCT02667964,FGF-21 and Exercise in Relation to Insulin Secretion,,Unknown status,No Results Available,Physical Activity,Other: spiroergometry,FGF-21 change after physical activity,"Charite University, Berlin, Germany",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,FGF-Exercise,Nov-15,Nov-16,Jun-17,29-Jan-16,null,29-Jan-16,"Charité, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT02667964
NCT02666430,Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus Patients,,Unknown status,No Results Available,Type 1 Diabetes Mellitus,Drug: Mylan's insulin glargine|Drug: Lantus®,"Change in HbA1c from baseline between two periods at 12 weeks|Change in basal insulin dose per unit body weight (U/Kg/day)|Change in immunogenicity|Rate of hypoglycemic events per 30 days; and occurrence of hypoglycemia|Occurrence of local reactions, systemic reactions and other adverse events|Change in fasting plasma glucose",Mylan Inc.|Mylan GmbH,All,"18 Years to 66 Years   (Adult, Older Adult)",Phase 3,138,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MYL-1501D-3003,Dec-15,Mar-17,Mar-17,28-Jan-16,null,14-Sep-16,"Mylan Investigator Site, Fresno, California, United States|Mylan Investigator Site, Greenbrae, California, United States|Mylan Investigator Site, La Jolla, California, United States|Mylan Investigator Site, Northridge, California, United States|Mylan Investigator Site, Tustin, California, United States|Mylan Investigator Site, Fort Lauderdale, Florida, United States|Mylan Investigator Site, New Port Richey, Florida, United States|Mylan Investigator Site, Palm Harbor, Florida, United States|Mylan Investigator Site, West Palm Beach, Florida, United States|Mylan Investigator Site, Atlanta, Georgia, United States|Mylan Investigator Site, Columbus, Georgia, United States|Mylan Investigator Site, Idaho Falls, Idaho, United States|Mylan Investigator Site, Crystal Lake, Illinois, United States|Mylan Investigator Site, Springfield, Illinois, United States|Mylan Investigator Site, Des Moines, Iowa, United States|Mylan Investigator Site, Overland Park, Kansas, United States|Mylan Investigator Site, Lexington, Kentucky, United States|Mylan Investigator Site, Billings, Montana, United States|Mylan Investigator Site, Omaha, Nebraska, United States|Mylan Investigator Site, Albany, New York, United States|Mylan Investigator Site, Staten Island, New York, United States|Mylan Investigator Site, Syracuse, New York, United States|Mylan Investigator Site, Asheville, North Carolina, United States|Mylan Investigator Site, Burlington, North Carolina, United States|Mylan Investigator Site, Greenville, North Carolina, United States|Mylan Investigator Site, Morehead City, North Carolina, United States|Mylan Investigator Site, Wilmington, North Carolina, United States|Mylan Investigator Site, Cincinnati, Ohio, United States|Mylan Investigator Site, Mentor, Ohio, United States|Mylan Investigator Site, Chattanooga, Tennessee, United States|Mylan Investigator Site, Austin, Texas, United States|Mylan Investigator Site, Dallas, Texas, United States|Mylan Investigator Site, San Antonio, Texas, United States|Mylan Investigator Site, Ogden, Utah, United States|Mylan Investigator Site, Salt Lake City, Utah, United States|Mylan Investigator Site, Chesapeake, Virginia, United States|Mylan Investigator Site, Renton, Washington, United States|Mylan Investigator Site, Tacoma, Washington, United States|Mylan Investigator Site, Vancouver, Washington, United States|Mylan Investigator Site, Red Deer, Alberta, Canada|Mylan Investigator Site., Vancouver, British Columbia, Canada|Mylan Investigator Site, Winnipeg, Manitoba, Canada|Mylan Investigator Site, Laval, Quebec, Canada|Mylan Investigator Site, Montreal, Quebec, Canada|Mylan Investigator Site, Brno Bohunice, Czech Republic|Mylan Investigator Site, Ceske Budejovice, Czech Republic|Mylan Investigator Site, Olomouc, Czech Republic|Mylan Investigator Site, Pardubice, Czech Republic|Mylan Investigator Site, Praha 10, Czech Republic|Mylan Investigator Site, Praha, Czech Republic|Mylan Investigator Site, Parnu, Estonia|Mylan Investigator Site, Tallinn, Estonia|Mylan Investigator Site, Tartu, Estonia|Mylan Investigator Site, Aschaffenburg, Bayern, Germany|Mylan Investigator Site, Munster, Nordrhein Westfalen, Germany|Mylan Investigator Site, Hohenmolsen, Sachsen Anhalt, Germany|Mylan Investigator Site, Hamburg, Germany|Mylan Investigator Site, Hamburg, Germany|Mylan Investigator Site, Budapest, Hungary|Mylan Investigator Site, Budapest, Hungary|Mylan Investigator Site, Eger, Hungary|Mylan Investigator Site, Letavertes, Hungary|Mylan Investigator Site, Miskolc, Hungary|Mylan Investigator Site, Szeged, Hungary|Mylan Investigator Site, Limbazi, Latvia|Mylan Investigator Site, Ogre, Latvia|Mylan Investigator Site, Riga, Latvia|Mylan Investigator Site, Riga, Latvia|Mylan Investigator Site, Sigulda, Latvia|Mylan Investigator Site, Talsi, Latvia|Mylan Investigator Site, Bratislava, Slovakia|Mylan Investigator Site, Bratislava, Slovakia|Mylan Investigator Site, Dolny Kubin, Slovakia|Mylan Investigator Site, Levice, Slovakia|Mylan Investigator Site, Lubochna, Slovakia|Mylan Investigator Site, Nove Zamky, Slovakia|Mylan Investigator Site, Prievidza, Slovakia|Mylan Investigator Site, Rimavska Sobota, Slovakia|Mylan Investigator Site, Sturovo, Slovakia|Mylan Investigator Site, Trebisov, Slovakia|Mylan Investigator Site, Zilina, Slovakia",,https://ClinicalTrials.gov/show/NCT02666430
NCT02663661,Insulin-Glucose-Glucagon Network: Defining a Type 1 Diabetes Progression Index,,Recruiting,No Results Available,"Diabetes Mellitus, Type 1",Procedure: Metabolic Challenge Admission|Other: CGM home test,Test the hypothesis that immunological abnormalities are associated with abnormally high glucagon responses to a meal and reduced glucagon responses to insulin induced hypoglycemia.|Correlate metrics derived from a minimally-invasive Continuous Glucose Monitor (CGM) home test with glucagon responses to a meal and hypoglycemia measured in the hospital.,University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"12 Years to 45 Years   (Child, Adult)",Not Applicable,63,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,18568|DP3DK106907-01,Feb-16,30-Jun-19,30-Jun-19,26-Jan-16,null,25-Mar-19,"University of Virginia, Center for Diabetes Technology, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02663661
NCT02660242,The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: G-Pen Mini™ (glucagon injection)|Other: Glucose Tabs|Other: Basal Insulin Reduction,Glycemic Response During Exercise and Early Recovery|Number of Participants With Hypoglycemia (<70 mg/dL) During Exercise and Early Recovery|Number of Participants With Hyperglycemia (≥250 mg/dL) During Exercise and Early Recovery|Continuous Glucose Monitor (CGM) Metrics During Late Recovery - Nadir Glucose|CGM Metrics During Late Recovery - Peak Glucose|CGM Metrics During Late Recovery - Mean Glucose|CGM Metrics During Late Recovery - Coefficient of Variation|CGM Metrics During Late Recovery - Time < 54 mg/dL|CGM Metrics During Late Recovery - Time < 70 mg/dL|CGM Metrics During Late Recovery - Time in Range (70-180 mg/dL)|CGM Metrics During Late Recovery - Time > 180 mg/dL|CGM Metrics During Late Recovery - Time > 250 mg/dL,Jaeb Center for Health Research|Xeris Pharmaceuticals,All,18 Years to 64 Years   (Adult),Phase 2,16,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,T1DX Mini-dose Exercise,Jan-16,15-Feb-17,15-Feb-17,21-Jan-16,7-Aug-18,7-Aug-18,"Joslin Diabetes Center, Boston, Massachusetts, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02660242/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02660242/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02660242
NCT02660827,Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects With Type 1 Diabetes,,"Active, not recruiting",Has Results,Type 1 Diabetes,Device: Insulin Pump,Age 7-13 Years Old Subjects Change in A1C|Age 7-13 Years Old Subjects Mean Change in % of Time in Euglycemia (70-180 mg/dL)|Age 7-13 Years Old Subjects Mean Change in % of Time in Hyperglycemia (> 180 mg/dL)|Age 7-13 Years Old Subjects Mean Change in % of Time in Hypoglycemia (<70 mg/dL)|Age 7-13 Years Old - Number of Severe Hypoglycemic Event|Age 7-13 Years Old - Number of Diabetic Ketoacidosis (DKA) Event|Age 7-13 Years Old Subjects PLGM Performance - Event Rate Without Hypoglycemia at YSI-FST <=65 mg/dL,Medtronic Diabetes,All,2 Years to 13 Years   (Child),Not Applicable,105,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CEP 302,18-Apr-16,28-Nov-18,Dec-19,21-Jan-16,11-Jan-19,11-Jan-19,"AMCR Institute, Escondido, California, United States|Stanford Hospital and Clinics, Palo Alto, California, United States|SoCal Diabetes, Torrance, California, United States|Barbara Davis Center, Aurora, Colorado, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|University of South Florida - USF Health, Tampa, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Indiana University, Indianapolis, Indiana, United States|University of Michigan, Ann Arbor, Michigan, United States|Sheba Medical Center, Tel Aviv, Israel","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02660827/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02660827/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02660827
NCT02657083,Prevention of Hypoglycemia After Exercise Using Closed Loop System in Children and Adolescents With Type 1 Diabetes,PHYSI-DREAM,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: DreaMed Substance Administration Device|Device: Sensor Augmented Pump (SAP),"to evaluate the safety and efficacy of blood glucose control using the DreaMed MD-AID in children and adolescents with T1D during and after planned physical activity, in a controlled in-hospital environment.|to evaluate the physiologic responses and risk of hypoglycemia among children and adolescents with T1D after afternoon exercise during closed-loop control in a controlled in-hospital environment","University of Ljubljana, Faculty of Medicine",All,10 Years to 17 Years   (Child),Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,PD-MC-01,Jan-16,Jun-16,Jun-16,15-Jan-16,null,21-Sep-17,"University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia",,https://ClinicalTrials.gov/show/NCT02657083
NCT02657213,Study of Insulin Pump in Prevention of Low Glucose Events in Adults With Type 1 Diabetes at Risk of Severe Hypoglycemia,ALPPHY,Completed,No Results Available,"Diabetes, Type 1",Device: Minimed 640G with smartguard activated|Device: Minimed 640G with smartguard off,Assessment of the Minimed 640G insulin pump with Smartguard activation in preventing the number of severe and non-severe hypoglycaemia in patients with diabetes type 1 at risk of severe hypoglycemia|Assessment of Improving of overall glycemic control with SmartGuard activation in type 1 diabetic patients at risk of severe hypoglycemia|Assessment of the quality of life of patients with smartguard activation|Assessment of the number of adverse events|Study of average cost per patient for each therapeutic strategy supported from the point of view of society,"University Hospital, Grenoble",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,38RC15.110,Feb-16,Jun-17,Jun-17,15-Jan-16,null,18-Oct-17,"Grenoble University Hospital, Grenoble, France|Montpellier University Hospital, Montpellier, France",,https://ClinicalTrials.gov/show/NCT02657213
NCT02656069,Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics,,Completed,Has Results,"Hypoglycemia|Diabetes Mellitus, Type 1",Drug: G-Pen (glucagon injection)|Drug: Lilly Glucagon (glucagon injection [rDNA origin]),Hypoglycemia Rescue: Intent-to-Treat Population|Hypoglycemia Rescue: Per Protocol Population|Hypoglycemia Rescue: Alternate Glucose Response Definition|Plasma Glucose Area Under the Curve (AUC)|Plasma Glucose Maximum Concentration (Cmax)|Plasma Glucose Time to Maximum Concentration (Tmax)|Plasma Glucose Time to Concentration > 70 mg/dL|Time to Resolution of Hypoglycemia Symptoms|Global Assessment of Hypoglycemia,Xeris Pharmaceuticals,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,80,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",XSGP-301,15-Mar-17,14-Aug-17,25-Sep-17,14-Jan-16,28-Sep-18,30-Oct-18,"University of Alabama at Birmingham, Birmingham, Alabama, United States|ProSciento, Inc., Chula Vista, California, United States|AMCR Institute, Escondido, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Rainier Research, Renton, Washington, United States|LMC Diabetes & Endocrinology, Toronto, Ontario, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT02656069/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02656069
NCT02652026,Effect of Non-surgical Periodontal Treatment on HbA1c in Type 2 Diabetic Patients,,Completed,No Results Available,Chronic Periodontitis|Type 2 Diabetes Mellitus,Procedure: Nonsurgical periodontal treatment|Procedure: Dental Prophylaxis,Change from baseline in Glycosylated Hemoglobin (HbA1c),University of Barcelona,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,UBarcelona,Jun-13,Sep-15,Sep-15,11-Jan-16,null,19-Oct-16,,,https://ClinicalTrials.gov/show/NCT02652026
NCT02651181,Feasibility Study to Evaluate the Hybrid-Logic Closed Loop System in Type 1 Diabetes The DREAMED Trail,,Unknown status,No Results Available,Type 1 Diabetes,Device: HLCL- Hybrid Logic Closed Loop System,"Time in range of sensor glucose data between 70 mg/dL to 180 mg/dL,|Time in range of sensor glucose data between 70 mg/dL to 180 mg/dL,during night time (12am-6am)|Time in range of sensor glucose data between 70 mg/dL to 180 mg/dL,during day time (6am-12am)|Event rate of Serious Adverse Events|Event rate of Serious Adverse Device Events|Event rate of unanticipated Adverse Device Effects|Incidence of Diabetic Ketoacidosis|Area under the curve of time in the hyperglycemia range|Area Under the curve of time in the hypoglycemic range|Incidence of Severe Hypoglycemia",Rabin Medical Center|Medtronic,All,18 Years to 40 Years   (Adult),Not Applicable,10,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RMC076215ctil,Jun-16,Sep-18,Sep-18,8-Jan-16,null,20-Dec-17,"Schneider Medical Center, Petach- Tikva, Israel",,https://ClinicalTrials.gov/show/NCT02651181
NCT02649010,A Performance Evaluation of the Enlite 3 Sensor,,Withdrawn,No Results Available,Type 1 Diabetes,Device: Enlite 3 Sensor,Enlite 3 Sensor inserted at Arm accuracy using a real time device: (640G pump) with the minimum calibration requirements (every 12 hours after the second calibration) will be evaluated.,Medtronic Diabetes,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Not Applicable,0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CEP309,Jan-16,May-16,May-16,7-Jan-16,null,23-Jun-16,"Diablo Clinical Research, Walnut Creek, California, United States|Rainier Clinical Research Center, Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT02649010
NCT02646878,A Feasibility Study to Evaluate the Performance of the Harmony 1 Sensors in Adults and Pediatrics,,Withdrawn,No Results Available,Type 1 Diabetes,Device: Harmony 1 Sensor,24 hour calibration requirement,Medtronic Diabetes,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Not Applicable,0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,CEP310,Jan-16,Jul-16,Jul-16,6-Jan-16,null,20-Nov-17,,,https://ClinicalTrials.gov/show/NCT02646878
NCT02647905,Evaluation of the Accuracy of an Implanted Glucose Sensor,PRECISEII,Completed,Has Results,Diabetes Mellitus,Device: Continuous Glucose Monitoring System,CGM Relative Difference to Laboratory Reference Reported as MARD,"Senseonics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,90,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,CTP-0023,Jan-16,Jul-16,Jul-16,6-Jan-16,5-Jun-18,5-Jun-18,"John Muir Physician Network Clinical Research Center, Concord, California, United States|AMCR Institute, Escondido, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Atlanta Diabetes Care, Atlanta, Georgia, United States|Mount Sinai Diabetes Center, New York, New York, United States|Worldwide Clinical Trials, San Antonio, Texas, United States|Clinical Trials of Texas, San Antonio, Texas, United States|UVA Diabetes and Endocrine Clinic, Charlottesville, Virginia, United States|Rainier Clinical Research, Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT02647905
NCT02644590,The Effect of Melatonin on Early Signs of Hypertension in Teenagers With Diabetes Mellitus Type 1,,Unknown status,No Results Available,"Diabetes Mellitus, Type 1|Hypertension",Drug: Melatonin,"blood pressure monitoring , pre and post treatment with melatonin",Sheba Medical Center,All,"12 Years to 21 Years   (Child, Adult)",Early Phase 1,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,311080,Feb-16,Sep-16,Feb-17,1-Jan-16,null,1-Jan-16,,,https://ClinicalTrials.gov/show/NCT02644590
NCT02644759,Transplantation of Autologous Stem Cells for the Treatment of Type 1 Diabetes Mellitus,,Completed,No Results Available,Diabetes Mellitus Type 1|Autoimmune Diseases|Endocrine System Diseases|Glucose Metabolism Disorders|Immune System Diseases|Metabolic Diseases,Biological: Stem Cell Transplantation,Exogenous insulin dose|Anti-GAD titres|C-peptide level|HbA1c level,Stem Cells Arabia,All,"8 Years to 55 Years   (Child, Adult)",Phase 1|Phase 2,100,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCA-DM1,Feb-14,Aug-17,May-18,1-Jan-16,null,6-Jun-18,"Stem Cells Arabia, Amman, Jordan",,https://ClinicalTrials.gov/show/NCT02644759
NCT02641522,Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes,,Completed,Has Results,Type 1 Diabetes,Drug: Siltuximab,Percent Change From Baseline in IL-6 Stimulated Intracellular p-STAT3 at Week 12,"Carla Greenbaum, MD|Janssen Research & Development, LLC|Benaroya Research Institute",All,18 Years to 45 Years   (Adult),Early Phase 1,10,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,EMU-002,8-Mar-16,16-Mar-17,16-Mar-17,29-Dec-15,8-Oct-18,2-Nov-18,"Benaroya Research Institute, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT02641522/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02641522
NCT02639130,GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes,,Completed,No Results Available,Type 2 Diabetes,Drug: Exendin [9-39]|Drug: Placebo,Ratio of integrated insulin secretion rates (total AUC ISR) over 4 hour following the meal|total AUC Glucose over 4 hour following the meal,Diabeteszentrum Bad Lauterberg im Harz,All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 4,67,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DZBL-2007-1,Feb-08,Jan-10,Jan-10,24-Dec-15,null,16-Aug-16,"Diabeteszentrum Bad Lauterberg, Bad Lauterberg, Niedersachsen, Germany",,https://ClinicalTrials.gov/show/NCT02639130
NCT02638246,Incentives for Internet-based Adherence to SMBG for Teens With T1D,,Completed,No Results Available,Contingent Versus Noncontingent Incentives,"Behavioral: Internet-delivered, Incentive-based intervention + Motivational Interviewing|Behavioral: Internet-delivered, non-contingent incentives + Motivational Interviewing",Daily frequency of self-monitoring blood glucose|Percentage of days conducted at least 4 tests per day.|Acceptability of the intervention|Feasibility,"Rowan University|National Development and Research Institutes, Inc.",All,"13 Years to 18 Years   (Child, Adult)",Not Applicable,52,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,R21HD061683-02,Apr-11,Dec-12,Dec-12,23-Dec-15,null,23-Dec-15,,,https://ClinicalTrials.gov/show/NCT02638246
NCT02637154,Motivational Interview in Adolescents With Poorly Controlled Type 1 Diabetes,,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 1",Behavioral: Motivational Interviewing|Behavioral: Standard Education,Change in HbA1C values (mmol/mol)|Change in glycaemic variability|Influence of changes in markers of vascular health (IMT)|Influence of changes in markers of vascular health (PWV)|Influence of changes in bone mineral density (BMD)|Influence of changes in quality of life|Influence of changes in markers of inflammation (IL-6 - pg/ml)|Influence of changes in markers of inflammation (high-sensitive-c-reactive-protein CRP - mg/l).|Influence of changes in insulin-like-growth-factor IGF-I levels|Influence of changes in markers of bone turnover (serum aminoterminal propeptide of type I collagen (PINP - ng/ml)).|Influence of changes in vitamin D status (25-hydroxy-D) ng/ml|Influence of changes in marker of bone turnover: osteocalcin (ng/ml)|Influence of changes in marker of bone turnover: aminoterminal telopeptide of type I collagen (INTP - ng/ml),Helsinki University Central Hospital,All,12 Years to 16 Years   (Child),Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,MoHa,15-Oct-15,Sep-18,Dec-18,22-Dec-15,null,3-Aug-18,"Helsinki University Central Hospital, Pediatric Diabetes Unit Espoo, Espoo, Finland|Helsinki University Central Hospital, Pediatric Endocrinology Unit, Helsinki, Finland|Oulu University Hospital, Pediatric Endocrinology Unit, Oulu, Finland",,https://ClinicalTrials.gov/show/NCT02637154
NCT02636491,Use of an Automated Insulin Delivery System Compared to Sensor Augmented Pump at Patients With Type 1 Diabetes (T1D),DREAM5,Completed,No Results Available,Type 1 Diabetes,Device: MD-Logic-Automated Insulin Delivery System|Device: MiniMed Paradigm® Veo™ System,normal glucose level|Hypoglycemia|increased glucose level|glucose sensor readings,Kinderkrankenhaus auf der Bult,All,"10 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,45,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MC-01,Dec-15,Jun-16,Jun-16,21-Dec-15,null,28-Feb-18,"Kinder - und Jugendkrankenhaus AUF DER BULT, Hannover, Germany",,https://ClinicalTrials.gov/show/NCT02636491
NCT02635243,"A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced Hypoglycemia",,Withdrawn,No Results Available,Type 1 Diabetes Mellitus,Drug: SAR438544|Drug: r-glucagon|Drug: insulin,Time to reach a smoothed blood glucose of 70 mg/dL after initial administration of investigational medicinal product|Assessment of PD parameter: continuous monitoring of blood glucose levels over a period of 6 hours post-dose|Assessment of PD parameter: area under plasma concentration of the BG-time curve between IMP dosing and time t (BG-AUC0-t)|Assessment of PD parameter: BG-maximum concentration (BG-Cmax)|Assessment of PD parameter: BG-time to Cmax (BG-tmax)|Assessment of PK parameter (recombinant glucagon and SAR438544): Cmax|Assessment of PK parameter (recombinant glucagon and SAR438544): tmax|Assessment of PK parameter (recombinant glucagon and SAR438544): tlast|Assessment of PK parameter (recombinant glucagon and SAR438544): terminal half-life|Assessment of PK parameter (recombinant glucagon and SAR438544): area under curve from zero time until the last measurable concentration (AUClast)|Assessment of PK parameter (recombinant glucagon and SAR438544): AUC|Assessment of PK parameter (recombinant glucagon and SAR438544): partial AUCs (AUC0-t)|Number of patients with adverse events|Time to reach a smoothed blood glucose of 90 mg/dL after initial administration of investigational medicinal product,Sanofi,All,18 Years to 60 Years   (Adult),Phase 1,0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Basic Science,PDY14452|U1111-1172-1152,Apr-16,Nov-16,Nov-16,18-Dec-15,null,2-Sep-16,,,https://ClinicalTrials.gov/show/NCT02635243
NCT02632747,Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study,,Recruiting,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Obesity",Drug: Empagliflozin|Drug: Placebo (matching empagliflozin)|Drug: ramipril,Change in glomerular filtration rate (GFR) after treatment with either empagliflozin added to ramipril or placebo added to ramipril.|Filtration status (GFR < 120 mL/min/1.73m^2; yes/no) after 4 weeks of treatment with either empagliflozin added to ramipril or placebo added to ramipril.,Boehringer Ingelheim|Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 2,74,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1245.1,10-May-16,30-Oct-19,6-Nov-19,17-Dec-15,null,14-May-19,"Toronto General Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02632747
NCT02634216,Effects of Capros in Patients With Type-1 Diabetes,CarposT1D,"Active, not recruiting",No Results Available,Type I Diabetes,Dietary Supplement: Capros,Effect of Capros on Blood Glycemic Index,"Ohio State University|Natreon, Inc.",All,"10 Years to 60 Years   (Child, Adult)",Not Applicable,20,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,2014H0206,Jan-15,Jun-19,Nov-19,17-Dec-15,null,23-Mar-18,"Carepoint East 543 Taylor Ave., Columbus, Ohio, United States|Martha Morehouse Medical Plaza 2050 Kenny Road, Columbus, Ohio, United States|Davis Heart and Lung Research Institute, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02634216
NCT02631265,Insulin-based Strategies to Prevent Hypoglycemia During Exercise,,Completed,No Results Available,Type 1 Diabetes,Other: Exercise 1|Other: Exercise 2|Other: Exercise 3,Percentage of time of capillary blood glucose levels spent below 4 mmol/L|Decrease in glucose levels|Decremental area under the curve of sensor glucose levels|Area under the curve of sensor glucose levels < 4 mmol/L|Number of patients with an exercise-induced hypoglycemia < 3.9 mmol/L|Number of patients with an exercise-induced hypoglycemia < 3.5 mmol/L|Number of patients requiring an oral treatment for hypoglycemia|Total number of hypoglycemia episode requiring treatment|Percentage of time spent between 4 and 10 mmol/L|Mean time (minutes) to the first hypoglycemic event|Percentage of time spent < 4.0 mmol/L|Percentage of time of sensor glucose levels spent below 4 mmol/L|Absolute difference between capillary blood glucose levels and sensor glucose levels|Relative difference between capillary blood glucose levels and sensor glucose levels,Institut de Recherches Cliniques de Montreal,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,22,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,RIDE-1,Jan-16,Sep-17,Sep-17,16-Dec-15,null,13-Sep-17,"Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02631265
NCT02632032,Impact of a Diabetes Camp on Glycemic Control Among Children and Adolescents Living With Type 1 Diabetes in Cameroon,,Completed,No Results Available,Type 1 Diabetes,Drug: Insulin,Changes in HbA1c|Changes in insulin doses|Hypoglycemic episode per camper per day|Changes in weight,Yaounde Central Hospital,All,"6 Years to 23 Years   (Child, Adult)",Not Applicable,46,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),CDiC-01,Jul-13,Aug-13,Aug-14,16-Dec-15,null,17-Dec-15,,,https://ClinicalTrials.gov/show/NCT02632032
NCT02632383,Young With Diabetes Type 1 - Test of an mHealth App,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: Young with Diabetes - app,Glycemic control measured by HbA1c|Problem areas in diabetes measured by PAID-20|Perceived competences in diabetes measured by PCD-questionnaire|Health Care Climate measured by HCCQ-questionnaire,Nordsjaellands Hospital|Herlev Hospital|Steno Diabetes Center Copenhagen|Zealand University Hospital,All,"14 Years to 22 Years   (Child, Adult)",Not Applicable,140,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,1,Dec-15,28-Mar-17,28-Mar-17,16-Dec-15,null,10-Apr-17,"Steno Diabetes Center, Gentofte, Denmark|Pediatric and Adolescent Department, Herlev Hospital, Herlev, Denmark|Department of Cardiology, Nephrology and Endocrinology, Nordsjællands Hospital, Hillerød, Hillerød, Denmark|Pediatric and Adolescent Department, Nordsjællands Hospital, Hillerød, Hillerød, Denmark|Department of Endocrinology, Køge Hospital, Køge, Denmark|Pediatric Department, Roskilde Hospital, Roskilde, Denmark",,https://ClinicalTrials.gov/show/NCT02632383
NCT02627911,Diabeloop WP6.2 : Crossover Evaluation of Glycemic Control,WP6-2,Completed,No Results Available,"Closed Loop|Diabetes Mellitus, Type 1",Device: Diabeloop System|Device: Continuous Glucose Monitoring|Device: Accelerometer and heart rate monitor|Dietary Supplement: Meals,"Percentage of time spent in the tight glycemic control area 80-140 mg / dl during the night, continuously measured for 3 days with CGM|Percentage of time spent in the area glycemic reference 70-180 mg / dl during the night measured continuously for 3 days with CGM|Percentage of time spent in the glycemic range 70-180 mg / dl at d3 versus d1 during closed-loop period comparing with d3 versus d1 during open-loop period|Measurement of time spent in blood glucose <70 mg / dl and blood glucose > 180 mg / dl|Average blood glucose levels throughout the period and sub- periods: sedentarity, prandial and physical activity.|Calculated risks of hypo- and hyperglycemia ( LBGI , HBGI ) throughout the period and sub- periods: physical inactivity, prandial and physical activity|Measuring the oral carbohydrates intake|Number of hypoglycemic events , defined by any threshold crossing 70 mg / dL ( 3.9 mml / L) , and < 54 mg / dL ( 3 mmol / l ) measured by the CGM|Total supplies of insulin during tests (total unit of insulin)|Average peak postprandial glycemic according meals and delays occurred|Number of technical problems causing interruptions of the closed loop|Comparison of postprandial blood glucose sensor 2h , 3h and 4h and AUC in identical conditions of meals, to evaluate the efficacy and safety ( time spent in hypoglycemia, hyperglycemia and euglycemia )|Nadir glycemic means after physical activity and time of occurrence.|Measurement of AUC during physical activity , the two hours, then to lunch time , during dinner and throughout the night",Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète,All,"18 Years and older   (Adult, Older Adult)",Phase 2,36,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015-A01294-45,Nov-15,Aug-16,Nov-16,11-Dec-15,null,21-Nov-16,"Hôpital Jean Minjoz, Besançon, France|Centre Hospitalier Universitaire, Caen, France|Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France|Centre Hospitalier Universitaire, Grenoble, France|Centre Hospitalier Universitaire, Marseille, France|Centre Hospitalier Universitaire, Montpellier, France|Centre Hospitalier Universitaire, Nancy, France|Centre Hospitalier Universitaire, Strasbourg, France|Centre Hospitalier Universitaire, Toulouse, France",,https://ClinicalTrials.gov/show/NCT02627911
NCT02626936,Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation,,Completed,No Results Available,Type 1 Diabetes,Other: Dual-hormone closed-loop|Drug: Insulin|Drug: Glucagon|Device: Dexcom G4 Platinum glucose sensor|Device: Accu Chek Combo insulin pump,Percentage of time below 4.0 mmol/L|Mean glucose|Percentage of time of glucose concentrations between 4.0 and 8.0 mmol/L|Percentage of time of glucose concentrations between 4.0 and 10.0 mmol/L|Percentage of time of glucose concentrations below 3.1 mmol/L|Area under the curve of glucose values below 4.0 mmol/L|Area under the curve of glucose values below 3.1 mmol/L|Number of patients with at least one hypoglycemic event with or without symptoms|Total number of hypoglycemic event below 3.1 mmol/L|Total carbohydrate intake for hypoglycemia correction|Total insulin delivery|Total glucagon delivery,Institut de Recherches Cliniques de Montreal,All,"18 Years and older   (Adult, Older Adult)",Phase 2,10,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,CLASS Safety meal study,Jan-16,Jun-16,Jun-16,10-Dec-15,null,10-Jun-16,"Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02626936
NCT02627287,A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen®,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Device: FlexPen®|Device: DV3316 pen-injector|Drug: placebo,"Injection success (full dose delivered s.c.) (yes/no)|Subjects' confidence in injection completion (delivery of correct, full dose)|Amount of liquid on the skin (placebo solution or tissue fluid)|Subjects' reaction time|Subjects evaluation of pen-injector experience|Number of technical complaints|Number of adverse device effects|Grading of bleeding, redness, bruising and swelling at the site of injection",Novo Nordisk A/S,All,"18 Years to 74 Years   (Adult, Older Adult)",Phase 1,150,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",INS-4208|2014-004802-13|U1111-1163-5039,1-Dec-15,25-Feb-16,25-Feb-16,10-Dec-15,null,7-Feb-18,"Novo Nordisk Investigational Site, Mainz, Germany|Novo Nordisk Investigational Site, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT02627287
NCT02625636,"A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients",,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: SAR438544|Drug: placebo|Drug: r-glucagon,Number of patients with adverse events|Assessment of PD parameter: continuous monitoring of blood glucose levels over a period of 6 hours post-dose|Assessment of PD parameter: area under plasma concentration of the BG-time curve between investigational medicinal product (IMP) dosing and time t (BG-AUC0-t)|Assessment of PD parameter: BG-maximum concentration (BG-Cmax)|Assessment of PD parameter: BG-time to Cmax (BG-tmax)|Assessment of PK parameter (recombinant glucagon and SAR438544): Cmax|Assessment of PK parameter (recombinant glucagon and SAR438544): tmax|Assessment of PK parameter (recombinant glucagon and SAR438544): tlast|Assessment of PK parameter (recombinant glucagon and SAR438544): terminal half life|Assessment of PK parameter (recombinant glucagon and SAR438544): area under curve from zero time until the last measurable concentration (AUClast)|Assessment of PK parameter (recombinant glucagon and SAR438544): AUC|Assessment of PK parameter (recombinant glucagon and SAR438544): partial AUCs (AUC0-t),Sanofi,All,18 Years to 60 Years   (Adult),Phase 1,20,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",TDU14518|U1111-1172-1152,Dec-15,Feb-16,Feb-16,9-Dec-15,null,23-Aug-16,"Investigational Site Number 840001, Chula Vista, California, United States",,https://ClinicalTrials.gov/show/NCT02625636
NCT02624804,A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes,,Recruiting,No Results Available,Diabetes Mellitus Type 1,Genetic: Stem Cell Educator Therapy,Treatment related adverse events|Number of patients unable to complete therapy,Hackensack Meridian Health,All,"18 Years and older   (Adult, Older Adult)",Phase 1,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro 6262,27-Jun-17,Jun-19,Jun-20,8-Dec-15,null,8-Aug-18,"Hackensack University Medical Center - John Theurer Cancer Center, Hackensack, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT02624804
NCT02620332,Multiple Islet Peptide Administration in Type 1 Diabetes (MultiPepT1De),MultiPepT1De,Unknown status,No Results Available,Type 1 Diabetes,Drug: MultiPepT1De injection|Other: Placebo,Assessment of MultiPepT1De safety profile|Assessment of residual beta cell function and markers of metabolic control|Assessment of T lymphocyte immune response to islet cell antigens,King's College London|Guy's and St Thomas' NHS Foundation Trust,All,18 Years to 45 Years   (Adult),Phase 1,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MultiPep001,Aug-15,Feb-17,Feb-17,3-Dec-15,null,3-Dec-15,"Guy's Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02620332
NCT02620553,Primary Intervention With Mucosal Insulin,Pre-POINT,Completed,No Results Available,Type 1 Diabetes,Drug: Human Insulin|Other: Oral Placebo,Change in Blood Glucose Levels|Daily Evaluation of Blood Glucose Levels|Evaluation of Blood Glucose Levels|Change in Total IgE and IgE.|T-cell responses related to potential immune response to Insulin,"University of Colorado, Denver|University Hospital Dresden|Diabetes Research Institute, Munich, Germany.|University of Bristol|Juvenile Diabetes Research Foundation|German Federal Ministry of Education and Research",All,2 Years to 7 Years   (Child),Phase 1|Phase 2,25,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",05-1043,Sep-07,Jun-13,Jan-14,3-Dec-15,null,20-Apr-17,"Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT02620553
NCT02620878,Artificial Pancreas in Pediatric Patients (PEDarPAN),PEDarPAN,Completed,No Results Available,Type 1 Diabetes,Device: artificial pancreas|Other: sensor augmented pump,Percentage of time spent with blood glucose < 3.9 mmol/L (or 70 mg/dl)|percentage of time spent in target range (70-180 mg/dl or 3.9-10.0 mmol/L)|percentage of time artificial pancreas is active,University of Padova,All,"6 Years to 18 Years   (Child, Adult)",Not Applicable,32,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3486/AO/15,Jul-15,Sep-15,Sep-15,3-Dec-15,null,7-Apr-16,,,https://ClinicalTrials.gov/show/NCT02620878
NCT02620072,Fr1da Insulin Intervention,,Recruiting,No Results Available,"Diabetes Mellitus, Type 1",Drug: Oral Insulin|Other: Placebo,(1) Immune response: The activation of a protective immune response against insulin (immune responder status) and (2) Immune efficacy: rate of progression to dysglycemia in immune responders vs. non-responders|Gene expression of single cells.|The change from baseline in IgG-binding to insulin|The change from baseline in IgG4-binding to insulin|Number of circulating Insulin-tetramer positive T cells|Progression to diabetes,Technische Universität München|Technische Universität Dresden|Ludwig-Maximilians - University of Munich|Helmholtz Zentrum München|The Leona M. and Harry B. Helmsley Charitable Trust,All,2 Years to 12 Years   (Child),Phase 2,220,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",808040019,11-Dec-15,Jun-21,Jun-21,2-Dec-15,null,13-Feb-18,"Forschergruppe Diabetes, Klinikum rechts der Isar, Technische Universität München, Lehrstuhl für Diabetes und Gestationsdiabetes, der Technischen Universität München, München, Deutschland (deu), Germany",,https://ClinicalTrials.gov/show/NCT02620072
NCT02617654,Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes,,Recruiting,No Results Available,Type 1 Diabetes,Drug: Liraglutide|Drug: Placebo for liraglutide,"The effect of 52 weeks of treatment with liraglutide 1.8 mg/day, compared to placebo, on stimulated C-peptide concentrations in patients with long-standing type 1 diabetes and residual insulin production|Change in C-peptide between 6 and 52 weeks of study|Change in C-peptide between after and prior to treatment with liraglutide 1.8 mg|Change in HbA1c between before and at end of liraglutide (1.8 mg) treatment|Change in HbA1c between 6 and 52 weeks of study|Change in HbA1c between after and prior to treatment with liraglutide 1.8 mg|Change in insulin doses between before and at end of liraglutide (1.8 mg) treatment|Change in insulin doses between 6 and 52 weeks of study|Change in insulin doses between after and prior to treatment with liraglutide 1.8 mg|Change in glucose variability between before and at end of liraglutide (1.8 mg) treatment|Change in glucose variability between 6 and 52 weeks of study|Change in glucose variability between after and prior to treatment with liraglutide 1.8 mg|Change in hypoglycemia frequency between before and at end of liraglutide (1.8 mg) treatment|Change in hypoglycemia frequency between 6 and 52 weeks of study|Change in hypoglycemia frequency between after and prior to treatment with liraglutide 1.8 mg|Change in Quality of Life (QoL) between before and at end of liraglutide (1.8 mg)|Change in QoL between 6 and 52 weeks of study|Change in QoL between after and prior to treatment with liraglutide",Per-Ola Carlsson|Uppsala University Hospital,All,18 Years to 30 Years   (Adult),Phase 2,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U1111-1166-6923,Nov-15,Sep-20,Sep-20,1-Dec-15,null,16-Apr-19,"Uppsala University Hospital, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT02617654
NCT02617160,Evaluation of Automated Insulin Pump Settings Using the Advisor Pro (Previously Called) MD-Logic Pump Advisor-three Segments Study,,Terminated,No Results Available,Type 1 Diabetes,Device: MD-Logic Pump Advisor|Other: Control Group,Percentage of glucose readings within range of 70-180 mg/dl|Percentage of glucose readings below 60 mg/dl|HbA1c levels|Percentage of glucose readings below 54 mg/dl|Percentage of glucose readings below 50 mg/dl,Rabin Medical Center|Novo Nordisk A/S|DreaMed,All,"6 Years to 30 Years   (Child, Adult)",Not Applicable,50,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RMC059315ctil,May-16,Dec-18,Dec-18,30-Nov-15,null,21-Dec-18,"Schneider Medical Center, Petach- Tikva, Israel",,https://ClinicalTrials.gov/show/NCT02617160
NCT02614768,Standardized Evaluation of Subcutaneous Glucose Monitoring Systems Under Routine Environmental Conditions,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: Glucose Sensor,Percentage of test-to-reference measurement pairs with an Absolute Relative Difference (ARD) ≤15%.,Medical University of Graz,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,12,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,SPIDIMAN_01,Jul-15,Aug-15,Sep-15,25-Nov-15,null,3-Mar-16,,,https://ClinicalTrials.gov/show/NCT02614768
NCT02612844,"A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 Diabetes",,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: NNC0143-0406|Drug: insulin aspart,The number of treatment emergent adverse events|Area under the serum NNC0143-0406 concentration-time curve|Area under the glucose infusion rate-time curve|The maximum glucose infusion rate,Novo Nordisk A/S,Male,18 Years to 55 Years   (Adult),Phase 1,48,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1406-4209|2014-005334-63|U1111-1164-6630,Nov-15,Jun-16,Jun-16,24-Nov-15,null,6-Dec-17,"Novo Nordisk Investigational Site, Graz, Austria",,https://ClinicalTrials.gov/show/NCT02612844
NCT02609633,Accu-Chek® CONNECT at School (CATS) Pediatric Study,CATS,Completed,Has Results,"Diabetes Mellitus, Type 1",Device: Accu-Chek® CONNECT DMS|Device: DMS,Change From Baseline in Diabetes-Related Distress Among Parents/Caregivers According to the Problem Areas in Diabetes (PAID) Child and Teen (C&T) Parent Questionnaire Score at Month 6|Change From Baseline in Diabetes-Related Distress Among Parents/Caregivers According to the PAID C&T Child Questionnaire Score at Month 3|Change From Baseline in Diabetes-Related Distress Among School-age Children/Adolescents and Adolescents According to the PAID C&T Child Questionnaire Score at Month 3 and 6|Change From Baseline in Perceived Family Conflict Among School-Age Children With Diabetes and Parent/Caregiver According to Diabetes Family Conflict Scale (DFCS) Parent Questionnaire Score at Months 3 and 6|Change From Baseline in Affect Towards Blood Glucose Monitoring Among School-Age Children With Diabetes and Parent/Caregiver According to Blood Glucose Monitoring Communication (BGMC) Parent Questionnaire Score at Months 3 and 6|Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) Among School-Age Children With Diabetes at Months 3 and 6|Change From Baseline in Percentage of Blood Glucose (BG) Measurements Among School-Age Children With Diabetes at Months 3 and 6 Within Glucose Target Range|Change From Baseline Blood Glucose Variability Among School-Age Children With Diabetes at Months 3 and 6|Change From Baseline in Percentage of Hypoglycemic BG Measurements Among School-Age Children With Diabetes at Months 3 and 6|Percentage of Participants Who Frequently Used Accu-Chek® CONNECT Diabetes Management System According to a Questionnaire About Usability|Percentage of Participants With Participants Preference for Accu-Chek® CONNECT Diabetes Management System With Previous Technology/Process|Percentage of Participants With Overall Treatment Satisfaction With the Use of Accu-Chek® CONNECT Diabetes Management System According to a Questionnaire,Hoffmann-La Roche,All,"7 Years to 18 Years   (Child, Adult)",Not Applicable,196,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RD002489,28-Dec-15,20-Jan-17,20-Jan-17,20-Nov-15,18-May-18,18-May-18,"Pediatric Endocrinology of Phoenix, Phoenix, Arizona, United States|Center of Excellence in Diabetes and Endocrinology, Sacramento, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Nemours Childrens Hospital, Pensacola, Florida, United States|Tallahassee Memorial Hospital, Tallahassee, Florida, United States|University of South Florida College of Medicine, Tampa, Florida, United States|Pediatric Endocrine Associates, Atlanta, Georgia, United States|Rocky Mountain Diabetes & Osteoporosis Center, Idaho Falls, Idaho, United States|Advocate Center for Pediatric Research, Oak Lawn, Illinois, United States|Indiana University Riley, Carmel, Indiana, United States|Childrens Hospital and Clinics of Minnesota, Saint Paul, Minnesota, United States|Women and Children's Hospital of Buffalo, Buffalo, New York, United States|East Caroline University - Pediatric specialty Care, Greenville, North Carolina, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02609633/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02609633/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02609633
NCT02610738,Junior KICkOFF: Diabetes Education for Children Under 11 Years,,Unknown status,No Results Available,Type 1 Diabetes,Behavioral: Junior KICk-OFF education programme,Qualitative assessment of curriculum|Educational evaluation through observation of junior KICk-OFF courses|Participant feedback on teaching|Change in frequency of blood glucose testing|Change in psychological outcomes: child participants in key stage two age group|Change in Knowledge assessment for key stage 2 children|Change in HbA1c between baseline and 6 months|change in blood glucose variability|change in weekly mean blood glucose level|Change in Quality of life - of child as assessed by parent participants|Change in perceived stress - parent participants,Sheffield Children's NHS Foundation Trust|University of Sheffield|University of Leeds|Derby Hospitals NHS Foundation Trust|Sheffield Hallam University,All,4 Years to 11 Years   (Child),Not Applicable,24,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,SCH/14/036,Jan-15,Nov-15,Nov-15,20-Nov-15,null,25-Nov-15,"Sheffield Children's NHS Foundation Trust, Sheffield, Sheffield (South Yorkshire district), United Kingdom",,https://ClinicalTrials.gov/show/NCT02610738
NCT02611232,Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults,,Enrolling by invitation,No Results Available,Type 1 Diabetes,Drug: Victoza®|Drug: Placebo,"FPIR (first phase insulin response)|Safety: serum and urine amylase, serum lipase, serum calcitonin, hypoglycemia|Tolerability|Serum C-peptide AUC",University of Oulu|Oulu University Hospital|Tampere University Hospital|Turku University Hospital,All,18 Years to 30 Years   (Adult),Phase 2,42,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",LiraAAB18-30|2014-003667-37|3-SRA-2014-301-M-R|U1111-1176-6062,Dec-15,Jun-19,Jun-19,20-Nov-15,null,26-Oct-17,"University of Oulu and Oulu University Hospital, Oulu, Finland|University of Tampere and Tampere University Hospital, Tampere, Finland|University of Turku and Turku University Hospital, Turku, Finland",,https://ClinicalTrials.gov/show/NCT02611232
NCT02605148,TEFA Family Prevention: Glutenfree Diet to Preserve Beta-cell Function,TEFA,Enrolling by invitation,No Results Available,Prediabetes|Type 1 Diabetes,Dietary Supplement: Gluten free diet|Dietary Supplement: Omega 3 fatty acid|Dietary Supplement: Vitamin D|Dietary Supplement: Probiotics,Change in first phase insulin response (FPIR) from IvGTT|Change in area under the curve (AUC) C-peptide|Change in glucose metabolism|Incidence of Treatment-Emergent Adverse Events,Lund University|Juvenile Diabetes Research Foundation,All,"2 Years to 49 Years   (Child, Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,TEFA/2015,Dec-15,Jan-20,Jul-20,16-Nov-15,null,14-May-19,"Lund University, Department of Clinical Sciences Malmö, Malmö, Sweden",,https://ClinicalTrials.gov/show/NCT02605148
NCT02605564,Effects of Gluten Free Diet on Type 1 Diabetes Mellitus in Children,,Enrolling by invitation,No Results Available,Type 1 Diabetes Mellitus,Other: Gluten Free Diet|Other: Placebo,Area Under the Curve (AUC) of C-peptide on mixed meal tolerance test,Loma Linda University,All,1 Year to 17 Years   (Child),Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,5140361,19-Jan-16,Mar-20,Mar-20,16-Nov-15,null,12-Apr-19,,,https://ClinicalTrials.gov/show/NCT02605564
NCT02604524,Reducing Risks and Improving Glucose Control During Extended Exercise in Youth With T1DM: The AP Ski Camp,,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: Closed-Loop Control|Other: Sensor Augmented Pump Therapy,Time in range when using closed-loop compared with SAP.|Reduction of hypoglycemia episodes when using closed-loop,"Daniel Chernavvsky, MD, CRC|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|DexCom, Inc.|University of Virginia",All,"10 Years to 25 Years   (Child, Adult)",Not Applicable,32,Other|NIH|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18529|DP3DK106826-01,Jan-16,Apr-16,Apr-16,13-Nov-15,null,19-Sep-18,"University of Colorado, Denver, Barbara Davis Center, Aurora, Colorado, United States|University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02604524
NCT02603510,Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: SAR342434|Drug: insulin lispro,Frequency of infusion set occlusions|Number of infusion set changes in each treatment period|Number of insulin pump alarms for infusion set occlusions|Number of adverse events,Sanofi,All,"19 Years and older   (Adult, Older Adult)",Phase 1,27,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PDY13502|U1111-1170-3739,Nov-15,Apr-16,Apr-16,11-Nov-15,null,19-May-16,"Investigational Site Number 840002, Little Rock, Arkansas, United States|Investigational Site Number 840001, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT02603510
NCT02600091,Mindfulness-based Cognitive Therapy to Improve Emotional Wellbeing and Glycaemic Control in Diabetes,MILESTONE,Completed,No Results Available,Anxiety|Depression|Diabetes,Behavioral: Mindfulness-Based Cognitive Therapy,Recruitment/Retention Rates|Acceptability,University of Aberdeen|NHS Grampian|University of Glasgow|NHS Greater Glasgow and Clyde,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,29,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RG12976-10,30-Oct-15,Dec-17,Dec-17,9-Nov-15,null,9-May-18,"University of Aberdeen, Aberdeen, United Kingdom",,https://ClinicalTrials.gov/show/NCT02600091
NCT02600845,ACCU-CHEK Connect Personal Diabetes Management Study (PDM CONNECT),,Completed,Has Results,"Diabetes Mellitus, Type 1",Device: ACCU-CHEK,Treatment Satisfaction: Diabetes Treatment Satisfaction Questionnaire (DTSQc) Score at Week 24|Change From Baseline to Week 24 in Diabetes Distress Scale (DDS) Score|Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Weeks 12 and 24|Mean Change From Baseline to Week 24 in Percentage of Glucose Readings in Target Range|Change From Baseline to Week 24 in Mean Blood Glucose Level|Change From Baseline to Week 24 in Glycemic Variability|Incidence of Hypoglycemia|Number of Participants With Competency in Self-monitoring of Blood Glucose (SMBG) at Week 24|Percent of Follow-Up Visits With Sufficient SMBG Data|Change From Baseline in the Number of Blood Glucose Checks at Weeks 12 and 24|Change From Baseline in Mean Daily Self-Monitoring of Blood Glucose (SMBG) Frequency at Weeks 12 and 24|Percentage of Blood Glucose Tagged Data,Hoffmann-La Roche|Roche Diabetes Care GmbH,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,122,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RD002206,30-Dec-15,29-Sep-16,20-Feb-17,9-Nov-15,6-Nov-17,6-Nov-17,"Montgomery, Alabama, United States|Huntington Beach, California, United States|Atlanta, Georgia, United States|Macon, Georgia, United States|Ocean Springs, Mississippi, United States|Lincoln, Nebraska, United States|Raleigh, North Carolina, United States|Wilmington, North Carolina, United States|Pottstown, Pennsylvania, United States|Bristol, Tennessee, United States|Plano, Texas, United States",,https://ClinicalTrials.gov/show/NCT02600845
NCT02597400,Drug-Drug Interaction Study of Glucokinase Activator HMS5552 and Metformin in T2DM,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Metformin|Drug: HMS5552,"The primary pharmacokinetics parameters of Cmax To assess the potential pharmacokinetic interaction between HMS5552 and metformin in subjects with T2DM|The pharmacokinetics parameters of Tmax To assess the potential pharmacokinetic interaction between HMS5552 and metformin in subjects with T2DM|The pharmacokinetics parameters of AUC0-24hr To assess the potential pharmacokinetic interaction between HMS5552 and metformin in subjects with T2DM|Safety assessments includes monitoring of adverse events (AEs), vital signs (blood pressure, pulse rate, respiratory rate and oral temperature), clinical laboratory findings, resting 12-lead electrocardiograms (ECGs), and physical examination findings.|Pharmacodynamic responses (serum levels) of glucose, insulin and C-peptide will be evaluated.",Hua Medicine Limited,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,12,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HMM0104,Oct-15,Oct-15,Oct-15,5-Nov-15,null,17-Feb-16,"Frontage Clinical Services Inc., Hackensack, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT02597400
NCT02596204,Diabetes Care Transformation: Diabetes Data Registry and Intensive Remote Monitoring,DCT1A,Completed,No Results Available,Type 1 Diabetes Mellitus,Other: Weekly Review|Device: FitBit,Change in Hemoglobin A1c|Health care utilization|PedsQL Inventory (PedsQL)|Diabetes Family Conflict Scale (DFCS)|Center for Epidemiology Scale- Depression (CES-D) survey|Problem Areas in Diabetes (PAID) survey,Children's Hospitals and Clinics of Minnesota|UnitedHealth Group,All,8 Years to 17 Years   (Child),Not Applicable,113,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1506-073,Sep-15,Dec-16,Dec-16,4-Nov-15,null,1-Aug-17,"Children's Hospitals and Clinics of Minnesota, Saint Paul, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02596204
NCT02595580,The GlucoPred Investigation II,GPI-II,Terminated,No Results Available,"Diabetes Mellitus, Type 1",Device: Glucopred,difference between Glucopred and the reference method,Norwegian University of Science and Technology|St. Olavs Hospital|Sykehuset Ostfold,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,16,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PM-GPI-II-2015,Jan-16,Feb-16,Feb-16,3-Nov-15,null,22-Nov-16,"Sykehuset Østvold, Frederikstad, Norway|St Olavs Hospital, Trondheim, Norway",,https://ClinicalTrials.gov/show/NCT02595580
NCT02589626,Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA,,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: empagliflozin 10mg|Drug: empagliflozin 25 mg|Drug: Placebo,Percentage of Patients With Drug-related Adverse Events (AEs) During 52 Weeks of Treatment|Change From Baseline in HbA1c After 52 Weeks of Treatment,Boehringer Ingelheim,All,"20 Years and older   (Adult, Older Adult)",Phase 4,65,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,1245.106,29-Oct-15,2-Jun-17,2-Jun-17,28-Oct-15,7-Jan-19,7-Jan-19,"Kunisaki Makoto Clinic, Fukuoka, Fukuoka, Japan|Seino I.M. Clinic, Fukushima, I.M., Fukushima, Koriyama, Japan|Nippon Kokan Fukuyama Hospital, Hiroshima, Fukuyama, Japan|Nakakinen Clinic, Ibaraki, Naka, Japan|Kubota Clinic, Kanagawa, Kawasaki, Japan|Medical Corporation Yuga Higashirinkan Kaneshiro Diabetes Clinic, Kanagawa, Yamato-shi, Japan|Yokohama Minoru Clinic, Kanagawa, Yokohama, Japan|Yokkaichi Diabetes Clinic, Mie, Yokkaichi, Japan|Shiraiwa Medical Clinic, Osaka, Kashiwara-shi, Japan|AMC Nishi-umeda Clinic, Osaka, Osaka-shi, Japan|OCROM Clinic, Osaka, Suita, Japan|Fukuwa Clinic, Tokyo, Chuo-ku, Japan|Tokyo-Eki Center-building Clinic, Tokyo, Chuo-ku, Japan|Minamino Heart Clinic, Tokyo, Hachioji, Japan|ToCROM Clinic, Tokyo, Shinjuku-ku, Japan|Shinjuku Research Park Clinic, Tokyo, Shinjuku-ku, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02589626/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02589626/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02589626
NCT02585778,Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin),,Completed,Has Results,Hypercholesterolaemia,Drug: Alirocumab|Drug: Placebo|Drug: Lipid-Modifying Therapy (LMT)|Drug: Antihyperglycemic Drug,Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis|Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs)|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Measured LDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Measured LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 24 - ITT Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percentage of Participants Reaching Calculated LDL-C <50 mg/dL (1.3 mmol/L) at Week 24 - On-Treatment Analysis|Percentage of Participants Reaching Calculated Non-HDL-C <100 mg/dL at Week 24 - On-Treatment Analysis|Percentage of Participants Reaching Calculated Non-HDL-C <80 mg/dL at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in LDL-C Particle Number at Week 24 - ITT Analysis|Percent Change From Baseline in LDL-C Particle Size at Week 24 - ITT Analysis|Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Weeks 12 and 24 - ITT Analysis|Absolute Change From Baseline in HbA1c at Weeks 12 and 24 - On-Treatment Analysis|Absolute Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 12 and 24 - ITT Analysis|Absolute Change From Baseline in FPG at Weeks 12 and 24 - On-Treatment Analysis|Absolute Change From Baseline in Total Daily Insulin Dose at Weeks 12 and 24 - ITT Analysis|Absolute Change From Baseline in Total Daily Insulin Dose at Weeks 12 and 24 - On-Treatment Analysis|Absolute Change From Baseline in Insulin Daily Dose/Kg at Weeks 12 and 24 - ITT Analysis|Absolute Change From Baseline in Insulin Daily Dose/Kg at Weeks 12 and 24 - On-Treatment Analysis|Absolute Change From Baseline in Number of Glucose-Lowering Treatments at Weeks 12 and 24 - ITT Analysis|Absolute Change From Baseline in Number of Glucose-Lowering Treatments at Weeks 12 and 24 - On-Treatment Analysis,Sanofi|Regeneron Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,517,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",LPS14355|2015-000799-92|U1111-1172-4772,23-Oct-15,3-Apr-17,3-Apr-17,23-Oct-15,17-May-18,17-May-18,"Investigational Site Number 840020, Encino, California, United States|Investigational Site Number 840002, Fresno, California, United States|Investigational Site Number 840029, Oakland, California, United States|Investigational Site Number 840027, Loveland, Colorado, United States|Investigational Site Number 840026, Atlantis, Florida, United States|Investigational Site Number 840006, Bradenton, Florida, United States|Investigational Site Number 840023, Jacksonville, Florida, United States|Investigational Site Number 840028, Palm Harbor, Florida, United States|Investigational Site Number 840022, Ponte Vedra Beach, Florida, United States|Investigational Site Number 840021, Roswell, Georgia, United States|Investigational Site Number 840007, Springfield, Illinois, United States|Investigational Site Number 840011, Indianapolis, Indiana, United States|Investigational Site Number 840015, Valparaiso, Indiana, United States|Investigational Site Number 840010, Des Moines, Iowa, United States|Investigational Site Number 840005, Louisville, Kentucky, United States|Investigational Site Number 840018, Auburn, Maine, United States|Investigational Site Number 840013, Hyattsville, Maryland, United States|Investigational Site Number 840016, Rockville, Maryland, United States|Investigational Site Number 840004, Minneapolis, Minnesota, United States|Investigational Site Number 840012, Jamaica, New York, United States|Investigational Site Number 840014, Maumee, Ohio, United States|Investigational Site Number 840009, Greer, South Carolina, United States|Investigational Site Number 840024, Chattanooga, Tennessee, United States|Investigational Site Number 840001, Austin, Texas, United States|Investigational Site Number 840003, Dallas, Texas, United States|Investigational Site Number 840019, Dallas, Texas, United States|Investigational Site Number 840025, Houston, Texas, United States|Investigational Site Number 840017, Ogden, Utah, United States|Investigational Site Number 840008, Salt Lake City, Utah, United States|Investigational Site Number 040002, Innsbruck, Austria|Investigational Site Number 040005, Linz, Austria|Investigational Site Number 040003, Salzburg, Austria|Investigational Site Number 040004, Salzburg, Austria|Investigational Site Number 040001, Wien, Austria|Investigational Site Number 056002, Edegem, Belgium|Investigational Site Number 056003, Haine-Saint-Paul, Belgium|Investigational Site Number 056001, Leuven, Belgium|Investigational Site Number 250-008, Besancon, France|Investigational Site Number 250-005, Corbeil Essonnes, France|Investigational Site Number 250-004, La Rochelle Cedex 1, France|Investigational Site Number 250-003, Le Creusot, France|Investigational Site Number 250-009, Mulhouse, France|Investigational Site Number 250-002, Nantes cedex 01, France|Investigational Site Number 250-007, Paris, France|Investigational Site Number 250-006, Strasbourg Cedex 2, France|Investigational Site Number 250-001, TOULOUSE Cedex 9, France|Investigational Site Number 276015, Aschaffenburg, Germany|Investigational Site Number 276002, Berlin, Germany|Investigational Site Number 276011, Dortmund, Germany|Investigational Site Number 276019, Dresden, Germany|Investigational Site Number 276014, Dresden, Germany|Investigational Site Number 276009, Dresden, Germany|Investigational Site Number 276021, Hamburg, Germany|Investigational Site Number 276018, Hamburg, Germany|Investigational Site Number 276005, Heidelberg, Germany|Investigational Site Number 276013, Lüneburg, Germany|Investigational Site Number 276022, Magdeburg, Germany|Investigational Site Number 276008, Neumünster, Germany|Investigational Site Number 276017, Neuwied, Germany|Investigational Site Number 276004, Oldenburg, Germany|Investigational Site Number 276003, Pirna, Germany|Investigational Site Number 276006, Riesa, Germany|Investigational Site Number 276010, Saarlouis, Germany|Investigational Site Number 276016, Sulzbach-Rosenberg, Germany|Investigational Site Number 380004, Catania, Italy|Investigational Site Number 380003, Catanzaro, Italy|Investigational Site Number 380011, Como, Italy|Investigational Site Number 380006, Milano, Italy|Investigational Site Number 380007, Milano, Italy|Investigational Site Number 380005, Moncalieri, Italy|Investigational Site Number 380009, Napoli, Italy|Investigational Site Number 380008, Padova, Italy|Investigational Site Number 380002, Palermo, Italy|Investigational Site Number 380001, Pisa, Italy|Investigational Site Number 380010, Roma, Italy|Investigational Site Number 380012, Verona, Italy|Investigational Site Number 528002, Apeldoorn, Netherlands|Investigational Site Number 528005, Groningen, Netherlands|Investigational Site Number 528003, Hoogeveen, Netherlands|Investigational Site Number 528001, Rotterdam, Netherlands|Investigational Site Number 528004, Utrecht, Netherlands|Investigational Site Number 724007, Badalona, Spain|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724006, Ferrol, Spain|Investigational Site Number 724013, Granada, Spain|Investigational Site Number 724005, Madrid, Spain|Investigational Site Number 724004, Madrid, Spain|Investigational Site Number 724011, Majadahonda, Spain|Investigational Site Number 724008, Málaga, Spain|Investigational Site Number 724014, Oviedo, Spain|Investigational Site Number 724009, Palma de Mallorca, Spain|Investigational Site Number 724002, Pamplona, Spain|Investigational Site Number 724010, Sant Joan Despí, Spain|Investigational Site Number 724012, Segovia, Spain|Investigational Site Number 724003, Sevilla, Spain|Investigational Site Number 756001, Olten, Switzerland|Investigational Site Number 756003, St. Gallen, Switzerland|Investigational Site Number 826010, Airdrie, United Kingdom|Investigational Site Number 826011, Bath, United Kingdom|Investigational Site Number 826009, Bournemouth, United Kingdom|Investigational Site Number 826005, Bradford, United Kingdom|Investigational Site Number 826004, Bristol, United Kingdom|Investigational Site Number 826001, Burton On Trent, United Kingdom|Investigational Site Number 826015, Durham, United Kingdom|Investigational Site Number 826012, High Wycombe, United Kingdom|Investigational Site Number 826007, Manchester, United Kingdom|Investigational Site Number 826006, Peterborough, United Kingdom|Investigational Site Number 826003, Southampton, United Kingdom|Investigational Site Number 826008, Truro, United Kingdom|Investigational Site Number 826002, Welwyn Garden City, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02585778/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02585778/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02585778
NCT02584582,The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate,ALFA-1,Unknown status,No Results Available,Type 1 Diabetes,Drug: Liraglutide|Drug: Exenatide|Procedure: Liquid meal test|Other: No drug (Baseline day),Glucagon concentration (postprandial)|Postprandial glucose concentrations|glucagon-like peptide-1 (GLP-1)|glucagon-like peptide-2 (GLP-2)|glucose-dependent insulinotropic polypeptide (GIP)|Cholecystokinin (CCK)|Peptide YY (PYY)|Ghrelin|Gastrin|Oxyntomodulin|Free fatty acids (FFA)|triacylglycerol (TAG),Hvidovre University Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,10,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-3-2014-128,Jul-15,Nov-15,null,22-Oct-15,null,22-Oct-15,,,https://ClinicalTrials.gov/show/NCT02584582
NCT02581488,Use of Santyl in Diabetic Foot Ulcers,,Completed,Has Results,"Diabetic Foot|Foot Ulcer, Diabetic",Biological: Santyl|Other: Product containing silver,Mean Percent Change in Ulcer Area From Baseline to the End of the Treatment.|Target Ulcer Infection Rates in Each Treatment Group During the Treatment Period as Determined by Investigator-reported Adverse Events,"Smith & Nephew, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 4,102,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,017-101-09-035,Oct-15,12-Jan-17,12-Jan-17,21-Oct-15,1-Aug-18,1-Aug-18,"Sylmar, California, United States|Melbourne, Florida, United States|Baltimore, Maryland, United States|Las Vegas, Nevada, United States|York, Pennsylvania, United States|Fort Worth, Texas, United States|McAllen, Texas, United States|Saint George, Utah, United States|Harrisonburg, Virginia, United States|Roanoke, Virginia, United States|Virginia Beach, Virginia, United States|Hamilton, Ontario, Canada|Boucherville, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02581488
NCT02582814,The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM,,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Dapagliflozin 5 mg|Drug: Dapagliflozin 10mg,"Overall Adverse Event Summary|Hypoglycemia|Diabetic Ketoacidosis (DKA)|Vital Signs (Heart Rate)|ECGs|Clinical Laboratory Measures, Urine Test Results (Any Marked Abnormality)|Vital Signs (Blood Pressure)|Adjusted Change From Baseline in HbA1c|Adjusted Percent Change From Baseline in Total Daily Insulin Dose|Adjusted Percent Change From Baseline in Body Weight|Adjusted Change From Baseline in Glycoalbumin|Adjusted Change From Baseline in Average Daily Glucose Measured by 6-point SMBG|Adjusted Change From Baseline in Post-prandial Glucose Measured by 6-point SMBG|Proportion of Subjects Achieving HbA1c Reduction of 0.5 Percent Without Severe Hypoglycemia|Proportion of Subjects Achieving HbA1c Reduction of 0.5 Percent|Proportion of Subjects Achieving HbA1c < 7.0 Percent|Adjusted Change From Baseline in SBP in Subjects With Baseline SBP/DBP >= 140/90 mmHg",AstraZeneca,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,151,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D1695C00001,26-Oct-15,15-Jun-17,15-Jun-17,21-Oct-15,12-Apr-19,12-Apr-19,"Research Site, Aizu Wakamatsu-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukuyama-shi, Japan|Research Site, Funabashi-shi, Japan|Research Site, Hamamatsu-shi, Japan|Research Site, Hirosaki-shi, Japan|Research Site, Ise-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Koriyama-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kunitachi-shi, Japan|Research Site, Minato-ku, Japan|Research Site, Nagoya-shi, Japan|Research Site, Oita-shi, Japan|Research Site, Otsu-shi, Japan|Research Site, Oyama-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinjyuku-ku, Japan|Research Site, Suita-shi, Japan|Research Site, Tama-shi, Japan|Research Site, Tsukuba-shi, Japan|Research Site, Yokohama-shi, Japan","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02582814/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02582814/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02582814
NCT02582840,The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM,,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Dapagliflozin 5mg|Drug: Dapagliflozin 10mg|Drug: Placebo tablet,Dapagliflozin Maximum Observed Plasma Concentration (Cmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set|Dapagliflozin Minimum Observed Plasma Concentration (Cmin) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set|Dapagliflozin Time of Maximum Observed Plasma Concentration (Tmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set|Dapagliflozin Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-T) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set|Dapagliflozin 3-O-Glucuronide Maximum Observed Plasma Concentration (Cmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set|Dapagliflozin 3-O-Glucuronide Minimum Observed Plasma Concentration (Cmin) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set|Dapagliflozin 3-O-Glucuronide Time of Maximum Observed Plasma Concentration (Tmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set|Dapagliflozin 3-O-Glucuronide Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-T) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set|Dapagliflozin Ratio of Metabolite to Parent AUC of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set|24-hour Urinary Glucose (g/24h) Mean Change From Baseline on Day 7 - Pharmacodynamic (PD) Set|Total Daily Insulin (IU) Percent Change From Baseline to Day 7 - Pharmacodynamic (PD) Set|Daily Basal Insulin (IU) Percent Change From Baseline to Day 7 - Pharmacodynamic (PD) Set|Daily Bolus Insulin (IU) Percent Change From Baseline to Day 7 - Pharmacodynamic (PD) Set|Fasting Plasma Glucose (FPG) (mg/dL) Change From Baseline to Day 7 - Pharmacodynamic (PD) Set|Seated Systolic Blood Pressure (mmHG) Change From Baseline to Day 7 - Pharmacodynamic (PD) Set,AstraZeneca,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,42,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,D1695C00001sub,Oct-15,Jun-16,Jun-16,21-Oct-15,18-Jan-19,18-Jan-19,"Fukuoka-shi, Japan",,https://ClinicalTrials.gov/show/NCT02582840
NCT02580591,Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3),,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Empagliflozin|Drug: Placebo,Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Full Analysis Set (FAS) (Observed Cases [OC])|Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD))|Rate Per Patient-year of Investigator-reported Symptomatic Hypoglycemic Adverse Events (AEs) With Confirmed Plasma Glucose (PG)|Change From Baseline in Body Weight at Week 26|Change From Baseline in Total Daily Insulin Dose (TDID) at Week 26|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 26,Boehringer Ingelheim|Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,977,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,1245.72|2014-005256-26,22-Dec-15,12-Sep-17,20-Sep-17,20-Oct-15,2-Nov-18,2-Nov-18,"Healthscan Clinical Trials LLC, Montgomery, Alabama, United States|John Muir Physician Network Clinical Research Center, Concord, California, United States|Valley Research, Fresno, California, United States|Marin Endocrine Care and Research, Greenbrae, California, United States|Pacific Research Partners, LLC, Oakland, California, United States|NorCal Endocrinology and Internal Medicine, San Ramon, California, United States|William Sansum Diabetes Center, Santa Barbara, California, United States|University of Colorado Denver, Aurora, Colorado, United States|International Research Associates, LLC, Hialeah, Florida, United States|Solutions Through Advanced Research, Inc., Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Suncoast Clinical Research, Inc., New Port Richey, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Physicians Research Associates, LLC, Lawrenceville, Georgia, United States|Sestron Clinical Research, Marietta, Georgia, United States|Eagle's Landing Diabetes and Endocrinology, Stockbridge, Georgia, United States|Northwest Endo Diabetes Research, LLC, Arlington Heights, Illinois, United States|Kentucky Diabetes Endocrinology Center, Lexington, Kentucky, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|MODEL Clinical Research, Baltimore, Maryland, United States|Clinical Research Consultants, LLC, Kansas City, Missouri, United States|Desert Endocrinology Clinical Research Center, Henderson, Nevada, United States|Palm Research Center, Las Vegas, Nevada, United States|Endocrine-Diabetes Care and Resource Center, Rochester, New York, United States|Endocrine Associates of Long Island, PC, Smithtown, New York, United States|Diabetes Endocrinology Research Center of Western New York, Williamsville, New York, United States|Diabetes and Endocrinology Consultants, PC, Morehead City, North Carolina, United States|Holzer Clinic LLC, Gallipolis, Ohio, United States|COR Clinical Research, LLC, Oklahoma City, Oklahoma, United States|Strand Physician Specialists dba Carolina Health Specialists, Myrtle Beach, South Carolina, United States|AM Diabetes and Endocrinology Center, Bartlett, Tennessee, United States|Holston Medical Group, Bristol, Tennessee, United States|University Diabetes and Endocrine Consultants, Chattanooga, Tennessee, United States|Texas Diabetes & Endocrinology PA, Austin, Texas, United States|Texas Health Physicians Group, Dallas, Texas, United States|Dallas Diabetes and Endocrine Center, Dallas, Texas, United States|Research Institute of Dallas, Dallas, Texas, United States|Endeavor Clinical Trials, PA, San Antonio, Texas, United States|Virginia Endocrinology Research, Chesapeake, Virginia, United States|Coffs Endocrine & Diabetes Services, Coffs Harbour, New South Wales, Australia|Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia|SA Endocrine Research P/L, Keswick, South Australia, Australia|Eastern Clinical Research Unit, East Ringwood, Victoria, Australia|Richmond Road and Diagnostic Treatment Centre, Calgary, Alberta, Canada|The Bailey Clinic, Red Deer, Alberta, Canada|Eastern Health (MUN), St. John's, Newfoundland and Labrador, Canada|Centre for Studies in Family Medicine, London, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Omnispec Recherche Clinique Inc., Mirabel, Quebec, Canada|Applied Medical Informatics Research INC., Westmount, Quebec, Canada|Clinique des maladies Lipidiques de Quebec, Quebec, Canada|University Hospital Brno, Brno, Czechia|Diahaza s.r.o.Intern.Med.Outpat.Clin.Dep.Diabetology,Holesov, Holesov, Czechia|AIDIN VK s.r.o.,Department Diabetology, Hranice, Hranice, Czechia|Univ. Hospital Kralovske Vinohrady, Prague, Czechia|DiaGolfova s.r.o., Department Diabetology, Prague, Prague, Czechia|Milan Kvapil s.r.o.,Diabetology ambulance,Prague, Prague, Czechia|ResTrial s.r.o.Diabetology Ambulance,Prague, Prague, Czechia|HUS, Lihavuustutkimusyksikkö Biomedicum Helsinki, Helsinki, Finland|Mehiläinen Jyväskylä, Jyväskylä, Finland|Satakunnan Diabetesasema, Pori, Pori, Finland|FinnMedi Oy, Tampere, Tampere, Finland|TYKS, Turku, Finland|HOP Jean Minjoz, Besancon, France|HOP Le Creusot, Le Creusot, France|HOP Paris Saint-Joseph, Paris, France|HOP Bichat, Paris, France|HOP de Poitiers, Poitiers, France|HOP Civil, Strasbourg, France|HOP Rangueil, Toulouse Cédex 04, France|Diabetes-Klinik Bad Mergentheim GmbH & Co. KG, Bad Mergentheim, Germany|Diabetologische Schwerpunktpraxis, Bosenheim, Bosenheim, Germany|Praxis Dr. Busch, Dortmund, Dortmund, Germany|GWT-TUD GmbH, Dresden, Germany|ZKS Südbrandenburg GmbH, Elsterwerda, Germany|InnoDiab Forschung GmbH, Essen, Germany|Praxis Dr. Kaiser, Frankfurt, Frankfurt, Germany|Institut für Diabetesforschung Münster GmbH, Münster, Germany|Diabetologische Schwerpunktpraxis, Münster, Germany|Praxis Dr. Behnke, Neuwied, Neuwied, Germany|Praxis Dr. Hilgenberg, Rehburg-Loccum, Germany|""Korgialeneio-Benakeio"" Hellenic Red Cross Hospital, Athens, Greece|General Hospital of Athens ""Laiko"", Athens, Greece|Univ. Gen. Hosp. of Ioannina, Ioannina, Greece|General Hospital of Nikaia, Nikaia, Greece|General Hopsital of Thessaloniki ""Ippokrateio"", Thessaloniki, Greece|General Hospital of Thessaloniki ""G. Papanikolaou"", Thessaloniki, Greece|Clinexpert Kft., Budapest, Hungary|Synexus Magyarorszag Kft., Budapest, Hungary|University Debrecen Hospital, Debrecen, Hungary|CRU Hungary Ltd, Private Practice, Miskolc, Miskolc, Hungary|Clinfan SMO Ltd., Szekszard, Hungary|Csongrad Country Dr Bugyi Istvan Hosp., Szentes, Hungary|Zala Country Hospital, Diabetic Outpatient Clinic, Zalaegerszeg, Hungary|Mater Misericordiae University Hospital, Dublin, Ireland|Inrca-Irccs, Ancona, Italy|A.O. Spedali Civili di Brescia, Brescia, Italy|Osp. Campo di Marte, Lucca, Italy|Azienda Ospedaliera Universitaria ""Federico II"", Napoli, Italy|Policlinico Gemelli, Roma, Italy|Osp. S. Giovanni Calibita Fatebenefratelli, Roma, Italy|IRCCS Gruppo Multimedica, Sesto San Giovanni (MI), Italy|A.O.U. Senese Policlinico Santa Maria alle Scotte, Siena, Italy|Ospedale Molinette, AO Città della Salute e della, Torino, Italy|Zemgales Center of diabetes, Jelgava, Jelgava, Latvia|A. Lucenko's Internist & Endocrinologist Doctor's Practice, Liepaja, Latvia|Dace Teterovska Doctor's Practice in Endocrinology,Ogre, Ogre, Latvia|P. Stradins Clinical University Hospital, Riga, Riga, Latvia|Riga Health Center, Private Practice, Riga, Latvia|Sigulda Hospital, Outpatient department, Sigulda, Latvia|VSV Centrs, Stalte Private Practice, Talsi, Talsi, Latvia|Clínica EndocrInol en Diabetes Obesidad y Tiroides (DOT), Aguascalientes, Mexico|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico|Unidad de Investigacion Clinica Cardiometabolica de Occident, Guadalajara, Mexico|Instituto Jaliscience de Inv. en Diabetes y Obesidad, S.C., Guadalajara, Mexico|Unidad de Patologia Clinica, Guadalajara, Mexico|Noordwest Ziekenhuisgroep, Alkmaar, Netherlands|Ziekenhuisgroep Twente locatie Almelo, Almelo, Netherlands|Meander Medisch Centrum, Amersfoort, Netherlands|Gelre Ziekenhuizen Apeldoorn, Apeldoorn, Netherlands|EB Utrecht Research, Utrecht, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|South Pacific Clinical Trials, Auckland, New Zealand, New Zealand|Lipid and Diabetes Research Group, Christchurch, New Zealand|M3 Helse AS, Hamar, Norway|Oslo Universitetssykehus HF, Lipidklinikken, Oslo, Norway|Stavanger Helseforskning, Stavanger, Norway|Universitetssykehuset Nord-Norge, Tromsø, Tromsø, Norway|DiabSerwis S.C., Chorzow, Chorzow, Poland|Medical Centre Pratia Gdynia, Gdynia, Poland|Medical Centre Pratia Katowice I, Katowice, Poland|Medical Centre Pratia Krakow, Krakow, Poland|University Hospital in Krakow, Krakow, Poland|Independent Public Clin.Hosp.no1Lublin,Dep.Internal Diseases, Lublin, Poland|Witold Chodzko Institute Rural Medic,Dep.Diabetology,Lublin, Lublin, Poland|Reg.Spec.Hosp.Olsztyn,Clin,Endocrinology,Diabetics.&Int.Med., Olsztyn, Poland|Clinical Research Center Medicome, Oswiecim, Oswiecim, Poland|Omedica Medical Centre, Poznan, Poznan, Poland|Medical Centre Pratia Warszawa, Warsaw, Poland|NZOZ Med-Art.Specialist Clinics, Zory, Zory, Poland|Hospital de Braga-Escala Braga, Braga, Portugal|Centro Hospitalar da Cova da Beira Hospital Pêro da Covilhã, Covilhã, Portugal|APDP - Associação Protectora dos Diabéticos de Portugal, Lisboa, Portugal|H. Santo António - Centro Hospitalar do Porto, Porto, Portugal|Centro Hospitalar São João,EPE, Porto, Portugal|ULSAM, EPE - Hospital de Santa Luzia, Viana do Castelo, Portugal|Centro Hospitalar de Vila Nova de Gaia, Vila Nova de Gaia, Portugal|Nicodiab SRL, Bucharest, Bucharest, Romania|Milit. Cent. Emerg. Univ. Hosp. Dr. Davila, Met. Dis. Dept., Bucharest, Romania|SC Medical Centre ""Sanatatea Ta"" SRL, Bucharest, Bucharest, Romania|SC Pelican Impex SRL, Cabinet Nr. 201, Diabetes Dept., Oradea, Bihor County, Romania|Centrul Medical Dr Negrisanu SRL, Timisoara, Romania|City Clinical Hospital no. 67, Moscow, Moscow, Russian Federation|CJSC""Polyclinic complex"",Dep.Endocrinology,St.Petersburg, St. Petersburg, Russian Federation|City Outpatient dep.no.107;clinc.pharmacology,st.petersburg, St. Petersburg, Russian Federation|Medical Academy named after I. Mechnikov, St. Petersburg, St. Petersburg, Russian Federation|City Hospital Saint Elizaveta, Dept. Endocrinology, St. Petersburg, Russian Federation|Policlinic No. 1 of Russian Academy of Sciences, St. Petersburg, St. Petersburg, Russian Federation|LCS Clinical Research Unit, Bryanston, South Africa|TREAD Research, Cape Town, South Africa|Dr Hilton Kaplan, Cape Town, South Africa|Dr. L. A.Distiller, Johannesburg, South Africa|VX Pharma (Pty) Ltd Pretoria, Pretoria, South Africa|Diabetes Care Centre, Pretoria, South Africa|Hospital A Coruña, A Coruña, Spain|CM Avances Médicos, Granada, Spain|Hospital de la Inmaculada Concepción, Granada, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Endo-Diabesidad-Clínica Durán & Asociados, Sevilla, Spain|Hospital Virgen Macarena, Sevilla, Spain|Hospital Clínico de Valencia, Valencia, Spain|CTC Sahlgrenska Universitetssjukhuset, Göteborg, Sweden|Karlskoga lasarett, Karlskoga, Sweden|Skånes universitetssjukhus, Lund, Lund, Sweden|S3 Clinical Research Centers, Vällingby, Sweden|Ängelholms Sjukhus, Ängelholm, Sweden|Royal Bournemouth and Christchurch Hospital, Bournemouth, United Kingdom|Bradford Royal Infirmary, Bradford, United Kingdom|Hull Royal Infirmary, Hull, United Kingdom|Ipswich Hospital, Ipswich, United Kingdom|Leicester General Hospital, Leicester, United Kingdom|Guy's Hospital, London, United Kingdom|King's College Hospital, London, United Kingdom|St Mary's Hospital, London, United Kingdom|James Cook University Hospital, Middlesbrough, United Kingdom|Royal Victoria Infirmary, Newcastle Upon Tyne, United Kingdom|Queen's Medical Centre, Nottingham, United Kingdom|George Eliot Hospital, Nuneaton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02580591/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02580591/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02580591
NCT02580877,Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20),,Completed,No Results Available,Type 1 Diabetes,Drug: 67.5 mg oral insulin crystals daily|Drug: 500mg oral insulin crystals every other week,Change in Immune Function,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Type 1 Diabetes TrialNet,All,"3 Years to 45 Years   (Child, Adult)",Phase 2,92,NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,Oral Insulin-TN20|UC4DK106993|UC4DK117009,Jan-16,Mar-18,Mar-18,20-Oct-15,null,14-May-19,"University of California - San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Emory Children's Center, Atlanta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Indiana University-Riley Hospital for Children, Indianapolis, Indiana, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Columbia University-Naomi Berrie Diabetes Center, New York, New York, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Texas Southwestern, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Benaroya Research Institute, Seattle, Washington, United States|Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia|The Hospital for Sick Children, Toronto, Ontario, Canada|San Raffaele Hospital, Milan, Italy",,https://ClinicalTrials.gov/show/NCT02580877
NCT02578498,Glucagon Efficiency After High and Low Carbohydrate Diet,HiLoCarb,Completed,No Results Available,Type 1 Diabetes|Hypoglycemia,Dietary Supplement: High carbohydrate intake|Dietary Supplement: Low carbohydrate intake,Incremental area under the glucose curve|Peak glucose value|Glucagon concentration|Insulin concentration|Triglycerides concentration|Katekolamine concentration|Ketone bodies concentration|Free fatty acids concentration|Nausea|Headache|Hypoglycemia symptoms|Vomit|Plasma glucose variation,Hvidovre University Hospital|Danish Diabetes Academy,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,10,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),H-15009662,Oct-15,Mar-16,Jul-16,19-Oct-15,null,16-Aug-16,"Hvidovre University Hospital, Hvidovre, Denmark",,https://ClinicalTrials.gov/show/NCT02578498
NCT02579148,Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes,,Withdrawn,No Results Available,Erectile Dysfunction|Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Biological: HUCMSC injection|Biological: collagen scaffolds/HUCMSC injection,Improvements in IIEF scores|Penile colour Doppler ultrasonography combined with prostaglandin-E1 injection|Safety and Tolerability assessed by Adverse Events,Leilei Zhu|Chinese Academy of Sciences|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,Male,"20 Years to 65 Years   (Adult, Older Adult)",Phase 1,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,DTH-922-DYT,Sep-15,Dec-16,Apr-17,19-Oct-15,null,8-Apr-16,"Drum Tower Hospital, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT02579148
NCT02569684,Effects of Prebiotics on GLP-1 in Type 2 Diabetes,,"Active, not recruiting",No Results Available,Diabetes Type 2,Dietary Supplement: Prebiotic fibers: oligofructose and inulin|Dietary Supplement: Maltodextrin,Changes in plasma GLP-1 in response to standardized test meal before and after six weeks of ingestion of prebiotic fibers or placebo,Oslo University Hospital|Norwegian Diabetes Association|Norwegian Extra Foundation for Health and Rehabilitation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,37,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1180 REK,Oct-15,Jan-18,Dec-19,7-Oct-15,null,13-Aug-18,"Oslo University Hospital, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT02569684
NCT02568501,Behavioral Economic Incentives to Improve Glycemic Control Among Adolescents and Young Adults,,Completed,No Results Available,Diabetes|Type 1 Diabetes,Behavioral: Daily feedback|Behavioral: Financial incentive,Change in HbA1c by 3 months|Change in HbA1c by 6 months|Glucose Monitoring Adherence by 3 months|Glucose Monitoring Adherence by 6 months,University of Pennsylvania|Children's Hospital of Philadelphia,All,"14 Years to 20 Years   (Child, Adult)",Phase 3,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,15-012160,Jan-16,Aug-16,Nov-16,6-Oct-15,null,11-Nov-16,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02568501
NCT02568280,Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart,Mean change in plasma glucose concentration|Rate of endogenous glucose production|Area under the serum insulin aspart concentration-time curve,Novo Nordisk A/S,All,18 Years to 64 Years   (Adult),Phase 1,42,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1218-3922|2014-004144-35|U1111-1162-2053,6-Oct-15,25-Apr-16,25-Apr-16,5-Oct-15,null,11-Dec-18,"Novo Nordisk Investigational Site, Graz, Austria",,https://ClinicalTrials.gov/show/NCT02568280
NCT02562313,A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: BioChaperone insulin lispro|Drug: Humalog®,Pharmacodynamics: ΔAUCBG 0-2h|Pharmacokinetics: AUClis 0-30min|AUClis_0-6h|Cmax|tCmax|BGmax|tBGmax|Compatibility|Adverse Events|Local tolerability,Adocia|Eli Lilly and Company,All,18 Years to 64 Years   (Adult),Phase 1,80,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",BC3-CT015,Sep-15,Nov-16,Nov-16,29-Sep-15,null,22-Nov-16,"Profil GmbH, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT02562313
NCT02558491,Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM,,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: Decision Support System,Feasibility and Safety of Decision Support System|Occurrence of hypoglycemia during and immediately after exercise|Glycemic Variability,University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,52,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,18348|5R01DK051562-18|G150172,Sep-15,Feb-17,Feb-17,24-Sep-15,null,2-May-17,"University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02558491
NCT02558296,Bexagliflozin Efficacy and Safety Trial (BEST),BEST,"Active, not recruiting",No Results Available,Type 2 Diabetes Mellitus,Drug: Bexagliflozin|Drug: Placebo,Change in HbA1c from baseline to week 24|Change in body weight from baseline to week 48|Change in systolic blood pressure from baseline to week 24,Theracos,All,"40 Years and older   (Adult, Older Adult)",Phase 3,1701,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",THR-1442-C-476,Oct-15,Jul-19,Dec-19,23-Sep-15,null,19-Dec-18,"Research Site 1090, Gilbert, Arizona, United States|Research Site 1041, Little Rock, Arkansas, United States|Research Site 1073, Azusa, California, United States|Research Site 1076, Concord, California, United States|Research Site 1078, Fresno, California, United States|Research Site 1089, Harbor City, California, United States|Research Site 1058, Lincoln, California, United States|Research Site 1051, Los Angeles, California, United States|Research Site 1004, Los Angeles, California, United States|Research Site 1068, Montclair, California, United States|Research Site 1077, Orange, California, United States|Research Site 1218, Denver, Colorado, United States|Research Site 1092, Golden, Colorado, United States|Research Site 1216, Norwalk, Connecticut, United States|Research Site 1083, Newark, Delaware, United States|Research Site 1057, Boca Raton, Florida, United States|Research Site 1059, Brooksville, Florida, United States|Research Site 1050, Panama City, Florida, United States|Research Site 1099, Port Charlotte, Florida, United States|Research Site 1066, Tampa, Florida, United States|Research Site 1072, Augusta, Georgia, United States|Research Site 1082, Pocatello, Idaho, United States|Research Site 1258, Champaign, Illinois, United States|Research Site 1043, Anderson, Indiana, United States|Research Site 1071, Avon, Indiana, United States|Research Site 1086, Des Moines, Iowa, United States|Research Site 1224, Covington, Kentucky, United States|Research Site 1228, Annapolis, Maryland, United States|Research Site 1221, Baltimore, Maryland, United States|Research Site 1079, Hyattsville, Maryland, United States|Research Site 1223, Midland, Michigan, United States|Research Site 1217, Petoskey, Michigan, United States|Research Site 1254, Ypsilanti, Michigan, United States|Research Site 1054, Saint Louis, Missouri, United States|Research Site 1060, Saint Louis, Missouri, United States|Research Site 1252, Kalispell, Montana, United States|Research Site 1052, Omaha, Nebraska, United States|Research Site 1263, Omaha, Nebraska, United States|Research Site 1080, Las Vegas, Nevada, United States|Research Site 1219, Somerset, New Jersey, United States|Research Site 1044, Albuquerque, New Mexico, United States|Research Site 1264, Bronx, New York, United States|Research Site 1220, Saratoga Springs, New York, United States|Research Site 1049, West Seneca, New York, United States|Research Site 1085, Chapel Hill, North Carolina, United States|Research Site 1074, Charlotte, North Carolina, United States|Research Site 1056, Morehead City, North Carolina, United States|Research Site 1229, Wilmington, North Carolina, United States|Research Site 1064, Winston-Salem, North Carolina, United States|Research Site 1075, Fargo, North Dakota, United States|Research Site 1266, Lindsay, Oklahoma, United States|Research Site 1055, Oklahoma City, Oklahoma, United States|Research Site 1265, Oklahoma City, Oklahoma, United States|Research Site 1046, Oklahoma City, Oklahoma, United States|Research Site 1260, Lancaster, Pennsylvania, United States|Research Site 1042, Cumberland, Rhode Island, United States|Research Site 1225, Austin, Texas, United States|Research Site 1259, Dallas, Texas, United States|Research Site 1048, Kingwood, Texas, United States|Research Site 1070, Lampasas, Texas, United States|Research Site 1222, Lewisville, Texas, United States|Research Site 1081, North Richland Hills, Texas, United States|Research Site 1226, San Antonio, Texas, United States|Research Site 1053, San Antonio, Texas, United States|Research Site 1063, Salt Lake City, Utah, United States|Research Site 1230, Salem, Virginia, United States|Research Site 5013, Vancouver, British Columbia, Canada|Research Site 5015, Cambridge, Ontario, Canada|Research Site 5012, Hamilton, Ontario, Canada|Research Site 5023, London, Ontario, Canada|Research Site 5016, Peterborough, Ontario, Canada|Research Site 5005, Sudbury, Ontario, Canada|Research Site 5022, Toronto, Ontario, Canada|Research Site 5014, Toronto, Ontario, Canada|Research Site 5008, Gatineau, Quebec, Canada|Research Site 5007, St-Charles-Borromee, Quebec, Canada|Research Site 5009, St. Georges, Quebec, Canada|Research Site 5006, Quebec, Canada|Research Site 3116, Benesov, Czechia|Research Site 3106, Brandys nad Labem, Czechia|Research Site 3107, Brno, Czechia|Research Site 3118, Brno, Czechia|Research Site 3109, Cesky Krumlov, Czechia|Research Site 3114, Havirov, Czechia|Research Site 3103, Hradec Kralove, Czechia|Research Site 3110, Krnov, Czechia|Research Site 3102, Kromeriz, Czechia|Research Site 3105, Marianske Lazne, Czechia|Research Site 3113, Plzen, Czechia|Research Site 3104, Praha, Czechia|Research Site 3111, Praha, Czechia|Research Site 3112, Praha, Czechia|Research Site 3115, Uherske Hradiste, Czechia|Research Site 6104, Copenhagen, Denmark|Research Site 6103, Copenhagen, Denmark|Research Site 6105, Copenhagen, Denmark|Research Site 7007, Chuncheon, Gangwon-Do, Korea, Republic of|Research Site 7001, Wonju, Gangwon-Do, Korea, Republic of|Research Site 7004, Anyang, Gyeonggi-do, Korea, Republic of|Research Site 7005, Guri, Gyeonggi-do, Korea, Republic of|Research Site 7006, Busan, Korea, Republic of|Research Site 7002, Gwangju, Korea, Republic of|Research Site 7008, Incheon, Korea, Republic of|Research Site 2015, Guadalajara, Jalisco, Mexico|Research Site 2013, Culiacan, Sinaloa, Mexico|Research Site 2008, Tampico, Tamaulipas, Mexico|Research Site 2012, Merida, Yucatan, Mexico|Research Site 2011, Aguascalientes, Mexico|Research Site 2009, Chihuahua, Mexico|Research Site 2014, Mexico, Mexico|Research Site 2016, Queretaro, Mexico|Research Site 2010, Veracruz, Mexico|Research Site 5110, Amsterdam, Netherlands|Research Site 5113, Harderwijk, Netherlands|Research Site 5101, Hertogenbosch, Netherlands|Research Site 5112, Hoofddorp, Netherlands|Research Site 5102, Hoogeveen, Netherlands|Research Site 5106, Rotterdam, Netherlands|Research Site 5103, Zwijndrecht, Netherlands|Research Site 7122, Aleksandrow Lodzki, Poland|Research Site 7113, Gdansk, Poland|Research Site 7119, Gdynia, Poland|Research Site 7109, Grodzisk Mazowiecki, Poland|Research Site 7115, Katowice, Poland|Research Site 7106, Katowice, Poland|Research Site 7121, Katowice, Poland|Research Site 7111, Kutno, Poland|Research Site 7104, Lodz, Poland|Research Site 7135, Lodz, Poland|Research Site 7120, Lublin, Poland|Research Site 7108, Olawa, Poland|Research Site 7118, Otwock, Poland|Research Site 7107, Pulawy, Poland|Research Site 7105, Sobotka, Poland|Research Site 7112, Sochaczew, Poland|Research Site 7123, Warsaw, Poland|Research Site 7117, Warszawa, Poland|Research Site 7116, Warszawa, Poland|Research Site 9309, Lomonosov, Russian Federation|Research Site 9303, Moscow, Russian Federation|Research Site 9315, Moscow, Russian Federation|Research Site 9314, Novosibirsk, Russian Federation|Research Site 9318, Novosibirsk, Russian Federation|Research Site 9301, Novosibirsk, Russian Federation|Research Site 9310, Saint Petersburg, Russian Federation|Research Site 9304, Saint Petersburg, Russian Federation|Research Site 9307, Saint Petersburg, Russian Federation|Research Site 9311, Saint Petersburg, Russian Federation|Research Site 9312, Saint Petersburg, Russian Federation|Research Site 9302, Tomsk, Russian Federation|Research Site 8001, Kaohsiung, Taiwan|Research Site 8002, New Taipei, Taiwan|Research Site 8006, Taichung, Taiwan|Research Site 8005, Tainan, Taiwan|Research Site 8007, Taipei, Taiwan|Research Site 8004, Taipei, Taiwan|Research Site 8003, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT02558296
NCT02556398,Use of Mobile-based Technologies to Improve Diabetes Self-management and Postprandial Glucose Control,,"Active, not recruiting",No Results Available,Type 1 Diabetes,Behavioral: Sugar Sleuth,area under the curve (AUC) above target (> 180 mg/dL),Joslin Diabetes Center,All,"25 Years to 75 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2015-07,Sep-15,Aug-17,31-Aug-19,22-Sep-15,null,19-Mar-19,"Joslin Diabetes Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02556398
NCT02556554,Pilot Prospective CGM Quality Improvement (QI) Project in Pregnancy,,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type I",Device: Dexcom G4 or G5 Platinum CGM system|Device: Dexcom G4 or G5 Platinum CGM system with Share,Changes in Glucose Variability|Change(s) in behavior and/or concerns of diabetics.|Change in A1C.|Progression of diabetes complications.|Evaluation of Maternal and fetal outcomes.,"University of Colorado, Denver|DexCom, Inc.",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-1006,Sep-15,Aug-17,Dec-18,22-Sep-15,null,11-Oct-18,"University of Colorado, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT02556554
NCT02547935,"A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD",,Completed,No Results Available,"Type 2 Diabetes Mellitus, CKD and Albuminuria",Drug: Dapagliflozin 10 mg|Drug: Dapagliflozin 10mg+Saxagliptin 2.5mg|Drug: Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg,Change in HbA1c (dapagliflozin 10 mg + saxagliptin 2.5 mg)|Percent change in Urine albumin to creatinine ratio (UACR) (dapagliflozin 10 mg + saxagliptin 2.5 mg)|Percent change in Urine albumin to creatinine ratio (UACR) (dapagliflozin 10 mg)|Percent change in total body weight|Change in FPG|Proportion of patients that achieve 30% reduction in UACR|Proportion of patients which achieve HbA1c<7%|Change in seated SBP|Change in HbA1c,AstraZeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 2|Phase 3,459,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",D1690C00023,14-Jul-15,18-May-18,18-May-18,14-Sep-15,null,18-Jun-18,"Research Site, Peoria, Arizona, United States|Research Site, Chula Vista, California, United States|Research Site, Concord, California, United States|Research Site, El Centro, California, United States|Research Site, La Mesa, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Gatos, California, United States|Research Site, North Hollywood, California, United States|Research Site, Riverside, California, United States|Research Site, San Diego, California, United States|Research Site, San Dimas, California, United States|Research Site, Hollywood, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Pompano Beach, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Meridian, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Bangor, Maine, United States|Research Site, Kansas City, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Bronx, New York, United States|Research Site, Springfield Gardens, New York, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Morehead City, North Carolina, United States|Research Site, Rocky Mount, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Greenville, South Carolina, United States|Research Site, Brownsville, Texas, United States|Research Site, Cypress, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Burke, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Box Hill, Australia|Research Site, Campbelltown, Australia|Research Site, Geelong, Australia|Research Site, Herston, Australia|Research Site, Winnipeg, Manitoba, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Ajax, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Saint-Jerome, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Chuo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Hachioji-shi, Japan|Research Site, Higashiosaka-shi, Japan|Research Site, Kisarazu-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Neyagawa-shi, Japan|Research Site, Nishinomiya-shi, Japan|Research Site, Oita-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Toyonaka-shi, Japan|Research Site, Ansan-si, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Wonju-si, Korea, Republic of|Research Site, Aguascalientes, Mexico|Research Site, Del. Cuauhtemoc, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico, Mexico|Research Site, Monterey, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, México, Mexico|Research Site, Queretaro, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Zapopan, Mexico|Research Site, Benoni, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Kuilsrivier, South Africa|Research Site, Mamelodi East, South Africa|Research Site, Muckleneuk, South Africa|Research Site, Paarl, South Africa|Research Site, Pretoria, South Africa|Research Site, A Coruña, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Sabadell (Barcelona), Spain|Research Site, Santiago(A Coruña), Spain|Research Site, Valencia, Spain|Research Site, Changhua, Taiwan|Research Site, Kaohsiung Hsien, Taiwan|Research Site, New Taipei City, Taiwan|Research Site, New Taipei, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Yong-Kang City, Taiwan",,https://ClinicalTrials.gov/show/NCT02547935
NCT02548494,Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes,,Recruiting,No Results Available,"Diabetes Mellitus, Type 1|Diabetic Ketoacidosis",Drug: Glargine|Drug: IV insulin|Other: Electrolyte Correction|Other: Correction of Fluid Loss,Blood glucose|blood pH|blood bicarbonate level|Urinalysis for levels of ketones & glucosuria,Chattanooga-Hamilton County Hospital Authority,All,"1 Year to 21 Years   (Child, Adult)",Not Applicable,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",15-Lantus,Nov-15,1-Dec-23,1-Dec-23,14-Sep-15,null,31-Jan-19,"Children's @ Erlanger, Chattanooga, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT02548494
NCT02548585,"A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus",,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: MEDI0382|Drug: Placebo,"Percent Change From Baseline in Mixed-meal Test (MMT) Glucose Area Under the Concentration-time Curve From Time 0 to 4 Hours to the End of Treatment (EOT) (Cohort 4)|Change From Baseline in Body Weight to the EOT (Cohort 4)|Percent Change From Baseline in MMT Glucose AUC0-4h to the EOT (Cohorts 1, 2, 3, 5, and 6)|Change From Baseline in Body Weight to the EOT (Cohorts 1, 2, 3, 5, and 6)|Percent Change From Baseline in Hemoglobin A1c (HbA1c) to the EOT (Cohorts 4, 5, and 6)|Change From Baseline in Fructosamine to the EOT (Cohorts 4, 5, and 6)|Change From Baseline in Fasting Glucose Prior to MMT to the EOT (Cohorts 1, 2, 3, 4, 5, and 6)|Percent Change From Baseline in Glucose Area Under the Concentration-time Curve From Time 0 to 24 Hours (AUC0-24h) After MMT to the EOT (Cohorts 1, 2, 3, 4, 5, and 6)|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)|Number of Participants With Abnormal Vital Signs and Physical Examination Reported as TEAEs|Number of Participants With Abnormal 12 Lead Electrocardiogram (ECG) Reported as TEAEs|Number of Participants With Abnormal Clinical Laboratory Reported as TEAEs|Number of Participants With Any Suicidal Ideation as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) Score (Cohorts 4, 5, and 6)|Number of Participants With Any Suicidal Behaviour as Assessed by C-SSRS Score (Cohorts 4, 5, and 6)|Terminal Elimination Half Life (t1/2) of MEDI0382 (Cohorts 1, 2, and 3)|Accumulation Ratio (Rac) of MEDI0382 (Cohorts 1, 2, and 3)|Area Under the Concentration Time Curve From Time Zero to End of Dosing Interval (AUC[0-tau]) of MEDI0382 (Cohorts 1, 2, 3, 4, 5, and 6)|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - Inf)] of MEDI0382 (Cohorts 1, 2, 3, 4, 5, and 6)|Maximum Observed Plasma Concentration (Cmax) of MEDI0382 (Cohorts 1, 2, 3, 4, 5, and 6)|Minimum Observed Plasma Concentration (Cmin) of MEDI0382 (Cohorts 1, 2, 3, 4, 5, and 6)|Time to Reach Maximum Observed Plasma Concentration (Tmax) of MEDI0382 (Cohorts 1, 2, 3, 4, 5, and 6)|Number of Participants With Positive Anti-drug Antibodies to MEDI0382 (Cohorts 1, 2, 3, 4, 5, and 6)|Percent Change From Baseline in Insulin AUC0-4h After MMT to EOT (Cohorts 1, 2, 3, 4, 5, and 6)|Percent Change From Baseline in Proinsulin AUC0-4h After MMT to EOT (Cohorts 1, 2, 3, and 4)|Percent Change From Baseline in C-peptide AUC0-4h After MMT to EOT (Cohorts 1, 2, 3, and 4)|Percent Change From Baseline in Incretin AUC0-4h After MMT to EOT (Cohorts 1, 2, 3, and 4)",MedImmune LLC,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,113,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D5670C00002,9-Dec-15,24-Feb-17,24-Feb-17,14-Sep-15,5-Apr-19,5-Apr-19,"Research Site, Berlin, Germany|Research Site, Erfurt, Germany|Research Site, Kiel, Germany|Research Site, Leipzig, Germany|Research Site, Lübeck, Germany|Research Site, Magdeburg, Germany|Research Site, Mainz, Germany|Research Site, Mannheim, Germany|Research Site, München, Germany|Research Site, Neu-Ulm, Germany|Research Site, Neuss, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT02548585/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT02548585/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02548585
NCT02547311,Shared Medical Appointments to Improve Outcomes in Adolescents With Type 1 Diabetes,,Unknown status,No Results Available,Type 1 Diabetes,Behavioral: Team Clinic,Glycemic control|Satisfaction Questionnaire|Diabetes distress Questionnaire|Cost effectiveness,University of Colorado Denver School of Medicine Barbara Davis Center|The Leona M. and Harry B. Helmsley Charitable Trust,All,11 Years to 17 Years   (Child),Not Applicable,320,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,#2015PG-T1D080,Jul-15,Apr-18,Apr-18,11-Sep-15,null,11-Sep-15,"University of Colorado Denver School of Medicine Barbara Davis Center, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT02547311
NCT02547519,Pre-POINT-Early Study,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Oral Insulin|Drug: Placebo,The activation of a CD4+ T cell immune response against insulin|The activation of an antibody response against insulin.|Gene expression of CD4+ T cell response to insulin.|Hypoglycemia|change in total IgE concentration|Study drug specific IgE|GAD and IA-2 autoantibodies,Technische Universität München|Technische Universität Dresden|Ludwig-Maximilians - University of Munich|Helmholtz Zentrum München|German Center for Diabetes Research,All,6 Months to 2 Years   (Child),Phase 2,44,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",808040017,Aug-15,Dec-17,Dec-17,11-Sep-15,null,13-Feb-18,"Forschergruppe Diabetes, Klinikum rechts der Isar, Technische Universität München, Lehrstuhl für Diabetes und Gestationsdiabetes der Technischen Universität München, München, Germany",,https://ClinicalTrials.gov/show/NCT02547519
NCT02546063,Carbohydrate Estimation Supported by the GoCARB System,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Carbohydrates",Other: Smartphone App,Average of the postprandial area under the glucose curve (AUC) measured over three hours after each meal's start using Continuous Glucose Monitoring|Composite of insulin-related parameters|Glucose-related parameters|Daily nutritional behavior in individuals with T1D|User satisfaction,"University Hospital Inselspital, Berne",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),100/15,Aug-15,Dec-15,Dec-15,10-Sep-15,null,10-Aug-16,"Division of Endocrinology, Diabetes and Clinical Nutrition, Bern University Hospital, Bern, Switzerland",,https://ClinicalTrials.gov/show/NCT02546063
NCT02546401,Comparison of Insulin's Injection Before or After the Meal in Type 1 Diabetic Patients Treated With Insulin Pump,BOLUS,Completed,No Results Available,Diabetes Type 1,Drug: Insulin Aspart,Area Under Curve (AUC) of glycemia|Mean Amplitude of Glycemic excursions (MAGE) = measure of glycemia instability|Area Under Curve (AUC) during 4H after a high-fat meal,"University Hospital, Brest",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,22,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RB 15-027,Sep-15,Mar-16,Mar-16,10-Sep-15,null,22-Apr-16,"CHRU Brest, Brest, France",,https://ClinicalTrials.gov/show/NCT02546401
NCT02544321,Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes,,Recruiting,No Results Available,Type 1 Diabetes,Drug: Bromocriptine|Other: Placebo,Mean glucose and glycemic variability|Insulin Dosing|Brachial artery distensibility|Hyperemia peripheral arterial tonometry (RH-PAT)|Hypoglycemia Awareness|Augmentation Index|Heart Rate Variability|Sleep quality|Metabolic markers,"University of Colorado, Denver|Juvenile Diabetes Research Foundation",All,"12 Years to 60 Years   (Child, Adult)",Phase 2,133,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",15-1309|UL1TR001082,Sep-15,Dec-19,Dec-19,9-Sep-15,null,26-Apr-19,"University of Colorado-Denver, Anshutz Medical Campus, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT02544321
NCT02545062,MoCa Test for the Early Detection of Mild Cognitive Impairment During Annual Assessment of Young Adults With Diabetes and in a Control Group Without Diabetes,,Unknown status,No Results Available,Diabetes Mellitus Type 1|Diabetes Mellitus Type 2|Mild Cognitive Impairment,Other: MoCa test,"The differences between the MoCa test score in diabetics and in a control group of non diabetics|The relation between the MoCa test score and glycemic control, in terms of HA1C value, in the past year before recruitment|The relation between the MoCa test score and the presence of microvascular complications, retinopathy, polyneuropathy and nephropathy|The relation between the MoCa test score and the presence of macrovascular complication, ischemic heart disease, non-fatal myocardial infarct, stable and unstable angina, heart failure, non-fatal stroke, peripheral vascular disease",Clalit Health Services,All,20 Years to 55 Years   (Adult),Not Applicable,170,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,DM- MOCA- 1,May-14,Aug-16,Aug-16,9-Sep-15,null,11-Sep-15,"Viviana Ostrovsky, Nes Tziona, Israel",,https://ClinicalTrials.gov/show/NCT02545062
NCT02541734,Effect of Gelofusine on GLP1-receptor Imaging,GLP1-EX-GELO,Completed,No Results Available,"Diabetes Mellitus, Non-Insulin-Dependent|Diabetes Mellitus",Drug: Gelofusine|Radiation: 111In-exendin 4 SPECT/CT|Drug: Placebo,Renal uptake as measured by uptake of 111In-exendin-4 on SPECT images and without co-infusion of Gelofusine.|Pancreas uptake as measured by uptake of 111In-exendin-4 on SPECT images,Radboud University,All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,NL50233.091.14|2014-003006-33,Aug-15,May-17,May-17,4-Sep-15,null,31-May-17,,,https://ClinicalTrials.gov/show/NCT02541734
NCT02537834,Tofogliflozin GLP-1 Analogue Combination Trial,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Tofogliflozin|Drug: GLP-1 analogue,Safety and Tolerability Assessed by Adverse Event and Adverse Drug Reaction|Change from Baseline in HbA1c at 52 weeks|Change in Fasting plasma glucose|Change in Body Weight|Change in Blood pressure|Change in Uric Acid|Change in Total cholesterol|Change in HDL-C|Change in LDL-C|Change in non HDL-C|Change in Free Fatty Acid,"Kowa Company, Ltd.|Sanofi",All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 4,65,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DEBT02|TOFOGL07279,Aug-15,Jul-17,Oct-17,2-Sep-15,null,27-Nov-17,"Atsuta-ku, Aichi, Japan|Minato-ku, Aichi, Japan|Kisarazu, Chiba, Japan|Annaka, Gunma, Japan|Naka, Ibaraki, Japan|Sagamihara, Kanagawa, Japan|Kasaoka, Okayama, Japan|Shimono, Tochigi, Japan|Adachi-ku, Tokyo, Japan|Chuo-ku, Tokyo, Japan|Mitaka, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT02537834
NCT02538120,Assessment of the Neurovascular Microcirculatory Response in Diabetes Type 1 Patients,NEURODIAB1,Completed,No Results Available,Diabetes Mellitus Type 1,Other: Microvascular assessment,Neurovascular microcirculatory response,"University Hospital, Angers",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2012-A010008-35,May-12,Sep-15,Sep-15,2-Sep-15,null,12-Feb-16,"University Hospital, Angers, France",,https://ClinicalTrials.gov/show/NCT02538120
NCT02536859,Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin glargine,Area under the glucose infusion rate curve,Novo Nordisk A/S,All,18 Years to 64 Years   (Adult),Phase 1,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1250-4227|2014-005602-37|U1111-1165-3940,31-Aug-15,14-Apr-16,14-Apr-16,1-Sep-15,null,1-May-19,"Novo Nordisk Investigational Site, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT02536859
NCT02536950,An Outpatient Study of Automated Blood Glucose Control With an Insulin-Only Bionic Pancreas,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: Fixed set point|Device: Variable set point,Mean glucose|% time <50 mg/dl|% time <70 mg/dl|% time 70-120 mg/dl|% time 70-180 mg/dl|% time >180 mg/dl|% time >250 mg/dl|% time < 60 mg/dl,Bruce A. Buckingham|Boston University|Massachusetts General Hospital|Stanford University,All,18 Years to 44 Years   (Adult),Not Applicable,16,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Device Feasibility,IRB34914,Aug-15,Jul-16,Jul-16,1-Sep-15,null,21-Jun-18,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT02536950
NCT02535715,A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED),,Completed,Has Results,Type 1 Diabetes,Drug: ORMD-0801 capsules- 2x8mg|Drug: ORMD-0801 capsules- 3x8mg|Drug: ORMD-0801 capsules- 1x16mg,Hepatic Glucose Production (Co-primary Outcome)|Plasma Insulin Concentrations|Plasma Glucose Concentrations|Plasma Glucagon Concentrations|Plasma Free Fatty Acid Concentrations,"The University of Texas Health Science Center at San Antonio|Oramed, Ltd.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,11,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HSC20140476H,Jan-15,Apr-17,Apr-17,31-Aug-15,21-Mar-19,21-Mar-19,"The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02535715/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02535715
NCT02533453,"A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.",Bydureon,Completed,No Results Available,Type 2 Diabetes Mellitus,Biological: Bydureon,"•Percentage of patients with treatment-emergent adverse events (AEs) and serious adverse events (SAEs) in patients who are treated with 2 mg exenatide once weekly|• Nature, incidence and severity of Adverse Events (AE) in patients who are treated with 2 mg exenatide once weekly.|• Change in HbA1c at 4, 12 and 24 weeks from start of the treatment(24 weeks just for patients allocated in long-term treatment)|• Change in fasting plasma glucose at 4, 12 and 24 weeks from start of the treatment(24 weeks just for patients allocated in long-term treatment)|• Change in blood pressure at 4, 12 and 24 weeks from start of the treatment(24 weeks just for patients allocated in long-term treatment)|• Change in body weight at 4, 12 and 24 weeks from start of the treatment(24 weeks just for patients allocated in long-term treatment)|• ""Subjective improvement of main indication"" will be assessed as either ""improved,"" ""slightly improved,"" ""unchanged,"" ""aggravated,"" or ""unable to evaluate.""",AstraZeneca,All,"19 Years to 75 Years   (Adult, Older Adult)",Phase 4,115,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D5551L00018,Jan-16,Dec-16,Dec-16,26-Aug-15,null,20-Dec-16,"Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Wonju-si, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02533453
NCT02531035,A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone,inTandem3,Completed,No Results Available,Type 1 Diabetes Mellitus (T1DM)|High Level of Sugar (Glucose) in the Blood,Drug: Sotagliflozin|Drug: Placebo,Proportion of patients with A1C <7.0% at Week 24 and no episode of severe hypoglycemia and no episode of DKA after randomization|Change from Baseline to Week 24 in A1C|Change from Baseline in body weight|Change from Baseline in systolic blood pressure (SBP),Sanofi|Lexicon Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1405,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LX4211.1-312-T1DM|LX4211.312,Sep-15,Apr-17,Apr-17,21-Aug-15,null,26-Dec-17,"Lexicon Investigational Site, Concord, California, United States|Lexicon Investigational Site, Escondido, California, United States|Lexicon Investigational Site, San Marcos, California, United States|Lexicon Investigational Site, Ventura, California, United States|Lexicon Investigational Site, Walnut Creek, California, United States|Lexicon Investigational Site, Aurora, Colorado, United States|Lexicon Investigational Site, Orlando, Florida, United States|Lexicon Investigational Site, West Palm Beach, Florida, United States|Lexicon Investigational Site, Atlanta, Georgia, United States|Lexicon Investigational Site, Macon, Georgia, United States|Lexicon Investigational Site, Roswell, Georgia, United States|Lexicon Investigational Site, New Orleans, Louisiana, United States|Lexicon Investigational Site, Rockville, Maryland, United States|Lexicon Investigational Site, Boston, Massachusetts, United States|Lexicon Investigational Site, Bloomfield Hills, Michigan, United States|Lexicon Investigational Site, Omaha, Nebraska, United States|Lexicon Investigational Site, Las Vegas, Nevada, United States|Lexicon Investigational Site, Albany, New York, United States|Lexicon Investigational Site, Asheville, North Carolina, United States|Lexicon Investigational Site, Chapel Hill, North Carolina, United States|Lexicon Investigational Site, Greenville, North Carolina, United States|Lexicon Investigational Site, Morehead City, North Carolina, United States|Lexicon Investigational Site, Bend, Oregon, United States|Lexicon Investigational Site, Austin, Texas, United States|Lexicon Investigational Site, San Antonio, Texas, United States|Lexicon Investigational Site, San Antonio, Texas, United States|Lexicon Investigational Site, Salt Lake City, Utah, United States|Lexicon Investigational Site, Seattle, Washington, United States|Lexicon Investigational Site, Parkville, Victoria, Australia|Lexicon Investigational Site, Aalst, Belgium|Lexicon Investigational Site, Ruse, Bulgaria|Lexicon Investigational Site, Smolyan, Bulgaria|Lexicon Investigational Site, Sofia, Bulgaria|Lexicon Investigational Site, Varna, Bulgaria|Lexicon Investigational Site, Vancouver, British Columbia, Canada|Lexicon Investigational Site, Barrie, Ontario, Canada|Lexicon Investigational Site, London, Ontario, Canada|Lexicon Investigational Site, Thornhill, Ontario, Canada|Lexicon Investigational Site, Toronto, Ontario, Canada|Lexicon Investigational Site, Sherbrooke, Quebec, Canada|Lexicon Investigational Site, St. Laurent, Quebec, Canada|Lexicon Investigational Site, Krnov, Czechia|Lexicon Investigational Site, Praha 10, Czechia|Lexicon Investigational Site, Praha 4, Czechia|Lexicon Investigational Site, Corbeil-Essonnes, France|Lexicon Investigational Site, Pierre-Bénite, France|Lexicon Investigational Site, Budapest, Hungary|Lexicon Investigational Site, Budapest, Hungary|Lexicon Investigational Site, Esztergom, Hungary|Lexicon Investigational Site, Gyor, Hungary|Lexicon Investigational Site, Sátoraljaújhely, Hungary|Lexicon Investigational Site, Holon, Israel|Lexicon Investigational Site, Petah Tikva, Israel|Lexicon Investigational Site, Petah Tikva, Israel|Lexicon Investigational Site, Milan, Italy|Lexicon Investigational Site, Rome, Italy|Lexicon Investigational Site, Epsom, Auckland, New Zealand|Lexicon Investigational Site, Papatoetoe, Auckland, New Zealand|Lexicon Investigational Site, Takapuna, Auckland, New Zealand|Lexicon Investigational Site, Christchurch, Canterbury, New Zealand|Lexicon Investigational Site, Dunedin, Otago, New Zealand|Lexicon Investigational Site, Newtown, Wellington, New Zealand|Lexicon Investigational Site, Christchurch, New Zealand|Lexicon Investigational Site, Gdynia, Poland|Lexicon Investigational Site, Katowice, Poland|Lexicon Investigational Site, Katowice, Poland|Lexicon Investigational Site, Lublin, Poland|Lexicon Investigational Site, Warsaw, Poland|Lexicon Investigational Site, Warsaw, Poland|Lexicon Investigational Site, Warszawa, Poland|Lexicon Investigational Site, Bardejov, Slovakia|Lexicon Investigational Site, Bratislava, Slovakia|Lexicon Investigational Site, Levice, Slovakia|Lexicon Investigational Site, Goodwood, Cape Town, South Africa|Lexicon Investigational Site, Middelburg, Mpumalanga, South Africa|Lexicon Investigational Site, Bloemfontein, South Africa|Lexicon Investigational Site, Johannesburg, South Africa|Lexicon Investigational Site, Barcelona, Spain|Lexicon Investigational Site, Barcelona, Spain|Lexicon Investigational Site, Malaga, Spain|Lexicon Investigational Site, Santiago De Compostela, Spain|Lexicon Investigational Site, Sevilla, Spain|Lexicon Investigational Site, Dundee, Scotland, United Kingdom|Lexicon Investigational Site, Guildford, United Kingdom",,https://ClinicalTrials.gov/show/NCT02531035
NCT02529449,"Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus",,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Placebo|Drug: ASP1941,Daily profile of plasma glucose levels|Area under the concentration-time curve (AUC) 0-24hr (AUC0-24h) of plasma glucose levels|AUC0-3h of plasma glucose levels|AUC0-4h of plasma glucose levels|AUC0-10h of plasma glucose levels|Fasting plasma glucose levels|Glycoalbumin|Urinary glucose excretion|Urinary glucose excretion rate|Urine volume|Urinary glucose concentration|Body weight|Renal glucose clearance|Plasma concentration of unchanged ASP1941|Urinary concentration of unchanged ASP1941|Pharmacokinetics (PK) parameter of ASP1941 in plasma: AUC from time 0 extrapolated to infinity (AUCinf)|PK parameter of ASP1941 in plasma: AUC from the time of dosing to the last measurable concentration (AUClast)|PK parameter of ASP1941 in plasma: AUC from the time of dosing to 24 hr (AUC0-24h)|PK parameter of ASP1941 in plasma: Oral Clearance (CL/F)|PK parameter of ASP1941 in plasma: Maximum concentration (Cmax)|PK parameter of ASP1941 in plasma: Terminal Elimination Half-life (t1/2)|PK parameter of ASP1941 in plasma: Time of the Maximum Concentration (tmax)|PK parameter of ASP1941 in urine: Amount excreted in urine between time (Ae)|PK parameter of ASP1941 in urine: % of the dose of excreted in urine (Ae%)|PK parameter of ASP1941 in plasma and urine: Renal Clearance (CLr)|Safety assessed by vital signs|Safety assessed by 12-lead electrocardiogram|Safety assessed by laboratory tests|Safety assessed by self-monitored blood glucose levels|Safety assessed by Adverse events,Astellas Pharma Inc,All,"20 Years to 74 Years   (Adult, Older Adult)",Phase 2,43,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1941-CL-6001,1-Sep-15,19-Mar-16,19-Mar-16,20-Aug-15,null,18-Mar-19,"Site JP00006, Aichi, Japan|Site JP00002, Fukuoka, Japan|Site JP00009, Gunma, Japan|Site JP00001, Ibaraki, Japan|Site JP00005, Kanagawa, Japan|Site JP00008, Kanagawa, Japan|Site JP00003, Okayama, Japan|Site JP00004, Osaka, Japan|Site JP00010, Osaka, Japan|Site JP00011, Osaka, Japan|Site JP00007, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT02529449
NCT02527525,First STEPS- Study of Type 1 in Early Childhood and Parenting Support,,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 1",Behavioral: Stepped Care,glycemic control|parental mood|glycemic variability,Children's Research Institute|Baylor College of Medicine|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"21 Years and older   (Adult, Older Adult)",Not Applicable,200,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,6270|1R01DK102561-01A1,Apr-16,Jul-21,Dec-21,19-Aug-15,null,3-May-19,,,https://ClinicalTrials.gov/show/NCT02527525
NCT02528396,To Investigate the Efficacy and Safety of Individualized Doses of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: BioChaperone insulin lispro|Drug: Humalog®,AUCΔBG0-2h (timepoint 0 = administration of the meal)|AUClispro 0-30min (timepoint 0 = time of dosing)|AUClispro_0-6h|Cmax_lispro|Tmax_lispro|AUCBG_0-6h|ΔBGmax|Adverse events|Local tolerability injection site reactions,Adocia|Eli Lilly and Company,All,18 Years to 64 Years   (Adult),Phase 1,36,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BC3-CT013,Aug-15,Dec-15,Dec-15,19-Aug-15,null,16-Mar-16,"Profil GmbH, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT02528396
NCT02526069,An ACT Based Application for Young People With Type 1 Diabetes,ACT,Terminated,No Results Available,Type 1 Diabetes,Behavioral: Acceptance and Commitment Therapy,Acceptability and feasibility of using SweetSpot|Change in Psychological Flexibility - Diabetes specific (DAAS)|Change in Psychological Flexibility (AFQ-Y8)|Change in Diabetes Related Distress (PAID-T)|Change in Glucose Management|Well-being,University of Edinburgh,All,"13 Years to 22 Years   (Child, Adult)",Not Applicable,17,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),15-SS-0064,May-15,Apr-16,Apr-16,18-Aug-15,null,12-May-16,"University of Edinburgh, Edinburgh, United Kingdom",,https://ClinicalTrials.gov/show/NCT02526069
NCT02527265,Afrezza Safety and Pharmacokinetics Study in Pediatric Patients,,Recruiting,No Results Available,Type 1 Diabetes Mellitus,Drug: Afrezza,Number of patients with adverse events|Number of patients with hypoglycemic events|insulin maximum observed concentration (Cmax)|insulin time to reach Cmax (tmax)|insulin area under concentration time curve (AUC)|Assessment of fumaryl diketopiperazine (FDKP) elimination half-life (t1/2)|Number of patients adhered to dose titration rules|Measurement of anti-insulin antibodies,Mannkind Corporation,All,4 Years to 17 Years   (Child),Phase 2,46,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MKC-TI-155|U1111-1166-5528,28-Sep-17,Jul-20,Jan-21,18-Aug-15,null,8-Mar-19,"Investigational Site 637, Aurora, Colorado, United States|Investigational Site 635, New Haven, Connecticut, United States|Investigational Site 636, Gainesville, Florida, United States|Investigational Site 643, Tampa, Florida, United States|Investigational Site 002, Atlanta, Georgia, United States|Investigational Site 639, Atlanta, Georgia, United States|Investigational Site 642, Atlanta, Georgia, United States|Investigational Site 638, Baltimore, Maryland, United States|Investigational Site 646, Las Vegas, Nevada, United States|Investigational Site 640, Philadelphia, Pennsylvania, United States|Investigational Site 641, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT02527265
NCT02524782,"A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes",,Completed,No Results Available,Type 2 Diabetes,Biological: MEDI-4166|Biological: Placebo,"Part A: Number of subjects with adverse events as a measure of safety and tolerability of MEDI4166|Part B: Change in glucose AUC measured up to 240 minutes after mixed meal tolerance test (MMTT) from baseline to Day 36|Part B: Change in LDL-C from baseline to Day 36|Part A: Pharmacokinetics of MEDI4166, maximum plasma concentration (Cmax)|Part A: Pharmacokinetics of MEDI4166, area under the curve concentration (AUC)|Part A: Change from baseline in LDL-C|Part A: Proportion of subjects with Anti-drug Antibodies (ADA) to MEDI4166|Part B: Number of subjects with adverse events as a measure of safety and tolerability of MEDI4166|Part B: Pharmacokinetics of MEDI4166, maximum plasma concentration (Cmax)|Part B: Pharmacokinetics of MEDI4166, area under the curve concentration (AUC)|Part B: Change from baseline in fructosamine levels|Part B: Proportion of subjects with ADA to MEDI4166|Part A: Pharmacokinetics of MEDI4166, time to maximum observed plasma drug concentration (Tmax)|Part A: Change from baseline in glucose AUC up to 240 minutes|Part B: Pharmacokinetics of MEDI4166, time to maximum observed plasma drug concentration (Tmax)",MedImmune LLC,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,103,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",D6240C00001,7-Oct-15,14-Apr-17,14-Apr-17,17-Aug-15,null,13-Mar-19,"Research Site, Anniston, Alabama, United States|Research Site, Chula Vista, California, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, South Miami, Florida, United States|Research Site, Durham, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Knoxville, Tennessee, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT02524782
NCT02523131,Home Testing of Day and Night Closed Loop With Pump Suspend Feature,APCam11,Completed,No Results Available,"Diabetes Mellitus|Diabetes Mellitus, Type 1|Glucose Metabolism Disorders|Endocrine System Diseases|Autoimmune Diseases",Device: FlorenceM|Device: Medtronic insulin pump 640G,"Time spent in the target glucose range from 3.9 to 10.0 mmol/l (70 to 180mg/dl) based on CGM glucose levels|HbA1c at the end of treatment period|Time spent below target glucose (3.9mmol/l)(70mg/dl)|Time spent above target glucose (10.0 mmol/l) (180 mg/dl)|Average of glucose levels|The time with glucose levels < 3.5 mmol/l (63mg/dl) and <2.8 mmol/l (50mg/dl)|The time with glucose levels in the significant hyperglycaemia (glucose levels > 16.7 mmol/l) (300mg/dl)|Total, basal and bolus insulin dose|AUC of glucose below 3.5mmol/l (63mg/dl)|Standard deviation of glucose levels|Coefficient of variation of glucose levels|Number of pump suspend events|Change of body weight from screening to end of study",University of Cambridge|Juvenile Diabetes Research Foundation|Jaeb Center for Health Research|Cambridge University Hospitals NHS Foundation Trust|University College London Hospitals|The Leeds Teaching Hospitals NHS Trust|Manchester University NHS Foundation Trust|International Diabetes Center at Park Nicollet|University of Colorado Denver School of Medicine Barbara Davis Center|University of Edinburgh,All,"6 Years and older   (Child, Adult, Older Adult)",Not Applicable,84,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APCam11,May-16,Mar-18,Mar-18,14-Aug-15,null,13-Mar-18,"University of Colorado Denver, Aurora, Colorado, United States|International Diabetes Center at Park Nicollet, Minneapolis, Minnesota, United States|International Diabetes Centre at Park Nicollet, Minneapolis, Minnesota, United States|University of Cambridge, Cambridge, United Kingdom|Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, United Kingdom|Royal Hospital for Sick Children, Edinburgh, United Kingdom|Leeds Teaching Hospitals, Leeds, United Kingdom|Manchester Diabetes Centre, Manchester Royal Infirmary, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT02523131
NCT02521675,Validation of Algorithms for Basal Insulin Rate Reductions in Type 1 Diabetic Patients Practising Physical Activity in Real Life Conditions,Diabrasport2,Recruiting,No Results Available,"Diabetes Mellitus, Type I|Adjustment of Basal Insulin Flow Rate During Physical Activity|Adjustment of Prandial Insulin in Case of Physical Activity","Behavioral: Usual algorithm|Behavioral: Diabrasport algorithm|Behavioral: Rest|Device: Holter Glycemic Ipro2, Medtronic","the number of hypoglycemic events, defined by any threshold crossing 60 mg / dL (3.33mmol / L), measured in the interstitial glucose sensor continuously over a period of 24h|percentage of time spent over 24 hours in the euglycemic range [70; 180] mg / dL ([3.89, 10] mmol / L)|percentage of time spent over 24 hours in hyperglycemia (> 180 mg / dL) (> 10 mmol / L)|Number of hypoglycemic events, defined by any threshold crossing 70 mg / dL (3.9 mml / L), and <54 mg / dL (3 mmol / l) measured by interstitial continuous glucose sensors|Number of hyperglycemic events, defined by any crossing of the threshold of 180 mg / dL (10 mml / L), measured by continuous interstitial glucose sensors.|Metabolic goals analysis:|Nadirs analysis of blood glucose during the night (value reached)|Nadirs analysis of blood glucose during the night (time to onset)|Analysis of quantities of glucose administration consumed during and at the waning of physical activity|Comparison of average values of continuous glucose measurements according to the period (DIABRASPORT, rest and Baseline) and at different times of the day and night.|Analysis by subgroups, depending on the type of physical activity and its duration, a link between a typology of physical activity or patients, and the number of hypoglycemia events during or waning of physical activity|Analysis of evaluation questionnaires intensity PA (Borg) and quality of life (EVA)|Comparison between number of hypoglycemic events predicted by the prediction function ""DIABRASPORT"" and number of hypoglycemic events actually occurred.",Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2015-A00709-40,Jan-16,Jan-20,Jan-20,13-Aug-15,null,1-Feb-19,"Hôpital Universitaire, Angers, France|Hôpital Henri Duffaut, Avignon, France|Hôpital Jean Minjoz, Besançon, France|Centre Hospitalier, Boulogne sur Mer, France|Hôpital Universitaire, Brest, France|Centre Hospitalier Alpes-Léman, Contamine sur Arve, France|Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France|Centre Hospitalier Louis Pasteur, Dole, France|Centre Hospitalier, Douai, France|Hôpital Pierre Zobda-Quitman, Fort De France, France|Hôpital Universitaire, Grenoble, France|Fondation Hôtel Dieu du Creusot, Le Creusot, France|Centre Hospitalier Régional Universitaire, Lille, France|Centre Hospitalier Universitaire, Lyon, France|Hôpital de la Conception, Marseille, France|Merignac, France|Noisy le Grand, France|Hôpital Cochin, Paris, France|Hôpital Lariboisière, Paris, France|Centre Hospitalier Universitaire, Rennes, France|Centre Hospitalier, Saint Dié des Vosges, France|Centre Hospitalier Régional Universitaire, Strasbourg, France|Hôpital Jean Bernard, Valenciennes, France|Centre Hospitalier Les Portes du Sud, Venissieux, France",,https://ClinicalTrials.gov/show/NCT02521675
NCT02520076,Aralast NP in Islet Transplant,,"Active, not recruiting",No Results Available,Type 1 Diabetes Mellitus,Drug: Alpha-1 Antitrypsin,To demonstrate AAT efficacy in preventing non-immunologic loss of transplanted islet mass in a single-donor islet transplant.|To demonstrate safety of AAT during islet isolation and culture|To demonstrate efficacy of AAT to improve islet isolation quantity and quality|To demonstrate safety of AAT in islet transplantation.|To demonstrate AAT efficacy in the prevention of long-term metabolic burn-out.,University of Alberta|Shire,All,"18 Years to 68 Years   (Adult, Older Adult)",Phase 1|Phase 2,12,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00047923,Aug-15,Mar-20,Mar-21,11-Aug-15,null,16-Apr-19,"University of Alberta, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT02520076
NCT02518945,Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes,,Unknown status,No Results Available,Type 1 Diabetes Mellitus,Drug: Dapagliflozin|Drug: Insulin|Drug: Liraglutide|Drug: Dapagliflozin placebo,To detect a difference from baseline in mean HbA1c before and after 12 weeks of addition of dapagliflozin compared to placebo.|Comparison of the time spent at glucose concentrations between 70-160; 160-240; 240--401; 55-70; <55 mg/dl before and after treatment with 12 weeks of dapagliflozin in addition to liraglutide and insulin.|Comparison of 24-hour urine glucose excretion before and after 12 weeks of treatment of dapagliflozin in addition to liraglutide and insulin.|Comparison of the total daily insulin requirements in units and units per kilogram before and after treatment 12 weeks of dapagliflozin in addition to liraglutide and insulin.|Comparison of Body weight in Kilograms before and after 12 weeks treatment with dapagliflozin in addition to liraglutide and insulin.|Comparison of Systolic and diastolic blood pressure in mm Hg before and after 12 weeks treatment with dapagliflozin in addition to liraglutide and insulin.|Comparison of Postprandial glucose concentrations following a test meal as areas under the curve for the data obtained from the meal challenge. before and after 12 weeks treatment with dapagliflozin in addition to liraglutide and insulin.|Comparison of Carbohydrate intake in grams and in terms of carbohydrate helpings(frequency) before and after 12 weeks treatment with dapagliflozin in addition to liraglutide and insulin.|Comparison of quality of life measures using Diabetes Specific Quality of Life Scale (DSQOLS) and problem areas in Diabetes survey (PAID) scores before and after 12 weeks treatment with dapagliflozin in addition to liraglutide and insulin.,University at Buffalo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1969,Aug-15,Apr-16,null,10-Aug-15,null,10-Aug-15,"ECMC Ambulatory Center, 3rd Floor, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT02518945
NCT02518022,How to be Safe With Alcoholic Drinks in Diabetes,BEER,Withdrawn,No Results Available,Type 1 Diabetes Mellitus|Hypoglycemia,Drug: Insulin,• Number of hypoglycaemic events <70 mg/dl per arm from begin of consumption until lunch next day (12:00 am)|• Area under the curve Glucose Sensor >120 mg/dl from begin of drinking to lunch next day|• Total Area under the curve|• average Sensor Glucose from begin of drinking to 12 hours past and to lunch next day|• Time from end of consumption to nadir of serum glucose|• Number of hypoglycaemic events <70 mg/dl per treatment arm until lunch|• Number of hyperglycaemic events > 180 mg/dl per treatment arm until lunch|• Time in Hypoglycaemia <70 mg/dl per treatment arm|• Max. alcohol in expiratory breath,Kinderkrankenhaus auf der Bult|Hannover Medical School,All,"16 Years to 21 Years   (Child, Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BEER2015,Sep-15,Jun-16,Jun-16,7-Aug-15,null,4-Aug-16,"Kinder - und Jugendkrankenhaus AUF DER BULT, Hannover, Germany",,https://ClinicalTrials.gov/show/NCT02518022
NCT02516150,Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon,,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Ethanol|Drug: Glucagon,AOCGIR (Area Over the Curve for Glucose Infusion Rate)|Maximum Change in GIR (Glucose Infusion Rate) From Baseline,Massachusetts General Hospital,All,"21 Years to 80 Years   (Adult, Older Adult)",Phase 4,26,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015P001323,Mar-16,May-17,Jun-17,5-Aug-15,31-Aug-17,31-Aug-17,"Massachusetts General Hospital Diabetes Research Center, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT02516150/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02516150
NCT02514954,Postprandial Blood Glucose Control With BioChaperone® Combo and Insulin Lispro (Humalog®) Mix 25 in People With Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Biochaperone® Combo|Drug: Humalog® Mix25,"Delta AUCBG,0-2h|Delta AUCBG,0-6h|BGmax|tBGmax|AUCLisp,0-6h,|AUCGlarg,0-6h|Cmax,Lisp|Cmax,Glarg|Adverse events|Local tolerability",Adocia,All,18 Years to 64 Years   (Adult),Phase 1,28,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",BC3-CT019,Jul-15,Nov-15,Nov-15,4-Aug-15,null,6-Nov-15,"Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT02514954
NCT02510664,Diabetes Strengths Study - Pilot of Provider-delivered Strengths-based Intervention,DSS,Completed,No Results Available,Type 1 Diabetes,Behavioral: Diabetes Strengths Study,Feasibility of Study Design|Acceptability|Diabetes regimen adherence|Glycemic control|Diabetes Burden|Diabetes-related Family Conflict|Healthcare Satisfaction|Diabetes Strengths,Baylor College of Medicine|Texas Children's Hospital|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"12 Years to 18 Years   (Child, Adult)",Not Applicable,84,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,H-34857|1K12DK097696,Jul-14,Aug-16,Aug-16,29-Jul-15,null,16-Jan-19,"Baylor College of Medicine, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02510664
NCT02509429,Comparison of an Artificial Pancreas Versus Threshold Low Glucose Suspend in Type 1 Diabetic Children,SHAN,Completed,No Results Available,Type 1 Diabetes,"Device: Insulin therapy (aspart, lispro ou glulisine) with Control-to-Range algorithm|Device: Insulin therapy ((aspart, lispro ou glulisine) withThreshold Low Glucose Suspend","Time spent with blood glucose <70 mg/dl|Percent time spent with blood glucose <70mg/dl|Percent time spent with blood glucose level in 70-180 mg/dl range|Percent time spent with blood glucose level in 80-150 mg/dl range|Mean blood glucose level|Number of needed interventions by the patients, the parents, and by the investigational team, to treat hypoglycemia|Number of needed interventions by the patients, the parents, and by the investigational team, to fix issues related to the functioning of the insulin delivery system|Score of the Artificial Pancreas Acceptance Questionnaire|Score of the Hypo Fear Survey","University Hospital, Montpellier",All,7 Years to 12 Years   (Child),Phase 2,24,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9525,16-Jun-15,Dec-16,Dec-16,28-Jul-15,null,14-Jun-18,"CHU d'Angers, Angers, France|CHU Montpellier - Hôpital Lapeyronie, Montpellier, France|AP-HP, Hôpital Robert Debré, Paris, France|CHU de Tours, Hôpital Clocheville, Tours, France",,https://ClinicalTrials.gov/show/NCT02509429
NCT02508779,BGAT (Blood Glucose Awareness Training) for Users Who Might Become Pregnant,Bump2Be,Completed,No Results Available,"Diabetes Mellitus, Type 1|Pregnancy",Behavioral: Bump2be|Other: Routine Care,"Reduced frequency of extreme BG (as defined by the low and high BG index)|Reduced consequences of extreme BG (e.g., diabetic ketoacidosis, SH)|Improved estimation of BG (as confirmed by BG Diary data)|Improved detection of low and high BG (as confirmed by BG Diary data)|Reduced fear of hypoglycemia (as confirmed by the Low Blood Sugar Survey)|Reduced extreme avoidance of hyperglycemia (as confirmed by the High Blood Sugar Survey)|Improved well-being (as confirmed by the Diabetes Distress Scale)|Improved internal locus of control (as confirmed by the Perceived Competence for Diabetes Scale and the Treatment Self-Regulation Questionnaire)",University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Female,18 Years to 64 Years   (Adult),Not Applicable,54,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,17117|5R21DK095206,Jul-15,Sep-16,Oct-16,27-Jul-15,null,26-Oct-16,"University of Viginia Center for Behavioral Health & Technology, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02508779
NCT02509065,The Set-Point Study: Evaluating Effects of Changing Glucose Target on Bionic Pancreas Performance,,Completed,Has Results,Type 1 Diabetes|Type 2 Diabetes,Device: Bionic Pancreas|Other: Usual Care,"Mean Continuous Glucose Monitor (CGM) Glucose Values|Percentage of Time With CGM < 60 mg/dl|Number of Subjects Discordant for Reaching a BG < 60 mg/dl for > 2 Consecutive Plasma Glucose Measurements During Inpatient Exercise Visit|Mean CGM Glucose|Nausea Severity|Percentage of Time Spent in: < 50 mg/dl, < 70 mg/dl, 70-120 mg/dl, 70-180 mg/dl, > 180 mg/dl, >250 mg/dl|Percentage of Subjects With Mean CGM < 154 mg/dl|Area Between the Glucose Curve and 60 mg/dl Calculated From BG Measurements|Area Between the Glucose Curve and 60 mg/dl Calculated From CGM Measurements|Time From Start of Exercise to First BG Measurement < 60 mg/dl|Time From Start of Exercise to First CGM Measurement < 60 mg/dl|Grams of Carbohydrates Given to the Subject to Treat Hypoglycemia|Total Glucagon Dosing by the Bihormonal Bionic Pancreas From the Start of Exercise Until the End of the Visit",Massachusetts General Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015P001260,Aug-15,Dec-17,Dec-17,27-Jul-15,31-Aug-18,20-Nov-18,"Masscahusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02509065/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02509065
NCT02506647,PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Gan & Lee insulin glargine followed by Lantus|Drug: Lantus followed by Gan & Lee insulin glargine,Pharmacodynamic effects|Pharmacokinetic effects|Safety assessment as measured by incidence and severity of adverse events,"Gan and Lee Pharmaceuticals, USA",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,41,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",GL-GLA-001,Dec-15,Sep-16,Sep-16,23-Jul-15,null,26-Jan-17,"Profil Institute for Clinical Research, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT02506647
NCT02505893,Minimal Islet Transplant at Diabetes Onset,MITO,Recruiting,No Results Available,"Diabetes Mellitus, Type 1",Biological: Human pancreatic islet|Drug: ATG|Drug: Pegylated G-CSF|Drug: Rapamycin,plasma C-peptide AUC (mixed meal tolerance test [MMTT])|Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)|plasma C-peptide AUC (MMTT)|stimulated plasma C-peptide|glucagon AUC (MMTT)|HbA1c|daily insulin dose|hypoglycaemic events|72-hour Continuous Glucose Monitoring,Ospedale San Raffaele|Italian Diabetes Foundation,All,18 Years to 45 Years   (Adult),Phase 2,6,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DRI-MITO 1/2014,Apr-15,May-18,May-18,22-Jul-15,null,8-Feb-18,"IRCCS San Raffaele Scientific Institute, Milan, Italy",,https://ClinicalTrials.gov/show/NCT02505893
NCT02502071,Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes,Alk-UA,Completed,Has Results,Type 1 Diabetes|Diabetic Nephropathy|Diabetic Kidney Disease,Drug: sodium bicarbonate,Change in Urine Uric Acid Concentration (Increased Solubility) by Assay|Change in Number of Participants With Urine Uric Acid Precipitation by Polarized Microscopy,University of Colorado Denver School of Medicine Barbara Davis Center,All,18 Years to 45 Years   (Adult),Phase 4,45,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-0541,Jan-17,Jul-17,Aug-17,20-Jul-15,20-Nov-18,20-Nov-18,"Barbara Davis Center for Diabetes, Aurora, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02502071/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02502071
NCT02500979,Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus,,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Pramlintide acetate|Drug: Placebo|Drug: Lispro insulin U-100|Drug: Regular insulin U-100,Efficacy of Pramlintide by Measurement of 24-hour Tissue Mean Weighted Glucose (MWG) Obtained With Continuous Glucose Monitoring (CGM)|Efficacy of Pramlintide by Measurement of Absolute Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC) Following Lunch|Efficacy of Pramlintide by Measurement of Absolute Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC) Following Dinner|Efficacy of Pramlintide by Measurement of Absolute Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC) Following Breakfast|Efficacy of Pramlintide by Measurement of Incremental 24-hour Tissue Glucose Area Under the Plasma Concentration-time Curve (AUC) Obtained With Continuous Glucose Monitoring (CGM)|Efficacy of Pramlintide by Measurement of Absolute 24-hour Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC)|Efficacy of Pramlintide by Measurement of Incremental 24-hour Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC)|Efficacy of Pramlintide Measured by Percent Time Spent in the Range of >70 mg/dL to <180 mg/dL Tissue Glucose Obtained With Continuous Glucose Monitoring (CGM)|Efficacy of Pramlintide by Measurement of Absolute 24-hour Plasma Glucagon Area Under the Plasma Concentration-time Curve (AUC)|Efficacy of Pramlintide by Measurement of Incremental 24-hour Plasma Glucagon Area Under the Plasma Concentration-time Curve (AUC)|Fasting Plasma Glucose Concentration|Pharmacokinetics of Insulin as Demonstrated by 24-hour Plasma Insulin Area Under the Plasma Concentration-time Curve (AUC)|Pharmacokinetics of Insulin as Demonstrated by 24-hour Average Plasma Insulin Concentration.|Pharmacokinetics of Insulin as Demonstrated by Maximum Plasma Insulin Concentration|Pharmacokinetics of Insulin as Demonstrated by the Time to the Maximum Plasma Insulin Concentration,AstraZeneca|Juvenile Diabetes Research Foundation,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,34,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,D5570C00002,17-Aug-15,5-Aug-16,5-Aug-16,17-Jul-15,2-Nov-18,2-Nov-18,"Research Site, Chula Vista, California, United States|Research Site, Portland, Oregon, United States|Research Site, Chattanooga, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT02500979
NCT02501850,The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a),EGLIPA,Unknown status,No Results Available,Diabetes Mellitus Type 2,Drug: Liraglutide|Drug: metformin,Change in blood levels of Lipoprotein (a) (Lp(a)),Hospital Universitari Vall d'Hebron Research Institute,All,"50 Years to 65 Years   (Adult, Older Adult)",Phase 4,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VHI-GLP-2014-01,Oct-14,Jul-15,Oct-15,17-Jul-15,null,21-Jul-15,"Hospital Universitari Vall d'Hebron, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT02501850
NCT02500706,Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes,onset®8,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart|Drug: insulin degludec,"Change From Baseline in HbA1c 26 Weeks After Randomisation|Change From Baseline in 1-hour Post Prandial Glucose (PPG) Increment 26 Weeks After Randomisation (Meal Test)|Change From Baseline in 1,5-anhydroglucitol 26 Weeks After Randomisation|Change From Baseline in Fasting Plasma Glucose (FPG) 26 Weeks After Randomisation|Percentage of Subjects Reaching HbA1c Targets (HbA1c < 7.0%) 26 Weeks After Randomisation|Percentage of Subjects Reaching HbA1c Targets (HbA1c < 7.0% Without Severe Hypoglycaemia) 26 Weeks After Randomisation|Percentage of Subjects Reaching HbA1c Targets (HbA1c < 7.0% Without Severe Hypoglycaemia and Minimal Weight Gain [<3.0%]) 26 Weeks After Randomisation|Change From Baseline in 30- Min, 1- Hour, 2- Hour, 3- Hour and 4- Hour PPG 26 Weeks After Randomisation|Change From Baseline in 30- Min, 1- Hour, 2- Hour, 3- Hour and 4- Hour PPG Increment 26 Weeks After Randomisation|Change From Baseline in 7-9-7-point Self-measured Plasma Glucose (SMPG) 26 Weeks After Randomisation: Mean of the 7-9-7-point Profile|Change From Baseline in 7-9-7-point SMPG 26 Weeks After Randomisation: PPG (Mean, Breakfast, Lunch, Main Evening Meal)|Change From Baseline in 7-9-7-point SMPG 26 Weeks After Randomisation: PPG Increment (Mean, Breakfast, Lunch, Main Evening Meal)|Change From Baseline in 7-9-7-point SMPG 26 Weeks After Randomisation: Fluctuation in 7-9-7-point Profile|Change From Baseline in 7-9-7-point SMPG 26 Weeks After Randomisation: Change in the Nocturnal Self-measured Plasma Glucose Measurements|Percentage of Subjects Reaching PPG Target (Overall Mean of Daily PPG Measurements in SMPG) 26 Weeks After Randomisation: Overall PPG (1 Hour) ≤7.8 mmol/L|Percentage of Subjects Reaching PPG Target (Overall Mean of Daily PPG Measurements in SMPG) 26 Weeks After Randomisation: Overall PPG (1 Hour) ≤7.8 mmol/L Without Severe Hypoglycaemia|Percentage of Subjects Reaching PPG Target (Overall Mean of Daily PPG Measurements in SMPG) 26 Weeks After Randomisation: Overall PPG (1 Hour) ≤7.8 mmol/L and HbA1c <7.0% and Minimal Weight Gain (<3.0%) Without Severe Hypoglycaemia|Change From Baseline in Lipids-lipoproteins Profile 26 Weeks After Randomisation (Total Cholesterol, High Density Lipoproteins [HDL] Cholesterol, Low Density Lipoproteins [LDL] Cholesterol)|Insulin Dose (Basal Insulin Dose, Total and Individual Meal Insulin Dose)|Number of Treatment Emergent Adverse Events During 26 Weeks After Randomisation|Number of Treatment-emergent Injection Site Reactions During the 26 Weeks After Randomisation|Number of Hypoglycaemic Episodes Classified Both According to the American Diabetes Association (ADA) Definition and Novo Nordisk (NN) Definition During 26 Weeks After Randomisation: Overall|Number of Hypoglycaemic Episodes Classified Both According to the ADA Definition and Novo Nordisk Definition During 26 Weeks After Randomisation: Daytime and Nocturnal Hypoglycaemic Episodes (00:01-05:59 - Inclusive)|Number of Hypoglycaemic Episodes Classified Both According to the ADA Definition and Novo Nordisk Definition During 26 Weeks After Randomisation: From Start of Meal Until 1,2, 4 Hours and From 2 Hours (Exclusive) to 4 Hours (Inclusive) After Start of Meal|Change From Baseline 26 Weeks After Randomisation in Clinical Evaluations (Physical Examination)|Change From Baseline in Blood Pressure 26 Weeks After Randomisation|Change From Baseline in Pulse 26 Weeks After Randomisation|Change From Baseline in Clinical Evaluation (Electrocardiogram) 26 Weeks After Randomisation|Change From Baseline in Clinical Evaluation (Fundoscopy/Fundus Photography) 26 Weeks After Randomisation|Change From Baseline in Erythrocytes 26 Weeks After Randomisation|Change From Baseline in Haematocrit 26 Weeks After Randomisation|Change From Baseline in Haemoglobin 26 Weeks After Randomisation|Change From Baseline in Leukocytes 26 Weeks After Randomisation|Change From Baseline in Thrombocytes 26 Weeks After Randomisation|Change From Baseline in Alanine Aminotransferase 26 Weeks After Randomisation|Change From Baseline in Albumin 26 Weeks After Randomisation|Change From Baseline in Alkaline Phosphatase 26 Weeks After Randomisation|Change From Baseline in Aspartate Aminotransferase 26 Weeks After Randomisation|Change From Baseline in Total Bilirubin 26 Weeks After Randomisation|Change From Baseline in Potassium 26 Weeks After Randomisation|Change From Baseline in Creatinine 26 Weeks After Randomisation|Change From Baseline in Total Protein 26 Weeks After Randomisation|Change From Baseline in Urinary Albumin-to-creatinine Ratio 26 Weeks After Randomisation|Change From Baseline in Urinalysis (Ketones) 26 Weeks After Randomisation|Change From Baseline in Urinalysis (Protein) 26 Weeks After Randomisation|Change From Baseline in Urinalysis (Erythrocytes) 26 Weeks After Randomisation|Change From Baseline in Anti-insulin Aspart (Specific and Cross-reacting With Human Insulin) Antibody Development 26 Weeks After Randomisation|Change From Baseline in Body Weight 26 Weeks After Randomisation|Change From Baseline in Body Mass Index 26 Weeks After Randomisation",Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1108,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1218-4131|2015-001047-36|U1111-1167-9495,4-May-16,17-Jul-17,16-Aug-17,16-Jul-15,10-Aug-18,30-Oct-18,"Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Encino, California, United States|Novo Nordisk Investigational Site, Escondido, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Fullerton, California, United States|Novo Nordisk Investigational Site, Huntington Beach, California, United States|Novo Nordisk Investigational Site, Monterey, California, United States|Novo Nordisk Investigational Site, Newport Beach, California, United States|Novo Nordisk Investigational Site, Santa Barbara, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Denver, Colorado, United States|Novo Nordisk Investigational Site, Golden, Colorado, United States|Novo Nordisk Investigational Site, Palm Harbor, Florida, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Rockville, Maryland, United States|Novo Nordisk Investigational Site, Flint, Michigan, United States|Novo Nordisk Investigational Site, Kalamazoo, Michigan, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, Jefferson City, Missouri, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, United States|Novo Nordisk Investigational Site, Hamilton, New Jersey, United States|Novo Nordisk Investigational Site, Lawrenceville, New Jersey, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, Rochester, New York, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Greenville, North Carolina, United States|Novo Nordisk Investigational Site, Wilmington, North Carolina, United States|Novo Nordisk Investigational Site, Bend, Oregon, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Amarillo, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Beaumont, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Mesquite, Texas, United States|Novo Nordisk Investigational Site, Round Rock, Texas, United States|Novo Nordisk Investigational Site, Murray, Utah, United States|Novo Nordisk Investigational Site, Ogden, Utah, United States|Novo Nordisk Investigational Site, Salt Lake City, Utah, United States|Novo Nordisk Investigational Site, Salt Lake City, Utah, United States|Novo Nordisk Investigational Site, Federal Way, Washington, United States|Novo Nordisk Investigational Site, Renton, Washington, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Tacoma, Washington, United States|Novo Nordisk Investigational Site, Graz, Austria|Novo Nordisk Investigational Site, Salzburg, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Dimitrovgrad, Bulgaria|Novo Nordisk Investigational Site, Pleven, Bulgaria|Novo Nordisk Investigational Site, Plovdiv, Bulgaria|Novo Nordisk Investigational Site, Ruse, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Varna, Bulgaria|Novo Nordisk Investigational Site, Calgary, Alberta, Canada|Novo Nordisk Investigational Site, Halifax, Nova Scotia, Canada|Novo Nordisk Investigational Site, Concord, Ontario, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Lingen, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Neuwied, Germany|Novo Nordisk Investigational Site, Schweinfurt, Germany|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Visakhapatnam, Andhra Pradesh, India|Novo Nordisk Investigational Site, Ahmedabad, Gujarat, India|Novo Nordisk Investigational Site, Ahmedabad, Gujarat, India|Novo Nordisk Investigational Site, Rohtak, Haryana, India|Novo Nordisk Investigational Site, Kozhikode, Kerala, India|Novo Nordisk Investigational Site, Indore, Madhya Pradesh, India|Novo Nordisk Investigational Site, Indore, Madhya Pradesh, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Bhubaneswar, Orissa, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Vellore, Tamil Nadu, India|Novo Nordisk Investigational Site, Chandigarh, India|Novo Nordisk Investigational Site, New Dehli, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, Pune, India|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Holon, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Petah Tikva, Israel|Novo Nordisk Investigational Site, Rishon Le Zion, Israel|Novo Nordisk Investigational Site, Ancona, Italy|Novo Nordisk Investigational Site, Bergamo, Italy|Novo Nordisk Investigational Site, Catanzaro, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Rome, Italy|Novo Nordisk Investigational Site, Sesto San Giovanni (MI), Italy|Novo Nordisk Investigational Site, Bunkyo-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Chuo-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Ebina-shi, Japan|Novo Nordisk Investigational Site, Fukuoka, Japan|Novo Nordisk Investigational Site, Hyogo, Japan|Novo Nordisk Investigational Site, Ibaraki, Japan|Novo Nordisk Investigational Site, Izumisano-shi, Japan|Novo Nordisk Investigational Site, Kobe-shi, Hyogo, Japan|Novo Nordisk Investigational Site, Koriyama-shi, Fukushima, Japan|Novo Nordisk Investigational Site, Kumamoto-shi,Kumamoto, Japan|Novo Nordisk Investigational Site, Matsumoto-shi, Nagano, Japan|Novo Nordisk Investigational Site, Mito-shi, Ibaraki, Japan|Novo Nordisk Investigational Site, Miyazaki-shi, Japan|Novo Nordisk Investigational Site, Naka-shi, Ibaraki, Japan|Novo Nordisk Investigational Site, Oita-shi, Japan|Novo Nordisk Investigational Site, Osaka-shi, Osaka, Japan|Novo Nordisk Investigational Site, Ota-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Takatsuki-shi, Osaka, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Yokohama-shi, Japan|Novo Nordisk Investigational Site, Ponce, Puerto Rico|Novo Nordisk Investigational Site, Barnaul, Russian Federation|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Tumen, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Taoyuan, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02500706/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02500706/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02500706
NCT02496156,Shared Medical Decision Making in Pediatric Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus,Behavioral: Usual Clinical Practice|Behavioral: Shared Medical Decision Making,Device utilization|Glycated hemoglobin (Hemoglobin A1C)|Hypoglycemia Diary|Decision quality|Knowledge of insulin pump or continuous glucose monitor|Diabetes Self Management Profile Self Report Form,Nemours Children's Clinic|Patient-Centered Outcomes Research Institute,All,11 Years to 17 Years   (Child),Not Applicable,153,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,PCORI 805,Feb-15,7-Feb-17,7-Feb-17,14-Jul-15,null,9-Feb-17,"Nemours Children's Clinic, Jacksonville, Florida, United States",,https://ClinicalTrials.gov/show/NCT02496156
NCT02497313,Effect of Metformin and Cholecystokinin-mediated Gallbladder Emptying on GLP-1 Secretion in Type 2 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Isotonic saline|Drug: Metformin placebo|Drug: Cholecystokinin|Drug: Metformin,Glucagon-like peptide-1 (GLP-1): Incremental and total area under the Concentration-Time Curve|Responses of various other gut hormones: Incremental and total area under the Concentration-Time Curve|Blood analysis of paracetamol as an assessment of gastric emptying|Indirect calorimetry: Basal metabolic rate|Gallbladder volume as assessed by Ultrasound measurements|Appetite as assessed by Visual analog scale score,"University Hospital, Gentofte, Copenhagen",All,"40 Years to 75 Years   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",H-15007280,Jul-15,Jul-16,Jul-16,14-Jul-15,null,3-May-17,"Center for Diabetes Research, Herlev-Gentofte Hospital, Hellerup, Denmark",,https://ClinicalTrials.gov/show/NCT02497313
NCT02494375,Sleep and Type 1 Diabetes,SLEEPT1D,"Active, not recruiting",No Results Available,Type 1 Diabetes,Other: Sleep and glucose assessments,Association between HbA1c and sleep characteristics|Glucose levels|Daily salivary amylase variation (Enzyme Activity)|Body composition (BMI fat and lean mass percentage),"Hospices Civils de Lyon|Institut National de la Santé Et de la Recherche Médicale, France",All,6 Years to 17 Years   (Child),Not Applicable,70,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,69HCL15_0219,28-Jun-15,Dec-17,Dec-17,10-Jul-15,null,22-Aug-17,"Hospices Civils de Lyon, Lyon, France",,https://ClinicalTrials.gov/show/NCT02494375
NCT02488278,GLUCOME USABILITY STUDY,,Unknown status,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Device: GlucoMe Glucose Monitoring Device,Operating the GlucoMe device: obtaining a glucose reading and recording the results|Time to completion of obtaining a glucose reading using the application and device|Frequency of attempts to ask for assistance during the use of the device and application|Participants' level of success in completing tasks related to the use of the device and application|Documenting specific user errors and inefficiencies related to the use of the device and application,GlucoMe,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,Clin-001-00,Jul-15,Sep-15,Oct-15,2-Jul-15,null,3-Jul-15,,,https://ClinicalTrials.gov/show/NCT02488278
NCT02485327,PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM),,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Technosphere Insulin SAR439065 Afrezza®,Assessment of PK parameter: area under the serum insulin concentration time curve from time 0 to 8H (INS-AUC0-8H)|Assessment of PD parameter: area under the glucose infusion rate curve (GIR) necessary to maintain euglycemia during the euglycemic clamp over 8 hours|Assessment of PK parameter: maximum Afrezza insulin serum concentration (INS-Cmax)|Assessment of PK parameter: time to INS-Cmax (INS-tmax)|Assessment of PD parameter: maximum smoothed GIR (GIRmax)|Assessment of PD parameter: time to GIRmax (GIR-Tmax),Mannkind Corporation,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,22,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PDY14329|2015-001008-74|U1111-1168-4442,Jul-15,Nov-15,Nov-15,30-Jun-15,null,15-Mar-17,"Investigational Site Number 276001, Mainz, Germany",,https://ClinicalTrials.gov/show/NCT02485327
NCT02470637,Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: SAR439065|Drug: Insulin lispro,Assessment of PD parameter: Area under the glucose infusion rate curve within 24 hours after administration of the investigational medicinal product or until administration of rescue insulin (GIR-AUC0-end)|Assessment of PD parameters: Maximum smoothed glucose infusion rate (GIRmax)|Assessment of PD parameters: Time to GIRmax (GIR-Tmax)|Duration of blood glucose control (time to elevation of smoothed blood glucose profile above different prespecified clamp levels)|Assessment of PK parameters: Area under the baseline-corrected serum insulin concentration-time curve over 24 hours or until administration of rescue insulin (INS-AUClast)|Assessment of PK parameters: Baseline-corrected maximum serum concentration (INS-Cmax)|Assessment of PK parameters: Time to INS-Cmax (INS-Tmax)|Assessment of PK parameters: Area under the concentration-time curve (INS-AUClast)|Number of patients with adverse events,Mannkind Corporation,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,30,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,PDY14324|2015-000231-33|U1111-1166-5431,Jun-15,Sep-15,Sep-15,12-Jun-15,null,13-Apr-17,"Investigational Site Number 276001, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT02470637
NCT02471040,Brain Ketone Metabolism in Type 1 Diabetes,,Recruiting,No Results Available,Type 1 Diabetes|Hypoglycemia,Drug: Beta-hydroxybutyrate|Other: Normal Saline,Cognitive Function,Yale University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,1208010648,Nov-14,Dec-19,Dec-19,12-Jun-15,null,21-Aug-18,"Yale New Haven Hospital, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02471040
NCT02464033,EDCR Study - Etanercept Diamyd Combination Regimen -Open Trial to Evaluate Safety in Children With Type 1 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: GAD-Alum|Drug: Vitamin D|Drug: Etanercept,"Reactions of the injection site as an assessment of the tolerability of a combination therapy with Diamyd, Vitamin D and etanercept at Month 6 (main study Period)|To Evaluate the tolerability of a combination therapy with Diamyd, Vitamin D and etanercept at Month 6 (main study Period)|Number of adverse events and number of participants with adverse events as an assessment of the tolerability of a combination therapy with Diamyd, Vitamin D and etanercept at Month 6 (main study Period)|Number of serious adverse events and number of participants with serious adverse events as an assessment of the tolerability of a combination therapy with Diamyd, Vitamin D and etanercept at Month 6 (main study Period)|Physical examinations, including neurological assessments as an assessment of the tolerability of a combination therapy with Diamyd, Vitamin D and etanercept at Month 6 (main study Period)|Laboratory measurements as an assessment of the tolerability of a combination therapy with Diamyd, Vitamin D and etanercept at Month 6 (main study Period)|GAD65AB titer measured to Evaluate the tolerability of a combination therapy with Diamyd, Vitamin D and etanercept at Month 6 (main study Period)|Change in immune system markers from baseline to Month 6 (main study period) and subsequent visits during the extension study period|C-peptide: Area Under the Curve (mean 0-120 min) during an MMTT, change from baseline|Proportion of patients with a stimulated maximum C-peptide level above 0.2 nmol/L|Hemoglobin A1c (HbA1c), change from baseline|Exogenous insulin dose per kg body weight and 24 hours, change from baseline|C-peptide: Fasting, 90 minute value, change from baseline","Johnny Ludvigsson|Swedish Child Diabetes Foundation|Ostergotland County Council, Sweden|Diamyd Medical AB|Linkoeping University",All,"8 Years to 18 Years   (Child, Adult)",Phase 2,20,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EDCR IIa,May-15,25-Feb-19,25-Feb-19,8-Jun-15,null,24-Apr-19,"Helsingborg Hospital, Helsingborg, Sweden|Linköping University Hospital, Linköping, Sweden|Lund University Hospital, Lund, Sweden|Skåne University Hospital, UMAS, Malmö, Sweden|Sachsska, Södersjukhuset, Stockholm, Sweden|Uddevalla Hospital, Uddevalla, Sweden|Västerås Hospital, Västerås, Sweden|Örebro University Hospital, Örebro, Sweden",,https://ClinicalTrials.gov/show/NCT02464033
NCT02464878,Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant,,Recruiting,No Results Available,Kidney Transplant|Type 1 Diabetes,Drug: Alpha 1-Antitrypsin|Procedure: Islet Transplantation|Drug: Thymoglobulin|Drug: Basiliximab|Drug: Etanercept,"The proportion of GLASSIA versus control CIT06 subjects achieving insulin independence after first infusion of single donor islets.|Estimated engrafted islet mass by FSIGT at post islet infusion comparing Glassia treated versus control subjects.|The proportion of GLASSIA treated versus control CIT06 subjects who are insulin independent after 1 or more islet infusions|Percent change from baseline insulin requirement comparing GLASSIA treated versus control CIT06 subjects|The relative functional engrafted islet mass comparing GLASSIA treated versus control CIT06 subjects using FSIGT testing|Correlation of markers of early islet loss as assessed by the rapid release of TAT, C3 and c-peptide, and insulin specific DNA with FSIGT and clinical markers of islet function|The proportion of GLASSIA treated versus CIT06 control subjects with both an HbA1c ≤ 6.5% AND an absence of severe hypoglycemic events|The proportion of GLASSIA treated versus control subjects with both an HbA1c < 7.0% AND free of severe hypoglycemic events|The proportion of GLASSIA treated versus control CIT06 subjects A reduction in HbA1c of 1 point AND an absence of severe hypoglycemia|ber of severe hypoglycemic events comparing GLASSIA treated versus control CIT06 subjects|HbA1c comparing GLASSIA treated versus control CIT06 subjects|The change in Clarke score from baseline in GLASSIA treated versus control CIT06 subjects|β-score comparing GLASSIA treated versus control CIT06 subjects|Glucose variability and hypoglycemia duration derived from the CGMS comparing GLASSIA treated versus control CIT06 subjects|Basal (fasting) and 90-min glucose and c-peptide derived from the mixed-meal tolerance test (MMTT) comparing GLASSIA treated versus control CIT06 subjects|MAGE comparing GLASSIA treated versus control CIT06 subjects|Glycemic lability index (LI) comparing GLASSIA treated versus CIT06 control subjects|Ryan hypoglycemia severity (HYPO) Score comparing GLASSIA treated versus control CIT06 Subjects|C-peptide: (glucose· creatinine) ratio (CPGCR) comparing GLASSIA treated versus control CIT06 subjects|Rate of favorable outcome at each center preparing islets (rate of subjects with HbA1c < 6.5% and absence of severe hypoglycemic events, or reduction in HbA1c of 1 point and absence of severe hypoglycemia|The proportion of subjects receiving a second islet transplant comparing GLASSIA treated versus control CIT06 subjects|The proportion of subjects receiving a third islet transplant comparing GLASSIA treated versus control CIT06 subjects|Cardiovascular events [death, cerebrovascular accident (CVA), myocardial infarction (MI)] and changes in atherogenic profile for GLASSIA treated versus control subjects|Renal impact measures including renal allograft survival and function measured by serum creatinine (SCr) and urinary albumin creatinine ratio comparing GLASSIA treated versus control subjects",Massachusetts General Hospital|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Iowa,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,20,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Islet after Kidney - AAT,Jan-17,Dec-19,Jan-20,8-Jun-15,null,21-Mar-18,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02464878
NCT02465411,Long Term CGM Treatment in Patients With Type 1 Diabetes Treated With Insulin Injections,,Completed,No Results Available,Diabetes Mellitus Type 1,Device: Dexcom G4 or later generation,HbA1c in venous sample|Mean glucose level measured by CGM during two weeks.|Mean Amplitude of Glycemic Excursions (MAGE) measured by CGM during two weeks.|Standard deviation of glucose levels measured by CGM during two weeks.|Treatment satisfaction: DTSQs scores|Well being: WHO 5 scores|Hypoglycemia fear: SWE-HFS scores|Problem areas: SWE-PAID-20 scores|Physical activity: IPAQ score|Treatment experience of CGM score|Proportion of time with low glucose levels measured by CGM during two weeks.|Proportion of time with high glucose levels measured by CGM during two weeks.|Proportion of time with euglycaemic levels measured by CGM during two weeks.|Proportion of patients lowering their HbA1c by 5 mmol/mol (0.5% in DCCT) or more.|Proportion of patients lowering their HbA1c 10 mmol/mol (1% in DCCT) or more|Number of self-reported severe hypoglycaemic events per year,"Vastra Gotaland Region|DexCom, Inc.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CGMMDI Extension,Jun-15,31-May-17,31-May-17,8-Jun-15,null,8-Nov-17,"Alingsås Hospital, Alingsås, Sweden|Angered Hospital, Angered, Sweden|Helsingborg Hospital, Helsingborg, Sweden|Öbackakliniken, Härnösand, Sweden|Central Hospital Kristianstad, Kristianstad, Sweden|Halland Hospital Kungsbacka, Kungsbacka, Sweden|Skåne University Hospital Malmö, Malmö, Sweden|Hospital in Motala, Motala, Sweden|Vrinnevi Hospital, Norrköping, Sweden|Södersjukhuset, Stockholm, Sweden|Hospital Trelleborg, Trelleborg, Sweden|NU Hospital Group, Uddevalla, Sweden|Academic Hospital Uppsala, Uppsala, Sweden|Ängelholm Hospital, Ängelholm, Sweden|University Hospital Örebro, Örebro, Sweden",,https://ClinicalTrials.gov/show/NCT02465411
NCT02462785,An Evaluation of Internet-based Carbohydrate Counting Education for Adolescents With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus,Behavioral: In-person Carbohydrate Counting Class|Behavioral: Online Carbohydrate Counting Tutorial,Change in Carbohydrate Counting Accuracy Measured Using a Standardized Meal & Snack Tray Test at Baseline and 3-months Post-Education|Change in Carbohydrate Counting Knowledge Tested Using the PedCarbQuiz (PCQ) at Baseline and 3-months Post-Education,The Hospital for Sick Children|The Lawson Foundation,All,12 Years to 17 Years   (Child),Not Applicable,48,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,1000042623,Jul-14,Apr-16,Sep-16,4-Jun-15,null,17-Nov-17,"The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02462785
NCT02463097,Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes,,Completed,Has Results,Type 1 Diabetes,Device: Insulin Pump,Change in A1C|Number of Severe Hypoglycemia Events|Number of Diabetic Ketoacidosis (DKA) Events,Medtronic Diabetes,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Not Applicable,124,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CEP 294,Jun-15,Mar-16,Oct-18,4-Jun-15,18-Apr-17,15-Apr-19,"AMCR Institute, Escondido, California, United States|Stanford University Medical Center, Palo Alto, California, United States|Barbara Davis Center for Childhood Diabetes (Adult), Aurora, Colorado, United States|Barbara Davis Center for Childhood Diabetes (Pediatric), Aurora, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Park Nicollet Clinic-International Diabetes Center - Adult and Pediatric, Minneapolis, Minnesota, United States|University of Virginia, Charlottesville, Virginia, United States|Rainer Clinical Research Center, Renton, Washington, United States|Institute of Endocrinology, Sheba Medical Center, Tel Aviv, Israel",,https://ClinicalTrials.gov/show/NCT02463097
NCT02463682,Early Feasibility Study of Zone-MPC and HMS With DiAs in the Outpatient Setting,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: CGM and Insulin Pump|Device: Closed-Loop Control System,"Safety and efficacy of the system, as assessed by the composite outcome of time in range for glucose levels of 70-180 mg/dL and time < 70 mg/dL.|Time in range for glucose 80-140 mg/dL|Time in range for glucose during the nocturnal period|Time in Range Postprandial|Markers of hypo- and hyperglycemia|Insulin Doses Given|Treatments for hypoglycemia|Number of alerts given by the HMS to prevent hypoglycemia|Outside interventions needed|Failure analysis of the devices/connectivity issues that may occur.","Sansum Diabetes Research Institute|University of California, Santa Barbara|Mayo Clinic|University of Virginia|University of Padova",All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,9,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,99796-JPIN,May-15,Oct-15,Oct-15,4-Jun-15,null,11-Apr-16,"William Sansum Diabetes Center, Santa Barbara, California, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02463682
NCT02460978,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,DEPICT 2,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Dapagliflozin|Other: Placebo for dapagliflozin,Adjusted Mean Change From Baseline in HbA1c at Week 24|Adjusted Mean Percentage Change From Baseline in Total Daily Insulin Dose at Week 24|Adjusted Mean Percentage Change From Baseline in Body Weight at Week 24|Adjusted Mean Change From Baseline in 24-hour Continuous Glucose Monitoring (CGM) Mean Value at Week 24|Adjusted Mean Change From Baseline in 24-hour CGM Mean Amplitude of Glycemic Excursion (MAGE) Value at Week 24|Change From Baseline in the Percent of 24-hour Glucose Readings Obtained From CGM That Falls Within the Target Range of > 70 mg/dL and <= 180 mg/dL (%) at Week 24|Percentage of Subjects With HbA1c Reduction From Baseline to Week 24 Last Observation Carried Forward (LOCF) >= 0.5% and Without Severe Hypoglycemia Events at Week 24,AstraZeneca|Bristol-Myers Squibb,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,815,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MB102-230|2014-004599-49|D1695C00007,8-Jul-15,2-Sep-17,18-Apr-18,3-Jun-15,6-Nov-18,5-Mar-19,"Research Site, Concord, California, United States|Research Site, Fresno, California, United States|Research Site, Los Angeles, California, United States|Research Site, Orange, California, United States|Research Site, San Mateo, California, United States|Research Site, San Ramon, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Golden, Colorado, United States|Research Site, Newark, Delaware, United States|Research Site, Bradenton, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami Springs, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Roswell, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Des Moines, Iowa, United States|Research Site, Overland Park, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Lexington, Kentucky, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Edina, Minnesota, United States|Research Site, Jefferson City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Reno, Nevada, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Albany, New York, United States|Research Site, Flushing, New York, United States|Research Site, Mineola, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, New York, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Amarillo, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Edinburg, Texas, United States|Research Site, Mesquite, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Bennington, Vermont, United States|Research Site, Federal Way, Washington, United States|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Corrientes, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Ramos Mejía, Argentina|Research Site, Brussels (Uccle), Belgium|Research Site, Leuven, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Smiths Falls, Ontario, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Temuco, Chile|Research Site, Dresden, Germany|Research Site, Essen, Germany|Research Site, Falkensee, Germany|Research Site, Freiburg im Breisgau, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Oldenburg, Germany|Research Site, Pohlheim, Germany|Research Site, Saarlouis, Germany|Research Site, Sulzbach-Rosenberg, Germany|Research Site, Wangen, Germany|Research Site, Aki-gun, Japan|Research Site, Amagasaki-shi, Japan|Research Site, Chitose-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukuyama-shi, Japan|Research Site, Higashiosaka-shi, Japan|Research Site, Ibusuki-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kamakura-shi, Japan|Research Site, Kashiwara-shi, Japan|Research Site, Kitakyushu-shi, Japan|Research Site, Koriyama-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kurume-shi, Japan|Research Site, Miura-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Obihiro-shi, Japan|Research Site, Oita-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Oyama-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Shibuya-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Shizuoka-shi, Japan|Research Site, Tsukuba-shi, Japan|Research Site, Ushiku-shi, Japan|Research Site, Uwajima-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Hoogeveen, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Białystok, Poland|Research Site, Białystok, Poland|Research Site, Gdańsk, Poland|Research Site, Krakow, Poland|Research Site, Kraków, Poland|Research Site, Kraków, Poland|Research Site, Lublin, Poland|Research Site, Warsaw, Poland|Research Site, Wroclaw, Poland|Research Site, Novosibirsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, Göteborg, Sweden|Research Site, Helsingborg, Sweden|Research Site, Linkoping, Sweden|Research Site, Uddevalla, Sweden|Research Site, Olten, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Zollikerberg, Switzerland|Research Site, Manchester, United Kingdom|Research Site, Northampton, United Kingdom|Research Site, Oldham, United Kingdom|Research Site, Swansea, United Kingdom|Research Site, Wakefield, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02460978/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02460978/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02460978
NCT02459899,Dose-ranging Study in Patients With Type 1 Diabetes Mellitus,inTandem4,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Placebo|Drug: Sotagliflozin,Change from Baseline to Week 12 in A1C|Change from Baseline to Week 12 in 2-hour PPG|Change from Baseline to Week 12 in Body Weight|Change from Baseline to Week 12 in UGE|Change from Baseline to Week 12 in FPG,Sanofi|Lexicon Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 2,141,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LX4211.1-206-T1DM|LX4211.206,Jul-15,Aug-16,Aug-16,2-Jun-15,null,26-Dec-17,"Lexicon Investigational Site, Concord, California, United States|Lexicon Investigational Site, Ventura, California, United States|Lexicon Investigational Site, Denver, Colorado, United States|Lexicon Investigational Site, Jacksonville, Florida, United States|Lexicon Investigational Site, Miami, Florida, United States|Lexicon Investigational Site, Metairie, Louisiana, United States|Lexicon Investigational Site, Auburn, Maine, United States|Lexicon Investigational Site, Rockville, Maryland, United States|Lexicon Investigational Site, Great Falls, Montana, United States|Lexicon Investigational Site, Omaha, Nebraska, United States|Lexicon Investigational Site, High Point, North Carolina, United States|Lexicon Investigational Site, Columbus, Ohio, United States|Lexicon Investigational Site, San Antonio, Texas, United States|Lexicon Investigational Site, Salt Lake City, Utah, United States|Lexicon Investigational Site, Manassas, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02459899
NCT02459938,Safety and Efficacy of ZP-Glucagon to Injectable Glucagon for Hypoglycemia,,Completed,No Results Available,Hypoglycemia,Drug: Glucagon (ZP-Glucagon)|Drug: Glucagon (GlucaGen),Percentage of subjects achieving normoglycemia|Time at which normoglycemia is first reached|Time at which maximal glucose levels are reached|Increases in blood glucose by 15 minute intervals|Peak Plasma Concentration (Cmax)|Area under the plasma concentration versus time curve (AUC),Zosano Pharma Inc.|Zosano Pharma Corporation,All,18 Years to 60 Years   (Adult),Phase 1,16,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CP-2014-004,Jan-15,Aug-15,Oct-15,2-Jun-15,null,16-Aug-16,"Nucleus Network, Melbourne, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT02459938
NCT02457858,Islet Isolation Using MnTE-2-PyP (BMX-010) - Pilot Study,,Completed,No Results Available,Type 1 Diabetes,Drug: Islet isolation using BMX-010,"Islet yield using BMX-010, compared to current standard islet isolation data|Islet isolation quantity and quality using BMX-010, compared to current standard islet isolation data|AE/SAE morbidity within 1 month post-transplant","University of Alberta|BioMimetix Pharmaceutical, Inc.",All,"18 Years to 68 Years   (Adult, Older Adult)",Phase 1,5,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00045961,Aug-14,Aug-16,Aug-16,29-May-15,null,30-Sep-16,"University of Alberta, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT02457858
NCT02445508,Effect of Bile Acid Secretion and Sequestration on GLP-1 Secretion,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Sevelamer|Drug: Cholecystokinin|Drug: Sevelamer placebo|Drug: Isotonic saline,Glucagon-like peptide-1 (GLP-1): Incremental and total area under the Concentration-Time Curve|Responses of various other gut hormones: Incremental and total area under the Concentration-Time Curve|Blood analysis of paracetamol as an assessment of gastric emptying|Indirect calorimetry: Basal metabolic rate|Gallbladder volume as assessed by Ultrasound measurements|Appetite as assessed by Visual analog scale score,"University Hospital, Gentofte, Copenhagen|Sanofi",All,"40 Years to 75 Years   (Adult, Older Adult)",Not Applicable,15,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",,May-15,Jul-16,Jul-16,15-May-15,null,3-May-17,"Center for Diabetes Research, Hellerup, Denmark",,https://ClinicalTrials.gov/show/NCT02445508
NCT02446054,A Study to Evaluate the Effect of Musashino Diabetes Diet in Type II Diabetes Mellitus Disease,,Completed,No Results Available,Type II Diabetes Mellitus,Dietary Supplement: Musashino T2DM diet,the change of glycosylated hemoglobin (HbA1c)|the change of patients' fasting blood Glucose|the change of patients' fasting serum Insulin|the change of patients' fasting serum C-peptide|the change of EuroQol EQ-5D questionnaire|the change of WHO‐QoL questionnaire|the patients' compliance questionnaire,Celio Technology Inc.,All,30 Years to 60 Years   (Adult),Not Applicable,30,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013CMP-V2,Feb-14,Sep-15,Dec-15,15-May-15,null,28-Jan-16,"NTUH, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT02446054
NCT02443532,Effects of Structured Group Education on Quality of Life and Glycemic Control in Type 1 Diabetes,,Terminated,No Results Available,"Diabetes Mellitus, Type 1",Behavioral: Structured group education|Behavioral: Individual education,"HbA1c (between-group difference in variation from baseline)|Quality of life (Well-being enquiry in Diabetics [WED] questionnaire)|Treatment satisfaction (Diabetes Treatment Satisfaction [DTS] questionnaire)|Fear of hypoglycemia (Fear of Hypoglycemia [FH-15] questionnaire)|Severe hypoglycemia (incidence of episodes of hypoglycemia requiring hospitalization and/or help from third parties, self-reported)",Azienda Ospedaliero-Universitaria Careggi,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,72,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DIAB120001,Mar-12,8-Jan-18,8-Jan-18,14-May-15,null,4-Jun-18,,,https://ClinicalTrials.gov/show/NCT02443532
NCT02442544,Prebiotic Fiber Supplement in T1DM Children,,"Active, not recruiting",No Results Available,Type 1 Diabetes,Dietary Supplement: Prebiotic|Dietary Supplement: Placebo,Glycemic control (serum hemoglobin A1c)|Gut microbiota composition (mRNA in stool)|Glycemic control (as measured by serum hemoglobin A1c),University of Calgary,All,8 Years to 17 Years   (Child),Early Phase 1,38,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",OFSDM1,Sep-15,Jun-18,Dec-19,13-May-15,null,18-Apr-19,"Alberta Children's Hospital, Calgary, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT02442544
NCT02443155,A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: NNC0114-0006|Drug: liraglutide|Drug: placebo,"Area under the curve (AUC)0-4h mixed meal tolerance test(MMTT) stimulated C-peptide concentration-time curve|Number of treatment emergent episodes of diabetic ketoacidosis (DKA)|Number of treatment emergent hypoglycaemic episodes according to the American Diabetes Association (ADA) and Novo Nordisk definitions|Area under the curve 0-4h for MMTT (mixed meal tolerance test) stimulated C-peptide concentration time curve|Area under the curve 0-2h for MMTT stimulated C-peptide concentration time curve|Maximum MMTT stimulated C-peptide concentration (Cmax, C-peptide)|Change in fasting C-peptide|Change in HbA1c (Glycosylated haemoglobin))|Change in fasting plasma glucose|Total daily insulin dose in units per kg (three day average)",Novo Nordisk A/S,All,18 Years to 45 Years   (Adult),Phase 2,308,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN9828-4150|2014-001215-39|U1111-1154-7172|REec-2015-1768,10-Nov-15,31-Aug-18,27-Feb-19,13-May-15,null,29-Mar-19,"Novo Nordisk Investigational Site, La Jolla, California, United States|Novo Nordisk Investigational Site, Northridge, California, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Teaneck, New Jersey, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Mesquite, Texas, United States|Novo Nordisk Investigational Site, Graz, Austria|Novo Nordisk Investigational Site, Innsbruck, Austria|Novo Nordisk Investigational Site, Salzburg, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Brussels, Belgium|Novo Nordisk Investigational Site, Edegem, Belgium|Novo Nordisk Investigational Site, Leuven, Belgium|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Vancouver, British Columbia, Canada|Novo Nordisk Investigational Site, Winnipeg, Manitoba, Canada|Novo Nordisk Investigational Site, Halifax, Nova Scotia, Canada|Novo Nordisk Investigational Site, Kingston, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Laval, Quebec, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Sherbrooke, Quebec, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Aarhus N, Denmark|Novo Nordisk Investigational Site, Esbjerg, Denmark|Novo Nordisk Investigational Site, Hellerup, Denmark|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Oulu, Finland|Novo Nordisk Investigational Site, Tampere, Finland|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Galway, Ireland|Novo Nordisk Investigational Site, Holon, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Petah Tikva, Israel|Novo Nordisk Investigational Site, Rehovot, Israel|Novo Nordisk Investigational Site, Bergamo, Italy|Novo Nordisk Investigational Site, Catanzaro, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Siena, Italy|Novo Nordisk Investigational Site, Oslo, Norway|Novo Nordisk Investigational Site, Stavanger, Norway|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Zabrze, Poland|Novo Nordisk Investigational Site, Almada, Portugal|Novo Nordisk Investigational Site, Amadora, Portugal|Novo Nordisk Investigational Site, Braga, Portugal|Novo Nordisk Investigational Site, Matosinhos, Portugal|Novo Nordisk Investigational Site, Porto, Portugal|Novo Nordisk Investigational Site, Viana do Castelo, Portugal|Novo Nordisk Investigational Site, Arkhangelsk, Russian Federation|Novo Nordisk Investigational Site, Chelyabinsk, Russian Federation|Novo Nordisk Investigational Site, Dzerzhinskiy, Russian Federation|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Penza, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Syktyvkar, Russian Federation|Novo Nordisk Investigational Site, Ulianovsk, Russian Federation|Novo Nordisk Investigational Site, Yoshkar-Ola, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Kragujevac, Serbia|Novo Nordisk Investigational Site, Barcelona, Spain|Novo Nordisk Investigational Site, Girona, Spain|Novo Nordisk Investigational Site, Málaga, Spain|Novo Nordisk Investigational Site, Palma de Mallorca, Spain|Novo Nordisk Investigational Site, Sabadell, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Valencia, Spain|Novo Nordisk Investigational Site, Göteborg, Sweden|Novo Nordisk Investigational Site, Karlstad, Sweden|Novo Nordisk Investigational Site, Lund, Sweden|Novo Nordisk Investigational Site, Stockholm, Sweden|Novo Nordisk Investigational Site, Kiev, Ukraine|Novo Nordisk Investigational Site, Kiev, Ukraine|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Vinnytsia, Ukraine|Novo Nordisk Investigational Site, Zhytomyr, Ukraine|Novo Nordisk Investigational Site, Belfast, United Kingdom|Novo Nordisk Investigational Site, Blackburn, United Kingdom|Novo Nordisk Investigational Site, Bristol, United Kingdom|Novo Nordisk Investigational Site, Cardiff, United Kingdom|Novo Nordisk Investigational Site, Chester, United Kingdom|Novo Nordisk Investigational Site, Edgbaston, Birmingham, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Newcastle upon Tyne, United Kingdom|Novo Nordisk Investigational Site, Plymouth, United Kingdom|Novo Nordisk Investigational Site, Sheffield, United Kingdom|Novo Nordisk Investigational Site, Stevenage, United Kingdom|Novo Nordisk Investigational Site, Swansea, United Kingdom",,https://ClinicalTrials.gov/show/NCT02443155
NCT02441504,Effects of Low Intensity Aerobic Exercise on the Microvascular Endothelial Function of Patients With Type 1 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Other: Low intensity Exercise,Change in Cutaneous Capillary Density in twelve weeks of aerobic physical activity,Instituto Nacional de Cardiologia de Laranjeiras|Rio de Janeiro State University,Male,25 Years to 50 Years   (Adult),Not Applicable,22,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,1988-CEP/HUPE,Jan-14,Sep-14,Oct-14,12-May-15,null,13-May-15,,,https://ClinicalTrials.gov/show/NCT02441504
NCT02438189,Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms,PHM2,Completed,No Results Available,Type 1 Diabetes,Device: Hyperglycemia Minimization Algorithm,Comparison of percent time in range overnight between the two treatment arms|Mean CGM glucose overnight|Percentage of time spent with CGM <50 mg/dL (2.8 mmol/L)|Percentage of time spent with CGM <60 mg/dL (3.3 mmol/L)|Percentage of time spent with CGM <70 mg/dL (3.9 mmol/L)|Percentage of time spent with CGM >180 mg/dL (10.0 mmol/L)|Percentage of time spent with CGM >250 mg/dL (13.9 mmol/L)|Percentage of time spent with CGM >300 mg/dL (16.7 mmol/L)|Percentage of nights with >30 min and >60 min consecutive CGM values <50 mg/dL (2.8 mmol/L)|Percentage of nights with >30 min and >60 min consecutive CGM values <60 mg/dL (3.3 mmol/L)|Percentage of nights with >30 min and >60 min consecutive CGM values <70 mg/dL (3.9 mmol/L)|Glucose coefficient of variation (CV)|Amount of total insulin boluses|Mean home glucose meter morning glucose|Morning glucose measured with home glucose meter >250 mg/dL (13.9 mmol/L)|Mean sensor glucose over 24 hours|Mean sensor glucose 4 hours post system deactivation|Percentage of sensor glucose values 70 to 180 mg/dL (3.9 to 10.0 mmol/L) overnight|Percentage of sensor glucose values 70 to 180 mg/dL (3.9 to 10.0 mmol/L) 4 hours after system deactivation|Percentage of sensor glucose values 70 to 180 mg/dL (3.9 to 10.0 mmol/L) over 24 hours|Change in HbA1c from clinical baseline to study completion,Jaeb Center for Health Research|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"15 Years to 45 Years   (Child, Adult)",Phase 2,33,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,PHM2|RFA-DK-08-012|5R01DK085591-05,Jun-15,Mar-16,Mar-16,8-May-15,null,29-Aug-16,"Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|St. Joseph's Health Care, London, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02438189
NCT02438670,MPC Versus PID for Closed Loop Insulin Delivery,,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: PID control algorithm|Device: MPC control algorithm,Time spent in safe blood glucose range|Glucose level extremes and need for outside intervention,"Sansum Diabetes Research Institute|University of California, Santa Barbara",All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13-68u,May-15,Sep-15,Sep-15,8-May-15,null,22-Jul-16,"William Sansum Diabetes Center, Santa Barbara, California, United States",,https://ClinicalTrials.gov/show/NCT02438670
NCT02432586,Pilot Study: Intensive Education in a Residential Camp Setting for Families of Young Children With Type 1 Diabetes,TotCamp,Completed,No Results Available,Type 1 Diabetes Mellitus,Behavioral: Intensive Education,"Change in Hemoglobin A1c one month pre-camp to one month post-camp Session 1|Change in Hemoglobin A1c one month pre-camp to one month post-camp Session 2|Change in Hypoglycemia frequency one month pre-camp to one month post-camp Session 1|Change in Hypoglycemia frequency one month pre-camp to one month post-camp Session 2|Medical system utilization ( emergency room visits, hospitalizations related to T1DM)|Change in PedsQL Family Impact Module one month pre-camp to one month post-camp Session 1|Change in PedsQL Family Impact Module one month pre-camp to one month post-camp Session 2|Change in PedsQL Pediatric Quality of Life Inventory one month pre-camp to one month post-camp Session 1|Change in PedsQL Pediatric Quality of Life Inventory one month pre-camp to one month post-camp Session 2|Change in PedsQL Diabetes Module one month pre-camp to one month post-camp Session 1|Change in PedsQL Diabetes Module one month pre-camp to one month post-camp Session 2|Change in Hypoglycemia Fear Survey one month pre-camp to one month post-camp Session 1|Change in Hypoglycemia Fear Survey one month pre-camp to one month post-camp Session 2|Change in Behavioral Pediatrics Feeding Assessment one month pre-camp to one month post-camp Session 1|Change in Behavioral Pediatrics Feeding Assessment one month pre-camp to one month post-camp Session 2",University of Texas Southwestern Medical Center,All,34 Months to 68 Months   (Child),Not Applicable,18,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,STU 042014-061,Jul-14,Aug-16,Jan-17,4-May-15,null,23-Jun-17,,,https://ClinicalTrials.gov/show/NCT02432586
NCT02430870,TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus,,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: TAK-648|Drug: Placebo,Percentage of Participants Who Have at Least 1 Treatment-Emergent Adverse Event (TEAE) for Part 1|Percentage of Participants Who Have at Least 1 Treatment-Emergent Adverse Event (TEAE) for Part 2|Percentage of Participants With Markedly Abnormal Laboratory Values at Least Once Post-dose During Dosing for Part 1|Percentage of Participants With Markedly Abnormal Laboratory Values at Least Once Post-dose During Dosing for Part 2|Percentage of Participants With Markedly Abnormal Vital Sign Values at Least Once Post-dose During Dosing for Part 1|Percentage of Participants With Markedly Abnormal Vital Sign Values at Least Once Post-dose During Dosing for Part 2|Percentage of Participants Who Have Severe Hypoglycemia at Least Once Post-dose During Dosing For Part 1|Percentage of Participants Who Have Severe Hypoglycemia at Least Once Post-dose During Dosing For Part 2|Cmax: Maximum Plasma Concentration for TAK-648 for Part 1|Cmax: Maximum Plasma Concentration for TAK-648 for Part 2|Tmax: Time to Reach Maximum Plasma Concentration (Tmax) for TAK-648 for Part 1|Tmax: Time to Reach Maximum Plasma Concentration (Tmax) for TAK-648 for Part 2|AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-648 for Part 1|AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-648 for Part 2|AUC∞: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for TAK-648 for Part 1|AUC∞: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for TAK-648 for Part 2|AUCtau: Area Under the Plasma Concentration-time Curve From Time 0 Over the Dosing Interval for TAK-648 for Part 1|AUCtau: Area Under the Plasma Concentration-time Curve From Time 0 Over the Dosing Interval for TAK-648 for Part 2,Takeda,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,48,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAK-648-1002|U1111-1165-3437,Apr-15,Sep-15,Nov-15,30-Apr-15,31-Aug-16,31-Aug-16,"Anaheim, California, United States|Chula Vista, California, United States",,https://ClinicalTrials.gov/show/NCT02430870
NCT02423993,Education Effectiveness for Type 1 Diabetes Mellitus on Insulin Pump Therapy,EASEDIAP,Completed,Has Results,"Diabetes Mellitus, Type 1",Behavioral: Education by structured programme|Device: CSII|Device: CGM-RT|Procedure: Screening for Complications|Procedure: Glycaemic control assessment|Procedure: QoL assessment|Procedure: Knowledge assessment,HbA1c|Severe Hypoglycaemia Frequency|Quality of Life (ADDQoL Questionnaire)|Nonsevere Hypoglycaemia Frequency|Glycaemic Variability|Treatment Compliance ( Frequency of SMBG and Bolus Calculator Use)|Quality of Life (SF36 Questionnaire),"Endocrinology Research Centre, Moscow",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,77,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,101-01-2010,Oct-09,Oct-12,Feb-13,22-Apr-15,11-Jan-16,11-Jan-16,,,https://ClinicalTrials.gov/show/NCT02423993
NCT02422043,Description of Socio-cognitive and Clinic Changes for Type 1 Diabetes Adolescents Cohort With Therapeutic Patient Education Program,,Unknown status,No Results Available,Type 1 Diabetes,Other: Questionnaires and audio-tape interviews,self-efficacy (Self-efficacy of Diabetes Management)|Quality of life (KIDSCREEN-27)|Adherence (Diabetes Self-Management Profile)|glycated hemoglobin (HbA1c)|socio-cognitive profile,Assistance Publique Hopitaux De Marseille,All,12 Years to 17 Years   (Child),Not Applicable,80,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),2014-28,Jan-15,Jan-17,Jan-18,21-Apr-15,null,23-Oct-15,"Hôpital de la Timone Assistance Publique Hôpitaux de Marseille, Marseille, France",,https://ClinicalTrials.gov/show/NCT02422043
NCT02421510,"Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy",inTandem2,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Sotagliflozin|Drug: Placebo,Change from Baseline to Week 24 in A1C|Change from Baseline in proportion of patients with A1C <7.0%|Change from Baseline in body weight|Mean change from Baseline in mean daily bolus insulin dose|Change from Baseline in fasting plasma glucose (FPG),Sanofi|Lexicon Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,782,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LX4211.1-310-T1DM|LX4211.310|2014-005153-39,May-15,Nov-16,Jul-17,20-Apr-15,null,26-Dec-17,"Lexicon Investigational Site, Vienna, Austria|Lexicon Investigational Site, Vienna, Austria|Lexicon Investigational Site, Vienna, Austria|Lexicon Investigational Site, Vienna, Austria|Lexicon Investigational Site, Brussels, Belgium|Lexicon Investigational Site, Leuven, Belgium|Lexicon Investigational Site, Sint Niklaas, Belgium|Lexicon Investigational Site, Wilrijk, Belgium|Lexicon Investigational Site, Sofia, Bulgaria|Lexicon Investigational Site, Beziers, France|Lexicon Investigational Site, Dijon cedex, France|Lexicon Investigational Site, Nantes, France|Lexicon Investigational Site, Nîmes, France|Lexicon Investigational Site, Duesseldorf, Germany|Lexicon Investigational Site, Hamburg, Germany|Lexicon Investigational Site, Hamburg, Germany|Lexicon Investigational Site, Hannover, Germany|Lexicon Investigational Site, Mainz, Germany|Lexicon Investigational Site, Muenster, Germany|Lexicon Investigational Site, Neuwied, Germany|Lexicon Investigational Site, Budapest, Hungary|Lexicon Investigational Site, Budapest, Hungary|Lexicon Investigational Site, Budapest, Hungary|Lexicon Investigational Site, Budapest, Hungary|Lexicon Investigational Site, Budapest, Hungary|Lexicon Investigational Site, Gyula, Hungary|Lexicon Investigational Site, Hodmezovasarhely, Hungary|Lexicon Investigational Site, Zalaegerszeg, Hungary|Lexicon Investigational Site, Haifa, Israel|Lexicon Investigational Site, Jerusalem, Israel|Lexicon Investigational Site, Petah Tikva, Israel|Lexicon Investigational Site, Tel Aviv, Israel|Lexicon Investigational Site, Tel Hashomer, Israel|Lexicon Investigational Site, Tzrifin, Israel|Lexicon Investigational Site, Catania, Italy|Lexicon Investigational Site, Milano, Italy|Lexicon Investigational Site, Palermo, Italy|Lexicon Investigational Site, Perugia, Italy|Lexicon Investigational Site, Pisa, Italy|Lexicon Investigational Site, Jonava, Lithuania|Lexicon Investigational Site, Kaunas, Lithuania|Lexicon Investigational Site, Kaunas, Lithuania|Lexicon Investigational Site, Klaipeda, Lithuania|Lexicon Investigational Site, Bratislava, Slovakia|Lexicon Investigational Site, Bratislava, Slovakia|Lexicon Investigational Site, Kosice, Slovakia|Lexicon Investigational Site, Nové Zámky, Slovakia|Lexicon Investigational Site, Vrutky, Slovakia|Lexicon Investigational Site, Štúrovo, Slovakia|Lexicon Investigational Site, Barcelona, Spain|Lexicon Investigational Site, Barcelona, Spain|Lexicon Investigational Site, Granada, Spain|Lexicon Investigational Site, Málaga, Spain|Lexicon Investigational Site, Sevilla, Spain|Lexicon Investigational Site, Sevilla, Spain|Lexicon Investigational Site, Sevilla, Spain|Lexicon Investigational Site, Valencia, Spain|Lexicon Investigational Site, Härnösand, Sweden|Lexicon Investigational Site, Kristianstad, Sweden|Lexicon Investigational Site, Stockholm, Sweden|Lexicon Investigational Site, St. Gallen, Switzerland|Lexicon Investigational Site, Blackburn, United Kingdom|Lexicon Investigational Site, Bristol, United Kingdom|Lexicon Investigational Site, Glasgow, United Kingdom|Lexicon Investigational Site, Leicester, United Kingdom|Lexicon Investigational Site, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT02421510
NCT02416765,Closed-loop Control of Postprandial Glucose Levels in Adults With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,"Other: 15-hour intervention|Drug: Insulin (Lispro, Aspart or guilisine)|Drug: Glucagon (Eli Lilly)|Other: Closed-loop strategy",Mean glucose levels as measured by the glucose sensor.|Mean glucose levels as measured by the glucose sensor|Percentage of time of sensor glucose concentrations between 4 and 8 mmol/L|Percentage of time of sensor glucose concentrations between 4 and 10 mmol/L|Percentage of time of sensor glucose concentrations above 10 mmol/L|Percentage of time of sensor glucose concentrations above 14 mmol/L|Percentage of time of glucose levels spent below 4 mmol/L|Percentage of time of glucose levels spent below 3.1 mmol/L|Area under the curve of glucose values below 4 mmol/L|Area under the curve of glucose values below 3.1 mmol/L|Number of patients with at least one hypoglycemic event below 3.1 mmol/L with or without symptoms|Total number of hypoglycemic event below 3.1 mmol/L|Total insulin delivery|Total glucagon delivery|Standard deviation of glucose levels|Total carbohydrate intake,Institut de Recherches Cliniques de Montreal,All,"18 Years and older   (Adult, Older Adult)",Phase 2,15,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLASS10,May-15,Oct-15,Oct-15,15-Apr-15,null,16-Nov-15,"Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02416765
NCT02414958,Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2),,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Empagliflozin|Drug: Placebo,Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26|Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD) )|Rate Per Patient-year of Investigator-reported Symptomatic Hypoglycaemia Adverse Events (AEs) With Confirmed Plasma Glucose (PG)|Change From Baseline in Body Weight at Week 26|Change From Baseline in Percentage of Time Spent in Target Glucose Range From Weeks 23 to 26|Change From Baseline in Interstitial Glucose Variability Based on the Interquartile Range (IQR) as Determined by CGM in Weeks 23 to 26|Change From Baseline in Total Daily Insulin Dose (TDID) at Week 26|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 26,Boehringer Ingelheim|Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,730,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,1245.69|2014-001922-14,30-Jun-15,20-Apr-17,23-Oct-17,13-Apr-15,20-Nov-18,3-Jan-19,"AMCR Institute, Inc., Escondido, California, United States|Diabetes/Lipid Management and Research Center, Huntington Beach, California, United States|National Research Institute, Los Angeles, California, United States|Mills-Peninsula Health Services, San Mateo, California, United States|Metabolic Institute of America, Tarzana, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|Creekside Endocrine Associates, PC, Denver, Colorado, United States|The Center for Diabetes and Endocrine Care, Fort Lauderdale, Florida, United States|East Coast Institute for Research, LLC, Jacksonville, Florida, United States|Baptist Diabetes Associates, PA, Miami, Florida, United States|Physicians Research Associates, LLC, Lawrenceville, Georgia, United States|Endocrine Research Solutions, Inc., Roswell, Georgia, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Northwest Endo Diabetes Research, LLC, Arlington Heights, Illinois, United States|Midwest Endocrinology, Crystal Lake, Illinois, United States|Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa, United States|Diabetes anddocrine Associates, PC, Omaha, Nebraska, United States|Desert Endocrinology Clinical Research Center, Henderson, Nevada, United States|Palm Research Center, Las Vegas, Nevada, United States|Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, United States|Albany Medical Center / Albany Medical College, Albany, New York, United States|University Physicians Group Research Division, Staten Island, New York, United States|Diabetes and Endocrinology Consultants, PC, Morehead City, North Carolina, United States|The Carl and Edyth Lindner Center for Research & Education at The Christ Hospital, Cincinnati, Ohio, United States|Diabetes and Obesity Clinical Trials Center, Nashville, Tennessee, United States|North Texas Endocrine Center, Dallas, Texas, United States|Office of Dr. Michelle Zaniewski-Singh, Houston, Texas, United States|Texas Diabetes and Endocrinology, Round Rock, Texas, United States|Bateman Horne Center, Salt Lake City, Utah, United States|Advanced Research Institute, South Ogden, Utah, United States|Larry D Stonesifer, MD Inc., PS, Federal Way, Washington, United States|Rainier Clinical Research Center, Inc, Renton, Washington, United States|The Polyclinic, Seattle, Washington, United States|MultiCare Institute for Research and Innovation, Tacoma, Washington, United States|Coffs Endocrine & Diabetes Services, Coffs Harbour, New South Wales, Australia|AIM Centre, Merewether, New South Wales, Australia|Royal Brisbane & Women's Hospital-Endocrinology, Herston, Queensland, Australia|VIVIT Instit.am LKH Feldkirch,Abt.f.Innere Med.u.Kardiologie, Feldkirch, Austria|LKH Steyr, Kardiologie, Steyr, Austria|KH Rudolfstiftung, 1. Med. Abt., Wien, Wien, Austria|Hospital Hietzing, Wien, Austria|Arlon - HOSP Sud Luxembourg - Vivalia, Arlon, Belgium|Bonheiden - HOSP Imelda, Bonheiden, Belgium|Brussels - UNIV UZ Brussel, Brussel, Belgium|ULB Hopital Erasme, Bruxelles, Belgium|Edegem - UNIV UZ Antwerpen, Edegem, Belgium|UNIV UZ Gent, Gent, Belgium|La Louvière - UNIV CHU Tivoli, La Louvière, Belgium|UZ Leuven, Leuven, Belgium|Centre Hospitalier Universitaire de Liège, Liège, Belgium|Liège - HOSP CHR de la Citadelle, Liège, Belgium|Merksem - HOSP ZNA Jan Palfijn, Merksem, Belgium|LMC Endocrinology Centres (Calgary) Ltd., Calgary, Alberta, Canada|The Bailey Clinic, Red Deer, Alberta, Canada|Royal Jubilee Hospital, Victoria, British Columbia, Canada|Health Sciences Centre Winnipeg, Winnipeg, Manitoba, Canada|CHUM - Pavillon R, Montreal, Migration Data, Canada|Capital District Health Auth., Halifax, Nova Scotia, Canada|Kingston General Hospital, Kingston, Ontario, Canada|LMC Thornhill/Vaughan, Thornhill, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada|General Univ.hosp.in Prague (VFN), Diabetes ambulance, Praha 2, Czechia|Diabetology and Internal Practice Dr. Vladimir Lelek, Slany, Czechia|Masaryk Hospital, Internal Department, Usti nad Labem, Czechia|Aalborg Sygehus Syd, Aalborg, Denmark|Aarhus Universitets Hospital, Aarhus C, Denmark|Steno Diabetes Center Copenhagen, Gentofte, Denmark|Nordsjællands Hospital - Hillerød, Hillerød, Denmark|Køge Sygehus, Køge, Denmark|IteLasaretti, Kuopio, Finland|Terveystalo Oulu, Diapolis, Oulu, Finland|TYKS, Turku, Finland|HOP Côte de Nacre, Caen, France|HOP Saint-Louis, La Rochelle Cedex 1, France|HOP de Narbonne, diabéto endo, Narbonne, Narbonne, France|HOP Robert Debré, Reims, France|HOP de Brabois, Vandoeuvre-lès-Nancy, France|HOP les Portes du Sud, Diabéto, Vénissieux, Vénissieux, France|Studienzentrum Aschaffenburg, Aschaffenburg, Germany|Gemeinschaftspraxis, Asslar, Asslar, Germany|ikfe - Institut für klinische Forschung und Entwicklung Berlin GmbH, Berlin, Germany|InnoDiab Forschung GmbH, Essen, Germany|Praxis Dr. Kosch, Pirna, Pirna, Germany|Allgemeinmedizinische und Diabetologische Schwerpunktpraxis, Rehlingen-Siersburg, Germany|Praxis Dr. Hirschhäuser, Saarbrücken, Germany|Praxis Dr. Segner, St. Ingbert, Saint Ingbert/Oberwürzbach, Germany|Ambulanzzentrum Schweinfurt, Schweinfurt, Germany|Noordwest Ziekenhuisgroep, Alkmaar, Netherlands|Academisch Medisch Centrum (AMC), Amsterdam, Netherlands|Rijnstate Hospital, Arnhem, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Bethesda Ziekenhuis Hoogeveen, Hoogeveen, Netherlands|Sint Franciscus Gasthuis, Rotterdam, Netherlands|Albert Schweitzer Ziekenhuis, Zwijndrecht, Zwijndrecht, Netherlands|Sykehuset Innlandet HF, Avd. Hamar, Hamar, Norway|Akershus Universitetssykehus HF, Lørenskog, Norway|Oslo Universitetssykehus HF, Aker Sykehus, Oslo, Norway|Helse Møre og Romsdal HF, Ålesund sjukehus, Ålesund, Norway|Med Univ Bialystok Clin Dep Endocrinol, Diabetol & Int Dis, Bialystok, Poland|NZOZ Specjalistyczny Osrodek Internistyczno-Diabetologiczny, Bialystok, Poland|Dobry Lekarz,Spec.Med.Clinics,Private Prac,Krakow, Krakow, Poland|NZOZ Specialized Ambulance ""MEDICA"", Lublin, Poland|Marcinkowski Poznan Univ of Med Sci, Clin Dept Diab, Poznan, Poznan, Poland|NZOZ Centrum Medyczne AESKULAP,Private Prac, Radom, Radom, Poland|Centrum Medyczne Medyk, Rzeszow, Poland|NBR Polska, Warsaw, Poland|C.A.P. Sardenya, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital de la Inmaculada Concepción, Granada, Spain|Hospital Virgen de la Victoria, Malaga, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Nuestra Señora de Valme, Sevilla, Spain|Hospital Virgen Macarena, Sevilla, Spain|Ladulaas Kliniska Studier, Borås, Sweden|Centralsjukhuset, Karlstad, Karlstad, Sweden|Läkarhuset, Vällingby, Vällingby, Sweden|Chung Shan Medical University Hospital, Taichung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Chi Mei Medical Center, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Milton Keynes Hospital, Buckinghamshire, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|Wellcome Trust Clinical Research Facility, Edinburgh, United Kingdom|Leicester General Hospital, Leicester, United Kingdom|Royal London Hospital, London, United Kingdom|Queen's Medical Centre, Nottingham, United Kingdom|George Eliot Hospital, Nuneaton, United Kingdom|East Surrey Hospital, Surrey, United Kingdom|Queen Elizabeth II Hospital, Welwyn Garden City, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT02414958/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT02414958/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02414958
NCT02411253,Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes,DIABIL-2,Recruiting,No Results Available,Type 1 Diabetes,Drug: rhIL-2|Drug: Placebo,"AUC (T0-T120) of serum C-peptide, determined after a mixed meal tolerance test at month 12, compared to baseline.|Serum concentrations of C-peptide|AUC (T0-T120) of serum C-peptide after a mixed meal tolerance test after treatment discontinuation|Diabetic monitoring (insulin use)|HbA1c and IDAA1c score|Number of hypoglycaemic episodes (< 0.5 g/L on capillary sample) over 15 days before each visit.|Number of clinically significant symptomatic episodes of hypoglycaemia between each visit.|Change in Tregs (expressed as percentage of CD4 and absolute numbers) at day 5 compared to baseline.|Change in trough level of Tregs (%CD4+ and absolute numbers) at month 1, month 3, month 6, month 9, month 12, compared to baseline; and then month 15 and 24 after treatment discontinuation.|Change in Foxp3 gene methylation|Cytokines and chemokines assays at day 5, month 1, month 3, month 6, month 9, and month 12 compared to baseline and then month 15 and month 24 after treatment discontinuation.|Transcriptome analysis.|Genotyping at baseline|Treg phenotype and functionality in adults and adolescents only including pStat5 analysis|Clinical examination.|Height/weight and pubertal stage especially for children and adolescents.|Routine laboratory tests|Haematology|Detection of IL-2 auto-antibodies|T cells repertory|Intestinal microbiota.|Adverse event.",Assistance Publique - Hôpitaux de Paris|Iltoo Pharma,All,"6 Years to 35 Years   (Child, Adult)",Phase 2,138,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P121001,Jun-15,Jul-19,Jul-21,8-Apr-15,null,18-Jan-19,"Pediatric Department, Centre Hospitalier Régional de la Citadelle, Liège, Province De Liège, Belgium|UZ - Diabetes voor Kinderen en Adolescenten-Leuven, Leuven, Belgium|CHU UCL Namur - site Godinne, Yvoir, Belgium|Centre d'Investigations Cliniques, CHU-HOPITAL HAUTEPIERRE, Strasbourg, Alsace, France|Centre d'Investigations Cliniques, HÔPITAL CIVIL, Strasbourg, Alsace, France|Service de pédiatrie 1CHU de HAUTEPIERRE, Strasbourg, Alsace, France|Structure d'Endocrinologie-Diabète-Nutrition et Addictologie HOPITAUX UNIVERSITAIRES NHC, Strasbourg, Alsace, France|Endocrinologie et diabétologie pédiatrique, Hôpital des Enfants - CHU-Bordeaux, Bordeaux, Aquitaine, France|Service d'endocrinologie, diabétologie, maladies métaboliques, et nutrition, CHU de Bordeaux, Hôpital Haut Levêque, Pessac, Aquitaine, France|Service d' Endocrinologie HOPITAL CAVALE BLANCHE, Brest, Brittany, France|Service de Pédiatrie, HOPITAL MORVAN, Brest, Brittany, France|Service de Pédiatrie CHRU DE NANTES, Nantes, Brittany, France|Service d' Endocrinologie Diabétologie CHRU DE RENNES, Rennes, Brittany, France|Médecine pédiatrique, CHU Jean Minjoz, Besançon, Franche-Compté, France|Service Diabétologie -Endocrinologie, CHU Jean Minjoz, Besançon, Franche-Comté, France|Service MME, ENDOCRINOLOGIE, GHU CAREMEAU, Nimes Cedex 9, Gard, France|CIC Paris-Est (Adultes), Hôpitaux Universitaires Pitié-Salpêtrière, Charles Foix, Paris, Ile De France, France|CIC pédiatrique Hôpital Necker Enfants Malades, Paris, Ile De France, France|Endocrinologie gynécologie diabétologie pédiatriques, Hôpital Universitaire Necker Enfants Malades., Paris, Ile De France, France|CIC Pédiatrique, Hôpital d'enfants Robert Debré, Paris, Ile De France, France|Institut E3M, Hôpital Pitié-Salpêtrière, Paris, Ile-de France, France|Service d'Endocrinologie Pédiatrique, Hôpital d'enfants Robert Debré, Paris, Ile-de France, France|Service de Diabétologie Endocrinologie Hôpital LARIBOISIERE, Paris, Ile-de-France, France|Service Pédiatrie - Pôle femmes enfants, CHU de Nîmes, Hôpital Universitaire Carémeau, Nïmes, Languedoc-Roussillon, France|Service Pédiatrie - Gastro-entérologie, Hépatologie, Nutrition, Diabétologie, Hôpital des Enfants Pôle Enfants, Toulouse, Midi Pyrénnées, France|CHRU de Lille, Hôpital Claude Huriez Service d'endocrinologie, Lille, Nord-Pas-de-Calais, France|Service d'endocrinologie-diabétologie gynécologie pédiatriques, CHRU de Lille, Hôpital Jeanne de Flandre,, Lille, Nord-Pas-de-Calais, France|Service d' Endocrinologie, maladies métaboliques HOPITAL NORD, Marseille, Paca, France|Service de Nutrition - Maladies Métaboliques - Endocrinologie HOPITAL DE LA CONCEPTION, Marseille, Paca, France|Hopital G&R Laënnec , Endocrinologie, Maladies Métaboliques et Nutrition, Saint Herblain, Pays De La Loire, France|Unité d'Endocrinologie et Diabétologie Pédiatriques, CHU de Marseille, Hôpital La Timone Enfants, Marseille, Provence-Alpes-Côte-d'Azur, France|Endocrinologie-Diabétologie-Maladies de la nutrition, Centre Hospitalier Lyon-Sud, Lyon, Rhones-Alpes, France|Service d'Endocrinologie pédiatrique - HFME, Bron, France|Division of Endocrinology and Diabetology, Department of Internal Medicine II, University Hospital of Freiburg, Freiburg, Baden-Württemberg, Germany|Division of Endocrinology, Diabetology and Metabolic Diseases, University Hospital of Freiburg, Department for children and adolescents, Freiburg, Baden-Württemberg, Germany|Institute of Diabetes Research, Helmholtz Zentrum München, München, Bayern, Germany|Institute of Diabetes Research, Helmholtz Zentrum München, München, Bayern, Germany|Center for Pediatric and Adolescent Diabetes Care and Research, Rotterdam, Randstad Holland, Netherlands|Dept. of Clinical Sciences Lund University, Skåne University Hospital., Malmö, Öresund Region, Sweden|Endocrinology and Diabetes department, University Hospital of Basel, Basel, Bâle-Ville, Switzerland",,https://ClinicalTrials.gov/show/NCT02411253
NCT02411578,Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: G-Pen Mini™ (glucagon injection)|Other: Glucose Tablets,"Number of Hypoglycemic Events ≥50 mg/dl 15 Minutes AND ≥ 70 mg/dl 30 Minutes After Initial Treatment|Continuous Glucose Monitor (CGM) Minimum Glucose, Event Level|CGM Maximum Glucose, Event Level|CGM Mean Glucose, Event Level|CGM Time in Range, Event Level|CGM Time Below 70 mg/dL, Event Level|CGM Minimum Glucose, Event Level|CGM Time Below 70 mg/dL|CGM Mean Glucose|CGM Time in Range|CGM Time Below 70|CGM Coefficient of Variation",Jaeb Center for Health Research|Xeris Pharmaceuticals,All,18 Years to 64 Years   (Adult),Phase 2,26,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,T1DX Mini-dose Non-Severe,Sep-15,Apr-16,May-16,8-Apr-15,23-Oct-17,27-Nov-17,"University of Colorado/Barbara Davis Center for Diabetes, Aurora, Colorado, United States|Yale University of Medicine, New Haven, Connecticut, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02411578
NCT02411929,A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020),,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Unlabeled ertugliflozin for oral use|Drug: 14^C-labeled ertugliflozin for IV use|Drug: 14^C-labeled ertugliflozin for oral use,"Area Under the Plasma Concentration-Time Profile From Time Zero to Time of the Last Quantifiable Concentration (AUC Last) (Dose Normalized to 1 mg) and Absolute Oral Bioavailability (F) (Period 1)|Area Under the Plasma Concentration-Time Profile From Time Zero to Time of the Last Quantifiable Concentration (AUC Last) Following Administration of Unlabeled Ertugliflozin 15 mg Oral + 14^C-Ert. 100 ug IV (Period 1) (Dose Not Normalized to 1 mg)|Pharmacokinetic Parameter: (AUC Inf) Following Administration of Unlabeled Ertugliflozin 15 mg Oral + 14^C-Ertugliflozin 100 ug IV (Period 1)|Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) Following Administration of Unlabeled Ertugliflozin 15 mg Oral + 14^C-Ertugliflozin 100 ug IV (Period 1) (Dose Normalized to 1 mg)|Pharmacokinetic Parameter: Time for Cmax (Tmax) Following Administration of Unlabeled Ertugliflozin 15 mg Oral + 14^C-Ertugliflozin 100 ug IV (Period 1)|Pharmacokinetic Parameter: Terminal Elimination Half-Life (t1/2) Following Administration of Unlabeled Ertugliflozin 15 mg Oral + 14^C-Ertugliflozin 100 ug IV (Period 1)|Pharmacokinetic Parameter: Apparent Oral Total Plasma Clearance (CL/F) - Oral, Following Administration of Unlabeled Ertugliflozin 15 mg Oral + 14^C-Ertugliflozin 100 ug IV (Period 1)|Pharmacokinetic Parameter: Systemic IV Total Plasma Clearance (CL) - IV, Following Administration of Unlabeled Ertugliflozin 15 mg Oral + 14^C-Ertugliflozin 100 ug IV (Period 1)|Pharmacokinetic Parameter: Apparent Volume of Distribution (Vz/F) Following Oral Administration - Oral, Following Administration of Unlabeled Ertugliflozin 15 mg Oral + 14^C-Ertugliflozin 100 ug IV (Period 1)|Pharmacokinetic Parameter: Steady-State Volume of Distribution (Vss) Following IV Infusion - IV, Following Administration of Unlabeled Ertugliflozin 15 mg Oral + 14^C-Ertugliflozin 100 ug IV (Period 1)|Pharmacokinetic Parameter: Fraction Absorbed (Fa, Radioactivity in Urine) (Periods 1 and 2) (Dose Normalized)|Number of Participants Who Experienced an Adverse Event (Periods 1 and 2)|Number of Participants Discontinuing Study Drug Due to Adverse Events (Periods 1 and 2)",Merck Sharp & Dohme Corp.|Pfizer,Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,8,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,8835-020|B1521043,29-Oct-14,30-Jan-15,9-Feb-15,8-Apr-15,17-Feb-16,18-Sep-18,,,https://ClinicalTrials.gov/show/NCT02411929
NCT02407899,Protective Effects of Saxagliptin (And Vitamin D3) on β Cell Function in Adult-onset Latent Autoimmune Diabetes,,Recruiting,No Results Available,"Diabetes Mellitus, Type 1",Drug: Saxagliptin|Drug: Vitamin D3|Drug: Insulin|Drug: Metformin,"Absolute changes from baseline in Fasting C-peptide levels at week 104.|Absolute changes from baseline in fasting C-peptide levels and at week 26, 52 and 78.|Absolute changes from baseline in C peptide at 60-min and 120-min (AUC) during a mixed-meal tolerance test and at week 26, 52, 78 and 104.|The proportion of subjects with increased (decreased, unchanged) fasting or post-stimulus C peptide level compared with baseline after 104 weeks of treatment.|The increased percentage of C peptide pre-and post mixed-meal tolerance test (Delta C peptide) after 104 weeks of treatment.|Changes of HbA1c levels from baseline and at week 26, 52, 78 and 104.|The proportion of subjects responding to glucose therapy (i.e. HbA1c<7%) after 104 weeks of treatment.|Changes of average daily insulin dose (U/kg/d) from baseline and at week 26, 52, 78 and 104|Changes of GADA titers from baseline and at week 52 and 104.|Absolute changes of body weight and BMI level from baseline and at week 26, 52, 78 and 104.",Second Xiangya Hospital of Central South University|Beijing Hospital|The First Affiliated Hospital with Nanjing Medical University|First Affiliated Hospital of Chongqing Medical University|The First Affiliated Hospital of Henan University of Science and Technology,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCRCMD LADA SAX 2015,Mar-15,Dec-20,Jun-21,3-Apr-15,null,20-Mar-19,"Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking, Beijing, China|Peking University People's Hospital, Peking, Beijing, China|Beijing Hospital of the Ministry of Health, Peking, Beijing, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China|Quanzhou First Hospital, Fujian, Quanzhou, Fujian, China|The First Affiliated Hospital of Fujian Medical University, Fujian, Fuzhou, China|Gansu Provincial Hospital, Lanzhou, Gansu, China|Dongguan People's Hospital, Dongguan, Guangdong, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China|The Second People's Hospital of Shenzhen, Shenzhen, Guangdong, China|The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China|The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China|Hainan General Hospital, Haikou, Hainan, China|Tangshan Gongren Hospital063000, Tangshan, Hebei, China|Harbin Medical University, Harbin, Heilongjiang, China|The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China|Henan Provincial People's Hospital, Zhengzhou, Henan, China|Renmin Hospital of Wuhan University, Wuhan, Hubei, China|The First People's Hospital of Changde, Changde, Hunan, China|Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China|The Third Xiangya Hospital of Central South University, Changsha, Hunan, China|The First Affiliated Hospital of South China University, Hengyang, Hunan, China|The Second Hospital University of South China, Hengyang, Hunan, China|The First People's Hospital of Huaihua, Huaihua, Hunan, China|The First People's Hospital of Yueyang, Yueyang, Hunan, China|The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|The Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The Second Hospital of Jilin University, Changchun, Jilin, China|Jilin Province People's Hospital, Changchun, Jilin, China|The First Hospital of China Medical University, Shenyang, Liaoning, China|The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China|Shanghai Xuhui District Central Hospital, Shanghai, Shanghai, China|Huashan Hospital, Fudan University, Shanghai, Shanghai, China|Heping Hospital of Changzhi Medical College, Changzhi, Shanxi, China|Affiliated Heji Hospital of Changzhi Medical College, Changzhi, Shanxi, China|The First Affiliated Hospital of The Fourth Military Medical University, Xi'an, Shanxi, China|The First Affiliated Hospital of Xinjiang Medical University, Ürümqi, Xinjiang, China|The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China|First People's Hospital of Yunnan Province, Kunming, Yunnan, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China",,https://ClinicalTrials.gov/show/NCT02407899
NCT02408705,Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Liraglutide|Drug: Placebo|Drug: Mixed Meal Tolerance Test with paracetamol,"Area under the curve of the endogenous glucose production from (=EGP) from begin of the hypoglycaemic clamp 5.5 mmol/L period until the end of recovery period (4.0 mmol/L), calculated from stable isotope labelled plasma glucose|Area under the curve of peripheral glucose uptake (=PGU), calculated from labelled PG from begin of the hypoglycaemic clamp period 5.5mmol/L until end of recovery period (4.0 mmol/L)|Area under the glucose infusion rate curve from begin of the hypoglycaemic clamp period 5.5mmol/L until end of recovery period (4.0 mmol/L)|Change in mean plasma glucagon concentrations from begin of the hypoglycaemic clamp period 5.5 mmol/L to 3.5 mmol/L to nadir and to recovery phase|Change in mean values of adrenaline from begin of the hypoglycaemic clamp period 5.5 mmol/L to 3.5 mmol/L to nadir and to recovery phase|Change in mean values of noradrenaline from begin the hypoglycaemic clamp period 5.5 mmol/L to 3.5 mmol/L to nadir and to recovery phase|Change in mean values of cortisol from begin the hypoglycaemic clamp period 5.5 mmol/L to 3.5 mmol/L to nadir and to recovery phase|Change in mean values of growth hormone from begin the hypoglycaemic clamp period 5.5 mmol/L to 3.5 mmol/L to nadir and to recovery phase|Change in number of regulatory T-cells detected by blood (fasting) and measured by a laboratory|Change in function of regulatory T-cells detected by blood (fasting) and measured by a laboratory|Area under the glucose curve during the Mixed Meal Tolerance Test|Area under the c-peptid concentration curve during the Mixed Meal Tolerance Test|Area under the paracetamol concentration curve to calculate gastric emptying during the Mixed Meal Tolerance Test|Area under the insulin curve during the Mixed Meal Tolerance Test|Area under the glucagon curve during the Mixed Meal Tolerance Test|Change in HbA1c during each period detected by blood (fasting) at the begin of the visits and measured by a laboratory (tube: K3 EDTA Plasma)|Change in fasting plasma glucose during each period detected by blood at the begin of the visits and measured by a laboratory (tube: lithium heparin plasma)",Medical University of Graz|Novo Nordisk A/S,All,18 Years to 64 Years   (Adult),Phase 2,14,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",LG_T1_EGP,Jan-15,May-16,May-16,3-Apr-15,null,12-Sep-16,"Medical University Graz, Graz, Austria",,https://ClinicalTrials.gov/show/NCT02408705
NCT02405260,Add Glucokinase Activator to Target A1c,AGATA,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: TTP399 400 mg|Drug: TTP399 800 mg|Drug: Sitagliptin 100 mg|Drug: Placebo,Change in HbA1c (Glycosylated haemoglobin)|HbA1c < 7% at 6 months|HbA1c < 6.5% at 6 months|Plasma Glucose Levels|Lipid Levels|Insulin Levels|Lactate Levels|C-peptide Levels|Glucagon Levels|Glucagon-like Peptide-1 Levels|Change in Body Weight|Adverse Events|Blood Pressure|Electrocardiogram Parameters|Hematology|Blood Chemistry|Urinalysis|Pulse,vTv Therapeutics,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,190,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",TTP399-202,Mar-15,Jul-16,Sep-16,1-Apr-15,null,10-Feb-17,"Mesa, Arizona, United States|Tuscon, Arizona, United States|Canoga Park, California, United States|Huntington Park, California, United States|Los Angeles, California, United States|West Hills, California, United States|Centennial, Colorado, United States|Littleton, Colorado, United States|Waterbury, Connecticut, United States|West Palm Beach, Florida, United States|Gurnee, Illinois, United States|Evansville, Indiana, United States|Rochester, Minnesota, United States|Greensboro, North Carolina, United States|Moncks Corner, South Carolina, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Schertz, Texas, United States|Norfolk, Virginia, United States|Richland, Washington, United States",,https://ClinicalTrials.gov/show/NCT02405260
NCT02403375,Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections to Reach HbA1c Targets in Children and Adolescents With Type 1 Diabetes,Insight Kids,Completed,No Results Available,Diabetes Mellitus Type 1,Device: Accu-Chek Insight Pump System,"Percentage of Children and Adolescents of Ages 2 to 17 Years Reaching an HbA1c target of <7.5%|Score on Insulin Pump Questionnaire|Score on Diabetes Treatment Satisfaction Questionnaire (DTSQ)|Score on Pediatric Quality of Life Inventory (PedsQL)|Change from Baseline in HbA1c|Change from Baseline in Blood Glucose|Number of Subjects, Who Report a Diabetes-Related Adverse Event (i.e., Symptomatic Hypoglycemia, Severe Hypoglycemia, Diabetic Ketoacidosis)",Hoffmann-La Roche|Roche Diabetes Care GmbH,All,2 Years to 17 Years   (Child),Not Applicable,43,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RD002177,17-May-15,26-Oct-17,26-Oct-17,31-Mar-15,null,27-Nov-17,"Medical University Graz, Graz, Austria|Universitatsklinik fur PadiatrieI, Padiatrische Diabetologie und Endokrinologie, Innsbruck, Austria|Medical University of Vienna-Dept of Pediatrics, Vienna, Austria|Kinderkrankenhaus auf der Bult, Hannover, Germany|Gemeinschaftspraxis für Kinder- und Jugendmedizin, Herford, Germany|Practice for Pediatric and Adolescent Diabetology, Munster, Germany|Universitatsklinikum Tubingen, Tubingen, Germany|Birmingham Children's Hospital Foundation Trust, Birmingham, United Kingdom|St. James's University Hospital, Leeds, United Kingdom",,https://ClinicalTrials.gov/show/NCT02403375
NCT02403427,The Expert System VoiceDiab in Children With Diabetes,VoiceDiab,Unknown status,No Results Available,Type 1 Diabetes Mellitus With Hyperglycemia|Type 1 Diabetes Mellitus With Hypoglycaemia,Device: VoiceDiab expert system,postprandial glucose|AUC|PPGE- postprandial glucose excursion|hypoglycemia|LBGI|Glucose variability parameters,"Instytut Diabetologii Sp. z o.o.|Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences|National Centre for Research and Development",All,"3 Years to 18 Years   (Child, Adult)",Not Applicable,42,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,PBS1/B9/13/2012-I,Mar-15,Sep-15,Dec-15,31-Mar-15,null,7-May-15,"Ewa Pankowska, Warsaw, Poland",,https://ClinicalTrials.gov/show/NCT02403427
NCT02402439,Treatment of Type I Diabetes by Islet Transplantation Into the Gastric Submucosa Study Protocol,,Recruiting,No Results Available,"Diabetes Mellitus, Type 1",Drug: Islet cells|Procedure: Islet transplantation into the gastrointestinal submucosa,Insulin independence|Changes in HbA1c|Changes (reduction) in insulin requirements|Incidence of adverse events,"University of California, San Francisco",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,6,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IGS,Mar-16,Jan-21,Jan-21,30-Mar-15,null,5-Apr-18,"University of California, San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT02402439
NCT02397265,"Clinical Assessment of a Closed-loop System With Glucagon, Exercise and Mixed Meals",,Suspended,No Results Available,Type 1 Diabetes,Device: Bi-hormonal closed loop pump|Device: Standard opened loop pump,Percentage time in target range defined as 3.9-10mmol/l.|Percentage time spent in euglycaemia (3.9-7.8mmol/l)|percentage time spent in hypoglycaemia (<3.9mmol/l)|Percentage time spent in hyperglycaemia (>10mmol/l)|Mean venous blood and sensor glucose|Glycaemic variability|Glycaemic risk as measured by LBGI and HBGI|Closed loop error grid analysis|Glucose area under the curve|Insulin requirement in units/kg/hr|Glucagon requirements,Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14SM2107,Dec-14,Dec-16,Dec-16,24-Mar-15,null,22-Mar-16,"Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02397265
NCT02390050,A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Type 2","Drug: Bexagliflozin tablets|Drug: Bexagliflozin tablets, placebo",Dose Identification|Change in HbA1c over time|Proportion of subjects with HbA1c <7%|Change in body weight over time|Change in Fasting Plasma Glucose (FPG) over time|Change in systolic and diastolic blood pressure over time|Safety of bexagliflozin in subjects with T2DM (adverse events),Theracos,All,"20 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,292,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",THR-1442-C-449,May-15,Jun-16,Jun-16,17-Mar-15,null,3-Feb-17,"Phoenix Medical Research Institute LLC, Peoria, Arizona, United States|Advanced Arizona Clinical Research, Tucson, Arizona, United States|Hope Clinical Research, LLC, Canoga Park, California, United States|Catalina Research Institute, Chino, California, United States|National Research Institute, Huntington Park, California, United States|Long Beach Clinical Trials, Long Beach, California, United States|Synergy San Diego, National City, California, United States|Northern California Research, Sacramento, California, United States|Artemis Institute for Clinical Research, LLC, San Diego, California, United States|Infosphere Clinical Research, Inc, West Hills, California, United States|M&O Clinical Research LLC, Fort Lauderdale, Florida, United States|AGA Clinical Trials, Hialeah, Florida, United States|Compass Research North, Leesburg, Florida, United States|Sweet Hope Research Specialty, Inc, Miami Lakes, Florida, United States|Sunshine Research Center, Opa Locka, Florida, United States|Compass Research LLC, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|PICR Clinic, Atlanta, Georgia, United States|Sundance Clinical Research, St. Louis, Missouri, United States|Premier Research Ltd, Trenton, New Jersey, United States|Regional Clinical Research, Inc, Endwell, New York, United States|Calabash Medical Center, Calabash, North Carolina, United States|Diabetes & Endocrinology Consultants PC, Morehead City, North Carolina, United States|PMG Research of Salisbury, Salisbury, North Carolina, United States|CTI Research, Cincinnati, Ohio, United States|Summit Research Group, LLC, Stow, Ohio, United States|Columbia Research Group, Inc., Portland, Oregon, United States|Detweiler Family Medicine and Associate, P.C., Lansdale, Pennsylvania, United States|North Myrtle Beach Family Practice, Myrtle Beach, South Carolina, United States|Global Medical Research, DeSoto, Texas, United States|Rockwood Medical Clinic, Fort Worth, Texas, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|Medical Corporation Hitomi-kai Motomachi Takatsuka Naika Clinic, Yokohama Naka-ku, Kanagawa, Japan|Medical Corporation Hayashi katagihara Clinic, Kyoto Nishikyo-ku, Kyoto, Japan|Medical Corporation KEISEIKAI Kajiyama clinic, Ukyou-ku, Kyoto, Japan|Ikeoka Medical Corp. Ikeoka Clinic, Joto-ku, Osaka, Japan|Miyauchi Medical Center, Takatsuki-shi, Osaka, Japan|Medical Corporation Senrichuo Ekimae Clinic, Toyonaka-shi, Osaka, Japan|Medical Corporation Segawa Hospital, Hikigun Ogawamachi, Saitama, Japan|Medical Corporation Yukeikai Asano Clinic, Kawagoe-shi, Saitama, Japan|Medical Corporation Ishii Internal Medicine Clinic, Kawaguchi, Saitama, Japan|Medical Corporation Fusanokai Shimizu Clinic Fusa, Saitama-shi, Saitama, Japan|Medical Corp. SEIKOUKAI New Medical Research System Clinic, Hachioji-shi, Tokyo, Japan|Medical Corporation Jototowakai Shinkoiwa ekimae sogo Clinic, Katsushika-ku, Tokyo, Japan|Medical Corporation IHL Pedi Shiodome Medical Clinic, Minato-ku, Tokyo, Japan|Medical Corporation IHL Shinagawa East One Medical Clinic, Minato-ku, Tokyo, Japan|Kenkokan Suzuki Clinic, Ota-ku, Tokyo, Japan|Medical Corporation Souyu-kai Hirahata Clinic, Shibuya-ku, Tokyo, Japan|Medical Corporation Yuhokai Miho-Clinic, Shinagawa-ku, Tokyo, Japan|Ikebukuro Metropolitan Clinic, Toshima-ku, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT02390050
NCT02387164,Prevention Trial: Immune-tolerance With Alum-GAD (Diamyd) and Vitamin D3 to Children With Multiple Islet Autoantibodies,DiAPREV-IT2,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 1|Prediabetic State",Drug: Alum-GAD|Drug: Vitamin D3,Type 1 diabetes|Impaired glucose metabolism|Safety as measured by occurrence of adverse events,Lund University|Region Skane,All,"4 Years to 18 Years   (Child, Adult)",Phase 2,26,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",DiAPREV/2014,Mar-15,Jan-20,Jan-20,12-Mar-15,null,15-Jan-19,"Clinical Research Center, Pediatric Endocrinology, Jan Waldenströms gata 35, 60:11, Malmö, Sweden",,https://ClinicalTrials.gov/show/NCT02387164
NCT02383940,Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Sotagliflozin|Drug: Placebo,A1C reduction|Change in bolus insulin|Change in 2-hour PPG following standardized mixed meal|Change in Continuous Glucose Monitoring area under the concentration time-curve outside target ranges|Change in Hypoglycemic events/day (≤70 mg/dL) by SMBG|Change in Total basal insulin,Sanofi|Juvenile Diabetes Research Foundation|Lexicon Pharmaceuticals,All,18 Years to 30 Years   (Adult),Phase 2,87,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",LX4211.1-204-T1DM|LX4211.204,Apr-15,Sep-16,Sep-16,10-Mar-15,null,26-Dec-17,"Lexicon Investigational Site, Tustin, California, United States|Lexicon Investigational Site, Aurora, Colorado, United States|Lexicon Investigational Site, New Haven, Connecticut, United States|Lexicon Investigational Site, Tampa, Florida, United States|Lexicon Investigational Site, West Palm Beach, Florida, United States|Lexicon Investigational Site, Atlanta, Georgia, United States|Lexicon Investigational Site, Roswell, Georgia, United States|Lexicon Investigational Site, Indianapolis, Indiana, United States|Lexicon Investigational Site, New Orleans, Louisiana, United States|Lexicon Investigational Site, Auburn, Maine, United States|Lexicon Investigational Site, Boston, Massachusetts, United States|Lexicon Investigational Site, Buffalo, New York, United States|Lexicon Investigational Site, Wilmington, North Carolina, United States|Lexicon Investigational Site, Austin, Texas, United States|Lexicon Investigational Site, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT02383940
NCT02384889,DFMO in Children With Type 1 Diabetes,,Recruiting,No Results Available,Type 1 Diabetes,Drug: Difluoromethylornithine|Drug: Placebo,Number of Participants with Dose Limiting Toxicities,Indiana University,All,"12 Years to 40 Years   (Child, Adult)",Phase 1,42,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",1411735324,Apr-15,Dec-19,Dec-20,10-Mar-15,null,16-Aug-18,"Riley Hospital for Children, Indianapolis, Indiana, United States|Women and Children's Hospital of Buffalo, Buffalo, New York, United States|Children's Hospital of Wisconsin, Wauwatosa, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02384889
NCT02384941,"Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy",inTandem1,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Sotagliflozin|Drug: Placebo,Change from baseline of either LX4211 high dose or low dose versus placebo on glycosylated hemoglobin A1C|Change from baseline in body weight|Change from baseline in bolus insulin dose|Change from baseline in fasting plasma glucose,Sanofi|Lexicon Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,793,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",LX4211.1-309-T1DM,Mar-15,Sep-16,Feb-17,10-Mar-15,null,26-Dec-17,"Lexicon Investigational Site, Birmingham, Alabama, United States|Lexicon Investigational Site, Little Rock, Arkansas, United States|Lexicon Investigational Site, Escondido, California, United States|Lexicon Investigational Site, Greenbrae, California, United States|Lexicon Investigational Site, Huntington Beach, California, United States|Lexicon Investigational Site, La Jolla, California, United States|Lexicon Investigational Site, Los Angeles, California, United States|Lexicon Investigational Site, Orange, California, United States|Lexicon Investigational Site, Palm Springs, California, United States|Lexicon Investigational Site, San Mateo, California, United States|Lexicon Investigational Site, Tarzana, California, United States|Lexicon Investigational Site, Tustin, California, United States|Lexicon Investigational Site, Walnut Creek, California, United States|Lexicon Investigational Site, Aurora, Colorado, United States|Lexicon Investigational Site, Longmont, Colorado, United States|Lexicon Investigational Site, Fleming Island, Florida, United States|Lexicon Investigational Site, Jacksonville, Florida, United States|Lexicon Investigational Site, Jacksonville, Florida, United States|Lexicon Investigational Site, New Port Richey, Florida, United States|Lexicon Investigational Site, Ormond Beach, Florida, United States|Lexicon Investigational Site, West Palm Beach, Florida, United States|Lexicon Investigational Site, Atlanta, Georgia, United States|Lexicon Investigational Site, Lawrenceville, Georgia, United States|Lexicon Investigational Site, Roswell, Georgia, United States|Lexicon Investigational Site, Honolulu, Hawaii, United States|Lexicon Investigational Site, Crystal Lake, Illinois, United States|Lexicon Investigational Site, Elgin, Illinois, United States|Lexicon Investigational Site, Springfield, Illinois, United States|Lexicon Investigational Site, Topeka, Kansas, United States|Lexicon Investigational Site, Lexington, Kentucky, United States|Lexicon Investigational Site, Bangor, Maine, United States|Lexicon Investigational Site, Baltimore, Maryland, United States|Lexicon Investigational Site, Boston, Massachusetts, United States|Lexicon Investigational Site, Detroit, Michigan, United States|Lexicon Investigational Site, Chesterfield, Missouri, United States|Lexicon Investigational Site, Saint Louis, Missouri, United States|Lexicon Investigational Site, Omaha, Nebraska, United States|Lexicon Investigational Site, Henderson, Nevada, United States|Lexicon Investigational Site, Las Vegas, Nevada, United States|Lexicon Investigational Site, Albany, New York, United States|Lexicon Investigational Site, New York, New York, United States|Lexicon Investigational Site, Asheville, North Carolina, United States|Lexicon Investigational Site, Chapel Hill, North Carolina, United States|Lexicon Investigational Site, Morehead City, North Carolina, United States|Lexicon Investigational Site, Columbus, Ohio, United States|Lexicon Investigational Site, Oklahoma City, Oklahoma, United States|Lexicon Investigational Site, Portland, Oregon, United States|Lexicon Investigational Site, Greer, South Carolina, United States|Lexicon Investigational Site, Rapid City, South Dakota, United States|Lexicon Investigational Site, Chattanooga, Tennessee, United States|Lexicon Investigational Site, Chattanooga, Tennessee, United States|Lexicon Investigational Site, Memphis, Tennessee, United States|Lexicon Investigational Site, Austin, Texas, United States|Lexicon Investigational Site, Dallas, Texas, United States|Lexicon Investigational Site, Dallas, Texas, United States|Lexicon Investigational Site, Dallas, Texas, United States|Lexicon Investigational Site, Houston, Texas, United States|Lexicon Investigational Site, Houston, Texas, United States|Lexicon Investigational Site, San Antonio, Texas, United States|Lexicon Investigational Site, Schertz, Texas, United States|Lexicon Investigational Site, Chesapeake, Virginia, United States|Lexicon Investigational Site, Renton, Washington, United States|Lexicon Investigational Site, Seattle, Washington, United States|Lexicon Investigational Site, Milwaukee, Wisconsin, United States|Lexicon Investigational Site, Calgary, Alberta, Canada|Lexicon Investigational Site, Vancouver, British Columbia, Canada|Lexicon Investigational Site, Winnipeg, Manitoba, Canada|Lexicon Investigational Site, Halifax, Nova Scotia, Canada|Lexicon Investigational Site, Barrie, Ontario, Canada|Lexicon Investigational Site, Hamilton, Ontario, Canada|Lexicon Investigational Site, London, Ontario, Canada|Lexicon Investigational Site, Ottawa, Ontario, Canada|Lexicon Investigational Site, Thornhill, Ontario, Canada|Lexicon Investigational Site, Toronto, Ontario, Canada|Lexicon Investigational Site, Montreal, Quebec, Canada|Lexicon Investigational Site, St. Laurent, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02384941
NCT02374879,User Performance and System Accuracy Evaluations Using Glucose Adjustment,,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: Blood Glucose Monitoring Systems.,User Performance (UP) evaluation.|System Accuracy (SA) evaluation,LifeScan,All,18 Years to 45 Years   (Adult),Not Applicable,12,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,3128466,1-Feb-15,1-Feb-15,1-Feb-15,2-Mar-15,null,16-Aug-17,"BioKinetic Europe Ltd, Belfast, Antrim, United Kingdom",,https://ClinicalTrials.gov/show/NCT02374879
NCT02371694,What is the Dose Response of Varying Meal Content of Fat on Postprandial Glycaemia in Children With T1DM?,REQINSOIL,Unknown status,No Results Available,"Diabetes Mellitus, Type 1",Other: Test drink,Glycaemic excursion|Maximal glucose excursion|Time to maximal glucose excursion|Time until the glucose level returns to baseline|Percent time in target glucose range|Number of hypoglycaemic events in the 24h post-test meal,"Cork University Hospital|National University of Ireland, Galway, Ireland|John Hunter Children's Hospital",All,"8 Years to 18 Years   (Child, Adult)",Not Applicable,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",CorkUH,Feb-15,Dec-17,Dec-18,26-Feb-15,null,13-Apr-17,"Cork University Hospital, Cork, Ireland",,https://ClinicalTrials.gov/show/NCT02371694
NCT02372253,Verapamil for Beta Cell Survival Therapy in Type 1 Diabetes,,"Active, not recruiting",Has Results,Type 1 Diabetes Mellitus,Drug: Verapamil|Drug: Placebo,Functional Beta Cell Mass|Percent Change From Baseline in Exogenous Insulin Requirements|HbA1C|HbA1c|Hypoglycemic Events,University of Alabama at Birmingham|Juvenile Diabetes Research Foundation,All,18 Years to 45 Years   (Adult),Phase 2,32,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",3-SRA-2014-302-M-R,Feb-15,Dec-17,Dec-19,26-Feb-15,30-Jan-19,30-Jan-19,"University of Alabama at Birmingham, Birmingham, Alabama, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT02372253/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02372253
NCT02373150,"Safety, Tolerability and PK of Imeglimin in Japanese Volunteers",,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Imeglimin|Drug: Placebo,"PK parameters of imeglimin after single and repeated doses: - Cmax: peak plasma concentration after dosing, AUC0-∞: area under the concentration-time curve from 0 extrapolated to infinite time, - Tmax: time of peak plasma concentration of imeglimin|Safety and tolerability of imeglimin: laboratory assessments",Poxel SA,All,20 Years to 45 Years   (Adult),Phase 1,48,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PXL008-011,Feb-15,Oct-15,Oct-15,26-Feb-15,null,10-Feb-17,"Hammersmith Medicines Research (HMR), London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02373150
NCT02367534,Islet Transplantation Through an Indwelling Catheter in the Umbilical Vein,,Completed,No Results Available,Type 1 Diabetes Mellitus,Procedure: umbilical vein catheterization,hemorrhage|Infection|Exogenous insulin requirement|Glucose|C-peptide,Fuzhou General Hospital,All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,12,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Umbilical-vein,Jun-08,Dec-12,Dec-13,20-Feb-15,null,20-Feb-15,,,https://ClinicalTrials.gov/show/NCT02367534
NCT02365740,Postprandial Blood Glucose Control and Gastric Emptying in Type 1 Diabetes: Pathogenetic Factors and Therapeutic Options,,Unknown status,No Results Available,"Diabetes Mellitus, Type 1",Other: gastric emptying test|Other: gut hormones determination|Other: Continuous Glucose Monitoring|Drug: Insulin single bolus|Drug: Insulin double-wave bolus,gastric emptying measure|gut hormones dosage|Continuous Glucose Monitoring|postprandial glucose variability after single insulin bolus|postprandial glucose variability after double-wave insulin bolus,Federico II University,All,18 Years to 55 Years   (Adult),Not Applicable,80,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,248/13,Nov-14,Nov-15,Nov-16,19-Feb-15,null,19-Feb-15,"Dept. of ""Medicina Clinica e Chirurgia"" of Federico II University, Naples, Italy",,https://ClinicalTrials.gov/show/NCT02365740
NCT02366767,Assessment of an Automatic Closed-loop Insulin Delivery System,,Completed,Has Results,"Diabetes Mellitus, Type 1",Device: Automatic closed-loop insulin delivery|Device: Control,Safety of Automatic Closed Loop Insulin Delivery System in Adolescents and Adults With Type 1 Diabetes|Feasibility of Using the Automatic Closed Loop Delivery System in Adolescents and Adults With Type 1 Diabetes|Efficacy of Hybrid Closed-loop System in Comparison With Control,Stanford University|Medtronic,All,"14 Years to 40 Years   (Child, Adult)",Not Applicable,21,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,G140095,Jun-14,Sep-14,Sep-14,19-Feb-15,6-Feb-17,17-Mar-17,"Camp Conrad-Chinnock, Angelus Oaks, California, United States|Packard El Camino Hospital, Mountain View, California, United States|Lucile Packard Children's Hospital, Palo Alto, California, United States",,https://ClinicalTrials.gov/show/NCT02366767
NCT02361606,An Internet Cognitive-Behavioral Intervention for Youth With Type 1 Diabetes - Participation and Efficacy,,Completed,No Results Available,Type 1 Diabetes,Behavioral: An Internet Cognitive-Behavioral Intervention,"Change in quality of life. (Diabetes Quality of Life (DQOL) questionnaire)|Perceived parent support. (Short version of the Social Provision Scale)|Youth satisfaction of the program. (Questionnaire regarding the degree that the session was helpful.)|Change in glycemic control. (HbaA1c levels, obtained from medical records)","Dr. Orit Hamiel|Academic College of Tel Aviv-Jaffa|Maccabi Healthcare Services, Israel|Sheba Medical Center",All,"13 Years to 20 Years   (Child, Adult)",Not Applicable,89,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2009108,Mar-09,Feb-11,Jan-13,12-Feb-15,null,12-Feb-15,,,https://ClinicalTrials.gov/show/NCT02361606
NCT02359617,Continuous Glucose Sensing at the Site of Subcutaneous Insulin Administration,,Completed,No Results Available,Type 1 Diabetes,Drug: insulin delivery|Device: glucose sensing,Mean absolute relative difference between sensor readings and capillary glucose readings,Medical University of Graz|European Commission,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,Single-Port@Home-01,Feb-13,Oct-14,Mar-15,10-Feb-15,null,27-Apr-15,"Medical University of Graz, Graz, Styria, Austria",,https://ClinicalTrials.gov/show/NCT02359617
NCT02356653,Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC,ExpMACs,Recruiting,No Results Available,Leukemia|Inborn Errors of Metabolism|Bone Marrow Failure Syndromes|Immunodeficiencies|Immunodysregulation Polyendocrinopathy Enteropathy X-linked Syndrome,Device: Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs),Overall Survival|Graft versus Host Disease|Graft Failure,Children's Hospital of Philadelphia,All,"up to 30 Years   (Child, Adult)",Early Phase 1,100,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13-010286|12BT125,Dec-13,Jan-20,Jan-20,5-Feb-15,null,12-Mar-19,"Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02356653
NCT02354911,Autologous Immunoregulatory Dendritic Cells for Type 1 Diabetes Therapy,,Unknown status,No Results Available,Type 1 Diabetes,Biological: Immunoregulatory Dendritic Cells|Other: Placebo Comparator: Placebo Control,"Change from baseline in the mean 2-hour area under the curve (AUC) for plasma c-peptide at 12 and 24 months|Reported adverse events|Change from baseline in number of potentially-tolerogenic/regulatory T-cells, B-cells and dendritic cells in circulating peripheral blood mononuclear cell fraction|Change from baseline in sub-populations of T-cells|Change from baseline in sub-populations of B-cells|Change from baseline in sub-populations of dendritic cells|Change from baseline in Fasting Plasma Glucose|Change from baseline in Hemoglobin A1c|Change from baseline in the baseline corrected, 2-hour AUC for glucose at 12 and 24 months|Change from baseline in Total Daily Insulin Dose","DiaVacs, Inc.|West Penn Allegheny Health System|University of Pittsburgh|Stanford University|University of Miami",All,"12 Years to 35 Years   (Child, Adult)",Phase 2,24,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",DV-0100-101,Oct-15,Jul-18,Jan-19,3-Feb-15,null,4-Feb-15,,,https://ClinicalTrials.gov/show/NCT02354911
NCT02352974,GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1),DIAGNODE,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 1",Drug: GAD-Alum|Drug: Vitamin D,"Safety of giving Diamyd directly into lymph glands in combination with an oral vitamin D regimen at Month 6 (main study period) and Month 15 and 30 (extension study period)|Change in immune system markers from baseline to Month 6 (main study period) and subsequent visits during the extension study period|C-peptide: Fasting, 90 minute value, and Area Under the Curve (mean 0-120 min) during an MMTT, change from baseline|Hemoglobin A1c (HbA1c), change from baseline|Exogenous insulin dose per kg body weight and 24 hours, change from baseline","Johnny Ludvigsson|Swedish Child Diabetes Foundation|Ostergotland County Council, Sweden|Diamyd Medical AB|Linkoeping University",All,"12 Years to 30 Years   (Child, Adult)",Phase 1,12,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DIAGNODE-1,Jan-15,Dec-19,Dec-19,2-Feb-15,null,28-Sep-18,"Linköping University, Linköping, Sweden",,https://ClinicalTrials.gov/show/NCT02352974
NCT02351232,The Lira Pump Trial,,Completed,No Results Available,Type 1 Diabetes,Drug: Liraglutide|Drug: Placebo,"Change in HbA1c|Change in weight|Change in insulin pump settings|Change in glucose variability as measured by continuous glucose monitoring|Change in body composition as measured by DXA-scan|Change in blood pressure|Change in lipid profile (LDL, HDL, VLDL, total cholesterol, triglycerides)|Frequency of hypoglycemia (patient reported number of episodes with blood glucose <3.9 mmol/l)|Change in kidney function as measured by urine albumine/creatinine ratio|Number of daily blood glucose measurements|Change in diet as measured by retrospective food recording|Change in treatment satisfaction as measured by Diabetes Treatment Satisfaction Questionnaire|Change in anxiety and depression as measured by Hospital Anxiety and Depression Scale",Hvidovre University Hospital|Steno Diabetes Center Copenhagen,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2|Phase 3,44,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LPT2015|2014-002285-76,Feb-15,Oct-16,Oct-16,30-Jan-15,null,21-Oct-16,"Steno Diabetes Center, Gentofte, Denmark|Hvidovre University Hospital, Hvidovre, Denmark",,https://ClinicalTrials.gov/show/NCT02351232
NCT02350374,Carbohydrate Counting in Children and Adolescents With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Other: carbohydrate counting,"The individual variation of CHO amount at each main meal : Breakfast, Lunch, Snacks, Dinner",Fondation Lenval,All,"1 Year to 18 Years   (Child, Adult)",Not Applicable,82,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,14-HPNCL-05,17-Nov-14,17-May-16,17-May-16,29-Jan-15,null,30-Jul-18,"Fondation Lenval, Nice, France",,https://ClinicalTrials.gov/show/NCT02350374
NCT02344602,The Effect of Uric Acid Lowering in Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Febuxostat,The Change in Glomerular Filtration Rate (GFR) After an 8 week Treatment with Febuxostat|The Change in Effective Renal Plasma Flow (ERPF) After an 8 week Treatment with Febuxostat|The Change in Renin Angiotensin Aldosterone System (RAAS) Markers and Neurohormonal Activation After an 8 week Treatment with Febuxostat|The Change in Levels of Vasodilators in Plasma After an 8 week Treatment with Febuxostat|The Change in Blood Pressure After an 8 week Treatment with Febuxostat|The Change in Flow Mediated Dilation After an 8 week Treatment with Febuxostat|The Change in Arterial Stiffness After an 8 week Treatment with Febuxostat|The Change in Skin Biopsy Measures of Neurohormonal Activation After an 8 week Treatment with Febuxostat,"University Health Network, Toronto|Canadian Institutes of Health Research (CIHR)|Toronto General Hospital|University of Toronto",All,18 Years to 40 Years   (Adult),Phase 4,73,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12-5427-A,18-Dec-12,22-Sep-15,22-Sep-15,26-Jan-15,null,16-Jan-18,"Renal Physiology Laboratory, University Health Network, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02344602
NCT02344992,Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog®) After Ingestion of a Standardized Meal,,Completed,No Results Available,Diabetes Mellitus Type 1,Drug: BioChaperone insulin lispro|Drug: Humalog®,"Area under the blood glucose time curve: AUCbg(0-2h)|Pharmacodynamic: Area under the blood glucose concentration time curve from 0-8 hours after a standardized meal: AUCbg(0-8h)|Pharmacodynamic: maximum blood glucose concentration after a standardized meal: BGmax|Pharmacokinetic: Area under the serum insulin lispro concentration time curve from 0-8hours: AUClisp(0-8h)|Pharmacokinetic: Maximum observed serum insulin lispro concentration: Cmax(lisp)|Safety and tolerability: adverse events, local tolerability, vital signs variation, ECG, laboratory safety parameters",Adocia,All,18 Years to 64 Years   (Adult),Phase 1,38,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",BC3-CT011|2014-005028-92,Jan-15,Jun-15,Jun-15,26-Jan-15,null,1-Jun-17,"Profil GmbH, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT02344992
NCT02344186,Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes,,Unknown status,No Results Available,Type 2 Diabetes,Drug: Liraglutide,Changes in unfolded protein response markers|Insulin sensitivity|Glucose control|Energy expenditure|Body weight|Body composition|Beta cell function,Temple University,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant),21440,May-14,Jun-16,Jun-16,22-Jan-15,null,11-Jan-16,"Temple University Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02344186
NCT02343146,"Healthy Eating, Physical Activity, and Glycemic Control in Young Children With T1D",,Enrolling by invitation,No Results Available,"Diabetes Mellitus, Type 1",Behavioral: Type One Training (TOT),Glycemic Control/HbA1c|Child eating as measured by 24 hour recall reported by the parent,Randi Streisand|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Children's Research Institute,All,"21 Years to 99 Years   (Adult, Older Adult)",Not Applicable,70,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,5649|DP3DK103998,Oct-15,Aug-19,Aug-19,21-Jan-15,null,13-Jul-18,"Children's Research Institute, Washington, District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT02343146
NCT02333539,Adherence Intervention to Promote Optimal Use of Insulin Pumps in Adolescents With Type 1 Diabetes,Pump It Up!,"Active, not recruiting",No Results Available,Type 1 Diabetes,Behavioral: Adherence behaviors and recommendations for improvement.|Behavioral: Adherence behavior that needs improvement is targeted,Frequency of Insulin Pump Adherence Behaviors|Change in Glycemic Control (A1C),"University of Colorado, Denver",All,10 Years to 17 Years   (Child),Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-0965,Sep-12,31-Mar-21,31-Mar-21,7-Jan-15,null,27-Mar-19,"Florida State University, Tallahassee, Florida, United States",,https://ClinicalTrials.gov/show/NCT02333539
NCT02330939,Fats And Carbohydrates Quality on Postprandial glycemIc Response in Type 1 Diabetes,FACILE,Unknown status,No Results Available,Type 1 Diabetes,Other: Low fat- Low glycemic index meal|Other: MUFA- Low glycemic index meal|Other: SAFA- Low glycemic index meal|Other: Low fat- High glycemic index meal|Other: MUFA- High glycemic index meal|Other: SAFA- High glycemic index meal,postprandial incremental glucose AUC,Federico II University,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,14,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,980/14,Jun-14,Dec-14,null,5-Jan-15,null,5-Jan-15,"Department of Clinical Medicine and Surgery, Naples, Italy",,https://ClinicalTrials.gov/show/NCT02330939
NCT02328040,Randomized Trial Comparing Sitagliptin to Placebo in Closed Loop,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Placebo and Insulin monotherapy via CL|Drug: Sitagliptin and insulin/novolog via CL,"Blood Glucose Measures in Subjects Treated With Sitagliptin, Compared to the Placebo|Measure of Glucagon Concentration in Subjects Treated With Sitagliptin, Compared to Placebo",Albert Einstein College of Medicine|Medtronic,All,"14 Years to 30 Years   (Child, Adult)",Phase 1,17,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2013-330-000,Sep-14,Jan-16,Jan-16,31-Dec-14,7-Aug-18,7-Aug-18,"Albert Einstein College of Medicine CRC, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT02328040
NCT02325206,Phase 1 Study to Explore the Safety and Pharmacokinetics of DAPAglifozin in Adolescents and Adults With Type 1 Diabetes,DAPA-IIT1,Completed,No Results Available,Type 1 Diabetes,Drug: dapagliflozin|Drug: Placebo,reduction of intravenous insulin dose|HbA1c effect|urinary glucose excretion,Kinderkrankenhaus auf der Bult,All,"12 Years to 21 Years   (Child, Adult)",Phase 1,36,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ESR-14-10179,Dec-14,Dec-15,Dec-15,24-Dec-14,null,19-Feb-16,"Kinder - und Jugendkrankenhaus AUF DER BULT, Hannover, Germany",,https://ClinicalTrials.gov/show/NCT02325206
NCT02316665,Effect of Sleep Apnea Treatment on Type 1 Diabetes,DIADEME,Completed,No Results Available,Type 1 Diabetes|Sleep Apnea Syndrome,Device: continuous positive airway pressure|Device: Sham-continuous positive airway pressure,change in mean nocturnal glycemia|Change in blood pressure|Change in the variability of nocturnal glycemia|Change in HbA1c|Changes in sleep duration after intervention|Change in mean systolic blood pressure after intervention|Chang in sleep timing after intervention|Change in daily activity after intervention|Change in mean diastolic blood pressure after intervention|Change in mean heart rate after intervention,"University Hospital, Grenoble|Société francophone de pneumologie de langue francaise|ResMed",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,81,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2012-A006336-40,Apr-13,Oct-14,Jun-15,15-Dec-14,null,6-Jan-16,"Grenoble University hospital, Grenoble, France",,https://ClinicalTrials.gov/show/NCT02316665
NCT02315274,Pilot Study of Between Visit Interaction to Improve Glycemic Control in Pregnancy With Pre-existing Diabetes,,Completed,No Results Available,"Type 1 Diabetes, Pregnancy",Other: Frequent remote contact between clinic visits.,Glucose variability|Changes is severe hypoglycemia,Mayo Clinic,Female,18 Years to 45 Years   (Adult),Not Applicable,12,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14-003219,Jun-14,Jan-19,Jan-19,11-Dec-14,null,6-Mar-19,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02315274
NCT02310009,"IL-1RA, Acute Exercise, and Beta-cell Function",ANEX,Withdrawn,No Results Available,Type 2 Diabetes Mellitus,Drug: Anakinra (AN)|Behavioral: Exercise (EX)|Behavioral: Control (CON),Beta-cell function|Glucose disposition,"Rigshospitalet, Denmark",All,"30 Years to 80 Years   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",ANEX,Dec-14,Jun-15,30-Jul-15,5-Dec-14,null,13-Feb-17,"Rigshospitalet, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT02310009
NCT02307110,Prevalence of DRP and DME Among Type 1 Diabetics Treated With Long-term Intensified Insulin Therapy,,Completed,No Results Available,Insulin-Dependent Diabetes Mellitus 1,Other: cross-sectional observation,prevalence (percentages) of the stages of diabetic retinopathy (DR)|prevalence (percentages) of the stages of diabetic macular edema (DME)|means of individual average 5year-/10year-/15year-/20year-/25year-HbA1c value (%)|the means of individual average 5year-/10year-/15year-/20year-/25year-blood pressure (mmHg)|mean BCVA score|mean contrast sensitivity score|mean NEI-VFQ 25 score,"Vista Klinik|University Hospital, Basel, Switzerland",All,"50 Years and older   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,DRP-2010-02,Aug-10,Dec-14,Dec-14,4-Dec-14,null,3-Jan-18,"Vista Klinik, Binningen, Switzerland",,https://ClinicalTrials.gov/show/NCT02307110
NCT02307695,The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes,,Unknown status,No Results Available,Type 1 Diabetes,Drug: Saxagliptin|Drug: Insulin,Change of Mean amplitude of glycemic excursions (MAGE) from baseline in patients with type 1 diabetes treated with saxagliptin plus insulin or insulin alone by continuous glucose monitoring system (CGMS)|Change of C-peptide area under the curve (AUC C-peptide) or fasting C-peptide from baseline in patients with type 1 diabetes treated with saxagliptin plus insulin or insulin alone by 3-hour mixed meal tolerance test(MMTT)|Change of Haemoglobin A1c (HbA1c) from baseline in patients with type 1 diabetes treated with saxagliptin plus insulin or insulin alone|Change of insulin dosage (U/kg/d) from baseline in patients with type 1 diabetes treated with saxagliptin plus insulin or insulin alone,Nanjing Medical University,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Phase 4,184,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014-SR-123,Nov-14,Mar-17,Mar-17,4-Dec-14,null,6-Jul-16,"First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT02307695
NCT02308293,The Role of Endogenous Lactate in Brain Preservation and Counterregulatory Defenses Against Hypoglycemia,,Completed,No Results Available,Type 1 Diabetes Mellitus|Hypoglycemia Unawareness,Behavioral: High intensity exercise|Behavioral: Lay down comfortably,"Plasma level of adrenaline in response to hypoglycemia (Adrenaline, measured in arterial plasma)|Plasma levels of other counter-regulatory hormones (Levels of counter-regulatory hormones measured in arterial plasma)|Glucose infusion rate (Amount of glucose 20% necessary to maintain plasma glucose at steady state values)|Plasma lactate levels (Lactate levels measured in arterial plasma)|Cognitive functioning, as measured by cognitive tests|Plasma levels of inflammatory markers (levels of cytokines)|Brain perfusion measured with ASL-MRI|Brain lactate accumulation measured with 1H-MRS",Radboud University|Dutch Diabetes Research Foundation|European Foundation for the Study of Diabetes,All,18 Years to 40 Years   (Adult),Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,End_lac_sympt,Jan-15,May-16,Jul-16,4-Dec-14,null,25-Nov-16,"Radboud umc, Nijmegen, Netherlands",,https://ClinicalTrials.gov/show/NCT02308293
NCT02302443,"A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12470",,Completed,No Results Available,Diabetes Mellitus,Biological: HM12470|Biological: Active comparator,Incidence and severity of treatment emergent adverse events|Peak Plasma Concentration(Cmax) of HM12470 following a single dose|Area under the concentration-time curve (AUC) of HM12470 following a single dose,Hanmi Pharmaceutical Company Limited,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,100,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HM-INS115-101,Jan-15,May-17,May-17,27-Nov-14,null,8-Nov-17,"Hanmi Pharmaceutical Company, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02302443
NCT02302963,USS Virginia Closed-Loop Versus SAP Therapy for Hypoglycemia Reduction in T1D,,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: AP System (DiAs or inControl) with USS Virginia|Device: Sensor-Augmented Pump Therapy (placebo),Reduction in hypoglycemia during closed loop control (assessed by Low Blood Glucose Index [LBGI]),"University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Stanford University|TypeZero Technologies, LLC",All,"12 Years to 70 Years   (Child, Adult, Older Adult)",Not Applicable,85,Other|NIH|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17725|1DP3DK101055,Jun-15,Jan-17,Jan-17,27-Nov-14,null,29-Mar-19,"Stanford University, Stanford, California, United States|University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02302963
NCT02299050,Effect of Cycloset on Glycemic Control When Added to GLP-1 Analogue Therapy,,Completed,No Results Available,Type 2 Diabetes,Drug: Cycloset,"HbA1C|Glucose metabolism during mixed meal tolerance test|Endothelial Function,|Body composition|Blood pressure|Oxidative stress|Arterial Stiffness|Inflammation",The University of Texas Health Science Center at San Antonio|VeroScience,All,"30 Years to 69 Years   (Adult, Older Adult)",Phase 4,20,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HSC20130330H,Jun-14,30-Apr-18,30-Apr-18,24-Nov-14,null,28-May-18,"University of Texas Health Science Center, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT02299050
NCT02293837,Tocilizumab (TCZ) in New-onset Type 1 Diabetes,EXTEND,"Active, not recruiting",No Results Available,Type 1 Diabetes Mellitus|New-onset Type 1 Diabetes Mellitus|T1DM|T1D,Drug: Tocilizumab (TCZ)|Drug: Placebo,2-Hour C-peptide Area Under the Curve (AUC) Result in Response to Standardized Mixed Meal Tolerance Test (MMTT)|MMTT-stimulated mean 2-hour C-peptide AUC|MMTT-stimulated mean 2-hour C-peptide AUC assessed longitudinally|MMTT-stimulated peak and 4-hour C-peptide AUC for subjects ≥12 years old|Insulin Use in Units Per Kilogram Body Weight Per Day|Glycemic Control|Hemoglobin A1c levels|Rate of Adverse Events (AEs) related to infusion reactions and hypersensitivity|Frequency of all AEs|Severity of all AEs.,National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN),All,6 Years to 17 Years   (Child),Phase 2,136,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DAIT ITN058AI,12-Mar-15,Aug-19,Aug-20,18-Nov-14,null,3-May-19,"University of California San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Yale University School of Medicine: Diabetes Endocrinology Research Center, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|University of Miami: Diabetes Research Institute, Miami, Florida, United States|University of South Florida: Diabetes Center, Tampa, Florida, United States|Indiana University Health - Riley Hospital for Children, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Harvard University, Joslin Diabetes Center, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Columbia University, Naomi Berrie Diabetes Center, New York, New York, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Sanford Research, Sioux Falls, South Dakota, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Benaroya Research Institute, Seattle, Washington, United States|The Children's Hospital at Westmead: Kids Research Institute, Westmead, New South Wales, Australia|Lady Cilento Children's Hospital: Department of Endocrinology, South Brisbane, Queensland, Australia",,https://ClinicalTrials.gov/show/NCT02293837
NCT02291874,"Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)",,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Ipragliflozin,"HbA1c|Fasting plasma glucose|Fasting serum insulin|Serum glucagon|Serum glycoalbumin|Serum leptin|Serum adiponectin|Body weight|Waist circumference|Self-measured blood glucose|Adverse events (AEs), vital signs, and laboratory tests",Astellas Pharma Inc,All,"20 Years and older   (Adult, Older Adult)",Phase 4,100,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1941-CL-0132,8-Oct-14,7-Jul-16,7-Jul-16,17-Nov-14,null,26-Apr-19,"Chubu, Japan|Chugoku, Japan|Hokkaido, Japan|Kansai, Japan|Kanto, Japan|Kyushu, Japan",,https://ClinicalTrials.gov/show/NCT02291874
NCT02292433,A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy,,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: PF-04937319 high dose|Drug: PF-04937319 low dose|Drug: Placebo,Number of Participants With Treatment Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)|Number of Participants With Protocol Defined Hypoglycaemic Adverse Events (HAEs)|Maximum Observed Plasma Concentration (Cmax) on Day 1 for PF-04937319|Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1 for PF-04937319|Area Under the Concentration-Time Curve (AUC24) From Time Zero to 24 Hour on Day 1 for PF-04937319|Maximum Observed Plasma Concentration (Cmax) on Day 7 for PF-04937319|Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 7 for PF-04937319|Area Under the Concentration-Time Curve (AUC24) From Time Zero to 24 Hour on Day 7 for PF-04937319|Pre-dose Plasma Concentration (Ctrough) on Day 7 for PF-04937319|Average Plasma Concentration (Cav) on Day 7 for PF-04937319|Apparent Oral Clearance on Day 7 for PF-04937319|Terminal Half-Life (t1/2) on Day 7 for PF-04937319|Apparent Volume of Distribution on Day 7 for PF-04937319|Accumulation Ratio (Rac) on Day 7 for PF-04937319|Maximum Observed Plasma Concentration (Cmax) on Day 1 for PF-06455349|Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1 for PF-06455349|Area Under the Concentration-Time Curve (AUC24) From Time Zero to 24 Hour on Day 1 for PF--06455349|Metabolite to Parent Ratio for AUC24 (MRAUC24) on Day 1|Maximum Observed Plasma Concentration (Cmax) on Day 7 for PF--06455349|Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 7 for PF-06455349|Area Under the Concentration-Time Curve (AUC24) From Time Zero to 24 Hour on Day 7 for PF--06455349|Pre-dose Plasma Concentration (Ctrough) on Day 7 for PF--06455349|Average Plasma Concentration (Cav) on Day 7 for PF--06455349|Terminal Half-Life (t1/2) on Day 7 for PF-06455349|Accumulation Ratio (Rac) on Day 7 for PF-06455349|Metabolite to Parent Ratio for AUC24 (MRAUC24) on Day 7|Change From Baseline in Weighted Mean Daily Glucose (WMDG) at Day 7|Change From Baseline in Fasting Plasma Glucose (FPG) at Last Day of Treatment|Change From Baseline in Pre-Meal Insulin at Day 7|Change From Baseline in Pre-Meal C-Peptide at Day 7,Pfizer,All,20 Years to 64 Years   (Adult),Phase 1,12,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",B1621018,Jan-15,Mar-15,Mar-15,17-Nov-14,15-Mar-16,15-Mar-16,"P-one Clinic, Keikokai Medical Corporation, Hachioji-shi, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT02292433
NCT02287285,Determinants of Diabetes Remission After Gastric Bypass Surgery,,"Active, not recruiting",No Results Available,Type 2 Diabetes Mellitus,Drug: Exendin9,Beta Cell Sensitivity (BCS)|Insulin Secretion Rate (ISR) after OGTT|Insulin Secretion Rate (ISR) after GGI|Maximal Beta Cell Function,Blandine Laferrere|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Columbia University,All,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,25,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AAAO1360|1R01DK098056-01A1|1F32DK113747-01A1,Oct-14,Aug-17,Jul-19,10-Nov-14,null,9-May-19,"New York Obesity Research Center, Columbia University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02287285
NCT02284815,Can Gluten-free Diet Prevent the Destruction of Beta-cells During Remission?,,Unknown status,No Results Available,"Diabetes Mellitus, Type 1",Dietary Supplement: Glutenfree diet,C-peptide change from baseline to 12 months follow-up|Insulin Adjusted HbA1c change from baseline to 12 months follow-up|Insulin per kg from baseline to 12 months follow-up|Microbiota (feces samples) change from baseline to 6 months follow-up|Immune system (Th1 and Th2 cytokines) change from baseline to 12 months follow-up,Herlev Hospital,All,"2 Years to 18 Years   (Child, Adult)",Early Phase 1,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DIRECT-2011-119,Mar-12,Jun-15,Aug-15,6-Nov-14,null,6-Nov-14,,,https://ClinicalTrials.gov/show/NCT02284815
NCT02283411,Effectiveness and Safety Study of the Abbott Sensor Based Glucose Monitoring Systems,,Completed,Has Results,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Device: Abbott Sensor Based Glucose Monitoring System,"The Device Performance Was Evaluated in Terms of Point Accuracy of the Abbott Sensor Based Glucose Monitoring Systems in Reference to Yellow Spring Instrument (YSI).|Safety of the Abbott Sensor Based Glucose Monitoring Systems Was Characterized by Adverse Device Effects and Serious Adverse Device Effects Experienced by Study Participants.|The Trend Accuracy of the System P Device Performance Was Evaluated.|The Temporal System Accuracy at Different Glucose Rates of Change and Different Glucose Ranges (Hypoglycemic, Euglycemic, and Hyperglycemic Ranges) Was Evaluated.|The Point Accuracy of the Device Performance Was Evaluated in Reference to Capillary Blood Glucose (BG).",Abbott Diabetes Care,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,156,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,ADC-US-VAL-14135,Nov-14,Mar-15,Mar-15,5-Nov-14,21-Feb-18,21-Feb-18,"William Sansum Diabetes Center, Santa Barbara, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Rocky Mountain Diabetes & Osteoporosis Center, Idaho Falls, Idaho, United States|Clinical Trials of Texas, San Antonio, Texas, United States|Rainier Clinical Research Center, Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT02283411
NCT02284009,Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus,,Completed,Has Results,"Diabetes Mellitus, Type 1",Biological: Albiglutide weekly injection|Biological: Placebo weekly injection|Biological: Insulin,"Mean Change From Baseline in Time Normalized Stimulated (From Mixed Meal Tolerance Test [MMTT]) 2-hour Plasma C-peptide Area Under the Curve (AUC) at Week 52|Mean Change From Baseline in Time Normalized Stimulated (From MMTT) 2 Hour Plasma C-peptide AUC at Week 16, 28 and Week 64|Maximum Stimulated Plasma C-peptide (MMTT) at Baseline, Week 16, 28, 52 and 64|Mean Change From Baseline in Time Normalized Plasma Glucagon AUC (From MMTT) at Week 16, 28, 52 and 64|Percentage of Responders at Baseline, Weeks 4, 8, 16, 28, 40, 52 and 64|Percentage of Participants Achieving Partial Remission Status (Insulin Dose-adjusted Hemoglobin A1c (IDAA1C)<= 9.0) at Baseline, Week 4, 8, 16, 28, 40, 52 and 64|Change From Baseline in Percent HbA1c at Week 52|Percent HbA1c Over Time (at Weeks 4, 8, 16, 28, 40, 52 and 64)|Change From Baseline in Mean Daily Insulin Use at Week 4, 8, 16, 28, 40, 52 and 64|Number of Events of Participant-reported Significant Hypoglycemia, Occurring > Week 24 and <= Week 52|Time Spent With Plasma Glucose Level <= 3.9, > 3.9 to <= 10.0, and > 10.0 Measured by 72 Hour Continuous Glucose Monitoring (CGM) at Baseline, Week 28 and 52|Number of Hypoglycemic Excursions for Each Participant From 7-Point Glucose Profile at Baseline, Week 28 and 52|Greatest Magnitude of Hypoglycemic Excursions for Each Participant From 7-Point Glucose Profile at Baseline, Week 28 and 52|Number of Hyperglycemic Excursions for Each Participant From 7-Point Glucose Profile at Baseline, Week 28 and 52|Greatest Magnitude of Hyperglycemic Excursions for Each Participant From 7-Point Glucose Profile at Baseline, Week 28 and 52|Change From Baseline in Body Weight (Kilograms) at Week 52|Weight Over Time (at Weeks 2, 4, 6, 8, 16, 28, 40, 52 and 64)|Population Estimates of Pharmacokinetic (PK) Parameters: Apparent Clearance [CL/F]|Population Estimates of PK Parameters: Apparent Volume of Distribution [V/F]|Population Estimates of PK Parameters: First-order Absorption Rate Constant [Ka]",GlaxoSmithKline,All,18 Years to 30 Years   (Adult),Phase 2,67,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",110933,10-Oct-14,18-Oct-17,18-Oct-17,5-Nov-14,25-Mar-19,25-Mar-19,"GSK Investigational Site, Bois-Guillaume, France|GSK Investigational Site, Caen Cedex 9, France|GSK Investigational Site, Lille Cedex, France|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Latina, Lazio, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Roma, Italy|GSK Investigational Site, Alzira/Valencia, Spain|GSK Investigational Site, Badalona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Granada, Spain|GSK Investigational Site, Hospitalet de Llobregat, Spain|GSK Investigational Site, Lleida, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Málaga, Spain|GSK Investigational Site, Pama de Mallorca, Spain|GSK Investigational Site, San Juan (Alicante), Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Birmingham, United Kingdom|GSK Investigational Site, Bristol, United Kingdom|GSK Investigational Site, Cardiff, United Kingdom|GSK Investigational Site, Darlington, United Kingdom|GSK Investigational Site, Dundee, United Kingdom|GSK Investigational Site, Durham, United Kingdom|GSK Investigational Site, Glasgow, United Kingdom|GSK Investigational Site, Liverpool, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Newcastle upon Tyne, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02284009/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02284009/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02284009
NCT02282254,Closed-loop Control of Overnight Glucose Levels (Artificial Pancreas) in Type 1 Diabètes Adults With Hypoglycemia Unawareness and Documented Nocturnal Hypoglycemia,,Completed,No Results Available,Type 1 Diabetes,Other: Overnight intervention,Percentage of time of plasma glucose levels spent below 4 mmol/L|Percentage of time of plasma glucose levels spent between 4 and 8 mmol/L|Percentage of time of plasma glucose levels spent between 4 and 10 mmol/L|Percentage of time of plasma glucose levels spent below 3.5 mmol/L|Percentage of time of plasma glucose levels spent below 3.3. mmol/L|Percentage of time of plasma glucose levels spent above 8 mmol/L|Percentage of time of plasma glucose levels spent above 10 mmol/L|Area under the curve of plasma glucose levels spent below 4 mmol/L|Area under the curve of plasma glucose levels spent below 3.5 mmol/L|Area under the curve of plasma glucose levels spent below 3.3 mmol/L|Area under the curve of plasma glucose levels spent above 8 mmol/L|Area under the curve of plasma glucose levels spent above 10 mmol/L|Mean plasma glucose levels|Standard deviation of plasma glucose levels|Total insulin delivery|Total glucagon delivery|Number of subjects experiencing at least one hypoglycemic event requiring oral treatment|Total number of hypoglycemic events requiring treatment,Institut de Recherches Cliniques de Montreal,All,"18 Years and older   (Adult, Older Adult)",Phase 2,35,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLASS-09,Oct-14,Jul-16,Jul-16,4-Nov-14,null,10-Nov-16,"Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02282254
NCT02280863,Hybrid Closed-Loop Hotel Studies With Medtronic PID Controller,,Completed,Has Results,Type 1 Diabetes,Device: Medtronic Hybrid Closed-loop System - Android Platform|Device: Medtronic Hybrid Closed-loop Integrated System,"Count of Participants With no More Than One Meter Glucose Value <50 mg/dL and no Values <40 mg/dL, no More Than Two Episodes With Meter Glucose Values Remaining >300 mg/dL for More Than 1 Hour, and no Ketonemia, Seizures, or Loss of Consciousness|Mean Glucose Values|Mean Glucose Values, Fingerstick Glucose Meter Value, Adult Cohorts|Median Glucose Values, Fingerstick Glucose Meter Value, Adolescent Cohort|Percentage of Time Within Glucose Range of 70-180 mg/dL|Percentage of Fingerstick Meter Glucose Value Tests <70 mg/dL|Percentage of Time With Sensor Glucose Values <70 mg/DL, Adult Cohorts|Percentage of Time With Sensor Glucose Values <70 mg/DL, Adolescent Cohort|Percentage of Fingerstick Meter Glucose Value Tests >300 mg/dL, Adult Cohort - Medtronic Android Interface|Percentage of Fingerstick Meter Glucose Value Tests >300 mg/dL, Adult Cohort - Integrated System Interface and Adolescent Cohort",Stanford University,All,"14 Years to 40 Years   (Child, Adult)",Not Applicable,24,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IDE: G140086|1-SRA-2014-238-|IRB 29973,Jul-14,May-15,May-15,3-Nov-14,3-Jul-18,3-Jul-18,"Stanford University Medical Center, Stanford, California, United States|UC Denver- Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Yale University- Department of Pediatric Endocrinology, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02280863
NCT02280564,Study of A Cell-Phone System to Improve Health of Youth With Diabetes,FL3X,Completed,No Results Available,Type 1 Diabetes,Behavioral: health coaching with technology support,Change from Baseline in HbA1c at 4 months|Change from Baseline in Quality of Life measures at 4 months,"University of North Carolina, Chapel Hill|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",All,12 Years to 16 Years   (Child),Not Applicable,74,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10-0240|R21DK085483-01,Mar-11,Mar-13,Mar-13,31-Oct-14,null,31-Oct-14,"University of Colorado Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|WakeMed Hospital, Raleigh, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02280564
NCT02276859,Normal Versus Dual Wave Insulin Bolus for High-protein Food,,Completed,No Results Available,Type 1 Diabetes,Drug: insulin aspart|Drug: insulin lispro|Drug: insulin glulisine,Postprandial glycemia|Hypoglycemia episodes|Glucose Area Under the Curve (AUC)|Mean amplitude of glycemic excursion,Medical University of Warsaw,All,"10 Years to 18 Years   (Child, Adult)",Phase 4,70,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,Protein Food Insulin Bolus,Oct-14,Sep-15,Sep-15,28-Oct-14,null,31-Jan-18,"Department of Pediatrics, Medical University of Warsaw, Poland, Warsaw, Poland",,https://ClinicalTrials.gov/show/NCT02276859
NCT02274103,Skype for Youth With Poorly Controlled Diabetes,SKYPE,Completed,No Results Available,Type 1 Diabetes,Behavioral: BFST,"HbA1c|Adherence to diabetes treatment using the Diabetes Self Management Profile (DSMP) (Harris et al, 2001).",Oregon Health and Science University,All,"12 Years to 18 Years   (Child, Adult)",Phase 4,92,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6000,Mar-10,Dec-12,Dec-12,24-Oct-14,null,24-Oct-14,,,https://ClinicalTrials.gov/show/NCT02274103
NCT02274740,Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients,,Terminated,No Results Available,Type II Diabetes Mellitus,Drug: LIXISENATIDE AVE0010|Drug: metformin,Change in plasma triglycerides after 10 weeks of treatment area under-the-time concentration curve between 0 and 480 minutes (AUC0-480 min)|Change from baseline in plasma triglyceride|Change from baseline in plasma cholesterol|Change from baseline in APO B48|Change from baseline in free fatty acid levels|Change from baseline in lipoprotein distribution|Change from baseline in LDL oxidation|Change from baseline in postprandial plasma glucose|Change from baseline in insulin|Change from baseline in C-peptide|Change from baseline in low grade inflammation (cytokines and stress oxidative markers)|Change in baseline coronary flow reserve to assess the effect of lixisenatide on microvascular dysfunction,Sanofi,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,2,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LIXISL07016|U1111-1153-3774,Apr-15,Aug-15,Aug-15,24-Oct-14,null,30-Jan-17,,,https://ClinicalTrials.gov/show/NCT02274740
NCT02273180,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,SORELLA1,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: SAR342434|Drug: Humalog|Drug: Insulin glargine HOE901,"Change in HbA1c From Baseline to Week 26|Percentage of Participants With HbA1c <7.0% at Week 26|Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26|Change in Mean 24-Hour Plasma Glucose Concentration From Baseline to Week 26|Change in Post Prandial Plasma Glucose (PPG) Excursion From Baseline to Week 26|Number of Hypoglycemia Events (Any Hypoglycemia, Documented Symptomatic Hypoglycemia and Severe Hypoglycemia) Per Participant-Year|Percentage of Participants With Hypersensitivity Reactions and Injection Site Reactions|Percentage of Participants With Treatment Emergent Anti-insulin Antibodies (AIAs)",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,507,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EFC12619|2013-002945-12|U1111-1131-5038,Oct-14,Dec-15,Jul-16,23-Oct-14,18-Jan-18,18-Jan-18,"Investigational Site Number 840049, Tucson, Arizona, United States|Investigational Site Number 840016, Bell Gardens, California, United States|Investigational Site Number 840048, Chula Vista, California, United States|Investigational Site Number 840046, Concord, California, United States|Investigational Site Number 840039, Fresno, California, United States|Investigational Site Number 840028, La Jolla, California, United States|Investigational Site Number 840022, Ventura, California, United States|Investigational Site Number 840003, Denver, Colorado, United States|Investigational Site Number 840037, Denver, Colorado, United States|Investigational Site Number 840005, Bradenton, Florida, United States|Investigational Site Number 840061, Miami Lakes, Florida, United States|Investigational Site Number 840057, Miami Lakes, Florida, United States|Investigational Site Number 840050, Miami, Florida, United States|Investigational Site Number 840042, Miami, Florida, United States|Investigational Site Number 840006, New Port Richey, Florida, United States|Investigational Site Number 840013, North Miami Beach, Florida, United States|Investigational Site Number 840031, Port Charlotte, Florida, United States|Investigational Site Number 840036, Atlanta, Georgia, United States|Investigational Site Number 840045, Roswell, Georgia, United States|Investigational Site Number 840020, Idaho Falls, Idaho, United States|Investigational Site Number 840019, Chicago, Illinois, United States|Investigational Site Number 840033, Chicago, Illinois, United States|Investigational Site Number 840012, McHenry, Illinois, United States|Investigational Site Number 840004, Des Moines, Iowa, United States|Investigational Site Number 840043, Marrero, Louisiana, United States|Investigational Site Number 840021, Metairie, Louisiana, United States|Investigational Site Number 840038, Baltimore, Maryland, United States|Investigational Site Number 840014, Rockville, Maryland, United States|Investigational Site Number 840060, Great Falls, Montana, United States|Investigational Site Number 840026, Omaha, Nebraska, United States|Investigational Site Number 840040, Omaha, Nebraska, United States|Investigational Site Number 840015, Albuquerque, New Mexico, United States|Investigational Site Number 840054, Albuquerque, New Mexico, United States|Investigational Site Number 840059, Mineola, New York, United States|Investigational Site Number 840030, Burlington, North Carolina, United States|Investigational Site Number 840051, Greenville, North Carolina, United States|Investigational Site Number 840062, Wilmington, North Carolina, United States|Investigational Site Number 840018, Gallipolis, Ohio, United States|Investigational Site Number 840007, Dakota Dunes, South Dakota, United States|Investigational Site Number 840027, Rapid City, South Dakota, United States|Investigational Site Number 840041, Dallas, Texas, United States|Investigational Site Number 840029, Dallas, Texas, United States|Investigational Site Number 840034, Dallas, Texas, United States|Investigational Site Number 840002, Houston, Texas, United States|Investigational Site Number 840011, Chesapeake, Virginia, United States|Investigational Site Number 840023, Tacoma, Washington, United States|Investigational Site Number 840009, Milwaukee, Wisconsin, United States|Investigational Site Number 250002, Corbeil Essonnes, France|Investigational Site Number 250005, Mantes La Jolie, France|Investigational Site Number 250003, Montpellier Cedex 5, France|Investigational Site Number 250001, Vandoeuvre Les Nancy, France|Investigational Site Number 276001, Berlin, Germany|Investigational Site Number 276004, Dortmund, Germany|Investigational Site Number 276006, Hannover, Germany|Investigational Site Number 276002, Heidelberg, Germany|Investigational Site Number 276003, Neumünster, Germany|Investigational Site Number 276008, Pirna, Germany|Investigational Site Number 276007, Potsdam, Germany|Investigational Site Number 276005, Sulzbach-Rosenberg, Germany|Investigational Site Number 348002, Budapest, Hungary|Investigational Site Number 348005, Budapest, Hungary|Investigational Site Number 348003, Budapest, Hungary|Investigational Site Number 348011, Budapest, Hungary|Investigational Site Number 348010, Budapest, Hungary|Investigational Site Number 348001, Budapest, Hungary|Investigational Site Number 348007, Debrecen, Hungary|Investigational Site Number 392006, Chuo-Ku, Japan|Investigational Site Number 392003, Higashiosaka-Shi, Japan|Investigational Site Number 392004, Izumisano-Shi, Japan|Investigational Site Number 392005, Kamakura-Shi, Japan|Investigational Site Number 392001, Shinjuku-Ku, Japan|Investigational Site Number 392002, Yamato-Shi, Japan|Investigational Site Number 616005, Krakow, Poland|Investigational Site Number 616001, Poznan, Poland|Investigational Site Number 616003, Szczecin, Poland|Investigational Site Number 616002, Warszawa, Poland|Investigational Site Number 616004, Zabrze, Poland|Investigational Site Number 643003, Moscow, Russian Federation|Investigational Site Number 643006, Samara, Russian Federation|Investigational Site Number 643002, Saratov, Russian Federation|Investigational Site Number 643004, St-Petersburg, Russian Federation|Investigational Site Number 643001, St-Petersburg, Russian Federation|Investigational Site Number 643005, St-Petersburg, Russian Federation|Investigational Site Number 643007, Tomsk, Russian Federation|Investigational Site Number 724002, A Coruña, Spain|Investigational Site Number 724001, Cáceres, Spain|Investigational Site Number 724004, Lérida, Spain|Investigational Site Number 724005, Málaga, Spain|Investigational Site Number 724003, Sabadell, Spain",,https://ClinicalTrials.gov/show/NCT02273180
NCT02273258,A Study to Compare Pharmacokinetics and Pharmacodynamics of SAR342434 to Insulin Lispro in Subjects With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Drug: SAR342434|Drug: Insulin Lispro,"Maximum plasma concentration (Cmax) of SAR342434, US-approved Humalog and EU-approved Humalog|Area under the concentration versus time curve (AUC) of SAR342434, US-approved Humalog and EU-approved Humalog|Area under the body weight standardized glucose infusion rate (GIR) versus time curve from 0 to 12 hours post administration (GIR-AUC0-12)|The fractional area under the concentration versus time curve from 0 or y to x hours post administration (INS-AUC0 or Y to X)|Time to 20% of AUC (t20%-AUC)|NS-tmax, INS-t1/2z|The fractional area under the body weight standardized GIR versus time curve from 0 or y to x hours post administration (GIR-AUC0 or Y to X)|Time to 20% of total GIR-AUC0-12h (t20%-GIR-AUC0-12h)|Maximum smoothed body weight standardized GIR (GIRmax)|Time to GIRmax (GIR-tmax)|Duration of blood glucose control (time to elevation of smoothed blood glucose profile above clamp level and to elevation above different pre-specified blood glucose levels)|Number of patients with AEs, SAEs, laboratory, vital signs and electrocardiographic abnormalities , injections site reaction assessment (ISR), and if any, hypoglycemia",Sanofi,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,30,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PDY12704|2012-004453-86|U1111-1134-4816,Mar-13,Jul-13,Jul-13,23-Oct-14,null,23-Oct-14,"Sanofi Administrative Office, Frankfurt, Germany",,https://ClinicalTrials.gov/show/NCT02273258
NCT02272348,Self-management of Type 1 Diabetes Under Functional Insulin Therapy,EVAUTODIAB,Unknown status,No Results Available,Type 1 Diabetes|Basal-bolus Multiple-dily Insulin Injections|Insulin Pump (CSII),Other: Training course to functional insulin therapy|Other: Usual diabetes management.,"To assess the impact of therapeutic education by functional insulin therapy in patients with type 1 diabetes on their ability to disease self-management.|To assess the effect of education to functional insulin therapy on HbA1c level|To assess the effect of education to functional insulin therapy on hypoglycemia frequency|To assess the effect of education to functional insulinotherapy on the score of each of the 20 items of CIDS questioonaire|To assess the validity, the concordance and the sensitivity to change of EAD questionnaire (specific for self-management of diabetes) in comparison with CIDS test","University Hospital, Montpellier",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,170,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),UF9372,Dec-14,Oct-15,Oct-15,22-Oct-14,null,22-Oct-14,"Lapeyronie Hospital - CHU de Montpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT02272348
NCT02269735,"A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001)",,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: MK-2640|Biological: Regular Human Insulin (RHI)|Drug: Dextrose|Biological: Insulin aspart|Drug: Rescue medication,Number of participants who experienced an adverse event|Pharmacokinetic parameter: steady state plasma concentration (Css)|Pharmacokinetic parameter: area under the plasma concentration curve from time 0 to infinity (AUC [0 to infinity])|Pharmacokinetic parameter: clearance (CL)|Pharmacokinetic parameter: volume of distribution (Vd)|Pharmacokinetic parameter: plasma apparent terminal half-life|Pharmacodynamic parameter: steady-state glucose infusion-rate (GIR) in Part II|Number of participants who discontinued study drug due to an adverse event|Number of participants with anti-drug antibody (ADA) formation,Merck Sharp & Dohme Corp.,All,18 Years to 55 Years   (Adult),Phase 1,74,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2640-001,26-Nov-14,29-Jul-16,29-Jul-16,21-Oct-14,null,15-Jan-19,,,https://ClinicalTrials.gov/show/NCT02269735
NCT02268214,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,DEPICT 1,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Dapagliflozin|Drug: Placebo for dapagliflozin,Adjusted Mean Change in HbA1c From Baseline at Week 24|Adjusted Mean Percent Change in Total Daily Insulin Dose From Baseline at Week 24|Adjusted Mean Percent Change in Body Weight From Baseline at Week 24|Adjusted Mean Change in 24-hour Mean Continuous Glucose Monitoring Glucose From Baseline at Week 24|Adjusted Mean Change in 24-hour Continuous Glucose Monitoring MAGE From Baseline at Week 24|Adjusted Mean Change in Percent 24-hour Continuous Glucose Monitoring Glucose > 70 and <= 180 (mg/dL) From Baseline at Week 24|Subjects With HbA1c Reduction From Baseline to Week 24 (LOCF) >= 0.5% and Without Severe Hypoglycemia Events,AstraZeneca|Bristol-Myers Squibb,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,833,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MB102-229|2013-004674-97|D1695C00006,11-Nov-14,4-Jan-17,25-Aug-17,20-Oct-14,29-Mar-18,13-Sep-18,"Research Site, Little Rock, Arkansas, United States|Research Site, Encino, California, United States|Research Site, La Mesa, California, United States|Research Site, San Diego, California, United States|Research Site, Tarzana, California, United States|Research Site, Torrance, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Cooper City, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Port Orange, Florida, United States|Research Site, Idaho Falls, Idaho, United States|Research Site, Des Moines, Iowa, United States|Research Site, Louisville, Kentucky, United States|Research Site, Portland, Maine, United States|Research Site, Hyattsville, Maryland, United States|Research Site, Rockville, Maryland, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Chesterfield, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Albany, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Greenville, North Carolina, United States|Research Site, Morehead City, North Carolina, United States|Research Site, Langhorne, Pennsylvania, United States|Research Site, Kingsport, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Amarillo, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Olympia, Washington, United States|Research Site, Concord, Australia|Research Site, Daw Park, Australia|Research Site, Fitzroy, Australia|Research Site, Heidelberg West, Australia|Research Site, Newcastle, Australia|Research Site, Southport, Australia|Research Site, Wollongong, Australia|Research Site, Innsbruck, Austria|Research Site, Saint Stefan/Stainz, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Bonheiden, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Vancouver, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, London, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Arhus C, Denmark|Research Site, Esbjerg, Denmark|Research Site, Odense, Denmark|Research Site, Randers NØ, Denmark|Research Site, Helsinki, Finland|Research Site, Jyvaskyla, Finland|Research Site, Kuopio, Finland|Research Site, Oulu, Finland|Research Site, Tampere, Finland|Research Site, Besançon Cedex, France|Research Site, Corbeil-Essonnes, France|Research Site, Dijon, France|Research Site, SAINT HERBLAIN Cedex, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Aschaffenburg, Germany|Research Site, Aßlar, Germany|Research Site, Bad Oeynhausen, Germany|Research Site, Falkensee, Germany|Research Site, Munich, Germany|Research Site, Munster, Germany|Research Site, Neuwied, Germany|Research Site, Oldenburg, Germany|Research Site, Pohlheim, Germany|Research Site, Schweinfurt, Germany|Research Site, Sulzbach, Germany|Research Site, Witten, Germany|Research Site, Baja, Hungary|Research Site, Balatonfured, Hungary|Research Site, Budapest, Hungary|Research Site, Létavértes, Hungary|Research Site, Szeged, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Safed, Israel|Research Site, Tel-Aviv, Israel|Research Site, Tikva, Israel|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Padowa, Italy|Research Site, Palermo, Italy|Research Site, Ravenna, Italy|Research Site, Sesto San Giovanni, Italy|Research Site, Siena, Italy|Research Site, Aguascalientes, Mexico|Research Site, Chihuahua, Mexico|Research Site, Cuernavaca, Mexico|Research Site, Guadalajara, Mexico|Research Site, Merida, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, Torreon, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Zapopan, Mexico|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Dolj, Romania|Research Site, Galati, Romania|Research Site, Iasi, Romania|Research Site, Timisoara, Romania|Research Site, A Coruña, Spain|Research Site, Almeria, Spain|Research Site, Barcelona, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Göteborg, Sweden|Research Site, Karlstad, Sweden|Research Site, Lund, Sweden|Research Site, Uppsala, Sweden|Research Site, Belfast, United Kingdom|Research Site, Chesterfield, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Welwyn Garden City, United Kingdom",,https://ClinicalTrials.gov/show/NCT02268214
NCT02265809,Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes,DILfrequency,Completed,No Results Available,Type 1 Diabetes,Drug: Aldesleukin,"Change from baseline of CD4 T regulatory cells, CD4 T effector cells and CD25 expression on T regulatory cells during treatment with ultra low dose IL-2|T regulatory cell number, phenotype and proliferation|T effector cell number, phenotype and proliferation|Natural Killer cell number, phenotype and proliferation|B lymphocyte cell number, phenotype and proliferation|T cell and Natural killer cell intracellular signalling|Full blood count|Blood levels of IL-2, IL-6, IL-10, TNF-alpha, soluble CD25, IP-10, soluble rIL-6, and CRP|Change in metabolic control|Safety and tolerability","Cambridge University Hospitals NHS Foundation Trust|University of Cambridge|Sir Jules Thorn Charitable Trust|Juvenile Diabetes Research Foundation|Wellcome Trust|National Institute for Health Research, United Kingdom",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,41,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,DILfrequency,3-Oct-14,26-May-16,26-May-16,16-Oct-14,null,21-Aug-18,"Wellcome Trust Clinical Research Facility, Addenbrookes Hospital, Cambridge, Cambridgeshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT02265809
NCT02261545,"The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient",,Unknown status,No Results Available,Diabetes Mellitus Type II,Dietary Supplement: n-3 Fatty Acid|Dietary Supplement: Placebo,Serum Fasting Blood Sugar(FBS)|Serum Insulin|Serum HbA1C|Serum Resistin|Serum adiponectin|Serum mcp-1|Gene Expression of AdipoR1|Gene Expression of AdipoR2|Gene Expression of Sirt-1|Beck depression score|Serum cholesterol|Serum LDL cholesterol|Serum TG|Serum HDL cholesterol,Tehran University of Medical Sciences,All,"30 Years to 65 Years   (Adult, Older Adult)",Phase 4,88,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care",25367,Sep-14,Jan-16,Feb-16,10-Oct-14,null,18-Nov-15,,,https://ClinicalTrials.gov/show/NCT02261545
NCT02258373,A Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Type 1 Diabetes,REPLACE-BG,Completed,Has Results,Type 1 Diabetes,Device: CGM+BGM|Device: CGM Only,"Percentage of Time in Range of 70 to 180 mg/dl, Measured With CGM|Mean Glucose|Measures of Glycemic Variability: Coefficient of Variation|Percentage of Time With Sensor Value <70 mg/dl, Measured With CGM|Percentage of Time With Sensor Values <60 mg/dl, Measured With CGM|Percentage of Time With Sensor Values <50 mg/dl, Measured With CGM|Percentage of Days With at Least 20 Minutes of Sensor Glucose Values <60 mg/dl|Percentage of Time With Sensor Values >180 mg/dl, Measured With CGM|Percentage of Time With Sensor Values > 250 mg/dl, Measured With CGM|Percentage of Time With Sensor Values > 300 mg/dl, Measured With CGM|Percentage of Days With at Least 20 Minutes of Sensor Glucose Values >300 mg/dl|Change in HbA1c|Number of Participants With no Worsening of HbA1c by Greater Than 0.3% AND no Severe Hypoglycemia Event|Number of Participants With >=1 Severe Hypoglycemia Events|Number of Participants With >=1 Diabetic Ketoacidosis (DKA) Events|Number of Participants With >=1 Ketotic Events Not Meeting Criteria for DKA With Blood Ketone Level >=0.6 mmol/L|Number of Participants With >=1 Ketotic Events Not Meeting Criteria for DKA With Blood Ketone Level >=1.0 mmol/L|Number of Participants With >=1 Serious Adverse Event Other Than SH",Jaeb Center for Health Research,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,226,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,T1DX-REPLACE-BG,Mar-15,Oct-16,Oct-16,7-Oct-14,9-Aug-18,9-Aug-18,"University of Southern California, Beverly Hills, California, United States|Scripps Health, San Diego, California, United States|Barbara Davis Center for Diabetes, Denver, Colorado, United States|University of South Florida, Tampa, Florida, United States|Atlanta Diabetes, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Iowa Diabetes and Endocrinology Center, Des Moines, Iowa, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|International Diabetes Center-Park Nicollet, Minneapolis, Minnesota, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02258373
NCT02256293,Acceptability and Feasibility of an ACT-Based Group to Improve Diabetes Self-Management,,Withdrawn,No Results Available,Type 1 Diabetes Mellitus,Behavioral: Diabetes self-management group based on Acceptance and Commitment Therapy (ACT).,Acceptability|Diabetes self-management,Duke University,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00040489,Jan-15,Jan-16,null,3-Oct-14,null,12-Jun-15,,,https://ClinicalTrials.gov/show/NCT02256293
NCT02248454,Insulin Bolus Required for High Fat Foods in Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Drug: Lispro,"Predictors of fat ""sensitivity""",Joslin Diabetes Center|Boston Children’s Hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,High fat bolus,Sep-14,Apr-15,Apr-15,25-Sep-14,null,26-Apr-17,,,https://ClinicalTrials.gov/show/NCT02248454
NCT02246582,Adult Accuracy Study of the Enlite 3 Glucose Sensor,E3,Completed,Has Results,Type 1 Diabetes|Type 2 Diabetes,Device: Enlite 3|Device: Guardian Mobile App|Device: 640G Insulin Pump,Enlite 3 Sensor Accuracy Mean Absolute Relative Difference (MARD)|Retrospective Re-Analysis (MARD With 1 Additional Calibration)|Retrospective Analysis (MARD for the GSR With Minimum and 1 Additional Calibration),Medtronic Diabetes,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Not Applicable,118,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),CEP292,Sep-14,Aug-15,Aug-15,23-Sep-14,2-Nov-16,2-Nov-16,"AMCR Institute, Escondido, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Barbara Davis Center, Aurora, Colorado, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Rainier Clinical Research Center, Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT02246582
NCT02246712,Influence of Diabetes on Tramadol Pharmacokinetics,,Completed,No Results Available,Neuropathic Pain|Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Drug: Single oral dose of 100 mg racemic tramadol|Other: CYP2D6 phenotype|Other: CYP3A phenotype|Genetic: CYP2B6 genotype,"Kinetic parameters (AUC, Cmax, Tmax, apparent total clearance, and apparent volume of distribution) of tramadol enantiomers were estimated.|Urinary concentration ratio (metoprolol/alfa-hydroxymetoprolol) as an in vivo measure of CYP2D6 activity|Clearance of midazolam as a measure of CYP3A in vivo activity|Pain scores on the visual analog scale",Universidade Estadual Paulista Júlio de Mesquita Filho|University of Sao Paulo,All,18 Years to 59 Years   (Adult),Phase 4,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DIABETRA,Jun-08,May-10,Dec-11,23-Sep-14,null,23-Sep-14,"Universidade Estadual Paulista Julio de Mesquita Filho, Araraquara, SP, Brazil",,https://ClinicalTrials.gov/show/NCT02246712
NCT02243072,Home-Based Interventions for Adolescents With Type 1 Diabetes,R34,Completed,No Results Available,Type 1 Diabetes,Behavioral: Fit Families plus Standard Medical Care,"Metabolic Control: Hemoglobin A1c (HbA1c)|DKA admissions and emergency room (ER) Visits: hospital information systems data extraction, Service Utilization Questionnaire (SUQ)|Quality of life|Regimen Adherence: Diabetes Management Scale (DMS), Glucose Meter Downloads",Wayne State University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,10 Years to 17 Years   (Child),Not Applicable,49,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1R34DK102091-01|R34DK102091,Dec-14,Dec-15,Jul-16,17-Sep-14,null,2-Jun-17,"Children's Hospital of Michigan, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02243072
NCT02241889,"Three-way, Cross-over Closed-loop Exercise Study",,Completed,Has Results,Type 1 Diabetes,Device: Insulin pump therapy|Device: Closed-loop Artificial Pancreas Controller,Percent of Time With Sensed Glucose < 70 mg/dl|Percent of Time With Sensed Glucose Between 70-180 mg/dl|Mean of the Mean Sensed Glucose Per Participant|Number of Carbohydrate Treatments|Percent of Time With Sensed Glucose < 50 mg/dl|Percent of Time With Sensed Glucose > 180 mg/dl|Number of Events Capillary Blood Glucose (CBG) <70 mg/dl|Number of Events With CBG Between 70 - 180 mg/dl|Number of Events With CBG <50 mg/dl|Percent of Time of CBG>180 mg/dl,Oregon Health and Science University,All,21 Years to 45 Years   (Adult),Not Applicable,23,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DP3-2014,Jan-15,Sep-15,Sep-15,16-Sep-14,28-Oct-15,22-May-17,"Oregon Health and Science University, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT02241889
NCT02239354,"A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus",,"Active, not recruiting",No Results Available,Type 1 Diabetes Mellitus,Device: VC-01™ Combination Product,Incidence of all adverse events reported during the study.|Change in C-peptide,ViaCyte|California Institute for Regenerative Medicine (CIRM),All,18 Years to 55 Years   (Adult),Phase 1|Phase 2,69,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,VC01-101,Sep-14,Jan-21,Jan-21,12-Sep-14,null,8-Jan-19,"University of California at San Diego, San Diego, California, United States|University of Alberta Hospital, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT02239354
NCT02236754,Evaluation of 18F-FP-DTBZ Pancreatic PET Scanning as a Tool to Measure Beta Cell Mass,,Withdrawn,No Results Available,"Healthy Volunteers|Diabetes Mellitus, Type 1",Drug: 18F-FP-DTBZ|Radiation: PET Scanning,Mean BPND (non-displaceable binding potential),Columbia University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years to 70 Years   (Adult, Older Adult)",Early Phase 1,0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,AAAJ5709|R01DK077493-03,Jul-13,30-Jan-17,1-Mar-17,11-Sep-14,null,1-Feb-17,"Naomi Berrie Diabetes Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02236754
NCT02232698,An Evaluation of Novel Glucose Sensing Technology on Hypoglycaemia in Type 1 Diabetes (IMPACT),IMPACT,Completed,Has Results,Type 1 Diabetes Mellitus,Device: Sensor Based Glucose Monitoring System|Device: Standard Blood Glucose Monitoring,"Time Spent <70 mg/dL|HbA1c at 6 Months|Time Spent <55 mg/dL and <40 mg/dL|Frequency of Episodes <70 mg/dL, <55 mg/dL and <40 mg/dL|Time Spent >180 mg/dL and >240 mg/dL|Time in Range|Number of Glucose Measurements Performed|System Utilisation|Change in Diabetes Treatment Satisfaction Questionnaire (DTSQc) Scores From Day 1 to Day 208",Abbott Diabetes Care,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,328,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,ADC-CI-APO-13019,Sep-14,Oct-15,Oct-15,5-Sep-14,10-Apr-17,10-Apr-17,"VIVIT-Institut am Akad. Lehrkrankenhaus Feldkirch, Innere Medizin und Kardiologie, Feldkirch, Austria|Medizinische Universität Graz Abteilung für Innere Medizin, Klin. Abteilung für Endokrinologie und Stoffwechsel, Graz, Austria|Medizinische Universität Innsbruck, Innsbruck, Austria|Diakonissen-Krankenhaus Salzburg, Salzburg, Austria|Klinik fuer Innere Medizin III Medizinische Universitaet Wien, Wien, Austria|Wilhelminenspital Medzin 5, Wien, Austria|Diabetes Klinik Bad Mergentheim, Bad Mergentheim, Germany|Zentrum für Diabetologie Hamburg Bergedorf, Hamburg, Germany|Diabetes-Zentrum Hannover-Nord, Hannover, Germany|Diabetes Center Quakenbruck, Quakenbrück, Germany|Versdias GmbH, Sūlzbach-Rosenberg, Germany|Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|Onze Lieve Vrouwe gasthuis ( OLVG), Amsterdam, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Medisch Centrum Haaglanden, Den Haag, Netherlands|Bethesda Diabetes Research Center, Hoogeveen, Netherlands|St. Antonius Ziekenhuis, Utrecht, Netherlands|Hospital Germans Trias i Pujol, Badalona, Spain|Clinica Diabetologica, Gijon, Spain|Servicio de Endocrinología Hospital Unversitario Cruces, Vizcaya, Spain|Falu Lasarett, Falun, Sweden|Karolinska Universitetssjukhuset Solna, Solna, Sweden|Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT02232698
NCT02232971,Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 Diabetes,GluST1,Unknown status,No Results Available,"Diabetes Mellitus, Type 1",Drug: Glucagon|Other: Isotonic saline solution,Maximum plasma glucose response|Duration of hyperglycemic effect of glucagon,Hvidovre University Hospital|The Novo Nordic Foundation|University of Copenhagen,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,8,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,GluST1_2014|2014-002267-15|H-1-2014-041,Sep-14,Jan-15,Jul-15,5-Sep-14,null,25-Mar-15,"Hvidovre University Hospital, Hvidovre, Denmark",,https://ClinicalTrials.gov/show/NCT02232971
NCT02230137,Text Message for Adolescents With Poorly Controlled Type 1 Diabetes,Diabeto-SMS,Completed,No Results Available,Type 1 Diabetes,Behavioral: Text message arm,HbA1c level|Compliance|Quality of life|Satisfaction survey,Assistance Publique - Hôpitaux de Paris,All,"12 Years to 20 Years   (Child, Adult)",Not Applicable,92,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2014-A00915-42,Feb-15,Jul-16,Jul-16,3-Sep-14,null,20-Jul-16,"AP-HP Necker, Paris, France",,https://ClinicalTrials.gov/show/NCT02230137
NCT02229240,Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus,,Withdrawn,No Results Available,"Diabetes Mellitus, Type 2",Drug: Albiglutide|Drug: Matching albiglutide placebo,"Percentage of subjects with severe or documented symptomatic hypoglycemia through Week 26|Change from baseline in glycosylated hemoglobin (HbA1c) at Week 26|Change from baseline in body weight at Week 26 and over time|Total daily insulin dose, basal insulin dose and bolus insulin dose at Week 26 and over time|HbA1c change from baseline in over time|Fasting plasma glucose (FPG) change from Baseline at Week 26 and over time|Proportion of subjects achieving a HbA1c <7.0% and < 6.5% at Week 26 and over time|Percentage of subjects achieving HbA1c <7.0% without weight gain after 26 weeks of treatment|Percentage of subjects achieving HbA1c <7.0% without severe or documented symptomatic hypoglycemia after 26 weeks of treatment|Percentage of subjects achieving HbA1c <7.0% without weight gain and without severe or documented hypoglycemia after 26 weeks of treatment|Number of subjects with non-serious adverse events (AE), serious adverse events (SAE), and AEs and SAEs leading to discontinuation|Incidence of hypoglycemic events|Assessment of clinical laboratory tests, lipids, vital signs, ECGs and physical examinations",GlaxoSmithKline|PPD,All,"18 Years and older   (Adult, Older Adult)",Phase 3,0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",111892,Aug-15,Dec-15,Dec-15,1-Sep-14,null,11-Jan-16,,,https://ClinicalTrials.gov/show/NCT02229240
NCT02229097,Efficacy of Coordinated Insulin Boluses in Type 1 Diabetic Patients,COBOL,Completed,No Results Available,Type 1 Diabetes,Drug: Normal bolus|Drug: Coordinated bolus,postprandial glycaemia|adverse events|severe hypoglycaemia frequency|insulin doses|mean glycaemia|standard deviation of glycaemia|frequency of glycaemia < or = 60mg/dl|frequency of glycaemia between 61-140mg/dl|frequency of glycaemia >140mg/dl|mean glycemia|standard deviation|time spent within glucose range < or = 60mg/dl|time spent within glucose range between 61-140mg/dl|time spent within glucose range mg/dl|fructosamine,"University Hospital, Toulouse",All,"18 Years and older   (Adult, Older Adult)",Phase 4,17,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13 7029 08|2014-000969-47|13-074,Oct-14,Nov-16,Nov-16,29-Aug-14,null,23-Feb-17,"University Hospital Toulouse Rangueil, Toulouse, Haute Garonne, France|Saint-André Hospital, Bordeaux, France|Lapeyronie Hospital, Montpellier, France",,https://ClinicalTrials.gov/show/NCT02229097
NCT02227849,Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus,,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Canagliflozin (TA-7284)|Drug: GLP-1 analogue,Safety and Tolerability Assessed by Adverse Events (Number of Participants Experiencing With Adverse Events)|Change in Percentage of HbA1c|Change in Fasting Plasma Glucose|Percentage Change in Body Weight|Change in Blood Pressure,Mitsubishi Tanabe Pharma Corporation,All,"20 Years and older   (Adult, Older Adult)",Phase 4,71,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TA-7284-12,Aug-14,Mar-16,Mar-16,28-Aug-14,14-Mar-19,10-Apr-19,"Reserch site, Chubu, Japan|Reserch site, Hokkaido, Japan|Reserch site, Kanto, Japan|Reserch site, Kinki, Japan",,https://ClinicalTrials.gov/show/NCT02227849
NCT02227862,Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1),INSTRIDE 1,Completed,No Results Available,Type 1 Diabetes,Drug: Mylan's insulin glargine|Drug: Lantus®,Change in HbA1c from baseline to 24 weeks|Immunogenicity: Change from baseline in titer and incidence of ADA|Rate per 30 days of hypoglycemic events|Insulin dose per body weight (U/kg),Mylan Inc.|Mylan GmbH,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,558,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MYL-GAI-3001,Aug-14,Jul-16,Jul-16,28-Aug-14,null,28-Feb-18,"Mylan Investigational Site, Bell Gardens, California, United States|Mylan Investigational Site, Fresno, California, United States|Mylan Investigational Site, Greenbrae, California, United States|Mylan Investigational Site, La Jolla, California, United States|Mylan Investigational Site, La Mesa, California, United States|Mylan Investigational Site, Long Beach, California, United States|Mylan Investigational Site, Los Gatos, California, United States|Mylan Investigational Site, Mission Hills, California, United States|Mylan Investigational Site, National City, California, United States|Mylan Investigational Site, Northridge, California, United States|Mylan Investigational Site, Tustin, California, United States|Mylan Investigational Site, Walnut Creek, California, United States|Mylan Investigational Site, Bradenton, Florida, United States|Mylan Investigational Site, Cooper City, Florida, United States|Mylan Investigational Site, Hialeah, Florida, United States|Mylan Investigational Site, Hollywood, Florida, United States|Mylan Investigational Site, Miami, Florida, United States|Mylan Investigational Site, Miami, Florida, United States|Mylan Investigational Site, New Port Richey, Florida, United States|Mylan Investigational Site, Palm Harbor, Florida, United States|Mylan Investigational Site, West Palm Beach, Florida, United States|Mylan Investigational Site, Atlanta, Georgia, United States|Mylan Investigational Site, Columbus, Georgia, United States|Mylan Investigational Site, Honolulu, Hawaii, United States|Mylan Investigational Site, Idaho Falls, Idaho, United States|Mylan Investigational Site, Crystal Lake, Illinois, United States|Mylan Investigational Site, LaGrange, Illinois, United States|Mylan Investigational Site, Springfield, Illinois, United States|Mylan Investigational Site, Anderson, Indiana, United States|Mylan Investigational Site, Muncie, Indiana, United States|Mylan Investigational Site, Council Bluffs, Iowa, United States|Mylan Investigational Site, Des Moines, Iowa, United States|Mylan Investigational Site, Overland Park, Kansas, United States|Mylan Investigational Site, Topeka, Kansas, United States|Mylan Investigational Site, Lexington, Kentucky, United States|Mylan Investigational Site, Billings, Montana, United States|Mylan Investigational Site, Omaha, Nebraska, United States|Mylan Investigational Site, Omaha, Nebraska, United States|Mylan Investigational Site, Las Vegas, Nevada, United States|Mylan Investigational Site, Albany, New York, United States|Mylan Investigational Site, Mineola, New York, United States|Mylan Investigational Site, Staten Island, New York, United States|Mylan Investigational Site, Syracuse, New York, United States|Mylan Investigational Site, Asheville, North Carolina, United States|Mylan Investigational Site, Burlington, North Carolina, United States|Mylan Investigational Site, Greensboro, North Carolina, United States|Mylan Investigational Site, Greenville, North Carolina, United States|Mylan Investigational Site, Hickory, North Carolina, United States|Mylan Investigational Site, Morehead City, North Carolina, United States|Mylan Investigational Site, Wilmington, North Carolina, United States|Mylan Investigational Site, Cincinnati, Ohio, United States|Mylan Investigational Site, Mentor, Ohio, United States|Mylan Investigational Site, Bend, Oregon, United States|Mylan Investigational Site, Corvallis, Oregon, United States|Mylan Investigational Site, Chattanooga, Tennessee, United States|Mylan Investigational Site, Memphis, Tennessee, United States|Mylan Investigational Site, Austin, Texas, United States|Mylan Investigational Site, Dallas, Texas, United States|Mylan Investigational Site, El Paso, Texas, United States|Mylan Investigational Site, Round Rock, Texas, United States|Texas Diabetes & Endocrinology, Round Rock, Texas, United States|Mylan Investigational Site, San Antonio, Texas, United States|Mylan Investigational Site, Ogden, Utah, United States|Mylan Investigational Site, Salt Lake City, Utah, United States|Mylan Investigational Site, Salt Lake City, Utah, United States|Mylan Investigational Site, Salt Lake City, Utah, United States|Mylan Investigational Site, South Jordan, Utah, United States|Mylan Investigational Site, Chesapeake, Virginia, United States|Mylan Investigational Site, Manassas, Virginia, United States|Mylan Investigational Site, Renton, Washington, United States|Mylan Investigational Site, Tacoma, Washington, United States|Mylan Investigational Site, Vancouver, Washington, United States|Mylan Investigational Site, Red Deer, Alberta, Canada|Mylan Investigational Site, Vancouver, British Columbia, Canada|Mylan Investigational Site, Winnipeg, Manitoba, Canada|Mylan Investigational Site, Laval, Quebec, Canada|Mylan Investigational Site, Mirabel, Quebec, Canada|Mylan Investigational Site, Montreal, Quebec, Canada|Mylan Investigational Site, Brno, Czechia|Mylan Investigational Site, Brno, Czechia|Mylan Investigational Site, Broumov, Czechia|Mylan Investigational Site, Bruntal, Czechia|Mylan Investigational Site, Ceske Budejovice, Czechia|Mylan Investigational Site, Olomouc, Czechia|Mylan Investigational Site, Pardubice, Czechia|Mylan Investigational Site, Praha 10, Czechia|Mylan Investigational Site, Praha 10, Czechia|Mylan Investigational Site, Parnu, Estonia|Mylan Investigational Site, Tallinn, Estonia|Mylan Investigational Site, Tartu, Estonia|Mylan Investigational Site, Wangen im Allgau, Baden Wuerttemberg, Germany|Mylan Investigational Site, Aschaffenburg, Bayern, Germany|Mylan Investigational Site, Schweinfurt, Bayern, Germany|Mylan Investigational Site, Frankfurt, Hessen, Germany|Mylan Investigational Site, Muenster, Nordrhein Westfalen, Germany|Mylan Investigational Site, Sankt Ingbert, Saarland, Germany|Mylan Investigational Site, Hohenmoelsen, Sachsen Anhalt, Germany|Mylan Investigational Site, Dresden, Sachsen, Germany|Mylan Investigational Site, Hamburg, Germany|Mylan Investigational Site, Hamburg, Germany|Mylan Investigational Site, Baja, Hungary|Mylan Investigational Site, Budapest, Hungary|Mylan Investigational Site, Budapest, Hungary|Mylan Investigational Site, Budapest, Hungary|Mylan Investigational Site, Eger, Hungary|Mylan Investigational Site, Gyula, Hungary|Mylan Investigational Site, Letavertes, Hungary|Mylan Investigational Site, Mako, Hungary|Mylan Investigational Site, Miskolc, Hungary|Mylan Investigational Site, Szeged, Hungary|Mylan Investigational Site, Kuldiga, Latvia|Mylan Investigational Site, Limbazi, Latvia|Mylan Investigational Site, Ogre, Latvia|Mylan Investigational Site, Riga, Latvia|Mylan Investigational Site, Riga, Latvia|Mylan Investigational Site, Riga, Latvia|Mylan Investigational Site, Sigulda, Latvia|Mylan Investigational Site, Talsi, Latvia|Mylan Investigational Site, Bacau, Romania|Mylan Investigational Site, Baia Mare, Romania|Mylan Investigational Site, Bucuresti, Romania|Mylan Investigational Site, Bucuresti, Romania|Mylan Investigational Site, Buzau, Romania|Mylan Investigational Site, Cluj Napoca, Romania|Mylan Investigational Site, Galati, Romania|Mylan Investigational Site, Iasi, Romania|Mylan Investigational Site, Oradea, Romania|Mylan Investigational Site, Oradea, Romania|Mylan Investigational Site, Timisoara, Romania|Mylan Investigational Site, Banska Bystrica, Slovakia|Mylan Investigational Site, Bardejov, Slovakia|Mylan Investigational Site, Bratislava, Slovakia|Mylan Investigational Site, Bratislava, Slovakia|Mylan Investigational Site, Bratislava, Slovakia|Mylan Investigational Site, Dolny Kubin, Slovakia|Mylan Investigational Site, Kosice, Slovakia|Mylan Investigational Site, Levice, Slovakia|Mylan Investigational Site, Lubochna, Slovakia|Mylan Investigational Site, Nove Mesto nad Vahom, Slovakia|Mylan Investigational Site, Nove Zamky, Slovakia|Mylan Investigational Site, Presov, Slovakia|Mylan Investigational Site, Prievidza, Slovakia|Mylan Investigational Site, Pruske, Slovakia|Mylan Investigational Site, Rimavska Sobota, Slovakia|Mylan Investigational Site, Sabinov, Slovakia|Mylan Investigational Site, Skalica, Slovakia|Mylan Investigational Site, Sturovo, Slovakia|Mylan Investigational Site, Trebisov, Slovakia|Mylan Investigational Site, Zilina, Slovakia|Mylan Investigational Site, Bloemfontein, Free State, South Africa|Mylan Investigational Site, Johannesburg, Gauteng, South Africa|Mylan Investigational Site, Johannesburg, Gauteng, South Africa|Mylan Investigational Site, Johannesburg, Gauteng, South Africa|Mylan Investigational Site, Krugersdorp, Gauteng, South Africa|Mylan Investigational Site, Pretoria, Gauteng, South Africa|Mylan Investigational Site, Durban, KwaZulu-Natal, South Africa|Mylan Investigational Site, Cape Town, Western Cape, South Africa|Mylan Investigational Site, Cape Town, Western Cape, South Africa|Mylan Investigational Site, Cape Town, Western Cape, South Africa|Mylan Investigational Site, Plymouth, Devon, United Kingdom|Mylan Investigational Site, Leicester, Leicestershire, United Kingdom|Mylan Investigational Site, Swansea, United Kingdom",,https://ClinicalTrials.gov/show/NCT02227862
NCT02225379,Development and Assessment of Feasibility of Non-invasive Multiple Sensor Hypo-Sense as a Tool for Detection of Hypoglycemia,Hypo-Sense,Completed,No Results Available,Type 1 Diabetes|Nocturnal Hypoglycemia,Device: Hypo-Sense (non invasive sensor),Sensitivity|Positive Predictive Value of the hypo-Sense,Rabin Medical Center|Night Sense Ltd,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,3,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,029514ctil,Sep-14,Jul-16,Jul-16,26-Aug-14,null,11-Jan-17,"Schneider Children's Medical Center, Petah-Tikva, Israel",,https://ClinicalTrials.gov/show/NCT02225379
NCT02225691,Effect of Paired Testing to Poorly Controlled Chinese Diabetes on Glycemic Control and Self Care,,Unknown status,No Results Available,"Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1",Device: Paired testing of blood glucose Accu-Chek®,Baseline change in HbA1c at month 3 and 6 between paired testing and control arms for each of the 3 patient segments.|Proportion of patients who achieve good glycemic control (HbA1c≤7%),Shanghai 6th People's Hospital,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,400,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2014-32,Dec-14,Sep-15,Mar-16,26-Aug-14,null,20-Nov-14,"Weiping Jia, Shanghai, China",,https://ClinicalTrials.gov/show/NCT02225691
NCT02221323,A Trial to Compare the PK and PD of Insulin Lispro Administered Into Different Tissues in Subjects With Diabetes Mellitus Type 1,,Completed,No Results Available,Diabetes Mellitus,Drug: Insulin LISPRO,AUCINS.0-4h and AUCGIR.0-4h,Profil Institut für Stoffwechselforschung GmbH,All,18 Years to 64 Years   (Adult),Phase 2,18,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,DBC-14LIPOINJ01,Sep-14,Nov-14,Nov-14,20-Aug-14,null,30-Dec-14,"Profil Institut für Stoffwechselforschung GmbH, Neuss, NRW, Germany",,https://ClinicalTrials.gov/show/NCT02221323
NCT02220296,"A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus",,Completed,No Results Available,"Healthy|Diabetes|Diabetes Mellitus, Type 1",Drug: Insulin 338|Drug: placebo|Drug: insulin glargine,"Incidence of adverse events|Incidence of hypoglycaemic episodes|Area under the serum insulin 338 concentration-time curve from zero to infinity|Maximum serum insulin 338 concentration observed|Time for maximum serum insulin 338 concentration|t1/2, the terminal half-life of insulin 338",Novo Nordisk A/S,All,18 Years to 64 Years   (Adult),Phase 1,62,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1438-4137|2014-000071-70|U1111-1151-9327,20-Aug-14,31-Mar-15,31-Mar-15,19-Aug-14,null,8-Dec-17,"Novo Nordisk Investigational Site, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT02220296
NCT02218619,Tauroursodeoxycholic Acid (TUDCA) in New-Onset Type 1 Diabetes,,"Active, not recruiting",No Results Available,Type 1 Diabetes,Drug: Tauroursodeoxycholic Acid (TUDCA)|Drug: Sugar Pill (placebo),C-peptide measurement as reflection of insulin secretion|Endoplasmic reticulum stress|liver function tests,"Robin Goland, MD|Juvenile Diabetes Research Foundation|Columbia University",All,18 Years to 45 Years   (Adult),Phase 2,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",AAAN2402,Aug-15,1-Oct-19,1-Oct-19,18-Aug-14,null,4-Dec-18,"Naomi Berrie Diabetes Center, Columbia University, 1150 St. Nicholas Ave., New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02218619
NCT02215200,ATG-GCSF in New Onset Type 1 Diabetes,ATG-GCSF,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 1",Drug: Anti-Thymocyte Globulin (ATG)|Drug: Granulocyte colony stimulating factor (GCSF)|Drug: Placebo (for ATG)|Drug: Placebo (for GCSF),Measure of area under the stimulated C-peptide curve over the first 2 hours of a mixed meal glucose tolerance test conducted at the one-year visit.,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Center for Research Resources (NCRR)|Juvenile Diabetes Research Foundation|American Diabetes Association|Sanofi|The Leona M. and Harry B. Helmsley Charitable Trust|Amgen,All,"12 Years to 45 Years   (Child, Adult)",Phase 2,84,NIH|Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",ATG-GCSF (IND)|Type 1 Diabetes TrialNet|TN19|UC4DK106993|UC4DK117009,Dec-14,Aug-17,Oct-18,13-Aug-14,null,26-Dec-17,"University of California - San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Barbara Davis Center, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|University of South Florida Diabetes Center, Tampa, Florida, United States|Indiana University-Riley Hospital for Children, Indianapolis, Indiana, United States|University of Minnesota, Minneapolis, Minnesota, United States|Columbia University-Naomi Berrie Diabetes Center, New York, New York, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt Eskind Diabetes Clinic, Nashville, Tennessee, United States|Benaroya Research Institute, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02215200
NCT02214641,"Resilient, Empowered, Active Living: REAL Diabetes Study",REAL,Completed,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2","Behavioral: Resilient, Empowered, Active Living with Diabetes|Behavioral: Information Control",Glycated hemoglobin (HbA1C)|Audit of Diabetes-Dependent Quality of Life (ADD-QoL)|Problem Areas in Diabetes (PAID) Scale - Short Form|Patient Health Questionnaire-8 (PHQ-8)|Satisfaction With Life Scale (SWLS)|Summary of Diabetes Self-Care Activities (SDSCA),University of Southern California|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,18 Years to 30 Years   (Adult),Not Applicable,81,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1K01DK099202-01A1,Oct-14,Jun-16,Jul-17,12-Aug-14,null,9-May-19,"USC, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT02214641
NCT02214719,"Edmonton Automated Sugar Intelligence - Intelligent Diabetes Management, EASI-IDM, App Program to Assist Diabetes Care",EASI-IDM,Unknown status,No Results Available,"Diabetes, Type 1",Behavioral: EASI-IDM use,Glucose control - A1c|Use of the app|Patient initiated changes to insulin regimen|Acceptance of app|Long term use,University of Alberta,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,EASI02IDM01,Aug-14,Dec-16,Dec-16,12-Aug-14,null,5-Apr-16,"University of Alberta, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT02214719
NCT02213003,Allogeneic Islet Cells Transplanted Onto the Omentum,,Recruiting,No Results Available,Type 1 Diabetes Mellitus|Hypoglycemia|Hypoglycemia Unawareness,Biological: Islet transplantation,A1c </= 6.5% and no severe hypoglycemia|procedural complications,Rodolfo Alejandro|Juvenile Diabetes Research Foundation|Diabetes Research Institute Foundation|University of Miami,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,6,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20140144,Sep-14,May-20,May-22,11-Aug-14,null,11-Dec-18,"Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT02213003
NCT02213146,"A Double-blinded, Randomised, Three-period Crossover Euglycaemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Human Insulin, Human Insulin (Huminsulin® Normal) and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes",,Completed,No Results Available,Diabetes Mellitus Type 1,Drug: BioChaperone human insulin|Drug: Huminsulin® Normal|Drug: Humalog®,"Area under the curve (AUCins(0-1h))|Pharmacokinetics: Early t0.5max ins/lisp|Glucodynamics: Area under the glucose infusion rate - time curve from t=0 to 10 hours|Glucodynamics: Early t0.5 Glucose Infusion Rate max (GIRmax)|Glucodynamics: GIRmax - Maximum glucose infusion rate|Pharmacokinetics: AUCins/lisp(0-10h): Area under the human insulin / insulin lispro serum concentration|Pharmacokinetics: Tmax(ins/lisp) - Time to maximum observed serum human insulin concentration and insulin lispro concentration|Safety and tolerability: adverse events, local tolerability, vital signs variation, ECG, laboratory safety parameters|Pharmacokinetics: Cmax(ins/lisp)|Glucodynamics: Area under the glucose infusion rate - time curve from t=0 to 2 hours",Adocia,Male,18 Years to 64 Years   (Adult),Phase 1|Phase 2,38,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BC3-CT010,Aug-14,Dec-14,Jun-15,11-Aug-14,null,1-Jun-17,"Profil GmbH, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT02213146
NCT02212158,Diabetes Intervention Program for Adolescents With Persistent High HA1c,,Unknown status,No Results Available,"Diabetes Mellitus, Type 1",Behavioral: motivational interviewing group,Change from Baseline HA1c at 6 months post baseline|Change from baseline HA1c at 3 months post baseline|Change from Baseline HA1c at 9 months post baseline|Change in Baseline HA1c at 12 months post baseline|Change from baseline in Self-efficacy for Diabetes scale (SED) at 8 weeks|Change from baseline in Self-efficacy for Diabetes scale (SED) at 16 weeks|Change from baseline in Self-efficacy for Diabetes scale (SED) at 60 weeks|Change from baseline in Diabetes Family Behavior Scale at 8 weeks|Change from baseline in Diabetes Family Behavior Scale at 16 weeks|Change from baseline in Diabetes Family Behavior Scale at 60 weeks|Change from baseline in Beck Depression Inventory for Youth (BDI-Y) at 8 weeks|Change from baseline in Beck Depression Inventory for Youth (BDI-Y) at 16 weeks|Change from baseline in Beck Depression Inventory for Youth (BDI-Y) at 60 weeks|Change from baseline in Diabetes Quality of LIfe for Youth at 8 weeks|Change from baseline in Diabetes Quality of LIfe for Youth at 16 weeks|Change from baseline in Diabetes Quality of LIfe for Youth at 60 weeks|Change from baseline in Diabetes Management Questionnaire at 8 weeks|Change from baseline in Diabetes Management Questionnaire at 16 weeks|Change from baseline in Diabetes Management Questionnaire at 60 weeks|Change from baseline in Child Behavior Checklist (Parent form) at 8 weeks|Change from baseline in Child Behavior Checklist (Parent form) at 16 weeks|Change from baseline in Child Behavior Checklist (Parent form) at 60 weeks|Change from baseline in Low Blood Sugar Survey at 8 weeks|Change from baseline in Low Blood Sugar Survey at 16 weeks|Change from baseline in Low Blood Sugar Survey at 60 weeks|Change from baseline in Children's Hope Scale at 8 weeks|Change from baseline in Children's Hope Scale at 16 weeks|Change from baseline in Children's Hope Scale at 60 weeks,University of Manitoba,All,13 Years to 17 Years   (Child),Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H2014:206,Sep-14,Apr-15,Nov-15,8-Aug-14,null,8-Aug-14,"Diabetes Resource for Children and Adolescence, Winnipeg, Manitoba, Canada",,https://ClinicalTrials.gov/show/NCT02212158
NCT02211261,"A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus",,Completed,Has Results,Type 2 Diabetes Mellitus,Biological: PF-06293620|Biological: Placebo,"Number of Participants With All-Causality and Treatment Related Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events|Number of Participants With Dose Limiting or Intolerable Adverse Events|Number of Participants With Positive Anti-drug Antibody (ADA) Result|Area Under the Serum Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06293620 (SAD Cohorts)|Dose-normalized AUCinf (AUCinf(dn)) of PF-06293620 (SAD Cohorts)|Area Under the Serum Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-06293620 (SAD Cohorts)|Dose-normalized AUClast (AUClast(dn)) of PF-06293620 (SAD Cohorts)|Clearance (CL) of PF-06293620 (SAD Cohorts)|Apparent Clearance (CL/F) of PF-06293620 (SAD Cohorts)|Maximum Serum Concentration (Cmax) of PF-06293620 (SAD Cohorts)|Time for Maximum Serum Concentration (Tmax) of PF-06293620 (SAD Cohorts)|Steady-state Volume of Distribution (Vss) of PF-06293620 (SAD Cohorts)|Apparent Volume of Distribution (Vz/F) of PF-06293620 (SAD Cohorts)|Terminal Elimination Half-life (Thalf) of PF-06293620 (SAD Cohorts)|Area Under the Concentration-Time Profile From Time 0 to Time Tau (AUCtau) of PF-06293620 (MAD Cohorts) After Day 1 and Day 57 Administration|Maximum Serum Concentration (Cmax) of PF-06293620 (MAD Cohorts) After Day 1 and Day 57 Administration|Average Concentration (Cav) of PF-06293620 (MAD Cohorts) After Day 1 and Day 57 Administration|Lowest Concentration Observed During the Dosing Interval (Cmin) of PF-06293620 (MAD Cohorts) After Day 57 Administration|Time for Maximum Serum Concentration (Tmax) of PF-06293620 (MAD Cohorts) After Day 1 and Day 57 Administration|Apparent Clearance (CL/F) of PF-06293620 (MAD Cohorts) After Day 57 Administration|Apparent Volume of Distribution (Vz/F) of PF-06293620 (MAD Cohorts) After Day 57 Administration|Terminal Elimination Half-life (Thalf) of PF-06293620 (MAD Cohorts) After Day 57 Administration|Observed Accumulation Ratio Based on AUC (Rac) of PF-06293620 (MAD Cohorts)|Observed Accumulation Ratio Based on Cmax (Rac,Cmax) of PF-06293620 (MAD Cohorts)",Pfizer,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,84,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",B3501001,15-Sep-14,27-Jan-17,27-Jan-17,7-Aug-14,16-Oct-18,16-Oct-18,"Profil Institute for Clinical Research, Inc., Chula Vista, California, United States|Profil Institute for Clinical Research, Incorporated, Chula Vista, California, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Orlando Clinical Research Center, Orlando, Florida, United States|Qps Mra, Llc, South Miami, Florida, United States|Qps-Mra Llc, South Miami, Florida, United States|High Point Clinical Trials Center, LLC, High Point, North Carolina, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT02211261/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT02211261/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02211261
NCT02211742,Dapagliflozin in Type 1 Diabetes,DapaT1DM,Unknown status,No Results Available,Fasting Glucose|Glucose Excursion|Glycemic Control,Drug: Dapagliflozin,fasting glucose homeostasis|postprandial glucose homeostasis,Medical University Innsbruck|Medical University of Graz|University of Bern,Male,18 Years to 60 Years   (Adult),Phase 4,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CUI_001,Aug-14,Sep-15,Nov-15,7-Aug-14,null,8-Apr-15,"Medical University Innsbruck, Department of Internal Medicine I, Innsbruck, Tirol, Austria",,https://ClinicalTrials.gov/show/NCT02211742
NCT02208115,Post-exercise Appetite Responses in Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus,Dietary Supplement: Meal composition - Low versus high GI.,Acute subjective appetite responses,Northumbria University|Newcastle University,Male,18 Years to 50 Years   (Adult),Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,West-Walker3.1,Nov-13,Nov-13,Nov-13,4-Aug-14,null,4-Aug-14,"Clinical Research Facility, Royal Victoria Infirmary, Newcastle upon Tyne, Tyne and Wear, United Kingdom",,https://ClinicalTrials.gov/show/NCT02208115
NCT02206152,A Randomized Double Blinded Study to Examine the Use of N-acetyl Cysteine for the Prevention and Treatment of HAAF in Patients With Type 1 Diabetes,NAC for HAAF,Completed,No Results Available,Type 1 Diabetes|Hypoglycemia Unawareness,Drug: N-acetyl cysteine|Drug: Placebo,difference in epinephrine secretion during the morning episodes of hypoglycemia on days one and two under the two treatment conditions,University of Minnesota - Clinical and Translational Science Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,28,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",Protocol 22498,Feb-15,Dec-17,Dec-17,1-Aug-14,null,18-Jan-18,"University of Minnesota Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02206152
NCT02206568,Pharmacokinetics of Ultra-Rapid-Acting Insulin Lispro (URAL) in Type 1 Diabetes Mellitus,,Withdrawn,No Results Available,Type 1 Diabetes Mellitus,Drug: URAL,Pharmacokinetics of URAL|Onset of appearance of serum insulin lispro|Number of subjects with adverse events,"Perosphere, Inc.|Profil Institut für Stoffwechselforschung GmbH",Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,0,Industry,Interventional,"Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",PER511,Jun-14,Aug-14,Sep-14,1-Aug-14,null,20-May-15,"Profil Institut fur Stoffwechselforschung GmbH, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT02206568
NCT02206607,Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.,,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: PF-04937319 IR MST|Drug: PF-04937319 MR 1|Drug: PF-04937319 MR 2|Drug: PF-04937319 MR 3,Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUCinf]|Change From Reference in Weighted-Mean-Daily-Glucose (WMDG) on Day 1|Maximum Observed PF-04937319 Plasma Concentration (Cmax)|PF-04937319 Plasma Concentration at 5 Hours After Morning Dose (C5)|PF-04937319 Plasma Concentration at 16 Hours After Morning Dose (C16)|PF-04937319 Plasma Concentration at 24 Hours After Morning Dose (C24)|Ratio of Maximum to Approximate Trough PF-04937319 Concentration (Cmax/C24)|Time to Reach Maximum Observed PF-04937319 Plasma Concentration (Tmax)|Area Under the Curve From Time Zero to Last Quantifiable PF-04937319 Concentration (AUClast)|Terminal Elimination Half-Life (t1/2)|Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs),Pfizer,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,39,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,B1621015,Sep-14,Jan-15,Jan-15,1-Aug-14,4-Mar-16,4-Mar-16,"High Point Clinical Trials Center, High Point, North Carolina, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT02206607
NCT02204397,Study of Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With TD1 Melitis,,Completed,No Results Available,Type 1 Diabetes Mellitus,"Drug: INGAP Peptide, Ustekinumab",Safety and tolerability|Composite C-Peptide efficacy according to specific parameters,Jewish General Hospital,All,19 Years to 40 Years   (Adult),Phase 2,5,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,JewishGH,Nov-15,8-Mar-17,8-Mar-17,30-Jul-14,null,30-May-17,"Montreal General Hospital, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02204397
NCT02204839,Combined Basal-bolus Insulin and Post-exercise Carbohydrate Feeding Strategy in T1DM,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Basal insulin dose,24 hour blood glucose area under the curve|Ketonaemia,Northumbria University|Newcastle University,Male,18 Years to 50 Years   (Adult),Not Applicable,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,West-Walker3,Jan-14,Jan-15,Jan-15,30-Jul-14,null,15-Jan-15,"Clinical Research Facility, Royal Victoria Infirmary, Newcastle upon Tyne, Tyne and Wear, United Kingdom",,https://ClinicalTrials.gov/show/NCT02204839
NCT02201199,Single Dose Clamp Study To Compare Concentration/Time Profile And Metabolic Activity Profile Of 2 New Formulations Of Insulin Glargine With Lantus,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: insulin glargine U200 HOE901|Drug: insulin glargine U500 HOE901|Drug: insulin glargine U100 HOE901,"Area under the serum insulin glargine (INS) concentration curve over the first 12 hours after dosing|INS-Area Under the Curve (AUC) over 24 and 36 hours after dosing (INS AUC 0-24 and INS AUC 0-36)|AUC up to the last measurable concentration|Time to reach 50% of INS-AUC 0-36|Time to reach INS-Cmax (INS-tmax)|Area under the body-weight-standardized Glucose Infusion Rate (GIR) over the first 12, 24 and 36 hours after dosing (GIR-AUC0-12, GIR-AUC0-24 and, GIR-AUC0-36)|Time to reach 50% of GIR-AUC0-36 (T50%-GIR-AUC0-36)|Maximum smoothed body weight standardized glucose infusion rate (GIRmax) and time to GIRmax (GIR-Tmax)|Duration of blood glucose control (time to elevation of smoothed blood glucose profile above different pre-specific blood glucose levels)|Safety and tolerability (Number of patients with adverse events, clinically significant changes in vital signs, laboratory parameters)",Sanofi,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,36,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",PDY13928|2014-001252-33|U1111-1153-3712,Aug-14,Nov-14,Nov-14,25-Jul-14,null,24-Dec-14,"Investigational Site Number 276001, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT02201199
NCT02199028,Hyaluronidase Effect on Infusion Set Life,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Hyaluronidase,Sensor and infusion set failure|Hyaluronidase effects on glucodynamics|Effect of hyaluronidase on glycemic control|Effect of Tylenol on Dexcom G4 sensor glucose values|Evaluate tolerability of hyaluronidase injections|Evaluate insulin precipitation in infusion site cannulas via DTZ staining,Stanford University|University of Colorado Denver School of Medicine Barbara Davis Center,All,"12 Years to 45 Years   (Child, Adult)",Phase 2|Phase 3,30,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,28949|JDRF 17-2013/471,Jul-14,Mar-15,Mar-15,24-Jul-14,null,2-Apr-15,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT02199028
NCT02194517,"Impact of ELKa, the Toolset for Food Exchanges Calculation on Metabolic Control in Pediatric Diabetic Patients.",,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: ELKa,HbA1c (glycated hemoglobin)|ELKa usage frequency|Post- prandial glycemia|mean diurnal glucose level|Mean daily insulin dose [Insulin/kg/24h]|BMI- standard deviation (BMI- sds)|Hypoglycemia episodes and severe hypoglycemia events|Mean Amplitude of Glycemic Excursions (MAGE)|Glucose Area Under the Curve (AUC),Medical University of Warsaw,All,"up to 18 Years   (Child, Adult)",Not Applicable,106,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,ELKA-01,Apr-13,Oct-14,Nov-14,18-Jul-14,null,17-Mar-15,"Medical University of Warsaw, Warsaw, Poland",,https://ClinicalTrials.gov/show/NCT02194517
NCT02192450,Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia,HypoDeg,"Active, not recruiting",No Results Available,Type 1 Diabetes Mellitus|Nocturnal Hypoglycemia|Recurrent Severe Hypoglycaemia,Drug: Insulin aspart/glargine|Drug: Insulin aspart/degludec,"Symptomatic nocturnal hypoglycaemia|Severe hypoglycaemia (total, night-time, daytime)|Any nocturnal hypoglycaemia (incl. asymptomatic/silent events)|Any daytime hypoglycaemia (symptomatic, asymptomatic/silent and severe)|Any CGM recorded hypoglycaemia (symptomatic, asymptomatic/silent and severe)|Any in-hospital nocturnal hypoglycaemia (incl. asymptomatic/silent events)|Change in HbA1c|Change in glycaemic variability|Insulin doses|Quality of life incl. pre-depression scale","Nordsjaellands Hospital|Steno Diabetes Center Copenhagen|Hvidovre University Hospital|Copenhagen University Hospital, Denmark|Zealand University Hospital|Odense University Hospital|Aarhus University Hospital|Sydvestjysk Hospital",All,"18 Years and older   (Adult, Older Adult)",Phase 4,149,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HypoDeg,Jan-15,Apr-19,Apr-19,16-Jul-14,null,4-Apr-18,"Nordsjaellands Hospital, Hilleroed, Denmark",,https://ClinicalTrials.gov/show/NCT02192450
NCT02189694,Closed-loop Control of Overnight Glucose Levels (Artificial Pancreas) in Children With Type 1 Diabetes in a Diabetes Camp,,Completed,No Results Available,Type 1 Diabetes,Device: Single-hormone closed-loop strategy|Device: Dual-hormone closed-loop strategy|Device: Insulin pump therapy,Percentage of time of glucose levels spent below 4.0 mmol/L.|Percentage of time of glucose levels spent between 4.0 and 8.0 mmol/L|Percentage of time of glucose levels spent below 3.5 mmol/L|Percentage of time of glucose levels spent below 3.3 mmol/L|Percentage of time of glucose levels spent above 8 mmol/L|Percentage of time of glucose levels spent above 10 mmol/L.|Area under the curve of glucose levels below 4.0 mmol/L|Area under the curve of glucose levels below 3.5 mmol/L|Area under the curve of glucose levels below 3.3 mmol/L|Area under the curve of glucose levels above 8.0 mmol/L|Area under the curve of glucose levels above 10.0 mmol/L.|Mean glucose levels.|Standard deviation of glucose levels|Total insulin delivery|Hypoglycemic risk assessed by the total number of hypoglycemic event (> 15 minutes) below 3.1 mmol/L|Hypoglycemic risk assessed by the number of patients experiencing at least one hypoglycemic event (> 15 minutes) below 3.1 mmol/L,Institut de Recherches Cliniques de Montreal|Montreal Children's Hospital of the MUHC,All,8 Years to 17 Years   (Child),Phase 2,33,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLASS-08,Jun-14,Aug-14,Aug-14,14-Jul-14,null,3-Sep-14,"Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02189694
NCT02185755,Internet Monitoring vs Medication to Control Blood Sugar in Type 2 Diabetes,,"Active, not recruiting",No Results Available,Type 2 Diabetes Mellitus,Other: Internet-Based Glucose Monitoring System|Drug: Normal Medication Positive Control,HbA1c Levels before and after intervention|The secondary endpoint include severe hypoglycemia defined as requiring external aid (hospital or other).|A secondary endpoint includes adverse events such as unplanned hospitalizations for any cause that last more than 24 hours|HbA1c levels remain at 8% or higher,Endocrine Research Society,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IBGMS standalone,Aug-14,Aug-16,null,10-Jul-14,null,22-Aug-17,"Dr. Hugh Tildesley Inc., Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT02185755
NCT02184455,Feasibility Study of DermGEN for Diabetic Foot Ulcer Treatment,,Unknown status,No Results Available,Diabetes Type I|Diabetes Type II,Biological: DermGEN,Mean and Median Wound Size|Proportion with Complete Healing at any time point|Incidence of adverse events|Incidence of reoccurrence after complete healing|Change in wound characteristic|Percent Change in Wound Area,Dr. Paul F. Gratzer|Canadian Institutes of Health Research (CIHR)|Nova Scotia Health Authority|DeCell Technologies Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DeCell-001,Aug-15,Jun-17,Dec-17,9-Jul-14,null,11-Oct-16,"Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada|St. Michael's Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02184455
NCT02184676,T1D Risk Assessment in Kids With Relatives,TRAKR,Recruiting,No Results Available,Type 1 Diabetes,Biological: Analysis of early immune modifications|Other: Collection of clinical and socio-demographic data,Autoreactive T lymphocytes|Metagenomic signatures|Metabolic signatures|Environmental factors|Incidence of autoantibodies,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé et de la Recherche Médicale (INSERM) U1016 – Institut Cochin, Immunology of Diabetes Team, Paris, France|INSERM U1153, Epidemiology Research Unit on Perinatal Health and Women and Children Health, Port-Royal Hospital, Paris, France|Institut National de la Recherche Agronomique|Commissariat A L'energie Atomique",All,"Child, Adult, Older Adult",Not Applicable,1200,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,P130405|ID RCB : 2014-A00453-44,28-May-15,Sep-19,Feb-20,9-Jul-14,null,2-Mar-18,"Cochin Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT02184676
NCT02183350,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes",,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: BI 1356 BS - single rising dose|Drug: Placebo,"Number of patients with adverse events|Number of patients with abnormal findings in physical examination|Number of patients with abnormal changes in Vital signs (blood pressure (BP), pulse rate (PR))|Number of patients with abnormal changes in 12-lead ECG (electrocardiogram)|Number of patients with abnormal changes in laboratory parameters|Assessment of tolerability by investigator on a 4-point scale|Cmax (maximum concentration of the analyte in plasma)|tmax (time from dosing to maximum concentration)|AUC (area under the concentration-time curve of the analyte in plasma)|Ae (amount of analyte that is eliminated in urine)|fe (fraction of analyte excreted in urine)|CLR (renal clearance of the analyte in plasma)|Cmin,ss (minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval)|Cpre,N (predose concentration of the analyte in plasma at steady state immediately before administration of the next dose N)|λz,ss (terminal rate constant in plasma at steady state)|t1/2,ss (terminal half-life of the analyte in plasma at steady state)|MRTpo,ss (mean residence time of the analyte in the body after 12 administrations at steady state)|CL/F,ss (apparent clearance of the analyte in the plasma after extravascular administration at steady state)|Vz/F,ss (apparent volume of distribution during the terminal phase λz following an extravascular dose at steady state)|Changes in PTF (peak trough fluctuation)|RA,Cmax based on Cmax|RA,AUC based on AUCτ|Changes in Dipeptidyl-Peptidase IV (DPP-IV) activity in plasma|Change in plasma glucose levels",Boehringer Ingelheim,Male,"21 Years to 65 Years   (Adult, Older Adult)",Phase 1,47,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,1218.2,Apr-05,Aug-05,null,8-Jul-14,null,8-Jul-14,,,https://ClinicalTrials.gov/show/NCT02183350
NCT02181127,Closed-Loop Glucagon Administration For Hypoglycemia Treatment,,Completed,Has Results,Type 1 Diabetes,Device: Glucagon-only Bionic Pancreas,"Continuous Glucose Monitor (CGM) Glucose Total Area Over the Curve and Less Than 60 mg/dl|Percentage of Time CGM Glucose Less Than 70 mg/dl Overnight and During Daytime|Number of Hypoglycemic Episodes With CGMG < 50 mg/dl|Number of Hypoglycemic Episodes With CGMG < 60 mg/dl|Number of Hypoglycemic Episodes With CGMG < 70 mg/dl|Fraction of Time Spent Within Each of the Following Glucose Ranges as Determined From All CGMG Measurements: < 70 mg/dl,70-120 mg/dl,70-180 mg/dl, >180 mg/dl, >250 mg/dl|Count of Subjects With Mean CGMG < 154mg/dl|Mean CGMG During Exercise|Mean Absolute Relative Deviation (MARD) vs. Subset of BG Measurements Before Meals and at Bedtime|Mean Absolute Relative Deviation (MARD) Between Capillary Blood Glucose and CGM Glucose Values|Number of Hypoglycemic Events (< 60 mg/dl) as Determined From BG Measurements|Average BG as Determined From the Measurements Taken Before Meals and Before Bedtime|Percentage of the BG Values Taken Before Meals and Before Bedimte Less Than 70 mg/dl|Number of All BG Values Less Than 70 mg/dl|Number of Study Days With Mean BG < 154 mg/dl|Fraction Measurements Within Each of the Following Glucose Ranges as Determined From HemoCue Measurements Taken Before Meals and Before Bed: < 70 mg/dl,70-120 mg/dl,70-180 mg/dl,>180 mg/dl,>250 mg/dl|Mean BG During Exercise|• Fraction of BG Values < 70 During Exercise Fraction of BG Values < 70 During Exercise|Number of Carbohydrate Interventions for Hypoglycemia|Total Number of Grams of Carbohydrate Taken for Hypoglycemia|Insulin Total Daily Dose|• Number of Carbohydrate Interventions for Hypoglycemia During the Daytime (7:00 AM - 11:00 PM)|Total Number of Grams of Carbohydrate Taken for Hypoglycemia During the Daytime (7:00 AM - 11:00 PM)|Number of Carbohydrate Interventions for Hypoglycemia Overnight (11:00 PM - 7:00 AM)|Total Number of Grams of Carbohydrate Taken for Hypoglycemia Overnight (11:00 PM - 7:00 AM)|Total Glucagon Dosing (mcg/kg/24 Hours)|Episodes of Nausea Per Day on Glucagon vs Placebo",Massachusetts General Hospital|Boston University,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,31,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2013P001663/MGH,Nov-14,Jun-15,Apr-17,3-Jul-14,26-Dec-16,10-Jan-19,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02181127
NCT02179281,Prevention of Hypoglycaemia With Predictive Insulin Suspend Using Sensor Augmented Insulin Pump in Children,SportGuard,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: Medtronic MiniMed™ 640G system,Significant between-group difference in number of hypoglycemic events,"University of Ljubljana, Faculty of Medicine",All,"8 Years to 18 Years   (Child, Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,SG-01,Oct-14,Feb-15,Feb-15,1-Jul-14,null,10-Mar-15,"Schneider Children's Medical Center of Israel, The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, Petah Tikva, Israel|University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia",,https://ClinicalTrials.gov/show/NCT02179281
NCT02175732,Reducing Distress And Improving Glycemic Control In Adults With Type 1 Diabetes,T1REDEEM,Completed,No Results Available,Type 1 Diabetes Mellitus,Behavioral: 'KnowIt'|Behavioral: 'OnTrack',Diabetes Distress|HbA1c|Self-efficacy|Hypoglycemia confidence|Depression,"University of California, San Francisco|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",All,"19 Years and older   (Adult, Older Adult)",Not Applicable,301,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,5R01DK094863,Sep-14,Dec-18,Dec-18,26-Jun-14,null,25-Mar-19,"UC San Francisco, Family and Community Medicine Dept., San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT02175732
NCT02171130,Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia,,Completed,No Results Available,Hypoglycemia|Diabetes Mellitus|Drug-Specific Antibodies,Drug: 3 mg glucagon powder,Proportion of Patients Awakening or Returning to a Normal Status Within 30 Minutes Following Studied Drug Administration|Assessment of Ease-of-use of Dry-Mist Nasal Glucagon by Completion of Questionnaires by the Caregiver|To evaluate local tolerability from the patient's perspective,Eli Lilly and Company,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,129,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16427|I8R-MC-B002|AMG108,May-14,Jul-15,Aug-15,24-Jun-14,null,23-Mar-17,"New England Diabetes and Endocrinology Center (NEDEC), Waltham, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Albany Medical College Division of Community Endocrinology, Albany, New York, United States|Winnipeg Clinic, Winnipeg, Manitoba, Canada|Diabetes Clinic, Smiths Falls, Ontario, Canada|IRCM, Montreal, Quebec, Canada|Centre de recherche d'endocrinologie Godin & St-Pierre, Sherbrooke, Quebec, Canada|Applied Medical Informatics Research, Westmount, Quebec, Canada|Centre Hospitalier de l'Université de Québec, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02171130
NCT02168491,Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin,LixiBIT,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Lixisenatide|Drug: Insulin glargine,"Change in HbA1c From Baseline to End|Change in Fasting Plasma Glucose (FPG, Mean Over 2 Weeks)|Change in Body Weight From Baseline to End of Study",Medical University of Vienna,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LixiBIT_V3|2013-005334-37,Nov-14,Jul-15,Aug-15,20-Jun-14,4-Apr-17,9-May-17,"Medical University Of Vienna, Department of Internal Medicine III, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT02168491
NCT02167243,A Reinforcement Approach to Improve Diabetes Management,,"Active, not recruiting",No Results Available,Type 1 Diabetes,Behavioral: Reinforcement for BG testing|Other: Standard of care,To determine if the reinforcement intervention increases SMBG testing.|To assess if the intervention reduces A1c,Yale University|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"12 Years to 21 Years   (Child, Adult)",Not Applicable,62,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1403013607|1DP3DK097705-01,Jul-14,Nov-19,Nov-19,19-Jun-14,null,25-Jan-19,"Yale University School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02167243
NCT02164266,"A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477",,Completed,No Results Available,"Healthy Volunteer, Type 2 Diabetes",Drug: Placebo|Drug: RO6799477,"Incidence of adverse events (AEs)|Pharmacokinetic parameters derived from plasma and urine concentrations of RO6799477, area under the concentration time curve (AUC), Cmax|Fasting serum glucose|Fasting serum insulin (Part 2 only)",Hoffmann-La Roche,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29205|2014-000718-78,Jun-14,Dec-14,Dec-14,16-Jun-14,null,14-Jun-17,"Leiden, Netherlands",,https://ClinicalTrials.gov/show/NCT02164266
NCT02164279,Validation of Biomarkers of Diabetic Nephropathy in Type I Diabetic Children,peeDIAB2,Completed,No Results Available,Type 1 Diabetes Mellitus With Diabetic Nephropathy,Other: Urinary sample collection,Identify predictive non-invasive urinary biomarkers|Relation of urinary markers with patient characteristics,"University Hospital, Toulouse|Laboratory Inserm U858 Team 5 – RF-lab",All,"6 Years to 30 Years   (Child, Adult)",Not Applicable,140,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,12 356 03|2012-A01097-36,Jun-13,Dec-15,Dec-15,16-Jun-14,null,12-Jan-16,"Purpan Children Hospital, Toulouse, France|Rangueil Hospital, Toulouse, France",,https://ClinicalTrials.gov/show/NCT02164279
NCT02162004,Continuous Correction,,Terminated,No Results Available,Type 1 Diabetes,Procedure: Continuous Correction,Percentage of time CGM values are in the target range 3.9-8.0 mmol/l in the time period 8:00-17:00.|Mean CGM glucose value.|Percentage of time when CGM values are < 3.9 mmol/l.|Percentage of time when CGM values are > 8.0 mmol/l.|CGM standard deviation.|Number of hypoglycemic episodes.|Amount of insulin delivered.|Positive Incremental Area Under the Curve,Hvidovre University Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CC2014,Jun-14,Dec-14,Dec-14,12-Jun-14,null,31-Aug-16,"Hvidovre University Hospital, Hvidovre, Denmark",,https://ClinicalTrials.gov/show/NCT02162004
NCT02159638,Accuracy of Two CGM Systems Tested Simultaneously in Ambulatory Patients With Type 1 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Blood Glucose",Device: Guardian Enlite sensor|Device: Dexcom G4 platinum sensor,Difference between the two CGM systems compared to capillary glucose value|the accuracy of the 2 CGM systems during each studied time interval (day 1-3 and day 4-6)|the accuracy of the 2 CGM systems for hypoglycaemia|the accuracy of the 2 CGM systems for normoglycaemia|the accuracy of the 2 CGM systems for hyperglycaemia|Evaluation of two CGM systems from questionnaire,Vastra Gotaland Region,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,38,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VGFOUREG-387191,May-13,1-Jul-14,1-Sep-14,10-Jun-14,null,19-Dec-17,"NU-hospital Organisation, Trollhattan, Sweden|Uddevalla hospital, Uddevalla, Sweden",,https://ClinicalTrials.gov/show/NCT02159638
NCT02160275,"Algorithm to Control Postprandial, Post Exercise and Night Glucose Excursions in a Portable Closed Loop Format",APPEL4,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: Artificial Pancreas (Inreda Diabetic BV)|Device: Insulin pump therapy,Mean sensor glucose concentration|Proportion of time spent in each glycemic category|Number of events in each glycemic category|Number of carbohydrate-treated hypoglycemic events|Proportion of time spent in euglycemia (≥ 3.9 mmol/l and ≤ 10 mmol/l)|Glycemic variability|Mean sensor glucose concentration during specific periods|Mean absolute relative difference between sensor values and self-monitored blood glucose values|Heart rate|Physical activity|Mean glucose concentration per day|Time that the control algorithm is inactive,J.H. DeVries|European Commission|Rijnstate Hospital|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,16,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NL43469.018.13,Jun-14,Jun-15,Jun-15,10-Jun-14,null,2-Oct-15,"Rijnstate Hospital, Arnhem, Gelderland, Netherlands|Academic Medical Center, Amsterdam, Noord-Holland, Netherlands",,https://ClinicalTrials.gov/show/NCT02160275
NCT02159417,Therapeutic Education of the Patients Diabetics Imprisoned at the Paris Jail,EPRIDIA,Completed,No Results Available,Type 1 or 2 Diabetes,Other: Therapeutic Education,"The feasibility of the application of the action ETP in the MAPLS|Estimation of the satisfaction of the prisoners and the nursing after participation of educational therapeutic workshops|biomedical parameters: HbA1c and IMC|The number of hours all in all, for all the activities ETP and by categories of tasks|The satisfaction of the staffs as for the implementation and the realization of the experiment",Assistance Publique - Hôpitaux de Paris,Male,"18 Years and older   (Adult, Older Adult)",Not Applicable,22,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013-A00704-41,Nov-13,Oct-14,Feb-15,9-Jun-14,null,21-Apr-15,"Hôpital COCHIN, Paris, France|Maison d'Arrêt Paris La Santé (MAPLS), Paris, France",,https://ClinicalTrials.gov/show/NCT02159417
NCT02157155,A Study of Intracellular Signaling in Muscle and Fat Cells During Ketosis,,Completed,No Results Available,Ketoacidosis|Diabetes Mellitus Type 1,Biological: LPS,Insulin signaling expressed as a CHANGE in phosphorylation of intracellular target proteins and CHANGE in mRNA expression of target genes in muscle- and fat-tissue.|Change in Intracellular markers of lipid metabolism in muscle- and fat tissue biopsies|Metabolism|Cytokines and stress hormones,University of Aarhus,Male,18 Years to 45 Years   (Adult),Not Applicable,9,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,1-10-72-98-14,Jun-14,Mar-15,Sep-15,5-Jun-14,null,2-Dec-15,"Aarhus University Hospital, Aarhus, Denmark",,https://ClinicalTrials.gov/show/NCT02157155
NCT02155023,Feasibility Study to Determine the Optimal Calibration Method for Glucose Sensors,REACT4SENSOR,Completed,No Results Available,Diabetes,"Drug: Insulin dosing|Device: Glucose sensors IR-Glucose Reader (Joanneum Research, Austria), IR-CGM (IMM, Germany)",difference between calibrated measurements and reference|evaluate necessary run-in procedures by assessment of error over time,Medical University of Graz|European Commission,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,8,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,REACTforSENSOR,Jan-14,Jan-15,Jan-15,4-Jun-14,null,26-Mar-15,"Medical University of Graz, Graz, Styria, Austria",,https://ClinicalTrials.gov/show/NCT02155023
NCT02155855,Telemedicine for Adolescents With Insulin-dependent Diabetes,,"Active, not recruiting",No Results Available,Type 1 Diabetes,Other: Telemedicine|Other: Control,hemoglobin A1c|Frequency of contact with diabetes care team,Texas Tech University Health Sciences Center,All,"10 Years to 18 Years   (Child, Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,L14-037,Dec-14,Jun-19,Dec-19,4-Jun-14,null,8-Jan-19,"TTUHSC Pediatric Clinic, Lubbock, Texas, United States",,https://ClinicalTrials.gov/show/NCT02155855
NCT02152384,A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Insulin Peglispro|Drug: Insulin Lispro|Drug: Insulin Glargine,"Pharmacodynamics (PD): Plasma Glucose Area Under the Concentration Curve Zero Through 5 Hours (AUC 0-5h), Above Pre Meal Baseline for Insulin Lispro|Pharmacokinetics (PK): Under the Concentration Curve Zero Through 5 Hours (AUC 0-5h) for Prandial Insulin Lispro|Pharmacodynamics (PD): Average Glucose Infusion Rate From Euglycemic 2-step Hyperinsulinemic Clamp (M-value)|Pharmacokinetics (PK): Area Under the Concentration Curve From Time Zero to Last Time (AUC [0 Tlast]) for Paracetamol|Appetite and Satiety Ratings, as Measured Using Visual Analog Scale (VAS) on Day 29|Pharmacodynamics (PD): Area Under the Concentration Zero Through 5 Hours (AUC 0-5h) for Triglycerides|Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) for Insulin Lispro During Clamp",Eli Lilly and Company,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,28,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,15406|I2R-MC-BIDU,Jun-14,Dec-14,Dec-14,2-Jun-14,1-Mar-19,1-Mar-19,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuss, Germany",,https://ClinicalTrials.gov/show/NCT02152384
NCT02153190,Hybrid Artificial Pancreas in Home Setting,AP Hybrid,Completed,No Results Available,Type 1 Diabetes Mellitus|Treatement by Insulin Pump,Device: HYBRID|Device: OPEN,Percent time spent in target range (3.9-10.0 mmol/L or 70-180 mg/dL) during each study period|Low Blood Glucose Index (LBGI),"University Hospital, Montpellier",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,36,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,8628 4,May-14,Jun-15,Jun-15,2-Jun-14,null,6-Nov-15,"CHU Montpellier, Montpellier, France|University of Padova, Padova, Italy|University of Amsterdam, Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT02153190
NCT02147860,Full Day and Night Closed-Loop With DiAs Platform,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: Diabetes Assistant (DiAs) with USS Virginia|Other: Sensor Augmented Pump Therapy,DiAs time within target,University of Virginia|Stanford University,All,"10 Years to 35 Years   (Child, Adult)",Not Applicable,44,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17375|2014PG-T1D038,May-14,Jan-15,Jan-15,28-May-14,null,19-Jul-16,"Stanford University, Stanford, California, United States|University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02147860
NCT02146651,"A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes",,Completed,No Results Available,Diabetes Mellitus Type 1,Drug: BioChaperone insulin lispro 0.2U/Kg|Drug: BioChaperone insulin lispro 0.1U/Kg|Drug: BioChaperone insulin lispro 0.4U/Kg|Drug: Humalog®,"Glucodynamic endpoint: Area Under the Curve GIR(0-last)|Glucodynamic endpoint: GIRMax|Pharmacokinetic endpoint: AUC Lisp(0-last)|Pharmacokinetic endpoint: Cmax(Lisp)|Pharmacokinetics: Tmax(lisp)|Glucodynamic: TGIRmax|Tonset of action|Safety and Tolerability: adverse events, local tolerability, vital signs variations, ECG, laboratory safety parameters.",Adocia,Male,18 Years to 64 Years   (Adult),Phase 2,38,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BC3-CT008,May-14,Jul-14,Dec-14,26-May-14,null,10-Dec-14,"Profil Institut für stoffwechselforschung GmbH, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT02146651
NCT02146404,The Effect of Hypoglycaemia on Brain Lactate Accumulation and Cerebral Blood Flow,,Completed,No Results Available,Type 1 Diabetes Mellitus|Hypoglycemia Unawareness,Other: hypoglycemia|Other: euglycemia,Brain lactate concentration|Plasma lactate levels|Hormone response,Radboud University|Dutch Diabetes Research Foundation|European Foundation for the Study of Diabetes,All,18 Years to 50 Years   (Adult),Not Applicable,21,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,1H_lac_acc,Aug-14,Oct-15,Oct-15,23-May-14,null,10-Nov-15,"Radboud umc, Nijmegen, Netherlands",,https://ClinicalTrials.gov/show/NCT02146404
NCT02144337,Physical Activity in Children With Type 1 Diabetes Study,,Completed,Has Results,Type 1 Diabetes Mellitus|Physical Activity,Behavioral: Steps To Active Kids (STAK) programme,"Feasibility: Response Rate|Feasibility: Rate of Adherence to the Intervention|Feasibility: Number of Participants With Adverse Events|Change in Children's Self-efficacy Using CSAPPA Scale (Children's Self‐Perceptions of Adequacy in and Predilection for Physical Activity)|Change in Children's Level of Physical Activity (Measured Subjectively Via Self-report Questionnaire)|Change in Clinical Outcome Measures (Hba1c, Height, Weight)|Change in Parental Hypoglycaemia Fear Using the Hypoglycaemia Fear Survey (HFS-Parent)",University of Nottingham,All,9 Years to 11 Years   (Child),Not Applicable,13,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),14005,May-14,Apr-15,May-15,22-May-14,17-Aug-15,17-Aug-15,"Nottingham University Hospitals Nhs Trust, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT02144337
NCT02139943,A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM),,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Canagliflozin 100 mg|Drug: Canagliflozin 300 mg|Drug: Placebo,Percentage of Participants With Hemoglobin A1c (HbA1c) Reduction Greater Than or Equal to (>=) 0.4 Percent (%) and no Increase in Body Weight|Percentage of Participants With Adverse Events,"Janssen Research & Development, LLC",All,"25 Years to 65 Years   (Adult, Older Adult)",Phase 2,352,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CR104173|2013-005078-24|28431754DIA2004,May-14,Jun-15,Jun-15,16-May-14,18-Jul-16,18-Jul-16,"Little Rock, Arkansas, United States|Concord, California, United States|La Jolla, California, United States|Los Angeles, California, United States|Los Gatos, California, United States|Northridge, California, United States|Orange, California, United States|San Francisco, California, United States|Temecula, California, United States|Tustin, California, United States|Ventura, California, United States|Walnut Creek, California, United States|Denver, Colorado, United States|Miami, Florida, United States|Palm Harbor, Florida, United States|Atlanta, Georgia, United States|Honolulu, Hawaii, United States|Council Bluffs, Iowa, United States|Des Moines, Iowa, United States|Baton Rouge, Louisiana, United States|Rockville, Maryland, United States|Billings, Montana, United States|Omaha, Nebraska, United States|El Paso, Nevada, United States|Las Vegas, Nevada, United States|Nashua, New Hampshire, United States|Billings, New York, United States|Smithtown, New York, United States|Morehead City, North Carolina, United States|Columbus, Ohio, United States|Mentor, Ohio, United States|Philadelphia, Pennsylvania, United States|Greer, South Carolina, United States|Bloomington, Tennessee, United States|Arlington, Texas, United States|Austin, Texas, United States|Dallas, Texas, United States|El Paso, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Schertz, Texas, United States|Tomball, Texas, United States|Ogden, Utah, United States|Salt Lake City, Utah, United States|Spokane, Washington, United States|Milwaukee, Wisconsin, United States|Calgary, Alberta, Canada|London, Ontario, Canada|Oakville, Ontario, Canada|Thornhill, Ontario, Canada|Toronto, Ontario, Canada|Laval, Quebec, Canada|Sainte-Foy, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02139943
NCT02138045,Treatment of Diabetic Neuropathy With Liraglutide,TODINELI,Unknown status,No Results Available,"Diabetes Mellitus, Type 1|Type 1 Diabetes Mellitus",Drug: Placebo treatment|Drug: Liraglutide treatment,"RIII withdrawal reflex activity (using standard electromyography)|Evoked brain potentials (using standard electroencephalographic brain imaging).|Heart rate variability/ alterations in simpatico-vagal balance (24 h Holter monitoring)|Resting brain activity (spectral analysis of resting brain activity)|Microstructural brain neurodegeneration (assessed by diffuse tensor imaging)|Variety in day/night blood pressure|Gut transit assessed by SmartPill (pH, pressure and transit in stomach, small and large intestine)|Quantitive sensory testing of pressure algometry in muscle|Capacity of descending pain inhibition induced by a cold pressor test (2C in 120 sec)|Profile of inflammatory cytokines including IL-beta, TNF-alfa, IL6, MCP-1 and specific markers sCD163, sMR, neopterin and HO-1.|Metabolic risk factors expressed as adipokines (adiponectin, leptin, resistin) and inflammatory cell markers|Self assessed symptomatology (Michigan neuropathy screening tool, Quality of life (SF-36), Pain catastrophizing scale (PCS) and self-assessed gastro-intestinal symptoms (PAGI-SYM))|OCT",Aalborg University Hospital|Novo Nordisk A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TODINELI,May-14,Feb-17,Feb-17,14-May-14,null,5-Jan-16,"Mech-Sense, Department of Medical Gastroenterology, Aalborg University Hospital, Aalborg, Jutland, Denmark",,https://ClinicalTrials.gov/show/NCT02138045
NCT02138331,Effect of Microvesicles and Exosomes Therapy on β-cell Mass in Type I Diabetes Mellitus (T1DM),,Unknown status,No Results Available,Diabetes Mellitus Type 1,Biological: MSC exosomes.,Total daily insulin dose|Pancreatic β-cell Mass,"General Committee of Teaching Hospitals and Institutes, Egypt",All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,666666|Cell Free MSC Exo,Apr-14,Jul-14,Sep-14,14-May-14,null,14-May-14,"Sahel Teaching Hospital, Sahel, Cairo, Egypt|Sahel Teaching Hospital - General Committee of Teaching Hospitals and Institutes, Shubra, Cairo, Egypt|Sahel Teaching Hospital, General Commettee of Teaching Hospitals and Institutes., Shubra, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT02138331
NCT02137031,Continuous Glucose Monitoring and Metabolic Control in Children With Type 1 Diabetes,CHILD,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: Mini Link REAL-Time Transmitter,HbA1c|Fear of Hypoglycemia|Frequency of Hypoglycemia|Frequency of Hyperglycemia|Frequency of Diabetic Ketoacidosis,University of Toronto,All,"6 Years to 18 Years   (Child, Adult)",Not Applicable,40,Other,Interventional,Primary Purpose: Treatment,27225,Sep-12,Apr-14,Apr-14,13-May-14,null,13-May-14,"Royal Victoria Hospital, Barrie, Ontario, Canada|Charles H. Best Centre, Whitby, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02137031
NCT02137174,Home and School Visits Intervention for Children With DM TYPE 1,,Completed,No Results Available,Diabetes Type 1,Other: Home and school visits,HBA1C|Number of DKA episodes|Number of Hospitalizations|Hypoglycemia rate,Ben-Gurion University of the Negev,All,"4 Years to 18 Years   (Child, Adult)",Phase 2|Phase 3,92,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,EH-diab013,Jan-12,May-13,Feb-14,13-May-14,null,13-May-14,"Pediatric Endocrinology Unit, Soroka Medical Center, Beer Sheva, Israel",,https://ClinicalTrials.gov/show/NCT02137174
NCT02137512,Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use,CTR3,Completed,Has Results,Type 1 Diabetes,Device: Closed-Loop Control System|Device: Sensor-Augmented Pump (SAP),"Time Spent <70 mg/dL - Main Phase, Night Only|Time Spent <70 mg/dL - Main Phase, Day and Night|Time Spent <70 mg/dL - Main Phase, Day Only|Time in Range 70-180 mg/dL - Main Phase, Day and Night|Time in Range 70-180 mg/dL - Main Phase, Night Only|Time in Range 70-180 mg/dL - Main Phase, Day Only|Mean Sensor Glucose - Main Phase, Day and Night|Mean Sensor Glucose - Main Phase, Night Only|Mean Sensor Glucose - Main Phase, Day Only|Glucose Coefficient of Variation - Main Phase, Day and Night|Glucose Coefficient of Variation - Main Phase, Night Only|Glucose Coefficient of Variation - Main Phase, Day Only|Glucose Standard Deviation - Main Phase, Day and Night|Glucose Standard Deviation - Main Phase, Night Only|Glucose Standard Deviation - Main Phase, Day Only|Time Spent >180 mg/dL - Main Phase, Day and Night|Time Spent >180 mg/dL - Main Phase, Night Only|Time Spent >180 mg/dL - Main Phase, Day Only|Time Spent <50 mg/dL - Main Phase, Day and Night|Time Spent <50 mg/dL - Main Phase, Night Only|Time Spent <50 mg/dL - Main Phase, Day Only|Time Spent <60 mg/dL - Main Phase, Day and Night|Time Spent <60 mg/dL - Main Phase, Night Only|Time Spent <60 mg/dL - Main Phase, Day Only|LBGI - Main Phase, Day and Night|LBGI - Main Phase, Night Only|LBGI - Main Phase, Day Only|AOC 70 mg/dL - Main Phase, Day and Night|AOC 70 mg/dL - Main Phase, Night Only|AOC 70 mg/dL - Main Phase, Day Only|HBGI - Main Phase, Day and Night|HBGI - Main Phase, Night Only|HBGI - Main Phase, Day Only|ADRR - Main Phase, Day and Night|AUC 180 mg/dL - Main Phase, Day and Night|AUC 180 mg/dL - Main Phase, Night Only|AUC 180 mg/dL - Main Phase, Day Only|Time Spent >250 mg/dL - Main Phase, Day and Night|Time Spent >250 mg/dL - Main Phase, Night Only|Time Spent >250 mg/dL - Main Phase, Day Only|Time Spent >300 mg/dL - Main Phase, Day and Night|Time Spent >300 mg/dL - Main Phase, Night Only|Time Spent >300 mg/dL - Main Phase, Day Only",Jaeb Center for Health Research,All,"18 Years to 69 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pilot 3 Outpatient CTR,Aug-14,Nov-15,Nov-15,13-May-14,19-Oct-16,29-Oct-18,"Sansum Diabetes Research Institute, Santa Barbara, California, United States|Stanford University, Stanford, California, United States|University of Virginia, Charlottesville, Virginia, United States|Montpellier University Hospital, Montpellier, France|National Center for Childhood Diabetes- Schneider Children's Medical Center, Petah Tikva, Israel|University of Padova, Padova, Italy",,https://ClinicalTrials.gov/show/NCT02137512
NCT02135068,Preventing Hypoglycemia During Exercise With Proactive Snacking on Closed Loop,,Completed,No Results Available,Type 1 Diabetes,Device: Medtronic MiniMed Closed Loop (CL) System|Other: Snacking,Nadir blood glucose levels during exercise|Episodes of hypoglycemia (blood glucose <60mg/dL) during exercise|Mean reduction in blood glucose during exercise|Mean time blood glucose in target during exercise|Mean time blood glucose levels are in target during the overnight period|Mean glucose values|Mean 24- hour glucose levels|insulin delivery during CL therapy|Incremental meal-related glucose Area Under the Curve|Nadir glucose levels following the meals|Area under the curve meal-related plasma insulin level excursion following meals|Nadir glucose levels overnight|Mean absolute relative difference (MARD) for each sensor|Mean daytime and nighttime glucose values,Yale University,All,"13 Years to 44 Years   (Child, Adult)",Early Phase 1,15,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1403013588,Jan-15,Jun-16,Dec-16,9-May-14,null,27-Jan-17,"Yale University School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02135068
NCT02131246,A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart,Mean plasma glucose concentration|Area under the serum insulin aspart concentration-time curve,Novo Nordisk A/S,All,18 Years to 64 Years   (Adult),Phase 1,33,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN1218-3921|2013-002890-23|U1111-1145-0195,May-14,Jul-14,Jul-14,6-May-14,null,18-Jan-17,"Novo Nordisk Investigational Site, Graz, Austria",,https://ClinicalTrials.gov/show/NCT02131246
NCT02131766,Unified Safety System (USS) Virginia Closed-Loop Versus Sensor Augmented Pump Therapy for Oversight Control in Type 1 Diabetes,,Completed,No Results Available,Diabetes Mellitus,Device: Diabetes Assistant (DiAs),USS Virginia time within target|Overnight target range|Decreased overnight hypoglycemia|Morning glucose levels,University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,42,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17351|1DP3DK101055-01,Jun-14,Mar-15,Mar-15,6-May-14,null,12-May-15,"Mayo Clinic, Rochester, Minnesota, United States|Mount Sinai Hospital, New York, New York, United States|University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States|University of Padova, Padova, Italy",,https://ClinicalTrials.gov/show/NCT02131766
NCT02131896,"The Effects of Mediterranean Diet on Remission, Lipid Profile, Weight and Body Composition in Children and Adolescents With Newly Diagnosed Type 1 Diabetes",,Terminated,No Results Available,Type 1 Diabetes,Other: Interventional arm-Mediterranean diet|Other: Control Arm- regular nutritional instructions in accordance with the accepted nutritional guidelines,"lipid profile|Metabolic control|mean and SD of blood glucose|Peak stimulated C peptide|Daily insulin dose|Percent of subjects who require a daily insulin dose < o,5 IU/kg|Frequency and severity of hypoglycemic episodes|Anthropometric parameters|weight change from at least 1 year before diagnosis to 12 months after diagnosis|Inflammatory parameters|Endothelial function",Rabin Medical Center,All,"5 Years to 18 Years   (Child, Adult)",Not Applicable,4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,rmc7800ctil,1-Dec-14,Jun-16,Jun-16,6-May-14,null,20-Oct-17,"Schneider Children's Medical Center, Petah-Tikva, Israel",,https://ClinicalTrials.gov/show/NCT02131896
NCT02130284,In Clinic Evaluation of the PLGM Feature,PLGM,Completed,Has Results,Type 1 Diabetes,Device: Predictive Low Glucose Management Feature in Insulin pump,Serious Adverse Events (SAE)|Unanticipated Device Effect (UADE)|Severe Hypoglycemia|Diabetic Ketoacidosis|Rescue Events During In-clinic Procedues,Medtronic Diabetes,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Not Applicable,80,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CEP 272 PLGM,Oct-14,Aug-15,Sep-15,5-May-14,4-Apr-17,28-Sep-17,"AMCR Institute, Inc., Escondido, California, United States|Stanford University Department of Pediatric Endocrinology, Stanford, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Barbara Davis Center of Childhood Diabetes, Denver, Colorado, United States|Yale University Diabetes Research Program, New Haven, Connecticut, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|University of Virgina, Charlottesville, Virginia, United States|Rainier Clinical Research, Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT02130284
NCT02129868,Automated Closed-loop in Children and Adolescents With Type 1 Diabetes,APCam09,Completed,No Results Available,"Diabetes Mellitus|Diabetes Mellitus, Type 1|Glucose Metabolism Disorders|Endocrine System Diseases|Autoimmune Diseases",Device: Closed-loop (Android Closed-Loop platform),Time spent with plasma glucose concentration in the target glucose range from 3.9 to 8.0 mmol/l.|Time spent with plasma glucose concentration below the target range (<3.9mmol/L) between 21:30 on Day 1 and 07:30 on Day 2 (10 hours).|Time spent with plasma glucose concentration above the target range (>8mmol/L) between 21:30 on Day 1 and 07:30 on Day 2 (10 hours).|Mean and standard deviation of plasma glucose levels between 21:30 on Day 1 and 07:30 on Day 2 (10 hours).|Total insulin delivery between 21:30 on Day 1 and 07:30 on Day 2 (10 hours).|Total basal insulin delivery between 21:30 on Day 1 and 07:30 on Day 2 (10 hours).|Plasma insulin concentrations between 21:30 on Day 1 and 07:30 on Day 2 (10 hours).|Absolute relative difference between matched pairs of subcutaneous glucose sensor and reference plasma glucose.,University of Cambridge|Cambridge University Hospitals NHS Foundation Trust,All,"6 Years to 18 Years   (Child, Adult)",Not Applicable,13,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APCam09,Apr-14,Apr-15,Apr-15,2-May-14,null,3-Mar-17,"University of Cambridge, Cambridge, United Kingdom",,https://ClinicalTrials.gov/show/NCT02129868
NCT02127762,The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy,AWARE,Completed,No Results Available,Diabetes Mellitus|Type I Diabetes|Type II Diabetes|Diabetic Peripheral Neuropathy|Chronic Pain,Behavioral: Mindfulness Based Stress Reduction,"Change from baseline in pain-related disability, as measured by the Brief Pain Inventory. Pain interference scale at 3-month post-intervention.|Change from baseline in pain severity, as measured by the Brief Pain Inventory - Pain Severity scale, at 3 months post-intervention|Change from baseline in mood states, as measured by the Profile of Mood States scale, at 3 months post-intervention.|Overall change in status from baseline, as measured by Patient Global Impression of Change scale, at 3 months post-intervention.|Change from baseline in stress, as measured by the Perceived Stress Scale, at 3 months post-intervention.|Change from baseline in depressive symptoms, as measured by the Patient Health Questionnaire - 9 scale, at 3 months post-intervention|Change from baseline in pain catastrophizing, as measured by the Pain Catastrophizing Scale, at 3 months post-intervention.|Change from baseline in mindfulness, as measured by the Five Facet Mindfulness Questionnaire, at 3 months post-intervention.|Change from baseline in quality of life, as measured by the Short-Form-12 Health Survey, at 3 months post-intervention.|Change from baseline in quality of life, as measured by the Neuropathy-Specific Quality of Life Questionnaire (NeuroQOL).|Change from baseline in quality of health and life, as measured by the The Summary of Diabetes Self-Care Activities (SDSCA).|Change from baseline in adverse reactions as a result of their glycemic control, as measured by the Blood Sugar Reactions Questionnaire.|Change from pre-intervention in biomarkers of stress, as measured by hair cortisol levels, at 3 months post-intervention.|Change from baseline in glycemic control, as measured by blood levels of Hemoglobin A1c.",Ottawa Hospital Research Institute|Canadian Diabetes Association,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,81,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,20120541-01H|# OG-2-12-3722-HN,Sep-12,Jun-16,Aug-16,1-May-14,null,13-Jun-18,"The Ottawa Hospital, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02127762
NCT02127047,Effects of Exercise and Inhibition of Dipeptidyl Peptidase-4 on Insulin Secretion in Subjects With Type 1 Diabetes,EXTYPE-1,Completed,No Results Available,Diabetes Mellitus Type 1,Drug: Sitagliptin|Drug: Exercise,Change in beta-cell function as derived from change in C-peptide and glucose levels during the mixed meal test|Change in insulin sensitivity as derived from change in C-peptide and glucose levels during the mixed meal test|Change in insulin requirements: 3-day average daily insulin dose|Change in HbA1c levels|Change in fasting glucose|Change in fasting glucagon and cortisol|Change in total number of hypoglycemic events compared to treatment groups|Change in markers of systemic inflammation|Change in composition of immune cells|Change in meal-stimulated GLP-1 and gastric inhibitory peptide|Change in lipids profile|Change in fatigue according to the Fatigue Scale for Motor and Cognitive Functions questionnaire|Change in plasma copeptin and procalcitonin levels|Change in retinal vascular diameter|Change in arterial stiffness|Change in fractalkine,"University Hospital, Basel, Switzerland",All,18 Years to 55 Years   (Adult),Phase 2,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EKBB 349/12,Nov-13,Jul-16,5-Aug-16,30-Apr-14,null,27-Jul-17,"University Hospital Basel, Basel, Switzerland",,https://ClinicalTrials.gov/show/NCT02127047
NCT02120794,Threshold Suspend in Pediatrics at Home,,Completed,Has Results,Type 1 Diabetes,Device: 530G Insulin pump,"Overall Mean Change in A1C|Mean Change in A1C From Baseline to 1 Year, Stratified by Different A1c Subgroups",Medtronic Diabetes,All,2 Years to 15 Years   (Child),Not Applicable,194,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CEP287,Jun-14,16-Jun-17,16-Jun-17,23-Apr-14,15-Aug-18,11-Sep-18,"Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|Sutter Institute for Medical Research Excellence in Diabetes and Endocrinology, Sacramento, California, United States|Madison Clinic for Pediatric Diabetes at UCSF, San Francisco, California, United States|Stanford University, Stanford, California, United States|SoCal Diabetes, Torrance, California, United States|University of Colorado Health Science Center, Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Nemours Children's Health System, Jacksonville, Florida, United States|Park Nicollet Clinic - International Diabetes Center, Minneapolis, Minnesota, United States|University of Minnesota Pediatric Endocrinology Clinic, Minneapolis, Minnesota, United States|Children's Hospital and Clinics of Minnesota, Saint Paul, Minnesota, United States|The Pediatric and Endocrine Diabetes Specialists, Las Vegas, Nevada, United States|Stony Brook Children's Hospital, East Setauket, New York, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Texas Children Hospital/Baylor College of Medicine, Houston, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02120794/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02120794/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02120794
NCT02117765,Pilot Clinical Trial of Ustekinumab in Patients With New-onset T1D,UST1D,Unknown status,No Results Available,Type 1 Diabetes,Drug: Ustekinumab,Primary Safety Endpoints (composite outcome measure)|Immunological Endpoints (composite outcome measure)|Exploratory (composite outcome measure),University of British Columbia|Juvenile Diabetes Research Foundation,All,18 Years to 35 Years   (Adult),Phase 1|Phase 2,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H14-00939,Mar-15,Feb-17,Jun-17,21-Apr-14,null,25-May-16,"BC Diabetes, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT02117765
NCT02115555,Advancing Diabetes Management in Adolescents Using Health Information Technology,,Completed,No Results Available,Type 1 Diabetes,Behavioral: HIT-aided approach|Behavioral: Contracted conflict management system|Behavioral: HIT plus contracted conflict management,Glycemic Control using HBA1C|Frequency of self monitoring blood glucose measurement|Quality of Life|Family dynamics|Treatment Adherence Behaviors,Indiana University,All,"12 Years to 18 Years   (Child, Adult)",Not Applicable,129,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"IRB-04, IRB00000219",May-14,Jun-16,Jun-16,16-Apr-14,null,20-Feb-19,"Riley Children's Specialties, Carmel, Indiana, United States|Riley Children's Hospital, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT02115555
NCT02109029,A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Insulin Peglispro|Drug: Human Insulin,Part B: Pharmacokinetics: Steady-State Concentrations in Adipose Tissue Interstitial Fluid (ISF)|Part B: Pharmacokinetics: ISF-to-Serum Concentrations,Eli Lilly and Company,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,14873|I2R-MC-BIDP,Apr-14,Mar-15,Mar-15,9-Apr-14,6-Mar-19,6-Mar-19,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Graz, Austria",,https://ClinicalTrials.gov/show/NCT02109029
NCT02109315,"Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.",DIAB-01,Withdrawn,No Results Available,Type 1 Diabetes Mellitus,Drug: Vitamine C|Drug: Liraglutide 6 mg,Endothelial dysfunction (Flow mediated dilation): Endothelial function is assessed measuring flow-mediated vasodilation (FMD) of the brachial artery.|Oxidative stress markers,Anna Cruceta|Fundacion Clinic per a la Recerca Biomédica,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DIAB-01,May-14,May-15,May-15,9-Apr-14,null,15-Feb-19,"Hospital Clinic i Provincial de Barcelona, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT02109315
NCT02107326,Randomized Crossover Study to Test the Impact of Using a Software for Smartphones and Tablets in Treating Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes|Quality of Life|Hypoglycaemia,Device: Webdia Software,Effect of Webdia Software use on HbA1C|Effect of Webdia Software use on quality of life|Effect of Webdia Software use on the incidence of hypoglycaemic events,"Philippe Klee|University Hospital, Geneva",All,"10 Years to 18 Years   (Child, Adult)",Not Applicable,55,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CER13-272,May-14,15-Aug-17,1-Oct-17,8-Apr-14,null,19-Oct-17,"University Hospital of Geneva, Geneva, GE, Switzerland",,https://ClinicalTrials.gov/show/NCT02107326
NCT02105103,"European, Open-label, Prospective, Multinational, Multicenter Study in Adult Subjects With Type 1 or Type 2 Diabetes Previously on MDI or CSII Therapy. Subjects Home Setting is Considered Routine Practice.",,Completed,No Results Available,"Type 2 Diabetes, Type 1 Diabetes",Device: Accu-Chek® Insight Insulin Pump,"The primary objective is to evaluate the Accu-Chek Insight Insulin Pump and associated pump devices in routine practice. This will be expressed by the rate of error messages per 100 patient years (confirmed by pump uploads).|Evaluate type and frequency of adverse events (serious/non-serious) possibly related or related to study devices and/or study procedures|Evaluate subject satisfaction based on surveys of important factors of health-related quality of life|Evaluate change in HbA1c from screening to month 3 and 6|Evaluate utilization of pump functions (e.g. basal rate profiles, temporary basal rates, bolus types)|Evaluate change in CGM-derived parameters from month 3 to month 6|Evaluate type and frequency of pump signals, i.e. reminders, errors, warnings, alarms, maintenance messages",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RD001514,Oct-13,Mar-15,Mar-15,7-Apr-14,null,9-Sep-16,"Graz, Austria|Vienna, Austria|Birmingham, United Kingdom|Birmingham, United Kingdom|Blackburn, United Kingdom|Leicester, United Kingdom|Middlesborough, United Kingdom|Stafford, United Kingdom",,https://ClinicalTrials.gov/show/NCT02105103
NCT02105324,The Summer Camp Study 2: Blood Glucose Control With a Bi-Hormonal Endocrine Pancreas,,Completed,Has Results,Type 1 Diabetes,Device: Bionic Pancreas|Other: Usual Care,"Mean Continuous Glucose Monitoring Glucose (CGMG) Values During Days 2 to 5|Percentage of Time Spent With CGMG Concentration < 60 mg/dL During Days 2 to 5|Mean CGMG Values|Percentage of Time With CGMG Concentration by Ranges During Day 1|Percentage of Time With CGMG Concentration by Ranges During Days 1 to 5|Percentage of Time With CGMG Concentration by Ranges During Days 2 to 5|Percentage of Participants With Mean CGMG Glucose <154 mg/dL|Percentage of Participants With Mean CGMG Glucose <169 mg/dL|Percentage of Participants With Mean CGMG Glucose <183 mg/dL|Number of CGMG Reported Hypoglycemic Events (< 70 mg/dL, < 60 mg/dL, <50 mg/dL)|Mean Plasma Glucose Values|Percentage of Time With Plasma Glucose Values by Ranges on Day 1|Percentage of Time With Plasma Glucose Values by Ranges on Days 1 to 5|Percentage of Time With Plasma Glucose Values by Ranges on Days 2 to 5|Percentage of Participants With Mean Plasma Glucose <154 mg/dL|Percentage of Participants With Mean Plasma Glucose <169 mg/dL|Percentage of Participants With Mean Plasma Glucose <183 mg/dL|Number of Plasma Glucose Reported Hypoglycemic Events (< 70 mg/dL, < 60 mg/dL, <50 mg/dL)|Percentage of Days That CGM Data Was Used by Participants as Part of Their Usual Care|Number of Carbohydrate Interventions for Hypoglycemia When Plasma Glucose <70 mg/dL|Grams of Carbohydrate Taken for Hypoglycemia When Plasma Glucose <70 mg/dL|Insulin Total Daily Dose|Glucagon Total Daily Dose Levels in the Bionic Pancreas Arm|Daily Basal Insulin Dose in the Bionic Pancreas Period|Daily Bolus Insulin Dose in the Bionic Pancreas Period|Carbohydrate Intake|Number of Unscheduled Infusion Set Changes|Number of Bionic Pancreas Local Infusion Site Reactions|Mean Nausea Index Score Using a Visual Analogue Scale (VAS)|Number of Severe Hypoglycemic Events|Percentage of Time Participants Were Not Under Bionic Pancreas Control During the Bionic Pancreas Period|Percentage of Time Without CGM Monitoring Data|Change From Baseline in Body Weight|Reliability Index|List of Technical Faults Associated With the Bionic Pancreas Including Cause and Resolution|Number of Unscheduled CGM Sensor Changes|Percentage of Participants Using a Glucagon-Like Peptide-1 (GLP-1) Agonist During the Usual Care Period|Percentage of Participants Using Pramlintide During the Usual Care Period",Massachusetts General Hospital|Boston University,All,6 Years to 11 Years   (Child),Not Applicable,19,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014P000630,Jun-14,Aug-14,Aug-14,7-Apr-14,20-Oct-17,20-Oct-17,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02105324
NCT02103595,A Study Evaluating the Perception of Insertion Pain With Accu-Chek FlexLink and FlexLink Plus Insulin Pump Devices Under Real Life Conditions in Diabetic Patients.,,Completed,No Results Available,"Diabetes Mellitus Type 2, Diabetes Mellitus Type 1",Device: Accu-Chek FlexLink|Device: Accu-Chek FlexLink Plus,"Perception of pain during infusion set insertion assessed by means of a visual analogue scale (VAS)|Incidence of kinked cannulas|Pump settings, including insulin dosage|Device satisfaction/preference as assessed by patient surveys|Investigator assessment of patient device use|Incidence of adverse events|Insulin set replacement pattern",Hoffmann-La Roche|Roche Diagnostics,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,80,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RD001494,1-Nov-13,30-Jun-14,30-Jun-14,4-Apr-14,null,4-Apr-17,"Aschaffenburg, Germany|Berlin, Germany|Berlin, Germany|Rostock, Germany|Ulm, Germany",,https://ClinicalTrials.gov/show/NCT02103595
NCT02101229,Validation of the Artificial Pancreas Diabeloop Algorithm in the Hospital,WP6-1,Completed,No Results Available,Type 1 Diabetes,"Drug: Insulin, Asp(B28)-",Time spent in blood glucose range [70-180 mg/dl]|Time spent Blood Glucose range [80-140 mg/dl]|time spent below 70 mg/dl and above 180 mg/dl,Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,17,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2013-A01657-38,May-14,Feb-15,Feb-15,2-Apr-14,null,30-Jul-15,"Centre Hospitalier du Sud Francillien, Evry, France|University Hospital of Grenoble, Grenoble, France|University Hospital of Montpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT02101229
NCT02100488,Improving Postprandial Glycaemia by a New Developed Closed-loop Control System - Closedloop4meals,CL4M-Controls,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: Closed-loop insulin infusion system|Other: Open-loop insulin infusion system,Intra-subject postprandial glycemic variability|CV_AUC-PG_3-8h,Fundación para la Investigación del Hospital Clínico de Valencia|Hospital Clinic of Barcelona|Universitat Politècnica de València|Universitat de Girona,All,18 Years to 60 Years   (Adult),Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,CL4M Controls|470/13/EC,Mar-14,Jul-15,Oct-15,1-Apr-14,null,17-Nov-15,"Hospital Clínic i Universitari de Barcelona, Barcelona, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT02100488
NCT02099981,Restoration of Retinal Vascular Responses in Type 1 Diabetic Patients,,Completed,No Results Available,Diabetic Retinopathy,Drug: Aminoguanidine,The vascular response to flicker|Contrast sensitivity,University of Minnesota - Clinical and Translational Science Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,34,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,Protocol 22503,Jul-16,Dec-17,Dec-17,31-Mar-14,null,18-Jan-18,"University of Minnesota Medical Center Fairview, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02099981
NCT02098395,The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes,ADJUNCT TWO™,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: liraglutide|Drug: placebo,Change From Baseline in Glycosylated Haemoglobin (HbA1c)|Change From Baseline in Body Weight|Number of Treatment-emergent Symptomatic Hypoglycaemic Episodes,Novo Nordisk A/S,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,835,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN9211-4083|2012-005778-74|U1111-1138-0619|NL47705.060.14|REec-2014-0884,May-14,Apr-15,Apr-15,28-Mar-14,3-Jun-16,9-Feb-17,"Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Little Rock, Arkansas, United States|Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Escondido, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Montclair, California, United States|Novo Nordisk Investigational Site, San Mateo, California, United States|Novo Nordisk Investigational Site, San Ramon, California, United States|Novo Nordisk Investigational Site, Ventura, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, Golden, Colorado, United States|Novo Nordisk Investigational Site, Maitland, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Marietta, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Champaign, Illinois, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Skokie, Illinois, United States|Novo Nordisk Investigational Site, Council Bluffs, Iowa, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Rockville, Maryland, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, Chesterfield, Missouri, United States|Novo Nordisk Investigational Site, Billings, Montana, United States|Novo Nordisk Investigational Site, Butte, Montana, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, Jamaica, New York, United States|Novo Nordisk Investigational Site, Staten Island, New York, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Morehead City, North Carolina, United States|Novo Nordisk Investigational Site, Wilmington, North Carolina, United States|Novo Nordisk Investigational Site, Fargo, North Dakota, United States|Novo Nordisk Investigational Site, Bristol, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Amarillo, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Round Rock, Texas, United States|Novo Nordisk Investigational Site, Murray, Utah, United States|Novo Nordisk Investigational Site, Ogden, Utah, United States|Novo Nordisk Investigational Site, Bennington, Vermont, United States|Novo Nordisk Investigational Site, Federal Way, Washington, United States|Novo Nordisk Investigational Site, Renton, Washington, United States|Novo Nordisk Investigational Site, Seattle, Washington, United States|Novo Nordisk Investigational Site, Graz, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Aalst, Belgium|Novo Nordisk Investigational Site, Bonheiden, Belgium|Novo Nordisk Investigational Site, Boussu, Belgium|Novo Nordisk Investigational Site, Brussels, Belgium|Novo Nordisk Investigational Site, Bruxelles, Belgium|Novo Nordisk Investigational Site, Edegem, Belgium|Novo Nordisk Investigational Site, Kortrijk, Belgium|Novo Nordisk Investigational Site, Leuven, Belgium|Novo Nordisk Investigational Site, Mouscron, Belgium|Novo Nordisk Investigational Site, Sint-Niklaas, Belgium|Novo Nordisk Investigational Site, Blagoevgrad, Bulgaria|Novo Nordisk Investigational Site, Pazardzhik, Bulgaria|Novo Nordisk Investigational Site, Plovdiv, Bulgaria|Novo Nordisk Investigational Site, Razgrad, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Calgary, Alberta, Canada|Novo Nordisk Investigational Site, Halifax, Nova Scotia, Canada|Novo Nordisk Investigational Site, Cornwall, Ontario, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Mississauga, Ontario, Canada|Novo Nordisk Investigational Site, Thornhill, Ontario, Canada|Novo Nordisk Investigational Site, Laval, Quebec, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Sherbrooke, Quebec, Canada|Novo Nordisk Investigational Site, Hvidovre, Denmark|Novo Nordisk Investigational Site, København, Denmark|Novo Nordisk Investigational Site, Odense, Denmark|Novo Nordisk Investigational Site, Århus C, Denmark|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Joensuu, Finland|Novo Nordisk Investigational Site, Jyväskylä, Finland|Novo Nordisk Investigational Site, Oulu, Finland|Novo Nordisk Investigational Site, Pori, Finland|Novo Nordisk Investigational Site, Turku, Finland|Novo Nordisk Investigational Site, LA ROCHELLE cedex, France|Novo Nordisk Investigational Site, Le Creusot, France|Novo Nordisk Investigational Site, MARSEILLE cedex 08, France|Novo Nordisk Investigational Site, MONTPELLIER cedex 5, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Pierre-Bénite, France|Novo Nordisk Investigational Site, Reims, France|Novo Nordisk Investigational Site, Strasbourg, France|Novo Nordisk Investigational Site, TOULOUSE cedex, France|Novo Nordisk Investigational Site, Trinité - La Martinique, France|Novo Nordisk Investigational Site, Bergamo, Italy|Novo Nordisk Investigational Site, Catanzaro, Italy|Novo Nordisk Investigational Site, Firenze, Italy|Novo Nordisk Investigational Site, Palermo, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, sesto san giovanni (MI), Italy|Novo Nordisk Investigational Site, Siena, Italy|Novo Nordisk Investigational Site, Amersfoort, Netherlands|Novo Nordisk Investigational Site, Apeldoorn, Netherlands|Novo Nordisk Investigational Site, Den Bosch, Netherlands|Novo Nordisk Investigational Site, Den Haag, Netherlands|Novo Nordisk Investigational Site, Eindhoven, Netherlands|Novo Nordisk Investigational Site, Utrecht, Netherlands|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Almería, Spain|Novo Nordisk Investigational Site, Gijón, Spain|Novo Nordisk Investigational Site, Segovia, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Linköping, Sweden|Novo Nordisk Investigational Site, Malmö, Sweden|Novo Nordisk Investigational Site, Stockholm, Sweden|Novo Nordisk Investigational Site, Umeå, Sweden|Novo Nordisk Investigational Site, Ängelholm, Sweden|Novo Nordisk Investigational Site, Örebro, Sweden",,https://ClinicalTrials.gov/show/NCT02098395
NCT02099409,Safety and Efficacy of Overnight Closed Loop in Children With Type 1Diabetes Mellitus in Luxembourg,,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: FLORENCED2,Time spent in normal glucose range ( mg/dl)|glucose variability ( excursions in mg/dl)|Time spent in low glucose range (< 60 mg/dl)|time spent in low glucose range (<70 mg/dl)|time spent in high glucose range (>180mg/dl),Centre Hospitalier du Luxembourg|University of Cambridge,All,6 Years to 12 Years   (Child),Not Applicable,15,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SPIDLUX 4,Jan-14,Aug-14,Aug-14,28-Mar-14,null,16-Sep-14,"DECCP Clinique Pédiatrique de Luxembourg/CHL, Luxembourg, Luxembourg|DECCP Pediatric Clinic , CHLuxembourg, Luxembourg, Luxembourg",,https://ClinicalTrials.gov/show/NCT02099409
NCT02097316,Feasibility Study of the JewelPump Version 3,,Completed,No Results Available,Type 1 Diabetes,Device: JewelPump|Device: usual insulin pump,"Time spent in glycemic area 70-180 mg / dl, measured continuously for 5 days with a continuous glucose monitoring (CGM) DEXCOM G4|Time spent in the strict glycemic area 80-140 mg / dl",Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète,All,"18 Years and older   (Adult, Older Adult)",Phase 3,21,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013-A00792-43,Jun-14,Sep-14,Sep-14,27-Mar-14,null,27-Oct-14,"Centre Hospitalier Sud Francilien, Evry, France|CHU Marseille-Hôpital Nord, Marseille, France|CHU Strasbourg, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT02097316
NCT02094534,"A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics",,Completed,Has Results,Diabetes Mellitus Type 1,Biological: ORMD-0801 Capsules|Other: Placebo,"Change From Baseline in Total, Basal, and Bolus Exogenous Insulin Requirements|Mean Nighttime, Daytime, and Fasting Glucose Levels","Oramed, Ltd.|Integrium",All,18 Years to 55 Years   (Adult),Phase 2,25,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORA-D-010,Mar-14,Aug-14,Oct-14,24-Mar-14,6-Jul-17,6-Jul-17,"Orange County Research Center, Tustin, California, United States",,https://ClinicalTrials.gov/show/NCT02094534
NCT02093676,"Applying the ""New Authority"" Model in the Treatment of Poorly Controlled Diabetic Adolescents and Their Families",,Completed,No Results Available,Type 1 Diabetes,"Behavioral: experimental protocol treatment ""The New Authority""",change in self monitoring of blood glucose|change in reported adherence|change in parents' helplessness|change in family conflict|change in parental monitoring,Sheba Medical Center|Juvenile Diabetes Research Foundation,All,12 Years to 17 Years   (Child),Not Applicable,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SHEBA-13-0770-YRK-CTIL,30-Jul-14,30-Mar-18,30-Mar-18,21-Mar-14,null,30-May-18,"Sheba Medical Center, Ramat Gan, Israel",,https://ClinicalTrials.gov/show/NCT02093676
NCT02093702,Impact of Structured Physical Activity Education Delivery in Patients With Type 2 Diabetes Mellitus,,Completed,Has Results,Type 2 Diabetes Mellitus,Behavioral: Physical activity and exercise education and behaviour counseling from a Registered Kinesiologist and a YMCA Wellness Coach|Behavioral: Unstructured Physical Activity and Exercise Education,Mean Change in Hemoglobin A1c (HbA1c) Levels|Mean Change in Systolic Blood Pressure|Mean Change in Waist Circumference|Mean Change in Body Mass Index|Mean Change in Serum Total Cholesterol|Mean Change in HDL-C|Mean Change in LDL-C|Mean Change in Triglycerides (TGs)|Mean Change in Total Cholesterol: HDL-C Ratio|Mean Change in Diastolic Blood Pressure|Mean Change in Adherence to the Canadian Diabetes Association's Clinical Practice Guidelines Aerobic Exercise Recommendations|Mean Change in Adherence to the Canadian Diabetes Association's Clinical Practice Guidelines Resistance Exercise Recommendations,"Royal Victoria Hospital, Canada",All,18 Years to 64 Years   (Adult),Not Applicable,5,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AW-100-SD,Apr-14,Sep-15,Jun-16,21-Mar-14,6-Oct-16,6-Oct-16,"Barrie and Community Family Health Team Diabetes Program, Barrie, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02093702
NCT02092220,A Multicenter Study of Outpatient Automated Blood Glucose Control With a Bihormonal Bionic Pancreas,,Completed,Has Results,Diabetes Mellitus Type 1,Device: Bionic Pancreas|Device: Insulin pump with or without CGM,"Mean Continuous Glucose Monitoring Glucose (CGMG) Values During Days 2 to 11|Percentage of Time Spent With CGMG Concentration < 60 mg/dL During Days 2 to 11|Mean CGMG Values|Percentage of Time With CGMG Concentration by Ranges During Day 1|Percentage of Time With CGMG Concentration by Ranges During Days 1 to 11|Percentage of Time With CGMG Concentration by Ranges During Days 2 to 11|Percentage of Participants With Mean CGMG < 154 mg/dl|Number of Hypoglycemic Events (< 70 mg/dL, < 60 mg/dL, <50 mg/dL)|Percentage of Days That CGM Was Used by Participants as Part of Their Usual Care|Glycated Albumin on Day 12|1,5-anhydroglucitol on Day 12|Anti-Insulin and Anti-Glucagon Antibodies on Day 12|Number of Participants With Severe Hypoglycemic Events|Number of Episodes of Symptomatic Hypoglycemia|Number of Reported Carbohydrate Interventions for Hypoglycemia|Total Grams of Carbohydrate Taken for Hypoglycemia|Insulin Total Daily Dose|Glucagon Total Daily Dose Levels in the Bionic Pancreas Arm|Mean Glucose Target Set by User (Time-weighted Average Over Study Period) in the Bionic Pancreas Arm|Percentage of Time Bionic Pancreas Off-line or Not Functioning Properly|Mean Nausea Index Score Using a Visual Analog Scale (VAS)|Change From Baseline in Body Weight|Change From Baseline in Hemoglobin|Number of Participants With Skin Rash",Massachusetts General Hospital|Boston University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,48,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Multicenter Study,Apr-14,Jul-15,Dec-16,20-Mar-14,20-Oct-17,22-Nov-17,"Stanford University, Stanford, California, United States|Massachusetts General Hospital (MGH) Diabetes Research Center, Boston, Massachusetts, United States|UMass Medical Center, Worcester, Massachusetts, United States|University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02092220
NCT02092896,Liraglutide as add-on to Insulin in Type 1 Diabetes,T1DMLIRA,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: Liraglutide|Drug: Placebo,Change from baseline in HbA1c (glycosylated haemoglobin)|Changes from baseline in EEG and cognitive performances|Change from baseline in gastric emptying rate|Change from baseline in glycemic control (CGM)|Change from baseline in total daily insulin dose|Changes from baseline in the counterregulatory hormone responses during hypoglycemia|Change from baseline in body weight|Change from baseline in auditory evoked potentials (AEP) during hypoglycemia|Change from baseline in corrected QTc-interval (QTc) during hypoglycemia|Change from baseline in hypoglycemic symptom score,"Hvidovre University Hospital|NNF Center for Basal Metabolic Research, Denmark|Hillerod Hospital, Denmark|Danish PhD schools of Molecular Metabolism and Endocrinology|Novo Nordisk A/S",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,40,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2012-002526-67,Mar-13,Oct-14,Oct-14,20-Mar-14,null,1-Apr-15,"Dept. of Endocrinology, Hvidovre University Hospital, Hvidovre, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT02092896
NCT02093221,Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus,,Terminated,Has Results,Type 1 Diabetes Mellitus,Biological: 180 mg/kg Alpha1-PI|Biological: 90 mg/kg Alpha1-PI|Biological: Placebo,Change From Baseline in Mixed Meal Tolerance Test (MMTMT) Stimulated C-peptide 2 Hour Area Under the Concentration-time Curve (AUC)|Change From Baseline for MMTT Stimulated C-peptide 2h AUC|Change From Baseline for HbA1c Levels|Number of Subjects With Overall Severe Hypoglycemic Episodes|Change From Baseline for Mean Daily Insulin Dose Requirements|Change From Baseline for Mean Daily Glucose Levels Prior to Meals and Bedtime,Grifols Therapeutics LLC,All,"6 Years to 35 Years   (Child, Adult)",Phase 2,76,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GTI1302,Mar-14,Jan-17,Jun-17,20-Mar-14,19-Apr-18,5-Sep-18,"University of Arizona, Tucson, Arizona, United States|Clinica Medica San Miguel, Los Angeles, California, United States|Diabetes Associates Medical Group, Orange, California, United States|Rady Children's Hospital San Diego, San Diego, California, United States|Metabolic Institute of America, Tarzana, California, United States|Ronald H Chochinov MD, Ventura, California, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Christiana Care Health Services, Newark, Delaware, United States|Solutions Through Advanced Research Inc., Jacksonville, Florida, United States|CCM Clinical Research, Miami, Florida, United States|Advanced Pharma CR LLC, Miami, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Cook County Hospital, Chicago, Illinois, United States|Methodist Research Institute, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Louisville, Louisville, Kentucky, United States|Barry J. Reiner MD, LLC., Baltimore, Maryland, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|Children's Hospitals and Clinics of Minnesota, Saint Paul, Minnesota, United States|Morristown Medical Center, Morristown, New Jersey, United States|University of New Mexico, Health Sciences Center, Albuquerque, New Mexico, United States|Women and Children's Hospital, Buffalo, New York, United States|WakeMed Children's Hospital, Raleigh, North Carolina, United States|Endocrinology Associates Inc, Columbus, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Pediatric Endocrinology, Genetics & Metabolism, Oklahoma City, Oklahoma, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Rapid City Regional Hospital/Health Clinical Research, Rapid City, South Dakota, United States|Research Institute of Dallas, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Northeast Clinical Research of San Antonio LLC, San Antonio, Texas, United States|University of Texas Health Science Center, San Antonio, Texas, United States|Consano Clinical Research, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT02093221
NCT02092051,CGM Treatment in Patients With Type 1 Diabetes Treated With Insulin Injections,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: Continuous glucose monitoring with DexCom G4 platina,Difference in HbA1c between week 26 and week 69|Difference in mean glucose level measured by CGM between week 23-26 and 66-69|Difference in mean amplitude glucose excursion (MAGE) measured by CGM between week 23-26 and week 66-69|Difference in standard deviation of glucose levels measured by CGM between week 23-26 and week 66-69|Difference in DTSQs scores between weeks 26 and 69|DTSQc score at week 69|Difference in WHO 5 scores between weeks 26 and 69|Difference in SWE-HFS scores between weeks 26 and 69|Difference in SWE-PAID-20 scores between weeks 26 and 69|Difference in the proportion of time with low glucose levels measured by CGM during two weeks between week 23-26 and week 66-69 measured by CGM (below 3.0 mmol/l and below 4.0 mmol/l respectively)|Difference in the proportion of time with high glucose levels measured by CGM during two weeks between week 23-26 and week 66-69 measured by CGM (above 10.0 mmol/l and above 13.9 mmol/l respectively)|Difference in the proportion of time with euglycaemic levels measured by CGM during two weeks between weeks 23-26 and weeks 66-69 (5.5-10.0 mmol/l and 3.9-10.0 mmol/l respectively)|Difference in the proportion of patients reducing their HbA1c by 5 mmol/mol (0.5% in DCCT) or more|Difference in the proportion of patients lowering their HbA1c 10 mmol/mol (1% in DCCT) or more|Difference in the mean number of severe hypoglycaemic events between weeks 1-26 and weeks 43-69 defined as unconsciousness due to hypoglycaemia or need of assistance from another person to resolve the hypoglycaemia,"Vastra Gotaland Region|DexCom, Inc.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,161,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CGMMDI,Jan-14,Jun-16,Jun-16,19-Mar-14,null,10-Jan-17,"Alingsås Hospital, Alingsås, Sweden|Angered Hospital, Angered, Sweden|Helsingborg Hospital, Helsingborg, Sweden|Öbackakliniken, Härnösand, Sweden|Centralhospital Kristianstad, Kristianstad, Sweden|Halland's Hospital Kungsbacka, Kungsbacka, Sweden|Malmö University Hospital, Malmö, Sweden|Motala Hospital, Motala, Sweden|Vrinnevisjukhuset, Norrköping, Sweden|Södersjukhuset, Stockholm, Sweden|Trelleborg Hospital, Trelleborg, Sweden|Uddevalla Hospital, Uddevalla, Sweden|Academic Hospital Uppsala, Uppsala, Sweden|Ängelholm Hospital, Ängelholm, Sweden|University Hospital Örebro, Örebro, Sweden",,https://ClinicalTrials.gov/show/NCT02092051
NCT02084498,Advanced Carbohydrate Counting and Automated Bolus Calculation,,Completed,No Results Available,Type 1 Diabetes,Device: Automated bolus calculator|Behavioral: Advanced Carbohydrate Counting,Change in HbA1c|Frequency of serious hypoglycemic events,Steno Diabetes Center Copenhagen|Hvidovre University Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,178,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,StenoABC,Sep-12,Nov-14,Nov-14,12-Mar-14,null,24-Nov-14,"Steno Diabetes Center, Gentofte, Denmark",,https://ClinicalTrials.gov/show/NCT02084498
NCT02082184,An Evaluation of a Novel Glucose Sensing Technology in Type 2 Diabetes,REPLACE,Completed,Has Results,Type 2 Diabetes Mellitus,Device: Sensor Based Glucose Monitoring System|Device: Standard Blood Glucose Monitoring,HbA1c at 6 Months|Time in Range|Time Spent <70 mg/dL and <55 mg/dL|Frequency of Episodes <70 mg/dL and <55 mg/dL|Time Spent >180 mg/dL and >240 mg/dL|Number of Glucose Measurements Performed|System Utilisation|Change in Diabetes Treatment Satisfaction Questionnaire (DTSQc) Scores From Day 1 to Day 194.,Abbott Diabetes Care,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,302,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,ADC-CI-APO-12018,Mar-14,Jun-15,Dec-15,10-Mar-14,14-Apr-17,30-May-17,"CHU Haut Lévêque, Bordeaux, France|Hôpital sainte Marguerite, Marseille, France|CHU Lapeyronie, Montpellier, France|CHU. Nancy, Nancy, France|Hopital Guillaume et René Laennec, Nantes, France|Hospital Lariboisere, Paris, France|Hôpital Cochin, Paris, France|Hôpital Rangueil, Toulouse, France|Diabetes Zentrum Mergentheim, Bad Mergentheim, Germany|Praris Dr Karin Schlecht, Eisenach, Germany|Diabetologische Schwenpunlet Praxis, Hamburg, Germany|Gemeiusilaftsproxis Fur Junere,, Hamburg, Germany|Vorstandsmitglied Deutsche Diabetes-Hilfe, Hamburg, Germany|Hohenzollernring, Münster, Germany|Diabetes Center Quakenbruck, Quakenbrück, Germany|Diabetes Schwerpunktpraxis Loccum, Rehburg-Loccum, Germany|An der Pforte, Rosenheim, Germany|Versdias GmbH, Sulzbach-Rosenberg, Germany|Ayr Hospital, Ayr, Ayrshire, United Kingdom|Diabetes Research, Linda McCartney Centre, Royal Liverpool University Hospital, Liverpool, Cheshire, United Kingdom|Royal United Hospital, Bath, United Kingdom|FRCPath Life and Health Sciences, Aston University, Birmingham, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|The Diabetes Centre, Ipswich Hospital NHS Trust, Ipswich, United Kingdom|St. James University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Rotherham General Hospital, Rotherham, United Kingdom",,https://ClinicalTrials.gov/show/NCT02082184
NCT02081001,PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients,,Completed,Has Results,Hypoglycemia,Drug: Novo Nordisk GlucaGen®|Drug: G-Pump™ (glucagon infusion),Time to Reach 50% of Maximum Glucose Concentration (Glucose T50%-Early)|Time to Reach 50% of Maximum Glucagon Concentration (Glucagon T50%-Early)|Glucagon Cmax|Glucose Cmax|Glucagon Tmax|Glucose Tmax|Glucagon AUC|Glucose AUC|Infusion Site Discomfort Score at 10 Minutes|Infusion Site Discomfort Score at 30 Minutes,Xeris Pharmaceuticals|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Emissary International LLC,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,19,Industry|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",XSGO-201|4R44DK096706-02,Mar-14,Aug-14,Sep-14,7-Mar-14,1-Aug-16,6-Apr-18,"Oregon Health & Science University, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT02081001
NCT02081014,Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes,,Completed,Has Results,Hypoglycemia,Drug: G-Pen Mini™ (glucagon injection),Serious Adverse Events|Glucagon Cmax (Fasting)|Glucagon Cmax (Post-insulin)|Glucagon Area Under the Curve (AUC) (Fasting)|Glucagon AUC (Post-insulin)|Glucagon Tmax (Fasting)|Glucagon Tmax (Post-insulin)|Glucose Cmax (Fasting)|Glucose Cmax (Post-insulin)|Glucose AUC (Fasting)|Glucose AUC (Post-insulin)|Glucose Tmax (Fasting)|Glucose Tmax (Post-insulin),Xeris Pharmaceuticals|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Emissary International LLC,All,18 Years to 50 Years   (Adult),Phase 2,13,Industry|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,XSMP-201|1R44DK096715-01A1,Mar-14,Nov-14,Nov-14,7-Mar-14,16-May-16,5-Apr-18,"Baylor College of Medicine, Children's Nutritional Research Center, Texas Children's Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02081014
NCT02081326,Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes,,Recruiting,No Results Available,"Diabetes Mellitus, Type One|Diabetes Mellitus, Type I|Autoimmune Diabetes",Biological: Bacillus Calmette-Guérin|Biological: Saline injection,Improvement in HbA1c|Change in Immune Response,Massachusetts General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,150,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2013P002633,Jun-15,Jul-20,Jul-23,7-Mar-14,null,22-Mar-17,"Immunobiology Labs CNY 149, Charlestown, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02081326
NCT02080741,Study in Leucocytes From Patients With Type 1 and Type 2 Diabetes Genetic Markers of Inflammation and Oxidative Stress (TÉLOMÈRES/ CANDIDATE GENES) According to the Type A or Type B Behavior Profile,Diatolepsy,Unknown status,No Results Available,Patients With Type 1 or Type 2 Diabetes|Patients With a Type A or B Behaviour Profile,Other: Blood sample of 12 ml,Telomere length|Level of expression of candidate genes,Centre Hospitalier Universitaire Dijon,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),CHAUVET-GELINIER APJ 2013,Sep-14,Feb-16,null,6-Mar-14,null,4-Dec-14,"CHU de DIJON, Dijon, France",,https://ClinicalTrials.gov/show/NCT02080741
NCT02077348,Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection.,,Completed,No Results Available,Diabetes Mellitus Type I|Ketoacidosis,Drug: Insulin withdrawal|Drug: Norditropin,"Insulin and growth hormone signalling, expressed as CHANGE in phosphorylation of intracellular target proteins and CHANGE in mRNA expression of target genes in muscle- and fat-tissue.|Change in Intracellular markers of lipid metabolism in muscle- and fat tissue biopsies.|Metabolism|Ghrelin",University of Aarhus,Male,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,9,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,1-10-72-247-13,May-14,Sep-15,Sep-15,4-Mar-14,null,24-Feb-16,"Institute of Clinical Medicine, Aarhus, Aarhus C, Denmark",,https://ClinicalTrials.gov/show/NCT02077348
NCT02075567,Exercise in Type 1 Diabetes Mellitus,ExT1DM,Completed,No Results Available,Blood Glucose Decrease During and After Defined Individual Exercise in T1DM,Procedure: Experimental,Number of Participants with no Adverse Events as a Measure of Safety and Tolerability|Hormonal Response,Medical University of Graz|University of Graz,Male,18 Years to 35 Years   (Adult),Not Applicable,7,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,ExT1DM,Jan-14,Sep-14,Dec-14,3-Mar-14,null,25-Mar-15,,,https://ClinicalTrials.gov/show/NCT02075567
NCT02074384,Patient and Provider Glucose Reporting Preferences Ambulatory Glucose Profile (AGP),,Completed,Has Results,Type 1 Diabetes,Device: Continuous Glucose Monitor|Device: Self Monitoring Blood Glucose|Other: Clinician,Portion of Study Participants Reporting Greater Utility From AGP vs. Traditional Glucose Data Reports,HealthPartners Institute|The Leona M. and Harry B. Helmsley Charitable Trust,All,"7 Years and older   (Child, Adult, Older Adult)",Not Applicable,161,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,04356-14-A,Mar-14,Jul-15,Jul-15,28-Feb-14,1-Jan-16,28-Mar-16,"Eda Cengiz, New Haven, Connecticut, United States|Larry Deeb, Tallahassee, Florida, United States|Henry Ford, Detroit, Michigan, United States|Park Nicollet International Diabetes Center, Minneapolis, Minnesota, United States|The Diabetes Center, PLLC, Ocean Springs, Mississippi, United States|St. Vincent's, Billings, Montana, United States|Columbia University, New York City, New York, United States",,https://ClinicalTrials.gov/show/NCT02074384
NCT02073188,Comparative Study of a Smartphone-Linked Self-Monitoring System Versus a Traditional One for Improving Metabolic Control and Compliance to Self-Monitoring of Blood Glucose,iNew Trend,Completed,No Results Available,Diabetes Mellitus,Device: iBGStar|Device: Traditional Glucometer,"Change in HbA1c levels from baseline|Proportion of participants performing at least 30% of the recommended Self-Monitoring Blood Glucose tests after 6 months from randomization|Percentage of participants with HbA1c ≤7.5%|Average number of recommended Self-Monitoring Blood Glucose tests daily, weekly, and monthly|Mean fasting plasma glucose (FPG) and postprandial glucose (PPG)|Mean Glycemic Variability|Average Insulin Dose|Number of Daily Injections|Number of Insulin Dose Adjustments|Quality of life: Audit of Diabetes Dependent Quality of Life (ADDQOL) (young adults 18-24 years)|Diabetes Quality of Life (DQOL-Y) (adolescents 14-17 years)|Participants satisfaction with SMBG meter assessed by Visual Analog Scale (VAS)|Number overall contacts between centers and participants|Type of overall contacts between centers and participants",Sanofi,All,"14 Years to 24 Years   (Child, Adult)",Phase 3,186,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),IBGST_L_05971,Jun-12,Sep-14,Sep-14,27-Feb-14,null,14-Apr-16,"Sanofi -Aventis Administrative Office, Milano, Italy",,https://ClinicalTrials.gov/show/NCT02073188
NCT02068638,Impact of Physical Activity on Blood Glucose Stability and Energy Stores in Individuals With Type 1 Diabetes,CARBEX1,Completed,No Results Available,Type 1 Diabetes Mellitus|Exercise|Hypoglycemia|Carbohydrate Metabolism,"Procedure: IHE first, CONT second|Procedure: CONT first, IHE second|Procedure: GLU first, GLU-FRU second|Procedure: GLU-FRU first, GLU second","Amount of exogenous glucose required to maintain glycemia within a range between 7-10mM|Exercise - related glycogen consumption|Glucose kinetics|Counterregulatory hormones, metabolites, and inflammatory response|Spiroergometric parameters|Pre- and post-exercise glycemic excursions|Heart rate variability","University Hospital Inselspital, Berne|University of Bern|University of Lausanne",Male,18 Years to 35 Years   (Adult),Not Applicable,27,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,001/14|320030_149321/1|191/10,Feb-14,Jul-16,Jul-16,21-Feb-14,null,10-Aug-16,"Division of Endocrinology, Diabetes and Clinical Nutrition, Bern University Hospital, Bern, Switzerland",,https://ClinicalTrials.gov/show/NCT02068638
NCT02065895,Effect of Gain on Closed-Loop Insulin,,Completed,Has Results,Type 1 Diabetes,Device: HIGH error|Device: NO error|Device: LOW error,Glucose Area Under the Curve (AUC) Breakfast|Peak and Nadir Postprandial Glucose Concentration,Joslin Diabetes Center|Juvenile Diabetes Research Foundation,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,8,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2012P-000401,Dec-13,Apr-15,Apr-15,19-Feb-14,6-Apr-18,17-May-18,"Joslin Diabetes Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02065895
NCT02066350,Cardiovascular Risk Factors After Single Pancreas Transplantation,Diamant,Completed,No Results Available,Diabetes Type 1|Endothelial Dysfunction,Procedure: Single pancreas transplantation,Endothelial function|Peripheral arterial tonometry|Changes in cardiac performance|Pulse wave velocity (arterial stiffness)|Heart rate variability|Plasma concentrations of endothelial dysfunction markers|Blood pressure|Lipid and lipoprotein concentrations|Bone mineral density and body composition|Glomerular filtration rate|Oral glucose tolerance test,Oslo University Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,35,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2013/1062|2013047,Jan-14,Feb-17,Feb-17,19-Feb-14,null,16-Mar-17,"Oslo University Hospital, Rikshospitalet, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT02066350
NCT02064023,Comparison of Insulin Pump and MDI for Pregestational Diabetes During Pregnancy,,Terminated,No Results Available,Type 1 Diabetes|Type 2 Diabetes|Pregnancy,Device: insulin pump|Other: multiple daily insulin injection,Composite obstetrical/perinatal endpoint consisting of specific elements (see description)|Mean maternal HbA1c during pregnancy,University of British Columbia,Female,"19 Years and older   (Adult, Older Adult)",Not Applicable,2,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,H12-02375,Apr-14,4-Dec-15,4-Dec-15,17-Feb-14,null,30-Oct-17,"Jim Pattison Outpatient Care and Surgery Centre, Surrey, British Columbia, Canada|B.C. Women's Hospital, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT02064023
NCT02064309,"An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macro-encapsulated Human Islets Within the Bioartificial Pancreas Beta-Air in Patients With Type 1 Diabetes Mellitus",,"Active, not recruiting",No Results Available,Long-standing Type 1 Diabetes Mellitus,Device: Beta-Air device for encapsulation of transplanted human islets,"Safety of device, as evaluated by incidence of adverse events or serious adverse events judged probable or highly probable related to the device|1. Incidence of local or systemic inflammation or infection, incl. C-reactive protein rise, judged related to the device during course of study.|2. Incidence and severity of fibrosis surrounding the device during course of study.|3. Signs of immunization in transplanted patients.|4. Oxygenation of tissue in the device, as evaluated at 4, 12 and 26 weeks post-transplantation|5. Survival of endocrine tissue in the device, as evaluated by [11C]-5-hydroxytryptophane positron emission tomography and histological analysis at 26 weeks post-transplantation.|6. Numbers of patients with peak c-peptide >0.20 nmol/l, in response to the mixed meal tolerance test at 12 and 26 weeks post-transplantation|7. C-peptide area under the curve in response to the mixed meal tolerance test at 12 and 26 weeks post-transplantation.|8. Number of patients with non-fasting c-peptide concentrations >0.003 nmol/l at 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 and 26 weeks post-transplantation; i.e. Kaplan-Meier analysis of survival time for islet grafts.",Uppsala University Hospital|Beta-O2 Technologies Ltd.,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,4,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AS Dnr2013/299,Feb-14,May-19,May-19,17-Feb-14,null,8-May-18,"Uppsala University Hospital, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT02064309
NCT02064647,Evaluation of Novel Trend Arrow Adjustment Tool for Diabetes Patients Using Continuous Glucose Monitoring to Guide Insulin Bolus Adjustment (TAAT Study),TAAT,Completed,No Results Available,"Diabetes Mellitus, Type 1",Other: Trend Arrow Adjustment Tool|Other: 10/20% bolus adjustment,Time spent with postprandial glucose level in target range|Frequency & duration of postprandial hyperglycemia|Frequency & duration of postprandial hypoglycemia,Children's Hospital of Eastern Ontario|Juvenile Diabetes Research Foundation,All,"5 Years to 18 Years   (Child, Adult)",Not Applicable,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,JDRF CCTN,Jul-14,Apr-15,May-15,17-Feb-14,null,28-Jan-16,"Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02064647
NCT02061488,Assessment of a New Closed-loop Algorithm in Type 1 Diabetes (Saddle Point Model Predictive Control : SP-MPC) (PPA),PPA,Completed,No Results Available,Type 1 Diabetes,Other: open-loop night|Other: closed-loop night,"Assessment of time spent in target range (glycemia between 70 and 145 mg/dl) and in hypoglycemia (glycemia <70 mg/dl), during the night (11 PM to 8 AM)|Assessment of time spent above 70 mg/dl, between 70-145 or 145-180 mg/dl and above 180 mg/dl (interstitial glucose) in the late post prandial period (9 to 11 PM) and during the night (11 PM to 8 AM)|Assessment of hypoglycemia occurrence during the night|Assessment of area under the curves (70-180mg/dl) during the night|Assessment of Low Blood Glucose Index (LBGI), High Blood Glucose Index (HBGI) and CONGA Index|Assessment of insulin doses delivered between 9 PM and 8 AM|Assessment of number of controller propositions rejected for security reasons|Assessment of glucose values during the night (glycemia and interstitial glucose values)",Rennes University Hospital,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),2013-A01604-41|35RC13_8806_PPA,Mar-14,Jul-14,Jul-14,12-Feb-14,null,23-Jul-14,"Rennes University Hospital, Rennes, France",,https://ClinicalTrials.gov/show/NCT02061488
NCT02059161,A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003),,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: MK-1293|Drug: Lantus™|Drug: Prandial Insulin,Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 24|Percentage of Participants With Any Confirmed Positive Anti-insulin Antibody (AIA) at Any Time Up Through Week 24|Percentage of Participants With Negative AIA at Baseline Who Develop Confirmed Positive AIA at Any Time Up Through Week 24|Change From Baseline in AIA Titer After 24 Weeks of Treatment|Percentage of Participants Who Develop Insulin Neutralizing Antibodies Up Through Week 24|Change From Baseline in A1C at Week 52|Total Insulin Dose at Week 24|Total Insulin Dose Per Kilogram (kg) of Body Weight (Unit/kg) at Week 24|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24|Percentage of Participants With Confirmed Positive AIA Up Through Week 52|Percentage of Participants With Negative AIA at Baseline Who Develop Confirmed Positive AIA at Any Time Up Through Week 52|Change From Baseline in AIA Titer After 52 Weeks of Treatment|Total Insulin Dose at Week 52|Total Insulin Dose Per Kilogram (kg) of Body Weight (Unit/kg) at Week 52|Change From Baseline in FPG at Week 52|Percentage of Participants Who Develop Insulin Neutralizing Antibodies Up Through Week 52|Change From Baseline in 7-point Self-monitored Blood Glucose (SMBG) at Week 24|Change From Baseline in 7-point SMBG at Week 52|Percentage of Participants Attaining A1C Glycemic Goals of <7% and <6.5% After 24 Weeks of Treatment.|Percentage of Participants Attaining A1C Glycemic Goals of <7% and <6.5% After 52 Weeks of Treatment.|Basal Insulin Dose at Week 52|Basal Insulin Dose Per kg of Body Weight at Week 52|Bolus Insulin Dose at Week 52|Bolus Insulin Dose Per kg of Body Weight at Week 52|Basal Insulin Dose at Week 24|Basal Insulin Dose Per kg of Body Weight at Week 24|Bolus Insulin Dose at Week 24|Bolus Insulin Dose Per kg of Body Weight at Week 24,Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,508,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1293-003|2011-003971-12,17-Oct-13,4-May-15,12-Nov-15,11-Feb-14,8-Mar-17,5-Sep-18,,,https://ClinicalTrials.gov/show/NCT02059161
NCT02059174,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)",,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: MK-1293|Drug: EU-Lantus™|Drug: Novolog™,Comparison of MK-1293 and EU-Approved Lantus Duration of Pharmacodynamic Action During a 30-Hour Euglycemic Clamp Study|PD: Area Under the Glucose Infusion Rate Versus Time Curve Over 24 Hours After Dosing (GIR-AUC0-24hr)|PD: Area Under the Glucose Infusion Rate Versus Time Curve Over the First 12 Hours After Dosing (GIR-AUC0-12hr)|PD: Area Under the Glucose Infusion Rate Versus Time Curve Over the Second 12 Hours After Dosing (GIR-AUC12-24hr)|PD: Maximum Glucose Infusion Rate (GIRmax)|M1 Glargine Metabolite Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve (AUC0-24)|M1 Glargine Metabolite PK: Maximum Plasma Concentration (Cmax)|M1 Glargine Metabolite PK: Area Under the Plasma Concentration Versus Time Curve Over the First 12 Hours After Dosing (AUC0-12)|M1 Glargine Metabolite PK: Area Under the Plasma Concentration Versus Time Curve Over the Second 12 Hours After Dosing (AUC12-24),Merck Sharp & Dohme Corp.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,76,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1293-005|2012-005656-41,10-Feb-14,30-Mar-15,27-Apr-15,11-Feb-14,8-Mar-17,5-Sep-18,,,https://ClinicalTrials.gov/show/NCT02059174
NCT02059564,A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus,,Unknown status,No Results Available,Diabetes Mellitus,Drug: HM11260C|Drug: Placebo|Drug: Victoza,PK profile of acetaminophen|Glucose metabolism|Safety and tolerability,Hanmi Pharmaceutical Company Limited,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,44,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HM-EXC-102,Dec-13,Oct-14,Dec-14,11-Feb-14,null,11-Feb-14,"Hanmi, California, California, United States",,https://ClinicalTrials.gov/show/NCT02059564
NCT02057211,Mesenchymal Stem Cells to Intervene in the Development of Type 1 Diabetes: a Blinded Randomized Study,,Suspended,No Results Available,Type 1 Diabetes Mellitus,Biological: autologous mesenchymal stem cell transplantation|Procedure: sham transplantation of mesenchymal stem cells,∆-change of C-peptide Area Under the Curve (AUC) (0-120 min) for a mixed meal tolerance test at two year follow-up when compared to pre-treatment values at enrolment.,Uppsala University Hospital,All,18 Years to 40 Years   (Adult),Phase 2,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",AS Dnr2013/195,Feb-14,May-20,May-20,7-Feb-14,null,16-Apr-19,"Uppsala University Hospital, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT02057211
NCT02057848,Carbohydrates to Prevent Hypoglycaemia During Physical Activity in Patients With Type 1 Diabetes,,Completed,No Results Available,Hypoglycaemia,Other: low amount of carbohydrates|Other: high amount of carbohydrates|Other: Rapid-acting carbohydrates,Plasma glucose,Michael A. Nauck|Diabeteszentrum Bad Lauterberg im Harz,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,37,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,DZBL-2014-1|2014-000561-46,Jul-11,Feb-14,Feb-14,7-Feb-14,null,7-Feb-14,"Diabeteszentrum, Bad Lauterberg, Germany",,https://ClinicalTrials.gov/show/NCT02057848
NCT02053051,Advanced Bolus Calculator for Type 1 Diabetes (ABC4D),ABC4D,Suspended,No Results Available,Type 1 Diabetes,Device: ABC4D|Drug: Novorapid,HbA1c|Post-prandial hypoglycaemia|Post-meal glucose at 60 and 120 minutes|Post-prandial area under the curve (AUC) at 120 minutes|Hypoglycaemia at 4-hours post-prandially|Glycaemic risk: LBGI and HBGI|Glycaemic variability: MAGE and CONGA-2|Change in weight (kg)|Number achieving target HbA1c ( ≤ 53 mmol/mol ),Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,176,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,13SM0091,Sep-13,Jul-16,Aug-19,3-Feb-14,null,1-Aug-18,"Imperial College London, Imperial College Healthcare NHS Trust, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02053051
NCT02047643,Accelerometer Use in the Prevention of Exercise-Associated Hypoglycemia in Type 1 Diabetes: Outpatient Exercise Protocol,,Unknown status,No Results Available,Type 1 Diabetes,Device: Algorithm ON,Hypoglycemia prevention during scheduled exercise,Stanford University,All,"8 Years to 25 Years   (Child, Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,29205,Jan-14,Jun-14,Jun-14,28-Jan-14,null,28-Jan-14,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT02047643
NCT02044848,Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus,,Terminated,Has Results,Type 1 Diabetes Mellitus,Drug: Secukinumab|Drug: Placebo,Stimulated C-peptide in Response to a Standard Mixed Meal Tolerance Test,Novartis Pharmaceuticals|Novartis,All,18 Years to 35 Years   (Adult),Phase 2,5,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CAIN457A2227,Feb-14,Sep-14,Sep-14,24-Jan-14,9-Oct-15,17-Feb-16,"Novartis Investigative Site, New York City, New York, United States|Novartis Investigative Site, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02044848
NCT02045290,Insulin Clamp Ancillary Study for Assessment of Insulin Resistance,,Completed,No Results Available,Type 1 Diabetes,Drug: Metformin|Drug: Placebo,Change in insulin resistance (IR) from baseline to 13 weeks|Change in Hepatic IR from baseline to 13 weeks|Change in Adipose IR from baseline to 13 weeks,Jaeb Center for Health Research|Juvenile Diabetes Research Foundation,All,"12 Years to 19 Years   (Child, Adult)",Phase 3,37,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",T1DX Insulin Clamp Ancillary,Jan-14,15-Feb-16,15-Feb-16,24-Jan-14,null,14-Mar-17,"Jaeb Center for Health Research, Tampa, Florida, United States",,https://ClinicalTrials.gov/show/NCT02045290
NCT02040571,The Performance of an Artificial Pancreas at Home in People With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Device: Closed Loop|Device: Open Loop,"Continuous glucose monitoring (CGM) time spent in target glycaemic range (4.0-8.0 mmol/L) overnight (0000h - 0800h) during the ambulatory phase (Phase 2) of the study.|Continuous glucose monitoring (CGM) time spent in target glycaemic range (4.0-8.0 mmol/L) from 2000h-0800h in clinical trial centre (phase 1 of the study).|CGM time and area under the curve (AUC) spent above target range (>8.0 mmol/L).|CGM time spent in hypoglycaemic range (<4.0 mmol/L and <3.0 mmol/L) and number of episodes of symptomatic hypoglycaemia (indicated by glucose sensor and confirmed by meter glucose).|CGM measures of glycaemic variability (standard deviation and margin of error).|Number of episodes of blood ketone-positive hyperglycaemia (blood glucose > 15 mmol/L indicated by glucose sensor and confirmed by meter glucose AND blood ketones greater than or equal to 0.6 mmol/L).|Yellow Springs Instrument (YSI) glucose measurements in target range (4.0-8.0 mmol/L).|YSI glucose measurements in hypoglycaemic range (<4.0 mmol/L and <3.0 mmol/L).|YSI glycaemic variability (standard deviation).|CGM time in glucose target range (4.0-8.0 mmol/L).|Total insulin delivered (based on pump data)|Total insulin delivered (based on pump data).|Rates and number of changes in the rate of insulin infusion (based on pump data).|Closed loop exits (with root cause identified) based on the monitoring by the investigator in real time from a co-located station.|Closed loop exits (with root cause identified) based on the remote monitoring by the investigator.|Total basal and total bolus insulin delivered (based on pump data)|Total basal and total bolus insulin delivered (based on pump data).|Urinary cortisol and catecholamines on 12-hour urine collection.|Area under the curve for overnight plasma cortisol, growth hormone, glucagon, adrenaline and noradrenaline (based on hourly blood sample collection).|Plasma metanephrines (based on blood sample collection)|Plasma Cortisol, growth hormone, glucagon, adrenaline , noradrenaline and metanephrines based on blood sample collection.|Sleep quality includes: total sleep time, sleep onset latency, sleep-efficiency, and wakefulness after sleep onset (WASO), total and average activity counts based on Actigraph data.|Sleep quality includes: total sleep time, sleep onset latency, sleep-efficiency, and wakefulness after sleep onset (WASO), total and average activity counts based on Actigraph data and the Pittsburgh Sleep Quality Index scores.|Parameters of Inflammation and Oxidative Stress include: Cell Adhesion Molecules, Myeloperoxidase, Oxidised LDL, hs-CRP (based on blood sample collection) and Urinary isoprostanes.|Parameters of Inflammation and Oxidative Stress include: Cell Adhesion Molecules, Myeloperoxidase, Oxidised LDL, hs-CRP (C reactive Protein) based on blood sample collection, and Urinary isoprostanes.|Diabetes Treatment Satisfaction Questionnaire and Semi-Structured Interviews (Questionnaires will generate total scores for treatment satisfaction, fear of hypoglycaemia, diabetes-related distress and hypoglycemia impaired awareness).|Cognitive Assessment: CogState assessment battery outcome measures will be generated. Each battery test point will record participant response times and accuracy rates for all tasks performed.",St Vincent's Hospital Melbourne|Juvenile Diabetes Research Foundation|Medtronic,All,"14 Years and older   (Child, Adult, Older Adult)",Not Applicable,28,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1151-3297,Jan-14,Dec-15,Dec-15,20-Jan-14,null,14-Apr-16,"St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT02040571
NCT02038764,A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Placebo|Biological: PF-06342674 Dose A|Biological: PF-06342674 Dose B|Biological: PF-06342674 Dose C|Biological: PF-06342674 Dose D,Number of Participants With Dose Limiting or Intolerable Treatment Related Adverse Events (AEs)|Number of Participants With All-Causality Treatment Emergent Adverse Events(TEAEs)|Number of Participants With Treatment-Related TEAEs|Number of Participants With All-Causality TEAEs Listed by Common Terminology Criteria for Adverse Events (CTCAE) Grade|Number of Participants With All-Causality Treatment-Emergent Hypoglycemic Adverse Events|Number of Participants With All-Causality Treatment-Emergent Hypoglycemic Adverse Events Listed by CTCAE Grade|Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)|Number of Participants With Vital Signs That Met the Criteria for Potential Clinical Concern(Absolute Values)|Number of Participants With Vital Signs That Met the Criteria for Potential Clinical Concern(Decreases From Baseline)|Number of Participants With Vital Signs That Met the Criteria for Potential Clinical Concern(Increases From Baseline)|Number of Participants With Electrocardiogram(ECG) Data That Met the Criteria for Potential Clinical Concern(Absolute Value)|Number of Participants With Electrocardiogram(ECG) Data That Met the Criteria for Potential Clinical Concern(Increases From Baseline)|Number of Participants With Serum Anti-PF-06342674 Antibody Response Listed by Visit|Area Under Concentration-Time Curve From Time Zero to Time Tau(AUCtau) on Day 1 and Day 71|Apparent Oral Clearance (CL/F) on Day 71|Maximum Observed Plasma Concentration (Cmax) on Day 1 and Day 71|Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1 and Day 71|Plasma Decay Half-Life (t1/2) on Day 71|Apparent Volume of Distribution (Vz/F) on Day 71|Accumulation Ratio (Rac) on Day 71,Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,37,Industry,Interventional,"Allocation: Randomized|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",B4351003,4-Jun-14,13-Sep-16,13-Sep-16,17-Jan-14,3-Aug-18,3-Aug-18,"VA San Diego Healthcare System (Drug Shipment), San Diego, California, United States|Veterans Administration San Diego Healthcare System, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Barbara Davis Center, Aurora, Colorado, United States|Yale School of Medicine, New Haven, Connecticut, United States|Yale New Haven Hospital - Investigational Drug Services, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Duchossois Center for Advanced Medicine, Chicago, Illinois, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|University of Chicago Clinical Resource Center, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Umass Memorial Medical Center, Worcester, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|University Of Minnesota Fairview Pharmacy Services, Minneapolis, Minnesota, United States|University Of Minnesota Medical School, Minneapolis, Minnesota, United States|Barnes- Jewish HOSP Att: Kathryn Vehe, Saint Louis, Missouri, United States|Washington University - Center for Advanced Medicine, Saint Louis, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Duke Clinical Research Unit, Durham, North Carolina, United States|Duke University Health Systems (DUHS) Investigational Drug Services, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02038764
NCT02036372,"Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus",PILGRIM,Completed,No Results Available,Diabetes Mellitus Type II,Drug: Liraglutide|Drug: Insulin bolus|Drug: GIK infusion,Median glucose|Total Insulin administration|Postoperative complications|Hypoglycemia|Hypo- and hyperkalemia|Glucose,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NL 41467.018.12,Jan-14,Jan-17,Jan-17,15-Jan-14,null,24-Jan-17,"Academic Medical Center Amsterdam, Amsterdam, Please Select, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Diakonessenhuis, Utrecht, Netherlands",,https://ClinicalTrials.gov/show/NCT02036372
NCT02036528,Safety and Efficacy of Gentamicin Topical Gel (AppliGel-G) for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers,,Terminated,No Results Available,Diabetic Foot Ulcers,Drug: Gentamicin Topical Gel|Drug: Ciprofloxacin|Drug: Doxycycline,Complete wound clearing of infection|Incidence of infection cleared|DFU Volume % Change|DFU Area % Change,"Royer Biomedical, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,9,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CP-RBM-2011-001 DFU,Jan-14,Dec-14,null,15-Jan-14,null,14-May-15,"Georgetown University Hospital Center, Washington, District of Columbia, United States|GF Professional Research, Corp., Miami Lakes, Florida, United States|Florida Medical Center & Research, Inc., Miami, Florida, United States|Advanced Foot and Ankle Institute of Georgia LLC, Smyrna, Georgia, United States|Union Memorial Hospital, Baltimore, Maryland, United States|Detroit Clinical Research Center, PC, Farmington Hills, Michigan, United States|Utah Valley Medical Center, Provo, Utah, United States",,https://ClinicalTrials.gov/show/NCT02036528
NCT02035371,"A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes",,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart,Area under the serum insulin aspart concentration-time curve|Maximum observed serum insulin aspart concentration,Novo Nordisk A/S,All,"6 Years to 64 Years   (Child, Adult)",Phase 1,41,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1218-3888|2011-002104-32|U1111-1121-1469,13-Jan-14,24-Jul-14,24-Jul-14,14-Jan-14,null,13-Mar-17,"Novo Nordisk Investigational Site, Hannover, Germany",,https://ClinicalTrials.gov/show/NCT02035371
NCT02034266,The Effect of Omega-3 Supplementation on Nerve Structure and Function in Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Dietary Supplement: Omega-3 supplementation,Change in corneal nerve fibre length|Nerve Conduction Studies|Corneal Nerve Fibre Length|Laser Doppler Imaging Flare (LDI Flare) sympathetic skin response|Vibration Perception Threshold|Cooling Detection Threshold Testing|Omega-3 status|Heart Rate Variability|R-R interval,"Eduardo Ng|Canadian Diabetes Association|University Health Network, Toronto",All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,T1DM Omega-3 study,Jan-14,Aug-16,Aug-16,13-Jan-14,null,28-Apr-17,"University Health Network, Division of Neurology, Toronto General Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02034266
NCT02034513,"A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes",SWITCH 1,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin glargine|Drug: insulin aspart,Number of Treatment Emergent Severe or BG (Blood Glucose) Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period|Number of Treatment Emergent Severe or BG Confirmed Symptomatic Nocturnal Hypoglycaemic Episodes During the Maintenance Period|Proportion of Subjects With One or More Severe Hypoglycaemic Episodes During the Maintenance Period|Incidence of Treatment Emergent Adverse Events|Change From Baseline in HbA1c (Glycosylated Haemoglobin)|FPG (Fasting Plasma Glucose),Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,501,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1250-3995|U1111-1129-9668|2012-001930-32,5-Jan-14,11-Jan-16,11-Jan-16,13-Jan-14,15-May-17,1-Jan-19,"Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Goodyear, Arizona, United States|Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Escondido, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, La Jolla, California, United States|Novo Nordisk Investigational Site, Long Beach, California, United States|Novo Nordisk Investigational Site, Rancho Cucamonga, California, United States|Novo Nordisk Investigational Site, San Mateo, California, United States|Novo Nordisk Investigational Site, San Ramon, California, United States|Novo Nordisk Investigational Site, Santa Monica, California, United States|Novo Nordisk Investigational Site, Upland, California, United States|Novo Nordisk Investigational Site, Ventura, California, United States|Novo Nordisk Investigational Site, Denver, Colorado, United States|Novo Nordisk Investigational Site, Cooper City, Florida, United States|Novo Nordisk Investigational Site, Fleming Island, Florida, United States|Novo Nordisk Investigational Site, Fort Lauderdale, Florida, United States|Novo Nordisk Investigational Site, Hialeah, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Miami Springs, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, New Port Richey, Florida, United States|Novo Nordisk Investigational Site, Pembroke Pines, Florida, United States|Novo Nordisk Investigational Site, Port Charlotte, Florida, United States|Novo Nordisk Investigational Site, Port Orange, Florida, United States|Novo Nordisk Investigational Site, Lawrenceville, Georgia, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Arlington Heights, Illinois, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Crystal Lake, Illinois, United States|Novo Nordisk Investigational Site, Skokie, Illinois, United States|Novo Nordisk Investigational Site, Anderson, Indiana, United States|Novo Nordisk Investigational Site, Indianapolis, Indiana, United States|Novo Nordisk Investigational Site, Council Bluffs, Iowa, United States|Novo Nordisk Investigational Site, West Des Moines, Iowa, United States|Novo Nordisk Investigational Site, Lenexa, Kansas, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Livonia, Michigan, United States|Novo Nordisk Investigational Site, Hazelwood, Missouri, United States|Novo Nordisk Investigational Site, Jefferson City, Missouri, United States|Novo Nordisk Investigational Site, Kansas City, Missouri, United States|Novo Nordisk Investigational Site, Billings, Montana, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Henderson, Nevada, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, United States|Novo Nordisk Investigational Site, Hamilton, New Jersey, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, Harrison, New York, United States|Novo Nordisk Investigational Site, Mineola, New York, United States|Novo Nordisk Investigational Site, Syracuse, New York, United States|Novo Nordisk Investigational Site, Asheville, North Carolina, United States|Novo Nordisk Investigational Site, Greenville, North Carolina, United States|Novo Nordisk Investigational Site, Morehead City, North Carolina, United States|Novo Nordisk Investigational Site, Raleigh, North Carolina, United States|Novo Nordisk Investigational Site, Toledo, Ohio, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, United States|Novo Nordisk Investigational Site, Jenkintown, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Amarillo, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Carrollton, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, El Paso, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Katy, Texas, United States|Novo Nordisk Investigational Site, Mesquite, Texas, United States|Novo Nordisk Investigational Site, Richardson, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Schertz, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Salt Lake City, Utah, United States|Novo Nordisk Investigational Site, Salt Lake City, Utah, United States|Novo Nordisk Investigational Site, Chesapeake, Virginia, United States|Novo Nordisk Investigational Site, Norfolk, Virginia, United States|Novo Nordisk Investigational Site, Federal Way, Washington, United States|Novo Nordisk Investigational Site, Renton, Washington, United States|Novo Nordisk Investigational Site, Richland, Washington, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Walla Walla, Washington, United States|Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Szczecin, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Zabrze, Poland|Novo Nordisk Investigational Site, Manati, Puerto Rico",,https://ClinicalTrials.gov/show/NCT02034513
NCT02033239,A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart,Area under the glucose infusion rate curve|Area under the serum insulin aspart concentration-time curve|Maximum glucose infusion rate|Maximum observed serum insulin aspart concentration,Novo Nordisk A/S,All,18 Years to 64 Years   (Adult),Phase 1,46,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1218-3887|2011-001580-41|U1111-1120-3772,Jan-14,Jun-14,Jun-14,10-Jan-14,null,18-Jan-17,"Novo Nordisk Investigational Site, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT02033239
NCT02029924,"A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes",,Completed,No Results Available,Diabetes Mellitus Type 1,Drug: BioChaperone insulin lispro|Drug: Humalog®,"Area under the curve (AUC)|Pharmacokinetics: Early t0.5max(Lisp)|Glucodynamics: Area under the glucose infusion rate - time curve from t=0 to 6 hours|Glucodynamics: Early t0.5(GIRmax)|Glucodynamic: GIRmax (Maximum glucose infusion rate)|Pharmacokinetics: Area under the insulin lispro serum concentration. Time curve from t=0 to 6 hours|Pharmacokinetics: tmax(Lisp) - Time from t=0 hours to maximum observed insulin lispro concentration|Safety and Tolerability: adverse events, local tolerability, vital signs variation, ECG, laboratory safety parameters",Adocia,Male,18 Years to 64 Years   (Adult),Phase 1,37,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BC3-CT006,Dec-13,Mar-14,Aug-14,8-Jan-14,null,1-Jun-17,"Neuss, Germany",,https://ClinicalTrials.gov/show/NCT02029924
NCT02028078,Pilot Study Investigating the Feasibility of Determining the Endogenous Glucose Production During a Hypoglycaemia,PILOT_EGP,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Insulin human,Tracer to Tracee Ratio (the absolute relative difference ARDi )|Tracer to tracee Ratio,Medical University of Graz,All,18 Years to 64 Years   (Adult),Phase 2,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,PILOT_EGP,Jan-14,Mar-16,Mar-16,6-Jan-14,null,12-Sep-16,"Medical University of Graz, Graz, Styria, Austria",,https://ClinicalTrials.gov/show/NCT02028078
NCT02024750,Tailored Diabetes Self-Management Resources,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Behavioral: Tailored Resources,Change in Hemoglobin A1c|Quality of Life for youth|Quality of Life for parent,"University of Wisconsin, Madison|Medical College of Wisconsin",All,8 Years to 16 Years   (Child),Not Applicable,214,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2013-1506|MSN164403|IRB 00016300,Sep-14,8-Aug-17,8-Aug-17,31-Dec-13,null,14-Aug-17,"University of Wisconsin - Madison, Madison, Wisconsin, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02024750
NCT02023489,Lipid and Glycogen Metabolism in Patients With Impaired Glucose Tolerance and Calcium Sensing Receptor Mutations,RISC_7T,Unknown status,No Results Available,"Type 2 Diabetes Mellitus|Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)|Familiar Hypocalcuric Hypercalcemia|Healthy Volunteers|Type 1 Diabetes Mellitus",Device: 1H/ 13C and 31P Magnetic Resonance Spectroscopy|Other: Meal Tolerance Test|Other: Hyperglycemic-hyperinsulinemic clamp,change in myocardial glycogen content|change in myocardial lipid composition,Medical University of Vienna,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,EK1128/2013,Jul-13,Dec-17,Jul-18,30-Dec-13,null,23-Mar-17,"Medical University Of Vienna, Department of Internal Medicine III, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT02023489
NCT02019186,Effects of Vitamin C and E on Endothelial Function in Adolescent Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus,Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin E,endothelial function|Endothelial progenitor cells,Nationwide Children's Hospital,All,8 Years to 15 Years   (Child),Phase 4,9,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CCRI-VITCE,Dec-13,Jan-15,Jan-15,24-Dec-13,null,3-Feb-15,"Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02019186
NCT02018627,Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon,,"Active, not recruiting",No Results Available,Type 1 Diabetes,Drug: Xeris glucagon|Drug: Lilly glucagon,tmax|AOCGIR|GIRmax|t½max|Injection pain|Injection site erythema|Maximal nausea|Dermal response (Draize scale for erythema and eschar formation)|Dermal response (Draize scale grade for edema formation),"Steven J. Russell, MD, PhD|Massachusetts General Hospital",All,"21 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,30,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013P002549,Apr-14,Dec-18,Dec-18,23-Dec-13,null,20-Jul-18,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02018627
NCT02017171,A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes,,"Active, not recruiting",No Results Available,Diabetic Nephropathies|Coronary Artery Disease,Drug: Allopurinol|Drug: Placebo,iGFR at the end of the wash-out period|eGFR at 4 months of treatment|iGFR the end of treatment period|iGFR time trajectory|eGFR time trajectory|Time to serum creatinine doubling or end stage renal disease (ESRD)|AER at the end of the wash-out period|AER at the end of the treatment period|Time to fatal or non-fatal cardiovascular events,"Alessandro Doria|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Juvenile Diabetes Research Foundation|Joslin Diabetes Center|University of Minnesota - Clinical and Translational Science Institute|University of Colorado, Denver|University of Michigan|University of Toronto|Feinberg School of Medicine, Northwestern University|Albert Einstein College of Medicine|Steno Diabetes Center Copenhagen|Washington University School of Medicine|University of Washington|Emory University|University of Calgary|University of Alberta|University of Texas Southwestern Medical Center|BCDiabetes.Ca",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,530,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",DK101108|UC4DK101108-01,Feb-14,Jun-19,Jun-19,20-Dec-13,null,22-Apr-19,"Barbara Davis Center / University of Colorado Denver, Aurora, Colorado, United States|Kaiser Permanente Colorado Institute of Health Research, Denver, Colorado, United States|Emory University - Grady Memorial Hospital, Atlanta, Georgia, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|University of Massachusetts Memorial Health Care, Worcester, Massachusetts, United States|Brehm Center for Diabetes Research / University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Albert Einstein College of Medicine / Montefiore Medical Center, Bronx, New York, United States|Jacobi Medical Center, Bronx, New York, United States|Winthrop-University Hospital, Mineola, New York, United States|ICAHN School of Medicine at Mount Sinai, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Texas Southwestern, Dallas, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States|University of Washington, Seattle, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Gunderson Health System, La Crosse, Wisconsin, United States|University of Calgary, Calgary, Alberta, Canada|Alberta Diabetes Institute, Edmonton, Alberta, Canada|BC Diabetes, Vancouver, British Columbia, Canada|LMC Diabetes and Endocrinology, Toronto, Ontario, Canada|Mount Sinai Hospital / University of Toronto, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Steno Diabetes Center, Gentofte, Denmark",,https://ClinicalTrials.gov/show/NCT02017171
NCT02008188,Early Feasibility Study of Adaptive Advisory/Automated (AAA) Control of Type 1 Diabetes (Italy),,Unknown status,No Results Available,Type 1 Diabetes Mellitus,Device: Closed Loop Control with the Advisory/Automated Adaptive (AAA) Control system,Assessment of the effect size of Advisory/Automated Adaptive (AAA) Control system preventing nocturnal hypoglycemia and increasing time within target (80-140 mg/dl) overnight as compared to CGM-augmented pump alone.,University of Virginia|National Institutes of Health (NIH),All,21 Years to 64 Years   (Adult),Not Applicable,12,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Italy - Phase 4|R01DK085623,Dec-13,May-15,May-15,11-Dec-13,null,3-Apr-15,"Azienda Ospedaliera di Padova (Padua Hospital), Padova, Italy",,https://ClinicalTrials.gov/show/NCT02008188
NCT02008851,"A Phase 1, Open-label Safety Study of NKA in Patients With Type 2 Diabetes",,Terminated,No Results Available,Chronic Kidney Disease,Biological: Neo-kidney augment,Number of adverse events related to study procedures or investigational product|Number of renal-specific adverse events,Tengion,All,"30 Years to 70 Years   (Adult, Older Adult)",Phase 1,1,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),TNG-CL011,Dec-13,Dec-14,Dec-14,11-Dec-13,null,11-Dec-14,"University of Chicago Medicine, Chicago, Illinois, United States|LSU Health Care Services, New Orleans, Louisiana, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|UNC Medical Center, Chapel Hill, North Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT02008851
NCT02005848,Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes,,Completed,No Results Available,New Onset Type-1 Diabetes,Biological: Alpha-1 Antitrypsin|Other: Placebo,Beta cell function|Glycemic control|Insulin dose|Hypoglycemic episodes|Safety parameters,"Kamada, Ltd.",All,"8 Years to 25 Years   (Child, Adult)",Phase 2,70,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Kamada-AAT(IV)-011,Apr-14,Feb-17,Feb-17,9-Dec-13,null,11-Oct-18,"Soroka Medical Center, Beer Sheva, Israel|Rambam Medical Center, Haifa, Israel|Schneider Children's Medical Center, Pethach Tikva, Israel|Assaf Harofe Medical Center, Zerifin, Israel",,https://ClinicalTrials.gov/show/NCT02005848
NCT02003274,Mixed Meal Test in Type 1 Diabetes on Insulin Pump Therapy: Optimization of Artificial Pancreas,,Unknown status,No Results Available,Type 1 Diabetes Mellitus,Other: Clamp-Mixed Meal|Other: IVGTT-Mixed Meal Arm,1. Composite plasma glucose and hormone responses to a mixed meal; 2. Glucose control coefficients|Composite plasma free fatty and amino acid responses to a mixed meal,Azienda Ospedaliera Universitaria Integrata Verona|Universita di Verona|European Foundation for the Study of Diabetes,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,Verona Artificial Pancreas,Oct-13,Oct-16,31-Oct-17,6-Dec-13,null,2-Jul-17,"Clinical Research Center-University Hospital of Verona, c/o Policlinico G.B. Rossi - Piazzale L.A. Scuro, 10, Verona, Italy|Division of Endocrinology and Metabolic Diseases - University Hospital of Verona, Piazzale Stefani 1-Pad. 22, Verona, Italy",,https://ClinicalTrials.gov/show/NCT02003274
NCT02003677,A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart,Area under the glucose infusion rate curve|Area under the serum insulin aspart concentration-time curve|Maximum observed serum insulin aspart concentration,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 1,67,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1218-3891|2011-002626-46|U1111-1121-8758,29-Nov-13,14-Aug-14,14-Aug-14,6-Dec-13,null,11-Dec-18,"Novo Nordisk Investigational Site, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT02003677
NCT02002130,The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes,GABA,"Active, not recruiting",No Results Available,Type I Diabetes,Drug: Placebo GABA and Placebo GAD-alum|Drug: GABA and Placebo GAD-alum|Drug: Active Oral GABA and Active GAD-alum injection,Compare the effect of oral GABA or oral GABA/GAD combination administration on pancreatic beta cell function by use of insulin|Compare the effect of oral GABA or oral GABA/GAD combination administration on pancreatic beta cell function by peptide secretion|Compare the effect of oral GABA or GABA/GAD administration on diabetes autoantibodies GAD-65|Compare the effect of oral GABA or GABA/GAD administration on diabetes autoantibodies IA2|Compare the effect of oral GABA or GABA/GAD administration on diabetes autoantibodies ICA,University of Alabama at Birmingham|Diamyd Inc|NOW Foods|Janssen Pharmaceuticals|Juvenile Diabetes Research Foundation,All,"4 Years to 18 Years   (Child, Adult)",Phase 1,101,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GABA-GAD,Jan-15,Jun-19,Jun-20,5-Dec-13,null,31-Aug-18,"Children's of Alabama, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT02002130
NCT02002143,GMVs in Primary Care: An RCT of Group-Based Versus Individual Appointments to Reduce HbA1c in Older People,GAP,Recruiting,No Results Available,Type 2 Diabetes Mellitus (T2DM),Behavioral: Group Appointments|Behavioral: Individual Appointments (IAs),"Patients' control (decreased levels) of HemoglobinA1C (clinical)|Resting systolic blood pressure (mmHg)) (clinical)|Resting diastolic blood pressure (mmHg)) (clinical)|Electrical activity of the heart (ECG) (clinical)|C-reactive protein (mg/L) (clinical)|plasma glucose (mmol/L) (clinical)|High-density lipoprotein - cholesterol (HDL-C; mmol/L) (clinical)|Fasting low-density lipoprotein (LDL; mmol/L) (clinical)|Triglycerides (mmol/L) (clinical)|Height (cm), weight (kg), waist & hip circumference (cm), fat and muscle mass (g) (clinical)|Quality of life (as measured by the health state utility values of EQ-5D3L questionnaire (patient-reported quality of life/economic))|Health Care Utilization|Anxiety|Depression|Satisfaction With Life Scale|Physical Activity (PASE)|Physical Activity (SenseWear)|Goal Setting and Action Planning|Food Diary|Patient Self-Management","University of British Columbia|Ministry of Health, British Columbia",All,65 Years and older   (Older Adult),Not Applicable,128,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,H13-02812,Jan-14,Feb-19,Feb-20,5-Dec-13,null,22-Nov-17,"Gateway Clinic / Kent Place Clinic, Abbotsford, British Columbia, Canada|Centre for Hip Health and Mobility (Vancouver Coastal Health Research Institute/University of British Columbia), Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT02002143
NCT02000817,"Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients",,Completed,No Results Available,"Diabetes Mellitus, Type 1",Biological: Otelixizumab|Biological: Placebo,INCIDENCE ADVERSE EVENTS RELATED TO CYTOKINE RELEASE SYNDROME (CRS)|EPSTEIN-BARR VIRUS (EBV) REACTIVATION|ABNORMAL HEMATOLOGY PARAMETERS|ABNORMAL CLINICAL CHEMISTRY PARAMETERS|ABNORMAL ECG CHANGES|ABNORMAL VITAL SIGNS|FREE SERUM OTELIXIZUMAB MAXIMUM OBSERVED PLASMA CONCENTRATION (CMAX)|TIME TO FREE SERUM OTELIXIZUMAB MAXIMUM OBSERVED PLASMA CONCENTRATION (TMAX )|FREE SERUM OTELIXIZUMAB AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE AUC(0-T)|FREE SERUM OTELIXIZUMAB AUC UP TO THE LAST MEASURABLE CONCENTRATION (AUC(0- TAU)|FREE SERUM OTELIXIZUMAB APPARENT TERMINAL PHASE HALF-LIFE (T1/2)|CHANGE FROM BASELINE IN GLUCOSE AFTER A MIXED MEAL TOLERANCE TEST|CHANGE FROM BASELINE IN C-PEPTIDE AFTER A MIXED MEAL TOLERANCE TEST|CHANGE FROM BASELINE IN C-PEPTIDE AUC HYPERGLYCEMIC PHASE|CHANGE FROM BASELINE IN C-PEPTIDE AUC EUGLYCEMIC PHASE|CHANGE FROM BASELINE IN INSULIN SENSITIVITY (IS) INDEX AFTER A HYPERGLYCEMIC CLAMP|CHANGE FROM BASELINE IN MEAN DAILY INSULIN USE OVER 7 CONSECUTIVE DAYS DURING THE WEEK PRECEDING THE VISIT OR TELEPHONE CALL|CHANGE FROM BASELINE IN HBA1C LEVEL|BODY WEIGHT|NUMBER OF HYPOGLYCEMIC EVENTS|NUMBER OF HYPERGLYCEMIC EVENTS|CHANGE FROM BASELINE CD4 + CELLS|NUMBER OF SUBJECTS WITH CHANGE CD8+ CELLS|CHANGE IN FREE CD3 CELLS|NUMBER OF SUBJECTS WITH CHANGE IN BOUND OTELIXIZUMAB ON CD4+|NUMBER OF SUBJECTS WITH CHANGE IN BOUND OTELIXIZUMAB ON CD8+|CHANGE FROM BASELINE IN ANTI-DRUG ANTIBODY LEVELS AT MONTHS 3,GlaxoSmithKline|Parexel,All,"16 Years to 27 Years   (Child, Adult)",Phase 2,30,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,116505,12-Mar-14,27-Sep-18,27-Sep-18,4-Dec-13,null,9-Oct-18,"GSK Investigational Site, Brussels, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Edegem, Belgium|GSK Investigational Site, Gent, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Liège, Belgium",,https://ClinicalTrials.gov/show/NCT02000817
NCT01999322,A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes,onset® 4,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart,Number of Microscopically Confirmed Episodes of Infusion Set Occlusions|Number of Unexplained Episodes of Hyperglycaemia (Confirmed by Self-measured Plasma Glucose (SMPG))|Number of Episodes of Possible Infusion Set Occlusions|Number of Premature Infusion Set Changes,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,37,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1218-3931|2013-002233-37|U1111-1143-2316,19-Nov-13,14-May-14,14-May-14,3-Dec-13,31-Oct-17,31-Oct-17,"Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01999322
NCT01999361,Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss,,Recruiting,No Results Available,Type 1 Diabetes Mellitus,Drug: Myfortic,allosensitization after complete islet graft loss,Rodolfo Alejandro|University of Miami,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,18,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,20071058,Jan-09,Jan-22,Dec-23,3-Dec-13,null,11-Dec-18,"Diabetes Research Institute, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT01999361
NCT01997411,Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Nasal Glucagon|Drug: Intramuscular Glucagon,Maximum Change From Baseline Concentration (Cmax) of Glucagon|Time to Maximum Concentration (Tmax) of Baseline Adjusted Glucagon|Area Under the Curve (AUC0-1.5) of Baseline Adjusted Glucagon|Maximum Concentration (Cmax) of Baseline-Adjusted Glucose|Time to Maximum Concentration (Tmax) of Baseline-Adjusted Glucose|Area Under the Effect Concentration Time Curve (AUEC0-1.5) of Baseline-Adjusted Glucose From Time Zero up to 90 Minutes|Nasal and Non-nasal Effects/Symptoms|Number of Participants Achieving at Least a 25 mg/dL Rise in Blood Glucose Above Nadir Level Within 30 Minutes|Time to Achieving ≥25 mg/dL Rise in Plasma Glucose Above Nadir Level Within 30 Minutes,Eli Lilly and Company|Jaeb Center for Health Research|Locemia Solutions ULC,All,4 Years to 16 Years   (Child),Phase 2|Phase 3,48,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",16418|I8R-MC-IGBB|INGluc002|AMG103,Nov-13,Jan-15,Jan-15,28-Nov-13,6-Mar-17,29-Aug-18,"Barbara Davis Center for Diabetes, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Riley Hospital for Children Indiana University Health, Indianapolis, Indiana, United States|University of Minnesota, Minneapolis, Minnesota, United States|UPA Buffalo, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT01997411
NCT01996228,Reversal of Type 1 Diabetes in Children by Stem Cell Educator Therapy,,Recruiting,No Results Available,Type 1 Diabetes,Device: Stem Cell Educator,Autoimmune control|Metabolic control,Tianhe Stem Cell Biotechnologies Inc.|Second Xiangya Hospital of Central South University,All,6 Years to 14 Years   (Child),Phase 1|Phase 2,20,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013-0002,Nov-13,Oct-19,Oct-19,27-Nov-13,null,5-Feb-19,"The Second Xiangya Hospital, Changsha, Hunan, China",,https://ClinicalTrials.gov/show/NCT01996228
NCT01994746,Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Nasal Glucagon|Drug: Intramuscular Glucagon,Increase in Plasma Glucose Level to >=70mg/dL or an Increase of >=20mg/dL From Glucose Nadir|Nasal and Non-nasal Effects/Symptoms|Recovery From Symptoms of Hypoglycemia|Time From Glucagon Administration to Blood Glucose >/=70 mg/dL or an Increase ≥20 mg/dL in Blood Glucose From Nadir|Area Under the Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) of Baseline-Adjusted Glucagon|Maximum Change From Baseline Concentration (Cmax) of Glucagon|Time to Maximum Change From Baseline Concentration (Tmax) of Glucagon|Area Under the Effect Concentration Time Curve (AUEC0-1.5) of Baseline-Adjusted Glucose From Time Zero up to 90 Minutes|Maximum Change From Baseline Concentration (Cmax) of Glucose|Time to Maximum Change From Baseline Concentration (Tmax) of Glucose,Eli Lilly and Company|Jaeb Center for Health Research|Locemia Solutions ULC,All,18 Years to 64 Years   (Adult),Phase 3,77,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16422|INGluc001|I8R-MC-IGBC|AMG106,Nov-13,Jan-15,Jan-15,26-Nov-13,10-Oct-16,29-Aug-18,"Barbara Davis Center for Diabetes, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|Riley Hospital for Children Indiana University Health, Indianapolis, Indiana, United States|University of Minnesota, Minneapolis, Minnesota, United States|UPA Buffalo, Buffalo, New York, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01994746
NCT01991548,User Evaluation of the MiniMed 640G Insulin Pump,,Completed,Has Results,Type 1 Diabetes|Type 2 Diabetes,Device: MiniMed® 640G Insulin Pump and Guardian® Link Transmitter,User Acceptance of the New MiniMed 640G Insulin Pump and Guardian Link Transmitter,Medtronic Diabetes,All,"7 Years and older   (Child, Adult, Older Adult)",Not Applicable,52,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CEP284,Nov-13,Nov-14,Nov-14,25-Nov-13,15-May-17,15-May-17,"St Vincent Hospital and The University of Melbourne, Fitzroy, Australia|The Royal Melbourne Hospital, Patkville, Australia|University College Hospital, London, United Kingdom|King's College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01991548
NCT01992588,A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart,CSII bolus related baseline corrected area under the serum insulin aspart concentration-time curve|CSII bolus related baseline corrected area under the glucose infusion rate curve,Novo Nordisk A/S,All,18 Years to 64 Years   (Adult),Phase 1,48,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1218-3890|2011-000913-37|U1111-1119-5358,Nov-13,Mar-14,Mar-14,25-Nov-13,null,8-Nov-16,"Novo Nordisk Investigational Site, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01992588
NCT01987206,Feasibility Study of PID Versus MPC and HMS,,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: MPC control algorithm|Device: PID control algorithm,time spent in safe blood glucose range|glucose level extremes and need for outside intervention,"Sansum Diabetes Research Institute|Juvenile Diabetes Research Foundation|University of California, Santa Barbara",All,"21 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,10,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),2013-11 C2T,Jul-14,Aug-15,Aug-15,19-Nov-13,null,22-Jul-16,"Sansum Diabetes Research Institute, Santa Barbara, California, United States",,https://ClinicalTrials.gov/show/NCT01987206
NCT01986231,Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver,,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Glucagon,Assess Difference in Hepatic Glycogen Measured in the Fasting State Before vs. After Repeated Glucagon Administration|Assess Difference in Hepatic Glycogen Measured in the Fed State Before vs. After Repeated Glucagon Administration,Legacy Health System|Juvenile Diabetes Research Foundation|Oregon Health and Science University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,12,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,IRB00006947,Jan-11,Dec-12,Dec-12,18-Nov-13,30-Apr-15,4-May-15,"Oregon Health and Science University, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT01986231
NCT01981031,A Trial to Assess the Efficacy and Safety of BioChaperone Combo and Humalog Mix 25 in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: BioChaperone® Combo|Drug: Humalog® Mix25,End of action of 0.8 U/kg BioChaperone® Combo (time from administration until blood glucose concentration is consistently above 8.3 mmol/L during the glucose clamp procedure)|Compare pharmacodynamics and pharmacokinetics profiles between BioChaperone® Combo and Humalog® Mix25|Number of Adverse Events,Adocia,Male,18 Years to 64 Years   (Adult),Phase 1,21,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BC3-CT005,Nov-13,Dec-13,Aug-14,11-Nov-13,null,1-Jun-17,"Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01981031
NCT01977833,"Meal Timing on Postprandial Glucose, Insulin and GLP-1 in Type 2 Diabetes",GLP-1inT2D,Unknown status,No Results Available,Type 2 Diabetes,Other: High Calorie Breakfast (BTdiet)|Other: High Caloric Dinner (DTdiet),"Postprandial GLP-1 plasma levels, after breakfast,lunch and dinner meal test|Postprandial Plasma Glucose levels after breakfast, lunch and dinner meal challenge",Tel Aviv University|Wolfson Medical Center,All,"30 Years to 70 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0145-13-WOMC,Oct-13,Dec-13,Jan-14,7-Nov-13,null,7-Nov-13,"Diabetes Unit E. Wolfson Medical center, Holon, Tel Aviv, Israel",,https://ClinicalTrials.gov/show/NCT01977833
NCT01978704,Glycaemic Load and Pre-meal Insulin Doses in Type 1 Diabetes Patients,GLUT,Completed,No Results Available,Type 1 Diabetes,Other: Adjustment of pre-prandial insulin doses on the bases of glycaemic load of the meal|Other: Adjustment of pre-prandial insulin doses on the bases of carbohydrates content of the meal,daily plasma glucose excursion|mean plasma glucose concentrations|postprandial plasma glucose concentrations,Federico II University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,9,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,37/13,Feb-13,Jul-13,Aug-13,7-Nov-13,null,7-Nov-13,,,https://ClinicalTrials.gov/show/NCT01978704
NCT01973920,Efficacy Safety and Tolerability of Multiple Doses of Oshadi Icp (Oshadi Oral Insulin) in Patients With Type 1 Diabetes Mellitus - Phase II Clinical Study,,Completed,No Results Available,Diabetes Mellitus|Insulin-Dependent|Type 1,Drug: Oshadi Icp,Adverse events and serious adverse events occurence|To assess the pharmacodynamic effect of multiple doses of Oshadi Icp as measured by the area under the glucose concentration-time curve,Oshadi Drug Administration,All,"21 Years and older   (Adult, Older Adult)",Phase 2,12,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OS-ICP-P2 -01,Dec-13,Feb-17,Feb-17,1-Nov-13,null,18-Apr-18,"Assaf-Harofeh Medical Center, Zerifin, Israel",,https://ClinicalTrials.gov/show/NCT01973920
NCT01974674,Allogeneic Islet Transplantation for the Treatment of Type 1 Diabetes,GRIIF,Recruiting,No Results Available,Patients With Type 1 Diabetes,Procedure: Allogeneic transplantation of intrahepatic islet,"restoration of normal glycemic control without insulin|Restoration of normal glycemic control without insulin for a year|Obtaining an improvement in glycemic control|Obtaining a remission of diabetes|Improved metabolic profile determined by the OGTT and hyperglycemic clamp|Decreased glycemic variability|Reduction of oxidative stress assessed by the urinary excretion of 24 hours of 8-iso-PGF2 rates.|Decrease in the frequency, severity or poor perception of hypoglycaemia defined Hypo score|quality of life|term graft survival|beta-cell function|potential of each infusion of islets|degenerative complications of diabetes",Assistance Publique - Hôpitaux de Paris,All,18 Years to 55 Years   (Adult),Phase 2,19,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P030415,Jul-13,Dec-16,Jan-22,1-Nov-13,null,29-Sep-16,"Saint Louis hospital, Paris, Ile de France, France",,https://ClinicalTrials.gov/show/NCT01974674
NCT01972893,"A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers",ZYD1,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: ZYD1|Drug: Placebo,To evaluate Safety and tolerability of ZYD1|Pharmacokinetics (PK) and Pharmacodynamic (PD) effect after single and multiple subcutaneous dose administrations in healthy adult male volunteers Gender effect study.,Cadila Healthcare Limited,All,18 Years to 45 Years   (Adult),Phase 1,56,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ZYD1/1001|CTRI/2011/04/001684,Feb-11,Mar-12,Jun-12,31-Oct-13,null,31-Oct-13,"Zydus Research Centre, Survey No. 396/403, Opp. Sarvotam Hotel, Nr. Nova Petrochemicals, Sarkhej-Bavla N.H. No. 8A, Village : Moraiya,, Ahmedabad, Gujarat, India",,https://ClinicalTrials.gov/show/NCT01972893
NCT01973400,Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus,VENUS,Completed,No Results Available,Diabetic Neuropathy|Cognitive Impairment,Dietary Supplement: Tocotrienol|Dietary Supplement: Placebo,"Total Symptoms Score (TSS) (pain, paresthesia, burning, and numbness)of patients with diabetes type 1 and 2 neuropathy.|Neuropathy Impairment Score (NIS) of patients with diabetes type 1 and 2 neuropathy","University of Science Malaysia|Clinical Research Centre, Malaysia|Malaysia Palm Oil Board",All,"20 Years and older   (Adult, Older Adult)",Phase 3,300,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",VENUS-7327|NMRR-10-948-7327,Jun-11,Sep-15,Dec-16,31-Oct-13,null,4-May-17,"Seberang Jaya Hospital, Seberang Jaya, Penang, Malaysia",,https://ClinicalTrials.gov/show/NCT01973400
NCT01973413,Diabetes Assistant (DiAs) Control-to-Range (CTR) Nocturnal Closed-Loop Camp Study,,Completed,Has Results,"Diabetes Mellitus, Type 1",Device: Diabetes Assistant (DiAs)|Device: Tandem t:slim Insulin Pump|Device: Dexcom G4 Platinum sensor,Percent Time Near Normoglycemia|Overnight Glucose|Glycemic Events,University of Virginia|Stanford University,All,"10 Years to 35 Years   (Child, Adult)",Not Applicable,32,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,001-Stanford,Jul-13,Aug-13,Aug-13,31-Oct-13,15-Aug-14,24-Apr-15,"Stanford University, Los Gatos, California, United States",,https://ClinicalTrials.gov/show/NCT01973413
NCT01971047,Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery,,Withdrawn,No Results Available,Type 1 Diabetes|Type 2 Diabetes,Drug: Regular Insulin|Drug: Humalog,"BG concentration differences at 1 and 2 hours post intervention and post operatively|Number and percentage of target BG readings|Episodes of hypoglycemia|Episodes of hyperglycemia|Total dose of insulin|Change in glucose concentration from baseline to one, two and three hours post treatment|Number of perioperative complications",Emory University,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB00067662,Oct-13,Sep-18,Sep-18,28-Oct-13,null,15-Mar-17,"Emory Healthcare Ambulatory Surgical Center, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT01971047
NCT01969747,Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Empagliflozin medium placebo|Drug: Empagliflozin low placebo|Drug: Empagliflozin high placebo|Drug: Empagliflozin medium|Drug: Empagliflozin low|Drug: Empagliflozin high,"Change From Baseline in 24 h UGE (g/24 h) After Seven Days of Treatment With Empagliflozin 2.5 mg, 10 mg, or 25 mg, or Placebo",Boehringer Ingelheim|Eli Lilly and Company,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,75,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,1245.78|2011-004354-25,Nov-13,Apr-14,Apr-14,25-Oct-13,8-Apr-15,8-Apr-15,"1245.78.43001 Boehringer Ingelheim Investigational Site, Graz, Austria|1245.78.49001 Boehringer Ingelheim Investigational Site, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01969747
NCT01966978,"The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study",SIMPLE,Completed,No Results Available,"Diabetes Mellitus, Type 2|Diabetes",Drug: Metformin|Drug: Detemir|Drug: Liraglutide|Drug: Insulin Aspart,"Mean change from randomization in A1c at week 26|Composite end-point|Percentage of patients reaching target A1c of <7% at week 26|Percentage of patients reaching pre-specified ""treatment failure"" outcome|Mean change from randomization in body weight|Percentage of patients who lost 5% or more of body weight from randomization|Hypoglycemic episodes|Percentage of patients experiencing any hypoglycemic episode|Diabetes Quality of Life (DQOL)questionnaire score|Short Form-36 (SF-36) questionnaire score|Number of daily injections|7-point glucose profiles over 2 consecutive days",University of Texas Southwestern Medical Center,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,157,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STU 072013-030,Nov-14,Dec-17,Dec-17,22-Oct-13,null,12-Apr-18,"UT Southwestern Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT01966978
NCT01967186,Intraportal or Intramuscular Site for Islets in Simultaneous Islet and Kidney Transplantation,,Unknown status,No Results Available,Type 1 Diabetes|End Stage Renal Disease,Procedure: Intraportal islet transplantation|Procedure: Intramuscular islet transplantation|Procedure: Intramuscular transpl with stemcells|Procedure: Kidney transplantation,C-peptide derived from the Mixed Meal Tolerance Test (MMTT),The Nordic Network For Clinical Islet Transplantation,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,36,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SIK01,Apr-07,Jan-16,Jul-16,22-Oct-13,null,6-Oct-15,,,https://ClinicalTrials.gov/show/NCT01967186
NCT01966393,Closed-loop Control of Glucose Levels (Artificial Pancreas) for 60 Hours in Adults With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Other: 60-hours intervention,Percentage of time of glucose levels (as measured by continuous glucose sensor) spent in the hypoglycemic range.|Percentage of time of glucose levels (as measured by continuous glucose sensor) spent in target range.|Percentage of time of glucose levels spent below 3.5 mmol/L|Percentage of time of glucose levels spent below 3.3 mmol/L|Area under the curve of glucose values below 4.0 mmol/L|Area under the curve of glucose values below 3.5 mmol/L|Area under the curve of glucose values below 3.3 mmol/L|Percentage of time of glucose levels spent above 8.0 mmol/L|Percentage of time of glucose levels spent above 10.0 mmol/L|Mean value of glucose levels|Standard deviation of glucose levels|Total insulin delivery|Number of patients with at least one hypoglycemic event with or without symptoms below 3.0 mmol/L based on glucose sensor reading,Institut de Recherches Cliniques de Montreal,All,"18 Years and older   (Adult, Older Adult)",Phase 2,23,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLASS-07,Apr-14,Apr-15,Apr-15,21-Oct-13,null,4-May-15,"Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01966393
NCT01961622,Closing the Loop in Adults With Sub-optimally Controlled Type 1 Diabetes Under Free Living Conditions,AP@home04,Completed,No Results Available,Type 1 Diabetes,Device: Florence D2A or similar closed loop glucose control system|Device: CSII with real-time CGM,Time spent in the target glucose range from 3.9 to 10.0 mmol/l based on subcutaneous glucose monitoring|HbA1c|Insulin dose|Adverse Events|Utility Evaluation|Continuous subcutaneous glucose monitoring (CGM) based outcome|Continuous subcutaneous glucose monitoring (CGM) based outcome during overnight period between 23:00 and 08:00|Continuous subcutaneous glucose monitoring (CGM) based outcome during day period between 08:00 to 23:00,University of Cambridge|Profil Institut für Stoffwechselforschung GmbH|Medical University of Graz,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,33,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AP@home04,Apr-14,May-15,May-15,11-Oct-13,null,8-Jun-15,"Medical University of Graz, Graz, Austria|Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany|University of Cambridge, Cambridge, United Kingdom",,https://ClinicalTrials.gov/show/NCT01961622
NCT01959334,Evaluate the Immunogenicity of a Novel Glucagon Formulation,,Completed,No Results Available,Drug-specific Antibodies|Hypoglycemia|Diabetes Mellitus,Drug: Glucagon IN|Drug: Glucagon IM,Immunogenicity data (titers)|Safety and tolerability,Eli Lilly and Company,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,75,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),16426|I8R-MC-IGBF|AMG105,Sep-13,Jan-14,Jan-15,10-Oct-13,null,25-May-16,"Algorithme Pharma Inc., Laval, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01959334
NCT01954459,Warming up to Sensors: Does Site Warming Improve Continuous Glucose Monitor Performance?,,Terminated,No Results Available,Type 1 Diabetes,Device: Insupatch|Device: Continuous glucose sensor,Point accuracy of the continuous glucose monitor plus Insupatch (CGM+IP) by mean absolute relative difference (MARD) calculation of sensors with and without IP use.,Yale University,All,"8 Years to 44 Years   (Child, Adult)",Early Phase 1,11,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),1306012208,Sep-13,Jun-16,Jun-16,1-Oct-13,null,3-Oct-16,"Yale University School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01954459
NCT01948986,"Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)",,Completed,Has Results,Renal Impairment|Type 2 Diabetes Mellitus,Drug: Ertugliflozin,Area Under the Plasma Concentration-Time Profile for Ertugliflozin From Time 0 Extrapolated to Infinite Time (AUCinf)|Area Under the Plasma Concentration-Time Profile for Ertugliflozin From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)|Apparent Clearance (CL/F) for Plasma Ertugliflozin|Maximum Observed Plasma Concentration (Cmax) for Ertugliflozin|Time for Cmax (Tmax) for Plasma Ertugliflozin|Terminal Half-Life (t1/2) for Plasma Ertugliflozin|Apparent Volume of Distribution Following Oral Administration (Vz/F) for Plasma Ertugliflozin|Unbound Fraction (Fu) for Plasma Ertugliflozin|Cumulative Amount of Drug Recovered Unchanged in Urine to 96 Hours Post Dose (Ae96)|Percent of Dose Recovered Unchanged in Urine From 0 to 96 Hours Postdose (for Ertugliflozin Only) (Ae96%)|Renal Clearance (CLr) for Urinary Ertugliflozin|Number of Participants Who Experienced an Adverse Event (AE)|Number of Participants Who Discontinued Study Due to an AE|Area Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06481944 From Time 0 Extrapolated to Infinite Time (AUCinf)|Area Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06481944 From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)|Maximum Observed Plasma Concentration (Cmax) for Glucuronide Metabolite PF-06481944|Time for Cmax (Tmax) for Plasma Glucuronide Metabolite PF-06481944|Terminal Half-life (t1/2) for Plasma Glucuronide Metabolite PF-06481944|Cumulative Amount of Drug Recovered Unchanged in Urine to 96 Hours Post Dose (Ae96) for Glucuronide Metabolite PF-06481944|CLr for Urinary Glucuronide Metabolite PF-06481944|Area Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06685948 From Time 0 Extrapolated to Infinite Time (AUCinf)|Area Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06685948 From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)|Maximum Observed Plasma Concentration (Cmax) for Glucuronide Metabolite PF-06685948|Time for Cmax (Tmax) for Plasma Glucuronide Metabolite PF-06685948|Terminal Half-life (t1/2) for Plasma Glucuronide Metabolite PF-06685948|Cumulative Amount of Drug Recovered Unchanged in Urine to 96 Hours Post Dose (Ae96) for Glucuronide Metabolite PF-06685948|Renal Clearance (CLr) for Urinary Glucuronide Metabolite PF-06685948|Change From Baseline in 24 Hour Inhibition of Glucose Reabsorption|Change From Baseline in 24 Hour Fluid Balance|Urinary Glucose Excretion Over 24 Hours (UGE0-24hr) for Ertugliflozin,Merck Sharp & Dohme Corp.|Pfizer,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,36,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,8835-009|B1521023|MK-8835-009,1-Oct-13,6-Oct-14,16-Oct-14,24-Sep-13,18-Feb-19,18-Feb-19,,,https://ClinicalTrials.gov/show/NCT01948986
NCT01947569,Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy,,Unknown status,No Results Available,Treatment of Type I Diabetes Mellitus.,Biological: Biological,The incidence of treatment-emergent adverse events.|2-hour area under the curve (AUC) average of C-peptide at 12 months after completion of administration of assigned therapy (Protocol Month 15).,"DiaVacs, Inc.",All,"12 Years to 35 Years   (Child, Adult)",Phase 1|Phase 2,90,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",DV-0100-100,Oct-13,Nov-14,null,20-Sep-13,null,23-Oct-13,"UPMC, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01947569
NCT01945060,Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator,,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: heart rate Control to Range System (hrCTR) using DiAs Platform|Other: DiAs Control-to-Range System not informed for heart rate,Low Blood Glucose Index (LBGI),"Marc Breton|Virginia Commonwealth University|DexCom, Inc.|Tandem Diabetes Care, Inc.|University of Virginia",All,12 Years to 17 Years   (Child),Not Applicable,18,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),HM15215 & 17256|17-2013-498,Sep-13,Apr-15,Apr-15,18-Sep-13,null,11-May-16,"University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01945060
NCT01945099,Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy,,Completed,No Results Available,Type 1 Diabetes,Device: ePID closed loop system|Drug: hyaluronidase|Drug: Lispro-PH20,"Peak post-prandial venous glucose levels obtained after breakfast, lunch, and dinner between CL alone and CL+PH20preRx and CL+INS-PH20|Peak post-prandial insulin levels following meals",Eda Cengiz|Yale University,All,"12 Years to 40 Years   (Child, Adult)",Early Phase 1,13,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HIC 1307012334,Sep-13,Dec-15,Jul-16,18-Sep-13,null,25-Jan-17,"Yale University School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01945099
NCT01944449,Effects of Whey Protein in Type 2 Diabetics,WHEY-T2D,Completed,No Results Available,Type 2 Diabetes,Dietary Supplement: Whey Protein (WPC) at breakfast|Dietary Supplement: Other Protein Sources at breakfast|Dietary Supplement: Low Protein at breakfast,Fasting circulating levels of HbA1c|Postprandial Glucose|Body Weight,Tel Aviv University|Hospital de Clinicas Caracas,All,"30 Years to 70 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HCCCBI 057-2011-165,Sep-13,Feb-16,Mar-16,17-Sep-13,null,11-Oct-17,"Daniela Jakubowicz, Holon, N/A = Not Applicable, Israel|Daniela Jakubowicz MD, Caracas, N/A = Not Applicable, Venezuela",,https://ClinicalTrials.gov/show/NCT01944449
NCT01939522,Protection Against Pneumococcal Infection in Children With T1DM,T1DM,Completed,No Results Available,Type 1 Diabetes Mellitus,Biological: 13-valent pneumococcal conjugate vaccine (PCV13),"Pneumococcal serotype-specific (SpVS) antibody concentrations at 3 months following a single dose of 13-valent pneumococcal conjugate vaccine (PCV13)|Pneumococcal serotype-specific GMC for serotypes 4, 7F & 19A at 3 months after immunisation with a single dose of PCV13 in the children who have had a prior dose of PPS23 vs those who have not.|Pneumococcal serotype-specific (SpVS) antibody concentrations at baseline and 12 months following a single dose of 13-valent pneumococcal conjugate vaccine (PCV13).|GMC of SpVS antibody at baseline, 3mnth and 12mnth following 1 dose of PCV13|Pneumococcal serotype-specific GMC for all vaccine-specific serotypes (VS) at baseline, 3 months and 12 months following immunisation with a single dose of PCV13 in children who have had a prior dose of PPS23 and those who have not.|Pneumococcal serotype-specific antibody concentrations for all VS in children who have had a prior dose of 23-valent pneumococcal polysaccharide vaccine (PPS23) and those who have not.|Vaccine-specific serotype antibody concentration between baseline and 3 months with HbA1C.|Blood glucose control in the week preceding and the week following immunisation with PCV13",University of Oxford,All,6 Years to 17 Years   (Child),Phase 4,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,OVG 2013/03|2013-001024-19,Aug-13,Apr-16,Jan-17,11-Sep-13,null,9-May-17,"Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT01939522
NCT01939834,Early Feasibility Study of Adaptive Advisory/Automated (AAA) Control of Type 1 Diabetes,,Terminated,No Results Available,Type 1 Diabetes Mellitus,Device: AAA control|Other: CGM + insulin pump at home,Evaluating the risk for hypoglycemia as measured by the Low Blood Glucose Index|Time in range overnight|Time within target range,"Sue Brown|DexCom, Inc.|Roche Diagnostics|University of Virginia",All,21 Years to 64 Years   (Adult),Not Applicable,6,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,16930,Dec-13,Jan-14,Jan-14,11-Sep-13,null,1-Apr-15,"University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01939834
NCT01938807,Audio Health Engagement Analysis in Diabetes: The AHEAD Study,,Unknown status,No Results Available,Type 1 Diabetes,Behavioral: CareCoach mobile application to assist in diabetes management,Diabetes Management|Hemoglobin A1c,"University of California, San Francisco",All,7 Years to 12 Years   (Child),Phase 1,60,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UCSF 12-09213,Oct-13,Jun-15,null,10-Sep-13,null,27-Oct-14,,,https://ClinicalTrials.gov/show/NCT01938807
NCT01935765,Sleep Apnea in Type 1 Diabetes,DIASOM,Unknown status,No Results Available,"Type 1 Diabetes, Sleep Apnea Syndrome",Other: Polysomnography|Other: Evaluation of the autonomous nervous system|Other: Clinical examination of the sleep|Other: Clinical examination of diabetology|Other: Biological dosages|Other: Electrocardiogram (ECG)|Other: Carotid echography|Other: Blood pressure,"Compare the prevalence of sleep apnea syndrome by polysomnography between type 1 diabetic patients and healthy volunteers|Precise if glycemic balance as defined by glycosylated hemoglobin<7% during the last three months is associated or not to sleep apnea syndrome|Precise if the presence of an autonomic neuropathy (positive at 2 tests) is associated or not to sleep apnea syndrome|Compare the patients with or without sleep apnea regarding consequences especially cardiovascular markers and coagulation factors|Determine if the presence of sleep apnea syndrome has an impact upon quality of life and diabetes complications, micro or macroangiopathy|Precise clinical symptoms in DT1 patients with Sleep apnea syndrome","Assistance Publique - Hôpitaux de Paris|Ministry of Health, France",All,18 Years to 60 Years   (Adult),Early Phase 1,145,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,P111009,Sep-13,Jun-16,Sep-16,5-Sep-13,null,29-May-15,"Véronique Viot-Blanc, Paris, Ile de France, France",,https://ClinicalTrials.gov/show/NCT01935765
NCT01935804,Effect of Pioglitazone Versus Metformin on Bone Health in Postmenopausal Women With Type 2 Diabetes,Pioglitazone,Completed,No Results Available,"Diabetes Mellitus|Diabetes Mellitus, Type 2|Glucose Metabolism Disorders",Drug: Pioglitazone|Drug: Metformin,"Change in mean percentage change in BMD at various sites by Dual energy X-ray absorptiometry(DXA) from baseline and at 6, 12 months in PIO versus MET treatment group.|Bone turnover Markers and other Biomarkers",King Abdulaziz University,Female,"50 Years to 65 Years   (Adult, Older Adult)",Phase 2,440,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CEOR-01-08,Jan-09,Jan-14,Jan-14,5-Sep-13,null,17-Jun-14,"Center of Excellence for Osteoporosis Research, King Abdulaziz University, Jeddah, Makkah, Saudi Arabia",,https://ClinicalTrials.gov/show/NCT01935804
NCT01934712,A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart,Area under the serum insulin aspart concentration-time curve|Area under the glucose infusion rate (GIR) curve,Novo Nordisk A/S,All,20 Years to 64 Years   (Adult),Phase 1,50,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1218-3918|U1111-1121-2896|JapicCTI-132253,30-Aug-13,28-Jan-14,28-Jan-14,4-Sep-13,null,11-Dec-18,"Novo Nordisk Investigational Site, Fukuoka, Japan",,https://ClinicalTrials.gov/show/NCT01934712
NCT01933672,Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes,,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: PF-04937319 once-daily|Drug: PF-04937319 split-dose|Drug: Sitagliptin once-daily,Change From Baseline in Weighted Mean Daily Glucose (WMDG) at Day 14|Change From Baseline in Fasting Plasma Glucose (FPG) at Day 14|Change From Baseline in Pre-meal C-Peptide on Day 14|Change From Baseline in Pre-meal Insulin on Day 14|Incidence of All Causality Treatment-Emergent Adverse Event by Preferred Term (Frequency Rate >5%)|Frequency of Laboratory Test Abnormalities Reported in Any Treatment Group|Change From Baseline in Body Weight (kg)|Number of Participants With Vital Signs Data Met Criteria of Potential Clinical Concern|Number of Participants With Post-baseline Electrocardiograms (ECGs) Data Met Criteria of Potential Clinical Concern|Plasma PF-04937319 Area Under the Concentration Time Curve From Time 0 to 24 Hours (AUC24) of PF-04937319 at Day 14|Plasma PF-04937319 Apparent Clearance (CL/F) on Day 14|Plasma PF-04937319 Average Concentration Over the 24-hour Period (Cav) on Day 14|Plasma PF-04937319 Highest Observed Concentration (Cmax) on Day 14|Plasma PF-04937319 Lowest Observed Concentration During the 24-hour Period (Cmin) on Day 14|Plasma PF-04937319 Time for Cmax (Tmax) on Day 14,Pfizer,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,33,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",B1621019,Oct-13,Mar-14,Mar-14,2-Sep-13,27-Sep-16,27-Sep-16,"Avail Clinical Research, LLC, DeLand, Florida, United States|Miami Research Associates, Inc., South Miami, Florida, United States|MRA Clinical Research, LLC, South Miami, Florida, United States|High Point Clinical Trials Center, LLC, High Point, North Carolina, United States|Community Research, Cincinnati, Ohio, United States|Clinical Trials of Texas, Inc, San Antonio, Texas, United States|Diabetes and Glandular Disease Clinic, San Antonio, Texas, United States|Spaulding Clinical Research, LLC, West Bend, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01933672
NCT01931982,Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes.,EGOFIP,Completed,No Results Available,Type 2 Diabetes|Microvascular Dysfunction,Drug: Victoza,Change in coronary flow reserve (CFR)|Change in Endothelial function:,Bispebjerg Hospital,All,"25 Years to 75 Years   (Adult, Older Adult)",Phase 4,20,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,eudraCT: 2012-005013-38|2012-005013-38,May-13,Apr-14,Apr-14,30-Aug-13,null,25-Jun-14,"Bispebjerg Hospital, Copenhagen, Capital region, Denmark",,https://ClinicalTrials.gov/show/NCT01931982
NCT01932476,Gluten Immunity and Islet Autoimmunity in Type-1 Diabetes,,Completed,No Results Available,Type 1 Diabetes|Celiac Disease,Dietary Supplement: Gluten Challenge|Dietary Supplement: Sham Challenge,Change in Markers of Autoimmunity|Gastrointestinal Symptoms,"Joslin Diabetes Center|ImmusanT, Inc.",All,18 Years to 50 Years   (Adult),Not Applicable,7,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic",GC001,Aug-13,Dec-14,Dec-14,30-Aug-13,null,17-Apr-17,"Joslin Diabetes Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01932476
NCT01929798,Crossover Feasibility Study of Portable AP Device With Zone-MPC and HMS and Adapted I:C and Basal Insulin,DP3,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: portable Artificial Pancreas,time spent in safe blood glucose range|glucose level extremes and need for outside intervention,"Sansum Diabetes Research Institute|University of Virginia|Mayo Clinic|University of California, Santa Barbara|University of Padova",All,"21 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,36,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),DP301,Nov-13,Nov-14,Nov-14,28-Aug-13,null,21-Oct-15,"Sansum Diabetes Research Institutute, Santa Barbara, California, United States",,https://ClinicalTrials.gov/show/NCT01929798
NCT01930097,Closed-loop Control of Glucose Levels After Meal Intake in Adults With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Other: 14 hours intervention,The positive incremental area under the curve of postprandial glucose excursions|Mean plasma glucose|Incremental two hours postprandial glucose|Incremental postprandial peak-glucose values|Percentage of time of plasma glucose levels between 4.0 and 10.0 mmol/L|Percentage of time of plasma glucose levels spent above 10.0 mmol/L|Percentage of time of plasma glucose levels spent below 4.0 mmol/L|Total insulin delivery|Total glucagon delivery|Standard deviation of glucose levels|Percentage of time of plasma glucose concentrations below 3.5 mmol/L|Percentage of time of plasma glucose concentrations above 14 mmol/L|Mean plasma insulin concentration|Mean plasma glucagon concentration|Number of patients experiencing hypoglycemia requiring oral treatment|Incremental area under the curve of the 4-hr postprandial glucose excursions but the reference glucose is set to 5.0 mmol/L if premeal glucose is less than 5.0 mmol/L.,Institut de Recherches Cliniques de Montreal|Juvenile Diabetes Research Foundation,All,"18 Years and older   (Adult, Older Adult)",Phase 2,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLASS-05,Aug-13,Feb-14,Feb-14,28-Aug-13,null,9-Apr-14,"Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01930097
NCT01930110,Closed-loop Control of Glucose Levels (Artificial Pancreas) During Exercise in Adults With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Other: 60-minute exercise|Other: 40-minute interval exercise,The number of patients experiencing exercise-induced hypoglycemia requiring dextrose infusion (< 3.3 mmol/L symptomatic or < 3.0 mmol/L regardless of symptoms).|Decrease in glucose levels during each exercise|Area under the curve of plasma glucose levels < 4 mmol/L|Percentage of time of plasma glucose levels < 4 mmol/L|Number of patients with an exercise-induced hypoglycemia < 3.9 mmol/L|Decremental area under the curve from the start of the exercise for 90 minutes.|Percentage of time-in-target defined as between 4 and 10 mmol/L|Mean time (minutes) to the first hypoglycemic event during the exercise period|The amount of dextrose infused,Institut de Recherches Cliniques de Montreal|Société Francophone du Diabète,All,"18 Years and older   (Adult, Older Adult)",Phase 2,15,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLASS-06,Apr-14,Apr-15,Apr-15,28-Aug-13,null,4-May-15,"Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01930110
NCT01928329,A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes,,"Active, not recruiting",No Results Available,Type I Diabetes,Drug: Exenatide (Bydureon®)|Drug: Placebo,Change from Baseline in HbA1c Levels,Yale University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,78,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",1307012371,Sep-13,Jun-18,May-19,23-Aug-13,null,11-Mar-19,"University of California, San Francisco, San Francisco, California, United States|Barbara Davis Center, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|University of Chicago, Chicago, Illinois, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|SUNY Upstate Medical University, Syracuse, New York, United States",,https://ClinicalTrials.gov/show/NCT01928329
NCT01925989,A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics,,Completed,Has Results,Type 1 Diabetes Mellitus,Biological: LY2605541|Biological: Insulin Glargine,"Sleep Respiratory Quotient (RQ) in Type 1 Diabetes Mellitus (T1DM)|Lipid Oxidation in T1DM and Healthy Participants|Basal Metabolic Rate (BMR) for T1DM|Sleep Respiratory Quotient (RQ) of Untreated Healthy Participants|Total Number of Minutes of Lipid Oxidation (RQ Below 7.6) in T1DM and Healthy Participants|Change in RQ, Pre-breakfast to Post-breakfast Meal, in T1DM",Eli Lilly and Company,All,18 Years to 60 Years   (Adult),Phase 1,27,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,14872|I2R-MC-BIDO,Nov-13,Oct-15,Oct-15,20-Aug-13,1-Mar-19,1-Mar-19,"Translational Research Institute for Metabolism and Diabetes, Orlando, Florida, United States",,https://ClinicalTrials.gov/show/NCT01925989
NCT01924637,A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart,Mean change in plasma glucose concentration|Area under the serum insulin aspart concentration-time curve,Novo Nordisk A/S,All,18 Years to 64 Years   (Adult),Phase 1,36,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1218-3889|2011-000941-19|U1111-1119-5708,Aug-13,Nov-13,Nov-13,16-Aug-13,null,18-Jan-17,"Novo Nordisk Investigational Site, Graz, Austria",,https://ClinicalTrials.gov/show/NCT01924637
NCT01923389,Multiple Dose Study Of PF-05231023 In Obese Adult Subjects,,Terminated,Has Results,Type 2 Diabetes Mellitus (T2DM),Other: Placebo|Drug: 100 mg PF-05231023,"Number of Participants With Adverse Events (AEs)|Number of Participants With Vital Signs Data Met Criteria of Potential Clinical Concern|Number of Participants With Electrocardiogram (ECG) Data Met Criteria of Potential Clinical Concern|Number of Participants With Positive Anti-PF-05231023 Antibodies and Neutralizing Antibodies.|Number of Participants With Abnormal Clinical Laboratory Measurements|Area Under the Concentration Versus Time Curve From Time 0 to Tau, the Dosing Interval (AUCtau) of PF-05231023 (C-terminus and N-terminus PF-05231023 and Total CVX-2000 Antibody Scaffold)|Maximum Plasma Concentration (Cmax) of PF-05231023 (C-terminus and N-terminus PF-05231023 and Total CVX-2000 Antibody Scaffold)|Lowest Concentration Observed During Dosing Interval (Cmin) of PF-05231023 (C-terminus and N-terminus PF-05231023 and Total CVX-2000 Antibody Scaffold)|Average Concentration at Steady State (Cav) of PF-05231023 (C-terminus and N-terminus PF-05231023 and Total CVX-2000 Antibody Scaffold)|Time for Cmax (Tmax)of PF-05231023 (C-terminus and N-terminus PF-05231023 and Total CVX-2000 Antibody Scaffold)|Clearance (CL)of PF-05231023 (C-terminus and N-terminus PF-05231023 and Total CVX-2000 Antibody Scaffold)|Terminal Elimination Half-life (t1/2)of PF-05231023 (C-terminus and N-terminus PF-05231023 and Total CVX-2000 Antibody Scaffold)|Observed Accumulation Ratio (Rac) for Cmax and AUCtau of PF-05231023 (C-terminus and N-terminus PF-05231023 and Total CVX-2000 Antibody Scaffold)",Pfizer,All,"21 Years to 70 Years   (Adult, Older Adult)",Phase 1,4,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",B2901009,Sep-13,Dec-13,Dec-13,15-Aug-13,17-Sep-14,17-Sep-14,"Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States",,https://ClinicalTrials.gov/show/NCT01923389
NCT01922817,DPP4inhibitors in Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes|Hypoglycaemia,Drug: Saxagliptin,Magnitude of epinephrine release at 2.5mmol/L,University of Dundee,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,14,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",2012DM07,Sep-12,Apr-14,Apr-14,14-Aug-13,null,5-May-16,"Clinical research centre, Ninewells Hospital and Medical School, Dundee, United Kingdom",,https://ClinicalTrials.gov/show/NCT01922817
NCT01919385,Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia,,Completed,No Results Available,Type 1 Diabetes,Device: Predictive Low Glucose Minimizer,Evaluate the performance of the System while the subject is under close medical supervision in the Clinical Research Center (CRC) setting|Capturing the number of Adverse Events as a measure of assessing subject safety,Animas Corporation,All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 1,12,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"3108873,",Jul-13,Sep-13,Sep-13,9-Aug-13,null,19-Sep-13,"Samsum Diabetes Reserach Inst., Santa Barbara, California, United States",,https://ClinicalTrials.gov/show/NCT01919385
NCT01919788,Intracellular Counter-regulatory Mechanisms Following Low Blood Glucose,,Completed,No Results Available,Diabetes Mellitus Type I.|Hypoglycemia.,Drug: Insulin (Insuman Rapid)|Drug: Glucose|Other: Saline,"Insulin and growth hormone signalling, expressed as CHANGE in phosphorylation of intracellular target proteins and mRNA expression of target genes in muscle- and fat-tissue.|Intracellular markers of lipid metabolism in muscle- and fat tissue biopsies.|Metabolism.|Ghrelin|Metabolism",University of Aarhus,Male,"18 Years and older   (Adult, Older Adult)",Not Applicable,9,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,VEK journal nr.: M-2013-113-13|VEK Journal nr. M-2013-113-13,Aug-13,Apr-14,Apr-14,9-Aug-13,null,24-Feb-16,"Institute of Clinical Medicine, Aarhus, Aarhus C, Denmark",,https://ClinicalTrials.gov/show/NCT01919788
NCT01918865,"Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes",,Completed,No Results Available,Type 2 Diabetes Mellitus|Obese,Drug: ISIS-PTP1BRx|Drug: Placebo|Drug: daily OAD (metformin and/or sulfonylurea),"Incidence, severity, dose-relationship of adverse effects, and changes in laboratory evaluations as a measure of safety|Change in plasma HbA1c levels at Week 27 compared to Baseline as a measure of efficacy|Change in FPG, weekly average SMPG, seven-point glucose profile, lipid profile, body weight, & BMI at Week 27 compared to Baseline as a measure of efficacy","Ionis Pharmaceuticals, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,92,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",ISIS 404173-CS2,Aug-13,Oct-14,Feb-15,8-Aug-13,null,3-Mar-15,"Isis Investigative Site, Mar del Plata, Buenos Aires, Argentina|Isis Investigative Site, Rosario, Santa Fe, Argentina|Isis Investigational Site, Edmonton, Alberta, Canada|Isis Investigational Site, Kelowna, British Columbia, Canada|Isis Investigational Site, Vancouver, British Columbia, Canada|Isis Investigational Site, Etobicoke, Ontario, Canada|Isis Investigational Site, Toronto, Ontario, Canada|Isis Investigative Site, Toronto, Ontario, Canada|Isis Investigational Site, Saskatoon, Saskatchewan, Canada|Isis Investigational Site, Centurion, Gauteng, South Africa|Isis Investigational Site, Mamelodi, Gauteng, South Africa|Isis Investigational Site, Pretoria, Gauteng, South Africa|Isis Investigational Site, Port Elizabeth, Korsten, South Africa|Isis Investigational Site, Durban, KwaZulu-Natal, South Africa|Isis Investigational Site, Middelburg, Mpumalanga, South Africa|Isis Investigational Site, Limpopo, Thabazimbi, South Africa|Isis Investigational Site, Cape Town, Western Cape, South Africa|Isis Investigational Site, Cape Town, Western Cape, South Africa|Isis Investigational Site, Benoni, South Africa|Isis Investigational Site, Bloemfontein, South Africa|Isis Investigational Site, Pretoria, South Africa",,https://ClinicalTrials.gov/show/NCT01918865
NCT01916265,Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon Dosages,,Completed,No Results Available,Diabetes Mellitus Type 1,Drug: Glucagon,AUCGlucose of different glucagon dosages given s.c.,Profil Institut für Stoffwechselforschung GmbH|European Union,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,6,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,PCDiab01,Aug-13,Nov-13,Nov-13,5-Aug-13,null,5-Feb-14,"Profil Institut für Stoffwechselforschung GmbH, Neuss, NRW, Germany",,https://ClinicalTrials.gov/show/NCT01916265
NCT01908894,Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog® in Subjects With Type 1 Diabetes Including Assessments of Injection Site Toleration,,Completed,No Results Available,Diabetes Mellitus,Drug: BIOD-123|Drug: BIOD-125|Drug: Humalog,Speed of absorption (TINS-50%-early) of BIOD-123 and BIOD-125 versus Humalog.,Biodel,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,12,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",3-101,Feb-12,Mar-12,Mar-12,26-Jul-13,null,26-Jul-13,,,https://ClinicalTrials.gov/show/NCT01908894
NCT01909245,Islet Cell Transplant for Type 1 Diabetes,TCD,Recruiting,No Results Available,Type 1 Diabetes Mellitus,Biological: Allogenic Human Islet Cells,"Proportion of subjects who are insulin independent, hypoglycemia free, AND with hemoglobin A1c < 6.5% at 1 year post-transplant|Proportion of subjects who are insulin independent, hypoglycemia free, AND with hemoglobin A1c < 6.5% at 2 years post-transplant|Proportion of subjects who are insulin independent, hypoglycemia free, AND with hemoglobin A1c < 6.5% at 5 years post-transplant|Proportion of subjects who are free of severe hypoglycemic episodes AND have a hemoglobin A1c < 7.0%","City of Hope Medical Center|University of California, Los Angeles",All,"18 Years to 68 Years   (Adult, Older Adult)",Phase 2,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12446,Oct-13,Jul-21,Jul-21,26-Jul-13,null,30-Jan-19,"City of Hope Medical Center, Duarte, California, United States",,https://ClinicalTrials.gov/show/NCT01909245
NCT01908530,Clinical Assessment of a Novel Microprobe Array Continuous Glucose Monitor for Type 1 Diabetes,,Completed,No Results Available,Diabetes Mellitus,Device: Microprobe glucose sensor,Skin inflammation|Correlation with venous blood glucose & ISF glucose|Pain score|Skin Penetration|Detectable signal|Correlation with venous blood glucose|Magnitude of current|Clarke error grid|Acceptability questionnaire,Imperial College London,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,36,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,13SM0639,Nov-13,Jun-17,Jun-18,25-Jul-13,null,2-Aug-18,"Imperial College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01908530
NCT01907113,"Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment",,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: BI 10773,"AUC0-∞ (Area Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 to Infinity)|Cmax (Maximum Concentration of the Analyte in Plasma)|Time to Maximum Concentration of the Analyte in Plasma|Half-life and Mean Residence Time of the Analyte in Plasma|Terminal Rate Constant in Plasma|Apparent Clearance of the Analyte in the Plasma After Extravascular Administration|Apparent Volume of Distribution During the Terminal Phase Lz|AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)|Ae0-96 (Amount of Analyte That is Eliminated in Urine Over the Time Interval 0 to 96 h)|fe0-96 (Fraction of Analyte Excreted Unchanged in Urine From Time Points 0 to 96 Hours)|Renal Clearance of the Analyte in Plasma After Extravascular Administration|%AUCtz-∞ (Percentage of Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From the Time of the Last Quantifiable Data Point Extrapolated to Infinity)|Plasma Protein Binding|Total Urinary Glucose Excretion (UGE)|Safety: Physical Examination, Vital Signs, ECG and Laboratory Measurements|Assessment of Tolerability by Investigator",Boehringer Ingelheim,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,40,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1245.12|2008-006086-86,Jul-09,Dec-09,Dec-09,24-Jul-13,14-Jul-14,14-Jul-14,"1245.12.1 Boehringer Ingelheim Investigational Site, Kiel, Germany|1245.12.2 Boehringer Ingelheim Investigational Site, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01907113
NCT01905020,Closed-loop Control of Overnight Glucose Levels in Adults and Adolescents With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Other: Carbohydrate-rich meal|Other: Exercise,Percentage of time in target range|Percentage of time in target range for each night separately|Percentage of time in target range for the pooled data|Percentage of time spent below 4.0 mmol/L|Percentage of time spent below 3.3 mmol/L|Area under the curve for glucose levels below 4.0 mmol/L|Area under the curve for glucose levels below 3.3 mmol/L|Percentage of time spent above 8.0 mmol/L|Percentage of time spent above 10.0 mmol/L|Area under the curve for glucose levels spent above 8.0 mmol/L|Area under the curve for glucose levels spent above 10.0 mmol/L|Mean glucose levels|Standard deviation of glucose levels|Total insulin delivery|Number of subjects experiencing at least one hypoglycemic event requiring treatment|Number of hypoglycemic events requiring treatment,"Institut de Recherches Cliniques de Montreal|Montreal Children's Hospital of the MUHC|Mount Sinai Hospital, New York|McGill University",All,"12 Years and older   (Child, Adult, Older Adult)",Phase 2,28,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLASS-04,Jul-13,Sep-14,Sep-14,22-Jul-13,null,21-Oct-14,"Mount Sinai Hospital, Toronto, Ontario, Canada|Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada|Montreal Children Hospital, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01905020
NCT01901861,Effect of the DPP-4 Inhibitor Sitagliptin on Islet Function After Mixed Meal in Patients With Type 2 Diabetes,,Completed,No Results Available,Type 2 Diabetes,Drug: Sitagliptin|Drug: Placebo,Release of incretins hormones,Lund University,Male,"20 Years to 75 Years   (Adult, Older Adult)",Not Applicable,12,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label),2012-005660-98,Jul-13,Dec-15,Dec-15,17-Jul-13,null,15-Dec-15,"Department of Clinical Science Lund,Lund University, Lund, Sweden",,https://ClinicalTrials.gov/show/NCT01901861
NCT01901913,MD-Logic Artificial Pancreas for Automatic Type 1 Diabetes Meals Management,,Completed,No Results Available,Type 1 Diabetes,Device: MD-bolus calculator for pre-meal bolus|Device: No MD-bolus calculator for pre-meal bolus,"Area under the curve above 180 mg/dl (10 mmol/l)|Time within range of 70-180 mg/dl over 4 hours from the beginning of the meal|The incremental glucose rise from premeal to peak postprandial level|Number of hypoglycemic events below 70 mg/dl (3.9 mmol/l)|The percentage of subjects who reached the desired glucose target (70-180 mg/dl) 4 hours postprandial.|Percentage of time spent below 70 mg/dl (3.9mmol/l)|Percentage of time spent above 180, 250, (10, 13.9 mmol/l)",Rabin Medical Center,All,"14 Years to 25 Years   (Child, Adult)",Not Applicable,26,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,rmc007418ctil,Oct-13,Apr-15,Apr-15,17-Jul-13,null,16-Apr-15,"Schneider Children's Medical Center, Petah-Tikva, Israel",,https://ClinicalTrials.gov/show/NCT01901913
NCT01899872,Effect of Acute Exercise on Endothelial Function in Patients With Type 1 Diabetes.,EAEEFD,Unknown status,No Results Available,Type 1 Diabetes Mellitus,Behavioral: Resistance exercise session|Behavioral: Aerobic exercise session,Circulating endothelial progenitor cells|Forearm vascular reactivity,Hospital de Clinicas de Porto Alegre,Male,18 Years to 45 Years   (Adult),Not Applicable,15,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,100400,Dec-11,Nov-13,Dec-13,16-Jul-13,null,16-Jul-13,"Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil",,https://ClinicalTrials.gov/show/NCT01899872
NCT01899274,Assessment of an iPhone Application on Glycemic Control in Type 1 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: bant iPhone application,Changes in Hemoglobin A1C levels|Hypoglycemic Events|Self-Efficacy|Self-Care Behaviour|Treatment Adherence|Quality of Life|bant Component Usage,"The Hospital for Sick Children|Thrasher Research Fund|University Health Network, Toronto|York University",All,11 Years to 16 Years   (Child),Not Applicable,92,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1000036524|11054,Jul-13,Jan-16,Jan-16,15-Jul-13,null,19-Apr-16,"Trillium Health Partners, Mississauga, Ontario, Canada|The Hostpital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01899274
NCT01897688,A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients,,"Active, not recruiting",No Results Available,Type 1 Diabetes|Severe Hypoglycemic Unawareness,Biological: Islet Cell Transplant,To demonstrate the safety and efficacy of islet transplantation under alemtuzumab induction for treatment of Type-1 Diabetes (T1D) in subjects with hypoglycemia unawareness and a history of severe hypoglycemic episodes.|To relate clinical transplant outcomes based upon islet quantity/quality to organ donor characteristics|To relate clinical transplant outcomes based upon islet quantity/quality to organ donor characteristics.,Northwestern University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STU00059469,Jun-12,Mar-25,Mar-27,12-Jul-13,null,30-Jan-19,"Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01897688
NCT01898286,Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277®,DIA-AID 2,Terminated,Has Results,Type 1 Diabetes,Drug: DiaPep277®,Hypoglycemic Events|Change From Baseline in Glucagon-stimulated C-peptide AUC at Early Termination Visit,Andromeda Biotech Ltd.,All,18 Years to 47 Years   (Adult),Phase 3,38,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1010|2013-002775-17,Oct-13,Sep-14,Dec-14,12-Jul-13,26-May-16,26-May-16,"Atlanta Diabetes associates, Atlanta, Georgia, United States|Henry Ford Medical Centers - New Center One, Detroit, Michigan, United States|Mountain Diabetes and Endocrine Center, Asheville, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01898286
NCT01892280,Optimizing Self-Management Adherence and Glycemic Control in Older Teens With Type 1 Diabetes: The Teenwork Study,,Completed,No Results Available,Type 1 Diabetes,Behavioral: Teenwork intervention|Behavioral: Text message reminders,Change in glycemic control from baseline to 1 year|Change in glycemic control from 1 year to 18 months|Psychosocial factors (self-report surveys),Joslin Diabetes Center|Baylor College of Medicine|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,13 Years to 17 Years   (Child),Not Applicable,310,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012-11|R01DK095273,Nov-13,Feb-16,Aug-16,4-Jul-13,null,9-Jan-19,"Joslin Diabetes Center, Boston, Massachusetts, United States|Texas Children's Hospital/Baylor College of Medicine, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01892280
NCT01890954,Optimizing Closed-Loop Control of Type 1 Diabetes Mellitus in Adolescents,,Completed,Has Results,"Diabetes Mellitus, Type 1",Device: Diabetes Assistant (DiAs),Percent of Time Spent Near Normoglycemia,University of Virginia,All,"13 Years to 18 Years   (Child, Adult)",Not Applicable,17,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16890,Aug-13,Feb-14,Feb-14,2-Jul-13,15-Apr-15,5-Jun-17,"University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01890954
NCT01887431,Telecare in Type 1 Diabetes (T1D) Patients Treated by Insulin Pump,,Completed,No Results Available,Type 1 Diabetes Mellitus,Other: Telecare|Other: Conventional therapy,Change in Glycosylated Hemoglobin (Hba1c)|Time spent on data analysis and telephone calls by team|Number of severe hypoglycemic and diabetic ketoacidosis (DKA) events and hospitalizations|Patients' quality of life|Patients' satisfaction,"Assuta Hospital Systems|Maccabi Healthcare Services, Israel",All,"22 Years and older   (Adult, Older Adult)",Not Applicable,66,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,71156,Oct-13,Nov-16,Nov-16,26-Jun-13,null,31-Jan-17,"Maccabi Healthcare Services, Ra'anana, Israel",,https://ClinicalTrials.gov/show/NCT01887431
NCT01885208,Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes,SUSTAIN™ 3,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: semaglutide|Drug: exenatide,Change From Baseline in HbA1c (Glycosylated Haemoglobin)|Change From Baseline in Body Weight|Change From Baseline in Fasting Plasma Glucose (FPG)|Change From Baseline in Systolic and Diastolic Blood Pressure|Change From Baseline in Patient Reported Outcome (PRO) Questionnaire Diabetes Treatment Satisfaction Questionnaire Status (DTSQs)|Subjects Who Achieve HbA1c Equal to or Below 6.5% (48 mmol/Mol) American Association of Clinical Endocrinologists (AACE) Target: (Yes/no),Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,813,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN9535-3624|2012-004826-92|U1111-1135-8647,2-Dec-13,13-Jul-15,13-Jul-15,24-Jun-13,30-Mar-18,26-Mar-19,"Novo Nordisk Investigational Site, Anniston, Alabama, United States|Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Pell City, Alabama, United States|Novo Nordisk Investigational Site, Glendale, Arizona, United States|Novo Nordisk Investigational Site, Mesa, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Burbank, California, United States|Novo Nordisk Investigational Site, Hawaiian Gardens, California, United States|Novo Nordisk Investigational Site, Lomita, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Northridge, California, United States|Novo Nordisk Investigational Site, Northridge, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, Tustin, California, United States|Novo Nordisk Investigational Site, Colorado Springs, Colorado, United States|Novo Nordisk Investigational Site, Colorado Springs, Colorado, United States|Novo Nordisk Investigational Site, Bradenton, Florida, United States|Novo Nordisk Investigational Site, Brandon, Florida, United States|Novo Nordisk Investigational Site, Coral Gables, Florida, United States|Novo Nordisk Investigational Site, Hialeah, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Miami Lakes, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Plantation, Florida, United States|Novo Nordisk Investigational Site, Savannah, Georgia, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Franklin, Indiana, United States|Novo Nordisk Investigational Site, Greenfield, Indiana, United States|Novo Nordisk Investigational Site, Muncie, Indiana, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, Madisonville, Kentucky, United States|Novo Nordisk Investigational Site, Hyattsville, Maryland, United States|Novo Nordisk Investigational Site, Kalamazoo, Michigan, United States|Novo Nordisk Investigational Site, Saint Louis, Missouri, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Mine Hill, New Jersey, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, North Massapequa, New York, United States|Novo Nordisk Investigational Site, Syracuse, New York, United States|Novo Nordisk Investigational Site, West Seneca, New York, United States|Novo Nordisk Investigational Site, Greensboro, North Carolina, United States|Novo Nordisk Investigational Site, Hickory, North Carolina, United States|Novo Nordisk Investigational Site, Whiteville, North Carolina, United States|Novo Nordisk Investigational Site, Akron, Ohio, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Cleveland, Ohio, United States|Novo Nordisk Investigational Site, Delaware, Ohio, United States|Novo Nordisk Investigational Site, Corvallis, Oregon, United States|Novo Nordisk Investigational Site, Portland, Oregon, United States|Novo Nordisk Investigational Site, Portland, Oregon, United States|Novo Nordisk Investigational Site, Lansdale, Pennsylvania, United States|Novo Nordisk Investigational Site, Norristown, Pennsylvania, United States|Novo Nordisk Investigational Site, Charleston, South Carolina, United States|Novo Nordisk Investigational Site, Mount Pleasant, South Carolina, United States|Novo Nordisk Investigational Site, Murrells Inlet, South Carolina, United States|Novo Nordisk Investigational Site, Spartanburg, South Carolina, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Carrollton, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Fort Worth, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Irving, Texas, United States|Novo Nordisk Investigational Site, Katy, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Alexandria, Virginia, United States|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Lanus Este, Argentina|Novo Nordisk Investigational Site, Mar del Plata, Argentina|Novo Nordisk Investigational Site, Karlovac, Croatia|Novo Nordisk Investigational Site, Osijek, Croatia|Novo Nordisk Investigational Site, Slavonski Brod, Croatia|Novo Nordisk Investigational Site, Virovitica, Croatia|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Kerava, Finland|Novo Nordisk Investigational Site, Oulu, Finland|Novo Nordisk Investigational Site, Turku, Finland|Novo Nordisk Investigational Site, Chalons-en-Champagne Cedex, France|Novo Nordisk Investigational Site, Corbeil Essonnes, France|Novo Nordisk Investigational Site, LA ROCHELLE cedex, France|Novo Nordisk Investigational Site, Le Creusot, France|Novo Nordisk Investigational Site, Nanterre, France|Novo Nordisk Investigational Site, Roubaix, France|Novo Nordisk Investigational Site, Strasbourg, France|Novo Nordisk Investigational Site, Venissieux, France|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Duisburg, Germany|Novo Nordisk Investigational Site, Hohenmölsen, Germany|Novo Nordisk Investigational Site, Mannheim, Germany|Novo Nordisk Investigational Site, Oldenburg, Germany|Novo Nordisk Investigational Site, Rehlingen-Siersburg, Germany|Novo Nordisk Investigational Site, Völklingen, Germany|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Piraeus, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Bologna, Italy|Novo Nordisk Investigational Site, Città di Castello, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Palermo, Italy|Novo Nordisk Investigational Site, Pavia, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Siena, Italy|Novo Nordisk Investigational Site, Amsterdam, Netherlands|Novo Nordisk Investigational Site, Apeldoorn, Netherlands|Novo Nordisk Investigational Site, Delft, Netherlands|Novo Nordisk Investigational Site, Hoofddorp, Netherlands|Novo Nordisk Investigational Site, Leeuwarden, Netherlands|Novo Nordisk Investigational Site, Rotterdam, Netherlands|Novo Nordisk Investigational Site, Rotterdam, Netherlands|Novo Nordisk Investigational Site, Venlo, Netherlands|Novo Nordisk Investigational Site, Zoetermeer, Netherlands|Novo Nordisk Investigational Site, Caguas, Puerto Rico|Novo Nordisk Investigational Site, Manati, Puerto Rico|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Kragujevac, Serbia|Novo Nordisk Investigational Site, Novi Sad, Serbia|Novo Nordisk Investigational Site, Basel, Switzerland|Novo Nordisk Investigational Site, Genève 14, Switzerland|Novo Nordisk Investigational Site, Luzern 16, Switzerland|Novo Nordisk Investigational Site, St. Gallen, Switzerland|Novo Nordisk Investigational Site, Zollikerberg, Switzerland|Novo Nordisk Investigational Site, Ayr, United Kingdom|Novo Nordisk Investigational Site, Bath, United Kingdom|Novo Nordisk Investigational Site, Bradford-on-Avon, United Kingdom|Novo Nordisk Investigational Site, Haxey, United Kingdom|Novo Nordisk Investigational Site, Headington, United Kingdom|Novo Nordisk Investigational Site, Rotherham, United Kingdom",,https://ClinicalTrials.gov/show/NCT01885208
NCT01883024,Insulin Pump-RT Advisor (IPRA©): a Decision Support Software for Diabetic Patients Treated by Insulin Pump and Using Continuous Glucose Monitoring. Experimental Study. Evaluation by an Expert Patient Panel.,IPRA,Completed,No Results Available,Type 1 Diabetes,Other: A decision support software|Other: Insulin Pump|Other: Continuous glucose monitoring,"Patient agreement with the IPRA© advices: global rate of agreement, according to advice subtypes, according to blood glucose levels, according to the situations (pre or post-meal, bedtime)|Assessment of similarity between patient decisions and IPRA© advices|Assessment of changes proposed by the experts|Assessment of frequency of software use|Assessment of patient satisfaction",Rennes University Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,6,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),2013-A00495-40|LOC 1308,Jun-13,Jul-13,Sep-13,21-Jun-13,null,17-Sep-13,"Service d'Endocrinologie-Diabétologie - CHU de Rennes - Hôpital Sud, Rennes, France",,https://ClinicalTrials.gov/show/NCT01883024
NCT01883804,Effect of Methyldopa on MHC Class II Antigen Presentation in Type 1 Diabetes,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Methyldopa,The Change From Baseline of DQ8 Antigen Presentation by Peripheral Blood Mononuclear Cells After 6 Weeks of Methyldopa Treatment.|The Change in C-Peptide AUC Following a MMTT From Baseline to Study Completion.|The Change in Hemoglobin A1c From Baseline to Study Completion.|The Change in Insulin Use From Baseline to Study Completion.,University of Colorado Denver School of Medicine Barbara Davis Center|Juvenile Diabetes Research Foundation,All,18 Years to 46 Years   (Adult),Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13-1408,Jun-13,Feb-16,Feb-16,21-Jun-13,29-Mar-18,4-May-18,"Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT01883804
NCT01881828,Metformin Therapy for Overweight Adolescents With Type 1 Diabetes,,Completed,Has Results,Type 1 Diabetes,Drug: Metformin (glucophage)|Other: oral placebo,"Change in Hemoglobin A1c From Baseline to 26 Weeks, Adjusted for Baseline Hemoglobin A1c.|Change in Total Daily Dose of Insulin (TDI) Per kg|Change in Body Mass Index (BMI)|Change in Waist Circumference|Change in Body Composition|Change in Serum Lipids|Change in Blood Pressure",Jaeb Center for Health Research|Juvenile Diabetes Research Foundation,All,"12 Years to 19 Years   (Child, Adult)",Phase 3,164,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",T1DX-17-2013-506|17-2013-506,Sep-13,Sep-14,Dec-14,20-Jun-13,19-Dec-18,19-Dec-18,"Jaeb Center for Health Research, Tampa, Florida, United States",,https://ClinicalTrials.gov/show/NCT01881828
NCT01881958,The Safety and Efficacy of Administrating DiaPep277® Vaccination in Type 1 Diabetes Patients.,,Withdrawn,No Results Available,Type One Diabetes,Drug: DiaPep277®,efficacy will be measured by comparing Hemoglobin A1c|Safety will be evaluated calculating number of Adverse Events.,Hadassah Medical Organization,All,20 Years to 45 Years   (Adult),Phase 1|Phase 2,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0224-13-HMO-CTIL,Jan-15,Jan-16,Jan-17,20-Jun-13,null,6-Mar-18,,,https://ClinicalTrials.gov/show/NCT01881958
NCT01880827,Splanchnic Blood Redistribution After Incretin Hormone Infusion and Obesity Surgery,GIP-PET,Unknown status,No Results Available,Type 2 Diabetes|Obesity,Procedure: Roux-en-Y|Drug: GIP-infusion|Drug: GLP-1|Drug: MMS|Procedure: Sleeve gastrectomy,Splanchnic blood flow|GIP and GLP-1 blood concetrations,Turku University Hospital|Lund University|Sigrid Jusélius Foundation|Academy of Finland,All,18 Years to 60 Years   (Adult),Phase 1,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2012-002689-10,Jan-13,Nov-15,Jan-16,19-Jun-13,null,12-May-15,"Turku univercity hospital, PET center, Turku, Finland",,https://ClinicalTrials.gov/show/NCT01880827
NCT01881009,Medtronic Minimed Overnight Closed-Loop System,,Completed,No Results Available,"Type 1 Diabetes Mellitus|Autoimmune Diabetes|Juvenile-Onset Diabetes|Diabetes, Mellitus, Type 1",Device: ePID Algorithm on an Android Platform with Remote Monitoring,Target sensor glucose 70-150 mg/dl|Percentage of time CGM glucose readings are <70 mg/dl and > 180 mg/dl,Bruce A. Buckingham|Stanford University,All,"10 Years to 35 Years   (Child, Adult)",Not Applicable,46,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,G130115,Jun-13,Jul-13,Jul-13,19-Jun-13,null,9-Mar-15,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT01881009
NCT01879917,Liraglutide in Newly Onset Type 1 Diabetes.,NewLira,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 1",Drug: Liraglutide|Drug: Placebo,Beta-cell function|Postprandial glucagon,"Hvidovre University Hospital|Steno Diabetes Center Copenhagen|Hillerod Hospital, Denmark|Bispebjerg Hospital|Odense University Hospital|Aarhus University Hospital|Aalborg University Hospital|Hospital of South West Denmark",All,18 Years to 40 Years   (Adult),Phase 2|Phase 3,65,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2012-005317-39|U1111-1137-3221,Oct-13,Nov-18,Dec-18,18-Jun-13,null,12-Dec-18,"Dep. of Endocrinology, Hvidovre University Hospital, Hvidovre, Capital, Denmark",,https://ClinicalTrials.gov/show/NCT01879917
NCT01874392,"Feasibility Study Using Zone-MPC Controller, HMS and Technosphere® Insulin Inhalation System From MannnKind Corp",,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Investigational inhaled insulin (Technosphere)|Device: Artificial Pancreas (AP) device (APS©),Test the safety of the AP device while the subject is under close medical supervision in the Clinical Research Center (CRC) setting.|Test the benefits of the AP device combined with the Technosphere® Insulin Powder System,Sansum Diabetes Research Institute|Juvenile Diabetes Research Foundation,All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,9,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,JDRF 17-2010-765,Oct-12,Jun-13,Jun-13,11-Jun-13,null,21-Apr-16,"Sansum Diabetes Research Institute, Santa Barbara, California, United States",,https://ClinicalTrials.gov/show/NCT01874392
NCT01871870,Artificial Pancreas Control System in an Outpatient Setting,,Completed,Has Results,Type 1 Diabetes Mellitus,Device: Artificial Pancreas Control Software,Verification of the Automation and Telemetry Components|Deviation From Target Blood Glucose,Legacy Health System|Juvenile Diabetes Research Foundation,All,21 Years to 60 Years   (Adult),Phase 2,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013.001,May-13,Sep-13,Oct-13,7-Jun-13,15-May-15,15-May-15,"Legacy Research Institute, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT01871870
NCT01873066,Closing the Loop 24/7 in Adolescents With Type 1 Diabetes,DAN04,Completed,No Results Available,"Diabetes Mellitus|Diabetes Mellitus, Type 1|Glucose Metabolism Disorders|Endocrine System Diseases",Device: Closed-loop system|Device: real-time CGM,"The proportion of time spent in the target glucose range from 3.9 to 10.0 mmol/l based on CGM|The proportion of time spent above and below the target glucose (3.9 to 10.0 mmol/l) based on CGM.|The proportion of time with glucose levels < 3.5 mmol/l and <2.8 mmol/l based on CGM|The proportion of time with glucose levels in significant hyperglycaemia, as based on CGM (glucose levels > 16.7 mmol/l)",University of Cambridge|Cambridge University Hospitals NHS Foundation Trust,All,"10 Years to 18 Years   (Child, Adult)",Not Applicable,24,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAN04,28-Aug-14,31-Jul-15,1-Jan-16,7-Jun-13,null,3-Mar-17,"University of Cambridge, Cambridge, United Kingdom",,https://ClinicalTrials.gov/show/NCT01873066
NCT01869790,Evaluation of Fats on Postprandial Glucose Control,Nabucco,Completed,No Results Available,Type 1 Diabetes,Other: Different fat types,Area under the curve (AUC),Joslin Diabetes Center|Boston Children’s Hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Prandial bolus coverage,Jun-13,Dec-14,Apr-15,5-Jun-13,null,26-Apr-17,"Joslin Diabetes Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01869790
NCT01868529,Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes Mellitus,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin glargine,Area under the glucose infusion rate curve|Area under the serum insulin concentration curve at steady state,Novo Nordisk A/S,All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 1,63,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1250-1876|2007-003534-41,Jan-08,Jun-08,Jun-08,4-Jun-13,null,28-Sep-15,"Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01868529
NCT01868568,Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin degludec/insulin aspart 30|Drug: insulin degludec/insulin aspart 40|Drug: insulin degludec/insulin aspart 45|Drug: insulin degludec/insulin aspart 55|Drug: insulin aspart|Drug: biphasic insulin aspart 30|Drug: placebo,Area under the insulin aspart concentration curve|Area under the glucose infusion rate curve|Area under the serum insulin 454 concentration curve,Novo Nordisk A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,55,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN5401-1959|2007-006110-42,Apr-08,Aug-08,Aug-08,4-Jun-13,null,22-Oct-15,"Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01868568
NCT01868594,Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type I Diabetes Mellitus,,Completed,Has Results,Type I Diabetes Mellitus,Drug: Subetta|Drug: Placebo,"Changes in the Mean Value of HbA1c|Change in Fasting Plasma Glucose (Based on the Data of Biochemical Analysis)|Change in Average Daily Blood Glucose From a 7-point Patient Self-monitoring of Blood Glucose (SMBG)|Changes in Lipids (Concentrations of Plasma Total Cholesterol, HDL Cholesterol, LDL Cholesterol and Triglycerides)|Changes in Dosage of Insulin (Basal, Prandial and Total Daily Dose Insulin Measured in IU)|Changes in Dosage of Total Insulin Measured in IU/kg of Body Weight|Satisfaction of Diabetes Treatment Based on Diabetes Treatment Satisfaction Questionnaire Data",Materia Medica Holding,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,200,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",MMH-SU-003,7-May-13,Jul-16,10-Jul-16,4-Jun-13,4-Mar-19,4-Mar-19,"Municipal budgetary authority ""Khimki Central Clinical Hospital"", Moscow region, Russian Federation|State Healthcare Institution of Moscow ""Central research institute of gastroenterology"" of Department of health care of Moscow, Moscow, Russian Federation|State Educational Institution of Higher Professional Education ""Moscow State Medical Academy named after I.M. Sechenov"", Moscow, Russian Federation|Nonstate Health Care Institution ""Central Clinical Hospital №2 named after N.A. Semashko of Public Limited Company ""Russian Railways"", Moscow, Russian Federation|The State Budgetary Institution of Health Care of the Nizhny Novgorod Region ""City clinical hospital No. 10 "", Nizhny Novgorod, Russian Federation|Nizhny Novgorod regional State Budgetary Health Institution "" Nizhny Novgorod regional Clinical Hospital named after N.A. Semashko "", Nizhny Novgorod, Russian Federation|State Budgetary Educational Institution of High Professional Training ""Rostov State Medical University"" of Ministry of Health of Russian Federation, Department of Endocrinology, Rostov-on-Don, Russian Federation|Co.Ltd "" Diabet Center"", Samara, Russian Federation|Private company ""Polyclinic Complex"", St. Petersburg, Russian Federation|St. Petersburg State Budgetary Health Care Institution ""City Polyclinic №6"", St. Petersburg, Russian Federation|St. Petersburg State Budgetary Health Care Institution ""Saint Venerable Martyr Elizaveta Municipal Hospital"", St. Petersburg, Russian Federation|State Budgetary Educational Institution of High Professional Training ""St. Petersburg State Medical University named after academician I.P. Pavlov"" of Ministry of Health of Russian Federation, Therapy Faculty Board, St. Petersburg, Russian Federation|St. Petersburg Sate Budgetary Institution ""Consultative-Diagnostic Polyclinic №1 of Coastal Area"", St. Petersburg, Russian Federation|Independent Health Care Institution of Voronezh Region ""Voronezh Regional Clinical Consultative-Diagnostic Center"", Voronezh, Russian Federation|State Budgetary Health Care Institution of Yaroslavl Region ""Regional Сlinical Hospital"", Yaroslavl, Russian Federation",,https://ClinicalTrials.gov/show/NCT01868594
NCT01866748,"Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects",,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 2|Healthy",Drug: semaglutide|Drug: placebo,"Part A: Number of treatment emergent adverse events (TEAEs)|Part B: Number of treatment emergent adverse events (TEAEs)|Part A: AUC0-24h,semaglutide: the area under the semaglutide plasma concentration curve|Part B: AUCτ,semaglutide: area under the semaglutide plasma concentration curve|Part B: Change in fasting plasma glucose (FPG) from baseline|Part B: Change in body weight from baseline",Novo Nordisk A/S,Male,18 Years to 64 Years   (Adult),Phase 1,170,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN9928-4048|2012-003199-38|U1111-1132-4190,May-13,Apr-14,Apr-14,31-May-13,null,28-Apr-14,"Berlin, Germany",,https://ClinicalTrials.gov/show/NCT01866748
NCT01865279,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Explorative Formulation of Insulin Degludec",,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: placebo|Drug: isophane human insulin,Frequency of adverse events (trial part 1 only)|Area under the glucose infusion rate curve (trial part 2 only)|Area under the serum insulin concentration curve,Novo Nordisk A/S,Male,18 Years to 55 Years   (Adult),Phase 1,64,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN5401-1718|2005-003974-65,Dec-05,Apr-06,Apr-06,30-May-13,null,23-Oct-15,"Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01865279
NCT01865292,Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: insulin glargine,Area under the glucose infusion rate curve|Area under the insulin degludec/insulin glargine curve,Novo Nordisk A/S,Male,"18 Years to 69 Years   (Adult, Older Adult)",Phase 1,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN5401-1719|2006-001915-31,Aug-06,Nov-06,Nov-06,30-May-13,null,19-Oct-15,"Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01865292
NCT01865305,Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Drug: insulin degludec/insulin aspart 30|Drug: insulin degludec/insulin aspart 40|Drug: insulin degludec/insulin aspart 50|Drug: insulin degludec|Drug: insulin aspart|Drug: biphasic insulin aspart 30,Area under the insulin aspart concentration curve from 0-2 hours (for subjects with type 1 diabetes)|Maximum glucose infusion rate divided by the average glucose infusion rate (for subjects with type 2 diabetes)|Area under the glucose infusion rate curve|Area under the serum insulin degludec concentration curve,Novo Nordisk A/S,Male,"18 Years to 69 Years   (Adult, Older Adult)",Phase 1,59,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN5401-1738|2006-002430-37,Sep-06,Feb-07,Feb-07,30-May-13,null,23-Oct-15,"Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01865305
NCT01865318,Investigation of Pharmacodynamic Characteristics of Explorative Formulation of Insulin Degludec in Male Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec,Area under the glucose infusion rate curve|Maximum glucose infusion rate (GIRmax)|Time to maximum glucose infusion rate (tGIRmax)|Area under the serum insulin degludec curve,Novo Nordisk A/S,Male,"18 Years to 69 Years   (Adult, Older Adult)",Phase 1,36,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN5401-1740|2006-002212-97,Sep-06,Jan-07,Jan-07,30-May-13,null,22-Oct-15,"Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01865318
NCT01862120,Dose Finding Study of Il-2 at Ultra-low Dose in Children With Recently Diagnosed Type 1 Diabetes,DFIL2-Child,Unknown status,No Results Available,Type 1 Diabetes,Drug: Dose D1 of interleukin-2|Drug: placebo|Drug: Dose D2 of Interleukin-2|Drug: Dose D3 of interleukin-2,Treg response following the induction cure period|Fasting plasma concentration of C-peptide|C-peptide AUC response to a mixed meal tolerance test|IDAA1C score|HbA1c|Treg response after the last administration|Treg response during the maintenance period compare to the baseline,Assistance Publique - Hôpitaux de Paris,All,7 Years to 14 Years   (Child),Phase 2,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,P101106,Jun-13,Dec-16,Mar-17,24-May-13,null,19-Apr-16,"Service d'Endocrinologie Pédiatrique, Le Kremlin Bicetre, France|Service de Pédiatrie - CHU de Nîmes, Nimes, France|CIC pédiatrique - CHU de Necker, Paris, France|Service d'endocrinologie pédiatrique - CHU de Necker, Paris, France|CIC 9202 CHU Rober Débré, Paris, France|Service d'endocrinologie Diabétologie pédiatrique CHU Robert Débré, Paris, France",,https://ClinicalTrials.gov/show/NCT01862120
NCT01858896,GLP-1 and Hypoglycemia,,"Active, not recruiting",No Results Available,Type 2 Diabetes Mellitus,Drug: Glucagon-Like Peptide- 1 (GLP-1) infusion|Other: Placebo Comparator: Saline Infusion,Change in Plasminogen Activation inhibitor-1 (PAi-1)|Change in Flow mediated dilation (FMD),University of Maryland,All,18 Years to 45 Years   (Adult),Early Phase 1,28,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,HP00055308,Jul-13,Dec-20,Dec-20,21-May-13,null,17-Apr-19,"University of Maryland, Baltimore, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01858896
NCT01857076,Surgical Treatment in Diabetic Patients With Grade 1 Obesity,,Completed,No Results Available,Obesity|Type 2 Diabetes Mellitus,Procedure: Gastric bypass surgery|Procedure: Surgical ileal transposition with sleeve|Other: Clinical,Glycemic blood rates|Diabetes remission evaluated by patients glycemic rates|Weight loss|Decrease in blood lipid|Quality of life evaluation|Number of Early Adverse Events|Number os Nutricional Complications|Number of Late Adverse Events,Hospital Sirio-Libanes,All,"25 Years to 65 Years   (Adult, Older Adult)",Not Applicable,75,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HSL 2012-01|00747112.3.0000.5461,Feb-13,May-15,null,20-May-13,null,20-Aug-15,"Hospital Sírio Libanês Teaching and Research Center, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT01857076
NCT01857973,Overnight Closed Loop Study in U.S.,OCL,Completed,Has Results,Type 1 Diabetes,Device: Hybrid Closed Loop,Percentage of Time in Euglycemic Range - Phase 3 (Closed-loop Using the NGP Pump Platform)|Percentage of Time in Euglycemic Range - Exploratory A Phase|Number of Subject With YSI (Yellow Spring Instrument) Dipped Below 50mg/dL - Exploratory B Phase|Number of Subject Under-calibrated to Introduce a Persistent Under-reading Sensor Measurement Bias- Phase 1|Percentage of Time in Euglycemic Range - Phase 2|Percentage of Time in Euglycemic Range - Phase 4|Percentage of Time in Euglycemic Range - Phase 6|Percentage of Time in Euglycemic Range - Phase 7,Medtronic Diabetes,All,"2 Years to 75 Years   (Child, Adult, Older Adult)",Not Applicable,78,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,CEP273,Jun-13,Jun-16,Oct-16,20-May-13,28-Feb-19,28-Feb-19,"AMCR Institute, Inc. 700 West El Norte Parkway, Suite 201, Escondido, California, United States|Barbara Davis Center, 1775 Aurora Court, A140, Aurora, Colorado, United States|Yale University School of Medicine, 2 Church Street South, Suite 404, New Haven, Connecticut, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|University of Virginia, 617 West Main Street, 4th Floor, Charlottesville, Virginia, United States|Rainier Clinical Research, 723 SW 10th Street, Suite 100, Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT01857973
NCT01856595,PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients,,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: PF-06291874|Drug: Placebo,"Number of Participants Had Protocol-Defined Total Hypoglycemic Adverse Event (HAE) - Part A|Number of Participants Had Protocol-Defined Total Hypoglycemic Adverse Event (HAE) - Part B|Number of Participants With Electrocardiograms (ECGs) Data Met Criteria of Potential Clinical Concern - Part A|Number of Participants With ECGs Data Met Criteria of Potential Clinical Concern - Part B|Number of Participants With Vital Signs Data Met Criteria of Potential Clinical Concern - Part A|Number of Participants With Vital Signs Data Met Criteria of Potential Clinical Concern - Part B|Number of Participants With Any Abnormal Laboratory Test Results - Part A|Number of Participants With Any Abnormal Laboratory Test Results - Part B|Single Dose Maximum Plasma Concentration (Cmax) for PF-06291874 - Part A|Single Dose Normalized Cmax (Cmax[dn]) for PF-06291874 - Part A|Single Dose Cmax for PF-06291874 - Part B|Single Dose Normalized Cmax (Cmax[dn]) for PF-06291874 - Part B|Single Dose Time at Which Cmax Occurred (Tmax) for PF-06291874 - Part A|Single Dose Tmax for PF-06291874 - Part B|Single Dose AUCtau (Area Under the Concentration-time Profile From Time Zero to Time Tau, the Dosing Interval, Where Tau = 24 Hours) for PF-06291874 - Part A|Single Dose AUCtau for PF-06291874 - Part B|Multiple Dose Cmax for PF-06291874 - Part A|Multiple Dose Cmax for PF-06291874 - Part B|Multiple Dose Tmax for PF-06291874 - Part A|Multiple Dose Tmax for PF-06291874 - Part B|Multiple Dose AUCtau for PF-06291874 - Part A|Multiple Dose AUCtau for PF-06291874 - Part B|Multiple Dose Half Life for PF-06291874|Multiple Dose Cmin (Lowest Plasma Concentration Observed During the Dosing Interval) for PF-06291874 - Part A|Multiple Dose Cmin for PF-06291874 - Part B|Multiple Dose Apparent Clearance (CL/F) for PF-06291874 - Part A|Multiple Dose CL/F for PF-06291874 - Part B|Multiple Dose Apparent Volume of Distribution (Vz/F) for PF-06291874- Part A and Part B|Multiple Dose Observed Accumulation Ratio (Rac) for PF-06291874 - Part A|Multiple Dose Rac for PF-06291874 - Part B|Multiple Dose Rac for Cmax (Rac,Cmax) for PF-06291874 - Part A|Multiple Dose Rac,Cmax for PF-06291874 - Part B|Multiple Dose Percent of Cumulative Amount of Drug Recovered Unchanged in Urine Over the Dosing Interval τ(Aetau%) for PF-06291874|Multiple Dose Renal Clearance (CLr) for PF-06291874|Changes From Baseline for Mean Daily Glucose (mg/dL) on Day 14 (AUC Approach) - Part A|Changes From Baseline for Mean Daily Glucose (mg/dL) on Day 14 (AUC Approach) - Part B|Changes From Baseline for Mean Daily Glucose (mg/dL) on Day 28 (AUC Approach)|Changes Relative to Baseline (Ratio) of AUC0-4 for Glucose Following MMTT on Day 14 - Part A|Changes Relative to Baseline (Ratio) of AUC0-4 for Glucose Following MMTT on Day 14 - Part B|Changes Relative to Baseline (Ratio) of AUC0-4 for Glucose Following MMTT on Day 28|Percent Changes From Baseline of AUC0-4 for Glucagon Following MMTT on Day 14 - Part A|Percent Changes From Baseline of AUC0-4 for Glucagon Following MMTT on Day 14 - Part B|Percent Changes From Baseline of AUC0-4 for Glucagon Following MMTT on Day 28|Changes Relative to Baseline (Ratio) of AUC0-4 for Insulin Following MMTT on Day 14 - Part A|Changes Relative to Baseline (Ratio) of AUC0-4 for Insulin Following MMTT on Day 14 - Part B|Changes Relative to Baseline (Ratio) of AUC0-4 for Insulin Following MMTT on Day 28|Changes Relative to Baseline (Ratio) of AUC0-4 for C-Peptide Following MMTT on Day 14 - Part A|Changes Relative to Baseline (Ratio) of AUC0-4 for C-Peptide Following MMTT on Day 14 - Part B|Changes Relative to Baseline (Ratio) of AUC0-4 for C-Peptide Following MMTT on Day 28|Absolute Values and Changes From Baseline in Fasting Plasma Glucose at at Days 2, 7, 14, 15, 21, 28 and 29 - Part A|Absolute Values and Changes From Baseline in Fasting Plasma Glucose at Days 2, 7, 14, 15, 21, 28 and 29 - Part B|Absolute Values and Changes From Baseline in Fasting Plasma Insulin at Days 14 and 28 - Part A|Absolute Values and Changes From Baseline in Fasting Plasma Insulin at Days 14 and 28 - Part B|Percent Change From Baseline in Lipid Parameters (mg/dL) by Treatment Group on Days 14 and 28 - Part A|Percent Change From Baseline in Lipid Parameters (mg/dL) by Treatment Group on Days 14 and 28 - Part B",Pfizer,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,117,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",B4801003,13-May-13,10-Jan-14,1-Mar-14,17-May-13,1-Nov-18,1-Nov-18,"Anaheim Clinical Trials, Anaheim, California, United States|Profil Institute for Clinical Research, Inc., Chula Vista, California, United States|MRA Clinical Research, LLC, South Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT01856595
NCT01856790,Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Device: ePID closed loop system|Drug: liraglutide,peak post-prandial venous glucose levels|the incremental meal-related glucose AUC,Jennifer Sherr|Juvenile Diabetes Research Foundation|Yale University,All,18 Years to 40 Years   (Adult),Early Phase 1,15,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1211011156,Feb-13,Nov-15,Nov-15,17-May-13,null,7-Apr-16,"Yale University School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01856790
NCT01855490,Study of the Acute Metabolic Effect of Exenatide in Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Drug: Exenatide,"Effect of exenatide on metabolic responses to an oral (as a mixed meal) or intravenous glucose challenge in subjects with established T1D with or without residual insulin production.|Effect of exenatide on insulin secretion, glucagon secretion, GLP-1 and GIP levels, and gastric emptying in these patients with T1D. - effect of exenatide on residual insulin production",Yale University,All,18 Years to 56 Years   (Adult),Phase 1,17,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1201009520,Jan-12,Jul-13,Oct-13,16-May-13,null,7-Jul-16,"Yale School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01855490
NCT01848990,CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM),,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Commercial Hylenex® recombinant (hyaluronidase human injection)|Drug: Precommercial Hylenex recombinant (hyaluronidase human injection)|Drug: Insulin lispro|Drug: Insulin aspart|Drug: Insulin glulisine,"Change From Baseline to 6 Months in Glycosylated Hemoglobin (HbA1c)|Change From Baseline to 12 Months in HbA1c|Rates of Hypoglycemia Events (HE) to Month 6|Rates of HEs to Month 12|Rates of Hyperglycemia Events to Month 6|Rates of Hyperglycemia Events to Month 12|Mean Glucose Excursions at 6 Months|Mean Glucose Excursions at 12 Months|Standard Deviation of Self-Monitoring Blood Glucose Values at 6 Months|Standard Deviation of Self-Monitoring Blood Glucose Values at 12 Months|Number of Participants Achieving HbA1c <7.0% and HbA1c ≤6.5% at Month 12|Change From Baseline in Body Weight to Month 12|Average of Daily Insulin Doses (Bolus, Basal, and Total)|Average Carbohydrate Factor (CarbF) Values|Average Correction Factor (CorrF) Values|Average of Bolus Times Relative to Meal Times|Average Glucose, Median Glucose, and Average Daily Standard Deviation|Time Per Day <56 Milligrams Per Deciliter (mg/dL), ≤70 mg/dL, >70 mg/dL, <140 mg/dL, ≥140 mg/dL, Outside of 71 to 180 mg/dL, and Outside of 71 to 139 mg/dL|Area Per Day <56 mg/dL, ≤70 mg/dL, ≥140 mg/dL, Outside of 71 to 180 mg/dL, and Outside of 71 to 139 mg/dL|Change From Baseline in Weighted Impact ADDQoL Values at Month 12|Change From Baseline in Average Weighted Impact ADDQoL Values at Month 12|Change From Baseline in DTSQs and DTSQc at Month 12|Mean Time to Change Infusion Site|Mean Additional Time for Hylenex Pre-administration|Number of Participants With the Indicated Responses to the Question Regarding the Difficulty of Infusion Site Change|Number of Participants With the Indicated Responses to the Device Handling Questions|Mean Times Per Week Participants Said They Were Eating to Avoid Going Low Due to Late Insulin Action",Halozyme Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 4,456,Industry,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Halo-117-403,Mar-13,Feb-14,Sep-14,8-May-13,29-Oct-14,7-Nov-18,"For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Concord, California, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Encino, California, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Escondido, California, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Greenbrae, California, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, La Jolla, California, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, San Mateo, California, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Aurora, Colorado, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Hollywood, Florida, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Miami, Florida, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Miami, Florida, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Roswell, Georgia, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Idaho Falls, Idaho, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Des Moines, Iowa, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Wichita, Kansas, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Hyattsville, Maryland, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Rockville, Maryland, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Detroit, Michigan, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Minneapolis, Minnesota, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Butte, Montana, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Henderson, Nevada, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Las Vegas, Nevada, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, New Hyde Park, New York, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Asheville, North Carolina, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Durham, North Carolina, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Morehead City, North Carolina, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Cincinnati, Ohio, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Portland, Oregon, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Bartlett, Tennessee, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Chattanooga, Tennessee, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Austin, Texas, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Dallas, Texas, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Round Rock, Texas, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Olympia, Washington, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Renton, Washington, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Seattle, Washington, United States|For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01848990
NCT01843114,Measurement of Total Retinal Blood Flow in Patients With Diabetes and Healthy Subjects,,Completed,No Results Available,Type I Diabetes,Device: FDOCT|Other: Dynamic Vessel Analyzer,Total retinal blood flow|Retinal vessel diameter|Retinal blood velocities,Medical University of Vienna,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,48,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science,OPHT-280113,12-Jan-15,26-Aug-16,1-Mar-17,30-Apr-13,null,21-Mar-17,"Department of Clinical Pharmacology, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT01843114
NCT01843127,A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Ranolazine|Drug: Placebo|Drug: Exenatide,"Area under the concentration-time curve (AUC) of plasma glucagon during the standard meal test (SMT)|Plasma glucose, serum insulin, and serum C-peptide AUCs during the SMT|Collapse under Acetaminophen PK|Area under the plasma acetaminophen concentration-time curve from time 0 to 240 min (AUC0-240 min)|Collapse all under ranolazine pharmacokinetics (PK)|Trough plasma ranolazine concentrations (Ctrough)|Average plasma ranolazine concentration during a dosing interval at steady state (Css,ave)|Area under the plasma ranolazine concentration-time curve over dosing interval (AUCtau)|Apparent elimination half-life (t1/2) of ranolazine|Adverse events, physical examinations, clinical laboratory determinations, electrocardiograms (ECG), and vital sign assessments.",Gilead Sciences,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,GS-US-259-0165,Apr-13,Sep-13,Sep-13,30-Apr-13,null,31-Mar-14,"Profil Institute for Clinical Research, Inc., Chula Vista, California, United States|SeaView Research, Inc, Miami, Florida, United States|Translational Research Institute-Florida Hospital, Orlando, Florida, United States",,https://ClinicalTrials.gov/show/NCT01843127
NCT01840189,Continuous Subcutaneous Hydrocortisone Infusion In Addison`s Disease and Type 1 Diabetes,,Completed,No Results Available,Addison Disease|Type 1 Diabetes,Other: Cortef|Other: Solu-cortef,nocturnal hypoglycemic events|o Nocturnal glycemic variability|hormone and metabolic profile|o Subjective health status,Haukeland University Hospital,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,2,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012/2218|2012/005516-26,May-13,Dec-16,Dec-16,25-Apr-13,null,1-Feb-17,"Haukeland University Hospiatl, Bergen, Norway",,https://ClinicalTrials.gov/show/NCT01840189
NCT01840358,Hypoglycemia at Initiation of Pump Therapy in Children With Type 1 Diabetes,,Unknown status,No Results Available,Type 1 Diabetes,Other: Observation of hypoglycemias frequency 3 days before and after pump initiation,Frequency of hypoglycemias|Frequency of hyperglycemias,St. Justine's Hospital,All,"up to 18 Years   (Child, Adult)",Not Applicable,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),HSJ-3638,Apr-13,Dec-13,null,25-Apr-13,null,26-Apr-13,"CHU Sainte-Justine, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01840358
NCT01839370,Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: Closed Loop with Pramlintide,Percent of Glucose Measurements within Target Range,"University of Virginia|DexCom, Inc.|Tandem Diabetes Care, Inc.",All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,9,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16666,Jul-13,Nov-13,Nov-13,24-Apr-13,null,19-Feb-14,"University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01839370
NCT01838083,Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus,,Completed,No Results Available,Type1 Diabetes,Drug: Insulin glargine new formulation HOE901,"Area under the serum insulin concentration curve within 24 hours (INS-AUC0-24) after dosing on Day 6|Maximum insulin concentration (INS-Cmax)|Time to INS-Cmax (INS-tmax)|Time to reach 50% of INS-AUC0-24 (T50%-INS-AUC0-24)|Area under the body-weight-standardized Glucose Infusion Rate (GIR) within 24 hours (GIR-AUC0-24h) after dosing on Day 6 during the clamp|Maximum smoothed body weight standardized glucose infusion rate (GIRmax)|Time to GIRmax (GIR-Tmax)|Time to reach at least 50% of GIR-AUC0-24 (T50%-GIR-AUC0-24)|Duration of blood glucose control (time to elevation of smoothed blood glucose profile above clamp level and to elevation above different prespecified blood glucose levels)|Safety as measured by adverse events/serious adverse events, ohypoglycemia events, physical examinations, clinical laboratory, electrocardiograms, vital signs, injection site reactions and anti-insulin antibodies.",Sanofi,All,18 Years to 64 Years   (Adult),Phase 1,50,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PKD13560|2012-005777-31|U1111-1139-3755,Apr-13,Aug-13,Aug-13,23-Apr-13,null,13-Aug-13,"Investigational Site Number 276001, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01838083
NCT01836523,The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes,ADJUNCT ONE™,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: liraglutide|Drug: placebo,Change From Baseline in HbA1c (Glycosylated Haemoglobin)|Change From Baseline in Body Weight|Change From Baseline in Total Daily Insulin Dose|Number of Treatment-emergent Symptomatic Hypoglycaemic Episodes,Novo Nordisk A/S,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,1398,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN9211-3919|2012-003580-21|U1111-1133-0590,Nov-13,Jun-15,Jun-15,22-Apr-13,6-Mar-17,6-Mar-17,"Novo Nordisk Investigational Site, Little Rock, Arkansas, United States|Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Encino, California, United States|Novo Nordisk Investigational Site, Escondido, California, United States|Novo Nordisk Investigational Site, Huntington Beach, California, United States|Novo Nordisk Investigational Site, La Mesa, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Monterey, California, United States|Novo Nordisk Investigational Site, San Mateo, California, United States|Novo Nordisk Investigational Site, San Ramon, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Denver, Colorado, United States|Novo Nordisk Investigational Site, Ft. Lauderdale, Florida, United States|Novo Nordisk Investigational Site, Hialeah, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Marietta, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Savannah, Georgia, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Indianapolis, Indiana, United States|Novo Nordisk Investigational Site, Council Bluffs, Iowa, United States|Novo Nordisk Investigational Site, Iowa City, Iowa, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Metarie, Louisiana, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, Chesterfield, Missouri, United States|Novo Nordisk Investigational Site, Springfield, Missouri, United States|Novo Nordisk Investigational Site, St. Charles, Missouri, United States|Novo Nordisk Investigational Site, St. Louis, Missouri, United States|Novo Nordisk Investigational Site, St. Peters, Missouri, United States|Novo Nordisk Investigational Site, Billings, Montana, United States|Novo Nordisk Investigational Site, Butte, Montana, United States|Novo Nordisk Investigational Site, Lawrenceville, New Jersey, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, Mineola, New York, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, Staten Island, New York, United States|Novo Nordisk Investigational Site, Syracuse, New York, United States|Novo Nordisk Investigational Site, Greensboro, North Carolina, United States|Novo Nordisk Investigational Site, Morehead City, North Carolina, United States|Novo Nordisk Investigational Site, Mentor, Ohio, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Upper Darby, Pennsylvania, United States|Novo Nordisk Investigational Site, Greer, South Carolina, United States|Novo Nordisk Investigational Site, Myrtle Beach, South Carolina, United States|Novo Nordisk Investigational Site, Summerville, South Carolina, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Memphis, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Amarillo, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, El Paso, Texas, United States|Novo Nordisk Investigational Site, Round Rock, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Salt Lake City, Utah, United States|Novo Nordisk Investigational Site, Bennington, Vermont, United States|Novo Nordisk Investigational Site, Norfolk, Virginia, United States|Novo Nordisk Investigational Site, Federal Way, Washington, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States|Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Capital Federal, Argentina|Novo Nordisk Investigational Site, Córdoba, Argentina|Novo Nordisk Investigational Site, Mendoza, Argentina|Novo Nordisk Investigational Site, Morón, Argentina|Novo Nordisk Investigational Site, Broadmeadow, New South Wales, Australia|Novo Nordisk Investigational Site, Elizabeth Vale, South Australia, Australia|Novo Nordisk Investigational Site, Keswick, South Australia, Australia|Novo Nordisk Investigational Site, Melbourne, Victoria, Australia|Novo Nordisk Investigational Site, Parkville, Victoria, Australia|Novo Nordisk Investigational Site, Arlon, Belgium|Novo Nordisk Investigational Site, Edegem, Belgium|Novo Nordisk Investigational Site, Leuven, Belgium|Novo Nordisk Investigational Site, Liège, Belgium|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Winnipeg, Manitoba, Canada|Novo Nordisk Investigational Site, Barrie, Ontario, Canada|Novo Nordisk Investigational Site, Cambridge, Ontario, Canada|Novo Nordisk Investigational Site, London, Ontario, Canada|Novo Nordisk Investigational Site, Mississauga, Ontario, Canada|Novo Nordisk Investigational Site, Oakville, Ontario, Canada|Novo Nordisk Investigational Site, Thornhill, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Sherbrooke, Quebec, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Pori, Finland|Novo Nordisk Investigational Site, Seinäjoki, Finland|Novo Nordisk Investigational Site, Seinäjoki, Finland|Novo Nordisk Investigational Site, Tampere, Finland|Novo Nordisk Investigational Site, Turku, Finland|Novo Nordisk Investigational Site, Besancon, France|Novo Nordisk Investigational Site, Brest, France|Novo Nordisk Investigational Site, Caen, France|Novo Nordisk Investigational Site, Corbeil Essonnes, France|Novo Nordisk Investigational Site, DIJON cedex, France|Novo Nordisk Investigational Site, Le Creusot, France|Novo Nordisk Investigational Site, Narbonne, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Pointe à Pitre, France|Novo Nordisk Investigational Site, Poitiers, France|Novo Nordisk Investigational Site, Saint Herblain, France|Novo Nordisk Investigational Site, Saint Priest en Jarez, France|Novo Nordisk Investigational Site, Venissieux, France|Novo Nordisk Investigational Site, Eisenach, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Hohenmölsen, Germany|Novo Nordisk Investigational Site, Marburg, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Pohlheim, Germany|Novo Nordisk Investigational Site, Rehlingen-Siersburg, Germany|Novo Nordisk Investigational Site, St. Ingbert, Germany|Novo Nordisk Investigational Site, Dublin 9, Ireland|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Galway, Ireland|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Holon, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Petah Tikva, Israel|Novo Nordisk Investigational Site, Rishon Le Zion, Israel|Novo Nordisk Investigational Site, Amsterdam, Netherlands|Novo Nordisk Investigational Site, Den Haag, Netherlands|Novo Nordisk Investigational Site, Hoogeveen, Netherlands|Novo Nordisk Investigational Site, Leiden, Netherlands|Novo Nordisk Investigational Site, Nijmegen, Netherlands|Novo Nordisk Investigational Site, Rotterdam, Netherlands|Novo Nordisk Investigational Site, Venlo, Netherlands|Novo Nordisk Investigational Site, Bergen, Norway|Novo Nordisk Investigational Site, Gjettum, Norway|Novo Nordisk Investigational Site, Hamar, Norway|Novo Nordisk Investigational Site, Kongsvinger, Norway|Novo Nordisk Investigational Site, Stavanger, Norway|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Pulawy, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Zabrze, Poland|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Penza, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Volgograd, Russian Federation|Novo Nordisk Investigational Site, Göteborg, Sweden|Novo Nordisk Investigational Site, Malmö, Sweden|Novo Nordisk Investigational Site, Stockholm, Sweden|Novo Nordisk Investigational Site, Stockholm, Sweden|Novo Nordisk Investigational Site, Kharkov, Ukraine|Novo Nordisk Investigational Site, Kharkov, Ukraine|Novo Nordisk Investigational Site, Kiev, Ukraine|Novo Nordisk Investigational Site, Poltava, Ukraine|Novo Nordisk Investigational Site, Zhytomir, Ukraine|Novo Nordisk Investigational Site, Blackburn, United Kingdom|Novo Nordisk Investigational Site, Bristol, United Kingdom|Novo Nordisk Investigational Site, Durham, United Kingdom|Novo Nordisk Investigational Site, Edgbaston, Birmingham, United Kingdom|Novo Nordisk Investigational Site, Edinburgh, United Kingdom|Novo Nordisk Investigational Site, Middlesbrough, United Kingdom|Novo Nordisk Investigational Site, Plymouth, United Kingdom|Novo Nordisk Investigational Site, Southall, United Kingdom|Novo Nordisk Investigational Site, St Helens, United Kingdom|Novo Nordisk Investigational Site, Stevenage, United Kingdom",,https://ClinicalTrials.gov/show/NCT01836523
NCT01835431,A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus,,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec/insulin aspart|Drug: insulin aspart|Drug: insulin detemir,Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%)|Change From Baseline in Fasting Plasma Glucose|Incidence of Treatment Emergent Adverse Events (TEAEs)|Number of Treatment Emergent Confirmed Hypoglycaemic Episodes (Plasma Glucose (PG) Below 3.1mmol/L (56mg/dL) or Severe Hypoglycaemia)|Number of Treatment Emergent Nocturnal Confirmed Hypoglycaemic Episodes|Number of Hyperglycaemic Episodes (PG Above 14.0 mmol/L (250 mg/dL) Where Subject Looks/Feels Ill|Number of Hyperglycaemic Episodes (PG Above 14.0 mmol/L (250 mg/dL) Where Subject Looks/Feels Ill With Ketosis (Blood Ketones Above 1.5 mmol/L),Novo Nordisk A/S,All,1 Year to 17 Years   (Child),Phase 3,362,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN5401-3816|2012-003566-41|U1111-1133-0958|PIP no. be confirmed,17-Oct-13,7-Nov-14,7-Nov-14,19-Apr-13,17-Nov-15,10-Sep-18,"Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Sacramento, California, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Maitland, Florida, United States|Novo Nordisk Investigational Site, Melbourne, Florida, United States|Novo Nordisk Investigational Site, Tallahassee, Florida, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Springfield, Illinois, United States|Novo Nordisk Investigational Site, Indianapolis, Indiana, United States|Novo Nordisk Investigational Site, Iowa City, Iowa, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Worcester, Massachusetts, United States|Novo Nordisk Investigational Site, Kansas City, Missouri, United States|Novo Nordisk Investigational Site, Buffalo, New York, United States|Novo Nordisk Investigational Site, Tulsa, Oklahoma, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Brussels, Belgium|Novo Nordisk Investigational Site, Brussels, Belgium|Novo Nordisk Investigational Site, Leuven, Belgium|Novo Nordisk Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Curitiba, Brazil|Novo Nordisk Investigational Site, Vancouver, British Columbia, Canada|Novo Nordisk Investigational Site, London, Ontario, Canada|Novo Nordisk Investigational Site, Mississauga, Ontario, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Olomouc, Czechia|Novo Nordisk Investigational Site, Pardubice, Czechia|Novo Nordisk Investigational Site, Prague 5, Czechia|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, New Dehli, New Delhi, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Beer Sheva, Israel|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Petah Tikva, Israel|Novo Nordisk Investigational Site, Tel Aviv, Israel|Novo Nordisk Investigational Site, Tel Hashomer, Israel|Novo Nordisk Investigational Site, Zerifin, Israel|Novo Nordisk Investigational Site, Skopje, Macedonia, The Former Yugoslav Republic of|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Tomsk, Russian Federation|Novo Nordisk Investigational Site, Ufa, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Nis, Serbia|Novo Nordisk Investigational Site, Novi Sad, Serbia|Novo Nordisk Investigational Site, Ljubljana, Slovenia|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Mayville, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Barcelona, Spain|Novo Nordisk Investigational Site, Esplugues Llobregat(Barcelona), Spain|Novo Nordisk Investigational Site, Leganés, Spain|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT01835431
NCT01835730,"Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus",,Completed,No Results Available,Type 2 Diabetes Mellitus (T2DM),Drug: PE0139 Injection|Drug: Placebo,Change in Vital Signs from baseline (Day 0 Pre-dose)|Change in ECGs from baseline (Day -1)|Change in Safety Labs from baseline (Pre-dose)|Incidence and severity of immunogenicity|Incidence and severity of adverse events including hypoglycemia|Pharmacokinetic Profile|Pharmacodynamic Response,PhaseBio Pharmaceuticals Inc.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,37,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PE0139-PT-CL-0001,Apr-13,May-14,May-14,19-Apr-13,null,15-Oct-14,"Pinnacle Research Group, LLC, Anniston, Alabama, United States|Palm Springs Research Institute, Hialeah, Florida, United States|Rainier Clinical Research, Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT01835730
NCT01835964,Biobehavioral Mechanisms of Glucose Variability,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Procedure: Glucose Variability Observation,Glucose Variability,"University of Virginia|DexCom, Inc.",All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,30,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),16723,Apr-13,Jan-14,Feb-14,19-Apr-13,null,19-Feb-14,"University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01835964
NCT01833988,The Summer Camp Study: Blood Glucose Control With a Bi-Hormonal Bionic Endocrine Pancreas,,Completed,Has Results,Type 1 Diabetes,Device: Bi-hormonal Bionic Pancreas|Other: Usual Care,"Difference in Average Blood Glucose (BG) Between Closed-loop (Bionic Pancreas Arm) and Open-loop (Insulin Pump Arm) Periods as Determined From All Scheduled HemoCue Measurements With Mean Evenly Weighted Across the Daytime and Nighttime Hours.|Percentage of Time With a Low Plasma Glucose Reading (Less Than 70mg/dl) in the Bionic Pancreas Arm as Compared to Insulin Pump Arm|Difference Between Closed-loop (Bionic Pancreas Arm) and Open-loop (Insulin Pump Arm) in Average BG as Determined From All HemoCue Measurements Taken During the Day/Nighttime Including All Extra Measurements.|Difference Between Closed-loop (Bionic Pancreas Arm) and Open-loop (Insulin Pump Arm) in Number of Subjects With Mean BG < 154 mg/dl|Difference in the Percentage of Study Days With Mean CGM BG </= 154 mg/dl Over the Duration of the Closed-loop Period vs. the Usual Care Period|Difference Between Closed-loop (Bionic Pancreas Arm) and Open-loop (Insulin Pump Arm) in Number of Hypoglycemic Events (BG <70mg/dl) as Determined From HemoCue Measurements|Difference Between Closed-loop (Bionic Pancreas Arm) and Open-loop (Insulin Pump Arm) in Fraction of Time Spent Within CGMG (Continuous Glucose Monitor) Ranges (< 70 mg/dl, 70-120 mg/dl, 70-180 mg/dl, > 180 mg/dl, > 250 mg/dl)|Difference Between Closed-loop (Bionic Pancreas Arm) and Open-loop (Insulin Pump Arm) in Mean BG During Exercise|Difference Between Closed-loop (Bionic Pancreas Arm) and Open-loop (Insulin Pump Arm) in Number of Severe Hypoglycemic Episodes and Nadir BG During Exercise|Difference in Mean CGMG on Day 1 vs. Remaining Days (Days 2-5) Between Closed Loop (Bionic Pancreas Arm) and Usual Care (Insulin Pump Arm)|Difference Between Closed-loop (Bionic Pancreas) and Open-loop (Insulin Pump) in Mean Continuous Glucose Monitoring Glucose (CGMG)|Difference Between Closed-loop and Open-loop in Area Over the Curve and Below 70 mg/dl (Measure of Total Hypoglycemia Exposure)|Difference Between Closed-loop (Bionic Pancreas Arm) and Open-loop (Insulin Pump Arm) in Area Over the Curve and Below 50 mg/dl (Measure of Total Hypoglycemia Exposure)|Difference Between Closed-loop (Bionic Pancreas Arm) and Open-loop (Insulin Pump Arm) in Number of Subjects With Mean CGMG < 154 mg/dl|Difference Between Closed-loop and Open-loop in Mean CGMG in the Four Hour Period Following Meals|Difference Between Closed-loop (Bionic Pancreas Arm) and Open-loop (Insulin Pump Arm) in Mean CGMG During Exercise|Difference Between Closed-loop (Bionic Pancreas Arm) and Open-loop (Insulin Pump Arm) in Standard Deviation of CGMG Values (Glycemic Variability) in Different BG Ranges.|Difference Between Closed-loop (Bionic Pancreas Arm) and Open-loop (Insulin Pump Arm) in Standard Deviation of CGMG Values at Night (11:00 PM to 7:00 AM)|Difference Between Closed-loop and Open-loop in Average BG as Determined From All HemoCue Measurements Taken During the Nighttime Including All Extra Measurements Taken for Hypoglycemia Monitoring.|Difference Between Closed-loop (Bionic Pancreas Arm) and Open-loop (Insulin Pump Arm) in Time Spent in Hypoglycemia (Plasma BG <Than 70 mg/dl) at Night|Difference Between Closed-loop and Open-loop in Fraction of Time at Night Spent Within Glucose Ranges (< 70 mg/dl, 70-120 mg/dl, 70-180 mg/dl, > 180 mg/dl, > 250 mg/dl)|Difference Between Closed-loop (Bionic Pancreas Arm) and Open-loop (Insulin Pump Arm) in Mean CGMG at Night|Difference Between Closed-loop (Bionic Pancreas Arm) and Open-loop (Insulin Pump Arm) in Fraction of Time Spent Within CGMG Ranges (< 70 mg/dl, 70-120 mg/dl, 70-180 mg/dl, > 180 mg/dl, > 250 mg/dl) at Night|Difference Between Closed-loop and Open-loop in Area Over the Curve and Below 70 mg/dl (Measure of Total Hypoglycemia Exposure) at Night|Difference Between Closed-loop and Open-loop in Area Over the Curve and Below 50 mg/dl (Measure of Total Hypoglycemia Exposure) at Night|Difference Between Closed-loop (Bionic Pancreas Arm) and Open-loop (Insulin Pump Arm) in Number of Carbohydrate Interventions for Hypoglycemia|Difference Between Closed-loop (Bionic Pancreas Arm) and Open-loop (Insulin Pump Arm) in Number of Carbohydrate Interventions for Hypoglycemia at Night",Massachusetts General Hospital|Boston University,All,"12 Years to 20 Years   (Child, Adult)",Not Applicable,32,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013p000561,Apr-13,Aug-13,Dec-14,17-Apr-13,11-Aug-17,8-Sep-17,"Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT01833988/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01833988
NCT01834144,The VIGORous Physical Activity for Glycaemic Control in Type 1 Diabetes (VIGOR) Trial,VIGOR,Terminated,Has Results,Type 1 Diabetes,Other: Exercise Training,"Time Spent in Hypoglycaemia in the 12-hour Period Following Exercise, Defined as an Interstitial Glucose Reading <4.0mmol/L and Measured by Continuous Glucose Monitor.|Glycaemic Variability, Measured by the Mean Amplitude of Glycaemic Excursions (MAGE), in the 12-hour Period Following Exercise. This is Calculated From the Same Continuous Glucose Monitor Data as the Primary Outcome.",University of Manitoba|Manitoba Institute of Child Health,All,"15 Years to 45 Years   (Child, Adult)",Not Applicable,4,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,B2012:136,May-13,15-Jun-15,15-Jun-15,17-Apr-13,20-Sep-18,20-Sep-18,"University of Calgary, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Manitoba Institute of Child Health, WInnipeg, Manitoba, Canada|McMaster University, Hamilton, Ontario, Canada|University of Ottawa, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01834144
NCT01831765,Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes,onset® 1,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin detemir|Drug: insulin aspart,Change From Baseline in HbA1c (Glycosylated Haemoglobin)|Change From Baseline in 2-hour PPG (Postprandial Glucose) Increment (Meal Test)|Change From Baseline in HbA1c (Post Meal Arm)|Number of Treatment Emergent Confirmed Hypoglycaemic Episodes|Change From Baseline in Body Weight|Frequency of Adverse Events|Change in HbA1c|Change in PPG (Postprandial Glucose),Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1290,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1218-3852|2010-024049-53|U1111-1118-2442,31-Aug-13,30-Jun-15,30-Jun-15,15-Apr-13,23-Jan-18,1-Jan-19,"Novo Nordisk Investigational Site, Mobile, Alabama, United States|Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Anaheim, California, United States|Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Escondido, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Fullerton, California, United States|Novo Nordisk Investigational Site, Inglewood, California, United States|Novo Nordisk Investigational Site, La Jolla, California, United States|Novo Nordisk Investigational Site, La Mesa, California, United States|Novo Nordisk Investigational Site, Long Beach, California, United States|Novo Nordisk Investigational Site, North Hollywood, California, United States|Novo Nordisk Investigational Site, Northridge, California, United States|Novo Nordisk Investigational Site, Poway, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, Santa Barbara, California, United States|Novo Nordisk Investigational Site, Santa Barbara, California, United States|Novo Nordisk Investigational Site, Ventura, California, United States|Novo Nordisk Investigational Site, Ventura, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Denver, Colorado, United States|Novo Nordisk Investigational Site, Newark, Delaware, United States|Novo Nordisk Investigational Site, Boca Raton, Florida, United States|Novo Nordisk Investigational Site, Coral Gables, Florida, United States|Novo Nordisk Investigational Site, Fleming Island, Florida, United States|Novo Nordisk Investigational Site, Fort Lauderdale, Florida, United States|Novo Nordisk Investigational Site, Fort Lauderdale, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Sanford, Florida, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Dunwoody, Georgia, United States|Novo Nordisk Investigational Site, Lawrenceville, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Nampa, Idaho, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Crystal Lake, Illinois, United States|Novo Nordisk Investigational Site, Springfield, Illinois, United States|Novo Nordisk Investigational Site, Muncie, Indiana, United States|Novo Nordisk Investigational Site, Lenexa, Kansas, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Portland, Maine, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Hyattsville, Maryland, United States|Novo Nordisk Investigational Site, Rockville, Maryland, United States|Novo Nordisk Investigational Site, Waltham, Massachusetts, United States|Novo Nordisk Investigational Site, Worcester, Massachusetts, United States|Novo Nordisk Investigational Site, Kalamazoo, Michigan, United States|Novo Nordisk Investigational Site, Eagan, Minnesota, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, Kansas City, Missouri, United States|Novo Nordisk Investigational Site, Springfield, Missouri, United States|Novo Nordisk Investigational Site, Butte, Montana, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Henderson, Nevada, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, United States|Novo Nordisk Investigational Site, Hoboken, New Jersey, United States|Novo Nordisk Investigational Site, Jersey City, New Jersey, United States|Novo Nordisk Investigational Site, Lawrenceville, New Jersey, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, Rochester, New York, United States|Novo Nordisk Investigational Site, Smithtown, New York, United States|Novo Nordisk Investigational Site, Staten Island, New York, United States|Novo Nordisk Investigational Site, Staten Island, New York, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Greenville, North Carolina, United States|Novo Nordisk Investigational Site, Morehead City, North Carolina, United States|Novo Nordisk Investigational Site, Columbus, Ohio, United States|Novo Nordisk Investigational Site, Mentor, Ohio, United States|Novo Nordisk Investigational Site, Portland, Oregon, United States|Novo Nordisk Investigational Site, Portland, Oregon, United States|Novo Nordisk Investigational Site, Jenkintown, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Greenville, South Carolina, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Amarillo, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Beaumont, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Lubbock, Texas, United States|Novo Nordisk Investigational Site, Plano, Texas, United States|Novo Nordisk Investigational Site, Round Rock, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Magna, Utah, United States|Novo Nordisk Investigational Site, Olympia, Washington, United States|Novo Nordisk Investigational Site, Renton, Washington, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Bonheiden, Belgium|Novo Nordisk Investigational Site, Brussels, Belgium|Novo Nordisk Investigational Site, Edegem, Belgium|Novo Nordisk Investigational Site, Gent, Belgium|Novo Nordisk Investigational Site, Leuven, Belgium|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Victoria, British Columbia, Canada|Novo Nordisk Investigational Site, Winnipeg, Manitoba, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, London, Ontario, Canada|Novo Nordisk Investigational Site, London, Ontario, Canada|Novo Nordisk Investigational Site, Mississauga, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Sherbrooke, Quebec, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Brno, Czechia|Novo Nordisk Investigational Site, Hradec Kralove, Czechia|Novo Nordisk Investigational Site, Prague 4, Czechia|Novo Nordisk Investigational Site, Praha 10, Czechia|Novo Nordisk Investigational Site, Praha, Czechia|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Kerava, Finland|Novo Nordisk Investigational Site, Lappeenranta, Finland|Novo Nordisk Investigational Site, Raisio, Finland|Novo Nordisk Investigational Site, Tampere, Finland|Novo Nordisk Investigational Site, Turku, Finland|Novo Nordisk Investigational Site, Bad Mergentheim, Germany|Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Damme, Germany|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Elsterwerda, Germany|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Friedrichsthal, Germany|Novo Nordisk Investigational Site, Fulda, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Hohenmölsen, Germany|Novo Nordisk Investigational Site, Lingen, Germany|Novo Nordisk Investigational Site, Ludwigshafen, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Neuwied, Germany|Novo Nordisk Investigational Site, Oldenburg, Germany|Novo Nordisk Investigational Site, Rehburg-Loccum, Germany|Novo Nordisk Investigational Site, Rehlingen-Siersburg, Germany|Novo Nordisk Investigational Site, Rostock, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Schweinfurt, Germany|Novo Nordisk Investigational Site, Völklingen, Germany|Novo Nordisk Investigational Site, Wangen, Germany|Novo Nordisk Investigational Site, Zwenkau, Germany|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Debrecen, Hungary|Novo Nordisk Investigational Site, Kaposvár, Hungary|Novo Nordisk Investigational Site, Szeged, Hungary|Novo Nordisk Investigational Site, Szombathely, Hungary|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Krakow, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Szczecin, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Bath, United Kingdom|Novo Nordisk Investigational Site, Gillingham, United Kingdom|Novo Nordisk Investigational Site, Glasgow, United Kingdom|Novo Nordisk Investigational Site, Guildford, United Kingdom|Novo Nordisk Investigational Site, Inverness, United Kingdom|Novo Nordisk Investigational Site, Inverness, United Kingdom|Novo Nordisk Investigational Site, Ipswich, United Kingdom|Novo Nordisk Investigational Site, Nottingham, United Kingdom|Novo Nordisk Investigational Site, Portsmouth, United Kingdom|Novo Nordisk Investigational Site, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT01831765
NCT01829555,A Pilot Study Examining a Reinforcement Approach to Improve Diabetes Management,,Completed,No Results Available,Type 1 Diabetes,Behavioral: contingency management,change from baseline in number of self-monitoring of blood glucose tests conducted|change from baseline in hemoglobin A1c levels,UConn Health|Yale University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"15 Years to 21 Years   (Child, Adult)",Not Applicable,10,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,13-043-2|1DP3DK097705,Feb-13,Aug-14,Aug-14,11-Apr-13,null,10-Nov-14,"Pediatric Endocrinology, Yale University, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01829555
NCT01827735,Regulatory T Cells in Type 1 Diabetes Patients Treated With IL-2,DILT1D,Completed,No Results Available,Type 1 Diabetes,Drug: Aldesleukin (Proleukin),The primary endpoint is based upon the percentage of CD4+T regulatory (defined as CD3+CD4+CD25highCD127low) cells within the CD3+CD4+T cell gate following treatment with IL-2.|T regulatory cell phenotype and stability|T effector cell number and phenotype|T cell subset proliferation and populations|Intracellular T cell and natural killer(NK) cell signalling|T regulatory cell function|IL-2 pathway genotype|Lymphocyte Subsets|Serum Cytokines|Glycaemic control|Number of Participants with Adverse Events as a Measure of Safety and Tolerability,"Cambridge University Hospitals NHS Foundation Trust|University of Cambridge|Juvenile Diabetes Research Foundation|National Institute for Health Research, United Kingdom|Wellcome Trust",All,18 Years to 50 Years   (Adult),Phase 1|Phase 2,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,A092737|ISRCTN27852285,Mar-13,May-14,May-14,10-Apr-13,null,23-Jun-15,"Wellcome Trust Clinical Research Facility, Addenbrooke's Hospital, Cambridge, United Kingdom",,https://ClinicalTrials.gov/show/NCT01827735
NCT01828125,Efficacy of Small Subcutaneous Glucagon Dose to Treat Hypoglycemia in Adults With Type 1 Diabetes,,Withdrawn,No Results Available,Type 1 Diabetes,Procedure: Hypoglycaemic hyperinsulinemic clamp|Drug: Glucagon,Incremental area under the curve of plasma glucose concentrations|Time to reach glucose levels ≥ 4 mmol/L|Time to reach glucose levels ≥ 5 mmol/L|Time-to-peak plasma glucagon concentration|Time for 25% of glucagon appearance|Time for 50% of glucagon appearance|Time for 75% of glucagon appearance,Institut de Recherches Cliniques de Montreal|Centre de Recherche du Centre Hospitalier de l'Université de Montréal,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",Mini-doses glucagon,Apr-13,Dec-13,Dec-13,10-Apr-13,null,4-Dec-13,"Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01828125
NCT01825382,"Role of Mobile Technology to Improve Diabetes Care in Adults With Type 1 Diabetes: the REMOTE-T1D Study, a Pilot Study",REMOTE-T1D,Completed,No Results Available,Type 1 Diabetes,Device: iBGStar meter,Patient Reported Outcomes as it relates to hypoglycemia fear and quality of life.|Improvement in glucose control and indices off glucose variability from SMBG and CGM data.,University of Colorado Denver School of Medicine Barbara Davis Center|Sanofi|Colorado Prevention Center,All,"18 Years and older   (Adult, Older Adult)",Phase 4,100,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,REMOTE-T1D,Dec-12,Aug-13,Nov-13,5-Apr-13,null,21-May-14,"Barbara Davis Center, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT01825382
NCT01823341,Outpatient Reduction of Nocturnal Hypoglycemia by Using Predictive Algorithms and Pump Suspension in Children,PSO4,Completed,Has Results,Type 1 Diabetes,Device: Pump suspension algorithm,"Comparison of the Time Spent in Hypoglycemia (<70 mg/dl, 3.9 mmol/L) Overnight on Intervention Nights Versus Control Nights, Normalized to an 8-hour Period.|Percentage of Nights With 1 or More Sensor Glucose Values <70 mg/dL (<3.9 mmol/L)|Percentage of Nights With 1 or More Sensor Glucose Values <50 mg/dL (<2.8 mmol/L)|Mean Sensor Glucose Overnight|Percentage of Time Overnight Sensor Glucose Values 71 to 180 mg/dL (3.9 to 10.0 mmol/L), Normalized to an 8-hour Period.|Percentage of Overnight Time Spent With CGM Value >250 mg/dL (13.9 mmol/L), Normalized to an 8-hour Period.|Mean Morning Blood Glucose|Percentage of Mornings With Blood Glucose >250 mg/dL (>13.9 mmol/L)|Morning Blood Ketones >=1.0 mmol/L|Percent of Mornings With Urine Ketones >/= 15 mg/dl",Jaeb Center for Health Research|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Juvenile Diabetes Research Foundation,All,3 Years to 14 Years   (Child),Phase 2,97,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,PSO4|5R01DK085591,May-13,Sep-14,Sep-14,4-Apr-13,24-Aug-15,30-Aug-16,"Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|St. Joseph's Health Care, London, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01823341
NCT01823406,Tissue-Specific Metabolic Reprogramming in Diabetic Complications,DP3,Completed,No Results Available,Type 1 Diabetes Mellitus,Procedure: Euglycemic clamp (normal blood sugar clamp) for 4 hours|Procedure: hyperglycemic clamp (elevated blood sugar to 300) for 4 hours,Difference in the levels of TCA cycle metabolites between groups during euglycemia and hyperglycemia,University of Michigan|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,35,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,HUM00060967|1DP3DK094292-01,May-12,Aug-17,Aug-17,4-Apr-13,null,28-Jun-18,"University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT01823406
NCT01824264,Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes,,Withdrawn,No Results Available,Type 2 Diabetes Mellitus,Drug: LIK066|Drug: Sitagliptin|Drug: Placebo,Change from baseline in glycated hemoglobin (HbA1c) after 12 weeks|Change from baseline in Fasting Plasma Glucose|Change from baseline in urinary glucose to creatinine ratio|Change from baseline in Body weight|Change from baseline in Blood pressure|Change from baseline in postprandial glucose during a meal test|Change from baseline in beta cell function during a meal test|Change from baseline in insulin secretion relative to glucose during a meal test|Change from baseline in oral glucose insulin sensitivity during a meal test|Change from baseline in glucagon-like peptide response during a meal test|Change from baseline in Peptide YY response during a meal test|Number of patients with adverse events to assess safety and tolerability of LIK066|Change from baseline in renal threshold for glucose excretion,Novartis Pharmaceuticals|Novartis,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CLIK066A2202|2012-005793-63,Nov-15,Nov-16,Nov-16,4-Apr-13,null,3-Apr-14,,,https://ClinicalTrials.gov/show/NCT01824264
NCT01817959,Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation,REP0211,Completed,No Results Available,Islet Transplantation in Diabetes Mellitus Type 1,Drug: Reparixin|Drug: Placebo,"Area Under the Curve (AUC) for the serum C-peptide level during the first 2 hours of an MMTT (Mixed Meal Tolerance Test), normalized by the number of Islet Equivalent (IEQ)/kg|Proportion of insulin-independent patients|Proportion of patients who achieve and maintain an HbA1c <7.0% (or o reduction in HbA1c > 2%) AND are free of severe hypoglycaemic events|Proportion of patients receiving a 2nd islet infusion|Cumulative number of severe hypoglycaemic events|Change in average daily insulin requirements (absolute decrease from pre-transplant levels and % decrease from pre-transplant levels).|HbA1c % (absolute decrease from pre-transplant levels and % decrease from pre-transplant levels).|Basal (fasting) and 0 to 120 min time course of glucose, C-peptide and insulin derived from the MMTT|β-cell function as assessed by β-score and Transplant Estimated Function (TEF)|Incidence and severity of Adverse Events and Serious Adverse Events|Changes in standard laboratory parameters, as a measure of safety|Changes in vital signs, as a measure of safety|ALT/AST, PT/PTT, fibrin degradation products (XDPs), C-reactive protein (CRP)",Dompé Farmaceutici S.p.A,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,51,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",REP0211|2011-006201-10,Oct-12,Dec-16,Dec-17,26-Mar-13,null,7-Sep-18,"The University of Chicago Medical Center, Department of Surgery, Division of Abdominal Organ Transplantation, Chicago, Illinois, United States|Institute for Clinical and Experimental Medicine (IKEM), Diabetes Centre; Department of Diabetes., Praha, Czechia|Dipartimento di Medicina Interna e Specialistica; IRCCS Ospedale San Raffaele, Milan, Italy|S.S.D. Diabetologia, Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Piazza Ospedale Maggiore 3, Milan, Italy|Transplant Institute - Sahlgrenska University Hospital, Göteborg, Sweden|Department of Nephrology and Transplantation; Skane University Hospital, Malmö, Sweden|Department of Transplantation Surgery; The Karolinska University Hospital, Stockholm, Sweden|Division for Transplantation and Liver Surgery; Department of Surgery; Uppsala University Hospital, Uppsala, Sweden|Institute of Transplantation, Newcastle upon Tyne Hospitals - NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, United Kingdom",,https://ClinicalTrials.gov/show/NCT01817959
NCT01816165,"Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes",AcT1,"Active, not recruiting",No Results Available,Type 1 Diabetes,Drug: Acipimox|Drug: Placebo,Change in Insulin sensitivity: M-value from hyperinsulinemic euglycemia clamp study|Change in 24 hour fatty acid levels (area under the curve)|Change in Percent flow-mediated brachial artery dilation|Change in State 3 mitochondrial oxygen consumption|Change in Oxidative stress and inflammatory markers|Change in Other mitochondrial measures|Change in Heart rate variability|Change in Arterial stiffness (PWV and AI)|Change in Metabolic markers,"University of Colorado, Denver",All,25 Years to 59 Years   (Adult),Phase 3,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",11-0649|6181,Jun-11,Dec-19,Dec-19,22-Mar-13,null,4-Jan-19,"University of Colorado Denver, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT01816165
NCT01813929,Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes,MeT1,"Active, not recruiting",No Results Available,Type 1 Diabetes,Drug: Metformin|Drug: Placebo,"Insulin Sensitivity by hyperinsulinemic euglycemic clamp|Flow-mediated brachial artery dilation|Arterial stiffness|Mitochondrial measures|Metabolic, inflammatory, vascular, and oxidative stress markers|Heart rate variability","University of Colorado, Denver|US Department of Veterans Affairs",All,25 Years to 59 Years   (Adult),Phase 4,100,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",11-0693,Jun-11,Dec-19,Dec-19,19-Mar-13,null,17-Jan-19,"University of Colorado Denver, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT01813929
NCT01811849,Pharmacokinetic and Injection Site Toleration of BIOD-238 and BIOD-250 Compared to Humalog® in Subjects With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Drug: Insulin LISPRO,Time to 1/2 maximal insulin concentration|Time to maximal insulin concentration|Time to 1/2 maximal insulin concentration after peak|Visual analog scale|AUC 0-30 and AUC 0-60,Biodel,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,12,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",4-102,Aug-12,Dec-12,Dec-12,15-Mar-13,null,15-Mar-13,,,https://ClinicalTrials.gov/show/NCT01811849
NCT01808690,EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes,EMERALD,Completed,No Results Available,Type 1 Diabetes,Drug: Metformin|Drug: Placebo,Change in Insulin Function|Change in Mitochondrial Function|Change in Central Vascular Function|Change in Cardiac Function,"University of Colorado, Denver|American Diabetes Association|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",All,"12 Years to 21 Years   (Child, Adult)",Phase 3,52,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",12-1528|R56DK078645,Mar-13,Dec-17,Dec-17,11-Mar-13,null,18-Jul-18,"Children's Hospital Colorado and University of Colorado Denver Health Sciences Center, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT01808690
NCT01805414,Breakfast Nutrition and Inpatient Glycemia,,Completed,No Results Available,"Diabetes, Type 1|Diabetes, Type 2|Cardiovascular Disease|Hyperglycemia",Other: Modified Carbohydrate Breakfast|Other: Control Breakfast,Relative change in Blood sugar,Duke University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,237,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),Pro00031605,Sep-12,Nov-12,Nov-12,6-Mar-13,null,14-Oct-15,"Duke Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01805414
NCT01805700,Effects of Acute Intake of Caffeinated Beverages in Type 1 Diabetes,REDBULL,Completed,No Results Available,Type 1 Diabetes,Other: Caffeine enhanced energy drink|Other: Glucose drink,"Changes in blood glucose level in all patients as a measure of tolerability|The effects on certain mood states, e.g. energetic arousal, tense arousal and hedonic tone following the consumption of caffeinated energy drinks in comparison with caffeine free glucose in patients with type 1 diabetes|Changes in reaction time and digit symbol substitution test score|Changes in heart rate, systolic and diastolic blood pressure in all patients.",The Royal Bournemouth Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Health Services Research",B091217,Jan-10,Jun-11,Jul-11,6-Mar-13,null,6-Mar-13,"The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, Dorset, United Kingdom",,https://ClinicalTrials.gov/show/NCT01805700
NCT01800734,Mixed Meal Test in Type 1 Diabetes: Optimization of Artificial Pancreas-Pilot Study,,Unknown status,No Results Available,Diabetes Mellitus Type 1,Other: Clamp-Mixed Meal Arm,1. Composite plasma glucose and hormone responses to a mixed meal 2. Glucose control coefficients|Composite plasma free fatty and amino acid responses to a mixed meal,Azienda Ospedaliera Universitaria Integrata Verona|Universita di Verona,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),RBonadonna artificial pancreas,Oct-12,Feb-14,Feb-15,28-Feb-13,null,19-Nov-13,"Division of Endocrinology and Metabolic Diseases - University Hospital of Verona-Piazzale Stefani 1, Verona, Italy",,https://ClinicalTrials.gov/show/NCT01800734
NCT01794650,Guidelines for Post-exercise Dietary Intake in T1DM,,Completed,No Results Available,Type 1 Diabetes Mellitus,Dietary Supplement: Meal composition,24 hour blood glucose area under the curve|Ketogenesis,Northumbria University,All,18 Years to 50 Years   (Adult),Not Applicable,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,West-Walker2,Mar-13,Nov-13,Nov-13,20-Feb-13,null,15-Nov-13,"Clinical Research Facility, Royal Victoria Infirmary, Newcastle upon Tyne, Tyne and Wear, United Kingdom",,https://ClinicalTrials.gov/show/NCT01794650
NCT01791907,Effect of Structured Nutrition Education in Type 1 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Behavioral: Structured education in carbohydrate counting|Behavioral: Structured education in healthy food choices and low glycemic index,HbA1c|Quality of life|CVD risk factors|Hypoglycemia|Food choices|Health economics,Göteborg University,All,"20 Years to 70 Years   (Adult, Older Adult)",Not Applicable,181,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EPN 304-12,Feb-13,Dec-14,Jul-17,15-Feb-13,null,5-Nov-18,,,https://ClinicalTrials.gov/show/NCT01791907
NCT01792284,A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus,IMAGINE 7,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: LY2605541|Drug: Insulin Lispro,"Hemoglobin A1c (HbA1c) at 12 Weeks|30-Day Adjusted Rate of Total and Nocturnal Hypoglycemic Events|Percentage of Participants With Total and Nocturnal Hypoglycemic Events|Fasting Blood Glucose (FBG) Measured by Self-Monitored Blood Glucose|Intra-Participant Variability of FBG at 12 Weeks|Fasting Serum Glucose (FSG) at 12 Weeks|Change From Randomization to 12 Weeks in 9-Point SMBG|Self-Monitored Blood Glucose (SMBG) at 12 Weeks|Intra-participant Variability in SMBG at 12 Weeks|Change From Randomization to 12 Weeks in Body Weight|Change From Day 1 of Lead-In Period to 36 Weeks in Body Weight|Change From Randomization to 12 Weeks in HbA1c|Participants With Treatment-Emergent Anti-LY2605541 Antibody Response|Basal, Bolus, and Total Insulin Doses at 12 Weeks|Proportion of Bolus to Total Insulin Doses at 12 Weeks|0300-Hour Blood Glucose to Fasting Blood Glucose Excursion|Change From Day 1 of Lead-in to 36 Weeks in Triglycerides, Total Cholesterol, Low-Density Lipoprotein Cholesterol (LDL-C), and High-Density Lipoprotein Cholesterol (HDL-C)|Percentage of Participants With HbA1c <7.0% and ≤6.5% at 12 Weeks",Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,212,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14184|I2R-MC-BIAX,Feb-13,Apr-14,Apr-14,15-Feb-13,20-Apr-18,20-Apr-18,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Concord, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Escondido, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fresno, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tustin, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aurora, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roswell, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Idaho Falls, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Crystal Lake, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Des Moines, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Topeka, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greer, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chattanooga, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Round Rock, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bayamon, Puerto Rico",,https://ClinicalTrials.gov/show/NCT01792284
NCT01792323,Absorption of Insulin Following Subcutaneous Bolus Administration With Different Bolus Durations,,Completed,No Results Available,Type 1 Diabetes,Drug: Insulin LISPRO,"tmax(GIR); time to maximum glucose infusion rate|GIRmax, maximum glucose infusion rate",Medical University of Graz|European Commission,All,18 Years to 60 Years   (Adult),Phase 1,20,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,CIPHER-Clamp,Aug-11,Nov-11,Jan-14,15-Feb-13,null,26-Feb-14,"Medical University of Graz, Graz, Styria, Austria",,https://ClinicalTrials.gov/show/NCT01792323
NCT01789593,A Trial Investigating the Effect of Acute Hypoglycaemia on Cognitive Function and Brain Activation Patterns in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Other: glucose clamp,Digit Symbol Substitution Test (DSST) score|Regional cerebral blood flow (rCBF) score|Paced Auditory Serial Addition Task (PASAT) score,Novo Nordisk A/S,All,18 Years to 64 Years   (Adult),Phase 1,29,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,NN1250-4001|U1111-1131-8749,14-Jan-13,1-Dec-13,1-Dec-13,12-Feb-13,null,12-Jan-18,"Novo Nordisk Investigational Site, Århus C, Denmark",,https://ClinicalTrials.gov/show/NCT01789593
NCT01789957,Extension Study for 2993-112,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: AC2993,Change in HbA1c from Day 1 of Protocol 2993-112 to Week 52 (or termination)|Change in body weight from Day 1 of Protocol 2993-112 to Week 52 (or termination),AstraZeneca,All,"16 Years to 75 Years   (Child, Adult, Older Adult)",Phase 3,225,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2993-112E,Sep-02,Jun-04,Jun-04,12-Feb-13,null,24-Feb-15,"Pinnacle Research Group, Anniston, Alabama, United States|Parkway Medical Center, Birmingham, Alabama, United States|Alabama Clinical Therapeutics, Birmingham, Alabama, United States|Eclectic Family Care, Eclectic, Alabama, United States|Winston Physician Services, Haleyville, Alabama, United States|Simon Williamson Clinic, Hueytown, Alabama, United States|Extended Arm Physicians/ Southern Drug, Montgomery, Alabama, United States|Southern Drug Research Network, Tallassee, Alabama, United States|Mesa Center for Clinical Research, Chandler, Arizona, United States|Clinic of Physicians and Surgeons, Ltd., Mesa, Arizona, United States|ANA Ventures, LLC, Mesa, Arizona, United States|Lovelace Scientific Resources, Phoenix, Arizona, United States|Physicians at the Peak, Phoenix, Arizona, United States|Advanced Clinical Therapeutics, Tucson, Arizona, United States|First Care Family Doctors, Fayetteville, Arkansas, United States|CAVHS, Little Rock, Arkansas, United States|Physicians Group Research Clinic, LLC, Little Rock, Arkansas, United States|Advanced Clinical Research Institute, Anaheim, California, United States|Endocrine Metabolic Medical Center, Atherton, California, United States|Mitchell Research Group, Inc., Bakersfield, California, United States|William Zigrang, M.D., Burlingame, California, United States|International Clinical Research Network, Chula Vista, California, United States|Arrowhead Regional Medical Center, Colton, California, United States|East Bay Clinical Trial Center, Concord, California, United States|Medical Group of Encino, Encino, California, United States|Mowry Clinical Research, Fremont, California, United States|SARC Research Center, Fresno, California, United States|Valley Research, Fresno, California, United States|Irvine Clinical Research Center, Irvine, California, United States|Whittier Institute for Diabetes, La Jolla, California, United States|Harriman Jones Medical Group, Long Beach, California, United States|Richard Cherlin, M.D., Los Gatos, California, United States|Tushar Modi, M.D., Modesto, California, United States|Dr. Martinez Medical Clinic, Moreno Valley, California, United States|Arroyo Seco Medical Group, Pasadena, California, United States|Elke Jost-Vu, M.D., Rancho Mirage, California, United States|Comprehensive Diabetes-Endocrine Medical Associates, Redwood City, California, United States|nTouch, San Diego, California, United States|Radiant Research, San Diego, California, United States|San Diego Endocrine and Medical Clinic, San Diego, California, United States|Veterans Medical Research Foundation, San Diego, California, United States|Diabetes Research Institute of Mills Peninsula, San Mateo, California, United States|Advanced Clinical Research Institute, Santa Ana, California, United States|Pacific Clinical Research, Santa Monica, California, United States|West Coast Clinical Trials, Signal Hill, California, United States|Protocare Trials at Sharp Mission Park, Vista, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|University of Colorado-Barbara Davis Center for Childhood Diabetes, Denver, Colorado, United States|Pheonix International Medicine Associates, Waterbury, Connecticut, United States|Health Core at Health Care Center Christiana, Newark, Delaware, United States|Medstar Clinical Research, Washington, District of Columbia, United States|George Washington University, Washington, District of Columbia, United States|Morton Plant Mease Health Care, Clearwater, Florida, United States|Clinical Research of West Florida, Inc., Clearwater, Florida, United States|Atlantic Institute of Clinical Research, Daytona Beach, Florida, United States|Halifax Clinical Research Institute, Daytona Beach, Florida, United States|Internal Medical Associates, Ft. Myers, Florida, United States|Clin Sci International, Gainesville, Florida, United States|University of FL, Gainesville, Florida, United States|South Florida Clinical Research Center, Hollywood, Florida, United States|Health Trials 3000, Jacksonville, Florida, United States|Jupiter Research Institute, Jupiter, Florida, United States|ICSL Clinical Studies, Maitland, Florida, United States|Baptist Diabetes Associates, Miami, Florida, United States|Suncoast Clinical Research, New Port Richey, Florida, United States|VRG Research, Orlando, Florida, United States|Highland Lakes Medical Center, Palm Harbor, Florida, United States|Tallahassee Endocrine Associates, Tallahassee, Florida, United States|Biostator / USF Diabetes Center, Tampa, Florida, United States|Tampa Medical Group, Tampa, Florida, United States|Diabetes and Endocrine Associates of the Treasure Co, Vero Beach, Florida, United States|Metabolic Research Institute, Inc., West Palm Beach, Florida, United States|Radiant Research, West Palm Beach, Florida, United States|ICSL-Clinical Studies, Atlanta, Georgia, United States|Clinical Research Atlanta, Atlanta, Georgia, United States|Columbus Metabolic Foundation, Columbus, Georgia, United States|nTouch Research Corporation, Decatur, Georgia, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|Radiant Research, Honolulu, Hawaii, United States|St. Luke's Family Health, Meridian, Idaho, United States|University Primary Care Center at Belvidere, Belvidere, Illinois, United States|Northwestern Memorail Physicians Group, Chicago, Illinois, United States|Illinois Center for Clinical Trials, Chicago, Illinois, United States|Cook County Hospital, Chicago, Illinois, United States|Lake Forest Internal Medicine, Libertyville, Illinois, United States|Winchester Research Group, Libertyville, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Springfield Diabetes and Endocrinology, Springfield, Illinois, United States|Medical Group of Fort Wayne, Fort Wayne, Indiana, United States|Indiana University Outpatient Clinical Research, Indianapolis, Indiana, United States|American Health Network, Indianapolis, Indiana, United States|Center for Metabolic and Hormonal Disorders, Indianapolis, Indiana, United States|nTouch Research Corporation, South Bend, Indiana, United States|Ramona Holiday Diabetes Center, Des Moines, Iowa, United States|Diabetes Clinical Research and Programs, Iowa City, Iowa, United States|Lipid, Atherosclerosis & Metabolic Clinic, Kansas City, Kansas, United States|Kentucky Diabetes Center, Lexington, Kentucky, United States|Central Kentucky Research Associates, Lexington, Kentucky, United States|University of Kentucky Metabolic Research Group, Lexington, Kentucky, United States|MedResearch, Inc., Louisville, Kentucky, United States|Drug Research Services, Metairie, Louisiana, United States|New Orleans Institute of Clinical Investigation, New Orleans, Louisiana, United States|New Orleans Center for Clinical Research, New Orleans, Louisiana, United States|Ochsner Clinic, New Orleans, Louisiana, United States|Diabetes, Endocrine and Nutrition Center, Bangor, Maine, United States|VA Medical Center, Baltimore, Maryland, United States|St. Agnes Health Care, Baltimore, Maryland, United States|Doctors Research Associates of Maryland, Lanham, Maryland, United States|University of Michigan-Endocrinology and Metabolism, Ann Arbor, Michigan, United States|Grunberger Diabetes Medical Center, Bloomfield Hills, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Grand Rapids Associated Interns, Grand Rapids, Michigan, United States|Westside Family Medical Center, Kalamazoo, Michigan, United States|Mayo Clinic, Division of Endocrinology and Metabolism, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Diabetes and Endocrinology Specialists, Chesterfield, Missouri, United States|Medical Arts Research Collaborative, Excelsior Springs, Missouri, United States|St Lukes Lipid and Diabetes Research Center, Kansas City, Missouri, United States|Mid Missouri Research Specialists, Inc., Rolla, Missouri, United States|St. Louis Center for Clinical Research, St. Louis, Missouri, United States|Radiant Research, St. Louis, Missouri, United States|Midwest Pharmaceutical Research, St. Peters, Missouri, United States|Mercury Street Medical, Butte, Montana, United States|Creighton Diabetes Center, Omaha, Nebraska, United States|Lovelace Scientific Resources, Las Vegas, Nevada, United States|ICSL, Las Vegas, Nevada, United States|Endocrinology and Diabetes Consultants, P.C., Dover, New Hampshire, United States|HIS Clinical Research, Jersey City, New Jersey, United States|Radiant Research, Moorestown, New Jersey, United States|Matrix Research Institute, Mt. Laurel, New Jersey, United States|New Jersey Physicians, Passaic, New Jersey, United States|Anderson and Collins Clinical Research, Inc., South Plainfield, New Jersey, United States|Lovelace Scientific Resources, Albuquerque, New Mexico, United States|Albert Einstein College of Medicine of Yeshiva University, Bronx, New York, United States|SUNY Downstate, Brooklyn, New York, United States|Medical Network Services, P.C., Brooklyn, New York, United States|Winthrop University Hospital, Mineola, New York, United States|St. Lukes Roosevelt Hospital, New York, New York, United States|Irving Diabetes Research Unit at Columbia University, New York, New York, United States|Naomi Berrie Diabetes Center at Columbia University, New York, New York, United States|Heights Medical Care, New York, New York, United States|Rochester Clinical Research, Rochester, New York, United States|DOCS at Beth Israel Medical Center, Yonkers, New York, United States|Metrolina Medical Research, Charlotte, North Carolina, United States|Charlotte Clinical Research, Charlotte, North Carolina, United States|UNC Diabetes Care Center, Durham, North Carolina, United States|Unifour Medical Research, Hickory, North Carolina, United States|New Hanover Medical Research Associates, Wilmington, North Carolina, United States|Piedmont Medical Research, Winston-Salem, North Carolina, United States|Rapid Medical Research, Cleveland, Ohio, United States|Ohio State University-Division of Endocrinology, Columbus, Ohio, United States|Radiant Research, Columbus, Ohio, United States|University Mednet, Mentor, Ohio, United States|Comprehensive Research Services, Inc., Mogadore, Ohio, United States|North Coast Institute of Diabetes and Endocrinology, Westlake, Ohio, United States|Prime Care Clinical Research, Clinton, Oklahoma, United States|COR Clinical Research, Oklahoma City, Oklahoma, United States|OU Health Sciences Center, Oklahoma City, Oklahoma, United States|nTouch Research Corporation, Oklahoma City, Oklahoma, United States|Utica Park Clinic, Tulsa, Oklahoma, United States|Americas Doctors, Medford, Oregon, United States|Medford Medical Clinic, Medford, Oregon, United States|Radiant Research, Portland, Oregon, United States|Portland Diabetes and Endocrinology Center, Portland, Oregon, United States|Pacific Coast Clinical Coordinators, Inc., Portland, Oregon, United States|Legacy Clinical Research, Portland, Oregon, United States|Physicians for Clinical Research, Camp Hill, Pennsylvania, United States|Argus Research Laboratories, Horsham, Pennsylvania, United States|Thomas Jefferson University Diabetes Research Center, Philadelphia, Pennsylvania, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States|Philadelphia Health Associates, Philadelphia, Pennsylvania, United States|Elite Medical Research, Inc., Sellersville, Pennsylvania, United States|Tipton Medical and Diagnostic Center, Tipton, Pennsylvania, United States|Safe Harbor Clinical Research, East Providence, Rhode Island, United States|ICSL-Providence, East Providence, Rhode Island, United States|Radiant Research, Charleston, South Carolina, United States|CNS Clinical Trials, Chester, South Carolina, United States|Coastal Carolina Research Center, Mt. Pleasant, South Carolina, United States|Tennessee Valley Clinical Research Associates, Alcoa, Tennessee, United States|Integrity Clinical Research, Jackson, Tennessee, United States|Harmony Clinical Research, Johnson City, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|Endocrine Consultants of ET, Knoxville, Tennessee, United States|The Endocrine Clinic, Memphis, Tennessee, United States|Integrity Clinical Research, Milan, Tennessee, United States|Mid State Endocrine Associates, Nashville, Tennessee, United States|Israel A. Hartman, M.D., Arlington, Texas, United States|Central Texas Clinical Research, Austin, Texas, United States|Dallas Diabetes and Endocrinology Research Center, Dallas, Texas, United States|Rafael Canadas M.D., P.A., Dallas, Texas, United States|Texas Tech University Health Sciences-Internal Medicine, El Paso, Texas, United States|Internal Medicine Associates, El Paso, Texas, United States|Lanier Education Research Network, Fort Worth, Texas, United States|North Texas Clinical Research, Irving, Texas, United States|Dr. Humberto Bruschetta, Kingsville, Texas, United States|R/D Clinical Research, Inc., Lake Jackson, Texas, United States|South Texas Applied Research, McAllen, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|University of Texas Health Sciences Center-Texas Diabetes Institute, San Antonio, Texas, United States|Diabetes and Glandular Disease Clinic, San Antonio, Texas, United States|SAM Clinical Research, San Antonio, Texas, United States|Utah Diabetes Center at the University of Utah, Salt Lake City, Utah, United States|Salt Lake Research, Salt Lake City, Utah, United States|Medical Associates of Northern Virginia, Arlington, Virginia, United States|Clinical Research Center-Eastern Virginia Medical School, Norfolk, Virginia, United States|Drs. Wigand, Wasserman, and Associates, Richmond, Virginia, United States|Evergreen Diabetes & Endocrinology, Kirkland, Washington, United States|Olympic Medical Services, Lacey, Washington, United States|West Olympia Internal Medicine, Olympia, Washington, United States|Rainier Clinical Research Center, Renton, Washington, United States|Northside Internal Medicine, Spokane, Washington, United States|Rockwood Clinic, Spokane, Washington, United States|Julia M. Hutchinson, M.D., Spokane, Washington, United States|Wenatchee Valley Clinic, Wenatchee, Washington, United States|Hyperion Clinical Research, Charleston, West Virginia, United States|CAMC Clinical Trials Center, Charleston, West Virginia, United States|University of Wisconsin West Clinic, Madison, Wisconsin, United States|Midwest Endocrinology Associates, Milwaukee, Wisconsin, United States|VRG Research, Milwaukee, Wisconsin, United States|Calgary Metabolic Education and Research Center, Calgary, Alberta, Canada|Walter McKenzie Health Sciences Centre, Edmonton, Alberta, Canada|St. Paul's Hospital, Research Services, Vancouver, British Columbia, Canada|Health Sciences Center, Winnipeg, Manitoba, Canada|University of Western Ontario, London, Ontario, Canada|McGill Nutrition and Food Science Center, Montreal, Quebec, Canada|Centre Hospitalier, Ste. Foy, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01789957
NCT01787903,The Effects of RT-CGM on Glycemia and QoL in Patients With T1DM and IHA,INCONTROL,Completed,No Results Available,Type 1 Diabetes Mellitus|Hypoglycemia Unawareness,Device: Real-time continuous glucose monitor,Time spent in the euglycemic range|Quality of life|Glycemia variables|Hypoglycemic episodes|Changes in hypoglycemia awareness score,VU University Medical Center|Eli Lilly and Company,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,52,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DC2012INCONTROL01,Feb-13,Apr-16,Apr-16,11-Feb-13,null,26-Jul-17,"VU University Medical Center, Amsterdam, Noord-Holland, Netherlands",,https://ClinicalTrials.gov/show/NCT01787903
NCT01787916,52 Week Trial of Liraglutide in Type 1 Diabetes,LIDO,Completed,Has Results,Type 1 Diabetes,Drug: Liraglutide|Drug: Placebos,Assessment of Changes in Glycemic Control by HbA1c.|Assessment of Changes on Adipose Tissue,CHU de Quebec-Universite Laval|Novo Nordisk A/S,All,18 Years to 50 Years   (Adult),Phase 4,15,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2013LIDO,Apr-13,Apr-15,Apr-15,11-Feb-13,5-Jan-18,5-Jan-18,"CHU de Québec, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01787916
NCT01788033,Effects of XOMA 052 on Insulin Production in Type 1 Diabetes,LATE STAGE,Completed,No Results Available,Diabetes Mellitus Type 1,Drug: XOMA 052|Drug: Placebo,"C-peptide level|Change in insulin requirements|HbA1c levels|fasting glucose|fasting glucagon|cortisol|markers of systemic inflammation (Interleukin-6, Interleukin-8, Tumor Necrosis Factor α, hs-CRP)|adipokines|meal-stimulated Glucagon like peptide-1|meal-stimulated gastric inhibitory polypeptide|lipids profile|Change in fatigue according to the Fatigue Scale for Motor and Cognitive Functions (FSMC) questionnaire|Anti XOMA 052 Antibodies|Number of Adverse Events",University of Zurich|XOMA (US) LLC,All,18 Years to 55 Years   (Adult),Phase 2,22,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",EK-189/10,Sep-09,Sep-13,Sep-13,11-Feb-13,null,11-Feb-14,"University Hospital Basel, Basel, Switzerland",,https://ClinicalTrials.gov/show/NCT01788033
NCT01788527,Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial,CONCEPTT,Completed,No Results Available,Type 1 Diabetics Who Are Pregnant or Planning Pregnancy,Device: CGM,"Glycemic Control in pre-pregnant group|Glycemic Control in pregnant group|Time in target in pre-pregnant group|HbA1c and time in target, in pre-pregnant group who became pregnant within 24 weeks from randomization|Time in target in pregnant group|HbA1c measurement in pregnant group|Hypertension in pregnant group|Caesarean sections in pregnant group|Gestational weight gain in pregnant group|AUC|Incidence of Clinical events|Glucose variability|Hospital stay|Infant Outcomes|Infant outcomes|Insulin requirements|Questionnaires|Study Contacts","Mount Sinai Hospital, Canada|Sunnybrook Research Institute|Jaeb Center for Health Research|Cambridge University Hospitals NHS Foundation Trust|University of Cambridge",Female,18 Years to 40 Years   (Adult),Not Applicable,325,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12-0037-A,Mar-13,Mar-16,Mar-16,11-Feb-13,null,19-Jul-17,"Sansum Diabetes Research Institute, Santa Barbara, California, United States|Alberta Health Services - Calgary Zone, Calgary, Alberta, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|McMaster University, Hamilton, Ontario, Canada|Kingston General Hospital, Kingston, Ontario, Canada|St Joseph's Health Care, London, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|St-Luc Hospital- Centre hospitalier de L'Universite de Montreal, Montreal, Quebec, Canada|Chuq-Chul, Quebec City, Quebec, Canada|Royal University Saskatoon, Saskatoon, Saskatchewan, Canada|Galway University Hospital, Galway, Ireland|Niguarda Ca' Granda Hospital, Milan, Italy|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|University of Aberdeen, Aberdeen, Scotland, United Kingdom|Royal Infirmary of Edinburgh, Edinburgh, Scotland, United Kingdom|Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom|Russells Hall Hospital, Dudley, West Midlands, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|Ipswich Hospital NHS Trust, Ipswich, United Kingdom|St James University Hospital, Leeds, United Kingdom|Guys & St. Thomas', London, United Kingdom|Kings College Hospital, London, United Kingdom|Manchester University Hospital NHS Trust, Manchester, United Kingdom|South Tees Hospital NHS Trust, Middlesbrough, United Kingdom|Royal Victoria Infirmary, Newcastle, United Kingdom|Norfolk and Norwich University Hospital, Norwich, United Kingdom|Queen's Medical Centre, Nottingham, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom|Princess Anne Hospital, Southampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT01788527
NCT01787318,Effect of the InsuPatch on Automated Closed-loop Glucose Control in Type 1 Diabetes,IPCL,Completed,No Results Available,Type 1 Diabetes,Device: ePID closed loop system|Device: InsuPatch,Peak Post-Prandial Glucose Excursions|Total Area Under Curve of the meal-related glucose excursion over target|Nadir glucose levels following the meals|Mean 24 hour glucose levels|Mean daytime and nighttime glucose levels|Peak post-prandial insulin levels following meals|Area Under Curve meal-related insulin excursion following meals,Yale University,All,"12 Years to 40 Years   (Child, Adult)",Early Phase 1,10,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HIC # 1208010682,Jan-13,Sep-14,Dec-15,8-Feb-13,null,14-Apr-16,"Yale University School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01787318
NCT01785108,DIABGAD - Trial to Preserve Insulin Secretion in Type 1 Diabetes Using GAD-Alum (Diamyd) in Combination With Vitamin D and Ibuprofen,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Biological: GAD-Alum (Diamyd) 20 µg|Biological: GAD-Alum (Diamyd) 20 µg X 2|Drug: Vitamin D|Drug: Ibuprofen,"Change in C-peptide (90 minute value and AUC mean 0-120 min) during a Mixed Meal Tolerance Test from baseline to month 6, 15 and 30|Proportion of patients with a stimulated maximum C-peptide level above 0.2 nmol/L|Hemoglobin A1c (HbA1c), change between baseline and subsequent visits|Exogenous insulin dose per kg body weight and 24 hours, change between baseline and subsequent visits|Th2-deviation of cell-mediated immune response seen, e.g. as increased ratio of IL-5, 10, 13 in comparison with IFN-gamma, TNF-alfa, IL-1 beta, IL-17, and increase of T-regulatory cells|Decrease in inflammatory markers, e.g. TNF-alfa, IL-1 beta, IL-2, IL-17|Fasting C-peptide, change between baseline and month 6, 15 and 30",Johnny Ludvigsson|Swedish Child Diabetes Foundation|The Research Council of South East Sweden (FORSS)|Diamyd Medical AB|Linkoeping University,All,"10 Years to 18 Years   (Child, Adult)",Phase 2,60,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DIABGAD-1,Feb-13,Mar-17,Mar-17,7-Feb-13,null,23-Aug-17,"Halmstad Hospital, Halmstad, Sweden|Astrid Lindgren Children's Hospital - Huddinge, Huddinge, Sweden|Kalmar Hospital, Kalmar, Sweden|Linköping University, Linköping, Sweden|Lund University Hospital, Lund, Sweden|Skåne University Hospital, UMAS, Malmö, Sweden|Sachsska, Södersjukhuset, Stockholm, Sweden|Astrid Lindgren Children's Hospital, Stockholm, Sweden|Uddevalla Hospital, Uddevalla, Sweden|Örebro University Hospital, Örebro, Sweden",,https://ClinicalTrials.gov/show/NCT01785108
NCT01785771,A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c,,Terminated,No Results Available,Type 2 Diabetes,Drug: ITCA 650 (exenatide in DUROS),Change in HbA1c between Week 39 and Day 0,Intarcia Therapeutics,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,100,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ITCA 650-CLP-103-Sub-Study,May-13,Jan-18,Jan-18,7-Feb-13,null,7-Mar-19,"Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States|Fundamental Research, Gulf Shores, Alabama, United States|East Valley Family Physicians, PLC, Chandler, Arizona, United States|Desert Clinical Research, Mesa, Arizona, United States|Clinical Research Advantage, Inc., Phoenix, Arizona, United States|eStudySite, Chula Vista, California, United States|Rocks Medical Research Institute, Inc., Fresno, California, United States|Rocks Medical Research Institute, Fresno, California, United States|Long Beach Center for Clinical Research, Long Beach, California, United States|Saviers Medical Group, Port Hueneme, California, United States|University Clinical Investigatons, Inc/Diabetes Research Center, Tustin, California, United States|Diablo Clinical Research, Inc., Walnut Creek, California, United States|Colorado Springs Health Partners-Briargate, Colorado Springs, Colorado, United States|Meridien Research, Bradenton, Florida, United States|East Coast Institute for Research, LLC, Jacksonville, Florida, United States|New Horizon Research Center, Inc., Miami, Florida, United States|International Research Assocaites, LLC, Miami, Florida, United States|Harmony Clinical Research, Inc., North Miami Beach, Florida, United States|Palm Harbor Medical Associates, Palm Harbor, Florida, United States|Andres Patron, D.O., P.A., Pembroke Pines, Florida, United States|Clinical Research of West Florida, Tampa, Florida, United States|Perimeter Institute for Clinical Research PRIME, Atlanta, Georgia, United States|Solaris Clinical Research, Meridian, Idaho, United States|Chicago Research Center, Chicago, Illinois, United States|American Health Network of Indiana, LLC, Avon, Indiana, United States|Medisphere Medical Research Center, LLC, Evansville, Indiana, United States|American Health Network of Indiana, Franklin, Indiana, United States|American Health Network of Indiana, LLC, Muncie, Indiana, United States|Bunyan Clinical Research, Valparaiso, Indiana, United States|Crescent City Clinical Research Center, Metairie, Louisiana, United States|Palm Research Center, Inc., Las Vegas, Nevada, United States|PMG Research of Charlotte, LLC, Charlotte, North Carolina, United States|University of North Carolina at Chapel Hill, Durham, North Carolina, United States|PMG Research of Salisbury, LLC, Salisbury, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Sentral Clinical Research Services, LLC, Cincinnati, Ohio, United States|Columbus Clinical Research, Columbus, Ohio, United States|Prestige Clinical Research, Franklin, Ohio, United States|Lynn Institute of Norman, Norman, Oklahoma, United States|Preferred Primary Care Physicians, Uniontown, Pennsylvania, United States|Greer, South Carolina, United States|BMG The Endocrine Clinic, Memphis, Tennessee, United States|Tekton Research, Inc., Austin, Texas, United States|3rd Coast Research Associates, Corpus Christi, Texas, United States|Dallas Diabetes and Endocrine Center, Dallas, Texas, United States|Galena Research, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Medstar Clinical Research and Associates, Houston, Texas, United States|Clinical Trials of Texas, Inc., San Angelo, Texas, United States|Sound Healthcare, Port Orchard, Washington, United States|Ranier Clinical Research Center, Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT01785771
NCT01784211,A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: LY2605541|Drug: Insulin Glargine,Part A: Pharmacokinetics: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUCτ) of LY2605541 and Insulin Glargine: Intra-Participant Variability|Part A: Pharmacokinetics: Maximum Drug Concentration (Cmax) of LY2605541 and Insulin Glargine: Intra-Participant Variability|Part A: Pharmacodynamics: Total Amount of Glucose Infused Over the Duration of the Clamp (Gtot): Intra-Participant Variability|Part B: Pharmacokinetics: AUCτ of LY2605541 and Insulin Glargine: Exercise Versus Non-Exercise|Part B: Pharmacokinetics: Cmax of LY2605541 and Insulin Glargine: Exercise Versus Non-Exercise,Eli Lilly and Company,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,76,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,14183|I2R-MC-BIAW,Feb-13,Nov-13,Nov-13,5-Feb-13,15-Mar-19,15-Mar-19,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01784211
NCT01782547,Telehealth Intervention for Youth With T1DM,,Completed,No Results Available,Type 1 Diabetes Mellitus,Behavioral: Telehealth Intervention|Other: Usual Care,Change in Hemoglobin A1c|% patients meeting ADA HbA1c target|Diabetes-related adverse events|Change in Diabetes self-efficacy|Change in Adherence to diabetes self-management|Change in competence with diabetes skills|Change in Health related quality of life|Change in Diabetes Knowledge,Boston Children’s Hospital,All,13 Years to 17 Years   (Child),Not Applicable,32,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P00006175,Jun-13,May-14,May-14,4-Feb-13,null,15-Aug-16,"Boston Children's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01782547
NCT01783327,Teens-Connect: Preventive Psycho-education for Transitioning Teens With Diabetes,TeensConnect,Completed,No Results Available,"Diabetes Mellitus, Type 1",Behavioral: Teens-Connect|Behavioral: Planet D,Change from baseline hemoglobin A1c over 12 months|Change from baseline quality of life over 12 months|Change from baseline coping/Stress over 12 months|Change from baseline self-efficacy over 12 months|Change from baseline problem-solving over 12 months|Change from baseline self-management over 12 months|Costs|Change from baseline quality adjusted life years over 12 months,Yale University|American Diabetes Association,All,11 Years to 14 Years   (Child),Not Applicable,124,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",1112009416,Jul-12,May-15,Aug-15,4-Feb-13,null,8-Jan-16,"Yale University School of Nursing, New Haven, Connecticut, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01783327
NCT01781533,Study to Test Software Algorithm for Insulin Therapy and New Glucose Sensor,,Completed,No Results Available,Diabetes,Procedure: algorithm,the percentage of glucose values obtained every 15 min in predefined glucose ranges|Injected insulin dose|Accuracy of the glucose monitoring unit,Medical University of Graz,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,REACTbyALGO-1,Jan-13,Jan-15,Jan-15,1-Feb-13,null,18-Mar-15,"Medical University of Graz, Graz, Styria, Austria",,https://ClinicalTrials.gov/show/NCT01781533
NCT01781884,Effects Of Gamma Aminobutyric Acid On The Progression Of New Onset Juvenile Type 1 Diabetes,,Unknown status,No Results Available,Type 1 Diabetes,Drug: Gamma Aminobutyric Acid (GABA)|Drug: Placebo,C-peptide value|HbA1C level,Huashan Hospital,All,"5 Years to 21 Years   (Child, Adult)",Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2012-024,Jan-13,Dec-14,Dec-14,1-Feb-13,null,1-Feb-13,"Department of Endocrinology and Metabolism，Huashan hospital, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT01781884
NCT01781975,Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus,,Completed,Has Results,"Diabetes Mellitus, Type I|Diabetes Mellitus, Insulin-Dependent, 1|Type 1 Diabetes Mellitus|Insulin-Dependent Diabetes Mellitus 1|IDDM",Drug: Imatinib Mesylate|Drug: Placebo (For imatinib mesylate),Area Under the Stimulated C-peptide Curve (AUC) Mean Over the First 2 Hours of a 4 Hour Mixed Meal Tolerance Test at the 1 Year Visit|Area Under the Stimulated C-peptide Curve (AUC) Mean Over 4 Hours at 24 Months|Change in HbA1c Levels Over Time|Change in Insulin Dose (Units/kg) Over Time|Number of Severe Hypoglycemic Events|Number and Severity of Adverse Events,"University of California, San Francisco|Juvenile Diabetes Research Foundation",All,18 Years to 45 Years   (Adult),Phase 2,67,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",17-2013-6,Jan-14,May-17,May-18,1-Feb-13,8-Aug-18,28-Sep-18,"University of California-San Francisco, San Francisco, California, United States|Barbara Davis Center, Aurora, Colorado, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Texas Southwestern, Dallas, Texas, United States|Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT01781975/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01781975
NCT01782261,Incretin Effect on the Immunological Phenotype,,Completed,No Results Available,Type 1 Diabetes,Drug: Liraglutide|Drug: Saxagliptin,Increase of regulatory FOXP3+ T cells|Immunophenotyping,Medical University of Graz,All,18 Years to 50 Years   (Adult),Phase 2,15,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ADPP004|2011-006300-12,Feb-12,Feb-15,Feb-15,1-Feb-13,null,11-Oct-16,"Medical University Graz, Graz, Austria",,https://ClinicalTrials.gov/show/NCT01782261
NCT01778348,Closing the Loop in Children and Adolescents With Type 1 Diabetes in the Home Setting,APCam08,Completed,No Results Available,"Diabetes Mellitus|Diabetes Mellitus, Type 1|Glucose Metabolism Disorders|Endocrine System Diseases|Autoimmune Diseases",Device: Overnight closed-loop|Device: Real-time CGM alone,"Time spent overnight in the target glucose range (3.9 to 8.0 mmol/l), as assessed by adjusted continuous subcutaneous glucose monitoring (CGM)|The proportion of nights when glucose levels drop below 3.5 mmol/l for 20 minutes or longer, as recorded by CGM|Time spent above and below the target glucose (3.9 to 8.0 mmol/l) based on CGM.|The time with glucose levels in the significant hyperglycaemia range (glucose levels > 16.7 mmol/l) as recorded by CGM|Metabolic control assessed by HbA1c|Average and standard deviation of glucose levels, as recorded by CGM|The time with glucose levels < 3.5 mmol/l as recorded by CGM.|The time with glucose levels in the widened target range, as recorded by CGM (glucose levels ≥ 3.9mmol/l to ≤ 10.0mmol/l )|Low Blood Glucose Index (LBGI), as recorded by CGM.|Standard deviation of the glucose rate of change, as recorded by CGM.|Overnight insulin dose|Total daily insulin dose|Episodes of symptomatic hypoglycaemia",University of Cambridge|Cambridge University Hospitals NHS Foundation Trust|University College London Hospitals|The Leeds Teaching Hospitals NHS Trust,All,"6 Years to 18 Years   (Child, Adult)",Phase 2,29,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APCam08,Dec-13,Mar-15,May-15,29-Jan-13,null,3-Mar-17,"University of Cambridge, Cambridge, United Kingdom|Leeds Teaching Hospitals, Leeds, United Kingdom|University College London Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01778348
NCT01775059,Collection of Performance Data From the Integrated Sensor and Infusion Set. TRIAL 4,,Unknown status,No Results Available,Diabetes Mellitus Type I|Diabetes Mellitus Type II,Device: Integrated sensor and infusion set.,Accuracy endpoint|Safety endpoint,Medtronic Diabetes R&D Denmark,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CEP 277|2012102304,Mar-13,Jul-13,null,24-Jan-13,null,5-Feb-13,"Fredericia Hospital, Fredericia, Denmark|Hilleroed Hospital, Hilleroed, Denmark|Hvidovre Hospital, Hvidovre, Denmark",,https://ClinicalTrials.gov/show/NCT01775059
NCT01773668,Feasibility Study - Integrated Sensor and Infusion Set. Trial III,,Completed,No Results Available,Type 1 Diabetes|Type 2 Diabetes,Device: Integrated sensor and infusion set.,Performance data|Performance characteristics|Functionality|Longevity|skin impact|Physical duration,Medtronic Diabetes R&D Denmark,All,"21 Years to 70 Years   (Adult, Older Adult)",Not Applicable,17,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CEP 271,Nov-12,Jan-13,Jan-13,23-Jan-13,null,5-Feb-13,"Skåne University Hospital, Department of Endokrinology, Malmö, Sweden",,https://ClinicalTrials.gov/show/NCT01773668
NCT01773707,CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1,,Recruiting,No Results Available,Abnormal Glucose Tolerance|Type 1 Diabetes,Drug: CTLA4-Ig (Abatacept)|Drug: Placebo,Change from Normal Glucose Tolerance to Abnormal Glucose Tolerance|Change in C-peptide response to Oral Glucose Tolerance Test (OGTT),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Juvenile Diabetes Research Foundation,All,"6 Years to 45 Years   (Child, Adult)",Phase 2,206,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",Abatacept (IND)|UC4DK106993|UC4DK117009,Mar-13,Nov-20,Nov-20,23-Jan-13,null,14-May-19,"University of California - San Francisco, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver, Colorado, United States|Yale Medical School, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|University of Miami School of Medicine, Miami, Florida, United States|University of Chicago, Chicago, Illinois, United States|Indiana University-Riley Hospital for Children, Indianapolis, Indiana, United States|University of Minnesota, Minneapolis, Minnesota, United States|Columbia University, New York, New York, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Texas Medical Center at Dallas, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States|The Hospital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01773707
NCT01773798,A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec/insulin aspart 15|Drug: insulin degludec/insulin aspart|Drug: insulin degludec|Drug: insulin aspart|Drug: placebo,Area under the glucose infusion rate curve|Area under the serum IDeg concentration-time curve|Area under the serum IAsp concentration-time curve,Novo Nordisk A/S,All,18 Years to 64 Years   (Adult),Phase 1,33,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1050-4008|2012-004215-31|U1111-1134-6222,Jan-13,Aug-13,Aug-13,23-Jan-13,null,5-Mar-15,"Graz, Austria",,https://ClinicalTrials.gov/show/NCT01773798
NCT01774149,Model Driven Diabetes Care,MDDC,Completed,Has Results,"Diabetes Mellitus, Type 1",Device: Few Touch Application|Device: Diastat,Change in the Frequency of Hyper- and Hypo-glycemic Events From Baseline to Week 8-12.|Change in HbA1c,University Hospital of North Norway|University of Tromso|The Research Council of Norway,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2011/1939 (REK),Mar-13,Aug-13,Aug-13,23-Jan-13,16-Sep-15,16-Sep-15,"University Hopital of North Norway, Tromsø, Norway",,https://ClinicalTrials.gov/show/NCT01774149
NCT01772251,Safety and Tolerability of Oshadi Icp In Patients With Type 1 Diabetes Mellitus - Phase Ib Clinical Study,,Completed,No Results Available,"Diabetes Mellitus, Insulin-Dependent, 1",Drug: Oshadi Icp,Adverse events and serious adverse events occurence|• To assess the pharmacodynamic effect of multiple doses of Oshadi Icp as measured by the area under the glucose concentration-time curve,Oshadi Drug Administration,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,10,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",OS-ICP-P1b-01|2012-004270-26,Feb-13,Jun-13,Jun-13,21-Jan-13,null,29-Oct-13,"Assaf-Harofeh Medical Center, Zerifin, Israel",,https://ClinicalTrials.gov/show/NCT01772251
NCT01770561,Feasibility Study of an Integrated Sensor and Infusion Set,,Completed,No Results Available,Diabetes Type 1,Device: Integrated sensor and infusion set.,Comparative analysis of performance characteristics|Gluco-dynamic effect|Performance longevity|Skin condition|Physical duration,Medtronic Diabetes R&D Denmark,All,"21 Years to 70 Years   (Adult, Older Adult)",Not Applicable,20,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,CER269,Oct-12,Oct-12,Oct-12,18-Jan-13,null,5-Feb-13,"Hvidovre Hospital, Hvidovre, Denmark",,https://ClinicalTrials.gov/show/NCT01770561
NCT01771250,A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes,,Completed,Has Results,"Diabetes Mellitus, Type 1",Biological: Insulin Peglispro|Biological: Insulin Glargine,Very Low Density Lipoprotein-Triglyceride (VLDL-TG) Concentrations|VLDL-TG Secretion Rate|VLDL-TG Oxidation Rate|VLDL-TG Clearance Rate,Eli Lilly and Company,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,15,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,14871|I2R-MC-BIDN,Oct-13,Dec-14,Dec-14,18-Jan-13,11-Mar-19,11-Mar-19,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aarhus, Denmark",,https://ClinicalTrials.gov/show/NCT01771250
NCT01771614,Glucotoxicity and Acute Exercise,,Withdrawn,No Results Available,Type 1 Diabetes|Type 2 Diabetes,Behavioral: Exercise|Procedure: Hyperglycemia,Pancreatic endocrine function|Glucose tolerance|Endothelial function|Oxidative stress,"Rigshospitalet, Denmark",Male,18 Years to 50 Years   (Adult),Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,GlucotoxEx,Aug-16,Dec-16,Jan-17,18-Jan-13,null,16-May-18,"University of Birmingham, Birmingham, West Midlands, United Kingdom",,https://ClinicalTrials.gov/show/NCT01771614
NCT01769404,A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Biological: LY2605541|Biological: Insulin Glargine,Time to Recovery Following Hypoglycemic Clamp|Blood Glucose|Cortisol|Glucagon|Growth Hormone|Norepinephrine|Epinephrine,Eli Lilly and Company,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,15,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),14870|I2R-MC-BIDM,Feb-13,Dec-13,Dec-13,16-Jan-13,null,17-Dec-13,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01769404
NCT01766362,Incidence of Macular Edema After Panretinal Photocoagulation (PRPC) Performed in a Single Session Versus Four Sessions in Diabetic Patients.,Pascal,Completed,No Results Available,Diabetes Type 1 or 2 With Diabetic Retinopathy,Procedure: PRPC using Pascal laser,Macular thickness,Centre Hospitalier Universitaire Dijon,All,"18 Years and older   (Adult, Older Adult)",Phase 3,83,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Creuzot Innov 2010,Oct-11,Nov-15,Nov-15,11-Jan-13,null,27-Dec-18,"CHU Dijon, Dijon, France|CHU de la Croix Rousse, Lyon, France|Hôpital Lariboisière, Paris, France",,https://ClinicalTrials.gov/show/NCT01766362
NCT01762644,The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Omeprazole for Insulin Independence Among Recent Onset Type 1 Diabetes Patients,IIT,Withdrawn,No Results Available,Type 1 Diabetes,Drug: Oral Cyclosporine and Oral Omeprazole|Drug: Oral Omeprazole,Insulin Independence and Hemoglobin A1c (A1C) < 6.5%|Safety and tolerability|Pancreatic beta cell function measured by glucagon stimulated C-peptide response|Proportion of participants achieving insulin independence|Blood glucose control measured by A1C|Average daily insulin requirement per week,"Perle Bioscience, Inc.|Syreon Corporation",All,"10 Years to 20 Years   (Child, Adult)",Phase 3,0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRL001-PB-01|2015-000105-39,Aug-15,May-16,Aug-16,8-Jan-13,null,18-Apr-16,,,https://ClinicalTrials.gov/show/NCT01762644
NCT01762657,The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Lansoprazole for Insulin Independence Among Patients With Existing Type 1 Diabetes,IIT,Withdrawn,No Results Available,Type 1 Diabetes,Drug: Oral Cyclosporine and Oral Lansoprazole|Drug: Placebos,Insulin Requirements Among Patients Treated with Oral Cyclosporine and Oral Lansoprazole|Glucagon C-peptide (under the curve) and Hemoglobin A1C levels among patients with existing type 1 diabetes treated with Cyclosporine and Lansoprazole,"Perle Bioscience, Inc.",All,"8 Years to 60 Years   (Child, Adult)",Phase 3,0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Perle-1102,Sep-14,Sep-15,Sep-15,8-Jan-13,null,19-Apr-16,,,https://ClinicalTrials.gov/show/NCT01762657
NCT01762059,Outpatient Automated Blood Glucose Control With a Bi-hormonal Bionic Endocrine Pancreas,,Completed,Has Results,Type 1 Diabetes,Device: Bi-homonal Bionic Pancreas|Other: Usual care,Average Blood Glucose (Co-primary Outcome)|Percentage of Time Blood Glucose Values Less Than 70 mg/dl (Co-primary Outcome)|Average BG During the Closed-loop Control Period as Determined From All HemoCue Measurements Taken During the Daytime and All Scheduled GlucoScout Measurements During the Nighttime.|Percentage of the Subset of BG Values Less Than 70 mg/dl as Determined From All All HemoCue Measurements Taken During the Daytime and Scheduled GlucoScout Measurements Taken During the Nighttime.|Difference in the Average BG Between the Closed-loop Control Period and the Usual Care Period.|Difference in the Percentage of the Above Subset of BG Values Between the Closed-loop Control and Usual Care Periods Less Than 70 mg/dl.|Percentage of Subjects With Mean BG < 154 mg/dl.|Difference in the Percentage of Subjects With Mean BG < 154 mg/dl During the Closed-loop Period vs. the Usual Care Period.|Number of Hypoglycemic Events as Determined From GlucoScout and HemoCue Measurements.|Nadir BG During Exercise.|Correlation Between Exercise Intensity and Likelihood of a Hypoglycemic Event|Average BG During the Closed-loop Control Period as Determined From All GlucoScout Measurements Taken During the Nighttime Monitoring.|Fraction of Time Spent Within Each of the Following Glucose Ranges as Determined From All GlucoScout and HemoCue Measurements.|Difference of Outcome Measures on Days 1-2 vs. on Remaining Days (Days 3-5) During the Closed-loop Period.|Mean BG During Exercise.|Number of Hypoglycemic Episodes During Exercise.|Difference of Outcome Measures on Day 1 vs. Remaining Days (Days 2-5) During the Closed-loop Period.,Massachusetts General Hospital|Boston University,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,32,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012P002317,Jan-13,Oct-13,Jun-14,7-Jan-13,21-Jul-17,21-Jul-17,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01762059
NCT01759953,Educational Efficacy Assessment of a Serious Game to Teach Insulin Therapy to Primary Care Physicians,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Knowledge, Attitudes, Practice",Other: Game|Other: Traditional CME,Knowledge on insulin therapy for diabetes|Attitudes regarding diabetes/insulin,Universidade Estadual de Londrina,All,"Child, Adult, Older Adult",Not Applicable,170,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),InsuOnline-01,Jul-14,Dec-15,Dec-15,3-Jan-13,null,7-Dec-15,"Hospital Universitário de Londrina, Londrina, PR, Brazil",,https://ClinicalTrials.gov/show/NCT01759953
NCT01757756,"Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects",,Completed,No Results Available,"Diabetes Mellitus|Diabetes Mellitus, Type 2|Glucose Metabolism Disorders",Drug: Pf-05175157|Drug: placebo|Drug: midazolam,"Maximum Observed Plasma Concentration (Cmax)|Area Under the Curve from Time Zero to end of dosing interval (AUCtau)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Plasma Decay Half-Life (t1/2)|Apparent Volume of Distribution (Vz/F)|Apparent Oral Clearance (CL/F)|Accumulation Ratio (Rac)|Ae,tau|Ae%|Clr|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]|fasting triglycerides|fasting LDL-cholesterol|fasting total cholesterol|fasting HDL cholesterol",Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,12,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science,B1731017,Oct-12,Nov-12,Nov-12,31-Dec-12,null,31-Dec-12,"Pfizer Investigational Site, South Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT01757756
NCT01755416,Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting,,Completed,Has Results,Type 1 Diabetes,"Drug: Closed loop with sensor and Insulin|Drug: Closed loop with sensor, Insulin and Liraglutide","Blood Glucose Measures in Subjects on Closed Loop With Insulin and Liraglutide, Compared to the Closed Loop With Insulin Alone",Albert Einstein College of Medicine|Medtronic,All,18 Years to 40 Years   (Adult),Phase 2,18,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012-503,Jan-13,Jan-15,Jan-15,24-Dec-12,21-Aug-18,21-Aug-18,"Albert Einstein College of Medicine West Campus CRC, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT01755416
NCT01755442,Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects,,Terminated,No Results Available,Diabetes Mellitus,Other: Placebo|Drug: AMG 151,Mean 24-hour systolic blood pressure|Mean 24-hour diastolic blood pressure|Mean 24-hour heart rate|24-hour concentration time profile of glucose level from continuous glucose monitoring|Fasting plasma glucose and fructosamine|Plasma glucose 2 hours after time 0 of mixed meal tolerance test|4-hour concentration time profile of glucose after the mixed meal tolerance test|Safety end points will include the incidence of treatment emergent adverse events.|Serum AMG 151 concentration|Safety end points will include laboratory safety tests.|Safety end points will include vital signs.|Safety end points will include ECGs.,Amgen,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,5,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20120189,Nov-12,Jan-13,Jan-13,24-Dec-12,null,22-Apr-13,"Research Site, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT01755442
NCT01755572,Blood Pressure Outcomes With Liraglutide Therapy,BOLT,Completed,No Results Available,Type 2 Diabetes|Systolic Hypertension,Drug: Liraglutide|Drug: Placebo,"Change in plasma ANP level at 1 Day|Change in plasma ANP level at 21 Days|Change in mean 24-Hr urinary sodium excretion rate following 21 days of liraglutide (titrated 1.8mg) compared to crossover with placebo (baseline-subtracted)|Change in mean Nighttime urinary sodium excretion rate following 21 days of liraglutide (titrated 1.8mg) compared to crossover with placebo (baseline-subtracted)|Change in mean 24-Hr systolic BP, liraglutide compared to crossover with placebo (baseline-subtracted)|Change in mean 24-hr diastolic BP, liraglutide compared to crossover with placebo (baseline-subtracted)|Change in mean 24-hr HR, liraglutide compared to crossover with placebo (baseline-subtracted)|Office-measured systolic BP; Treatment difference for liraglutide compared to crossover with placebo|Office-measured diastolic BP;Treatment difference for liraglutide compared to crossover with placebo|Office-measured heart rate;Treatment difference for liraglutide compared to crossover with placebo","Mount Sinai Hospital, Canada|Novo Nordisk A/S",All,"30 Years to 70 Years   (Adult, Older Adult)",Phase 4,22,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",MSH-12-0020-A,Jan-13,Jan-14,Mar-14,24-Dec-12,null,25-Mar-15,"Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Canada, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01755572
NCT01754181,Initial Testing of the Diabeloop Algorithm in T1D Patients on Pump Therapy Over the Prandial Period and Physical Activity.,DiabeloopWP6-0,Completed,No Results Available,Type 1 Diabetes,Drug: Insulin,"Time spent in glucose reference intervals|Measuring glucose sensor 2h, 3h and 4h post-prandial and AUC, in every situation tested to evaluate the efficacy and safety (time spent in hypoglycemia)",Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète,All,"18 Years and older   (Adult, Older Adult)",Phase 3,18,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2012-A01489-34,Mar-13,Jun-13,Jul-13,21-Dec-12,null,27-Oct-14,"Centre Hospitalier Sud Francilien, Evry, France|University Hospital of Grenoble, Grenoble, France|University Hospital of Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT01754181
NCT01754259,Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD,RAND-CFR,Completed,Has Results,"Diabetes, Type I|Diabetes, Type II|Angina|Coronary Artery Disease",Drug: Ranolazine|Drug: Placebo,Change in Post-exercise Coronary Vasodilator Reserve|Change in LV Diastolic Function,Brigham and Women's Hospital,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 3,47,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",2012P002537,Apr-13,Oct-15,Dec-15,21-Dec-12,24-Jul-17,24-Jul-17,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01754259
NCT01754337,Closed-loop Control of Glucose Levels (Artificial Pancreas) for 24 Hours in Adults and Adolescents With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Other: Closed-loop system,Percentage of time of plasma glucose levels spent in target range.|Percentage of time of plasma glucose levels spent in the low range|Percentage of overnight time of plasma glucose levels spent in the low range|Standard deviation of glucose levels|Total insulin delivery|Mean plasma glucose level|Mean plasma insulin concentration|Mean plasma glucagon concentration|Number of subjects experiencing hypoglycemia requiring oral treatment|Percentage of time of plasma glucose levels spent between 4.0 and 10.0 mmol/L|Percentage of overnight time of plasma glucose levels spent between 4.0 and 8.0 mmol/L|Percentage of overnight time of plasma glucose levels spent between 4.0 and 10.0 mmol/L|Percentage of time of plasma glucose levels spent in the high range|Percentage of overnight time of plasma glucose levels spent in the high range,Institut de Recherches Cliniques de Montreal|McGill University|Montreal Children's Hospital of the MUHC,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 2,30,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLASS-03,Dec-12,Jun-14,Jun-14,21-Dec-12,null,4-Jul-14,"Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01754337
NCT01753362,Liraglutide In Overweight Patients With Type 1 Diabetes,,Unknown status,No Results Available,Type 1 Diabetes,Drug: liraglutide|Drug: placebo,HbA1c|difference from baseline in mean weekly glucose concentrations,University at Buffalo|Juvenile Diabetes Research Foundation,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,84,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1965,Dec-12,Dec-17,Feb-18,20-Dec-12,null,6-Nov-17,"diabetes endocrinology center of WNY, Buffalo, New York, United States|Diabetes Endocrinology Research Center of WNY, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT01753362
NCT01747967,Immune Biomarkers of Residual Beta-cell Mass in Type 1 Diabetes,IMMADIAB,Completed,No Results Available,Type 1 Diabetes,Other: Meal Test,Correlation between residual insulin secretion and T-cell responses against beta-cell antigens.|Correlation between residual insulin secretion estimated by serum and urine C-peptide measurement.|Correlation between residual insulin and glucagon secretion.,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|Recherche Clinique Paris Descartes Necker Cochin Sainte Anne",All,"6 Years to 60 Years   (Child, Adult)",Not Applicable,156,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,K 091101,15-Nov-11,30-May-17,30-May-17,12-Dec-12,null,1-Aug-17,"INSERM U1016 - DeAR Lab Avenir, Hôpital Cochin, Paris, France",,https://ClinicalTrials.gov/show/NCT01747967
NCT01745549,"Efficacy, Safety and Satisfaction of the New Pen Needle 33 Gauge x 4 mm.",AGO01,Completed,No Results Available,Type 1 Diabetes|Type 2 Diabetes,"Device: Needle for insulin pen, 4 mm long and with a diameter of 33 gauge|Device: Needle for insulin pen, 4 mm long and with a diameter of 32 gauge",hematic fructosamine levels|mean amplitude of glucose excursions (MAGE)|pain|leakage at the site injection|hypoglycemia|insulin dosage|patient's weight|patient's satisfaction,Consorzio Mario Negri Sud|Artsana SpA,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,87,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AGO01,Dec-12,Sep-13,Nov-13,10-Dec-12,null,18-Mar-14,"UO Malattie Metaboliche e Diabetologia - Ospedale di Treviglio-Caravaggio, Treviglio, BG, Italy|UO Diabetologia per Trattamento e Educazione dei Diabetici - Spedali Civili di Brescia, Brescia, BS, Italy|U.O.S. Diabetologia e Malattie Metaboliche - PO Cantù - Mariano Comense, Mariano Comense, CO, Italy|Struttura Complessa Dietologia-Diabetologia Malattie Metaboliche - Ospedale Pertini, Roma, RM, Italy",,https://ClinicalTrials.gov/show/NCT01745549
NCT01744236,SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies,,Completed,No Results Available,Type 2 Diabetes,Drug: Liraglutide|Drug: Sitagliptin|Drug: Exenatide|Drug: Liraglutide placebo|Drug: Sitagliptin placebo|Drug: Exenatide placebo|Drug: L-NMMA,"Changes from baseline following infusion of GLP-1RA (acute effects) and the changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on resting heart rate variability, as derived from electrocardiographic measurements.|Changes from baseline following infusion of GLP-1RA (acute effects) and the changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on Glomerular Filtration Rate, measured by the inulin-clearance technique.|Changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on pancreatic exocrine function, measured as fecal Elastase-1.|Changes from baseline following infusion of GLP-1RA (acute effects) and the changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on the following cardiovascular parameters:|Changes from baseline following infusion of GLP-1RA (acute effects) and the changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on the following renal parameters:|Changes from baseline following infusion of GLP-1RA (acute effects*) and changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on the following gastrointestinal parameters:",VU University Medical Center|EU FP7: SAFEGUARD consortium,All,"35 Years to 75 Years   (Adult, Older Adult)",Phase 4,70,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DC2012SAFE001|U1111-1130-8248|2012-003256-36,Apr-13,Aug-15,Aug-15,6-Dec-12,null,9-Dec-15,"VU University Medical Center, Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT01744236
NCT01742208,Safety and Efficacy of LX4211 in Patients With Inadequately Controlled Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: LX4211|Drug: LX4211 Placebo,To assess the effect of LX4211 on the total daily bolus amount of exogenous insulin required to maintain or improve glycemic control|Assess total exogenous daily bolus and basal insulin use|Assess the amount of exogenous use at each meal|Change from baseline in fasting plasma glucose|Change in glucose levels as measured by Continuous Glucose Monitoring (CGM)|Change in postprandial glucose by Area Under Curve (AUC),Sanofi|Lexicon Pharmaceuticals,All,18 Years to 55 Years   (Adult),Phase 2,36,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LX4211.1-203-T1DM|LX4211.203,Feb-13,Jan-14,Jan-14,5-Dec-12,null,26-Dec-17,"Lexicon Investigational Site, Aurora, Colorado, United States|Lexicon Investigational Site, Atlanta, Georgia, United States|Lexicon Investigational Site, Baton Rouge, Louisiana, United States|Lexicon Investigational Site, Omaha, Nebraska, United States|Lexicon Investigational Site, Bronx, New York, United States|Lexicon Investigational Site, Durham, North Carolina, United States|Lexicon Investigational Site, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT01742208
NCT01742741,Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy (France),,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: Diabetes Assistant (DiAs),Effect size of Control-to-Range (CTR) vs. Continuous Glucose Monitor (CGM)-augmented insulin pump treatment in an outpatient setting.|Time spent in target range,"University of Virginia|Juvenile Diabetes Research Foundation|University of Padova|University of California, Santa Barbara",All,21 Years to 64 Years   (Adult),Not Applicable,5,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,France|JDRF 22-2011-649,May-13,May-13,May-13,5-Dec-12,null,9-Sep-13,"Centre d'Investigation Clinique CHU Montipellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT01742741
NCT01739829,Open-label Investigation of the Safety and Effectiveness of DIABECELL® in Patients With Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes,Device: DIABECELL (R),To establish the safety and efficacy of xenotransplantation of DIABECELL,Diatranz Otsuka Limited,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,8,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LCT/DIA-09,Aug-11,Jun-14,Jun-14,4-Dec-12,null,20-Oct-17,"Hospital Interzonal General de Agudos Eva Perón, Buenos Aires, Argentina",,https://ClinicalTrials.gov/show/NCT01739829
NCT01740921,GLP-1 and Microvascular Function in Type 2 Diabetes,GLP-1ADDS,Completed,No Results Available,Type 2 Diabetes,Drug: Liraglutide|Other: diet|Drug: Aspirin,change of baseline skin maximum hyperaemia at 4 months|change of baseline peripheral arterial tone at 4 months|change of baseline endothelial-dependent vasodilation at 4 months|change of baseline capillary density at 4 months,Royal Devon and Exeter NHS Foundation Trust|University of Exeter,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,39,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,066|10/H0106/29,Jan-11,Dec-15,Feb-16,4-Dec-12,null,17-Feb-17,"Peninsula Clinical Research Facility, Exeter, United Kingdom",,https://ClinicalTrials.gov/show/NCT01740921
NCT01741103,Sitagliptin in Type I Diabetic Patients,,Unknown status,No Results Available,Diabetes Type I,Drug: sitagliptin|Drug: Placebo,"change from baseline in mean glucose concentrations|Glycemic changes|Post meal hyperglycemia|Changes in post prandial glucose, glucagon, insulin, c-peptide, DPP-IV, GIP and, GLP-1 concentrations following meal challenge.|Changes in NF kappa B in the fasting state.|Change in NFkappaB following meal challenge.",Kaleida Health,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,36,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,1957,Jun-11,Sep-13,Sep-13,4-Dec-12,null,4-Dec-12,"115 Flint Road, Williamsville, New York, United States",,https://ClinicalTrials.gov/show/NCT01741103
NCT01739283,GIP and GLP-1 in Type 1 Diabetes,,Completed,No Results Available,Hypoglycemia,Other: GIP|Other: GLP-1|Other: Saline,"plasma glucagon area under curve values|plasma gut hormones and nutrients (absolute, incremental and area under curve values)","Mikkel Christensen|University of Copenhagen|University Hospital, Gentofte, Copenhagen",Male,18 Years to 50 Years   (Adult),Not Applicable,10,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",H-2-2009-078 33269,Jul-12,Apr-13,Nov-13,3-Dec-12,null,13-Jul-15,"Gentofte Hospital, Hellerup, Denmark",,https://ClinicalTrials.gov/show/NCT01739283
NCT01739712,Sleep Intervention for Youth With Type 1 Diabetes,,Completed,No Results Available,Diabetes,Behavioral: Sleep extension|Behavioral: Fixed Sleep Duration,Academic Rating Scale|Glucose control|Neurocognitive performance|Academic performance,University of Arizona,All,10 Years to 16 Years   (Child),Not Applicable,114,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care",12-0733091,Oct-12,Aug-16,Aug-16,3-Dec-12,null,21-Nov-16,"Angel Wing Clinic for Diabetes, Tucson, Arizona, United States",,https://ClinicalTrials.gov/show/NCT01739712
NCT01736228,Open-label Investigation of the Safety and Efficacy of DIABECELL in Patients With Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes,Device: DIABECELL,to establish the efficacy and safety of DIABECELL|Porcine β-cell function as demonstrated by measurement of porcine pro-insulin in xenotransplant recipients|Improvement in the quality-of-life of xenotransplant recipients,Living Cell Technologies,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,14,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LCT/DIA-12,Nov-12,Dec-14,Dec-14,29-Nov-12,null,17-Mar-15,"Hospital Interzonal General de Agudos Eva Perón, San Martin, Buenos Aires, Argentina",,https://ClinicalTrials.gov/show/NCT01736228
NCT01736930,An Outpatient Pump Shutoff Pilot Feasibility and Safety Study,PSO1,Completed,Has Results,Type 1 Diabetes,Device: Pump suspension,Mean Morning Blood Glucose (mg/dL)- Algorithm 1|Mean Morning Blood Glucose (mg/dL)- Algorithm 2|Mean Morning Blood Glucose (mg/dL)- Algorithm 3|Percent Morning Blood Glucose >250 mg/dL - Algorithm 1|Percent Morning Blood Glucose >250 mg/dL - Algorithm 2|Percent Morning Blood Glucose >250 mg/dL - Algorithm 3|Mornings With Blood Ketones >0.6 mmol/L - Algorithm 1|Mornings With Blood Ketones >0.6 mmol/L - Algorithm 2|Mornings With Blood Ketones >0.6 mmol/L - Algorithm 3|Mornings With Urine Ketones Characterized as Moderate or Large - Algorithm 1|Mornings With Urine Ketones Characterized as Moderate or Large - Algorithm 2|Mornings With Urine Ketones Characterized as Moderate or Large - Algorithm 3|Mean Sensor Glucose Overnight - Algorithm 1|Mean Sensor Glucose Overnight - Algorithm 2|Mean Sensor Glucose Overnight - Algorithm 3|Percentage of Sensor Glucose Values 71 to 180 mg/dL - Algorithm 1|Percentage of Sensor Glucose Values 71 to 180 mg/dL - Algorithm 2|Percentage of Sensor Glucose Values 71 to 180 mg/dL - Algorithm 3,Jaeb Center for Health Research|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years and older   (Adult, Older Adult)",Phase 2,20,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,PSO1|R01DK085591,Jan-12,Jun-12,Jun-12,29-Nov-12,14-Apr-14,30-Aug-16,"Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT01736930
NCT01735123,Early Dietary Intervention and Later Signs of Beta-Cell Autoimmunity,EDIA,Completed,No Results Available,"Diabetes Mellitus, Type 1",Dietary Supplement: dietary intervention,"Intestinal permeability will be determined at the age of 3, 6, 9 and 12 months with the lactulose/mannitol test Intestinal permeability at the age of 9 months assessed with the lactulose/mannitol test|Serum metabolic profile","Helsinki University|University of Turku|National Institute for Health and Welfare, Finland|Tampere University Hospital",All,up to 12 Months   (Child),Not Applicable,87,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention",1DP3DK094338-01,Jan-13,Jul-16,Aug-16,28-Nov-12,null,27-Feb-17,"Tampere University Hospital, Tampere, Finland",,https://ClinicalTrials.gov/show/NCT01735123
NCT01733524,Pet Ownership and Glucose Control in Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus,Behavioral: Pet Fish|Behavioral: Picture of a fish,Glycemic control|HRQoL|Self Management of Diabetes in Adolescents,"University of Texas Southwestern Medical Center|University of Massachusetts, Worcester",All,10 Years to 17 Years   (Child),Not Applicable,29,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,1R03HD071263-01,Oct-12,Dec-15,Dec-15,27-Nov-12,null,2-Jun-16,"University of Texas Southwestern Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT01733524
NCT01730014,"A Trial Investigating the Safety, Tolerability, and Distribution and Activity in the Body of NNC0148-0000-0287 Injected Under the Skin in Healthy Subjects and in Subjects With Type 1 Diabetes",,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1|Healthy",Drug: 148-0287-A-4.2mM-cartridge|Drug: placebo|Drug: insulin glargine|Drug: sodium chloride 0.9% w/v,"Incidence of adverse events (AE)|Incidence of hypoglycaemic episodes|AUC, the area under the serum insulin 287 concentration-time curve|Cmax, the maximum serum insulin 287 concentration|tmax, the time for maximum serum insulin 287 concentration|Average morning fasting blood glucose (FBG) concentration|Average morning fasting serum C-peptide concentration|Average morning fasting serum free fatty acid (FFA) concentration|Area under the glucose infusion rate (GIR)-time curve|The maximal GIR (glucose infusion rate) observed",Novo Nordisk A/S,Male,18 Years to 64 Years   (Adult),Phase 1,70,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1436-3955|2011-005172-41|U1111-1125-2924,Oct-12,Jul-13,Jul-13,21-Nov-12,null,31-Jul-13,"Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01730014
NCT01730885,A Trial Investigating the Accuracy and Precision of the BGStar® and iBGStar® Blood Glucose Meter in Subjects With Type 1 Diabetes,,Completed,No Results Available,Diabetes Mellitus,Other: Comparison of different Blood Glucose Meters,"Mean absolute relative deviation (MARD) from paired reference values of BGStar®, iBGStar® and comparator BG meter measurements at stable hypoglycaemic, euglycaemic and hyperglycaemic levels and overal",Profil Institut für Stoffwechselforschung GmbH|Sanofi,All,"18 Years to 74 Years   (Adult, Older Adult)",Phase 4,20,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label),BGStar,Nov-12,Jan-14,null,21-Nov-12,null,5-Feb-14,"Profil Institut für Stoffwechselforschung GmbH, Neuss, NRW, Germany",,https://ClinicalTrials.gov/show/NCT01730885
NCT01729117,A Trial of Meal Replacement at a Community Diabetes Clinic Serving a Low Socioeconomic Hispanic Population,,Completed,No Results Available,Type 2 Diabetes|Obesity,Other: Meal Replacement|Other: Standard Care,Change in BMI|Severe Hypoglycemic Events,University of Southern California,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HS-08-00646,May-09,Apr-12,Apr-12,20-Nov-12,null,20-Nov-12,"Roybal Diabetes Management Clinic, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT01729117
NCT01727817,Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy (Italy),,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: Diabetes Assistant (DiAs),Effect size of Control-to-Range (CTR) vs. Continuous Glucose Monitor (CGM)-augmented insulin pump treatment in an outpatient setting.|Time spent in target range,"University of Virginia|Juvenile Diabetes Research Foundation|Sansum Diabetes Research Institute|University Hospital, Montpellier",All,21 Years to 64 Years   (Adult),Not Applicable,5,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0052904|JDRF 22-2011-649,Jan-13,May-13,May-13,16-Nov-12,null,30-Sep-14,"University of Padova, Padova, Italy",,https://ClinicalTrials.gov/show/NCT01727817
NCT01726621,User Evaluation of the MiniMed 620G and 640G Insulin Pumps,,Completed,Has Results,Type 1 Diabetes|Type 2 Diabetes,Device: Medtronic MiniMed 620G or 640G Insulin Pump,User Acceptance of the New MiniMed 620G and 640G Insulin Pumps and Guardian Link Transmitter,Medtronic Diabetes,All,"7 Years to 99 Years   (Child, Adult, Older Adult)",Not Applicable,55,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),CEP267,Mar-13,Nov-14,Dec-14,15-Nov-12,18-Apr-16,18-Apr-16,"St Vincent Hospital and The University of Melbourne, Fitzroy, Australia|The Royal Melbourne Hospital, Patkville, Australia|Herlev Hospital, Herlev, Denmark|Barcelona University Hospital, Barcelona, Spain|University College Hospital, London, United Kingdom|King's College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01726621
NCT01726829,Overnight Type 1 Diabetes Control Under MD-Logic Closed Loop System at the Patient's Home,,Completed,No Results Available,Type 1 Diabetes,Device: MD-Logic Artificial Pancreas (MDLAP) system|Procedure: sensor augmented pump therapy,"time sensor glucose level spent below 70mg/dl|The percentage of nights mean overnight sensor glucose levels was within90-140 mg/dl|The time sensor glucose level spent within 70-140 mg/dl|The number and frequency of hypoglycemic events below 63, 79 mg/dl|The time sensor glucose level spent above 140, 180 mg/dl|The area under the curve <63, <70, >140, >180 mg/dl|Glucose variability|The total insulin dose during the overnight period|Artificial pancreas technical performance defined as total frequency of technical failures|Artificial pancreas technical performance defined as total frequency of lost or inaccurate sensor records|Percentage of time of active closed loop control|Fear of Hypoglycemia questionnaire|Acceptance questionnaire|Artificial Pancreas Satisfaction Questionnaire",Rabin Medical Center,All,"10 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,75,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,rmc007053ctil,Nov-12,Nov-15,Dec-15,15-Nov-12,null,8-Apr-16,"Diabetes -Zentrum fuer kinder und jugendliche, Hannover, Germany|Schneider Children's Medical Center, Petah-Tikva, Israel|University Children's Hospital, Slovenia, Slovenia",,https://ClinicalTrials.gov/show/NCT01726829
NCT01725672,Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers,,Terminated,No Results Available,"Diabetes Mellitus, Type 2","Drug: Metformin, 500 mg extended release tablet|Drug: Metformin, 1000 mg extended release tablet|Drug: Glimepiride, 1 mg immediate release tablet|Drug: Glimepiride, 2 mg immediate release tablet|Drug: Metformin, 500 mg and Glimepiride, 1 mg extended release film coated tablet containing release controlling polymers|Drug: Metformin, 1000 mg and Glimepiride, 2 mg extended release film coated tablet containing release controlling polymers|Drug: Metformin, 500 mg and Glimepiride, 1 mg extended release tablet coated with release controlling polymers|Drug: Metformin, 1000 mg and Glimepiride, 2 mg extended release tablet coated with release controlling polymers","Cmax of metformin|AUC(0-t) and AUC(0-inf) for metformin and glimepiride|Tmax and t1/2 of of metformin and glimepiride|Percentage AUCex for metformin and glimepiride; and AUC(0-∞), AUC (0-t) for metformin and glimepiride in relevant treatments|Number of subjects with adverse events (AE)s",GlaxoSmithKline,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,116806,27-Sep-12,21-Aug-13,21-Aug-13,14-Nov-12,null,12-Jun-17,"GSK Investigational Site, Randwick, New South Wales, Australia",,https://ClinicalTrials.gov/show/NCT01725672
NCT01724814,"A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A",HM12460A,Completed,No Results Available,Healthy|Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Drug: HM12460A|Drug: Placebo,Incidence and severity of treatment emergent adverse events|Peak Plasma Concentration(Cmax) of HM12460A following a single dose in Parts 1-3,Hanmi Pharmaceutical Company Limited,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,86,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HM-INS-101,20-Dec-12,1-Jul-14,1-Jul-14,12-Nov-12,null,8-Nov-17,"Hanmi pharma, Chula Vista, California, United States",,https://ClinicalTrials.gov/show/NCT01724814
NCT01724190,Effect of Vitamin D on the Honeymoon Period in Children and Adolescents With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Drug: Vitamin D|Drug: Placebo,IDAA1c|fasting c-peptide|high sensitivity c-reactive protein (hsCRP)|interleukin-6 (IL-6)|tumor necrosis factor-alpha (TNF-alpha)|25-(OD)D,Nationwide Children's Hospital,All,"4 Years to 18 Years   (Child, Adult)",Not Applicable,36,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)",285412,Nov-12,Jun-14,Jun-14,9-Nov-12,null,22-Jun-15,"Nationwide Children's Hospital, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01724190
NCT01722643,"Incentives, Cognitive Training and Internet Therapy for Teens With Poorly Controlled Type 1 Diabetes",,Completed,Has Results,Type 1 Diabetes,Behavioral: MAxIM|Behavioral: Usual Care,HbA1c at 12 Months|Daily Frequency of Self Monitoring of Blood Glucose Checks 12 Months Following Enrollment,Dartmouth-Hitchcock Medical Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),All,13 Years to 17 Years   (Child),Not Applicable,61,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,23559|1DP3HD076602-01,Jan-14,Sep-16,Sep-16,7-Nov-12,6-Jun-18,6-Jun-18,"Dartmouth College, Hanover, New Hampshire, United States",,https://ClinicalTrials.gov/show/NCT01722643
NCT01722682,Bone Marrow vs Liver as Site for Islet Transplantation,IsletBOM2,Completed,No Results Available,Type 1 Diabetes,Biological: Human pancreatic islet transplantation,Insulin secretion under stimulation|Incidence and severity of Adverse Events (AE) and Serious Adverse Events (SAE)|Insulin requirement|Islet function,"Ospedale San Raffaele|Ministry of Health, Italy",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,9,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IsletBOM2,Jun-12,Sep-17,Dec-17,7-Nov-12,null,9-Feb-18,"Ospedale San Raffaele, Milan, Italy",,https://ClinicalTrials.gov/show/NCT01722682
NCT01722227,Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes,,Withdrawn,No Results Available,Type 1 Diabetes,Drug: Liraglutide|Drug: Placebo,Mean weekly blood glucose concentrations.|HbA1c,University at Buffalo|American Diabetes Association,All,"15 Years to 30 Years   (Child, Adult)",Phase 3,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",1964 Liraglutide ADA|1-12-CT-20,Nov-12,Nov-17,May-18,6-Nov-12,null,9-Feb-17,"Diabetes-Endocrinology Center of WNY, Williamsville, New York, United States",,https://ClinicalTrials.gov/show/NCT01722227
NCT01722240,Liraglutide in Type 1 Diabetes,1966,Recruiting,No Results Available,Type 1 Diabetes,Drug: Liraglutide 1.8mg|Drug: Placebo,HbA1c|Mean weekly glucose concentrations.,University at Buffalo|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,96,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",1966,Nov-12,Nov-18,Nov-19,6-Nov-12,null,6-Nov-17,"Diabetes-Endocrinology Center of WNY, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT01722240
NCT01722266,Liraglutide in the Treatment of Type 1 Diabetes Mellitus,,Completed,Has Results,Type 1 Diabetes,Drug: Liraglutide|Drug: Placebo,"Change in Mean Weekly Glucose Concentrations From Baseline at 12 Weeks|Change in HbA1c From Baseline at 12 Weeks|Change in Body Weight From Baseline at Week 12|Change in Total Insulin Dose From Baseline at 12 Weeks|Percent Time Spent in Hyperglycemia and Hypoglycemia|Reduction in the Area Under Curve(AUC) of Glucose Following the Meal|Serum Acetaminophen Concentrations Following Meal Challenge|Carbohydrate Intake|Insulin, C-peptide, Glucagon, GLP-1(Glucagon Like Peptide-1) and GIP(Gastric Inhibitory Polypeptide) Concentrations Following Meal Challenge.",Kaleida Health|Novo Nordisk A/S,Female,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,72,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",NN1962,Nov-12,Apr-14,Apr-14,6-Nov-12,13-Mar-15,13-Mar-15,"Diabetes-Endocrinology Center of Western NY, Williamsville, New York, United States",,https://ClinicalTrials.gov/show/NCT01722266
NCT01718093,A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Drug: Sitagliptin|Drug: Metformin|Drug: Sitagliptin + Metformin,To determine the glucose lowering effect of metformin and sitagliptin alone and as combination therapy when used as adjuncts to insulin in adolescents with T1DM.,Baylor College of Medicine|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"13 Years to 18 Years   (Child, Adult)",Phase 4,21,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-29924|DK096067,Oct-12,Dec-15,Dec-15,31-Oct-12,null,24-Apr-17,"Baylor College of Medicine, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01718093
NCT01714505,Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy,,Completed,Has Results,"Diabetes Mellitus, Type 1",Device: Diabetes Assistant (DiAs),"Safety, Low Blood Glucose Index (LBGI)|Safety, Frequency of Hypoglycemia|Efficacy, Time Spent in Target Range","University of Virginia|Juvenile Diabetes Research Foundation|Sansum Diabetes Research Institute|University of Padova|University Hospital, Montpellier",All,21 Years to 64 Years   (Adult),Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16457|JDRF 22-2011-649,Oct-12,Jan-13,Jan-13,26-Oct-12,9-Sep-14,9-Sep-14,"Sansum Diabetes Research Institute, Santa Barbara, California, United States|University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01714505
NCT01714895,Effect of Different Plasma Insulin Levels on the Accuracy of Continuous Subcutaneous Glucose Monitoring,,Completed,No Results Available,Type 1 Diabetes|Continuous Glucose Monitoring|Hypoglycemia,Other: High insulin eu-hypoglycemic clamp|Other: Low insulin eu-hypoglycemic clamp,Normalized current signal from the CGM devices,Fundación para la Investigación del Hospital Clínico de Valencia|Universitat Politècnica de València,All,18 Years to 60 Years   (Adult),Not Applicable,14,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science",FP7-PEOPLE-2009-IEF #252085-2|Spanish Ministry of Science,Oct-11,Sep-12,Oct-12,26-Oct-12,null,26-Oct-12,"Servicio de Endocrinología y Nutrición, Hospital Clínico Universitario de Valencia, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT01714895
NCT01713023,Fructose and Glucose and TAS1R2 in Type 1 Diabetes,TAS1R2,Completed,No Results Available,Type 1 Diabetes,Dietary Supplement: Glucose|Dietary Supplement: Fructose,"Compare the effects of fructose and glucose and TAS1R2 in postprandial metabolism of individuals with type 1 diabetes|Effect of fructose or glucose on blood glucose|Effect of fructose or glucose on triglycerides levels|Effect of fructose or glucose on uric acid, pyruvic acid, and lactate|Effect of fructose or glucose on oxidative stress|Effect of two polymorphisms in the gene TAS1R2 in the sweet taste perception|Effect of fructose or glucose on appetite and palatability|Effect of fructose or glucose on glucagon levels|Effect of fructose or glucose on leptin levels",Universidade Federal do Rio de Janeiro|Rio de Janeiro State Research Supporting Foundation (FAPERJ),All,18 Years to 50 Years   (Adult),Not Applicable,16,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,Debora-TAS1R2|CEP-151/2011,Mar-13,Dec-14,Jan-16,24-Oct-12,null,15-Apr-16,"University Hospital of Rio de Janeiro, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil",,https://ClinicalTrials.gov/show/NCT01713023
NCT01712594,Safety and Effectiveness Study of a Closed Loop System Maintaining Patients' Glucose Levels During an Overnight Period,,Completed,No Results Available,Type 1 Diabetes,Device: Closed Loop Procedure (Medtronic),Amount of time spent in the target range defined as 3.8-8.8 mmol/l (70 to 160 mg/dL) YSI glucose during in-clinic overnight visits|Glucose Area under the curve (AUC) below 3.8 mmol/l (70 mg/dL ) YSI glucose obtained during in-clinic overnight visits|Glucose AUC above 8.8mmol/l (160 mg/dL) YSI glucose obtained during in-clinic overnight visits,Medtronic Diabetes,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,9,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CEP223,May-13,Dec-13,Dec-14,23-Oct-12,null,12-May-17,"King's College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01712594
NCT01709929,Safety of Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus,PREDICTIVE™,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Drug: insulin detemir,Incidence of serious adverse drug reactions (SADRs) including major hypoglycaemic events|Number of adverse events (all and serious)|Number of all hypoglycaemic events|Change in weight|HbA1c (glycosylated haemoglobin)|Treatment satisfaction as assessed by Insulin Treatment Satisfaction Questionnaire (ITSQ-22),Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2287,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN304-1713,Oct-05,Apr-06,Apr-06,18-Oct-12,null,3-Mar-16,"Mississauga, Canada",,https://ClinicalTrials.gov/show/NCT01709929
NCT01709123,Effects of Micronutrient (Chromium) Supplementation on Diabetes,,Unknown status,No Results Available,"Diabetes Mellitus, Type 1",Drug: chromium niacinate|Drug: placebo,Blood levels of glycemia|Lipid levels|Blood levels of cytokines/inflammatory biomarkers,Louisiana State University Health Sciences Center Shreveport|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"8 Years to 21 Years   (Child, Adult)",Not Applicable,150,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",H-08-028|3R01DK072433-03S1,Aug-07,Sep-13,Sep-13,17-Oct-12,null,30-Oct-12,"Louisiana State University Health Sciences Center in Shreveport, Shreveport, Louisiana, United States",,https://ClinicalTrials.gov/show/NCT01709123
NCT01708044,Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM,,Completed,No Results Available,Type 1 Diabetes,Drug: Pramlintide acetate|Other: Placebo,"Incremental area under the concentration-time curve (AUC(0-3 h)) of plasma glucose concentrations for each treatment|Incremental AUC (0-3 h) of plasma glucagon|Absolute AUC (0-3 h), peak plasma concentration (Cmax), Cave, and Tmax of glucagon of plasma glucose.|PK of pramlintide|Safety",AstraZeneca|Juvenile Diabetes Research Foundation,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,32,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,D5570C00001,Nov-12,Sep-13,Sep-13,16-Oct-12,null,20-Oct-14,"Research Site, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT01708044
NCT01705899,Islet Allotransplantation in Type 1 Diabetes,,Enrolling by invitation,No Results Available,Type 1 Diabetes,Drug: Human Pancreatic Islets,Incidence of adverse events|Incidence of serious adverse events|Incidence of infectious complications|Incidence of procedural-related events|Incidence of elevated liver function tests|Incidence of hypoglycemia|Incidence of abnormalities in lipids|Incidence of donor-specific antibody development|Change in microalbumin level|Change in measured creatinine clearance|Amount of daily insulin units required|Measurement of C-peptide|Change in c-peptide level from fasting following administration of mixed meal|Change in acute insulin response to glucose|Incidence of blood glucose level <140mg/dl two hours after oral glucose tolerance tests|Change in Quality of Life|Change in hypoglycemia score|Change in glycemic lability score,Ohio State University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB 2006H0200,Nov-06,Oct-21,Oct-21,12-Oct-12,null,20-Mar-19,"The Ohio State University Medical Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01705899
NCT01704417,"A Trial Comparing the Effect of Exercise on Blood Glucose in Subjects With Type 1 Diabetes, Who Are Treated With Either Insulin Degludec or Insulin Glargine",,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin glargine,"BGpre-exe - BGminimum,exe, difference between blood glucose concentration before exercise and the minimum blood glucose concentration observed during exercise|BGmean,exe, mean blood glucose concentration during exercise|BGmean,30-180min,post-exe, mean blood glucose concentration|BGminimum,30-180min,post-exe, minimum blood glucose concentration",Novo Nordisk A/S,All,18 Years to 45 Years   (Adult),Phase 1,40,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN1250-3999|2012-000329-37|U1111-1127-3402,Oct-12,Mar-13,Mar-13,11-Oct-12,null,16-Dec-16,"Novo Nordisk Investigational Site, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01704417
NCT01697150,Outpatient Control-to-Range: System and Monitoring Testing,,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: DiAs Diabetes Assistant Wearable Artificial Pancreas Platform,Percent time of active CTR|Frequency analysis of failed data caused by system components|Frequency of inaccurate data caused by system components|Frequency analysis of lost data caused by system components,"Sansum Diabetes Research Institute|University of California, Santa Barbara|University of Virginia",All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,5,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,JDRF 22-2011-649 SB,Apr-12,Dec-15,Dec-15,2-Oct-12,null,21-Apr-16,"Sansum Diabetes Research Institute, Santa Barbara, California, United States",,https://ClinicalTrials.gov/show/NCT01697150
NCT01697228,The Effects of Vitamin D on Glycemic Control and Proinflammatory Markers in Adolescents With T1DM,,Completed,No Results Available,Type 1 Diabetes|Vitamin D Deficiency/Insufficiency,Dietary Supplement: Vitamin D,Hemoglobin A1c|Pro-inflammatory markers|Vitamin D level and proinflammatory markers|Vitamin D levels on insulin requirements|Vitamin D level and HbA1c|Baseline differences between vitamin D deficient & sufficient subjects,Children's Hospital Los Angeles,All,"13 Years to 21 Years   (Child, Adult)",Not Applicable,26,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,11-00352,Oct-12,Mar-14,Jun-14,2-Oct-12,null,8-May-17,"Children's Hospital Los Angeles, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT01697228
NCT01697657,Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir in Well Controlled Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin detemir|Drug: insulin NPH|Drug: insulin aspart,Incidence of total self-recorded hypoglycaemic episodes|Incidence of total major hypoglycaemic episodes|HbA1c (glycosylated haemoglobin)|8-point plasma glucose profiles|Serum glucose profiles|72-hours glucose profile|Within-subject variation in home-measured fasting plasma glucose|Incidence of adverse events,Novo Nordisk A/S,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 3,131,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN304-1375,Sep-01,Nov-02,Nov-02,2-Oct-12,null,27-Jan-17,"Novo Nordisk Investigational Site, Camperdown, New South Wales, Australia|Novo Nordisk Investigational Site, Ashford, Australia|Novo Nordisk Investigational Site, Box Hill, Australia|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Køge, Denmark|Novo Nordisk Investigational Site, Århus C, Denmark|Novo Nordisk Investigational Site, Citta' Di Castello, Italy|Novo Nordisk Investigational Site, Perugia, Italy|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Linköping, Sweden|Novo Nordisk Investigational Site, Trelleborg, Sweden",,https://ClinicalTrials.gov/show/NCT01697657
NCT01693302,Timing of Meal Insulin Boluses for Optimal Postprandial Glycemic Control in Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Other: Insulin,Blood glucose area under the curve|Glucose values one hour after the meal|Glucose values two hours after the beginning of the meal,"University of Colorado, Denver|Sanofi",All,"12 Years to 30 Years   (Child, Adult)",Not Applicable,23,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,06-0994,Aug-07,May-09,May-09,26-Sep-12,null,26-Sep-12,"Barbara Davis Center, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT01693302
NCT01691287,MICHAEL Method- Fulfilling Individual Potential to Attain Excellence - as a Tool for Improving Metabolic Control and Quality of Life Among Adolescence With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Behavioral: Michael Method,Metabolic Control measured as HbA1c level|Diabetes Quality of Life questionnaire (DQOLY)|Self assessment questionnaire|Number of severe hypoglycemic events|Number of Diabetic Keto Acidosis events,Rabin Medical Center,All,12 Years to 17 Years   (Child),Not Applicable,23,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,rmc006444ctil,Oct-12,Dec-13,Dec-13,24-Sep-12,null,1-May-14,"Schneider Medical Center, Petah-TTikva, Israel",,https://ClinicalTrials.gov/show/NCT01691287
NCT01689129,Comparison of a New Formulation of Insulin Glargine With Lantus® in Japanese Patients With Type 1 Diabetes Mellitus,EDITION JP I,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Insulin glargine new formulation (HOE901)|Drug: Insulin glargine (HOE901) (Lantus),Change from baseline in HbA1c|Percentage of HbA1c responders (HbA1c < 7%; < 6.5%)|Change from baseline in FPG|Change from baseline in pre-basal insulin injection SMPG|Change from baseline in 8-point SMPG profiles|Change from baseline in 24-hour mean plasma glucose of SMPG profiles (mean of 8-point values)|Change from baseline in variability of plasma glucose profile|Change from baseline in daily basal insulin dose|Number of Patients with various types of Hypoglycemia Events,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,243,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EFC12449|U1111-1130-3513,Sep-12,Oct-13,Apr-14,21-Sep-12,null,9-Jun-14,"Investigational Site Number 392119, Amagasaki-Shi, Japan|Investigational Site Number 392106, Chuo-Ku, Japan|Investigational Site Number 392107, Chuo-Ku, Japan|Investigational Site Number 392110, Ebina-Shi, Japan|Investigational Site Number 392115, Higashiosaka-Shi, Japan|Investigational Site Number 392117, Izumisano-Shi, Japan|Investigational Site Number 392109, Kamakura-Shi, Japan|Investigational Site Number 392101, Koriyama-Shi, Japan|Investigational Site Number 392121, Kurashiki-Shi, Japan|Investigational Site Number 392112, Nagoya-Shi, Japan|Investigational Site Number 392120, Nishinomiya-Shi, Japan|Investigational Site Number 392113, Osaka-Shi, Japan|Investigational Site Number 392116, Osaka-Shi, Japan|Investigational Site Number 392118, Osaka-Shi, Japan|Investigational Site Number 392104, Shinjuku-Ku, Japan|Investigational Site Number 392105, Shinjuku-Ku, Japan|Investigational Site Number 392111, Shizuoka-Shi, Japan|Investigational Site Number 392114, Takatsuki-Shi, Japan|Investigational Site Number 392122, Tokushima-Shi, Japan|Investigational Site Number 392103, Tomioka-Shi, Japan|Investigational Site Number 392102, Ushiku-Shi, Japan|Investigational Site Number 392108, Yokohama-Shi, Japan",,https://ClinicalTrials.gov/show/NCT01689129
NCT01689051,Vasodilatory and Metabolic Effects of Glucagon-like Peptide-1 in Periphery Circulation in Patients With and Without Type 2 Diabetes Mellitus,,Completed,No Results Available,Type 2 Diabetes|Blod Pressure|Glucagon-like Peptide-1|Human Physiology|Blood Flow,Other: human glucagon-like peptide 1 (7-36)amide|Other: human glucagon-like peptide 1 (9-36)amide,Femoral artery blood flow|Leg glucose uptake,"University Hospital, Gentofte, Copenhagen|Danish Heart Foundation",Male,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,1-Sivertsen,Mar-12,Apr-13,Apr-13,20-Sep-12,null,31-Jan-14,"Gentofte Hospital, Department of Cardiology, Hellerup, Denmark",,https://ClinicalTrials.gov/show/NCT01689051
NCT01689090,Diameter Changes of Retinal Vessels During Hypoxia,,Completed,No Results Available,Diabetes Mellitus Type 1|Diabetic Maculopathy,Other: COX inhibitor|Other: L-NG-monomethyl arginine citrate|Other: COX inhibitor + L-NG-monomethyl arginine citrate,Diameter changes of retinal vessels,University of Aarhus,All,"20 Years to 65 Years   (Adult, Older Adult)",Not Applicable,58,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,HypNOCOX,Nov-12,Mar-16,Mar-16,20-Sep-12,null,16-Oct-18,"Department of Ophthalmology, Aarhus University Hospital, Aarhus, Denmark",,https://ClinicalTrials.gov/show/NCT01689090
NCT01687582,Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients,,Completed,No Results Available,Type 2 Diabetes|Psoriasis,Drug: GLP-1 analog,Improvement of PASI score|Evolution of BMI (body mass index)|Evolution of immunological data|Evolution of histopathological data|Evolution of glycaemic control|Evolution of routine laboratory measures|Evolution of BMI,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,All,"20 Years to 75 Years   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UCL-DIAB-02,Jan-12,Dec-12,Mar-13,19-Sep-12,null,12-Mar-19,"Cliniques universitaires Saint-Luc, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT01687582
NCT01686620,A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®),,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: BIOD-123|Drug: Lispro (Humalog),Change in HbA1C|Hypoglycemic event rates|Insulin dose|Daily blood glucose measures,Biodel,All,"18 Years and older   (Adult, Older Adult)",Phase 2,132,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3-201,Aug-12,Jun-13,Jun-13,18-Sep-12,null,28-Jul-15,"Anaheim Clinical Trials, LLC, Anaheim, California, United States|Profil Research Institute, Chula Vista, California, United States|John Muir Physician Network Clinical Research Center, Concord, California, United States|Scripps Whittier Diabetes Institute, La Jolla, California, United States|Private Practice - Richard Cherlin, MD., Los Gatos, California, United States|Providence Clinical Research Pharmaseek, North Hollywood, California, United States|Monteagle Medical Center, San Francisco, California, United States|Mills-Peninsula Health Services, San Mateo, California, United States|The Center for Diabetes and Endocrine Care, Hollywood, Florida, United States|University of Miami Diabetes Research Institute, Miami, Florida, United States|Progressive Medical Research Pharmaseek, Port Orange, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Endocrine Research Solutions, Roswell, Georgia, United States|Rocky Mountain Diabetes and Osteoporosis Center PA, Idaho Falls, Idaho, United States|MidAmerica Diabetes Associates, PA, Wichita, Kansas, United States|Kentucky Diabetes, Lexington, Kentucky, United States|Diabetes & Glandular Disease Research, Rockville, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|Mercury Street Medical, Butte, Montana, United States|Desert Endocrinolgy, Henderson, Nevada, United States|Research Foundation of SUNY Upstate Medical University, Syracuse, New York, United States|Diabetes & Endocrinology Consultants, PC, Morehead City, North Carolina, United States|Sentral Clinical Research Services, LLC, Cincinnati, Ohio, United States|Oregon Health Sciences University, Portland, Oregon, United States|Texas Diabetes and Endocrinology, Austin, Texas, United States|Mountain Diabetes & Endrocrine Center, Dallas, Texas, United States|Dallas Diabetes and Endocrine Research Center, Dallas, Texas, United States|Research Institute of Dallas, Dallas, Texas, United States|Baylor Endocrine Center, Dallas, Texas, United States|Texas Diabetes and Endocrinology, Round Rock, Texas, United States|Sonterra Clinical Research, San Antonio, Texas, United States|Capital Clinical Research Center, Olympia, Washington, United States|Ranier Clinical Research, Inc, Renton, Washington, United States|Rockwood Clinic, Spokane, Washington, United States",,https://ClinicalTrials.gov/show/NCT01686620
NCT01686945,"Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes",,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 2|Healthy",Drug: semaglutide|Drug: placebo,Number of treatment emergent adverse events (TEAEs) recorded|Area under the plasma concentration curve over the dosing interval (0-24 hours)|Change from baseline in fasting plasma glucose (FPG)|Change from baseline in C-peptide|Change from baseline in insulin|Change from baseline in glucagon|Change from baseline in glycosylated haemoglobin type A1c (HbA1c),Novo Nordisk A/S,Male,18 Years to 64 Years   (Adult),Phase 1,107,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN9924-3991|2012-000361-20|U1111-1127-4408,19-Sep-12,8-Apr-13,8-Apr-13,18-Sep-12,null,4-Jan-19,"Novo Nordisk Investigational Site, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT01686945
NCT01686139,Safety Study of Stem Cells Treatment in Diabetic Foot Ulcers,,Unknown status,No Results Available,Type I Diabetes Mellitus With Ulcer|Type II Diabetes Mellitus With Ulcer,Biological: ABMD-MSC,Frequency of Adverse Events,Sheba Medical Center,All,"18 Years to 81 Years   (Adult, Older Adult)",Phase 1,12,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SHEBA-11-8802-IS-SMC,Mar-16,Mar-17,Dec-17,17-Sep-12,null,27-Jan-16,"Orthopedic Rehabilitation out-patient clinic, Sheba Medical Center, Ramat Gan, Israel",,https://ClinicalTrials.gov/show/NCT01686139
NCT01684943,Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling,,Unknown status,No Results Available,Type 1 Diabetes,Other: Multiplex pharmacokinetic profiling|Other: Continuous insulin monitoring,For Multiplex PK profiling: Aggregate mean difference in tmax between the analog with greatest and the analog with the least value of tmax for individuals|For Continuous Insulin Monitoring: Agreement between plots of insulin concentration in the blood and plots of insulin concentration in the microdialysate vs. time by both the CIM lab-on-a-chip and by immunoassays performed on fractions of microdialysate|Multiplex PK: Correlation between HbA1c at study entry and use of insulin analog with most favorable PK as an outpatient for subjects with a difference in tmax between analogs.|Multiplex PK: Fraction of subjects with difference in tmax between the analog with greatest and the analog with the least value of tmax that is > 25%|Multiplex PK: Correlation between HbA1c at study entry and use of insulin analog with tmax < 60 minutes as an outpatient vs. use of an insulin analog with tmax > 60 minutes as an outpatient.|Multiplex PK: Correlation between number of monthly self-reported or meter recorded incidents of hypoglycemia at study entry and use of insulin analog with best PK kinetics.,Massachusetts General Hospital,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 2,33,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010P001005,Jul-10,Sep-16,Dec-17,13-Sep-12,null,7-Feb-17,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01684943
NCT01684956,Pharmacokinetic Comparison of Intradermal Versus Sub-cutaneous Insulin and Glucagon Delivery in Type 1 Diabetes,,Unknown status,No Results Available,Type 1 Diabetes,Procedure: Intradermal injection|Procedure: Subcutaneous injection,"Aggregate mean difference in tmax between the delivery methods (the insulin and glucagon data will be evaluated separately)|Aggregate mean difference in t1/2max between the methods|Aggregate mean difference in Cmax between the methods|Aggregate mean difference in area under the curve (AUC) between methods|AUC of 0-1 hour (and by subtraction hours 1-5)|AUC of 0-2 hours (and by subtraction hours 2-5)|Time to 50% of Total AUC (or said another way, time to 50% exposure)|Fraction of subjects with difference in tmax between the methods of > 25%|Fraction of ""dry"" injections with no reflux of fluid from the injection site|Difference in mean visual analog pain score between the two methods|Difference in mean visual analog pain score between insulin and glucagon with subcutaneous injection|Difference in mean visual analog pain score between insulin and glucagon with intradermal injection",Massachusetts General Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012P001098,Aug-12,Jul-14,Dec-17,13-Sep-12,null,7-Sep-16,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01684956
NCT01682902,A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart,Mean change in plasma glucose concentration|Self-measured plasma glucose (SMPG) 7-point profile|Self-measured plasma glucose (SMPG) 9-point profile|Number of adverse events (AEs) (including infusion site reactions/infections)|Number of hypoglycaemic episodes|Number of unexplained self-reported episodes of hypoglycaemia or hyperglycaemia (confirmed by SMPG)|Number of episodes of infusion set occlusions,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 1,43,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1218-3930|U1111-1121-5106,Sep-12,Mar-13,Mar-13,11-Sep-12,null,9-Jan-17,"Novo Nordisk Investigational Site, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT01682902
NCT01683266,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus,EDITION IV,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: HOE901-U300 (Insulin glargine new formulation)|Drug: Lantus (Insulin glargine),Change In HbA1c From Baseline to Month 6 Endpoint|Percentage of Participants With HbA1c <7% at Month 6 Endpoint|Percentage of Participants With HbA1c Less Than or Equal to 6.5% at Month 6 Endpoint|Change In Average Pre-Injection Self-Monitored Plasma Glucose (SMPG) From Baseline Month 6 Endpoint|Change in Variability of Pre-injection SMPG From Baseline to Month 6 Endpoint|Change in Fasting Plasma Glucose From Baseline to Month 6 Endpoint|Percentage of Participants With Fasting Plasma Glucose (FPG) <5.6 mmol/L (100 mg/dL) At Month 6|Percentage of Participants With FPG <7.2 mmol/L (130 mg/dL) at Month 6 Endpoint|Change in 8--Point SMPG Profiles Per Time Point From Baseline to Month 6 Endpoint|Change in Daily Average Total Insulin Dose From Baseline to Month 6 Endpoint|Change in Total Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint|Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline to Month 12,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,549,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EFC12456|2012-001524-35|U1111-1128-5517,Sep-12,Sep-13,Mar-14,11-Sep-12,23-Apr-15,24-Jun-15,"Investigational Site Number 840156, Chandler, Arizona, United States|Investigational Site Number 840177, Little Rock, Arkansas, United States|Investigational Site Number 840430, Bell Gardens, California, United States|Investigational Site Number 840131, Escondido, California, United States|Investigational Site Number 840140, Fresno, California, United States|Investigational Site Number 840107, Greenbrae, California, United States|Investigational Site Number 840149, Huntington Beach, California, United States|Investigational Site Number 840120, La Jolla, California, United States|Investigational Site Number 840123, La Mesa, California, United States|Investigational Site Number 840159, La Mesa, California, United States|Investigational Site Number 840114, Long Beach, California, United States|Investigational Site Number 840189, Mission Hills, California, United States|Investigational Site Number 840105, Temecula, California, United States|Investigational Site Number 840155, Tustin, California, United States|Investigational Site Number 840115, Walnut Creek, California, United States|Investigational Site Number 840160, Denver, Colorado, United States|Investigational Site Number 840188, Denver, Colorado, United States|Investigational Site Number 840196, New Haven, Connecticut, United States|Investigational Site Number 840113, Bradenton, Florida, United States|Investigational Site Number 840102, Hialeah, Florida, United States|Investigational Site Number 840134, Hollywood, Florida, United States|Investigational Site Number 840185, Jacksonville, Florida, United States|Investigational Site Number 840116, Jacksonville, Florida, United States|Investigational Site Number 840126, Miami, Florida, United States|Investigational Site Number 840179, Miami, Florida, United States|Investigational Site Number 840117, New Port Richey, Florida, United States|Investigational Site Number 840174, Orlando, Florida, United States|Investigational Site Number 840110, Oviedo, Florida, United States|Investigational Site Number 840178, Palm Harbor, Florida, United States|Investigational Site Number 840181, Tampa, Florida, United States|Investigational Site Number 840420, West Palm Beach, Florida, United States|Investigational Site Number 840195, Atlanta, Georgia, United States|Investigational Site Number 840124, Honolulu, Hawaii, United States|Investigational Site Number 840167, Idaho Falls, Idaho, United States|Investigational Site Number 840163, Nampa, Idaho, United States|Investigational Site Number 840162, Springfield, Illinois, United States|Investigational Site Number 840172, Avon, Indiana, United States|Investigational Site Number 840197, Indianapolis, Indiana, United States|Investigational Site Number 840108, Des Moines, Iowa, United States|Investigational Site Number 840407, Iowa City, Iowa, United States|Investigational Site Number 840170, Topeka, Kansas, United States|Investigational Site Number 840421, Lexington, Kentucky, United States|Investigational Site Number 840426, Metairie, Louisiana, United States|Investigational Site Number 840104, Baltimore, Maryland, United States|Investigational Site Number 840180, Rockville, Maryland, United States|Investigational Site Number 840137, Haverhill, Massachusetts, United States|Investigational Site Number 840408, Detroit, Michigan, United States|Investigational Site Number 840153, Madison Heights, Michigan, United States|Investigational Site Number 840171, St Louis Park, Minnesota, United States|Investigational Site Number 840184, St Louis, Missouri, United States|Investigational Site Number 840106, Omaha, Nebraska, United States|Investigational Site Number 840145, Omaha, Nebraska, United States|Investigational Site Number 840139, Las Vegas, Nevada, United States|Investigational Site Number 840151, Albuquerque, New Mexico, United States|Investigational Site Number 840191, New Hyde Park, New York, United States|Investigational Site Number 840173, Syracuse, New York, United States|Investigational Site Number 840133, Asheville, North Carolina, United States|Investigational Site Number 840175, Chapel Hill, North Carolina, United States|Investigational Site Number 840161, Morganton, North Carolina, United States|Investigational Site Number 840169, Mentor, Ohio, United States|Investigational Site Number 840119, Norman, Oklahoma, United States|Investigational Site Number 840112, Bend, Oregon, United States|Investigational Site Number 840136, Greer, South Carolina, United States|Investigational Site Number 840122, Dakota Dunes, South Dakota, United States|Investigational Site Number 840144, Chattanooga, Tennessee, United States|Investigational Site Number 840187, Nashville, Tennessee, United States|Investigational Site Number 840109, Austin, Texas, United States|Investigational Site Number 840157, Austin, Texas, United States|Investigational Site Number 840150, Dallas, Texas, United States|Investigational Site Number 840412, Dallas, Texas, United States|Investigational Site Number 840130, Houston, Texas, United States|Investigational Site Number 840141, Houston, Texas, United States|Investigational Site Number 840166, San Antonio, Texas, United States|Investigational Site Number 840101, Murray, Utah, United States|Investigational Site Number 840125, Burke, Virginia, United States|Investigational Site Number 840427, Chesapeake, Virginia, United States|Investigational Site Number 840103, Manassas, Virginia, United States|Investigational Site Number 840132, Renton, Washington, United States|Investigational Site Number 840403, Seattle, Washington, United States|Investigational Site Number 840402, Spokane, Washington, United States|Investigational Site Number 840127, Tacoma, Washington, United States|Investigational Site Number 840411, Milwaukee, Wisconsin, United States|Investigational Site Number 124110, Coquitlam, Canada|Investigational Site Number 124104, Laval, Canada|Investigational Site Number 124108, Mirabel, Canada|Investigational Site Number 124109, Montreal, Canada|Investigational Site Number 124105, Thornhill, Canada|Investigational Site Number 124101, Toronto, Canada|Investigational Site Number 203102, Brno, Czech Republic|Investigational Site Number 203104, Praha 10, Czech Republic|Investigational Site Number 203103, Praha 8, Czech Republic|Investigational Site Number 208103, Esbjerg, Denmark|Investigational Site Number 208105, Gentofte, Denmark|Investigational Site Number 208104, København Nv, Denmark|Investigational Site Number 208107, Køge, Denmark|Investigational Site Number 208102, Ålborg, Denmark|Investigational Site Number 233104, Pärnu, Estonia|Investigational Site Number 233105, Tallinn, Estonia|Investigational Site Number 233106, Tartu, Estonia|Investigational Site Number 233101, Tartu, Estonia|Investigational Site Number 233103, Viljandimaa, Estonia|Investigational Site Number 246102, Kokkola, Finland|Investigational Site Number 246101, Kuopio, Finland|Investigational Site Number 246106, Loimaa, Finland|Investigational Site Number 246105, Oulu, Finland|Investigational Site Number 246103, Tampere, Finland|Investigational Site Number 348103, Budapest, Hungary|Investigational Site Number 348108, Budapest, Hungary|Investigational Site Number 348107, Budapest, Hungary|Investigational Site Number 348106, Debrecen, Hungary|Investigational Site Number 348102, Gyula, Hungary|Investigational Site Number 348101, Urhida, Hungary|Investigational Site Number 392110, Aisai-Shi, Japan|Investigational Site Number 392105, Ise-Shi, Japan|Investigational Site Number 392104, Karatsu-Shi, Japan|Investigational Site Number 392111, Kitakyushu-Shi, Japan|Investigational Site Number 392112, Matsumoto-Shi, Japan|Investigational Site Number 392108, Matumoto, Japan|Investigational Site Number 392103, Midori-Shi, Japan|Investigational Site Number 392107, Mito-Shi, Japan|Investigational Site Number 392101, Sakai-Shi, Japan|Investigational Site Number 392102, Tomishiro, Japan|Investigational Site Number 392106, Yamagata-Shi, Japan|Investigational Site Number 428106, Limbazi, Latvia|Investigational Site Number 428103, Riga, Latvia|Investigational Site Number 428105, Riga, Latvia|Investigational Site Number 428102, Sigulda, Latvia|Investigational Site Number 428101, Ventspils, Latvia|Investigational Site Number 528101, Almere, Netherlands|Investigational Site Number 528103, Beek, Netherlands|Investigational Site Number 528105, Nijmegen, Netherlands|Investigational Site Number 528104, Venlo, Netherlands|Investigational Site Number 528102, Zwijndrecht, Netherlands|Investigational Site Number 840602, Ponce, Puerto Rico|Investigational Site Number 642107, Bacau, Romania|Investigational Site Number 642103, Brasov, Romania|Investigational Site Number 642109, Oradea, Romania|Investigational Site Number 642106, Resita, Romania|Investigational Site Number 642104, Sibiu, Romania|Investigational Site Number 642101, Targu Mures, Romania|Investigational Site Number 642102, Targu Mures, Romania|Investigational Site Number 642105, Timisoara, Romania|Investigational Site Number 642108, Timisoara, Romania|Investigational Site Number 752103, Goteborg, Sweden|Investigational Site Number 752105, Kristianstad, Sweden|Investigational Site Number 752101, Stockholm, Sweden|Investigational Site Number 752104, Vällingby, Sweden",,https://ClinicalTrials.gov/show/NCT01683266
NCT01681550,A Cohort Study of Incretin-based Therapy Combined With Insulin in Type 2 Diabetic Patients for 5 Years,,Unknown status,No Results Available,Type 2 Diabetes Mellitus,Drug: Incretin-based therapy,Death|HbA1c|BMI|Blood pressure|Insulin dose|Hypoglycemia|Microvascular complications including renal anemia|Macrovasular complications,Nagaoka Red Cross Hospital,All,"20 Years to 95 Years   (Adult, Older Adult)",Not Applicable,500,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,8-Kamoi,Oct-12,Oct-18,Oct-18,10-Sep-12,null,11-Sep-12,"Nagaoka Red Cross Hospital, Nagaoka, Niigata, Japan",,https://ClinicalTrials.gov/show/NCT01681550
NCT01681693,Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans,#6113,Completed,No Results Available,Healthy|Type 2 Diabetes Mellitus,Drug: Metformin,Renal Clearance of the Metformin|Plasma glucose,"University of California, San Francisco",All,"18 Years and older   (Adult, Older Adult)",Phase 1,33,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,6113,Feb-10,Jul-13,Jul-13,10-Sep-12,null,23-Oct-14,"San Francisco General Hospital, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT01681693
NCT01680328,Investigation of Pain During Subcutaneous Injections With Different Injection Speed and Volume Combinations,,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Delivery Systems",Other: 19 injections|Drug: sodium chloride 0.9% solution,Injection Pain (VAS mm)|Acceptance of Injection Pain After Injection of Different Volumes.|Acceptance of Injection Pain After Injection at Different Speeds.|Acceptance of Injection Pain After Injection in the Thighs Versus Abdomen.|Estimated Mean Differences in the Volume of Backflow (uL) in the Abdomen After Different Injection Volumes and Speeds as Compared to Needle Insertion|Estimated Mean Differences in the Volume of Backflow (uL) in the Thighs After Different Injection Volumes and Speeds as Compared to Needle Insertion,Novo Nordisk A/S,All,"18 Years to 74 Years   (Adult, Older Adult)",Phase 1,82,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care",INS-4011|U1111-1129-4191,Aug-12,Oct-12,Oct-12,7-Sep-12,19-Jun-14,3-Mar-17,"Novo Nordisk Investigational Site, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01680328
NCT01680653,Testing State of the Art Remote Glucose Monitoring at Diabetes Camp,,Completed,Has Results,Type 1 Diabetes,Drug: Mini-glucagon|Device: Remote monitoring|Dietary Supplement: Carbohydrates,Duration of Nocturnal Hypoglycemia|Duration of Glucose Readings <70 mg/dl,"Stanford University|University of Virginia|DexCom, Inc.|The Leona M. and Harry B. Helmsley Charitable Trust",All,"7 Years to 21 Years   (Child, Adult)",Not Applicable,57,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2012PG-T1D001|IRB 27428,May-12,Sep-12,Sep-12,7-Sep-12,5-Mar-18,5-Mar-18,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT01680653
NCT01680926,Metabolic Activation With Almased for Type 2 Diabetes Patients,Almased100,Completed,No Results Available,Type 2 Diabetes Mellitus,Dietary Supplement: Almased,insulin demand per day|HbA1c|body weight,West German Center of Diabetes and Health|Almased Wellness GmbH,All,"35 Years to 75 Years   (Adult, Older Adult)",Early Phase 1,22,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Almased100,Jul-09,Feb-11,Oct-11,7-Sep-12,null,11-Sep-12,"West German Center of Diabetes and Health, Düsseldorf, Germany",,https://ClinicalTrials.gov/show/NCT01680926
NCT01681290,Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes,,Completed,No Results Available,Diabetic Peripheral Neuropathy,Drug: CBX129801,Bilateral change in sensory nerve conduction velocity|Vibration perception threshold|Clinical composite score|Pain Intensity due to DPN|Sexual function questionnaires|Quality of life questionnaire,Cebix Incorporated,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,250,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CBX129801-DN-201,Oct-12,Nov-14,Jan-15,7-Sep-12,null,30-Jan-15,"Escondido, California, United States|Fresno, California, United States|Irvine, California, United States|Los Angeles, California, United States|San Diego, California, United States|San Francisco, California, United States|Torrance, California, United States|Tustin, California, United States|Walnut Creek, California, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Idaho Falls, Idaho, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Butte, Montana, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|New York, New York, United States|Dallas, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Toronto, Ontario, Canada|Laval, Quebec, Canada|Göteborg, Sweden|Linköping, Sweden|Malmo, Sweden|Stockholm, Sweden|Umea, Sweden",,https://ClinicalTrials.gov/show/NCT01681290
NCT01677546,Bolus Calculator and Wireless Communication With Blood Glucose Meter in Management of Type 1 Diabetes Mellitus (T1DM).,,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: CSII+BC+CL|Device: CSII+BC,HbA1c (Glycated hemoglobin)|Post- prandial glycaemia|Treatment satisfaction|Hypoglycaemia episodes and severe hypoglycaemia events|Frequency of self- blood glucose monitoring|Hyperglycaemic episodes|Frequency of meal boluses|Frequency of bolus calculator using,Medical University of Warsaw,All,"7 Years to 18 Years   (Child, Adult)",Not Applicable,156,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),Bolus-calculator,Jan-11,Jul-12,Jul-12,3-Sep-12,null,3-Sep-12,"Medical University of Warsaw, Warsaw, Poland",,https://ClinicalTrials.gov/show/NCT01677546
NCT01678235,Insulin Glulisine and Aspart in Postprandial Glycemic Control After High-GI Meal in Children With Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Insulin glulisine|Drug: Insulin aspart,Postprandial glycemia|Hypoglycemia episodes|Glucose Area Under the Curve (AUC)|Mean amplitude of glycemic excursion (MAGE)|Difference between the maximum and baseline glycemia,Medical University of Warsaw,All,"10 Years to 18 Years   (Child, Adult)",Phase 4,64,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Glulisine_Aspart,Sep-11,Sep-12,Sep-12,3-Sep-12,null,7-Oct-14,"Department of Pediatrics, Medical University of Warsaw, Poland, Warsaw, Poland",,https://ClinicalTrials.gov/show/NCT01678235
NCT01676116,The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy,DUAL™ III,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/liraglutide|Drug: liraglutide|Drug: exenatide,"Change in Glycosylated Haemoglobin (HbA1c) From Baseline (Randomisation, Visit 2)|Responders Achieving Pre-defined Target: HbA1c Below 7.0% (53 mmol/Mol)|Responders Achieving Pre-defined Target: HbA1c Below or Equal to 6.5% (48 mmol/Mol)|Change From Baseline in Body Weight|Change From Baseline in Fasting Plasma Glucose (FPG)|Number of Severe or Minor Hypoglycaemic Episodes|Number of Adverse Events (AEs)|Change From Baseline in Patient Reported Outcomes (PROs) Based on the Treatment Related Impact Measure - Diabetes (TRIM-D)|Change From Baseline in Patient Reported Outcomes (PROs) Based on Diabetes Treatment Satisfaction Questionnaire (DTSQ).",Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,438,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN9068-3851|2012-000209-63|U1111-1127-1321,29-Aug-12,11-Mar-14,11-Mar-14,30-Aug-12,9-Jul-18,3-Jan-19,"Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Goodyear, Arizona, United States|Novo Nordisk Investigational Site, Mesa, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Encino, California, United States|Novo Nordisk Investigational Site, Fair Oaks, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Greenbrae, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Lomita, California, United States|Novo Nordisk Investigational Site, Long Beach, California, United States|Novo Nordisk Investigational Site, Montclair, California, United States|Novo Nordisk Investigational Site, Northridge, California, United States|Novo Nordisk Investigational Site, San Mateo, California, United States|Novo Nordisk Investigational Site, San Ramon, California, United States|Novo Nordisk Investigational Site, Tarzana, California, United States|Novo Nordisk Investigational Site, Van Nuys, California, United States|Novo Nordisk Investigational Site, Colorado Springs, Colorado, United States|Novo Nordisk Investigational Site, Bradenton, Florida, United States|Novo Nordisk Investigational Site, Fort Myers, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Miami Springs, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Plant City, Florida, United States|Novo Nordisk Investigational Site, Winter Haven, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, United States|Novo Nordisk Investigational Site, Arlington Heights, Illinois, United States|Novo Nordisk Investigational Site, Indianapolis, Indiana, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Rockville, Maryland, United States|Novo Nordisk Investigational Site, Kalamazoo, Michigan, United States|Novo Nordisk Investigational Site, Troy, Michigan, United States|Novo Nordisk Investigational Site, Saint Charles, Missouri, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Henderson, Nevada, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Reno, Nevada, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, United States|Novo Nordisk Investigational Site, Berlin, New Jersey, United States|Novo Nordisk Investigational Site, Flemington, New Jersey, United States|Novo Nordisk Investigational Site, Hamilton, New Jersey, United States|Novo Nordisk Investigational Site, Lawrenceville, New Jersey, United States|Novo Nordisk Investigational Site, Toms River, New Jersey, United States|Novo Nordisk Investigational Site, Mineola, New York, United States|Novo Nordisk Investigational Site, North Massapequa, New York, United States|Novo Nordisk Investigational Site, West Seneca, New York, United States|Novo Nordisk Investigational Site, Morehead City, North Carolina, United States|Novo Nordisk Investigational Site, Columbus, Ohio, United States|Novo Nordisk Investigational Site, Dayton, Ohio, United States|Novo Nordisk Investigational Site, Altoona, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Myrtle Beach, South Carolina, United States|Novo Nordisk Investigational Site, Sumter, South Carolina, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Jellico, Tennessee, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Tullahoma, Tennessee, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Fort Worth, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Plano, Texas, United States|Novo Nordisk Investigational Site, Round Rock, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Schertz, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Orem, Utah, United States|Novo Nordisk Investigational Site, Saint George, Utah, United States|Novo Nordisk Investigational Site, Salt Lake City, Utah, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Coffs Harbour, New South Wales, Australia|Novo Nordisk Investigational Site, Merewether, New South Wales, Australia|Novo Nordisk Investigational Site, Keswick, South Australia, Australia|Novo Nordisk Investigational Site, Box Hill, Victoria, Australia|Novo Nordisk Investigational Site, Melbourne, Victoria, Australia|Novo Nordisk Investigational Site, Antibes, France|Novo Nordisk Investigational Site, Boulogne Billancourt, France|Novo Nordisk Investigational Site, LA ROCHELLE cedex, France|Novo Nordisk Investigational Site, Montigny-les-Metz, France|Novo Nordisk Investigational Site, Narbonne, France|Novo Nordisk Investigational Site, Nimes, France|Novo Nordisk Investigational Site, Sète, France|Novo Nordisk Investigational Site, Venissieux, France|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Debrecen, Hungary|Novo Nordisk Investigational Site, Nyíregyhaza, Hungary|Novo Nordisk Investigational Site, Székesfehérvár, Hungary|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Kosice, Slovakia|Novo Nordisk Investigational Site, Lucenec, Slovakia|Novo Nordisk Investigational Site, Nitra, Slovakia|Novo Nordisk Investigational Site, Presov, Slovakia",,https://ClinicalTrials.gov/show/NCT01676116
NCT01676233,Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: insulin glargine (HOE901)|Drug: insulin glargine- new formulation (HOE901),Change in 24-hour blood glucose profile measured by continuous glucose monitoring|Hypoglycemia categorized by the definition of American Diabetes Association|Change in fasting plasma glucose from baseline to each treatment end by treatment|Change in self monitoring plasma glucose profile from baseline to each treatment end by treatment|Change in HbA1c from baseline to each treatment end by treatment,Sanofi,All,"20 Years and older   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PDY12335|U1111-1129-3633,Sep-12,Aug-13,Aug-13,30-Aug-12,null,19-Aug-13,"Investigational Site Number 392001, Kumamoto-Shi, Japan",,https://ClinicalTrials.gov/show/NCT01676233
NCT01673178,Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus,,Completed,Has Results,"Diabetes Melliuts, Type 2",Other: Placebo|Drug: 25 mg PF-05231023|Drug: 50 mg PF-05231023|Drug: 100 mg PF-05231023|Drug: 150 mg PF-05231023,"Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Laboratory Abnormalities|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Electrocardiogram Findings|Number of Participants With Abnormal Physical Examinations|Thyroid Stimulating Hormone (TSH) Level at Baseline|Thyroid Stimulating Hormone (TSH) Level at Day 1|Thyroid Stimulating Hormone (TSH) Level at Day 25|Thyroid Stimulating Hormone (TSH) Level at Day 39|Thyroid Stimulating Hormone (TSH) Level at Day 49|Phosphate Level at Baseline|Change From Baseline in Phosphate Level at Day 8|Change From Baseline in Phosphate Level at Day 15|Change From Baseline in Phosphate Level at Day 25|Change From Baseline in Phosphate Level at Day 49|Creatine Phosphokinase (CPK) Level at Baseline|Change From Baseline in Creatine Phosphokinase (CPK) Level at Day 8|Change From Baseline in Creatine Phosphokinase (CPK) Level at Day 15|Change From Baseline in Creatine Phosphokinase (CPK) Level at Day 25|Change From Baseline in Creatine Phosphokinase (CPK) Level at Day 49|Serum N-terminal Propeptides of Type 1 Collagen (PINP) and C-Telopeptide Cross-Linking of Type 1 Collagen (CTX) Levels at Baseline|Percent Change From Baseline in Serum N-terminal Propeptides of Type 1 Collagen (PINP) and C-Telopeptide Cross-Linking of Type 1 Collagen (CTX) Levels at Day 25|Percent Change From Baseline in Serum N-terminal Propeptides of Type 1 Collagen (PINP) and C-Telopeptide Cross-Linking of Type 1 Collagen (CTX) Levels at Day 39|Percent Change From Baseline Serum N-terminal Propeptides of Type 1 Collagen (PINP) and C-Telopeptide Cross-Linking of Type 1 Collagen (CTX) Levels at Day 49|Blood Osteocalcin and Bone-Specific Alkaline Phosphatase Levels at Baseline|Percent Change From Baseline in Blood Osteocalcin and Bone-Specific Alkaline Phosphatase Levels at Day 25|Percent Change From Baseline in Blood Osteocalcin and Bone-Specific Alkaline Phosphatase Levels at Day 39|Percent Change From Baseline in Blood Osteocalcin and Bone-Specific Alkaline Phosphatase Levels at Day 49|Tartrate-resistant Acid Phosphatase Isoform 5b (TRAP 5b) Levels at Baseline|Percent Change From Baseline in Tartrate-resistant Acid Phosphatase Isoform 5b (TRAP 5b) Levels at Day 25|Percent Change From Baseline in Tartrate-resistant Acid Phosphatase Isoform 5b (TRAP 5b) Levels at Day 39|Percent Change From Baseline in Tartrate-resistant Acid Phosphatase Isoform 5b (TRAP 5b) Levels at Day 49|Average Urinary Calcium and Phosphate Levels Over 24 Hours at Baseline|Change From Baseline in Average Urinary Calcium and Phosphate Levels Over 24 Hours at Day 24|Number of Participants With Anti-PF-05231023 Antibodies and Neutralizing Antibodies at Day 1|Number of Participants With Anti-PF-05231023 Antibodies and Neutralizing Antibodies at Day 39|Number of Participants With Anti-PF-05231023 Antibodies and Neutralizing Antibodies at Day 49|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-05231023 After Single Dose|Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-05231023 After Single Dose|Maximum Observed Plasma Concentration (Cmax) of PF-05231023 After Single Dose|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-05231023 After Last Dose|Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-05231023 After Last Dose|Maximum Observed Plasma Concentration (Cmax) of PF-05231023 After Last Dose|Accumulation Ratio for Area Under the Curve From Time Zero to End of Dosing Interval (Rac) of PF-05231023|Accumulation Ratio for Maximum Observed Plasma Concentration (Rac,Cmax) of PF-05231023|Minimum Observed Plasma Trough Concentration (Cmin) of PF-05231023 After Last Dose|Average Plasma Concentration (Cav ) of PF-05231023 After the Last Dose|Plasma Decay Half-Life (t1/2) of PF-05231023|Apparent Clearance (CL) of PF-05231023",Pfizer,All,"30 Years to 70 Years   (Adult, Older Adult)",Phase 1,107,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B2901011,Oct-12,Aug-13,Sep-13,27-Aug-12,14-Jan-15,16-Feb-15,"Anaheim Clinical Trials, LLC, Anaheim, California, United States|Profil Institute for Clinical Research, Inc., Chula Vista, California, United States|Diablo Clinical Research, Inc., Walnut Creek, California, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Elite Research Institute, Miami, Florida, United States|Miami Research Associates, Inc., South Miami, Florida, United States|MRA Clinical Research, LLC, South Miami, Florida, United States|Central Kentucky Research Associates, Inc., Lexington, Kentucky, United States|L-MARC Research Center, Louisville, Kentucky, United States|Prism Research, Saint Paul, Minnesota, United States|High Point Clinical Trials Center, LLC, High Point, North Carolina, United States|Carolina Phase 1 Research, Raleigh, North Carolina, United States|Wake Internal Medicine Consultants, Raleigh, North Carolina, United States|Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States|Community Research, Cincinnati, Ohio, United States|Mercy Hospital Pharmacy, Cincinnati, Ohio, United States|Covance Clinical Research Unit, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT01673178
NCT01672255,Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM),,Recruiting,No Results Available,Type 1 Diabetes|Hypoglycemia Associated Autonomic Failure,Drug: Fluoxetine|Drug: Placebo control,Change in Catecholamines,"University of Maryland|National Heart, Lung, and Blood Institute (NHLBI)",All,18 Years to 45 Years   (Adult),Early Phase 1,64,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HP-00044537; SSRI and Exercise,Oct-12,Dec-20,Dec-20,24-Aug-12,null,17-Apr-19,"University of Maryland, Baltimore, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01672255
NCT01669473,"A Primary Care, EHR- Based Strategy to Promote Safe and Appropriate Drug Use",,Completed,No Results Available,Diabetes Mellitus Type I|Diabetes Mellitus Type II,Other: EHR Based Strategy to promote Safe and Appropriate Drug Use,"Medication adherence|Clinical outcomes-systolic blood pressure, HbA1, and LDL cholesterol.",Northwestern University|University of Illinois at Chicago,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,541,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,1U19HS021093-01,Jun-13,Aug-16,Sep-16,21-Aug-12,null,22-Sep-16,"Northwestern University, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01669473
NCT01668485,Mechanisms of Glucose Counterregulation in Pancreatic Islet Transplantation,,Completed,No Results Available,Type 1 Diabetes Mellitus,Procedure: Hypoglycemic and euglycemic glucose clamp,Whole body glucose counterregulation|Systemic glucose release|Skeletal muscle glucose disposal|Gluconeogenesis from lactate,University of Giessen,All,"Child, Adult, Older Adult",Phase 4,36,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,T1DM/ITX,Nov-01,Nov-10,Nov-11,20-Aug-12,null,21-Aug-12,"Justus Liebig University, Giessen, Hessia, Germany",,https://ClinicalTrials.gov/show/NCT01668485
NCT01666028,Short Term Closed-loop Glucose Control in Adults With Type 1 Diabetes,AP@home02,Completed,No Results Available,Type 1 Diabetes,Device: FlorenceD or similar closed loop glucose control system|Device: CSII with real-time CGM,"Time spent in the target glucose range from 3.9 to 10.0 mmol/l based on subcutaneous glucose monitoring (CGM) adjusted for sensor error.|Time spent above and below the target glucose (3.9 to 10.0 mmol/l) based on continuous subcutaneous glucose monitoring (CGM)|Average and standard deviation glucose levels based on continuous subcutaneous glucose monitoring|The time with glucose levels < 3.5 mmol/l and <2.8 mmol/l based on continuous subcutaneous glucose monitoring|The time with glucose levels in the significant hyperglycaemia, as based on continuous subcutaneous glucose monitoring (glucose levels > 16.7 mmol/l)|Low Blood Glucose Index (LBGI) based on continuous subcutaneous glucose monitoring|During 24 hour in-patient stay - Same glucose metrics as during 7 day home stay but calculated based on continuous subcutaneous glucose monitoring (CGM) and plasma glucose measurements.|Number of episodes of hypoglycaemia, severe hypoglycaemia as well as nature and severity of any other adverse events.",University of Cambridge|Cambridge University Hospitals NHS Foundation Trust|Profil Institut für Stoffwechselforschung GmbH|Medical University of Graz,All,"18 Years and older   (Adult, Older Adult)",Phase 2,18,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AP@home02,Nov-12,Nov-13,Nov-13,16-Aug-12,null,2-Dec-14,"Medical University of Graz, Graz, Austria|Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany|Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT01666028
NCT01666223,Effect of Bile Acids on GLP-1 Secretion,,Completed,No Results Available,Type 2 Diabetes|Obesity,Drug: Colesevelam|Drug: Chenodeoxycholic Acid|Other: saline|Drug: Colesevelam 3750 mg + chenodeoxycholic acid 1250 mg,"Change in GLP-1|Change in insulin|Change in C-peptide|Change in glucagon|Change in glucagon-like-peptide 2 (GLP-2)|Change in glucose-dependent insulinotropic polypeptide (GIP)|Change in peptide YY (PYY)|Change in oxyntomodulin|Change in bile acids|Change in gastrin|Change in CCK|Change in appetite, satiety and prospective food consumption|Change in gallbladder volume|Change in basal metabolic rate|Change in bile acid composition","University Hospital, Gentofte, Copenhagen",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",H-1-2012-049,Nov-12,Jun-13,Jun-13,16-Aug-12,null,24-Dec-13,"Diabetes Research Division, Department of Internal Medicine, Gentofte Hospital, University of Copenhagen, Hellerup, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT01666223
NCT01664624,Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes,,Completed,Has Results,Type 2 Diabetes,Drug: Roflumilast|Drug: Alogliptin|Drug: Exenatide|Drug: Placebo to roflumilast|Drug: Placebo to alogliptin,Change From Baseline in Postprandial Area Under the Curve From Time 0 to 8 Hours (AUC[0-8]) for Active Glucagon-like Peptide-1|Change From Baseline in AUC(0-8) of Postprandial Plasma Glucose|Change From Baseline in Postprandial AUC(0-8) of C-peptide|Change From Baseline in Postprandial AUC(0-8) of Insulin|Change From Baseline to Day 11 in AUC(0-8) of Appetite Sensation|Change From Baseline to Day 11 in 24-hour Average Plasma Glucose,AstraZeneca,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ROF-T2D_107|U1111-1128-6945,Jul-12,Nov-12,Nov-12,14-Aug-12,20-Feb-14,1-Feb-17,"Chula Vista, California, United States|Orlando, Florida, United States",,https://ClinicalTrials.gov/show/NCT01664624
NCT01664637,Diabetic Gastroparesis Efficacy/Safety Study of TZP-102,DIGEST,Terminated,No Results Available,Diabetic Gastroparesis,Drug: 10 mg TZP-102|Drug: Placebo,"Change from baseline in symptoms associated with diabetic gastroparesis|Change from baseline in health-related quality of life|Adverse events (AEs), vital signs, ECGs, clinical laboratory parameters","Tranzyme, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TZP-102-CL-G004,Aug-12,Jan-13,Feb-13,14-Aug-12,null,20-Dec-12,"Tranzyme Investigational Site, Huntsville, Alabama, United States|Tranzyme Investigational Site, Tucson, Arizona, United States|Tranzyme Investigational Site, North Little Rock, Arkansas, United States|Tranzyme Investigational Site, Long Beach, California, United States|Tranzyme Investigational Site, Ventura, California, United States|Tranzyme Investigational Site, Hialeah, Florida, United States|Tranzyme Investigational Site, Inverness, Florida, United States|Tranzyme Investigational Site, Jacksonville, Florida, United States|Tranzyme Investigational Site, Miami, Florida, United States|Tranzyme Investigational Site, Miami, Florida, United States|Tranzyme Investigational Site, New Smyrna Beach, Florida, United States|Tranzyme Investigational Site, Anderson, Indiana, United States|Tranzyme Investigational Site, Indianapolis, Indiana, United States|Tranzyme Investigational Site, Kansas City, Kansas, United States|Tranzyme Investigational Site, Monroe, Louisiana, United States|Tranzyme Investigational Site, Boston, Massachusetts, United States|Tranzyme Investigational Site, Mexico, Missouri, United States|Tranzyme Investigational Site, Raleigh, North Carolina, United States|Tranzyme Investigational Site, Salisbury, North Carolina, United States|Tranzyme Investigational Site, Winston-Salem, North Carolina, United States|Tranzyme Investigational Site, Oklahoma City, Oklahoma, United States|Tranzyme Investigational Site, Portland, Oregon, United States|Tranzyme Investigational Site, El Paso, Texas, United States|Tranzyme Investigational Site, Bialystok, Poland|Tranzyme Investigational Site, Bialystok, Poland|Tranzyme Investigational Site, Bydgoszcz, Poland|Tranzyme Investigational Site, Kielce, Poland|Tranzyme Investigational Site, Krakow, Poland|Tranzyme Investigational Site, Lodz, Poland|Tranzyme Investigational Site, Lublin, Poland|Tranzyme Investigational Site, Lublin, Poland|Tranzyme Investigational Site, Olsztyn, Poland|Tranzyme Investigational Site, Rzeszow, Poland|Tranzyme Investigational Site, Warsaw, Poland|Tranzyme Investigational Site, Zgierz, Poland",,https://ClinicalTrials.gov/show/NCT01664637
NCT01661192,"Long Term Treatment Effect of the Safety, Tolerability and Efficacy of AAT in Type 1 Diabetes",AAT Extension,Completed,No Results Available,Type 1 Diabetes|Beta Cell Preservation,Drug: AAT( Alpha 1 Antitrypsin),Safety and tolerability of AAT in terms of adverse events and serious adverse events|Safety and tolerability of the AAT in terms of laboratory values|Beta cell function-AUC (Area Under the Curve) of stimulated C-Peptide from stimulated MMTT (mixed meal tolerance test)|Percentage of patients that maintain stimulated peak C-peptide >=0.2 nmol/L|Percentage of patients that achieve glycemic target of HbA1c <=7.5%|Daily insulin dose adjusted to body weight,"Rabin Medical Center|Kamada, Ltd.",All,"10 Years to 25 Years   (Child, Adult)",Phase 2,12,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,006971ctil,Jan-13,Jan-17,Jan-17,9-Aug-12,null,11-Jan-17,"Schneider Children's Medical Center, Petah-Tikva, Israel|Assaf Haroffeh Medical Center, Zerifin, Israel",,https://ClinicalTrials.gov/show/NCT01661192
NCT01658579,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin,,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: HOE901-U300 (new formulation of insulin glargine)|Drug: Lantus (insulin glargine),"Percentage of Time in Target Plasma Glucose Range (4.4-7.8 mmol/L [80-140 mg/dL])|Percentage of Time Above the Upper Limit of Glycemic Range (Greater Than [>] 7.8 mmol/L [(140 mg/dL])|Percentage of Time Below The Lower Limit of Glycemic Range (<4.4 mmol/L [80 mg/dL])|Evaluation of Diurnal Glucose Exposure, Variability, and Stability|Percentage of Time in Target Plasma Glucose Range (4.4-7.8 mmol/L [80-140 mg/dL]) in the Last Four Hours of Each Dosing Interval at Weeks 7 and 8 in Period A and Weeks 15 and 16 in Period B|Change in HbA1c From Baseline to Week 8 and 16|Change in Fasting Plasma Glucose (FPG) From Baseline to Week 8 and 16|Change in Average 7-Point Self-Monitored Plasma Glucose (SMPG) Profile From Baseline to Week 8 and 16|Change in Basal Insulin Daily Dose From Baseline to Week 8 and 16|Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline Up to Week 16",Sanofi,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,59,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PDY12777|U1111-1130-3593,Aug-12,May-13,May-13,7-Aug-12,7-May-15,1-Jun-15,"Investigational Site Number 840002, Temecula, California, United States|Investigational Site Number 840001, Minneapolis, Minnesota, United States|Investigational Site Number 840003, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT01658579
NCT01653899,Caspase Inhibition in Islet Transplantation,,Completed,No Results Available,Diabetes,Drug: IDN-6556,To assess the safety of the IDN-6556 caspase inhibitor in adult Type 1 diabetic participants receiving their first islet transplant|1. To determine the proportion of subjects treated with IDN-6556 who achieve and maintain insulin independence after the first or subsequent islet transplant.|2. To obtain preliminary data on the efficacy of IDN-6556 to maintain adequate immunological protection against both allo- and autoimmunity of islet transplant recipients.,University of Alberta|Conatus Pharmaceuticals Inc.,All,"18 Years to 68 Years   (Adult, Older Adult)",Phase 1|Phase 2,12,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00024049,Jun-12,Jun-16,Jun-16,31-Jul-12,null,7-Jul-16,"University of Alberta, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT01653899
NCT01654120,Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics,,Completed,No Results Available,"Diabetes Mellitus, Type II",Drug: Liraglutide|Drug: Insulin,Change from baseline in HbA1c at six months|Hypoglycemia|Total Daily Insulin Dose (TDID)|Weight|GlycoMark,Mountain Diabetes and Endocrine Center,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,36,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,high dose and lira 001,Dec-11,Nov-13,Nov-13,31-Jul-12,null,20-Apr-15,"Mountain Diabetes and Endocrine Center, Asheville, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01654120
NCT01654380,A Study of LY2605541 Versus Insulin Glargine on Blood Sugar,,Completed,Has Results,"Healthy Volunteers|Diabetes Mellitus, Type 1",Drug: LY2605541|Other: Insulin glargine,Part B: Glucodynamics: Endogenous Glucose Output|Part B: Glycodynamics: Glucose Disposal|Part B: Glycodynamics: Maximum Rate of Glucose Disposal,Eli Lilly and Company,Male,18 Years to 50 Years   (Adult),Phase 1,22,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,12157|I2R-MC-BIAV,Jul-12,Oct-13,Oct-13,31-Jul-12,8-Mar-19,8-Mar-19,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT01654380
NCT01652911,A Phase I/II Study of the Safety and Efficacy of Sernova's Cell PouchTM for Therapeutic Islet Transplantation,,Terminated,No Results Available,Type I Diabetes,Device: Sernova Cell Pouch,To assess the safety of the Sernova Cell Pouch™ in adult participants with Type-1 diabetes receiving islet transplantation for the first time.|To determine the proportion of subjects implanted with the Cell Pouch™ and transplanted with islets into the Cell Pouch™ who achieve insulin independence after islet transplantation.|To obtain preliminary data on the efficacy of the Cell Pouch™.,University of Alberta|Sernova Corp,All,"18 Years to 68 Years   (Adult, Older Adult)",Phase 1|Phase 2,3,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00028097,Jun-12,Mar-16,Mar-16,30-Jul-12,null,11-Jul-16,"University of Alberta - Clinical Islet Transplant Program, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT01652911
NCT01650324,A Single-dose Phase 1 Study of DBPR108 in Healthy Male Subjects,,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: DBPR108|Drug: matching placebo,Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Profile of Pharmacokinetics - Area Under the Plasma Concentration-Time Curve (AUC From 0 to Infinity)|Profile of Pharmacokinetics - Observed Maximum Plasma Concentration (Cmax)|Profile of Pharmacokinetics - Time of Maximum Plasma Concentration (Tmax)|Change of Dipeptidyl Peptidase 4 (DPP4) Activities Between 48 Hrs Post Dose and 0 hr Predose,"National Health Research Institutes, Taiwan",Male,20 Years to 45 Years   (Adult),Phase 1,32,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",DBPR108-101,Jul-12,Dec-12,Dec-12,26-Jul-12,28-Aug-14,28-Aug-14,"Taipei Medical University - Wanfang Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT01650324
NCT01645696,"Three-day, In-clinic Evaluation of the BD 2nd Generation Continuous Glucose Sensor Device in Type 1 Diabetics",,Completed,No Results Available,Diabetes,Device: BD CGM with Outer Layer|Device: BD CGM without Outer Layer|Device: Medtronic iPro2 Professional CGM,Blood Glucose|Number of participants with adverse events|Skin Effects-Draize Scoring for Skin Irritation|Skin thickness using ultrasound|Insulin levels|antibodies against the glucose binding protein,"Becton, Dickinson and Company",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,BDT-11-CGM002,Jun-12,Sep-12,Sep-12,20-Jul-12,null,22-Apr-13,">LMC Endocrinology Centre, Clinical Research Unit, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01645696
NCT01646047,Diabetes Visual Function Supplement Study,DiVFuSS,Completed,No Results Available,Diabetes Mellitus - Type 1|Diabetes Mellitus - Type 2|Non-proliferative Diabetic Retinopathy,Dietary Supplement: multi-component nutritional supplement capsules|Dietary Supplement: multi-component dietary supplement,Changes in visual function|Changes in serum markers|Changes in retinal structure,"ZeaVision, LLC",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,70,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",20112190,May-12,Aug-14,Sep-14,20-Jul-12,null,22-Jan-15,"Chous Eye Care Associates, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT01646047
NCT01640834,Study of LY2409021 in Participants With Type 1 Diabetes,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: LY2409021|Drug: Placebo|Drug: Glucagon,Pharmacodynamics: Change From Baseline to Day 2 in 24-hour Insulin Dose|Pharmacodynamics: Percentage Change From Baseline to Day 2 in 24-hour Insulin|Pharmacokinetics: Maximum Concentration (Cmax) of LY2409021|Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2409021|Pharmacodynamics: Change From Baseline in 24 Hour Insulin Dose During Drug Washout Period|Pharmacodynamics: Change From Baseline in 24 Hour Insulin Dose Needed to Maintain Euglycemia|Pharmacodynamics: Maximum Concentration (Cmax) of Glucose Concentration After 1 Milligram (mg) Glucagon Injection on Day 3|Pharmacodynamics: Area Under the Glucose Concentration Curve After a Single Dose of Glucagon on Day 3,Eli Lilly and Company,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",14576|I1R-MC-GLBR|2011-006178-19,Jul-12,Sep-12,Sep-12,16-Jul-12,29-Oct-18,29-Oct-18,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01640834
NCT01640210,Technical Evaluation Of JewelPUMP In Type 1 Diabetic Patients Treated With Extern Insulin Pump,DIABELOOP,Completed,No Results Available,Type1diabetes,Device: JewelPUMP (insulin patch pump),weight of the insulin pump (JewelPUMP and usual pump)|satisfaction of patients|handling|acceptability,Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,28,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2011-A00666-35,Nov-11,Mar-12,Mar-12,13-Jul-12,null,13-Jul-12,"CHU Jean Minjoz, Besancon, France|University Hospital Grenoble, Grenoble, France",,https://ClinicalTrials.gov/show/NCT01640210
NCT01640223,"Creation of a Patient Database for Silicon Patient Simulation, Glucose Sensor Variability and Pharmacokinetic Study of Debiotech Jewelpump",DiabeloopWP3,Completed,No Results Available,Type 1 Diabetes,Device: Dexcom7,Percentage of data collected,Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2011-A00726-35,Mar-12,Oct-12,Oct-12,13-Jul-12,null,27-Oct-14,"CHU Jean Minjoz, Besancon, France|CHU de Caen, Caen, France|Centre Hospitalier Sud Francilien, Corbeil Essonnes, France|University Hospital Grenoble, Grenoble, France|Chu Montpellier, Montpellier, France|CHU de Nancy, Nancy, France|CHU Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT01640223
NCT01638260,GLP-1 and Non-exercise Activity Thermogenesis in RHZ,,Terminated,No Results Available,Type 2 Diabetes Mellitus,Drug: Liraglutide|Behavioral: NEAT,Change in HbA1c from baseline and end of treatment (26 weeks) and end of follow-up (52 weeks)|Change in weight from baseline and end of treatment (26 weeks) and end of follow-up (52 weeks)|Change in blood pressure from baseline and end of treatment (26 weeks) and end of follow-up (52 weeks)|Change in quality of life from baseline and end of treatment (26 weeks) and end of follow-up (52 weeks)|Change in NEAT from baseline and end of treatment (26 weeks) and end of follow-up (52 weeks)|Health-care related costs,Maastricht University Medical Center,All,"40 Years to 75 Years   (Adult, Older Adult)",Phase 4,22,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,METC 12-2-033,Oct-12,Nov-13,Nov-13,11-Jul-12,null,17-Dec-13,"Maastricht University Medical Center, Maastricht, Netherlands",,https://ClinicalTrials.gov/show/NCT01638260
NCT01638299,Study Assessing an Insulin Pump-controlling Algorithm to Minimize Hypo and Hyper in Type 1 During CRC Setting,,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: Hypo-Hyper Minimizer (HHM) System,Evaluation of the performance of the HHM system response to meal insulin while the subject is under close medical supervision in the Clinical Research Center (CRC) setting.|Number of Safety Events and any additional information that can be used for product development,Animas Corporation,All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"3076823, V3.0",Jul-12,Sep-12,Sep-12,11-Jul-12,null,21-Sep-12,"Samsum Diabetes Reserach Inst., Santa Barbara, California, United States|UVA Diabetes Technology Center, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01638299
NCT01630850,"Islet Transplantation in Patients With ""Brittle"" Type I Diabetes",,Recruiting,No Results Available,"Diabetes Mellitus, Type 1","Biological: Allogenic islet cells (human, U. Chicago)|Procedure: Intraportal infusion of islet cells",HbAlc <7.0% and an absence of severe hypoglycemic events,University of Chicago,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11-0684,May-12,May-25,Jun-30,28-Jun-12,null,19-Apr-19,"University of Chicago Medical Center, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01630850
NCT01629251,Closing the Loop for 36 Hours in Adolescents With Type 1 Diabetes: Evaluation of Reduced Meal Bolusing,,Completed,No Results Available,Type 1 Diabetes,Device: Closed-loop insulin delivery,Primary efficacy endpoint|Secondary efficacy endpoints,University of Cambridge|Cambridge University Hospitals NHS Foundation Trust,All,"12 Years to 18 Years   (Child, Adult)",Phase 2,8,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAN02,Apr-11,Sep-11,Sep-11,27-Jun-12,null,27-Jun-12,"Wellcome Trust Clinical Research Facility, Addenbrooke's Hospital, Cambridge, United Kingdom",,https://ClinicalTrials.gov/show/NCT01629251
NCT01629277,Closing the Loop in Adolescents During Non-compliance Behaviours,,Completed,No Results Available,Type 1 Diabetes,Device: Closed-loop|Device: standard insulin pump,Primary efficacy outcome measure|Secondary efficacy outcome measure,University of Cambridge|Cambridge University Hospitals NHS Foundation Trust,All,"12 Years to 18 Years   (Child, Adult)",Phase 2,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAN03,Jul-11,May-12,May-12,27-Jun-12,null,27-Jun-12,"Wellcome Trust Clinical Research Facility, Addenbrooke's Hospital, Cambridge, United Kingdom",,https://ClinicalTrials.gov/show/NCT01629277
NCT01626586,Diabetes Adolescent and Family Group Therapy,,Recruiting,No Results Available,Type 1 Diabetes Mellitus,Behavioral: Group Therapy,Diabetes-related Outcomes|Diabetes-related medical outcome data,"Children's Hospital Medical Center, Cincinnati|Marquette University",All,10 Years to 17 Years   (Child),Not Applicable,80,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012-1200,May-12,Aug-20,Aug-20,25-Jun-12,null,12-Jun-18,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01626586
NCT01626053,The Efficacy and Treatment Adherence With an Integrated Program on HbA1c Scores in Patients With Type 2 Diabetes,ASMART,Completed,No Results Available,Type 2 Diabetes Mellitus,Behavioral: ASMART|Other: Control Group,Changes in A1c levels for pretest and post test (Preset baseline and post-test 2 years,KRJG Services Inc.|K21 Health Foundation|Kosciusko County Health Department,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,182,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,ASMART-01|2008-4-03,Mar-09,Mar-11,Jun-11,22-Jun-12,null,22-Jun-12,"Northern Lakes Medicine, Warsaw, Indiana, United States",,https://ClinicalTrials.gov/show/NCT01626053
NCT01621776,Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia,,Completed,Has Results,Type 1 Diabetes,Drug: Apidra|Drug: Humalog|Drug: Novolog,The Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Lunch.|Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Dinner|Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Breakfast,University of Florida|Sanofi,All,9 Years to 14 Years   (Child),Not Applicable,107,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,3842011,Jun-11,Aug-12,Aug-12,18-Jun-12,13-Sep-13,13-Sep-13,"Camp Winona, DeLeon Springs, Florida, United States",,https://ClinicalTrials.gov/show/NCT01621776
NCT01618188,A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart,Area under the glucose infusion rate curve|Maximum glucose infusion rate|Time to maximum glucose infusion rate,Novo Nordisk A/S,All,18 Years to 64 Years   (Adult),Phase 1,52,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1218-3978|U1111-1126-0900|2011-005796-16,11-Jun-12,7-Sep-12,7-Sep-12,13-Jun-12,null,11-Dec-18,"Novo Nordisk Investigational Site, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01618188
NCT01616784,The REPOSE (Relative Effectiveness of Pumps Over MDI and Structured Education) Trial,REPOSE,Completed,No Results Available,Type 1 Diabetes,Other: CSII (Insulin Pump) plus DAFNE|Other: MDI (levemir® & quick acting insulin) plus DAFNE,The change in HbA1c after 2 years in those participants whose baseline HbA1c was at or above 7.5% (58mmol/mol).|The proportion of participants reaching the NICE target of an HbA1c level of 7.5% (58mmol/mol) or less|Diabetes specific quality of life|Hypoglycaemia (severe & moderate)|Insulin dose|Body weight|Blood lipids & proteinuria|Diabetic Ketoacidosis|Fear of hypoglycaemia|Diabetes Treatment Satisfaction|Emotional Wellbeing|Participant views regarding the pump/multiple injection course & treatment|Educator views regarding the pump/multiple injection course & treatment|Costs and Outcomes|Incremental cost-effectiveness ratio|Costs|General Quality of Life|Quality of adjusted life years,Sheffield Teaching Hospitals NHS Foundation Trust|Cambridge University Hospitals NHS Foundation Trust|NHS Dumfries & Galloway|NHS Lothian|NHS Greater Glasgow and Clyde|Harrogate & District NHS Foundation Trust|King's College Hospital NHS Trust|Nottingham University Hospitals NHS Trust,All,"18 Years and older   (Adult, Older Adult)",Phase 3,267,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STH15295|08/107/01|2010-023198-21|11/H1002/10|61215213|10997 (DRN 628),Nov-11,Jun-15,Nov-15,12-Jun-12,null,23-Nov-15,"Addenbrookes Wolfson Diabetes and Endocrine Clinic, Box 281, Addenbrookes Hospital, Hills Road, Cambridge, Cambridgeshire, United Kingdom|Harrogate District Hospital, Diabetes Centre, Lancaster Park Road,, Harrogate, North Yorkshire, United Kingdom|Dumfries and Galloway Royal Infirmary, Diabetes Centre, Cluden West, Crichton Hall,, Dumfries, Scotland, United Kingdom|Royal Infirmary of Edinburgh, Department of Diabetes, 51 Little France Crescent, Edinburgh, Scotland, United Kingdom|Stobhill ACH, Diabetes Clinic, 133 Balornock Road, Glasgow, Scotland, United Kingdom|Sheffield Teaching Hospital, Diabetes Centre, Northern General Hospital, PO Box 1, Herries Road, Sheffield, South Yorkshire, United Kingdom|Kings College Hospital, Diabetes Centre, Suite 3, Golden Jubilee Wing, Denmark Hill, London, United Kingdom|Nottingham University Hospitals NHS Trust, Queens Medical Centre Campus, Derby Road, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT01616784
NCT01611363,A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: ASP1941|Drug: Placebo,"Part A: Assessment of glucose homeostasis in fasted condition and after an oral glucose load, following multiple doses of ipragliflozin in healthy subjects and subjects with T2DM|Part A: Assessment of peripheral glucose utilization after an oral glucose load, following multiple doses of ipragliflozin|Part A: Assessment of splanchnic uptake after an oral glucose load, following multiple doses of ipragliflozin|Part A: Assessment of mean glucose levels in fasted condition and after an oral glucose load, following multiple doses of ipragliflozin|Part B: Assessment of the relationship between the exposure to ipragliflozin in plasma, urinary glucose excretion and plasma glucose levels in subjects with T2DM|Part A: Assessment of steady state urinary sodium excretion and urinary glucose excretion following multiple doses of ipragliflozin|Part A: Assessment of energy production and utilization of energy sources following multiple doses of ipragliflozin|Part A: Safety and tolerability following multiple doses of ipragliflozin assessed by recording adverse events, laboratory assessments, vital signs, electrocardiograms (ECGs) and signs and symptoms of hypoglycemia|Part B: Safety and tolerability following multiple doses of ipragliflozin assessed by recording adverse events, laboratory assessments, vital signs, electrocardiograms (ECGs) and signs and symptoms of hypoglycemia",Astellas Pharma Europe B.V.|Astellas Pharma Inc,All,"35 Years to 65 Years   (Adult, Older Adult)",Phase 1,44,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",1941-CL-0050|2010-024070-19,27-Oct-11,3-Feb-12,3-Feb-12,5-Jun-12,null,22-Aug-17,"Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01611363
NCT01612468,Liraglutide in Type 1 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Overweight",Drug: Liraglutide|Drug: Placebo,Change in HbA1c|Body weight|Cardiovascular|Standardised liquid meal test|Glycaemic excursions|Quality of life,"Steno Diabetes Center Copenhagen|University Hospital, Gentofte, Copenhagen|University of Copenhagen",All,"18 Years and older   (Adult, Older Adult)",Phase 4,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Lira1,Jun-12,Feb-15,Feb-15,5-Jun-12,null,27-Jan-16,"Steno Diabetes Center, Gentofte, Denmark",,https://ClinicalTrials.gov/show/NCT01612468
NCT01610934,The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY),,Completed,No Results Available,Maturity-onset Diabetes of the Young,Drug: liraglutide|Drug: Glimepiride,Fasting Plasma Glucose|Serum Fructosamine|Hypoglycemic events|Plasma concentrations of insulin and C-peptide|Plasma glucagon|Plasma concentrations of incretin hormones,"University Hospital, Gentofte, Copenhagen|Novo Nordisk A/S|University of Copenhagen",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,15,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MODY-TREAT|2012-000592-17,Aug-12,Aug-13,Aug-13,4-Jun-12,null,5-Sep-13,"Diabetes research Division, University Hospital Gentofte, Hellerup, Denmark",,https://ClinicalTrials.gov/show/NCT01610934
NCT01607450,Modulation of Human Myocardial Metabolism by GLP-1 Dose Response,,Completed,Has Results,Type 2 Diabetes Mellitus|Healthy,Drug: GLP-1 Low Dose|Drug: GLP-1 Mid-Range Dose|Drug: GLP-1 High Dose|Drug: Saline,Myocardial Glucose Uptake.|Myocardial Blood Flow|Myocardial Total Oxidation Rate|Cardiac Index|GLP-1 Concentrations,"Indiana University|National Heart, Lung, and Blood Institute (NHLBI)",All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,33,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,1010002497|R21HL092799,May-10,Dec-12,Dec-12,30-May-12,17-Feb-16,17-Feb-16,"Indiana Clinical Research Center, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT01607450
NCT01603121,Lisofylline as Continuous Subcutaneous and Intravenous Administration in Subjects With Type 1 Diabetes Mellitus,,Terminated,Has Results,Type 1 Diabetes Mellitus,Drug: Lisofylline,Safety and Tolerability of Study Drug|Study Drug Bioavailability After Subcutaneous and Intravenous Infusion|Evaluation of Early Efficacy of Study Drug,Eastern Virginia Medical School,All,18 Years to 45 Years   (Adult),Phase 1|Phase 2,1,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,DL-001,Feb-12,May-13,May-13,22-May-12,18-Aug-16,18-Aug-16,"Eastern Virginia Medical School Strelitz Diabetes Center, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01603121
NCT01600664,"The Effect of the Use of Computer Game- ""My Diabetic Friend"" in Children With Type 1 Diabetes",,Completed,No Results Available,Type 1 Diabetes,Behavioral: Interactive computer game|Behavioral: Convertible PC,Quality of life|Metabolic control|Diabetes knowledge|Patient's gaming duration|Compliance to diabetes treatment|Average glucose levels|Average number of blood glucose measurements|Measurements within normal range|Hypoglycemia events|Hyperglycemia events,Rabin Medical Center|Intel Corporation,All,7 Years to 11 Years   (Child),Not Applicable,30,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,rmc006814ctil,Jun-12,Aug-13,Aug-13,17-May-12,null,6-May-14,"Schneider Medical Center, Petach- Tikva, Israel",,https://ClinicalTrials.gov/show/NCT01600664
NCT01600950,A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: LY2963016|Drug: Lantus,Pharmacodynamics: Duration of Action of LY2963016 and Lantus|Maximum Glucose Infusion Rate (Rmax)|Total Glucose Infused (Gtot)|Time of Maximum Glucose Infusion Rate (tRmax)|Pharmacokinetics: Maximum Concentration (Cmax) of LY2963016 and Lantus|Pharmacokinetics: Area Under the Concentration-time Curve (AUC) of LY2963016 and Lantus,Eli Lilly and Company,All,18 Years to 60 Years   (Adult),Phase 1,20,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",13831|I4L-MC-ABEE,May-12,Jul-12,Jul-12,17-May-12,7-Oct-14,7-Oct-14,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01600950
NCT01599338,"Impact of Liraglutide on Sensory Perception, Sensory Specific Satiety, Liking and Wanting in Type 2 Diabetic Patients",,Completed,No Results Available,Type 2 Diabetes Mellitus|Overweight,Drug: Liraglutide,"Change in liking and wanting for protein, lipid and glucid foods|Change in sensory specific satiety for protein, lipid and glucid foods|Change in gustative detection thresholds for sweet, bitter and salty tastes|Change in appetite, desire to eat, pleasure in eating|Change in body mass composition (Dual Energy XRay Absorptiometry)|Change in plasma ghrelin, leptin, and HbA1c levels",Centre Hospitalier Universitaire Dijon,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,A100991-10|2010-022618-19,Jan-11,Jan-11,Sep-11,16-May-12,null,1-Jun-12,"CHU Dijon, Dijon, Bourgogne, France",,https://ClinicalTrials.gov/show/NCT01599338
NCT01594801,Testing the Effect of the InsuPad Device in Daily Life Conditions,,Completed,No Results Available,Diabetics Mellitus Type 1|Diabetes Mellitus Type 2,Device: InsuPad,Efficacy|Safety,Insuline Medical Ltd.,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,145,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CP-PP-003,May-12,Feb-13,Mar-13,9-May-12,null,13-Mar-13,"Gemeinschaftspraxis Dr. Klausmann/ Dr. Welslau, Aschaffenburg, Germany|Diabeteszentrum Bad Mergentheim, Bad Mergentheim, Germany|ikfe GmbH, Berlin, Berlin, Germany|GWT-TUD GmbH, Zentrum für Klinische Studien, Dresden, Germany|ikfe GmbH Mainz, Mainz, Germany|Zentrum Für Klinische Studien Neuwied, Neuwied, Germany|ikfe GmbH, Potsdam, Potsdam, Germany|Dr. Notghi Clinical Trials, Potsdam, Germany|Allgemeinärztliche Berufsausübungs-gemeinschaft Waldfischbach-Burgalben, Waldfischbach-Burgalben, Germany",,https://ClinicalTrials.gov/show/NCT01594801
NCT01591681,Outpatient Pump Shutoff Pilot Feasibility and Efficacy Study,,Completed,Has Results,Type 1 Diabetes,Device: Pump suspension,Hypoglycemia Outcome: Percentage of Nights With Sensor Glucose Value </=60 mg/dl|Percentage of Sensor Glucose Values 71 to 180 mg/dL|Percentage of Nights With a Sensor Glucose Value </= 70 mg/dL|Proportion of Nights With a Sensor Glucose Value </= 50 mg/dL|Median Morning Blood Glucose|Percent of Mornings With Glucose >250 mg/dL|Percent of Mornings With Blood Ketones >1.0 mmol/L|Percent of Mornings With Urine Ketones >/= 15 mg/dl|Overall Mean Sensor Glucose Overnight|Overnight Area Under the Curve 250 mg/dl Per 8 Hour|Percent of Nights With Sensor Glucose >250 mg/dL,Jaeb Center for Health Research|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"15 Years to 45 Years   (Child, Adult)",Phase 2,49,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,PSO3|1R01DK085591-01,Nov-12,Jul-13,Jul-13,4-May-12,5-Jun-14,30-Aug-16,"Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|St. Joseph's Health Care, London, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01591681
NCT01590836,A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin degludec/insulin aspart,Area under the glucose infusion rate curve during one dosing interval|Maximum glucose infusion rate (GIRmax)|Area under the serum insulin degludec concentration-time curve during one dosing interval|Maximum observed serum insulin degludec concentration|Area under the serum insulin aspart concentration-time curve|Maximum observed serum insulin aspart concentration,Novo Nordisk A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,22,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN5401-1979|2011-003797-90|U1111-1123-3837,Apr-12,Jun-12,Jun-12,3-May-12,null,10-Feb-17,"Novo Nordisk Investigational Site, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01590836
NCT01588093,IGF-I Induced Muscle Glucose Uptake and Interstitial IGF-I Concentrations,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Increlex|Drug: 0.9% Saline,Difference in MD (microdialysate) IGF-1 over time (expressed as AUC or peak microdialysate IGF-I) between saline and IGF-I injection.,Peter Bang|Karolinska University Hospital,All,18 Years to 23 Years   (Adult),Not Applicable,8,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,MDIGF-1,Apr-11,Sep-11,Sep-11,30-Apr-12,null,30-Apr-12,"Pediatric Endocrinology Unit, Dept of Women's and Children's Health, Karolinska Institute & University Hospital, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01588093
NCT01586065,Continuous Glucose Monitoring in Adolescents With Poorly Controlled Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Device: Continuous Glucose Monitor (CGM)|Other: Fingerstick BGs only,A1c|Frequency of hypoglycemia,Nemours Children's Clinic,All,"12 Years to 18 Years   (Child, Adult)",Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R03HD067329-01A1,Feb-12,Jun-14,Jun-14,26-Apr-12,null,14-Jun-16,"Nemours Children's Clinic, Jacksonville, Florida, United States",,https://ClinicalTrials.gov/show/NCT01586065
NCT01585051,Effect of Vitamin D Supplementation on Blood Pressure and HbA1c Levels in Patients With T2D,,Completed,No Results Available,Diabetes Mellitus Type 2,Drug: 25(OH) vitamin D|Drug: 0.9 % NaCl,Change in HBA1-c levels|24 hour mean blood pressure|plasma glucose|HOMA,Kantonsspital Baselland Bruderholz,All,"18 Years and older   (Adult, Older Adult)",Phase 3,51,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",x335/08,Jan-09,Jun-10,Jun-10,25-Apr-12,null,25-Apr-12,"Department of medicine, Kantonsspital Bruderholz, Bruderholz/Basel, Basel-Landschaft, Switzerland",,https://ClinicalTrials.gov/show/NCT01585051
NCT01584232,A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus,,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: LY2189265|Drug: Insulin glargine|Drug: Sulfonylureas (SU)|Drug: Biguanide (BG),Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks|Percentage of Participants Who Achieved Glycosylated Hemoglobin (HbA1c) <=6.5% or <7% at 26 Weeks|Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks|Change From Baseline in 8-Point Self-Monitored Blood Glucose (SMBG) at 26 Weeks|Change From Baseline in Body Weight at 26 Weeks|Percentage of Participants With Hypoglycemic Episodes,Eli Lilly and Company,All,"20 Years and older   (Adult, Older Adult)",Phase 3,361,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14359|H9X-JE-GBDY,Apr-12,Jul-13,Jul-13,24-Apr-12,20-Oct-14,20-Oct-14,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aichi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ehime, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hokkaido, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kagoshima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kumamoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagano, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagasaki, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ooita, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yamaguchi, Japan",,https://ClinicalTrials.gov/show/NCT01584232
NCT01581476,Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial,AdDIT,Completed,No Results Available,Type 1 Diabetes,Drug: Statin|Drug: ACE inhibitor|Drug: Placebo|Drug: Combination therapy,Albumin creatinine ratio|Changes in CVD risk markers|Changes in glomerular filtration rate (GFR)|Retinopathy|Quality of Life and Health Economics,"University of Cambridge|Juvenile Diabetes Research Foundation|Diabetes UK|British Heart Foundation|Pfizer|The University of Western Australia|The Hospital for Sick Children|University of Oxford|St Thomas' Hospital, London",All,10 Years to 16 Years   (Child),Phase 3,443,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",RP06|2007-001039-72,Jan-09,Apr-17,Jun-17,20-Apr-12,null,28-Jun-18,"University of Western Australia, Perth, Australia|Hospital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01581476
NCT01582139,Feasibility Study of Closed Loop Control in Type 1 Diabetes Using Heart Rate Monitoring as an Exercise Marker,,Completed,Has Results,Type 1 Diabetes Mellitus,Device: Heart rate informed SSM+HMM,Hypoglycemic Events|Low Blood Glucose Index|Average Glucose Drop|Time in Range,"University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|DexCom, Inc.|Insulet Corporation|Abbott Diabetes Care",All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,12,Other|NIH|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15970|5R21DK085641,May-12,Aug-12,Aug-12,20-Apr-12,15-Aug-14,15-Aug-14,"University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01582139
NCT01582243,Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients,,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Vildagliptin,Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24|Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12|Mean Change From Baseline in Fasting Plasma Glucose(FPG) at Week 12 and 24|Mean Change From Baseline in Postprandial Plasma Glucose(PPG) at Week 12 and 24|Mean Change From Baseline in Mean Amplitude of Glycemic Excursions (MAGE) Detected by Continuous Glucose Monitoring System (CGMS) After 24-week|The Percentage of Patients Achieving the Two Glycemic Goals After 12- and 24-week Treatment,Novartis Pharmaceuticals|Novartis,All,"20 Years and older   (Adult, Older Adult)",Phase 4,40,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLAF237ATW03,Apr-13,Sep-15,Sep-15,20-Apr-12,3-Nov-16,3-Nov-16,"Novartis Investigative Site, Changhua, Taiwan",,https://ClinicalTrials.gov/show/NCT01582243
NCT01579981,The Importance of GLP-1 in Post RYGB Improvement in Glycaemic Control Type 2 Diabetic Subjects,,Completed,No Results Available,Type 2 Diabetes,Procedure: Roux-en-Y Gastric Bypass,Beta cell glucose sensitivity|Glucose tolerance|Ad libitum food intake,Hvidovre University Hospital,All,"25 Years and older   (Adult, Older Adult)",Not Applicable,9,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,H-A-2008-080-31742,Apr-12,Nov-12,Nov-12,18-Apr-12,null,10-Feb-17,"Dept. of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark",,https://ClinicalTrials.gov/show/NCT01579981
NCT01578980,Outpatient Control-to-Range: System and Monitoring Testing,,Completed,Has Results,Type 1 Diabetes Mellitus,Device: Outpatient Control-to-Range,Percent Time of Active CTR|Frequency of Unplanned System Resets or Restarts,"University of Virginia|Juvenile Diabetes Research Foundation|University of California, Santa Barbara",All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16130,Apr-12,Jun-12,Jun-12,17-Apr-12,25-Aug-14,16-Sep-14,"Sansum Diabetes Research Institute, Santa Barbara, California, United States|University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01578980
NCT01572753,Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 2|Healthy",Drug: semaglutide,AUC 0-24h; Area under the semaglutide concentration curve from time 0-24 hours after the 10th dosing|Cmax; The maximum plasma semaglutide concentration|tmax; Time to maximum plasma semaglutide concentration|t1/2; the terminal half-life of semaglutide,Novo Nordisk A/S,Male,18 Years to 55 Years   (Adult),Phase 1,161,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN9924-3794|2010-019653-17|U1111-1120-6776,12-Apr-12,8-Sep-12,8-Sep-12,6-Apr-12,null,27-Feb-17,"Novo Nordisk Investigational Site, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT01572753
NCT01571622,"Whey Protein on Posprandial Glucose, Insulin GLP-1, GIP and DPP4 in Type 2 Diabetes",WheyGLP-1,Completed,No Results Available,Type 2 Diabetes Mellitus,Dietary Supplement: Whey before Breakfast|Dietary Supplement: Water before breakfast,"Glucose response|Insulin GLP-1, GIP and DPP4",Tel Aviv University,All,"40 Years to 70 Years   (Adult, Older Adult)",Not Applicable,19,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0175-11-WOMC,Apr-12,Jan-13,Sep-13,5-Apr-12,null,31-Mar-14,"Diabetes Unit E. Wolfson Hospital, Holon, Tel Aviv, Israel",,https://ClinicalTrials.gov/show/NCT01571622
NCT01571817,Pancreatic Islet Transplantation Into the Gastric Submucosa,,Unknown status,No Results Available,Type 1 Diabetes,Biological: Isolated Human Pancreatic Islets,,"University of California, San Francisco",All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 1,4,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Islet-Tx-Sub-DERC,Apr-12,Dec-14,Dec-14,5-Apr-12,null,9-Aug-13,"University of California, San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT01571817
NCT01569841,A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes,,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin glargine,Average Time Within Glycaemic Target Range (Above 70 mg/dL and Below 130 mg/dL)|Mean Interstitial Glucose (IG) Based on 14 Days of CGM|Fasting Plasma Glucose (FPG)|Glycosylated Haemoglobin (HbA1c)|Number of Treatment Emergent Adverse Events (AEs)|Number of Treatment Emergent Confirmed Hypoglycaemic Episodes,Novo Nordisk A/S,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN1250-3874|U1111-1125-7495,Apr-12,Nov-12,Nov-12,3-Apr-12,17-Nov-15,18-Feb-16,"Novo Nordisk Clinical Trial Call Center, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01569841
NCT01567254,The Effect of Guided Imagery in Children With Type 1 Diabetes Mellitus on Glucose Levels and on Glycemic Control,,Completed,No Results Available,"Diabetes Mellitus, Insulin-Dependent",Behavioral: guided imaginary|Behavioral: music ONLY,"Blood glucose values before and after listening to the recording.|The delta of HA1C between before and after three months of periodic listening to auditory guided imagery, compared to listening to music.",Assaf-Harofeh Medical Center,All,7 Years to 16 Years   (Child),Not Applicable,13,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care,54/11,Apr-12,May-12,May-12,30-Mar-12,null,5-Jan-15,"Assaf Haroffeh Medical center, Zerifin, Israel",,https://ClinicalTrials.gov/show/NCT01567254
NCT01565824,Web-based Support During Pregnancy and Early Motherhood in Women With Type 1 Diabetes (MODIAB-web),MODIAB-web,Completed,No Results Available,Diabetes Type 1|Pregnancy|Early Motherhood,Other: web-based support,Diabetes Empowerment Scale (SWE-DES-10)|Well-Being Questionnaire (W-BQ12),Göteborg University|Swedish Diabetes Association|Vastra Gotaland Region,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,174,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,MODIAB-web,Nov-11,Mar-16,Mar-16,29-Mar-12,null,4-Mar-19,"Sahlgrenska Academy, Institute of Health Care Sciences, Gothenburg, Sweden",,https://ClinicalTrials.gov/show/NCT01565824
NCT01566110,Celiac Disease and Diabetes- Dietary Intervention and Evaluation Trial,CD-DIET,Completed,No Results Available,"Celiac Disease|Diabetes Mellitus, Type 1",Dietary Supplement: Gluten Free Diet,Metabolic Control|Hypoglycemic Episodes|Continuous Glucose Monitoring,The Hospital for Sick Children,All,"8 Years to 45 Years   (Child, Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1000030346,Mar-12,Mar-18,Mar-18,29-Mar-12,null,5-Sep-18,"McMaster University, Hamilton, Ontario, Canada|Kingston General Hospital, Kingston, Ontario, Canada|London Health Sciences, London, Ontario, Canada|St. Joseph's Healthcare, London, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|LMC Diabetes and Endocrinology, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01566110
NCT01563887,Identifying Driving Risk Factors in Type 1 Diabetes and Their Reduction Via Internet Program (DiabetesDriving.Com),,Completed,No Results Available,Type 1 Diabetes|Hypoglycemia,Behavioral: DD.com|Behavioral: DD.com + MI,The change in the number of hypoglycemia-related driving mishaps,University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,568,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15360|5R01DK028288-25,Feb-12,Oct-14,Oct-14,27-Mar-12,null,7-Dec-15,"University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01563887
NCT01561508,Effect of GABA Supplementation in the Progression of Type 1 Diabetes in Children,GABA,Withdrawn,No Results Available,Diabetes Mellitus,Drug: gamma-amino-butyric acid|Dietary Supplement: Xylitol,change in stimulated c-peptide|change in HbA1C|change in total daily insulin dose per kilogram,University of Alabama at Birmingham,All,"8 Years to 18 Years   (Child, Adult)",Phase 2,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",UAB-GABA,Jun-12,Apr-13,null,23-Mar-12,null,24-Dec-12,"University of Alabama at Birmingham, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT01561508
NCT01557907,Multi-day (3) In-patient Evaluation of Intradermal Versus Subcutaneous Basal and Bolus Insulin Infusion,,Completed,No Results Available,Diabetes,Device: Subcutaneous delivery via Medtronic Quick-Set|Device: Intradermal delivery via the BD Research Catheter Set,Insulin levels|Blood Glucose|Device performance - adhesion|Skin thickness using ultrasound|Device performance - Leakage of fluid (insulin) at injection site|Device performance-pump alarm|Skin effects-Draize Scoring for Skin Irritation|Number of participants with adverse events,"Becton, Dickinson and Company",All,18 Years to 55 Years   (Adult),Phase 1|Phase 2,23,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BDT-11-ADC001,Feb-12,May-12,May-12,20-Mar-12,null,26-Jul-12,"Profil Institut fur Stoffwechselfforschung GmbH, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01557907
NCT01558271,A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus,,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: LY2189265|Drug: Placebo|Drug: Liraglutide,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks|Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 52 Weeks|Percentage of Participants Who Achieved HbA1c <=6.5% or <7%|Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks and 52 Weeks|Change From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) at 26 Weeks and 52 Weeks|Change From Baseline in Body Weight at 26 Weeks and 52 Weeks|Change From Baseline in Insulin Sensitivity Using Updated Homeostasis Model Assessment (HOMA 2) at 26 Weeks and 52 Weeks|Change From Baseline in Beta-cell Function Using Updated Homeostasis Model Assessment (HOMA 2) at 26 Weeks and 52 Weeks|Percentage of Participants With Hypoglycemic Episodes|30-Day Rate of Hypoglycemic Episodes|Number of Participants With Adjudicated Cardiovascular Events at 26 Weeks and 52 Weeks|Change From Baseline in Pulse Rate at 26 Weeks and 52 Weeks|Change From Baseline in Blood Pressure at 26 Weeks and 52 Weeks|Number of Participants With Adjudicated Pancreatitis at 26 Weeks and 52 Weeks|Change From Baseline in Pancreatic Enzymes at 26 Weeks and 52 Weeks|Change From Baseline in Serum Calcitonin at 26 Weeks and 52 Weeks|Number of Participants With Treatment-Emergent LY2189265 Anti-Drug Antibodies (ADAs) at 26 Weeks and 52 Weeks|Number of Participants Requiring Additional Intervention Due to Hyperglycemia at 26 Weeks and 52 Weeks|Change From Baseline in Electrocardiogram Parameters at 26 Weeks and 52 Weeks,Eli Lilly and Company,All,"20 Years and older   (Adult, Older Adult)",Phase 3,492,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",13990|H9X-JE-GBDP,Mar-12,Oct-13,May-14,20-Mar-12,30-Oct-14,22-May-15,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hokkaido, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ibaraki, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ishikawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kumamoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miyagi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagano, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toyama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yamaguchi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yokohama, Japan",,https://ClinicalTrials.gov/show/NCT01558271
NCT01559025,Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes Mellitus,,Unknown status,No Results Available,Type 1 Diabetes|Insulin Dependent Diabetes|Juvenile Onset Diabetes Mellitus|Autoimmune Diabetes,Drug: Vildagliptin,Beta cell function|Immune and inflammatory profile|Secretion of Glucagon and GLP-1|Glycemic variability,Federal University of São Paulo|Novartis,All,18 Years to 35 Years   (Adult),Phase 3,44,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLAF237ABR01T,Mar-14,Mar-15,Mar-17,20-Mar-12,null,14-May-14,"Federal University of São Paulo, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT01559025
NCT01557634,Closing the Loop in Young Children With Type 1 Diabetes,,Unknown status,No Results Available,Type 1 Diabetes,Procedure: Overnight closed-loop insulin delivery,Time in target|Time below target|Glucose variability,Daniela Elleri|Cambridge University Hospitals NHS Foundation Trust|University of Cambridge,All,2 Years to 6 Years   (Child),Phase 2,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APCam10,Dec-12,Dec-13,null,19-Mar-12,null,4-Apr-13,"Wellcome Trust Clinical Research Facility, Addenbrooke's hospital, Cambridge, United Kingdom",,https://ClinicalTrials.gov/show/NCT01557634
NCT01556594,Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia,AMG102,Completed,Has Results,Hypoglycemia,Drug: Nasal Glucagon 1 mg|Drug: Nasal Glucagon 2 mg|Drug: SC Glucagon|Drug: Nasal Glucagon 3 mg,Percentage of Responders|Number of Participants With at Least One Adverse Event|Maximum Concentration (Cmax) of Baseline-Adjusted Glucose|Time to Maximum Concentration (Tmax) of Baseline-Adjusted Glucose|Maximum Change From Baseline Concentration (Cmax) of Glucagon|Time to Maximum Concentration (Tmax) of Baseline Adjusted Glucagon|Area Under the Curve (AUC0-last) of Baseline Adjusted Glucagon,Eli Lilly and Company|Locemia Solutions ULC,All,18 Years to 55 Years   (Adult),Phase 2,18,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16416|I8R-MC-IGBA|AMG102,Mar-12,Jul-12,Jul-12,16-Mar-12,13-Aug-14,15-Aug-18,"Algorithme Pharma, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01556594
NCT01554566,Metabolic Effects of Honey in Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes Mellitus,Dietary Supplement: honey,serum lipids|C-peptide,Ain Shams University,All,"4 Years to 18 Years   (Child, Adult)",Phase 2,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,honey1010,Jan-10,Jun-11,Oct-11,15-Mar-12,null,15-Mar-12,"National Institute of Diabetes and Endocrinology, Cairo, Kasr El Ainy, Egypt",,https://ClinicalTrials.gov/show/NCT01554566
NCT01555008,Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment,,Completed,No Results Available,Type 2 Diabetes Mellitus|Renal Impairment,Drug: LX4211|Drug: LX4211 Placebo,Change from baseline in postprandial glucose|Number of subjects experiencing an adverse event|Change from baseline in fasting plasma glucose|Change from baseline in glucagon-like peptide 1 (Glp-1)|Area Under Curve (AUC),Lexicon Pharmaceuticals,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,31,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LX4211.1-107-DM|LX4211.107,Mar-12,Aug-13,null,15-Mar-12,null,9-Sep-13,"Lexicon Investigational Site, Anniston, Alabama, United States|Lexicon Investigational Site, Chula Vista, California, United States|Lexicon Investigational Site, Edgewater, Florida, United States|Lexicon Investigational Site, Minneapolis, Minnesota, United States|Lexicon Investigational Site, San Antonio, Texas, United States|Lexicon Investigational Site, Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT01555008
NCT01555788,DiaPort Closed-Loop Artificial Pancreas,,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: Artificial Pancreas for DiaPort system with Zone-MPC algorithm,Percentage of time spent with blood glucose between 3.9 and 8.0 mmol/L (79 - 144 mg/dl)|Mean and standard deviation blood glucose|Percentage of time spent in hypoglycemia with blood glucose <3.3mmol/l (60 mg/dl)|Percentage of time spent in hyperglycemia,"University Hospital, Montpellier",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UF 8829|ID-RCB : 2011-A001212-39,Feb-12,Mar-13,Mar-13,15-Mar-12,null,3-Dec-14,"Montpellier University Hospital, Montpellier, France",,https://ClinicalTrials.gov/show/NCT01555788
NCT01552603,Artificial Pancreas Control System in an Inpatient Setting,,Completed,Has Results,Type I Diabetes Mellitus,Device: Artificial Pancreas Control Software,Mean Percent of Time in Target Blood Glucose Range|Mean Deviation From Target Blood Glucose,Legacy Health System|Juvenile Diabetes Research Foundation,All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 2,14,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2011.11,Mar-12,Aug-13,Sep-13,13-Mar-12,17-Sep-14,3-Jun-16,"Legacy Good Samaritan Hospital, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT01552603
NCT01550809,New Strategies for Postprandial Glycemic Control Using Insulin Pump Therapy,,Completed,Has Results,Type 1 Diabetes,Other: iBolus|Other: tBolus (traditional bolus),The Area Under the Curve (AUC) of Plasma Glucose (PG) Concentrations During the 5-hour Postprandial Period (AUC-PG0-5 h).|The Area Under the Curve (AUC) of the Glucose Infusion Rate (GIR) During the 5-hour Postprandial Period (AUC-GIR0-5h).|The Area Under the Curve (AUC) of Plasma Glucose (PG) Above the Threshold of 140 mg/dl (AUC-PG>140).,"Fundación para la Investigación del Hospital Clínico de Valencia|European Union|Ministerio de Ciencia e Innovación, Spain",All,18 Years to 60 Years   (Adult),Phase 3,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",FP7-PEOPLE-2009-IEF #252085|DPI2010-20764-C02-01,Feb-10,Jun-11,Jun-11,12-Mar-12,29-Aug-12,29-Aug-12,"Hospital Clínico Universitario, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT01550809
NCT01546558,"Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg",,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Metformin|Drug: Ranolazine,"Maximum observed plasma concentration (Cmax) of metformin|Area under the plasma concentration vs time curve over the dosing interval, at steady state (AUCtau) of metformin|Number of participants with adverse events|Maximum observed plasma concentration (Cmax) of ranolazine and metabolites|Area under the plasma concentration versus time curve over the dosing interval, at steady state (AUCtau) of ranolazine and metabolites",Gilead Sciences,All,"30 Years to 65 Years   (Adult, Older Adult)",Phase 1,25,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),GS-US-259-0143,Feb-12,Mar-12,Mar-12,7-Mar-12,null,11-Jul-12,"SeaView Research Inc., Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT01546558
NCT01546597,Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Metformin|Drug: Ranolazine,"Maximum observed plasma concentration (Cmax) of metformin|Time to reach maximum observed plasma concentration (Cmax) of metformin|Area under the plasma concentration versus time curve over the dosing interval, at steady state (AUCtau) of metformin|Number of participants with adverse events|Maximum observed plasma concentration (Cmax) of ranolazine and metabolites|Time to reach maximum observed plasma concentration (Cmax) of ranolazine and metabolites|Area under the plasma concentration versus time curve over the dosing interval, at steady state (AUCtau) of ranolazine and metabolites",Gilead Sciences,All,"30 Years to 65 Years   (Adult, Older Adult)",Phase 1,24,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),GS-US-259-0137,Feb-12,Mar-12,Mar-12,7-Mar-12,null,11-Jul-12,"Cetero Research, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01546597
NCT01544881,Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Technosphere Insulin Inhalation Powder|Drug: Rapid Acting Analog,"PK measures for TI Inhalation Powder (20U) as measured by area under the concentration-time curve (AUC 0-360) - timepoints: 0, 3, 6, 9, 12, 15, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, 240, 300 and 360 minutes post-TI dosing|PK measures for RAA (8U) as measured by area under the concentration-time curve (AUC 0-360) - timepoints 0, 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, 210, 240, 270, 300 and 360 minutes post-RAA dosing|Safety variables including adverse events (AEs), clinical laboratory tests, vital signs and physical examinations|Area under serum glucose infusion rate (GIR AUC 0-360) for TI Inhalation Powder (20U) as measured by: GIR AUC 0-360 timepoints: 0, 3, 6, 9, 12, 15, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, 240, 300 and 360 minutes post-TI dosing|Area under serum glucose infusion rate (GIR AUC 0-360) for RAA (8U) as measured by: GIR AUC 0-360 timepoints: 0, 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, 210, 240, 270, 300 and 360 minutes post-RAA dosing",Mannkind Corporation,All,18 Years to 60 Years   (Adult),Phase 1,17,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,MKC-TI-177,Mar-12,Sep-12,Jan-13,6-Mar-12,null,25-Jan-13,"Profil Institute for Clinical Research, Chula Vista, California, United States",,https://ClinicalTrials.gov/show/NCT01544881
NCT01542450,Pharmacokinetics of Insulin Detemir in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin detemir|Drug: insulin NPH,"The ratio of area under the glucose infusion rate curve (AUCGIR) 0-5 hours to AUCGIR 0-24 hours|AUCGIR, area under the glucose infusion rate value curve|GIRmax, the maximum GIR value|tmax GIR, time to maximum GIR value|Cmax, maximum concentration|Area under the curve|tmax, time to maximum concentration|MRT, mean residence time|t½, terminal half-life|Adverse events",Novo Nordisk A/S,All,"20 Years and older   (Adult, Older Adult)",Phase 1,23,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN304-1475|JapicCTI-R070015,Aug-02,Feb-03,Feb-03,2-Mar-12,null,27-Jan-17,"Novo Nordisk Investigational Site, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT01542450
NCT01537497,A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: PF-05175157|Drug: Placebo,Modulation of carbohydrate and lipid metabolism|Cmax of PF-05175157 after single oral doses|Tmax of PF-05175157 after single oral doses|Area under the curve (AUC) of PF-05175157 after single oral doses,Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,31,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",B1731013,Mar-12,May-12,May-12,23-Feb-12,null,10-Jul-12,"Pfizer Investigational Site, South Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT01537497
NCT01536431,Safety Study to Assess Whether Proinsulin Peptide Injections Can Slow or Stop the Body Damaging Its Own Insulin-making Cells in the Pancreas in Patients Newly Diagnosed With Type 1 Diabetes,MonoPepT1De,Completed,No Results Available,Type 1 Diabetes,Drug: Pro insulin peptide|Drug: Saline,Safety|Allergy and hypersensitivity|Safety of frequent dosing|Protective effects of insulin preservation|T cell (immune) response to islet cell antigens,Cardiff University|Diabetes Vaccine Development Centre|Juvenile Diabetes Research Foundation,All,18 Years to 40 Years   (Adult),Phase 1|Phase 2,27,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SPON817-10|2007-003759-35|66760879,Jan-12,Feb-15,Feb-15,22-Feb-12,null,28-Jul-15,"Countess of Chester, Chester, England, United Kingdom|Bristol Royal Infirmary, Bristol, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Guy's Hospital, London, United Kingdom|Royal Victoria Hospital, Newcastle, United Kingdom",,https://ClinicalTrials.gov/show/NCT01536431
NCT01536665,The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: liraglutide|Drug: placebo,Geometric mean glucagon concentration during hypoglycaemia (nadir glucose (target 2.5 mmol/L) )|Geometric mean glucagon concentration at plasma glucose levels other than nadir|Geometric mean concentrations of adrenaline and noradrenaline at nadir|Time from termination of insulin infusion at nadir to reach plasma glucose 4.0,Novo Nordisk A/S,All,18 Years to 64 Years   (Adult),Phase 1,45,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN9211-3953|U1111-1123-9882|2011-004240-22,Feb-12,Aug-12,Aug-12,22-Feb-12,null,8-Feb-17,"Novo Nordisk Investigational Site, Graz, Austria",,https://ClinicalTrials.gov/show/NCT01536665
NCT01536028,"Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes",,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: biphasic insulin aspart 30|Drug: biphasic insulin aspart 50|Drug: biphasic insulin aspart 70|Drug: insulin aspart,"Area under the GIR (glucose infusion rate)-curves in the first two hours post-dosing|Maximum GIR value|Time to maximum GIR value|Area under the GIR-curves|Maximum drug concentration for insulin aspart (IAsp)|Time to maximum IAsp concentration|Area under the curve of the IAsp profiles|Minimum drug concentration in NEFA (Nonesterified fatty acids)|Time to minimum plasma concentration, NEFA|Area under the curve of the NEFA profiles|Adverse events|Hypoglycaemic episodes",Novo Nordisk A/S,All,18 Years to 55 Years   (Adult),Phase 1,32,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BIASP-1746|2005-004965-40,Apr-06,Jul-06,Jul-06,20-Feb-12,null,6-Jan-17,"Novo Nordisk Investigational Site, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01536028
NCT01534013,Clinical Assessment of a Closed-loop Insulin Delivery System,,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: The Imperial College Closed-Loop Insulin Delivery System,% time in euglycaemia|% time in hypoglycaemia|% time spent in hyperglycaemia|Glycaemic variability as measured by MAGE and SD|Glycaemic risk as measured by LBGI and HBG|Closed loop error grid analysis|Glucose area under the curve|Insulin requirement in units/kg/hr,Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,21,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CRO1710,Aug-11,Aug-14,Aug-18,16-Feb-12,null,2-Aug-18,"Imperial College London, St Mary's Campus, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01534013
NCT01531855,Post-exercise Insulin Reductions in Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Other: Reducing post-exercise rapid-acting insulin (insulin lispro or aspart) dose,24 hour blood glucose area under the curve|Ketogenesis,Northumbria University|Diabetes UK,Male,18 Years to 50 Years   (Adult),Not Applicable,13,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,west-walker1,Feb-12,Aug-12,Aug-12,13-Feb-12,null,4-Aug-14,"Clinical Research Facility, Newcaslte upon Tyne, Tyne and Wear, United Kingdom",,https://ClinicalTrials.gov/show/NCT01531855
NCT01530178,Sitagliptin Dose Determination Study,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Sitagliptin|Drug: Placebo Oral Tablet,Better Targeted Blood Glucose Levels,Albert Einstein College of Medicine,All,"13 Years to 30 Years   (Child, Adult)",Phase 4,8,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2011-246,Nov-11,Mar-15,Mar-15,9-Feb-12,16-Jul-18,16-Jul-18,"Albert Einstein College of Medicine CRC, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT01530178
NCT01530347,Non Invasive Breath Based Acetone-meter- Easy Check,,Terminated,No Results Available,Type 1 Diabetes,Device: Easy Check,correlation between the acetone values generated by study device and blood beta Hydroxybutyrate|correlation between the acetone values generated by study device and blood glucose|correlation between the acetone values generated by study device and HbA1c|correlation between the acetone values generated by study device and oxygen|Clarke Error Grid (segment 1 only),Rabin Medical Center,Male,"18 Years and older   (Adult, Older Adult)",Phase 1,6,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,rmc006631ctil,Mar-12,Jul-12,Jul-12,9-Feb-12,null,15-May-18,"Schneider Children's Medical Center, Petah- Tikva, Israel",,https://ClinicalTrials.gov/show/NCT01530347
NCT01527981,Cognitive Behavioral Therapy (CBT) for Adherence and Depression in Type 1 Diabetes,,Completed,No Results Available,Depression|Type 1 Diabetes,Behavioral: Cognitive behavioral therapy for adherence and depression,Changes in glucose monitoring|Changes in insulin adherence|Changes in depression severity|Changes in hemoglobin A1C|Changes in glucose levels,Massachusetts General Hospital,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,9,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,MGHBMED2172010,Mar-08,Nov-10,Nov-10,7-Feb-12,null,7-Feb-12,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01527981
NCT01526733,"Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase",,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Sham Injection|Drug: Recombinant human hyaluronidase PH20|Drug: Insulin aspart|Drug: Insulin lispro,Early Insulin Exposure (%AUC[0-60])|Maximum Glucose Infusion Rate (GIRmax)|Time to First Occurrence of Maximum Glucose Infusion Rate (tGIRmax)|Time to 50% Maximum Glucose Infusion Rate (tGIR50%Max)|Time to 50% Total Glucose Infused (50%Gtot)|Area Under the Glucose Concentration Curve (AUC[0-360])|Duration of Insulin Action (AUMC[0-360]/AUC[0-360]),Halozyme Therapeutics,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,25,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Halo-117-401,Dec-11,Aug-12,Sep-13,6-Feb-12,29-Sep-14,26-Feb-19,"Profil Institute for Clinical Research, Chula Vista, California, United States",,https://ClinicalTrials.gov/show/NCT01526733
NCT01526941,Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: biphasic insulin aspart 30|Drug: biphasic insulin aspart 70,"Steady state area under the glucose infusion rate profile, 6-12 hours|GIRmax, the maximal glucose infusion rate value|tmax, time to maximum glucose infusion rate value|area under the glucose infusion rate profile|Time to 50% of area under the glucose infusion rate profile, 0-12 hours|Cmax, maximum concentration|tmax, time to reach Cmax|Area under the curve|t½, terminal half-life|Adverse events",Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 1,27,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BIASP-1318,May-01,Jul-01,Jul-01,6-Feb-12,null,5-Jan-17,"Novo Nordisk Investigational Site, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01526941
NCT01524809,Pharmacokinetics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: biphasic insulin aspart 30|Drug: biphasic insulin aspart 70,"Area under the serum insulin curve 6-14 hours after dinner at day 15|Area under the serum insulin curve 6-14 hours after dinner at day 1|Area under the serum insulin curve 0-6 hours after dinner|Area under the curve 0-24 hours|Serum insulin|Apparent t½ (apparent elimination half life)|Cmax, maximum concentration|tmax, time to reach Cmax|Adverse events",Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 1,26,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BIASP-1317,Jan-01,Jun-01,Jun-01,2-Feb-12,null,5-Jan-17,"Novo Nordisk Investigational Site, Århus C, Denmark",,https://ClinicalTrials.gov/show/NCT01524809
NCT01520428,Interventions to Prevent Adolescents With Type 1 Diabetes From Long-term Complications,,Unknown status,No Results Available,"Diabetes Mellitus, Type 1","Behavioral: Motivational Interviewing, CBT and E-mail support",HbA1C|Predictors of positive effects on glycaemic control|Motivational changes|HbA1c,Medical University of Vienna|National Bank of Austria,All,"13 Years to 20 Years   (Child, Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,ÖNB13686,Jun-10,Jan-13,Jan-14,30-Jan-12,null,27-Sep-12,"Medical University of Vienna, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT01520428
NCT01520818,Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Drug: biphasic insulin aspart 50|Drug: biphasic insulin aspart 70|Drug: biphasic human insulin 30,HbA1c (glycosylated haemoglobin A1c)|Blood glucose profiles|Adverse events|Hypoglycaemic episodes|Quality of Life (QoL) assessed via World Health Organization Diabetes Treatment Satisfaction Questionnaire (WHO DTSQ)|Quality of Life (QoL) assessed via Diabetes Health Profile (DHP-2),Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,666,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BIASP-1075,Mar-00,Apr-01,Apr-01,30-Jan-12,null,4-Jan-17,"Novo Nordisk Investigational Site, Aalst, Belgium|Novo Nordisk Investigational Site, Brussels, Belgium|Novo Nordisk Investigational Site, Brussels, Belgium|Novo Nordisk Investigational Site, Edegem, Belgium|Novo Nordisk Investigational Site, Genk, Belgium|Novo Nordisk Investigational Site, Jumet, Belgium|Novo Nordisk Investigational Site, Liège, Belgium|Novo Nordisk Investigational Site, Amiens, France|Novo Nordisk Investigational Site, Avignon, France|Novo Nordisk Investigational Site, Bagnols-sur-ceze, France|Novo Nordisk Investigational Site, Bordeaux, France|Novo Nordisk Investigational Site, Caen, France|Novo Nordisk Investigational Site, Colmar, France|Novo Nordisk Investigational Site, DIJON cedex, France|Novo Nordisk Investigational Site, Dommartin Les Toul, France|Novo Nordisk Investigational Site, GRENOBLE cedex, France|Novo Nordisk Investigational Site, LA ROCHELLE cedex, France|Novo Nordisk Investigational Site, Le Creusot, France|Novo Nordisk Investigational Site, Lorient, France|Novo Nordisk Investigational Site, Lyon, France|Novo Nordisk Investigational Site, Macon, France|Novo Nordisk Investigational Site, Marseille, France|Novo Nordisk Investigational Site, Nanterre, France|Novo Nordisk Investigational Site, Narbonne, France|Novo Nordisk Investigational Site, NEVERS cedex, France|Novo Nordisk Investigational Site, Nimes, France|Novo Nordisk Investigational Site, Orleans, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Reims, France|Novo Nordisk Investigational Site, Roubaix, France|Novo Nordisk Investigational Site, Saint Etienne, France|Novo Nordisk Investigational Site, Strasbourg, France|Novo Nordisk Investigational Site, TOULOUSE cedex, France|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Alkmaar, Netherlands|Novo Nordisk Investigational Site, Amersfoort, Netherlands|Novo Nordisk Investigational Site, Arnhem, Netherlands|Novo Nordisk Investigational Site, Beverwijk, Netherlands|Novo Nordisk Investigational Site, Delft, Netherlands|Novo Nordisk Investigational Site, Den Bosch, Netherlands|Novo Nordisk Investigational Site, Den Haag, Netherlands|Novo Nordisk Investigational Site, Einhoven, Netherlands|Novo Nordisk Investigational Site, Hengelo, Netherlands|Novo Nordisk Investigational Site, Rotterdam, Netherlands|Novo Nordisk Investigational Site, Rotterdam, Netherlands|Novo Nordisk Investigational Site, Ayrsh, United Kingdom|Novo Nordisk Investigational Site, Ayr, United Kingdom|Novo Nordisk Investigational Site, Bath, United Kingdom|Novo Nordisk Investigational Site, Birmingham, United Kingdom|Novo Nordisk Investigational Site, Brighton, United Kingdom|Novo Nordisk Investigational Site, Coventry, United Kingdom|Novo Nordisk Investigational Site, Dundee, United Kingdom|Novo Nordisk Investigational Site, Edgware, United Kingdom|Novo Nordisk Investigational Site, Edinburgh, United Kingdom|Novo Nordisk Investigational Site, Exeter, United Kingdom|Novo Nordisk Investigational Site, Glasgow, United Kingdom|Novo Nordisk Investigational Site, Haywards Heath, United Kingdom|Novo Nordisk Investigational Site, Ipswich, United Kingdom|Novo Nordisk Investigational Site, Leeds, United Kingdom|Novo Nordisk Investigational Site, Leicester, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Manchester, United Kingdom|Novo Nordisk Investigational Site, Manchester, United Kingdom|Novo Nordisk Investigational Site, Nottingham, United Kingdom|Novo Nordisk Investigational Site, Paisley, United Kingdom|Novo Nordisk Investigational Site, Poole, United Kingdom|Novo Nordisk Investigational Site, Rugby, United Kingdom|Novo Nordisk Investigational Site, Scunthorpe, United Kingdom|Novo Nordisk Investigational Site, Southampton, United Kingdom|Novo Nordisk Investigational Site, Sunderland, United Kingdom|Novo Nordisk Investigational Site, Swansea, United Kingdom|Novo Nordisk Investigational Site, Watford, United Kingdom|Novo Nordisk Investigational Site, Whiston, United Kingdom",,https://ClinicalTrials.gov/show/NCT01520818
NCT01519466,Impact of a built-in Insulin Calculator Feature on Diabetes Control - Pilot Study,,Completed,Has Results,Type 1 Diabetes,Device: FreeStyle InsuLinx|Device: FreeStyle Freedom Lite,Time in Target Blood Glucose Range|HbA1c|Change in Diabetes Treatment Satisfaction Questionnaire (DTSQc) Scores From Day 1 to Day 60.,Abbott Diabetes Care,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,55,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,ADC-PMR-INX-11012,Jan-12,Oct-12,Oct-12,27-Jan-12,1-Apr-16,1-Apr-16,"Diabetes Zentrum Mergentheim, Bad Mergentheim, Germany|Diabetes-Zentrum für Kinder und Jugendliche, Hannover, Germany|Institut für Diabetes - Technology Forschungs - und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany|VU University Medical Centre (VUMC), Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT01519466
NCT01519102,Comparison of Closed-loop Operation After Morning Meal With and Without Carbohydrate Counting,CLASS02,Completed,No Results Available,Type-1 Diabetes,Device: Dual Hormone closed-loop system,Incremental area under the curve of plasma glucose concentration as compared to pre-meal glucose value of the postprandial glucose excursions|Percentage of postprandial time of plasma glucose concentrations spent in the high range (above 10.0 mmol/l).|Mean plasma glucose concentration.|Total insulin delivery|Total glucagon delivery|Plasma glucose concentration and incremental plasma glucose concentration at 2 hours postmeal|Postprandial peak and incremental postprandial peak of plasma glucose concentration|Percentage of time of plasma glucose concentrations spent in target range. Target range is defined to be between 4.0 and 10.0 mmol/l for 150 minutes postmeal and between 4.0 and 8.0 mmol/l afterwards|Percentage of postprandial time of plasma glucose concentrations spent in the low range (below 4.0mmol/l),Institut de Recherches Cliniques de Montreal|McGill University|Montreal Children's Hospital of the MUHC,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLASS-02,Jan-12,Nov-12,Nov-12,26-Jan-12,null,10-Dec-12,"Institut de Recherches Cliniques de Montréal (IRCM), Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01519102
NCT01517269,PETS-D (Parent Education Thru Simulation-Diabetes),,Completed,No Results Available,Type 1 Diabetes,Behavioral: Parent education with human patient simulator|Behavioral: Standard care,Change in baseline of Diabetes Knowledge|Change in Baseline of Problem solving|Change in Baseline of Diabetes management|Change in Baseline of Diabetes self efficacy|Change in Baseline of Fear of hypoglycemia|Change in Baseline of Parent anxiety,"University of Massachusetts, Worcester",All,"18 Years and older   (Adult, Older Adult)",Phase 3,191,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,13643,Apr-10,Mar-15,Mar-15,25-Jan-12,null,9-Mar-15,"University of Massachusetts, Worcester, Worcester, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01517269
NCT01515202,Japanese Phase 1 Multiple Ascending Dose Study,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: BMS-823778|Drug: Placebo matching with BMS-823778,"Safety and tolerability, as measured by the number, frequency and intensity of adverse events, vital sign measurements, ECGs, physical examinations, and clinical laboratory tests|Maximum observed plasma concentration (Cmax) of BMS-823778, as measured by plasma/urine concentration|Trough observed plasma concentration (Cmin) of BMS-823778, as measured by plasma/urine concentration|Time of maximum observed plasma concentration (Tmax) of BMS-823778, as measured by plasma/urine concentration|Area under the plasma concentration-time curve in one dosing interval [AUC(TAU)] of BMS-823778, as measured by plasma/urine concentration|Accumulation Index following multiple dosing (AI) of BMS-823778, as measured by plasma/urine concentration|Plasma half-life (T-HALF) of BMS-823778, as measured by plasma/urine concentration|Percent urinary recovery (% UR) of BMS-823778, as measured by plasma/urine concentration|Apparent total body clearance (CLT/F) of BMS-823778, as measured by plasma/urine concentration|Renal clearance from plasma (CLR) of BMS-823778, as measured by plasma/urine concentration|Peak to trough ratio (Cmax/Cmin) of BMS-823778, as measured by plasma/urine concentration|Effective plasma half-life (T-HALFeff) of BMS-823778, as measured by plasma/urine concentration|Pharmacodynamics, as measured by Serum concentration of cortisol and cortisone after an oral dose of cortisone and biomarkers for HPA axis activity (urinary free cortisol and cortisone, salivary cortisol, ACTH, DHEA-S and 4-androstenedione)",Bristol-Myers Squibb,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 1,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MB121-009,Mar-12,Sep-12,Sep-12,24-Jan-12,null,5-Dec-12,"Local Institution, Hachioji-Shi, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT01515202
NCT01515384,A Trial of 18F-AV-133 Positron Emission Tomography (PET),,Suspended,No Results Available,Type 1 Diabetes|Type 2 Diabetes,Drug: 18F-AV-133,Pancreatic uptake and clearance of 18F-AV-133 tracer as determined by SUVR,Avid Radiopharmaceuticals,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,35,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,18F-AV-133-D01,Jun-10,Apr-13,Apr-13,24-Jan-12,null,9-Nov-12,"Research Site, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01515384
NCT01513473,A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus,BEGIN™,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin detemir|Drug: insulin aspart,"Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%) at 26 Weeks (Analysed by Central Laboratory)|Change From Baseline in HbA1c (%) at 52 Weeks (Analysed by Central Laboratory)|Change From Baseline in Fasting Blood Glucose (FPG) at 26 Weeks (Analysed by Central Laboratory)|Change From Baseline in Fasting Blood Glucose (FPG) at 52 Weeks (Analysed by Central Laboratory)|Number of Treatment Emergent Adverse Events (TEAEs)|Number of Hypoglycaemic Episodes|Number of Self-measured Hyperglycaemia (Episodes of PG Above 11.1 mmol/L (200 mg/dL))|Number of Episodes With Self Monitored Blood Ketones Above 1.5 mmol (Capillary Blood Ketone Measurement to be Performed if Self-measured Plasma Glucose (SMPG) Exceeds 14.0 mmol/l (250 mg/dL))|Steady-state Plasma Concentrations of Insulin Degludec and Insulin Detemir on Three Different Visits (Three Different Weeks) During the First 26 Weeks of Treatment|Insulin Antibodies (Insulin Degludec Specific, Insulin Detemir Specific, Insulin Aspart Specific and Antibodies Cross-reacting to Human Insulin)",Novo Nordisk A/S,All,1 Year to 17 Years   (Child),Phase 3,350,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN1250-3561|2011-003148-39|P/44/2010|U1111-1122-4758,Jan-12,Jul-13,Jul-13,20-Jan-12,12-Jan-16,3-Mar-17,"Novo Nordisk Investigational Site, Little Rock, Arkansas, United States|Novo Nordisk Investigational Site, Orange, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, New Haven, Connecticut, United States|Novo Nordisk Investigational Site, Gainesville, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Maitland, Florida, United States|Novo Nordisk Investigational Site, Melbourne, Florida, United States|Novo Nordisk Investigational Site, Tallahassee, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Worcester, Massachusetts, United States|Novo Nordisk Investigational Site, Buffalo, New York, United States|Novo Nordisk Investigational Site, Akron, Ohio, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Hershey, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Norfolk, Virginia, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Varna, Bulgaria|Novo Nordisk Investigational Site, Espoo, Finland|Novo Nordisk Investigational Site, Kuopio, Finland|Novo Nordisk Investigational Site, Mikkeli, Finland|Novo Nordisk Investigational Site, Oulu, Finland|Novo Nordisk Investigational Site, Pori, Finland|Novo Nordisk Investigational Site, BRON cedex, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Rennes, France|Novo Nordisk Investigational Site, Toulouse, France|Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Hannover, Germany|Novo Nordisk Investigational Site, Ludwigshafen, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Chieti, Italy|Novo Nordisk Investigational Site, Genova, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Chuo-shi, Yamanashi, Japan|Novo Nordisk Investigational Site, Iruma-gun, Saitama, Japan|Novo Nordisk Investigational Site, Kobe-shi, Hyogo, Japan|Novo Nordisk Investigational Site, Kochi-shi, Kochi, Japan|Novo Nordisk Investigational Site, Koriyama-shi, Fukushima, Japan|Novo Nordisk Investigational Site, Kumamoto-shi, Kumamoto, Japan|Novo Nordisk Investigational Site, Maebashi-shi, Gunma, Japan|Novo Nordisk Investigational Site, Musashino-shi, Tokyo, Japan|Novo Nordisk Investigational Site, Niigata-shi, Niigata, Japan|Novo Nordisk Investigational Site, Osaka-shi, Osaka, Japan|Novo Nordisk Investigational Site, Sendai-shi, Miyagi, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Toyonaka-city, Osaka, Japan|Novo Nordisk Investigational Site, Tsu-shi, Mie, Japan|Novo Nordisk Investigational Site, Skopje, Macedonia, The Former Yugoslav Republic of|Novo Nordisk Investigational Site, Almere, Netherlands|Novo Nordisk Investigational Site, Amersfoort, Netherlands|Novo Nordisk Investigational Site, Eindhoven, Netherlands|Novo Nordisk Investigational Site, Nijmegen, Netherlands|Novo Nordisk Investigational Site, Rotterdam, Netherlands|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Aberdeen, United Kingdom|Novo Nordisk Investigational Site, Birmingham, United Kingdom|Novo Nordisk Investigational Site, Manchester, United Kingdom|Novo Nordisk Investigational Site, Norwich, United Kingdom|Novo Nordisk Investigational Site, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT01513473
NCT01512108,Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone,,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: oral anti-diabetic drug,Incidence of Treatment Emergent Adverse Events (AEs)|Number of Confirmed Hypoglycaemic Episodes|Change in HbA1c From Baseline to Week 52|Change in FPG From Baseline to Week 52,Novo Nordisk A/S,All,"20 Years and older   (Adult, Older Adult)",Phase 3,363,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN2211-3924|U1111-1121-3457|JapicCTI-121744,10-Jan-12,26-Apr-13,26-Apr-13,19-Jan-12,28-May-14,18-Dec-17,"Novo Nordisk Investigational Site, Chuo-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Chuo-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Ehime, Japan, Japan|Novo Nordisk Investigational Site, Fukuoka, Japan, Japan|Novo Nordisk Investigational Site, Fukuoka-shi, Fukuoka, Japan|Novo Nordisk Investigational Site, Fukuoka, Japan|Novo Nordisk Investigational Site, Fukuoka, Japan|Novo Nordisk Investigational Site, Fukuoka, Japan|Novo Nordisk Investigational Site, Kamagaya-shi, Chiba, Japan|Novo Nordisk Investigational Site, Kashiwara-shi, Osaka, Japan|Novo Nordisk Investigational Site, Kawagoe-shi, Saitama, Japan|Novo Nordisk Investigational Site, Kitakyushu-shi, Fukuoka, Japan|Novo Nordisk Investigational Site, Koriyama-shi, Fukushima, Japan|Novo Nordisk Investigational Site, Kumamoto-shi,Kumamoto, Japan|Novo Nordisk Investigational Site, Kurume-shi, Fukuoka, Japan|Novo Nordisk Investigational Site, Miyazaki-shi, Japan|Novo Nordisk Investigational Site, Naka-shi, Ibaraki, Japan|Novo Nordisk Investigational Site, Niigata-shi, Niigata, Japan|Novo Nordisk Investigational Site, Oita, Japan|Novo Nordisk Investigational Site, Okawa-shi, Fukuoka, Japan|Novo Nordisk Investigational Site, Osaka-shi, Osaka, Japan|Novo Nordisk Investigational Site, Osaka-shi, Osaka, Japan|Novo Nordisk Investigational Site, Ota-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Oyama-shi, Tochigi, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Shimotsuke-shi, Tochigi, Japan|Novo Nordisk Investigational Site, Shizuoka-shi, Japan|Novo Nordisk Investigational Site, Tagajo-shi, Japan|Novo Nordisk Investigational Site, Takatsuki-shi, Osaka, Japan|Novo Nordisk Investigational Site, Tochigi, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Yamaguchi, Japan|Novo Nordisk Investigational Site, Yokohama-shi, Japan",,https://ClinicalTrials.gov/show/NCT01512108
NCT01512654,Personalized Glucose Predictive and Therapy Advisory System - DIAdvisor 2,,Completed,No Results Available,"Diabetes Mellitus,|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Device: Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor),"Percentage of total time spent by patients in safe range (70-180mg/dL)|Percentage of total time spent in hypoglycemia (< 70 mg/dL)|Percentage of total of time spent in hyperglycemia (>180 mg/dL)|Mean of YSI blood glucose during total period, night time and meal periods|Percentage paired glucose values|Coherence between system advices and physician recommendations > 0.80|Score of patient survey regarding the acceptability of DIAdvisor-2 system","University Hospital, Montpellier",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,60,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),UF 8266 3|ID-RCB : 2011-A00513-38,Sep-08,Feb-09,Jun-12,19-Jan-12,null,3-Dec-14,"Institute for Clinical and Experimental Medicine, Prague, Czech Republic|Montpellier University Hospital, Montpellier, France|Universita Degli Studi di Padova, Padova, Italy",,https://ClinicalTrials.gov/show/NCT01512654
NCT01512680,Evaluation of Functional Insulin Therapy in Type 1 Diabetic Patients,IFOPI,Completed,No Results Available,Type 1 Diabetes,Behavioral: Education to Functional Insulin Therapy,"Difference between HbA1c at Month 12 and Month 0 > 0.5%|Difference between HbA1c at Month 3 and Month 0 > 0.3%|Difference between HbA1c at Month 6 and Month 0 > 0.5%|Difference between HbA1c at Month 9 and Month 0 > 0.5%|Reduction of 50% of hypoglycemia < 60mg/dl|Reduction of 30% of hypoglycemia between 60 and 80mg/dl|Reduction of number of patients who have severe hypoglycemia|Better score at surveys of quality of life (SF-6D, DQOL) and auto-management","University Hospital, Montpellier",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,52,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),8749|ID-RCB : 2011-A00645-36,Nov-11,Dec-14,Nov-15,19-Jan-12,null,29-Nov-16,"Montpellier University Hospital, Montpellier, France",,https://ClinicalTrials.gov/show/NCT01512680
NCT01509157,MDRS for Prevention of Nocturnal Hypoglycemia,MDRS,Completed,No Results Available,Type 1 Diabetes,Device: MDRS System (Remote & Safety diabetes management system)|Procedure: Continuous Glucose Monitoring,"Reduction in time spent in hypoglycemia|Parental fear of hypoglycemia|Change in Treatment Satisfaction|Percentage of time spent in the target range|Percentage of time spent in the tight normal range|Average and median of blood glucose levels|Percentage of time spent below 63 mg/dl|Percentage of time spent above 140,180,250 mg/dl|Glucose variability|Hypoglycemic events-number and severity of episodes",Rabin Medical Center,All,"4 Years to 24 Years   (Child, Adult)",Phase 1,38,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,rmc006447ctil,Jan-12,Feb-13,Apr-13,12-Jan-12,null,16-Jul-13,"Schneider Medical Center, Petah-Tikva, Israel",,https://ClinicalTrials.gov/show/NCT01509157
NCT01507597,The Effect of GLP-1 on the Inhibition of Glucagon Secretion,,Completed,No Results Available,Type 2 Diabetes|Type 1 Diabetes,Drug: Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|Drug: NaCl,Plasma Glucagon response to the GLP-1 infusion / glucose clamp|Plasma GLP-1 response to the GLP-1 infusion / glucose clamp|Plasma Glucose response to the GLP-1 infusion / glucose clamp|Resting Metabolic Rate response to the GLP-1 infusion / glucose clamp|Hunger scores response to the GLP-1 infusion / glucose clamp|plasma Insulin response to the GLP-1 infusion / glucose clamp|plasma GIP response to the GLP-1 infusion / glucose clamp|Food Intake,"University Hospital, Gentofte, Copenhagen",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,GlukaStase|H-3-2011-088,Dec-11,Aug-13,Aug-13,11-Jan-12,null,10-Dec-13,"Gentofte University Hospital, Hellerup, Denmark",,https://ClinicalTrials.gov/show/NCT01507597
NCT01500928,Performance Study of the SOLO 2.0 Insulin Pump,,Unknown status,No Results Available,Type 1 Diabetes,Device: SOLO insulin pump,Device related safety issues|SOLO use errors|Device-related adverse outcome|Diabetes-related adverse outcome|Satisfaction iwth SOLO|Product quality (MTBF),Medingo Ltd,All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,40,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VTR-135; VTR-075,Jul-11,Jul-12,null,29-Dec-11,null,29-Dec-11,"Schneider Medical Center, Petach Tikva, Israel|Sourasky Medical Center,, Tel Aviv, Israel",,https://ClinicalTrials.gov/show/NCT01500928
NCT01501032,Inpatient Evaluation of the MD-Logic Artificial Pancreas System in Patients With Type 1 Diabetes,MD-Logic- Cont,Withdrawn,No Results Available,Diabetes Type 1,Device: MD-logic artificial pancreas system,Percent of glucose values 71-180 mg/dL of combined day and night readings during the first admission visit|Percent of subjects with blood glucose reading of 71-180 mg/dL 4 hours following the breakfast with a missed meal bolus|Percent of subjects with blood glucose reading of 71-180 mg/dL 5 hours following the breakfast with a meal bolus 30% more than the recommended bolus amount|Percent of subjects with a blood glucose nadir <=60 mg/dL following exercise|Overall frequency of hypoglycemia|Overall frequency of hyperglycemia|Percent of subjects with a peak blood glucose >400 mg/dL following the breakfast with a meal bolus 30% more than the recommended bolus amount|Percent of blood glucose values 71-180 mg/dL during the day (9:00AM-11:00PM) of the first admission visit|Percent of blood glucose values 70-180 mg/dL during the night (11:00PM-8:00AM) of the first admission visit|Percent of blood glucose values >400 mg/dL during the first admission visit|Percent of blood glucose values <=60 mg/dL during the first admission visit|Percent of subjects with a peak blood glucose >400 mg/dL following the breakfast with a missed meal bolus|Percent of subjects with a nadir blood glucose <=60 mg/dL following the breakfast with a missed meal bolus|Percent of subjects with a nadir blood glucose <=60 mg/dL following the breakfast with a meal bolus 30% more than the recommended bolus amount,Rabin Medical Center,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Phase 1,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,rmc006385ctil,Oct-13,Dec-14,Dec-14,29-Dec-11,null,19-Mar-15,"Schneider children's Medical center, Petah-tikva, Israel",,https://ClinicalTrials.gov/show/NCT01501032
NCT01497912,Treatment Effects of Atorvastatin on Hemostasis and Skin Microcirculation in Patients With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus|Dyslipidemia,Drug: Atorvastatin|Drug: Placebo,Fibrin network permeability|platelet and endothelial microparticles|skin microvascular reactivity,Karolinska Institutet,All,"30 Years to 70 Years   (Adult, Older Adult)",Phase 4,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Dnr 04-681/2|Dnr 151:2004/52378,Jan-05,Jan-09,Jan-10,23-Dec-11,null,23-Dec-11,"Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01497912
NCT01497938,Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature,ASPIRE,Completed,Has Results,Type 1 Diabetes,Device: Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature|Device: Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump,Change in A1C From Baseline to End of Study Participation|The Event Area Under the Curve (AUC) Was Used to Demonstrate the Reduction of Nocturnal Hypoglycemia With the Low Glucose Suspend (LGS) Feature (LGS ON),Medtronic Diabetes,All,"16 Years to 70 Years   (Child, Adult, Older Adult)",Phase 3,247,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CEP 237,Dec-11,Jun-13,Jun-13,23-Dec-11,17-Mar-14,17-Mar-14,"Arkansas Diabetes Clinic and Research Center, Little Rock, Arkansas, United States|AMCR Institute, Inc, Escondido, California, United States|Frank Diabetes Research Institute/ Mills-Peninsula Health Center, San Mateo, California, United States|University of Colorado Denver/ Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Metabolic Research Institute, West Palm Beach, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Physicians Research Associates, Lawrenceville, Georgia, United States|Endocrine Research Solutions, Roswell, Georgia, United States|Rocky Mountains Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Iowa Diabetes and Endocrinology Research Center, Des Moines, Iowa, United States|International Diabetes Center, Minneapolis, Minnesota, United States|Naomie Barrie Diabetes Center, New York, New York, United States|Joslin Diabetes Center, Syracuse, New York, United States|Ohio University College of Osteopathic Medicine, Athens, Ohio, United States|Texas Diabetes, Austin, Texas, United States|Rainier Clinical Research Center, Renton, Washington, United States|University of Wisconsin - Madison, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01497938
NCT01498185,"BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes",,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Dapagliflozin|Drug: Placebo matching Dapagliflozin,Mean Change From Baseline in 7-Point Glucose Monitoring (7-PGM) at Day 7|Dapagliflozin Pharmacokinetic Parameters on Day 7 - Maximum Observed Plasma Concentration (Cmax)|Dapagliflozin Pharmacokinetic Parameters on Day 7 - Time of Maximum Observed Plasma Concentration (Tmax)|Dapagliflozin Pharmacokinetic Parameters on Day 7 - Area Under the Concentration-Time Curve in One Dosing Interval (AUC[TAU])|Dapagliflozin 3-O-glucuronide Pharmacokinetic Parameters on Day 7 - Maximum Observed Plasma Concentration (Cmax)|Dapagliflozin 3-O-glucuronide Pharmacokinetic Parameters on Day 7 - Time of Maximum Observed Plasma Concentration (Tmax)|Dapagliflozin 3-O-glucuronide Pharmacokinetic Parameters on Day 7 - Area Under the Concentration-Time Curve in One Dosing Interval (AUC[TAU])|Pharmacokinetic Parameters on Day 7 - Ratio of Metabolite (RM) to Parent AUC[TAU],"AstraZeneca|Astra Zeneca, Bristol-Myers Squibb",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,171,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",MB102-072,Feb-12,Oct-12,Oct-12,23-Dec-11,10-Feb-17,10-Feb-17,"Profil Institute For Clinical Research, Inc., Chula Vista, California, United States|Va San Diego Healthcare System, San Diego, California, United States|La Biomed Research Inst. At Harbor Ucla Med Ctr., Torrance, California, United States|Compass Research Phase 1, Llc, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Vince And Associates Clinical Research, Overland Park, Kansas, United States|Central Kentucky Research Associates, Inc., Lexington, Kentucky, United States|Louisiana Research Associates, Inc., New Orleans, Louisiana, United States|Jasper Clinic, Inc., Kalamazoo, Michigan, United States|Kansas City University Of Medicine And Biosciences, Kansas City, Missouri, United States|Regional Medical Clinic-Endocrinology, Rapid City, South Dakota, United States|Dallas Diabetes & Endocrine Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT01498185
NCT01497522,Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Vildagliptin|Drug: Placebo,"Change from baseline in glycosylated hemoglobin (HbA1c) at 12 weeks between treatment groups|Change from baseline in HbA1c at 12 weeks within subgroups of metformin doses|Change from baseline in Fasting plasma glucose (FPG) at 12 weeks|Percentage of patients meeting Responder rates in HbA1c|Number of patients with adverse events (including hypoglycemia), serious adverse events and death",Novartis Pharmaceuticals|Novartis,All,"20 Years and older   (Adult, Older Adult)",Phase 3,183,Industry,Interventional,"Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CLMF237A1301,Dec-11,Feb-13,Feb-13,22-Dec-11,null,27-Feb-17,"Novartis Investigative Site, Kitakyushu, Fukuoka, Japan|Novartis Investigative Site, Kurume, Fukuoka, Japan|Novartis Investigative Site, Ohkawa-city, Fukuoka, Japan|Novartis Investigative Site, Kawasaki-city, Kanagawa, Japan|Novartis Investigative Site, Yokohama, Kanagawa, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Takatsuki, Osaka, Japan|Novartis Investigative Site, Ageo-city, Saitama, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Edogawa-ku, Tokyo, Japan|Novartis Investigative Site, Hachioji, Tokyo, Japan|Novartis Investigative Site, Kiyose, Tokyo, Japan|Novartis Investigative Site, Minato-ku, Tokyo, Japan|Novartis Investigative Site, Minato-ku, Tokyo, Japan|Novartis Investigative Site, Nerima-ku, Tokyo, Japan|Novartis Investigative Site, Shinagawa-ku, Tokyo, Japan|Novartis Investigative Site, Toshima-ku, Tokyo, Japan|Novartis Investigative Site, Fukuoka, Japan|Novartis Investigative Site, Fukuoka, Japan|Novartis Investigative Site, Kyoto, Japan",,https://ClinicalTrials.gov/show/NCT01497522
NCT01497574,Within-subject Variability of Insulin Detemir in Children and Adolescents With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin detemir|Drug: insulin glargine,Area under the insulin concentration curve (AUC)|Maximum insulin concentration (Cmax)|Time to maximum insulin concentration (tmax)|Adverse events,Novo Nordisk A/S,All,6 Years to 17 Years   (Child),Phase 1,32,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN304-1633|2004-001692-19,May-05,Oct-05,Oct-05,22-Dec-11,null,30-Jan-17,"Novo Nordisk Investigational Site, Hannover, Germany",,https://ClinicalTrials.gov/show/NCT01497574
NCT01496339,Human Menstrual Blood-derived Mesenchymal Stem Cells Transplantation in Treating Type 1 Diabetic Patients,,Unknown status,No Results Available,Type 1 Diabetes Mellitus,Biological: MenSCs transplantation|Drug: exogenous indulin injection daily,Glycosylated hemoglobin (HbA1c)|The acute reaction and severity of adverse events related to the stem cell infusion procedure|Number of severe and documented hypoglycemic events|C-peptide release test|The reduction in fasting blood glucose (FBG)|The increase in basal C-peptide|The postprandial blood glucose|The random glucose level,"S-Evans Biosciences Co., Ltd.|Zhejiang University|Wenzhou Medical University|First Affiliated Hospital of Zhejiang University",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,50,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SEB-1213-T1DM,Jan-12,Dec-13,May-14,21-Dec-11,null,7-Jun-12,"The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China",,https://ClinicalTrials.gov/show/NCT01496339
NCT01492465,Single Ascending Dose Trial in Patients With Type 2 Diabetes,,Terminated,No Results Available,Diabetes Mellitus,Drug: AMG 876,"Subject incidence of treatment-emergent adverse events|Safety laboratory analytes, vital signs, and ECGs|Subject incidence of anti-AMG 876 antibodies.|AMG 876 serum PK parameters|Pharmacodynamic parameters:",Amgen,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,47,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20100015,Nov-11,Jul-12,Oct-12,15-Dec-11,null,15-Feb-13,"Research Site, Omaha, Nebraska, United States|Research Site, San Antonio, Texas, United States|San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01492465
NCT01493115,Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Insulin glargine HOE901|Drug: Insulin glargine - New formulation HOE901,"Glucose infusion rate|Pharmacokinetic parameter : Cmax|Pharmacokinetic parameter : Tmax|Pharmacokinetic parameter : AUC|Number of patients with adverse events|Safety-related parameters including electrocardiogram, vital signs and laboratory tests",Sanofi,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 1,18,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PKD12270|U1111-1120-0463,Nov-11,Apr-12,Apr-12,15-Dec-11,null,1-May-12,"Investigational Site Number 392001, Fukuoka-Shi, Japan",,https://ClinicalTrials.gov/show/NCT01493115
NCT01492062,A Study to Evaluate a Multiple Model Probabilistic Predictive Controller (MMPPC) for Closed Loop Insulin Delivery,,Withdrawn,No Results Available,Type 1 Diabetes Mellitus,Device: Multiple Model Predictive Controller,Test the feasibility of using MMPPC controller for closed loop insulin delivery in a monitored inpatient clinical research environment.|Efficacy,Stanford University,All,21 Years to 45 Years   (Adult),Not Applicable,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SU-09222010-6910|SPO: 47012|eProtocol: 8566,Feb-11,Nov-13,Nov-13,14-Dec-11,null,2-Apr-15,"CTRU located in Blake Wilbur, Stanford, California, United States|Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT01492062
NCT01490619,Resilience Promotion in Teens With Type 1 Diabetes: Preventing Negative Outcomes,,"Active, not recruiting",No Results Available,Type 1 Diabetes,Behavioral: Healthy Thinking In Teens|Other: Advanced Diabetes Education.,Change in Depressive symptoms from baseline to post intervention and change in Depressive symptoms over the two year study period.|Change in Glycemic Control from baseline to post-intervention and change in Glycemic Control over time during the two year study period.,Ann & Robert H Lurie Children's Hospital of Chicago,All,"14 Years to 18 Years   (Child, Adult)",Not Applicable,280,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,R01DK090030-01A1,Oct-11,Sep-16,Sep-17,13-Dec-11,null,24-Jul-17,"Ann and Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01490619
NCT01490151,Medtronic Treat to Range (TTR) Closed-Loop Control,,Completed,Has Results,Diabetes Mellitus|Type 1 Diabetes|Metabolic and Nutritional Disorders,Device: TTR controller (Medtronic),Safety and Feasibility of TTR Closed-loop Control System as Measure by the Count of Successful Hospital Admissions,Stanford University|Medtronic,All,"15 Years to 30 Years   (Child, Adult)",Not Applicable,22,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,G110143|SPO 53117,Dec-11,Dec-13,Dec-13,12-Dec-11,29-Sep-17,29-Sep-17,"Stanford University and Stanford Hospital & Clinics, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT01490151
NCT01488136,Use of Diazoxide in Acute Hypoglycaemia,,Unknown status,No Results Available,Type 1 Diabetes,Drug: Diazoxide|Drug: Placebo,"Adrenaline response(pmol/L) at 2.5mmol/L of glucose|Glucose Thresholds (calculated when hormone release is greater than 2SD of hormone level at euglycaemia 4.0mmol/L blood sugar) of each of the counter-regulatory hormones (adrenaline, noradrenalin, glucagon)",University of Dundee|Juvenile Diabetes Research Foundation,All,18 Years to 55 Years   (Adult),Phase 4,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",2010DM03|2011-005011-93,Jan-12,Dec-12,Dec-12,8-Dec-11,null,6-Jun-12,"NHS Tayside, Dundee, United Kingdom",,https://ClinicalTrials.gov/show/NCT01488136
NCT01488877,A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy,,Terminated,Has Results,Type 2 Diabetic Nephropathy,Drug: PF-03882845|Drug: Spironolactone|Other: placebo,Change From Baseline in Serum Potassium at Day 8|Change From Baseline in Serum Potassium at Day 15|Number of Participants With Confirmed and Severe Hyperkalemia|Plasma Pharmacokinetic (PK) Parameters|Change From Baseline in Sitting Systolic and Diastolic Blood Pressure at Day 15|Change From Baseline in Sitting Pulse Rate at Day 15,Pfizer,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,6,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",B0171011,Jan-12,Jul-12,Jul-12,8-Dec-11,23-Sep-13,29-Oct-13,"Pfizer Investigational Site, Chula Vista, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, DeLand, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Kalamazoo, Michigan, United States|Pfizer Investigational Site, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01488877
NCT01486940,Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin detemir|Drug: insulin aspart|Drug: insulin NPH|Drug: human soluble insulin,HbA1c (glycosylated haemoglobin)|Intra-subject variation in home measured blood glucose (3-point blood glucose profiles)|8-point blood glucose profiles|Incidence of self-recorded hypoglycaemic episodes|Incidence of adverse events,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,598,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN304-1374,Mar-02,Oct-02,Oct-02,7-Dec-11,null,27-Jan-17,"Novo Nordisk Investigational Site, Junin, Argentina|Novo Nordisk Investigational Site, Moron, Argentina|Novo Nordisk Investigational Site, Varazdin, Croatia|Novo Nordisk Investigational Site, Hradec Kralove, Czech Republic|Novo Nordisk Investigational Site, Liberec, Czech Republic|Novo Nordisk Investigational Site, Plzen - Lochotin, Czech Republic|Novo Nordisk Investigational Site, Praha 10, Czech Republic|Novo Nordisk Investigational Site, Praha 2, Czech Republic|Novo Nordisk Investigational Site, Praha 4, Czech Republic|Novo Nordisk Investigational Site, Praha 5, Czech Republic|Novo Nordisk Investigational Site, Hillerød, Denmark|Novo Nordisk Investigational Site, Hjørring, Denmark|Novo Nordisk Investigational Site, Holbæk, Denmark|Novo Nordisk Investigational Site, København, Denmark|Novo Nordisk Investigational Site, Køge, Denmark|Novo Nordisk Investigational Site, Silkeborg, Denmark|Novo Nordisk Investigational Site, Slagelse, Denmark|Novo Nordisk Investigational Site, Svendborg, Denmark|Novo Nordisk Investigational Site, Århus C, Denmark|Novo Nordisk Investigational Site, Kemi, Finland|Novo Nordisk Investigational Site, Kokkola, Finland|Novo Nordisk Investigational Site, Kuopio, Finland|Novo Nordisk Investigational Site, Oulu, Finland|Novo Nordisk Investigational Site, Pärnu, Finland|Novo Nordisk Investigational Site, Rovaniemi, Finland|Novo Nordisk Investigational Site, Viljandi, Finland|Novo Nordisk Investigational Site, Angers, France|Novo Nordisk Investigational Site, GRENOBLE cedex, France|Novo Nordisk Investigational Site, Lille, France|Novo Nordisk Investigational Site, Lorient, France|Novo Nordisk Investigational Site, MONTPELLIER cedex 5, France|Novo Nordisk Investigational Site, Mougins, France|Novo Nordisk Investigational Site, Narbonne, France|Novo Nordisk Investigational Site, Paris Cedex 10, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Poitiers, France|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Alessandria, Italy|Novo Nordisk Investigational Site, Asti, Italy|Novo Nordisk Investigational Site, Bari, Italy|Novo Nordisk Investigational Site, Bergamo, Italy|Novo Nordisk Investigational Site, Catania, Italy|Novo Nordisk Investigational Site, Catania, Italy|Novo Nordisk Investigational Site, Genova, Italy|Novo Nordisk Investigational Site, Lucca, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Padova, Italy|Novo Nordisk Investigational Site, Prato, Italy|Novo Nordisk Investigational Site, Ravenna, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Torino, Italy|Novo Nordisk Investigational Site, Skopje, Macedonia, The Former Yugoslav Republic of|Novo Nordisk Investigational Site, Arendal, Norway|Novo Nordisk Investigational Site, Gjettum, Norway|Novo Nordisk Investigational Site, Gjøvik, Norway|Novo Nordisk Investigational Site, Kongsberg, Norway|Novo Nordisk Investigational Site, Kongsvinger, Norway|Novo Nordisk Investigational Site, Kristiansand S, Norway|Novo Nordisk Investigational Site, Rådal, Norway|Novo Nordisk Investigational Site, Bydgoszcz, Poland|Novo Nordisk Investigational Site, Bydgoszcz, Poland|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Krakow, Poland|Novo Nordisk Investigational Site, Lodz, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Szczecin, Poland|Novo Nordisk Investigational Site, Timisoara, Romania|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Kosice, Slovakia|Novo Nordisk Investigational Site, Moldava nad Bodvou, Slovakia|Novo Nordisk Investigational Site, Falun, Sweden",,https://ClinicalTrials.gov/show/NCT01486940
NCT01486381,Long Term Safety of Biphasic Insulin Aspart 30 in Juveniles With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: biphasic insulin aspart 30,"Number of hypoglycaemic episodes|Occurence of adverse events|Standard safety parameters: Haematology, biochemistry and vital signs|HbA1c (glycosylated haemoglobin)|Blood glucose level at each time-point in the 8-point glucose profile|BMI (Body Mass Index)",Novo Nordisk A/S,All,10 Years to 17 Years   (Child),Phase 3,22,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BIASP-1459,20-Mar-02,30-May-03,30-May-03,6-Dec-11,null,24-Feb-17,"Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa",,https://ClinicalTrials.gov/show/NCT01486381
NCT01484457,Controlled Insulin Delivery: Combining Technology With Treatment,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: Closed-loop session,Restoration of Euglycemia|Average percent-of-time-in-range (80 - 180 mg/dL),"Sansum Diabetes Research Institute|Juvenile Diabetes Research Foundation|Schneider Children's Medical Center, Israel",All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,19,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,JDRF 22-2009-796,Jul-08,Jan-10,Jan-10,2-Dec-11,null,7-Jun-12,"Sansum Diabetes Research Institute, Santa Barbara, California, United States|Schneider Children's Medical Center of Israel, Petah Tikva, Israel",,https://ClinicalTrials.gov/show/NCT01484457
NCT01483352,"Evaluation of Accu-Chek DiaPort, a Port System for Continuous Intraperitoneal Insulin Infusion, in Patients With Type I Diabetes",,Completed,Has Results,"Diabetes Mellitus, Type 1",Device: Accu-Chek DiaPort,Suitability of the Device - Overall Suitability Score|Percentage of Participants With Problems Involving the Tight Connection Between Port and Skin|Percentage of Participants With Dislocation of Port|Percentage of Participants With Signs of Redness/Swelling in the Tissue Around the Port|Percentage of Participants With Signs of Infection in the Tissue Around the Port|Percentage of Participants With Signs of Pain in the Tissue Around the Port|Percentage of Participants With Persistent Dull Pain Due to Catheter|Percentage of Participants With Signs of Infection/Allergic Reaction at the Site of Implant|Percentage of Participants Categorized by Ability of the Port to Deliver Insulin Intraperitonally|Insulin Doses Dispensed From Insulin Pump|Hemoglobin A1c Levels|Self Monitored Blood Glucose Levels|Continuous Glucose Measurement (CGM) - Glucose Levels|Glycemic Variability: Percent Coefficient of Variation in Blood Glucose|Percentage of Participants Achieving Target Glucose Levels|Design Validation Participant Questionnaire - Percentage of Participants With a Positive Response,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,12,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RD001211,Nov-11,Mar-13,Mar-13,1-Dec-11,3-Mar-16,15-Apr-16,"Bad Heilbrunn, Germany",,https://ClinicalTrials.gov/show/NCT01483352
NCT01483560,REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL),REMOVAL,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Metformin|Drug: Placebo,Change in averaged mean far wall common carotid artery IMT|Change in HbA1c|Change in LDL Cholesterol|Change in albuminuria & estimated glomerular filtration rate|Change in retinopathy stage|Change in weight|Change in insulin dose|Change in endothelial function,"University of Glasgow|NHS Greater Glasgow and Clyde|Juvenile Diabetes Research Foundation|Imperial College London|University of Wisconsin, Madison|University of Dundee|Merck Serono S.A., Geneva|Itamar-Medical, Israel|University of Western Ontario, Canada|University of Melbourne|Steno Diabetes Center Copenhagen|Maastricht University Medical Center",All,"40 Years and older   (Adult, Older Adult)",Phase 3,502,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",GN10DI406|2011-000300-18,Dec-11,19-Mar-17,18-Apr-17,1-Dec-11,null,27-Apr-17,"Royal Melbourne Hospital, Melbourne, Australia|St Vincent's Hospital, Melbourne, Australia|Royal Prince Albert Hospital, Sydney, Australia|St Joseph's Health Care, Ontario, Canada|Ottawa Hospital Riverside Campus, Ottawa, Canada|Steno Diabetes Centre, Gentofte, Denmark|Maastricht University Medical Centre, Maastricht, Netherlands|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|Ayr Hospital, Ayr, United Kingdom|University Hospitals Bristol, Bristol, United Kingdom|Diabetes Support Unit, Ninewells Hospital and Medical School, Dundee, United Kingdom|University Hospital North Durham, Durham, United Kingdom|Edinburgh Royal Infirmary, Edinburgh, United Kingdom|Edinburgh Western Infirmary, Edinburgh, United Kingdom|Peninsula NIHR Clinical Research Facility, Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom|Stobhill Hospital, Diabetes Clinic, Glasgow, United Kingdom|Gloucestershire Royal Hospital, Gloucester, United Kingdom|Michael White Diabetes Centre, Hull Royal Infirmary, Hull, United Kingdom|Clinical Sciences Centre, University Hospital, Liverpool, United Kingdom|Clinical Investigation Unit, International Centre for Circulatory Health, Imperial College Healthcare NHS Trust, London, United Kingdom|Wellcome Trust Clinical Research Facility, Manchester Royal Infirmary, Manchester, United Kingdom|Newcastle NIHR Clinical Research Facility, Royal Victoria Hospital, Newcastle, United Kingdom|Diabetes Clinical Research Centre, Plymouth, Plymouth, United Kingdom|Salford Royal NHS Foundation Trust, Salford, United Kingdom",,https://ClinicalTrials.gov/show/NCT01483560
NCT01483651,Physiologic Response to Glucagon at Varying Insulin Levels,,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Glucagon|Drug: Insulin,Area Under the Curve for Glucose Above Baseline,Legacy Health System|Juvenile Diabetes Research Foundation|Oregon Health and Science University,All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,11,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,kw02,Nov-11,Mar-13,Mar-13,1-Dec-11,22-Sep-14,29-Mar-16,"Legacy Health System, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT01483651
NCT01481779,A Study in Participants With Type 1 Diabetes Mellitus,IMAGINE 1,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Glargine|Drug: LY2605541|Drug: Insulin Lispro,"Hemoglobin A1c (HbA1c) at 26 Weeks|Hemoglobin A1c (HbA1c)|Change From Baseline in Hemoglobin A1c (HbA1c)|Percentage of Participants With Hemoglobin A1c (HbA1c) Less Than 7.0% or Less Than or Equal to 6.5% Using Last Observation Carried Forward (LOCF)|Proportion of Participants With Hemoglobin A1c (HbA1c) Less Than 7.0% Without Nocturnal Hypoglycemia|Total Hypoglycemia Rates (Adjusted by 30 Days)|Percentage of Participants With Total Hypoglycemia Events|Nocturnal Hypoglycemia Rates (Adjusted by 30 Days)|Percentage of Participants With Nocturnal Hypoglycemic Events|Fasting Serum Glucose (FSG) by Laboratory Measurement|Fasting Blood Glucose (FBG) Intra-participant Variability|0300-hour Blood Glucose (BG) to Fasting Blood (FBG) Glucose Excursion|9 Point Self-monitored Blood Glucose (SMBG)|Change From Baseline in Body Weight|Basal, Bolus, and Total Insulin Dose|Lipid Profile|Percentage of Participants With Change in Anti-LY2605541 Antibodies|Insulin Treatment Satisfaction Questionnaire (ITSQ)|Low Blood Sugar Survey (LBSS)|European Quality of Life-5 Dimension (EQ-5D)|Rapid Assessment of Physical Activity (RAPA)",Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,455,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12146|I2R-MC-BIAN|2011-001261-40,Jan-12,May-13,Jun-14,30-Nov-11,17-Apr-18,17-Apr-18,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Concord, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Escondido, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fresno, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenbrae, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Huntington Beach, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Mateo, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aurora, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Idaho Falls, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Las Vegas, Nevada, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Renton, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spokane, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Graz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vienna, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bar Le Duc, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Corbeil-Essonnes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montpellier, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nantes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nice, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Mande, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Venissieux, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eisenach, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Falkensee, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mayen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Münster, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuwied, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pohlheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cagliari, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Catania, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lecce, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Padova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Perugia, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ravenna, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hokkaido, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kumamoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara Jalisco, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Katowice, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lodz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poznan, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arkhangelsk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation",,https://ClinicalTrials.gov/show/NCT01481779
NCT01481623,Identification and Characterization of Monogenic Diabetes,DIAGENE,Unknown status,No Results Available,Diabetes,Other: Constitution of a biological bank|Other: Metabolic studies,"Identification and genetic, clinical and metabolic characterization of monogenic diabetes forms|Diagnosis of monogenic diabetes|Clinical and biological characterization of total or partial deficiency of the genes responsible for monogenic diabetes",Assistance Publique - Hôpitaux de Paris,All,"Child, Adult, Older Adult",Not Applicable,1000,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,P081230,Sep-12,Sep-15,Sep-15,29-Nov-11,null,3-Jun-15,"Lariboisiere hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT01481623
NCT01480297,Pilot Study to Determine Effects of Salsalate in Type 1 Diabetes and Painful Peripheral Neuropathy,SALP,Completed,Has Results,Peripheral Neuropathy|Type 1 Diabetes,Drug: Salsalate,Intra-epidermal Nerve Fiber Density (IENFD) Fibers Per mm,University of Michigan,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,8,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SALP,Nov-11,Apr-12,Sep-14,28-Nov-11,24-Apr-15,24-Apr-15,"University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT01480297
NCT01478399,"Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function",,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: PB1023 Injection,Pharmacokinetics|Safety/Tolerability,PhaseBio Pharmaceuticals Inc.,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 1,16,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PB1023-PT-CL-0003,Dec-11,Oct-12,Oct-12,23-Nov-11,null,15-Apr-13,"Prism Research, Saint Paul, Minnesota, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT01478399
NCT01477476,Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes,,Withdrawn,No Results Available,Type I Diabetes,Drug: Anakinra|Other: Placebo Comparator,Frequency of Adverse Events,"University of Colorado, Denver|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",All,"8 Years to 18 Years   (Child, Adult)",Phase 2,0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",11-0814|P30DK057516,Mar-12,Mar-16,22-Apr-16,22-Nov-11,null,18-Apr-19,"Childrens Hospital Colorado, Aurora, Colorado, United States|University of Colorado, Anschutz Medical Campus, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT01477476
NCT01474083,"A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes",,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: GK1-399 (formerly TTP399)|Drug: Placebo,Pharmacokinetic parameters of GK1-399 from plasma concentrations|Pharmacodynamic parameters of plasma glucose,vTv Therapeutics,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,248,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",GK1-MS-201,Nov-11,Aug-12,Sep-12,18-Nov-11,null,13-Sep-13,"Forest Investigative Site 009, Little Rock, Arkansas, United States|Forest Investigative Site 006, Chula Vista, California, United States|Forest Investigative Site 002, Deland, Florida, United States|Forest Investigative Site 001, Miami, Florida, United States|Forest Investigative Site 010, Overland Park, Kansas, United States|Forest Investigative site 011, St. Paul, Minnesota, United States|Forest Investigative Site 005, Springfield, Missouri, United States|Forest Investigative Site 003, Neptune, New Jersey, United States|Forest Investigative Site 008, Willingboro, New Jersey, United States|Forest Investigative Site 007, New York, New York, United States|Forest Investigative Site 004, San Antonio,, Texas, United States",,https://ClinicalTrials.gov/show/NCT01474083
NCT01474889,Glucose Counterregulation in Long Standing Type 1 Diabetes,,Recruiting,No Results Available,Hypoglycemia Unawareness|Type 1 Diabetes|Healthy,Device: RT-CGM,Endogenous glucose production|Endogenous Glucose Production|Magnitude of counter-regulatory Hormonal and Symptom Responses|Magnitude and Glycemic thresholds for counter-regulatory Hormonal and Symptom Responses,University of Pennsylvania|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"25 Years to 70 Years   (Adult, Older Adult)",Not Applicable,36,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,814114|R01DK091331-01,Oct-11,Dec-19,Jun-20,18-Nov-11,null,10-Apr-19,"Clinical and Translational Research Center, Hospital of University of Pennsylvania, Philadelphia, Pennsylvania, United States|Rodebaugh Diabetes Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pennsylvania - Institute for Diabetes, Obesity and Metabolism, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01474889
NCT01473147,Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic Patients,AGAC2,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Exenatide|Drug: Normal saline,Mean amplitude of glycaemic excursions (MAGE)|homeostasis model assessment(HOMA),Chang Gung Memorial Hospital,All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,51,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CMRPG3A0911,Oct-11,Jun-13,Jun-13,17-Nov-11,null,30-Jul-13,"Chang Gung Memorial Hospital, Taoyuan, Taiwan",,https://ClinicalTrials.gov/show/NCT01473147
NCT01472159,Can Glucose Monitoring Improve (CGMi Study),,Completed,No Results Available,Type 1 Diabetes,Behavioral: CGM Family Teamwork Intervention,"Change in glycemic control, assessed by hemoglobin A1c|Change in psychosocial factors (e.g., self-efficacy, fear of hypoglycemia, quality of life, diabetes-specific family conflict, diabetes responsibility sharing, diabetes-specific burden, anxiety, depressive symptoms)",Joslin Diabetes Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Jaeb Center for Health Research,All,8 Years to 17 Years   (Child),Not Applicable,130,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,2010-28|R01DK089349,Oct-11,May-14,Aug-15,16-Nov-11,null,10-Jan-19,"Joslin Diabetes Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01472159
NCT01472406,Feasibility Study Using Zone-MPC Controller (Zone-Model Predictive Control) and Health Monitoring System (HMS),,Unknown status,No Results Available,Type 1 Diabetes Mellitus,Device: Sansum Closed-Loop Artificial Pancreas|Device: Insulin infusion pump|Device: Continuous Glucose Monitor|Device: zone-Model Predictive Control algorithm|Device: Safety Health Monitoring System,"% of time within zone [80-140] mg/dL except 5 hours post-prandial and during exercise and 3 hours post-exercise|% of time within zone [80-140] mg/dL during night between 12:00 am and 7:00 am|% of time within zone [70-180] mg/dL 5 hours after unannounced evening meal, and breakfast|% of time within zone [70-150] mg/dL during the 30 min exercise|% of time within zone [70-150] mg/dL during the 3 hours following exercise","Sansum Diabetes Research Institute|University of California, Santa Barbara",All,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DK085628,Nov-11,Mar-14,Mar-14,16-Nov-11,null,24-May-13,"Sansum Diabetes Research Institute, Santa Barbara, California, United States",,https://ClinicalTrials.gov/show/NCT01472406
NCT01470807,Pilot Study 1 of Outpatient Control-to-Range - System and Monitoring Testing,,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: portable artificial pancreas system with CTR algorithms,estimation of the failure rates of system components|frequency analysis of lost or inaccurate CGM records|percent time of active CTR,"University of Virginia|University Hospital, Montpellier|University of Padova|University of California, Santa Barbara",All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,5,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,54961,Oct-11,Dec-11,Dec-11,11-Nov-11,null,29-Nov-12,"University of Padova, Padova, Italy",,https://ClinicalTrials.gov/show/NCT01470807
NCT01469065,A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes,,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: PF-04991532|Drug: PF-0499132|Drug: Placebo,"Change From Baseline (Day -1) in Mean Daily Glucose at Day 14|Area Under the Curve From Time Zero to 24 Hours Postdose (AUC24) of PF-04991532|Area Under the Curve From Time Zero to 10 Hours Postdose (AUC10) of PF-04991532|Maximum Observed Plasma Concentration of PF-04991532 After Morning Dose Administration (Cmax(AM))|Maximum Observed Plasma Concentration of PF-04991532 After Evening Dose Administration (Cmax(PM))|Minimum Observed Plasma Trough Concentration (Cmin) of PF-04991532|Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04991532 After Morning Dose Administration (Tmax(AM))|Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04991532 After Evening Dose Administration (Tmax(PM))|Apparent Oral Clearance (CL/F) of PF-04991532|Observed Accumulation Ratio of Area Under the Curve From Time Zero to 10 Hours Postdose of PF-04991532 (Rac)|Observed Accumulation Ratio of Maximum Observed Plasma Concentration of PF-04991532 After Morning Dose Administration (Rac, Cmax(AM))|Dose Normalized Area Under the Curve From Time Zero to 24 Hours Postdose (AUC24(dn)) of PF-04991532|Dose Normalized Maximum Plasma Concentration After Morning Dose Administration (Cmax(AM)(dn)) of PF-04991532|Change From Baseline (Day -2) in Mean Daily Glucose at Day 13|Change From Baseline in Area Under the Curve of Glucose From Time 2 to 6 Hours Post Morning Dose (Glucose AUC(2-6)) Following Mixed Meal Tolerance Test (MMTT) at Day 14|Change From Baseline in Fasting Plasma Glucose (FPG)|Change From Baseline in Area Under the Curve of Insulin From Time 2 to 6 Hours Post Morning Dose (Insulin AUC(2-6)) Following Mixed Meal Tolerance Test (MMTT) at Day 14|Change From Baseline in Area Under the Curve of C-peptide From Time 2 to 6 Hours Post Morning Dose (C-peptide AUC(2-6)) Following Mixed Meal Tolerance Test (MMTT) at Day 14|Change From Baseline in Fasting Lipid Parameters at Day 14 and 16",Pfizer,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,82,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",B2611005,Dec-11,May-12,May-12,10-Nov-11,29-Aug-13,30-Oct-13,"Pfizer Investigational Site, Chula Vista, California, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Hachioji-shi, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT01469065
NCT01469143,A Trial Investigating the Pharmacokinetic Properties of Formulations of NN1218 in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart,Area under the serum insulin aspart concentration-time curve|Maximum observed serum insulin aspart concentration|Time to maximum observed serum insulin aspart concentration,Novo Nordisk A/S,All,18 Years to 64 Years   (Adult),Phase 1,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1218-3977|2011-004081-15|U1111-1123-6692,Nov-11,Jan-12,Jan-12,10-Nov-11,null,23-Feb-15,"Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01469143
NCT01469468,A Study To Estimate The Effect Of Repeated Dosing of PF-05175157 On The Pharmacokinetics Of A Single Dose Of Simvastatin In Healthy Adult Subjects,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Simvastatin|Drug: PF-05175157,"Area under the plasma concentration curve of simvastatin and simvastatin acid|Maximum observed plasma concentration of simvastatin and simvastatin acid|Time at which maximum plasma concentration of simvastatin and simvastatin acid is observed|If the data permit, area under the plasma concentration curve of simvastatin and simvastatin acid extrapolated to infinite time|If the data permit, terminal elimination half-life of simvastatin and simvastatin acid",Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,14,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,B1731012,Nov-11,Dec-11,Dec-11,10-Nov-11,null,14-Nov-18,"Pfizer Investigational Site, South Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT01469468
NCT01469559,Safety Study of Intranasal Insulin in Type 1 Diabetes and Diabetic Peripheral Neuropathy,IIDPN,Completed,No Results Available,Diabetic Peripheral Neuropathy,Drug: Novolin Toronto insulin|Drug: Normal saline,Hypoglycemia monitoring|Treatment satisfaction questionnaire for medication (TSQM)|Adverse effects|The UTAH early neuropathy scale|Corneal confocal microscopy|Electrophysiology|McGill pain questionnaire|Short Form-36 (SF-36) Quality of life scale,University of Calgary,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",UCALG-IIDPN,Aug-11,Jul-12,Jul-12,10-Nov-11,null,10-Aug-12,"Heritage Medical Research Clinic, Calgary, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT01469559
NCT01469715,A Clinical Study of the Performance of a Glucose Blinding Protein-Based Continuous Glucose Monitor (GBP CGM),SMA002,Completed,Has Results,Type 1 Diabetes Mellitus,Device: GBP CGM,Absolute Relative Difference (ARD),"University of Virginia|Juvenile Diabetes Research Foundation|Becton, Dickinson and Company",All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 2,16,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,15696,Nov-11,Jul-12,Jul-12,10-Nov-11,31-Jul-15,31-Jul-15,"University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01469715
NCT01467063,Glutamine and Insulin Sensitivity in Type I Diabetes,,Unknown status,No Results Available,Type I Diabetes Mellitus,Dietary Supplement: Glutamine|Dietary Supplement: Placebo,Insulin Sensitivity|Glutamine mechanism of action,Nemours Children's Clinic|Thrasher Research Fund,All,"13 Years to 19 Years   (Child, Adult)",Not Applicable,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",IRC# 11-29,Oct-11,Jun-13,Jul-13,8-Nov-11,null,3-May-13,"Nemours Children's Clinic, Jacksonville, Florida, United States",,https://ClinicalTrials.gov/show/NCT01467063
NCT01467141,Safety and Efficacy of Insulin Aspart in Children With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin aspart|Drug: human insulin|Drug: isophane human insulin,Incidence of hypoglycaemic episodes during the treatment|Change in HbA1c (glycosylated haemoglobin A1c)|Incidence of Adverse Events (AEs),Novo Nordisk A/S,All,2 Years to 6 Years   (Child),Phase 4,26,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANA-1415,19-Jun-02,15-Oct-03,15-Oct-03,8-Nov-11,null,23-Feb-17,"Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Hagen, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Hannover, Germany|Novo Nordisk Investigational Site, Osnabrück, Germany",,https://ClinicalTrials.gov/show/NCT01467141
NCT01464099,Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin aspart,Area under the insulin aspart bolus concentration-time curve|Maximum plasma concentration (Cmax) of insulin aspart|Time to maximum concentration (Tmax) of insulin aspart|AUC (area under the curve) of insulin aspart,Novo Nordisk A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ANA-3501,Jun-08,Nov-08,Nov-08,3-Nov-11,null,28-Oct-16,"Novo Nordisk Investigational Site, Chula Vista, California, United States",,https://ClinicalTrials.gov/show/NCT01464099
NCT01464346,A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use,,Completed,Has Results,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Device: Enlite Sensor,"Mean Daily Agreement (Percent of Sensor Values Within 30% of Reference Value) With Minimum Calibration, Combined Abdomen and Buttock Insertion Sites|Mean Daily Agreement (Percent of Sensor Values Within 30% of Reference Value) With 3-4 Calibrations Per Day, Combined Abdomen and Buttock Insertion",Medtronic Diabetes,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,90,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,CEP247,Nov-11,Mar-12,Mar-12,3-Nov-11,30-May-18,30-May-18,"Profil Institute for Clinical Research, Chula Vista, California, United States|AMCR Institue, Escondido, California, United States|University of California, San Diego, La Jolla, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|University of Colorado Denver/Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Oregon Health & Science University, Portland, Oregon, United States|Rainier Clinical Research Center, Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT01464346
NCT01462227,Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia,,Completed,Has Results,Hypoglycemia,Drug: Naltrexone High Dose|Drug: Naltrexone Low Dose,Glucose (mg/dL)|Glucose Infusion Rate (mg/kg.Min)|Glucagon (pg/mL)|Cortisol (ug/dL)|Epinephrine (pg/mL)|Norepinephrine (pg/mL),Yale University|National Institutes of Health (NIH),All,18 Years to 55 Years   (Adult),Not Applicable,17,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HIC1006006927,Aug-11,Oct-13,Oct-13,31-Oct-11,18-Feb-16,18-Feb-16,"Yale School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01462227
NCT01461577,Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure,GAUDI,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: INSULIN GLARGINE HOE 901,Efficacy assessment of insulin glargine measured by changes of HbA1c levels from baseline|Responder rate (HbA1c levels <7%) without severe hypoglycemia|Responder rate (HbA1c levels <6.5% and <7%)|Changes of fasting plasma glucose (FPG) levels from baseline|Changes of beta cell marker: C-peptide from baseline|Changes of Lipid profile: Lipid profile from baseline|Weight change from baseline|Total insulin dose (per kg body weight)|Evaluation of patient's treatment satisfaction|Number of patients with hypoglycemia|Number of patients with treatment-emergent adverse events,Sanofi,All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 4,89,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LANTU_L_05477|U1111-1118-8753,Nov-11,Dec-12,Dec-12,28-Oct-11,null,30-Jan-13,"Administrative office, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT01461577
NCT01461616,"Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP Axis",,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: NPH|Drug: Detemir|Drug: Glargine,"IGF-I(ng/ml)|IGFBP-1(ng/ml)|IGFBP-2(ng/ml)|IGFBP-3(ng/ml)|Growth Hormone(ng/ml)|plasma glucose concentration (mmol/L) after a single injection of either NPH insulin, insulin Detemir or insulin glargine|insulin concentration (mmol/L) after a single injection of either NPH insulin, insulin Detemir or insulin glargine",University of Aarhus,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,19,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NPH-Detemir-Glargine-2011,Feb-12,Nov-12,Nov-12,28-Oct-11,null,4-Dec-12,"Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark",,https://ClinicalTrials.gov/show/NCT01461616
NCT01460251,OPen Label Study to Evaluate Long Term Treatment Effect of DiaPep277,,Terminated,No Results Available,Type 1 Diabetes,Drug: DiaPep277,Adverse events|DiaPep277-specific antibodies|Beta cell function-AUC of stimulated C-peptide from stimulated MMTT measured by radioimmunoassay|Percentage of patients that maintain stimulated C-peptide >/= 0.2nmol/L|percentage of patients that achieve glycemic target of HbA1c</=7%|Daily insulin dose adjusted to body weight at study end,Rabin Medical Center,All,18 Years to 50 Years   (Adult),Phase 3,11,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,rmc006492ctil,Jan-12,Dec-14,Feb-15,26-Oct-11,null,19-Mar-15,"Hadassah Medical Center, Jerusalem, Israel|Schneider Children's Medical Center, Petah-Tikva, Israel",,https://ClinicalTrials.gov/show/NCT01460251
NCT01460446,ACCU-CHEK® Aviva Expert Study: Does Use of a Bolus Advisor Improve Glycemic Control in Patients Not Achieving Optimal Control Using Multiple Daily Injections (MDI)?,ABACUS,Completed,Has Results,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Device: Aviva Expert blood glucose meter|Device: Aviva Nano blood glucose meter,"Change in Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Week 24|Percentage of Blood Glucose Measurements Within the Blood Glucose Target Range From Screening to Baseline and From Week 23 to Week 24|Number of Symptomatic Hypoglycemic Episodes Per Subject Year From Screening to Baseline and From Week 23 to Week 24|Change in the Mean Amplitude of Glucose Excursion (MAGE) From Baseline to Week 24|Percentage of Bolus Opportunities Where the Accu-Chek® Aviva Expert Blood Glucose Meter Bolus Advisor Was Used During the Study|Number of Accu-Chek® Aviva Expert Blood Glucose Meter Bolus Advices Modified Per Day by Participants During the Study|Correct and Incorrect Use of Insulin:Carbohydrate Ratio (I:CHO) and Insulin Sensitivity Factor (ISF) Advice by Participants Using the Aviva Nano Blood Glucose Meter During the Study|Change in Carbohydrate Counting Accuracy From Baseline to Week 24|Change in the Patient Health Questionnaire Depression Scale (PHQ-8) Score From Baseline to Week 24|Number of Participants With None, Mild, Moderate, Moderately Severe, and Severe Depression at Baseline and Week 24|Change in the Problem Area in Diabetes (PAID) Scale Score From Baseline to Week 24|Change in the Hypoglycemia Fear Survey (HFS-II) Score From Baseline to Week 24|The Diabetes Treatment Satisfaction Questionnaire at Baseline (DTSQs) Score and the Diabetes Treatment Satisfaction Questionnaire for Change From Baseline (DTSQc) Score",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,218,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RD001333,Oct-11,Sep-12,Sep-12,26-Oct-11,6-Feb-14,6-Feb-14,"Aschaffenburg, Germany|Augsburg, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Duisburg, Germany|Essen, Germany|Furth im Wald, Germany|Köln-Weiden, Germany|Leipzig, Germany|München, Germany|Münster, Germany|Rostock, Germany|Simmern, Germany|Unterhaching, Germany|Wurzen, Germany|Blackburn, United Kingdom|Bournemouth, United Kingdom|Bradford, United Kingdom|Chester, United Kingdom|Cosham, United Kingdom|Coventry, United Kingdom|Derby, United Kingdom|Exeter, United Kingdom|Leicester, United Kingdom|Lindley, Huddersfield, United Kingdom|Middlesborough, United Kingdom|Northampton, United Kingdom|Nottingham, United Kingdom|Rotherham, United Kingdom|Scunthorpe, United Kingdom|Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT01460446
NCT01457911,Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Glimepiride and Metformin hydrochloride combination (HOE490)|Drug: Glimepiride (HOE490),"Absolute change in HbA1c|Percentage of patients reaching HbA1c < 7% or HbA1c ≤ 6.5%, respectively|Absolute change in Fasting Plasma Glucose|Number of patients reporting adverse events|Number of patients reporting serious adverse events|Hypoglycemia|Vital signs|Hematology, Serum chemistry and lipids",Sanofi,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,244,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EFC11761|U1111-1121-6792,Oct-11,Feb-13,Feb-13,24-Oct-11,null,8-May-14,"Investigational Site Number 156001, Beijing, China|Investigational Site Number 156016, Beijing, China|Investigational Site Number 156003, Beijing, China|Investigational Site Number 156018, Beijing, China|Investigational Site Number 156002, Beijing, China|Investigational Site Number 156019, Changchun, China|Investigational Site Number 156017, Chengdu, China|Investigational Site Number 156014, Guangzhou, China|Investigational Site Number 156022, Guangzhou, China|Investigational Site Number 156011, Hangzhou, China|Investigational Site Number 156012, Hefei, China|Investigational Site Number 156020, Jinan, China|Investigational Site Number 156023, Jinan, China|Investigational Site Number 156010, Shanghai, China|Investigational Site Number 156006, Shanghai, China|Investigational Site Number 156009, Shanghai, China|Investigational Site Number 156021, Shenyang, China|Investigational Site Number 156005, Shijiazhuang, China|Investigational Site Number 156004, Taiyuan, China|Investigational Site Number 156024, Tianjin, China|Investigational Site Number 156008, Wuhan, China|Investigational Site Number 156015, Xiamen, China",,https://ClinicalTrials.gov/show/NCT01457911
NCT01456650,R230C and C230C Variants of ABCA1 and Glyburide Response,,Completed,No Results Available,Type 2 Diabetes,Drug: Glyburide,Change in plasma fasting glucose|HbA1c levels,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,All,"20 Years to 79 Years   (Adult, Older Adult)",Phase 4,85,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science,INNSZ-ABCA1,Mar-11,Nov-12,Dec-12,21-Oct-11,null,15-Jan-14,"Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, DF, Mexico",,https://ClinicalTrials.gov/show/NCT01456650
NCT01455441,The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes,,Completed,No Results Available,Type 2 Diabetes,Other: Training and liraglutide|Other: Training and placebo,HbA1c|Maximal oxygen uptake (VO2peak)|Body weight|Blood pressure|Glycaemic control|Meal test|Myocardial echocardiography,"Tina Vilsboll|University Hospital, Gentofte, Copenhagen",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",60 - TrainIncretin,Oct-11,Jun-13,Jun-14,20-Oct-11,null,29-May-15,"Department of Internal Medicine, Gentofte Hospital, Hellerup, Denmark",,https://ClinicalTrials.gov/show/NCT01455441
NCT01454700,Effect of CSII and CGM on Progression of Late Diabetic Complications,,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: Insulin pump therapy (CSII) plus continuous glucose monitoring (CGM)|Other: Multiple daily insulin injections (MDI),"difference in change in urine albumine excretion from baseline to end of study (12 months)|difference in change of HbA1c from baseline to 12 months|difference in change in self-monitored blood glucose (SMBG) measurement 4-point glucose profiles|difference in change of 24-hour blood pressure|difference in change of glomerular filtration rate (GFR)|difference in the occurence or progression of retinopathy|difference in change of cardiovascular biomarkers of inflammation, lipid metabolism and NT-proBNP|difference in endothelial cell dysfunction|difference in carotid intima media thickness (CIMT)",Steen Andersen|Medtronic|Steno Diabetes Center Copenhagen,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,60,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-3-2011-122,Dec-11,Dec-14,Dec-14,19-Oct-11,null,14-Jan-15,"Steno Diabetes Center, Gentofte, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT01454700
NCT01455142,A Trial to Test for Bioequivalence Between NN1045 and NN5401 in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec/insulin aspart,Area under the serum insulin degludec concentration-time curve|Maximum observed serum insulin degludec concentration|Area under the serum insulin aspart concentration-time curve|Maximum observed serum insulin aspart concentration|Area under the glucose infusion rate curve|Maximum glucose infusion rate,Novo Nordisk A/S,All,18 Years to 64 Years   (Adult),Phase 1,32,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1045-3834|2011-001569-42|U1111-1120-3922,Oct-11,Jan-12,Jan-12,19-Oct-11,null,23-Feb-15,"Graz, Austria",,https://ClinicalTrials.gov/show/NCT01455142
NCT01453842,Diet Oil Induced Stimulation of GLP-1,,Completed,No Results Available,Type 2 Diabetes Mellitus,Dietary Supplement: Diet oil|Dietary Supplement: Olive oil|Dietary Supplement: Carrot,Plasma GLP-1|Plasma insulin|Plasma glucose|Plasma GIP|Plasma glucagon|Plasma PYY|Plasma paracetamol,University of Copenhagen,All,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,Diet oil,Mar-11,Dec-11,Mar-12,18-Oct-11,null,2-Dec-14,"Department of Clinical Physiology, Glostrup, Denmark",,https://ClinicalTrials.gov/show/NCT01453842
NCT01454284,A Study in Participants With Type I Diabetes Mellitus,IMAGINE 3,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Glargine|Drug: LY2605541|Drug: Insulin Lispro,"Hemoglobin A1c (HbA1c)|Change From Baseline to 52 Weeks in HbA1c|Total Hypoglycemia Events|Percentage of Participants With Total Hypoglycemic Events|Percentage of Participants With HbA1c Equal to or Less Than 6.5% and Less Than 7.0%|Percentage of Participants With HbA1c Less Than 7.0% and Without Nocturnal Hypoglycemia|Nocturnal Hypoglycemia Rates|Percentage of Participants With Nocturnal Hypoglycemic Events|Change in Body Weight|9 Point Self-monitored Blood Glucose (SMBG)|Fasting Serum Glucose (by Laboratory Measurement)|Fasting Blood Glucose (by Participant Self Monitored Blood Glucose Readings)|Intra-participant Variability of Fasting Blood Glucose (FBG)|0300 Hours Blood Glucose (BG) to Fasting BG Excursion|Triglycerides, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C), and Total Cholesterol|Percentage of Participants With Change in Anti-LY2605541 Antibodies|Basal, Meal Time, and Total Insulin Dose Per Body Weight|Insulin Treatment Satisfaction Questionnaire|European Quality of Life -5 Dimension (EQ-5D-3L)|Adult Low Blood Sugar Survey|Rapid Assessment of Physical Activity (RAPA)",Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1114,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",12147|I2R-MC-BIAO|2011-001253-82,Jan-12,Feb-14,Feb-14,18-Oct-11,17-Apr-18,17-Apr-18,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Concord, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fresno, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Mesa, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lancaster, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tustin, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aurora, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Longmont, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bradenton, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hollywood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jacksonville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Port Richey, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Palm Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roswell, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Honolulu, Hawaii, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Idaho Falls, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Springfield, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Des Moines, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Topeka, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Metairie, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eagan, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Minneapolis, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chesterfield, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Springfield, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Billings, Montana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Las Vegas, Nevada, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashua, New Hampshire, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albany, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durham, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Morehead City, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mentor, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eugene, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greer, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Myrtle Beach, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chattanooga, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Round Rock, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ogden, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Federal Way, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spokane, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tacoma, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Merewether, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Keswick, South Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Box Hill, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Parkville, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edegem, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Huy, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sint-Niklaas, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fortaleza, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto Alegre, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edmonton, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Red Deer, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winnipeg, Manitoba, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Halifax, Nova Scotia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oakville, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Laval, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montreal, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osijek, Croatia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kobenhavn, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Rochelle, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Le Creuzot, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rouen, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chalkida, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Thessaloniki, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dublin, Ireland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haifa, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jerusalem, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Petah Tikva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Petah Tiqva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Hashomer, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jonava, Lithuania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaunas, Lithuania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dordrecht, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Groningen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Christchurch, New Zealand|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wellington, New Zealand|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdansk, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Katowice, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Krakow, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lubin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szczecin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sturovo, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houghton, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pretoria, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Somerset West, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Alcala De Henares, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Alcira, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Málaga, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seville, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Alingsås, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Helsingborg, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Huddinge, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Karlstad, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bristol, Avon, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portsmouth, Hampshire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Blackburn, Lancashire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leicester, Leicestershire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Inverness, Scotland, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ipswich, Suffolk, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guildford, Surrey, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Swansea, Wales, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glasgow, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Northampton, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT01454284
NCT01452815,Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis,,Completed,No Results Available,"Gastroparesis|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Drug: Placebo|Drug: 10mg TZP-102|Drug: 20mg TZP-102,"Change from baseline in symptoms associated with diabetic gastroparesis|Change from baseline on health-related quality of life|Adverse Events (AEs)|Cardiovascular Parameters (blood pressure, heart rate, 12-Lead ECG)|Clinical Chemistry and Hematology Parameters","Tranzyme, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,201,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TZP-102-CL-G003,Sep-11,Nov-12,Nov-12,17-Oct-11,null,25-Apr-13,"Tranzyme Investigational Site, Huntsville, Alabama, United States|Tranzyme Investigational Site, Tucson, Arizona, United States|Tranzyme Investigational Site, Jonesboro, Arkansas, United States|Tranzyme Investigational Site, Little Rock, Arkansas, United States|Tranzyme Investigational Site, Long Beach, California, United States|Tranzyme Investigational Site, Stanford, California, United States|Tranzyme Investigational Site, Ventura, California, United States|Tranzyme Investigational Site, Hialeah, Florida, United States|Tranzyme Investigational Site, Inverness, Florida, United States|Tranzyme Investigational Site, Jacksonville, Florida, United States|Tranzyme Investigational Site, Miami, Florida, United States|Tranzyme Investigational Site, Miami, Florida, United States|Tranzyme Investigational Site, New Smyrna Beach, Florida, United States|Tranzyme Investigational Site, Port Orange, Florida, United States|Tranzyme Investigational Site, Oak Lawn, Illinois, United States|Tranzyme Investigational Site, Anderson, Indiana, United States|Tranzyme Investigational Site, Kansas City, Kansas, United States|Tranzyme Investigational Site, Monroe, Louisiana, United States|Tranzyme Investigational Site, Boston, Massachusetts, United States|Tranzyme Investigational Site, Mexico, Missouri, United States|Tranzyme Investigational Site, Fayetteville, North Carolina, United States|Tranzyme Investigational Site, Raleigh, North Carolina, United States|Tranzyme Investigational Site, Salisbury, North Carolina, United States|Tranzyme Investigational Site, Winston-Salem, North Carolina, United States|Tranzyme Investigational Site, Oklahoma City, Oklahoma, United States|Tranzyme Investigational Site, Portland, Oregon, United States|Tranzyme Investigational Site, Philadelphia, Pennsylvania, United States|Tranzyme Investigational Site, Jackson, Tennessee, United States|Tranzyme Investigational Site, El Paso, Texas, United States|Tranzyme Investigational Site, Houston, Texas, United States|Tranzyme Investigational Site, Tacoma, Washington, United States|Tranzyme Investigational Site, Brugge, Belgium|Tranzyme Investigational Site, Bruxelles, Belgium|Tranzyme Investigational Site, Gent, Belgium|Tranzyme Investigational Site, Aarhus, Denmark|Tranzyme Investigational Site, Gentofte, Denmark|Tranzyme Investigational Site, Odense, Denmark|Tranzyme Investigational Site, Porvoo, Finland|Tranzyme Investigational Site, Tampere, Finland|Tranzyme Investigational Site, Essen, Germany|Tranzyme Investigational Site, Mainz, Germany|Tranzyme Investigational Site, Stuttgart, Germany|Tranzyme Investigational Site, Bergen, Norway|Tranzyme Investigational Site, Bialystok, Poland|Tranzyme Investigational Site, Bydgoszcz, Poland|Tranzyme Investigational Site, Kielce, Poland|Tranzyme Investigational Site, Krakow, Poland|Tranzyme Investigational Site, Lodz, Poland|Tranzyme Investigational Site, Olsztyn, Poland|Tranzyme Investigational Site, Warszawa, Poland|Tranzyme Investigational Site, Stockholm, Sweden|Tranzyme Investigational Site, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT01452815
NCT01452113,Effect of Autonomic Neuropathy on the Efficacy of a DPP-IV Inhibitor (Galvus) Therapy,DPPNAC,Completed,No Results Available,Diabetes Mellitus,Drug: Vildagliptin,plasma glucagon concentration|GLP-1|GIP,"University Hospital, Toulouse|Institute of Molecular Medicine of Rangueil (I2MR)|Faculty of Medicine, Toulouse|Novartis Pharmaceuticals",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,21,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,1004003,Oct-10,Jan-13,Mar-13,14-Oct-11,null,12-Mar-14,"UH Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT01452113
NCT01452451,"Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus",,Completed,No Results Available,Diabetes Mellitus,Drug: HM11260C|Drug: Placebo,Number of subjects with adverse events as a measure of safety and tolerability|The pharmacokinetics in repeat-dose|The pharmacodynamics in repeat-dose,Hanmi Pharmaceutical Company Limited,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,72,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",HM-EXC-202,Dec-11,Jun-13,null,14-Oct-11,null,9-Aug-16,"Ohio, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01452451
NCT01449019,The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM),DFG_5,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: exendin(9-39)amide|Drug: saline|Other: duodenal meal|Other: duodenal saline,The incretin effect|Plasma concentrations of glucagon|Plasma concentrations of insulin|Plasma concentrations of C-peptide|Plasma concentrations of Glucagon-like peptide-1(7-36) (GLP-1(7-36))|Plasma concentrations of Glucose-dependent insulinotropic polpypeptide (GIP),Ludwig-Maximilians - University of Munich,All,"30 Years to 70 Years   (Adult, Older Adult)",Phase 1,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",DPI,Dec-06,Aug-07,Jul-10,7-Oct-11,null,7-Oct-11,"Ludwig Maximilians-University, Clinical Research Unit, Munich, Germany|Clinical Research unit, Dept. of Internal Medicine II - Großhadern, University of Munich, Munich, Germany",,https://ClinicalTrials.gov/show/NCT01449019
NCT01447940,Prospective Assessment of Meos Telemedicine E-portal on Ambulatory Care of Type 1 Diabetic Patients,TELEDIAB-3,Unknown status,No Results Available,"Diabetes Mellitus, Type 1",Device: Meos ePortal use,"HbA1c measured at 12 months in Meos ePoral group versus conventional care group. Non-inferiority level is defined at a 0.15% threshold for an expected HbA1c of 8.5% at 12 months|HbA1c measured at 6 months in each group|HbA1c measured at 12 months in each group|HbA1c measured at 6 months in each group according to initial HbA1c level (higher than 8% or to median)|HbA1c measured at 12 months in each group according to initial HbA1c level (higher than 8% or to median)|Definition of failure: study withdraws or emergency hospitalization linked to diabetes or HbA1c increase of 0.5 % up to 12 months of follow up|Annual cost of diabetes care from hospital and health insurance' points of view|Quality of life at inclusion and 12 months, using the Diabetes Health Profile (DHP-1) scale and the Satisfaction items of the Diabetes Quality of Life (DQOL) questionnaire|Qualitative analysis by semi-structured interviews, then quantitative survey by questionnaire","University Hospital, Grenoble",All,"18 Years and older   (Adult, Older Adult)",Phase 3,720,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,DCIC10 20,Jan-12,Jul-14,Dec-15,6-Oct-11,null,9-Dec-14,"University Hospital of Caen (Hospital Côte de nacre), Caen, Basse-Normandie, France|University Hospital of Besancon - Hospital Jean Minjoz, Besancon, Franche Comté, France|Hospital Sud Francilien, Corbeil Essonne, Ile de France, France|Hospital University of Montpellier, Montpellier, Languedoc-Roussillon, France|University Hospital of Reims, Reims, Marne, France|University Hospital of Nantes, Nantes, Pays-de-la-Loire, France|University Hospital, Department of Endocrinology, Grenoble, Rhône-Alpes, France|University Hospital of Lyon (HCL Lyon sud), Lyon, Rhônes-Alpes, France",,https://ClinicalTrials.gov/show/NCT01447940
NCT01447979,Feasibility Study of a Portable Artificial Pancreas System in Type 1 Diabetes Mellitus (T1DM) - Montpellier,HomeCTR1_1,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: portable artificial pancreas system with Control-To-Range algorithms,estimation of the failure rates of system components|frequency analysis of lost or inaccurate CGM records|percent time of active CTR,"University of Virginia|University Hospital, Montpellier|University of Padova|University of California, Santa Barbara",All,"21 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,5,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2011-A01096-35|JDRF 22-2011-649,Mar-12,Apr-12,Apr-12,6-Oct-11,null,29-Nov-12,"Centre d'Investigation Clinique CHU Montpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT01447979
NCT01447992,Feasibility Study of a Portable Artificial Pancreas System in Type 1 Diabetes Mellitus (T1DM) - Padova,HomeCTR1_2,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: Portable artificial pancreas system with Control-To-Range,estimation of the failure rates of system components|frequency analysis of lost or inaccurate CGM records|percent time of active CTR,"University of Virginia|University of Padova|University Hospital, Montpellier|University of California, Santa Barbara",All,"21 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,5,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2433P|JDRF 22-2011-649,Sep-11,Apr-12,Apr-12,6-Oct-11,null,19-Jun-14,"Azienda Ospedaliera E Universita Degli Study Di Padova, Padova, Veneto, Italy",,https://ClinicalTrials.gov/show/NCT01447992
NCT01445951,Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period,,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Technosphere® Insulin with MedTone C Inhaler|Drug: Technosphere ®Insulin with Gen2 Inhaler|Drug: Insulin Aspart in combination with a basal insulin,Change From Baseline to Week 24 in HbA1c|FEV1 Change From Baseline to Week 24|FPG Change From Baseline to Week 24|Mean 7-point Glucose Baseline Values|Mean 7-point Glucose Week 24 Values|Change in Body Weight From Baseline to Week 24|Proportion of Responders Achieving HbA1c <= 7.0%,Mannkind Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 3,518,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MKC-TI-171,Sep-11,May-13,Jun-13,4-Oct-11,22-Oct-14,22-Oct-14,"Burlingame, California, United States|Escondido, California, United States|Huntington Beach, California, United States|La Jolla, California, United States|La Mesa, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Los Gatos, California, United States|San Mateo, California, United States|Santa Barbara, California, United States|Tustin, California, United States|Aurora, Colorado, United States|Hialeah, Florida, United States|Hollywood, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Palm Harbor, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Dunwoody, Georgia, United States|Lawrenceville, Georgia, United States|Roswell, Georgia, United States|Chicago, Illinois, United States|Vincennes, Indiana, United States|Des Moines, Iowa, United States|Baton Rouge, Louisiana, United States|Metairie, Louisiana, United States|New Orleans, Louisiana, United States|Edina, Minnesota, United States|Jefferson City, Missouri, United States|St Peters, Missouri, United States|St. Louis, Missouri, United States|Billings, Montana, United States|Omaha, Nebraska, United States|Omaha, Nebraska, United States|Paramus, New Jersey, United States|Albuquerque, New Mexico, United States|Flushing, New York, United States|New Hyde Park, New York, United States|New York, New York, United States|Asheville, North Carolina, United States|Greenville, North Carolina, United States|Morehead City, North Carolina, United States|Portland, Oregon, United States|Greer, South Carolina, United States|Bartlett, Tennessee, United States|Arlington, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Murray, Utah, United States|Federal Way, Washington, United States|Renton, Washington, United States|Wenatchee, Washington, United States|Porto Alegre, RS, Brazil|Sao Paulo, SP, Brazil|St. Petersburg, Russia, Russian Federation|St. Petersburg, Russia, Russian Federation|Kemerovo, RUS, Russian Federation|Moscow, RUS, Russian Federation|Moscow, RUS, Russian Federation|Moscow, RUS, Russian Federation|Moscow, RUS, Russian Federation|Moscow, RUS, Russian Federation|Moscow, RUS, Russian Federation|Moscow, RUS, Russian Federation|Moscow, RUS, Russian Federation|Petrozavodsk, RUS, Russian Federation|Smolensk, RUS, Russian Federation|St Petersburg, RUS, Russian Federation|St Petersburg, RUS, Russian Federation|St Petersburg, RUS, Russian Federation|St. Petersburg, RUS, Russian Federation|St. Petersburg, RUS, Russian Federation|St. Petersburg, RUS, Russian Federation|Yaroslavl, RUS, Russian Federation|Yaroslavl, RUS, Russian Federation|Dnipropetrovsk, UKR, Ukraine|Donetsk, UKR, Ukraine|Kharkiv, UKR, Ukraine|Kiev, UKR, Ukraine|Kiev, UKR, Ukraine|Kyiv, UKR, Ukraine|Odesa, UKR, Ukraine|Odesa, UKR, Ukraine|Vinnytsya, UKR, Ukraine",,https://ClinicalTrials.gov/show/NCT01445951
NCT01443741,Evaluation of Interests of FIT Therapy on Diabetics Children Insulin-dependent,DIABFIT,Unknown status,No Results Available,Diabetes Insulin Dependent,Other: Therapeutic education,Variation in HbA1c|Severe hypoglycemia over 6 months and quality of life,"University Hospital, Angers",All,1 Year to 17 Years   (Child),Phase 2,88,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PHRC 2009- 03,Jan-12,Jan-15,Jul-15,30-Sep-11,null,30-Sep-11,"University Hospital of Brest, Brest, Bretagne, France|University Hospital of Toulouse, Toulouse, Midi-Pyrénées, France|University Hospital of Angers Service of Pediatric Diabetology and Endocrinology, Angers, Pays de Loire, France|University Hospital of Nantes, Nantes, Pays de Loire, France|University Hospital of Lyon, Lyon, Rhône Alpes, France|University Hospital of Tours, Tours, Région Centre, France",,https://ClinicalTrials.gov/show/NCT01443741
NCT01444443,DiaCon Overnight Closed-Loop Glucose Control Study,DiaCon2,Completed,No Results Available,Type 1 Diabetes,Device: Closed-loop control|Other: Open-loop control,Number of hypoglycemic events|Time spent in euglycemia (3.9-8.0 mmol/l); mean blood glucose level; LBGI,Hvidovre University Hospital|Technical University of Denmark|Novo Nordisk A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,12,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2106-07-0034,Nov-11,Jun-12,Jun-12,30-Sep-11,null,20-Nov-12,"Hvidovre University Hospital, Hvidovre, Denmark",,https://ClinicalTrials.gov/show/NCT01444443
NCT01444534,Mobile Phone Applications and Quality of Life,,Completed,No Results Available,Type 1 Diabetes,Device: Dbees; diabetes mobile phone application|Device: control group,Quality of Life|HbA1c|usability of the application|Self-monitoring of blood glucose (SMBG),"Medical Research Foundation, The Netherlands",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,65,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Pameijer-2011,Sep-11,Apr-12,Apr-12,30-Sep-11,null,24-Oct-12,"Isala Clinics, Zwolle, Netherlands",,https://ClinicalTrials.gov/show/NCT01444534
NCT01441232,A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: LX4211|Drug: Januvia®,Change from baseline in gut hormones|Change from baseline in fasting plasma glucose|Change from baseline in postprandial glucose|Change from baseline in insulin|Change from baseline in peptide YY|Change from baseline in urinary glucose excretion,Lexicon Pharmaceuticals,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,18,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LX4211.1-105-DM|LX4211.105,Oct-11,Nov-11,null,27-Sep-11,null,31-Jan-12,"Lexicon Investigational Site, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01441232
NCT01440140,Closing the Loop in Adults With Type 1 Diabetes in the Home Setting,,Completed,No Results Available,Type 1 Diabetes Mellitus,Other: Closed-loop|Other: Conventional insulin pump delivery,"Percentage of CGM (Continuous glucose monitoring) values in target (3.9 - 8.0 mmol/l).|Percentage of CGM values below 3.9 mmol/l.|Time spent with glucose levels below 3.9 mmol/l and above 8.0 mmol/l, as recorded by CGM and other CGM-based metrics|Glycaemic control assessed by fructosamine and HbA1c",University of Cambridge|Diabetes UK,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,24,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANGELA03,Dec-12,Dec-13,Jan-14,26-Sep-11,null,29-Jan-14,"Addenbrooke's Hospital, Cambridge, United Kingdom|King's College London, London, United Kingdom|Northern General Hospital, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT01440140
NCT01440439,Comparing Long-acting Insulins During Exercise in Type 1 Diabetes,,Unknown status,No Results Available,"Diabetes Mellitus, Type 1",Drug: Insulin glargine|Drug: Insulin detemir,"Glucose excursion (which, as defined below, is the change in blood glucose between the start and finish of one hour of exercise)|Lactate|NEFA (Non-esterified fatty acids)|B-OHB (beta-hydroxybutyrate)|Catecholamines|Glucagon|Human growth hormone (hGH)|Cortisol|IL-6 (interleukin 6)|High sensitivity CRP (Hs-CRP)|RQ (Respiratory Quotient)|Frequency of hypoglycaemic events|Time spent in hypoglycaemia|Blood glucose",Buckinghamshire Healthcare NHS Trust|Novo Nordisk A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,30,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RXQ425|2011-001209-28|U1111-1119-8890,Nov-11,Jun-12,Jun-12,26-Sep-11,null,8-Nov-11,"Wycombe Hospital, High Wycombe, Buckinghamshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT01440439
NCT01439672,"Insulin Sensitivity, Impaired Counterregulation, and Glucose Variability",BPK005,Completed,Has Results,Type 1 Diabetes Mellitus,Dietary Supplement: Mixed meal and insulin challenge,Insulin Sensitivity,University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,21 Years to 64 Years   (Adult),Not Applicable,35,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15131|R01DK085623,Aug-10,Mar-12,Mar-12,23-Sep-11,14-Apr-15,6-Dec-16,"University of Virginia, Center for Diabetes Technology, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01439672
NCT01434862,Pramlintide Combined With Model Predictive Control Algorithm,ALM002,Terminated,No Results Available,Type 1 Diabetes Mellitus,Drug: Closed loop with pramlintide|Device: Closed loop without pramlintide|Drug: Open loop with pramlintide,Percent of Blood glucose tests within target range of 70 to 180 mg/dl|Percent of Continuous Glucose Monitoring (CGM) System estimated blood glucose within target range of 70 to 180 mg/dl,University of Virginia|The Paul Manning Foundation,All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,2,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15401,Feb-11,Feb-12,Feb-12,15-Sep-11,null,1-May-14,"University of Virginia, Center for Diabetes Technology, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01434862
NCT01434030,Development of a Behavioral Observer for Type 1 Diabetes Mellitus,Phase1,Completed,Has Results,"Diabetes Mellitus, Type 1",Behavioral: Focus Group,Desire to Receive Advice From Personal Glucose Advisory System (PGASystem)|Willingness to Follow PGASystem Advice,University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,57,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),14956|R01DK085623,Apr-10,Jun-11,Jun-11,14-Sep-11,25-Aug-14,4-Sep-14,"University of Virginia - Center for Diabetes Technology, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01434030
NCT01433380,A Study To Evaluate PF-05175157 In Healthy Volunteers,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: PF-05175157|Drug: Placebo,"Changes in carbohydrate and lipid metabolism|Pharmacokinetics: 0.5, 1, 1.5, 2.5, 6.5, 10.5, 24 hrs after dosing, parameters: Cmax, Tmax and Area under the Curve (AUC)",Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,22,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",B1731004,Jul-11,May-12,May-12,13-Sep-11,null,18-May-12,"Pfizer Investigational Site, Baton Rouge, Louisiana, United States",,https://ClinicalTrials.gov/show/NCT01433380
NCT01429467,Glucose Variability in Type 1 Diabetes and Its Effect on Factors That Influence New Vessel Formation,INDIGO 2,Completed,No Results Available,Type 1 Diabetes,Device: Continuous Glucose Monitor (CGM) and Telemedicine (Enlite Guardian real-time system Medtronic®),Correlation of HbA1c and level of Hypoxia-inducible Factor|Correlation of HbA1c and level of Vascular Endothelial Growth Factor|Correlation of HbA1c and level of Erythropoietin|Correlation of HbA1c and level of cortisol|Change in Mean Area of Glucose Excursion (MAGE) following CGM|Change in levels of Hypoxia-inducible factor following CGM|Change in levels of Vascular Endothelial Growth Factor following CGM|Change in levels of erythropoietin following CGM|Change in levels of cortisol following CGM,University of Dundee,All,"5 Years to 18 Years   (Child, Adult)",Not Applicable,35,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,AT/V01/010911,Aug-12,Feb-14,Dec-15,7-Sep-11,null,30-May-16,"University Of Dundee, Dundee, Angus, United Kingdom",,https://ClinicalTrials.gov/show/NCT01429467
NCT01427257,Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Single Dose PB1023,Pharmacokinetics|Safety/Tolerability,PhaseBio Pharmaceuticals Inc.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,10,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PB1023-PT-CL-0002,Feb-12,Sep-12,Sep-12,1-Sep-11,null,1-Oct-12,"Prism Research, Saint Paul, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01427257
NCT01427699,A Study of the Safety and Pharmacokinetics of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes,,Completed,No Results Available,Type 2 Diabetes,Drug: T2-18C3 therapeutic antibody,Safety and Tolerability|Pharmacokinetics|Preliminary Efficacy,"XBiotech, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,7,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010-PT011,Jun-11,Oct-12,null,1-Sep-11,null,31-Oct-12,"University Hospital of Basel, Basel, Switzerland",,https://ClinicalTrials.gov/show/NCT01427699
NCT01424046,Health Care for Type 1 Diabetes in Developing World,,Completed,No Results Available,Type 1 Diabetes,Drug: basal insulin glargine|Drug: standard therapy,HbA1c|Microalbuminuria,"University of Pittsburgh|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National University, Rwanda|Association Rwandaise des Diabetiques",All,"1 Year to 24 Years   (Child, Adult)",Not Applicable,50,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RC4 pitt 1|RC4DK090809,May-11,Jun-14,Nov-14,26-Aug-11,null,5-Dec-14,"Association Rwandese des Diabetiques, Kigali, Kigali Provence, Rwanda",,https://ClinicalTrials.gov/show/NCT01424046
NCT01421147,A Study in Adults With Type 1 Diabetes,ELEMENT 1,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: LY2963016|Drug: Lantus|Drug: Insulin Lispro,Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c)|Change From Baseline in Insulin Antibody Levels|Change From Baseline in Hemoglobin A1c (HbA1c)|7-Point Self-Monitored Blood Glucose (SMBG) Profiles|Glycemic Variability of Fasting Blood Glucose|Change From Baseline in Body Weight|Adult Low Blood Sugar Survey (ALBSS)|Insulin Treatment Satisfaction Questionnaire (ITSQ)|Insulin Dose Per Body Weight (U/kg) (Total and by Component [Basal and Bolus (Lispro)])|Insulin Dose - Units [Total and by Component [Basal and Bolus (Lispro)])|Percentage of Participants With Hemoglobin A1c (HbA1c) <7.0% and HbA1c ≤6.5%|Incidence of Hypoglycemic Events|Rate Per 30 Days of Hypoglycemic Events,Eli Lilly and Company|Boehringer Ingelheim,All,"18 Years and older   (Adult, Older Adult)",Phase 3,536,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13712|I4L-MC-ABEB|2011-000829-73,Aug-11,Aug-12,Apr-13,22-Aug-11,9-Oct-14,9-Oct-14,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hollywood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Port Richey, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Palm Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roswell, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Springfield, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Des Moines, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Topeka, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Metairie, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kalamazoo, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashua, New Hampshire, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mineola, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Hyde Park, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Syracuse, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Asheville, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., LiÃ¨ge, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fulda, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. Ingbert-OberwÃ¼rzbach, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haidari/Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Thessaloniki, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Debrecen, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salgotarjan, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kumamoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miyazaki, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagasaki, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Puebla, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampico, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Krakow, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lodz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szczecin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Galati, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iasi, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oradea, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Timisoara, Romania",,https://ClinicalTrials.gov/show/NCT01421147
NCT01421225,Closed-Loop Insulin Delivery in Children Less Than 7 Years of Age,,Completed,Has Results,Type 1 Diabetes Mellitus,Device: Closed-loop Insulin Pump therapy|Device: Standard Insulin Pump Therapy,Nocturnal Glycemic Control|Post-prandial Glycemic Control|Number of Interventions for Hypoglycemia|Pre-lunch Blood Glucose Level,Boston Children’s Hospital,All,6 Months to 7 Years   (Child),Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB-P00000231,Aug-11,15-Aug-13,15-Aug-13,22-Aug-11,7-Aug-18,9-Aug-18,"Children's Hospital Boston, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01421225
NCT01421355,A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus,,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Atazanavir,Change in Brachial Artery Diameter,Brigham and Women's Hospital|National Institutes of Health (NIH),All,"18 Years and older   (Adult, Older Adult)",Phase 1,15,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),1R03DK094510-01,May-12,Feb-14,Feb-14,22-Aug-11,21-Jul-14,21-Jul-14,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01421355
NCT01418703,Feasibility Study of a Modular Control to Range System in Type 1 Diabetes Mellitus,MDB003,Completed,Has Results,Type 1 Diabetes Mellitus,Device: Closed Loop Control (CLC)|Device: Open Loop,Hypoglycemic Events|Percent Time Spent in Near Normoglycemia|Mean Glucose,"University of Virginia|Abbott Diabetes Care|Insulet Corporation|DexCom, Inc.|University of California, Santa Barbara",All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,38,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,14356,Oct-09,Dec-10,Dec-10,17-Aug-11,13-Nov-14,13-Nov-14,"University of Virginia Health System, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01418703
NCT01407315,"Accuracy, Reliability and Safety of GlucoMen®Day, a New Generation Microdialysis Continuous Glucose Monitor",,Completed,No Results Available,Type 1 Diabetes,Device: GlucoMenDay,Accuracy of the GlucoMenDay|Safety of the GlucoMenDay System,Medical University of Graz|Menarini Group,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,20,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,GMD_03,Nov-10,Dec-10,Dec-10,2-Aug-11,null,20-Apr-12,"Medical University of Graz, Graz, Austria",,https://ClinicalTrials.gov/show/NCT01407315
NCT01407640,Diagnosis and Physiopathology of Insulin Allergy,Allerdiab,Completed,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Hypersensitivity|Immediate Hypersensitivity|Allergy",Procedure: Allergy tests,Validation of cutaneous insulin tests|Immunogenetic of patients with IA (Insulin Allergy),"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,55,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,P081223,6-Feb-12,27-Jul-16,27-Jul-16,2-Aug-11,null,19-Mar-18,"Cochin Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT01407640
NCT01406496,Best Timing of Insulin Bolus Before Meals of Different Contents,,Unknown status,No Results Available,Type 1 Diabetes Mellitus,Drug: insulin,Post-prandial blood glucose excursions following three different meals and three different timings of insulin bolus.,Kaplan Medical Center,All,"8 Years to 30 Years   (Child, Adult)",Not Applicable,24,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PP1,Aug-11,Oct-13,Dec-13,1-Aug-11,null,22-Feb-13,"Pediatric Endocrinology Unit, Kaplan Medical Center, Rehovot, Israel",,https://ClinicalTrials.gov/show/NCT01406496
NCT01405261,Trial Investigating the Safety of NNC 0113-0987 in Healthy Male Subjects,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 2|Healthy",Drug: oral NNC 0113-0987|Drug: I.v. NNC 0113-0987|Drug: oral placebo,"Overview of Treatment Emergent Adverse Events (AEs)|Frequency of hypoglycaemic episodes|AUC0-240h; area under the NNC 0113-0987 concentration-time curve|AUC, area under the curve|Cmax; maximum concentration of NNC 0113-0987 in plasma|The time to maximum concentration (tmax) of NNC 0113-0987 in plasma",Novo Nordisk A/S,Male,18 Years to 50 Years   (Adult),Phase 1,101,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN9926-3894|U1111-1119-1560|2011-000297-57,Aug-11,May-12,May-12,29-Jul-11,null,28-Nov-13,"Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT01405261
NCT01404676,"The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes",,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Add Vildagliptin|Drug: Add Glimepiride,Change in mean amplitude of glycemic excursion(MAGE) for 12 weeks(12weeks - 0 week).|Change from baseline in oxidative stress markers and inflammatory markers at 12 weeks. Change from baseline in endothelial cell function at 12 weeks.,Samsung Medical Center|Novartis,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,34,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010-02-053,Jun-10,May-12,May-12,28-Jul-11,null,18-Sep-18,"Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01404676
NCT01402037,Beta Cell Function in (Pre)Type 1 Diabetes,,Unknown status,No Results Available,Type 1 Diabetes,Drug: Glucose|Device: Continuous glucose monitoring,evaluate the hyperglycemic clamp to measure the functional beta cell mass test|Follow up of OGTT's and HbA1c levels in high risk first degree relatives and patients|evaluate the continuous glucose monitoring to measure within- and between-day glycemic variability,"AZ-VUB|Vrije Universiteit Brussel|University Hospital, Ghent|University Hospital, Antwerp",All,"5 Years to 39 Years   (Child, Adult)",Not Applicable,100,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,KD_BF_02,Jul-11,Jul-15,Jul-16,26-Jul-11,null,30-Dec-13,"UZ Brussels, Brussels, Belgium|UZ Antwerpen, Edegem, Belgium|UZ Gent, Gent, Belgium",,https://ClinicalTrials.gov/show/NCT01402037
NCT01401751,Feasibility Study Assessing The Ability Of An Insulin Pump-Controlling Algorithm To Minimize Hypoglycemia And Hyperglycemia In Patients With Type 1 Diabetes In A Clinical Research Setting,,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: Hypoglycemia-Hyperglycemia Minimizer System,To evaluate the performance of the System while the subject is under close medical supervision in the Clinical Research Center (CRC) setting.|Safety Evaluation,Animas Corporation,All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,13,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,3076823,1-Jul-11,1-Nov-11,1-Dec-11,25-Jul-11,null,1-Aug-17,"Sansum Diabetes Research Institute, Santa Barbara, California, United States",,https://ClinicalTrials.gov/show/NCT01401751
NCT01401790,Use of a Telehomecare Program for Young Patients With New Onset Type 1 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: Telehomecare (Intelligent Distance Patient Monitoring)|Other: Standard education and follow up at diabetes clinic,Patients' health (reported number of hypoglycemias and nocturnal hypoglycemias)|Patients and parents' health|Knowledge of diabetes|Organizational impacts|Family satisfaction with the software application,"Huot, Celine, M.D.",All,"6 Months to 18 Years   (Child, Adult)",Not Applicable,86,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,CHUSTEJUSTINE2644,Feb-08,Aug-09,Aug-09,25-Jul-11,null,25-Jul-11,"Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01401790
NCT01399892,Effect of Fiber Supplementation in Children With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Dietary Supplement: soluble fiber in the form of benefiber,incidence of hypoglycemia after fiber supplementation,Mayo Clinic,All,4 Years to 16 Years   (Child),Not Applicable,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,08-002142,Sep-08,May-10,Dec-10,22-Jul-11,null,22-Jul-11,,,https://ClinicalTrials.gov/show/NCT01399892
NCT01400659,Pizza-Salami Study in Children and Adolescents With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus,Procedure: CFP counting|Procedure: CARB counting,CGM-Glucose Area Under the Curve|Time of glucose nadir|hyperglycemia (6h-AUC >180 mg/dl)|frequency and amount of interventional hypoglycemic therapy|frequency of adverse events (incl. SAE),Kinderkrankenhaus auf der Bult|Medtronic,All,"6 Years to 21 Years   (Child, Adult)",Phase 4,42,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PPS2008,Mar-09,Jul-09,Nov-09,22-Jul-11,null,18-Dec-15,,,https://ClinicalTrials.gov/show/NCT01400659
NCT01398995,Managing Insulin Pumps for Exercise (Study 2),,Terminated,No Results Available,Type 1 Diabetes,Other: Reduction of basal insulin infusion to 50% of normal,"Comparison of glucose excursion (change in blood glucose) between baseline and the end of exercise between the four conditions.|Comparison between the four conditions of change in blood glucose levels between baseline and the beginning of exercise, and between the beginning and end of exercise.|Levels of NEFA and lactate will be compared between the four conditions|Correlation between levels of NEFA and lactate and blood glucose will be considered.|Ratio of respiratory quotient (RQ) at the beginning of exercise to RQ at the end of exercise compared between the four conditions.",Buckinghamshire Healthcare NHS Trust|Animas Corporation,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,6,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),RXQ404,May-11,Sep-11,Sep-11,21-Jul-11,null,21-Jul-11,"Wycombe Hospital, High Wycombe, Buckinghamshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT01398995
NCT01399346,Investigation of the Impact of Different Application Volumes of Insulin Aspart in Subjects With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Drug: Insulin aspart,"tmax(ins), time to maximum observed serum insulin aspart concentration|t10%max(ins), time to reach 10% of maximum observed serum insulin aspart concentration",Medical University of Graz|European Commission,All,18 Years to 60 Years   (Adult),Phase 1,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,SPRINK-01,Apr-11,Jun-11,Jun-11,21-Jul-11,null,20-Apr-12,"Medical University of Graz, Graz, Austria",,https://ClinicalTrials.gov/show/NCT01399346
NCT01398670,Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics,,Withdrawn,No Results Available,Type I Diabetes,Biological: Insulin Lispro,Change in HbA1c|Percentage change in the immunogenic response|Correlation of the immunogenicity with hypoglycemia,Wockhardt,All,18 Years to 55 Years   (Adult),Phase 3,0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P3-LIS-IMSFDA-01,Feb-12,Mar-13,May-13,20-Jul-11,null,25-Jan-13,,,https://ClinicalTrials.gov/show/NCT01398670
NCT01397513,Effects of Aspirin Treatment on Fibrin Network Formation in Patients With Type 1 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Aspirin,Fibrin network permeability|Platelet microparticles,Karolinska Institutet,All,"30 Years to 70 Years   (Adult, Older Adult)",Phase 4,48,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,151:2005/76316|2005/1403-31/2,Mar-06,Jul-10,Feb-11,19-Jul-11,null,19-Jul-11,"Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01397513
NCT01396161,A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients,,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: PF-05175157 or Placebo,"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)|Accumulation Ratio for Area Under the Concentration-Time Curve (Rˇac, AUC)|Renal Clearance (CLr)|Plasma Decay Half-Life (t1/2)|Urinary Recovery",Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,64,Industry,Interventional,"Allocation: Randomized|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",B1731007,Jul-11,Feb-12,Feb-12,18-Jul-11,7-Nov-16,7-Nov-16,"Miami Research Associates, South Miami, Florida, United States|MRA Clinical Research, South Miami, Florida, United States|Pulmonary Physicians of South Florida, South Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT01396161
NCT01396187,Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes,,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: PF-05231023|Other: Placebo,"Number of Participants With Abnormal Physical Examination Findings|Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)|Number of Participants With Abnormal Laboratory Values|Number of Participants With Vital Signs Abnormalities|Number of Participants With Electrocardiogram (ECG) Abnormalities|Number of Participants With Blood Glucose Abnormalities|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-05231023 After Single Dose|Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-05231023 After Single Dose|Maximum Observed Plasma Concentration (Cmax) of PF-05231023 After Single Dose|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-05231023 at Steady State|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-05231023 at Steady State|Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-05231023 at Steady State|Maximum Observed Plasma Concentration (Cmax) of PF-05231023 at Steady State|Accumulation Ratio for Area Under the Curve From Time Zero to End of Dosing Interval of PF-05231023 (Rac)|Accumulation Ratio for Maximum Observed Plasma Concentration (Rac,Cmax) of PF- 05231023|Plasma Terminal Half-Life (t1/2) of PF-05231023 at Steady State|Apparent Clearance (CL) of PF-05231023 at Steady State|Volume of Distribution of PF-05231023 at Steady State (Vss)|Minimum Observed Plasma Trough Concentration (Cmin) of PF-05231023 at Steady State|Average Plasma Concentration (Cav) of PF-05231023 at Steady State",Pfizer,All,"30 Years to 70 Years   (Adult, Older Adult)",Phase 1,50,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",B2901002,Jul-11,May-12,May-12,18-Jul-11,12-Jan-15,12-Jan-15,"Pfizer Investigational Site, Chula Vista, California, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, South Miami, Florida, United States|Pfizer Investigational Site, Overland Park, Kansas, United States|Pfizer Investigational Site, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01396187
NCT01394055,Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis,,Completed,No Results Available,Diabetes Mellitus Type 1 and 2|Diabetes Mellitus Complications|Gastroparesis|Gastrointestinal Motility Disorder,Drug: RM-131|Drug: Placebo,Pharmacodynamic (PD) effects of RM-131 on gastric emptying|Safety and tolerability of RM-131|Pharmacokinetics (PK) of RM-131,"Motus Therapeutics, Inc.",All,18 Years to 60 Years   (Adult),Phase 1,20,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RM-131-003,Jul-11,Nov-12,Dec-12,14-Jul-11,null,22-Sep-16,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01394055
NCT01392560,Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: BI 10773,Change in Glomerular Filtration Rate (GFR) After 8 Weeks of Treatment With Empagliflozin Under Controlled Conditions of Euglycaemia and Hyperglycaemia,Boehringer Ingelheim,All,"18 Years and older   (Adult, Older Adult)",Phase 2,52,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1245.46,Jun-11,Aug-12,Aug-12,12-Jul-11,17-Jun-14,17-Jun-14,"1245.46.10001 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01392560
NCT01392677,Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea,,Completed,Has Results,Type 2 Diabetes Mellitus|High HbA1c Level|Inadequate Glycaemic Control,Drug: dapagliflozin|Drug: placebo,Adjusted Mean Change From Baseline in HbA1c Levels|Adjusted Mean Change From Baseline in FPG|Adjusted Mean Change From Baseline in Total Body Weight|Proportion of Participants With HbA1c Value < 7.0% at Week 24 (LOCF)|Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure,AstraZeneca|Bristol-Myers Squibb,All,"18 Years and older   (Adult, Older Adult)",Phase 3,311,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D1693C00005,Oct-11,Jan-13,Aug-13,12-Jul-11,27-Dec-13,12-Mar-14,"Research Site, Edmonton, Alberta, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Sydney Mines, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Etobicoke, Ontario, Canada|Research Site, Markham, Ontario, Canada|Research Site, Smiths Falls, Ontario, Canada|Research Site, Kensington, Prince Edward Island, Canada|Research Site, Laval, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Beroun, Czech Republic|Research Site, Ceske Budejovice, Czech Republic|Research Site, Jilove U Prahy, Czech Republic|Research Site, Praha 5, Czech Republic|Research Site, Praha 6, Czech Republic|Research Site, Praha, Czech Republic|Research Site, Semily, Czech Republic|Research Site, Vyskov, Czech Republic|Research Site, Asslar, Germany|Research Site, Aßlar, Germany|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Falkensee, Germany|Research Site, Neuwied, Germany|Research Site, Pirna, Germany|Research Site, Kielce, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Poznań, Poland|Research Site, Warszawa, Poland|Research Site, Zgierz, Poland|Research Site, Łódź, Poland|Research Site, Banska Bystrica, Slovakia|Research Site, Kosice, Slovakia|Research Site, Povazska Bystrica, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Oviedo, Asturias, Spain|Research Site, Sta Coloma de Gramanet (bcn), Catalu?a, Spain|Research Site, Barcelona, Cataluna, Spain|Research Site, A Coruna, Galicia, Spain|Research Site, A Coruña, Spain|Research Site, Barcelona, Spain|Research Site, Oviedo, Spain|Research Site, Sta Coloma de Gramenet (BCN), Spain",,https://ClinicalTrials.gov/show/NCT01392677
NCT01390259,Hypoglycemia Prevention After Exercise in Adolescent T1DM Patients Using a Control to Range System,MDB005,Completed,Has Results,Type 1 Diabetes Mellitus,Device: Open-Loop|Device: Closed-Loop,Hypoglycemic Events|Percent Time in Euglycemia|Mean Glucose,"University of Virginia|Abbott Diabetes Care|DexCom, Inc.|Insulet Corporation|University of California, Santa Barbara",All,"12 Years to 18 Years   (Child, Adult)",Not Applicable,11,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,14758,Jan-10,Feb-11,Feb-11,11-Jul-11,15-Aug-14,15-Aug-14,"University of Virginia Health System, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01390259
NCT01390480,Effects of Vitamin D Supplementation in Subjects With New Onset of Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Drug: Cholecalciferol,Increase and function of regulatory T-cells|Immunophenotyping|Insulin secretion|Calcium levels,Medical University of Graz|Medical University of Vienna,All,"6 Years to 60 Years   (Child, Adult)",Phase 4,31,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",ENM-DA-017,Nov-10,Nov-13,Feb-14,11-Jul-11,null,17-Apr-15,"Medical University Graz, Graz, Austria",,https://ClinicalTrials.gov/show/NCT01390480
NCT01381926,Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist,CMBD,Terminated,Has Results,Type 2 Diabetes Mellitus|Bone Remodeling,Drug: exenatide|Drug: Saline,Determine Changes in Bone Resorption Markers During the Treatment With a GLP-1 Receptor Agonist (Exenatide) Compared to Placebo in Patients With T2DM.|Determine Changes in Bone Turnover Markers by Serum N-Telo Peptide During the Treatment With a GLP-1 Receptor Agonist (Exenatide) Compared to Placebo in Patients With T2DM.|Determine Changes in Bone Turnover Markers by Tartrate-Resistant Acid Phosphatase 5b (TRACP5b) During the Treatment With a GLP-1 Receptor Agonist (Exenatide) Compared to Placebo in Patients With T2DM.,"University of Alabama at Birmingham|Amylin Pharmaceuticals, LLC.",Female,"45 Years and older   (Adult, Older Adult)",Phase 4,14,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",F100929001,Feb-11,Aug-15,Aug-15,27-Jun-11,14-Jun-17,14-Jun-17,"University of Alabama at Birmingham, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT01381926
NCT01379729,Bet Cell Therapy in Diabetes Type 1,,Unknown status,No Results Available,Type 1 Diabetes,Other: Transplantation of encapsulated beta cells.,"Primary outcome measurement is a parameter of functional beta cell mass at 6 months PT. Functional beta-cell mass will be calculated using the AUC/min between 150 and 160 min during hyperglycemic clamp at 180 mg/dl.|Functional beta-cell mass at 2,12,18,24,36,48 and 60 months PT.|Changes from Baseline",AZ-VUB|Universitair Ziekenhuis Brussel|Universitaire Ziekenhuizen Leuven,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,10,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BK_TX_07,May-11,Dec-13,May-18,23-Jun-11,null,30-Dec-13,"UZ Brussel, Brussels, Belgium|UZ Leuven, Leuven, Belgium",,https://ClinicalTrials.gov/show/NCT01379729
NCT01374854,Umbilical Mesenchymal Stem Cells and Mononuclear Cells Infusion in Type 1 Diabetes Mellitus,,Unknown status,No Results Available,Type 1 Diabetes Mellitus,Biological: Umbilical mesenchymal stem cell (UC-MSCs) infusion|Drug: traditional therapy,c-peptide area under the curve during OGTT|The incidence and severity of adverse events related to the stem cell infusion procedure|The reduction in fasting blood glucose (FBG)|The increase in basal C-peptide|The reduction in exogenous insulin requirements|Decrease in HbA1c|insulin area under the curve during OGTT,Fuzhou General Hospital,All,18 Years to 40 Years   (Adult),Phase 1|Phase 2,44,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UCMSC-T1DM,Jan-09,Dec-10,Dec-14,16-Jun-11,null,20-Nov-12,"Fuzhou General Hospital, Fuzhou, Fujian, China",,https://ClinicalTrials.gov/show/NCT01374854
NCT01373450,Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222),,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Oxyntomodulin|Drug: Liraglutide 0.6 mg|Drug: Liraglutide 1.2 mg|Drug: Placebo for Oxyntomodulin|Drug: Placebo for Liraglutide,"Change From Baseline in Time-weighted Average of Glucose Measured by Area Under the Curve (AUC) After a Single Dose of Oxyntomodulin (OXM)|Change From Baseline in Maximum Ambient Glucose Concentration (Gmax) After a Single Dose of OXM|Change From Baseline in Beta Cell Sensitivity to Glucose (Φ) After a Single Dose of OXM|Change From Baseline in Insulinotrophic Effect (ISR/G) at the Highest Glucose Infusion Rate After Two Periods of Placebo Treatment|Change From Baseline in Gmax After Single Doses of 0.6 mg Lg, or 1.2 mg Lg, Compared With Single Doses of Placebo or OXM|Change From Baseline in Insulinotrophic Effect (ISR/G) After Single Doses of 0.6 mg Lg, or 1.2 mg Lg, Compared With Single Doses of Placebo or OXM",Merck Sharp & Dohme Corp.,Male,18 Years to 64 Years   (Adult),Phase 1,12,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",0000-222,Jun-11,Jul-11,Jul-11,15-Jun-11,8-Jul-13,2-Sep-15,,,https://ClinicalTrials.gov/show/NCT01373450
NCT01372163,A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients,,Terminated,No Results Available,"Diabetes Mellitus, Type 2",Drug: PF-05190457 or Placebo,"Number of participants with Adverse Events as a measure of safety and tolerability.|The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of Area Under the Curve (AUC) and its accumulation ratio on days 1, 13, and 14, as appropriate and the data permit.|The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of Maximum Concentration (Cmax) on days 1, 13, and 14, as appropriate and the data permit.|The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of Time of Maximum concentration (Tmax) on days 1, 13, and 14, as appropriate and the data permit.|The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of the Minimum Amount of concentration (Cmin) on days 13 and 14, as appropriate and the data permit.|The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of Elimination of half-life (t ½ ) on day 14, as the data permit.|The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of apparent total clearance of the drug from plasma after oral administration (CL/F) on days 13 and 14, as the data permit.|The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of apparent volume of distribution during terminal phase after non-intravenous administration (Vz/F) on days 13 and 14, as the data permit.|Urinary recovery and renal clearance of PF-05190457 will be estimated via comparison of the plasma AUC and urinary excretion to provide AE0-τ, AE0-τ%, and CLR as the data permit.",Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,35,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",B3301002,Jul-11,Apr-12,Apr-12,13-Jun-11,null,23-May-12,"Pfizer Investigational Site, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01372163
NCT01368978,Pediatric Diabetics Type 1 Using InsuPatch,,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: InsuPatch,Efficacy,Insuline Medical Ltd.,All,12 Years to 17 Years   (Child),Phase 3,27,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,G090175,Dec-09,May-12,May-12,8-Jun-11,null,5-Sep-14,"Yale University, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01368978
NCT01369277,"A Single Dose Study In Japanese And Western Healthy Subjects To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-04991532",,Completed,No Results Available,"Diabetes Mellitus|Diabetes Mellitus, Type 2|Glucose Metabolism Disorders",Drug: PF-04991532|Drug: Placebo,"Maximum Plasma Concentration (Cmax)|Time for Cmax (Tmax)|Area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (AUClast)|Area under the plasma concentration-time profile from time zero to 24 hours (AUC0-24)|Total amount of unchanged drug excreted in the urine over 24 hours, expressed as percent of dose (Ae24%)|Renal clearance (CLr)",Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,22,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)",B2611013,Jun-11,Sep-11,Sep-11,8-Jun-11,null,22-Sep-11,"Pfizer Investigational Site, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01369277
NCT01357603,Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM,,Completed,No Results Available,Type1 Diabetes,Biological: Glargine,Bioequivalence based on Pharmacokinetic parameter:AUC INS-GLR 0-24h.|Bioequivalence based on Pharmacodynamic parameter: AUC GIR 0-24hrs|Pharmacokinetic Parameters: Maximum concentration (Cmax)|Safety parameters|Pharmacodynamic parameters: Area under curve glucose infusion rate from 0-24hrs|Pharmacokinetic parameter: Area under curve from 0-24hrs|Pharmacokinetic Parameters: tmax and t1/2|Pharmacodynamic parameter: GIR max and tGIR max,Wockhardt,All,18 Years to 60 Years   (Adult),Phase 1,111,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research",Glaritus/PK-PD/FDA/2011,Jun-11,May-12,Aug-12,20-May-11,null,25-Jan-13,"Profil Institute for clinical Research, Chula Vista, California, United States",,https://ClinicalTrials.gov/show/NCT01357603
NCT01353833,Dose-effect Relationship of Low-dose IL-2 in Type 1 Diabetes,DF-IL2,Completed,No Results Available,Type 1 Diabetes,Drug: Aldesleukin,Kinetic parameters of Treg proportions variation within CD4+ T cells in peripheral blood|Improvement of residual secretion of insulin assessed by the AUC of peptide C during a standardized test meal in IL-2 vs placebo treated patients,Assistance Publique - Hôpitaux de Paris,All,18 Years to 50 Years   (Adult),Phase 1|Phase 2,25,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",P101101|2010-024499-24,May-11,Oct-11,Apr-12,16-May-11,null,23-Apr-12,"Hôpital Pitié-Salpêtrière, Paris, France",,https://ClinicalTrials.gov/show/NCT01353833
NCT01354288,Therapeutic Education in Very Young Children With Diabetes Mellitus,DIAB-EDUC,Unknown status,No Results Available,Type 1 Diabetes|Diabetes Mellitus,Other: Educational tool,HbA1c 12 months after therapeutic education|HbA1C 24 months after therapeutic education|Acute events number (hypoglycemia and ketosis) over a 12 and 24 months period|Evolution of the parental knowledge about the disease 12 and 24 months after therapeutic education (evaluated by questionnaire)|Evolution of the parental stress 12 and 24 months after therapeutic education (evaluated by questionnaire)|Evolution of the parental and child quality of life 12 and 24 months after therapeutic education (evaluated by questionnaire),Assistance Publique - Hôpitaux de Paris,All,12 Months to 6 Years   (Child),Not Applicable,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,P081254,Oct-11,Dec-15,Jul-16,16-May-11,null,21-Apr-15,"Bicêtre Hospital, Le Kremlin Bicêtre, France",,https://ClinicalTrials.gov/show/NCT01354288
NCT01352663,Immunogenicity Safety Study of Wockhardt's Recombinant Insulin Analogue in Type 1 Diabetic Patients,,Unknown status,No Results Available,Type I Diabetes,Biological: Wockhardt's Insulin Analogue (Recomb)|Biological: Lantus®,Change in HbAlc from baseline till the end of treatment period.|Percentage change in immunogenic response.,Wockhardt,All,18 Years to 55 Years   (Adult),Phase 3,500,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P3-GLR-IMSFDA-01,May-15,Jul-16,Jan-17,12-May-11,null,29-May-14,,,https://ClinicalTrials.gov/show/NCT01352663
NCT01352767,The InsuPad in Daily Life Study - Effect of Local Heating on Postprandial Glucose Excursions Using the InsuPad Device,,Completed,No Results Available,Type 1 Diabetes Mellitus With Diabetic Neuralgia,Device: InsuPad,efficacy|Efficacy|Safety|Satisfaction,Insuline Medical Ltd.|Forschungsinstitut der Diabetes Akademie Mergentheim,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,20,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CP-PP-002,Jul-11,May-13,May-13,12-May-11,null,5-Sep-14,"Bad Mergentheim, Bad Mergentheim, Germany",,https://ClinicalTrials.gov/show/NCT01352767
NCT01351857,Diabetes Care Management Compared to Standard Diabetes Care in Adolescents and Young Adults With Type 1 Diabetes,TransClin,Completed,No Results Available,Type 1 Diabetes,Other: Transition Coordinator,The proportion of subjects who fail to attend at least one outpatient adult endocrinology visit during the second year after transition to adult diabetes care.|In the 2 year transfer to adult care-Frequency of A1C (glycated hemoglobin test),"University of Western Ontario, Canada|Juvenile Diabetes Research Foundation|Western University, Canada",All,"17 Years to 20 Years   (Child, Adult)",Phase 4,188,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CCTN1102,Apr-12,28-Jun-17,30-Jun-17,11-May-11,null,9-Nov-18,"St. Joseph's Health Care, London, Ontario, Canada|London Health Sciences Centre - Children's Hospital, London, Ontario, Canada|Trillium Pediatric Diabetes Clinic, Mississauga, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01351857
NCT01349855,Repeated Dosing Study With a New Insulin Glargine Formulation and Lantus® in Patients With Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Insulin glargine HOE901,"Safety in terms of adverse and serious adverse events, vital signs, ECG, safety laboratory|Glucose infusion rate|Pharmacokinetic parameter : Cmax|Pharmacokinetic parameter : Tmax|Pharmacokinetic parameter : AUC",Sanofi,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,30,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",TDR11626|2010-023771-26,Mar-11,May-11,May-11,9-May-11,null,1-Jun-11,"Investigational site number 276001, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01349855
NCT01350102,The Relationship of Hemoglobin A1c and Diabetic Wound Healing,,Terminated,Has Results,"Diabetes, Type 1|Diabetes, Type 2|Foot Ulcer, Diabetic",Drug: Bacitracin|Drug: AmeriGel®|Dietary Supplement: Vitamin C,Hgb A1c Level|Length of Time for Wound Closure|Wound Area Measurements,Susan Hassenbein|Milton S. Hershey Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 4,2,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB-35832,Feb-12,Mar-14,Mar-14,9-May-11,12-Dec-17,12-Dec-17,"Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01350102
NCT01350219,Stem Cell Educator Therapy in Type 1 Diabetes,,Recruiting,No Results Available,Type 1 Diabetes,Device: Stem Cell Educator,Autoimmune control|Metabolic control|Analysis of islet beta cell function,Tianhe Stem Cell Biotechnologies Inc.|Chinese government fundings,All,"14 Years to 60 Years   (Child, Adult)",Phase 2,100,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010-037,Sep-10,Sep-19,Sep-19,9-May-11,null,5-Feb-19,"The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|The Second Xiangya Hospital of Central South University, Changsha, Hunan, China|General Hospital of Jinan Military Command, Jinan, Shandong, China|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain",,https://ClinicalTrials.gov/show/NCT01350219
NCT01345227,Bone Marrow as an Alternative Site for Islet Transplantation,,Completed,No Results Available,Type 1 Diabetes|Postpancreatectomy Hyperglycemia,Procedure: Intra bone marrow islet infusion,Adverse events related to the procedure of intra bone marrow islet infusion|Beta-cell function,Ospedale San Raffaele|European Union,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,8,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BMT1,Aug-09,Apr-11,Oct-11,2-May-11,null,6-Mar-15,"IRCCS San Raffaele, Milan, Italy",,https://ClinicalTrials.gov/show/NCT01345227
NCT01345435,Effects of Telemonitoring and Telemedicine Service for Type 2 Diabetes Care,Smart-DM,Completed,No Results Available,Type 2 Diabetes,Procedure: Telemonitoring group|Procedure: Telemonitoring & Telemedicine|Other: SMBG,Changes in Hemoglobin A1c|Changes in FBS (Fasting blood sugar)|Changes in lipid profile|Percentage of subjects who achieved goal Hemoglobin A1c|Changes in body mass index (BMI)|SMBG(Self-monitoring of blood glucose) compliance|Changes in body weight|Assessment of patients' satisfaction|Medication compliance,"Chang Hee, Lee|LG Electronics Inc.",All,20 Years to 60 Years   (Adult),Not Applicable,417,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Smartcare-DM,Jan-11,Apr-13,Dec-13,2-May-11,null,14-May-15,"Kyungpook National University Hospital, Daegu, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Yonsei University Health System, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01345435
NCT01346085,Calcineurin Inhibitor (CNI)-Free Immunosuppressive Regimen in T1D Patients Receiving Islet Transplantation,ECIT-1,Completed,Has Results,Type 1 Diabetes,Drug: CNI free immunosuppression,The Proportion of Insulin Free Patients 3 Years After the Last Islet Infusion|Insulin Independence With Adequate Glycemic Control Throughout Follow-up|Glycated Hemoglobin Levels Throughout Follow-up|Basal and Stimulated Blood C-peptide Levels in Response to Arginine Challenge Throughout Follow-up|the Reduction in Insulin Requirement Compared to Baseline|Severe Hypoglycemic Events Since Completion of Transplant|Any Adverse Event Throughout Follow-up,Ospedale San Raffaele|Juvenile Diabetes Research Foundation,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ECIT-1,Oct-06,Jun-09,Jun-12,2-May-11,9-May-14,9-May-14,"IRCCS San Raffaele Scientific Institute, Milan, Italy|Universitè de Geneve, Geneve, Switzerland",,https://ClinicalTrials.gov/show/NCT01346085
NCT01342484,Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes,,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: placebo|Drug: BI1356 low dose|Drug: BI1356 high dose,Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 12 Weeks of Treatment|Dipeptidyl-peptidase-4 (DPP-4) Inhibition (%) at Trough at Steady State|Change From Baseline in Fasting Plasma Glucose (FPG) After 12 Weeks of Treatment,Boehringer Ingelheim|Eli Lilly and Company,All,10 Years to 17 Years   (Child),Phase 2,40,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,1218.56|2009-017004-91,Apr-11,Feb-16,Feb-16,27-Apr-11,15-Sep-16,15-Sep-16,"1218.56.01006 Boehringer Ingelheim Investigational Site, San Antonio, Texas, United States|1218.56.01004 Boehringer Ingelheim Investigational Site, Norfolk, Virginia, United States|1218.56.11001 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|1218.56.33003 Boehringer Ingelheim Investigational Site, Fort de France cedex, France|1218.56.33006 Boehringer Ingelheim Investigational Site, Rouen, France|1218.56.50202 Boehringer Ingelheim Investigational Site, Guatemala, Guatemala|1218.56.50203 Boehringer Ingelheim Investigational Site, Guatemala, Guatemala|1218.56.39005 Boehringer Ingelheim Investigational Site, Firenze, Italy|1218.56.82005 Boehringer Ingelheim Investigational Site, Busan, Korea, Republic of|1218.56.82001 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1218.56.82002 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1218.56.82003 Boehringer Ingelheim Investigational Site, Suwon, Korea, Republic of|1218.56.52008 Boehringer Ingelheim Investigational Site, Chihuahua, Mexico|1218.56.52002 Boehringer Ingelheim Investigational Site, Guadalajara, Mexico|1218.56.52001 Boehringer Ingelheim Investigational Site, León, Mexico|1218.56.52003 Boehringer Ingelheim Investigational Site, Monterrey, Mexico|1218.56.52004 Boehringer Ingelheim Investigational Site, Oaxaca, Mexico|1218.56.48002 Boehringer Ingelheim Investigational Site, Gdansk, Poland|1218.56.48001 Boehringer Ingelheim Investigational Site, Gliwice, Poland|1218.56.48004 Boehringer Ingelheim Investigational Site, Warszawa, Poland|1218.56.48003 Boehringer Ingelheim Investigational Site, Wroclaw, Poland|1218.56.70001 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|1218.56.70003 Boehringer Ingelheim Investigational Site, Saratov, Russian Federation|1218.56.70004 Boehringer Ingelheim Investigational Site, Ufa, Russian Federation|1218.56.70006 Boehringer Ingelheim Investigational Site, Yekaterinburg, Russian Federation",,https://ClinicalTrials.gov/show/NCT01342484
NCT01341899,Efficacy and Safety Study of Autologous Hematopoietic Stem Cell Transplantation to Treat New Onset Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Procedure: immunosuppression and stem cell transplantation,Changes in C-peptide levels during standard-meal tolerance test from baseline to different time points after transplantation|Changes in serum levels of HbA1c from baseline to different time points after transplantation|Temporal changes of exogenous insulin requirement from baseline to different time points after transplantation|Dynamic changes in islet antibody status from baseline to different time points after transplantation|Dynamic changes in lymphocyte immunophenotyping and cytokine profiles from baseline to different time points after transplantation|mortality and dysfunction of other endocrine glands,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,All,"8 Years to 35 Years   (Child, Adult)",Phase 2,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ZKX07012,Jun-06,Dec-12,Dec-15,26-Apr-11,null,1-Nov-16,"at Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT01341899
NCT01341587,Smart Glucose Meter Project,,Terminated,Has Results,Type 1 Diabetes|Type 2 Diabetes,Device: Telcare Blood Glucose Meter (BGM),Change in HbA1c,"University of Maryland|Maryland Industrial Partnerships|Telcare, Inc",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,14,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HP-00045527,Apr-11,Jun-12,Jun-12,25-Apr-11,12-Mar-18,12-Mar-18,"University of Maryland, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01341587
NCT01338922,Psychosocial Issues in Insulin Pump Therapy in Children With Type 1 Diabetes Mellitus (DM),pumpkin,Completed,No Results Available,"Diabetes Mellitus, Insulin-Dependent",Device: Continuous subcutaneous insulin infusion therapy|Device: Multiple daily injection therapy,Health related quality of life (HRQOL) (patient)|Diabetes burden (main carer)|Parental stress level|Hypoglycemia fear (main carer)|Family conflicts|HbA1c|Severe Hypoglycemia International Society for Pediatric and Adolescent Diabetes (ISPAD) II/III|Diabetes treatment satisfaction,University of Schleswig-Holstein|German Research Foundation|Roche Diagnostics|University of Luebeck,All,6 Years to 16 Years   (Child),Not Applicable,211,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PUMPKIN|WA 2929/2-1/ AOBJ 582855,Apr-11,Jul-15,Aug-16,20-Apr-11,null,2-Feb-18,"Endokrinologikum Berlin, Berlin, Germany|Kinderklinik Charite, Berlin, Germany|Klinik für Kinder- und Jugendmedizin, Ruhr-Universität-Bochum, Bochum, Germany|PRIMA Kinderkliniken Darmstadt, Darmstadt, Germany|Marienhospital / Kinderklinik, Gelsenkirchen, Germany|Universitätsklinik Gießen, Gießen, Germany|Klinik am Eichert, Göppingen, Germany|Kinderkrankenhaus Wilhelmstift, Hamburg, Germany|Altonaer Kinderkrankenhaus, Hamburg, Germany|Gemeinschaftskrankenhaus, Herdecke, Germany|Praxis für Kinder- und Jugendmedizin, Herford, Germany|Kinderklinik Städt. Klinikum, Karlsruhe, Germany|UK-SH, Klinik für Allg. Pädiatrie, Kiel, Germany|Kinderkrankenhaus Kliniken der Stadt Köln GmbH, Köln, Germany|Universität Leipzig, Kinderklinik, Leipzig, Germany|UK SH Campus Lübeck, Klinik für Kinder- und Jugendmedizin, Lübeck, Germany|Ev.Krankenhaus, Oberhausen, Germany|Kinderhospital Osnabrück, Osnabrück, Germany|Klinik f. Kinder- und Jugendmedizin, Ravensburg, Germany|Universitäts- Kinder- und Jugendklinik, Rostock, Germany|Bethlehem Gesundheitszentrum Stolberg, Stolberg, Germany|Olgahospital, Stuttgart, Germany|Universitätsklinik Tübingen, Tübingen, Germany|HSK-Kinderklinik, Wiesbaden, Germany",,https://ClinicalTrials.gov/show/NCT01338922
NCT01337141,A Telematic Program for Optimization of Metabolic Control in Diabetes Mellitus Type 1 (DM1) Patients,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Metabolic Disorder",Other: Control|Device: Telecare system,Optimise metabolic control|Patient costs|Medical team costs|Quality of life|Treatment adherence,Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders,All,18 Years to 50 Years   (Adult),Not Applicable,154,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CIBERDEM-TELEMED-DIABETES,May-11,Apr-12,Nov-12,18-Apr-11,null,29-Jan-15,"Hospital de Cruces, Barakaldo, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Clínico de Madrid, Madrid, Spain|Hospital Carlos Haya, Malaga, Spain|Hospital Clínico de Valencia, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT01337141
NCT01337362,Recurrent Hypoglycaemia in Type 1 Diabetes,HypoNeuro,Completed,No Results Available,Hypoglycaemia,Procedure: Insulin clamp,EEG|QTc interval|Skin temperature|Auditory evoked potentials|Cognitive function,"Hillerod Hospital, Denmark|University of Southern Denmark|Rigshospitalet, Denmark|UNEEG Medical A/S",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,23,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,H-1-2011-024,May-11,Jun-13,Jun-13,18-Apr-11,null,16-Oct-14,"Hillerod Hospital, Hillerød, Denmark",,https://ClinicalTrials.gov/show/NCT01337362
NCT01336023,"Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes",DUAL™ I,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/liraglutide|Drug: insulin degludec|Drug: liraglutide,Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26.|Mean Change From Baseline in Body Weight at Week 26|Number of Hypoglycaemic Episodes|Change From Baseline in Incremental Area Under the Curve 0-4h (iAUC0-4h) Derived From the Glucose Concentration Profile During Meal Test|Mean Actual Daily Insulin Dose,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1663,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN9068-3697|U1111-1119-1174|2010-021560-15,23-May-11,24-May-12,22-Nov-12,15-Apr-11,2-Jun-17,19-Feb-18,"Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Anaheim, California, United States|Novo Nordisk Investigational Site, Bermuda Dunes, California, United States|Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Encino, California, United States|Novo Nordisk Investigational Site, Fair Oaks, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Greenbrae, California, United States|Novo Nordisk Investigational Site, La Jolla, California, United States|Novo Nordisk Investigational Site, Long Beach, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Montclair, California, United States|Novo Nordisk Investigational Site, Monterey, California, United States|Novo Nordisk Investigational Site, Orange, California, United States|Novo Nordisk Investigational Site, Poway, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, San Mateo, California, United States|Novo Nordisk Investigational Site, Santa Barbara, California, United States|Novo Nordisk Investigational Site, Tustin, California, United States|Novo Nordisk Investigational Site, Valencia, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Colorado Springs, Colorado, United States|Novo Nordisk Investigational Site, Denver, Colorado, United States|Novo Nordisk Investigational Site, Golden, Colorado, United States|Novo Nordisk Investigational Site, Waterbury, Connecticut, United States|Novo Nordisk Investigational Site, Newark, Delaware, United States|Novo Nordisk Investigational Site, Clearwater, Florida, United States|Novo Nordisk Investigational Site, Delray Beach, Florida, United States|Novo Nordisk Investigational Site, Fort Lauderdale, Florida, United States|Novo Nordisk Investigational Site, Hialeah, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Kissimmee, Florida, United States|Novo Nordisk Investigational Site, Melbourne, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Pembroke Pines, Florida, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Columbus, Georgia, United States|Novo Nordisk Investigational Site, Conyers, Georgia, United States|Novo Nordisk Investigational Site, Decatur, Georgia, United States|Novo Nordisk Investigational Site, Lawrenceville, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Woodstock, Georgia, United States|Novo Nordisk Investigational Site, Meridian, Idaho, United States|Novo Nordisk Investigational Site, Nampa, Idaho, United States|Novo Nordisk Investigational Site, Avon, Illinois, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Gurnee, Illinois, United States|Novo Nordisk Investigational Site, O'Fallon, Illinois, United States|Novo Nordisk Investigational Site, Fishers, Indiana, United States|Novo Nordisk Investigational Site, Franklin, Indiana, United States|Novo Nordisk Investigational Site, Indianapolis, Indiana, United States|Novo Nordisk Investigational Site, Michigan City, Indiana, United States|Novo Nordisk Investigational Site, Muncie, Indiana, United States|Novo Nordisk Investigational Site, Crestview Hills, Kentucky, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Metairie, Louisiana, United States|Novo Nordisk Investigational Site, Metairie, Louisiana, United States|Novo Nordisk Investigational Site, Hyattsville, Maryland, United States|Novo Nordisk Investigational Site, North East, Maryland, United States|Novo Nordisk Investigational Site, Rockville, Maryland, United States|Novo Nordisk Investigational Site, Buckley, Michigan, United States|Novo Nordisk Investigational Site, Southfield, Michigan, United States|Novo Nordisk Investigational Site, Southfield, Michigan, United States|Novo Nordisk Investigational Site, Troy, Michigan, United States|Novo Nordisk Investigational Site, Chesterfield, Missouri, United States|Novo Nordisk Investigational Site, Kansas City, Missouri, United States|Novo Nordisk Investigational Site, Saint Charles, Missouri, United States|Novo Nordisk Investigational Site, Henderson, Nevada, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, United States|Novo Nordisk Investigational Site, Flemington, New Jersey, United States|Novo Nordisk Investigational Site, Toms River, New Jersey, United States|Novo Nordisk Investigational Site, Toms River, New Jersey, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, Bronx, New York, United States|Novo Nordisk Investigational Site, Northport, New York, United States|Novo Nordisk Investigational Site, Syracuse, New York, United States|Novo Nordisk Investigational Site, West Seneca, New York, United States|Novo Nordisk Investigational Site, Asheboro, North Carolina, United States|Novo Nordisk Investigational Site, Asheville, North Carolina, United States|Novo Nordisk Investigational Site, Burlington, North Carolina, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Greensboro, North Carolina, United States|Novo Nordisk Investigational Site, Greenville, North Carolina, United States|Novo Nordisk Investigational Site, Morehead City, North Carolina, United States|Novo Nordisk Investigational Site, Shelby, North Carolina, United States|Novo Nordisk Investigational Site, Statesville, North Carolina, United States|Novo Nordisk Investigational Site, Winston-Salem, North Carolina, United States|Novo Nordisk Investigational Site, Canton, Ohio, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Cleveland, Ohio, United States|Novo Nordisk Investigational Site, Columbus, Ohio, United States|Novo Nordisk Investigational Site, Franklin, Ohio, United States|Novo Nordisk Investigational Site, Kettering, Ohio, United States|Novo Nordisk Investigational Site, Mason, Ohio, United States|Novo Nordisk Investigational Site, Maumee, Ohio, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, United States|Novo Nordisk Investigational Site, Beaver, Pennsylvania, United States|Novo Nordisk Investigational Site, Bridgeville, Pennsylvania, United States|Novo Nordisk Investigational Site, Norristown, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, East Providence, Rhode Island, United States|Novo Nordisk Investigational Site, Columbia, South Carolina, United States|Novo Nordisk Investigational Site, Greer, South Carolina, United States|Novo Nordisk Investigational Site, Pelzer, South Carolina, United States|Novo Nordisk Investigational Site, Simpsonville, South Carolina, United States|Novo Nordisk Investigational Site, Spartanburg, South Carolina, United States|Novo Nordisk Investigational Site, Taylors, South Carolina, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, DeSoto, Texas, United States|Novo Nordisk Investigational Site, Fort Worth, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Irving, Texas, United States|Novo Nordisk Investigational Site, Killeen, Texas, United States|Novo Nordisk Investigational Site, Lubbock, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Ogden, Utah, United States|Novo Nordisk Investigational Site, Saint George, Utah, United States|Novo Nordisk Investigational Site, Salt Lake City, Utah, United States|Novo Nordisk Investigational Site, Burke, Virginia, United States|Novo Nordisk Investigational Site, Manassas, Virginia, United States|Novo Nordisk Investigational Site, Newport News, Virginia, United States|Novo Nordisk Investigational Site, Virginia Beach, Virginia, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States|Novo Nordisk Investigational Site, Broadmeadow, New South Wales, Australia|Novo Nordisk Investigational Site, Camperdown, New South Wales, Australia|Novo Nordisk Investigational Site, Coffs Harbour, New South Wales, Australia|Novo Nordisk Investigational Site, Penrith, New South Wales, Australia|Novo Nordisk Investigational Site, Meadowbrook, Queensland, Australia|Novo Nordisk Investigational Site, Keswick, South Australia, Australia|Novo Nordisk Investigational Site, East Ringwood, Victoria, Australia|Novo Nordisk Investigational Site, Melbourne, Victoria, Australia|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Chilliwack, British Columbia, Canada|Novo Nordisk Investigational Site, Vancouver, British Columbia, Canada|Novo Nordisk Investigational Site, Winnipeg, Manitoba, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Burlington, Ontario, Canada|Novo Nordisk Investigational Site, Cornwall, Ontario, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Mississauga, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Drummondville, Quebec, Canada|Novo Nordisk Investigational Site, Laval, Quebec, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Hanko, Finland|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Imatra, Finland|Novo Nordisk Investigational Site, Kokkola, Finland|Novo Nordisk Investigational Site, Oulu, Finland|Novo Nordisk Investigational Site, Bad Neuenahr-Ahrweiler, Germany|Novo Nordisk Investigational Site, Eisenach, Germany|Novo Nordisk Investigational Site, Esslingen, Germany|Novo Nordisk Investigational Site, Frankfurt, Germany|Novo Nordisk Investigational Site, Grevenbroich, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Herrenberg, Germany|Novo Nordisk Investigational Site, Hohenmölsen, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Oldenburg, Germany|Novo Nordisk Investigational Site, Pohlheim, Germany|Novo Nordisk Investigational Site, Rehburg-Loccum, Germany|Novo Nordisk Investigational Site, Rehlingen-Siersburg, Germany|Novo Nordisk Investigational Site, Stuttgart, Germany|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Debrecen, Hungary|Novo Nordisk Investigational Site, Eger, Hungary|Novo Nordisk Investigational Site, Gyula, Hungary|Novo Nordisk Investigational Site, Pécs, Hungary|Novo Nordisk Investigational Site, Szeged, Hungary|Novo Nordisk Investigational Site, Ahmedabad, Gujarat, India|Novo Nordisk Investigational Site, Gurgaon, Haryana, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Cochin, Kerala, India|Novo Nordisk Investigational Site, Kochi, Kerala, India|Novo Nordisk Investigational Site, Thiruvanathapuram, Kerala, India|Novo Nordisk Investigational Site, Trivandrum, Kerala, India|Novo Nordisk Investigational Site, Indore, Madhya Pradesh, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Bhubaneswar, Orissa, India|Novo Nordisk Investigational Site, Jaipur, Rajasthan, India|Novo Nordisk Investigational Site, Jaipur, Rajasthan, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Trichy, Tamil Nadu, India|Novo Nordisk Investigational Site, Kolkatta, West Bengal, India|Novo Nordisk Investigational Site, Hyderabad, India|Novo Nordisk Investigational Site, Kolkata, India|Novo Nordisk Investigational Site, Patna, India|Novo Nordisk Investigational Site, Pune, India|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Galway, Ireland|Novo Nordisk Investigational Site, Cosenza, Italy|Novo Nordisk Investigational Site, Forlì, Italy|Novo Nordisk Investigational Site, Monserrato, Cagliari, Italy|Novo Nordisk Investigational Site, Novara, Italy|Novo Nordisk Investigational Site, Olbia, Italy|Novo Nordisk Investigational Site, Palermo, Italy|Novo Nordisk Investigational Site, Siena, Italy|Novo Nordisk Investigational Site, Torino, Italy|Novo Nordisk Investigational Site, Cheras, Malaysia|Novo Nordisk Investigational Site, Kota Bharu, Kelantan, Malaysia|Novo Nordisk Investigational Site, Penang, Malaysia|Novo Nordisk Investigational Site, Pulau Pinang, Malaysia|Novo Nordisk Investigational Site, Putrajaya, Malaysia|Novo Nordisk Investigational Site, Seremban, Malaysia|Novo Nordisk Investigational Site, Guadalajara, Jalisco, Mexico|Novo Nordisk Investigational Site, Monterrey, Nuevo León, Mexico|Novo Nordisk Investigational Site, San Juan, Puerto Rico|Novo Nordisk Investigational Site, Kursk, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Penza, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Stavropol, Russian Federation|Novo Nordisk Investigational Site, Voronezh, Russian Federation|Novo Nordisk Investigational Site, Vsevolozhsk, Russian Federation|Novo Nordisk Investigational Site, Singapore, Singapore|Novo Nordisk Investigational Site, Singapore, Singapore|Novo Nordisk Investigational Site, Singapore, Singapore|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Lucenec, Slovakia|Novo Nordisk Investigational Site, Moldava nad Bodvou, Slovakia|Novo Nordisk Investigational Site, Nove Zamky, Slovakia|Novo Nordisk Investigational Site, Port Elizabeth, Eastern Cape, South Africa|Novo Nordisk Investigational Site, Bloemfontein, Free State, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Vaderbijlpark, Gauteng, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Umkomaas, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Brits, North West, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Almería, Spain|Novo Nordisk Investigational Site, Granada, Spain|Novo Nordisk Investigational Site, La Coruña, Spain|Novo Nordisk Investigational Site, Partida De Bacarot, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Valencia, Spain|Novo Nordisk Investigational Site, Valladolid, Spain|Novo Nordisk Investigational Site, Taichung City, Taiwan|Novo Nordisk Investigational Site, Tainan city, Taiwan|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Taoyuan, Taiwan|Novo Nordisk Investigational Site, Bangkoknoi, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Chiang Mai, Thailand|Novo Nordisk Investigational Site, Belfast, United Kingdom|Novo Nordisk Investigational Site, Bury St Edmunds, United Kingdom|Novo Nordisk Investigational Site, Carmarthen, United Kingdom|Novo Nordisk Investigational Site, Dundee, United Kingdom|Novo Nordisk Investigational Site, Edgbaston, Birmingham, United Kingdom|Novo Nordisk Investigational Site, Fife, United Kingdom|Novo Nordisk Investigational Site, Glasgow, United Kingdom|Novo Nordisk Investigational Site, Gloucester, United Kingdom|Novo Nordisk Investigational Site, Headington, United Kingdom|Novo Nordisk Investigational Site, Lancaster, United Kingdom|Novo Nordisk Investigational Site, Letchworth, United Kingdom|Novo Nordisk Investigational Site, Llantrisant, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, St Helens, United Kingdom|Novo Nordisk Investigational Site, Stevenage, United Kingdom|Novo Nordisk Investigational Site, Weston Super Mare, United Kingdom|Novo Nordisk Investigational Site, Wrexham, United Kingdom",,https://ClinicalTrials.gov/show/NCT01336023
NCT01334151,Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes,,Completed,No Results Available,Diabetes Mellitus Type 1,Drug: Insulin LISPRO|Drug: recombinant human insulin,Speed of absorption,Biodel,All,"19 Years to 70 Years   (Adult, Older Adult)",Phase 1,13,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",VIAject 039J,Mar-11,Aug-11,Aug-11,13-Apr-11,null,26-Jul-13,"Profil Institute for Clinical Research, Inc. (PICR), Chula Vista, California, United States",,https://ClinicalTrials.gov/show/NCT01334151
NCT01334125,Adjunctive Metformin Therapy in Double Diabetes,AMTIDD,Completed,Has Results,Diabetes Mellitus,Drug: Metformin|Drug: Placebo,"Baseline Adjusted Hemoglobin A1c Over Time|Baseline Adjusted Changes in Lipid Profile Over Time|Baseline Adjusted Changes in Adiponectin/Leptin Ratio Over Time|Number of Participants With Minor, Major, and Nocturnal Hypoglycemia","University of Massachusetts, Worcester",All,"10 Years to 20 Years   (Child, Adult)",Phase 3,28,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",13938,Feb-11,Dec-14,Dec-14,12-Apr-11,4-Mar-16,4-Mar-16,"UmassMemorial Medical Center, Worcester, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01334125
NCT01333176,Point of Care HbA1c as a Screening Test for Type 2 Diabetes in First Nations,,Unknown status,No Results Available,Type 2 Diabetes,"Procedure: Point-of-care ""finger-poke"" HbA1c determination.|Procedure: HbA1c blood test|Procedure: HbA1c finger poke test|Procedure: Blood test","Does the HbA1c identify the same individuals as fasting and 2-hr pc glucose tests to identify diabetes and pre-diabetes in a First Nation community|Provide estimates of prevalence of diabetes and prediabetes in a First Nation community|To identify the response rate of ""gold standard"" diabetes testing in a First nation community",University of British Columbia|Vancouver General Hospital,All,"14 Years and older   (Child, Adult, Older Adult)",Not Applicable,320,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,H10-02551,Apr-11,Jun-12,Dec-12,11-Apr-11,null,25-Apr-12,"Vancouver General Hospital, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT01333176
NCT01331317,Effect of a Vitamin D Analogue vs Placebo on p-NT-proBNP in Patients With Type 1 DM and Diabetic Nephropathy,,Completed,No Results Available,Cardiovascular Disease|Diabetic Nephropathy,Drug: Paricalcitol,Change in plasma NT-proBNP|Change in Glomerular Filtration Rate (GFR)|Change in Urinary Albumin Excretion Rate,Peter Rossing|Abbott|Steno Diabetes Center Copenhagen,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,48,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2009-011255-44,Apr-10,Apr-12,Apr-12,8-Apr-11,null,13-Apr-12,"Steno Diabetes Center A/S, Gentofte, Denmark",,https://ClinicalTrials.gov/show/NCT01331317
NCT01331343,Effectiveness Study of the Guardian RT in Type 1 Diabetics,,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: Guardian RT Telemetered Glucose Monitoring System,Difference in Change in A1c (%) between continuous use of CGM and control|Difference in change in A1c (%) between biweekly use of CGM and control|Difference in change in A1c (%) between biweekly use of CGM and continuous use of CGM,Medtronic Diabetes,All,"8 Years to 59 Years   (Child, Adult)",Phase 4,156,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EU007_022004,Jun-04,Jun-05,Jun-05,8-Apr-11,null,18-Apr-11,"Hospital Sud Francilien, Corbeil-Essonnes Cedex, France|CH Robert Debre, Paris, France|Klinik fur Allgemeine Charite, Berlin, Germany|Schneider Children Centre, Petah Tikva, Israel|U.O. Medicina Generale, Milano, Italy|University Children's Hospital, Ljubljana, Slovenia|Huddinge University Hospital, Huddinge, Sweden|Royal Bournemouth Hospital, Dorset, United Kingdom",,https://ClinicalTrials.gov/show/NCT01331343
NCT01322789,Safety and Efficacy of Mesenchymal Stem Cells in Newly-diagnosed Type 1 Diabetic Patients,,Unknown status,No Results Available,"Diabetes Mellitus, Insulin-Dependent",Biological: Intravenous Mesenchymal stem cell infusion,AUC C-peptide levels during mixed meal tolerance test|Safety|Daily insulin use|Hemoglobin A1C|Anti-GAD titres|Immunologic reconstitution parameters,University of Sao Paulo,All,"12 Years to 35 Years   (Child, Adult)",Phase 1|Phase 2,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HCFMRPUSP 2|CNPQ 552266/2005-1,Sep-08,Nov-15,Dec-15,25-Mar-11,null,25-Mar-11,"Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT01322789
NCT01322321,ACZ885 in Type 1 Diabetes Mellitus,,Withdrawn,No Results Available,Diabetes Mellitus|Diabetes Type 1,Drug: ACZ885|Drug: Placebo,"Measure: Change from baseline of stimulated C-peptide after a mixed meal tolerance test at 13 months|Measure: Change from baseline of stimulated C-peptide after a mixed meal tolerance test at 4, 7, 10, 18, 24, 30 and 36 months|Measure: Change from baseline of fasted C-peptide at 4, 7, 10, 13, 18, 24, 30 and 36 months|Measure: number of hypoglycemic events|Measure: daily insulin dose|Measure: anti-ACZ885 antibodies",Novartis Pharmaceuticals|Novartis,All,"6 Years to 35 Years   (Child, Adult)",Phase 2,0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CACZ885I2208|2010-020166-20,Mar-11,Jun-11,null,24-Mar-11,null,5-Sep-12,"Aurora St Luke's Medical Center, Endocrine & Diabetes Center, Milwaukee, Wisconsin, United States|LMC Endocrinology Centres (Barrie) Ltd, Barrie, Ontario, Canada|LMC Endocrinology Centres (Bayview) Ltd, Toronto, Ontario, Canada|Novartis Investigative Site, Dusseldorf, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Neuwied, Germany|Novartis Investigative Site, Bristol, United Kingdom|Novartis Investigative Site, Exeter, United Kingdom|Novartis Investigative Site, Hull, United Kingdom|Novartis Investigative Site, Liverpool, United Kingdom",,https://ClinicalTrials.gov/show/NCT01322321
NCT01319734,Vitamin C Supplementation Plus Hypoglycemic Agents Versus Hypoglycemic Agents Alone in Type 2 Diabetes Mellitus,Vit C,Unknown status,No Results Available,Type 2 Diabetes Mellitus,Dietary Supplement: Vitamin C|Drug: glyburide,improving the renal function|Vitamin C can improve the visual fields,Al-Neelain University,All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 1,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,22,Feb-11,Dec-15,null,22-Mar-11,null,18-Sep-13,"Jaber abo aliz, Khartoum, Sudan",,https://ClinicalTrials.gov/show/NCT01319734
NCT01320345,A Trial in Adults With Type 1 Diabetes Mellitus Evaluating the Effects of Fenofibrate Versus Placebo on Macular Thickness and Volume,FAME 1 EYE,Unknown status,No Results Available,Type 1 Diabetes Mellitus|Retinopathy|Diabetic Nephropathy,Drug: Fenofibrate|Drug: Inert lactose placebo,Central zone macular thickness measured using optical coherence tomography|Total macular volume measured using optical coherence tomography.|Albuminuria measured as urinary albumin:creatinine ratio.|Visual acuity using Snellen Chart|Corneal confocal microscopic measurement of neural damage (only assessed in a representative subset of the participants at sites with the specialised confocal microscope).|Estimated glomerular filtration rate using MDRD formula|Peripheral neuropathy status assessed by temperature sensation and monofilament sensation.|Vascular function using non-invasive pulse wave techniques and plethysmography.|Blood lipids and biomarkers in plasma,"University of Sydney|Abbott|University of Melbourne|St Vincent's Hospital Melbourne|Melbourne Health|Royal Prince Alfred Hospital, Sydney, Australia",All,"18 Years and older   (Adult, Older Adult)",Phase 3,300,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FAME0001|ACTRN12611000249954,Sep-11,Sep-14,Sep-14,22-Mar-11,null,18-Jan-12,"Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, United States|NHMRC Clinical Trials Centre, Camperdown, New South Wales, Australia|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Westmead Children's Hospital, Westmead, New South Wales, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincents Hospital, Melbourne, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT01320345
NCT01319331,The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes,,Completed,No Results Available,Diabetes|Type 1 Diabetes,"Drug: Alpha 1-Antitrypsin (AAT, Aralast NP)",To assess participant safety & feasibility of study drug administration|To assess AAT treatment on the maintenance of c-peptide production|Assess the effects of AAT on glycemic variability and A1c.,"University of Colorado, Denver|Omni Bio Pharmaceutical, Inc.",All,"6 Years to 45 Years   (Child, Adult)",Phase 1,12,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,09-0667,Oct-10,Oct-15,May-16,21-Mar-11,null,24-Mar-17,"Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT01319331
NCT01317459,Guided Self-determination - Promoting Self-management in Type 1 Diabetes,GSD,"Active, not recruiting",No Results Available,Diabetes,Behavioral: Guided self-determination,Change in HbA1c|Who 5|TSRQ scales|PAID scales|Rosenberg's self-esteem scale|PCD scales|HCCQ scales|DDS scales,Haukeland University Hospital,All,18 Years to 55 Years   (Adult),Not Applicable,216,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2010/1325,Mar-11,Dec-16,Dec-21,17-Mar-11,null,10-Sep-15,"Helse Vest HF, Haukeland University Hospital, Bergen, Norway",,https://ClinicalTrials.gov/show/NCT01317459
NCT01315171,Effect of a Medium Chain Triglyceride Supplemented Diet on Cognitive Function and Brain Activation in Type 1 Diabetes.,,Completed,No Results Available,Hypo-unawareness|Type 1 Diabetes Mellitus,Dietary Supplement: Medium chain triglycerides,Cognitive function tests|Brain activity,Yale University|Juvenile Diabetes Research Foundation,All,18 Years to 55 Years   (Adult),Not Applicable,12,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1009007394,Jan-12,Aug-15,Oct-16,15-Mar-11,null,17-Jan-18,"Yale University School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01315171
NCT01311076,TAK-329 Glucose Clamp Study,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: TAK-329|Drug: Insulin|Drug: Placebo,(AUCGIR 0-360): Area Under the Curve of the Glucose Infusion Rate From Time 0 to 360 minutes post dose Pharmacodynamic Parameter.|GIRmax: Maximum Observed Glucose Infusion Rate Pharmacodynamic Parameter.|TGIRmax: Time to Reach the Maximum Glucose Infusion Rate (GIRmax) Pharmacodynamic Parameter.|Maximum Observed Pharmacodynamic Response (Emax) of Cortisol During Hypoglycemic Clamp.|Area under the effect versus time curves (AUEC) of Cortisol During Hypoglycemic Clamp.|Incidence of Treatment-Emergent Adverse Events.|Incidence of Hypoglycemia.,Takeda,All,18 Years to 50 Years   (Adult),Phase 1,37,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",TAK-329_102|U1111-1119-7141,Mar-11,Dec-11,Jan-12,9-Mar-11,null,13-Feb-12,"Chula Vista, California, United States",,https://ClinicalTrials.gov/show/NCT01311076
NCT01308437,Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics,,Terminated,No Results Available,Type I Diabetes,Biological: Wosulin (N or 70/30 with R)|Biological: Novolin® (N or 70/30 with R),"Change in HbAlc from baseline to 6 months of treatment between Wosulin arm and Novolin arm(as surrogate indicator of change in insulin antibodies titers between the two treatment arms).|Correlation between change in HbA1c and change in anti insulin and insulin neutralizing antibodies.|To compare the change from baseline in the level of serum anti insulin antibodies and insulin neutralizing antibodies between the two arms|Compare the change in Insulin dose between the two arms|Correlation of the immunogenicity with hypoglycemia, local allergic reactions and systemic allergic reactions will be evaluated.",Wockhardt,All,18 Years to 55 Years   (Adult),Phase 3,134,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P3-WOS-IMS-01,Mar-11,Apr-13,Apr-13,4-Mar-11,null,22-Aug-13,"University Clinical Investigators, Inc. dba Diabetes Research Center, Tustin,, California, United States|International Research Associates, Hialeah, Florida, United States|The Center for Diabetes and Endocrine Care, Hollywood, Florida, United States|Baptist Diabetes Associates, PA, Miami, Florida, United States|Suncoast Clinical Research, New Port Richie, Florida, United States|Ormond Medical Arts Pharmaceutical Research Center, Ormond Beach, Florida, United States|Suncoast Clinical Research, Palm Harbor, Florida, United States|International Clinical Research - US, LLC, Sanford, Florida, United States|Cotton-O'Neil Clinical Research Center, Diabetes & Endocrinology, Topeka, Kansas, United States|Kentucky Diabetes Endocrinology Center, Lexington, Kentucky, United States|Endocrine & Metabolic Consultants, Rockville,, Maryland, United States|ActivMed Practices and Research, Haverhill, Massachusetts, United States|Alzohaili Medical Consultants, Dearborn, Michigan, United States|ActivMed Practices and Research, Rochester, New Hampshire, United States|University Diabetes & Endocrine Association, Chattanooga, Tennessee, United States|Sergio Rovner, MD, El Paso, Texas, United States|Optimum Clinical Research, Inc., Salt Lake City, Utah, United States|Dr Rakesh Sahay, Hyderabad, Andhra Pradesh, India|Dia Care - A Complete Diabetes Care Centre, Ahmedabad, Gujrat, India|Dr Sanjay Kalra, Karnal, Haryana, India|Dr Mala Dharmalingam, Bangalore, Karnataka, India|Bangalore Diabetes Hospital, Bangalore, Karnataka, India|Dr Sharad Pendsey, Nagpur, Maharashtra, India|Diabetes Thyroid &Endocrine Centre, Jaipur, Rajasthan, India|Bhandari's Clinic, Jaipur, Rajasthan, India",,https://ClinicalTrials.gov/show/NCT01308437
NCT01308164,MD Logic Pump Advisor -Pediatric Study,,Completed,No Results Available,Type 1 Diabetes,Device: MD Logic Pump Advisor,Time spent in the normal range|Number of iterations required to achieve the maximal time spent in the normal range|Time spent above glucose level of 180 mg/dl|Time spent below glucose level of 70 mg/dl|Number of hypoglycemic events below glucose value of 63 mg/dl|Adverse event|Glucose variability|Quality of life questionaire|Number of recommendations the physician would not institute|Number of recommendations for changes in setting per patient and per iPRO wear,Rabin Medical Center|Medtronic,All,"10 Years to 18 Years   (Child, Adult)",Not Applicable,25,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,rmc005814ctil,Mar-11,Jan-17,Jan-17,3-Mar-11,null,11-Jan-17,"Schneider Children's Medical center, Petach-Tikva, Israel|University Children's Hospital, Ljubljana, Slovenia",,https://ClinicalTrials.gov/show/NCT01308164
NCT01304537,Study of the Safety and Efficacy of Intravenous Alpha-1 Antitrypsin in Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes Mellitus,"Drug: Alpha-1 Antitrypsin 40mg (AAT, Glassia®)|Drug: Alpha-1 Antitrypsin 60mg (AAT, Glassia®)|Drug: Alpha-1 Antitrypsin 80mg (AAT, Glassia®)",Safety and Tolerability|Efficacy,"Kamada, Ltd.",All,"10 Years to 25 Years   (Child, Adult)",Phase 1|Phase 2,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Kamada-AAT (IV) - 008,Jun-11,Nov-12,Nov-12,25-Feb-11,null,9-Jun-16,"Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes at Schneider Children's Medical Center of Israel, Petach Tikva 49202, Israel|Assaf Haroffeh Medical Center, Zerifin, Israel",,https://ClinicalTrials.gov/show/NCT01304537
NCT01302327,GLP Analogs for Diabetes in Wolfram Syndrome Patients,,Unknown status,No Results Available,Diabetes Mellitus Associated With Genetic Syndrome|Wolfram Syndrome,Drug: Exenatide,beta cell function,Hadassah Medical Organization,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,wolfram-HMO-CTIL,Mar-11,Mar-13,null,24-Feb-11,null,24-Feb-11,,,https://ClinicalTrials.gov/show/NCT01302327
NCT01303315,TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy,,Terminated,No Results Available,"Diabetes Mellitus, Type 2",Device: TANTALUS System,Decrees in HbA1c of at least 0.5 points and Weight loss of at least 3% of total body weight after 6 month of treatment|Glycemic and metabolic parameters,"MetaCure (USA), Inc.",All,"21 Years to 70 Years   (Adult, Older Adult)",Not Applicable,20,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MC CPTAN2010-017|Position II,Jan-11,Jul-11,Jul-11,24-Feb-11,null,22-Sep-16,"Fakultni Nemocnice U SV. Anny V Brne, Brno, Czech Republic|Klinika gerontologická a metabolická,, Hradec Kralove, Czech Republic|General University Hospital,, Prague, Czech Republic|Prednosta OB Kliniky a.s.,, Prague, Czech Republic|Diabetes Zentrum, Bad Mergentheim, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Diabetes-Praxis Muenster, Münster, Germany|'N. Paulescu' National Institute of Diabetes, Nutrition and Metabolic Diseases, Bucharest, Romania|CMI Dr Busegeanu Mihaela Magdalena-Ploiesti, Bucharest, Romania|Fundeni Hospital - Surgical, Bucharest, Romania|Sanatatea Ta Medical Center, Bucharest, Romania|Sf. Ioan Hospital - Surgical, Bucharest, Romania|Spitalul Pelican, Orada, Bucharest, Romania",,https://ClinicalTrials.gov/show/NCT01303315
NCT01301456,Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females,,Completed,Has Results,"Diabetes Mellitus|Diabetes Mellitus, Type 2|Glucose Metabolism Disorders|Metabolic Diseases|Endocrine System Diseases",Biological: Placebo|Biological: PF-04856883,"Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Physical Examination Findings|Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)|Number of Participants With Vital Sign Abnormalities|Number of Participants With Clinically Significant Abnormalities in Laboratory Measurements|Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 1|Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 2|Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 1|Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 2|Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞]) of PF-04856883: Stage 1|Area Under the Concentration Time Curve From Time Zero to Time Tau (AUCtau) of PF-04856883: Stage 2|Apparent Clearance (CL/F) of PF-04856883: Stage 1|Apparent Clearance (CL/F) of PF-04856883: Stage 2|Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 1|Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 2|Terminal Elimination Half- Life (t1/2) of PF-04856883: Stage 1|Terminal Elimination Half-life (t1/2) of PF-04856883: Stage 2|Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1|Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2|Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1|Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2|Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1|Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2|Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1|Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2|Change From Baseline in 24 Hours Glucose Normalized Area Under the Curve (NAUC) Profile at Day 30: Stage 2|Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Day 29 and 50: Stage 2|Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1|Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2|Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1|Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2|Number of Participants With Anti-Drug Antibodies (ADA): Stage 1|Number of Participant With Anti-Drug Antibodies (ADA): Stage 2",Pfizer,Female,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,84,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",B1111002,Mar-11,Dec-11,Apr-12,23-Feb-11,9-Feb-18,9-Feb-18,"Profil Institute for Clinical Research, Inc., Chula Vista, California, United States|Elite Research Institute, Miami, Florida, United States|Comprehensive Phase One (A Division of Comprehensive NeuroScience, Inc.), Miramar, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|ICON Clinical Pharmacology, LLC, Omaha, Nebraska, United States|CRI Worldwide, LLC, Philadelphia, Pennsylvania, United States|Healthcare Discoveries LLC d/b/a ICON Development Solutions, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01301456
NCT01298518,A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients,,Completed,Has Results,Type 2 Diabetes Patients,Drug: PF-04620110|Drug: Placebo,Change From Baseline in Post-Prandial Glucose Area Under the Concentration-Time Curve From Time 2 to 6 Hours (AUC 2-6) After a Mixed Meal Tolerance Test (MMTT) at Day 28|Change From Baseline in 24-Hour Average Plasma Glucose (APG) Post-Dose at Day 28|Change From Baseline in Post-Prandial Insulin Area Under the Concentration-Time Curve From Time 2 to 6 Hours (AUC 2-6) After a Mixed Meal Tolerance Test (MMTT) at Day 28|Change From Baseline in Post-Prandial C-Peptide Area Under the Concentration-Time Curve From Time 2 to 6 Hours (AUC 2-6) After a Mixed Meal Tolerance Test (MMTT) at Day 28|Change From Baseline in Post-Prandial Net Triglyceride Area Under the Concentration-Time Curve From Time 2 to 6 Hours (AUC 2-6) After a Mixed Meal Tolerance Test (MMTT) at Day 28|Change From Baseline in Total Amide Glucagon Like Peptide-1 (GLP-1) and Active Glucagon Like Peptide-1 (GLP-1) Area Under the Concentration-Time Curve From Time 2 to 6 Hours (AUC 2-6) at Day 28|Change From Baseline in Gastric Inhibitory Peptide (GIP) Area Under the Concentration-Time Curve From Time 2 to 6 Hours (AUC 2-6) at Day 28|Change From Baseline in Peptide YY (PYY) Area Under the Concentration-Time Curve From Time 2 to 6 Hours (AUC 2-6) at Day 28|Change From Baseline in Fasting Glucose at Day 28|Change From Baseline in Fasting Insulin at Day 28|Change From Baseline in Fasting Net Triglycerides at Day 28|Change From Baseline in Post-Lunch Glucose Excursions Area Under the Concentration-Time Curve From Time 6 to 10 Hours (AUC 6-10) Post-dose at Day 28|Change From Baseline in Post-Dinner Glucose Excursions Area Under the Concentration-Time Curve From Time 12 to 16 Hours (AUC 12-16) Post-dose at Day 28|Maximum Observed Plasma Concentration (Cmax) of PF-04620110|Minimum Observed Plasma Trough Concentration (Cmin) of PF-04620110|Time to Cmax (Tmax) of PF-04620110|Area Under the Concentration-Time Curve AUC (0-24) of PF-04620110,Pfizer,All,18 Years to 60 Years   (Adult),Phase 1,48,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",B0961007,Feb-11,May-11,May-11,17-Feb-11,6-Nov-12,6-Nov-12,"Pfizer Investigational Site, Chula Vista, California, United States|Pfizer Investigational Site, DeLand, Florida, United States|Pfizer Investigational Site, Miami Gardens, Florida, United States",,https://ClinicalTrials.gov/show/NCT01298518
NCT01295788,Timing of Initiation of Continuous Glucose Monitoring in Established Pediatric Diabetes (The CGM TIME Trial),,"Active, not recruiting",No Results Available,Type 1 Diabetes,Device: Simultaneous RT-CGM and Pump Initiation|Device: Delayed Initiation of RT-CGM,Adherence to CGM (hours per week)|A1C|Readiness for change|Treatment Satisfaction and Quality of Life|Fear of Hypoglycemia|Barriers to Adherence|Perception of Barriers/Facilitators to RT-CGM Use,Children's Hospital of Eastern Ontario|JDRF Canadian Clinical Trial Network|Juvenile Diabetes Research Foundation,All,"5 Years to 18 Years   (Child, Adult)",Not Applicable,144,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CHEO 09/05E,Jun-11,Jun-14,Dec-17,15-Feb-11,null,13-Jul-17,"McMaster Children's Hospital, Hamilton, Ontario, Canada|Children's Hospital of Western Ontario, London, Ontario, Canada|Markham-Stouffville Hospital, Markham, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|Hospital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01295788
NCT01296438,"A Trial Investigating the Pharmacokinetic Properties of NN1218 in Subjects With Diabetes Mellitus, Type 1",,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart,Area under the serum insulin aspart concentration-time curve,Novo Nordisk A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1218-3872|2010-022222-33|U1111-1118-6955,Feb-11,Mar-11,Mar-11,15-Feb-11,null,23-Feb-15,"Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01296438
NCT01292993,A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: 400 mg LX4211|Drug: 1000 mg metformin,Plasma concentration of LX4211 and metformin after concurrent single-dose administration|Urinary glucose excretion|Fasting plasma glucose|Postprandial glucose|Insulin|Peptide YY|Glucagon-like peptide (GLP-1)|Glucose-dependent insulinotropic peptide,Lexicon Pharmaceuticals,All,18 Years to 55 Years   (Adult),Phase 1,18,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LX4211.1-103-DDI|LX4211.103,Feb-11,Mar-11,null,10-Feb-11,null,30-Mar-11,"Lexicon Investigational Site, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01292993
NCT01293461,Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes|Diabetes Mellitus|Peripheral Diabetic Neuropathy,Drug: CBX129801|Drug: Placebo,"To assess the single and multiple dose pharmacokinetics of plasma CBX129801 after subcutaneous (SC) administration of CBX129801 by estimating parameters of Cmax, Tmax, Cmin, AUClast, AUCinf, Tlag, Cav, CL/F, Vz/F, and half life.|To assess the safety and tolerability of CBX129801 when administered SC by adverse events, injection site assessments, clinical laboratory tests, vital signs, physical examinations, and electrocardiograms.|To evaluate the technique of sensory nerve conduction velocity (SNCV) in the sural nerves in patients with type 1 diabetes mellitus.|To assess the immunogenicity of CBX129801 by occurrence of anti-CBX129801 antibody formation.|To evaluate the technique of motor nerve conduction velocity (MNCV) in the peroneal nerves in patients with type 1 diabetes mellitus.|To evaluate the technique of vibration perception threshold (VPT) in patients with type 1 diabetes (Part 2 only)",Cebix Incorporated,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,72,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CBX129801-PK-101,Apr-11,Aug-12,Oct-12,10-Feb-11,null,1-Mar-13,"Escondido, California, United States|Tustin, California, United States|Walnut Creek, California, United States|Aurora, Colorado, United States|Butte, Montana, United States|San Antonio, Texas, United States|Olympia, Washington, United States|Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT01293461
NCT01292590,Effect of Dietary Fat on Glycemic Control in Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Other: High fat meal,Change in insulin requirements,Joslin Diabetes Center|Beth Israel Deaconess Medical Center,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010-P-000140/1; BIDMC,Sep-10,Sep-11,Sep-11,9-Feb-11,null,26-Apr-17,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01292590
NCT01286350,FL3X Study: An Adaptive Intervention to Improve Outcomes for Youth With Type 1 Diabetes (FL3X),FL3X,Completed,No Results Available,Type 1 Diabetes,Behavioral: FL3X: Flexible Lifestyle Empowering Change,Hemoglobin A1c|Motivation|Problem solving skills|Hypoglycemia|Diabetes self-management behaviors|Risk factors for diabetes complications|Health-related quality of life,"University of North Carolina, Chapel Hill|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Children's Hospital Medical Center, Cincinnati|University of Colorado Denver School of Medicine Barbara Davis Center|University of Washington|Nemours Children's Clinic|University of Pittsburgh",All,13 Years to 16 Years   (Child),Not Applicable,258,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13-2856 (UNC IRB)|1UC4DK101132-01,May-14,Dec-17,Jan-18,31-Jan-11,null,18-Feb-19,"University of Colorado Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01286350
NCT01285518,Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes,,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: PF-05231023|Other: Placebo,"Number of Participants With Abnormal Physical Examination Findings|Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)|Number of Participants With Abnormal Laboratory Values|Number of Participants With Vital Signs Abnormalities|Number of Participants With Electrocardiogram (ECG) Abnormalities|Number of Participants With Hypoglycemic Adverse Event Based on Capillary Glucose Levels|Number of Participants With Blood Glucose Abnormalities|Number of Participants With Anti-Drug Antibodies (ADA): Day 1|Number of Participants With Anti-Drug Antibodies (ADA): Day 8|Number of Participants With Anti-Drug Antibodies (ADA): Day 15|Number of Participants With Anti-Drug Antibodies (ADA): Day 22|Number of Participants With Anti-Drug Antibodies (ADA): Day 34|Insulin-like Growth Factor - 1 (IGF-1), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-2 (IGFBP-2), Growth Hormone (GH) Levels: Day 1|Insulin-like Growth Factor - 1 (IGF-1), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-2 (IGFBP-2), Growth Hormone (GH) Levels: Day 2|Insulin-like Growth Factor - 1 (IGF-1), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-2 (IGFBP-2), Growth Hormone (GH) Levels: Day 3|Insulin-like Growth Factor - 1 (IGF-1), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-2 (IGFBP-2), Growth Hormone (GH) Levels: Day 5|Insulin-like Growth Factor - 1 (IGF-1), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-2 (IGFBP-2), Growth Hormone (GH) Levels: Day 7|Insulin-like Growth Factor - 1 (IGF-1), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-2 (IGFBP-2), Growth Hormone (GH) Levels: Day 15|Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels: Day 1|Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels: Day 2|Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels: Day 3|Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels: Day 5|Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels: Day 7|Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels: Day 15|Number of Participants With Abnormal Cardiac Rhythms Recorded by Telemetry|Area Under the Curve From Time Zero to Time of Last Quantifiable Plasma Concentration (AUClast) of PF-05231023|Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-05231023|Maximum Observed Plasma Concentration (Cmax) of PF-05231023|Plasma Terminal Half-Life (t1/2) of PF-05231023|Apparent Clearance (CL) of PF-05231023 for Intravenous Bolus Dosing|Apparent Volume of Distribution (Vz) of PF-05231023|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of PF-05231023|Back-extrapolated Concentration at Time Zero (C0) of PF-05231023|Volume of Distribution at Steady State (Vss) of PF-05231023",Pfizer,All,"30 Years to 65 Years   (Adult, Older Adult)",Phase 1,84,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",B2901001,Feb-11,Jul-11,Jul-11,28-Jan-11,18-Nov-16,18-Nov-16,"Profil Institute for Clinical Research, Inc., Chula Vista, California, United States|Comprehensive Phase One (A Division of Comprehensive NeuroScience, Inc.), Ft. Meyers, Florida, United States|Elite Research Institute, Miami, Florida, United States|Comprehensive Phase One (A Division of Comprehensive NeuroScience, Inc.), Miramar, Florida, United States|Cetero Research, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01285518
NCT01285934,Hematopoietic Stem Cell Support Versus Insulin in T1D,,Withdrawn,No Results Available,"Diabetes Mellitus, Type 1",Biological: Autologous Hematopoietic Stem Cell Transplantation|Drug: intensive insulin therapy,C-peptide|Insulin dose|Serum levels of hemoglobin A1c|Stimulated C-peptide levels during mixed meal tolerance test,Northwestern University|University of Sao Paulo General Hospital,All,"16 Years to 35 Years   (Child, Adult)",Phase 1|Phase 2,0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Diabetes2008,Jan-09,Aug-15,Aug-15,28-Jan-11,null,21-Aug-15,,,https://ClinicalTrials.gov/show/NCT01285934
NCT01285245,Effect of Anakinra on Insulin Sensitivity in Type 1 Diabetes Mellitus,,Unknown status,No Results Available,Diabetes Mellitus,Drug: kineret,insulin sensitivity as determined by euglycemic hyperinsulinemic clamp|glycemic control|adipocyte insulin sensitivity|circulating hormonal and inflammatory factors and lipid profile,Radboud University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,16,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NL34377.091.10|2010-023479-24,Apr-11,Sep-11,Dec-11,27-Jan-11,null,14-Apr-11,"Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands",,https://ClinicalTrials.gov/show/NCT01285245
NCT01283425,Evaluation of the Safety Use of the InsuPatch Device in Daily Life Conditions,Daily Life,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: InsuPatch,"frequency of mild hypoglycemia events (Blood Glucose<60mg/dl) with InsuPatch and without.|Frequency of hyperglycemic events (BG>300 mg/dl, Fasting BG>250 mg/dl) with InsuPatch and without.|Adverse events (AE's) count with InsuPatch and without.",Insuline Medical Ltd.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,147,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,G080106/B,Feb-11,Apr-12,Apr-12,26-Jan-11,null,4-Sep-14,"Mills-Peninsula Health Services, San Mateo, California, United States|Soroka Medical Center, Beer Sheva, Israel|Hillel Yaffe, Hadera, Israel|Rambam Medical Center, Haifa, Israel|Wolfson Medical Center, Holon, Israel|Haddasah Medical Organization, Jerusalem, Israel|Schneider Children's hospital, Petah Tikva, Israel|Sheba Medical Center, Ramat Gan, Israel",,https://ClinicalTrials.gov/show/NCT01283425
NCT01282567,Study for the Artificial Pancreas Project : Determination of a Tuning Strategy of Metabolic Profiles,,Completed,No Results Available,Type 1 Diabetes,Other: Blood samples,Dosage of plasma insulin concentration and blood glucose every 20 minutes during 6 hours and 40 minutes,Rennes University Hospital,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,3,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),2010-A01455-34|LOC/10-18,May-11,Sep-11,Sep-11,25-Jan-11,null,3-Feb-12,"Rennes University Hospital, Rennes, Brittany, France",,https://ClinicalTrials.gov/show/NCT01282567
NCT01280682,Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes,,Unknown status,No Results Available,"Diabetes Mellitus, Type 1",Drug: rituximab,CD19+ cells|C-peptide level|glycated hemoglobin level|insulin dose,Nanjing Medical University,All,"8 Years to 45 Years   (Child, Adult)",Phase 4,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010-SR-021,Jul-10,Dec-12,Dec-13,21-Jan-11,null,21-Jan-11,"First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT01280682
NCT01281098,"Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.",,Completed,No Results Available,High Risk Proliferative Diabetic Retinopathy|Diabetes Mellitus Type I|Diabetes Mellitus Type II,Procedure: Panretinal Photocoagulation (PRP)|Drug: Intravitreous injection of pegaptanib,Regression of retinal neovascularization|Changes from baseline in Best-Corrected Visual Acuity (BCVA)|Changes from baseline in macular retinal thickness by Optical Coherent Tomography (OCT)|Changes from baseline in Visual Fields|Recurrence of retinal neovascularization|Number of treatments needed|Additional focal or grid laser for DME|Adverse events|Need for vitrectomy due to occurrence of vitreous hemorrhage or retinal detachment,Association for Innovation and Biomedical Research on Light and Image,All,"18 Years and older   (Adult, Older Adult)",Phase 2,22,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CC-02-2009|2009-016760-36,Mar-10,Oct-12,Feb-13,21-Jan-11,null,19-Mar-15,"Center for Clinical Trials - Aibili, Coimbra, Portugal",,https://ClinicalTrials.gov/show/NCT01281098
NCT01281228,The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes,Braini-Ex,Completed,No Results Available,"Diabetes Mellitus|Diabetes Mellitus, Type 2|Obesity",Drug: exenatide|Drug: exenatide + exendin (9-39)|Drug: placebo,Differences in neuronal activity in CNS reward and satiety circuits|Feeding behavior|Self-reported hunger,VU University Medical Center|Eli Lilly and Company|Bristol-Myers Squibb,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,48,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant),DC2010Exbrain001|2010-023635-42,Sep-11,Oct-13,Oct-13,21-Jan-11,null,3-Jun-15,"VU University Medical Center, Amsterdam, De Boelelaan 1117, Netherlands",,https://ClinicalTrials.gov/show/NCT01281228
NCT01277913,"The Effect of Supplementation With Two Different Doses of Vitamin D on Bone Mineral Density, Vitamin D Levels and Hand Grip Strength in Children With Diabetes Mellitus Type 1",,Completed,No Results Available,Diabetes Mellitus Type 1,Drug: Vitamin D3,"Percentage of patients with normal bone mineral density (z-score>-1)at lumbar spine(L2-L4)and total body after 12mo of supplementation|Percentage of patients with adequate 25 hydroxyvitamin level ( >50 ng/ml)|Mean bone mineral density z-score (L2-L4, total body) after 12 mo of supplementation|Mean isometric hand grip force|Mean bone mineral density change after 12 mo of supplementation|Mean serum level of TNF-alfa, osteoprotegerin, IL-6|Mean HBA1C level|% patients with HbA1C < 7,5 mg%|% patients with vitamin D hypervitaminosis (>200 ng/ml (500 nmol/L) and or hypercalcemia (>2.7 mmol/l) assessed at summer,spring, autumn, and winter",Medical University of Warsaw,All,8 Years to 11 Years   (Child),Phase 4,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",Jan-11,Jan-11,Nov-13,Nov-13,17-Jan-11,null,5-Nov-13,"Department of Pediatrics, Warsaw, Poland",,https://ClinicalTrials.gov/show/NCT01277913
NCT01277965,Validation of Algorithms for Basal Insulin Rate Reductions in Type 1 Diabetic Patients Practising Physical Activity,DIABRASPORT,Completed,No Results Available,Type 1 Diabetes With a Subcutaneous Insulin Pump|Adjustment of the Recommended Basal Insulin Flow Rate in the Event of Physical Activity|Adjustment of the Recommended Prandial Insulin in the Event of Physical Activity,Other: 50%VO2maxTBR50|Other: 50%VO2max TBR80|Other: 75%VO2max TBR80|Other: 75%VO2max TBR100|Other: Rest,Number of episodes of symptomatic or non-symptomatic hypoglycaemia|Duration of hypoglycaemia,Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète|European Association for the Study of Diabetes,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,2009 A01136 51,Mar-10,Feb-13,Feb-13,17-Jan-11,null,22-Apr-13,"Centre Hospitalier Sud Francilien, Corbeil Essonnes, Essonne, France",,https://ClinicalTrials.gov/show/NCT01277965
NCT01276106,Study of AC-201 in Patients With Type 2 Diabetes Mellitus,,Completed,Has Results,Type 2 Diabetes Mellitus,"Drug: AC-201, 25mg|Drug: AC-201, 50mg|Drug: AC-201, 75mg|Drug: Placebo",Change in HbA1c From Baseline,"TWi Biotechnology, Inc.",All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 2,259,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",AC-201-DM-001,Jan-11,Feb-12,Mar-12,13-Jan-11,18-Nov-14,22-May-18,"Catalina Research Institute, LLC, Chino, California, United States|National Research Institute, Los Angeles, California, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Jacksonville Impotence Treatment Center, Jacksonville, Florida, United States|Chicago Clinical Research Institute, Inc., Chicago, Illinois, United States|Clinical Investigation Specialists, Inc., Gurnee, Illinois, United States|Midwest Institute for Clinical Research, Inc., Indianapolis, Indiana, United States|L-MARC Research Center, Louisville, Kentucky, United States|New Orleans Center for Clinical Research, New Orleans, Louisiana, United States|Sterling Research Group, Ltd, Cincinnati, Ohio, United States|PriMed Clinical Research, Kettering, Ohio, United States|National Clinical Research-Richmond, Inc., Richmond, Virginia, United States|Rainier Clinical Research Center, Inc., Renton, Washington, United States|Changhua Christian Hospital, Changhua, Taiwan|Cheng Ching General Hospital, Taichung, Taiwan|Chung Shan Medical University Hospital, Taichung, Taiwan|Kuang Tien General Hospital, Taichung, Taiwan|Cardinal Tien Hospital, Taipei, Taiwan|Taipei Medical University Hospital, Taipei, Taiwan|Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT01276106
NCT01275131,"Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)",,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Insulin aspart|Drug: Recombinant human hyaluronidase PH20 (rHuPH20),"Early Insulin Exposure (%AUC[0-60]), Stage 1|Early Exposure to Insulin (%AUC[0-60]), Stage 3|Maximum Glucose Infusion Rate (GIRmax), Stage 1|Maximum Glucose Infusion Rate (GIRmax), Stage 3|Time to First Occurrence of Maximum Glucose Infusion Rate (tGIRmax), Stage 1|Time to First Occurrence of Maximum Glucose Infusion Rate (tGIRmax), Stage 3|Time to 50% Maximum Glucose Infusion Rate (tGIR50%Max), Stage 1|Time to 50% Maximum Glucose Infusion Rate (tGIR50%Max), Stage 3|Time to 50% Total Glucose Infused (50%Gtot), Stage 1|Time to 50% Total Glucose Infused (50%Gtot), Stage 3|Area Under the Glucose Concentration Curve (AUC[0-360]), Stage 1|Area Under the Glucose Concentration Curve (AUC[0-360]), Stage 3|Duration of Insulin Action (AUMC[0-360]/AUC[0-360]), Stage 1|Duration of Insulin Action (AUMC[0-360]/AUC[0-360]), Stage 3",Halozyme Therapeutics,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,45,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",HALO-117-105,Jan-11,Dec-11,Dec-11,12-Jan-11,25-Jul-14,25-Jul-14,"Profil Institute for Clinical Research, Chula Vista, California, United States",,https://ClinicalTrials.gov/show/NCT01275131
NCT01274663,A Study Of PF-05175157 In Healthy Volunteers,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: PF-05175157 or Placebo,Safety and tolerability of escalating single doses of PF-05175157 in healthy subjects|Single dose pharmacokinetics of PF-05175157|Exploratory pharmacodynamic biomarkers,Pfizer,All,18 Years to 45 Years   (Adult),Phase 1,63,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",B1731001,Nov-10,May-11,May-11,11-Jan-11,null,12-Oct-11,"Pfizer Investigational Site, South Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT01274663
NCT01272583,Dipeptidyl Peptidase-4 Inhibitors and Alpha-cell Recovery,DARE,Completed,Has Results,Type 1 Diabetes|Hypoglycemia,Drug: Sitagliptin|Drug: Placebo,"Glucagon Response to Acute Hypoglycaemia|Intact and Total Glucagon Like Peptide-1 (GLP-1), Intact and Total Gastric Inhibitory Peptide (GIP) Response to Acute Hypoglycaemia|Epinephrine Response to Acute Hypoglycaemia|Norepinephrine Response to Acute Hypoglycaemia|Growth Hormone Response to Acute Hypoglycaemia|Cortisol Response to Acute Hypoglycaemia|Symptomatic Hormone Responses to Acute Hypoglycaemia.",Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Merck Sharp & Dohme Corp.,Male,18 Years to 55 Years   (Adult),Not Applicable,16,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)",DARE_2010,Mar-11,Jun-12,Oct-12,10-Jan-11,17-Feb-14,14-Mar-14,"Academic Medical Center, Amsterdam, Noord Holland, Netherlands",,https://ClinicalTrials.gov/show/NCT01272583
NCT01272804,Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes,,Completed,Has Results,"Diabetes Mellitus, Type 2|NIDDM",Drug: PF-04937319|Drug: Placebo,"Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Maximum Observed Plasma Concentration (Cmax) On Day 1|Maximum Observed Plasma Concentration (Cmax) On Day 6|Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1|Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 6|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) on Day 1|Maximum Observed Plasma Concentration at Steady State (Cmax, ss) On Day 14|Time to Reach Maximum Observed Plasma Concentration at Steady State (Tmax, ss) on Day 14|Area Under the Curve From Time Zero to End of Dosing Interval at Steady State (AUCtau, ss) on Day 14|Plasma Decay Half-Life (t1/2) on Day 14|Minimum Observed Plasma Trough Concentration at Steady State (Cmin, ss) on Day 14|Percentage of Unchanged Drug Excreted in the Urine Over Dosing Interval (Ae[%]) on Day 14|Apparent Oral Clearance (CL/F) on Day 14|Apparent Volume of Distribution (Vz/F) on Day 14|Observed Accumulation Ratio for AUCtau (Rac)|Observed Accumulation Ratio for Cmax (Rac, Cmax)|Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1|Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 14|Percent Change From Baseline in Insulin Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14|Percent Change From Baseline in C-peptide Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14|Change From Baseline in Average Plasma Glucose at Day 1, 6, 14|Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15|Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up|Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up|Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up|Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up|Change From Baseline in Lactate Level at Day 6 and 14",Pfizer,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,61,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",B1621003,Feb-11,Jul-11,Jul-11,10-Jan-11,1-Feb-17,1-Feb-17,"Elite Research Institute, Miami, Florida, United States|Miami Research Associates, South Miami, Florida, United States|MRA Clinical Research, South Miami, Florida, United States|Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01272804
NCT01272973,"Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects",,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 2|Healthy",Drug: semaglutide|Drug: placebo,"Frequency of adverse events (AEs)|Hypoglycaemic episodes|Laboratory safety variables (haematology, biochemistry, and urinalysis)|Maximum plasma concentration of NN9924|Area under the plasma concentration curve over the dosing interval (0-24 hours)|Terminal phase elimination half-life",Novo Nordisk A/S,Male,18 Years to 60 Years   (Adult),Phase 1,96,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN9924-3692|U1111-1118-0257|2010-019951-23,Jan-11,Jul-11,Jul-11,10-Jan-11,null,23-Feb-15,"Berlin, Germany",,https://ClinicalTrials.gov/show/NCT01272973
NCT01271023,Inpatient Evaluation of an Automated Closed-Loop Control-to-Range System,CTR,Completed,No Results Available,Type 1 Diabetes,Device: Control-to-Range Automated Insulin Management System,Percent of glucose values 71-180 mg/dL of combined day and night readings during the first admission visit|Percent of subjects with blood glucose reading of 71-180 mg/dL 4 hours following the breakfast with a missed meal bolus|Percent of subjects with blood glucose reading of 71-180 mg/dL 5 hours following the breakfast with a meal bolus 30% more than the recommended bolus amount|Percent of subjects with a blood glucose nadir <=60 mg/dL following exercise|Overall frequency of hypoglycemia|Overall frequency of hyperglycemia|Percent of blood glucose values 71-180 mg/dL during the day (9:00AM-11:00PM) of the first admission visit|Percent of blood glucose values 70-180 mg/dL during the night (11:00PM-8:00AM) of the first admission visit|Percent of blood glucose values >400 mg/dL during the first admission visit|Percent of blood glucose values <=60 mg/dL during the first admission visit|Percent of subjects with a peak blood glucose >400 mg/dL following the breakfast with a missed meal bolus|Percent of subjects with a nadir blood glucose <=60 mg/dL following the breakfast with a missed meal bolus|Percent of subjects with a peak blood glucose >400 mg/dL following the breakfast with a meal bolus 30% more than the recommended bolus amount|Percent of subjects with a nadir blood glucose <=60 mg/dL following the breakfast with a meal bolus 30% more than the recommended bolus amount,Jaeb Center for Health Research,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Phase 1,57,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CTR,Mar-11,Aug-12,Aug-12,6-Jan-11,null,9-Sep-16,"Sansum Diabetes Research Institute, Santa Barbara, California, United States|Stanford University, Stanford, California, United States|University of Colorado Health Sciences Center- Barbara Davis, Aurora, Colorado, United States|University of Virginia, Charlottesville, Virginia, United States|Montpellier University Hospital, Montpellier, France|Schneider Children's Medical Center of Israel, Petah Tikva, Israel|University of Padova, Padova, Italy",,https://ClinicalTrials.gov/show/NCT01271023
NCT01271517,Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis,BAS,Unknown status,No Results Available,Diabetes Mellitus Type 1,Drug: NPH insulin|Drug: Glargine|Drug: Detemir,HbA1c|Stimulated C-peptide|IGF-I,Karolinska Institutet,All,7 Years to 17 Years   (Child),Phase 4,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Eudract-number 2005-001726-80,Sep-05,Mar-11,null,6-Jan-11,null,6-Jan-11,"Division of Pediatrics, Karolinska University Hospital, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01271517
NCT01269008,Closed Loop System With Pramlintide Versus Exenatide,Closedloop,Completed,No Results Available,Type 1 Diabetes,Device: Medtronic ePID 2.0,Better meal and post meal sugars on the closed loop device using the study medications.,Albert Einstein College of Medicine,All,18 Years to 30 Years   (Adult),Phase 1,13,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010 -434,Dec-10,Jan-13,Jan-13,4-Jan-11,null,20-Feb-18,"Albert Einstein College of Medicine CRC, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT01269008
NCT01269034,New Onset Type 1 Diabetes: Role of Exenatide,,Recruiting,No Results Available,Type 1 Diabetes,Drug: Exenatide|Drug: Rapid and long acting insulin|Drug: long acting insulin + rapid acting + 1.25 mcg Exenatide,"The role of exenatide as compared to insulin monotherapy in reducing postprandial hyperglycemia.|The role of exenatide on postprandial glucagon and gastric emptying.|Postprandial glucose excursions, glucagon concentrations and gastric emptying in normal healthy controls.",Albert Einstein College of Medicine|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"12 Years to 18 Years   (Child, Adult)",Phase 4,20,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010-435|3R01DK077166-05S1,Dec-10,Dec-19,Jun-20,4-Jan-11,null,29-Jan-19,"Albert Einstein CRC- West Campus, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT01269034
NCT01269047,Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia,,Completed,Has Results,Type 1 Diabetes,Drug: Pramlintide|Drug: Exenatide|Drug: Insulin,"Post-prandial Blood Glucose Concentration in Both Pramlintide and Exenatide Treated Groups in Acute and Chronic Setting, Compared to Insulin Monotherapy in Type 1 Diabetes Mellitus.|Difference in HbA1C Between the Treatment and the Control Groups",Albert Einstein College of Medicine|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"12 Years to 21 Years   (Child, Adult)",Phase 4,37,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010 -436|R01DK077166,Aug-09,Aug-16,Dec-16,4-Jan-11,8-Feb-18,12-Apr-18,"Albert Einstein College of Medicine West Campus Clinical Research Center, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT01269047
NCT01269606,Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin aspart|Drug: insulin human,Clearance at steady state (CLss) for IV treatment group|Area under the curve (AUC) for IM treatment group|Steady state concentration (Css) for IV treatment group|Hypoglycaemic episodes|Adverse Events (AEs),Novo Nordisk A/S,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 1,13,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANA-3877|U1111-1117-1353|JapicCTI-111383,Jan-11,Mar-11,Mar-11,4-Jan-11,null,16-Jun-14,"Fukuoka, Japan",,https://ClinicalTrials.gov/show/NCT01269606
NCT01268644,Effects of Metreleptin in Type 1 Diabetes Mellitus,,Terminated,No Results Available,Type 1 Diabetes,Drug: Leptin,Change in HgbA1c|Mean and standard deviation of blood glucose|change in liver and muscle fat as measured by Liver and soleus triglycerides on MRS.|Change in Glycomark,"University of Texas Southwestern Medical Center|Juvenile Diabetes Research Foundation|Amylin Pharmaceuticals, LLC.",All,18 Years to 50 Years   (Adult),Phase 1,7,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FBA937|CTRC # 953,Sep-10,Jan-13,Aug-14,31-Dec-10,null,4-May-16,"UT Southwestern Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT01268644
NCT01267175,"United Kingdom User Evaluation, MiniMed Paradigm® X54 System",X54User,Completed,Has Results,"Diabetes Mellitus, Type 1",Device: X54 insulin pump with low suspend feature,Usability of the X54 Insulin Pump Meets Expectations|Usability of the Training Material Meets Expectations,Medtronic Diabetes,null,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,31,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),ETP08-2625,Jan-09,Feb-09,Feb-09,28-Dec-10,14-Feb-11,18-Feb-11,"Addenbrookes Hospital, Cambridge, Cambridgeshire, United Kingdom|Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom|Kings College Hospital, Denmark Hill, London, United Kingdom|Harrogate District Hospital, Harrogate, N. Yorkshire, United Kingdom|Newcastle General Hospital, Newcastle Upon Tyne, Tyne and Wear, United Kingdom|Guy's Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01267175
NCT01265017,Role of Pregnancy Related Hormones in Lowering the Insulin Requirement in Pregnant Women With Type 1 Diabetes,,Withdrawn,No Results Available,Type 1 Diabetes,"Drug: Estradiol, medroxyprogesterone, hydrocortisone, GH|Drug: Matching placebo","stimulated C-peptide response|Clinical, immunologic and hormonal responses|Insulin requirement",Sansum Diabetes Research Institute,Female,"18 Years and older   (Adult, Older Adult)",Phase 1,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",SDRI 2009-06,Jul-12,Jun-20,Jun-20,22-Dec-10,null,18-Apr-18,"Sansum Diabetes Research Institute, Santa Barbara, California, United States",,https://ClinicalTrials.gov/show/NCT01265017
NCT01261052,Real-time Adaptation to Changes in Insulin Sensitivity,,Completed,Has Results,Type 1 Diabetes Mellitus,Device: The Fading Memory Proportional Derivative/Adaptive Proportional Derivative Algorithm|Device: The Adaptive Proportional Derivative Algorithm,Measurement of the Effectiveness of APD and FMPD/APD Intervention in Adapting to Reduced Insulin Sensitivity|Measurement of APD and FMPD/APD Interventions in Controlling Post-prandial Blood Glucose With Reduced Insulin Sensitivity.,Legacy Health System|Juvenile Diabetes Research Foundation,All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 2,14,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2010.005,Nov-10,Apr-11,Apr-11,16-Dec-10,29-Nov-12,3-Dec-12,"Legacy Good Samaritan Hospital, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT01261052
NCT01253733,MD2Me - Texting to Promote Chronic Disease Management,,Completed,No Results Available,Cystic Fibrosis|Inflammatory Bowel Disease|Type 1 Diabetes|Chronic Disease Management,Behavioral: MD2ME,Health related self-efficacy|Health knowledge|Health literacy|Quality of Life,"Huang, Jeannie, M.D.|University of California, San Diego",All,"14 Years to 22 Years   (Child, Adult)",Not Applicable,81,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,91146,Oct-09,Mar-12,Mar-12,3-Dec-10,null,26-Jan-16,"University of California, San Diego, La Jolla, California, United States",,https://ClinicalTrials.gov/show/NCT01253733
NCT01249742,Sugarsquare. Focus on the Adolescent: Digital Treatment of Type 1 Diabetes Through the Internet,,Completed,No Results Available,Diabetes Mellitus,Behavioral: Internet intervention,Patients' Evaluation of Quality of Care|Health Related Quality of Life|Adolescents' disease knowledge|Confidence In Diabetes Selfcare|Glycemic control (HbA1c)|Degree of use of intervention,Radboud University|Dutch Diabetes Research Foundation,All,"12 Years to 21 Years   (Child, Adult)",Not Applicable,65,Other,Interventional,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Supportive Care,2007.13.003,Feb-09,Apr-10,Nov-10,30-Nov-10,null,30-Nov-10,"Children's Diabetes Center Nijmegen, Nijmegen, Gelderland, Netherlands",,https://ClinicalTrials.gov/show/NCT01249742
NCT01247649,Assessing Continuous Non- Invasive Blood Glucose Sensor- Physical Logic AG,,Terminated,No Results Available,Type 1 Diabetes,Device: Physical Logic Continuous Glucose Monitoring System,Correlation between continuous glucose measurements using study device and YSI(yellow springs instrument),Rabin Medical Center,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,4,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,rmc006039ctil,Nov-10,Feb-11,Feb-11,24-Nov-10,null,20-Nov-12,"Schneider Children's Medical center, Petach-Tikva, Israel",,https://ClinicalTrials.gov/show/NCT01247649
NCT01247896,Single Dose Escalation Study of PF-05190457 in Healthy Volunteers,,Completed,No Results Available,"Diabetes Mellitus, Type II",Drug: PF-05190457|Drug: Placebo,"Safety and tolerability of PF-05190457 will be assessed by physical examinations, adverse event monitoring, 12-lead ECGs, continuous cardiac monitoring over the first 8 hours after dosing, vital sign and clinical safety laboratory measurements|The single dose PK of PF-05190457 will be described by estimating parameters of AUC(0-infinity), AUC(0-last), AUC(0-24), Cmax, Tmax, CL/F, Vz/F and half-life (t1/2), as the data permit|PK of PF-05190457 in the fed condition will be described by estimating parameters of AUC(0-infinity), AUC(0-last), AUC(0-24), Cmax, Tmax, CL/F, Vz/F and half-life (t1/2),|Gastric half-emptying time (GET½), the duration of the lag phase (Tlag), gastric emptying coefficient (GEC)",Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,26,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",B3301001,Dec-10,Jun-11,Jun-11,24-Nov-10,null,6-Jul-11,"Pfizer Investigational Site, Bruxelles, Belgium",,https://ClinicalTrials.gov/show/NCT01247896
NCT01241864,Islet Transplantation in Type 1 Diabetic Kidney Allograft,,Recruiting,No Results Available,"Diabetes Mellitus, Type 1","Biological: Allogenic islet cells (human, U. Chicago)|Procedure: Intraportal infusion of islet cells",HbAlc <6.5% and an absence of severe hypoglycemic events|HbAlc < 6.5% and an absence of severe hypoglycemic events measured after last transplant,University of Chicago,All,"18 Years to 68 Years   (Adult, Older Adult)",Phase 2,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10-479-A|BB-IND 11228,Dec-10,Dec-25,Dec-25,16-Nov-10,null,22-Apr-19,"The University of Chicago, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01241864
NCT01240252,Insulin Receptor Substrate 1 (IRS-1) Regulation in Insulin Resistance,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Human insulin,Proportion of insulin resistant patients with elevated serine/threonine phosphorylation of IRS-1 in muscle.|Quantitative assay of the ability of insulin to clear glucose from the blood in insulin resistant patients.,Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"30 Years to 65 Years   (Adult, Older Adult)",Phase 1,14,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,10-003382|R01DK047936,Mar-12,Jul-12,Jul-12,15-Nov-10,null,5-Jun-13,"Mayo Clinic in Arizona, Scottsdale, Arizona, United States",,https://ClinicalTrials.gov/show/NCT01240252
NCT01240980,"Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)",,Completed,No Results Available,Diabetes,Drug: BMS-903452|Drug: Placebo,"Safety and Tolerability of the investigational drug, as assessed by adverse event monitoring, physical examinations, clinical laboratory determinations, electrocardiograms (ECG), and vital sign assessments|Pharmacodynamic activity of the investigational drug on glucose and hormones regulating glucose metabolism|Effect on electrocardiographic (ECG) parameters|Percent urinary recovery (% UR)|Renal clearance (CLR) from plasma|The single-dose pharmacokinetics parameter maximum observed concentration in plasma (Cmax) of BMS-903452 will be derived from the plasma concentration versus time data|The single-dose pharmacokinetics parameter time to reach maximum observed concentration in plasma (Tmax) of BMS-903452 will be derived from the plasma concentration versus time data|The single-dose pharmacokinetics parameter time Area under the plasma concentration-time curve from time zero extrapolated to infinity AUC(INF) of BMS-903452 will be derived from the plasma concentration versus time data|The single-dose pharmacokinetics parameter Area under the plasma concentration-time curve from time zero to last measurable sampling time AUC (0-T) of BMS-903452 will be derived from the plasma concentration versus time data|The single-dose pharmacokinetics parameter Terminal-phase elimination half-life in plasma (T-Half) of BMS-903452 will be derived from the plasma concentration versus time data|The single-dose pharmacokinetics parameter apparent clearance from plasma after extra-vascular administration (CLT/F) of BMS-903452 will be derived from the plasma concentration versus time data",Bristol-Myers Squibb,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,104,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MB125-001,Nov-10,Jan-12,Jan-12,15-Nov-10,null,15-Mar-12,"Comprehensive Phase One, Miramar, Florida, United States|Ppd Development, Lp, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT01240980
NCT01238406,Overnight MD-Logic,,Completed,No Results Available,Type 1 Diabetes,Device: MD-logic Artificial Pancreas (MDLAP)|Device: Standard treatment with insulin pump,"Number of hypoglycemic events|Time spent in hypoglycemia|Reduction in overnight mean glucose level|Increase in time spent in the target range|Increase in time spent in the target range of sensor glucose level within 70-180 mg/dl|Sleep efficacy|Percentage of time spent in the target range|Percentage of time spent in the tight target range|Average (SD) of blood glucose levels|Percentage of time spent below 60 mg/dl and below 70 mg/dl|Percentage of time spent above 140, 180, 250 mg/dl (7.8, 10, 13.9 mmol/l)|Glucose variability|Control Variability Grid Analysis (CVGA)|number of accurate alerts related to the remote safety and control diabetes management system|Number of hypoglycemic events below 60 and 70 mg/dl (3.3, 3.9 mmol/l)|Area under the curve <60,<63,<70,>140,>180,>250 mg/dl(3.3,3.5,3.9,7.8,10,13.9)|• The percentage of nights mean overnight sensor glucose levels was within 90-140mg/dl (5-7.8 mmol/l)|Postprandial peak blood glucose and 2 hours postprandial blood glucose (segment 4 and 6 only)|Artificial Pancreas technical performance, defined as the total frequency of failures|Analysis of the number of sensor data point not received to the artificial pancreas device divided by the total number of possible data points to be received.|Percent time of active closed-loop control|sensor accuracy|The time spent in hypoglycemia|The number of hypoglycemic events below 60 and 50 mg/dl|The time sensor glucose level spent within 70 to 140 mg/dl (3.9 to 7.8 mmol/l)|The time spent in hyperglycemia|Patient's diabetes treatment satisfaction|Acceptance and use intention of an Artificial Pancreas|Fear of hypoglycemia|Satisfaction with Artificial Pancreas|Average percentage of overnight operation of the closed-loop control|Percentage of time spent below 50, 60, 70 mg/dl|Number of hypoglycemic events below 50, 60, 70 mg/dl|Percentage of time spent above 180, 250 mg/dl|Number of readings below 70 mg/dl|Automatic Caller System (ACS) technical performance and number of accurate alerts|number of research team intervention|HbA1c|Number of awake bouts per night|Total wake up time per night",Rabin Medical Center,All,"10 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,151,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,rmc006000ctil,Mar-11,Jan-17,Jan-17,10-Nov-10,null,11-Jan-17,"Diabetes -Zentrum fuer kinder und jugendliche, Hannover, Germany|Schneider Children's Medical center, Petach-Tikva, Israel|University Children's Hospital, Ljubljana, Slovenia",,https://ClinicalTrials.gov/show/NCT01238406
NCT01235819,Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes,Drug: Insulin|Drug: Sitagliptin|Drug: Exenatide,change in insulin requirement|C peptide response,"Command Hospital, India",All,"12 Years to 30 Years   (Child, Adult)",Phase 4,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DM/CHCC/03/2010,Nov-10,Sep-11,Sep-11,8-Nov-10,null,27-Jul-16,"Command Hospital, Lucknow, UP, India",,https://ClinicalTrials.gov/show/NCT01235819
NCT01236365,Statins in Children With Type 1 Diabetes and Hypercholesterolemia,,Completed,Has Results,"Diabetes Mellitus, Insulin-Dependent|Hypercholesterolemia",Drug: Atorvastatin|Drug: Atorvastatin Placebo,LDL-C Levels Assessed at Randomization and 6 Months|Hs-CRP Levels Assessed at Randomization and 6 Months|Relationship Between Glycemic Variability- Measured by the Mean Amplitude of Glycemic Excursion With Continuous Glucose Monitoring.|Gene Expression and Concentration of Key Molecules That Participate in the Inflammatory Process and Arterial Plaque Formation.|Subclinical Atherosclerosis and Vascular Stiffness With the Use of Abdominal Aortic MRI.,Nemours Children's Clinic|Pfizer|Medtronic|Quest Diagnostics,All,"10 Years to 20 Years   (Child, Adult)",Phase 3,42,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB# 185500,Oct-10,Oct-13,Nov-14,8-Nov-10,21-May-15,18-Jun-15,"Alfred I duPont Hospital, Wilmington, Delaware, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Nemours Children's Clinic, Orlando, Florida, United States|Nemours Children's Clinic, Pensacola, Florida, United States|Nemours Children's Clinic-Jefferson, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01236365
NCT01236404,"Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus",,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl)|Drug: Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl),Safety/Tolerability|Pharmacokinetic Profile|Pharmacodynamic Response,PhaseBio Pharmaceuticals Inc.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,80,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PB1023-PT-CL-0001,Nov-10,Nov-11,Nov-11,8-Nov-10,null,21-May-13,"Diablo Clinical Research, Walnut Creek, California, United States|Prism Research, Saint Paul, Minnesota, United States|Rainier Clinical Research Center, Inc., Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT01236404
NCT01235039,A Study Evaluating the Bioequivalence of VIAject®7 Compared to VIAject®25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject®7 to Insulin Lispro in Subjects With Type 1 Diabetes Mellitus,,Completed,No Results Available,Diabetes Mellitus,Drug: VIAject®25|Drug: VIAject®7|Drug: Insulin Lispro,Serum insulin concentration|Glucose infusion rate,Biodel,All,"19 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,43,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",VIAject -030J,Jul-09,Sep-09,Sep-09,5-Nov-10,null,29-Jul-15,"Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01235039
NCT01231984,Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles,,Completed,Has Results,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Device: 4 mm x 32G Pen Needle|Device: 8mm x 31G Pen Needle|Device: 12.7mm x 29G Pen Needle,"Glycemic Control as Measured by HbA1c (4 mm vs. 8 mm)|Glycemic Control as Measured by HbA1c (4 mm vs. 12.7 mm)|Glycemic Control as Measured by HbA1c, in High Dose Insulin (at Least One Dose of ≥ 40 Units) Users|Injection Pain Scores (4 mm vs. 8 mm)|Injection Pain Scores (4 mm vs. 12 mm)|Number of Serious, Unexplained Hypoglycemic Events, Reported as Number of Events by Needle.|Number of Serious, Unexplained Hyperglycemic Events, Reported as Number of Events by Needle.","Becton, Dickinson and Company",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,293,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),DBC-10-SQUIR05,Oct-10,May-12,May-12,2-Nov-10,27-Jun-14,27-Jun-14,"AMCR Institute, Inc., Escondido, California, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Springfield Diabetes and Endocrine Center, Springfield, Illinois, United States|International Diabetes Center (IDC), Minneapolis, Minnesota, United States|Diabetes and Endocrine Associates, Omaha, Nebraska, United States|The Molly Diabetes Center for Adults and Children at Hackensack University Medical Center, Hackensack, New Jersey, United States|Mountain Diabetes and Endocrine Center, Asheville, North Carolina, United States|University Diabetes and Endocrine Consultants, Chattanooga, Tennessee, United States|Clinical Trials of Texas, Inc, San Antonio, Texas, United States|Corporate Lane Internal Medicine and Research Center, Virgina Beach, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01231984
NCT01227460,Effects of Sitagliptin (Januvia®) on Blood Glucose Control in Patients With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Drug: Sitagliptin|Drug: Sugar Pill,"To demonstrate a decrease in post-prandial glucagon release as assessed by glucagon area under the curve (AUC) for 3 hours during 4 hour meal tolerance tests|Secondary objectives: 1. To demonstrate a 0.3% decrease in A1c in patients with type 1 diabetes after 16 weeks of treatment with sitagliptin. 2. To evaluate changes in total, basal and bolus insulin dose while on sitagliptin.",University of Colorado Denver School of Medicine Barbara Davis Center,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,140,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",MRK-SI-100,Nov-10,Jul-11,Jul-11,25-Oct-10,null,21-May-14,"University of Colorado/Barbara Davis Center for Diabetes, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT01227460
NCT01226537,Effect of Taurine on Glycemic Control in Type I and Type II Diabetic Patients,,Unknown status,No Results Available,"it is a Group of Metabolic Diseases in|Which a Person Has High Blood Sugar, Either|Because the Body Does Not Produce Enough Insulin,|or Because Cells do Not Respond to the Insulin That|is Produced.",Drug: Taurine,Fasting glucose 2) HbA1c 3) Lipid profile 4) Taurine 5) Insulin 6) Urine Micro albumin 7) Eye test,Hamad Medical Corporation,All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,20,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,Nov-12,Nov-13,Dec-14,22-Oct-10,null,9-Nov-12,,,https://ClinicalTrials.gov/show/NCT01226537
NCT01223339,"Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041)",,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Ertugliflozin|Drug: Placebo,Maximum plasma concentration (Cmax) of ertugliflozin for the Single Dose Cohort|Time taken to reach the maximum observed plasma concentration (Tmax) of ertugliflozin for the Single Dose Cohort|Area under the plasma concentration-time curve (AUC) from time 0 to time of the last quantifiable concentration (AUClast) for ertugliflozin for the Single Dose Cohort|AUC from Hour 0 to infinity (AUCinf) for ertugliflozin for the Single Dose Cohort|Ertugliflozin half life (t1/2) for the Single Dose Cohort|Apparent clearance (CL/F) of ertugliflozin for the Single Dose Cohort|Apparent volume of distribution (Vz/F) for the Single Dose Cohort|Accumulation Ratio of Area Under the Curve for the dosing interval of ertugliflozin (Rac) for the Single Dose Cohort|Number of participants who experienced an adverse event (AE) for the Single Dose Cohort|Number of participants who discontinued study drug due to an AE for the Single Dose Cohort|Urinary Glucose Excretion over 24 hours for the Single Dose Cohort|Cmax of ertugliflozin for the Multiple Dose Cohort|Tmax of ertugliflozin for the Multiple Dose Cohort|AUClast for ertugliflozin for the Multiple Dose Cohort|AUCinf for ertugliflozin for the Multiple Dose Cohort|t1/2 for the Multiple Dose Cohort|CL/F of ertugliflozin for the Multiple Dose Cohort|Vz/F for the Multiple Dose Cohort|Rac for the Single Dose Cohort|Number of participants who experienced an AE for the Multiple Dose Cohort|Number of participants who discontinued study drug due to an AE for the Multiple Dose Cohort|Urinary Glucose Excretion over 24 hours for the Multiple Dose Cohort,Merck Sharp & Dohme Corp.|Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",8835-041,Oct-10,Feb-11,Feb-11,19-Oct-10,null,20-May-16,,,https://ClinicalTrials.gov/show/NCT01223339
NCT01223547,Study of the Effects of Carbohydrate Counting,,Completed,No Results Available,Type 1 Diabetes,Other: Education,Change in HbA1c|Variation in blood glucose|Number of hypoglycemic events|Treatment satisfaction|Total daily insulin dose|Weight,Hvidovre University Hospital|The Danish Council for Strategic Research|Medtronic|Roche Pharma AG|Novo Nordisk A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,64,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BOLUSCAL,Oct-10,Aug-11,Aug-11,19-Oct-10,null,28-Jan-14,"Hvidovre University Hospital, Hvidovre, Denmark",,https://ClinicalTrials.gov/show/NCT01223547
NCT01223560,Collection of Information-Rich Type 1 Diabetes Data,,Completed,No Results Available,Type 1 Diabetes,Drug: Insulin Aspart|Other: Exercise|Dietary Supplement: Carbohydrate,,Hvidovre University Hospital|The Danish Council for Strategic Research|Technical University of Denmark|Novo Nordisk A/S,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,12,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Prevention,DiaCon Study 01,Oct-09,May-10,May-10,19-Oct-10,null,19-Oct-10,"Hvidovre University Hospital, Hvidovre, Denmark",,https://ClinicalTrials.gov/show/NCT01223560
NCT01223651,Performance of Continuous Glucose Monitoring Systems at Altitude,,Terminated,No Results Available,"Diabetes Mellitus, Type 1",Procedure: two step hyperinsulinaemic glucose clamp study.,Accuracy of continuous glucose monitoring system (CGMS).|The effect of altitude on the recognition of hypoglycaemic symptoms.,The Royal Bournemouth Hospital,All,18 Years to 60 Years   (Adult),Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,10/H0505/73,Jan-12,Mar-13,Mar-13,19-Oct-10,null,7-Sep-18,"Royal Airforce Base Henlow, Henlow, Bedfordshire, United Kingdom|Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, Dorset, United Kingdom",,https://ClinicalTrials.gov/show/NCT01223651
NCT01222078,Investigating Re-Dosing With Otelixizumab in Adults With Newly-Diagnosed Type 1 Diabetes Mellitus,,Terminated,Has Results,"Diabetes Mellitus, Type 1",Biological: otelixizumab,"Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs)|Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Mean Change From Baseline in Respiration Rate|Mean Change From Baseline in Temperature|Mean Change From Baseline in Heart Rate|Number of Participants With Values Outside the Normal Range for Vitals|Mean Change From Baseline in Value of Albumin and Total Protein|Mean Change From Baseline in Value of Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatinine Kinase, Follicle Stimulating Hormone, Gamma Glutamyl Tranferase and Lactate Dehydrogenase|Mean Change From Baseline in Value of Direct Bilirubin, Total Bilirubin, Creatinine and Uric Acid|Mean Change From Baseline in Value of Calcium, Chloride, Carbon Dioxide Content/Bicarbonate, Glucose, Potassium, Magnesium, Sodium, Inorganic Phosphorus and Urea/Blood Urea Nitrogen|Mean Change From Baseline in Value of Estradiol|Mean Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelet Count and White Blood Cell Count|Mean Change From Baseline in Glycosylated Hemoglobin Value|Mean Change From Baseline in Hemoglobin Value|Mean Change From Baseline in Red Blood Cell Count|Mean Epstein-Barr Virus (EBV) Viral Load|Mean Change in Total Lymphocyte Count|Mean Change in CD4+ and CD8+ T-cell Counts|Mean Change in Circulating Peripheral T Lymphocytes|Mean Change in Circulating Peripheral CD4+ and CD8+ Subset Counts|Mean Serum Levels of Anti-otelixizumab Binding Antibodies|Proportion of Anti-otelixizumab Neutralizing Antibodies|Mean Circulating Peripheral T Lymphocytes Count|Mean Circulating CD4+ and CD8+ Subset Counts|Mean Saturation of CD3 Antigen on Peripheral Blood T Cells|Mean Individual Serum Concentrations of Otelixizumab|Maximum Observed Serum Concentration (Cmax) of Otelixizumab|Time to Cmax (Tmax) of Otelixizumab|Area Under the Serum Concentration-time Curve [AUC(0-tlast)] of Otelixizumab|Time of Last Observed Quantifiable Concentration (Tlast) of Otelixizumab|Terminal Phase Half-life (Thalf) of Otelixizumab",GlaxoSmithKline,All,18 Years to 45 Years   (Adult),Phase 2,1,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,113390,22-Nov-10,19-May-11,19-May-11,18-Oct-10,16-Jun-17,25-Aug-17,"GSK Investigational Site, Paris Cedex 18, France|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany",,https://ClinicalTrials.gov/show/NCT01222078
NCT01223131,Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.,Lantus-P-CN,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Insulin glargine (HOE901)|Drug: NPH insulin,"Absolute change of glycosylated hemoglobin (HbA1c)|Percentage of patients reaching HbA1c < 7.5%|Change in Fasting Blood Glucose (FBG)|Change in nocturnal Blood Glucose (BG)|Change in 24-hour blood glucose profile based on 8-point self-monitoring blood glucose (SMBG)|Change in total insulin dose and basal insulin dose|Rate of asymptomatic and/or symptomatic, severe, nocturnal, nocturnal symptomatic hypoglycemia.|Anti-glargine and anti-human insulin antibody assessment",Sanofi,All,6 Years to 17 Years   (Child),Phase 3,162,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EFC11681|U1111-1116-3661,Feb-11,Mar-14,Mar-14,18-Oct-10,null,1-Apr-14,"Investigational Site Number 156006, Beijing, China|Investigational Site Number 156001, Beijing, China|Investigational Site Number 156007, Beijing, China|Investigational Site Number 156009, Changsha, China|Investigational Site Number 156008, Guangzhou, China|Investigational Site Number 156004, Hangzhou, China|Investigational Site Number 156016, Shanghai, China|Investigational Site Number 156005, Shanghai, China|Investigational Site Number 156019, Taiyuan, China|Investigational Site Number 156002, Wuhan, China",,https://ClinicalTrials.gov/show/NCT01223131
NCT01221467,Closing the Loop in Youth With Type 1 Diabetes in the Home Setting,,Completed,No Results Available,Type 1 Diabetes,Device: Overnight closed-loop,Primary Efficacy Outcome|Secondary outcomes,University of Cambridge|Cambridge University Hospitals NHS Foundation Trust,All,"12 Years to 18 Years   (Child, Adult)",Phase 2,17,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APCam06,Jun-12,Mar-13,Mar-13,15-Oct-10,null,24-Sep-13,"Department of Paediatrics, Weston paediatric diabetes centre, Cambridge, Cambridgeshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT01221467
NCT01220479,Exercise Training Intervention in Children With Type 1 Diabetes,Diabex,Completed,No Results Available,Type 1 Diabetes Mellitus,Behavioral: Exercise training program,Bone mineral density and content|Anthropometrics|Blood lipids levels|Physical activity|Nutrition|Circulating bone biomarkers levels|Glycated Haemoglobin|Systemic blood pressure|Body composition,"University Hospital, Geneva|Swiss National Science Foundation",All,8 Years to 16 Years   (Child),Not Applicable,59,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,snf n°63164,Sep-01,Dec-08,Jun-09,14-Oct-10,null,14-Oct-10,"University Hospital of Geneva, Geneva, Switzerland",,https://ClinicalTrials.gov/show/NCT01220479
NCT01220557,Evaluation of a Treatment and Education Programme for Type 1 Diabetic Patients (PRIMAS),PRIMAS,Completed,Has Results,Type 1 Diabetes,Behavioral: PRIMAS|Behavioral: DTTP,Changes in Glycemic Control Measured by A1c|Diabetes Knowledge|Hypoglycaemia Awareness Score|Diabetes Empowerment Score (DES)|Summary of Diabetes Self-Care Activities (SDSCA)|Diabetes Distress Scale (DDS)|CES-D Score|Diabetes Self-Efficacy Scale|Treatment Satisfaction / Problem Areas in Dealing With Diabetes|Evaluation of the Diabetes Education Course,Forschungsinstitut der Diabetes Akademie Mergentheim,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,162,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NH062010,Sep-10,Mar-12,Mar-12,14-Oct-10,26-Aug-14,26-Aug-14,,,https://ClinicalTrials.gov/show/NCT01220557
NCT01220856,Reparixin in Pancreatic Islet Transplantation,,Completed,No Results Available,Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus,Drug: Reparixin,"The proportion of insulin-independent patients following a single donor-single islet cell transplantation|The proportion of insulin-independent patients after a single donor-single islet cell transplantation|Time to achieve insulin-independence after the transplant|Total time of insulin independence after the transplant|Change in average daily insulin requirements (absolute and % decrease from pre-transplant levels)|HbA1c (absolute and % decrease from pre-transplant levels)|The proportion of patients free of severe hypoglycaemic events|The proportion of patients free of hypoglycaemic events with reduced awareness|Basal (fasting) and -10 to 120 min time course of glucose, C-peptide and insulin derived from the mixed meal tolerance test|Beta-cell function as assessed by beta-score and Transplant Estimated Function|Incidence and severity of Adverse Events and Serious Adverse Events|Standard laboratory tests (hematology, clinical chemistry, coagulation)|Blood pressure and heart rate|ALT/AST, PT/PTT, fibrin degradation products, C-reactive protein|Time course of inflammatory chemokines/cytokines|Plasma levels of reparixin and its major metabolite|ALT/AST|Auto-antibodies and anti-HLA antibodies",Dompé Farmaceutici S.p.A,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,9,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,REP0110|2010-019424-31,Jul-10,Sep-12,Jun-14,14-Oct-10,null,30-Jun-14,"University Hospital Carl Gustav Carus Dresden, Dresden, Germany|Ospedale San Raffaele, Milan, Italy",,https://ClinicalTrials.gov/show/NCT01220856
NCT01219465,Umbilical Cord Mesenchymal Stem Cells Infusion for Initial Type 1 Diabetes Mellitus,,Unknown status,No Results Available,"Diabetes Mellitus|Diabetes Mellitus, Type 1|Mesenchymal Stem Cells|Umbilical Cord",Biological: umbilical cord mesenchymal stem cells,C peptide release test|Exogenous insulin dose|blood glucose|glycosylated Hemoglobin A1c|Number of severe and documented hypoglycemic events|Immunologic reconstitution parameters,Qingdao University,All,"3 Years to 35 Years   (Child, Adult)",Phase 1|Phase 2,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSCT1DM003,Sep-10,Sep-12,Dec-12,13-Oct-10,null,13-Oct-10,"Stem Cell Research Center of Medical School Hospital of Qingdao University, Qingdao, Shandong, China",,https://ClinicalTrials.gov/show/NCT01219465
NCT01220349,Alteration of Myocardial Deformations in Diabetes: Relationship to Micro-angiopathy,ECHO-DIAB,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: Echocardiographic 2D strain analysis,"Measurement of the alteration of left ventricular myocardial strain (≤ 18% in absolute value) by echocardiography and the relationship to micro-angiopathy.|Analyses of this association (alteration of myocardial strain and micro-angiopathy) in relation with the duration of diabetes, and other co-factors such as dyslipidemia, unstable diabetes, and coexisting macro-angiopathy.","University Hospital, Bordeaux",All,18 Years to 45 Years   (Adult),Not Applicable,61,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,CHUBX 2009/27,Jan-11,Oct-12,Oct-12,13-Oct-10,null,19-Apr-13,"Hôpital Cardiologique du Haut-Lévêque, Service de Cardiologie et Maladies Vasculaires, Pessac, France",,https://ClinicalTrials.gov/show/NCT01220349
NCT01217112,GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes,,Completed,Has Results,"Dyslipidemias|Diabetes Mellitus, Type 2",Drug: GWP42003|Drug: GWP42004|Drug: Placebo,The Change From Baseline in Mean Serum High Density Lipoprotein Cholesterol Concentration After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean High Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Serum Total Cholesterol Concentration After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Total Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Serum Low Density Lipoprotein Cholesterol Concentration After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Low Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Serum High Density Lipoprotein : Low Density Lipoprotein Cholesterol Ratio After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean High Density Lipoprotein : Low Density Lipoprotein Cholesterol Ratio by Ultracentrifugation After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Very Low Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Serum Triglyceride Concentration After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Triglyceride Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Serum Apolipoprotein A Concentration After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Serum Apolipoprotein B Concentration After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Serum Apolipoprotein B : Apolipoprotein A Ratio After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Serum Non-Esterified Fatty Acid Concentration After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Fasting Glucose Concentration After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Fructosamine Concentration After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Glycated Haemoglobin Concentration After 91 Days (13 Weeks) of Treatment|The Change From Baseline to the End of 91 Days (13 Weeks) of Treatment in the Mean Serum Glucose Concentration Two Hours Post Glucose Challenge (Oral Glucose Tolerance Test [OGTT])|The Change From Baseline to the End of 91 Days (13 Weeks) of Treatment in the Mean Serum Insulin Concentration Two Hours Post Glucose Challenge (Oral Glucose Tolerance Test)|The Change From Baseline in Mean Fasting Insulin Concentration After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean C-peptide Concentration After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Insulin Resistance Measured by Homeostasis Model Assessment 2 (HOMA2-IR) After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Insulin Sensitivity Measured by Homeostasis Model Assessment 2 (HOMA2) After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Insulin B Cell Function Measured by Homeostasis Model Assessment 2 (HOMA2) After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Body Mass Index After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Waist-to-hip Ratio After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Body Weight After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Waist Measurement After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Hip Measurement After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Visceral Abdominal Fat After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Subcutaneous Abdominal Fat After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Total Abdominal Fat After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Internal Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Subcutaneous Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Total Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Total Internal Fat After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Total Subcutaneous Fat After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Total Fat After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Abdominal Adiposity After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean % Liver Fat After 91 Days (13 Weeks) of Treatment|The Change From Baseline in Mean Appetite 0-10 Numerical Rating Scale Score After 91 Days (13 Weeks) of Treatment|Adverse Events as a Measure of Patient Safety|The Change From Baseline in Mean Beck Depression Inventory-II (BDI-II) Score at the End of 91 Days (13 Weeks) of Treatment,GW Research Ltd,All,"18 Years and older   (Adult, Older Adult)",Phase 2,62,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GWMD1092|2010-020458-33,Oct-10,May-12,Sep-12,8-Oct-10,20-Jan-14,18-Sep-14,"Woolpit Health Centre, Bury St Edmonds, United Kingdom|Mount Farm Surgery, Bury St Edmonds, United Kingdom|University of Nottingham, Medical School at Derby, Royal Derby Hospital, Derby, United Kingdom|James Paget University Hospital, Gorleston-on-Sea, Norfolk, United Kingdom|MAC UK Neuroscience Ltd., Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT01217112
NCT01216618,Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies,,Completed,No Results Available,"Diabetes Mellitus, Insulin-Dependent",Device: InsuPatch,Efficacy|Safety|pharmacokinetics|Pharmacodynamic,Insuline Medical Ltd.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,55,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,G080106/A,Oct-10,Jun-11,Jun-11,7-Oct-10,null,4-Sep-14,"Mills-Peninsula Health Services, San Mateo, California, United States|Wolfson Medical Center, Holon, Israel|Haddasah Medical Organization, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT01216618
NCT01215435,Comparison of Two Biphasic Insulin Aspart 30 Treatment Regimens in Subjects With Type 2 Diabetes Not Achieving HbA1c Treatment Targets on OADs Alone,,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: biphasic insulin aspart 30,Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 11|Change in FPG (Fasting Plasma Glucose) From Baseline to Week 36|Number of Treatment Emergent Hypoglycaemic Episodes,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 4,245,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BIASP-3858|U1111-1116-2121,Mar-11,Sep-12,Sep-12,6-Oct-10,25-Nov-13,30-Oct-14,"Teheran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01215435
NCT01210664,T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs,Treg,Completed,Has Results,Type 1 Diabetes Mellitus,Biological: Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells,Adverse Events (AEs) as a Measure of Safety and Tolerability|Number of Participants Experiencing Severe or Life Threatening Laboratory Abnormalities|Percent Change From Baseline in C-peptide Area Under the Curve|Insulin Use|Hemoglobin A1c,"University of California, San Francisco|Juvenile Diabetes Research Foundation|National Institute of Allergy and Infectious Diseases (NIAID)",All,18 Years to 45 Years   (Adult),Phase 1,16,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UCSFDC411AI|JDRF4-2005-1168,Nov-10,Dec-16,Jan-17,28-Sep-10,11-Jul-18,11-Jul-18,"University of California, San Francisco Medical Center, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01210664
NCT01209312,Timing of Pre-meal Insulin Versus Accurate Carbohydrate Counting in Youth With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Other: Bolus timing and dosing,Blood glucose area under the curve,"University of Colorado, Denver",All,"7 Years to 21 Years   (Child, Adult)",Not Applicable,21,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,09-0931,Dec-09,Dec-10,Dec-10,27-Sep-10,null,22-Nov-12,"Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT01209312
NCT01206101,Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation,,Terminated,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: liraglutide|Drug: placebo,Proportion Of Insulin-independent Subjects After Receiving Only One (Single-Donor) Islet Cell Transplant|Number of Hypoglycaemic Episodes|Proportion of Subjects With HbA1c Below Or Equal to 6.5% At Week 52 That Are Free From Severe Hypoglycaemic Events|Proportion of Insulin-Independent Subjects|Change in Islet Cell Yield During Culture|Glucose Level Variability And Hypoglycaemia Duration Derived From The Continuous Glucose Monitoring System (CGMS),Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 2,3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN2211-3619|2009-013090-18|U1111-1114-8952,21-Mar-12,3-Jun-13,3-Jun-13,21-Sep-10,3-Jul-14,30-Mar-17,"Novo Nordisk Investigational Site, Duarte, California, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Madison, Wisconsin, United States|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Vancouver, British Columbia, Canada|Novo Nordisk Investigational Site, Besancon, France|Novo Nordisk Investigational Site, Grenoble, France|Novo Nordisk Investigational Site, Lille, France|Novo Nordisk Investigational Site, MONTPELLIER cedex 5, France|Novo Nordisk Investigational Site, Strasbourg, France|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Genève 14, Switzerland|Novo Nordisk Investigational Site, Zürich, Switzerland|Novo Nordisk Investigational Site, Headington, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01206101
NCT01205308,Plant Stanols and Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Dietary Supplement: Vegetable oil based margarine with plant stanol ester enrichment,serum lipids|squalene|non-cholesterol sterols,Marjukka Kolehmainen|Kuopio University Hospital|Raisio Plc|University of Eastern Finland,All,"18 Years to 72 Years   (Adult, Older Adult)",Not Applicable,24,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",125/2009,Jan-10,Oct-10,Mar-11,20-Sep-10,null,17-Apr-12,"University of Eastern Finland, Kuopio, Finland",,https://ClinicalTrials.gov/show/NCT01205308
NCT01204593,baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus,SUBSTITUTE,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: INSULIN GLARGINE|Drug: INSULIN GLULISINE,Change in hemoglobin A1c (HbA1c) values (following the reference of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC))|Change of HbA1c|Percentage of patients with HbA1c < 7%|Fasting Blood Glucose (FBG)|7-point Self Monitoring of Blood Glucose (SMBG)|Daily dose for insulin glulisine|Daily dose for insulin glargine|Symptomatic hypoglycemias,Sanofi,All,18 Years to 60 Years   (Adult),Phase 4,206,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LANTU_R_05033|U1111-1116-3450,Nov-10,Jan-13,Jan-13,17-Sep-10,null,17-Mar-14,"Investigational Site Number 01201, Algeries, Algeria|Investigational Site Number 01202, Algiers, Algeria|Investigational Site Number 01203, Algiers, Algeria|Investigational Site Number 01204, Algiers, Algeria|Investigational Site Number 03201, Caba, Argentina|Investigational Site Number 03202, Caba, Argentina|Investigational Site Number 03203, Caba, Argentina|Investigational Site Number 03204, Caba, Argentina|Investigational Site Number 03205, Morón, Argentina|Investigational Site Number 076-007, Curitiba, Brazil|Investigational Site Number 076-003, Distrito Federal, Brazil|Investigational Site Number 076-010, Fortaleza, Brazil|Investigational Site Number 076-006, Marília, Brazil|Investigational Site Number 076-004, Porto Alegre, Brazil|Investigational Site Number 076-002, São Paulo, Brazil|Investigational Site Number 17003, Barranquilla, Colombia|Investigational Site Number 17004, Bogotá, Colombia|Investigational Site Number 17005, Bogotá, Colombia|Investigational Site Number 17007, Bogotá, Colombia|Investigational Site Number 17006, Medellin, Colombia|Investigational Site Number 01, Kuwait, Kuwait|Investigational Site Number 48401, Guadalajara, Mexico|Investigational Site Number 48402, Guadalajara, Mexico|Investigational Site Number 48404, Guadalajara, Mexico|Investigational Site Number 48403, Monterrey, Mexico|Investigational Site Number 1, Riyadh, Saudi Arabia|Investigational Site Number 12468, Benoni, South Africa|Investigational Site Number 710004, Benoni, South Africa|Investigational Site Number 12466, Bloemfontein, South Africa|Investigational Site Number 710006, Bloemfontein, South Africa|Investigational Site Number 12464, Durban, South Africa|Investigational Site Number 12465, Durban, South Africa|Investigational Site Number 710001, Durban, South Africa|Investigational Site Number 710002, Durban, South Africa|Investigational Site Number 12484, Port Elizabeth, South Africa|Investigational Site Number 710003, Port Elizabeth, South Africa|Investigational Site Number 12467, Pretoria, South Africa|Investigational Site Number 710005, Pretoria, South Africa|Investigational Site Number 78801, Sfax, Tunisia|Investigational Site Number 78805, Sfax, Tunisia|Investigational Site Number 78803, Tunis, Tunisia|Investigational Site Number 78802, Tunis, Tunisia|Investigational Site Number 78804, Tunis, Tunisia",,https://ClinicalTrials.gov/show/NCT01204593
NCT01202266,A Multiple Dose Study Of PF-05161704 In Healthy Volunteers,,Terminated,No Results Available,"Diabetes Mellitus, Type 2",Drug: PF-05161704 or Placebo,"Safety and tolerability endpoints evaluated by adverse event monitoring, laboratory values, cardiovascular monitoring|Pharmacokinetic Endpoints: single dose and steady state pharmacokinetics of PF-05161704 and its metabolite PF-05200145. Urinary recovery will also be assessed for PF-05161704 and PF-05200145|Pharmacodynamic Endpoints: Absolute value and change from Day 0 baseline in postprandial GLP-1. Postprandial plasma PYY, triglycerides and apoB48. Absolute value and change from baseline in apoB100 and VLDL|Exploratory Parameters: absolute value and change from Day 0 baseline in concentrations of fasting serum lipids and body weight",Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,32,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",B2911002,Aug-10,Dec-10,Dec-10,15-Sep-10,null,11-Mar-11,"Pfizer Investigational Site, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01202266
NCT01202474,Apidra Children & Adolescents Study,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: INSULIN GLULISINE|Drug: INSULIN GLARGINE,Percentage of patients achieving HbA1c level < 8% (in patients 6-12 year-old) and HbA1c level < 7.5 % (in patients 13-17 year-old)|Change in HbA1c plasma level|Monthly rate of hypoglycaemia|Change in daily dose of glargine and glulisine,Sanofi,All,6 Years to 17 Years   (Child),Phase 4,100,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APIDR_L_04884|U1111-1116-8645,May-11,Oct-12,Oct-12,15-Sep-10,null,18-Dec-12,"Administrative office, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT01202474
NCT01195454,Euglycemic Clamp Dose-response Study Comparing a New Insulin Glargine Formulation With Lantus®,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Insulin glargine (HOE901),"The area under the body weight standardized glucose infusion rate curve (GIR) within 36 hours (GIR-AUC0-36)|The area under the insulin glargine concentration curve within 36 hours (INS-AUC0-36) -|Time to 50% of the GIR-AUC0-36 (T50%-GIR AUC0-36)|Time to 50% of INS-AUC0-36 (T50% INS-AUC0-36)|Duration of blood glucose control (time to elevation of smoothed blood glucose profile above clamp level and to elevation above different pre-specified blood glucose levels)|Maximum smoothed body weight standardized glucose infusion rate GIRmax, and time to GIRmax (GIR-Tmax)|Maximum insulin concentration INS-Cmax, and time to Cmax (INS-Tmax)",Sanofi,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PKD11627|2010-020914-27,Aug-10,Nov-10,Dec-10,6-Sep-10,null,31-Oct-11,"Sanofi-Aventis Administrative Office, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT01195454
NCT01194479,Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes.,,Completed,Has Results,Type 1 Diabetes,Drug: Formoterol|Other: Placebo,Glucagon (pg/mL)|Epinephrine (pg/mL)|Norepinephrine (pg/mL)|Blood Glucose Levels (Average),Yale University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,18 Years to 55 Years   (Adult),Not Applicable,14,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HIC1005006832|R37-20495,Aug-10,Aug-14,Aug-14,3-Sep-10,29-Mar-16,29-Mar-16,"Yale University School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01194479
NCT01194882,Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: HUMAN INSULIN (BIOSYNTHETIC)|Drug: Insuplant,"Refill accuracy between the 2 insulin groups|Change in glycosylated hemoglobin (HbA1c)|Occurrence of Hypoglycaemia (asymptomatic and symptomatic hypoglycaemia, severe and serious symptomatic hypoglycaemia|Occurrence of hyperglycaemia|Occurrence of diabetic ketoacidosis|Change in insulin dose|Antibody assessments (anti-Insulin antibodies)",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,479,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,HUBIN_L_05335|2010-021373-37|U1111-1116-7658,16-Nov-10,1-Feb-18,1-Feb-18,3-Sep-10,null,15-Feb-18,"Investigational Site Number 056-001, Leuven, Belgium|Investigational Site Number 250-004, Corbeil Essonnes, France|Investigational Site Number 250-008, Dijon, France|Investigational Site Number 250-003, Dommartin Les Toul, France|Investigational Site Number 250-012, Le Mans Cedex 9, France|Investigational Site Number 250-009, LILLE Cedex, France|Investigational Site Number 250-007, Marseille, France|Investigational Site Number 250-001, MONTPELLIER Cedex 5, France|Investigational Site Number 250-005, Paris, France|Investigational Site Number 250-010, Pessac Cedex, France|Investigational Site Number 250-011, ST PRIEST EN JAREZ Cedex, France|Investigational Site Number 250-002, Strasbourg, France|Investigational Site Number 250-006, TOULOUSE Cedex 9, France|Investigational Site Number 528003, Den Haag, Netherlands|Investigational Site Number 528002, Roermond, Netherlands|Investigational Site Number 528001, Zwolle, Netherlands|Investigational Site Number 752-001, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01194882
NCT01194245,Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Insulin lispro|Drug: recombinant human hyaluronidase PH20|Drug: Insulin aspart|Drug: Insulin glulisine|Drug: Insulin glargine,Change From Baseline in Glycosylated Hemoglobin A1C (HbA1c) at the End of Each Treatment Period|Mean Daily Insulin Dose|Percentage of Participants Meeting Glucose Targets|Rates of Hypoglycemia at the End of Each Treatment Period|Change From Baseline in Body Weight at the End of Each Treatment Period|Mean Daily Postprandial Glucose (PPG) Excursions,Halozyme Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 2,135,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HALO-117-205,Aug-10,Aug-11,Aug-11,2-Sep-10,19-Aug-14,26-Feb-19,"AMCR Institute, Inc., Escondido, California, United States|Scripps Whittier Diabetes Institute, La Jolla, California, United States|Mills-Peninsula Health Services, San Mateo, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Center for Diabetes and Endocrine Care, Hollywood, Florida, United States|Diabetes Research Institute, Miami, Florida, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Mid-America Diabetes Associates, Wichita, Kansas, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Medstar Research Institute, Hyattsville, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|International Diabetes Center, Minneapolis, Minnesota, United States|Mercury Street Medical, Butte, Montana, United States|Desert Endocrinology, Henderson, Nevada, United States|UT Southwestern Medical Center at Dallas, Dallas, Texas, United States|Texas Diabetes and Endocrinology, Round Rock, Texas, United States|Cetero Research-San Antonio, San Antonio, Texas, United States|West Olympia Internal Medicine, Olympia, Washington, United States|University of Washington School of Medicine, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01194245
NCT01192711,Insulin Administration Plus a Telemedicine System (Diabetes Interactive Diary - DID) vs Insulin Plus Common Practice,DID3,Unknown status,No Results Available,Type 1 Diabetes,Device: Diabetes Interactive Diary (DID),"Blood levels of glycosylated hemoglobin|blood glucose (BG) levels|Glucose variability|Change in body weight and BMI|Total daily insulin dose, total basal insulin dose, total prandial insulin dose|Quality of life|Frequency of patients with hypoglycemic episodes and frequency of hypoglycemic episodes overall|Frequency of patients with severe and/or symptomatic hypoglycemia and frequency of severe and/or symptomatic hypoglycemic episodes overall|Frequency and times of hypoglycemic events with regard to occurrence during the day (24 hours) and total treatment duration (24 weeks)",Consorzio Mario Negri Sud|Sanofi|LifeScan,All,"18 Years and older   (Adult, Older Adult)",Phase 3,130,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MTD003,May-09,Oct-11,null,1-Sep-10,null,2-Sep-10,"Ospedale G.B. Morgagni - L. Pierantoni, Forlì, Italy|P.O. di Grosseto - Stabilimento Misericordia, Grosseto, Italy|Az. Osp. S. Anna - Presidio Ospedaliero Cantù - Mariano Comense, Mariano Comense, Italy|Istituto Scientifico San Raffaele, Milan, Italy|Ospedale Niguarda Cà Granda, Milan, Italy|II Università di Napoli Centro Regionale di Diabetologia Pediatrica ""G. Stoppoloni"", Naples, Italy|Università degli Studi di Padova Dipartimento di Medicina Clinica e Sperimentale, Padua, Italy|Ospedale Cisanello, Pisa, Italy|U.O. di Diabetologia, Dip. di Malattie Digestive & Metaboliche, Ravenna, Italy|Ospedale Infermi, Rimini, Italy|Ospedale Sandro Pertini, Rome, Italy|Ospedale Magati, Scandiano, Italy|Azienda Ospedaliera-Universitaria S. Giovanni Battista, Turin, Italy",,https://ClinicalTrials.gov/show/NCT01192711
NCT01189890,Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251),,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: sitagliptin phosphate|Drug: Glimepiride|Drug: Placebo to Sitagliptin|Drug: Placebo to Glimepiride,Least Squares (LS) Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 30|Number of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 30|Number of Participants Experiencing An Adverse Event (AE)|Number of Participants Discontinuing Study Treatment Due to An AE|LS Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30|Percentage of Participants With HbA1c <7.0% at Week 30|Percentage of Participants With HbA1c <6.5% at Week 30|LS Mean Change From Baseline in Participant Body Weight at Week 30,Merck Sharp & Dohme Corp.,All,65 Years to 85 Years   (Older Adult),Phase 3,480,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0431-251,16-Aug-10,31-Oct-12,31-Oct-12,27-Aug-10,27-Jun-13,5-Jun-17,,,https://ClinicalTrials.gov/show/NCT01189890
NCT01188863,Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: 300 mg LX4211 (150 mg tablets)|Drug: 300 mg LX4211 (50 mg tablets)|Drug: 300 mg LX4211 (liquid),Maximum observed plasma concentration|Time at which maximum observed plasma concentration occurs|Half-life of the drug in plasma|Plasma glucose|Urinary glucose excretion|Insulin|Peptide YY|Glucagon-like Peptide 1,Lexicon Pharmaceuticals,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,15,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LX4211.1-102-DM|LX4211.102,Sep-10,Oct-10,null,26-Aug-10,null,30-Mar-11,"Lexicon Investigational Site, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01188863
NCT01189422,Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes,SUBCUE,Terminated,No Results Available,Type 1 Diabetes Mellitus,Drug: teplizumab or placebo,Dose regimen,MacroGenics|Eli Lilly and Company,All,18 Years to 35 Years   (Adult),Phase 1,1,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",CP-MGA031-06,Aug-10,Feb-11,Feb-11,26-Aug-10,null,24-Sep-15,,,https://ClinicalTrials.gov/show/NCT01189422
NCT01184703,Low Glycemic Index Diet in Patients With Type 1 Diabetes,LGID1,Completed,No Results Available,"Diabetes Mellitus, Type 1",Other: Low GI food,HbA1c|LDL-cholesterol,Steno Diabetes Center Copenhagen,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 3,65,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,GI-project_1,Jun-07,Aug-09,Dec-09,19-Aug-10,null,6-Sep-10,"Steno Diabetes Center, Gentofte, Denmark",,https://ClinicalTrials.gov/show/NCT01184703
NCT01185236,Study to Compare the Effect of Vytorin (Simvastatin/Ezetimibe) 10/20mg Versus Atorvastatin 20mg on ApoB/ApoA1 Ratio in Subjects With Diabetes,,Unknown status,No Results Available,Type 2 Diabetes Mellitus Without Insulin Treatment,Drug: simvastatin/ezetimibe|Drug: atorvastatin 20mg,change of ApoB/ApoA1|change of lipid profile|change of HbA1c|change of HOMA index|change of hsCRP|safety,Seoul National University Hospital|Merck Sharp & Dohme Corp.,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 4,132,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-1007-100-324,Sep-10,Aug-11,Aug-11,19-Aug-10,null,19-Aug-10,"Seoul national university hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01185236
NCT01183715,A Single Dose Study Of PF-05161704 In Healthy Volunteers,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: PF-05161704 or placebo,Safety and tolerability of escalating single oral doses of PF-05161704 in healthy subjects|Single dose pharmacokinetics of PF-05161704 and its metabolite PF-05200145|Preliminary pharmacodynamics of PF-05161704,Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,18,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",B2911001,Jul-10,Sep-10,Sep-10,18-Aug-10,null,24-Sep-10,"Pfizer Investigational Site, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01183715
NCT01183455,A Research Trial of Aralast NP in New Onset Diabetes (RETAIN) - Part II,RETAIN,Withdrawn,No Results Available,"Diabetes Mellitus, Type 1",Drug: Aralast NP|Drug: Placebo,Mixed-Meal Tolerance Test (MMTT)-Stimulated 2-hour C-peptide Area Under the Curve (AUC)|MMTT-Stimulated Peak and 4-hour C-peptide AUC|MMTT-Stimulated 2-hour C-Peptide AUC Assessed Over Time|Insulin Use in Units Per Kilogram Body Weight Per Day|Hypoglycemic Events Occurring from Randomization to End of Trial|Glycosylated Hemoglobin (HbA1c) Levels|Emergence of Anti-Alpha 1-Antitrypsin (AAT) Antibodies|Frequency and Severity of All Adverse Events (AEs)|Changes in D-dimer Levels Indicating Alteration in Coagulant/Anticoagulant Balance|Pharmacokinetic Parameters of Aralast NP,National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)|Juvenile Diabetes Research Foundation,All,"8 Years to 35 Years   (Child, Adult)",Phase 2,0,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DAIT ITN041AI Part II,Oct-10,Aug-14,Aug-14,17-Aug-10,null,31-Dec-14,"University of California San Diego, La Jolla, California, United States|Barbara Davis Center, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|University of Iowa, Iowa City, Iowa, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Calvert Memorial Hospital, Prince Frederick, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|University of Massachusetts Medical School, Worchester, Massachusetts, United States|Columbia University, New York, New York, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|The Children's Hospital of Philadelphia, Philadephia, Pennsylvania, United States|Cetero Research San Antonio, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01183455
NCT01183468,A Research Trial of Aralast in New Onset Diabetes (RETAIN),RETAIN,Terminated,Has Results,"Diabetes Mellitus, Type 1",Biological: Aralast NP 45 mg dose|Biological: Aralast NP 90 mg dose|Biological: Aralast NP 180 mg dose,C-peptide 2-hour AUC in Response to a Mixed-meal Tolerance Test at Week 52,National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)|Juvenile Diabetes Research Foundation,All,"8 Years to 35 Years   (Child, Adult)",Phase 1,17,NIH|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAIT ITN041AI Part 1,Oct-10,Jul-13,Jul-13,17-Aug-10,16-Jan-15,13-Jun-18,"RADY Children's Hospital (University of California, San Diego), San Diego, California, United States|Barbara Davis Center (University of Colorado), Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Children's Hospital of Atlanta (Emory University), Atlanta, Georgia, United States|University of Iowa Children's Hospital, Iowa City, Iowa, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Naomi Berrie Diabetes Center (Columbia University), New York, New York, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Pacific Northwest Research Institute-University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01183468
NCT01178476,Prevention of Severe Hypoglycaemia With Hypo-Safe Hypoglycaemia Alarm Device,,Withdrawn,No Results Available,Type 1 Diabetes,Device: Hyposafe Hypoglycaemia alarm device,"The frequency of severe hypoglycaemia event|The frequency of clinical hypoglycaemia (sensation of hypoglycaemia and BG<3.5mmol/l), biochemical hypoglycaemia (BG<3.5mmol/l), and nocturnal hypoglycaemia (waking up with a sensation of hypoglycaemia and BG<3.5mmol/l)",UNEEG Medical A/S,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,Hyposafe-hypo-02,Nov-09,Jan-10,Mar-11,10-Aug-10,null,10-Mar-14,"Hillerød Sygehus, Hillerød, Denmark",,https://ClinicalTrials.gov/show/NCT01178476
NCT01177163,"A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus",,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Placebo|Drug: JNJ 28431754 300 mg/placebo|Drug: JNJ 28431754 100 mg/placebo,The proportion of patients who need to decrease insulin dosage from prestudy dosage levels because of hypoglycemia|The number of patients with specific treatment-emergent adverse events|The number of patients with symptomatic hypoglycemia and severe hypoglycemia|Plasma concentrations and pharmacokinetics parameters for JNJ 28431754|Plasma glucose concentration-time profiles (pharmacodynamics parameter)|Change in urine glucose excretion (pharmacodynamics parameter),"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,29,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CR014881,May-08,null,Mar-09,6-Aug-10,null,29-May-13,"Chula Vista, California, United States|San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01177163
NCT01176097,"To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes",,Completed,No Results Available,Type 2 Diabetes,Drug: AZD5658|Drug: Placebo,To investigate the safety and tolerability of AZD5658 following oral administration of single ascending doses and to estimate the maximum tolerated dose (MTD).|To investigate the pharmacokinetics of AZD5658 after single ascending oral doses in type 2 diabetes mellitus patients.|Pharmacodynamics (plasma glucose and serum insulin)|Effect of fasting on the pharmacokinetics and explore the pharmacodynamics of AZD5658.,AstraZeneca,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 1,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,D2920C00001,Jul-10,Feb-11,Feb-11,5-Aug-10,null,2-Feb-12,"Research Site, Chula Vista, California, United States",,https://ClinicalTrials.gov/show/NCT01176097
NCT01173991,Carbohydrate Counting in Adults With Type 1 Diabetes Treated With Continuous Subcutaneous Insulin Infusion,GIOCAR,Completed,No Results Available,"Diabetes Mellitus, Type 1|Insulin Pump, Programmable",Behavioral: Carbohydrate counting training,"Glycated haemoglobin (HbA1c)|Fasting glucose|Glycemic variability (mean, sd, min, max, variability range, BG in target range, LBGI, HBGI) based on capillary glucose data|Daily insulin requirement (basal daily requirement, bolus daily requirement, total daily requirement)|Body Mass Index (BMI)|Waist circumference|Quality of life by Diabetes Specific Quality of Life Scale (DSQOLS) questionnaire|Hypoglycemia (capillary glucose<50 mg/dl)",IRCCS San Raffaele,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,61,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GIOCAR,Oct-08,Sep-09,Jan-10,3-Aug-10,null,3-Aug-10,"San Raffaele Scientific Institute, Milano, Italy",,https://ClinicalTrials.gov/show/NCT01173991
NCT01174303,A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec/insulin aspart|Drug: biphasic insulin aspart 30,Area under the Glucose Infusion Rate curve (only for NN5401)|Area under the glucose infusion rate curve (only for biphasic insulin aspart 30),Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 1,28,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN5401-1981|U1111-1114-9373|2009-017280-42,Aug-10,Nov-10,Nov-10,3-Aug-10,null,10-Feb-17,"Novo Nordisk Investigational Site, Graz, Austria",,https://ClinicalTrials.gov/show/NCT01174303
NCT01173926,Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin degludec/insulin aspart|Drug: insulin aspart,Area under the glucose infusion rate curve|Area under the serum insulin degludec concentration-time curve|Area under the serum insulin aspart concentration-time curve,Novo Nordisk A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,27,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN5401-3857|U1111-1114-9348|2010-019641-26,Jul-10,Nov-10,Nov-10,2-Aug-10,null,27-Nov-13,"Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01173926
NCT01170208,Insulin Dosage Software Program for People With Type 1 and Type 2 Diabetes,,Completed,Has Results,Diabetes|Insulin,Device: insulin dose software,Weekly Mean Blood Glucose|Clinical Evaluation of ―Over-ride‖ to Determine if the Reason for ―Over-ride‖ Will Affect a Change in the Algorithm.|Reduction in HbA1c.|Reduction in Fructosamine.|Incidence of Severe or Serious Hypoglycemia.,"HealthPartners Institute|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Hygieia, Inc|International Diabetes Center at Park Nicollet",All,"21 Years to 70 Years   (Adult, Older Adult)",Not Applicable,46,Other|NIH|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,03985-10-A|R41DK085974,Jun-10,Mar-11,Mar-11,27-Jul-10,6-Jan-14,29-Dec-15,"International Diabetes Center, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01170208
NCT01162694,Comparing Internet Blood Glucose Monitoring System and Continuous Glucose Monitoring System,,Suspended,No Results Available,Type 2 Diabetes Mellitus,Other: Remote Blood Glucose Monitoring|Other: Continuous Glucose Monitoring,The primary endpoint is the A1c level or the change in A1c level|The secondary endpoint include severe hypoglycemia defined as requiring external aid (hospital or other).|A secondary endpoint includes adverse events such as unplanned hospitalizations for any cause that last more than 24 hours,Endocrine Research Society,All,"25 Years to 70 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IBGMS vs CGMS,Jul-10,Feb-11,null,15-Jul-10,null,11-Sep-14,"St. Paul's Hospital, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT01162694
NCT01161862,Integration of Continuous Glucose Monitoring Into a BiHormonal Closed-Loop Artificial Pancreas,CL2,Completed,Has Results,Diabetes Mellitus,Device: Bi-hormonal (insulin and glucagon) artificial pancreas,Mean Plasma Blood Glucose Achieved by the Bionic Pancreas (mg/dl)|Percentage of Time Spent With Blood Glucose < 60 mg/dl|Percentage of Time Spent With Blood Glucose <70 mg/dl|Percentage of Time Spent With Blood Glucose 70-180 mg/dl|Insulin Total Daily Dose|Number of Carbohydrate Interventions for Hypoglycemia|Number of Blood Glucose Events < 70 mg/dl|Nadir Blood Glucose in Each Arm,Boston University Charles River Campus|Massachusetts General Hospital|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Juvenile Diabetes Research Foundation|The Leona M. and Harry B. Helmsley Charitable Trust,All,"12 Years and older   (Child, Adult, Older Adult)",Not Applicable,24,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-29293|1R01DK085633-01,Jul-10,Dec-12,Jun-13,14-Jul-10,14-Nov-17,14-Nov-17,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01161862
NCT01161030,Almonds and Diabetes Management,,Completed,No Results Available,Type 2 Diabetes,Other: almonds,,Arizona State University,All,"30 Years to 70 Years   (Adult, Older Adult)",Not Applicable,32,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,almond1,Aug-08,Jun-09,Nov-09,13-Jul-10,null,13-Jul-10,,,https://ClinicalTrials.gov/show/NCT01161030
NCT01159847,Protective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes (LADA),DPP-ⅣLADA,Completed,No Results Available,Type 1 Diabetes,Drug: sitagliptin|Drug: Insulin,The effects of sitagliptin on β cell function and insulin sensitivity of LADA patients|The possible immunomodulatory effects of sitagliptin on LADA patients,European Foundation for the Study of Diabetes|Chinese Medical Association|Eli Lilly and Company,All,"25 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EFSD DPP-Ⅳ LADA,Jan-10,Jul-12,Dec-12,12-Jul-10,null,31-Jul-18,"Diabetes Center, Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China",,https://ClinicalTrials.gov/show/NCT01159847
NCT01159249,Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes,,Completed,No Results Available,Type 2 Diabetes,Drug: Vildagliptin,"Measure AEs, vital signs, laboratory evaluations|HBA1c|Fasting Plasma Glucose|Fasting Insulin|Fasting C-peptide|HOMA-B",Novartis Pharmaceuticals|Novartis,All,"20 Years and older   (Adult, Older Adult)",Phase 3,245,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLAF237A1308,Jun-10,Jan-12,Jan-12,9-Jul-10,null,15-Jun-15,"Novartis Investigative Site, Hunabashi, Chiba, Japan|Novartis Investigative Site, Chikushino, Fukuoka, Japan|Novartis Investigative Site, Itoshima-shi, Fukuoka, Japan|Novartis Investigative Site, Koriyama, Fukushima, Japan|Novartis Investigative Site, Kobe, Hyogo, Japan|Novartis Investigative Site, Kawasaki, Kanagawa, Japan|Novartis Investigative Site, Kawasaki, Kanagawa, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, Japan|Novartis Investigative Site, Yokohama, Kanagawa, Japan|Novartis Investigative Site, Izumisano, Osaka, Japan|Novartis Investigative Site, Hannou, Saitama, Japan|Novartis Investigative Site, Hiki-Gun, Saitama, Japan|Novartis Investigative Site, Kawaguchi, Saitama, Japan|Novartis Investigative Site, Koshigaya city, Saitama, Japan|Novartis Investigative Site, Tokorozawa, Saitama, Japan|Novartis Investigative Site, Edogawa-ku, Tokyo, Japan|Novartis Investigative Site, Hachioji, Tokyo, Japan|Novartis Investigative Site, Katsushika-ku, Tokyo, Japan|Novartis Investigative Site, Minato-ku, Tokyo, Japan|Novartis Investigative Site, Shinagawa-ku, Tokyo, Japan|Novartis Investigative Site, Toshima-ku, Tokyo, Japan|Novartis Investigative Site, Fukuoka, Japan|Novartis Investigative Site, Fukuoka, Japan|Novartis Investigative Site, Fukuoka, Japan",,https://ClinicalTrials.gov/show/NCT01159249
NCT01157403,Autologous Transplantation of Mesenchymal Stem Cells for Treatment of Patients With Onset of Type 1 Diabetes,,Unknown status,No Results Available,Evidence of Liver Transplantation,Biological: Autologous transplantation,C peptide release test,Lu Debin|Third Military Medical University,All,"10 Years to 40 Years   (Child, Adult)",Phase 2|Phase 3,80,Other,Interventional,"Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ldb201001,Jul-10,Jul-14,Aug-14,7-Jul-10,null,18-Jun-13,"Endocrine Department, the south west Hospital of the Third Military Medical University, Chongqing, Chongqing, China",,https://ClinicalTrials.gov/show/NCT01157403
NCT01157611,The Effect of Online Based Mentoring Program on the Blood Glucose and Satisfaction Score in Type 1 Diabetes Patients,,Completed,No Results Available,Type 1 Diabetes,Behavioral: Mentoring program,change of the blood glucose|satisfaction score,Samsung Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,57,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010-05-065,Jul-10,Aug-13,Aug-13,7-Jul-10,null,17-Nov-15,"Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01157611
NCT01157923,MD Logic Pump Advisor- Adults Study,,Completed,No Results Available,Type 1 Diabetes|Insulin Pump Therapy,Device: MD Logic Pump Advisor,Time spent in the normal range|number of iterations required to achieve the maximal meaningful improvement in the primary outcome|time spent above 180 mg/dl|time spent below 70 mg/dl|Number of Hypoglycemic events below 63 mg/dl|Adverse event|glucose variability- area under the curve|Quality of Life Questionaires|Number of MDLAP-recommendations that were rejected by the physician|Number and type of changes in any pump setting per iteration,Rabin Medical Center|Medtronic,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,18,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,rmc005816ctil,Jul-10,Jul-16,Jul-16,7-Jul-10,null,11-Jan-17,"Schneider Children's Medical center, Petaach-Tikva, Israel|University Children's Hospital, Ljubljana, Slovenia",,https://ClinicalTrials.gov/show/NCT01157923
NCT01155284,Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes,REPAIR-T1D,Completed,Has Results,Type 1 Diabetes,Drug: Sitagliptin and Lansoprazole|Drug: Placebo,2 Hour C-peptide AUC in Response to MMTT,Sanford Health|Juvenile Diabetes Research Foundation,All,"11 Years to 45 Years   (Child, Adult)",Phase 2,70,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",REPAIR-T1D,Aug-10,May-14,Mar-15,1-Jul-10,18-Sep-17,18-Sep-17,"Rady Children's Hospital, San Diego, California, United States|Children's - St. Paul, Saint Paul, Minnesota, United States|Sanford Research/USD, Sioux Falls, South Dakota, United States",,https://ClinicalTrials.gov/show/NCT01155284
NCT01154348,Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus,,Completed,No Results Available,Type 2 Diabetes Mellitus,"Drug: S-707106|Drug: Placebo|Drug: Metformin, S-707106 plus metformin|Drug: Metformin, placebo plus metformin",Safety and pharmacokinetics of multiple-dose oral administration of S-707106 in fed state in patients with type 2 diabetes mellitus|Safety and pharmacokinetics of multiple-dose oral co-administration of S-707106 and metformin in fed state in patients with type 2 diabetes mellitus|The effect of multiple doses of S-707106 on pharmacokinetics of metformin|The effect of multiple doses of metformin on pharmacokinetics of S-707106,Shionogi|Shionogi Inc.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,34,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1011N0913,Jun-10,Nov-10,Dec-10,30-Jun-10,null,27-Apr-18,"Dennis Ruff, MD, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01154348
NCT01153048,Trial on an Educative Structured Intervention by Peer Educators to Improve HbA1c of Patients With Type 2 Diabetes in the Sikasso Region in Mali,,Unknown status,No Results Available,Type 2 Diabetes,Other: Intensification of education,"compare the improvement of HbA1c 1 year after an intervention led by peer educators, versus a conventional care in health centre|Study the evolution of bio clinical parameters: fasting glucose, weight, BMI, blood pressure, waist size",Sante Diabete Mali|Société Francophone du Diabète|French Development Agency|Centre hospitalo-universiaire du Point G de Bamako (CHU Pt G),All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 1,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care,SDMSFD01,Jun-10,Jul-11,Sep-11,29-Jun-10,null,21-Jul-11,"ONG Santé Diabète Mali, Bamako, Mali",,https://ClinicalTrials.gov/show/NCT01153048
NCT01146886,"Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI135585 XX Administered as Tablet and as Solution in Healthy Volunteers",,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Placebo to BI 135585|Drug: BI 135585,"Change from baseline in Physical examination (occurrence of findings)|Change from baseline in Vital signs (blood pressure [BP], pulse rate [PR], respiratory rate [RR])|Change from baseline in 12-lead ECG with special attention to QTc prolongation|Cardiopulmonary monitoring resulting in clinically relevant findings|Change from baseline in Clinical laboratory parameters including hormones of the HPA axis and thyroid gland|Number of patients with Adverse events (AE)|Assessment of tolerability by the investigator|AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)|(5α-THF + 5β-THF)/THE ratio as an indicator of 11β-HSD1 inhibition|AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)|Cmax (maximum measured concentration of the analyte in plasma)|tmax (time from dosing to maximum measured concentration)|%AUCtz-∞ (percentage of the AUC0-∞ that was obtained by extrapolation)|λz (terminal rate constant in plasma)|t1/2 (terminal half-life of the analyte in plasma)|MRToral (mean residence time of the analyte in the body after oral administration)|CL/F (total/apparent clearance of the analyte in plasma after extravascular administration)|Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)|Aet1-t2 (amount of analyte eliminated in urine from timepoint t1 to timepoint t2) SRD part only|fet1-t2 (fraction of analyte eliminated in urine from timepoint t1 to timepoint t2) SRD part only|CLR,t1-t2 (renal clearance of the analyte from timepoint t1 to timepoint t2) SRD part only[|UFF/UFE ratio as an indicator of 11β-HSD2 inhibition|Total urinary corticosteroids (5α-THF + 5β-THF + THE + UFF + UFE) as an indicator of the activation of the HPA axis",Boehringer Ingelheim,Male,18 Years to 45 Years   (Adult),Phase 1,60,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,1283.1|2010-018856-28,Jun-10,Sep-10,null,22-Jun-10,null,1-Nov-13,"1283.1.1 Boehringer Ingelheim Investigational Site, Biberach, Germany",,https://ClinicalTrials.gov/show/NCT01146886
NCT01147276,Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes,,Completed,No Results Available,Diabetes|Hypoglycemia,Drug: Vildagliptin,Glucagon response to hypoglycemia|Catecholamine response to hypoglycemic,Lund University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,28,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",Lund University Diabetes 002,Sep-10,Sep-11,Dec-11,22-Jun-10,null,25-Sep-12,"Department of Clinical Sciences Lund, Lund University, Lund, Sweden",,https://ClinicalTrials.gov/show/NCT01147276
NCT01147861,"A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics",,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: GSK256073|Other: Placebo,"Weighted mean AUC for glucose|Weighted mean AUC for NEFA, glycerol, triglycerides, insulin, and C-peptide",GlaxoSmithKline,All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 1,39,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,114187,1-Jul-10,7-Sep-10,7-Sep-10,22-Jun-10,null,14-Jun-17,"GSK Investigational Site, Anniston, Alabama, United States|GSK Investigational Site, Miami Gardens, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01147861
NCT01148680,Trial Comparing Metabolic Efficiency of Islet Graft to Intensive Insulin Therapy for Type 1 Diabetes's Treatment,TRIMECO,Unknown status,No Results Available,"Diabetes Mellitus, Type 1",Biological: Islet Graft,"ß score evaluation 6 months after first infusion (group 1 'immediate registration on infusion waiting list') or 6 months after inclusion (group 2: 'delayed registration on infusion waiting list')|Evaluation of metabolism indicators : ß-score and individual analysis of the 4 components of the ß-score|Measure of quality of life (SF36, DQOL, DHP)|Cost evaluation of islet cell infusion|Evaluation of side effects and iatrogenic effects","University Hospital, Grenoble",All,18 Years to 64 Years   (Adult),Phase 3,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCIC 08 31,Jun-10,Aug-17,Dec-17,22-Jun-10,null,21-Jul-17,"University Hospital, Department of Endocrinology, Strasbourg, Alsace, France|University Hospital Gabriel Montpied, Department of Endocrinology, Clermont Ferrand, Auvergne, France|University Hospital Besançon, Department of Endocrinology, Besançon, Franche-Comté, France|University Hospital, Department of Endocrinology, Montpellier, Languedoc-Roussillon, France|University Hospital, Department of Endocrinology, Nancy, Lorraine, France|University Hospital, Department of General Surgery and Endocrinology, Lille, Nord Pas de Calais, France|University Hospital, Department of Endocrinology, Grenoble, Rhône-Alpes, France|HCL Sud, Department of Endocrinology, Lyon, Rhône-Alpes, France|Hopitaux Universitaires de Genève, Department of Visceral Surgery and Transplant, Geneve, Switzerland",,https://ClinicalTrials.gov/show/NCT01148680
NCT01148862,Assess the Efficacy of the Low Glucose Suspend (LGS) Feature in the MiniMed Paradigm® X54 System,,Completed,Has Results,Type 1 Diabetes Mellitus,Device: The MiniMed Paradigm® X54 System,The Primary Treatment Comparison is the Evaluation of the Duration (Minutes) of Induced Hypoglycemia.|The Primary Treatment Comparison is the Evaluation of the Severity (Milligrams Per Deciliter) of Induced Hypoglycemia.,Medtronic Diabetes,All,"16 Years to 60 Years   (Child, Adult)",Not Applicable,50,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CEP235/Z25,Jun-10,Nov-11,Nov-11,22-Jun-10,30-Mar-17,30-Mar-17,"AMCR Institute, Escondido, California, United States|Stanford University, Stanford, California, United States|Barbara Davis Center of Childhood Diabetes, Aurora, Colorado, United States|Barbara Davis Center for Childhood Diabetes, Denver, Colorado, United States|Rainier Clinical Research Institute, Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT01148862
NCT01146678,Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Insulin glargine HOE901|Drug: Lixisenatide AVE0010,Area under the plasma lixisenatide concentration curve (LIX-AUClast)|Lixisenatide maximum plasma/serum peak concentration (LIX-Cmax)|Area under the plasma lixisenatide concentration curve (AUC)|Time to Cmax (Tmax ) for lixisenatide|Area under the body weight standardized glucose infusion rate curve (GIR) within 24 h (GIR-AUC0-24)|Time to 50% of the GIR-AUC within 24 h (T50%-GIR AUC0-24)|Maximum smoothed body weight standardized glucose infusion rate GIRmax|Time to GIRmax (GIR-Tmax),Sanofi,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,22,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BDR11578|2010-019228-30|U1111-1116-8960,Jun-10,Sep-10,Jan-11,17-Jun-10,null,2-Mar-11,"Sanofi-Aventis Administrative Office, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT01146678
NCT01145547,Continuous Glucose Monitoring to Measure Effect of Glycemic Index,,Completed,Has Results,Type 1 Diabetes Mellitus,Device: Dexcom Seven® Plus Continuous Glucose Monitoring sensor,Mean Area Under the Curve for Rise in Breakfast Post-prandial.,Legacy Health System|Juvenile Diabetes Research Foundation,All,"Child, Adult, Older Adult",Not Applicable,7,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,kw01,Apr-09,Oct-09,Oct-09,16-Jun-10,5-Oct-15,23-Oct-15,"Legacy Health System--Holladay Park Campus, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT01145547
NCT01143168,Stem Cell Therapy for Type 1 Diabetes Mellitus,,Unknown status,No Results Available,Type 1 Diabetes Mellitus,Biological: autologous bone marrow mononuclear cells and umbilical cord mesenchymal stem cells,Rate of reducing exogenous insulin requirement; Hemoglobin A1c; Fast blood glucose (FBG) and postmeal blood glucose (PBG); C-peptide levels.|Serious adverse event frequency and severity,Cellonis Biotechnology Co. Ltd.,All,18 Years to 50 Years   (Adult),Phase 1,24,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Cellonis-CR-1.3,Aug-10,Aug-11,Dec-11,14-Jun-10,null,14-Jun-10,"Armed Police General Hospital, P. R. China, Beijing, China",,https://ClinicalTrials.gov/show/NCT01143168
NCT01140438,Treatment of Latent Autoimmune Diabetes of the Adult,LADA,Completed,No Results Available,Diabetes,Drug: metformin+ NPH insulin|Drug: metformin + sitagliptin +/- repaglinide,insulin secretion|glycemic control,Norwegian University of Science and Technology,All,"30 Years to 75 Years   (Adult, Older Adult)",Not Applicable,64,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LADA,Mar-09,Nov-18,Nov-18,9-Jun-10,null,20-Mar-19,"Valdemar Grill, Trondheim, Norway",,https://ClinicalTrials.gov/show/NCT01140438
NCT01138488,"A Trial Investigating the Total Exposure of NN5401 (Insulin Degludec/Insulin Aspart) in Children, Adolescents and Adult Subjects With Type 1 Diabetes",,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec/insulin aspart,Area under the serum insulin degludec concentration-time curve|Area under the serum insulin aspart concentration-time curve|Maximum observed insulin degludec concentration of NN5401 (insulin degludec/insulin aspart) observed|Maximum observed insulin aspart concentration of NN5401 (insulin degludec/insulin aspart) observed,Novo Nordisk A/S|HNEC TEST,All,"6 Years to 65 Years   (Child, Adult, Older Adult)",Phase 1,38,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN5401-1982|U1111-1113-6874|2009-016779-31,Jun-10,Nov-10,Nov-10,7-Jun-10,null,10-Feb-17,"Novo Nordisk Investigational Site, Hannover, Germany",,https://ClinicalTrials.gov/show/NCT01138488
NCT01135927,A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin detemir,Area under the NN1250 GIR (glucose infusion rate) curve|Area under the serum insulin detemir concentration-time curve,Novo Nordisk A/S,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 1,22,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1250-1996|U1111-1113-6722|JapicCTI-101158,Jun-10,Oct-10,Oct-10,3-Jun-10,null,20-Jan-17,"Novo Nordisk Investigational Site, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT01135927
NCT01134107,Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Insulin Lispro 6 Day (6D)|Drug: Insulin Aspart 6 Day (6D),"Mean of Last Six 7-point Self Monitored Blood Glucose (SMBG) Taken on Day 6 for Insulin Lispro 6D and Insulin Aspart 6D Pump Reservoir In-use|Mean SMBG|Mean Daily Insulin Dose (Total, Basal, and Bolus)|Change From Baseline to 12 Weeks for Each Treatment in Glycated Hemoglobin A1c (HbA1c) Values|Number of Participants Who Achieve or Maintain a Glycated Hemoglobin A1c (HbA1c) Less Than or Equal to 6.5% and Less Than 7%",Eli Lilly and Company,All,"13 Years and older   (Child, Adult, Older Adult)",Phase 3,133,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",12175|F3Z-MC-IOPW,Nov-10,Dec-11,Dec-11,31-May-10,26-Oct-12,11-Apr-13,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caen, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Corbeil-Essonnes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Rochelle, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marseille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montpellier, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Narbonne, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ludwigshafen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Münster, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuwied, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Potsdam, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bekescsaba, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nyiregyhaza, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zalaegerszeg, Hungary",,https://ClinicalTrials.gov/show/NCT01134107
NCT01129232,"Diabetes Virus Detection Project, Intervention With GAD-alum",DiViD,Terminated,No Results Available,"Diabetes, Type I|Enterovirus Infections|Autoimmunity",Drug: GAD-alum|Other: Placebo,"Intensity of insulitis in proportion to living, insulin-staining beta cells in pancreatic biopsies|Prevalence of virus infected islets in pancreatic biopsies|Residual insulin secretion (C-peptide) measured by Mixed Meal Tolerance Test|Insulin dosage/kilo bodyweight/24 hours|Glycosylated hemoglobin A1 (HbA1c)",Oslo University Hospital,All,18 Years to 40 Years   (Adult),Phase 2,6,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2009/1907 (REK)|2008-002027-82,Jan-11,Jan-13,Jan-13,24-May-10,null,17-May-18,"Endokrinologisk poliklinikk, Oslo Universitetssykehus Aker, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT01129232
NCT01129258,Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes,,Completed,No Results Available,"Diabetes Mellitus|Diabetes Mellitus, Type 2|Glucose Metabolism Disorders",Drug: PF-04991532|Drug: Placebo,"Safety Endpoints: Safety and tolerability of PF-04991532 will be assessed by physical examinations, adverse event monitoring, 12-lead ECGs, vital sign, and clinical safety laboratory measurements.|Single-Dose PK Endpoints for PF-04991352: Cmax, Tmax, and AUC(0-tau).|Multiple-Dose PK Endpoints for PF-04991532: Cmax(ss), Tmax(ss), AUC(0-tau,ss), AUC(0-last), half-life, Cmin(ss), Cav(ss), Ae%, CL/F, Vz/F, CLrenal; accumulation ratios AUC(0-tau,ss)/AUC(0-tau,sd) and Cmax(ss)/Cmax(sd), as the data permit.|PD Endpoint: glucose excursion (change from Day -1 baseline) in response to a liquid meal test (MMTT) on Days 1 and 14.|Insulin and C-peptide (changes from Day -1 baseline) during an MMTT on Days 1 and 14.|Mean daily glucose (change from Day -1 baseline) on Days 1 and 14.|Fasting plasma glucose (change from Day -1 baseline) on Days 1, 3, 6, 10, and 14.|Lipids (change from Day -1 baseline), including: TG, TC, HDL-cholesterol, LDL-cholesterol, FFA, beta-OHB, and ACAC, at times specified in the SOA.|Lactate (change from Day -1 baseline), at times specified in the SOA.",Pfizer,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,110,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)",B2611004,Jun-10,Dec-10,Dec-10,24-May-10,null,9-Mar-11,"Pfizer Investigational Site, Chula Vista, California, United States|Pfizer Investigational Site, Fountain Valley, California, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01129258
NCT01127308,"A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)",,Completed,No Results Available,Type 2 Diabetes Mellitus (T2DM),Drug: Ertugliflozin,"Mean Percent of Dose Recovered in Urine and Feces Following a Single Oral Dose of [^14C]Ertugliflozin (100 µCi).|Area under the plasma concentration-time curve (AUC) from time 0 to time of the last quantifiable concentration (AUClast) for ertugliflozin|AUC from Hour 0 to infinity (AUCinf) for ertugliflozin|Maximum plasma concentration (Cmax) of ertugliflozin|Time taken to reach the maximum observed plasma concentration (Tmax) of ertugliflozin|Ertugliflozin half life (t1/2)|Amount of Ertugliflozin and metabolites in plasma, urine, and feces|Number of Participants Experiencing an Adverse Event (AE)",Merck Sharp & Dohme Corp.|Pfizer,Male,18 Years to 55 Years   (Adult),Phase 1,6,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,8835-038,Jun-10,Jul-10,Jul-10,20-May-10,null,23-Mar-16,,,https://ClinicalTrials.gov/show/NCT01127308
NCT01123083,Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2,DEFEND-2,Completed,Has Results,"Diabetes Mellitus, Type 1",Biological: Otelixizumab|Biological: Placebo,"Change From Baseline in 2 Hour Mixed Meal-stimulated C-peptide Area Under Curve (AUC) (Normalized for 120-minute Time Interval) at Month 12|Change From Baseline in 2 Hour Mixed Meal-stimulated C-peptide AUC (Normalized for 120-minute Time Interval) at Week 12 and 6 Months|Change From Baseline in Stimulated C-Peptide Mean AUC at Week 12, Month 6, 12 and 18|Number of Participants With Responder Status|Change From Baseline in Mean Daily Insulin Use Over 7 Consecutive Days During the 2 Weeks Prior to the Assessment|Change From Baseline in HbA1c Levels Over 7 Consecutive Days During the 2 Weeks Prior to the Assessment|Average Number of Severe Hypoglycemic Events and Documented Symptomatic Hypoglycemic Events From Baseline to Month 12|Percentage of Participants With Change From Baseline in Severe Hypoglycemic Events and Documented Symptomatic Hypoglycemic Events at Month 12|Composite Rank Sum: HbA1c and Exogenous Insulin Use at 6 and 12 Months|Composite Rank Sum: C-Peptide AUC, HbA1c and Exogenous Insulin Use at 6 and 12 Months",GlaxoSmithKline|Juvenile Diabetes Research Foundation,All,12 Years to 17 Years   (Child),Phase 3,179,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",115494|TRX4018,17-May-10,9-Mar-12,9-Mar-12,14-May-10,15-Sep-17,15-Sep-17,"GSK Investigational Site, Roma, Italy",,https://ClinicalTrials.gov/show/NCT01123083
NCT01123122,A Comparison of Strict Glucose Control With Usual Care at the Time of Islet Cell Transplantation,,Withdrawn,No Results Available,"Diabetes Mellitus, Type 1|Islet Transplantation",Other: Strict glucose control,Islet cell function,Vancouver Coastal Health,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,VGHEndo0510,Sep-11,Sep-15,Sep-15,14-May-10,null,1-Apr-15,"Vancouver General Hospital, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT01123122
NCT01123187,Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation,,Completed,No Results Available,Type 1 Diabetes|Organ Transplantation|Immunosuppression,Procedure: islet transplantation,Composite criteria: insulin independence and Glycosylated Hemoglobin (HbA1c) under 8% at one year after the transplantation|The number of adverse events|Number of severe episodes of hypoglycemia|Evaluation of Diabetes complications|Lipid metabolism|Evaluation of kidney function,"University Hospital, Lille|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,14,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CP 95/120|98001|DGS 980032,Mar-03,Mar-14,Apr-16,14-May-10,null,10-Jan-18,"University Hospital of Lille, Lille, Nord, France",,https://ClinicalTrials.gov/show/NCT01123187
NCT01122446,Diabetes Prevention - Immune Tolerance,DIAPREV-IT,Completed,Has Results,Prediabetes|Type 1 Diabetes,Other: Placebo comparator|Drug: Diamyd,Adverse Events|Number of Participants With Type 1 Diabetes|Fasting Glucose Over Time|120 Minutes Glucose From OGTT Over Time|AUC Glucose From OGTT Over Time|Fasting C-peptide Over Time|120 Min C-peptide on OGTT Over Time|AUC C-peptide From OGTT Over Time|HbA1c|First-phase Insulin Response From IvGTT Over Time,Lund University|Region Skane,All,"4 Years to 18 Years   (Child, Adult)",Phase 2,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",DIAPREV/2008,Apr-09,Dec-16,Dec-16,13-May-10,6-May-19,6-May-19,"Clinical Research Center, Pediatric Endocrinology, Jan Waldenströms gata 35, 60:11, Malmö, Sweden",,https://ClinicalTrials.gov/show/NCT01122446
NCT01121029,Hematopoietic Stem Cell Transplantation in Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes Mellitus,Procedure: Autologous hematopoietic stem cell transplantation,C-peptide levels before and after the hematopoietic stem cell transplantation|Serum levels of Hb A1C before and after the hematopoietic stem cell transplantation,Dra. Olga Graciela Cantu Rodriguez|Hospital Universitario Dr. Jose E. Gonzalez,All,"2 Years to 35 Years   (Child, Adult)",Phase 1|Phase 2,15,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EN10-011,May-10,Dec-11,Dec-12,12-May-10,null,10-Dec-12,"Hospital Universitario Dr. José Eleuterio González, Monterrey, Nuevo Leon, Mexico",,https://ClinicalTrials.gov/show/NCT01121029
NCT01121276,A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Drug: Faster-acting insulin aspart|Drug: insulin aspart,Area under the blood glucose concentration-time curve,Novo Nordisk A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,82,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1218-3824|U1111-1113-6897|2009-017627-25,Apr-10,Sep-10,Sep-10,12-May-10,null,18-Jan-17,"Novo Nordisk Investigational Site, Chula Vista, California, United States",,https://ClinicalTrials.gov/show/NCT01121276
NCT01121289,A Trial Investigating NN1218 in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: NN1218|Drug: insulin aspart,Area under the serum NN1218 concentration-time curve,Novo Nordisk A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,26,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1218-3808|U1111-1113-6955|2009-017121-19,Apr-10,Jul-10,Jul-10,12-May-10,null,10-Dec-13,"Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01121289
NCT01120444,Study on the Effects on Blood Glucose Following Intradermal and Subcutaneous Dosing of Insulin in Diabetic Patients,,Completed,No Results Available,Diabetes,Device: BD Research Catheter with 34G x 1.5 mm needle|Device: Subcutaneous delivery of insulin using Disetronic Accu-Chek Rapid D infusion set,Blood Glucose|Insulin levels,"Becton, Dickinson and Company",All,18 Years to 55 Years   (Adult),Phase 1|Phase 2,20,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,BDT-09-ADC004,Apr-10,Oct-10,Oct-10,11-May-10,null,18-Apr-11,"Profil Institute of Clinical Research, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01120444
NCT01120912,Safety and Efficacy of Single Administration of Oshadi Oral Insulin in Type I Diabetes Patients,,Completed,No Results Available,Diabetes,Drug: Oshadi Oral Insulin,Adverse events occurrence|Evaluate the glucose lowering effect of Oshadi Oral Insulin,Oshadi Drug Administration,All,"18 Years and older   (Adult, Older Adult)",Phase 1,8,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,OS-INS-P1-01,Oct-10,Feb-11,Feb-11,11-May-10,null,17-Apr-12,"Assaf Harofe Medical Center, Zrifin, Beer-Yaakov, Israel",,https://ClinicalTrials.gov/show/NCT01120912
NCT01117350,Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure,EAGLE,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Insulin glargine|Drug: Liraglutide|Drug: Metformin,Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) <7% at the End of the Comparative Period|Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) Has Decreased But Remains ≥7% at the End of the Comparative Period|Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) Has Increased at the End of the Comparative Period|Glycosylated Haemoglobin (HbA1c): Change From Baseline to the End of Comparative Period|Glycosylated Haemoglobin (HbA1c): Change From Beginning to the End of the Extension Period|Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) <7% at the End of the Extension Period|Self-Monitored Fasting Plasma Glucose (SMFPG) Measurements: Change From Baseline to the End of the Comparative Period|Self-Monitored Fasting Plasma Glucose (SMFPG) Measurements: Change From Beginning to the End of the Extension Period|Self-Monitored 7-point Plasma Glucose (PG) Profile: Change From Baseline to the End of the Comparative Period|Self-Monitored 7-point Plasma Glucose (PG) Profile: Change From Beginning to the End of the Extension Period|Body Weight: Change From Baseline to the End of the Comparative Period|Body Weight: Change From Beginning to End of the Extension Period|Daily Dose of Insulin Glargine|Daily Dose of Liraglutide|Daily Dose of Insulin Glargine Administered During the Extension Period|Hypoglycemia Occurence: Number of Patients With at Least One Episode of Symptomatic / Severe Symptomatic Hypoglycemia During the Comparative Period|Hypoglycemia Occurence: Number of Patients With at Least One Episode of Symptomatic / Severe Symptomatic Hypoglycemia During the Extension Period,Sanofi,All,"35 Years to 75 Years   (Adult, Older Adult)",Phase 4,978,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LANTU_C_03680|2010-018437-21|U1111-1116-9684,Jul-10,Oct-12,Mar-13,5-May-10,29-Jan-14,11-Apr-14,"Investigational Site Number 840023, Birmingham, Alabama, United States|Investigational Site Number 840002, Goodyear, Arizona, United States|Investigational Site Number 840047, Phoenix, Arizona, United States|Investigational Site Number 840017, La Jolla, California, United States|Investigational Site Number 840036, La Mesa, California, United States|Investigational Site Number 840037, Loma Linda, California, United States|Investigational Site Number 840045, Long Beach, California, United States|Investigational Site Number 840048, Mission Hills, California, United States|Investigational Site Number 840033, Mission Viejo, California, United States|Investigational Site Number 840019, Palm Springs, California, United States|Investigational Site Number 840039, San Diego, California, United States|Investigational Site Number 840042, San Diego, California, United States|Investigational Site Number 840043, Tustin, California, United States|Investigational Site Number 840028, Denver, Colorado, United States|Investigational Site Number 840034, Grand Junction, Colorado, United States|Investigational Site Number 840026, Longmont, Colorado, United States|Investigational Site Number 840022, Lawrenceville, Georgia, United States|Investigational Site Number 840029, Roswell, Georgia, United States|Investigational Site Number 840009, Arlington Heights, Illinois, United States|Investigational Site Number 840051, Springfield, Illinois, United States|Investigational Site Number 840050, Indianapolis, Indiana, United States|Investigational Site Number 840031, Kansas City, Kansas, United States|Investigational Site Number 840004, Paducah, Kentucky, United States|Investigational Site Number 840010, Rockville, Maryland, United States|Investigational Site Number 840038, Eagan, Minnesota, United States|Investigational Site Number 840030, Minneapolis, Minnesota, United States|Investigational Site Number 840012, St Louis, Missouri, United States|Investigational Site Number 840044, St. Louis, Missouri, United States|Investigational Site Number 840015, Atco, New Jersey, United States|Investigational Site Number 840008, Blackwood, New Jersey, United States|Investigational Site Number 840027, Mineola, New York, United States|Investigational Site Number 840011, Staten Island, New York, United States|Investigational Site Number 840005, Hickory, North Carolina, United States|Investigational Site Number 840052, Winston-Salem, North Carolina, United States|Investigational Site Number 840049, Fargo, North Dakota, United States|Investigational Site Number 840006, Bryan, Ohio, United States|Investigational Site Number 840035, Cincinnati, Ohio, United States|Investigational Site Number 840016, Carnegie, Pennsylvania, United States|Investigational Site Number 840020, Uniontown, Pennsylvania, United States|Investigational Site Number 840024, Rapid City, South Dakota, United States|Investigational Site Number 840001, Dallas, Texas, United States|Investigational Site Number 840007, Dallas, Texas, United States|Investigational Site Number 840013, Houston, Texas, United States|Investigational Site Number 840014, Renton, Washington, United States|Investigational Site Number 840046, Spokane, Washington, United States|Investigational Site Number 040-006, Salzburg, Austria|Investigational Site Number 040-007, Salzburg, Austria|Investigational Site Number 040-003, Stockerau, Austria|Investigational Site Number 040-005, Vienna, Austria|Investigational Site Number 040-002, Vienna, Austria|Investigational Site Number 040-001, Vienna, Austria|Investigational Site Number 040-004, Vienna, Austria|Investigational Site Number 076-004, Belém, Brazil|Investigational Site Number 076-007, Fortaleza, Brazil|Investigational Site Number 076-001, Fortaleza, Brazil|Investigational Site Number 076-006, Fortaleza, Brazil|Investigational Site Number 076-005, Marília, Brazil|Investigational Site Number 076-002, São Paulo, Brazil|Investigational Site Number 124-003, Mississauga, Canada|Investigational Site Number 124-001, Montreal, Canada|Investigational Site Number 124-006, Montreal, Canada|Investigational Site Number 124-004, Toronto, Canada|Investigational Site Number 124-008, Vancouver, Canada|Investigational Site Number 124-007, Victoria, Canada|Investigational Site Number 203001, Hradec Kralove, Czech Republic|Investigational Site Number 203003, Krnov, Czech Republic|Investigational Site Number 203005, Kromeriz, Czech Republic|Investigational Site Number 203002, Olomouc, Czech Republic|Investigational Site Number 203006, Praha 5, Czech Republic|Investigational Site Number 246003, Harjavalta, Finland|Investigational Site Number 246001, Kuopio, Finland|Investigational Site Number 246002, Oulu, Finland|Investigational Site Number 246004, Turku, Finland|Investigational Site Number 250-007, Annecy, France|Investigational Site Number 250-017, Bois Guillaume Cedex, France|Investigational Site Number 250-003, Boulogne Billancourt, France|Investigational Site Number 250-011, Brest, France|Investigational Site Number 250-008, Cahors Cedex 9, France|Investigational Site Number 250-012, Corbeil Essonnes, France|Investigational Site Number 250-009, La Rochelle Cedex 1, France|Investigational Site Number 250-004, Le Creusot, France|Investigational Site Number 250-006, Mantes La Jolie, France|Investigational Site Number 250-021, Nanterre, France|Investigational Site Number 250022, Strasbourg, France|Investigational Site Number 250-020, Strasbourg, France|Investigational Site Number 250-002, Toulouse, France|Investigational Site Number 250-016, Venissieux, France|Investigational Site Number 300003, Athens, Greece|Investigational Site Number 300004, Athens, Greece|Investigational Site Number 300001, Haidari, Athens, Greece|Investigational Site Number 372001, Dublin 4, Ireland|Investigational Site Number 376004, Hadera, Israel|Investigational Site Number 376002, Petah Tiqwa, Israel|Investigational Site Number 376003, Tel-Aviv, Israel|Investigational Site Number 484004, Guadalajara, Mexico|Investigational Site Number 484001, Mexico, Mexico|Investigational Site Number 484002, Mexico, Mexico|Investigational Site Number 484003, Zapopan, Mexico|Investigational Site Number 528001, Beek, Netherlands|Investigational Site Number 528006, Enschede, Netherlands|Investigational Site Number 528002, Hoogeveen, Netherlands|Investigational Site Number 528007, Nijverdal, Netherlands|Investigational Site Number 528003, Rotterdam, Netherlands|Investigational Site Number 528004, s-Hertogenbosch, Netherlands|Investigational Site Number 528005, Woerden, Netherlands|Investigational Site Number 643-009, Kazan, Russian Federation|Investigational Site Number 643008, Kirov, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643006, Samara, Russian Federation|Investigational Site Number 643007, Samara, Russian Federation|Investigational Site Number 643005, Saratov, Russian Federation|Investigational Site Number 643004, St-Petersburg, Russian Federation|Investigational Site Number 643003, St-Ptetersburg, Russian Federation|Investigational Site Number 703002, Bratislava, Slovakia|Investigational Site Number 703004, Kosice, Slovakia|Investigational Site Number 703001, Nitra, Slovakia|Investigational Site Number 703005, Nove Mesto nad Vahom, Slovakia|Investigational Site Number 703003, Zilina, Slovakia|Investigational Site Number 724007, Bilbao, Spain|Investigational Site Number 724006, Cádiz, Spain|Investigational Site Number 724001, Las Palmas de Gran Canaria, Spain|Investigational Site Number 724005, LLeida, Spain|Investigational Site Number 724008, Madrid, Spain|Investigational Site Number 724003, Málaga, Spain|Investigational Site Number 724009, Sabadell, Spain|Investigational Site Number 721002, Valencia, Spain|Investigational Site Number 724004, Valencia, Spain|Investigational Site Number 724010, Vigo, Spain|Investigational Site Number 752-002, Göteborg, Sweden|Investigational Site Number 752-005, Karlskoga, Sweden|Investigational Site Number 752-006, Motala, Sweden|Investigational Site Number 752-001, Stockholm, Sweden|Investigational Site Number 752-03, Ängelholm, Sweden|Investigational Site Number 752-007, Örebro, Sweden|Investigational Site Number 792-001, Antalya, Turkey|Investigational Site Number 792-002, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT01117350
NCT01115621,BABYDIET-Study - Primary Prevention of Type 1 Diabetes in Relatives at Increased Genetic Risk,,Unknown status,No Results Available,Type 1 Diabetes,Other: Glutenfree diet during the first year of life,Effect of dietary intervention on the development of islet autoantibodies|Effect of dietary intervention on the development of Type 1 diabetes.,"Institut fur Diabetesforschung, Munich, Germany",All,up to 3 Months   (Child),Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ZI310/14-1,Feb-01,Dec-09,Dec-16,4-May-10,null,4-May-10,"Institut für Diabetesforschung, München, Germany",,https://ClinicalTrials.gov/show/NCT01115621
NCT01116180,Cognitive Function and Electrocardiogram (ECG) During Hypoglycemia and Blockade of the Renin-angiotensin System,,Completed,No Results Available,Type 1 Diabetes|Hypoglycemia,Drug: Angiotensin II receptor antagonists (Candesartan)|Drug: Placebo,Cognitive function and brain cortical activity assessed by EEG|Symptoms of hypoglycaemia assessed by Edinburgh Hypoglycaemia Symptom Score questionnaire|Hormonal counter-regulatory response and substrates|Blood pressure and pulse|Cardiac conduction evaluated by a three channel digital Holter Monitor.,"Louise Faerch|Hillerod Hospital, Denmark",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,9,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",HypoRas,Apr-10,Aug-12,Feb-13,4-May-10,null,5-Feb-13,"Department of Cardiology and Endocrinology, Hillerød Hospital, Hillerød, Denmark",,https://ClinicalTrials.gov/show/NCT01116180
NCT01114542,A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin glargine,Area under the glucose infusion rate curve during one dosing interval of Insulin Degludec at steady state|Area under the glucose infusion rate curve during one dosing interval of insulin glargine at steady state|Area under the concentration-time curve during one dosing interval at steady state for Insulin Degludec|Area under the concentration-time curve during one dosing interval at steady state for insulin glargine,Novo Nordisk A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,66,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1250-1993|2009-015897-36|U1111-1113-6772,3-May-10,10-Aug-10,10-Aug-10,3-May-10,null,9-Oct-17,"Novo Nordisk Investigational Site, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01114542
NCT01113801,A Study in Participants With Diabetic Kidney Disease,,Terminated,Has Results,Diabetic Kidney Disease|Diabetic Nephropathy|Diabetic Glomerulosclerosis,Drug: LY2382770|Drug: Placebo,Change in Log Transformed (In) Serum Creatinine From Baseline to 12 Month Endpoint|Change in Log Transformed (ln) Urine Protein/Creatinine Ratio From Baseline to 12 Month Endpoint|Population Pharmacokinetics (PK) - Model-Estimated Area Under the Concentration -Time Curve (AUC ) Over a Dosing Interval|Log Transformed (ln) Serum Creatinine Slope of Change From Baseline Through 12 Months|Estimated Glomerular Filtration Rate (eGFR) Slope of Change From Baseline Through 12 Months,Eli Lilly and Company,All,"25 Years and older   (Adult, Older Adult)",Phase 2,417,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",10168|H9V-MC-GFRF,Jul-10,May-14,Jul-14,30-Apr-10,13-Dec-17,13-Dec-17,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Inglewood, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Northridge, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denver, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Port Charlotte, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Idaho Falls, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kenner, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rockville, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kansas City, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chapel Hill, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charlotte, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durham, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenville, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winston-Salem, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beachwood, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bend, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Providence, Rhode Island, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orangeburg, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lufkin, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint George, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suffolk, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milwaukee, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Camperdown, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Concord, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gosford, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liverpool, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Adelaide, South Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Launceston, Tasmania, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Box Hill, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fitzroy, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Melbourne, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Parkville, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Reservoir, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nedlands, Western Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cesky Krumlov, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Decin, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jilemnice, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liberec, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ostrava, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prague, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tabor, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Teplice, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Grenoble, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lyon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nanterre Cedex, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valenciennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vandoeuvre Les Nancy, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baja, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Balatonfured, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gyongyos, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gyor, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaposvar, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagykanizsa, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szeged, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szigetvar, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zalaegerszeg, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ashkelon, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hadera, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haifa, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Holon, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jerusalem, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kfar Saba, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nahariya, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rehovot, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Safed, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Aviv, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Hashomer, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zerifin, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cidra, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio Piedras, Puerto Rico",,https://ClinicalTrials.gov/show/NCT01113801
NCT01112696,An Inpatient Performance Evaluation of a New Subcutaneous Glucose Sensor,,Completed,Has Results,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Device: Sensor wear,Glucose Sensor Accuracy When Compared to Laboratory Standard (YSI): Proportion of Glucose Sensor Readings That Met Accuracy Criteria|Device Related Moderate or Device Related Severe Adverse Events,Medtronic Diabetes,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,100,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,CEP 221,Apr-10,Nov-10,Nov-10,28-Apr-10,27-Aug-12,16-Jan-18,"AMCR Institute, Inc., Escondido, California, United States|Sansum Diabetes Research Institute, Santa Barbara, California, United States|Rainier Clinical Research Center, Inc., Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT01112696
NCT01110746,"To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy",,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Viaject 7|Drug: LISPRO,"3 hour incremental area under the glucose curve after a standardized high glycemic index meal.|Draize scores at insulin infusion site at 24 hour and 72 hour follow-up visits, frequency of discomfort with insulin infusion, and severity of discomfort with insulin infusion (ratings of mild, moderate, or severe).",Biodel,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,20,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",VIAject -032J,Feb-10,Jun-10,Jun-10,27-Apr-10,null,3-Aug-15,"Oregon Health and Science University/Legacy Health System, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT01110746
NCT01109316,Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Insulin lispro 2 day reservoir in-use|Drug: Insulin lispro 6 day reservoir in-use|Drug: Insulin aspart 6 day reservoir in-use,"Mean of Last Five 7-point Self Monitored Blood Glucose (SMBG) Taken on Day 6 for Insulin Lispro 6D and Day 2 for Insulin Lispro 2D and Day 6 for Insulin Aspart 6D Pump Reservoir In-use|Mean SMBG|Mean Daily Insulin Dose (Total, Basal, and Bolus)|Change From Baseline to 8 Weeks Endpoint for Each Treatment in Hemoglobin A1c (HbA1c) Values|Number of Participants Who Achieve or Maintain an HbA1c Less Than or Equal to 6.5% and Less Than 7%|Percentage of Participants With Hyperglycemia|Hyperglycemic Episode Rate Per 30 Days|Percentage of Participants With Pump Complications|Pump Complication Rate Per 30 Days|Percentage of Participants With Hypoglycemia|Hypoglycemia Episode Rate Per 30 Days|Change From Baseline to 8 Weeks Endpoint for Each Treatment in Weight|Change From Baseline to 8 Weeks Endpoint for Each Treatment in Blood Pressure",Eli Lilly and Company,All,"13 Years and older   (Child, Adult, Older Adult)",Phase 3,132,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12174|F3Z-MC-IOPV,Apr-10,Aug-11,Aug-11,23-Apr-10,30-Oct-12,27-Mar-19,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Concord, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aurora, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hollywood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Palm Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Idaho Falls, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Topeka, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashua, New Hampshire, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albany, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Syracuse, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Asheville, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT01109316
NCT01109797,Transition of Adolescents and Young Adults With Diabetes From Pediatric to Adult Care,,Completed,No Results Available,Type 1 Diabetes,Behavioral: Transition Social Behavioral Intervention|Behavioral: Diabetes Transition Clinic,"Measure and compare change in self-efficacy and change in diabetes knowledge, diabetes quality of life, family conflict, and treatment satisfaction for and between the two groups.|Make exploratory baseline comparisons between the two groups regarding locus of diabetes care (kind of provider), comparing numbers of subjects in each group who made a successful transition to adult care|Make exploratory baseline comparisons between the two groups of using some form of social networking by the two groups as an adjunt of diabetes care.|Make exploratory baseline comparisons between the two groups regarding provider and educator time devoted in each arm of the intervention (in order to prepare for a robust comparative effectiveness analysis in a subsequent study).|Make exploratory baseline comparisons between the two groups of HgbA1c",University of Kansas|University of Kansas Medical Center,All,"16 Years to 29 Years   (Child, Adult)",Not Applicable,28,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12157,Apr-10,May-12,May-12,23-Apr-10,null,26-May-14,"University of Kansas Medical Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT01109797
NCT01106157,Reversing Type 1 Diabetes After it is Established,,"Active, not recruiting",Has Results,"Diabetes Mellitus, Type 1",Drug: Anti-Thymocyte Globin (ATG)|Drug: Placebo|Drug: Pegylated GCSF,"Change in Metabolic Function Baseline to 12 Months.|Percent Change in Regulatory T Cells (Treg) Baseline to 12 Months|A1c|Change in Insulin Requirements, Baseline to 12 Months|Change in Glutamic Acid Decarboxylase Antibodies (GADA) From Baseline to 12 Months|Change in Insulin Autoantibodies (IAA) From Baseline to 12 Months|Change in Insulinoma Associated 2 Autoantibodies (IA-2A) From Baseline to 12 Months|Change in Zinc Transporter 8 Autoantibodies (ZnT8A) From Baseline to 12 Months|Percentage of Neutrophils|Change in White Blood Count (WBC) From Baseline to 12 Months","University of Florida|The Leona M. and Harry B. Helmsley Charitable Trust|Genzyme, a Sanofi Company",All,"12 Years to 45 Years   (Child, Adult)",Phase 1|Phase 2,25,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,UF-ATG-GCSF001|IRB201702525|041-2010|OCR16038,Apr-10,Jan-15,Sep-19,19-Apr-10,20-Jan-16,31-Dec-18,"University of California, San Francisco, San Francisco, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|University of Florida, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT01106157
NCT01103817,Influence of Vitamin D on Vascular Function in Adolescents and Young Adults With Type 1 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Dietary Supplement: Vitamin D,Comparison of Endothelial Function|Change in Endothelial Function after Treatment with Vitamin D|Monitoring of Vitamin D Levels in Vitamin D deficient subjects|Monitoring of Calcium Creatine Ratio in Vitamin D deficient subjects|Comparison of Systemic Blood Pressure|Comparison of Urinary Albumin/Creatinine Ratio,The Hospital for Sick Children,All,"12 Years to 18 Years   (Child, Adult)",Phase 2,33,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1000014567,Mar-10,Jan-11,Jan-11,15-Apr-10,null,1-Jun-16,"The Hospital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01103817
NCT01103284,Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults,DIA-AID2,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: DiaPep277|Drug: Placebo,Change From Baseline in Glucagon-Stimulated C-Peptide AUC at 24 Months|Percentage of Subjects That Achieve Good Glycemic Control: HbA1c<7%|Frequency of Hypoglycemic Events|Mean Number of Days With at Least One Hypoglycemic Event,Andromeda Biotech Ltd.,All,20 Years to 45 Years   (Adult),Phase 3,475,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DiaPep277-1001,Apr-10,Oct-14,Oct-14,14-Apr-10,26-May-16,26-May-16,"Los Gatos, California, United States|Sutter Gold Medical Foundation, Modesto, California, United States|San Diego Clinical Trials, San Diego, California, United States|University of Colorado Hospital - Anschutz Outpatient Pavilion, Aurora, Colorado, United States|Creekside Endocrine Associates, Inc., Denver, Colorado, United States|George Washington University Medical Faculty Associates, Washington, District of Columbia, United States|Innovative Medical Research of South Florida Inc., Aventura, Florida, United States|DeLand, Florida, United States|Orlando Diabetes & Endocrine Specialists, P.A., Orlando, Florida, United States|Tallahassee Endocrine Associates, Tallahassee, Florida, United States|Diabetes and Hormonal Disease Center, Tampa, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Kentucky Diabetes Endocrinology Center, Lexington, Kentucky, United States|Washington University, St. Louis, Missouri, United States|Palm Medical Research Center, Las Vegas, Nevada, United States|Soutwest Clinical Research Center, LLC, Santa Fe, New Mexico, United States|Mountain Diabetes and Endocrine Center, Ashville, North Carolina, United States|University of North Carolina Diabetes Care Center, Durham, North Carolina, United States|The Lindner Research Center, The Christ Hospital, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Legacy Clinical Research & Technology Center, Portland, Oregon, United States|AM Diabetes & Endocrinology Center, Bartlett, Tennessee, United States|Research Institute of Dallas, Dallas, Texas, United States|Cetero Research, San Antonio, Texas, United States|Northside Internal Medicine Associates, PS, Spokane, Washington, United States|Multicare Specialties Research, Tacoma, Washington, United States|Universitatsklinik fur Innere Medzin I, Landeskrankenhaus, Innsbruck, Austria|Rudolfstiftung Hospital, Vienna, Austria|Endocrinological Unit 1st City Clinical Hospital, Minsk, Belarus|Republican center of Medical Rehabilitation and Balneotherapy, Minsk, Belarus|Health Institution City Endocrinological Dispensary, Minsk, Belarus|Belarusian Medical Academy of Postgraduate Education, Minsk, Belarus|Health Institution Mogilev Diagnostic Center, Mogilov, Belarus|LMC Endocrinology Centres, Calgary, Alberta, Canada|LMC Endocrinology Centres, Oakville, Ontario, Canada|LMC Endocrinoly Centres, Toronto, Ontario, Canada|Fakultni nemocnice Kralovske Vinohrady - II. internal department, Prague, Czech Republic|IKEM/Diabetes Centre/Videnska, Prague, Czech Republic|Tutkimusyksikko, Oulu, Finland|DDZ Studienzentrum Deutsches Diabetes Zentrum, Dusseldorf, Germany|Universitatsklinikum Giessen, Giessen, Germany|Diabetes Centre for Children and Adolescents, Kinderkrankenhaus auf der Bult, Hannover, Germany|Institut für Diabetesforschung an der Klinik und Hochschulambulanz für Kinder- und Jugendmedizin, Munchen, Germany|Institut für Diabetesforschung Münster GmbH, Munster, Germany|University of Szeged Faculty of Medicin, Szeged, Hungary|Veszprem Megyei Csolnoky Ferenc Korhaz es Rendelointezet Diabetologia Centrum, Veszprem, Hungary|Zala Megyei Korhaz es Rendelointezet Diabetologia Centrum, Zalaegerszeg, Hungary|Diabetes Clinic Soroka University, Beer Sheva, Israel|Soroka University Medical Center, Beer Sheva, Israel|Rambam Medical Cent, Haifa, Israel|Wolfson Medical Center, Holon, Israel|Hadassah Medical Center, Jerusalem, Israel|Institute for Endocrinology and Diabetes Schneider Children's MC, Petach-Tiqva, Israel|. Endocrinologia e Malattie Metaboliche, Dipartimento biomedico di medicina interna e specialistica, Ex Istituto di clinica medica, Università di Palerm, Palermo, Italy|Dept. of Endocrinology and Diabetes University Campus Bio-Medico, Rome, Italy|University La Sapienza, Policlinico Umberto I, Rome, Italy|Private Clinic JSC 'Kristavita', Jonava, Lithuania|Kaunas Medical University Hospital, Kaunas, Lithuania|Public Institution 'Seskines Outpatient Clinic', Vilnius, Lithuania|Vilnius Medical University Hospital, Santariskiu Clinic's, Vilnius, Lithuania|NZOZ OmniMed, Lodz, Poland|State Educational Institution for Additional Professional Education (SEIAPE) ""Ural State Medical, Chelyabinsk, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Endocrinological scientific center of Rosmedtechnology, Moscow, Russian Federation|SEIAPE Endocrinology and Diabetology, Moscow, Russian Federation|City Clinical Hospital #81, Endocrinology Department, Moscow, Russian Federation|Clinic of New Medical Technology, LLC, Moscow, Russian Federation|State Healthcare Institution (SHI) ""Nizhegorodskaya, Nizhni Novgorod, Russian Federation|State Healthcare Institution Perm Region Clinical Hospital, Perm, Russian Federation|Limited Liability Company (LLC), Diabetes Center, Samara, Russian Federation|State Educational Institution of Higher Professional Education, St Petersburg, Russian Federation|St. Petersburg State Healthcare Institution, St. Petersburg, Russian Federation|Siberian State Medical University of Roszdrav, Tomsk, Russian Federation|Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain",,https://ClinicalTrials.gov/show/NCT01103284
NCT01102673,Single Dose Study of PF-04991532 in Healthy Subjects,,Completed,No Results Available,"Diabetes Mellitus|Diabetes Mellitus, Type 2|Glucose Metabolism Disorders",Drug: PF-04991532|Drug: Placebo,"Safety and Tolerability Endpoints: physical exams, AE monitoring, 12-lead ECGs, continuous cardiac monitoring, vital sign and clinical safety laboratory (including frequent glucose assessments via glucometer) measurements.|PK Endpoints: AUC(0-inf), AUC(0-last), AUC(0-24), Cmax, Tmax, CL/F, Vz/F and half-life (t1/2), as the data permit.|none-see my comment",Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,18,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)",B2611001,Apr-10,Jun-10,Jun-10,13-Apr-10,null,5-Aug-10,"Pfizer Investigational Site, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01102673
NCT01099618,Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment,,Completed,Has Results,Ketosis Prone Diabetes|Diabetes Ketoacidosis|Hyperglycemia,Drug: metformin|Drug: placebo|Drug: Sitagliptin,Length of Remission,Dawn Smiley MD|Emory University,All,"19 Years to 65 Years   (Adult, Older Adult)",Phase 4,48,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",IRB00026272,Mar-10,Feb-14,Aug-14,7-Apr-10,18-Jun-15,18-Jun-15,"Grady Memorial Hospital, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT01099618
NCT01098994,"Haptoglobin Phenotype, Vitamin E and High-density Lipoprotein (HDL) Function in Type 1 Diabetes",HAP-E,Completed,No Results Available,Type 1 Diabetes|Heart Disease,Dietary Supplement: Vitamin E|Other: Dummy pills,Demonstrate the presence of HDL dysfunction among individuals with the Haptoglobin 2/1 and 2/2 compared to those with the Hp 1/1 phenotype and improvement in HDL dysfunction with natural d-α-tocopherol supplementation|Feasibility of recruitment of individuals with type 1 diabetes for a randomized clinical trial|Assessment of adherence to the clinical trial study protocol in a random sample of individuals with type 1 diabetes recruited from the ACR and CHP/EDC Diabetes Registries,University of Pittsburgh|American Diabetes Association,All,"30 Years and older   (Adult, Older Adult)",Not Applicable,87,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1-10-CT-12,Feb-10,Dec-13,Dec-13,6-Apr-10,null,3-Jun-14,"University of Pittsburgh Diabetes and Lipid Research Clinic, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01098994
NCT01094899,Abnormal Structure and Bone Density in Diabetes,,Unknown status,No Results Available,Type 1 Diabetes|Type 2 Diabetes,Radiation: Radiography|Other: Urine and Blood sampling|Other: Echography,"evaluate the MicroScanner, alterations quantitative and qualitative bone in the foot in patients with type 1 diabetes 2 with or without neuropathy|correlation involving bone and extension of neuropathy Assessment criteria associated with biological abnormalities qualitative and quantitative bone in diabetic subjects","Institut National de la Santé Et de la Recherche Médicale, France",Male,"30 Years to 70 Years   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C08-25,Mar-10,Sep-11,Mar-13,29-Mar-10,null,31-Jan-12,"Hotel Dieu, Paris, France",,https://ClinicalTrials.gov/show/NCT01094899
NCT01093833,A Comparison Study of Prototype Continuous Glucose Sensors in the Intradermal and Subcutaneous Spaces,,Completed,No Results Available,Diabetes,Device: BD Continuous glucose monitor (BD CGM)|Device: YSI Glucose Analyzer|Device: Medtronic Guardian CGM,Blood Glucose,"Becton, Dickinson and Company",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,40,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,BDT-08-CGM-02,Jan-09,Apr-09,Apr-09,26-Mar-10,null,6-May-16,"Profil Institute for Clinical Research Inc, Chula Vista, California, United States",,https://ClinicalTrials.gov/show/NCT01093833
NCT01088451,Joint Application of Human Insulin and Rapid Insulin Analogue in Control of Postprandial Glycemia,CPIT,Unknown status,No Results Available,"Diabetes Mellitus, Type 1",Drug: Combined prandial insulin therapy (CPIT),"Differences in mean blood glucose concentrations and the pattern of fluctuation on control and study days; and changes in the glycated hemoglobin A1c after the study period. Occurrence of side effects especially hypoglycemic episodes.|The difference in postprandial areas under the curve when comparing conventional therapy and experimental combined prandial insulin therapy in the 5 to 6 hours following meal ingestion, taking into account the glycemic index profile of the meal.",University Hospital Hradec Kralove,All,"12 Years to 25 Years   (Child, Adult)",Not Applicable,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,200912S24|MZO00179906-01,Dec-09,Mar-10,Sep-10,17-Mar-10,null,17-Mar-10,"University Hospital Hradec Králové, Hradec Králové, Czech Republic",,https://ClinicalTrials.gov/show/NCT01088451
NCT01084005,Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes,,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: linagliptin|Drug: placebo,HbA1c Change From Baseline to Week 24|HbA1c Change From Baseline to Week 6|HbA1c Change From Baseline to Week 12|HbA1c Change From Baseline to Week 18|FPG Change From Baseline to Week 24|FPG Change From Baseline to Week 6|FPG Change From Baseline to Week 12|FPG Change From Baseline to Week 18|Percentage of Patients With HbA1c <7.0% at Week 24|Percentage of Patients Who Have a HbA1c Lowering by at Least 0.5% at Week 24|Number of Patients With Rescue Therapy,Boehringer Ingelheim|Eli Lilly and Company,All,70 Years and older   (Older Adult),Phase 3,241,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,1218.63|2009-015255-25,Mar-10,Jun-11,null,10-Mar-10,18-Jul-12,29-Jan-14,"1218.63.61005 Boehringer Ingelheim Investigational Site, Gosford, New South Wales, Australia|1218.63.61006 Boehringer Ingelheim Investigational Site, Herston, Queensland, Australia|1218.63.61003 Boehringer Ingelheim Investigational Site, Adelaide, South Australia, Australia|1218.63.61002 Boehringer Ingelheim Investigational Site, Daw Park, South Australia, Australia|1218.63.61007 Boehringer Ingelheim Investigational Site, East Ringwood, Victoria, Australia|1218.63.61001 Boehringer Ingelheim Investigational Site, Parkville, Victoria, Australia|1218.63.61004 Boehringer Ingelheim Investigational Site, Reservoir, Victoria, Australia|1218.63.10008 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada|1218.63.10003 Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada|1218.63.10005 Boehringer Ingelheim Investigational Site, Hawkesbury, Ontario, Canada|1218.63.10007 Boehringer Ingelheim Investigational Site, Newmarket, Ontario, Canada|1218.63.10006 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|1218.63.10001 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|1218.63.10002 Boehringer Ingelheim Investigational Site, St-Romuald, Quebec, Canada|1218.63.10004 Boehringer Ingelheim Investigational Site, Saskatoon, Saskatchewan, Canada|1218.63.45007 Boehringer Ingelheim Investigational Site, Aalborg, Denmark|1218.63.45002 Boehringer Ingelheim Investigational Site, Aarhus C, Denmark|1218.63.45003 Boehringer Ingelheim Investigational Site, Aarhus C, Denmark|1218.63.45001 Boehringer Ingelheim Investigational Site, Birkerød, Denmark|1218.63.45008 Boehringer Ingelheim Investigational Site, Hellerup, Denmark|1218.63.45006 Boehringer Ingelheim Investigational Site, Hillerød, Denmark|1218.63.45004 Boehringer Ingelheim Investigational Site, Hvidovre, Denmark|1218.63.45005 Bispebjerg Hospital, København NV, Denmark|1218.63.31008 Boehringer Ingelheim Investigational Site, Beek en Donk, Netherlands|1218.63.31007 Boehringer Ingelheim Investigational Site, Beerzerveld, Netherlands|1218.63.31012 Boehringer Ingelheim Investigational Site, Doetinchem, Netherlands|1218.63.31014 Boehringer Ingelheim Investigational Site, Etten-Leur, Netherlands|1218.63.31009 Boehringer Ingelheim Investigational Site, Oude Pekela, Netherlands|1218.63.31001 Boehringer Ingelheim Investigational Site, Tubbergen, Netherlands|1218.63.46004 Boehringer Ingelheim Investigational Site, Göteborg, Sweden|1218.63.46003 Boehringer Ingelheim Investigational Site, Järfälla, Sweden|1218.63.46001 Boehringer Ingelheim Investigational Site, Malmö, Sweden|1218.63.46002 Boehringer Ingelheim Investigational Site, Sundsvall, Sweden|1218.63.46005 Boehringer Ingelheim Investigational Site, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT01084005
NCT01083433,Study to Find Out if Intensive Diabetes Clinic and Continuous Glucose Monitors Help Teenagers With Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus,Behavioral: Diabetes related psychological counseling and education|Device: Continuous Glucose Monitor,Glycemic Control|Insulin dose changes|Episodes of Hypoglycemia (blood glucose <70 mg/dL)|Glycemic Variability|Adherence to prescribed diabetes regimen|Satisfaction with intensive diabetes clinic and usage of the continuous glucose monitor|Diabetes Knowledge,University Hospitals Cleveland Medical Center|National Institute of Mental Health (NIMH),All,"10 Years to 18 Years   (Child, Adult)",Not Applicable,62,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RBCDM-01|MH018830,May-10,Sep-11,Oct-11,9-Mar-10,null,13-Jun-12,"UHCMC, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01083433
NCT01079234,Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes,BEGIN™,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin glargine|Drug: insulin aspart,Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment|Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes|Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes|Extension Trial (Secondary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment|Main Trial (Secondary Endpoint): Change in Fasting Plasma Glucose (FPG) After 26 Weeks of Treatment|Extension Trial (Secondary Endpoint): Change in Fasting Plasma Glucose (FPG) After 52 Weeks of Treatment,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,493,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN1250-3770|U1111-1112-8813|2009-012923-27,Mar-10,Nov-10,May-11,3-Mar-10,31-Dec-15,9-Feb-17,"Novo Nordisk Investigational Site, Encino, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Huntington Beach, California, United States|Novo Nordisk Investigational Site, Long Beach, California, United States|Novo Nordisk Investigational Site, Redondo Beach, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, Denver, Colorado, United States|Novo Nordisk Investigational Site, DeLand, Florida, United States|Novo Nordisk Investigational Site, Hollywood, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Lawrenceville, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Nampa, Idaho, United States|Novo Nordisk Investigational Site, Crystal Lake, Illinois, United States|Novo Nordisk Investigational Site, Des Moines, Iowa, United States|Novo Nordisk Investigational Site, Des Moines, Iowa, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Jefferson City, Missouri, United States|Novo Nordisk Investigational Site, Springfield, Missouri, United States|Novo Nordisk Investigational Site, St. Louis, Missouri, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, United States|Novo Nordisk Investigational Site, Flemington, New Jersey, United States|Novo Nordisk Investigational Site, Smithtown, New York, United States|Novo Nordisk Investigational Site, Staten Island, New York, United States|Novo Nordisk Investigational Site, Asheville, North Carolina, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Greenville, North Carolina, United States|Novo Nordisk Investigational Site, Morehead City, North Carolina, United States|Novo Nordisk Investigational Site, Greer, South Carolina, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Memphis, Tennessee, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Round Rock, Texas, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Aalst, Belgium|Novo Nordisk Investigational Site, Arlon, Belgium|Novo Nordisk Investigational Site, Bonheiden, Belgium|Novo Nordisk Investigational Site, Brussels, Belgium|Novo Nordisk Investigational Site, Leuven, Belgium|Novo Nordisk Investigational Site, Bad Kreuznach, Germany|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Hohenmölsen, Germany|Novo Nordisk Investigational Site, Rehburg-Loccum, Germany|Novo Nordisk Investigational Site, Rehlingen-Siersburg, Germany|Novo Nordisk Investigational Site, St. Ingbert, Germany|Novo Nordisk Investigational Site, Völklingen, Germany|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Bergen, Norway|Novo Nordisk Investigational Site, Elverum, Norway|Novo Nordisk Investigational Site, Hamar, Norway|Novo Nordisk Investigational Site, Kongsvinger, Norway|Novo Nordisk Investigational Site, Stavanger, Norway|Novo Nordisk Investigational Site, Ålesund, Norway|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Poznan, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Belfast, United Kingdom|Novo Nordisk Investigational Site, Bristol, United Kingdom|Novo Nordisk Investigational Site, Guildford, United Kingdom|Novo Nordisk Investigational Site, Hull, United Kingdom|Novo Nordisk Investigational Site, Inverness, United Kingdom|Novo Nordisk Investigational Site, Ipswich, United Kingdom|Novo Nordisk Investigational Site, Newcastle, United Kingdom|Novo Nordisk Investigational Site, Rugby, United Kingdom|Novo Nordisk Investigational Site, Southall, United Kingdom|Novo Nordisk Investigational Site, Stevenage, United Kingdom|Novo Nordisk Investigational Site, Swansea, United Kingdom|Novo Nordisk Investigational Site, Welwyn Garden City, United Kingdom",,https://ClinicalTrials.gov/show/NCT01079234
NCT01079325,Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Diabetic Polyneuropathy",Drug: SB-509|Other: Saline,"To compare the effect of SB-509 versus placebo in subjects with moderately severe diabetic neuropathy (DN) on sural Nerve Conduction Velocity (NCV) at six-months|To evaluate the effect of SB-509 on Neuropathy Impairment Score - Lower Limb (NIS-LL), motor Nerve Conduction Velocity (NCV), Quantitative Sensory Testing (QST), Intraepidermal Nerve Fiber Density (IENFD), and Lower Extremity Neurological Sensory Exam|To evaluate the effect of SB-509 using a multi-endpoint analysis that includes NIS-LL, Sural NCV, and IENFD|To evaluate the safety of SB-509 in subjects with moderately severe diabetic neuropathy",Sangamo Therapeutics|Juvenile Diabetes Research Foundation,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,170,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",SB-509-0901,Nov-09,May-15,Apr-16,3-Mar-10,null,19-Apr-16,"Phoenix, Arizona, United States|Scottsdale, Arizona, United States|Tucson, Arizona, United States|Chino, California, United States|Fresno, California, United States|La Jolla, California, United States|Los Angeles, California, United States|National City, California, United States|San Francisco, California, United States|Walnut Creek, California, United States|Boulder, Colorado, United States|DeLand, Florida, United States|Fort Meyers, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Idaho Falls, Idaho, United States|Meridan, Idaho, United States|Lexington, Kentucky, United States|Boston, Massachusetts, United States|Kansas City, Missouri, United States|Las Vegas, Nevada, United States|Winston-Salem, North Carolina, United States|Tulsa, Oklahoma, United States|Greer, South Carolina, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01079325
NCT01076634,Comparison of Two NN1250 Formulations in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec,"Area under the glucose infusion rate curve during one dosing interval at steady-date""|Area under the serum Insulin Degludec concentration-time curve",Novo Nordisk A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,33,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1250-3678|2009-014555-68|U1111-1112-7714,Feb-10,Jul-10,Jul-10,26-Feb-10,null,23-Jan-17,"Novo Nordisk Investigational Site, Graz, Austria",,https://ClinicalTrials.gov/show/NCT01076634
NCT01074268,Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes,BEGIN™,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin detemir|Drug: insulin aspart,Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment|Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs)|Extension Trial (Secondary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment|Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 26|Extension Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 52|Main Trial (Secondary Endpoint): Change in Fasting Plasma Glucose (FPG) After 26 Weeks of Treatment|Extension Trial (Secondary Endpoint): Change in Fasting Plasma Glucose (FPG) After 52 Weeks of Treatment|Main Trial (Secondary Endpoint): Rate of Confirmed Hypoglycaemic Episodes|Main Trial (Secondary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes|Extension Trial (Secondary Endpoint): Rate of Confirmed Hypoglycaemic Episodes|Extension Trial (Secondary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,456,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN1250-3585|2009-011672-29|U1111-1111-7249|JapicCTI-101067|2009-015721-36|U1111-1114-9479|JapicCTI-22-0677,Feb-10,Dec-10,Dec-10,24-Feb-10,16-Nov-15,6-Mar-17,"Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Ciudad Autónoma de Bs As, Argentina|Novo Nordisk Investigational Site, Mar del Plata, Argentina|Novo Nordisk Investigational Site, Rosario, Argentina|Novo Nordisk Investigational Site, Porto Alegre, Rio Grande do Sul, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Marília, Brazil|Novo Nordisk Investigational Site, Porto Alegre, Brazil|Novo Nordisk Investigational Site, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Hämeenlinna, Finland|Novo Nordisk Investigational Site, Kuopio, Finland|Novo Nordisk Investigational Site, Lahti, Finland|Novo Nordisk Investigational Site, Seinäjoki, Finland|Novo Nordisk Investigational Site, Tampere, Finland|Novo Nordisk Investigational Site, Turku, Finland|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Ahmedabad, India|Novo Nordisk Investigational Site, Bilaspur, India|Novo Nordisk Investigational Site, Dhantoli, Nagpur, India|Novo Nordisk Investigational Site, Hyderabad, India|Novo Nordisk Investigational Site, New Dehli, India|Novo Nordisk Investigational Site, Ramdaspeth / Nagpur, India|Novo Nordisk Investigational Site, Thriruvananthapuram, India|Novo Nordisk Investigational Site, Bari, Italy|Novo Nordisk Investigational Site, Forlì, Italy|Novo Nordisk Investigational Site, Gazi, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Olbia, Italy|Novo Nordisk Investigational Site, Palermo, Italy|Novo Nordisk Investigational Site, Partinico, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Torino, Italy|Novo Nordisk Investigational Site, Treviglio, Italy|Novo Nordisk Investigational Site, Treviso, Italy|Novo Nordisk Investigational Site, Chuo-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Ebina-shi, Japan|Novo Nordisk Investigational Site, Imizu-shi, Japan|Novo Nordisk Investigational Site, Izumisano-shi, Japan|Novo Nordisk Investigational Site, Koriyama-shi, Fukushima, Japan|Novo Nordisk Investigational Site, Kumamoto-shi,Kumamoto, Japan|Novo Nordisk Investigational Site, Miyazaki-shi, Japan|Novo Nordisk Investigational Site, Naka-shi, Ibaraki, Japan|Novo Nordisk Investigational Site, Nishinomiya-shi, Hygo, Japan|Novo Nordisk Investigational Site, Oita-shi, Japan|Novo Nordisk Investigational Site, Ota-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Yokohama-shi, Japan|Novo Nordisk Investigational Site, Skopje, Macedonia, The Former Yugoslav Republic of|Novo Nordisk Investigational Site, Bath, United Kingdom|Novo Nordisk Investigational Site, Blackburn, United Kingdom|Novo Nordisk Investigational Site, Carmarthen, United Kingdom|Novo Nordisk Investigational Site, Edinburgh, United Kingdom|Novo Nordisk Investigational Site, Leicester, United Kingdom|Novo Nordisk Investigational Site, Manchester, United Kingdom|Novo Nordisk Investigational Site, Middlesbrough, United Kingdom|Novo Nordisk Investigational Site, Northampton, United Kingdom|Novo Nordisk Investigational Site, Nottingham, United Kingdom|Novo Nordisk Investigational Site, Penarth, United Kingdom|Novo Nordisk Investigational Site, Plymouth, United Kingdom|Novo Nordisk Investigational Site, Sheffield, United Kingdom|Novo Nordisk Investigational Site, Torquay, United Kingdom|Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom",,https://ClinicalTrials.gov/show/NCT01074268
NCT01074801,Closing the Loop for 36 Hours in Adolescents With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Other: Closed-loop insulin delivery|Other: Standard insulin pump treatment,The primary outcome measure is time spent with plasma glucose concentration in the target range (3.9-10.0 mmol/L) between 24:00 on Day 1 to 08:00 on Day 3.|Secondary outcomes will include: (i) Total and basal insulin delivery between 24:00 on Day 1 and 08:00 on Day 3 (36 hours) (ii) CGM glucose levels between 24:00 on Day 1 and 08:00 on Day 3 (36 hours),University of Cambridge|Cambridge University Hospitals NHS Foundation Trust,All,"12 Years to 18 Years   (Child, Adult)",Phase 2,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAN01,Mar-10,Oct-10,Oct-10,24-Feb-10,null,6-Apr-11,"Wellcome Trust Clinical Research Facility, Addenbrooke's Hospital, Cambridge, United Kingdom",,https://ClinicalTrials.gov/show/NCT01074801
NCT01068951,Treatment of Patients With Newly Onset of Type 1 Diabetes With Mesenchymal Stem Cells,,Completed,No Results Available,Type 1 Diabetes,Biological: Mesenchymal stem cells,The concentration of stimulated c-peptide at 90 minutes after the start of a mixed meal tolerance test at 365+/-10 days following the infusion or not with mesenchymal stem cells,Uppsala University Hospital,All,18 Years to 40 Years   (Adult),Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AS2010-0180,Jun-10,Sep-13,Sep-13,17-Feb-10,null,5-Feb-14,"Uppsala University Hospital, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT01068951
NCT01069393,Alternative Delivery of Dose Adjustment For Normal Eating (DAFNE) Trial in Patients With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus,Other: DAFNE course (Timing of delivery of education),"Improvement in HbA1c (glycosylated haemoglobin)|Number of severe hypoglycaemic episodes|Psychosocial measures, such as quality of life, emotional well-being, self-efficacy,will be assessed via questionnaires|Qualitative evaluation via in-depth interviews to assess patients' experiences of the intervention","Sheffield Teaching Hospitals NHS Foundation Trust|University Hospitals, Leicester|Cambridge University Hospitals NHS Foundation Trust|University College London Hospitals|Northumbria Healthcare NHS Foundation Trust|NHS Greater Glasgow and Clyde|Norfolk and Norwich University Hospitals NHS Foundation Trust|East Lancashire Hospitals NHS Trust",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,170,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STH15581,Jun-10,Jun-12,Jun-12,17-Feb-10,null,19-Nov-14,"Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|NHS Greater Glasgow & Clyde, Glasgow, United Kingdom|East Lancashire Hospitals NHS Trust, Lancashire, United Kingdom|University Hospitals, Leicester, Leicester, United Kingdom|University College London, London, United Kingdom|Norfolk and Norwich University Hospitals NHS Foundation Trust, Norfolk, United Kingdom|Northumbria Healthcare NHS Foundation Trust, Northumbria, United Kingdom",,https://ClinicalTrials.gov/show/NCT01069393
NCT01068652,"Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs",,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin detemir|Drug: insulin aspart|Drug: biphasic insulin aspart 30|Drug: metformin,Glycosylated Haemoglobin (HbA1c)|Change in Glycosylated Haemoglobin (HbA1c) After 14 Weeks of Treatment|Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment|Change in Glycosylated Haemoglobin (HbA1c) After 38 Weeks of Treatment|Change in Glycosylated Haemoglobin (HbA1c) at Week 50|Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 14 Weeks of Treatment|Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 26 Weeks of Treatment|Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 38 Weeks of Treatment|Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 50 Weeks of Treatment|Mean of Prandial Plasma Glucose (PG) Increment After 14 Weeks of Treatment|Mean of Prandial Plasma Glucose (PG) Increment After 26 Weeks of Treatment|Mean of Prandial Plasma Glucose (PG) Increment After 38 Weeks of Treatment|Mean of Prandial Plasma Glucose (PG) Increment After 50 Weeks of Treatment|Mean of 8-point Plasma Glucose (PG) Profile After 14 Weeks of Treatment|Mean of 8-point Plasma Glucose (PG) Profile After 26 Weeks of Treatment|Mean of 8-point Plasma Glucose (PG) Profile After 38 Weeks of Treatment|Mean of 8-point Plasma Glucose (PG) Profile After 50 Weeks of Treatment,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 4,403,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INS-3782|U1111-1112-6407,Mar-10,May-12,May-12,15-Feb-10,8-Apr-13,13-Jan-17,"Novo Nordisk Investigational Site, Ain Témouchent, Algeria|Novo Nordisk Investigational Site, Alger, Algeria|Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Constantine, Algeria|Novo Nordisk Investigational Site, Oran, Algeria|Novo Nordisk Investigational Site, Setif, Algeria|Novo Nordisk Investigational Site, Sidi Bel Abbes, Algeria|Novo Nordisk Investigational Site, Alexandria, Egypt|Novo Nordisk Investigational Site, Casablanca, Morocco|Novo Nordisk Investigational Site, Port Elizabeth, Eastern Cape, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Vaderbijlpark, Gauteng, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Kimberly, Northern Cape, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Sandton, South Africa|Novo Nordisk Investigational Site, Tunisia, Tunisia",,https://ClinicalTrials.gov/show/NCT01068652
NCT01067950,Pancreas Allotransplantation for Diabetic Nephropathy and Mild Chronic REnal fAilure Stage Study,PANCREAS,Unknown status,No Results Available,Type 1 Diabetes,Procedure: Isolated Pancreas Transplant|Drug: Intensive Insulin Therapy,"The primary end-point is the 5-year evaluation of efficacy/failure rate, a composite end-point including: (i) patient mortality and (ii) renal function impairment|Secondary objectives are to evaluate and to compare the safety and the efficacy of the two treatments (IPT versus IIT).",Nantes University Hospital,All,25 Years to 55 Years   (Adult),Phase 3,180,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BRD 09/5-J,Mar-10,null,null,12-Feb-10,null,2-Jun-10,"University of Minnesota, Minneapolis, Minnesota, United States|Albert Einstein Jewish Hospital, Sao Paulo, Brazil|Diabetes Center - Institute for Clinical and Experimental Medicine, Praha, Czech Republic|Hôpital Edouard-Herriot - Hospices Civils de Lyon, Lyon, France|Centre Hospitalier et Universitaire de Nantes, Nantes, France|Istituto Scientifico Ospedale San Raffaele, Milano, Italy|Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy",,https://ClinicalTrials.gov/show/NCT01067950
NCT01065948,A Feasibility Study to Assess Critical Aspects of Fluorescence Affinity Sensor (FAS) Performance and Safety Over Several Hours,FAS,Completed,No Results Available,Diabetes,Device: Subcutaneous glucose monitoring device,"examine accuracy of FAS response to glucose changes in subcutaneous tissue (compared to blood glucose concentrations measured with reference method)|monitor safety and performance of FAS response in two different body sites (abdomen, forearm)|examine insertion site while the FAS is worn, and after seven days of FAS removal|assess comfort level during FAS insertion, when worn during normal activities, and during FAS removal","BioTex, Inc.|Endocrinoloogy Associates Houston",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,12,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,FAS-2009-05,Nov-09,Jun-12,Aug-12,10-Feb-10,null,4-Feb-16,"Practice of Eric Orzeck, MD, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01065948
NCT01064687,A Study in Participants With Type 2 Diabetes Mellitus,AWARD-1,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY2189265|Drug: Exenatide|Drug: Placebo|Drug: Metformin|Drug: Pioglitazone,"Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)|Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)|Change From Baseline to 26 Weeks for Body Weight|Change From Baseline to 52 Weeks for Body Weight|Change From Baseline to 26 Weeks on Body Mass Index (BMI)|Change From Baseline to 52 Weeks on Body Mass Index (BMI)|Change From Baseline to 26 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles|Change From Baseline to 52 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles|Percentage of Participants Attaining Glycosylated Hemoglobin (HbA1c) Less Than 7% and Less Than or Equal to 6.5% at 26 Weeks|Percentage of Participants Attaining Glycosylated Hemoglobin (HbA1c) Less Than 7% and Less Than or Equal to 6.5% at 52 Weeks|Change From Baseline to 26 Weeks in Updated Homeostasis Model Assessment of Beta-cell Function (HOMA2-%B) and Updated Homeostasis Model Assessment of Insulin Sensitivity (HOMA2-%S)|Change From Baseline to 52 Weeks in Updated Homeostasis Model Assessment of Beta-cell Function (HOMA2-%B) and Updated Homeostasis Model Assessment of Insulin Sensitivity (HOMA2-%S)|Change From Baseline to 26 Weeks in the EuroQol 5|Change From Baseline to 52 Weeks in the EuroQol 5|Change From Baseline to 26 Weeks in the Diabetes Treatment Satisfaction Questionnaire Status (DTSQs) Version|Change From Baseline to 52 Weeks in the Diabetes Treatment Satisfaction Questionnaire Status (DTSQs) and Change (DTSQc) Versions|Change From Baseline to 26 Weeks in the Impact of Weight on Activities of Daily Living|Change From Baseline to 52 Weeks in the Impact of Weight on Activities of Daily Living|Change From Baseline to 26 Weeks on the Impact of Weight on Self-Perception|Change From Baseline to 52 Weeks on the Impact of Weight on Self-Perception|Number of Participants With Adjudicated Cardiovascular Events at 52 Weeks|Change From Baseline to 26 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval|Change From Baseline to 52 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval|Change in Baseline to 26 Weeks on Pulse Rate|Change in Baseline to 52 Weeks on Pulse Rate|Change From Baseline to 26 Weeks on Blood Pressure|Change From Baseline to 52 Weeks on Blood Pressure|Number of Participants With Adjudicated Pancreatitis at 26 Weeks|Number of Participants With Adjudicated Pancreatitis at 52 Weeks|Change From Baseline to 26 Weeks on Pancreatic Enzymes|Change From Baseline to 52 Weeks on Pancreatic Enzymes|Change From Baseline to 26 Weeks on Serum Calcitonin|Change From Baseline to 52 Weeks on Serum Calcitonin|Number of Self-reported Hypoglycemic Events at 26 Weeks|Number of Self-reported Hypoglycemic Events at 52 Weeks|Rate of Self-reported Hypoglycemic Events at 26 Weeks|Rate of Self-reported Hypoglycemic Events at 52 Weeks|Number of Participants Requiring Rescue Therapy Due to Hyperglycemia at 26 Weeks|Number of Participants Requiring Rescue Therapy Due to Hyperglycemia at 52 Weeks|Number of Participants With LY2189265 Antibodies at 26 Weeks|Number of Participants With LY2189265 Antibodies at 52 Weeks and 4 Weeks After Last Dose of Study Drug|Number of Participants With Treatment Emergent Adverse Events at 26 Weeks|Number of Participants With Treatment Emergent Adverse Events at 52 Weeks|Change From Baseline to 26 Weeks in Hematological and Biochemical Lab Values|Change From Baseline to 52 Weeks in Hematological and Biochemical Lab Values|Change From Baseline to 26 Weeks in N Terminal Pro Brain Natriuretic Peptide (NT-proBNP)|Pharmacokinetics: Area Under the Concentration Curve (AUC) for LY2189265",Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,978,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",11373|H9X-MC-GBDA,Feb-10,Nov-11,May-12,8-Feb-10,26-Jan-15,26-Jan-15,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Goodyear, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cathedral City, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Concord, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fresno, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenbrae, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lancaster, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mission Hills, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterey, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., National City, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oceanside, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paramount, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roseville, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Ramon, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tustin, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Britain, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Lauderdale, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hollywood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pembroke Pines, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Palm Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Honolulu, Hawaii, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boise, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Idaho Falls, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Meridian, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Crystal Lake, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Peoria, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vincennes, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Topeka, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madisonville, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Orleans, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangor, Maine, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Biddeford, Maine, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Elkridge, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bloomfield Hills, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Flint, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashua, New Hampshire, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toms River, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albany, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Flushing, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Syracuse, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Asheville, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cary, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durham, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Morehead City, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cincinnati, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cleveland, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbus, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dayton, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Delaware, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Perrysburg, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bend, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Corvallis, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eugene, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beaver, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Danville, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Levittown, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wilkes Barre, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenville, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greer, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Myrtle Beach, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arlington, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Corpus Christi, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., El Paso, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Schertz, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ogden, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. George, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Jordan, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spokane, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tacoma, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caguas, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hato Rey, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manati, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San German, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yabucoa, Puerto Rico",,https://ClinicalTrials.gov/show/NCT01064687
NCT01061216,Pharmacokinetics/Dynamics of Basal (Continuous) Insulin Infusion Administered Either Intradermally or Subcutaneously,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Device: Intradermal insulin delivery: BD Research Catheter Set|Device: Subcutaneous insulin delivery:ACCU-CHEK Rapid-D Infusion Set,Insulin measurements will be used to compute PK model parameters: absorption rate(s) and elimination rate using an appropriate transport model.|Pharmacodynamic glycemic parameters will be as follows: time from insulin infusion onset to glycemic nadir; time from test insulin shutoff to return to baseline glucose; amount of additional drop in blood glucose following test insulin infusion shutoff|Evidence of safety and tolerability of intradermally infused insulin|Feasibility of RCS for longer-term ID infusion,"Becton, Dickinson and Company",Male,18 Years to 55 Years   (Adult),Phase 1|Phase 2,20,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,BDT-09-ADC003|2009-016164-36,Jan-10,Mar-10,Mar-10,3-Feb-10,null,10-Mar-10,"Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01061216
NCT01060241,Effect of Internet Therapeutic Intervention on A1C Levels in Type 2 Diabetes Mellitus (DM) on Combination Oral Therapy,,Suspended,No Results Available,Type 2 Diabetes Mellitus,Other: Internet Intervention,"The primary endpoint is the A1c level or the change in A1c level|The secondary endpoints include severe hypoglycemia defined as requiring external aid, hospital admissions for any CVD related intervention, and adverse events such as unplanned hospitalizations for any cause that last more than 24 hours",Endocrine Research Society,All,"25 Years to 79 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,T2D Combination-Internet BGM,Feb-10,null,null,2-Feb-10,null,29-Jun-11,"St. Paul's Hospital, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT01060241
NCT01060605,Pre Transplant Rapamycin Treatment in Islet Transplantation Alone,ITA-Rp,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: rapamycin,"Evidence of insulin independence with adequate control of blood glucose (<140 mg/mL fasting; < 180 mg/mL post prandial, after the final infusion|basal and stimulated C-peptide levels|glycated haemoglobin|rapamycin and tacrolimus trough levels|renal and liver function, white blood cells count, total lymphocytes and lymphocytes subpopulations (CD24, CD19), hemoglobin, fibrinogen (FG), cross-linked fibrin degradation products, C-reactive protein (CRP)","IRCCS San Raffaele|Ministry of Education, Universities and Research, Italy|Juvenile Diabetes Research Foundation|Telethon-JDRF Center for Beta cell replacement: clinical core.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,11,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,emendament 2001 to C99B901251,Oct-01,Dec-05,Sep-09,2-Feb-10,null,2-Feb-10,"Transplant Unit, IRCCS San Raffaele, Milano, Italy",,https://ClinicalTrials.gov/show/NCT01060605
NCT01060917,Glucose Clamp Study to Prove Hypo- and Hyperglycemic Episodes Using a Non-invasive Glucose Monitoring Device,,Completed,No Results Available,Diabetes Mellitus,Device: Non-invasive CGMS (continuous glucose monitoring system)|Procedure: Hyperglycemic and hypoglycemic glucose clamp|Device: Non-invasive CGMS (GlucoDay),"skin tissue glucose concentration|serum and urine electrolyte concentrations (sodium, potassium, chloride, calcium, magnesium, urea, osmolarity, pH, lactate, p(O2), standard bicarbonate, p(CO2), blood glucose concentration",Profil Institut für Stoffwechselforschung GmbH|Pendragon Medical AG Switzerland,All,18 Years to 40 Years   (Adult),Phase 1|Phase 2,21,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,06/0097-Study 4,Jan-03,Mar-03,May-03,2-Feb-10,null,2-Feb-10,"Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01060917
NCT01055951,Feasibility Study of the Solo™ Insulin Pump,,Completed,No Results Available,Type 1 Diabetes|Insulin Pump Users,Device: Solo MicroPump,Device-related adverse outcome|Mechanical dysfunction and diabetes-related adverse outcome,Medingo Ltd,All,"16 Years to 60 Years   (Child, Adult)",Phase 1,90,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VTR-045, VTR-075",May-09,Jun-11,Jun-11,26-Jan-10,null,2-Jun-11,"Medical University Graz, Gratz, Austria|Rambam Healthcare Campus, Haifa, Israel|Sourasky Medical Center, Tel-Aviv, Israel",,https://ClinicalTrials.gov/show/NCT01055951
NCT01055080,Insulin-free Cow Milk Formula in Prevention of Type 1 Diabetes Associated Autoimmunity - FINDIA Pilot Study,FINDIA,Completed,No Results Available,Beta-cell Autoimmunity,Dietary Supplement: Cow's milk formula,Beta-cell autoantibodies,"National Institute for Health and Welfare, Finland|Valio Ltd|University of Turku|Helsinki University|University of Eastern Finland",All,"Child, Adult, Older Adult",Not Applicable,987,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",FINDIA2002,May-02,Jun-06,Dec-09,25-Jan-10,null,25-Jan-10,,,https://ClinicalTrials.gov/show/NCT01055080
NCT01054300,"Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)",,Completed,Has Results,"Diabetes Mellitus, Type 2|Adult",Drug: Ertugliflozin 2 mg single dose|Drug: Ertugliflozin 2 mg split into twice daily|Drug: Ertugliflozin 4 mg single dose|Drug: Ertugliflozin 4 mg split into twice daily|Drug: Placebo,Cumulative Urinary Glucose Excretion Over 0 to 24 Hours|Urinary Glucose Excretion by Time Period|24-hour Weighted Mean Plasma Glucose|Weighted Mean Postprandial Plasma Glucose|Fasting Plasma Glucose|Fasting C-peptide|Number of Participants Experiencing an Adverse Event|Number of Participants Discontinuing Study Drug Due to an Adverse Event|Area Under the Plasma Concentration-time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUClast) for Ertugliflozin|Maximum Plasma Concentration (Cmax) of Ertugliflozin|Time Taken to Reach the Maximum Observed Plasma Concentration (Tmax) of Ertugliflozin,Merck Sharp & Dohme Corp.|Pfizer,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,52,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",8835-040|B1521007|MK-8835-040,17-Feb-10,7-Apr-10,7-Apr-10,22-Jan-10,7-Nov-18,7-Nov-18,,,https://ClinicalTrials.gov/show/NCT01054300
NCT01053078,Naltrexone and Hypoglycemia in Type 1 Diabetes,Naltrexone,Completed,Has Results,Type 1 Diabetes|Hypoglycemia Unawareness,Drug: Naltrexone,Cerebral Blood Flow|Rates of Hypoglycemia,University of Minnesota - Clinical and Translational Science Institute|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|American Diabetes Association,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,29,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Protocol 10087|R01DK062440|7-09-DCS-02,Oct-09,Jun-14,Jun-14,21-Jan-10,12-Sep-14,24-Jan-18,"University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01053078
NCT01053728,Study of How Single Rising Doses of SAR161271 Are Absorbed and Act in Patients With Type 1 Diabetes Mellitus (T1DM),,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: SAR161271|Drug: Insulin glargine HOE901,"- Safety in terms of adverse and serious adverse events, vital signs, ECG, safety laboratory for each cohort|- Pharmacodynamics (Glucose infusion rate) time-action profile|- Pharmacokinetic parameters|- anti-insulin antibody production",Sanofi,Male,18 Years to 60 Years   (Adult),Phase 1|Phase 2,46,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",TDU10987|TDU10948,Feb-10,May-10,Nov-10,21-Jan-10,null,26-Jul-11,"Sanofi-Aventis Administrative Office, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT01053728
NCT01050868,Comparison of the Management of Post-prandial Hyperglycemia by Multiple Bolus Calculators,,Completed,No Results Available,Diabetes Mellitus Type 1,Device: Accu-Chek Combo Kit mg DE/de,"To compare the difference between the self-monitoring blood glucose (SMBG) value achieved at 6 hours after meals with induced post-prandial hyperglycemia and the mean target value of 110 mg/dL. Target post-prandial range is 80-140 mg/dL.|To compare the absolute difference between the SMBG value and the target value between the calculators|To compare theto compare the relative difference (multiplied by 100) between the SMBG value and the target value between the calculators|To compare the absolute relative difference (RAD, multiplied by 100) between the SMBG value and the target value between the calculators",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,24,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RD000811,Jun-09,Dec-09,Dec-09,18-Jan-10,null,3-Mar-16,"Ulm, Germany",,https://ClinicalTrials.gov/show/NCT01050868
NCT01051102,Effect of NN5401 in Japanese Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec/insulin aspart|Drug: biphasic insulin aspart 30,Area under the Glucose Infusion Rate curve after a single dose|Area under the insulin aspart concentration-time curve after a single dose,Novo Nordisk A/S,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 1,21,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN5401-1983|U1111-1112-3698,Jan-10,Apr-10,Apr-10,18-Jan-10,null,10-Feb-17,"Novo Nordisk Investigational Site, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT01051102
NCT01049412,A Study for Patients With Type 1 Diabetes,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: LY2605541|Drug: Insulin glargine,"Daily Average Blood Glucose (Avg. BG) at Week 8 Endpoint as Measured by the 8-Point Self-Monitored Blood Glucose (SMBG) Profiles|Change From Baseline in Daily Average Blood Glucose (Avg. BG) at Week 8 Endpoint as Measured by the 8-Point Self-Monitored Blood Glucose (SMBG) Profiles|Change From Baseline in Hemoglobin (HbA1c) at Week 8 Endpoint of Period I|Percentage of Participants With HbA1c <7.0% and HbA1c ≤6.5% at Week 8 Endpoint of Period I|Percentage of Participants With HbA1c <7.0% and HbA1c ≤6.5% at Week 8 Endpoint Who Did Not Experience a Hypoglycemic Episode During Treatment (Period I)|8-Point Self-Monitored Blood Glucose (SMBG) Measures at Week 8 Endpoint|Daily Basal Insulin Dose at Week 2 and Week 8 Endpoint|Pharmacokinetics - Drug (LY2605541) Concentration at Steady State (Css) at Week 8 Endpoint|Percentage of Participants With Antibody Status Change From Baseline to Week 8, Week 16 and Week 20|Percentage of Participants With Hypoglycemia Baseline Through Week 8|Rate of Hypoglycemia Per 30 Days Baseline Through Week 8|Glycemic Variability in Fasting Blood Glucose (FBG) at Week 8 Endpoint",Eli Lilly and Company,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,138,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12151|I2R-MC-BIAD,Jan-10,Dec-10,Jan-11,14-Jan-10,17-Apr-18,17-Apr-18,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chula Vista, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Idaho Falls, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Topeka, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Metairie, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Minneapolis, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Renton, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Holon, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Petah Tiqva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Hashomer, Israel",,https://ClinicalTrials.gov/show/NCT01049412
NCT01045707,"Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes",BOOST™,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/insulin aspart|Drug: insulin glargine,Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment|Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes|Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes|Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs)|Extension Trial (Secondary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment|Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 26,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,530,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN5401-3590|2009-011271-78|U1111-1111-7178|2009-015839-33|U1111-1114-9237,Jan-10,Oct-10,Oct-10,11-Jan-10,20-Nov-15,8-Dec-16,"Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Vestavia, Alabama, United States|Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Greenbrae, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Waterbury, Connecticut, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, North Miami, Florida, United States|Novo Nordisk Investigational Site, Pembroke Pines, Florida, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Council Bluffs, Iowa, United States|Novo Nordisk Investigational Site, Metairie, Louisiana, United States|Novo Nordisk Investigational Site, New Orleans, Louisiana, United States|Novo Nordisk Investigational Site, Detroit, Michigan, United States|Novo Nordisk Investigational Site, Troy, Michigan, United States|Novo Nordisk Investigational Site, Springfield, Missouri, United States|Novo Nordisk Investigational Site, St. Charles, Missouri, United States|Novo Nordisk Investigational Site, Brooklyn, New York, United States|Novo Nordisk Investigational Site, Smithtown, New York, United States|Novo Nordisk Investigational Site, Greensboro, North Carolina, United States|Novo Nordisk Investigational Site, Greenville, North Carolina, United States|Novo Nordisk Investigational Site, Morehead City, North Carolina, United States|Novo Nordisk Investigational Site, Wilson, North Carolina, United States|Novo Nordisk Investigational Site, Tulsa, Oklahoma, United States|Novo Nordisk Investigational Site, Portland, Oregon, United States|Novo Nordisk Investigational Site, Portland, Oregon, United States|Novo Nordisk Investigational Site, Greer, South Carolina, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Memphis, Tennessee, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Lubbock, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Tomball, Texas, United States|Novo Nordisk Investigational Site, St. George, Utah, United States|Novo Nordisk Investigational Site, Newport News, Virginia, United States|Novo Nordisk Investigational Site, Olympia, Washington, United States|Novo Nordisk Investigational Site, Ebreichsdorf, Austria|Novo Nordisk Investigational Site, Feldbach, Austria|Novo Nordisk Investigational Site, Innsbruck, Austria|Novo Nordisk Investigational Site, Salzburg, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Jaipur, Rajasthan, India|Novo Nordisk Investigational Site, Trichy, Tamil Nadu, India|Novo Nordisk Investigational Site, Bangalore, India|Novo Nordisk Investigational Site, Kerala, India|Novo Nordisk Investigational Site, Patna, India|Novo Nordisk Investigational Site, Pucheon, Korea, Republic of|Novo Nordisk Investigational Site, Pusan, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Krakow, Poland|Novo Nordisk Investigational Site, Lodz, Poland|Novo Nordisk Investigational Site, Lodz, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Pruszkow, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Bayamon, Puerto Rico|Novo Nordisk Investigational Site, Arkhangelsk, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Nizhniy Novgorod, Russian Federation|Novo Nordisk Investigational Site, Orenburg, Russian Federation|Novo Nordisk Investigational Site, Samara, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Smolensk, Russian Federation|Novo Nordisk Investigational Site, Stavropol, Russian Federation|Novo Nordisk Investigational Site, Yaroslavl, Russian Federation|Novo Nordisk Investigational Site, Barcelona, Spain|Novo Nordisk Investigational Site, Málaga, Spain|Novo Nordisk Investigational Site, Mérida, Spain|Novo Nordisk Investigational Site, Palma de Mallorca, Spain|Novo Nordisk Investigational Site, Partida de Bacarot, Spain|Novo Nordisk Investigational Site, Pozuelo de Alarcon, Spain|Novo Nordisk Investigational Site, San Sebastián de los Reyes, Spain|Novo Nordisk Investigational Site, Santiago de Compostela, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Valencia, Spain|Novo Nordisk Investigational Site, Valladolid, Spain|Novo Nordisk Investigational Site, Antalya, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT01045707
NCT01045954,A Study of the Rules for Insulin Dosing in Patients Using Multiple Daily Injections,,Unknown status,No Results Available,Diabetes Mellitus Type 1,Drug: Lispro Insulin and glargine insulin,"Determine the mean value for the slop between the variables of total daily dose versus total basal dose.|Determine the slope between the other variables: weight, total daily dose, total basal dose, insulin correction carbohydrate rate, correction factor",Diabetes Care Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCC 02-09,Jan-10,Aug-10,Oct-10,11-Jan-10,null,11-Jan-10,"Diabetes Care Center, Salinas, California, United States",,https://ClinicalTrials.gov/show/NCT01045954
NCT01044537,"A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus",,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Placebo|Drug: PF-04937319,Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)|Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Apparent Oral Clearance (CL/F)|Apparent Volume of Distribution (Vz/F)|Plasma Decay Half-Life (t1/2)|Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)|Change From Baseline in Ratio of C-peptide Area Under Curve (C-peptide AUC) to Glucose Area Under Curve (Glucose AUC) After a Mixed Meal Tolerance Test (MMTT) on Day 1|Percent Change From Baseline in Post-Prandial Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) on Day 1|Percent Change From Baseline in Post-Prandial Insulin Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) on Day 1|Percent Change From Baseline in Post-Prandial C-peptide Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) on Day 1|Change From Baseline in Ratio of Insulin Delta C30 to Glucose Delta C30 After a Mixed Meal Tolerance Test (MMTT) on Day 1|Change From Baseline in Ratio of C-peptide Delta C30 to Glucose Delta C30 After a Mixed Meal Tolerance Test (MMTT)|Change From Baseline in Ratio of Insulin Area Under Curve (Insulin AUC) to Glucose Area Under Curve (Glucose AUC) After a Mixed Meal Tolerance Test (MMTT) on Day 1,Pfizer,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,50,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other",B1621001,Feb-10,May-10,May-10,8-Jan-10,10-Mar-17,10-Mar-17,"Dedicated Phase 1, Phoenix, Arizona, United States|West Coast Clinical Trials, LLC, Cypress, California, United States|Elite Research Institute, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT01044537
NCT01045005,Doppler Ultrasound Investigation of Microcirculations,,Unknown status,No Results Available,Type 1 Diabetes Mellitus,Other: Administration ofOxygen and carbon dioxide|Other: Administration of Oxygen and carbon dioxide,Doppler Blood flow velocity waveforms measured at rest and after administration of oxygen and carbon dioxide|Radial Artery pressure waveforms,"Queen's University, Belfast",All,18 Years to 60 Years   (Adult),Not Applicable,72,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,05060CL−A,Jan-06,May-07,May-11,8-Jan-10,null,8-Jan-10,"Department of Therapeutics and Pharmacology, Queens University Belfast, Belfast, Antrim, United Kingdom",,https://ClinicalTrials.gov/show/NCT01045005
NCT01044368,Effect of Internet Therapeutic Intervention on A1C Levels in Type 2 Diabetes Mellitus (DM) on Monotherapy,,Suspended,No Results Available,Type 2 Diabetes Mellitus,Other: Internet Intervention,"The primary endpoint is the A1c level or the change in A1c level|The secondary endpoints include severe hypoglycemia defined as requiring external aid, hospital admissions for any CVD related intervention, and adverse events such as unplanned hospitalizations for any cause that last more than 24 hours",Endocrine Research Society,All,"25 Years to 79 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,T2D Monotherapy-Internet BGM,Jan-10,null,null,7-Jan-10,null,15-Sep-11,"St. Paul's Hospital, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT01044368
NCT01042301,Profiling of Original Cellular and Humoral Biomarkers of Type 1 Diabetes,Lymphoscreen,Completed,No Results Available,Type 1 Diabetes,Other: Blood samplings,Identification and characterization of new CD8+ T lymphocytes related to type 1 diabetes and its evolution (2009-2012)|Identification and characterization of new profiles of humoral and cellular markers (including T cell reactivity and miRNA) related to type 1 diabetes (2010-2014).,Nantes University Hospital,All,"7 Years to 70 Years   (Child, Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,BRD07/5-A,Sep-07,Oct-14,Oct-14,5-Jan-10,null,9-Sep-15,"CHU de Nantes, Nantes, France",,https://ClinicalTrials.gov/show/NCT01042301
NCT01035801,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Insulin (IN-105) in Type 1 Diabetes Patients",,Terminated,No Results Available,Type 1 Diabetes Mellitus,Drug: IN-105|Drug: Insulin Lispro Injection,AUC (Insulin and Blood Glucose)|Frequency of Adverse Events,Biocon Limited,All,18 Years to 45 Years   (Adult),Phase 1,20,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IN105-CT1-005-09,21-Aug-10,12-Mar-11,12-Mar-11,21-Dec-09,null,23-Jan-18,"Care Hospital, Hyderabad, Andhra Pradesh, India|Bharti Research Institute of Diabetes and Endocrinology, Karnal, Hariyana, India|Diacon Hospital,(Diabetes Care and Research Centre), Bangalore, Karnataka, India|Bangalore Diabetes Hospital, Bangalore, Karnataka, India|Belgaum Diabetic Centre, Belgaum, Karnataka, India",,https://ClinicalTrials.gov/show/NCT01035801
NCT01033500,"Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients",,Withdrawn,No Results Available,"Islets of Langerhans Transplantation|Diabetes Mellitus, Type 1|Kidney Transplantation",Drug: Belatacept,Achieve and consistently maintain insulin independence in simultaneous islet-kidney transplant recipients for one year.,"University of Wisconsin, Madison|Bristol-Myers Squibb",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-2010-0042,Jul-10,Dec-12,Dec-12,16-Dec-09,null,8-May-13,"University of Wisconsin, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01033500
NCT01030861,"Teplizumab for Prevention of Type 1 Diabetes In Relatives ""At-Risk""",,"Active, not recruiting",No Results Available,Autoantibody Positive|Non-diabetic Relatives at Risk for Type 1 Diabetes|High Risk|Impaired Glucose Tolerance,Drug: Teplizumab|Drug: Placebo infusion,"Criteria are met for diabetes onset as defined by the American Diabetes Association (ADA) based on glucose testing or the presence of unequivocal hyperglycemia with acute metabolic decompensation.|effects on teplizumab based on age, gender, race/ethnicity,weight, BMI, immunologic, genetic , demographic, and lifestyle factors.",National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Center for Research Resources (NCRR)|Juvenile Diabetes Research Foundation|American Diabetes Association,All,"8 Years to 45 Years   (Child, Adult)",Phase 2,76,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TrialNet - tep (IND)|UC4DK106993,Aug-10,Nov-18,Jun-19,14-Dec-09,null,15-May-19,"University of California in San Francisco, San Francisco, California, United States|University of California-San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes/ University of Colorado, Denver, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Indiana University, Indianapolis, Indiana, United States|University of Minnesota, Minneapolis, Minnesota, United States|The Children's Mercy Hospital, Kansas City, Missouri, United States|Columbia University, New York, New York, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Texas, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Benaroya Research Institute, Seattle, Washington, United States|The Hospital for Sick Children, Toronto, Ontario, Canada|Forschergruppe Diabetes, Munich, Germany",,https://ClinicalTrials.gov/show/NCT01030861
NCT01030926,"A Trial Investigating the Concentration in the Blood of NN1250 in Children, Adolescents and Adults With Type 1 Diabetes",,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin glargine,Area under the NN1250 concentration-time curve after single dose|Maximum observed NN1250 concentration after single dose|Time to maximum observed NN1250 concentration after single dose,Novo Nordisk A/S,All,"6 Years to 65 Years   (Child, Adult, Older Adult)",Phase 1,39,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1250-1995|2008-008306-43|U1111-1112-4715,Dec-09,May-10,May-10,14-Dec-09,null,20-Jan-17,"Novo Nordisk Investigational Site, Hannover, Germany",,https://ClinicalTrials.gov/show/NCT01030926
NCT01030471,Supporting Treatment Adherence Needs in Diabetes,STAND,Unknown status,No Results Available,Type 1 Diabetes,Behavioral: Family-based cognitive-behavioral treatment,Children's Depression Inventory (CDI)-Measure of adolescent depressive symptoms|Diabetes-Related Family Conflict Scale (DFCS)-Measure of family conflict around diabetes-specific tasks|Hemoglobin A1c value,"Children's Hospital Medical Center, Cincinnati|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",All,13 Years to 17 Years   (Child),Not Applicable,52,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,DK81711|R03DK081711,Sep-09,Sep-12,Sep-12,11-Dec-09,null,22-Jun-11,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01030471
NCT01029392,Prevalence of Vitamin D Deficiency in Type 1 Diabetes Mellitus and Effect of Supplementation on Insulin Requirements,,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Vitamin D,Change in Hemoglobin A1c|Change in Insulin Requirements,William Beaumont Hospitals,All,"1 Year to 18 Years   (Child, Adult)",Phase 3,75,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2009-189,Nov-09,Jun-12,Jun-12,10-Dec-09,17-Apr-17,17-Apr-17,"WilliamBH, Royal Oak, Michigan, United States",,https://ClinicalTrials.gov/show/NCT01029392
NCT01029795,A Study of LY2599506 (Oral Agent Medication: Glucokinase Activator 1) in Type 2 Diabetes Mellitus,,Terminated,Has Results,"Diabetes Mellitus, Type 2",Drug: LY2599506|Drug: Glyburide|Drug: Placebo,"Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 12 Weeks|Change From Baseline in the QT Interval in Electrocardiogram (ECG) at 12 Weeks and 16 Weeks|Change From Baseline in the Homeostasis Model Assessment (HOMA2) Pancreatic Beta Cell Function (%B) at 12 Weeks and 16 Weeks|Change From Baseline in the Homeostasis Model Assessment (HOMA2) of Insulin Sensitivity (%S) at 12 Weeks and 16 Weeks|Change From Baseline in Triglycerides, Low-density Lipoprotein Cholesterol (LDL-C), High-density Lipoprotein Cholesterol (HDL-C), Non-HDL-C, Total Cholesterol, and Free Fatty Acids at 12 Weeks and 16 Weeks|Change From Baseline in the European Quality of Life -5 Dimension (EQ-5D) at 12 Weeks and 16 Weeks|Change From Baseline in the Diabetes Treatment Satisfaction Questionnaire (DTSQ) at 12 Weeks and 16 Weeks|Change From Baseline in the Adult Low Blood Sugar Survey (LBSS-33 Item Scale) at 12 Weeks and 16 Weeks|Changes From Baseline in the Diabetes Symptoms Checklist-Revised (DSC-R) at 12 Weeks and 16 Weeks|Change From Baseline in the Perceptions About Medications - Diabetes (PAM-D) Questionnaire at 12 Weeks and 16 Weeks|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at 12 Weeks and 16 Weeks|Number of Hypoglycemic Episodes During 12-week Treatment Period and 4-week Follow-up Period|Change From Baseline in Body Weight at 12 Weeks and 16 Weeks|Change From Baseline in the Seven-Point Self-Monitored Blood Glucose (7-point SMBG) at 4 Weeks, 12 Weeks, and 16 Weeks|Percentage of Participants With Lipase and Amylase Measurements Above 2-fold Upper Limits of Normal (ULN) During the 12-week Treatment Period|Percentage of Participants With Clinically-Significant Elevations of Alanine Aminotransferase/Serum Glutamate Pyruvate Transaminase (ALT/SGPT) During the 12-week Treatment Period|Maximum Plasma Concentration (Cmax) at the Steady State for LY2599506|Area Under the Concentration-Time Curve (AUC) at a Dosing Interval (AUCtau) at the Steady State for LY2599506|30-day Adjusted Rates of Self-reported Hypoglycemic Episodes Overall|Change From Baseline in Heart Rate at 12 Weeks and 16 Weeks|Mean Morning Dose of LY2599506 During the 12-week Treatment Period|Mean Afternoon Dose of LY2599506 During the 12-week Treatment Period|Percentage of Participants Requiring Dose Adjustments During the 12-week Treatment Period|Mean Total Daily Dose of LY2599506 During the 12-week Treatment Period",Eli Lilly and Company,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,38,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",13272|I2Q-MC-GMAJ,Feb-10,Jun-10,Jun-10,10-Dec-09,26-Oct-11,2-Dec-11,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Elizabeth Vale, South Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., East Ringwood, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vienna, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Holesov, Czech Republic|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prague, Czech Republic|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuss, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jerusalem, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nahariya, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rostov-On-Don, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cordoba, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dos Hermanas, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Teruel, Spain",,https://ClinicalTrials.gov/show/NCT01029795
NCT01028404,A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Healthy",Drug: NN1952|Drug: insulin aspart|Drug: placebo,Number and severity of adverse events for trial part 1|Number and severity of adverse events for trial part 2|Area under the serum insulin concentration-time curve after a single dose|Area under the glucose infusion rate-time curve after a single dose,Novo Nordisk A/S,All,18 Years to 55 Years   (Adult),Phase 1,84,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1952-3646|U1111-1112-2892|2009-013282-26,Nov-09,Jun-10,Jun-10,9-Dec-09,null,25-Jul-17,"Novo Nordisk Investigational Site, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT01028404
NCT01023165,Effects of Intensive Bolus Intravenous Insulin Delivery on Metabolic Integrity in Type 1 and Type 2 Diabetes,,Unknown status,No Results Available,Diabetes Mellitus|Metabolic Integrity,"Procedure: Humulin, Humalog, Novolog",Researchers will assess whether restoring metabolic integrity to diabetic patients improves quality of life and complications associated with diabetes,"Global Infusion and Aspiration Systems, LLC",All,"18 Years to 95 Years   (Adult, Older Adult)",Phase 3,2000,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GI-001,Nov-09,Nov-14,Nov-15,2-Dec-09,null,22-Jun-11,"Global Infusion and Aspiration Systems, LLC, Batesville, Mississippi, United States",,https://ClinicalTrials.gov/show/NCT01023165
NCT01023945,A Study of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: ASP1941|Drug: Placebo,"Change in plasma glucose levels|Urinary glucose excursion|Pharmacokinetic parameter of ASP1941|Safety by adverse events, routine safety laboratories and vital signs.|Change in serum insulin levels",Astellas Pharma Inc,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 1,30,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1941-CL-0070,7-Nov-09,26-Mar-10,26-Mar-10,2-Dec-09,null,9-Aug-18,"Kantou, Japan",,https://ClinicalTrials.gov/show/NCT01023945
NCT01019486,Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D),RABIT1D,Completed,Has Results,Coronary Artery Disease|Type 1 Diabetes Mellitus,Drug: Regadenoson myocardial perfusion imaging|Drug: Regadenoson MRI myocardial blood flow,Coronary Blood Flow Assessment With Regadenoson Stress by Cardiac MRI Between Non-diabetic and Type 1 Diabetic Subjects.|Measured Coronary Blood Flow is Directly Correlated With Coronary Flow Reserve Measured Invasively in the Cardiac Catheterization Laboratory After Regadenoson Pharmacologic Stress.|Myocardial Perfusion Index,"University of Colorado, Denver",All,"25 Years to 65 Years   (Adult, Older Adult)",Phase 4,26,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,09-0426,Nov-09,Dec-11,Dec-11,25-Nov-09,14-Dec-15,14-Dec-15,"Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|University of Colorado Denver, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|University Hospital, the University of Colorado Health Sciences Center, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT01019486
NCT01016457,Real-Time Continuous Glucose Monitoring in Pre-School Children With Type-1 Diabetes Mellitus,,Unknown status,No Results Available,Diabetes Mellitus,Device: Guardian RT,HbA1C|Quality of life|Number of night hypoglycemias|Mean glucose level,Sheba Medical Center,All,1 Year to 6 Years   (Child),Phase 4,15,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,SHEBA-07-4980-KMA-CTIL,Dec-08,Aug-09,Dec-09,19-Nov-09,null,19-Nov-09,"Sheba Medical Center, Ramat Gan, Israel",,https://ClinicalTrials.gov/show/NCT01016457
NCT01014832,Efficacy and Safety of Frequently Modified Intensive Insulin,,Completed,No Results Available,Diabetes,Drug: Intensive insulin therapy,Hemoglobin A1C|Mean weekly glucose|Frequency of hypoglycemia,"Hygieia, Inc|TKL Research, Inc.",All,"25 Years to 65 Years   (Adult, Older Adult)",Not Applicable,14,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Hygieia study -2|CS950308,Dec-08,Aug-09,Aug-09,17-Nov-09,null,17-Nov-09,"TKL Research INC., Paramus, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT01014832
NCT01013571,Self Titration With Apidra to Reach Target Study (START),,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: insulin glargine|Drug: Apidra (insulin glulisine),"Percentage of subjects reaching target HbA1c <=7.0% without severe hypoglycemia|Change in HbA1c, FG, and 7-point glucose profile|Change in weight|Incidence of hypoglycemia|Treatment satisfaction (DTSQ for patient )|Adherence with the patient-managed monitoring algorithm",Sanofi,All,"30 Years and older   (Adult, Older Adult)",Phase 4,493,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LANTU_L_04695,Oct-09,Jan-12,Jan-12,13-Nov-09,null,21-Mar-12,"Sanofi-Aventis Administrative Office, Laval, Canada",,https://ClinicalTrials.gov/show/NCT01013571
NCT01009580,Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes,BOOST™,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/insulin aspart|Drug: biphasic insulin aspart 30,Change in Glycosylated Haemoglobin (HbA1c)|Mean of 9-point Self Measured Plasma Glucose Profile (SMPG)|Rate of Confirmed Hypoglycaemic Episodes|Rate of Nocturnal Confirmed Hypoglycaemic Episodes,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,447,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN5401-3592|2008-005768-15|U1111-1111-8545,5-Nov-09,23-Aug-10,23-Aug-10,6-Nov-09,20-Nov-15,19-Dec-18,"Novo Nordisk Investigational Site, St Leonards, New South Wales, Australia|Novo Nordisk Investigational Site, Wollongong, New South Wales, Australia|Novo Nordisk Investigational Site, East Ringwood, Victoria, Australia|Novo Nordisk Investigational Site, Melbourne, Victoria, Australia|Novo Nordisk Investigational Site, Garran, Australia|Novo Nordisk Investigational Site, Gentofte, Denmark|Novo Nordisk Investigational Site, Hjørring, Denmark|Novo Nordisk Investigational Site, Horsens, Denmark|Novo Nordisk Investigational Site, Hvidovre, Denmark|Novo Nordisk Investigational Site, København, Denmark|Novo Nordisk Investigational Site, Svendborg, Denmark|Novo Nordisk Investigational Site, Århus C, Denmark|Novo Nordisk Investigational Site, Kuopio, Finland|Novo Nordisk Investigational Site, Lahti, Finland|Novo Nordisk Investigational Site, Oulu, Finland|Novo Nordisk Investigational Site, Pori, Finland|Novo Nordisk Investigational Site, Ylitornio, Finland|Novo Nordisk Investigational Site, Karnal, Haryana, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Trivandrum, Kerala, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Kolkata, India|Novo Nordisk Investigational Site, Mumbai, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, Cheras, Malaysia|Novo Nordisk Investigational Site, Kota Bharu, Kelantan, Malaysia|Novo Nordisk Investigational Site, Pulau Pinang, Malaysia|Novo Nordisk Investigational Site, Putrajaya, Malaysia|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Bydgoszcz, Poland|Novo Nordisk Investigational Site, Gniewkowo, Poland|Novo Nordisk Investigational Site, Plock, Poland|Novo Nordisk Investigational Site, Rawa Mazowiecka, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Falun, Sweden|Novo Nordisk Investigational Site, Karlstad, Sweden|Novo Nordisk Investigational Site, Lund, Sweden|Novo Nordisk Investigational Site, Lund, Sweden|Novo Nordisk Investigational Site, Malmö, Sweden|Novo Nordisk Investigational Site, Stockholm, Sweden|Novo Nordisk Investigational Site, Changhua, Taiwan|Novo Nordisk Investigational Site, Chiayi City, Taiwan|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Chiang Mai, Thailand|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Kocaeli, Turkey",,https://ClinicalTrials.gov/show/NCT01009580
NCT01002768,Comparison of Hypoglycaemic Response Between NN1250 and Insulin Glargine in Type 1 Diabetics,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin glargine,Baseline-adjusted hypoglycaemic symptoms score at nadir plasma glucose concentration|Baseline-adjusted hypoglycaemic symptoms score at each level of plasma glucose|Time from start of hypoglycaemic induction until each level of plasma glucose is reached|Time to increase from nadir plasma glucose to a plasma glucose concentration of 3.9 mmol/L|Hypoglycaemic symptoms score during recovery from hypoglycaemia,Novo Nordisk A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,28,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1250-3538|U1111-1111-8843|2008-008356-16,Oct-09,Mar-10,Mar-10,27-Oct-09,null,20-Jan-17,"Novo Nordisk Investigational Site, Graz, Austria",,https://ClinicalTrials.gov/show/NCT01002768
NCT01000922,"A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro",,Completed,No Results Available,Diabetes Mellitus,Drug: Regular Human Insulin|Drug: Lispro|Drug: VIAject|Drug: VIAject 50%|Drug: VIAject/Insulin Glargine|Drug: Insulin Glargine/VIAject,"To compare the maximal post prandial blood glucose concentration and the time to maximal post prandial glucose concentration between the different treatments|To compare the ppGlucmax for all treatments, the ppTGluc-max, the AUCGluc 0-180 and the AUCGluc 0-360, CGluc-baseline for all treatments.",Biodel,All,"19 Years to 70 Years   (Adult, Older Adult)",Phase 2,24,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VIAJECT™-010JM,Jun-06,Jan-08,Jan-08,23-Oct-09,null,29-Jul-15,"Profil Institute for Clinical Research, Inc. (PICR), Chula Vista, California, United States",,https://ClinicalTrials.gov/show/NCT01000922
NCT00999375,Cultivating Healthy Environments in Families With Type 1 Diabetes (CHEF),,Completed,No Results Available,Type I Diabetes,Behavioral: Education|Behavioral: Problem Solving|Behavioral: Social Learning|Behavioral: Behavior Modification,"Change in glycemic control, change in dietary intake|Change in social cognitive mediators of behavior; change in psychosocial status; change in body composition, lipids, oxidative stress, and inflammation",Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC),All,8 Years to 17 Years   (Child),Phase 2,293,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,999909234|09-CH-N234,18-Sep-09,27-Nov-13,27-Nov-13,21-Oct-09,null,25-Sep-18,"Joslin Diabetes Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00999375
NCT00998699,Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Drug: Xoma 052|Drug: Placebo,"Change in beta-cell function as measured by change in C-peptide level during thd MMTT (Mixed meal tolerance test) at Day 112 compared to baseline (Day 0 pre-dose)|Safety assessed by pre- and post-treatment serial measurements of vital signs, clinical laboratory assessments, and treatment-emergent adverse events.|Change in insulin requirements|Change in HbA1c levels|Change in fasting glucose|Change in fasting glucagon and cortisol|Change in systemic inflammation markers|Change in meal-stimulated GLP-1 and GIP|Change in lipids profile|Measurement of serum concentrations of XOMA 052",XOMA (US) LLC|Juvenile Diabetes Research Foundation,All,18 Years to 55 Years   (Adult),Phase 2,22,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",X052076,Feb-10,Aug-13,Aug-13,20-Oct-09,null,4-Mar-14,"Basel, Switzerland|Zurich, Switzerland",,https://ClinicalTrials.gov/show/NCT00998699
NCT00995540,"Tolerability, Safety, and Efficacy Study of INGAP Peptide to Treat Type 1 Diabetes Mellitus in Adults",,Terminated,No Results Available,Type 1 Diabetes Mellitus,Drug: INGAP Peptide|Drug: Placebo,Injection tolerability|C-peptide,Exsulin Corporation,All,19 Years to 60 Years   (Adult),Phase 2,23,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",E-201,Nov-09,Dec-11,Dec-11,15-Oct-09,null,12-Feb-14,"Mayo Clinic, Rochester, Minnesota, United States|McGill University - Montreal General Hospital, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00995540
NCT00993473,6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes,PRESCHOOL,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Insulin glargine (HOE901)|Drug: Neutral Protamine Hagedorn (NPH) insulin|Drug: Insulin lispro,"Event Rate of ""All Hypoglycemia"" Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years (Events Per Patient-year)|Event Rate of Symptomatic Hypoglycemia (Individual Component of Primary Endpoint) Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years (Events Per Patient-year)|Event Rate of Severe Symptomatic Hypoglycemia Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years|Event Rate of Nocturnal Hypoglycemia Defined as the Total Number of ""All Hypoglycemia"" Episodes Divided by the Total Duration of the On-treatment Period in Years|Event Rate of Nocturnal Symptomatic Hypoglycemia Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years|Event Rate of Severe Nocturnal Hypoglycemia Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years|Glycosylated Hemoglobin A1c (HbA1c): End of Treatment and Change From Baseline to End of Treatment|Glycosylated Hemoglobin A1c (HbA1c): End of Treatment and Change From Baseline to End of Treatment (ANCOVA Estimates)|Percentage of Patients Reaching HbA1c Target of Less Than 7.5% at the End of Treatment Visit|Average Daily Blood Glucose (BG) Based on CGMS Values: End of Treatment and Change From Baseline to End of Treatment",Sanofi,All,1 Year to 6 Years   (Child),Phase 3,125,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EFC11202|2009-011231-12,Oct-09,Mar-11,Mar-11,12-Oct-09,22-Jun-12,27-Jun-12,"Sanofi-Aventis Investigational Site Number 840006, Sacramento, California, United States|Sanofi-Aventis Investigational Site Number 840014, San Diego, California, United States|Sanofi-Aventis Investigational Site Number 840005, Greenwood Village, Colorado, United States|Sanofi-Aventis Investigational Site Number 840008, Baltimore, Maryland, United States|Sanofi-Aventis Investigational Site Number 840007, Buffalo, New York, United States|Sanofi-Aventis Investigational Site Number 840011, Philadelphia, Pennsylvania, United States|Sanofi-Aventis Investigational Site Number 840010, Houston, Texas, United States|Sanofi-Aventis Investigational Site Number 840002, San Antonio, Texas, United States|Sanofi-Aventis Investigational Site Number 040001, Wien, Austria|Sanofi-Aventis Investigational Site Number 076001, Brasilia, Brazil|Sanofi-Aventis Investigational Site Number 076003, Curitiba, Brazil|Sanofi-Aventis Investigational Site Number 076005, Fortaleza, Brazil|Sanofi-Aventis Investigational Site Number 076004, Fortaleza, Brazil|Sanofi-Aventis Investigational Site Number 076002, Porto Alegre, Brazil|Sanofi-Aventis Investigational Site Number 076006, Rio De Janeiro, Brazil|Sanofi-Aventis Investigational Site Number 152002, Santiago, Chile|Sanofi-Aventis Investigational Site Number 152003, Santiago, Chile|Sanofi-Aventis Investigational Site Number 152001, Santiago, Chile|Sanofi-Aventis Investigational Site Number 152004, Viña Del Mar, Chile|Sanofi-Aventis Investigational Site Number 203001, Olomouc, Czech Republic|Sanofi-Aventis Investigational Site Number 203003, Pardubice, Czech Republic|Sanofi-Aventis Investigational Site Number 203002, Usti Nad Labem, Czech Republic|Sanofi-Aventis Investigational Site Number 276002, Düsseldorf, Germany|Sanofi-Aventis Investigational Site Number 276003, Münster, Germany|Sanofi-Aventis Investigational Site Number 348004, Budapest, Hungary|Sanofi-Aventis Investigational Site Number 348005, Budapest, Hungary|Sanofi-Aventis Investigational Site Number 348003, Miskolc, Hungary|Sanofi-Aventis Investigational Site Number 348002, Szeged, Hungary|Sanofi-Aventis Investigational Site Number 348001, Szombathely, Hungary|Sanofi-Aventis Investigational Site Number 356003, Bangalore, India|Sanofi-Aventis Investigational Site Number 356005, Bangalore, India|Sanofi-Aventis Investigational Site Number 356001, Bangalore, India|Sanofi-Aventis Investigational Site Number 356002, Indore, India|Sanofi-Aventis Investigational Site Number 356004, Karnal, India|Sanofi-Aventis Investigational Site Number 484002, Guadalajara, Mexico|Sanofi-Aventis Investigational Site Number 484003, Monterrey, Mexico|Sanofi-Aventis Investigational Site Number 484001, Puebla, Mexico|Sanofi-Aventis Investigational Site Number 604003, Lima, Peru|Sanofi-Aventis Investigational Site Number 604002, Lima, Peru|Sanofi-Aventis Investigational Site Number 604001, Lima, Peru|Sanofi-Aventis Investigational Site Number 616002, Gdansk, Poland|Sanofi-Aventis Investigational Site Number 616001, Warszawa, Poland|Sanofi-Aventis Investigational Site Number 642008, Bucharest, Romania|Sanofi-Aventis Investigational Site Number 642001, Cluj Napoca, Romania|Sanofi-Aventis Investigational Site Number 642011, Constanta, Romania|Sanofi-Aventis Investigational Site Number 642006, Sibiu, Romania|Sanofi-Aventis Investigational Site Number 643001, Moscow, Russian Federation|Sanofi-Aventis Investigational Site Number 643002, Moscow, Russian Federation|Sanofi-Aventis Investigational Site Number 643003, St-Petersburg, Russian Federation|Sanofi-Aventis Investigational Site Number 643004, Ufa, Russian Federation|Sanofi-Aventis Investigational Site Number 643005, Yaroslavl, Russian Federation|Sanofi-Aventis Investigational Site Number 710004, Durban, South Africa|Sanofi-Aventis Investigational Site Number 710002, Johannesburg, South Africa|Sanofi-Aventis Investigational Site Number 710001, Observatory, South Africa|Sanofi-Aventis Investigational Site Number 710003, Pretoria, South Africa|Sanofi-Aventis Investigational Site Number 724003, Santiago De Compostela, Spain|Sanofi-Aventis Investigational Site Number 724001, Sevilla, Spain|Sanofi-Aventis Investigational Site Number 724005, Valencia, Spain|Sanofi-Aventis Investigational Site Number 724004, Zaragoza, Spain|Sanofi-Aventis Investigational Site Number 792001, Ankara, Turkey|Sanofi-Aventis Investigational Site Number 792003, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT00993473
NCT00993720,"Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes",,Completed,No Results Available,Diabetes Mellitus,Drug: Liraglutide|Other: continuous insulin therapy,"insulin-dose|24-hours glucose profiles with and without treatment of Victoza|risk of hypoglycemia during physical activity with and without Victoza|gastric emptying rate during hypoglycemia with and without Victoza|weight change from baseline, change in fructosamine from baseline",Hvidovre University Hospital,All,18 Years to 50 Years   (Adult),Phase 2|Phase 3,30,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2009-001930-80,Oct-09,Oct-10,Oct-10,12-Oct-09,null,21-Jan-11,"Hvidovre University Hospital, Hvidovre, Denmark",,https://ClinicalTrials.gov/show/NCT00993720
NCT00992537,Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Type 1 Diabetics,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin degludec/insulin aspart|Drug: insulin aspart,Area under the glucose infusion rate curve|Area under the insulin degludec concentration-time curve|Maximum observed insulin degludec concentration|Area under the insulin aspart concentration-time curve|Maximum observed insulin aspart concentration,Novo Nordisk A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,27,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN5401-1977|2008-008357-32|U1111-1111-9043,Oct-09,Jan-10,Jan-10,9-Oct-09,null,27-Nov-13,"Neuss, Germany",,https://ClinicalTrials.gov/show/NCT00992537
NCT00993096,Investigation of the Response Relationship of NN5401 in Type 1 Diabetics,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec/insulin aspart|Drug: biphasic insulin aspart 30,Area (AUC) under the glucose infusion rate curve|Area (AUC) under the insulin aspart concentration time curve,Novo Nordisk A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,33,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN5401-3539|2008-008472-14|U1111-1111-9032,Sep-09,Dec-09,Dec-09,9-Oct-09,null,10-Feb-17,"Novo Nordisk Investigational Site, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT00993096
NCT00989898,Automated Overnight Closed-loop Glucose Control in Young People With Type 1 Diabetes,APCam05,Completed,No Results Available,Type 1 Diabetes,Other: Automated closed-loop insulin delivery,The primary outcome measure is overnight glucose control as measured by plasma glucose concentration between midnight and 8:00 a.m. in the two Time Schedules (closed-loop control starting at 1800 or 2100).,University of Cambridge|Cambridge University Hospitals NHS Foundation Trust,All,"6 Years to 18 Years   (Child, Adult)",Not Applicable,16,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CI/2008/0036,Feb-09,May-11,Dec-11,6-Oct-09,null,25-Jun-12,"Wellcome Trust Clinical Research Facility, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT00989898
NCT00989547,Cord Blood Infusion for Type 1 Diabetes Mellitus (T1DM),,Unknown status,No Results Available,Type 1 Diabetes|Children,Other: Umbilical Cord Blood VITA 34,"insulin production|Insulin Dose, Autoantibody levels, T-cell functional response assays, Cytokine levels",Technische Universität München,All,"1 Year and older   (Child, Adult, Older Adult)",Phase 1,18,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,593,Sep-08,Sep-14,null,5-Oct-09,null,23-Jul-13,"Forschergruppe Diabetes der Technischen Universität, München, Bavaria, Germany",,https://ClinicalTrials.gov/show/NCT00989547
NCT00989079,"A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)",,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Ertugliflozin|Drug: Placebo to Ertugliflozin,Number of Participants Experiencing an Adverse Event (AE)|Number of Participants Discontinuing Study Drug Due to an AE|Change from baseline in 24-hour urinary glucose excretion|Area under the plasma concentration-time curve (AUC) from Time 0 to infinity (AUCinf) for ertugliflozin|Area under the plasma concentration-time curve (AUC) from Time 0 to time of the last quantifiable concentration (AUClast) for ertugliflozin|Maximum plasma concentration (Cmax) of ertugliflozin|Time taken to reach the maximum observed plasma concentration (Tmax) of ertugliflozin|Ertugliflozin half life (t1/2)|Apparent clearance (CL/F) after a single dose of ertugliflozin|Apparent volume of distribution (Vz/F)|Urinary glucose excretion over 72 hours|Change from baseline in 24-hour weighted mean glucose|Inhibition of glucose reabsorption|Renal clearance (CLr) of Ertugliflozin|Urinary recovery of Ertugliflozin,Merck Sharp & Dohme Corp.|Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)",8835-036,Oct-09,Dec-09,Dec-09,2-Oct-09,null,18-Mar-16,,,https://ClinicalTrials.gov/show/NCT00989079
NCT00986375,Online Program Assisting Lifestyle Changes (Asterix 1.0 & Obelix 2.0),OPAL,Completed,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: Intervention Group (IG)|Behavioral: Active Control Group (ACG),"physical activity fruit & vegetable consumption|subjective health & well-being|motivation/volition|social-cognitive predictors of behavior (self-efficacy, action control etc.)|intervention engagement",Freie Universität Berlin,All,"9 Years and older   (Child, Adult, Older Adult)",Not Applicable,1000,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",FU-10-4711-001|Asterix_1.0|Obelix_2.0,Oct-09,Sep-10,Jun-11,30-Sep-09,null,14-Nov-12,"Freie Universitaet Berlin, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT00986375
NCT00985361,Effect of Vitamin D Supplementation on Hemoglobin A1c in Patients With Uncontrolled Type 2 Diabetes Mellitus,,Completed,No Results Available,Type 2 Diabetes Mellitus,Dietary Supplement: Vitamin D3 2000 international units daily|Dietary Supplement: Vitamin C 500mg daily,Hemoglobin A1c,ProMedica Health System,All,"21 Years to 75 Years   (Adult, Older Adult)",Not Applicable,37,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,09-055,Oct-09,Mar-10,Mar-10,28-Sep-09,null,6-May-10,"Flower Hospital Family Medicine Residency, Sylvania, Ohio, United States|Center for Health Services, Toledo, Ohio, United States|Toledo Hospital Family Medicine Residency, Toledo, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00985361
NCT00985712,A Study on the Effect of 2 Pen Devices on HbA1c,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Insulin Lispro|Drug: Huminsulin Regular|Device: HumaPen Memoir|Device: HumaPen Luxura,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 Endpoint|Percentage of Participants Achieving Hemoglobin A1c (HbA1c) ≤7.5% and ≤7.0% at Week 24 Endpoint|Score in Insulin Delivery System Questionnaire (IDSQ) - Willingness to Continue at Week 24 Endpoint|30-Day Adjusted Rates of Self-Reported Hypoglycemic Episodes at Any Time From Baseline Through Week 24|30-Day Adjusted Rates of Self-Reported Hyperglycemic Episodes at Any Time From Baseline Through Week 24,Eli Lilly and Company,All,"8 Years and older   (Child, Adult, Older Adult)",Phase 4,263,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12704|H9D-SB-ITAE,Oct-09,Jul-11,Jul-11,28-Sep-09,4-Jun-12,4-Jun-12,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aschaffenburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Asslar, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bad Mergentheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bosenheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Diez, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dresden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Erlangen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Essen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Falkensee, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Flensburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fulda, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Giessen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Herdecke, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leipzig, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Münster, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuwied, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rehlingen-Siersburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rotenburg-Fulda, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saarbrücken, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Schkeuditz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Schwedt/Oder, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tuebingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wuppertal, Germany",,https://ClinicalTrials.gov/show/NCT00985712
NCT00983775,Pharmacology of Insulin Injected With Jet-Injection,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: jet injector (SQ pen/Novopen III),(time to) maximal glucose infusion rate|(time to) maximal insulin concentration,Radboud University,All,18 Years to 50 Years   (Adult),Not Applicable,48,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PKPD_SQ_1,Nov-09,Nov-10,Nov-10,24-Sep-09,null,11-Aug-11,"Radboud University Nijmegen Medical Centre, Nijmegen, P.O. Box 9101, Netherlands",,https://ClinicalTrials.gov/show/NCT00983775
NCT00982228,Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes,BEGIN™,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin glargine|Drug: insulin aspart,Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment|Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs)|Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes|Extension Trial (Primary Endpoint): Cross-reacting Antibodies to Human Insulin|Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes|Extension Trial (Secondary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 104 Weeks of Treatment|Extension Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 104 of Treatment|Main Trial (Secondary Endpoint): Rate of Confirmed Hypoglycaemic Episodes|Main Trial (Secondary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes|Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 52,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,629,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN1250-3583|2008-005774-13|U1111-1111-8789|2009-015755-24|U1111-1116-1578,1-Sep-09,8-Nov-10,8-Nov-10,23-Sep-09,29-Dec-15,6-Apr-17,"Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Huntsville, Alabama, United States|Novo Nordisk Investigational Site, Peoria, Arizona, United States|Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Greenbrae, California, United States|Novo Nordisk Investigational Site, Huntington Beach, California, United States|Novo Nordisk Investigational Site, La Mesa, California, United States|Novo Nordisk Investigational Site, Los Gatos, California, United States|Novo Nordisk Investigational Site, Santa Barbara, California, United States|Novo Nordisk Investigational Site, Tustin, California, United States|Novo Nordisk Investigational Site, Ventura, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, Hollywood, Florida, United States|Novo Nordisk Investigational Site, Lake Mary, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Lawrenceville, Georgia, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Vincennes, Indiana, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Scarborough, Maine, United States|Novo Nordisk Investigational Site, Hyattsville, Maryland, United States|Novo Nordisk Investigational Site, Rockville, Maryland, United States|Novo Nordisk Investigational Site, Brockton, Massachusetts, United States|Novo Nordisk Investigational Site, Flint, Michigan, United States|Novo Nordisk Investigational Site, Livonia, Michigan, United States|Novo Nordisk Investigational Site, Eagan, Minnesota, United States|Novo Nordisk Investigational Site, Chesterfield, Missouri, United States|Novo Nordisk Investigational Site, Jefferson City, Missouri, United States|Novo Nordisk Investigational Site, St. Charles, Missouri, United States|Novo Nordisk Investigational Site, Great Falls, Montana, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Dover, New Hampshire, United States|Novo Nordisk Investigational Site, Lawrenceville, New Jersey, United States|Novo Nordisk Investigational Site, Flushing, New York, United States|Novo Nordisk Investigational Site, Rochester, New York, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Raleigh, North Carolina, United States|Novo Nordisk Investigational Site, Columbus, Ohio, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Rapid City, South Dakota, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Lubbock, Texas, United States|Novo Nordisk Investigational Site, Round Rock, Texas, United States|Novo Nordisk Investigational Site, St. George, Utah, United States|Novo Nordisk Investigational Site, Renton, Washington, United States|Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States|Novo Nordisk Investigational Site, Boisguillaume, France|Novo Nordisk Investigational Site, Brest, France|Novo Nordisk Investigational Site, Grenoble, France|Novo Nordisk Investigational Site, LA ROCHELLE cedex, France|Novo Nordisk Investigational Site, Montpellier, France|Novo Nordisk Investigational Site, Nice, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Aschaffenburg, Germany|Novo Nordisk Investigational Site, Bad Kreuznach, Germany|Novo Nordisk Investigational Site, Dormagen, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, St. Ingbert, Germany|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Saint-Peterburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Tumen, Russian Federation|Novo Nordisk Investigational Site, Yaroslavl, Russian Federation|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Aberdeen, United Kingdom|Novo Nordisk Investigational Site, Birmingham, United Kingdom|Novo Nordisk Investigational Site, Bradford, United Kingdom|Novo Nordisk Investigational Site, Glasgow, United Kingdom|Novo Nordisk Investigational Site, Guildford, United Kingdom|Novo Nordisk Investigational Site, Leeds, United Kingdom|Novo Nordisk Investigational Site, Llantrisant, United Kingdom|Novo Nordisk Investigational Site, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT00982228
NCT00978627,Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes,BOOST™,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec/insulin aspart|Drug: insulin detemir|Drug: insulin aspart,Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment|Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes|Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes|Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs)|Main Trial (Secondary Endpoint): Rate of Confirmed Hypoglycaemic Episodes|Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 26|Extension Trial (Secondary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment|Main Trial (Secondary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes|Extension Trial (Secondary Endpoint): Change in Fasting Plasma Glucose (FPG) After 52 Weeks of Treatment,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,548,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN5401-3594|2008-005769-71|U1111-1111-8943|2009-013412-13|U1111-1113-2475,Aug-09,May-10,May-10,17-Sep-09,20-Nov-15,20-Mar-17,"Novo Nordisk Investigational Site, La Mesa, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Mission Hills, California, United States|Novo Nordisk Investigational Site, North Hollywood, California, United States|Novo Nordisk Investigational Site, Salinas, California, United States|Novo Nordisk Investigational Site, Valencia, California, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Lawrenceville, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Shawnee Mission, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Eagan, Minnesota, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, St. Peters, Missouri, United States|Novo Nordisk Investigational Site, Butte, Montana, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Henderson, Nevada, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, Northport, New York, United States|Novo Nordisk Investigational Site, Morehead City, North Carolina, United States|Novo Nordisk Investigational Site, Greer, South Carolina, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Seattle, Washington, United States|Novo Nordisk Investigational Site, Broadmeadow, New South Wales, Australia|Novo Nordisk Investigational Site, Camperdown, New South Wales, Australia|Novo Nordisk Investigational Site, Coffs Harbour, New South Wales, Australia|Novo Nordisk Investigational Site, Keswick, South Australia, Australia|Novo Nordisk Investigational Site, Box Hill, Victoria, Australia|Novo Nordisk Investigational Site, Fitzroy, Australia|Novo Nordisk Investigational Site, Geelong, Australia|Novo Nordisk Investigational Site, Aalborg, Denmark|Novo Nordisk Investigational Site, Gentofte, Denmark|Novo Nordisk Investigational Site, Århus C, Denmark|Novo Nordisk Investigational Site, Auxerre, France|Novo Nordisk Investigational Site, Narbonne, France|Novo Nordisk Investigational Site, Nimes, France|Novo Nordisk Investigational Site, Pointe à Pitre, France|Novo Nordisk Investigational Site, Petah Tikva, Israel|Novo Nordisk Investigational Site, Rishon Le Zion, Israel|Novo Nordisk Investigational Site, Tel Hashomer, Israel|Novo Nordisk Investigational Site, Lodz, Poland|Novo Nordisk Investigational Site, Lodz, Poland|Novo Nordisk Investigational Site, Sopot, Poland|Novo Nordisk Investigational Site, Szczecin, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Bayamon, Puerto Rico|Novo Nordisk Investigational Site, Cluj Napoca, Cluj, Romania|Novo Nordisk Investigational Site, Brasov, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Buzau, Romania|Novo Nordisk Investigational Site, Iasi, Romania|Novo Nordisk Investigational Site, Oradea, Romania|Novo Nordisk Investigational Site, Sibiu, Romania|Novo Nordisk Investigational Site, Kemerovo, Russian Federation|Novo Nordisk Investigational Site, Kursk, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Penza, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Samara, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Smolensk, Russian Federation|Novo Nordisk Investigational Site, Volgograd, Russian Federation|Novo Nordisk Investigational Site, Bristol, United Kingdom|Novo Nordisk Investigational Site, Dundee, United Kingdom|Novo Nordisk Investigational Site, Edinburgh, United Kingdom|Novo Nordisk Investigational Site, Leicester, United Kingdom|Novo Nordisk Investigational Site, Liverpool, United Kingdom|Novo Nordisk Investigational Site, Oxford, United Kingdom|Novo Nordisk Investigational Site, Salford, United Kingdom|Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom",,https://ClinicalTrials.gov/show/NCT00978627
NCT00978796,Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Drug: Sitagliptin|Drug: Sugar Pill,The primary objective of this pilot study is to compare 24-hour blood glucose values (overnight and pre- and post- prandial glucoses) in adult subjects with type 1 diabetes receiving either sitagliptin or placebo|Determine differences in fructosamine values|Time spent in hypoglycemic and hyperglycemic excursions recorded on the DexCom STS continuous glucose monitor (CGM) at 3 time periods throughout the study,University of Colorado Denver School of Medicine Barbara Davis Center,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Merck IISP-32888,Sep-09,Jan-10,Mar-10,17-Sep-09,null,30-Mar-10,"Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT00978796
NCT00977808,Pilot Study of Closed-Loop Glucose Control in People With Type 1 Diabetes (BPK004),,Completed,Has Results,Type 1 Diabetes,"Device: Closed-Loop, Model Predictive Control (MPC)|Device: Open-Loop",Occurrence of Hypoglycemic Episodes,University of Virginia|Juvenile Diabetes Research Foundation,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,12,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12998|BPK004,May-08,Feb-09,Feb-09,16-Sep-09,25-Aug-14,4-Sep-14,"University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00977808
NCT00974051,Use of Terbutaline or a Reduction in Basal Insulin in the Prevention of Nocturnal Hypoglycemia,,Completed,Has Results,Type 1 Diabetes,Drug: Terbutaline|Other: 20% basal insulin reduction|Other: Control,Blood Glucose Nadir|Percent of Nighttime Glucose Levels <80|Percent of Nighttime Glucose Levels <70|Percent of Nighttime Glucose Levels >250 mg/dl,"University of Colorado, Denver",All,10 Years to 17 Years   (Child),Not Applicable,16,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,07-0392,Mar-08,Dec-08,Dec-08,10-Sep-09,11-Oct-13,11-Oct-13,"Barbara Davis Center, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT00974051
NCT00974740,DIATOR-Diabetes Intervention With Atorvastatin,,Terminated,No Results Available,Type 1 Diabetes,Drug: Atorvastatin|Drug: atorvastatin matching placebo,C-peptide after a liquid mixed meal stimulation|HbA1c|insulin dose|adverse events|serum lipids|plasma CRP,Profil Institut für Stoffwechselforschung GmbH|Pfizer,All,18 Years to 39 Years   (Adult),Phase 1,63,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",33/0136-Diator,Mar-04,Jan-08,Mar-09,10-Sep-09,null,19-Jun-17,"Diabetes-Zentrum Mergentheim, Bad Mergentheim, Germany|Gemeinschaftskrankenhaus Havelhöhe, Berlin, Germany|Helios Klinikum Emil von Behring, Berlin, Germany|Praxis Dr. Friedhelm Schmitten, Bestwig-Ramsbeck, Germany|DDZ Deutsches Diabetes Zentrum, Düsseldorf, Germany|St. Josefs Krankenhaus, Heidelberg, Germany|St. Antonius Krankenhaus, Med. Klinik, Köln, Germany|Praxisklinik Leipzig, Leipzig, Germany|Praxis Dr. Gerhard Willms, Leverkusen, Germany|Praxis Dr. Heinz-Georg Ley, Marl, Germany|Diabetologische Schwerpunktpraxis, Angiologie, Münster, Germany|Praxis Dr. Werner Stürmer, Würzburg, Germany",,https://ClinicalTrials.gov/show/NCT00974740
NCT00971659,Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes,,Completed,No Results Available,Type 2 Diabetes,Drug: insulin glargine + exenatide + preexisting metformin|Drug: insulin glargine + sitagliptin + preexisting metformin|Drug: insulin glargine + preexisting metformin,"the unadjusted 6-hour postprandial blood glucose excursion (AUCBG0-6h) following ingestion of a standardized breakfast|mean daily blood glucose (BG) from 7-point 24h BG profiles, fasting BG, self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid profiles, HOMA-IR index, hypoglycemic episodes",Profil Institut für Stoffwechselforschung GmbH|Sanofi,All,"35 Years to 70 Years   (Adult, Older Adult)",Phase 1,48,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,49/0316-Adjunct,Jan-08,Sep-08,Nov-08,4-Sep-09,null,4-Sep-09,"Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT00971659
NCT00971503,Safety and Efficacy of Arterial Delivery of Autologous Bone Marrow Cells in the Treatment of Insulin-Dependent Diabetes,,Withdrawn,No Results Available,Type 1 Diabetes Mellitus,Procedure: autologous bone marrow implantation|Other: Saline injection,Significant increase in C-peptide levels after transplant in 70% of the patient.|Reduction by 50% of the insulin requirement after the transplant in 70% of the patients.|Normalization of the hemoglobin A1C after transplant in 70% of the patients. Normalization of blood glucose levels.,University of Moron,All,18 Years to 30 Years   (Adult),Phase 2,34,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,CM 02,Feb-11,Feb-11,Feb-12,3-Sep-09,null,27-Jul-11,"School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile, Chile",,https://ClinicalTrials.gov/show/NCT00971503
NCT00970567,Ketoacidosis in Individuals With Type I Diabetes Mellitus (T1DM),,Completed,No Results Available,Type 1 Diabetes,Behavioral: Different insulin therapy at different time points,"glucose metabolism, time course of positive ketone bodies","Charite University, Berlin, Germany|Abbott",All,18 Years to 60 Years   (Adult),Not Applicable,19,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),EA4/039/07,Nov-07,Dec-08,Dec-08,2-Sep-09,null,2-Sep-09,"Charité-Universitätsmedizin Berlin, Department of Endocrinology, Diabetes and Nutrition, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT00970567
NCT00964418,A Trial Investigating the Effect of NN1250 in Young and Elderly Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin glargine,Area under the glucose infusion rate curve during one dosing interval at steady state (for NN1250)|Area under the NN1250 concentration-time curve during one dosing interval at steady state,Novo Nordisk A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,27,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1250-1994|2008-008601-21,Aug-09,Nov-09,Nov-09,25-Aug-09,null,20-Jan-17,"Novo Nordisk Investigational Site, Graz, Austria",,https://ClinicalTrials.gov/show/NCT00964418
NCT00964574,Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus,PORTAL 1,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: INSULIN GLULISINE (HMR1964)|Drug: INSULIN GLARGINE,"Mean change in Glycosylated haemoglobin (HbA1c)|Mean Glycosylated haemoglobin (HbA1c)|Mean Fasting Blood Glucose and mean Post Prandial Glycemia|Number of documented symptomatic hypoglycaemic episodes|Mean dose and mean dose change of insulin glulisine, basal glulisine and total insulin from baseline|Mean change of Fasting Blood Glucose and Post Prandial Glycemia",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 4,68,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APIDR_L_02483,Jul-09,Jul-10,Jul-10,25-Aug-09,null,17-Jul-12,"Sanofi-Aventis Administrative Office, Minsk, Belarus",,https://ClinicalTrials.gov/show/NCT00964574
NCT00964964,"A Trial Assessing Changes in Blood Sugar and the Number of Periods Where Supplementation of Carbohydrate is Needed to Treat Low Blood Sugar, During Two Different Treatment Regimens of NN1250 in Type 1 Diabetics",,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: placebo,Total number of periods where carbohydrate supplementation is needed during the treatment|Frequency of adverse events (AEs)|Number of periods with low blood sugar during treatment,Novo Nordisk A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,18,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1250-3765|2009-011959-53,Aug-09,Sep-09,Sep-09,25-Aug-09,null,27-Nov-13,"Neuss, Germany",,https://ClinicalTrials.gov/show/NCT00964964
NCT00965458,Inducing Remission in Type 1 Diabetes With Alefacept,T1DAL,Terminated,Has Results,New-onset Type 1 Diabetes Mellitus,Biological: Alefacept|Drug: Placebo,2-Hour C-peptide Area Under the Curve (AUC) Result in Response to Standardized Mixed Meal Tolerance Test (MMTT)|4-Hour C-peptide Area Under the Curve (AUC) Result in Response to Standardized Mixed Meal Tolerance Test (MMTT)|Insulin Use in Units Per Kilogram Body Weight Per Day|Major Hypoglycemic Events Occurring From Randomization|Hemoglobin A1c,National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)|Juvenile Diabetes Research Foundation|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"12 Years to 35 Years   (Child, Adult)",Phase 2,49,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DAIT ITN045AI,Mar-11,Mar-13,Apr-14,25-Aug-09,7-Jan-15,6-Jul-17,"University of Arizona, Tucson, Arizona, United States|Children's Hospital of Los Angeles, Los Angeles, California, United States|University of California - San Francisco, San Francisco, California, United States|Barbara Davis Center for Childhood Diabetes - University of Colorado, Aurora, Colorado, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa Hospital & Clinics, Iowa City, Iowa, United States|University of Maryland, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|Creighton University, Omaha, Nebraska, United States|University of North Carolina, Durham, North Carolina, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00965458
NCT00964184,Phenotypic and Genetic Correlates of Diabetes (Non-Type 1) in Young Non-Obese Asian Indians in North India and A Study to Evaluate the Efficacy of Sitagliptin (DPP-4 Inhibitor) in a Sub-group of the Study Population,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Metformin|Behavioral: Lifestyle modification,HbA1c|HbA1C|Assessment of safety profile of sitagliptin|insulin,"Diabetes Foundation, India",All,"14 Years to 40 Years   (Child, Adult)",Phase 4,133,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LeanDM-01,Sep-09,Jul-15,Jul-15,24-Aug-09,null,6-Aug-15,"Fortis Flt Lt Rajan Dhall Hospital, New Delhi, Delhi, India",,https://ClinicalTrials.gov/show/NCT00964184
NCT00961974,Intensive Care Program for Youth With Diabetes,,Completed,No Results Available,Type 1 Diabetes,Behavioral: Care Ambassador Intervention|Behavioral: Psychoeducational Intervention,"Glycemic control, assessed by hemoglobin A1c|Psychosocial factors (diabetes-specific family conflict, responsibility-sharing for diabetes management tasks, quality of life, affect regarding blood glucose monitoring, disordered eating behaviors)|Weight, assessed by z-BMI (age- and gender-adjusted body mass index)|Frequency of hospitalizations, emergency department visits, and episodes of severe hypoglycemia",Joslin Diabetes Center|Charles H. Hood Foundation|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,8 Years to 16 Years   (Child),Not Applicable,154,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,02-06|R01DK046887,Apr-02,Jun-05,Jun-05,19-Aug-09,null,9-Jan-19,"Joslin Diabetes Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00961974
NCT00962026,Rilonacept in Diabetes Mellitus Type 1: Safety Study,RID-A,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Rilonacept,"Incidence and severity of infection in study participants|Incidence and severity of other adverse effects in study participants|Changes in participants' sex steroids (testosterone/estradiol)|Changes in participants' HbA1c levels, insulin doses, and beta cell preservation",University of Texas Southwestern Medical Center,All,"16 Years to 45 Years   (Child, Adult)",Phase 1,13,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IL1T-AI-1022,Feb-11,Mar-13,Jun-13,19-Aug-09,null,24-Feb-14,"Children's Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00962026
NCT00960635,Immunointervention With Calcitriol in New-Onset Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,"Drug: 1,25-dihydroxy-vitamin D3 (calcitriol)|Drug: placebo",,"Institut fur Diabetesforschung, Munich, Germany",All,18 Years to 39 Years   (Adult),Phase 2,null,Other,Interventional,Primary Purpose: Prevention,336/00,Jun-01,Aug-08,Aug-08,18-Aug-09,null,18-Aug-09,"Institut fuer Diabetesforschung, Munich, Germany",,https://ClinicalTrials.gov/show/NCT00960635
NCT00961207,Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients,,Terminated,No Results Available,Microalbuminuria|Macroalbuminuric Diabetic Nephropathy|Diabetes|Proteinuria|Albuminuria,Drug: Aliskiren,"Reduction in albuminuria/proteinuria|Safety of Triple RAAS inhibition with ACE-I, ARB and DRI",John H. Stroger Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 4,2,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,JHStrogerH09-083,Aug-09,Jul-12,Sep-12,18-Aug-09,null,28-Oct-13,"John H Stroger Hospital of Cook County, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00961207
NCT00961324,A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin glargine,Area under the glucose infusion rate curve during one dosing interval at steady state|Area under the NN1250 concentration-time curve during one dosing interval at steady state,Novo Nordisk A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,54,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN1250-1991|2008-008308-42,27-Jul-09,26-Oct-09,26-Oct-09,18-Aug-09,null,9-Oct-17,"Novo Nordisk Investigational Site, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT00961324
NCT00954694,Analysis of the NuStep as an Introductory Fitness Regimen,,Unknown status,No Results Available,Diabetes|Inactivity,Device: NuStep fitness apparatus,"The primary endpoint of the study is the qualitative measurement, by use of a questionnaire, of attitude and interest toward exercise in participants by assessing if they choose to seek and perform other modes of exercise.|Secondary endpoints are the quantitative measurement of the change in weight, waist-to-hip ratio, heart rate, blood pressure, 6-minute walk test, and A1C levels.",University of Nebraska,All,"19 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,328-09-FB,Aug-09,Nov-09,Nov-09,7-Aug-09,null,7-Aug-09,"The Nebraska Medical Center Diabetes Center, Omaha, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT00954694
NCT00950963,Nurse Telephone Management of Cholesterol in Diabetes,NATCHOS,Completed,Has Results,Type 1 Diabetes|Type 2 Diabetes,Behavioral: Phone Counseling|Other: Standard Clinical Care,Number of Patients With a Low Density Lipid (LDL) Value Less Than 100 mg/dL|Number of CVD Patients With LDL Less Than 70 mg/dL.|Number of Patients With BP Less Than 130/80 mm Hg|Number of Patients With Hgb A1c Less Than 7 Percent at the End of the Study,Denver Health and Hospital Authority|American Diabetes Association,All,"17 Years and older   (Child, Adult, Older Adult)",Not Applicable,762,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,05-509,Sep-05,May-07,Jun-08,3-Aug-09,3-Aug-09,28-Apr-15,"Denver Health, Westside Clinic, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT00950963
NCT00949091,Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: TAK-875,"TAK-875 maximum observed plasma concentration (Cmax)|TAK-875 time at which Cmax occurred (Tmax)|TAK-875 area under the plasma concentration-time curve from time 0 to time tau, where tau is the length of a dosing interval AUC(0-tau)|TAK-875 renal clearance (CLr)|TAK-875 metabolite (M-I) Cmax|TAK-875 M-I Tmax|TAK-875 M-I AUC(0-tau)|TAK-875 M-I renal clearance CLr|TAK-875 Cmax|TAK-875 Tmax|TAK-875 AUC(0-tau)|TAK-875 renal clearance CLr|M-I Tmax|M-I Cmax|M-I AUC(0-tau)|M-I renal clearance CLr|TAK-875 and M-I Cmax ratio|TAK-875 and M-I AUC(0-tau) ratio|Percent changes from baseline to Day 14 in mean 4-hour concentration values for plasma glucose|Percent changes from baseline to Day 14 in mean 4- hour concentration values for insulin|Percent changes from baseline to Day 14 in mean 4- hour concentration values for proinsulin|Percent changes from baseline to Day 14 in mean 4- hour concentration values for C-peptide|Percent changes from baseline to Day 14 in mean 4- hour concentration values for glucagon|Percent changes from baseline to Day 14 in mean 4- hour concentration values for total gastric inhibitory polypeptide (GIP)|Percent changes from baseline to Day 14 in mean 4- hour concentration values for total glucagon-like peptide-1 (GLP-1)|Percent changes from baseline to Day 14 in mean 24-hour concentration values for plasma glucose|Percent changes from baseline to Day 14 in mean 24- hour concentration values for insulin|Percent changes from baseline to Day 14 in mean 24- hour concentration values for proinsulin|Percent changes from baseline to Day 14 in mean 24- hour concentration values for C-peptide|Percent changes from baseline to Day 14 in mean 24- hour concentration values for glucagon|Percent changes from baseline to Day 14 in mean 24- hour concentration values for total gastric inhibitory polypeptide (GIP)|Percent changes from baseline to Day 14 in mean 24- hour concentration values for total glucagon-like peptide-1 (GLP-1)|Absolute changes from baseline to Day 14 in mean 4-hour concentration values for plasma glucose|Absolute changes from baseline to Day 14 in mean 4- hour concentration values for insulin|Absolute changes from baseline to Day 14 in mean 4- hour concentration values for proinsulin|Absolute changes from baseline to Day 14 in mean 4- hour concentration values for C-peptide|Absolute changes from baseline to Day 14 in mean 4- hour concentration values for glucagon|Absolute changes from baseline to Day 14 in mean 4- hour concentration values for total gastric inhibitory polypeptide (GIP)|Absolute changes from baseline to Day 14 in mean 4- hour concentration values for total glucagon-like peptide-1 (GLP-1)|Absolute changes from baseline to Day 14 in mean 24-hour concentration values for plasma glucose|Absolute changes from baseline to Day 14 in mean 24- hour concentration values for insulin|Absolute changes from baseline to Day 14 in mean 24- hour concentration values for proinsulin|Absolute changes from baseline to Day 14 in mean 24- hour concentration values for C-peptide|Absolute changes from baseline to Day 14 in mean 24- hour concentration values for glucagon|Absolute changes from baseline to Day 14 in mean 24- hour concentration values for total gastric inhibitory polypeptide (GIP)|Absolute changes from baseline to Day 14 in mean 24- hour concentration values for total glucagon-like peptide-1 (GLP-1)|Percent change from baseline to 24-hours post Day 13 dose in homeostasis model assessment of ß-cell function|Percent change from baseline to 24-hours post Day 14 dose in homeostasis model assessment of ß-cell function|Absolute change from baseline to 24-hours post Day 13 dose in homeostasis model assessment of ß-cell function|Absolute change from baseline to 24-hours post Day 14 dose in homeostasis model assessment of ß-cell function|Percent change from baseline to Day 14 in insulinogenic index|Absolute change from baseline to Day 14 in insulinogenic index",Takeda,All,"18 Years to 68 Years   (Adult, Older Adult)",Phase 1,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",TAK-875_102|U1111-1114-2888,Jan-09,Jul-09,Jul-09,30-Jul-09,null,11-Jun-10,,,https://ClinicalTrials.gov/show/NCT00949091
NCT00949221,Study of Insulin Therapy Augmented by Real Time Sensor IN Type 1 Children and Adolescents (START-IN!),START-IN,Completed,No Results Available,Type 1 Diabetes,"Device: monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE","Comparison of the effect of 2 strategies of real time continuous glucose monitoring vs conventional SMBG on glycated haemoglobin = HbA1c measured at inclusion, 3, 6, 9, 12 months|HbA1c and associated factors with HbA1c changes, others parameters of glycemic control, tolerance, acceptability, quality of life, satisfaction after use of real time continuous glucose monitoring in 150 pediatric patients|Frequency of acute metabolic events (severe hypoglycaemia or ketoacidosis)|Frequency of non-severe or symptomatic hypoglycaemia|Average blood glucose and glycemic variability|Tolerance of using the device of continuous glucose monitoring (skin tolerance)|Acceptability of the device (percentage of time of use)|General and diabetes-related Quality of life|Satisfaction to use the device|Medico-economic evaluation",Assistance Publique - Hôpitaux de Paris,All,"2 Years to 18 Years   (Child, Adult)",Phase 2|Phase 3,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P070152|2007-A01330-53,Sep-09,Jul-12,Jul-12,30-Jul-09,null,27-Jul-12,"Hôpital Robert Debré, Paris, France",,https://ClinicalTrials.gov/show/NCT00949221
NCT00947427,Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes,anti IL-1,Completed,Has Results,Type 1 Diabetes|Preservation of Insulin Secretion|Newly Diagnosed Type 1 Diabetes|Canakinumab in Type 1 Diabetes,Drug: canakinumab (anti IL-1beta)|Drug: Placebo,C-peptide Response to Mixed Meal Glucose Tolerance Test (MMTT) at One Year for Subjects Given Canakinumab Compared to Placebo,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"6 Years to 45 Years   (Child, Adult)",Phase 2,71,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",TrialNet-cana (IND),Oct-10,Apr-13,Apr-13,28-Jul-09,18-Oct-16,18-Oct-16,"University of California-San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Yale Medical School, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|University of Miami School of Medicine, Miami, Florida, United States|Indiana University-Riley Hospital for Children, Indianapolis, Indiana, United States|University of Minnesota, Minneapolis, Minnesota, United States|Columbia University, New York, New York, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Texas-Southwestern Medical School, Dallas, Texas, United States|Benaroya Research Institute, Seattle, Washington, United States|Hospital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00947427
NCT00947635,Cholesterol and Fatty Acid Synthesis in Islet and Liver Transplant Patients and Effect of Dietary Intervention,,Completed,No Results Available,"Immunosuppression|Hyperlipidemias|Diabetes Mellitus, Type 1",Dietary Supplement: Dietary intervention - supplements,Cholesterol and fatty acid synthesis|Blood lipid levels,University of Alberta|Canadian Institutes of Health Research (CIHR),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,46,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Islet-Liver-MTC,Nov-05,Jun-09,Jun-09,28-Jul-09,null,28-Jul-09,"University of Alberta, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT00947635
NCT00945659,Use of Continuous Glucose Sensors by Adolescents With Inadequate Diabetic Control,CGM-Teens,Completed,Has Results,Type 1 Diabetes Mellitus,Device: Continuous Glucose Sensor|Other: Standard Care|Behavioral: CGS + Behavior Therapy,Glycated Hemoglobin (HbA1c)|Diabetes Technology Questionnaire-Adolescents|Diabetes Technology Questionnaire-Parents' Total Scores on DTQ Current Items|Blood Glucose Monitoring Communication Questionnaire-Adolescent|Blood Glucose Monitoring Communication Questionnaire-Parents|Diabetes Family Conflict Scale-Adolescent|Diabetes Family Conflict Scale-Parent|Diabetes Family Responsibility Questionnaire-Adolescent|Diabetes Family Responsibility Questionnaire-Parent|Diabetes Self Management Profile-Adolescent|Diabetes Self Management Profile-Parent|Hypoglycemia Fear Survey-Adolescent|Hypoglycemia Fear Survey-Parent,Nemours Children's Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,11 Years to 16 Years   (Child),Not Applicable,116,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,1R01DK080831,Aug-09,30-Jun-17,30-Jun-17,24-Jul-09,10-Sep-18,10-Sep-18,"Nemours Children's Clinic, Jacksonville, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT00945659/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT00945659/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT00945659
NCT00946257,Subcutaneous Administration of Otelixizumab to T1DM Patients,RAO112438,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Otelixizumab,Safety and tolerability after a single dose of otelixizumab in T1DM patients,GlaxoSmithKline,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,33,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,112438,8-Jul-09,1-Aug-11,25-Jun-13,24-Jul-09,null,1-Jun-17,"GSK Investigational Site, Brussels, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Gent, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Liège, Belgium|GSK Investigational Site, Merksem, Belgium",,https://ClinicalTrials.gov/show/NCT00946257
NCT00944619,Closing the Loop in Adults With Type 1 Diabetes - Alcohol Consumption,ANGELA02,Completed,No Results Available,Type 1 Diabetes,Device: Closed loop|Device: Conventional insulin pump delivery,Percentage of plasma glucose values in target (3.9-8.0 mmol/L)|Percentage of CGM (continuous glucose monitoring) values in target (3.9-8.0 mmol/L)|Percentage of plasma glucose and CGM values in target (3.9-8.0 mmol/L)|Percentage of plasma glucose and CGM values below 3.9 mmol/L|Percentage of plasma glucose and CGM values above 8.0 mmol/L|Average plasma and CGM glucose|Average plasma insulin concentration|Total dose of insulin administered|Low blood glucose index (LBGI) score|High blood glucose index (HBGI) score|Percentage of plasma glucose and CGM values below 3.0 mmol/L,University of Cambridge|Cambridge University Hospitals NHS Foundation Trust,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,09/H0306/44,Sep-09,Dec-09,Dec-09,23-Jul-09,null,12-May-10,"Addenbrooke's Hospital, Cambridge, United Kingdom",,https://ClinicalTrials.gov/show/NCT00944619
NCT00943787,Counter-Regulatory Impairment and the Effect of Microvascular Insulin Transfer in Type 1 Diabetes Mellitus,BPK003,Completed,Has Results,"Diabetes Mellitus, Type 1","Procedure: Hyperinsulinemic, euglycemic and hypoglycemic clamp",Maximum Epinephrine Response (LBGI Groups)|Maximum Epinephrine Response (ADRR Groups),University of Virginia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,41,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),12252,Jan-06,May-09,May-09,22-Jul-09,8-Sep-14,8-Sep-14,"University of Virginia Health System - Behavioral Medicine Center, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00943787
NCT00940173,Open-label Investigation of the Safety and Effectiveness of DIABECELL(R) in Patients With Type I Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes,Device: DIABECELL(R),"To establish the safety of xenotransplantation of DIABECELL(R) [immunoprotected (alginate-encapsulated) porcine islets]|To establish preliminary evidence of the efficacy of DIABECELL(R), as measured by a reduction in serial HbA1C levels|To establish whether DIABECELL(R) causes an improvement in glucose lability determined from continuous glucose monitoring|To determine whether DIABECELL(R) causes a reduction in hypoglycaemia and nocturnal hypoglycaemia|To determine whether DIABECELL(R) causes a reduction in insulin dose|To determine whether DIABECELL(R) causes an improvement in endogenous insulin secretion|To determine whether DIABECELL(R) causes an improvement in quality-of-life",Diatranz Otsuka Limited,All,"35 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,16,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LCT/DIA-06,Jul-09,Oct-13,Oct-13,15-Jul-09,null,20-Oct-17,"Centre for Clinical Research and Effective Practice, Auckland, New Zealand",,https://ClinicalTrials.gov/show/NCT00940173
NCT00938405,Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Hyperlipidemias",Drug: Colesevelam HCl|Drug: Placebo,"To demonstrate a 10% LDL reduction in type 1 diabetic subjects with initial LDL > 100 after twelve weeks in the colesevelam group.|To evaluate colesevelam use for glucose control as measured by A1c using a 0.4% confidence interval at baseline and after one, two, and three months of therapy.|To evaluate colesevelam use for non-inferiority of percent of target range glucose values and time spent in hyper- and hypoglycemic ranges as determined by CGM readings at baseline and after one, two, and three months of therapy.|In addition change in insulin dose at one, two and three months from baseline will be evaluated.","University of Colorado Denver School of Medicine Barbara Davis Center|Daiichi Sankyo, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,45,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DSI-WCH-100,Jul-09,Dec-09,Dec-09,13-Jul-09,null,20-May-14,"Barbara Davis Center for Diabetes, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT00938405
NCT00934336,Importance in Type 1 Diabetes Patients of an Optimized Control of Post-Prandial Glycaemia on Oxidant Stress Prevention,ITOPOS,Completed,No Results Available,Type 1 Diabetes,Other: Therapeutic and preventive strategies,"Assay of isoprostane-F2, an indicator of lipid peroxidase derivative production, in the 24 hour urine",Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète,All,18 Years to 50 Years   (Adult),Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2007-A01036-47,Nov-08,Apr-11,Apr-11,8-Jul-09,null,7-Aug-15,"CH sud francilien, Corbeil Essonnes, France",,https://ClinicalTrials.gov/show/NCT00934336
NCT00935051,Matrix Metalloproteinase-1/Tissue Inhibitor of Metalloproteinase-1 (MMP-1/TIMP-1) Ratio and Diabetic Foot Ulcers,DIAB-MMP2,Completed,No Results Available,Diabetic Foot Ulcer,Other: Picture + MMPs and TIMP1 at week 0 and week 4,"MMP-1/TIMP-1 ratio at Week 0 assessed by ELISA and percent change in wound area of diabetic foot ulcer between week 0, week 4 and week 12|Evaluation of a MMP-1/TIMP-1 ratio = 0.4 at Week 0 as a predictor of wound healing at week 12|Recognized clinical prognostic factors such as wound duration, wound area, wound depth and other possible confounding factors affecting the validity of the MMP-1/TIMP-1 ratio|Correlation between MMP9, MMP13, MMP9/TIMP1 and MMP13/ TIMP1 ratios and wound healing expressed by the percent change in wound area between week 0, week 4 and week 12.","University Hospital, Grenoble",All,18 Years to 40 Years   (Adult),Early Phase 1,59,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2008-A00155-50,May-09,Jul-13,Nov-13,8-Jul-09,null,18-Dec-13,"Diabetology department, Grenoble, Isere, France|Service de Diabétologie du Pr Halimi, CHU Grenoble, Grenoble Cedex 9, France",,https://ClinicalTrials.gov/show/NCT00935051
NCT00935129,Treatment Satisfaction of Using OmniPod System Compared With Conventional Insulin Pump in Adults With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Device: OmniPod system|Device: Patient's conventional pump,Treatment satisfaction|Comfort and function|HbA1C|Fructosamine|7 points glucose profile|Pump related technical difficulties|continuous glucose measurements,Rabin Medical Center,All,18 Years to 35 Years   (Adult),Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,rmc005431ctil,Aug-09,Feb-11,Feb-11,8-Jul-09,null,8-May-12,"Schnider children's medical center, Petach-Tikva, Israel",,https://ClinicalTrials.gov/show/NCT00935129
NCT00930865,Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Bumetanide|Drug: Dapagliflozin,"Exposure to the investigational drug will be measured to compare with and without the co-administration of other drugs|To assess the safety and tolerability of bumetanide and dapagliflozin following multiple oral doses of 1 mg bumetanide and 10 mg dapagliflozin, administered together, either simultaneously or after adaptation to either agent alone, in healthy subjects|Explore potential pharmacodynamic (serum/urine electrolytes) effects of bumetanide + dapagliflozin following multiple doses of 1 mg bumetanide + 10 mg dapagliflozin, administered together, either simultaneously or after adaptation to either agent alone",AstraZeneca|Bristol-Myers Squibb,All,18 Years to 45 Years   (Adult),Phase 1,42,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MB102-057,Jul-09,Sep-09,Sep-09,2-Jul-09,null,17-Oct-16,"Ppd Development, Lp, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT00930865
NCT00931372,Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2,RESTORE,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Lixisenatide (AVE0010)|Drug: Placebo,Area under the insulin secretion curve,"Sanofi|Profil GmbH, Neuss, Germany",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,22,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PDY10433|EudraCT:2008-003242-28,Jun-09,Aug-09,Aug-09,2-Jul-09,null,23-Feb-12,"Sanofi-Aventis Administrative Office, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT00931372
NCT00929812,Glucagon Modulation of Ghrelin Secretion,,Unknown status,No Results Available,"Healthy Subjects|Obesity|Diabetes Mellitus, Type 1",Drug: Glucagon hydrochloride (GlucaGen®)|Drug: NaCl 0.9%,"Changes in satiety scale, total and acylated ghrelin concentrations.|Changes in glucose, insulin and NEFA concentrations.","Charite University, Berlin, Germany",All,18 Years to 60 Years   (Adult),Phase 3,38,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",GluGhr-study 01082005|EudoraCT 2005-003714-15|Prüfplancode 01082005|BfArM 61-3910-4031020|EK EA4/108/05,Jun-06,Jan-08,Dec-09,30-Jun-09,null,30-Jun-09,"Charite Campus Benjamin Franklin, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT00929812
NCT00928876,Interleukin-1 Receptor Antagonist and Insulin Sensitivity,,Unknown status,No Results Available,"Diabetes Mellitus, Type 2|Insulin Resistance",Drug: Anakinra (Kineret)|Drug: Placebo,"to determine the effect of Interleukin-1 receptor antagonist on insulin sensitivity, as derived from glucose infusion rate measured by euglycemic hyperinsulinemic clamp|pancreatic beta cell function als tested by oral glucose tolerance test, pro-insulin/insulin ratio|lipid profile|systemic inflammation",Radboud University,All,"18 Years and older   (Adult, Older Adult)",Phase 2,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",UMCN001,Jun-09,Mar-10,Jul-10,26-Jun-09,null,17-Dec-10,"Rabdoud University Nijmegen Medical Centre, Nijmegen, Netherlands",,https://ClinicalTrials.gov/show/NCT00928876
NCT00927524,Insulin Exposure and Glucose Response to Meals in Type 1 Diabetic Subjects Administered Two Different Insulin Regimens Compared to the Endogenous Insulin Exposure and Glucose Response to Meals In Healthy Adult Controls,,Completed,No Results Available,Type 1 Diabetes,Drug: Insulin glulisine|Drug: Insulin,Insulin levels,Vanderbilt University|Sanofi,All,18 Years to 55 Years   (Adult),Not Applicable,24,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,50116,Apr-05,Apr-06,Dec-10,25-Jun-09,null,11-Dec-14,,,https://ClinicalTrials.gov/show/NCT00927524
NCT00928057,Comparison of Glycemic Control Among Diabetics Using Three Different Pen Needles,,Completed,Has Results,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Device: 4mm x 32G pen needle|Device: 8mm x 31G pen needle|Device: 5mm x 31G pen needle,"Percent (%) Absolute Change in Fructosamine|Percent Absolute Change in Fructosamine, by Dose Group|Number of Subjects With Severe Unexplained Hypoglycemic Events|Number of Subjects With Severe Unexplained Hyperglycemic Events|Relative Injection Pain Score Assessed by Subject","Becton, Dickinson and Company",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,173,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),BDDC-08-011,Jun-09,Nov-09,Nov-09,25-Jun-09,20-Oct-10,20-Oct-10,"Radiant Research, Birmingham, Alabama, United States|AMCR Institute, Inc., Escondido, California, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Rainier Clinical Research Center, Inc., Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT00928057
NCT00925977,Treatment Satisfaction of Insulin Glargine Plus Insulin Apidra Compared With NPH Insulin Plus Insulin Apidra in Recently Diagnosed Type 1 Diabetes Children and Adolescents,,Terminated,No Results Available,Diabetes Type 1,Drug: insulin Glargine + Insulin Apidra|Drug: Insulin NPH + Insulin Apidra: Active Comparator,Treatment satisfaction|HbA1c|4 and 7 points glucose profile|Insulin doses|Hypoglycemic events,Rabin Medical Center|Sanofi,All,"7 Years to 20 Years   (Child, Adult)",Not Applicable,44,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,rmc005275ctil,Jul-09,Feb-12,Feb-12,23-Jun-09,null,5-Jun-12,"Soroka hospital, Bear Sheva, Israel|Rambam Hospital, Haifa, Israel|Health care unit- Jerusalem, Jerusalem, Israel|Schnider children medical center, Petach-Tikva, Israel",,https://ClinicalTrials.gov/show/NCT00925977
NCT00923962,Endothelial and Metabolic Effects of Glucagon-like Peptide-1 (GLP-1) in Coronary Circulation in Patients With Type 2 Diabetes Mellitus,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Glucagon like peptide-1|Drug: Adenosine,Coronary blood flow|Coronary metabolite uptake,"University Hospital, Gentofte, Copenhagen|Merck Sharp & Dohme Corp.",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,35,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",GLP-1 Coronary circulation 01,Jun-09,Jan-12,Jan-12,18-Jun-09,null,18-Sep-12,"University Hospital Gentofte, Department of Cardiology, Gentofte, Denmark",,https://ClinicalTrials.gov/show/NCT00923962
NCT00924105,"Safety, Tolerability and Pharmacodynamics of CYT013-IL1bQb in Patients With Type 2 Diabetes",,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: CYT013-IL1bQb|Drug: Placebo,Incidence of adverse events|Biological measures of glycemia and inflammation,Cytos Biotechnology AG,All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 1,48,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CYT013-IL1bQb 01,Jun-09,Nov-11,Nov-11,18-Jun-09,null,13-Feb-12,"Cytos Investigator sites, Hamburg, Germany|Cytos Investigator sites, Basel, Switzerland|Cytos Investigator sites, Zuerich, Switzerland",,https://ClinicalTrials.gov/show/NCT00924105
NCT00922376,Assessment of the Clinical Efficacy and Acceptability of Think Positive (T+) in Diabetes Management,T+,Completed,No Results Available,"Diabetes (Insulin-requiring, Type 1 or Type 2)",Device: Mobile phone telehealth application: Think Positive (T+),Blood sugar levels (HbA1c)|BMI|Number of Hypoglycemic events|Blood pressure|Diabetes self-care|Diabetes self- efficacy|Quality of life|Health status|Illness representations|User acceptability of T+|Nurses' Perceptions of T+|Self efficacy in using T+|Health care utilization|Self management,"University College London Hospitals|University College, London|Department of Health, United Kingdom",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,86,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,09/0201,Jun-10,Nov-11,Nov-11,17-Jun-09,null,10-Apr-12,"University College London (UCL), London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00922376
NCT00920582,Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Teplizumab (MGA031)|Drug: Placebo,"Successful versus unsuccessful clinical responses. A successful response requires that both components of a composite endpoint are met. The composite endpoint includes both the subject's total daily insulin usage and his/her HbA1c levels.|Successful versus unsuccessful clinical responses. A successful response requires that both components of a composite endpoint are met. The composite endpoint includes both the subject's total daily insulin usage and his/her HbA1c levels|C-peptide secretory responses, as defined by the total area under the curve of the C-peptide response to a mixed meal",MacroGenics|Eli Lilly and Company,All,"8 Years to 35 Years   (Child, Adult)",Phase 3,254,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CP-MGA031-03,Sep-09,Apr-12,Jul-12,15-Jun-09,null,7-Mar-13,"University of Alabama at Birmingham, Birmingham, Alabama, United States|NEA Clinic, Jonesboro, Arkansas, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Clinical Innovations Inc. Research Facility, Costa Mesa, California, United States|Axis Clinical Trials, Los Angeles, California, United States|Diabetes Associates Medical Group, Inc, Orange, California, United States|Clinical Innovations, Inc., Riverside, California, United States|San Diego Clinical Trials, San Diego, California, United States|Ronald Chochinov Md Inc, Ventura, California, United States|Yale University, New Haven, Connecticut, United States|Christiana Care Research Institute, Newark, Delaware, United States|Richard Hays, MD, Wellington, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|John H Stoger Jr. Hospital of Cook County, Cook County Hospital, Chicago, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Iowa Children's Hospital, Iowa City, Iowa, United States|Mid-America Diabetes Associates, Wichita, Kansas, United States|St. Agnes Hospital, Baltimore, Maryland, United States|Maryland Diabetes & Endocrine Associates, Rockville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Alzohaili Medical Consultants, Dearborn, Michigan, United States|Children's Hospitals and Clinics of Minnesota, St Paul, Minnesota, United States|University of Missouri - Columbia, Cosmopolitan Diabetes and Endocrinology, Columbia, Missouri, United States|The Children's Mercy Hospital, Kansas City, Missouri, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Albany Medical College, Albany, New York, United States|Bassett Healthcare, Cooperstown, New York, United States|East Carolina University, Brody School of Medicine, Greenville, North Carolina, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|GHS Pediatric Endocrinology, Greenville, South Carolina, United States|AM Diabetes & Endocrinology Center, Bartlett, Tennessee, United States|University Diabetes & Endocrine Consultants, Chattanooga, Tennessee, United States|LeBonheur Children's Medical Center, Memphis, Tennessee, United States|Research Institute of Dallas, Dallas, Texas, United States|Southwest Clinical Trials, Houston, Texas, United States|Houston Center for Clinical Research, Houston, Texas, United States|Medical & Surgical Clinic of Irving, Irving, Texas, United States|InVisions Consultants, LLC, San Antonio, Texas, United States|Diabetes and Glandular Disease Research Associates, PA, San Antonio, Texas, United States|Endocrine Research Specialists, Ogden, Utah, United States|Virginia Commonwealth University-Division of Pediatric Endocrinology & Metabolism, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States|Universitair Ziekenhuis Antwerpen, Edegem, Antwerp, Belgium|Cliniques du Sud Luxembourg - Vivalia, Luxembourg, Belgium|I. Detska interni klinika,Fakultni nemocnice Brno Detska nemocnice, Brno, Czech Republic|Klinika deti a dorostu FN Kralovske Vinohrady, Praha, Czech Republic|Centrum diabetologie, Institut klinicke a experimentalni mediciny, Praha, Czech Republic|Pediatricka klinika UK 2.LF a FN Motol, Fakultni nemocnice v Motole, Praha, Czech Republic|Detska klinika, Masarykova nemocnice v Usti nad Labem, o.z., Usti nad Labem, Czech Republic|Kuopio University Hospital, Kuopio, Finland|Central Hospital of Mikkeli, Mikkeli, Finland|Oulu University Hospital, Oulu, Finland|CHU de Brest Hôpital de la Cavale Blanche, Brest, France|CHU de Besançon, Cedex, France|CHU de Reims, Cedex, France|Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France|CHU de Bordeaux, Pessac, France|Hôpitaux Universitaires de Strasbourg Hôpital Civil, Strasbourg, France|Diabetes-Klinik Bad Nauheim GmbH, Bad Nauheim, Germany|Herz und Diabeteszentrum Nordrhein-Westfallen, Bad Oeyenhausen, Germany|Charite, Campus Benjamin Franklin, Berlin, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Universitatsklinik Giessen, Giessen, Germany|Asklepios Westklinikum Hamburg, Hamburg, Germany|Kinderkrankenhaus auf der Bult, Hannover, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Medwin Hospitals, Hyderabad, Andhra Pradesh, India|King George Hospital, Visakhapatnam, Andhra Pradesh, India|Maulana Azad Medical College and Associated Hospitals, New Delhi, Delhi, India|DHL Research Centre, Ahmedabad, Gujarat, India|Bangalore Diabetes Centre, Bangalore, Karnataka, India|Health & Research Centre, Trivandrum, Kerala, India|Gandhi's Research Institute, Nagpur, Maharashtra, India|Grant Medical Foundation, Pune, Maharashtra, India|KEM Hospital Research Center, Pune, Maharashtra, India|Kalinga Hospital Limited, Bhubaneswar, Orissa, India|Diabetes-Thyroid-Hormone Research Institute Pvt. Ltd., Madhya, Pradesh, India|Dayanand Medical College and Hospital, Ludhiana, Punjab, India|Fortis Escorts Hospital, Jaipur, Rajasthan, India|Hormone Care & Research Center, Ghaziabad, Uttar Pradesh, India|B. P. Poddar Hospital & Medical Research Limited, Kolkata, West Bengal, India|Apollo Glenagles Hospital, Kolkata, West Bengal, India|Mayer Children's Hospital of Haifa, Bat-Galim, Haifa, Israel|Hillel Yaffe Medical Center, Hadera, Israel|The E. Wolfson Medical Center, Holon, Israel|Schneider Children's Medical, Petach-Tikva, Israel|The Safra Children's Hospital, The Chaim Sheba Medical Center, Ramat-Gan, Israel|U.O. di Malattie del Metabolismo, Genova Pisa, Italy|Struttura Complessa di Pediatria, Azienda Ospedaliero-Universitaria di Modena,, Modena, Italy|U.O. di Malattie Metaboliche e Diabetologia, Pisa, Italy|Hospital y Clinica OCA / Monterrey International Research Center, Monterrey, Nuevo León, Mexico|Medical Care & Research, Merida, Yucatan, Mexico|Centro Especializado en Diabetes, Obesidad y Prevención de Enfermedades Cardiovasculares, S.C., Mexico, Distrito Federal, Mexico|Stichting Diabeter, Rotterdam, Netherlands|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Wojewódzki Specjalistyczny Szpital Dzieciecy, Kielce, Poland|Samodzielny Publiczny Dzieciecy Szpital Kliniczny w Warszawie-Filia, Warszawa, Poland|Samodzielny Publiczny Szpital Kliniczny Nr1 we Wroclawiu, Wroclaw, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Uniwersytecki Szpital Kliniczny Nr 4, Łódź, Poland|S.C. Minimed S.R.L., Bacau, Romania|Institutul National De Diabet, Nutritie si Boli Metabolice, Bucuresti, Romania|Spitalul Judetean de Urgenta Satu Mare, Satu-Mare, Romania|Hospital Universitario Principe de Asturias, Alcala de Henares, Spain|Hospital Dr. Josep Trueta, Girona, Spain|Donetsk Regional Children Clinical Hospital, Donetsk, Ukraine|Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivsk, Ukraine|Ivano-Frankivsk State Regional Pediatric Clinical Hospital, Ivano-Frankivsk, Ukraine|Kharkiv Regional Clinical Children Hospital, Department of Endocrinology, Kharkiv, Ukraine|Ukrainian Children Specialized Clinical Hospital, Kyiv, Ukraine|Institute of Endocrinology and Metabolism named after V.Komisarenko of AMS Ukraine, Kyiv, Ukraine|Regional Clinical Endocrinology Dispensary of MoH Ukraine, Vinnitsa, Ukraine|George Eliot Hospital NHS Trust, Nuneaton, Warwickshire, United Kingdom|University of Bristol Henery Wellcome laboratories for Integrative Neuroscience and Endocrinology,, Bristol, United Kingdom|Aintree University Hospitals NHS Foundation Trust, Liverpool, United Kingdom|Kings College, Clinical Research Unit, Department of Diabetes and Endocrinology, London, United Kingdom|Queens Medical Centre, Diabetes and Endocrinology Unit, Nottingham, United Kingdom|Sheffield Children's Hospital NHS Foundation Trust, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT00920582
NCT00917267,A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects,,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: exenatide once weekly|Drug: exenatide twice daily,Change in HbA1c From Baseline to Week 26.|Percentage of Patients Achieving HbA1c Targets <=7% at Week 26|Percentage of Patients Achieving HbA1c Targets <=6.5% at Week 26|Change in Fasting Serum Glucose (FSG) From Baseline to Week 26|Change in Body Weight (BW) From Baseline to Week 26|Change in Total Cholesterol (TC) From Baseline to Week 26|Change in High-Density Lipoprotein (HDL) From Baseline to Week 26|Ratio of Triglycerides (TG) at Week 26 to Baseline|Change in Blood Pressure From Baseline to Week 26|Assessment of Event Rate of Treatment-emergent Hypoglycemic Events,AstraZeneca|Eli Lilly and Company,All,"20 Years and older   (Adult, Older Adult)",Phase 3,691,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H8O-MC-GWCK,Jul-09,Sep-10,Apr-11,10-Jun-09,31-Dec-12,9-Apr-15,"Research Site, Beijing, China|Research Site, Chengdu, China|Research Site, Chongqin, China|Research Site, Guangzhou, China|Research Site, Shanghai, China|Research Site, Ahmedabad, India|Research Site, Aligarh, India|Research Site, Bangalore, India|Research Site, Ghaziabad, India|Research Site, Hyderabaad, India|Research Site, Indore, India|Research Site, Kolkata, India|Research Site, Mumbai, India|Research Site, Pune, India|Research Site, Trivandrum, India|Research Site, Uttar Pradesh, India|Research Site, Varanasi, India|Research Site, Ageo, Japan|Research Site, Chiyoda-ku, Japan|Research Site, Izumisano, Japan|Research Site, Kashiwara, Japan|Research Site, Kitaazumi-gun, Japan|Research Site, Kumamoto, Japan|Research Site, Kurume, Japan|Research Site, Matsumoto, Japan|Research Site, Matsuyama, Japan|Research Site, Miyazaki-shi, Japan|Research Site, Ooita-shi, Japan|Research Site, Osaka, Japan|Research Site, Ota-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Takatsuki, Japan|Research Site, Yokohama, Japan|Research Site, Bucheon, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Changhua, Taiwan|Research Site, Chia-Yi, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan",,https://ClinicalTrials.gov/show/NCT00917267
NCT00915954,Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT),,Completed,No Results Available,Acromegaly|Type 2 Diabetes Mellitus,Diagnostic Test: Oral Glucose Tolerance Test|Diagnostic Test: Subcutaneous administration of recombinant human IGF-1|Diagnostic Test: Placebo,Growth hormone suppression|The difference in IGFBP-1 levels in each cohort|The difference in insulin in each cohort|The difference in bioactive IGF-1 in each cohort,Cedars-Sinai Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,28,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,17015,Dec-08,Aug-13,Jun-14,8-Jun-09,null,5-Feb-19,"Cedars-Sinai Medical Center Pituitary Center, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00915954
NCT00913367,Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes Mellitus,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: glimepiride + insulin glargine (Amaryl + Lantus)|Drug: glimepiride/metformin fixed combination+insulin glargine (AmarylM + Lantus),"Mean change in HbA1c from baseline to the last visit|Mean change in FPG, insulin, c-peptide from baseline to the last visit Safety; Episodes of hypoglycemia & other adverse events|Response rate based on HbA1c and FPG levels measured at the last visit|Mean change in Lantus® dose from baseline to the last visit|Compliance|Frequency with hypoglycemic episode|Adverse events","Handok Pharmaceuticals Co., Ltd.",All,"20 Years and older   (Adult, Older Adult)",Phase 4,110,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HANDOK2008.10,May-09,Nov-10,Nov-10,4-Jun-09,null,28-Mar-13,"HeeYoung Lee, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00913367
NCT00913497,The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: insulin glulisine|Drug: insulin aspart,Difference in the two hour and four hour post prandial blood glucose levels following administration of insulin glulisine versus insulin aspart at the end of the twenty study days|Incidence of symptomatic hypoglycemia; hyperglycemia with ketonuria; systemic allergic reactions; localized injection site reactions,Spectrum Health Hospitals|Helen DeVos Children's Hospital,All,4 Years to 11 Years   (Child),Phase 4,16,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2009-089,Jun-09,Jan-12,Jan-12,4-Jun-09,null,4-Apr-14,"Helen DeVos Childrens Hospital, Grand Rapids, Michigan, United States",,https://ClinicalTrials.gov/show/NCT00913497
NCT00910767,Closing the Loop in Adults With Type 1 Diabetes,ANGELA01,Completed,No Results Available,Type 1 Diabetes,Device: Conventional insulin pump delivery|Device: Closed loop,Percentage of plasma glucose values in target (3.9 - 8.0 mmol/L)|Percentage of CGM (continuous glucose monitoring) values in target (3.9-8.0 mmol/L)|Percentage of plasma glucose and CGM values in target (3.9-8.0 mmol/L)|Percentage of plasma glucose and CGM values below 3.9 mmol/L|Percentage of plasma glucose and CGM values above 8.0 mmol/L|Average plasma and CGM glucose|Average plasma insulin concentration|Total dose of insulin administered|low blood glucose index (LBGI) score|high blood glucose index (HBGI) score|Percentage of plasma glucose and CGM values below 3.0 mmol/L,University of Cambridge|Cambridge University Hospitals NHS Foundation Trust|Diabetes UK,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,08/H0308/297,Feb-09,Jul-09,Jul-09,1-Jun-09,null,17-Sep-09,"Addenbrooke's Hospital, Cambridge, United Kingdom",,https://ClinicalTrials.gov/show/NCT00910767
NCT00905255,GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS),GETGOAL-MONO,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Lixisenatide (AVE0010)|Device: Pen auto-injector,"Overview of Adverse Event Profile (Treatment Emergent Adverse Events) of the One-Step and Two-Step Titration Arms Assessed Through Adverse Events Collection and Vital Signs, Electrocardiogram (ECG) and Laboratory Monitoring|Overview of Adverse Event Profile (Treatment Emergent Adverse Events) of All Patients During On-Treatment Period Assessed Through Adverse Events Collection and Vital Signs, ECG and Laboratory Monitoring|Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) for All Patients at Week 52 and 76|Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 52 and 76|Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 52 and 76|Change From Baseline in Body Weight for All Patients at Week 52 and 76|Change From Baseline in Fasting Plasma Glucose (FPG) for All Patients at Week 52 and 76",Sanofi,All,"20 Years and older   (Adult, Older Adult)",Phase 3,69,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LTS10888,May-09,Jan-11,Jan-11,20-May-09,21-Dec-16,21-Dec-16,"Sanofi-Aventis Administrative Office, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00905255
NCT00898534,Effect of Immediate Hemoglobin A1c on Glycemic Control in Children With Type I Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes Mellitus|Glycemic Control,Device: Bayer DCA2000+ Hemoglobin A1c analyzer,"Hemoglobin A1c|Pain rating of hemoglobin A1c test|Change in diabetes management (insulin, diet, exercise, glucose self-monitoring)|Episodes of severe hypoglycemia|Hospital admissions for diabetes related event|Number of phone and/or email contacts between practitioner and patient",Boston Children’s Hospital,All,"2 Years to 18 Years   (Child, Adult)",Phase 4,234,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,03-07-121,Nov-03,Sep-05,Jan-06,12-May-09,null,12-May-09,"Children's Hospital Boston, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00898534
NCT00896077,Subcutaneous Administration of Lisofylline to Healthy Normal Subjects and Subjects With Type 1 Diabetes,,Completed,No Results Available,Healthy|Type 1 Diabetes,Drug: Lisofylline,"Safety (based on AEs, vital signs assessments, resting 12-lead ECG evaluations, physical examination findings and clinical laboratory test results)|Pharmacokinetic (PK) parameters will include AUC0-t, AUC0-inf, Cmax, Tmax, t1/2, kel, CL, Vdss and F|Pharmacodynamic (PD) assessments (blood will be collected for determination of serum cytokine, chemokine, insulin and FFA levels at time points noted previously)","DiaKine Therapeutics, Inc.",All,18 Years to 45 Years   (Adult),Phase 1|Phase 2,8,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),DT-002,May-09,Dec-09,Dec-09,11-May-09,null,29-Jul-14,"Advanced Biomedical Research, Inc. (ABR), Hackensack, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00896077
NCT00891995,Effect of Metabolic Control at Onset of Diabetes on Progression of Type 1 Diabetes,,Terminated,Has Results,Type 1 Diabetes,Device: Closed loop|Device: Home glucose monitoring|Device: Insulin pump|Device: Continuous glucose monitor,C-peptide Average Area Under the Curve (AUC) in Response to a Mixed Meal at 1 Year Following Enrollment.|Peak C-peptide in Response to a Mixed Meal at 1 Year Following Enrollment|Incidence of the Loss of the 2 Hour Peak C-peptide < 0.2 Pmol/ml on a Semi-annual MMTT|HbA1c|Adverse Events (Severe Hypoglycemia)|CGM Mean Glucose|CGM Measured Glucose Outcomes|Daily Insulin Dose|BMI Percentile,Jaeb Center for Health Research,All,"6 Years to 45 Years   (Child, Adult)",Phase 2|Phase 3,71,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DirecNet 012,Sep-10,Oct-13,Oct-13,1-May-09,27-Oct-16,30-Dec-16,"Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|Indiana University, Indianapolis, Indiana, United States|Vanderbilt University, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00891995
NCT00889668,Evaluation of the Performance and Use of Non-Invasive Glucose Monitoring Device,CR-01-001,Unknown status,No Results Available,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Device: GlucoTrack,Clarke Error Grid|User Satisfaction,Integrity Applications Ltd.,All,"10 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,180,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,CR-01-001 CTIL,May-09,Oct-12,Oct-12,29-Apr-09,null,1-May-12,"Soroka University Medical Center, Beer-Sheva, Israel",,https://ClinicalTrials.gov/show/NCT00889668
NCT00890331,Prevention of Self-care Deterioration in Early Adolescents With Diabetes,,Completed,No Results Available,Type 1 Diabetes,Behavioral: TeamWork CS Sessions|Behavioral: Diabetes Education,"Parental involvement and Disease care behaviors|Glycohemoglobin levels, Adverse effects and Blood glucose variability",Virginia Commonwealth University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Children's Research Institute,All,11 Years to 14 Years   (Child),Phase 1,285,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,DK70917|R01DK070917,Apr-07,Mar-14,Mar-14,29-Apr-09,null,8-Jan-16,"Children's National Medical Center, Washington, District of Columbia, United States|Virginia Commonwealth University, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00890331
NCT00888732,"A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, BIAsp70, BIAsp50 and Fast-acting Human Insulin",,Completed,No Results Available,"Diabetes Mellitus, Type 1","Drug: Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin","Cmaxglu: Peak plasma glucose following test meal (breakfast). A comparison will be made between fast-acting human insulin vs. IAsp, BIAsp 50 and BIAsp 70, IAsp vs BIAsp 50 and BIAsp 70, BIAsp 50 vs. BIAsp 70.|AUCglu: The area under the plasma glucose concentration (0-12, 0-6, 6-12, 0-4, 4-8, 8-12 hours after test meal) after a single injection of one of the four insulins: IAsp, Biphasic insulin aspart 50 and 70 & fast-acting human insulin|AUCins: The area under insulin aspart/human insulin concentration (0-12, 0-6, 6-12, 0-4, 4-8, 8-12 hours after test meal) after a single injection of one of the four insulins: IAsp, Biphasic insulin aspart 50 and 70 & fast-acting human insulin|tmaxins: Time to maximum serum insulin aspart/human insulin concentration|Serum GH, total IGF-I, IGF-I bioactivity, IGFBP-1, IGFBP-2, binary complex of IGF-I, IGFBP-3 and the acid-labile subunit (ALS)",University of Aarhus|Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,24,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Asp-BIAsp-HI-2008|2008-007176-22,Jun-09,Jun-10,Jun-10,28-Apr-09,null,28-Apr-11,"Dept of Medicine M, Aarhus University Hospital, Aarhus, Denmark",,https://ClinicalTrials.gov/show/NCT00888732
NCT00888628,Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients,,Completed,Has Results,"Diabetes Mellitus, Type I",Biological: Purified Pancreatic Islets|Drug: Etanercept,"Insulin Independence With Both an HbA1c ≤ 6.5% and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant or a Reduction in HbA1c of at Least 1 Point and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant.|Number of Participants With a Decrease in HbA1c|Stable or Decrease in Urinary Albumin and Creatinine Ratio and Serum Creatinine|An Absence Cardiovascular Events, Cerebral Vascular Accident, and Myocardial Infarction|Impact on Vision|Absence of Negative Renal Impact Measures|Improvement of Metabolic Control|Number of Participants With a Decrease of Severe Hypoglycemic Events|Reduction of Insulin Requriements",Massachusetts General Hospital|Boston Area Diabetes Endocrinology Research Center (funded by NIDDK),All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,7,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IAK,May-09,Aug-14,Aug-16,27-Apr-09,27-Jan-17,29-Nov-17,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00888628
NCT00886821,A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics,,Completed,Has Results,"Diabetes Mellitus, Type 2",Biological: CVX-096,Stage 1: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04856883 on Day 1|Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883 on Day 1|Stage 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883 on Day 8|Stage 2: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883 on Day 22|Maximum Observed Plasma Concentration (Cmax) of PF-04856883 on Day 1|Stage 1: Maximum Observed Plasma Concentration (Cmax) of PF-04856883 on Day 8|Stage 2: Maximum Observed Plasma Concentration (Cmax) of PF-04856883 on Day 22|Stage 1: Apparent Terminal Elimination Half-Life (t1/2) of PF-04856883 on Day 1|Stage 1: Apparent Terminal Half-Life (t1/2) of PF-04856883 on Day 8|Stage 2: Apparent Terminal Elimination Half-Life (t1/2) of PF-04856883 on Day 22|Stage 1: Mean Residence Time (MRT) of PF-04856883 on Day 1|Stage 1: Apparent Oral Clearance (CL/F) of PF-04856883 on Day 1|Stage 1: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC[0 - Inf]) of PF-04856883 on Day 1,Pfizer,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,114,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B1111001|CVX-096-101,Oct-08,Jun-11,Jun-11,23-Apr-09,18-Apr-17,18-Apr-17,"Cetero Research, Miami Gardens, Florida, United States|Cetero Research - San Antonio, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00886821
NCT00884611,Development of Algorithms for a Hypoglycemic Prevention Alarm: Closed Loop Study,,Completed,Has Results,Type 1 Diabetes Mellitus,Device: Predictive Low Glucose Suspend Algorithm ON|Device: Predictive Low Glucose Suspend Algorithm OFF,Percentage of Nights With CGM (Continuous Glucose Monitor) Sensor Values < 60 mg/dL|Percentage of Nights With CGM Values >180 mg/dL|Mean Morning Blood Glucose (BG),"Stanford University|University of Colorado, Denver",All,"12 Years to 46 Years   (Child, Adult)",Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SU-10162008-1321|Stanford eprotocol # 6789,May-07,Jul-11,Aug-11,21-Apr-09,28-Feb-18,28-Feb-18,"Stanford University School of Medicine, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, University of Colorado, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT00884611
NCT00885118,4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM),,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo (middle dose)|Drug: Placebo|Drug: BI 10773|Drug: Placebo (high dose)|Drug: Placebo (low dose),"Change From Baseline in Urine Glucose Excretion|Change From Baseline in Fasting Plasma Glucose|Change From Baseline in 8-point Glucose|Change From Baseline in HbA1c|Change From Baseline in Fructosamine|Change From Baseline in 1,5-anhydroglucitol|Change From Baseline in Fasting Insulin|Change From Baseline in the Area Under the Curve of Plasma Glucose Levels Until 4 Hours After Intake of a Standardised Food (Meal Tolerance Test)|Change From Baseline in the Area Under the Curve of Glucagon Levels Until 4 Hours After Intake of a Standardised Food (Meal Tolerance Test)|Change From Baseline in the Area Under the Curve of Insulin Levels Until 4 Hours After Intake of a Standardised Food (Meal Tolerance Test)|AUCτ,1|AUC0-tz|AUC0-∞|Cmax|t1/2|CL/F|Vz/F|Ae0-24|fe0-24|CLR,0-24|AUCτ,ss|Cmax,ss|t1/2,ss|CL/F,ss|Vz/F,ss|RA,Cmax|RA,AUC|Ae0-24,ss|fe0-24,ss|CLR,ss",Boehringer Ingelheim,All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,1245.15,Apr-09,Oct-09,null,21-Apr-09,16-Jun-14,25-Nov-14,"1245.15.003 Boehringer Ingelheim Investigational Site, Hachioji, Tokyo, Japan|1245.15.002 Boehringer Ingelheim Investigational Site, Koganei, Tokyo, Japan|1245.15.001 Boehringer Ingelheim Investigational Site, Nakano-ku, Tokyo, Japan|1245.15.005 Boehringer Ingelheim Investigational Site, Suita, Osaka, Japan|1245.15.004 Boehringer Ingelheim Investigational Site, Yokohama, Kanagawa, Japan",,https://ClinicalTrials.gov/show/NCT00885118
NCT00883558,Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Insulin Lispro|Drug: regular human insulin|Drug: recombinant human hyaluronidase PH20|Drug: Insulin glargine,Postprandial Glucose Excursion|Time Spent With Blood Glucose Value Outside a 71-139 Milligrams Per Deciliter (mg/dL) Range During Continuous Glucose Monitoring|Number of Participants With Hypoglycemic Events,Halozyme Therapeutics,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,48,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),HALO-117-203,May-09,Feb-10,Apr-10,17-Apr-09,8-Sep-14,8-Sep-14,"Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Diabetes Research Institute, Miami, Florida, United States|Henry Ford Health System, Detroit, Michigan, United States|Mercury Street Medical, Butte, Montana, United States|UNC Diabetes Care Center/Highgate Specialty Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Texas Diabetes and Endocrinology, Austin, Texas, United States|West Olympia Internal Medicine, Olympia, Washington, United States",,https://ClinicalTrials.gov/show/NCT00883558
NCT00882726,"A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus",,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: CNTO 3649 IV (Healthy participants)|Drug: CNTO 3649 SC (Healthy participants)|Drug: CNTO 3649 SC (Diabetic patients)|Drug: Placebo,"Safety and tolerability of a single IV or SC administration of CNTO 3649 in healthy participants; Safety and tolerability of multiple SC injections of CNTO 3649 in Type 2 Diabetic Patients|Pharmacokinetics, pharmacodynamics and immunogenicity of CNTO 3649 following single and multiple administrations.","Centocor, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,133,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CR015562|CNTO3649DIB1001,Feb-09,Apr-10,Apr-10,16-Apr-09,null,16-Dec-13,"Miramar, Florida, United States|San Antonio, Texas, United States|Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT00882726
NCT00881543,"""Effect of Dipeptidyl Peptidase IV After Diets in näive Type 2 Diabetic Patients""",,Completed,No Results Available,Diabetes Type 2,Drug: Dipeptidyl Peptidase IV inhibitors,"secretion of glucose, insulin, glucagon, C-peptide and lipid profile after isocaloric diets|Washout of dipeptidyl peptidase IV inhibitors after one month without the drug",University of Sao Paulo General Hospital|University of Sao Paulo,All,"40 Years to 70 Years   (Adult, Older Adult)",Not Applicable,45,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,USaoPauloGH,Jun-09,Jun-10,Oct-11,15-Apr-09,null,28-May-12,"University of São Paulo General Hospital, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT00881543
NCT00879710,Effect of Diabetes Mellitus on Cholesterol Metabolism,,Completed,Has Results,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus|Hypercholesterolemia,Drug: simvastatin or ezetimibe,Changes in LDL Cholesterol|Changes in Cholesterol Absorption or Synthesis Rates From the Baseline,Medical College of Wisconsin,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,57,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRO00002485,Aug-08,Jul-13,Jul-13,10-Apr-09,18-Apr-16,18-Apr-16,"Medical College of Wisconsin /Froedtert Hospital, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00879710
NCT00875290,The Effectiveness of Continuous Glucose Monitoring in Diabetes Treatment for Infants and Young Children,Gerber RTSA,Unknown status,No Results Available,"Diabetes Mellitus, Type I",Device: Real-time glucose sensor,Reduce blood glucose variability among 0-3 year old children with type I diabetes.|Number of adverse events,Seattle Children's Hospital|The Gerber Foundation|Medtronic,All,3 Months to 3 Years   (Child),Phase 3,40,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GerberPumpStudy,Nov-08,Nov-14,Nov-14,3-Apr-09,null,5-Aug-11,"Seattle Children's Hospital, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00875290
NCT00875459,"An Open Label, Multi-Center, Follow-on Study Examining the Long-Term Safety and Efficacy of Insulin VIAject™ in Subjects With Type 1 Diabetes Mellitus",,Completed,No Results Available,Diabetes Mellitus,Drug: VIAject™,"The frequency of occurrence of hypoglycemia measured quarterly over one year.|Changes in total daily:prandial insulin dose, insulin dose, body weight, insulin antibody titers, the effects of insulin antibodies on glycemic control, individual and group mean %HbA1c measured quarterly and over one year.",Biodel,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,233,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VIAject™-07J,Apr-07,Feb-10,Feb-10,3-Apr-09,null,29-Jul-15,,,https://ClinicalTrials.gov/show/NCT00875459
NCT00873925,Cord Blood Plus Vitamin D and Omega 3s in T1D,,Completed,No Results Available,Type 1 Diabetes,Biological: Autologous UCB|Dietary Supplement: Omega 3 FA|Dietary Supplement: Vitamin D,C-Peptide following the 1 year mixed meal tolerance test|DHA Level|Vitamin D Level|HbA1c and Insulin Dose|Peripheral Blood T-cell assays,University of Florida|Juvenile Diabetes Research Foundation|National Institutes of Health (NIH),All,"1 Year to 18 Years   (Child, Adult)",Phase 1,15,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UF IRB 696-2008,Mar-09,Mar-12,Oct-12,2-Apr-09,null,4-Apr-13,"University of Florida, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT00873925
NCT00873561,A Study to Evaluate NBI-6024 in Adult and Adolescent Patients With New Onset of Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: NBI-6024,"To assess the effect of repeated administrations of NBI-6024 on endogenous insulin production as measured by C-peptide levels in adult and adolescent patients with new onset type 1 diabetes mellitus|To examine the effects of repeated administrations of NBI-6024 on insulin usage, glycemic control, and immune function (immunodynamics and pharmacodynamics) To examine the safety and tolerability of repeated administrations of NBI-6024",Neurocrine Biosciences,All,"10 Years to 35 Years   (Child, Adult)",Phase 1,188,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",NBI 6024-0101,Dec-01,Apr-06,Jul-06,1-Apr-09,null,1-Apr-09,"Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|Center Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|Centre de recherche clinique de Laval, Laval, Canada|University Hospital and School of Medicine, Olomouc, Czech Republic|Faculty Hospital Motol, Prague, Czech Republic|Helsinki University Hospital, Helsinki, Finland|Hôpital Debrousse, Lyons, France|Hôpital St Vincent de Paul, Paris, France|Diabetes Center for Children and Adolescents, Hannover, Germany|Institut für Diabetesforschung, Munchen, Germany|New Groote Schuur Hospital, Cape Town, South Africa|Parklands Medical Center, Durban, South Africa|Center for Diabetes and Endocrinology, Johannesburg, South Africa|Donald Gordon Medical Center, Johannesburg, South Africa|Medigate Medical Center, KwaZulu Natal, South Africa|Helderberg Diabetic Clinic and Practice, Somerset West, South Africa|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital de Cruces, Cruces-Baracado, Spain|Hospital Materno-Infantil, Malaga, Spain|University Hospital Virgen del Rocío, Sevilla, Spain|Maternal and Child Health Services 2, Dundee, United Kingdom",,https://ClinicalTrials.gov/show/NCT00873561
NCT00870818,Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01),,Terminated,No Results Available,Type 1 Diabetes Mellitus,Drug: Teplizumab,"Primary outcome measures will include the number and percentage of subjects who experience a SAE, Adverse Event of Special Interest (including Opportunistic Infection, Lymphopoliferative disease), or other Immediately Reportable Event.|A secondary endpoint will be determining the efficacy of teplizumab by measuring the subject's total daily insulin usage and HbA1c levels.|C-peptide secretory response will be analyzed in terms of basal levels of C-peptide produced before a mixed meal and stimulated levels after a mixed meal, measured as AUC and peak post-meal production.|Immunophenotyping of blood mononuclear cells will be summarized by visit and graphed over time, as appropriate.|A secondary efficacy endpoint will be assessing Heath Related Quality of Life Questionnaires filled out by subjects at different timepoints in the study.",MacroGenics|Eli Lilly and Company,All,"10 Years to 37 Years   (Child, Adult)",Phase 2|Phase 3,219,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CP-MGA031-02,Feb-09,Feb-11,May-11,27-Mar-09,null,8-Mar-12,"Atlanta Diabetes Associates, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT00870818
NCT00869414,"Glycemic Effects of Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes",,Terminated,Has Results,Type 1 Diabetes|Hypoglycemia,Drug: Evening only administration of insulin glargine|Drug: Morning only administration of insulin glargine|Drug: split dose insulin glargine,Time Spent (Mean Number of Minutes Per 24 Hour Day) in Hypoglycemic Range (<70mg/dl)|Change in the Mean Minutes Per 24 Hour Day in the Hyperglycemic Range of > 180 mg/dL.,Johns Hopkins University,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,16,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,NA_00024168,Jul-09,Mar-10,Mar-10,26-Mar-09,29-Jun-17,29-Jun-17,"Johns Hopkins Hospital, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00869414
NCT00867594,Effectiveness of Oral Insulin in Unstable Type 1 Diabetes Patients,,Completed,No Results Available,Brittle Type I Diabetes Mellitus,Drug: ORMD 0801,To determine the safety and tolerability of multi-doses of Oramed oral insulin in people with type 1 diabetes|To determine if oral insulin is likely to improve glycemic stability assessed by the reduction of the frequency and severity of hypoglycemic episodes in people with unstable type 1 diabetes,Hadassah Medical Organization|Oramed Pharmaceutical Inc.,All,18 Years to 50 Years   (Adult),Phase 2,12,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0566-08-HMO-CTIL,Jul-08,Aug-08,Aug-08,24-Mar-09,null,11-Aug-11,"Hadassah University Hospital, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT00867594
NCT00866658,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)",GETGOAL-L-ASIA,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Lixisenatide (AVE0010)|Drug: Placebo|Device: Pen auto-injector|Drug: Sulfonylurea|Drug: Basal Insulin,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24|Change From Baseline in 2-hour Postprandial Plasma Glucose (PPG) at Week 24|Change From Baseline in Body Weight at Week 24|Change From Baseline in Average 7-Point Self Monitored Plasma Glucose (SMPG) Profile at Week 24|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24|Change From Screening in Total Insulin Dose at Week 24|Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24|Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24|Percentage of Patients Requiring Rescue Therapy During 24-Week Period,Sanofi,All,"19 Years and older   (Adult, Older Adult)",Phase 3,311,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EFC10887,Mar-09,Jun-10,Jun-10,20-Mar-09,11-Oct-16,11-Oct-16,"Sanofi-Aventis Administrative Office, Tokyo, Japan|Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of|Sanofi-Aventis Administrative Office, Makati City, Philippines|Sanofi-Aventis Administrative Office, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT00866658
NCT00861809,The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis,,Completed,No Results Available,Gastroparesis,Drug: GSK962040 25 mg|Drug: Placebo|Drug: GSK962040 50 mg|Drug: GSK962040 1250 mg,"Gastric emptying, as measured by the 13C octanoic acid breath test (Gastric half emptying time (t1/2b), Duration of the lag time (tlag), Gastric evacuation coefficient (GEC))|Safety and tolerability of GSK962040 (Change from baseline and number of patients outside the normal range for blood pressure, heart rate, 12-lead ECG parameters)|Pharmacokinetic parameters of GSK962040: Cmax, Tmax, AUC(0-t), AUC(0-inf) for single-dose, CL/F, V/F, and, if possible, half-life|Safety and tolerability of GSK962040 (Adverse events)|Safety and tolerability of GSK962040 (Change from baseline in clinical chemistry and hematology parameters)|Bowel movement parameters (Time to first bowel movement after first dose, Bowel movement count, Stool consistency (Bristol Stool Form scale))|PK/PD relationship of PP, plasma glucagon, GLP-1, and ghrelin after a single dose of GSK962040.|Plasma glucose|Food intake",GlaxoSmithKline,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,11,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",111809,Jun-09,Nov-10,Nov-10,13-Mar-09,null,30-Jan-17,"GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT00861809
NCT00858897,Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study A,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Other: Cysteine isotope infusion at normoglycemia vs hyperglycemia|Drug: Regular Insulin,Increase in glutathione concentration under normoglycemia,Nemours Children's Clinic|Juvenile Diabetes Research Foundation,All,"14 Years to 18 Years   (Child, Adult)",Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,JDRF 1-2006-627-A,Jun-07,Feb-08,Feb-09,10-Mar-09,null,15-Jul-09,"Nemours Children's Clinic, Jacksonville, Florida, United States",,https://ClinicalTrials.gov/show/NCT00858897
NCT00859079,Efficacy of GLP-1 Infusion in Comparison to an Insulin Infusion Protocol to Reach Normoglycemia Type 2 Diabetic Patients,,Completed,No Results Available,Diabetes Mellitus Type 2|Hyperglycemia,Drug: GLP-1|Drug: Human regular insulin intravenously,time to reach a plasma glucose below 115 mg/dl|plasma glucose after 2 and 4 hours as well as maximum glycemia|number of hypoglycaemic episodes,Medical University of Graz,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,8,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TCW-GLP1-1,Jun-06,Dec-06,Jan-07,10-Mar-09,null,10-Mar-09,"Medical University of Graz, Department for Internal Medicine, Graz, Austria",,https://ClinicalTrials.gov/show/NCT00859079
NCT00858273,Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study B,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Dietary Supplement: Antioxidant supplement|Other: Diabetes treatment|Drug: Regular Insulin,"Restoration of glutathione homeostasis, measured by glutathione concentration while at near normoglycemia|Decrease in markers of oxidative stress (plasma protein bound 3-nitrotyrosine, urinary 8OH-2'-deoxyguanosine, urinary F2-isoprostane)",Nemours Children's Clinic|Juvenile Diabetes Research Foundation,All,"12 Years to 21 Years   (Child, Adult)",Not Applicable,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",JDRF 1-2006-627-B,Mar-08,Mar-11,Aug-11,9-Mar-09,null,4-May-12,"Nemours Children's Clinic, Jacksonville, Florida, United States",,https://ClinicalTrials.gov/show/NCT00858273
NCT00853424,A Comparison of Islet Cell Transplantation With Medical Therapy for the Treatment of Diabetic Eye Disease,,Withdrawn,No Results Available,Diabetic Retinopathy|Diabetic Macular Edema,Procedure: islet cell transplant|Other: Medical therapy,"Composite outcome consisting of progression of DR, development of significant ME, or moderate visual loss in patients who have significant ME at randomization.",University of British Columbia,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 3,0,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,H08-02859,Dec-09,Dec-10,Dec-10,2-Mar-09,null,17-Mar-14,,,https://ClinicalTrials.gov/show/NCT00853424
NCT00853944,Effect of Sitagliptin on Graft Function Following Islet Transplantation,,Terminated,No Results Available,Islet Transplantation,Drug: sitagliptin,Islet function as measured by hyperglycemic clamp|Change in insulin requirement (absolute and % decrease from pre-transplant dose),University of British Columbia|Merck Sharp & Dohme Corp.,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 3,12,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",H08-01947,Jul-09,1-Nov-13,1-Nov-13,2-Mar-09,null,30-Oct-17,"Vancouver General Hospital, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT00853944
NCT00850161,Intranasal Insulin and Its Effect on Postprandial Metabolism in Comparison to Subcutaneous Insulin,,Withdrawn,No Results Available,Type 1 Diabetes Mellitus,Drug: aspart|Drug: Nasulin™,The primary endpoint is to determine whether intranasal administration of Nasulin™ will stimulate glucose disposal and suppress endogenous glucose production.,CPEX Pharmaceuticals Inc.,All,18 Years to 50 Years   (Adult),Phase 2,0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,Nasulin™-BNT-US-100-PK009,Jul-09,Aug-09,Sep-10,24-Feb-09,null,15-Feb-16,,,https://ClinicalTrials.gov/show/NCT00850161
NCT00848705,Adolescent Self-Management of Type 1 Diabetes: an Intervention (Completed),YourWay,Completed,No Results Available,Adolescent Type 1 Diabetes,Behavioral: YourWay Internet Intervention,Self-management behaviors|Self-management Problem solving,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,13 Years to 17 Years   (Child),Early Phase 1,72,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,DK70026-01A2,Oct-07,Jan-09,May-09,20-Feb-09,null,2-Feb-11,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00848705
NCT00846898,"Is There a Metabolic Effect of Cinnamon on HbA1c, Blood Pressure and Serum Lipids in Type 2 Diabetes Mellitus?",cinnamon,Completed,No Results Available,Type 2 Diabetes Mellitus,Dietary Supplement: cinnamon 2g per day for 12 weeks,"HbA1c|Plasma glucose concentration Plasma lipid profiles (HDL, LDL, Triglycerides and total cholesterol) systolic and diastolic blood pressures. Body Mass Index. Waist circumference. Total calorie intake.","Thames Valley University|Wembley Health Care centre, NHS, UK.|Monks Park Primary care centre, NHS UK.|Willesden Health centre, NHS, UK.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,58,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07/H0717/47,Mar-08,Jan-09,Feb-09,19-Feb-09,null,14-Nov-11,"Brent teaching Primary Care trust (NHS), Wembley, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00846898
NCT00847327,Parental Management of Young Children's Diabetes,YCP,Completed,No Results Available,Type 1 Diabetes,Behavioral: Parental Support|Behavioral: Diabetes Education,Glycemic variability|Parent Quality of Life|Child Quality of Life|Hemoglobin A1C,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Children's Research Institute|Virginia Commonwealth University,All,1 Year to 6 Years   (Child),Not Applicable,134,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",DK80102|R01DK080102,Apr-08,Aug-13,Aug-13,19-Feb-09,null,14-Mar-18,"Children's National Medical Center, Washington, District of Columbia, United States|Virginia Commonwealth University, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00847327
NCT00843388,A Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria,,Unknown status,No Results Available,Diabetes Mellitus|Nephropathy|Blood Pressure,Drug: Spironolacton (hexalacton(R))|Drug: placebo tablet,"albuminuria, expected decrease|GFR|ambulatory blood pressure|plasma renin, angiotensin, aldosteron",Steno Diabetes Center Copenhagen,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2306|Eudra CT: 2008-004839-38,Mar-09,Mar-10,Mar-10,13-Feb-09,null,13-Feb-09,,,https://ClinicalTrials.gov/show/NCT00843388
NCT00843609,International Navigator Hypoglycaemia Study,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Hypoglycemia",Device: Navigator continuous glucose monitor (Freestyle Navigator®),"Reduction in time spent in hypoglycaemia, defined as continuous glucose <3.5mmol/l (63mg/dl) (with or without symptomatic hypoglycaemia).|No concomitant rise in HbA1c|Glycaemic variability|Frequency and area under the curve (AUC) of hypoglycaemia|Quality of Life measures (Fear of Hypoglycaemia score and subject satisfaction questionnaire);","University Medical Centre Ljubljana|Karolinska Institutet|Schneider Children's Medical Center, Israel",All,"10 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,122,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INHS1,Oct-08,Dec-09,Jan-10,13-Feb-09,null,5-Feb-10,"Schneider Children's Medical Center of Israel, Petah Tikva, Israel|UMC Ljubljana - University Children's Hospital, Ljubljana, Slovenia|Karolinska Institutet, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT00843609
NCT00842075,Pramlintide in Adolescents With Type 1 Diabetes,,Completed,Has Results,Type 1 Diabetes,Drug: pramlintide,HbA1c Value After 28 Days|Weight Change After 28 Days Intervention Period,"University of Colorado, Denver|Amylin Pharmaceuticals, LLC.",All,13 Years to 17 Years   (Child),Not Applicable,10,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,05-0724(2),Dec-06,Dec-09,Dec-09,12-Feb-09,19-Oct-12,23-Jun-15,"Barbara Davis Center, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT00842075
NCT00841087,"Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes",,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin detemir|Drug: insulin aspart,Rate of Major and Minor Hypoglycaemic Episodes|Rate of Nocturnal Major and Minor Hypoglycaemic Episodes|Number of Treatment Emergent Adverse Events (AEs)|Change in Body Weight|Electrocardiogram (ECG)|Diastolic Blood Pressure (BP)|Systolic Blood Pressure (BP),Novo Nordisk A/S,All,"20 Years and older   (Adult, Older Adult)",Phase 2,65,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN1250-3569|JapicCTI-090711,Jan-09,May-09,May-09,11-Feb-09,16-Nov-15,3-Mar-17,"Novo Nordisk Investigational Site, Chuo-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Ebina-shi, Japan|Novo Nordisk Investigational Site, Koriyama-shi, Fukushima, Japan|Novo Nordisk Investigational Site, Kumamoto-shi,Kumamoto, Japan|Novo Nordisk Investigational Site, Oita-shi, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Yokohama-shi, Japan",,https://ClinicalTrials.gov/show/NCT00841087
NCT00837512,Insulin Delivery Using Microneedles in Type 1 Diabetes,,Completed,Has Results,Type 1 Diabetes Mellitus,Device: Microneedle|Device: Subcutaneous insulin catheter,Onset Time (Tmax),Emory University|Thrasher Research Fund,All,"8 Years to 18 Years   (Child, Adult)",Phase 2|Phase 3,16,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1348-2005|FWA00005792,Sep-08,Dec-12,Jul-13,5-Feb-09,8-Jan-14,8-Jan-14,"Emory University, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT00837512
NCT00837759,Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes,,Terminated,Has Results,Diabetes Mellitus Type 1|Autoimmune Diabetes,Drug: Insulin|Drug: Lansoprazole|Drug: Sitagliptin|Biological: Diamyd|Drug: GAD65 (Diamyd),Change in C-peptide|Glycemia Control (Change in HbA1c Level)|Change in Insulin Dose|Change in Anti-GAD Autoantibody Titers|Change in Anti-IA2 Titer|Change in ZnT8 Autoantibody Titer,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC),All,"16 Years to 30 Years   (Child, Adult)",Phase 2,7,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,090056|09-DK-0056,Feb-09,Mar-11,Mar-11,5-Feb-09,24-Oct-12,3-Jan-13,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00837759
NCT00831389,Effect of Closed Loop Glucose Control on Exercise-Associated Hypoglycemia,ePID-03,Completed,Has Results,Type 1 Diabetes Mellitus,Device: Closed Loop,Plasma Glucose (PG) Response to Exercise|Incidence of Hypoglycemia Immediately Following Exercise|Incidence of Nocturnal Hypoglycemia Following Exercise|Peak Post-prandial Plasma Glucose (PG)|Nadir Plasma Glucose (PG) Immediately Following Exercise|Overnight Nadir Plasma Glucose (PG)|Percentage of Time Plasma Glucose (PG) is Within the Euglycemic Range.|Percentage of Time Plasma Glucose (PG) is Above the Euglycemic Range.|Percentage of Time Plasma Glucose (PG) is Below the Euglycemic Range.,Medtronic Diabetes|Juvenile Diabetes Research Foundation,All,"12 Years to 30 Years   (Child, Adult)",Not Applicable,13,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,ePID-03,Jan-09,Nov-10,Nov-10,28-Jan-09,11-Oct-12,12-Dec-17,"Yale Pediatrics Diabetes Research, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00831389
NCT00829062,Expanding Coverage of Continuous Subcutaneous Insulin Infusion in Pediatric Patients With Diabetes,,Withdrawn,No Results Available,Type 1 Diabetes,Device: Continuous glucose glucose sensor- physician ordered,The aim of this project is to present evidence based practice to Missouri Medicaid to expand coverage of continuous subcutaneous insulin infusion (CSII) in pediatric patients with diabetes. - Hemoglobin A1C|Glycemic variability as shown by continuous glucose recording,Children's Mercy Hospital Kansas City,All,12 Months to 17 Years   (Child),Not Applicable,0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),08-11-178E,Jan-09,Jul-10,Jul-10,26-Jan-09,null,30-Jul-10,"Children's Mercy Hospital and Clinics, Kansas City, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00829062
NCT00824694,Impact of Accu-Chek 360 in Veterans With Type 2 Diabetes,,Completed,No Results Available,Type 2 Diabetes,Other: Targeted Self-Monitoring Of Blood Glucose (SMBG)|Other: Provider Training|Other: Patient Education,"Principal endpoints will be measured 48 weeks after group assignment and include the number of medication changes and HbA1c. Interim analysis will include HbA1c measurement at 3 mont intervals.|Secondary endpoints include changes in patient attitudes toward SMBG, daily carbohydrate consumption, physical activity level, BMI, and medication compliance (for subjects on OHA).",Biomedical Research Institute of New Mexico|New Mexico VA Healthcare System|Carl T. Hayden VA Medical Center|Southern Arizona VA Health Care System,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,348,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Investigator Initiated,Mar-09,May-10,May-10,19-Jan-09,null,23-Jun-11,"Carl T. Hayden VAMC, Phoenix, Arizona, United States|Southern Arizona VA Healthcare System, Tucson, Arizona, United States|New Mexico VA Health Care System, Albuquerque, New Mexico, United States",,https://ClinicalTrials.gov/show/NCT00824694
NCT00823940,A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Healthy Normal Subjects,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: GSK1362885|Drug: Glucagon|Drug: Glucagon + GSK1362885,"Safety and tolerability assessments including adverse events, clinical laboratory tests, electrocardiogram (ECG) and vital signs|Pharmacokinetic parameters: AUC, Cmax, Tmax, t1/2, tlag, Cl/F, and V/F|Pharmacokinetic parameters to assess dose proportionality and food effect|Pharmacodynamic parameters may include change from baseline in glucose, insulin, C-peptide and AUC following administration of IV glucagon in a standardized GC test with and without prior administration of GSK1362885",GlaxoSmithKline,All,18 Years to 55 Years   (Adult),Phase 1,42,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",111497,13-Jan-09,27-Apr-09,27-Apr-09,16-Jan-09,null,7-Jul-17,"GSK Investigational Site, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00823940
NCT00824148,Use of Real-time Continuous Glucose Monitoring System in Patients With Type 1 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: Guardian REAL-Time Continuous Glucose Monitoring System|Other: Conventional self-monitoring of plasma glucose,"Level of HbA1c concentration|Quality of life assessed by SF-36, DTSQs and DTSQc|Number of hypoglycemic events",Norwegian University of Science and Technology|Norwegian Diabetes Association,All,18 Years to 50 Years   (Adult),Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4.2008.1607|19637,Jan-09,Sep-09,Sep-09,16-Jan-09,null,27-Feb-17,"Department of Endocrinology, St. Olavs Hospital, Trondheim, Norway",,https://ClinicalTrials.gov/show/NCT00824148
NCT00821899,Bone Marrow Autotransplantation in Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus,Biological: administration of autologous bone marrow blood,"Evaluate glycosylated hemoglobin 1,3,6, and 12 months after autologous bone marrow blood administration.|Evaluate number of hypoglycemias 1,3,6, and 12 months after autologous bone marrow blood administration.|Evaluate insulin dose 1,3,6, and 12 months after autologous bone marrow blood administration.|Evaluate GADab titers and treatment tolerance 1,3,6, and 12 months after autologous bone marrow blood administration.",Hospital Clinic of Barcelona,All,18 Years to 50 Years   (Adult),Not Applicable,3,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BMATxDM1,Jan-09,May-10,May-10,14-Jan-09,null,20-Mar-12,"Enric Esmatjes, Barcelona, Spain|Hospital Clinic, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT00821899
NCT00819091,"Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug",,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: BI 1356|Drug: Placebo,Change From Baseline in HbA1c (Glycosylated Hemoglobin) at Week 18|Change From Baseline in Fasting Plasma Glucose at Week 18|Percentage of Patients With Absolute Efficacy Response (HbA1c < 7%) at Week 18|Percentage of Patients With Absolute Efficacy Response (HbA1c < 6.5%) at Week 18|Percentage of Patients With HbA1c Lowering by at Least 0.5% From Baseline at Week 18|Mixed Model Repeated Measurements Analysis of Change From Baseline in HbA1c at Week 6|Mixed Model Repeated Measurements Analysis of Change From Baseline in HbA1c at Week 12|Mixed Model Repeated Measurements Analysis of Change From Baseline in HbA1c at Week 18|Change From Baseline in Fasting Plasma Glucose at Week 6|Change From Baseline in Fasting Plasma Glucose at Week 12,Boehringer Ingelheim,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,245,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,1218.35|2008-003118-86,Dec-08,Jan-10,null,8-Jan-09,1-Aug-11,27-Jun-14,"1218.35.10002 Boehringer Ingelheim Investigational Site, Birmingham, Alabama, United States|1218.35.10001 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States|1218.35.10016 Boehringer Ingelheim Investigational Site, National City, California, United States|1218.35.10017 Boehringer Ingelheim Investigational Site, Ft. Lauderdale, Florida, United States|1218.35.10021 Boehringer Ingelheim Investigational Site, Ft. Lauderdale, Florida, United States|1218.35.10013 Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States|1218.35.10015 Boehringer Ingelheim Investigational Site, Flint, Michigan, United States|1218.35.10018 Boehringer Ingelheim Investigational Site, Asheville, North Carolina, United States|1218.35.10004 Boehringer Ingelheim Investigational Site, Cincinnati, Ohio, United States|1218.35.10005 Boehringer Ingelheim Investigational Site, Portland, Oregon, United States|1218.35.10020 Boehringer Ingelheim Investigational Site, Greenville, South Carolina, United States|1218.35.10009 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States|1218.35.10019 Boehringer Ingelheim Investigational Site, Sugar Land, Texas, United States|1218.35.54003 Boehringer Ingelheim Investigational Site, Capital Federal, Argentina|1218.35.54005 Boehringer Ingelheim Investigational Site, Corrientes, Argentina|1218.35.54001 Boehringer Ingelheim Investigational Site, Mar del Plata, Argentina|1218.35.54006 Boehringer Ingelheim Investigational Site, Parque Velez Sarfield, Argentina|1218.35.36001 Boehringer Ingelheim Investigational Site, Budapest, Hungary|1218.35.36002 Boehringer Ingelheim Investigational Site, Budapest, Hungary|1218.35.36004 Boehringer Ingelheim Investigational Site, Budapest, Hungary|1218.35.36005 Boehringer Ingelheim Investigational Site, Budapest, Hungary|1218.35.36003 Boehringer Ingelheim Investigational Site, Debrecen, Hungary|1218.35.91003 Boehringer Ingelheim Investigational Site, Aligarh, Uttar Pradesh, India|1218.35.91007 Boehringer Ingelheim Investigational Site, Aminjikarai, Tamilnadu, India|1218.35.91001 Boehringer Ingelheim Investigational Site, Bangalore, Karnataka, India|1218.35.91004 Boehringer Ingelheim Investigational Site, Bangalore, Karnataka, India|1218.35.91002 Boehringer Ingelheim Investigational Site, Indore, India|1218.35.91008 Boehringer Ingelheim Investigational Site, Mumbai, Maharastra, India|1218.35.91005 Boehringer Ingelheim Investigational Site, Nagpur, Maharashtra, India|1218.35.91006 Boehringer Ingelheim Investigational Site, Pune, Maharastra, India|1218.35.81003 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan|1218.35.81001 Boehringer Ingelheim Investigational Site, Shinjyuku-ku,Tokyo, Japan|1218.35.81002 Boehringer Ingelheim Investigational Site, Suita, Osaka,, Japan|1218.35.48002 Boehringer Ingelheim Investigational Site, Bialystok, Poland|1218.35.48004 Boehringer Ingelheim Investigational Site, Lublin, Poland|1218.35.48003 Boehringer Ingelheim Investigational Site, Poznan, Poland|1218.35.48001 Boehringer Ingelheim Investigational Site, Rzeszow, Poland|1218.35.48005 Boehringer Ingelheim Investigational Site, Wroclaw, Poland|1218.35.70008 Boehringer Ingelheim Investigational Site, Arkhangelsk, Russian Federation|1218.35.70001 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|1218.35.70002 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|1218.35.70003 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|1218.35.70006 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|1218.35.70009 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|1218.35.70007 Boehringer Ingelheim Investigational Site, Yaroslavl, Russian Federation",,https://ClinicalTrials.gov/show/NCT00819091
NCT00817505,To Evaluate the Bioavailability of a Tablet of AZD1656,,Completed,No Results Available,Type 1 Diabetes,Drug: AZD1656,"Pharmacokinetic variables ( Area under the plasma concentration vs. time curve (AUC), maximum plasma concentration (Cmax), time to reach maximum plasma concentration (tmax), terminal elimination half-life (t½) and apparent oral clearance (CL/F)|Pharmacodynamic variables (Plasma glucose)|Safety Variables (AEs, BP, pulse, electrocardiogram (ECG), hypoglycaemic symptoms and laboratory variables)",AstraZeneca,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 1,11,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D1020C00010,Dec-08,Mar-09,Sep-09,6-Jan-09,null,3-Nov-09,"Research site, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00817505
NCT00814190,Effect of Internet Therapeutic Intervention on A1C Levels in Type 2 Diabetes Mellitus (DM),,Completed,No Results Available,Type 2 Diabetes Mellitus,Other: Internet Intervention,"The primary endpoint is the A1c level or the change in A1c level.|The secondary endpoints include severe hypoglycemia defined as requiring external aid, hospital admissions for any CVD related intervention, and adverse events such as unplanned hospitalizations for any cause that last more than 24 hours.",Endocrine Research Society,All,"25 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Supportive Care,Internet Intervention in T2D,Jan-09,Nov-09,Nov-09,24-Dec-08,null,7-Jan-10,"St. Paul's Hospital, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT00814190
NCT00814476,The Effects of Regular Home Use Vs Diabetic Team- Supported Use of the Medtronic CareLink Therapy Management System.,CareLink,Completed,No Results Available,Type 1 Diabetes,Other: Medtronic CareLink therapy management system|Other: regular home use and Medtronic CareLink Therapy Management,HbA1c|Hypoglycemic events|DKA and ketosis events|Patient's satisfaction and quality of life questionnaire|7 points glucose profile,Rabin Medical Center,All,"up to 35 Years   (Child, Adult)",Phase 4,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,rmc005047ctil,Jan-09,Dec-12,Dec-12,24-Dec-08,null,10-Jul-13,"Schnider children medical center, Petach-Tikva, Israel",,https://ClinicalTrials.gov/show/NCT00814476
NCT00813410,Evaluation of a Novel Method for Integrating Insulin Delivery and Glucose Sensing in Adipose Tissue of Diabetic Patients,,Completed,No Results Available,Type 1 Diabetes,Procedure: Glucose measurement at the sc. insulin delivery site,glucose concentration at the subcutaneous insulin delivery site,Medical University of Graz,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,14,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,ZIG96,Feb-07,Dec-07,Dec-07,23-Dec-08,null,23-Dec-08,"Medical University of Graz, Graz, Styria, Austria",,https://ClinicalTrials.gov/show/NCT00813410
NCT00812591,Integrating Insulin Delivery and Glucose Sensing in Subcutaneous Tissue for the Treatment of Type-1 Diabetic Patients,,Completed,No Results Available,Type 1 Diabetes,Procedure: OGTT and CLAMP,Ratio between the plasma glucose level and the glucose concentration at the subcutaneous insulin delivery site,Medical University of Graz,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,ZIG26,May-06,Mar-11,Mar-11,22-Dec-08,null,19-Oct-11,"Medical University of Graz, Graz, Styria, Austria",,https://ClinicalTrials.gov/show/NCT00812591
NCT00813020,A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 2",Drug: semaglutide,"AUC0-8 (NN9535), the area under the plasma NN9535 plasma-concentration-time curve in the interval 0-8 after investigational medicinal product administration|Cmax of the plasma NN9535 curve",Novo Nordisk A/S,Male,18 Years to 55 Years   (Adult),Phase 1,44,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN9535-3679|2008-004990-17,Jan-09,Apr-09,Apr-09,22-Dec-08,null,23-Feb-15,"Berlin, Germany",,https://ClinicalTrials.gov/show/NCT00813020
NCT00813215,Postprandial Dysmetabolism,PPDysMet,Unknown status,No Results Available,Type 2 Diabetes Mellitus,Dietary Supplement: Meal challenge,Incremental AUC og the triglyceride response|Gene expression of genes involved in lipid metabolism and inflammation,Aarhus University Hospital|Diabetesforeningen,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,34,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant),CERN-PPDysMet-AP,Jan-09,Dec-10,Aug-11,22-Dec-08,null,8-Mar-11,"Aarhus University Hospital, Aarhus, Denmark",,https://ClinicalTrials.gov/show/NCT00813215
NCT00813228,Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals,,Completed,No Results Available,Diabetes Mellitus Type 1|Diabetes Mellitus Type 2,Drug: Sitagliptin (Januvia),"Changes in plasma TGF-Beta 1 levels.|Changes in plasma or stimulated PBMC cytokines levels, changes in stimulated PBMC proliferation, changes in peripheral blood gene expression and changes in immune phenotyping.",National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",Phase 1,76,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,090055|09-DK-0055,18-Dec-08,17-Jun-11,17-Jun-11,22-Dec-08,null,19-Apr-19,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00813228
NCT00810589,"A Randomised, Single Centre, Double-Blind, Two-Period Crossover, Glucose Clamp Trial",ENM-HS-001,Completed,No Results Available,"Diabetes, Type I",Drug: Levemir|Drug: Humalog NPL Insulin,"Duration of action, time from onset of action until end of action|GIRmax, maximum glucose infusion AUCGIR,0-32h, AUCGIR,0-12h, AUCGIR,12-32h, tinf=0, Cmax,ins, tmax,ins, AUCins,0-24h AUCins,0-∞ AUCins,0-12h AUCins,12-24h",Medical University of Graz,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ENM-HS-001,Nov-08,Dec-08,Dec-08,18-Dec-08,null,18-Dec-08,"Medical University Graz, Graz, Austria",,https://ClinicalTrials.gov/show/NCT00810589
NCT00811317,Closed-loop Glucose Control for Automated Management of Type 1 Diabetes,,Completed,Has Results,Type 1 Diabetes,Device: Closed-loop,Average Blood Glucose Over the Closed-loop Control Period|Percentage of Time Spent Within 70-180 mg/dl|Peak Hyperglycemia Following Each Meal|Percentage of Time Spent in Hyperglycemia (BG> 180 mg/dl) After Meals|Percentage of Peak Post-prandial Hyperglycemias < 180 mg/dl (ADA Target)|Percentage of Time Spent With BG < 70 mg/dl|Number of Hypoglycemic Events|Nadir Blood Glucose Level for Each Hypoglycemic Event|Percentage of Time Spent With BG > 180 mg/dl|Total Insulin Dose|Glucagon T-max|Total Glucagon Dose|Blood Glucagon Levels|Average Glucose and Glycemic Variability (MAGE) During Closed Loop Control in Diabetic Subjects Compared to the Comparable 24-hour Period the Day Prior to Admission as Measured by Navigator CGM Data|Number of Carbohydrate Interventions|Number of Participants Achieving a Stable Glucose Response to Insulin Dosing|Number of Participants Achieving a Stable Glucose Response to Insulin Dosing Around Idle Times Prior to Meals|Accuracy of the Continuous Glucose Monitor (CGM) Using Blood Glucose Measurement as the Standard|Average Glucose and Glycemic Variability During Closed Loop Control in Diabetic Subjects Compared to the Comparable 24 Hour Period in Non-diabetic Subjects|Insulin and Glucagon Levels During the Closed-loop Admission as Compared to the Comparable 24 Hour Period During the Open Loop Admission of Diabetic Subjects|Sensitivity for Hypo- and Hyperglycemia of the CGM Devices Using the BG Measurement as the Standard|Set Point Using CGM Data as the Input to the Controller for Future Studies|Insulin and Glucagon Levels During Closed Loop and Open Loop Admissions of Diabetic Subjects Compared to the Comparable 24 Hour Period During the Admission of Non-diabetic Subject,Boston University Charles River Campus|Massachusetts General Hospital|Juvenile Diabetes Research Foundation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,11,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2007P-000101|H-27207|SPID#0813,May-08,Oct-09,Oct-09,18-Dec-08,25-Oct-17,25-Oct-17,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00811317
NCT00807651,Autologous Hematopoietic Stem Cell Transplantation for Early Onset Type 1 Diabetes,,Unknown status,No Results Available,Type 1 Diabetes Mellitus,Procedure: AHSCT|Drug: Insulin therapy,Exogenous insulin dose|Anti-GAD titres|C-peptide level|HbA1c level,Shanghai Jiao Tong University School of Medicine,All,"14 Years to 35 Years   (Child, Adult)",Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CCEMD006,Feb-08,Jun-16,Dec-16,12-Dec-08,null,7-Jun-16,"Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT00807651
NCT00806572,Treatment With hOKT3gamma1(Ala-Ala) in T1DM,,Terminated,No Results Available,"Diabetes Mellitus, Type 1",Drug: hOKT3gamma1(Ala-Ala),4-hour C-peptide AUC|Insulin usage,National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN),All,"7 Years to 30 Years   (Child, Adult)",Phase 2,10,NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAIT ITN007AI|NDB01,May-02,Jul-04,Aug-07,11-Dec-08,null,8-Feb-17,"University of California San Francisco, San Francisco, California, United States|Naomie Berrie Diabetes Center, Columbia University, New York, New York, United States|Benaroya Research Institute, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00806572
NCT00805974,Study of the Relationship Between Sleep Quality and Daytime-Nighttime Variations of Blood Pressure and Plasma Glucose Type I,DIAPASOM,Terminated,No Results Available,Type 1 Diabetes,Biological: Biological examinations (blood and urinary).,Polysomnographic measurements during the D0-D1 night spend at the hospital|Ambulatory blood pressure monitoring on 24 hours|Glycemic measurements on 24h (D0-D1).,"University Hospital, Grenoble|Pr Mallion Jean-Michel|Pr BAGUET Jean-Philippe|Pr BENHAMOU Pierre-Yves|Pr LEVY Patrick|Dr MOURET Sandrine|Dr ORMEZZANO Olivier|Pr PEPIN Jean-Louis|Dr TAMISIER Renaud",All,18 Years to 60 Years   (Adult),Not Applicable,23,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,0513|2005/0479,Oct-05,Dec-07,Dec-07,10-Dec-08,null,14-Jan-09,"University Hospital, Grenoble, France",,https://ClinicalTrials.gov/show/NCT00805974
NCT00804232,Childhood Diabetes,,Unknown status,No Results Available,"Diabetes, Type I",Behavioral: childhood diabetes,"Primary Outcome Measure: the child's metabolic control as shown in HbA1C|Quality of life, Satisfaction with care, Family impact and family climate, psychological variables, parental absenteeism from work; time use which is conditional on the child's diabetes etc), formal health care utilisation",Vardalinstitutet The Swedish Institute for Health Sciences|Lund University Hospital|Sahlgren´s University Hospital,All,3 Years to 15 Years   (Child),Not Applicable,210,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DiabetesVardal,Jan-08,Sep-10,Dec-15,8-Dec-08,null,8-Dec-08,"Queen Silvia's Childrens' hospital, Gothenburg, Sweden|Lund University Childrens' hospital, Lund, Sweden",,https://ClinicalTrials.gov/show/NCT00804232
NCT00800085,Beta Cell Function in (Pre) Type 1 Diabetes,,Unknown status,No Results Available,Type 1 Diabetes,Drug: glucose 20%,The systematic and simultaneous determination of markers of functional beta cell mass and immune status allows stratification according to the stage of the pathogenic process rather than according to a late metabolic consequence of this process,AZ-VUB,All,"5 Years to 40 Years   (Child, Adult)",Phase 1|Phase 2,200,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),KD_BF_01,Oct-06,Oct-14,Oct-15,1-Dec-08,null,30-Dec-13,"Universitair Ziekenhuis Antwerpen, Antwerpen, Belgium|UZ Brussels, Brussels, Belgium|UZ Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium",,https://ClinicalTrials.gov/show/NCT00800085
NCT00799435,Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure,,Terminated,Has Results,"Diabetes Mellitus, Type 2|Heart Failure, Diastolic",Drug: Exenatide,"Change in Aortic Stiffness, as Measured by the Change in the Mean Aortic Pulse Wave Velocity|Changes in Left Ventricular Diastolic Stiffness, Serum Levels of Advanced Glycation End Products, Serum Biomarkers of Collagen Synthesis, and Serum Levels of Brain Natriuretic Peptide","Baylor College of Medicine|National Heart, Lung, and Blood Institute (NHLBI)",All,"30 Years and older   (Adult, Older Adult)",Phase 4,2,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,613|1K01HL092585|1K01HL092585-01|H-22906,Jul-09,Apr-12,Apr-12,27-Nov-08,21-Sep-17,21-Sep-17,"Baylor College of Medicine, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00799435
NCT00798785,Long-term Function of Beta Cell Allografts in Non-uremic Type 1 Diabetic Patients,,Unknown status,No Results Available,"Diabetes Mellitus, Type 1",Drug: ATG-MMF-TAC|Drug: ATG-Rituximab-MMF-TAC|Drug: ATG-basilixumab-MMF-TAC|Procedure: omentum,Evidence of clinically relevant beta cell graft function,AZ-VUB,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BK_TX_06,Oct-06,Dec-14,Dec-14,26-Nov-08,null,30-Dec-13,"Universitair Ziekenhuis Antwerpen, Antwerpen, Belgium|University Hospital Brussels, Brussels, Belgium|Hopital Erasme, Brussel, Belgium|University Hospital Leuven, Leuven, Belgium",,https://ClinicalTrials.gov/show/NCT00798785
NCT00797823,Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone,,Completed,Has Results,Type 1 Diabetes,"Drug: Insulin, Asp(B28)-|Drug: Glucagon|Drug: Placebo",Effectiveness of Closed Loop Diabetes Control|Percent of Time Venous Blood Glucose <70 mg/dl,Legacy Health System|Juvenile Diabetes Research Foundation|Oregon Health and Science University,All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 2,14,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,IRB4311,Nov-08,Sep-09,Sep-09,25-Nov-08,26-Sep-11,7-Oct-11,"Legacy Research, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT00797823
NCT00791076,The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 & Post-pancreatectomy Diabetic Patients,,Terminated,Has Results,"Diabetes Mellitus, Type 1",Drug: Placebo|Drug: Pancreatic Polypeptide (PP),Total Amount of Insulin Administered While on Placebo/PP.|Frequency of Hypoglycemia Defined as < 60 mg/dl.,Johns Hopkins University,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,8,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,NA_00010957,Oct-07,Jun-10,Jun-10,14-Nov-08,12-Jul-17,12-Jul-17,"Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00791076
NCT00789945,Timing of Insulin Before Meals Everyday,TIME,Completed,No Results Available,Type 1 Diabetes,Other: Control|Other: Study Arm B,To determine the changes in A1C.|To determine changes in postprandial glucose excursion during the meal's 5 hour postprandial period.,University of New Mexico|American Diabetes Association,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic",08-147,Dec-08,Dec-11,Dec-11,13-Nov-08,null,5-Apr-13,"University of New Mexico, Health Sciences Center, Albuquerque, New Mexico, United States",,https://ClinicalTrials.gov/show/NCT00789945
NCT00790257,Safety and Efficacy Study of Encapsulated Human Islets Allotransplantation to Treat Type 1 Diabetes,,Withdrawn,No Results Available,Type 1 Diabetes Mellitus,"Device: Encapsulated human islets in a ""Monolayer Cellular Device""",Inflammatory/immunological reaction and insulin production|- Encapsulated human islets function and biocompatibility,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 1,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UCL-HIA-002,Nov-08,Sep-15,Sep-15,13-Nov-08,null,15-Mar-18,"University clinical Hospital Saint-Luc, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT00790257
NCT00790439,Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant,,Withdrawn,No Results Available,"Diabetes Mellitus, Type I",Drug: Low Molecular Weight Sulfated Dextran|Drug: Heparin|Drug: Mycophenolate Mofetil|Drug: Sirolimus|Drug: Tacrolimus|Drug: Cyclosporine|Drug: Daclizumab|Drug: Basiliximab|Biological: Allogeneic Pancreatic Islet Cells,Level of Stimulated C-peptide at 90-minutes in Response to a Mixed-Meal Tolerance Test (MMTT)|Incidence and Severity of Adverse Events Related to the Islet Transplantation Procedure|Incidence and Severity of Adverse Events Related to the Immunosuppression|Incidence of Immune Sensitization Defined by Detecting Anti-HLA (Human Leukocyte Antigen) Antibodies not present prior to transplantation|Incidence of a Change in the Immunosuppression Drug Regimen|Incidence of Worsening Retinopathy,National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAIT CIT-01B|CIT-01B,Jul-08,Oct-09,Oct-09,13-Nov-08,null,12-Jun-14,,,https://ClinicalTrials.gov/show/NCT00790439
NCT00790699,Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port,,Terminated,No Results Available,Type 1 Diabetes|Type 2 Diabetes,Device: I-PORT|Other: standard injections,"The primary outcome will be measured by HbA1c values taken at baseline and the final visit.|The secondary outcome will measure patient satisfaction, opinions and attitudes toward using the multiple injection port for insulin and Symlin administration compared to standard Symlin injections (measured through using questionnaires).","Texas Diabetes & Endocrinology, P.A.|Amylin Pharmaceuticals, LLC.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,31,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TDE 001,Aug-09,Nov-11,Nov-11,13-Nov-08,null,17-Nov-11,"Texas Diabetes & Endocrinology, PA, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT00790699
NCT00788827,Autologous Adult Stem Cells to Patients With Type 1 Diabetes and a Successful Renal Transplant,,Completed,No Results Available,Type 1 Diabetes|Type 2 Diabetes,Biological: Autologous CD34+ stem cells,Safety will be evaluated in terms of adverse events graded according to CTC toxicity criteria and laboratory test results. All adverse events will also be graded for relationship to treatment and as expected and unexpected.|To assess improvement in endocrine pancreatic function as measured by serological and biochemical analysis and determine any symptomatic improvements as they are reported by the patients.,Imperial College London,All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Phase 1,7,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HHSC 005|CRO0472,Nov-08,May-13,May-13,11-Nov-08,null,22-Jan-15,"Imperial College NHS Healthcare Trust, Hammersmith Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00788827
NCT00789308,Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation,,Completed,No Results Available,"Diabetes Mellitus, Type I",Drug: Low Molecular Weight Sulfated Dextran (LMW-SD)|Drug: Heparin|Drug: CellCept® (Mycophenolate mofetil) OR Rapamune® (Sirolimus)|Drug: Prograf® (Tacrolimus) OR Cyclosporine|Drug: Thymoglobulin® (Anti-thymocyte Globulin) - at first transplant|Drug: Simulect® (Basiliximab) - at 2nd or 3rd transplant|Drug: Klexane® (Enoxaparinsodium)|Drug: Trombyl® or Albyl-E® (Acetylsalicylicacid- ASA)|Drug: Enbrel® (Etanercept),"Level of stimulated c-peptide at 90-minute derived from the mixed-meal tolerance test (MMTT)|Number of participants who achieve and maintain a 7.0% HbA1c level|Number of severe hypoglycemic events|Percent reduction in insulin requirements|Ryan hypoglycemia severity score ( HYPO) score|Proportion of participants with full graft function|C-peptide to glucose creatinine ratio|Proportion of participants receiving a second islet infusion and proportion of participants receiving a third islet transfusion|Incidence and severity of adverse events related to islet infusion procedure|Incidence of worsening retinopathy|HbA1c level|Mean amplitude of glycemic excursions (MAGE)|Glycemic lability index (LI)|Clarke hypoglycemia awareness score|Basal (fasting) and 90-minute glucose and c-peptide derived from MMTT|Beta-score|Acute insulin response to glucose, insulin sensitivity, and disposition index derived from the insulin-modified frequently-sampled intravenous glucose tolerance (FSIGT) test,|Glucose variability and hypoglycemic duration derived from continuous glucose monitoring system(CGMS)|Incidence of a change in the immunosuppression drug regimen|Incidence of immune sensitization defined by detecting anti-HLA antibodies not present prior to transplantation",National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Clinical Islet Transplantation Consortium,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,24,NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAIT CIT-01|CIT-01|2008-001210-25,11-Jul-08,Jul-13,21-Aug-14,11-Nov-08,null,22-Feb-19,"University Hospital Rikshospitalet, Oslo, Norway|Karolinska University Hospital, Stockholm, Sweden|Uppsala University Hospital, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT00789308
NCT00786825,Measurement of Glucose/Glycogen Metabolism in Humans Using Magnetic Resonance at 4 or 7 Tesla,Glycogen,Completed,No Results Available,Type 1 Diabetes,Drug: somatostatin,determine the effects of diabetes and the hypoglycemic consequences of intensive therapy on in vivo brain glucose metabolism,University of Minnesota - Clinical and Translational Science Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,57,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,9412M09040,Dec-04,Dec-17,Dec-17,6-Nov-08,null,18-Jan-18,"University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00786825
NCT00784966,Islet After Kidney Transplant for Type 1 Diabetes,,Withdrawn,No Results Available,Type 1 Diabetes Mellitus,Drug: etanercept,The functional capability of the islet allograft to normalize glucose metabolism in the absence of insulin therapy.|Reduction in insulin requirements in those patients who do not achieve insulin independence with improved metabolic control.,Virginia Commonwealth University|University of Miami,All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VCU IRB 4196,Aug-11,Sep-15,Sep-17,5-Nov-08,null,16-Sep-14,"Virginia Commonwealth University Health System, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00784966
NCT00780650,"Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine",,Completed,No Results Available,Type 1 Diabetes,Drug: Atomoxetine|Drug: Placebo,Change in level of catecholamines in blood from baseline,"University of Maryland|National Heart, Lung, and Blood Institute (NHLBI)",All,18 Years to 50 Years   (Adult),Early Phase 1,56,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HP-00044873,May-09,21-Aug-18,21-Aug-18,27-Oct-08,null,21-Nov-18,"Univerisity of Maryland, Baltimore, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00780650
NCT00776607,Randomized Controlled Trial of Insulin Versus Tablets for Latent Autoimmune Diabetes in Adults (LADA),LIT,Unknown status,No Results Available,Latent Autoimmune Diabetes in Adults LADA,Drug: NovoMix 30|Drug: Tablet treatment,Change in fasting serum C-peptide level over 24 months and (2) change in HbA1c level over 24 months in patients with LADA.|Hypoglycaemic events,Abertawe Bro Morgannwg University NHS Trust|Novo Nordisk A/S,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,200,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2006-004662-14|ISRCTN63815121|07/MRE09/8,Apr-07,Apr-11,Apr-11,21-Oct-08,null,21-Oct-08,"Diabetes Unit, Cardiff, Wales, United Kingdom|Clinical Research Unit, Swansea, Wales, United Kingdom",,https://ClinicalTrials.gov/show/NCT00776607
NCT00774800,Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus,,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Humalog|Drug: Humulin-R|Drug: Recombinant human hyaluronidase PH20 (rHuPH20)|Other: Liquid meal,Area Under the Insulin Concentration-time Curve for the First Hour (AUC0-60)|Maximum Serum Insulin Concentration (Cmax)|Time to Maximum Serum Insulin Concentration (Tmax)|Area Under the Blood Glucose Time-Concentration Curve Blood Glucose (AUC[BG]),Halozyme Therapeutics,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,22,Industry,Interventional,Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,HZ2-08-05|HALO-117-201,Oct-08,Mar-09,Mar-09,17-Oct-08,5-Sep-14,26-Feb-19,"Profil Institute for Clinical Research, Inc., Chula Vista, California, United States",,https://ClinicalTrials.gov/show/NCT00774800
NCT00773279,"Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics",,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Delivery Systems",Device: FlexTouch®|Device: FlexPen®,"HbA1c (Glycosylated Haemoglobin) for Participants Treated With PDS290 and FlexPen®|Percentage of Subject Having Preference for PDS290 Versus FlexPen® in Terms of Convenience and Ease of Use|Summary Score for Treatment Satisfaction|Score for Treatment Impact Measure for Diabetes|Clinical Technical Complaints (CTCs)|Number of Hypoglycaemic Episodes|Number of Adverse Device Effects|Hypoglycaemic Episodes, Number of Events Per Subject Day",Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,242,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PDS290-1971,Sep-08,Jun-09,Jun-09,16-Oct-08,27-Mar-17,27-Mar-17,"Novo Nordisk Investigational Site, Burlingame, California, United States|Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Encino, California, United States|Novo Nordisk Investigational Site, Escondido, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Mission Viejo, California, United States|Novo Nordisk Investigational Site, Orange, California, United States|Novo Nordisk Investigational Site, Poway, California, United States|Novo Nordisk Investigational Site, Salinas, California, United States|Novo Nordisk Investigational Site, Santa Monica, California, United States|Novo Nordisk Investigational Site, Tustin, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, Colorado Springs, Colorado, United States|Novo Nordisk Investigational Site, Golden, Colorado, United States|Novo Nordisk Investigational Site, Boca Raton, Florida, United States|Novo Nordisk Investigational Site, Hollywood, Florida, United States|Novo Nordisk Investigational Site, Maitland, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Ocala, Florida, United States|Novo Nordisk Investigational Site, Tallahassee, Florida, United States|Novo Nordisk Investigational Site, Athens, Georgia, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Savannah, Georgia, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Lafayette, Indiana, United States|Novo Nordisk Investigational Site, Wichita, Kansas, United States|Novo Nordisk Investigational Site, Bowling Green, Kentucky, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Metairie, Louisiana, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Hyattsville, Maryland, United States|Novo Nordisk Investigational Site, Rockville, Maryland, United States|Novo Nordisk Investigational Site, Jefferson City, Missouri, United States|Novo Nordisk Investigational Site, St. Louis, Missouri, United States|Novo Nordisk Investigational Site, Butte, Montana, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Berlin, New Jersey, United States|Novo Nordisk Investigational Site, Lawrenceville, New Jersey, United States|Novo Nordisk Investigational Site, Asheville, North Carolina, United States|Novo Nordisk Investigational Site, Tabor City, North Carolina, United States|Novo Nordisk Investigational Site, Fargo, North Dakota, United States|Novo Nordisk Investigational Site, Dayton, Ohio, United States|Novo Nordisk Investigational Site, Gallipolis, Ohio, United States|Novo Nordisk Investigational Site, Kettering, Ohio, United States|Novo Nordisk Investigational Site, Mentor, Ohio, United States|Novo Nordisk Investigational Site, Medford, Oregon, United States|Novo Nordisk Investigational Site, Altoona, Pennsylvania, United States|Novo Nordisk Investigational Site, Carlisle, Pennsylvania, United States|Novo Nordisk Investigational Site, Little River, South Carolina, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Hurst, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Ogden, Utah, United States|Novo Nordisk Investigational Site, Virginia Beach, Virginia, United States|Novo Nordisk Investigational Site, Renton, Washington, United States|Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00773279
NCT00772356,"A Monocenter, Open-Label Glucose Clamp Study Examining the Metabolic Effect of Insulin Infusion Intervals for Basal Insulin Infusion in Patients With Type I Diabetes",,Completed,No Results Available,Diabetes Mellitus Type 1,Device: Accu-Chek Spirit Insulin Pump|Device: Comparator insulin pump,Comparison of glucose infusion rate necessary to keep blood glucose constant|Serum insulin and free fatty acid levels,Hoffmann-La Roche,Male,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,14,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RD000559|05/0377-Basal,Jan-08,May-08,May-08,15-Oct-08,null,3-Mar-16,"Neuss, Germany",,https://ClinicalTrials.gov/show/NCT00772356
NCT00768651,Incretin Effect and Use After Clinical Islet Transplantation,,Completed,Has Results,Type 1 Diabetes,Drug: Pantoprazole|Drug: Sitagliptin,The Primary Endpoint Will be Insulin Independence After 6 Months of Therapy.|Number of Participants Not Using Insulin for at Least One Week After 6 Months of Therapy|Number of Participants With HbA1c < 6.0 % After 6 Months of Therapy|Number of Participants With Fasting Plasma Glucose (FPG) < 7 mmol/l After 6 Months of Therapy|Mean Daily Insulin Use (U/Day) After 6 Months of Therapy|Change From Baseline of GLP-1 Level After One Month of Therapy|Change From Baseline on Gastrin Level After One Month of Therapy|HbA1c Plasma Laboratory Value for Participants After 6 Months of Therapy|Acute Insulin Responses to Arginine After 6 Months of Therapy|C-peptide Laboratory Value at 90 Minutes After a Mixed Meal Tolerance Test (MMTT) After 6 Months of Therapy|C-peptide Laboratory Value Before a Mixed Meal Tolerance Test (MMTT) After 6 Months of Therapy|Glucose Laboratory Value at 90 Minutes After Mixed Meal Tolerance Test (MMTT) After 6 Months of Therapy.|Blood Glucose Laboratory Value Before Mixed Meal Tolerance Test (MMTT) After 6 Months of Therapy|Weight Change From Baseline After 6 Months of Therapy|Insulin Independence After the 3 Month Washout Period|Insulin Dose (U/Day)|Acute Insulin Response to Arginine After the 3 Month Washout Period|HbA1c Plasma Laboratory Value for Participants After the 3 Month Washout Period|C-peptide Plasma Laboratory Value at 90 Minutes After a Mixed Meal Tolerance Test (MMTT) at the End of the 3 Month Washout Period.|C-peptide Laboratory Value Before a Mixed Meal Tolerance Test (MMTT) After the 3 Month Washout Period.|Glucose Laboratory Value at 90 Minutes After Mixed Meal Tolerance Test (MMTT) After the 3 Month Washout Period.|Blood Glucose Laboratory Value Before Mixed Meal Tolerance Test (MMTT) After the 3 Month Washout Period,University of Alberta|Juvenile Diabetes Research Foundation,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,8,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7331,Oct-08,Jul-11,Dec-11,8-Oct-08,18-Jun-15,18-Jun-15,"University of Alberta - Clinical Islet Transplant Program, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT00768651
NCT00768040,Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema,,Terminated,Has Results,Diabetic Macular Edema,Drug: Aliskiren|Drug: Placebo,"Change From Baseline in Central Retinal Thickness in Patients With Type 1 or Type 2 Diabetes, After 12 Weeks of Treatment",Novartis Pharmaceuticals|Novartis,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,39,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CSPP100A2244|EudraCT 2008-00581-23,Sep-08,Feb-11,Feb-11,7-Oct-08,6-Mar-12,6-Mar-12,"Retinal Consultants of Arizona, Phoenix, Arizona, United States|Retina-Vitreous Associates, Los Angeles, California, United States|National Ophthalmic Research Institute, Fort Myers, Florida, United States|Georgia Retina, Atlanta, Georgia, United States|Elman Retina Group, Baltimore, Maryland, United States|Joslin Clinic, Boston, Massachusetts, United States|Vitreo-Retinal Associates, Grand Rapids, Michigan, United States|Charlotte Eye, Ear, Nose and Throat Associate, Charlotte, North Carolina, United States|Retina-Associates of Cleveland, Inc, Beachwood, Ohio, United States|Retinal Consultants of Houston, Houston, Texas, United States|Novartis Investigative Site, Arhus, Denmark|Novartis Investigative Site, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT00768040
NCT00767000,Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED),,Terminated,Has Results,"Diabetes Mellitus, Type 2",Drug: MK-0941|Drug: Comparator: Placebo|Biological: Lantus|Drug: Metformin,Change in Hemoglobin A1c (HbA1c) Level|Percentage of Participants Who Experienced at Least One Adverse Event|Percentage of Participants Who Discontinued Study Medication Due to an Adverse Event|Change in the Two-hour Post Meal Glucose Level|Change in the Fasting Plasma Glucose Level|Percentage of Participants Who Achieve an HbA1c of <7.0%|Percentage of Participants Achieving an HbA1c of <7.0% at Week 54 Who Maintain an HbA1c of <7.0%,Merck Sharp & Dohme Corp.,All,"21 Years to 70 Years   (Adult, Older Adult)",Phase 2,813,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0941-007|2008_557,Oct-08,Apr-10,Jun-10,6-Oct-08,3-Sep-12,19-Feb-15,,,https://ClinicalTrials.gov/show/NCT00767000
NCT00763451,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin",GETGOAL-F1,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Lixisenatide (AVE0010)|Drug: Placebo|Device: Pen auto-injector|Drug: Metformin,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24|Change From Baseline in Body Weight at Week 24|Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24|Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24|Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,484,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EFC10743|2008-001002-16,Sep-08,Jan-11,Jan-11,1-Oct-08,14-Dec-16,14-Dec-16,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Sao Paulo, Brazil|Sanofi-Aventis Administrative Office, Santiago, Chile|Sanofi-Aventis Administrative Office, Santafe de Bogota, Colombia|Sanofi-Aventis Administrative Office, Tallinn, Estonia|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Milano, Italy|Sanofi-Aventis Administrative Office, Vilnius, Lithuania|Sanofi-Aventis Administrative Office, Kuala Lumpur, Malaysia|Sanofi-Aventis Administrative Office, Mexico, Mexico|Sanofi-Aventis Administrative Office, Makati City, Philippines|Sanofi-Aventis Administrative Office, Warszawa, Poland|Sanofi-Aventis Administrative Office, Bucuresti, Romania|Sanofi-Aventis Administrative Office, Brastislava, Slovakia|Sanofi-Aventis Administrative Office, Kiev, Ukraine",,https://ClinicalTrials.gov/show/NCT00763451
NCT00763815,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone",GETGOAL-P,Completed,Has Results,Diabetes Mellitus Type 2,Drug: Lixisenatide (AVE0010)|Drug: Placebo|Device: Pen auto-injector|Drug: Pioglitazone|Drug: Metformin,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24|Change From Baseline in Body Weight at Week 24|Change From Baseline in Fasting Plasma Insulin (FPI) at Week 24|Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24|Percentage of Patients With HbA1c Level Less Than or Equal to 6.5% at Week 24|Change From Baseline in Beta-cell Function Assessed by Homeostasis Model Assessment for Beta-cell Function (HOMA-beta) at Week 24|Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,484,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EFC6017|EudraCT: 2007-005884-92,Sep-08,Jun-11,Jun-11,1-Oct-08,11-Oct-16,28-Nov-16,"Sanofi-Aventis Investigational Site Number 840723, Birmingham, Alabama, United States|Sanofi-Aventis Investigational Site Number 840744, Birmingham, Alabama, United States|Sanofi-Aventis Investigational Site Number 840867, Birmingham, Alabama, United States|Sanofi-Aventis Investigational Site Number 840720, Birmingham, Alabama, United States|Sanofi-Aventis Investigational Site Number 840855, Mobile, Alabama, United States|Sanofi-Aventis Investigational Site Number 840863, Mobile, Alabama, United States|Sanofi-Aventis Investigational Site Number 840775, Chandler, Arizona, United States|Sanofi-Aventis Investigational Site Number 840722, Mesa, Arizona, United States|Sanofi-Aventis Investigational Site Number 840769, Phoenix, Arizona, United States|Sanofi-Aventis Investigational Site Number 840729, Harrisburg, Arkansas, United States|Sanofi-Aventis Investigational Site Number 840776, Mountain Home, Arkansas, United States|Sanofi-Aventis Investigational Site Number 840795, Artesia, California, United States|Sanofi-Aventis Investigational Site Number 840782, Chino, California, United States|Sanofi-Aventis Investigational Site Number 840785, Huntington Beach, California, United States|Sanofi-Aventis Investigational Site Number 840858, La Jolla, California, United States|Sanofi-Aventis Investigational Site Number 840784, Los Banos, California, United States|Sanofi-Aventis Investigational Site Number 840773, Mission Hills, California, United States|Sanofi-Aventis Investigational Site Number 840707, Mission Viejo, California, United States|Sanofi-Aventis Investigational Site Number 840733, Northridge, California, United States|Sanofi-Aventis Investigational Site Number 840864, Roseville, California, United States|Sanofi-Aventis Investigational Site Number 840772, San Diego, California, United States|Sanofi-Aventis Investigational Site Number 840743, San Mateo, California, United States|Sanofi-Aventis Investigational Site Number 840721, Stockton, California, United States|Sanofi-Aventis Investigational Site Number 840763, West Hills, California, United States|Sanofi-Aventis Investigational Site Number 840872, Colorado Springs, Colorado, United States|Sanofi-Aventis Investigational Site Number 840868, Colorado Springs, Colorado, United States|Sanofi-Aventis Investigational Site Number 840727, Jacksonville, Florida, United States|Sanofi-Aventis Investigational Site Number 840745, New Port Richey, Florida, United States|Sanofi-Aventis Investigational Site Number 840761, Oviedo, Florida, United States|Sanofi-Aventis Investigational Site Number 840799, Wellington, Florida, United States|Sanofi-Aventis Investigational Site Number 840857, Augusta, Georgia, United States|Sanofi-Aventis Investigational Site Number 840724, Idaho Falls, Idaho, United States|Sanofi-Aventis Investigational Site Number 840791, Chicago, Illinois, United States|Sanofi-Aventis Investigational Site Number 840738, Avon, Indiana, United States|Sanofi-Aventis Investigational Site Number 840794, Indianapolis, Indiana, United States|Sanofi-Aventis Investigational Site Number 840767, Kansas City, Kansas, United States|Sanofi-Aventis Investigational Site Number 840779, Lansing, Kansas, United States|Sanofi-Aventis Investigational Site Number 840739, Wichita, Kansas, United States|Sanofi-Aventis Investigational Site Number 840789, Lexington, Kentucky, United States|Sanofi-Aventis Investigational Site Number 840850, Lexington, Kentucky, United States|Sanofi-Aventis Investigational Site Number 840862, Baton Rouge, Louisiana, United States|Sanofi-Aventis Investigational Site Number 840879, Shreveport, Louisiana, United States|Sanofi-Aventis Investigational Site Number 840764, Hyattsville, Maryland, United States|Sanofi-Aventis Investigational Site Number 840871, Rockville, Maryland, United States|Sanofi-Aventis Investigational Site Number 840851, Dartmouth, Massachusetts, United States|Sanofi-Aventis Investigational Site Number 840708, Kalamazoo, Michigan, United States|Sanofi-Aventis Investigational Site Number 840774, Bloomington, Minnesota, United States|Sanofi-Aventis Investigational Site Number 840704, Eagan, Minnesota, United States|Sanofi-Aventis Investigational Site Number 840717, Picayune, Mississippi, United States|Sanofi-Aventis Investigational Site Number 840765, St Louis, Missouri, United States|Sanofi-Aventis Investigational Site Number 840875, Las Vegas, Nevada, United States|Sanofi-Aventis Investigational Site Number 840866, Pahrump, Nevada, United States|Sanofi-Aventis Investigational Site Number 840766, New York City, New York, United States|Sanofi-Aventis Investigational Site Number 840865, New York, New York, United States|Sanofi-Aventis Investigational Site Number 840874, Staten Island, New York, United States|Sanofi-Aventis Investigational Site Number 840762, West Seneca, New York, United States|Sanofi-Aventis Investigational Site Number 840747, Burlington, North Carolina, United States|Sanofi-Aventis Investigational Site Number 840760, Greensboro, North Carolina, United States|Sanofi-Aventis Investigational Site Number 840712, High Point, North Carolina, United States|Sanofi-Aventis Investigational Site Number 840780, Bismarck, North Dakota, United States|Sanofi-Aventis Investigational Site Number 840877, Fargo, North Dakota, United States|Sanofi-Aventis Investigational Site Number 840777, Athens, Ohio, United States|Sanofi-Aventis Investigational Site Number 840741, Cleveland, Ohio, United States|Sanofi-Aventis Investigational Site Number 840728, Dayton, Ohio, United States|Sanofi-Aventis Investigational Site Number 840709, Mentor, Ohio, United States|Sanofi-Aventis Investigational Site Number 840716, Norman, Oklahoma, United States|Sanofi-Aventis Investigational Site Number 840701, Medford, Oregon, United States|Sanofi-Aventis Investigational Site Number 840751, Beaver, Pennsylvania, United States|Sanofi-Aventis Investigational Site Number 840798, Red Lion, Pennsylvania, United States|Sanofi-Aventis Investigational Site Number 840792, Columbia, South Carolina, United States|Sanofi-Aventis Investigational Site Number 840740, Simpsonville, South Carolina, United States|Sanofi-Aventis Investigational Site Number 840726, Taylors, South Carolina, United States|Sanofi-Aventis Investigational Site Number 840711, Bristol, Tennessee, United States|Sanofi-Aventis Investigational Site Number 840853, Colleyville, Texas, United States|Sanofi-Aventis Investigational Site Number 840730, Houston, Texas, United States|Sanofi-Aventis Investigational Site Number 840854, San Antonio, Texas, United States|Sanofi-Aventis Investigational Site Number 840796, Clinton, Utah, United States|Sanofi-Aventis Investigational Site Number 840755, Salt Lake City, Utah, United States|Sanofi-Aventis Investigational Site Number 840756, Salt Lake City, Utah, United States|Sanofi-Aventis Investigational Site Number 840758, Salt Lake City, Utah, United States|Sanofi-Aventis Investigational Site Number 840753, Norfolk, Virginia, United States|Sanofi-Aventis Investigational Site Number 840770, Norfolk, Virginia, United States|Sanofi-Aventis Investigational Site Number 840752, Richmond, Virginia, United States|Sanofi-Aventis Investigational Site Number 840757, Virginia Beach, Virginia, United States|Sanofi-Aventis Investigational Site Number 840735, Spokane, Washington, United States|Sanofi-Aventis Investigational Site Number 040706, Graz, Austria|Sanofi-Aventis Investigational Site Number 040704, Vienna, Austria|Sanofi-Aventis Investigational Site Number 040707, Wels, Austria|Sanofi-Aventis Investigational Site Number 040702, Wien, Austria|Sanofi-Aventis Investigational Site Number 040701, Wien, Austria|Sanofi-Aventis Investigational Site Number 040705, Wien, Austria|Sanofi-Aventis Investigational Site Number 124710, London, Canada|Sanofi-Aventis Investigational Site Number 124712, Mirabel, Canada|Sanofi-Aventis Investigational Site Number 124703, Saskatoon, Canada|Sanofi-Aventis Investigational Site Number 124713, Scarborough, Canada|Sanofi-Aventis Investigational Site Number 124711, Sherbrooke, Canada|Sanofi-Aventis Investigational Site Number 124704, Smiths Falls, Canada|Sanofi-Aventis Investigational Site Number 124705, St-Romuald, Canada|Sanofi-Aventis Investigational Site Number 124716, Sudbury, Canada|Sanofi-Aventis Investigational Site Number 124701, Thornhill, Canada|Sanofi-Aventis Investigational Site Number 124708, Vancouver, Canada|Sanofi-Aventis Investigational Site Number 250704, Armentieres, France|Sanofi-Aventis Investigational Site Number 250707, La Rochelle Cedex, France|Sanofi-Aventis Investigational Site Number 250705, Labarthe Sur Leze, France|Sanofi-Aventis Investigational Site Number 250702, Le Creusot, France|Sanofi-Aventis Investigational Site Number 250701, Strasbourg, France|Sanofi-Aventis Investigational Site Number 276708, Asslar, Germany|Sanofi-Aventis Investigational Site Number 276704, Berlin, Germany|Sanofi-Aventis Investigational Site Number 276703, Künzing, Germany|Sanofi-Aventis Investigational Site Number 276706, Leipzig, Germany|Sanofi-Aventis Investigational Site Number 276707, Pirna, Germany|Sanofi-Aventis Investigational Site Number 276702, Sulzbach-Rosenberg, Germany|Sanofi-Aventis Investigational Site Number 276701, Würzburg, Germany|Sanofi-Aventis Investigational Site Number 300705, Athens, Greece|Sanofi-Aventis Investigational Site Number 300703, Athens, Greece|Sanofi-Aventis Investigational Site Number 300704, Athens, Greece|Sanofi-Aventis Investigational Site Number 300701, Thessaloniki, Greece|Sanofi-Aventis Investigational Site Number 320702, Guatemala, Guatemala|Sanofi-Aventis Investigational Site Number 320701, Guatemala, Guatemala|Sanofi-Aventis Investigational Site Number 320703, Guatemala, Guatemala|Sanofi-Aventis Investigational Site Number 320704, Guatemala, Guatemala|Sanofi-Aventis Investigational Site Number 356701, Bangalore, India|Sanofi-Aventis Investigational Site Number 356703, Bangalore, India|Sanofi-Aventis Investigational Site Number 356702, Hyderabad, India|Sanofi-Aventis Investigational Site Number 356704, Nagpur, India|Sanofi-Aventis Investigational Site Number 484703, Merida, Mexico|Sanofi-Aventis Investigational Site Number 484701, Tlalnepantla, Mexico|Sanofi-Aventis Investigational Site Number 484704, Zapopan, Mexico|Sanofi-Aventis Investigational Site Number 604703, Lima, Peru|Sanofi-Aventis Investigational Site Number 604701, Lima, Peru|Sanofi-Aventis Investigational Site Number 604702, Lima, Peru|Sanofi-Aventis Investigational Site Number 604705, Lima, Peru|Sanofi-Aventis Investigational Site Number 630714, Carolina, Puerto Rico|Sanofi-Aventis Investigational Site Number 630715, Carolina, Puerto Rico|Sanofi-Aventis Investigational Site Number 642711, Alba Iulia, Romania|Sanofi-Aventis Investigational Site Number 642702, Bacau, Romania|Sanofi-Aventis Investigational Site Number 642709, Baia Mare, Romania|Sanofi-Aventis Investigational Site Number 642701, Brasov, Romania|Sanofi-Aventis Investigational Site Number 642712, Bucuresti, Romania|Sanofi-Aventis Investigational Site Number 642714, Bucuresti, Romania|Sanofi-Aventis Investigational Site Number 642705, Constanta, Romania|Sanofi-Aventis Investigational Site Number 642707, Galati, Romania|Sanofi-Aventis Investigational Site Number 642703, Ploiesti, Romania|Sanofi-Aventis Investigational Site Number 642713, Resita, Romania|Sanofi-Aventis Investigational Site Number 642708, Satu Mare, Romania|Sanofi-Aventis Investigational Site Number 642706, Targu Mures, Romania|Sanofi-Aventis Investigational Site Number 642715, Timisoara, Romania|Sanofi-Aventis Investigational Site Number 642710, Timisoara, Romania|Sanofi-Aventis Investigational Site Number 792702, Erzurum, Turkey|Sanofi-Aventis Investigational Site Number 792705, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT00763815
NCT00760448,Comparison of Insulin Detemir and NPH With Respect to Lowering the Blood Sugar and Symptoms Experienced by Type 1 Diabetics During Hypoglycaemia,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin detemir|Drug: insulin NPH,"Baseline-adjusted hypoglycaemic symptoms score at nadir plasma glucose concentration based on the Edinburgh Hypoglycaemia Scale: autonomic symptoms, neuroglycopenic symptoms and general malaise",Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 1,25,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN304-1449,Apr-04,Oct-05,Oct-05,26-Sep-08,null,27-Jan-17,"Novo Nordisk Investigational Site, Guildford, United Kingdom",,https://ClinicalTrials.gov/show/NCT00760448
NCT00760526,Randomized Trial to Assess Efficacy and Safety of Continuous Glucose Monitoring in Children 4-<10 Years With T1DM,,Completed,Has Results,"Diabetes Mellitus, Type 1",Device: Continuous glucose monitor|Device: Home blood glucose monitor,Number of Participants With a Decrease >=0.5% HbA1c With no Severe Hypoglycemic Events|Number of Severe Hypoglycemic Events Experienced by Participants|CGM Glucose Values (mg/dL)|Biochemical Hypoglycemia (Percentage of Sensor Values </= 70 mg/dL)|Measures of Variability: Standard Deviation (SD)|Measures of Variability: Mean Absolute Rate of Change|Measures of Variability: Mean Amplitude of Glycemic Excursions (MAGE)|Parental Quality of Life Measures: Hypoglycemia Fear Survey|Parental Quality of Life Measures: PAID (Problem Areas in Diabetes)|Parental Quality of Life Measures: Blood Glucose Monitoring System Rating Scale|Parental Quality of Life Measures: CGM Satisfaction Scale,Jaeb Center for Health Research|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,4 Years to 9 Years   (Child),Phase 3,146,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"DirecNet 011|HD041919-01,|HD041915-01,|HD041890,|HD041918-01,|HD041908-01,|HD041906-01,|M01RR000069|RR00059,|RR 06022,|RR00070-41",Sep-10,Jun-11,Jan-12,26-Sep-08,4-Dec-13,19-Oct-16,"Stanford University Medical Center, Stanford, California, United States|Yale University, School of Medicine, New Haven, Connecticut, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Children's Hospital of Iowa, Department of Pediatrics, Iowa City, Iowa, United States|Washington University School of Medicine, St. Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00760526
NCT00758082,Reinforcement of the Impact of a Functional Insulin Therapy Training Course by Telemonotoring With a PDA-phone in Type 1 Diabetic Patients. The TELFIT Study Patients,TELFIT,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: paper support|Device: PDA-phone + telemonitoring,"Comparison of HbA1c means|Difference between theoretical insulin dose and actual dose, one week before the 3-month reevaluation session|DHP scale of quality of life and satisfaction dimension of the DQOL questionnaire|Time spent by physicians and nurses in the different groups|Weight changes during the 3-month period|Number of hypoglycemias (moderate and severe) during the 3-month period","University Hospital, Grenoble|AGIR à Dom",All,"18 Years and older   (Adult, Older Adult)",Phase 3,62,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2008-A00389-46,Jul-08,Mar-10,Mar-10,23-Sep-08,null,11-Mar-10,"University Hospital Grenoble, Grenoble, France",,https://ClinicalTrials.gov/show/NCT00758082
NCT00754689,Study of Rimonabant/Metformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 Diabetes,,Withdrawn,No Results Available,"Diabetes Mellitus, Type 2",Drug: Rimonabant|Drug: Metformin|Drug: placebo,Change from baseline in A1C|Change from baseline in fasting plasma glucose|Change from baseline in body weight|Percent change from baseline in triglycerides|Percent change from baseline in HDL-C,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EFC10231|2008-002500-26,Sep-08,Nov-08,Nov-08,18-Sep-08,null,17-May-16,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00754689
NCT00754143,Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy,,Completed,No Results Available,Diabetes Mellitus|Diabetic Nephropathy,Drug: FG-3019,Safety and tolerability of FG-3019|Pharmacokinetic parameters|Change from baseline in first morning urinary albumin creatinine ratio (ACR),FibroGen,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,38,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",FGCL-3019-029,Mar-08,Dec-09,Dec-09,17-Sep-08,null,11-Aug-17,"Birmingham, Alabama, United States|Tempe, Arizona, United States|La Mesa, California, United States|Torrance, California, United States|Kissimmee, Florida, United States|Atlanta, Georgia, United States|Springfield, Massachusetts, United States|Omaha, Nebraska, United States|Flushing, New York, United States|New York, New York, United States|Chapel Hill, North Carolina, United States|Cleveland, Ohio, United States|Portland, Oregon, United States|Hershey, Pennsylvania, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Fairfax, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00754143
NCT00752180,"Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Type 1 Diabetics",,Completed,No Results Available,Diabetes,Biological: Wosulin R|Biological: Actrapid,"Mean AUCins.0-12h and Cins.max|PK endpoints: AUC0-4h, AUC0-6h, AUC6-12h,tmax, t½ and elimination rate constant.PD endpoints: AUCGIR0-4h, AUCGIR0-6h, AUCGIR6-12h, AUCGIR0-12h, GIRmax and tGIRmax .Safety endpoints: AEs, hematology, biochemistry, urinalyses, physical exam",Wockhardt,All,18 Years to 45 Years   (Adult),Phase 1,28,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research",WosulinR/PK-PD/type1/EMEA/2008,Aug-08,Mar-09,Apr-09,15-Sep-08,null,27-Dec-12,"Profil Institute for Clinical Research, Chula Vista, California, United States",,https://ClinicalTrials.gov/show/NCT00752180
NCT00751842,A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT,,Terminated,No Results Available,Type 1 Diabetes Mellitus,Drug: rhGAD65|Drug: Placebo,Meal Stimulated C-peptide (area under the curve)|HbA1c|Insulin Dose,Diamyd Therapeutics AB,All,"10 Years to 20 Years   (Child, Adult)",Phase 3,331,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D/P3/07/5,Sep-08,Mar-12,Jul-12,12-Sep-08,null,10-Oct-12,"University of Arizona, Tucson, Arizona, United States|Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States|Alex Endocrine Associates, Rogers, Arkansas, United States|Children's Hospital Orange County, Orange, California, United States|Rady Children's Hospital, San Diego, California, United States|Stanford University Medical Center, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Christina Care Research institute, Newark, Delaware, United States|University of Florida, Gainsville, Florida, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Miami Children's Hospital Research Institute, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|University of Iowa Hospitals and Clinicals, Iowa City, Iowa, United States|Mid America Diabetes Associates, Wichita, Kansas, United States|University of Kentucky College of Medicine, Lexington, Kentucky, United States|University of Louisville Research Foundation, Louisville, Kentucky, United States|Children's Hospital, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Alzohaili Medical Consultants, Dearborn, Michigan, United States|The Children's Mercy Hospital, Kansas City, Missouri, United States|St. Louis Children's Hospital, St. Louis, Missouri, United States|Creighton Diabetes Center, Omaha, Nebraska, United States|Kathryn Eckert, Reno, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Morristown Memorial Hospital, Morristown, New Jersey, United States|Winthrop University Hospital, Mineola, New York, United States|Naomi Berrie Diabetes Center of Columbia University, New York, New York, United States|University of Rochester, Rochester, New York, United States|SUNY Institute for Human Performance, Syracuse, New York, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|University of Oklahoma, Schustermann Center Clinic, Tulsa, Oklahoma, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Regional Medical Clinic - Endocrinology, Rapid City, South Dakota, United States|LeBonheur Children's Medical Center, Memphis, Tennessee, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|CHRISTUS Santa Rosa Children's Hospital, San Antonio, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Benaroya Research Institute, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00751842
NCT00749190,BI 10773 add-on to Metformin in Patients With Type 2 Diabetes,,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: BI 10773|Drug: placebo|Drug: sitagliptin,Change From Baseline in HbA1c After 12 Weeks of Treatment|Change of FPG From Baseline After 12 Weeks of Treatment|Change of HbA1c From Baseline Over Time|Proportion of Patients Who Achieve an HbA1c ≤7.0% After 12 Weeks of Treatment|Proportion of Patients Who Achieve an HbA1c Lowering of at Least 0.5% After 12 Weeks of Treatment|Change From Baseline to Week 12 in Fasting Plasma Insulin (FPI)|Change in Homeostasis Model Assessment Index for Insulin Resistance (HOMA-IR)|Change in Homeostasis Model Assessment Index for Beta Cell Function (HOMA-%B)|Change of Body Weight After 12 Weeks of Treatment|Trough Concentrations of Empagliflozin in Plasma,Boehringer Ingelheim,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 2,495,Industry,Interventional,Intervention Model: Parallel Assignment|Primary Purpose: Treatment,1245.10|EudraCT 2008-000641-54,Aug-08,Oct-09,null,9-Sep-08,13-Jun-14,13-Jun-14,"1245.10.10026 Boehringer Ingelheim Investigational Site, Chula Vista, California, United States|1245.10.10001 Boehringer Ingelheim Investigational Site, Mission Viejo, California, United States|1245.10.10011 Boehringer Ingelheim Investigational Site, Pasadena, California, United States|1245.10.10028 Boehringer Ingelheim Investigational Site, Spring Valley, California, United States|1245.10.10027 Boehringer Ingelheim Investigational Site, Walnut Creek, California, United States|1245.10.10004 Boehringer Ingelheim Investigational Site, Clearwarter, Florida, United States|1245.10.10021 Boehringer Ingelheim Investigational Site, Melbourne, Florida, United States|1245.10.10005 Boehringer Ingelheim Investigational Site, Miami, Florida, United States|1245.10.10019 Boehringer Ingelheim Investigational Site, Miami, Florida, United States|1245.10.10024 Boehringer Ingelheim Investigational Site, St. Cloud, Florida, United States|1245.10.10014 Boehringer Ingelheim Investigational Site, Roswell, Georgia, United States|1245.10.10016 Boehringer Ingelheim Investigational Site, Staten Island, New York, United States|1245.10.10009 Boehringer Ingelheim Investigational Site, Shelby, North Carolina, United States|1245.10.10006 Boehringer Ingelheim Investigational Site, Wadsworth, Ohio, United States|1245.10.10023 Boehringer Ingelheim Investigational Site, Norristown, Pennsylvania, United States|1245.10.10010 Boehringer Ingelheim Investigational Site, Clemson, South Carolina, United States|1245.10.10015 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States|1245.10.10012 Boehringer Ingelheim Investigational Site, Temple, Texas, United States|1245.10.10025 Boehringer Ingelheim Investigational Site, Federal Way, Washington, United States|1245.10.54002 Boehringer Ingelheim Investigational Site, Capital Federal, Argentina|1245.10.54004 Boehringer Ingelheim Investigational Site, Capital Federal, Argentina|1245.10.54008 Boehringer Ingelheim Investigational Site, Capital Federal, Argentina|1245.10.54006 Boehringer Ingelheim Investigational Site, Mar del Plata, Argentina|1245.10.54005 Boehringer Ingelheim Investigational Site, Mendoza, Argentina|1245.10.43002 Boehringer Ingelheim Investigational Site, Graz, Austria|1245.10.43004 Boehringer Ingelheim Investigational Site, Innsbruck, Austria|1245.10.43001 Boehringer Ingelheim Investigational Site, Wien, Austria|1245.10.43003 Boehringer Ingelheim Investigational Site, Wien, Austria|1245.10.42001 Boehringer Ingelheim Investigational Site, Breclav, Czech Republic|1245.10.42003 Boehringer Ingelheim Investigational Site, Brno, Czech Republic|1245.10.42005 Boehringer Ingelheim Investigational Site, Brno, Czech Republic|1245.10.42002 Boehringer Ingelheim Investigational Site, Hodonin, Czech Republic|1245.10.37201 Boehringer Ingelheim Investigational Site, Tallin, Estonia|1245.10.37202 Boehringer Ingelheim Investigational Site, Tartu, Estonia|1245.10.58006 Boehringer Ingelheim Investigational Site, Kerava, Finland|1245.10.58003 Boehringer Ingelheim Investigational Site, Oulu, Finland|1245.10.58004 Boehringer Ingelheim Investigational Site, Tampere, Finland|1245.10.58001 Boehringer Ingelheim Investigational Site, Turku, Finland|1245.10.3302A Boehringer Ingelheim Investigational Site, Bondy Cedex, France|1245.10.3302B Boehringer Ingelheim Investigational Site, Bondy Cedex, France|1245.10.3310A Boehringer Ingelheim Investigational Site, Caen Cedex 5, France|1245.10.3310B Boehringer Ingelheim Investigational Site, Caen Cedex 5, France|1245.10.3310C Boehringer Ingelheim Investigational Site, Caen Cedex 5, France|1245.10.3301A Boehringer Ingelheim Investigational Site, Corbeil Essonnes, France|1245.10.3301B Boehringer Ingelheim Investigational Site, Corbeil Essonnes, France|1245.10.3303A Boehringer Ingelheim Investigational Site, La Rochelle Cedex 1, France|1245.10.3303B Boehringer Ingelheim Investigational Site, La Rochelle Cedex 1, France|1245.10.3303C Boehringer Ingelheim Investigational Site, La Rochelle Cedex 1, France|1245.10.3303D Boehringer Ingelheim Investigational Site, La Rochelle Cedex 1, France|1245.10.3308A Boehringer Ingelheim Investigational Site, Le Grau du Roi, France|1245.10.3308B Boehringer Ingelheim Investigational Site, Le Grau du Roi, France|1245.10.3309A Boehringer Ingelheim Investigational Site, Nanterre Cedex, France|1245.10.3306A Boehringer Ingelheim Investigational Site, Narbonne Cedex, France|1245.10.3306B Boehringer Ingelheim Investigational Site, Narbonne Cedex, France|1245.10.3307A Boehringer Ingelheim Investigational Site, Quimper, France|1245.10.3304A Boehringer Ingelheim Investigational Site, Reims Cedex, France|1245.10.3304B Boehringer Ingelheim Investigational Site, Reims Cedex, France|1245.10.3304C Boehringer Ingelheim Investigational Site, Reims Cedex, France|1245.10.3311A Boehringer Ingelheim Investigational Site, Saint Mandé, France|1245.10.3311B Boehringer Ingelheim Investigational Site, Saint Mandé, France|1245.10.3311C Boehringer Ingelheim Investigational Site, Saint Mandé, France|1245.10.3311D Boehringer Ingelheim Investigational Site, Saint Mandé, France|1245.10.3305A Boehringer Ingelheim Investigational Site, Valenciennes, France|1245.10.3305B Boehringer Ingelheim Investigational Site, Valenciennes, France|1245.10.3305C Boehringer Ingelheim Investigational Site, Valenciennes, France|1245.10.3305D Boehringer Ingelheim Investigational Site, Valenciennes, France|1245.10.49001 Boehringer Ingelheim Investigational Site, Erlangen, Germany|1245.10.49003 Boehringer Ingelheim Investigational Site, Frankfurt, Germany|1245.10.49002 Boehringer Ingelheim Investigational Site, Hamburg, Germany|1245.10.49004 Boehringer Ingelheim Investigational Site, Rehlingen-Siersburg, Germany|1245.10.36001 Boehringer Ingelheim Investigational Site, Budapest, Hungary|1245.10.36003 Boehringer Ingelheim Investigational Site, Budapest, Hungary|1245.10.36004 Boehringer Ingelheim Investigational Site, Budapest, Hungary|1245.10.36005 Boehringer Ingelheim Investigational Site, Gyor, Hungary|1245.10.36002 Boehringer Ingelheim Investigational Site, Szombathely, Hungary|1245.10.37101 Boehringer Ingelheim Investigational Site, Daugavpils, Latvia|1245.10.37105 Boehringer Ingelheim Investigational Site, Kuldiga, Latvia|1245.10.37106 Boehringer Ingelheim Investigational Site, Ogre, Latvia|1245.10.37103 Boehringer Ingelheim Investigational Site, Riga, Latvia|1245.10.37107 Boehringer Ingelheim Investigational Site, Riga, Latvia|1245.10.37102 Boehringer Ingelheim Investigational Site, Talsi, Latvia|1245.10.37104 Boehringer Ingelheim Investigational Site, Valmiera, Latvia|1245.10.47003 Boehringer Ingelheim Investigational Site, Hamar, Norway|1245.10.47005 Boehringer Ingelheim Investigational Site, Oslo, Norway|1245.10.47001 Boehringer Ingelheim Investigational Site, Stavanger, Norway|1245.10.47004 Boehringer Ingelheim Investigational Site, Ålesund, Norway|1245.10.40001 Boehringer Ingelheim Investigational Site, Alba Iulia, Romania|1245.10.40005 Boehringer Ingelheim Investigational Site, Baia Mare Maramures, Romania|1245.10.40003 Boehringer Ingelheim Investigational Site, Brasov, Romania|1245.10.40002 Boehringer Ingelheim Investigational Site, Bucharest, Romania|1245.10.40007 Boehringer Ingelheim Investigational Site, Bucharest, Romania|1245.10.40004 Boehringer Ingelheim Investigational Site, Galati, Romania|1245.10.40006 Boehringer Ingelheim Investigational Site, Satu Mare, Romania|1245.10.70001 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|1245.10.70002 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|1245.10.70003 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|1245.10.70007 Boehringer Ingelheim Investigational Site, Saratov, Russian Federation|1245.10.70004 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|1245.10.70005 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|1245.10.70006 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|1245.10.62003 Boehringer Ingelheim Investigational Site, Bratislava, Slovakia|1245.10.62001 Boehringer Ingelheim Investigational Site, Nitra, Slovakia|1245.10.62002 Boehringer Ingelheim Investigational Site, Nitra, Slovakia|1245.10.62004 Boehringer Ingelheim Investigational Site, Presov, Slovakia|1245.10.34002 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1245.10.34001 Boehringer Ingelheim Investigational Site, Girona, Spain|1245.10.34010 Boehringer Ingelheim Investigational Site, L'Hospitalet de Llobregat (Barcelona), Spain|1245.10.34004 Boehringer Ingelheim Investigational Site, Málaga, Spain|1245.10.34005 Boehringer Ingelheim Investigational Site, Palma (Mallorca), Spain|1245.10.34006 Boehringer Ingelheim Investigational Site, Palma de Mallorca, Spain|1245.10.34008 Boehringer Ingelheim Investigational Site, Santander, Spain|1245.10.38002 Boehringer Ingelheim Investigational Site, Dnepropetrovsk, Ukraine|1245.10.38005 Boehringer Ingelheim Investigational Site, Kharkiv, Ukraine|1245.10.38004 Boehringer Ingelheim Investigational Site, Kharkov, Ukraine|1245.10.38003 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|1245.10.38001 Boehringer Ingelheim Investigational Site, Vinnitsa, Ukraine",,https://ClinicalTrials.gov/show/NCT00749190
NCT00747968,The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET,,Completed,No Results Available,Type 2 Diabetes,"Drug: Byetta, Exenatide",steady glucose metabolism in the heart and brain during hyperglycemia with GLP-1-analogue infusion compared to placebo.,University of Aarhus|Eli Lilly and Company|Aarhus University Hospital,Male,"50 Years to 70 Years   (Adult, Older Adult)",Phase 2|Phase 3,8,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",Brainandheart,Feb-10,Nov-10,Mar-11,8-Sep-08,null,30-Jun-11,"Aarhus University Hospital, Investigational Dept. M of Endocrinology, Aarhus, Aarhus C, Denmark|Aarhus University Hospital, Investigational Dept. M of Endocrinology, Aarhus, Denmark|Aarhus University Hospital, Investigational Dept. M of Endocrinology, Aarhus, Denmark",,https://ClinicalTrials.gov/show/NCT00747968
NCT00748137,Bolus Insulin Card Calculator Randomised Controlled Study,,Unknown status,No Results Available,Type 1 Diabetes,Device: ezy-BICC dose calculation card|Other: Fixed dose,24 hours BGL > 8.3mmol/l (CGMS)|HbA1c,"John Hunter Children's Hospital|Royal North Shore Hospital|Sydney Children's Hospitals Network|Royal Children's Hospital|Lady Cilento Children's Hospital, Brisbane|NovoNordisk Pharmaceuticals",All,"11 Years to 18 Years   (Child, Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,06/04/26/5.01,Mar-08,Oct-10,Jan-11,8-Sep-08,null,8-Feb-10,"Gosford District Hospital, Gosford, New South Wales, Australia|John Hunter Children's Hospital, Newcastle, New South Wales, Australia|Sydney Children's Hospital, Sydney, New South Wales, Australia|Mater Children's Hospital, Brisbane, Queensland, Australia|Royal Children's Hospital, Brisbane, Queensland, Australia",,https://ClinicalTrials.gov/show/NCT00748137
NCT00747383,How Improvement in Control of Diabetes Influences the Production of a Hormone Produced in the Gut Which Improves the Release and Action of Insulin.,MSD-GLP1,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Glimepiride|Drug: Sitagliptin,Comparison of GLP-1 response at baseline and after 3 months treatment of both groups.,The Royal Bournemouth Hospital|Merck Sharp & Dohme Corp.,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,74,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",08/H0201/57,Sep-08,Sep-10,Sep-10,5-Sep-08,null,5-Dec-12,"Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom",,https://ClinicalTrials.gov/show/NCT00747383
NCT00747006,Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake,,Terminated,Has Results,"Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1",Drug: TI Inhalation Powder and Humalog (Amendment 1)|Drug: TI Inhalation Powder (original protocol),Lunch Plasma Glucose Time 0 Corrected AUC (0-240) - Original Protocol (TI Treated Type 1 Subjects)|Breakfast Plasma Glucose Time 0 Corrected AUC(0-240) - Original Protocol (TI Treated Type 1 Subjects)|Lunch Plasma Glucose Time 0 Corrected AUC(0-240) - Amendment 1 (TI Treated Type 2 Subjects)|Lunch Plasma Glucose Time 0 Corrected AUC(0-240) - Amendment 1 (Humalog Treated Type 2 Subjects)|Lunch Plasma Glucose Excursion - Original Protocol (TI Treated Type 1 Subjects)|Breakfast Plasma Glucose Excursion - Original Protocol (TI Treated - Type 1 Subjects)|Lunch Plasma Glucose Excursion - Amendment 1 ( TI Treated Type 2 Subjects)|Lunch Plasma Glucose Excursion - Amendment 1 (Humalog Treated Type 2 Subjects)|Lunch Plasma Glucose AOC (0-240) - Original Protocol (TI Treated Type 1 Subjects)|Breakfast Plasma Glucose AOC(0-240) - Original Protocol (TI Treated Type 1 Subjects)|Lunch Plasma Glucose AOC(0-240) - Amendment 1 (TI Treated Type 2 Subjects)|Lunch Plasma Glucose AOC(0-240) - Amendment 1 (Humalog Treated Type 2 Subjects),Mannkind Corporation,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,18,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MKC-TI-119,Sep-08,Feb-11,May-11,4-Sep-08,21-Oct-14,30-Oct-14,"Sansum Medical Research Institute, Santa Barbara, California, United States",,https://ClinicalTrials.gov/show/NCT00747006
NCT00742521,"Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q.3",,Completed,No Results Available,Type 1 Diabetes,Procedure: glucose clamp,catecholamine measures,Vanderbilt University,All,18 Years to 50 Years   (Adult),Not Applicable,22,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant),IRB#010733|HL056693-10,Mar-01,Nov-08,Jun-09,27-Aug-08,null,10-Jun-15,"Vanderbilt University, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00742521
NCT00741390,Evaluation of Blood Volume and Perceived Pain During Fingerstick Monitoring of Blood Glucose,,Completed,Has Results,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Device: BD/33G|Device: OTM / 33G|Device: OTU/28G|Device: ACC/28G|Device: OTM/28G,"Blood Sample of Sufficient Volume to Yield a Valid Meter Reading|Difference in Lancing Pain for Device Pair at Visit 2. (For Subjects Assigned to Arms A, B, C Only)|Difference in Lancing Pain for Devices in Visit 2 Only. (For Subjects Assigned to Arm D Only)|Reported Device Preference Within Lancing Pair at Visit 2","Becton, Dickinson and Company",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,250,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant),BDDC-08-001,Aug-08,Sep-08,Sep-08,26-Aug-08,10-Mar-10,10-Mar-10,"Thomas J. Stephens & Associates, Colorado Springs, Colorado, United States|TKL Research, Inc., Carlstadt, New Jersey, United States|TKL Research, Inc, Paramus, New Jersey, United States|TKL Research, Inc., Ramsey, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00741390
NCT00740012,Glycemic Rises After Waking Up In Response To An Alarm Clock In Type 1-Diabetic Patients Analysed With Continuous Glucose Monitoring (GlucoDay®),,Completed,No Results Available,Stress|Type 1 Diabetes,"Other: Continuous glucose monitoring|Other: alarm- clock intervention, patient perform blood glucose self monitoring|Other: nurse intervention|Other: Taking the patients pulse|Other: Venous blood drawing|Other: Other capillary sample","Glucose (continuous glucose monitoring)|Hormones (norepinephrine, cortisol, glucagon, growth hormone, prolactin), Pulse, Blood glucose",Diabeteszentrum Bad Lauterberg im Harz|Berlin-Chemie Menarini,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,32,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),Glucoday BL,Mar-07,Sep-08,Sep-08,22-Aug-08,null,29-Sep-08,"Diabeteszentrum Bad Lauterberg im Harz, Bad Lauterberg, Lower Saxony, Germany",,https://ClinicalTrials.gov/show/NCT00740012
NCT00737763,Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab,BRiTE,Withdrawn,No Results Available,"Diabetes Mellitus, Type 1",Drug: efalizumab|Drug: placebo,The primary endpoint for this study will be the difference from baseline in the body's ability to respond to a Mixed Meal Tolerance Test at 12 months after enrollment.,"Emory University|Juvenile Diabetes Research Foundation|Genentech, Inc.",All,"12 Years to 35 Years   (Child, Adult)",Phase 2,0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB0007365|BRiTE Trial for T1DM,Oct-08,Nov-09,Nov-09,20-Aug-08,null,12-May-14,,,https://ClinicalTrials.gov/show/NCT00737763
NCT00738660,Efficacy of Telmisartan and the Combination of Telmisartan and Ramipril in type1 Diabetes Patients With Nephropathy,START1DM,Completed,No Results Available,Diabetic Nephropathy,"Drug: Telmisartan, Ramipril","Reduction in albumin excretion rate|24 hr ambulatory BP reduction,nocturnal BP reduction, proportion of dippers",Postgraduate Institute of Medical Education and Research,All,"14 Years and older   (Child, Adult, Older Adult)",Phase 3,30,Other,Interventional,Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,START1DM,Feb-07,May-08,May-08,20-Aug-08,null,20-Aug-08,"Post Graduate Institute of Medical Education and Research, Chandigarh, India",,https://ClinicalTrials.gov/show/NCT00738660
NCT00732602,The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes,,Completed,No Results Available,Diabetes Mellitus,Other: GIP-infusion|Other: Sodium-chloride|Other: GLP-2 infusion,plasma-glucagon Area Under Curve at 0-90 min. and 90-180 min.,"University Hospital, Gentofte, Copenhagen|University of Copenhagen",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,8,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,H-D-2007-0058,Jan-08,Aug-08,null,12-Aug-08,null,13-Feb-09,"University Hospital, Gentofte, Hellerup, Capital Region, Denmark",,https://ClinicalTrials.gov/show/NCT00732602
NCT00730392,Etanercept in New Onset Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Drug: Etanercept|Drug: Placebo,"The primary end points of this study are percent change from baseline for HbA1c and C-peptide area under the curve (AUC).|Secondary end points are insulin dose and number of insulin injection discontinued, if any",University at Buffalo|Amgen,All,"3 Years to 18 Years   (Child, Adult)",Phase 1|Phase 2,18,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",20020197,Oct-02,Oct-07,Jan-08,8-Aug-08,null,8-Aug-08,,,https://ClinicalTrials.gov/show/NCT00730392
NCT00729365,PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease),PREVENTKD,Terminated,Has Results,Type 1 Diabetes,Drug: Ramipril|Drug: Placebo,"Development of Microalbuminuria (High Urine Albumin). Hypertension, Urine and Blood Markers Will Also be Evaluated for Assessment of Kidney Disease State.|We Will Assess Changes in the Relative Stiffness of Your Arteries (Endothelial Dysfunction) in Persons With Type 1 Diabetes Over the 5year Study.",Northwestern University|Juvenile Diabetes Research Foundation|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"13 Years to 50 Years   (Child, Adult)",Phase 3,65,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",1U01DK071733-01A1,Jul-08,Jun-10,Jun-10,7-Aug-08,9-Jan-15,17-Mar-15,"University of Florida, Gainesville, Florida, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Rush University Medical Center, Endocrinology Section, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Loyola University Chicago, Maywood, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00729365
NCT00728351,Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%),,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: vildagliptin + metformin|Drug: metformin,HbA1c reduction after 24 weeks of treatment in patients with T2DM inadequately controlled with metformin monotherapy|FPG reduction|Safety and tolerability|Body weight change from baseline|Changes in the fasting lipid profile,Novartis Pharmaceuticals|Novartis,All,"18 Years to 78 Years   (Adult, Older Adult)",Phase 3,317,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CLMF237A2309,Jun-08,Feb-10,null,5-Aug-08,null,4-Jan-13,"Pine Bluff, Arkansas, United States|Long Beach, California, United States|Denver, Colorado, United States|Bangor, Maine, United States|Billings, Montana, United States|Novartis Investigative Site, New Brunswick, New Jersey, United States|Trenton, New Jersey, United States|Wilmington, North Carolina, United States|Oklahoma City, Oklahoma, United States|Uniontown, Pennsylvania, United States|Taylors, South Carolina, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Norfolk, Virginia, United States|Wenatchee, Washington, United States|Cabinet d'Endocrinologie-Maladies Métaboliques, Annecy, France|Service Endocrinologic & Metabolisme, Paris, France|Polycliniques des minguettes, Venissieux, France|Hausärztliche Praxis, Aschaffenburg, Germany|Klinische Forschung Berlin Mitte GmbH, Berlin, Germany|AVK, Berlin, Germany|Gemeinschaftspraxis, Celle, Germany|Malteser KM, Duisburg, Germany|Untertrintroper Hausarztzentrum, Essen, Germany|Gefrees, Germany|Diabeteszentrum Billstedt/Horn, Hamburg, Germany|Diabetologische Schwerpunktpraxis, Hamburg, Germany|St. Elisabeth Krankenhaus Leipzig, Leipzig, Germany|Diabetes-Schwerpunktpraxis Studienambulanz, Leipzig, Germany|Institut für Diabetes-forschung Münster, Münster, Germany|Praxis Dr. Alawi, Saarlouis, Germany|DDT, Siegen, Germany|Diabetologische Schwerpunktpraxis, Sinsheim, Germany|Praxis, Wangen, Germany|Synexus Magyarorszag, Budapest, Hungary|Uzsoki Hospital, Budapest, Hungary|Budapest, Hungary|Europ-Med Orvosi Szolgaltato Kft, Budaörs, Hungary|Kenezy Hospital, Debrecen, Hungary|Gyngyosi Korhaz Kft, Gyongyos, Hungary|Petz Aladar County, Györ, Hungary|Selye Janos Korhaz es Rendelointezet, Komarom, Hungary|DIAPED Kft., MRC, Meggyesalja u., Hungary|Josa Andras Teaching Hospital, Nyiregyhaza, Hungary|Vas Megyei Markuscvszky Lajos Korhaz, Szombathely, Hungary|Zala County Hospital, Zalaegerszeg, Hungary|NZOZ Specjalistyczny Ośrodek Internistyczno - Diabetologiczny Białystok, Bialystok, Poland|Gdanska Poradnia Cukrzycowa, Gdansk, Poland|Gabinet Kardiologiczny Mediplus, Gdynia, Poland|NZOZ ""Esculap"" S.C., Gniewkowo, Poland|SZPZOZ Szpital Zachodni im. Jana Pawla II, Grodzisk Mazowiecki, Poland|NZOZ Terapia Optima, Katowice, Poland|Poradnia Diabetologiczna, Zespol Opieki Zdrowotnej w Leczycy, Leczyca, Poland|Zespół Opieki Zdrowotnej w Łęczycy, Poradnia Diabetologiczna Łeczyca, Leczyca, Poland|Instytut Cantrum Zdrowia Matki Polki, Lodz, Poland|NZOZ Special-Med, Lublin, Poland|Szspital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Ponza, Poznan, Poland|Lecznica Prosen-SMO NZOZ, Warszawa, Poland|Centrum Leczenia Chorob Cywilizacyjnych, Warszawa, Poland|NZCZ Regionalna Poradnia Diabetologiczna, Wroclaw, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1, Wroclaw, Poland|Samodzielny Publiczny Szpital Kliniczny NR 1 im. Prof. Stanislawa Szysko SAM, Zabrze, Poland",,https://ClinicalTrials.gov/show/NCT00728351
NCT00726440,Are the Continuous Glucose Monitoring Systems Able to Improve Long Term Glycaemic Control in Type 1 Diabetic Patients?,,Completed,No Results Available,Type 1 Diabetes,Device: Navigator®|Device: Placebo,"Comparison of HbA1c mean between the 3 groups|Comparison of glucose stability in the 3 groups|Frequency of severe hypoglycaemic episodes and ketoacidosis episodes during the study period|Frequency of symptomatic benign hypoglycaemic episodes during the week prior to each visit. inclusion and prior to M3, M6, M9, M12|Comparison of HbA1c in patients treated by pump to those treated by multiple daily injection|Evaluation of the Quality of Life (DQOL and SF36) and patient's satisfaction in the 3 groups|Comparison of weight, insulin doses, in each group|comparison of the sensors consumption in group 1 and 2 and the evolution in time of this consumption",Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète|Abbott,All,"8 Years to 60 Years   (Child, Adult)",Not Applicable,180,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2007-A01022-51,Feb-08,Jun-10,Jun-10,1-Aug-08,null,9-Feb-12,"CHU Sart Tilman Liège, Liege, Belgium|CHU Jean Minjoz, Besancon, France|CH SUD Francilien, Corbeil Essonnes, France|University Hospital Grenoble, Grenoble, France|Hopital Edouard Herriot, Lyon, France|CHU Marseille Hôpitaux Sud, Marseille, France|Chu Montpellier, Montpellier, France|CHU Hôpital Jeanne d'Arc, Nancy, France|CHU Nantes, Nantes, France|Hopital Hotel Dieu, Paris, France|CHU La Pitié Salpetrière, Paris, France|CHU Robert Debré, Paris, France|Hopital Haut Leveque, Pessac, France|CHU de Reims-Hôpital Américain, Reims, France|CHU de Reims-Hôpital Robert debré, Reims, France|CHU Rennes, Rennes, France|Hopital Bellevue, Saint Etienne, France|CHU Strasbourg, Strasbourg, France|CHU Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT00726440
NCT00725036,Long Term Safety Trial to Compare Insulin Treatment With Preprandial Inhaled Human Insulin to s.c. Insulin Aspart Both Combined With NPH in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: inhaled human insulin|Drug: insulin aspart|Drug: insulin NPH,"Long term pulmonary safety profiles|Glycaemic control as measured by HbA1c|Incidence of hypoglycaemic episodes|Long-term safety profiles (laboratory, ECG, insulin antibodies)|Physical examination and body weight and vital signs|Adverse events|Treatment satisfaction",Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,305,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN1998-1496,2-Sep-02,14-Dec-04,14-Dec-04,30-Jul-08,null,1-Mar-17,"Novo Nordisk Investigational Site, Broadmeadow, New South Wales, Australia|Novo Nordisk Investigational Site, Camperdown, New South Wales, Australia|Novo Nordisk Investigational Site, St Leonards, New South Wales, Australia|Novo Nordisk Investigational Site, Wollongong, New South Wales, Australia|Novo Nordisk Investigational Site, Woolloongabba, Queensland, Australia|Novo Nordisk Investigational Site, Keswick, South Australia, Australia|Novo Nordisk Investigational Site, Fremantle, Western Australia, Australia|Novo Nordisk Investigational Site, Ashford, Australia|Novo Nordisk Investigational Site, Auckland, Australia|Novo Nordisk Investigational Site, Box Hill, Australia|Novo Nordisk Investigational Site, Christchurch, Australia|Novo Nordisk Investigational Site, Clayton, Australia|Novo Nordisk Investigational Site, Garran, Australia|Novo Nordisk Investigational Site, Heidelberg, Australia|Novo Nordisk Investigational Site, Parkville, Australia|Novo Nordisk Investigational Site, Perth, Australia|Novo Nordisk Investigational Site, Randwick, Australia|Novo Nordisk Investigational Site, Stones Corner, Australia",,https://ClinicalTrials.gov/show/NCT00725036
NCT00723411,A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU),,Terminated,No Results Available,Type 1 Diabetes Mellitus,Drug: rhGAD65|Drug: Placebo,Meal stimulated C-peptide (area under the curve)|HbA1c|Insulin Dose,Diamyd Therapeutics AB,All,"10 Years to 20 Years   (Child, Adult)",Phase 3,334,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D/P3/07/4,Jul-08,May-11,Aug-11,28-Jul-08,null,10-Oct-11,"Helsingin yliopistollinen keskussairaala, Lasten ja nuorten sairaala, Helsinki, Finland|Kuopion yliopistollinen sairaala, Lasten klinikka, Kuopio, Finland|Oulun yliopistollinen sairaala, Lasten ja nuorten klinikka, Oulu, Finland|Seinäjoen keskussairaala, Lastentautien poliklinikka, Seinäjoki, Finland|Tampereen yliopistollinen sairaala, Lasten klinikka, Tampere, Finland|Turun yliopistollinen keskussairaala, Lastentautien Klinikka, Turku, Finland|Medecine B, Angers, France|Centre Hospitalier Universitaire de Besançon, Besançon, France|Hôpital Pellegrin Enfants, Service d'endocrinologie pédiatrique, Bordeaux, France|Hôpital Jeanne de Flandre Sce Pédiatrie, Lille, France|CHU Timone Enfants, Service de pédiatrie multidisciplinaire, Marseilles, France|CHU Montpellier Hôpital Arnaud de Villeneuve, Service de Pédiatrie 1, Montpellier, France|C.H.U.Serv.Pediatrie, Nantes, France|Hopital Robert Debré, Service d'Endocrinologie, Paris, France|Hôpital Necker, Clinique Robert Debré, Diabète de l'Enfant et de l'Adolescent,, Paris, France|CHU Rennes, Rennes, France|Hôpital des Enfants, Gastroentero-nutrition-diabétologie pédiatrique, Toulouse, France|Charité Campus Virchow Childrens Hospital, Berlin, Germany|DRK Kliniken Westend, Berlin, Germany|KHK Wilhelmstift, Hamburg-Rahlstedt, Germany|Hannover Kinderkrankenhaus auf der Bult, Hannover, Germany|Klinik und Poliklinik fȕr Kinder und Jugendliche der Universität Leipzig, Leipzig, Germany|Klinik fȕr Kinder- und Jugendmedizin, Mȕnchen, Germany|Universitätsklinik fȕr Kinder- und Jugendmedizin, Tȕbingen, Tȕbingen, Germany|Unità Operativa di Pediatria, Policlinico, Bologna, Italy|Struttura Complessa di Diabetologia, Ospedale S. Michele, Cagliari, Italy|S.S. Annunziata, Clinica Pediatrica, Chieti, Italy|Clinica Pediatrica, Università di Genova, Genova, Italy|Reparto di Pediatria, Ospedale S. Raffaele, Milano, Italy|Diabetologia - Dipartimento Clinica Pediatrica, Ospedale Luigi Sacco, Milano, Italy|Azienda Ospedaliero, Universitaria di Parma, Pediatria, Parma, Italy|Campus Bio-Medico, Dipartimento di Diabetologia e Endocrinologia, Roma, Italy|Diabetologia - Dipartimento Scienze Pediatriche, Ospedale Infantile, Regina Margherita, Torino, Italy|Meander Medisch Centrum, Lokatie Elisabeth, Amersfoort, Netherlands|Haga Ziekenhuis, Lokatie Juliana Kinderziekenhuis, Den Haag, Netherlands|Diabeter, Rotterdam, Netherlands|Orbis Medisch Centrum, Sittard-Geleen, Netherlands|University Medical Centre Ljubljana, Department of Pediatric Endocrinology, Ljubljana, Slovenia|Hospital Materno-Infantil Vall Hebrón, Barcelona, Spain|Hospital Materno-Infantil de Cruces, Cruces / Barakaldo, Spain|Hospital Materno-Infantil Ramón y Cajal, Madrid, Spain|Hospital Materno-Infantil La Paz, Madrid, Spain|Hospital Materno-Infantil Carlos Haya, Málaga, Spain|Hospital Materno-Infantil Vírgen del Camino, Pamplona, Spain|Hospital Materno-Infantil Vírgen del Rocío, Sevilla, Spain|Hospital Materno-Infantil Clínico de Valencia, Valencia, Spain|Hospital Materno-Infantil Miguel Servet, Zaragoza, Spain|Barn- och ungdomskliniken, Lasarettet, Borås, Sweden|Barn- och ungdomskliniken, Länssjukhuset, Gävle, Sweden|Drottning Silvias Barnsjukhus, Barn- och ungdomssjukvården, Göteborg, Sweden|Barn- och ungdomskliniken, Länssjukhuset, Halmstad, Sweden|Barn- och ungdomsmedicin, Lasarettet, Helsingborg, Sweden|Barnkliniken, Hudiksvalls Sjukhus, Hudiksvall, Sweden|Barn- och ungdomskliniken, Länssjukhuset Ryhov, Jönköping, Sweden|Barn- och ungdomskliniken, Lasarettet, Kalmar, Sweden|Barn- och ungdomskliniken, Centralsjukhuset, Karlstad, Sweden|Barn och ungdomsmedicinska kliniken, Centralsjukhuset, Kristianstad, Sweden|Barn- och ungdomskliniken, Universitetssjukhuset, Linköping, Sweden|Barn- och ungdomskliniken, Universitetssjukhuset, Lund, Sweden|Barn- och ungdomscentrum, Universitetssjukhuset MAS, Malmö, Sweden|Barn- och ungdomskliniken, Vrinnevi sjukhus, Norrköping, Sweden|Sachsska Barnsjukhuset, Södersjukhuset, Stockholm, Sweden|Barn- och ungdomskliniken, NU-sjukvården/NÄL, Trollhättan, Sweden|Barn- och ungdomskliniken, Uddevalla Sjukhus, Uddevalla, Sweden|Barn- och ungdomskliniken, Centrallasarettet, Västerås, Sweden|Barn- och ungdomskliniken, Centrallasarettet, Växjö, Sweden|Barn- och ungdomskliniken, Universitetssjukhuset, Örebro, Sweden|Maternal & Child Health Sciences, University of Dundee, Dundee, United Kingdom|Children's Admin Centre, Leicester, United Kingdom|Centre for Diabetes and Metabolic Medicine (DMM), Barts and The London School of Medicine and Dentistry, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00723411
NCT00717977,Continuous Glucose Sensor Profiles in Non-Diabetic Subjects,,Completed,Has Results,Healthy Subjects Without Type 1 Diabetes,Device: Continuous glucose monitor,Overall Mean Sensor Glucose by Age Group|Daytime (6:00 a.m. - Midnight) Mean Sensor Glucose by Age Group|Nighttime (Midnight - 6:00 a.m.) Mean Sensor Glucose by Age Group|Peak Daytime Sensor Glucose Value by Age Group|Peak Nightime Sensor Glucose Value by Age Group|Daytime Nadir Sensor Glucose Value by Age Group|Nighttime Nadir Sensor Glucose Value by Age Group|Percentage of Sensor Glucose Levels Between 71-120 mg/dL by Age Group|Percentage of Sensor Glucose Levels 71-120 mg/dL by Time of Day|Distribution of Sensor Glucose Levels <=70 mg/dL by Age Group|Percentage of Sensor Glucose Levels <=70 mg/dl by Time of Day|Percentage of Sensor Glucose Levels <=60 mg/dL by Age Group|Percentage of Sensor Glucose Levels <=60 mg/dl by Time of Day|Percentage of Sensor Glucose Levels >120 mg/dL by Age Group|Percentage of Sensor Glucose Levels >120 mg/dl by Time of Day|Percentage of Sensor Glucose Levels >140 mg/dL by Age Group|Percentage of Sensor Glucose Levels >140 mg/dl by Time of Day|Glucose Variability Measure- Standard Deviation by Age Group|Glucose Variability Measure- Standard Deviation by Time of Day|Glucose Variability Measure- Absolute Rate of Change by Age Group|Glucose Variability Measure- Absolute Rate of Change by Time of Day|Glucose Variability Measure- Coefficient of Variation by Age Group|Glucose Variability Measure- Coefficient of Variation by Time of Day|Glucose Variability Measure: Mean Amplitude of Glycemic Excursions by Age Group|Glucose Variability Measure: Amplitude of Glycemic Excursions by Time of Day,Jaeb Center for Health Research|JDRF Artificial Pancreas Project,All,"8 Years and older   (Child, Adult, Older Adult)",Phase 4,74,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),2008-2403,Jul-08,Dec-08,Mar-09,18-Jul-08,18-Oct-10,19-Oct-16,"Kaiser Permanente, San Diego, California, United States|Stanford University, Stanford, California, United States|University of Colorado, Aurora, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Children's Hospital of Iowa, Iowa City, Iowa, United States|Joslin Diabetes Center - Adults, Boston, Massachusetts, United States|Joslin Diabetes Center - Children, Boston, Massachusetts, United States|University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00717977
NCT00718614,Choroidal Blood Flow Changes During Dark/Light Transitions in Patients With Insulin-dependent Diabetes Mellitus (IDDM),,Terminated,No Results Available,"Diabetes Mellitus, Type 1|Diabetic Retinopathy",Procedure: Light will be switched from 0.5µW/cm2/sr to 115µW/cm2/sr.,fundus pulsation amplitude|choroidal blood flow|Nerve conduction velocity|Pupil diameter during infra-red pupillometry|heart rate variability,Medical University of Vienna,All,"19 Years and older   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,OPHT-300505-2,Jun-07,Jul-07,Jul-07,18-Jul-08,null,25-Nov-14,"Department of Clinical Pharmacology, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT00718614
NCT00715624,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin",GETGOAL-L,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Lixisenatide (AVE0010)|Drug: Placebo|Drug: Basal Insulin|Drug: Metformin|Device: Pen auto-injector,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24|Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) at Week 24|Change From Baseline in Average 7-Point Self Monitored Plasma Glucose (SMPG) Profiles at Week 24|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24|Change From Baseline in Body Weight at Week 24|Change From Baseline in Total Insulin Dose at Week 24|Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24|Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24|Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,496,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFC6016|2007-005886-36,Jul-08,Feb-11,Feb-11,15-Jul-08,11-Oct-16,28-Nov-16,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Sao Paulo, Brazil|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Santiago, Chile|Sanofi-Aventis Administrative Office, Cairo, Egypt|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Mumbai, India|Sanofi-Aventis Administrative Office, Milano, Italy|Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of|Sanofi-Aventis Administrative Office, Mexico, Mexico|Sanofi-Aventis Administrative Office, Puerto Rico, Puerto Rico|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Istanbul, Turkey|Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom",,https://ClinicalTrials.gov/show/NCT00715624
NCT00713830,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea",GETGOAL-S,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Lixisenatide (AVE0010)|Drug: Placebo|Device: Pen auto-injector|Drug: Sulfonylurea|Drug: Metformin,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24|Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) at Week 24|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24|Change From Baseline in Body Weight at Week 24|Change From Baseline in Beta-cell Function Assessed by HOMA-beta at Week 24|Change From Baseline in Fasting Glucagon and 2-hour Postprandial Glucagon at Week 24|Change From Baseline in Fasting Plasma Insulin (FPI) and 2-hour Postprandial Plasma Insulin at Week 24|Change From Baseline in Fasting Proinsulin and 2-hour Postprandial Proinsulin at Week 24|Change From Baseline in Fasting C-peptide and 2-hour Postprandial C-peptide at Week 24|Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24|Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24|Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,859,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EFC6015|EudraCT 2007-005881-11,Jul-08,Jan-11,Jan-11,14-Jul-08,14-Dec-16,14-Dec-16,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Sofia, Bulgaria|Sanofi-Aventis Administrative Office, Praha, Czech Republic|Sanofi-Aventis Administrative Office, Cairo, Egypt|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Mumbai, India|Sanofi-Aventis Administrative Office, Natanya, Israel|Sanofi-Aventis Administrative Office, Tokyo, Japan|Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of|Sanofi-Aventis Administrative Office, Gouda, Netherlands|Sanofi-Aventis Administrative Office, Bucuresti, Romania|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Taipei, Taiwan|Sanofi-Aventis Administrative Office, Bangkok, Thailand|Sanofi-Aventis Administrative Office, Megrine, Tunisia|Sanofi-Aventis Administrative Office, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT00713830
NCT00712673,"GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin",GETGOAL-M,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Lixisenatide (AVE0010)|Drug: Placebo|Device: Pen auto-injector|Drug: Metformin,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24|Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) at Week 24|Change From Baseline in Body Weight at Week 24|Change From Baseline in Fasting Plasma Insulin (FPI) at Week 24|Change From Baseline in 2-Hour Postprandial Plasma Insulin (PPI) at Week 24|Change From Baseline in Fasting Proinsulin at Week 24|Change From Baseline in 2-Hour Postprandial Proinsulin at Week 24|Change From Baseline in Fasting C-Peptide at Week 24|Change From Baseline in 2-Hour Postprandial C-Peptide at Week 24|Change From Baseline in Fasting Glucagon at Week 24|Change From Baseline in 2-Hour Postprandial Glucagon at Week 24|Change From Baseline in Adiponectin at Week 24|Change From Baseline in Beta-cell Function Assessed by Homeostasis Model Assessment for Beta-cell Function (HOMA-beta) at Week 24|Percentage of Patients Requiring Rescue Therapy During the Main 24-Week Period|Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24|Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,680,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EFC6014|EudraCT 2007-005880-80,Jun-08,Mar-11,Mar-11,10-Jul-08,15-Dec-16,15-Dec-16,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, Australia|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Santiago, Chile|Sanofi-Aventis Administrative Office, Zagreb, Croatia|Sanofi-Aventis Administrative Office, Praha, Czech Republic|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Mexico, Mexico|Sanofi-Aventis Administrative Office, Casablanca, Morocco|Sanofi-Aventis Administrative Office, Makati City, Philippines|Sanofi-Aventis Administrative Office, Bucuresti, Romania|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Midrand, South Africa|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Kiev, Ukraine|Sanofi-Aventis Administrative Office, Caracas, Venezuela",,https://ClinicalTrials.gov/show/NCT00712673
NCT00711503,Anti-Interleukin-1 in Diabetes Action,AIDA,Completed,No Results Available,Type 1 Diabetes,Drug: anakinra|Drug: saline,"Δ 2-h AUC C-peptide response|Incremental and/or peak C-peptide response, Time to peak C-peptide, insulin requirement per kg body weight per day,frequency of insulin free state with maintenance of HbA1c <7.5%, HbA1c, Means of fasting glucose values, circulating IL-6 and CRP",Steno Diabetes Center Copenhagen|Juvenile Diabetes Research Foundation|Oeresund Diabetes Academy,All,18 Years to 35 Years   (Adult),Phase 2|Phase 3,69,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2007-007146-34|EudraCT 2007-007146-34|Danish EthicalH-D-2008-060|Danish Datatilsyn2007-41-1652|JDRF file no. 17-2007-1804,Jan-09,Jan-12,Jun-12,9-Jul-08,null,3-Sep-12,"Aalborg Hospital, Aalborg, Denmark|Aarhus Universitetshospital, Aarhus, Denmark|Bispebjerg Universitetshospital, Copenhagen, Denmark|Steno Diabetes Center, Gentofte, Denmark|Nordsjællands Hospital, Hillerød, Hillerød, Denmark|Ulm University, Dept. of Internal Medicine, Ulm, Donau, Germany|Leibniz Center for Diabetes research, Heinrich-Heine University, Duesseldorf, Germany|University of Frankfurt am Main, Frankfurt am Main, Germany|Institut für Diabetesforschung, Munich University of Technology, Munich, Germany|University Campus Bio-Medico, Rome, Italy|Leiden University Medical Center, Leiden, Netherlands|Medical University of Bialystok, Bialystok, Poland|Hospital de Cruces, Diabetes Research Group, Barakaldo, Bizkaia, Spain|Hospital Unversitario Insular de Gran Canaria, Las Palmas, Gran Canaria, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Arnua de Vilanova, Lleida, Spain|University Hospital Zürich, Zürich, Switzerland",,https://ClinicalTrials.gov/show/NCT00711503
NCT00708604,Islet After Kidney Transplantation (IAK) in Patients With Type 1 Diabetes,,Completed,No Results Available,Diabetes Mellitus,Procedure: Islet Transplantation|Biological: Islet cell transplantation,Percent of subjects who have achieved insulin sufficiency post transplant.|Stimulated C-peptide response >0.6 ng/ml|Insulin use </= 0.2 units/kg/day|Reduction/elimination of hypoglycemic episodes|HgAlc</= 6.5%,City of Hope Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,3,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,04033|DK56952,Aug-05,Jun-14,Jun-14,2-Jul-08,null,4-Jul-14,"City of Hope Medical Center, Duarte, California, United States",,https://ClinicalTrials.gov/show/NCT00708604
NCT00707031,"GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin",GETGOAL-X,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Lixisenatide (AVE0010)|Device: Pen auto-injector|Drug: Exenatide|Device: Prefilled pen injector|Drug: Metformin,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24|Change From Baseline in Body Weight at Week 24|Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24|Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24|Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,639,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EFC6019|2007-005883-28,Jun-08,Nov-10,Nov-10,30-Jun-08,11-Oct-16,2-Dec-16,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Buenos Aires, Argentina|Sanofi-Aventis Administrative Office, Wien, Austria|Sanofi-Aventis Administrative Office, Sao Paulo, Brazil|Sanofi-Aventis Administrative Office, Santafe de Bogota, Colombia|Sanofi-Aventis Administrative Office, Horsholm, Denmark|Sanofi-Aventis Administrative Office, Helsinki, Finland|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Athens, Greece|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Milano, Italy|Sanofi-Aventis Administrative Office, Gouda, Netherlands|Sanofi-Aventis Administrative Office, Lysaker, Norway|Sanofi-Aventis Administrative Office, Warszawa, Poland|Sanofi-Aventis Administrative Office, Puerto Rico, Puerto Rico|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Bromma, Sweden",,https://ClinicalTrials.gov/show/NCT00707031
NCT00706420,Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen,,"Active, not recruiting",No Results Available,Diabetes Mellitus,Procedure: Islet Transplantation + Immunosuppression|Biological: Islet cell transplantation,Percent of subjects who have achieved insulin independence post transplant.|Stimulated C-peptide response >0.6 ng/ml|Insulin use </=0.2units/kg/day|Reduction/elimination of hypoglycemic episodes|HgAlc</= 6.5%,City of Hope Medical Center|National Institutes of Health (NIH),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,20,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,01083|RR-01-002,Jan-02,Apr-19,Apr-19,27-Jun-08,null,22-May-18,"City of Hope Medical Center, Duarte, California, United States",,https://ClinicalTrials.gov/show/NCT00706420
NCT00706693,Skittles(TM) Effective for Treating Hypoglycemia in Children With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus|Hypoglycemia,Dietary Supplement: Ingestion of BD glucose tablets (TM)|Dietary Supplement: Ingestion of Skittles (TM)|Dietary Supplement: Ingestion of Fruit to Go (TM),To determine if sucrose and fructose are equally effective as glucose in the treatment of spontaneous hypoglycemia in children with type 1 diabetes.|To determine present hypoglycemia treatment practices of children and teens with type 1 diabetes (prior to entry into the study).|To determine preferred mode of treatment for hypoglycemia after completing the study.,"University of Calgary|Canadian Diabetes Association|LifeScan Canada|Becton, Dickinson and Company",All,"3 Years to 18 Years   (Child, Adult)",Not Applicable,33,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17089-AH,Aug-03,Sep-06,Sep-06,27-Jun-08,null,9-Jul-08,"Alberta Children's Hospital, Calgary, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT00706693
NCT00703989,Reactive Oxygen Species in the Pathogenesis of Diabetic Complications,,Completed,No Results Available,Type 1 Diabetes,"Dietary Supplement: benfotiamine, α-lipoic acid",intracellular advanced glycation endproducts|hexosamine pathway|prostacyclin synthase activity,Albert Einstein College of Medicine|Juvenile Diabetes Research Foundation|National Institutes of Health (NIH),Male,18 Years to 45 Years   (Adult),Not Applicable,21,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CCI#: 2004-582|JDRF grant #8-2003-784|GCRC grant # MO1-RR12248,Feb-05,Oct-06,Feb-08,24-Jun-08,null,24-Jun-08,"GCRC, Albert Einstein College of Medicine, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT00703989
NCT00703599,Safety and Efficacy of Autologous Adipose-Derived Stem Cell Transplantation in Patients With Type 1 Diabetes,,Unknown status,No Results Available,Type 1 Diabetes Mellitus,Procedure: Autologous Adipose-derived Stem cells,"Lowering of insulin-dependence and anti-hyperglycemic medication dosages|Lowering of glycosylated hemoglobin (HbA1C).|Increased circulating C-Peptide levels|Increased general well-being of patients.|No detrimental change seen in kidney function tests, liver function tests and other haematological parameters.",Adistem Ltd,All,"16 Years to 60 Years   (Child, Adult)",Phase 1|Phase 2,30,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Ad-003,Nov-07,Nov-09,Dec-09,23-Jun-08,null,1-Jul-08,"Beverly Hills Medical Group, Makati City, Manila, Philippines|Veterens Memorial Medical Centre, Quezon City, Manila, Philippines",,https://ClinicalTrials.gov/show/NCT00703599
NCT00700908,Impact of an Automated Telephone Intervention on Glycosylated Hemoglobin (HbA1c) in Type 2 Diabetes,,Completed,No Results Available,Type 2 Diabetes,Behavioral: automated telephone intervention vs. usual care,Change in HbA1c|Change in adherence to SMBG frequency,University of Minnesota - Clinical and Translational Science Institute|Novo Nordisk A/S,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,120,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0701M99406,Jun-07,Jun-08,Jun-08,19-Jun-08,null,22-Feb-13,"Primary Care Center University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00700908
NCT00700622,Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks,,Terminated,Has Results,"Diabetes, Type 1",Drug: Technosphere Insulin|Drug: Insulin glargine|Drug: Insulin lispro,Change From Baseline in HbA1c to Week 16,Mannkind Corporation,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,130,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MKC-TI-117,May-08,Nov-09,Mar-10,18-Jun-08,16-Oct-14,16-Oct-14,"Diabetes/Lipid Management and Research Center, Huntington Beach, California, United States|The Whittier Institute for Diabetes Clinical Trials, La Jolla, California, United States|Dorothy L & James E Frank Diabetes Research Institute, San Mateo, California, United States|Barbara Davis Center for Diabetes Young Adult Clinic, Aurora, Colorado, United States|University of Miami Diabetes Research Institute, Miami, Florida, United States|University of Miami School of Medicine, Miami, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Deaconess Billings Clinic Research Center, Billings, Montana, United States|Mountain Diabetes & Endocrine Center, Asheville, North Carolina, United States|Endocrine Research Physicians East PA, Greenville, North Carolina, United States|Your Diabetes Endocrine Nutrition Group, Inc., Mentor, Ohio, United States|OHSU Diabetes Center Research Oregon Health & Science University, Portland, Oregon, United States|AM Diabetes and Endocrinology Center, Barrtlett, Tennessee, United States|Dallas Diabetes & Endocrine Center, Dallas, Texas, United States|Baylor Endocrine Center, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Diabetes Research Center -Fletcher Allen Health Care, South Burlington, Vermont, United States|Diabetes Care Center, Seattle, Washington, United States|Centro de Pesquisas em Diabetes Ltda, Porto Alegre, RS, Brazil|CPClin-Centro de Pesquisas Clinicas, Sao Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT00700622
NCT00694122,Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon,DAWN,Completed,Has Results,Type 1 Diabetes|Dawn Phenomenon,Drug: Lantus (glargine),Blood Glucose Area Under the Curve (AUC)|Blood Glucose|Insulin Dose|Cortisol|Glucagon|Growth Hormone,Massachusetts General Hospital|Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,27,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2005-P-002515/24,Jun-05,Nov-10,Nov-10,10-Jun-08,21-Oct-14,21-Oct-14,"Massachusettes General Hospital/ Diabetes Research Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00694122
NCT00692562,Simultaneous Islet-Kidney Transplantation in Patients of Type 1 Diabetes With End-stage Renal Disease,,Completed,No Results Available,Type 1 Diabetes Mellitus|End-stage Renal Disease,Procedure: simultaneous islet-kidney transplantation,Exogenous insulin requirement|kidney function|Hemoglobin A1c|Glucose and C-peptide levels|Portal vein Ultrasound|liver function|Complete Blood Count|autoantibodies,Fuzhou General Hospital,All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,7,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SIK2005,Jun-05,Dec-06,Dec-07,6-Jun-08,null,16-Sep-11,"Fuzhou General Hospital, Fuzhou, Fujian, China",,https://ClinicalTrials.gov/show/NCT00692562
NCT00690066,PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM),,Completed,No Results Available,"Type 1 Diabetes Mellitus|Type 1 Diabetes|Diabetes Mellitus, Insulin-Dependent|Juvenile Diabetes",Drug: PROCHYMAL®|Drug: Placebo,C-peptide AUC response (MMTT)|Peak C-peptide response (MMTT)|Basal C-peptide response|Total daily insulin dose (units/kg)|Glycosylated hemoglobin (HbA1c) levels|Number of severe and documented hypoglycemic events|Changes in levels of GAD or IA-2 autoantibodies,"Mesoblast International Sàrl|Juvenile Diabetes Research Foundation|Mesoblast, Ltd.",All,"12 Years to 35 Years   (Child, Adult)",Phase 2,63,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",901,Jun-08,Dec-10,Dec-11,4-Jun-08,null,4-Dec-14,"University of Alabama, Division of Endocrinology & Metabolism, Birmingham, Alabama, United States|Scripps Whittier Diabetes Institute, LaJolla, California, United States|Stanford University, Stanford, California, United States|University of Florida, Gainesville, Florida, United States|Diabetes Research Institute, Miami, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|University of Minnesota, Minneapolis, Minnesota, United States|Desert Endocrinology CRC, Henderson, Nevada, United States|Nevada Alliance Against Diabetes, Las Vegas, Nevada, United States|University of North Carolina Diabetes Care Center, Chapel Hill, North Carolina, United States|American Health Research, Inc., Charlotte, North Carolina, United States|The Lindner Clinical Trial Center, Cincinnati, Ohio, United States|Providence Health Partners - Center for Clinical Research, Dayton, Ohio, United States|Cumberland Valley Endocrinology, Carlisle, Pennsylvania, United States|AM Diabetes & Endocrinology Center, Bartlett, Tennessee, United States|The University of Texas Southwestern Medical Center, Dallas, Texas, United States|Optimum Clinical Research, Inc., Salt Lake City, Utah, United States|The Strelitz Diabetes Center, Eastern VA Medical School, Norfolk, Virginia, United States|University of Wisconsin Health- West Clinic, Madison, Wisconsin, United States|Clinical and Transitional Science Institute, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00690066
NCT00688701,GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy,GETGOAL-MONO,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Lixisenatide (AVE0010)|Drug: Placebo|Device: Pen auto-injector,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12|Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) at Week 12|Change From Baseline in Body Weight at Week 12|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12|Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 12|Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 12|Percentage of Patients Requiring Rescue Therapy During the Double-Blind Treatment Period,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,361,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFC6018|EudraCT 2007-005887-29,May-08,Dec-09,Dec-09,3-Jun-08,12-Dec-16,12-Dec-16,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Diegem, Belgium|Sanofi-Aventis Administrative Office, Mumbai, India|Sanofi-Aventis Administrative Office, Natanya, Israel|Sanofi-Aventis Administrative Office, Tokyo, Japan|Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of|Sanofi-Aventis Administrative Office, Mexico, Mexico|Sanofi-Aventis Administrative Office, Warszawa, Poland|Sanofi-Aventis Administrative Office, Bucuresti, Romania|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Megrine, Tunisia|Sanofi-Aventis Administrative Office, Kiev, Ukraine",,https://ClinicalTrials.gov/show/NCT00688701
NCT00689026,Efficacy of Lubiprostone in Combination With Standard PEG Preparation,,Terminated,Has Results,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Drug: Lubiprostone|Other: Polyethylene glycol with electrolytes,The Percentage of Patients That Received a Quality of Colonoscopy Preparation Rating of <=2 on a 5 Point Likert Scale.,"Augusta University|Takeda Pharmaceuticals North America, Inc.",All,"50 Years and older   (Adult, Older Adult)",Not Applicable,60,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic,MCG 08-02-186,May-08,Mar-10,Mar-10,3-Jun-08,20-Oct-14,20-Oct-14,"Medical College of Georgia, Augusta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT00689026
NCT00688363,Blood Glucose Self Monitoring and HbA1c Effects on Glucose Control,,Completed,No Results Available,Type 2 Diabetes,Procedure: weekly blood glucose profile|Procedure: three-monthly haemoglobin A1c|Procedure: no blood-glucose self-control,"Haemoglobin A1c after one year|a representative blood glucose profile (self monitoring) during the week before the end of the trial|body weight at the end of the trial|serum, triglycerides and cholesterol (total HDL as well as LDL-cholesterol) at the end of the trial|therapy-satisfaction (questionnaire)|changes of the antidiabetic therapy|number of hospitalization as a result of hypoglycaemic episodes|the number of serious hypoglycaemic episodes (hypoglycaemic episodes when the patient needs help from other people)",Deutsche Diabetes Gesellschaft|Bayer,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 4,300,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,KKS 2003-Nauck-01,Feb-03,Sep-08,Dec-08,2-Jun-08,null,1-Aug-11,"Diabeteszentrum Bad Lauterberg, Bad Lauterberg, Niedersachsen, Germany|Koch, Peter, Bad Harzburg, Germany|Maxeiner, Stefan, Bad Kreuznach, Germany|Friedrichs, Michael, Bad Lauterberg, Germany|Jödicke, Carmen, Bad Lauterberg, Germany|Mulch-Wiemer, Christa, Bad Nauheim, Germany|Bellmann, Renate, Berlin, Germany|Schoch, Daniela, Berlin, Germany|Warmers, Ulrike, Bitburg, Germany|Leupold, Manfred, Borna, Germany|Kamke, Wolfram, Burg/Sreewald, Germany|Hildebrandt, Rüdiger, Clausthal-Zellerfeld, Germany|Lemmerhirt, Jürgen, Cuxhaven, Germany|Preuß, Uwe, Datteln, Germany|Weller, Ulrich, Dorsten, Germany|Fischer, Harald, Düren, Germany|Krege, Peter, Emsdetten, Germany|Gölz, Stefan, Esslingen, Germany|Wollersen, Karin, Freiburg, Germany|Hendel, Andreas, Grassau, Germany|Pfeiffer, Martha, Gronau, Germany|Jäger, Michael, Höchst, Germany|Müller, Ulrich. A., Jena, Germany|Niemetz, Ingo, Kassel, Germany|Schmitz, Ulrike, Krefeld, Germany|Kourbanova, Zarema, Langenfeld, Germany|Willms, Gerhard, Leverkusen, Germany|Ley, Heinz-Georg, Marl, Germany|Grossmann, J., Mönchengladbach, Germany|Füchtenbusch, Martin, München, Germany|Fueting, Frank, Nassau, Germany|Behnke, Thomas, Neuwied, Germany|Böhme, Rainer, Nordhausen, Germany|Fels, Stefan, Oldenburg, Germany|Klein, Frank, Schenklengsfeld, Germany|Naumann, Rainer, Schöppenstedt, Germany|Rieth-Kunert, Anna, Stade, Germany|Nowack, Kirsten, Torgau, Germany|Schmidt-Reinwald, Astrid, Waldrach, Germany|Bödecker, A.-W., Wiehl, Germany|Oerter, Erika-Maria, Würzburg, Germany",,https://ClinicalTrials.gov/show/NCT00688363
NCT00684658,TEENCOPE: An Internet Coping Skills Training Program for Teens With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Behavioral: TeenCope|Behavioral: Managing Diabetes,Hemoglobin A1c (HbA1c)|Pediatric Quality of Life Inventory (PedsQL)|Perceived Stress Scale (PSS)|Self-Efficacy for Diabetes Scale|Children's Depression Inventory|Self-Perception Profile for Adolescents|Responses to Stress Questionaire (RSQ)|Diabetes Family Behavior Scale|Self Management of Type 1 Diabetes|Diabetes Conflict,Yale University|National Institute of Nursing Research (NINR),All,11 Years to 14 Years   (Child),Phase 3,320,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R01NR004009,May-08,May-12,May-12,26-May-08,null,18-Oct-12,"University of Arizona, Tucson, Arizona, United States|Yale University School of Nursing, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00684658
NCT00682903,Use of a Bearable Continuous Interstitial Glucose Monitoring Device (GuardianR) During Teaching Sessions to Functional Insulin Therapy Concept in Patients Suffering From Type 1 Diabetes: Evaluation at 6 and 12 Months,,Completed,No Results Available,Diabetes Complications,Device: GuardianR,"The HbA1c, the witness of the quality of the metabolic balance, in 6 and 12 months. We shall compare the deltae of HbA1c between the period of inclusion and 6 and 12 months following the training course in the ""fonctional"" insulin therapy",Assistance Publique Hopitaux De Marseille,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,64,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2007/24,Jan-08,Feb-11,Feb-11,23-May-08,null,28-Aug-14,"CHU timone, Marseille, Bouches du Rhone, France",,https://ClinicalTrials.gov/show/NCT00682903
NCT00678886,Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1,DEFEND-1,Completed,Has Results,"Diabetes Mellitus, Type 1",Biological: otelixizumab infusion plus physician determined standard of care|Biological: placebo infusion plus physician determined standard of care,"Change From Baseline in 2-hour Mixed Meal Stimulated C-peptide Area Under Curve [AUC] (Normalized for 120-minute Time Interval) at Month 12|Number of Participants Who Were Responders for (Glycosylated Hemoglobin) HbA1c/Insulin Use Response at Week 12 and Months 6 and 12|Mean Daily Insulin Use at Week 12 and Months 6 and 12.|HbA1c Level at Week 12 and Months 6 and 12|Number of Hypoglycemic Events Defined by Hypoglycemic Event Categories From Baseline Upto Month 12|Number of Participants With Hypoglycemic Events Defined by Hypoglycemic Event Categories From Baseline Upto Month 12|Number of Hypoglycemic Excursions (<=70 mg/dL) With Most Complete Glucose at Week 12 and Months 6 and 12.|Magnitude of Greatest Hypoglycemic Excursions With Most Complete Glucose at Week 12 and Months 6 and 12.|Number of Participants With Hypoglycemic Excursions With Most Complete Glucose at Week 12 and Months 6 and 12|Number of Hyperglycemic Excursions With Most Complete Glucose at Week 12 and Months 6 and 12.|Magnitude of Greatest Hyperglycemic Excursions With Most Complete Glucose at Week 12 and Months 6 and 12.|Number of Participants With Hyperglycemic Excursions With Most Complete Glucose at Week 12 and Months 6 and 12|Change From Baseline in Average Daily Risk Range (ADRR) at Week 12 and Months 6 and 12.|Composite Rank Summary for HbA1c and Exogenous Insulin Use at Month 6 and Month 12|Composite Rank Summary for C-Peptide AUC, HbA1c and Exogenous Insulin Use at Month 6 and Month 12|Change From Baseline in Level of Cytokines Interleukin (IL-6), IL-10 and Tumor Necrosis Factor-alpha (TNF-a) at Day 1, Day 4, Day 8|Percent Change From Baseline in Circulating Peripheral Lymphocytes CD4+CD25+FoxP3+ T Cells and CD4+CD25hiFoxP3+ T Cells in Type 1 Diabetes Mellitus (TIDM) up to Month 12|Percent Change From Baseline in Cell-bound Otelixizumab on CD4+ T Cells at Day 1, Day 4, Day 8|Percent Change From Baseline in CD3/TCR Saturation on CD4+ T Cells and CD8+ T Cells at Day 1, Day 4, Day 8|Percent Change From Baseline in CD3/TCR Modulation on CD4+ T Cells and CD8+ T Cells at Day 1, Day 4, Day 8",GlaxoSmithKline|Juvenile Diabetes Research Foundation,All,"12 Years to 45 Years   (Child, Adult)",Phase 3,272,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",115495|TRX4006,29-Jul-08,31-Jan-12,31-Jan-12,16-May-08,3-Oct-17,3-Oct-17,"GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Costa Mesa, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Riverside, California, United States|GSK Investigational Site, Santa Ana, California, United States|GSK Investigational Site, Torrance, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Aurora, Colorado, United States|GSK Investigational Site, Washington, D.C., District of Columbia, United States|GSK Investigational Site, Boca Raton, Florida, United States|GSK Investigational Site, Jupiter, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Pembroke Pines, Florida, United States|GSK Investigational Site, Trinity, Florida, United States|GSK Investigational Site, Winter Park, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Honolulu, Hawaii, United States|GSK Investigational Site, Boise, Idaho, United States|GSK Investigational Site, Idaho Falls, Idaho, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Baltimore, Kansas, United States|GSK Investigational Site, Topeka, Kansas, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Worcester, Massachusetts, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Kalamazoo, Michigan, United States|GSK Investigational Site, Gulfport, Mississippi, United States|GSK Investigational Site, Columbia, Missouri, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Neptune City, New Jersey, United States|GSK Investigational Site, Buffalo, New York, United States|GSK Investigational Site, Mineola, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Rochester, New York, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Dayton, Ohio, United States|GSK Investigational Site, Mentor, Ohio, United States|GSK Investigational Site, Tulsa, Oklahoma, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Langhorne, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Rapid City, South Dakota, United States|GSK Investigational Site, Chattanooga, Tennessee, United States|GSK Investigational Site, Memphis, Tennessee, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Hurst, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Schertz, Texas, United States|GSK Investigational Site, Ogden, Utah, United States|GSK Investigational Site, Tacoma, Washington, United States|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Oakville, Ontario, Canada|GSK Investigational Site, Smiths Falls, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Pointe-Claire, Quebec, Canada|GSK Investigational Site, Arhus C, Denmark|GSK Investigational Site, Tampere, Finland|GSK Investigational Site, Turku, Finland|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Bad Nauheim, Hessen, Germany|GSK Investigational Site, Bad Lauterberg, Niedersachsen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Latina, Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Monserrato, Sardegna, Italy|GSK Investigational Site, Palermo, Sicilia, Italy|GSK Investigational Site, Milano, Italy|GSK Investigational Site, Roma, Italy|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Gerona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Sant Joan, Spain|GSK Investigational Site, Tarrasa, Barcelona, Spain|GSK Investigational Site, Göteborg, Sweden|GSK Investigational Site, Halmstad, Sweden|GSK Investigational Site, Harnosand, Sweden|GSK Investigational Site, Karlskrona, Sweden|GSK Investigational Site, Karlstad, Sweden|GSK Investigational Site, Kristianstad, Sweden|GSK Investigational Site, Motala, Sweden|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Umeå, Sweden|GSK Investigational Site, Växjö, Sweden|GSK Investigational Site, Bath, Somerset, United Kingdom|GSK Investigational Site, Blackburn, United Kingdom|GSK Investigational Site, Bristol, United Kingdom|GSK Investigational Site, Hull, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Newcastle upon Tyne, United Kingdom",,https://ClinicalTrials.gov/show/NCT00678886
NCT00679042,Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol,,"Active, not recruiting",No Results Available,Type 1 Diabetes Mellitus,Drug: Islets of Langerhans transplantation,"Safety: Incidence and severity of events related to islet infusion, immunosuppression, and islet preparations|The proportion of subjects with an HbA1c ≤ 6.5% and free of severe hypoglycemic events|Insulin independence|Hypoglycemic episodes by HYPO score|Glucose variability and hypoglycemia duration",CellTrans Inc.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,50,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IND11807-2007-0330,Jun-07,Jul-17,Jul-27,16-May-08,null,24-Jan-19,"University of Illinois at Chicago Medical Center, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00679042
NCT00675311,Remote Monitoring in Diabetes Disease Management,,Completed,No Results Available,Type 1 Diabetes|Type 2 Diabetes,Behavioral: DM-Standard|Behavioral: Disease Management Plus,"The primary study measures for this study include glycemic control and LDL levels, satisfaction with diabetes care, and adherence to diabetes medications and self-monitoring recommendations|Secondary measures include diabetes-related health-care utilization and physiologic data.",LifeScan,All,18 Years to 64 Years   (Adult),Not Applicable,300,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7021,Mar-08,Dec-09,Dec-09,9-May-08,null,18-Dec-09,"Marietta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT00675311
NCT00674466,A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Who Are Currently on Metformin Monotherapy,,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: 1.5 mg or 2.0 mg CJC-1134-PC|Drug: Placebo,Reduction of HbA1c From Baseline|Reduction in Fasting Plasma Glucose From Baseline|Reduction in Fasting Body Weight From Baseline,ConjuChem,All,"25 Years and older   (Adult, Older Adult)",Phase 2,90,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DM200-102,Mar-08,Nov-08,Nov-08,7-May-08,2-Jun-17,2-Jun-17,"Maggie Wang, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00674466
NCT00672204,Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes,RAPTIVA,Terminated,Has Results,Type 1 Diabetes Mellitus|Hypoglycemia,Biological: Allogeneic islets of Langerhans transplant|Drug: Raptiva|Drug: Sirolimus|Drug: anti-thymocyte globulin,The Proportion of Insulin-independent Subjects With Full Islet Graft Function,University of Minnesota - Clinical and Translational Science Institute|Juvenile Diabetes Research Foundation,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,23,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0612M98726,Nov-07,Dec-10,Aug-12,6-May-08,27-Mar-13,25-Oct-17,"Universtiy of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00672204
NCT00668850,Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin,,Unknown status,No Results Available,Diabetes Mellitus,Drug: Generex Oral-lyn™|Drug: Regular human insulin,"To compare the efficacy of Generex Oral-lyn™ RapidMist™ System and standard regular human insulin therapy as measured by HbA1c, in type-1 diabetes mellitus subjects on BID NPH intermediate acting insulin therapy|To evaluate the safety, tolerability, and satisfaction with Generex Oral-lyn™ therapy when administered by the RapidMist™ Diabetes Management System","Generex Biotechnology Corp.|OSMOS Clinical Research, Inc|PSI Pharma Support Intl|Nextrials, Inc.|eResearch Technology, Inc.|Hoffmann-La Roche|ACM Pivotal Global Central Laboratory",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,500,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GEN-084-OL,Apr-08,Aug-11,Sep-11,29-Apr-08,null,8-Jun-11,"Coastal Biomedical Research Inc. at Santa Monica, 2001 Santa Monica Blvd Suite 390W, California, United States|The Center for Diabetes & Endocrine Care at Hollywood, 1150 N. 35th Ave Suite 590, Florida, United States|Physicians Research Group at Indianapolis, 7400 North Shadeland Ave, Indiana, United States|MODEL Clinical Research at Baltimore, 6535 North Charles Street Suite 400N, Maryland, United States|Grunberger Diabetes Institute at Bloomfield Hills, 43494 Woodward Ave Suite 208, Michigan, United States|Beth Israel Medical Center, Geral J. Friedman Diabetes Institute at New York, 317 East 17th Street Room 7F05 8th Floor, New York, United States|Multiple Health Research, LLC. at Arlington, 501 Rita Lane Suite 113, Texas, United States|University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Texas, United States|University Multiprofile Hospital for Active Treatment ""Aleksandrovska"", 1 St. Georgi Sofiysky St, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment at Varna, 1 Hristo Smirnensky St, Bulgaria|Multiprofile Hospital for Active Treatment at Stara Zagora, 11 Armeyska St., Bulgaria|University Multiprofile Hospital for Active Treatment at Plovdiv, 15A Vassil Aprilov Blvd, Bulgaria|Multiprofile Hospital for Active Treatment at Ruse, 2 Nezavisimost St, Bulgaria|University Multiprofile Hospital for Active Treatment at Pleven, 8A Georgi Kotchev St, Bulgaria|The Bailey Clinic at Red Deer, #108 3947 50A Avenue, Alberta, Canada|Calgary Metabolic Education & Research Centre at Calgary, #23, 4411-16th Avenue NW, Alberta, Canada|West Edmonton Diabetes Centre, 10230 142 St Nw # 25, Edmonton, Alberta, Canada|Instituto de Endocrinologia IEMYR, Avenida La Coruña Nº 6337 y San Ignacio, Quito, Ecuador|Bydgoszcz Diabetology and Endocrinology Center at Bydgoszcz, ul. Baczynskiego 17, Poland|OSTEOMED Medical Center at Warszawa, ul. Bialobrzeska 40A, Poland|Chair and Department of Internal Medicine and Diabetology, Voivodship Brodnowski Hospital at Warszawa, ul. Kondratowicza 8, Poland|Diabetology Clinic for Adults, NZOZ Elblag Diabetology Center, ul. Krolewiecka 146, Poland|TeMeD - Clinical Trials at Rzeszow, ul. Mazowiecka 56, Poland|Provincial Centre of Diabetology and Metabolic Diseases, M.Pirogow Provincial Specialist Hospital at Lodz, ul. Nowa 30/32, Poland|Silesia Osteoporosis Center at Katowice, ul. Opolska 11/3, Poland|TeMeD - Clinical Trials at Nowy Targ, ul. Wojska Polskiego 14, Poland|NZOZ Specialist Centre of Internal Medicine and Diabetology Malgorzata Arciszewska at Bialystok, ul. Zamenhofa 10/20, Poland|Celis Aguilera 10B, Fajardo, Puerto Rico|Puerto Medical Center, San Juan, Puerto Rico|Clinical Research, Puerto Rico, San Juan, Puerto Rico|""Nicolae Malaxa"" Clinical Hospital, Department of Diabetes, Nutrition and Metabolic Diseases at Bucharest, 12 Vergului St Sector 2, Romania|Timisoara Emergency Clinical County Hospital, Clinic of Diabetes, Nutrition and Metabolic Diseases at Timisoara, 156 Iosif Bulbuca Av, Romania|Satu Mare County Hospital, Department of Diabetology and Nutrition Diseases at Satu Mare, 2-3 Eroii Revolutiei Square, Romania|Private Practice at Galati, 25 Constructorilor St, Bl. E5/64, Romania|Cluj Emergency Clinical County Hospital, Department of Diabetes, Nutrition and Metabolic Diseases at Cluj-Napoca, 3-5 Clinicilor St, Romania|Oradea Clinical County Hospital, Department of Diabetes, Nutrition and Metabolic Diseases at Oradea, 33 Republicii St, Romania|National Institute of Diabetes, Nutrition and Metabolic Diseases, 1st Clinical Department of Diabetes, Nutrition and Metabolic Diseases at Bucharest, 5-7 Ion Movila St Sector 2, Romania|Cardiology Private Practice at Bala Mare, 6/72 Independentei St, Romania|Private Practice Nicodiab SRL at Bucharest, 92 Polona St, Bl 17 A+B, Sc. 1, Ap. 2, Romania|Municipal Medical Institution: City Hospital # 2, Municipal Diabetology and Rehabilitation Center, 1 3rd -Transportnaya str., Omsk, Russian Federation|St. Petersburg State Medical Institution: St. George Municipal Hospital, 1 Severny Pr., St.Petersburg, Russian Federation|Municipal Medical Institution: Medical Unit ""Izhmash"", Municipal Endocrinology Center, 1 Truda str., Izhevsk, Russian Federation|St. Petersburg State Medical Institution: Municipal Consulting and Diagnostic Center #1, St. Petersburg Territorial Diabetology Center, 10 Siqueirosa str., St. Petersburg, Russian Federation|Federal State Institution: Endocrinology Research Center under the Federal Agency for High-Tech Medical Care, Department of Therapeutic and Surgical Methods for Treatment of Diabetic Foot, 11 Dmitriya Ulyanova str., Moscow, Russian Federation|Federal State Institution: Endocrinology Research Center under the Federal Agency for High-Tech Medical Care, Department of Training and Psychosocial Rehabilitation of Patients with Diabetes Mellitus, 11 Dmitriya Ulyanova str., Moscow, Russian Federation|St. Petersburg State Medical Institution: Municipal Hospital of St. Elizabeth, 14 Vavilovykh str., St. Petersburg, Russian Federation|State Medical Institution: Nizhny Novgorod Regional Clinical Hospital n.a. N.A. Semashko, 190 Rodionova str., Nizhny Novgorod, Russian Federation|Medical Institution Municipal Clinical Hospital #67, 2 ""b"" Salyama Adilya str., Moscow, Russian Federation|State Medical Institution: Kemerovo Regional Clinical Hospital, 22 Oktyabrsky Pr., Kemerovo, Russian Federation|State Medical Institution: Arkhangelsk Regional Clinical Hospital, 292 Lomonosova pr., Arkhangelsk, Russian Federation|State Medical Institution: Republican Hospital, 3 Pirogova str., Petrozavodsk, ,, Russian Federation|St. Petersburg State Medical Institution:Municipal Outpatient Clinic #51, 33/35 Kosmonavtov Pr., St. Petersburg, Russian Federation|Moscow State Medical Institution Municipal Clinical Hospital #68, 4 Shkuleva str., Moscow, Russian Federation|St. Petersburg State Medical Institution: City Aleksandrovskaya Hospital, 4 Solidarnosti Pr., St. Petersburg, Russian Federation|Federal State Medical Institution: All-Russia Center for Urgent Care and Radiation Medicine n.a. A.M. Nikiforov under the Russian Emergency Control Ministry, 4/2 Lebedeva str., St.Petersburg, Russian Federation|St. Petersburg State Medical Institution: Municipal Multifield Hospital #2, 5 Uchebny Per., St. Petersburg, Russian Federation|State Higher Educational Institution: Tyumen State Medical Academy under the Federal Agency for Healthcare and Social Development, Multifield Clinic, 54 Odesskaya str., Tyumen, Russian Federation|""Diabetes"" Center Company Limited, 56 Sovetskoi Armii str., Samara, Russian Federation|State Medical Institution: Consulting and Diagnostic Center of Komi Republic, Diabetology Center, 6 Kuratova str., 167981, Russian Federation|State Medical Institution: Murmansk Regional Consulting and Diagnostic Center, 6 Pavlova str., Building 4, Murmansk, Russian Federation|Municipal Medical Institution: Municipal Clinical Hospital #1, Municipal Diabetology Center, 6 Zalesskogo str., Novosibirsk, Russian Federation|State Higher Educational Institution: St. Petersburg State Medical University n.a. I.P. Pavlov under the Federal Agency for Healthcare and Social Development, 6/8 L. Tolstogo str., St. Petersburg, Russian Federation|State Institution: Moscow Regional Research Clinical Institute n.a. M.F.Vladimirsky, 61/2 Shchepkina str., Moscow, Russian Federation|State Higher Educational Institution: Ural State Medical Academy under the Federal Agency for Healthcare and Social Development; Family Medicine Clinic, 7 Kluchevskaya str., Ekaterinburg, Russian Federation|State Medical Healthcare Institution: Chelyabinsk Regional Clinical Hospital, 70 Vorovskogo str., Medgorodok, Chelyabinsk, Russian Federation|State Medical Institution:Territorial Endocrinology Center, Territorial Diabetology Center, 9 Artema str., Stavropol, Russian Federation|Regional Endocrinology Center, Diabetology Department at Lviv, 1, Ostrozskoho St., Lviv, Ukraine|Ukrainian Research and Development Center for Endocrine Surgery and Endocrine Organ and Tissue Transplantation under the Ministry of Health of Ukraine, General Endocrine Pathology Department at Kiev, 121, Kharkovskoe Shosse, Kiev, Ukraine|M.V. Sklifosovskyi Regional Clinical Hospital, Endocrinology Department at Poltava, 23, Shevchenko St., Ukraine|City Clinical Hospital #9, Endocrinology Department at Dnipropetrovsk, 29, Vorontsova St., Ukraine|M.O. Semashko Republican Clinical Hospital, Endocrinology Department at Simferopol, 69 Kievskaya St., Ukraine|V.P. Komisarenko Institute for Endocrinology and Metabolism under the Ukrainian Academy of Medical Sciences, Clinical Diabetology Department at Kiev, 69, Vyshgorodskaya St., Kiev, Ukraine|V.P. Komisarenko Institute for Endocrinology and Metabolism under the Ukrainian Academy of Medical Sciences, General Endocrine Pathology Department at Kiev, 69, Vyshgorodskaya St., Kiev, Ukraine|V.Ya. Danylevskyi Institute for Endocrine Pathology under the Ukrainian Academy of Medical Sciences, Clinical Endocrinology Department at Kharkov, Pomerky 27, Kharkov, Ukraine",,https://ClinicalTrials.gov/show/NCT00668850
NCT00665145,Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Diabetic Polyneuropathy",Drug: SB-509|Drug: Placebo,Stem cells circulating in peripheral blood|Safety and Efficacy of SB-509,Sangamo Therapeutics,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,23,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,SB-509-0703,Jan-08,Oct-09,Oct-09,23-Apr-08,null,1-Nov-12,"La Jolla,, California, United States|Walnut Creek, California, United States|Houston, Texas, United States|San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00665145
NCT00662519,Neulasta in Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Drug: Neulasta (Pegylated)|Drug: Placebo|Dietary Supplement: Mixed Meal Tolerance Test (MMTT)|Other: Blood test|Other: DNA Test,"Area Under the Curve C-peptide Changed Time 0, 12 weeks, 24 weeks, 48 weeks and 96 weeks.|Number of participants with adverse events|Hemoglobin A1c (HbA1c) levels have the same target distribution for treatment and placebo|Increase T regulatory cells (Treg) from the bone marrow",University of Florida|Juvenile Diabetes Research Foundation|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"12 Years to 45 Years   (Child, Adult)",Phase 1,21,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",UF IRB 280-2006|JDRF 11-2007-825|1R21DK078863-01A1|GCRC 683,Apr-08,Mar-14,Mar-14,21-Apr-08,null,9-Apr-15,"University of Florida, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT00662519
NCT00662857,A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro,,Completed,Has Results,Diabetes Mellitus: Type 1,Drug: Technosphere® Insulin Inhalation Powder|Drug: Technosphere Insulin® Inhalation Powder|Drug: RAA Population,Bioequivalence of Two 15 U Cartridges (TI Inhalation Powder A) and One 30 U Cartridge (TI Inhalation Powder B) Based on Baseline Corrected Insulin AUC0-360|Bioequivalence of Two 15 U Cartridges (TI Inhalation Powder A) and One 30 U Cartridge (TI Inhalation Powder B) Based on Baseline Corrected Insulin Cmax.|Bioequivalence of Two 15 U Cartridges (TI Inhalation Powder A) and One 30 U Cartridge (TI Inhalation Powder B) Based on Baseline Corrected Insulin Tmax|Relative Bioavailability of 30 U of TI (TI Inhalation Powder B) Versus 10 U of sc Insulin Lispro,Mannkind Corporation,All,18 Years to 60 Years   (Adult),Phase 2,29,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MKC-TI-116,Apr-08,Nov-08,Dec-08,21-Apr-08,16-Oct-14,16-Oct-14,"Profil Institute for Clinical Research Inc., Chula Vista, California, United States|Diabetes & Glandular Disease Research Assoc PA, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00662857
NCT00660998,Evaluation of Efficacy and Safety of Vardenafil in Patients With Erectile Dysfunction and Type 1 Diabetes,,Completed,No Results Available,Erectile Dysfunction,"Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo",Sexual Encounter Profile Question 2|Sexual Encounter Profile Question 3|International Index of Erectile Function - Erectile Function Domain|Safety and Tolerability,Bayer,Male,"18 Years and older   (Adult, Older Adult)",Phase 4,318,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",100540,Feb-03,null,Jan-04,18-Apr-08,null,11-Dec-14,,,https://ClinicalTrials.gov/show/NCT00660998
NCT00659165,Insulin Detemir Compared to Insulin Glargine: Appetite and Calories Consumed in Type 1 Diabetes,,Completed,Has Results,Diabetes Mellitus,Drug: Insulin Detemir|Drug: Insulin Glargine,Calories Consumed After Fast.,University of New Mexico,All,18 Years to 60 Years   (Adult),Not Applicable,10,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other",UNM HRRC # 08-043,Apr-08,Dec-10,Jan-11,16-Apr-08,5-Oct-11,22-Mar-18,"University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States",,https://ClinicalTrials.gov/show/NCT00659165
NCT00655603,Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of Glucagon-Like Peptide-1 (GLP-1) in Patients With Type 2 Diabetes Mellitus,,Unknown status,No Results Available,Type 2 Diabetes Mellitus,Other: Infusion of native hormones from the pancreas and gut (GLP-1),"Glucose turn-over|The inhibitory effect of GLP-1 on glucagon, and the role of this in its anti-diabetic potential, measured by looking at glucose turn-over.","University Hospital, Gentofte, Copenhagen|University of Copenhagen|Hvidovre University Hospital|Glostrup University Hospital, Copenhagen",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,H-C-2007-0072,Mar-08,May-09,Sep-09,10-Apr-08,null,6-Apr-09,,,https://ClinicalTrials.gov/show/NCT00655603
NCT00654121,Prevention of Clinical Onset of Type 1 Diabetes in High Risk First Degree Relatives,,Completed,No Results Available,"Diabetes, Type I",Drug: Actrapid HM,Fasting glycemia;|fasting and stimulated plasma C-peptide and proinsulin values;|islet cell autoantibodies;|body weight gain.,AZ-VUB|Novo Nordisk A/S,All,"5 Years to 39 Years   (Child, Adult)",Phase 2,112,Other|Industry,Interventional,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,EVDM IT 001,Feb-00,Apr-04,Nov-07,7-Apr-08,null,7-Apr-08,"Universitair Ziekenhuis Antwerpen, Antwerpen, Belgium|Academisch Ziekenhuis and Diabetes Research Center - Brussels Free University-VUB, Brussels, Belgium|Department of Endocrinology and Nephrology, UZ Gasthuisberg, Katholieke Universiteit Leuven -KUL, Leuven, Belgium",,https://ClinicalTrials.gov/show/NCT00654121
NCT00652288,Evaluation of Pharmacokinetics and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs,PK/PD,Completed,No Results Available,"Diabetes Mellitus, Type I",Drug: Insulin analogs (Lispro and Aspart)|Drug: Insulin analogs (Aspart and Detemir)|Drug: Insulin analogs (Lispro and Glargine),Maximum Glucose Infusion Rate (GIR) to maintain euglycemia|Time to Maximum Glucose Infusion Rate,Yale University,All,8 Years to 17 Years   (Child),Phase 1,36,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,403026582|JDRF Hypoglycemia Grant,Apr-07,Sep-11,Sep-11,3-Apr-08,null,1-Sep-16,,,https://ClinicalTrials.gov/show/NCT00652288
NCT00651105,Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects,,Completed,No Results Available,Type-2 Diabetes|Healthy,Drug: Vildagliptin|Drug: Placebo,"GLP-1 and non GLP-1 effects of LAF237 on glucagon secretion in patients with Type-2 diabetes and matching healthy subjects|Effects of LAF237 on prandial glucose profiles, prandial insulin, and gastric-emptying in patients with Type-2 diabetes and in matching healthy subjects.",Novartis,All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 3,63,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CLAF237A2347,Feb-08,May-09,null,2-Apr-08,null,18-Nov-16,"Novartis Investigator Site, Bad Lauterberg im Harz, Germany|Novartis Investigator Site, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT00651105
NCT00645840,Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Anakinra,Change in EGR2 expression in PBMCs upon treatment with anakinra in subjects with newly diagnosed type 1 diabetes|Effect size on preservation of C-peptide secretory capacity,University of Texas Southwestern Medical Center|Children's Medical Center Dallas,All,"6 Years to 18 Years   (Child, Adult)",Phase 1|Phase 2,15,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UTSW 112007-037,Mar-08,Sep-09,Sep-09,28-Mar-08,null,14-Jun-12,"Children's Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00645840
NCT00646724,Cotransplantation of Islet and Mesenchymal Stem Cell in Type 1 Diabetic Patients,,Unknown status,No Results Available,Type 1 Diabetes Mellitus,Biological: cotransplantation of islet and mesenchymal stem cell,Exogenous insulin requirement|Hemoglobin A1c|Glucose and C-peptide levels|liver function|kidney function|Portal vein Ultrasound|autoantibodies|Complete Blood Count,Fuzhou General Hospital,All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,fuzhough0712,Jan-08,Jan-12,Jan-14,28-Mar-08,null,16-Jun-11,"Fuzhou General Hospital, Fuzhou, Fujian, China",,https://ClinicalTrials.gov/show/NCT00646724
NCT00643110,Milk as Treatment for Hypoglycemia,,Withdrawn,No Results Available,Type 1 Diabetes,Drug: D50 glucose,Completion of 6 subjects.,Creighton University,All,"19 Years and older   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Rendell 01|Dairy Council - Rendell 01,Apr-08,Jan-09,Jan-09,26-Mar-08,null,25-Mar-15,"Creighton Diabetes Center, Omaha, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT00643110
NCT00644501,Long-Term Treatment Effect of DiaPep277 in Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Drug: DiaPep277,"Preservation of endogenous insulin secretion/beta-cell function, as measured by mixed-meal tolerance test stimulated C-peptide secretion.|improved metabolic control and the insulin dose required to maintain it.",Andromeda Biotech Ltd.,All,18 Years to 48 Years   (Adult),Phase 3,43,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,910,Sep-08,May-13,Jun-13,26-Mar-08,null,11-Jul-13,"Wolfson Medical Centre, Holon, Israel|Diabetic Unit, Hadassah Medical Center, Jerusalem, Israel|Schneider Children's Medical Centre, Petach Tikva, Israel",,https://ClinicalTrials.gov/show/NCT00644501
NCT00642278,"An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes",,Completed,Has Results,"Diabetes Mellitus, Type II|Diabetes Mellitus, Non Insulin Dependent",Drug: Canagliflozin (JNJ-28431754)|Drug: Sitagliptin|Drug: Placebo,Change in HbA1c From Baseline to Week 12|Change in Fasting Plasma Glucose (FPG) From Baseline to Week 12|Percentage of Patients With Symptoms of Hypoglycemia|Change in Overnight Urine Glucose/Creatinine Ratio From Baseline to Week 12|Absolute Change in Body Weight From Baseline to Week 12|Percent Change in Body Weight From Baseline to Week 12,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,451,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CR014587|28431754DIA2001,Apr-08,Jan-09,Jan-09,25-Mar-08,17-May-13,19-Jul-13,"Birmingham, Alabama, United States|Mesa, Arizona, United States|Tucson, Arizona, United States|Encinitas, California, United States|Lincoln, California, United States|Los Angeles, California, United States|Merced, California, United States|Roseville, California, United States|Denver, Colorado, United States|Golden, Colorado, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Boise, Idaho, United States|Nampa, Idaho, United States|Topeka, Kansas, United States|Haverhill, Massachusetts, United States|Cherry Hill, New Jersey, United States|Albuquerque, New Mexico, United States|New Hyde Park, New York, United States|Salisbury, North Carolina, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Portland, Oregon, United States|Greer, South Carolina, United States|Dallas, Texas, United States|Houston, Texas, United States|New Braunfels, Texas, United States|Odessa, Texas, United States|San Antonio, Texas, United States|Milwaukee, Wisconsin, United States|Buenos Aires, Argentina|Bueos Aires, Argentina|Pleven, Bulgaria|Sofia N/A, Bulgaria|Sofia, Bulgaria|Chilliwack, British Columbia, Canada|Coquitlam, British Columbia, Canada|Brampton, Ontario, Canada|Sarnia, Ontario, Canada|Toronto, Ontario, Canada|Pointe-Claire, Quebec, Canada|St Romuald, Quebec, Canada|Saskatoon, Saskatchewan, Canada|Olomouc 9, Czech Republic|Pisek 1, Czech Republic|Praha 28, Czech Republic|Praha 5, Czech Republic|Praha, Czech Republic|Bangalore, India|Hyderabad, India|Nagpur, India|Pune, India|Kota Bharu, Malaysia|Kuala Lumpur N/A, Malaysia|Kuala Lumpur, Malaysia|Ciudad De Mexico, Mexico|Mexico, Mexico|Monterrey, Mexico|Zapopan, Mexico|Bydgoszcz, Poland|Gdansk, Poland|Kutno 001, Poland|Lodz, Poland|Lublin N/A, Poland|Torun, Poland|Warszawa, Poland|Wroclaw, Poland|Ponce Pr, Puerto Rico|San Juan, Puerto Rico|Baia Mare, Romania|Brasov, Romania|Bucharest, Romania|Cluj, Romania|Galati, Romania|Ploiesti, Romania|Moscow N/A, Russian Federation|Moscow, Russian Federation|Saint Petersburg, Russian Federation|Samara, Russian Federation|St Petersburg N/A, Russian Federation|St-Petersburg, Russian Federation|Belfast, United Kingdom|Bolton, United Kingdom|Exeter, United Kingdom|Lincoln, United Kingdom",,https://ClinicalTrials.gov/show/NCT00642278
NCT00642538,A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: MKC253 Inhalation Powder|Drug: Technosphere Inhalation Powder|Drug: subcutaneous injection,AUC 0-240 min post-prandial serum glucose,Mannkind Corporation,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MKC-253-002|EudraCT #: 2007-003430-42,Feb-08,Sep-08,Sep-08,25-Mar-08,null,14-Jun-12,"University Medical Centre Groningen, Zuidlaren, Netherlands",,https://ClinicalTrials.gov/show/NCT00642538
NCT00642616,Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease,,Terminated,Has Results,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus|Moderate Chronic Obstructive Pulmonary Disease|Asthma,Drug: Technosphere® Insulin|Drug: Usual Care,Change in Post-bronchodilator FEV1 From Baseline to Week 52|Number of Participants With Asthma Exacerbation by Treatment Arm|Number of Participants With COPD Exacerbation by Treatment Arm|Change in HbA1C From Baseline to Week 52,Mannkind Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 3,34,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MKC-TI-134,Mar-09,Nov-14,Nov-14,25-Mar-08,15-Feb-16,14-Apr-17,"Mission Hills, California, United States|San Diego, California, United States|Palm Harbor, Florida, United States|Flint, Michigan, United States|Morehead City, North Carolina, United States|Medford, Oregon, United States|Greenville, South Carolina, United States|Spartanburg, South Carolina, United States|Dallas, Texas, United States|Dallas, Texas, United States|Federal Way, Washington, United States|Tacoma, Washington, United States|Yaroslavl, RUS, Russian Federation|Kemerovo, RU, Russian Federation|Moscow, RU, Russian Federation|St Petersburg, RU, Russian Federation|St. Petersburg, RU, Russian Federation|St. Petersburg, RU, Russian Federation|St. Petersburg, RU, Russian Federation|Kiev, UA, Ukraine|Kyiv, UA, Ukraine",,https://ClinicalTrials.gov/show/NCT00642616
NCT00639600,Transplantation of Pancreatic Islets in Patients With Type 1 Diabetes Mellitus and Functional Kidney Graft,GRAGIL1,Terminated,No Results Available,Type 1 Diabetes Mellitus,Procedure: human pancreatic islet transplantation,"Rate of insulin-independence at 6 and 12 months after transplantation, duration of insulin-independence, survival curves|Tolerance (Measurement of portal pressure during islet injection) Quality of life (Questionnaires SF-36 and DQOL at inclusion time, then every 6 months during their waiting period and then 6 months and 12 months after transplantation) Costs","University Hospital, Grenoble",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,21,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,95/CHUG/10/C2,Jun-08,May-10,May-10,20-Mar-08,null,31-May-10,"University Hospital, Besancon, France|University Hospital, Department of Endocrinology, Grenoble, France|University Hospital, Department of Endocrinology, Lyon, France|University Hospital, Department of Endocrinology, Montpellier, France|University Hospital, Department of Endocrinology, Nancy, France|University Hospital, Department of Endocrinology, Strasbourg, France|University Hospital, Department of Surgery, Geneva, Switzerland",,https://ClinicalTrials.gov/show/NCT00639600
NCT00639964,Exploration of the Lipid Metabolism During the Diabetic Pregnancies,DIAMANT,Completed,No Results Available,Pregnancy|Pregnancy in Diabetes|Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Other: blood tests|Other: diet questionnaire|Other: umbilical cord blood collect|Other: placenta collect,"fetal weight corrected by gestational age|cholesterol (total, HDL, LDL)|triglycerides|Apolipoprotein A/B rate|erythrocytary and plasmatic fatty acid distribution","University Hospital, Lille|Ministry of Health, France",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,186,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),2007/0714|2007-A00534-49|PHRC 2007/R1901|DGS 2007-0340,Jan-08,Jan-12,Dec-13,20-Mar-08,null,1-Jun-16,"CHRU, Lille, Lille, France",,https://ClinicalTrials.gov/show/NCT00639964
NCT00638313,Single-Dose Study Of PF-04603629 In Type 2 Diabetic Subjects,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Biological: Placebo|Biological: PF-04603629,"To characterize the pharmacokinetics of PF-04603629 in serum after administration, under fasted conditions, of single, escalating, subcutaneous doses of PF-04603629 to adult subjects with T2DM.|To characterize the pharmacodynamic effect (glucose AUC lowering) of single, escalating, subcutaneous doses of PF-04603629 administered to adult subjects with T2DM.|To evaluate the safety and tolerability of escalating, single subcutaneous doses of PF-04603629 administered to adult subjects with T2DM.|No secondary outcomes listed in the protocol.",Pfizer,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,71,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",B0571001,Aug-07,null,Feb-08,19-Mar-08,null,31-Jul-09,"Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00638313
NCT00638716,A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus Who Are Currently on Metformin Monotherapy,DM200-101,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: CJC-1134-PC|Drug: Placebo,Reduction of HbA1c From Baseline|Reduction in FPG From Baseline|Reduction in Fasting Body Weight From Baseline,ConjuChem,All,"25 Years and older   (Adult, Older Adult)",Phase 2,122,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DM200-101,Feb-08,Nov-08,Nov-08,19-Mar-08,2-Jun-17,2-Jun-17,"ConjuChem Biotechnologies Inc., Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00638716
NCT00637338,Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus,,Terminated,No Results Available,"Diabetes Mellitus, Type 2",Biological: PF-04603629|Biological: Placebo,"To characterize the pharmacokinetics of PF-04603629 in serum after administration of escalating, multiple, subcutaneously injected doses of PF-04603629 to subjects with T2DM.|To evaluate the effects of multiple, escalating, subcutaneously injected doses of PF-04603629, on the pharmacodynamic responses of glucose, insulin, C-peptide and glucagon during a mixed meal tolerance test (MMTT).|To describe the safety and tolerability of escalating, multiple, subcutaneously injected doses of PF-04603629 administered to subjects with T2DM.|To evaluate the effect of multiple, escalating, subcutaneously injected doses of PF-04603926 on additional exploratory efficacy biomarkers related to this drug's target in subjects with T2DM.",Pfizer,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,42,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",B0571002,Apr-08,Sep-08,Sep-08,17-Mar-08,null,31-Jul-09,"Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Wichita, Kansas, United States|Pfizer Investigational Site, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT00637338
NCT00634842,Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily,TITRATE™,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin detemir,"Percentage of Participants Achieving Glycosylated Haemoglobin A1c (HbA1c) Less Than 7%|Percentage of Participants Achieving Glycosylated Haemoglobin A1c (HbA1c) Less Than or Equal to 6.5%|Change in Glycosylated Haemoglobin A1c (HbA1c) Percentage From Baseline|Incidence of Hypoglycaemic Episodes (All, Major, Minor and Symptoms Only)",Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 4,244,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN304-3502,Feb-08,Oct-08,Oct-08,13-Mar-08,22-Dec-09,10-Mar-17,"Novo Nordisk Investigational Site, Goodyear, Arizona, United States|Novo Nordisk Investigational Site, Scottsdale, Arizona, United States|Novo Nordisk Investigational Site, Searcy, Arkansas, United States|Novo Nordisk Investigational Site, Artesia, California, United States|Novo Nordisk Investigational Site, Escondido, California, United States|Novo Nordisk Investigational Site, Fullerton, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Orange, California, United States|Novo Nordisk Investigational Site, Spring Valley, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Parker, Colorado, United States|Novo Nordisk Investigational Site, Norwalk, Connecticut, United States|Novo Nordisk Investigational Site, Prospect, Connecticut, United States|Novo Nordisk Investigational Site, Boca Raton, Florida, United States|Novo Nordisk Investigational Site, Clearwater, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Lake Mary, Florida, United States|Novo Nordisk Investigational Site, Plantation, Florida, United States|Novo Nordisk Investigational Site, Athens, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Savannah, Georgia, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Terre Haute, Indiana, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, New Orleans, Louisiana, United States|Novo Nordisk Investigational Site, Pikesville, Maryland, United States|Novo Nordisk Investigational Site, St. Paul, Minnesota, United States|Novo Nordisk Investigational Site, Chesterfield, Missouri, United States|Novo Nordisk Investigational Site, St. Louis, Missouri, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Berlin, New Jersey, United States|Novo Nordisk Investigational Site, Camden, New Jersey, United States|Novo Nordisk Investigational Site, Lawrenceville, New Jersey, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, Staten Island, New York, United States|Novo Nordisk Investigational Site, West Seneca, New York, United States|Novo Nordisk Investigational Site, Shelby, North Carolina, United States|Novo Nordisk Investigational Site, Statesville, North Carolina, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Dayton, Ohio, United States|Novo Nordisk Investigational Site, Dayton, Ohio, United States|Novo Nordisk Investigational Site, Mentor, Ohio, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, United States|Novo Nordisk Investigational Site, Altoona, Pennsylvania, United States|Novo Nordisk Investigational Site, Norristown, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Spartanburg, South Carolina, United States|Novo Nordisk Investigational Site, Taylors, South Carolina, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Midland, Texas, United States|Novo Nordisk Investigational Site, Odessa, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States|Novo Nordisk Investigational Site, Caguas, Puerto Rico|Novo Nordisk Investigational Site, San Juan, Puerto Rico|Novo Nordisk Investigational Site, Trujillo Alto, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00634842
NCT00629304,Multicenter Assessment of the PDA-FIT System in Type 1 Diabetic Patients,TELEDIAB-1,Completed,No Results Available,Type 1 Diabetes,Device: placebo|Device: VISITS + PDA-FIT system|Device: PDA-FIT System + telephone follow-up,"Comparison of HbA1c mean between the 3 groups|Absolute HbA1c differences (M0-M6)|HbA1c changes at M0, M3 and M6|Percentage of patients reaching HbA1c <7.5% at 6 months|Mean of blood glucose values as provided by glucose meters during the 14 days prior to inclusion and prior to the 6 months-visit|Frequency of severe hypoglycaemic episodes and ketoacidosis episodes during the study period|Frequency of symptomatic benign hypoglycaemic episodes during the week prior to inclusion and prior to the 6 months-visit|8-point blood glucose profiles at inclusion and 6 months|Quality of life at inclusion and 6 months, using the DHP scale and the Satisfaction item of the DQOL questionnaire|Improvement in diabetes care, as assessed by the change in blood glucose testing frequency, reflected by the glucose meter memory|Time spent by physicians with patients during visits (either face to face visits or phone call visits) and time spent by patients during transport, waiting time and lost working time|Satisfaction of patients and physicians with the system and willingness to carry on the use of the system in routine care|Effective number of patients carrying on the use of the system in routine care, at their own expense and in agreement with their physician","Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète|University Hospital, Grenoble",All,"18 Years and older   (Adult, Older Adult)",Phase 3,180,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,DCIC 07 08,Sep-07,Mar-09,Aug-09,5-Mar-08,null,9-Feb-12,"Centre Hospitalier de Belfort Montbéliard, Belfort, France|CHU Jean Minjoz, Besancon, France|CH SUD Francilien, Corbeil Essonnes, France|University Hospital Grenoble, Grenoble, France|CHRU Lille, Lille, France|Hopital Edouard Herriot, Lyon, France|CHU Marseille Hôpitaux Sud, Marseille, France|Chu Montpellier, Montpellier, France|CHU Hôpital Jeanne d'Arc, Nancy, France|CHU Nantes, Nantes, France|Hopital Hotel Dieu, Paris, France|Hopital COCHIN, Paris, France|HOPITAL Saint Louis, Paris, France|Hopital Haut Leveque, Pessac, France|CHU Rennes, Rennes, France|Hopital Bellevue, Saint Etienne, France|Centre Hospitalier Strasbourg, Strasbourg, France|CHU Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT00629304
NCT00626080,Insulin Detemir Action in Cerebro,INcEREBRO,Completed,No Results Available,Type 1 Diabetes,Drug: Insulin detemir|Drug: Insulin NPH,"Cerebral metabolic rate of glucose, in brain regions associated with appetite control, as determined by FDG-PET|Cerebral blood flow, in brain regions associated with appetite control, as determined by H2O-PET|CSF insulin concentration|Activity in brain regions associated with appetite control, as determined by fMRI|Weight change",VU University Medical Center,Male,18 Years to 60 Years   (Adult),Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),DC2007Det001|2007-007255-13,Jan-09,Dec-11,Dec-11,29-Feb-08,null,30-Dec-11,"VU University Medical Center, Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT00626080
NCT00627146,Extension of Phase II Therapeutic Trial With a Humanized Non-Mitogenic CD3 (ChAgly CD3) Monoclonal Antibody in Recently Diagnosed Type 1 Diabetic Patients,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: ChAgly CD3|Drug: Placebo,"The difference in change in daily insulin need between baseline and month 48, between placebo and ChAgly CD3 treated patients",AZ-VUB|KU Leuven|Universiteit Antwerpen|Erasme University Hospital,All,"12 Years to 45 Years   (Child, Adult)",Phase 2,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BK-AntiCD3-02,Jun-00,Mar-07,Mar-07,29-Feb-08,null,29-Sep-08,"Universitair Ziekenhuis Antwerpen, Antwerpen, Belgium|Universitair Ziekenhuis and Diabetes Research Center - Brussels Free University-VUB, Brussels, Belgium|Hopital Erasme, Brussel, Belgium|Department of Endocrinology and Nephrology, UZ Gasthuisberg, Katholieke Universiteit Leuven -KUL, Leuven, Belgium|Hopital Schwabbing, Munich, Germany",,https://ClinicalTrials.gov/show/NCT00627146
NCT00623610,Beta-Cell Transplantation in Pre-Uremic Patients With Type 1 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Procedure: islet cell grafts,Evidence of clinically relevant beta cell function.,AZ-VUB|Vrije Universiteit Brussel|Universitaire Ziekenhuizen Leuven|Universiteit Antwerpen|Erasme University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,36,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BK-Tx-04,Sep-00,Oct-05,Oct-05,26-Feb-08,null,26-Feb-08,"Universitair Ziekenhuis and Diabetes Research Center - Brussels Free University-VUB, Brussels, Belgium|Department of Endocrinology and Nephrology, UZ Gasthuisberg, Katholieke Universiteit Leuven -KUL, Leuven, Belgium",,https://ClinicalTrials.gov/show/NCT00623610
NCT00622271,Intervention Groups for Adolescents With Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes Mellitus,Behavioral: Group Therapy,"Enroll patients and their families into either a treatment group or a wait list control (WLC) group to determine the impact of a peer and family-based group intervention on improving adjustment, coping, and functioning among adolescents with diabetes.|Cost-effectiveness will be demonstrated through decreased health care utilization (e.g., emergency room visits, extra outpatient visits, and inpatient hospitalizations).|Diabetes-related medical improvements from baseline to post-treatment and maintained at 4 months and 6 months post-treatment.","Children's Hospital and Health System Foundation, Wisconsin",All,13 Years to 17 Years   (Child),Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GTP1,Feb-08,Mar-10,Mar-10,25-Feb-08,null,17-Nov-11,"Children's Hospital of Wisconsin Child and Adolescent Psychiatry and Behavioral Medicine Center and the Diabetes Clinic, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00622271
NCT00623194,Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689,,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin detemir|Drug: insulin aspart,"Insulin Detemir-insulin Aspart Cross-reacting Antibodies|Development of Insulin Detemir Specific Antibodies and Insulin Aspart Specific Antibodies|Glycosylated Haemoglobin A1c (HbA1c)|Fasting Plasma Glucose Values|Hypoglycaemic Episodes|BMI (Body Mass Index)|SD-score (Z-score) for Body Weight|Diabetic Ketoacidosis|Insulin Dose|Laboratory Values: Albumin Serum and Total Protein Serum (g/dL)|Laboratory Values: Creatine Serum Umol/L|Laboratory Values: Sodium Serum, Potassium Serum and Haemoglobin (mmol/L)|Laboratory Values: Alkaline Phosphatase Serum, Alanine Aminotransferase Serum and Lactate Dehydrogenase Serum (U/L)|Laboratory Values: Leukocytes and Thrombocytes|Fundoscopy/Fundus Photography|Vital Signs: Blood Pressure|Vital Signs: Pulse",Novo Nordisk A/S,All,3 Years to 17 Years   (Child),Phase 3,146,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN304-1690|2006-002478-23,Feb-08,Sep-09,Sep-09,25-Feb-08,24-Jan-11,28-Nov-16,"Novo Nordisk Investigational Site, Pleven, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Varna, Bulgaria|Novo Nordisk Investigational Site, Olomouc, Czech Republic|Novo Nordisk Investigational Site, Pardubice, Czech Republic|Novo Nordisk Investigational Site, Prague 5, Czech Republic|Novo Nordisk Investigational Site, Glostrup, Denmark|Novo Nordisk Investigational Site, Kolding, Denmark|Novo Nordisk Investigational Site, Odense, Denmark|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Oulu, Finland|Novo Nordisk Investigational Site, Seinäjoki, Finland|Novo Nordisk Investigational Site, Turku, Finland|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Toulouse, France|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Miskolc, Hungary|Novo Nordisk Investigational Site, Skopje, Macedonia, The Former Yugoslav Republic of|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Kielce, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Altunizade-Istanbul, Turkey|Novo Nordisk Investigational Site, Antalya, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Izmir, Turkey|Novo Nordisk Investigational Site, Aberdeen, United Kingdom|Novo Nordisk Investigational Site, Dundee, United Kingdom|Novo Nordisk Investigational Site, Norfolk, United Kingdom",,https://ClinicalTrials.gov/show/NCT00623194
NCT00617565,Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Drug: biphasic insulin aspart|Drug: biphasic human insulin,2-hr postprandial plasma glucose (PPPG) excursion|HbA1c|Fasting plasma glucose,Novo Nordisk A/S,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,219,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BIASP-1536,8-Jul-03,26-Nov-03,26-Nov-03,18-Feb-08,null,24-Feb-17,"Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Beijing, China",,https://ClinicalTrials.gov/show/NCT00617565
NCT00615264,Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients,DIA-AID,Completed,Has Results,Type 1 Diabetes,Drug: DiaPep277|Drug: Placebo,Change From Baseline in Glucagon-stimulated C-peptide AUC at 24 Months|Change From Baseline in Mixed-meal Stimulated C-peptide AUC at 24 Months,Andromeda Biotech Ltd.,All,"16 Years to 45 Years   (Child, Adult)",Phase 3,457,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",901|ISRCTN55429664,Sep-05,Sep-11,Jan-12,14-Feb-08,6-Jun-16,6-Jun-16,"Rudolfstiftung Hospital, Vienna, Austria|Faculty Hospital, Olomouc, Czech Republic|Faculty hospital Motol., Prague, Czech Republic|IKEM/Diabetes Centre, Praha, Czech Republic|Pohjois-Karjala projektin tutkimussäätiö, Joensuu, Finland|Tutkimusyksikkö Oulu, Oulu, Finland|Diabetestutkimus, Vantaa, Finland|CHU de Grenoble, Grenoble, France|Hopital Edouard Herriot, Lyon, France|Hopital La Timone, Marseille, France|CHU de Nîmes/ Hôpital Caremeau, Nimes, France|Universitätsklinikum, Giessen, Germany|Diabetes Centre for Children and Adolescents, Hannover, Germany|Institut für Diabetesforschung an der Klinik und Hochschulambulanz für Kinder- und Jugendmedizin, Munich, Germany|Laiko hospital, Athens, Greece|Wolfson Medical Centre, Holon, Israel|Hadassah University Hospital, Jerusalem, Israel|Schneider Children's Medical Centre, Petach Tikva, Israel|Universita' degli Studi di Bari, Bari, Italy|Ex Istituto di clinica medica, Palermo, Italy|University Campus Bio-Medico, Rome, Italy|Università ""La Sapienza"", Rome, Italy|Istituto Clinico Humanitas, Rozzano, Italy|Helderberg Clinical Trials Unit, Cape Town, South Africa|New Groote Schuur Hospital, Cape Town, South Africa|102 Parklands Medical Centre, Durban, South Africa|Donald Gordon Medical Center, Johannesburg, South Africa|Centre for Diabetes and Endocrinology, Johannesburg, South Africa|Hospital de la Santa Creu, Barcelona, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|Hospital de Sabadell, Sabadell, Spain|Hospital Nuestra Señora de La Candelaria, Tenerife, Spain|St. Bartholomew's Hospital, London, United Kingdom|Royal Shrewsbury Hospital, Shrewsbury, United Kingdom",,https://ClinicalTrials.gov/show/NCT00615264
NCT00615368,Treatment With Erythropoietin and Cognition During Hypoglycaemia,,Completed,No Results Available,Type 1 Diabetes|Hypoglycemia,Drug: Epoetin alfa|Drug: Isotonic NaCl (Placebo),Cognitive function|Hypoglycaemic counter regulatory symptoms|Hypoglycemic hormonal response,"Hillerod Hospital, Denmark|Maastricht University Medical Center|Rigshospitalet, Denmark|Steno Diabetes Center Copenhagen|Erasmus Medical Center|Aarhus University Hospital",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,11,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2007-185|2007-005651-41|H-A-2007-0116,May-08,Dec-09,Dec-10,14-Feb-08,null,24-Aug-15,"Hillerød Hospital, Hillerød, Denmark",,https://ClinicalTrials.gov/show/NCT00615368
NCT00612625,Near Normalisation of BG Improves the Potentiating Effect of GLP-1,,Completed,No Results Available,Diabetes Mellitus Type 2,Drug: glucagon-like peptide-1|Drug: Saline,insulin secretion rate (ISR) were derived by deconvolution of c-peptide. ISR is expressed as pmol/kg/min|The calculated ISR values was plotted against the ambient plasma glucose. The slopes of this linear relationships were calculated by cross-correlation analysis and is and estimation of beta-cell responsiveness (pmol/kg/min)/mmol/l,Hvidovre University Hospital,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,9,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,KF 01 - 198/03|KA 01 - 198/03,Feb-04,Jul-04,Dec-04,12-Feb-08,null,12-Feb-08,"Dept. of Endocrinology, Hvidovre Hospital, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT00612625
NCT00612950,Beta-Cell Function After Near-Normalisation of Blood Glucose,,Completed,No Results Available,Type 2 Diabetes,"Drug: glucagon-like peptide-1,|Drug: glucose dependent insulinotropic polypeptide|Drug: Saline","2.phase insulin response measured as incremental area under the curve from 10-120 minutes|2.phase insulin response measured as incremental area under the curve from 10-120 minutes, after 4 weeks of insulin treatment",Hvidovre University Hospital,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,8,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,KA 03005,Oct-06,Feb-07,May-07,12-Feb-08,null,12-Feb-08,"Dept. of Endocrinology, Hvidovre Hospital, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT00612950
NCT00612040,"Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes",,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin glargine|Drug: insulin aspart,Change in Glycosylated Haemoglobin (HbA1c)|Change in Fasting Plasma Glucose (FPG)|Mean of 9-point Self Measured Plasma Glucose Profile (SMPG)|Rate of Major and Minor Hypoglycaemic Episodes|Rate of Nocturnal Major and Minor Hypoglycaemic Episodes|Rate of Treatment Emergent Adverse Events (AEs)|Laboratory Safety Parameters (Biochemistry): Alanine Aminotransferase (ALAT)|Laboratory Safety Parameters (Biochemistry): Aspartate Aminotransferase (ASAT)|Laboratory Safety Parameters (Biochemistry): Serum Creatinine|Vital Signs: Diastolic BP (Blood Pressure)|Vital Signs: Systolic BP (Blood Pressure)|Vital Signs: Pulse|Physical Examination,Novo Nordisk A/S,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,178,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN1250-1835|2007-002474-60,Jan-08,Jun-08,Jun-08,11-Feb-08,16-Nov-15,3-Mar-17,"Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Des Moines, Iowa, United States|Novo Nordisk Investigational Site, Hyattsville, Maryland, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Renton, Washington, United States|Novo Nordisk Investigational Site, Wollongong, New South Wales, Australia|Novo Nordisk Investigational Site, Keswick, South Australia, Australia|Novo Nordisk Investigational Site, East Ringwood, Victoria, Australia|Novo Nordisk Investigational Site, Geelong, Australia|Novo Nordisk Investigational Site, Miranda, Australia|Novo Nordisk Investigational Site, Aschaffenburg, Germany|Novo Nordisk Investigational Site, Bad Kreuznach, Germany|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Hohenmölsen, Germany|Novo Nordisk Investigational Site, Neuwied, Germany|Novo Nordisk Investigational Site, St. Ingbert, Germany|Novo Nordisk Investigational Site, Bergen, Norway|Novo Nordisk Investigational Site, Bergen, Norway|Novo Nordisk Investigational Site, Elverum, Norway|Novo Nordisk Investigational Site, Kristiansand S, Norway|Novo Nordisk Investigational Site, Oslo, Norway|Novo Nordisk Investigational Site, Stavanger, Norway|Novo Nordisk Investigational Site, Alingsås, Sweden|Novo Nordisk Investigational Site, Karlstad, Sweden|Novo Nordisk Investigational Site, Lund, Sweden|Novo Nordisk Investigational Site, Stockholm, Sweden|Novo Nordisk Investigational Site, Stockholm, Sweden|Novo Nordisk Investigational Site, Umeå, Sweden",,https://ClinicalTrials.gov/show/NCT00612040
NCT00607646,Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes,Drug: Dehydroepiandrosterone|Drug: Placebo,Change in level of catecholamines in blood from baseline,University of Maryland|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,18 Years to 45 Years   (Adult),Early Phase 1,50,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other,HP-00044672-DHEA|R01DK069803-03,Oct-10,9-Oct-18,9-Oct-18,6-Feb-08,null,21-Nov-18,"University of Maryland, Baltimore, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00607646
NCT00608101,Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus,,Withdrawn,No Results Available,Type 1 Diabetes,Drug: Fludrocortisone|Drug: Dexamethasone,catecholamines,Vanderbilt University,All,18 Years to 45 Years   (Adult),Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant),"IRB #040907-HAAF in T1DM, Q1|R01DK069803-03",Sep-10,Sep-10,Sep-10,6-Feb-08,null,11-Dec-14,,,https://ClinicalTrials.gov/show/NCT00608101
NCT00609154,Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates,,Unknown status,No Results Available,Type 2 Diabetes,Drug: glucagon like peptide-1|Drug: glucose control,Insulin biosynthesis rate,Albert Einstein College of Medicine|Merck Sharp & Dohme Corp.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,16,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,1999-041|Sub-study 4,Nov-07,Nov-08,Nov-08,6-Feb-08,null,6-Feb-08,"Albert Einstein College of Medicinie, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT00609154
NCT00607087,Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus,PUMP,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Insulin glulisine|Drug: Insulin lispro|Drug: Insulin aspart,"Percentage of Patients With at Least One Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion|Monthly Rate of Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion|Percentage of Patients With at Least One Unexplained Hyperglycemia|Monthly Rate of Unexplained Hyperglycemia|Percentage of Patients With at Least One Confirmed Infusion Set Occlusion|Monthly Rate of Confirmed Infusion Set Occlusion|Percentage of Patients With at Least One Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis|Monthly Rate of Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis|Rate of Symptomatic Hypoglycemia With a Plasma Glucose (PG) ≤ 70 mg/dL Per Patient-year|Rate of Severe Symptomatic Hypoglycemia Per Patient-year|Rate of Nocturnal Symptomatic Hypoglycemia With a Plasma Glucose (PG) ≤70 mg/dL Per Patient-year|Patients With at Least One Site Infection, Site Inflammation/Erythema, Pruritus or Isolated Pain at Injection Site|Time Interval Between Infusion Set Changes: All Changes|Time Interval Between Infusion Set Changes in Routine|Glycosylated Hemoglobin: HbA1c|Total Daily Basal Insulin Infusion|Total Daily Bolus Insulin Dose",Sanofi,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,289,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APIDR_C_02083|2007-003579-38,Jan-08,Jun-09,Jun-09,5-Feb-08,30-Jul-10,31-Aug-10,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Macquarie Park, Australia|Sanofi-Aventis Administrative Office, Vienna, Austria|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Natanya, Israel|Sanofi-Aventis Administrative Office, Milan, Italy|Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of|Sanofi-Aventis Administrative Office, PE Gouda, Netherlands|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Bromma, Sweden|Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom",,https://ClinicalTrials.gov/show/NCT00607087
NCT00607230,Determination of Dosing and Frequency of BCG Administration to Alter T-Lymphocyte Profiles in Type I Diabetics,,Completed,No Results Available,Type 1 Diabetes Mellitus,Biological: BCG|Biological: Saline,"concentration of autoreactive t-cells|Concentration of TNF, TNF-receptors, other cytokines, and c-peptide levels",Massachusetts General Hospital,All,18 Years to 55 Years   (Adult),Phase 1,25,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2007p-001347,Nov-07,Dec-10,Feb-11,5-Feb-08,null,5-Nov-13,"Diabetes Research Center at Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00607230
NCT00607503,A Pilot Study to Evaluate the Safety of Terbutaline in Children With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Drug: Terbutaline,Safety of bedtime administration of the epinephrine simulating β2 adrenergic agonist terbutaline to reduce the incidence of nocturnal hypoglycemia without compromising glycemic control in youth with type 1 diabetes (T1D).,Jaeb Center for Health Research|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"12 Years to 18 Years   (Child, Adult)",Phase 1,9,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,DirecNet 010|HD041919-01|HD041915-01|HD041890|HD041918-01|HD041908-01|HD041906-01|M01RR000069|RR00059|RR 06022|RR00070-41.,Feb-08,Sep-08,Sep-08,5-Feb-08,null,5-Sep-16,"Division of Pediatric Endocrinology and Diabetes, Stanford University, Stanford, California, United States|Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Jaeb Center for Health Research, Tampa, Florida, United States|Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, Iowa, United States|Washington University, St. Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00607503
NCT00605592,UVA Islet Cell Transplantation in Patients With Type I Diabetes,,Unknown status,No Results Available,"Diabetes Mellitus, Type 1",Procedure: Pancreatic Islets of Langerhans Cell Transplant,A decrease in the average daily insulin requirement post-islet cell transplantation.,University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Wyeth is now a wholly owned subsidiary of Pfizer,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,20,Other|NIH|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12839,Jan-07,Jan-12,Jan-12,31-Jan-08,null,18-Feb-09,"University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00605592
NCT00605839,Mobile Communication Technology for Adolescents With Diabetes,,Completed,Has Results,Type 1 Diabetes,Device: GlucoPak|Device: Cell Phone|Other: Usual Care,Quality of Parent-child Relationship,Indiana University,All,"14 Years to 18 Years   (Child, Adult)",Not Applicable,105,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,ADA-HenryBecton-DGM-01,Jan-08,Dec-08,Dec-08,31-Jan-08,20-Nov-13,11-Oct-17,"Riley Hospital Diabetes Clinics, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT00605839
NCT00604344,Efficacy and the Safety of Insulin Detemir in Subjects With Insulin Requiring Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin detemir|Drug: insulin NPH,HbA1c|Blood glucose profiles|Hypoglycaemic episodes|Adverse events|Body weight|Insulin antibodies,Novo Nordisk A/S,All,"20 Years and older   (Adult, Older Adult)",Phase 3,401,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN304-1476|JapicCTI-R070008,Apr-03,Mar-05,Mar-05,30-Jan-08,null,27-Jan-17,"Novo Nordisk Investigational Site, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00604344
NCT00604383,Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study,,Completed,Has Results,Diabetic Retinopathy,Drug: ruboxistaurin|Drug: placebo,Percentage of Participants Who Had Sustained Moderate Visual Loss (SMVL) as Defined as a Visual Acuity Loss of ≥15 Letters Measured Twice During a 6-month Period|Percentage of Participants Who Developed Center Involved or Imminently Threatened Diabetic Macular Edema (DME)|Percentage of Participants Who Experienced the Development of Proliferative Diabetic Retinopathy (PDR)|Change From Baseline up to 36 Months in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25)|Change From Baseline up to 36 Months in Mental and Physical Components of the Medical Outcomes Study 36-Item Short Form (SF-36) Health Status Questionnaire,"Chromaderm, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,685,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",4743|B7A-MC-MBCM,Mar-01,Jun-05,Jun-05,30-Jan-08,28-Jan-16,6-Oct-16,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT -5 hours, EST) or speak with your personal physician., Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT00604383
NCT00604656,Comparison of Insulin Aspart Produced by the NN2000 Process to the Current Process in Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin aspart,Insulin aspart antibodies|Occurrence of adverse events|Incidence of hypoglycaemic episodes|HbA1c,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,241,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN2000-1542,5-May-03,29-Jan-04,29-Jan-04,30-Jan-08,null,1-Mar-17,"Novo Nordisk Investigational Site, Hradec Králové, Czech Republic|Novo Nordisk Investigational Site, Praha 5, Czech Republic|Novo Nordisk Investigational Site, Bad Kreuznach, Germany|Novo Nordisk Investigational Site, Bad Neuenahr-Ahrweiler, Germany|Novo Nordisk Investigational Site, Diez, Germany|Novo Nordisk Investigational Site, Frankfurt, Germany|Novo Nordisk Investigational Site, Friedrichsthal, Germany|Novo Nordisk Investigational Site, Karlsruhe, Germany|Novo Nordisk Investigational Site, Marktheidenfeld, Germany|Novo Nordisk Investigational Site, Marl, Germany|Novo Nordisk Investigational Site, Oberursel, Germany|Novo Nordisk Investigational Site, Rehlingen-Siersburg, Germany|Novo Nordisk Investigational Site, Saarbrücken, Germany|Novo Nordisk Investigational Site, Simmern, Germany|Novo Nordisk Investigational Site, Speyer, Germany|Novo Nordisk Investigational Site, St. Ingbert, Germany|Novo Nordisk Investigational Site, Würzburg, Germany|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Nyíregyháza, Hungary|Novo Nordisk Investigational Site, Cagliari, Italy|Novo Nordisk Investigational Site, Chiavari, Italy|Novo Nordisk Investigational Site, Citta' Di Castello, Italy|Novo Nordisk Investigational Site, Lucca, Italy|Novo Nordisk Investigational Site, Orvieto, Italy|Novo Nordisk Investigational Site, Parma, Italy|Novo Nordisk Investigational Site, Perugia, Italy|Novo Nordisk Investigational Site, Rimini, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Bytom, Poland|Novo Nordisk Investigational Site, Mazowieckie, Poland|Novo Nordisk Investigational Site, Radom, Poland|Novo Nordisk Investigational Site, Warsaw, Poland|Novo Nordisk Investigational Site, Wroclaw, Poland",,https://ClinicalTrials.gov/show/NCT00604656
NCT00605137,Safety of Insulin Detemir in Children With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin detemir|Drug: insulin NPH,"Incidence of hypoglycaemic episodes|Adverse events|Laboratory assessments and other safety endpoints|HbA1C, self monitored blood glucose and within-subject variability of glucose|Height|Insulin doses",Novo Nordisk A/S,All,"7 Years to 18 Years   (Child, Adult)",Phase 3,83,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN304-1604|JapicCTI-R070014,21-May-04,23-Apr-05,23-Apr-05,30-Jan-08,null,24-Feb-17,"Novo Nordisk Investigational Site, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00605137
NCT00603031,Effect of GLP-1 and GIP on Insulin Secretion in Type-1 Diabetes Mellitus,,Completed,No Results Available,Type-1 Diabetes Mellitus,Other: glucagon like peptide -1|Other: NaCl|Other: glucose dependent insulinotropic polypeptide,phase insulin response and phase insulin response measured as incremental area under the curve from 0-10 minutes and incremental area under the curve from 10-45 minutes respectively after iv glucose|maximal insulin response defined as mean insulin at time 47 and 49 minutes (2 and 4 minutes after infusion of L-Arginine),Hvidovre University Hospital,All,18 Years to 60 Years   (Adult),Not Applicable,9,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,H-D-2007-0076|2008-000305-11,Jan-08,Jun-08,Jun-08,28-Jan-08,null,21-Jan-11,"Dept. of Endocrinology, Hvidovre Hospital, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT00603031
NCT00598663,SWITCH - Sensing With Insulin Pump Therapy to Control HbA1c,SWITCH,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System)|Device: insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump),HbA1c|Change in glycemic variability|Change in occurrence of hypoglycemia|Time spent in euglycaemia|Change in postprandial glycaemia|Quality of Life (paeds) and Treatment Satisfaction (adults)|Severe hypo or Diabetic Ketoacidosis events,Medtronic,All,"6 Years to 70 Years   (Child, Adult, Older Adult)",Phase 4,154,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),EUR03|ISRCTN09806152,Jan-08,Jul-10,Jul-10,22-Jan-08,null,20-Sep-10,"Hospital Hietzing, Vienna, Austria|Steno Diabetes Center, Copenhagen, Denmark|Glostrup Hospital, Glostrup, Denmark|Clinica Pediatrica, Policlinico Umberto I, Rome, Italy|Center Hospitalier de Luxembourg, Luxembourg, Luxembourg|Groene Hart Ziekenhuis, Gouda, Netherlands|University Children's Hospital, Ljubljana, Slovenia|Hospital Clinic i Universitari, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT00598663
NCT00597233,Human Insulin NPH and Insulin Aspart in Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin aspart|Drug: soluble human insulin|Drug: insulin NPH,Prandial blood glucose lowering profile|Hypoglycaemic events|Adverse events|Serious adverse events,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 4,91,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANA-1529,Oct-02,Dec-02,Dec-02,18-Jan-08,null,22-Dec-16,"Novo Nordisk Investigational Site, Junin, Argentina",,https://ClinicalTrials.gov/show/NCT00597233
NCT00595374,Efficacy and Safety of Insulin Detemir in Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin detemir|Drug: insulin NPH|Drug: insulin aspart,HbA1c|Plasma glucose profiles|Change in body weight|Quality of Life|Incidence of adverse events|Incidence of hypoglycaemic episodes,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,114,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN304-1582,2-Dec-03,7-Oct-04,7-Oct-04,16-Jan-08,null,24-Feb-17,"Novo Nordisk Investigational Site, Amersfoort, Netherlands|Novo Nordisk Investigational Site, Apeldoorn, Netherlands|Novo Nordisk Investigational Site, Den Haag, Netherlands|Novo Nordisk Investigational Site, Den Haag, Netherlands|Novo Nordisk Investigational Site, Den Helder, Netherlands|Novo Nordisk Investigational Site, Deventer, Netherlands|Novo Nordisk Investigational Site, Enschede, Netherlands|Novo Nordisk Investigational Site, Gouda, Netherlands|Novo Nordisk Investigational Site, Hoogeveen, Netherlands|Novo Nordisk Investigational Site, Leidschendam, Netherlands|Novo Nordisk Investigational Site, Meppel, Netherlands|Novo Nordisk Investigational Site, Rotterdam, Netherlands|Novo Nordisk Investigational Site, Stadskanaal, Netherlands|Novo Nordisk Investigational Site, Utrecht, Netherlands|Novo Nordisk Investigational Site, Waalwijk, Netherlands|Novo Nordisk Investigational Site, Weert, Netherlands|Novo Nordisk Investigational Site, Zevenaar, Netherlands|Novo Nordisk Investigational Site, Zwolle, Netherlands",,https://ClinicalTrials.gov/show/NCT00595374
NCT00592332,"Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2",,Completed,No Results Available,Type 1 Diabetes,Drug: Alprazolam|Other: control group,Catecholamine levels,Vanderbilt University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,18 Years to 45 Years   (Adult),Not Applicable,56,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant),IRB#040908-HAAF-T1DM-Q2|DK69803,Jun-05,Jun-07,Jun-09,14-Jan-08,null,11-Dec-14,"Vanderbilt University, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00592332
NCT00592670,Hypoglycemia Associated Autonomic Failure in Type 1 DM,,Completed,No Results Available,Type 1 Diabetes,Drug: Fluoxetine|Drug: Placebo,Catecholamine measures,Vanderbilt University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,18 Years to 45 Years   (Adult),Not Applicable,48,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)",IRB#040912-HAAF-T1DM-Q6|DK69803,Mar-05,Jun-07,Oct-08,14-Jan-08,null,11-Dec-14,"Vanderbilt University, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00592670
NCT00593255,Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Drug: soluble human insulin|Drug: insulin aspart|Drug: insulin NPH,2-hours postprandial plasma glucose (PPPG)|Percentage of subjects achieving 2-hours PPPG treatment target|Percentage of subjects achieving HbA1c treatment target|HbA1c|Fasting plasma glucose|Hypoglycaemic episodes,Novo Nordisk A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,220,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANA-1634,Jul-04,Apr-05,Apr-05,14-Jan-08,null,22-Dec-16,"Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Harbin, Heilongjiang, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT00593255
NCT00592072,Effect of Medium Chain Fatty Acids on Cognitive Function During Acute Hypoglycemia in Patients With Type 1 Diabetes,,Completed,Has Results,"Diabetes Mellitus, Type 1",Dietary Supplement: Medium chain fatty acid (Octanoic and Decanoic acid)|Other: Splenda (Placebo Control),Immediate Verbal Memory|Delayed Verbal Memory|Verbal Memory Recognition|Digit Span Backward|Letter/Number Sequencing|Digit Symbol Coding|Map Search (2min)|Map Search (1min)|Telephone Search,Yale University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Juvenile Diabetes Research Foundation,All,18 Years to 55 Years   (Adult),Not Applicable,12,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DK66108b_0505000079|R37DK020495|DK20495,Jul-05,Jul-08,Jul-08,11-Jan-08,5-Jan-15,22-Jan-15,"Yale University School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00592072
NCT00588172,Genetic Variation in OCT1 and Response to Metformin,,Withdrawn,No Results Available,Type 2 Diabetes,Drug: Metformin,Change in glucose area under the curve after a mixed meal in response to metformin|Change in glucose disappearance and suppression of endogenous glucose production in response to metformin,Mayo Clinic,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,07-004310|OCT1 and metformin,Jun-10,Jun-10,Jun-11,8-Jan-08,null,17-Aug-10,,,https://ClinicalTrials.gov/show/NCT00588172
NCT00579371,Cadaveric Islet Transplantation in Patients With Insulin-Dependent Diabetes Mellitus,,Terminated,No Results Available,"Islets of Langerhans Transplantation|Diabetes Mellitus, Type 1",Drug: Islets of Langerhans,Incidence of insulin independence with a single islet transplant|Islet mass resulting in insulin independence/reduced exogenous insulin requirement|Graft survival|Metabolic functional assessments of the islet graft,University of Nebraska,All,"19 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,149-03-FB|BB IND 11397,17-Mar-04,Mar-11,Mar-11,24-Dec-07,null,15-Jun-18,"The Nebraska Medical Center, Omaha, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT00579371
NCT00577590,Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM,T2DM,Completed,Has Results,"Diabetes Mellitus, Type II",Drug: Metformin|Drug: Rosiglitazone|Drug: Lovaza,Percent Change in Plasma Triglycerides,Washington University School of Medicine,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,78,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",487,Oct-03,Aug-12,Sep-12,20-Dec-07,31-Aug-18,31-Aug-18,"Washington University in St. Louis, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00577590
NCT00576862,Extension to Study HMR1964A/3011 in Belgium,,Completed,No Results Available,Diabetes Mellitus,Drug: INSULIN GLARGINE,Evolution of efficacy parameters between first study visit (V1) and last study visit (V5),Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 4,32,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HOE901_4046,Nov-02,null,Apr-04,19-Dec-07,null,9-Jan-08,"Sanofi-Aventis, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT00576862
NCT00575159,A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: GSK189075|Drug: placebo,"Number of Participants With All Adverse Events (AE) and Serious Adverse Events (SAE)|Number of Participants With Hypoglycemia Episodes/Events|Change From Baseline Vital Signs: Systolic and Diastolic Blood Pressure (SBP and DBP)|Change From Baseline Vital Signs: Heart Rate|Number of Participants With Abnormal Electrocardiogram (ECG) Findings|Number of Participants With Abnormal Clinical Chemistry Data|Number of Participants With Abnormal Hematology Data|Summary of Urine Osmolality|Mean Creatinine Clearance|Summary of Fluid Balance|Mean of Derived Plasma Glucose Parameters|Incremental Adjusted Weighted Means of Plasma Glucose AUC(0-4) and AUC(0-10) on Day 1|Urinary Glucose Excretion (UGE) for Timed Subintervals up to 24 Hours Post Dose (0-24 H)|Percent of Filtered Glucose in the Urine.|Mean Total Urine Volume 0-24 H|Mean Creatinine Clearance 0-24 H|Area Under the Plasma Concentration vs. Time Curve (AUC) From Time Zero (Time of Dosing) to the Last Time Point With Measurable Analyte Concentration, AUC(0-last), AUC From Time Zero to Infinite Time, AUC(0-inf) of GSK189075 Over Period|Maximum Observed Plasma Concentration (Cmax) of GSK189075 Over Period|Time to Maximum Observed Plasma Concentration (Tmax) and Terminal Half Life, (T1/2) of GSK189075 Over Period|AUC From Time Zero to 4 Hours Post Dose, AUC(0-4) for GSK189074 Over Period|Oral Clearance (CL/F) Over Period|The Metabolite to Parent AUC Ratio, AUCmetabolite/AUCparent Ratio for GSK189074 Over Period|The Metabolite to Parent AUC Ratio, AUCmetabolite/AUCparent Ratio for GSK279782 Over Period",GlaxoSmithKline,All,18 Years to 55 Years   (Adult),Phase 2,10,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",KGI107465,31-Mar-08,18-Dec-08,18-Dec-08,18-Dec-07,9-Oct-17,9-Oct-17,"GSK Investigational Site, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT00575159
NCT00574639,Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2,Alp Ex,Completed,No Results Available,Type 1 Diabetes,Drug: Alprazolam|Drug: Placebo,Change in Epinephrine Levels,"University of Maryland|National Heart, Lung, and Blood Institute (NHLBI)",All,18 Years to 50 Years   (Adult),Early Phase 1,14,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,HP-00044868|HL056693,Jul-07,Jun-16,Jun-16,17-Dec-07,null,10-Feb-17,"University of Maryland, Baltimore, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00574639
NCT00574665,Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 1,,Completed,No Results Available,Type 2 Diabetes,Other: Hyperinsulinemic Hyperglycemic Clamp,Endothelial function and fibrinolytic balance,"Vanderbilt University|National Heart, Lung, and Blood Institute (NHLBI)",All,18 Years to 60 Years   (Adult),Not Applicable,32,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,IRB#060227-SCCOR-Q1|RFAHL04016,Oct-06,Dec-09,Dec-10,17-Dec-07,null,11-Dec-14,"Vanderbilt University, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00574665
NCT00571935,Efficacy and Safety of Insulin Aspart in MDI or CSII in Children Below 7 Years of Age With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin aspart|Drug: soluble human insulin,HbA1c|Overall glycaemic control|Occurrence of adverse events|Occurrence of serious adverse events|Frequency of hypoglycaemia episodes|Quality of Life (QoL),Novo Nordisk A/S,All,up to 7 Years   (Child),Phase 4,61,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANA-1507,Aug-03,Oct-04,Oct-04,12-Dec-07,null,21-Dec-16,"Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Gliwice, Poland|Novo Nordisk Investigational Site, Kielce, Poland|Novo Nordisk Investigational Site, Krakow, Poland|Novo Nordisk Investigational Site, Warszawa, Poland",,https://ClinicalTrials.gov/show/NCT00571935
NCT00572052,Comparison of Glycemic Control Achieved With 2 Different Needles,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Delivery Systems",Device: NovoFine® needle 6 mm|Device: Ultra-Fine needle 12.7 mm,HbA1c|Subject preference and handling|Frequency of hypoglycaemic episodes|Quality of Life,Novo Nordisk A/S,All,18 Years to 60 Years   (Adult),Phase 4,62,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NEEDLEN-2168,Dec-02,Oct-03,Oct-03,12-Dec-07,null,19-Jan-17,"Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Berlin, New Jersey, United States|Novo Nordisk Investigational Site, Lawrenceville, New Jersey, United States|Novo Nordisk Investigational Site, Kettering, Ohio, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00572052
NCT00569998,Comparison of Two Pen Systems in Patients With Diabetes Treated With Insulin,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Delivery Systems",Device: NovoPen™ 4|Device: NovoPen® 3,Evaluation of overall pen preference|HbA1c|Adverse device effects|Adverse events,Novo Nordisk A/S,All,"9 Years and older   (Child, Adult, Older Adult)",Phase 3,208,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MS236-1544,Aug-03,Feb-04,Feb-04,10-Dec-07,null,19-Jan-17,"Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Köln, Germany|Novo Nordisk Investigational Site, Leverkusen, Germany|Novo Nordisk Investigational Site, München, Germany|Novo Nordisk Investigational Site, Speyer, Germany|Novo Nordisk Investigational Site, St. Ingbert, Germany|Novo Nordisk Investigational Site, Völklingen, Germany|Novo Nordisk Investigational Site, Catania, Italy|Novo Nordisk Investigational Site, Palermo, Italy|Novo Nordisk Investigational Site, Parma, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Torino, Italy|Novo Nordisk Investigational Site, Almere, Netherlands|Novo Nordisk Investigational Site, Amsterdam, Netherlands|Novo Nordisk Investigational Site, Den Haag, Netherlands|Novo Nordisk Investigational Site, Heerlen, Netherlands|Novo Nordisk Investigational Site, Rotterdam, Netherlands|Novo Nordisk Investigational Site, Veldhoven, Netherlands|Novo Nordisk Investigational Site, Belfast, United Kingdom|Novo Nordisk Investigational Site, Belfast, United Kingdom|Novo Nordisk Investigational Site, Leeds, United Kingdom|Novo Nordisk Investigational Site, Sidcup, United Kingdom",,https://ClinicalTrials.gov/show/NCT00569998
NCT00569400,Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: human insulin,Change of human insulin antibodies|Frequency of adverse events,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,241,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN729-1541,1-May-03,19-Jan-04,19-Jan-04,7-Dec-07,null,27-Feb-17,"Novo Nordisk Investigational Site, Broadmeadow, New South Wales, Australia|Novo Nordisk Investigational Site, Keswick, South Australia, Australia|Novo Nordisk Investigational Site, Dunedin, Australia|Novo Nordisk Investigational Site, Hamilton, Australia|Novo Nordisk Investigational Site, Kippa Ring, Australia|Novo Nordisk Investigational Site, Miranda, Australia|Novo Nordisk Investigational Site, Stones Corner, Australia|Novo Nordisk Investigational Site, Shatin, New Territories, Hong Kong|Novo Nordisk Investigational Site, Cheras, Malaysia|Novo Nordisk Investigational Site, Georgetown, Penang, Malaysia|Novo Nordisk Investigational Site, Kota Bharu, Kelantan, Malaysia|Novo Nordisk Investigational Site, Cebu City, Philippines|Novo Nordisk Investigational Site, Iloilo, Philippines|Novo Nordisk Investigational Site, Makati City, Philippines|Novo Nordisk Investigational Site, Marikina City, Philippines",,https://ClinicalTrials.gov/show/NCT00569400
NCT00569426,Evaluating the Use of Two Different Needles in Subjects With Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Delivery Systems",Device: NovoFine® needle 6 mm|Device: NovoFine® needle 8 mm,Overall needle preference|Injection pressure|Pain perception|Handling and acceptance of needles,Novo Nordisk A/S,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 4,119,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NEEDLEN-1637,Apr-05,Jun-05,Jun-05,7-Dec-07,null,19-Jan-17,"Novo Nordisk Investigational Site, Cambridge, United Kingdom|Novo Nordisk Investigational Site, Cardiff, United Kingdom|Novo Nordisk Investigational Site, Church Village, United Kingdom|Novo Nordisk Investigational Site, Dundee, United Kingdom|Novo Nordisk Investigational Site, Haywards Heath, United Kingdom|Novo Nordisk Investigational Site, Liverpool, United Kingdom|Novo Nordisk Investigational Site, Livingstone, United Kingdom|Novo Nordisk Investigational Site, Penarth, United Kingdom|Novo Nordisk Investigational Site, Plymouth, United Kingdom|Novo Nordisk Investigational Site, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT00569426
NCT00569452,Comparison of Basal (Fasting) Glycemic Control in Type 1 Diabetic Patients With CSII Achieved by the Circadian Slide Ruler Scale or Flat Basal Rate,,Completed,No Results Available,Diabetes Mellitus Type 1,Device: Accu-Chek Spirit Insulin Pump,"Pilot trial to establish endpoints such as ""time within target range of a composite fasting day""|AUC, MAGE, HbA1c, body weight change",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,12,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RD000278|DMS-01-CIRCADIAN-01,Jan-06,May-06,May-06,7-Dec-07,null,3-Mar-16,"Ulm, Germany",,https://ClinicalTrials.gov/show/NCT00569452
NCT00567775,Comparison of Human Insulin to Insulin Inhalation Solution in Children With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: human insulin|Drug: inhaled human insulin,Area under the serum insulin curve|Maximum serum insulin concentration|Time to maximum serum insulin concentration,Novo Nordisk A/S,All,6 Years to 17 Years   (Child),Phase 2,27,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN1998-1274,21-Oct-02,20-Nov-02,20-Nov-02,5-Dec-07,null,1-Mar-17,"Novo Nordisk Investigational Site, Glostrup, Denmark",,https://ClinicalTrials.gov/show/NCT00567775
NCT00566813,Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Islet Cell Transplant|Drug: Islet Cell Transplant plus,Number of Participants With Adverse Events Including Laboratory Abnormalities at the End of Study Participation|Number of Participants With Insulin Independence at End of Study Participation|Number of Participants With HbA1c Less Than or Equal to 6.5 & Free of Severe Hypoglycemic Events,University of Illinois at Chicago,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IND11807-2004-0532,Nov-04,Jan-07,Jan-07,4-Dec-07,19-Nov-18,19-Nov-18,"University of Illinois at Chicago, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00566813
NCT00566475,School Centered Telemedicine Program for Children With Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes,Other: telemedicine,"hemoglobin A1c|glucose levels, hypoglycemia, quality of life, satisfaction",State University of New York - Upstate Medical University|Department of Health and Human Services|New York State Department of Health|Children's Miracle Network,All,5 Years to 14 Years   (Child),Not Applicable,41,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB#5302,Jan-07,Jan-08,Jan-08,3-Dec-07,null,30-Dec-09,"SUNY Upstate Medical University, Syracuse, New York, United States",,https://ClinicalTrials.gov/show/NCT00566475
NCT00564395,Detemir: Role in Type 1 Diabetes,,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Insulin Detemir mixed with RAI injection|Drug: Insulin Detemir and RAI injection,Assess the Mean Area Under the Curve (AUC) for Blood Glucose Concentration in Subjects Treated With Either Insulin Detemir Mixed With Rapid Acting Insulin (RAI) or Insulin Detemir and RAI as Separate Subcutaneous Injections,Montefiore Medical Center,All,"10 Years to 25 Years   (Child, Adult)",Phase 4,18,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-16541,Aug-07,Dec-09,May-10,28-Nov-07,17-Jul-18,17-Jul-18,"Texas Children's Hospital Endocrine and Diabetes Clinic, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00564395
NCT00564018,"Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH",,Terminated,No Results Available,Type 1 Diabetes,Drug: Insulin detemir|Drug: Glargine|Drug: NPH,C-peptide area under the curve in response to a mixed meal tolerance test 6 months after diagnosis of diabetes.|Glycemic control as determined by HgbA1c values at quarterly intervals after diagnosis of diabetes.,University of Texas Southwestern Medical Center|Novo Nordisk A/S,All,"6 Years to 18 Years   (Child, Adult)",Not Applicable,33,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UTSW-052006-056|GCRC Protocol #816,Sep-06,Feb-09,Apr-11,27-Nov-07,null,14-Jun-12,"Children's Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00564018
NCT00561704,Adiponectin in Obese Women With T2DN and Effects by RAS Blocker,,Completed,No Results Available,Obese|Type 2 Diabetes|Diabetic Nephropathy|Glucose Metabolism|Angiotensin II Type 1 Receptor Blockers,Drug: losartan,"GFR, HbA1c and the adiponectin concentration.",Shanghai Jiao Tong University School of Medicine,Female,"30 Years and older   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ADL,Apr-07,null,Oct-07,21-Nov-07,null,21-Nov-07,,,https://ClinicalTrials.gov/show/NCT00561704
NCT00557518,Study of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria,,Terminated,No Results Available,"Diabetes Mellitus, Type 1|Diabetic Nephropathy",Drug: Alagebrium|Drug: Placebo,"Change from baseline in albumin excretion rate (µg/min)|Albumin:creatinine ratio(mg/g), plasma renin level, collagen markers, AGE related markers, 24 hour blood pressure determinations","Synvista Therapeutics, Inc|Juvenile Diabetes Research Foundation",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,80,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALT-711-0424,Nov-07,Sep-09,Nov-09,14-Nov-07,null,30-Jan-09,"Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|International Diabetes Institute, Caulfield, Victoria, Australia|Dept. of Clinical and Biomedical Science Myers House, Geelong, Victoria, Australia|Austin Health, Heidelburg, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Steno Diabetes Center, Gentofte, Denmark",,https://ClinicalTrials.gov/show/NCT00557518
NCT00554281,Using Glucose Sensors to Prevent Hypoglycemia,,Completed,No Results Available,Type 1 Diabetes|Hypoglycemia,Device: Use of glucose sensor (Paradigm Guardian),Decrease in HYPO score|Number of episodes of severe hypoglycemia|Number of patients who decide to continue using the device,University of Alberta,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,16,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UAHREB6344,Oct-06,Aug-08,Aug-08,6-Nov-07,null,13-Sep-11,"University of Alberta Hospital, Edmonton, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT00554281
NCT00553488,Feasibility Study of the Effect of Intra-Dermal Insulin Injection on Blood Glucose Levels After Eating,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Regular insulin (Humulin)|Drug: Insulin lispro (Humalog),"Area Under Curve (AUC) of the blood glucose (BG) profile after the meal, with and without baseline correction.|Maximal BG (BGmax)|Total BG-AUC0-4 h|Minimal BG (BGmin, time to BGmin (tBGmin)|Insulin pharmacokinetics|Number and seriousness of adverse events|Vital signs, examination of insulin application|Time to BGmax (tBGmax)","Becton, Dickinson and Company",Male,18 Years to 55 Years   (Adult),Phase 2,30,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BDT-ADD-07-002|EudraCT number 2007-003924-39,Sep-07,Dec-07,Jan-08,5-Nov-07,null,22-Aug-08,"Profil Institut fur Stoffwechselforschung GmbH, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT00553488
NCT00546702,Glulisine + Lantus in Type I Patients,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Insuline Glulisine,"Change of HbA1c.|Change in HbA1c.|Blood glucose parameters, hypoglycaemic episodes and dosage of the mealtime and basal insulins.",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,142,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HMR1964A_3505,Sep-04,Feb-05,Feb-05,19-Oct-07,null,15-Jun-09,"Sanofi-aventis, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT00546702
NCT00546325,REASSURE: The Effect of Rimonabant on HbA1c in Overweight or Obese Patients With Type 2 Diabetes Not Adequately Controlled on 2 Oral Antidiabetic Agents,REASSURE,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Rimonabant|Drug: Placebo,"Absolute change in HbA1c between both placebo and rimonabant group.|Percentage of participants reaching the treat-to-target objective of HbA1c ≤ 6.5% and ≤ 7.0%|Percentage of participants responding to treatment|Rate of asymptomatic, symptomatic, and severe hypoglycaemia|Change in physical examinations, vital signs, laboratory parameters, adverse events|Change in insulin sensitivity, fasting plasma glucose, hypoglycaemia rate.|Change in BMI, waist and hip circumference, waist/hip ratio, weight|Changes in Quality of Life|Change in lipid measures: HDL (High Density Lipoprotein), LDL (Low-Density Lipoprotein), TG (Triglycerides), TC (Total Cholesterol), ApoB (Apolipoprotein B)|Change in adiponectin, fasting insulin, Blood Pressure, concomitant medications, health resource use, CRP (C Reactive Protein), ALT (Alanine Aminotransferase), albumin/creatinine ratio",Sanofi,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,358,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RIMON_L_01661,Oct-07,Feb-09,Feb-09,18-Oct-07,null,10-Dec-10,"Sanofi-Aventis Administrative Office, North Ryde, Australia",,https://ClinicalTrials.gov/show/NCT00546325
NCT00545337,Glulisine + Lantus in Type I Patients,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Insuline glulisine,"Change of HbA1c|Blood glucose parameters, hypoglycemic episodes and dosage of the mealtime and basal insulins",Sanofi,All,"19 Years and older   (Adult, Older Adult)",Phase 3,60,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HMR1964A_3505UA,Sep-04,Jun-05,Jun-05,17-Oct-07,null,16-Oct-09,"Sanofi-Aventis, Kiev, Ukraine",,https://ClinicalTrials.gov/show/NCT00545337
NCT00545727,Blood Glucose Response to Meals of Varying Glycemic Index in Youth With Type 1 & 2 Diabetes,,Completed,No Results Available,Type 1 Diabetes|Type 2 Diabetes|Impaired Glucose Metabolism,Behavioral: Diet|Other: Standard diet,Blood glucose level,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),All,7 Years to 16 Years   (Child),Not Applicable,36,NIH,Interventional,Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,06-CH-N182,Jul-06,null,Aug-06,17-Oct-07,null,17-Oct-07,,,https://ClinicalTrials.gov/show/NCT00545727
NCT00545857,Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: pioglitazone|Drug: Placebo control,C-peptide response to a Sustacal meal|Insulin requirement|Hemoglobin A1c,Stony Brook University,All,"6 Years to 18 Years   (Child, Adult)",Phase 1,15,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20064114,Jun-02,May-12,May-12,17-Oct-07,null,31-May-12,"Thomas A. Wilson, MD, Stony Brook, New York, United States",,https://ClinicalTrials.gov/show/NCT00545857
NCT00542399,Comparing the Metabolic Control of Once to Twice-daily Insulin Detemir Injections,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Levemir (insulin detemir)|Drug: Levemir twice a day,HbA1C|SBGM|CGMS|Total daily basal and bolus insulin|documentation of hypoglycemic and hyperglycemic episodes,Rabin Medical Center,All,"6 Years to 18 Years   (Child, Adult)",Phase 4,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,rmc004543ctil,Nov-07,Jan-10,Mar-10,11-Oct-07,null,2-Nov-11,"Schneider Children's Medical Center, Petach-Tikva, Israel",,https://ClinicalTrials.gov/show/NCT00542399
NCT00542620,Comparison of Insulin Detemir and Insulin Aspart in 2 Separate Injections Twice Daily to Extemporaneous Mixing Injection Regimen Twice Daily - The Paediatric Mixing Trial,MIXING,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin detemir|Drug: insulin aspart,"Glycosylated Haemoglobin A1c (HbA1c)|Fructosamine|Self-measured Plasma Glucose Profile (Before Breakfast)|Self-measured Plasma Glucose Profile (After Breakfast)|Self-measured Plasma Glucose Profile (Before Dinner)|Self-measured Plasma Glucose Profile (After Dinner)|Pharmacokinetics: Cmax of Free Insulin|Pharmacokinetics: Tmax of Free Insulin|Pharmacokinetics: Area Under the Concentration vs. Time Curve From Time Zero to the Time of the Last Measured Level of Free Insulin|Pharmacokinetics: Area Under the Concentration vs. Time Curve From Time Zero to Infinity of Free Insulin|Pharmacokinetics: Terminal Phase Elimination Half-life (T½) - Parameter of Free Insulin|Pharmacokinetics: Cmax of Insulin Detemir|Pharmacokinetics: Tmax of Insulin Detemir|Pharmacokinetics: Area Under the Concentration vs. Time Curve From Time Zero to the Time of the Last Measured Level of Insulin Detemir|Pharmacokinetics: Area Under the Concentration vs. Time Curve From Time Zero to Infinity of Insulin Detemir|Pharmacokinetics: Terminal Phase Elimination Half-life (T½) - Parameter of Insulin Detemir|Pharmacokinetics: Cmax of Insulin Aspart|Pharmacokinetics: Tmax of Insulin Aspart|Pharmacokinetics: Area Under the Concentration vs. Time Curve From Time Zero to the Time of the Last Measured Level of Insulin Aspart|Pharmacokinetics: Area Under the Concentration vs. Time Curve From Time Zero to Infinity of Insulin Aspart|Pharmacokinetics: Terminal Phase Elimination Half-life (T½) - Parameter of Insulin Aspart|Weight Z Score|Body Mass Index (BMI) Z Score|Incidence of Hypoglycaemic Episodes - All Episodes|Incidence of Hypoglycaemic Episodes - Glycaemia Below 0.56 g/L|Incidence of Hypoglycaemic Episodes - Glycaemia Above or Equal to 0.56 g/L|Percentage of Children Assessing Insulin Therapy Injection Pain as ""Sad Face""|Percentage of Children Assessing Insulin Therapy Injection Pain as ""Happy Face""|Percentage of Children Assessing Insulin Therapy Injection Pain as ""Very Happy Face""",Novo Nordisk A/S,All,"6 Years to 18 Years   (Child, Adult)",Phase 4,25,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN304-1813|2006-006715-77,Sep-07,Mar-09,Mar-09,11-Oct-07,18-Jan-13,3-Nov-14,"Paris, France",,https://ClinicalTrials.gov/show/NCT00542620
NCT00542724,"An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus",,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: VIAject™|Drug: Regular Human Insulin,Change in HbA1c,Biodel,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,462,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VIAject™-06J,Sep-06,Jul-08,null,11-Oct-07,null,3-Aug-15,,,https://ClinicalTrials.gov/show/NCT00542724
NCT00541229,Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED),,Completed,Has Results,Type 2 Diabetes,Drug: sitagliptin phosphate|Drug: Comparator: Placebo,24-hour Weighted Mean Glucose (WMG),Merck Sharp & Dohme Corp.,All,"30 Years to 65 Years   (Adult, Older Adult)",Phase 1,103,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0431-077|2007_533,24-Aug-07,17-Jun-08,1-Jul-08,10-Oct-07,28-Jul-09,12-May-17,,,https://ClinicalTrials.gov/show/NCT00541229
NCT00541515,Closing the Loop Between Glucose Sensor and Insulin Pump-developing an Algorithm,,Completed,No Results Available,"Diabetes, Type I",Device: continuous glucose sensors and insulin pump,Blood glucose levels,Rabin Medical Center,All,"10 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,38,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,rmc004706ctil,Oct-07,Jul-15,Sep-15,10-Oct-07,null,8-Apr-16,"schneider children medical center of Israel, Petach-Tikva, Israel",,https://ClinicalTrials.gov/show/NCT00541515
NCT00539396,"A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine",,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Technosphere Insulin,Change in blood glucose following a standard meal|Mean change from baseline HbA1c,Mannkind Corporation,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,110,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MKC-TI-101,Mar-05,null,Dec-05,4-Oct-07,null,14-Oct-09,,,https://ClinicalTrials.gov/show/NCT00539396
NCT00539448,"Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study",GLANS,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: insulin glargine|Drug: insulin glulisine,Evaluating the Glycemic control of the regimen : Change in A1C levels|Average daily dose : - For both insulin Glulisine & insulin Glargine. - FBG and PPBG if possible ?,Sanofi,All,18 Years to 45 Years   (Adult),Phase 4,98,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LANTU_L_01578,Apr-07,Dec-08,Dec-08,4-Oct-07,null,25-Sep-09,"Sanofi-aventis administrative office, Manama, Bahrain|Sanofi-aventis administrative office, Kuwait City, Kuwait|Sanofi-Aventis Administrative Office, Doha, Qatar|Sanofi-aventis administrative office, Dubai, United Arab Emirates",,https://ClinicalTrials.gov/show/NCT00539448
NCT00537251,"32 Week, Open, Randomized, 2 Way Cross Over Multicentre Trial to Compare Safety & Efficacy of Combination of HOE901 Insulin Analogue Once Daily at Bedtime + Lispro Insulin Before Meals vs NPH Insulin (Twice a Day) + Regular in Type 1 Diabetes Mellitus",,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Insulin glargine,"Compare efficacy of insulin glargine & short acting insulin (Lispro), NPH insulin regime as basal insulin and regular insulin for meal insulin for metabolic control, evaluated by means of HbA1c .",Sanofi,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,80,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HOE901_4023,Nov-01,null,Feb-04,1-Oct-07,null,1-Oct-07,,,https://ClinicalTrials.gov/show/NCT00537251
NCT00533442,Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients,,Completed,Has Results,Type 1 Diabetes,Drug: Rapamycin|Drug: Mycophenolate Mofetil|Drug: Tacrolimus|Drug: Steroids,"Event-Specific Survival Comparisons|Overall Kidney Transplant Function at 12, 36, and 60 Months Post-transplant.|Overall Pancreas Transplant Function at 12, 36, and 60 Months Post-transplant.",University of Miami|Astellas Pharma Inc,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,170,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,20000176,Sep-00,May-16,May-16,21-Sep-07,12-Jul-17,12-Jul-17,"University of Miami, Miller School of Medicine, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT00533442
NCT00530023,Feasibility Study for Training Pump Naïve Subjects To Use The Paradigm® System And Evaluate Effectiveness,STAR2,Completed,Has Results,Type 1 Diabetes,Device: MiniMed Paradigm REAL-Time System,Change in A1C From Baseline to Week 15|Incidence of Severe Hypoglycemia Events Baseline to Week 15|Blood Glucose Monitoring System - Ratings Questionnaire (BGMS-RQ) Assessed at Baseline and Week 15|Insulin Delivery System - Ratings Questionnaire (IDS-RQ) Assessed at Baseline and Week 15|Hypoglycemia Fear Scale (HFS) Assessed at Baseline and Week 15,Medtronic Diabetes,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,29,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CEP195/Z25,Feb-06,Sep-06,Sep-06,17-Sep-07,10-Jun-11,10-Jun-11,"Diabetes Treatment Center, Loma Linda University, Loma Linda, California, United States|Portland Diabetes & Endocrinology, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT00530023
NCT00530686,Pancreatic Islet Cell Transplantation - A Novel Approach to Improve Islet Quality and Engraftment,,Completed,No Results Available,Islet Cell Transplantation|Type 1 Diabetes,Drug: Islet cell transplantation,1)Presence or absence of hypoglycemic unawareness 2) To assess incidence of hypoglycemic episodes 3) To assess insulin requirements in patients who did not become insulin independent.|To assess the achievement of insulin independence at 12 month and 24 month post transplant in patients who underwent allo islet cell transplantation.,Baylor Research Institute|Baylor Health Care System,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,1,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,008-095,Jul-08,Apr-17,Apr-17,17-Sep-07,null,24-Apr-17,"Annette C. & Harold C. Simmons Transplant Institute - Baylor University Medical Center, Dallas Texas, USA - Baylor All Saints Medical Center, Fort Worth Texas, USA, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00530686
NCT00529191,Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM),TIDM,Completed,Has Results,Type 1 Diabetes,Drug: Atorvastatin|Other: Placebo,"Efficacy of a Daily Dose of Atorvastatin to Maintain Islet Cell Function as Measured by a 4-hour C-peptide Area Under Curve (AUC) in Patients With Newly Diagnosed Type 1 Diabetes Mellitus|% Subjects Without Change in 2-hour C-peptide AUC in Response to the MMTT at Baseline vs. 12 Months|Mean Daily Insulin Dose Per kg Body Weight for 7 Days|Levels of HbA1c at Months 3, 6, 9, 12 and 18|Blood Glucose Control (Number of Participants With Hypoglycemia)|Number of Episodes of Hypoglycemia Requiring Any Treatment|Study Drug Compliance Rate Overall|HDL and LDL Cholesterol Levels in Participants Stratified by the Preservation of Islet Cell Function",Children's Hospital of Philadelphia|FDA Office of Orphan Products Development|Medical University of South Carolina,All,"10 Years to 19 Years   (Child, Adult)",Phase 2,40,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2006-5-4824|R01FD003340,Jul-07,Jul-11,Jul-13,14-Sep-07,8-Mar-13,13-Mar-17,"Diabetes Center for Children & Clinical Translational Research Center, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00529191
NCT00529399,Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects,,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: GAD-Alum|Drug: GAD-Alum and Aluminum hydroxide|Drug: Aluminum hydroxide,The Primary Outcome is the Area Under the Stimulated C-peptide Curve (AUC) at the One Year Visit,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|National Center for Research Resources (NCRR)|American Diabetes Association|Juvenile Diabetes Research Foundation,All,"3 Years to 45 Years   (Child, Adult)",Phase 2,145,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",GAD65 (IND),Feb-09,May-12,May-12,14-Sep-07,7-Dec-16,7-Dec-16,"Childrens Hospital of Los Angeles, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|University of California-San Francisco, San Francisco, California, United States|Barbara Davis Center for Childhood Diabetes/University of Colorado Health Sciences Center, Aurora, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|University of Miami/ Miller School of Medicine, Miami, Florida, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Columbia University, New York, New York, United States|Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Texas/Southwestern Medical School, Dallas, Texas, United States|Benaroya Research Institute, Seattle, Washington, United States|Hospital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00529399
NCT00526513,Study of Safety and Effectiveness of Apidra® in Combination With Basal Insulin in Patients With Type 1 & 2 Diabetes Mellitus,SCALE,Completed,No Results Available,Diabetes Mellitus,Drug: Insulin Glulisine,Glycosylated Haemoglobin (HbA1c)|Control of Fasting Blood Glucose (FBG)|Control of Post-Prandial Glycemia (PPBG),Sanofi,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,188,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APIDR_L_01913,Jul-07,May-08,May-08,10-Sep-07,null,13-Sep-10,"Sanofi-Aventis Administrative Office, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT00526513
NCT00527397,"Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Patients With Type1 or Type2 Diabetes",,Terminated,Has Results,"Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1","Drug: CP-464,005",Self-Monitoring Blood Glucose Levels: Change From Baseline|Daily Inhaled Insulin Dose|The Values of Hemoglobin A1c:Change From Baseline|The Value of Fasting Plasma Glucose:Change From Baseline|The Incidence of Hypoglycaemia at the Cumulative Doses of Inhaled Insulin|The Values of Forced Expiratory Volume at 1 Second:Change From Baseline|The Values of Forced Vital Capacity:Change From Baseline|The Values of Forced Expiratory Volume at 1 Second/Forced Vital Capacity:Change From Baseline|Insulin Antibody Levels : Change From Baseline,Pfizer,All,"16 Years to 75 Years   (Child, Adult, Older Adult)",Phase 3,24,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A2171105,Aug-07,Jul-08,Jul-08,10-Sep-07,5-Oct-09,15-Oct-09,"Pfizer Investigational Site, Nagoya-shi, Aichi, Japan|Pfizer Investigational Site, Yokohama-shi, Kanagawa, Japan|Pfizer Investigational Site, Tenri-shi, Nara, Japan|Pfizer Investigational Site, Takatsuki-shi, Oosaka, Japan|Pfizer Investigational Site, Bunkyo-ku, Tokyo, Japan|Pfizer Investigational Site, Meguro-ku, Tokyo, Japan|Pfizer Investigational Site, Toyama-shi, Toyama, Japan|Pfizer Investigational Site, Kyoto, Japan|Pfizer Investigational Site, Osaka, Japan|Pfizer Investigational Site, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00527397
NCT00525889,Proleukin and Rapamune in Type 1 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: IL-2|Drug: Rapamycin,Incidence and severity of adverse events and laboratory anomalies|AUC for C-peptide responses following MMTT|Frequency of severe hypoglycemia|Insulin dose in units per kilogram|HbA1c levels,National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN),All,18 Years to 45 Years   (Adult),Phase 1,9,NIH|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAIT ITN018AI,Aug-07,Sep-11,Sep-13,6-Sep-07,null,8-Feb-17,"Naomi Berrie Diabetes Center, Columbia University, New York, New York, United States|Oregon Health Sciences University, Portland, Oregon, United States|Benaroya Research Institute, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00525889
NCT00523042,Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma,iINHALE 9,Terminated,No Results Available,"Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Asthma",Drug: insulin aspart|Drug: inhaled human insulin,"Changes in lung function, chest X-rays, or asthma exacerbation frequency|Diabetes control measured by change in HbA1c|Laboratory assessments (biochemistry, insulin antibodies, blood count)|Preprandial insulin doses",Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,10,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN1998-1616,30-Aug-07,28-Feb-08,28-Feb-08,30-Aug-07,null,5-Sep-18,"Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, New Orleans, Louisiana, United States|Novo Nordisk Investigational Site, Kansas City, Missouri, United States|Novo Nordisk Investigational Site, Columbus, Ohio, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Ogden, Utah, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Broadmeadow, New South Wales, Australia|Novo Nordisk Investigational Site, Camperdown, New South Wales, Australia|Novo Nordisk Investigational Site, Keswick, South Australia, Australia|Novo Nordisk Investigational Site, Box Hill, Victoria, Australia|Novo Nordisk Investigational Site, East Ringwood, Victoria, Australia|Novo Nordisk Investigational Site, Parkville, Victoria, Australia|Novo Nordisk Investigational Site, Auchenflower, Australia|Novo Nordisk Investigational Site, Kippa Ring, Australia|Novo Nordisk Investigational Site, Belgrade, Former Serbia and Montenegro|Novo Nordisk Investigational Site, Chandigarh, Punjab, India|Novo Nordisk Investigational Site, Vellore, Tamil Nadu, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Hyderabad, India|Novo Nordisk Investigational Site, Mumbai, India|Novo Nordisk Investigational Site, Pune, India|Novo Nordisk Investigational Site, Cheras, Malaysia|Novo Nordisk Investigational Site, Kota Bharu, Kelantan, Malaysia|Novo Nordisk Investigational Site, Pulau Pinang, Malaysia|Novo Nordisk Investigational Site, Kosice, Slovakia|Novo Nordisk Investigational Site, Lubochna, Slovakia|Novo Nordisk Investigational Site, Moldava nad Bodvou, Slovakia|Novo Nordisk Investigational Site, Zilina, Slovakia|Novo Nordisk Investigational Site, Zilina, Slovakia",,https://ClinicalTrials.gov/show/NCT00523042
NCT00522210,Comparison of a Twice Daily Versus a Three Times Daily Insulin Regimen in Children With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Drug: Detemir|Other: Novolin NPH or Humulin N,Hemoglobin A1C|Number of episodes of hypoglycemia (severe and mild)|Number of episodes of diabetic ketoacidosis (DKA)|Body Mass Index (BMI) kg/m2|Diabetes Quality of Life Questionaire-youth version,University of Calgary,All,6 Years to 17 Years   (Child),Not Applicable,18,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E-20635,Mar-08,Mar-11,Mar-11,29-Aug-07,null,3-Sep-14,"Alberta Children's Hospital, Calgary, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT00522210
NCT00521105,Assessment of an Alternative Model of Follow-up of Children and Adolescents With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus,Other: Virtual visit,"Medical outcomes: HbA1c, rates of severe hypoglycemia, rates of DKA|Resource utilization: physicians, nurses, and dietitians, emergency room visits|Family satisfaction with diabetes care|Associated costs to the family (time away from school and work, travel, etc)",University of Calgary|Canadian Diabetes Association,All,1 Year to 17 Years   (Child),Not Applicable,82,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,AR-2-05-1823-DP,Aug-05,Nov-09,Nov-09,27-Aug-07,null,6-Oct-11,"Endocrine Clinic, Alberta Children's Hospital, Calgary, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT00521105
NCT00519935,Testing MST to Improve Adherence Among Youth With Chronic Poor Metabolic Control,,Completed,No Results Available,Type 1 Diabetes,Behavioral: Multisystemic Therapy,"Metabolic Control: Hemoglobin A1c (HbA1c)|Regimen Adherence: Diabetes Management Scale (DMS), Glucose Meter Downloads|DKA admissions and emergency room (ER) Visits: hospital information systems data extraction, Service Utilization Questionnaire (SUQ)|Quality of life",Wayne State University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Medical University of South Carolina,All,10 Years to 16 Years   (Child),Not Applicable,127,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DK59067A (completed)|R01DK059067,Jul-01,Mar-06,Mar-06,23-Aug-07,null,2-Jun-17,"Children's Hospital of Michigan, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT00519935
NCT00519623,Transdermal Basal Insulin Patch Study in Type 1 Diabetes,,Completed,Has Results,Type 1 Diabetes,Other: PassPort(R) Transdermal Insulin Delivery System,Pharmacokinetics of the PassPort(R) Transdermal Insulin Delivery System in Type 1 Diabetes Patients (Cmax)|Pharmacodynamics of the PassPort(R) Transdermal Insulin Delivery System in Type 1 Diabetes Patients (GIRmax)|Skin Response to the Application of the PassPort(R) Transdermal Insulin Delivery System in Type 1 Diabetes Patients,Altea Therapeutics,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,9,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IN2007001,Aug-07,Nov-07,Dec-07,22-Aug-07,30-Dec-10,30-Dec-10,"Altea Therapeutics Clinical Research Center, 387 Technology Circle, NW, Suite 100, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT00519623
NCT00515801,Sulfonylurea Effects on Glucagon Regulation During Hypoglycemia in Type 1 DM,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: glibenclamide|Drug: placebo,plasma glucagon concentrations during insulin induced hypoglycemia with and without glibenclamide pretreatment|rate of glucose recovery following insulin induced hypoglycemia with and without glibenclamide pretreatment|cognitive function during insulin induced hypoglycemia with and without glibenclamide pretreatment,"University Hospital, Basel, Switzerland",All,18 Years to 50 Years   (Adult),Phase 2|Phase 3,18,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,EKBB 57/07 SB,Jun-07,null,null,14-Aug-07,null,9-Mar-12,"University Hospital Basel, Basel, Switzerland",,https://ClinicalTrials.gov/show/NCT00515801
NCT00515099,Study of Antithymocyte Globulin for Treatment of New-onset T1DM,START,Terminated,Has Results,New-onset Type 1 Diabetes Mellitus,Drug: Antithymocyte globulin|Drug: Placebo,2-Hour C-peptide Area Under the Curve (AUC) Result in Response to Standardized Mixed Meal Tolerance Test (MMTT)|4-Hour C-peptide Area Under the Curve (AUC) Result in Response to Standardized Mixed Meal Tolerance Test (MMTT)|Insulin Use in Units Per Kilogram Body Weight Per Day|Number of Participants Who Are Exogenous-Insulin-Free|Number of Participants With Major Hypoglycemic Event(s) Post Treatment Randomization/Initiation|2-Hour and 4-Hour C-peptide Area Under the Curve (AUC) Results in Response to Standardized Mixed Meal Tolerance Test (MMTT)|Hemoglobin A1c,National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN),All,"12 Years to 35 Years   (Child, Adult)",Phase 2,58,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",DAIT ITN028AI,Aug-07,Jun-12,Jul-13,13-Aug-07,21-Apr-14,11-May-17,"Children's Hospital/USC School of Medicine, Los Angeles, California, United States|Children's Hospital and Research Center, Oakland, California, United States|UCSD/San Diego Children's Hospital, San Diego, California, United States|Diabetes Center at UCSF, San Francisco, California, United States|Barbara Davis Center for Childhood Diabetes, University of Colorado, Aurora, Colorado, United States|Emory Children's Center, Atlanta, Georgia, United States|University of Minnesota, Minneapolis, Minnesota, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00515099
NCT00513214,Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus,,Completed,No Results Available,Type 2 Diabetes,Drug: XOMA 052|Drug: Placebo,Safety assessed by pre- and post-treatment serial measurements of vital signs.|Safety assessed by treatment-emergent adverse events.,XOMA (US) LLC,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,68,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",X052073,Jul-07,Jun-09,Feb-10,8-Aug-07,null,4-Oct-11,"Escondido, California, United States|Miami Gardens, Florida, United States|Omaha, Nebraska, United States|San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00513214
NCT00509925,Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes,,Terminated,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin detemir|Drug: insulin NPH|Drug: insulin aspart,"Total Energy Expenditure, Double-labelled Water Method|Total Energy Expenditure, Dietary Record Method|Component of Total Energy Expenditure: Resting Energy Expenditure (REE)|Component of Total Energy Expenditure: Diet Induced Thermogenesis (DIT)|Component of Total Energy Expenditure: Physical Activity Thermogenesis|Component of Total Energy Expenditure: Non-exercise Activity Thermogenesis (NEAT)|Body Weight|Lean Body Mass|Fat Mass|Waist:Hip Ratio|Hormonal Assessment: Adiponectin|Hormonal Assessment: Insulin-like Growth Factor-1|Hormonal Assessment: Resistin|Hormonal Assessment: Leptin|Glycosylated Haemoglobin A1c (HbA1c)|Fasting Plasma Glucose|Hypoglycaemic Episodes|Hypoglycaemic Episodes, Diurnal/Nocturnal",Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 4,23,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN304-1761|2006-003060-59,Jul-07,Jul-08,Jul-08,1-Aug-07,4-Aug-10,10-Mar-17,"Novo Nordisk Investigational Site, Guildford, United Kingdom",,https://ClinicalTrials.gov/show/NCT00509925
NCT00509236,Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1),,Completed,Has Results,"Diabetes Mellitus, Type 2|End-Stage Kidney Disease",Drug: Sitagliptin|Drug: Glipizide,Change From Baseline in Hemoglobin A1c After Sitagliptin Treatment|Number of Participants With Clinical Adverse Events|Number of Participants With Symptomatic Hypoglycemic Adverse Events|Change From Baseline in Fasting Plasma Glucose (FPG)|Change From Baseline in Hemoglobin A1c for Sitagliptin Versus Glipizide Treatment,Merck Sharp & Dohme Corp.,All,"30 Years and older   (Adult, Older Adult)",Phase 3,129,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0431-073|2007_550,19-Oct-07,14-Mar-11,14-Mar-11,31-Jul-07,3-May-12,12-May-17,,,https://ClinicalTrials.gov/show/NCT00509236
NCT00509262,Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1),,Completed,Has Results,"Diabetes Mellitus, Type 2|Renal Insufficiency, Chronic",Drug: Sitagliptin|Drug: Glipizide|Drug: Placebo for Sitagliptin|Drug: Placebo for Glipizide,Change From Baseline in Hemoglobin A1c (A1C) Levels at Week 54|Percentage of Participants With Hypoglycemic Events|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 54|Change From Baseline in Body Weight at Week 54,Merck Sharp & Dohme Corp.,All,"30 Years and older   (Adult, Older Adult)",Phase 3,426,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",0431-063|2007_549,9-Oct-07,16-Mar-11,16-Mar-11,31-Jul-07,28-Mar-12,12-May-17,,,https://ClinicalTrials.gov/show/NCT00509262
NCT00505882,Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes,,Withdrawn,No Results Available,Type 1 Diabetes,Drug: Pramlintide|Drug: Glargine|Drug: Lispro|Drug: Aspart,The change in weight (kg) will be compared between as well as within the placebo and the pramlintide treatment group from baseline to the end of the study.|mixed meal tolerance test-the C-peptide area under the curve The HOMA R and McAuley's index HbA1c The event rate of severe hypoglycemia Waist circumference Cardio C-reactive protein level DQOL Safety parameter,University of Texas Southwestern Medical Center,All,"12 Years to 70 Years   (Child, Adult, Older Adult)",Phase 4,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,032007-054,Jul-07,Dec-08,Dec-08,25-Jul-07,null,8-Jan-19,"UT Southwestern at Dallas, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00505882
NCT00505375,Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus,,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: CTLA-4 Ig|Other: Placebo,Area Under the Stimulated C-peptide Curve Over the First 2 Hours of a 4 Hour Mixed Meal Tolerance Test at the 2 Year Visit,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Juvenile Diabetes Research Foundation|American Diabetes Association,All,"6 Years to 45 Years   (Child, Adult)",Phase 2,112,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CTLA (IND),Feb-08,May-12,May-12,23-Jul-07,16-Aug-16,16-Aug-16,"Childrens Hospital Los Angeles, Los Angeles, California, United States|University of California - San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|The Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Columbia University, Naomi Berrie Diabetes Center, New York, New York, United States|University of Pittsburgh, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Texas, Southwestern Medical School, Dallas, Texas, United States|Benaroya Research Institute, Seattle, Washington, United States|The Hospital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00505375
NCT00502710,A Study of Dipeptidyl-peptidase IV (DPP-IV) RO4876904 in Patients With Type 2 Diabetes.,,Completed,No Results Available,Diabetes Mellitus Type 2,Drug: Placebo|Drug: RO4876904,"Absolute change in hemoglobin A1c (HbA1c)|Absolute change in fasting plasma glucose (FPG), HbA1c response rate, absolute/relative change in insulin sensitivity, beta cell function, lipid profile.|Adverse events (AEs), vital signs, laboratory parameters.",Hoffmann-La Roche,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,289,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BC20779,Jul-07,Apr-08,Apr-08,18-Jul-07,null,5-Aug-16,"Hot Springs, Arkansas, United States|Concord, California, United States|Los Angeles, California, United States|Chicago, Illinois, United States|Avon, Indiana, United States|Indianapolis, Indiana, United States|Oxon Hill, Maryland, United States|Troy, Michigan, United States|Omaha, Nebraska, United States|Binghamton, New York, United States|Charlotte, North Carolina, United States|Beaver, Pennsylvania, United States|Adelaide, Australia|Canberra, Australia|St. Leonards, Australia|Sao Paulo, Brazil|Sao Paulo, Brazil|Guatemala City, Guatemala|Hong Kong, Hong Kong|Aguascalientes, Mexico|Chihuahua, Mexico|Guadalajara, Mexico|Guadalajara, Mexico|Mexico City, Mexico|Pachuca, Mexico|Tampico, Mexico|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Saratov, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|Yaroslavl, Russian Federation|Yaroslavl, Russian Federation|Alzira, Spain|Bacarot Alicant, Spain|Badalona, Spain|Barcelona, Spain|Ferrol, Spain|Bath, United Kingdom|Frome, United Kingdom|Glasgow, United Kingdom|Liverpool, United Kingdom|Motherwell, United Kingdom",,https://ClinicalTrials.gov/show/NCT00502710
NCT00502138,A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes,,Completed,No Results Available,IDDM,Drug: Continuous Pramlintide infusion,"Fasting and postprandial pramlintide pharmacokinetics|Hemoglobin A1c, body weight, blood glucose variability, patient satisfaction|Hemoglobin A1c","University Diabetes & Endocrine Consultants|Amylin Pharmaceuticals, LLC.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,12,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pramlintide Infusion in IDDM,Jul-07,Jan-08,Jan-08,17-Jul-07,null,16-Jan-13,"University Diabetes & Endocrine Consultants, Chattanooga, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00502138
NCT00501709,Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes,Drug: Belatacept and Raptiva,lnsulin independence,"University of California, San Francisco|Juvenile Diabetes Research Foundation",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,39-42C,Feb-07,Dec-16,Dec-16,16-Jul-07,null,14-Jan-19,"University of California, San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT00501709
NCT00501072,Safety and Efficacy of RT-CGMS in Patients With Type 1 Diabetes Mellitus Treated With an Implantable Pump,IP_RT-CGMS,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: Real-Time Continuous Glucose monitoring System (RT-CGMS),"Clinical effectiveness: percentage of time spent in euglycaemia|Clinical effectiveness: Percentage of time spent in hypoglycaemia and hyperglycaemia.|Safety: incidence of adverse effects|Incidence of hypoglycaemia; Number of SMBG performed, Number of adjustments of insulin therapy, Patient satisfaction, agreement of paired SMBG and RT-CGMS measurements.","Medical Research Foundation, The Netherlands",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,07.0644|NL12530.075.06,Nov-07,Apr-08,Apr-08,13-Jul-07,null,11-Apr-08,"Diabetes Outpatient Clinic, Isala clinics, Zwolle, Netherlands",,https://ClinicalTrials.gov/show/NCT00501072
NCT00500331,Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM),,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: GSK189075|Drug: pioglitazone|Other: Placebo,"Change From Baseline (Week 0) in Glycosylated Hemoglobin (HbA1c) (%) at Week 12|Change From Baseline in HbA1c (%) at Weeks 4 and 8|Change From Baseline to Week 12 in Fasting Plasma Glucose (FPG) at Weeks 4, 8 and 12|Change From Baseline to Week 12 in Fructosamine|Change From Baseline to Week 12 in Fasting Insulin|Number of Participants at Week 12 With: HbA1c <= 6.5%, HbA1c <7.0%; FPG <7 Mmo/L, FPG <7.8 mmol/L; FPG <5.5 mmol/L; a Decrease From Baseline of HbA1c >= 0.7%; a Decrease From Baseline of FPG ≥1.7 mmol/L|Percent Change From Baseline in Lipid Parameters at Weeks 4, 8 and 12(Triglycerides [TG], Total Cholesterol [TC], Low-density Lipoprotein Cholesterol [LDL-C] and High-density Lipoprotein Cholesterol [HDL-C])|Change From Baseline to Week 12 in Body Weight|Change From Baseline to Week 12 in Waist Circumference|Change From Baseline in 24-hour Percent of Filtered Glucose Excreted in Urine|Change From Baseline in Plasma Glucose Area Under the Curve (AUC) During a 2-hour Oral Glucose Tolerance Test (OGTT)|Change From Baseline in Insulin AUC During a 2-hour OGTT|Change From Baseline in C-peptide AUC During a 2-hr OGTT|Number of Participants With On-therapy Adverse Events (AE) and Serious Adverse Events (SAE)|Number of Participants With On-therapy Hypoglycemia|Number of Participants With Change From Baseline Vital Signs of Potential Clinical Concern|Number of Participants With Electrocardiogram (ECG) Values of Potential Clinical Concern|Number of Participants With Change From Baseline in Standard Laboratory Parameters of Potential Clinical Concern",GlaxoSmithKline,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,334,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",KG2105255,23-Jan-07,14-Feb-08,14-Feb-08,12-Jul-07,6-Dec-17,6-Dec-17,"GSK Investigational Site, Mesa, Arizona, United States|GSK Investigational Site, Hollywood, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Saint Cloud, Florida, United States|GSK Investigational Site, Sunset, Louisiana, United States|GSK Investigational Site, Oxon Hill, Maryland, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Albuquerque, New Mexico, United States|GSK Investigational Site, Canal Fulton, Ohio, United States|GSK Investigational Site, Simpsonville, South Carolina, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Burke, Virginia, United States|GSK Investigational Site, Buenos Aries, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Cordoba, Córdova, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Cordoba, Argentina|GSK Investigational Site, Mendoza, Argentina|GSK Investigational Site, Quilmes, Argentina|GSK Investigational Site, Tucuman, Argentina|GSK Investigational Site, Pleven, Bulgaria|GSK Investigational Site, Plovdiv, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Varna, Bulgaria|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, San José, Costa Rica|GSK Investigational Site, Brno, Czechia|GSK Investigational Site, Brno, Czechia|GSK Investigational Site, Brno, Czechia|GSK Investigational Site, Ceske Budejovice, Czechia|GSK Investigational Site, Cheb, Czechia|GSK Investigational Site, Havirov - Soumbrak, Czechia|GSK Investigational Site, Olomouc, Czechia|GSK Investigational Site, Prague, Czechia|GSK Investigational Site, Praha 5, Czechia|GSK Investigational Site, Praha 5, Czechia|GSK Investigational Site, Praha 5, Czechia|GSK Investigational Site, Semily, Czechia|GSK Investigational Site, Sumperk, Czechia|GSK Investigational Site, Usti nad Labem, Czechia|GSK Investigational Site, Znojmo, Czechia|GSK Investigational Site, Bammental, Baden-Wuerttemberg, Germany|GSK Investigational Site, Kippenheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Mannheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Weinheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Haag, Bayern, Germany|GSK Investigational Site, Hoehenkirchen-Siegertsbrunn, Bayern, Germany|GSK Investigational Site, Lampertheim, Hessen, Germany|GSK Investigational Site, Damme, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Hildesheim, Niedersachsen, Germany|GSK Investigational Site, Bergkamen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Mainz, Rheinland-Pfalz, Germany|GSK Investigational Site, Rhaunen, Rheinland-Pfalz, Germany|GSK Investigational Site, Speyer, Rheinland-Pfalz, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Debrecen, Hungary|GSK Investigational Site, Erd, Hungary|GSK Investigational Site, Győr, Hungary|GSK Investigational Site, Miskolc, Hungary|GSK Investigational Site, Miskolc, Hungary|GSK Investigational Site, Mosonmagyaróvár, Hungary|GSK Investigational Site, Nyirtegyhaza, Hungary|GSK Investigational Site, Pécs, Hungary|GSK Investigational Site, Szentes, Hungary|GSK Investigational Site, Szigetvar, Hungary|GSK Investigational Site, Szombathely, Hungary|GSK Investigational Site, Veszprem, Hungary|GSK Investigational Site, Zalaegerszeg, Hungary|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Kochi, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, New Delhi, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Jelgava, Latvia|GSK Investigational Site, Limbazi, Latvia|GSK Investigational Site, Riga, Latvia|GSK Investigational Site, Riga, Latvia|GSK Investigational Site, Riga, Latvia|GSK Investigational Site, Riga, Latvia|GSK Investigational Site, Riga, Latvia|GSK Investigational Site, Talsi, Latvia|GSK Investigational Site, Tukums, Latvia|GSK Investigational Site, Kaunas, Lithuania|GSK Investigational Site, Kaunas, Lithuania|GSK Investigational Site, Kaunas, Lithuania|GSK Investigational Site, Vilnius, Lithuania|GSK Investigational Site, Vilnius, Lithuania|GSK Investigational Site, Tijuana, Baja California Norte, Mexico|GSK Investigational Site, Mexico City, Estado De México, Mexico|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, Durango, Mexico|GSK Investigational Site, Mexico, Mexico|GSK Investigational Site, Mexico, Mexico|GSK Investigational Site, Auckland, New Zealand|GSK Investigational Site, Auckland, New Zealand|GSK Investigational Site, Hamilton, New Zealand|GSK Investigational Site, Rotorua, New Zealand|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Bydgoszcz, Poland|GSK Investigational Site, Grudziadz, Poland|GSK Investigational Site, Lodz, Poland|GSK Investigational Site, Porabka, Poland|GSK Investigational Site, Siemianowice Slaskie, Poland|GSK Investigational Site, Wroclaw, Poland|GSK Investigational Site, Ponce, Puerto Rico|GSK Investigational Site, Brasov, Romania|GSK Investigational Site, Bucharest, Romania|GSK Investigational Site, Deva, Romania|GSK Investigational Site, Iasi, Romania|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St.-Petersburg, Russian Federation|GSK Investigational Site, Tomsk, Russian Federation|GSK Investigational Site, Tumen, Russian Federation|GSK Investigational Site, Ufa, Russian Federation|GSK Investigational Site, Bellville, South Africa|GSK Investigational Site, Gauteng, South Africa|GSK Investigational Site, Orangegrove, Linksfield West, South Africa|GSK Investigational Site, Parow, South Africa|GSK Investigational Site, Roodepoort, South Africa",,https://ClinicalTrials.gov/show/NCT00500331
NCT00499707,Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: rosiglitazone maleate/metformin hydrochloride,"Change from baseline in hemoglobin A1c (HbA1c) at week 32.|Key Secondary Measures: Change in FPG HbA1c and FPG responders Change in insulin, C-peptide, free fatty acids, lipids, insulin sensitivity and beta cell function Adverse Events Vital Signs Weight 32 weeks",GlaxoSmithKline,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,453,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",712753/007,8-Oct-03,1-Dec-04,16-Dec-04,11-Jul-07,null,21-Mar-18,"GSK Investigational Site, Anniston, Alabama, United States|GSK Investigational Site, Chandler, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Encinitas, California, United States|GSK Investigational Site, Fullerton, California, United States|GSK Investigational Site, Los Banos, California, United States|GSK Investigational Site, Mission Viejo, California, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Melbourne, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Saint Cloud, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Fayetteville, Georgia, United States|GSK Investigational Site, Woodstock, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Evansville, Indiana, United States|GSK Investigational Site, Newburgh, Indiana, United States|GSK Investigational Site, Slidell, Louisiana, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, Chesterfield, Missouri, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Kingston, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Rochester, New York, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Mogadore, Ohio, United States|GSK Investigational Site, Downingtown, Pennsylvania, United States|GSK Investigational Site, Warminster, Pennsylvania, United States|GSK Investigational Site, West Chester, Pennsylvania, United States|GSK Investigational Site, Bristol, Tennessee, United States|GSK Investigational Site, Johnson City, Tennessee, United States|GSK Investigational Site, Arlington, Texas, United States|GSK Investigational Site, Beaumont, Texas, United States|GSK Investigational Site, Bryan, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Midland, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Spokane, Washington, United States|GSK Investigational Site, Wenatchee, Washington, United States|GSK Investigational Site, Camperdown, New South Wales, Australia|GSK Investigational Site, St Leonards, New South Wales, Australia|GSK Investigational Site, Wollongong, New South Wales, Australia|GSK Investigational Site, Kippa Ring, Queensland, Australia|GSK Investigational Site, Woolloongabba, Queensland, Australia|GSK Investigational Site, North Adelaide, South Australia, Australia|GSK Investigational Site, Caulfield, Victoria, Australia|GSK Investigational Site, Fremantle, Western Australia, Australia|GSK Investigational Site, Perth, Western Australia, Australia|GSK Investigational Site, Recife, Pernambuco, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Coquitlam, British Columbia, Canada|GSK Investigational Site, Langley, British Columbia, Canada|GSK Investigational Site, Moncton, New Brunswick, Canada|GSK Investigational Site, Halifax, Nova Scotia, Canada|GSK Investigational Site, Brampton, Ontario, Canada|GSK Investigational Site, Burlington, Ontario, Canada|GSK Investigational Site, Courtice, Ontario, Canada|GSK Investigational Site, Kitchener, Ontario, Canada|GSK Investigational Site, North Bay, Ontario, Canada|GSK Investigational Site, Oshawa, Ontario, Canada|GSK Investigational Site, Peterborough, Ontario, Canada|GSK Investigational Site, Peterborough, Ontario, Canada|GSK Investigational Site, Renfrew, Ontario, Canada|GSK Investigational Site, Stoney Creek, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Laval, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Plessisville, Quebec, Canada|GSK Investigational Site, Pointe-Claire, Quebec, Canada|GSK Investigational Site, Saint Insidore De Dorchester, Quebec, Canada|GSK Investigational Site, Saint Marc Des Carrieres, Quebec, Canada|GSK Investigational Site, Sainte Jerome, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Regina, Saskatchewan, Canada|GSK Investigational Site, Regina, Saskatchewan, Canada|GSK Investigational Site, Saskatoon, Saskatchewan, Canada|GSK Investigational Site, Pusan, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Uijeongbu,, Korea, Republic of|GSK Investigational Site, Tijuana, Baja California Norte, Mexico|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, Durango, Mexico|GSK Investigational Site, Mexico, D.F., Mexico|GSK Investigational Site, Mexico, D.F., Mexico|GSK Investigational Site, Auckland, New Zealand|GSK Investigational Site, Auckland, New Zealand|GSK Investigational Site, Christchurch, New Zealand|GSK Investigational Site, Rotorua, New Zealand|GSK Investigational Site, Wellington, New Zealand",,https://ClinicalTrials.gov/show/NCT00499707
NCT00497536,Pharmacokinetics of IAsp Following CSII in Patients With T1DM,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Insulin Aspart (IAsp)|Drug: Insulin Aspart (IAsp).,"CV SSPIasp|• Δ SSPIAsp (S.C. /I.V.) • AUC IAsp • Tmax IAsp • Cmax IAsp - Bioequivalence of Iasp under SS (GIR, S-FFA, S-glycerol)",University of Aarhus,All,18 Years to 60 Years   (Adult),Phase 4,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2007-001912-21,Jul-07,Jul-08,Jul-08,6-Jul-07,null,5-Feb-09,"Medicinsk Endokrinologisk Afdeling M, Aarhus C, Region Midtjylland, Denmark",,https://ClinicalTrials.gov/show/NCT00497536
NCT00495469,Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive,,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: GSK189075|Drug: Placebo,Mean Change From Baseline in Hemoglobin A1c (Glycosylated Hemoglobin) (HbA1c) at Week 12|Mean Change From Baseline in HbA1c at Weeks 4 and 8|Mean Change From Baseline to Week 12 in Fasting Plasma Glucose (FPG)|Mean Change From Baseline to Week 12 in Fructosamine (Corrected)|Number of Participants Who Were HbA1c Responders at Week 12|Number of Participants Who Were Fasting Plasma Glucose (FPG) Responders at Week 12|Mean Change From Baseline to Week 12 in Triglycerides|Mean Change From Baseline to Week 12 in Total Cholesterol|Mean Change From Baseline to Week 12 in Low Density Lipoprotein Cholesterol (LDL-c)|Mean Change From Baseline to Week 12 in High Density Lipoprotein Cholesterol (HDL-c)|Mean Change From Baseline to Week 12 in LDL-c/HDL-c Ratio|Mean Change From Baseline to Week 12 in Total Cholesterol/HDL-c Ratio|Mean Change From Baseline to Week 12 in Body Weight|Number of Participants With Any On-therapy Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With On-therapy Hypoglycemia|Number of Participants With Vital Signs of Potential Clinical Importance (PCI) at Any Time on Therapy|Number of Participants With Abnormal Electrocardiogram (ECG) Findings at Any Time Post-Baseline|Number of Participants With Abnormal Chemistry Value of PCI at Any Time on Therapy|Number of Participants With Abnormal Hematology Value of PCI at Any Time on Therapy,GlaxoSmithKline,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,250,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",KG2110375,17-Aug-07,5-Jun-08,5-Jun-08,3-Jul-07,30-Oct-17,30-Oct-17,"GSK Investigational Site, Mesa, Arizona, United States|GSK Investigational Site, Artesia, California, United States|GSK Investigational Site, Buena Park, California, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Greenbrae, California, United States|GSK Investigational Site, La Jolla, California, United States|GSK Investigational Site, Norwalk, California, United States|GSK Investigational Site, Petaluma, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, San Mateo, California, United States|GSK Investigational Site, Santa Ana, California, United States|GSK Investigational Site, Tarzana, California, United States|GSK Investigational Site, Torrance, California, United States|GSK Investigational Site, Deland/Florida, Florida, United States|GSK Investigational Site, Hollywood, Florida, United States|GSK Investigational Site, Jacksonville/Florida, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Ocoee/Florida, Florida, United States|GSK Investigational Site, Saint Cloud, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Bloomingdale, Illinois, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Oak Brook, Illinois, United States|GSK Investigational Site, South Bend, Indiana, United States|GSK Investigational Site, Lafayette, Louisiana, United States|GSK Investigational Site, Lake Charles, Louisiana, United States|GSK Investigational Site, Oxon Hill, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Gulfport, Mississippi, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, Kosciusko, Mississippi, United States|GSK Investigational Site, Rolling Fork, Mississippi, United States|GSK Investigational Site, Chesterfield, Missouri, United States|GSK Investigational Site, St. Louis/Missouri, Missouri, United States|GSK Investigational Site, Henderson, Nevada, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Clifton, New Jersey, United States|GSK Investigational Site, Albuquerque, New Mexico, United States|GSK Investigational Site, Commack, New York, United States|GSK Investigational Site, Ithaca, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Asheboro/North Carolina, North Carolina, United States|GSK Investigational Site, Canal Fulton, Ohio, United States|GSK Investigational Site, Bensalem/Pennsylvania, Pennsylvania, United States|GSK Investigational Site, West Chester, Pennsylvania, United States|GSK Investigational Site, Manning, South Carolina, United States|GSK Investigational Site, Simpsonville, South Carolina, United States|GSK Investigational Site, Athens/Tennessee, Tennessee, United States|GSK Investigational Site, Corpus Christi, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Harlingen/Texas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Midland, Texas, United States|GSK Investigational Site, San Anonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Burke, Virginia, United States|GSK Investigational Site, Bellevue, Washington, United States|GSK Investigational Site, Langley, British Columbia, Canada|GSK Investigational Site, Bathurst, New Brunswick, Canada|GSK Investigational Site, Bay Roberts, Newfoundland and Labrador, Canada|GSK Investigational Site, Brampton, Ontario, Canada|GSK Investigational Site, Mississauga, Ontario, Canada|GSK Investigational Site, Oakville, Ontario, Canada|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Thornhill, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, L'ancienne-Lorette, Quebec, Canada|GSK Investigational Site, Québec, Canada|GSK Investigational Site, Brno, Czechia|GSK Investigational Site, Brno, Czechia|GSK Investigational Site, Praha 10, Czechia|GSK Investigational Site, Praha 5, Czechia|GSK Investigational Site, Parnu, Estonia|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tallin, Estonia|GSK Investigational Site, Tartu, Estonia|GSK Investigational Site, Allmendingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Wangen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Grossheirath, Bayern, Germany|GSK Investigational Site, Hohenau, Bayern, Germany|GSK Investigational Site, Kuenzing, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Parsberg, Bayern, Germany|GSK Investigational Site, Ruhmannsfelden, Bayern, Germany|GSK Investigational Site, Sulzbach-Rosenberg, Bayern, Germany|GSK Investigational Site, Falkensee, Brandenburg, Germany|GSK Investigational Site, Brinkum/Stuhr, Niedersachsen, Germany|GSK Investigational Site, Einbeck, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Lueneburg, Niedersachsen, Germany|GSK Investigational Site, Tostedt, Niedersachsen, Germany|GSK Investigational Site, Hassloch, Rheinland-Pfalz, Germany|GSK Investigational Site, Ingelheim, Rheinland-Pfalz, Germany|GSK Investigational Site, Wolmirstedt, Sachsen-Anhalt, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Freital, Sachsen, Germany|GSK Investigational Site, Schmiedeberg, Sachsen, Germany|GSK Investigational Site, Luebeck, Schleswig-Holstein, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Thessaloniki,, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Chennai, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Kaunas, Lithuania|GSK Investigational Site, Kaunas, Lithuania|GSK Investigational Site, Kaunas, Lithuania|GSK Investigational Site, Vilnius, Lithuania|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Cuernavaca, Morelos, Mexico|GSK Investigational Site, Mérida, Yucatán, Mexico|GSK Investigational Site, Durango, Mexico|GSK Investigational Site, Rotorua, New Zealand|GSK Investigational Site, Bydgoszcz, Poland|GSK Investigational Site, Porabka, Poland|GSK Investigational Site, Siemianowice Slaskie, Poland|GSK Investigational Site, Wroclaw, Poland|GSK Investigational Site, Aibonito/Puerto Rico, Puerto Rico|GSK Investigational Site, Caguas, Puerto Rico|GSK Investigational Site, Carolina, Puerto Rico|GSK Investigational Site, Ponce, Puerto Rico|GSK Investigational Site, Rio Piedras, Puerto Rico|GSK Investigational Site, Trujillo Alto/Puerto Rico, Puerto Rico|GSK Investigational Site, Arad, Romania|GSK Investigational Site, Brasov, Romania|GSK Investigational Site, Sfantu Gheorghe, Romania|GSK Investigational Site, Timisoara, Romania|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Saint-Peterburgh, Russian Federation|GSK Investigational Site, St.Petersburg, Russian Federation|GSK Investigational Site, Tomsk, Russian Federation|GSK Investigational Site, Tumen, Russian Federation|GSK Investigational Site, Lenasia South, Gauteng, South Africa|GSK Investigational Site, Bellville, South Africa|GSK Investigational Site, Gauteng, South Africa|GSK Investigational Site, Parow, South Africa|GSK Investigational Site, Roodepoort, South Africa|GSK Investigational Site, Dnipropetrovsk, Ukraine|GSK Investigational Site, Kyiv, Ukraine|GSK Investigational Site, Vinnitsa, Ukraine",,https://ClinicalTrials.gov/show/NCT00495469
NCT00491465,The Role of Physical Activity in the Treatment of Children With Type 1 Diabetes.,4301,Unknown status,No Results Available,Type 1 Diabetes,Behavioral: Intensive Physical activity|Behavioral: Control- regular physical activity,HbA1C|fructosamine|Body composition & BMR|Self esteem & QOL questionnaires|3 days CGMS & SBGM profile,Rabin Medical Center,All,8 Years to 16 Years   (Child),Not Applicable,2007,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,rmc074301ctil,Jul-07,null,Jul-09,26-Jun-07,null,26-Jun-07,"Schnider children's medical center, Petach-Tikva, Israel",,https://ClinicalTrials.gov/show/NCT00491465
NCT00489190,APIDRA Registration Study,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Insulin Glulisine,"Dynamics НbA1c in the final point compared with the initial level.|Dynamics compared with the initial level of glycemia and insulin dosages.|Evaluation of frequency of glycemia episodes. Also undesirable events, Influence on indexes of general clinical analysis of blood and biochemical analysis of blood.",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 4,45,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APIDR_L_00041,Aug-05,null,null,21-Jun-07,null,16-Mar-09,"Sanofi-Aventis, Almaty, Kazakhstan",,https://ClinicalTrials.gov/show/NCT00489190
NCT00489645,Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide,,Completed,No Results Available,Type 1 Diabetes,Drug: placebo|Drug: pramlintide,"• To examine the influence of acute glycaemia (normoglycaemia and hyperglycaemia) on gastric emptying kinetics in patients with type 1 diabetes and non diabetic subjects when treated with subcutaneous (SC) injections of pramlintide.|• Gastric peristalsis derived from high-resolution scintigraphy by means of Fast Fourier Transform (FFT) analysis. • Effects on gastric emptying and on the rate of appearance of ingested glucose appearance, postprandial glucose sequestration, endoge",Ludwig-Maximilians - University of Munich|University of Rochester,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,27,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,PRAM025/04|DFG Schi 527/1-2,Jan-05,Mar-07,Apr-07,21-Jun-07,null,16-Jan-08,,,https://ClinicalTrials.gov/show/NCT00489645
NCT00487240,Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes,IOOZ,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Insulin Lispro Protamine Suspension|Drug: Insulin Levemir,"Change in Hemoglobin A1c (HbA1c) From Baseline to Endpoint|Actual and Change From Baseline Hemoglobin A1c (HbA1c) Values|Percentage of Patients With Hemoglobin A1c (HbA1c) Less Than or Equal to 7.0% and HbA1c Less Than or Equal to 6.5%|7-Point Self-Monitored Blood Glucose (SMBG) at Endpoint|Glycemic Variability at Endpoint|Number of Self-Reported Hypoglycemic Episodes (Including Nocturnal, Non-Nocturnal, and Severe Hypoglycemia) Overall and at Endpoint|1-Year Adjusted Rates of Self-Reported Hypoglycemic Episodes (Including Nocturnal, Non-Nocturnal, and Severe) Overall and at Endpoint|30-Day Adjusted Rates of Self-Reported Hypoglycemic Episodes (Including Nocturnal, Non-Nocturnal, and Severe) Overall and at Endpoint|Change From Baseline in Absolute Body Weight at 32 Week Endpoint|Insulin Dose Per Body Weight (Total and By Component [Basal and Bolus])|Insulin Dose (Total and By Component [Basal and Bolus])",Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,387,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10937|F3Z-MC-IOOZ,Jun-07,Aug-08,Aug-08,18-Jun-07,25-Sep-09,4-Nov-10,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Idaho Falls, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Springfield, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Topeka, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Plata, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wollongong, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Box Hill, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fortaleza, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Thessaloniki, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mosonmagyarovar, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pecs, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szentes, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zalaegerszeg, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pachuca, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Puebla, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baia Mare, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brasov, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iasi, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arkhangelsk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rostov-On-Don, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation",,https://ClinicalTrials.gov/show/NCT00487240
NCT00486109,"A Prospective, Randomized, Parallel Crossover Study Demonstrating Subject Wearability and Usability of the I-Port Injection Port",,Completed,No Results Available,Type 1 Diabetes|Type 2 Diabetes,Device: I-Port(TM) Injection Port,"Glycosylated albumin levels|Participants' satisfaction evaluated with standard quality of life questionnaires and adverse events related to the study device including incidents of erythema > 2cm diameter, incidence of induration > 1cm dimater and incidence of suppuration.","Patton Medical Devices|Medstar Health Research Institute|Valeritas, Inc.",All,"14 Years to 70 Years   (Child, Adult, Older Adult)",Not Applicable,74,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,PTN 012.1,Oct-06,null,Jan-07,13-Jun-07,null,11-Mar-08,"Atlanta Diabetes Associates, Atlanta, Georgia, United States|Diabetes and Endocrine Associates, Omaha, Nebraska, United States|Texas Diabetes & Endocrinology, Austin, Texas, United States|Research Institute of Dallas, Dallas, Texas, United States|Diabetes and Glandular Disease Clinic, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00486109
NCT00482443,Assessing the Effectiveness of Diabetes Interactive Diary (DID) in Diabetes Management,DID,Completed,No Results Available,Type 1 Diabetes Mellitus,Other: A software programme in mobile telephone|Other: Standard Education Programme.,"The difference in HbA1c between the patient in the DID group and in the standard education group.|The differences between the two groups in terms of, lipid profile, blood pressure, the number of hypoglycaemic episodes, daily blood sugar fluctuation, total insulin dose, weight changes and patients' satisfaction with the treatment.",The Royal Bournemouth Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,DID,Mar-07,Apr-08,Apr-08,5-Jun-07,null,10-Jul-08,"Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom",,https://ClinicalTrials.gov/show/NCT00482443
NCT00481598,Non Invasive Assessment of Liver Glycogen Kinetics and ATP Synthesis in Type1 Diabetics,,Completed,No Results Available,Type 1 Diabetes Mellitus,Procedure: magnet resonance spectroscopy,"glycogen metabolism, gluconeogenesis, after 3 months of treatment;",Landsteiner Institut|University of Coimbra,All,18 Years to 50 Years   (Adult),Not Applicable,28,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,JDRF Grant Number: 1-2006-74,Jan-06,Jul-08,Sep-08,4-Jun-07,null,12-Sep-08,"Landsteiner Institute for Endocrinology and Metabolic Diseases, Hanusch Hospital Heinrich Collin Straße 30, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT00481598
NCT00480493,STEP: Social Support To Empower Parents,STEP,Completed,Has Results,Type 1 Diabetes,Behavioral: STEP,Maternal Confidence Scale|Parent Concern|Worry,"University of Massachusetts, Worcester",All,"18 Years and older   (Adult, Older Adult)",Phase 3,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,1R15NR008391-01,Jun-04,May-08,May-08,31-May-07,30-Jul-12,30-Jul-12,"University of Massachusetts, Worcester, Worcester, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00480493
NCT00479258,Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents,,Terminated,Has Results,"Diabetes Mellitus, Type 1",Drug: Inhaled insulin (Exubera)|Drug: Subcutaneous Insulin (subject's prescribed),"To Assess Pulmonary Safety and Glycemic Control of Exubera Over a 12 Month Controlled Period|Change From Baseline in Other PFT Parameters|Slope From Baseline to Week 52 and Slope From Week 12 to Week 52 for FEV1 and FVC as a Percent of Predicted;|Treatment Preferences.|Change From Baseline in FVC|Slope for Other PFT Parameters;|Proportion of Subjects Achieving ADA Age Appropriate Guidelines for HbA1c|Change From Baseline in Insulin Antibodies (microU/mL);|Change From Baseline in Body Weight (kg), Height (cm), and Body Mass Index (BMI; kg/m2) and z Score (%);Dose of Insulin;|Hypoglycemic Event Rates;|7 Point Home Glucose",Pfizer,All,6 Years to 17 Years   (Child),Phase 3,2,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A2171083,Oct-07,Oct-07,Oct-07,28-May-07,3-Nov-08,1-Oct-18,"Pfizer Investigational Site, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT00479258
NCT00476788,Fast Track CSII Using a Novel Device in Young Children With Newly Diagnosed T1DM,,Completed,Has Results,Type 1 Diabetes Mellitus,Device: Omnipod Insulin Management System,Mean Glycated Hemoglobin (A1c)|Number of Reported Adverse Events,University of Alabama at Birmingham,All,1 Year to 8 Years   (Child),Not Applicable,14,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,X060928006,Apr-07,Aug-09,Sep-09,22-May-07,24-Jan-11,17-Apr-17,"Children's Hospital, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT00476788
NCT00476931,Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Diabetic Polyneuropathy",Biological: SB-509|Other: Placebo,"Total Neuropathy Score (TNS),Evoked nerve conduction velocity (NCV), Quantitative Sensory Testing (QST), %of subjects with conversion of unmeasurable to measurable NCV and NIS-LL|Safety",Sangamo Therapeutics,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,91,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,SB-509-0701,May-07,Jul-10,Dec-10,22-May-07,null,1-Nov-12,"Coordinated Clinical Research, La Jolla, California, United States|Advanced Medical Research, LLC, Lakewood, California, United States|Torrance Clinical Research, Lomita, California, United States|SF Clinical Research Center, San Francisco, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Bradenton Research Center, Bradenton, Florida, United States|Neurology Clinical Research, Sunrise, Florida, United States|Laszlo J. Mate', M.D., West Palm Beach, Florida, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Creighton Diabetes Center, Omaha, Nebraska, United States|Advanced Biomedical Research of America, Las Vegas, Nevada, United States|Upstate Clinical Research, Albany, New York, United States|Peripheral Neuropathy Center, Weill Medical College of Cornell University, New York, New York, United States|Neurological Institute Columbia University College of Physicians and Surgeons, New York, New York, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Nerve and Muscle Center of Texas, Houston, Texas, United States|Diabetes Center of the Southwest, Midland, Texas, United States|DGD Research, San Antonio, Texas, United States|Rainier Clinical Research Center, Renton, Washington, United States|Instituto Mexicano de Investigación Clinica, Mexico City, Col. Roma, Mexico",,https://ClinicalTrials.gov/show/NCT00476931
NCT00477204,Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes,,Completed,Has Results,Type 1 Diabetes Mellitus|Dyslipidemia,Drug: Simvastatin|Drug: Ezetimibe/Simvastatin,Change in LDL-c From Baseline to 6 Months in Subjects With Type 1 Diabetes Taking Vytorin or Zocor.|No Secondary Outcomes,"University of Colorado, Denver|Merck Sharp & Dohme Corp.|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",All,"12 Years to 18 Years   (Child, Adult)",Phase 2,9,Other|Industry|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",06-1036|K23DK075360,May-07,Aug-10,Aug-10,22-May-07,21-Jun-13,28-Aug-13,"Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT00477204
NCT00475345,Impact of Optimized Titration and Delivery of Bedtime Insulin on Prevention of Nocturnal Hypoglycemia,,Completed,No Results Available,Type 1 Diabetes Mellitus,Behavioral: Bedtime snacks,"Incidence of nocturnal hypoglycemia (< 4mmol/L) occurring between 11pm and 7am, as determined with the Continuous Glucose Monitoring System (CGMS) and hemoglobin A1c|Nadir nocturnal BG, timing and duration of nocturnal hypoglycemia, fasting BG, lipid profile, psychosocial factors, total insulin dose, insulin sensitivity and body composition (weight, BMI, % fat, waist circumference).",McGill University|Canadian Diabetes Association,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,29,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,A05-M27-00,Aug-00,null,Sep-01,21-May-07,null,21-May-07,"Royal Victoria Hospital, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00475345
NCT00475371,"A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males",,Completed,No Results Available,"Diabetes Mellitus, Type 2|Healthy Males",Drug: MKC253 Inhalation Powder,Determine the safety and tolerability of ascending doses of MKC253 Inhalation Powder|Incidence of pulmonary and other AEs|Pharmacokinetic (PK) parameters of plasma GLP-1,Mannkind Corporation,Male,18 Years to 45 Years   (Adult),Phase 1,26,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MKC-253-001|EudraCT Number 2007-000361-37,Apr-07,Jun-07,null,21-May-07,null,14-Jun-12,"University Medical Centre Groningen, Zuidlaren, Netherlands",,https://ClinicalTrials.gov/show/NCT00475371
NCT00474045,Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes,,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin detemir|Drug: NPH insulin|Drug: insulin aspart,Glycosylated Haemoglobin (HbA1c) for Full Analysis Set (Pregnant Subjects) at GW 36|Glycosylated Haemoglobin (HbA1c) for Per Protocol Analysis Set (Pregnant Subjects) at GW 36|Glycosylated Haemoglobin (HbA1c) During Pregnancy|Subjects Reaching HbA1c at or Below 6.0% Both at GW 24 and GW 36|Fasting Plasma Glucose (FPG)|8-point Self-monitored Plasma Glucose (SMPG) Profile at GW 24|8-point Self Monitored Plasma Glucose (SMPG) Profile at GW 36|Maternal Safety - Number of Subjects With Adverse Events (AEs)|Safety in Children - Number of Subjects (Foetuses and Newborns) With Adverse Events|Maternal Safety - Hypoglycaemic Episodes|Maternal Safety - Nocturnal Hypoglycaemic Episodes|Maternal Safety - Change in Albumin Serum Level (Biochemistry)|Maternal Safety - Change in Alanine Aminotransferase Serum Level (Biochemistry)|Maternal Safety - Change in Alkaline Phosphatase Serum Level (Biochemistry)|Maternal Safety - Change in Creatinine Serum Level (Biochemistry)|Maternal Safety - Change in Lactate Dehydrogenase Serum Level (Biochemistry)|Maternal Safety - Change in Potassium Serum Level (Biochemistry)|Maternal Safety - Change in Sodium Serum Level (Biochemistry)|Maternal Safety - Change in Total Protein Serum Level (Biochemistry)|Maternal Safety - Change in Haemoglobin Level (Haematology)|Maternal Safety - Change in Leukocytes Level (Haematology)|Maternal Safety - Change in Thrombocytes Level (Haematology)|Maternal Safety - Change in Urine Albumin Level (Urinalysis)|Maternal Safety - Change in Albumin/Creatinine Ratio (Urinalysis)|Maternal Safety - Change in Urine N (Creatinine) (Urinalysis)|Maternal Safety - Change in Insulin Detemir Specific Antibodies|Maternal Safety - Change in Insulin Aspart Specific Antibodies|Maternal Safety - Change in Insulin Detemir/Insulin Aspart Cross Reacting Antibodies|Pregnancy Outcome Safety - Level of Detemir Specific Antibodies (AB) in Umbilical Cord Blood|Pregnancy Outcome Safety - Level of Aspart Specific Antibodies (AB) in Umbilical Cord Blood|Pregnancy Outcome Safety - Level of Cross-Reacting Antibodies (AB) in Umbilical Cord Blood|Ratio Between Detemir Specific Antibodies in Cord Blood and Maternal Antibodies|Pregnancy Outcome Safety - Level of Insulin Detemir in Umbilical Cord Blood|Maternal Safety - Change From Visit P1 in Body Weight During Pregnancy by Visit|Maternal Safety - Change From Visit P1 in Systolic Blood Pressure During Pregnancy and at Follow-Up by Visit|Maternal Safety - Change From Visit P1 in Diastolic Blood Pressure During Pregnancy and at Follow-Up by Visit|Maternal Safety - Change From Visit P1 in Pulse During Pregnancy and at Follow-Up|Maternal Safety - Electrocardiogram (ECG)|Maternal Safety - Acceleration of Retinopathy in Any Eye|Maternal Safety - Acceleration of Nephropathy|Maternal Safety - Mode of Delivery|Pregnancy Outcome at Delivery|Pregnancy Outcome at Follow-Up|Safety - Total Daily Insulin Dose During Pregnancy|Safety - Composite Pregnancy Outcome|Ratio Between Aspart Specific Antibodies in Cord Blood and Maternal Antibodies|Ratio Between Cross-reacting Antibodies in Cord Blood and Maternal Antibodies,Novo Nordisk A/S,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,470,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN304-1687|2006-004861-33,May-07,Aug-10,Aug-10,16-May-07,5-Dec-11,10-Mar-17,"Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Mar del Plata, Argentina|Novo Nordisk Investigational Site, Pcia de Cordoba, Argentina|Novo Nordisk Investigational Site, Salta, Argentina|Novo Nordisk Investigational Site, Broadmeadow, New South Wales, Australia|Novo Nordisk Investigational Site, Camperdown, New South Wales, Australia|Novo Nordisk Investigational Site, St Leonards, New South Wales, Australia|Novo Nordisk Investigational Site, Elizabeth Vale, South Australia, Australia|Novo Nordisk Investigational Site, Clayton, Australia|Novo Nordisk Investigational Site, Garran, Australia|Novo Nordisk Investigational Site, South Brisbane, Australia|Novo Nordisk Investigational Site, Subiaco, Australia|Novo Nordisk Investigational Site, Wollongong, Australia|Novo Nordisk Investigational Site, Feldkirch, Austria|Novo Nordisk Investigational Site, Innsbruck, Austria|Novo Nordisk Investigational Site, Salzburg, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Curitiba, Parana, Brazil|Novo Nordisk Investigational Site, Porto Alegre, Brazil|Novo Nordisk Investigational Site, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Brazil|Novo Nordisk Investigational Site, Calgary, Alberta, Canada|Novo Nordisk Investigational Site, Cambridge, Ontario, Canada|Novo Nordisk Investigational Site, London, Ontario, Canada|Novo Nordisk Investigational Site, Edmonton, Canada|Novo Nordisk Investigational Site, Montreal, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Toronto, Canada|Novo Nordisk Investigational Site, Toronto, Canada|Novo Nordisk Investigational Site, Vancouver, Canada|Novo Nordisk Investigational Site, Winnipeg, Canada|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Aalborg, Denmark|Novo Nordisk Investigational Site, Aarhus N, Denmark|Novo Nordisk Investigational Site, København ø, Denmark|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Amiens, France|Novo Nordisk Investigational Site, Angers, France|Novo Nordisk Investigational Site, Bondy, France|Novo Nordisk Investigational Site, Lille, France|Novo Nordisk Investigational Site, Marseille, France|Novo Nordisk Investigational Site, MONTPELLIER cedex 5, France|Novo Nordisk Investigational Site, Nimes, France|Novo Nordisk Investigational Site, Strasbourg, France|Novo Nordisk Investigational Site, TOULOUSE cedex 9, France|Novo Nordisk Investigational Site, Valenciennes, France|Novo Nordisk Investigational Site, Dublin 1, Ireland|Novo Nordisk Investigational Site, Dublin 2, Ireland|Novo Nordisk Investigational Site, Dublin 8, Ireland|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Petach Tikva, Israel|Novo Nordisk Investigational Site, Bergen, Norway|Novo Nordisk Investigational Site, Trondheim, Norway|Novo Nordisk Investigational Site, Tønsberg, Norway|Novo Nordisk Investigational Site, Krakow, Poland|Novo Nordisk Investigational Site, Lodz, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Olsztyn, Poland|Novo Nordisk Investigational Site, Szczecin, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Wroclaw, Poland|Novo Nordisk Investigational Site, Zabrze, Poland|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Samara, Russian Federation|Novo Nordisk Investigational Site, Tumen, Russian Federation|Novo Nordisk Investigational Site, Port Elizabeth, Eastern Cape, South Africa|Novo Nordisk Investigational Site, Port Elizabeth, Eastern Cape, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Alcoy, Spain|Novo Nordisk Investigational Site, Alicante, Spain|Novo Nordisk Investigational Site, Barcelona, Spain|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Santander, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Valencia, Spain|Novo Nordisk Investigational Site, Belfast, United Kingdom|Novo Nordisk Investigational Site, Birmingham, United Kingdom|Novo Nordisk Investigational Site, Blackburn, United Kingdom|Novo Nordisk Investigational Site, Bristol, United Kingdom|Novo Nordisk Investigational Site, Edinburgh, United Kingdom|Novo Nordisk Investigational Site, Exeter, United Kingdom|Novo Nordisk Investigational Site, Leicester, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Middlesbrough, United Kingdom|Novo Nordisk Investigational Site, Northampton, United Kingdom|Novo Nordisk Investigational Site, Norwich, United Kingdom|Novo Nordisk Investigational Site, Plymouth, United Kingdom|Novo Nordisk Investigational Site, Southampton, United Kingdom|Novo Nordisk Investigational Site, Watford, United Kingdom",,https://ClinicalTrials.gov/show/NCT00474045
NCT00472875,Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia?,,Unknown status,No Results Available,Type 1 Diabetes Mellitus,Drug: Glibenclamide,Glucose threshold for development of symptoms and cognitive impairment due to hypoglycaemia|Improvement in counter regulatory hormone response to hypoglycaemia,King's College Hospital NHS Trust,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,10,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,07/Q0703/18|JDRF grant number 5-2007-478,May-07,null,null,14-May-07,null,14-May-07,"King's College Hospital NHS Foundation Trust, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00472875
NCT00472953,Safety of Inhaled Human Insulin in Subjects With Diabetes Mellitus and Chronic Obstructive Pulmonary Disease (COPD),iINHALE 8,Terminated,No Results Available,"Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Chronic Obstructive Pulmonary Disease",Drug: inhaled human insulin|Drug: insulin aspart,To evaluate pulmonary safety comparing inhaled insulin to subcutaneous injections|Patient Reported Outcomes|Diabetes control measured by change in HbA1c from baseline|Preprandial Insulin Doses,Novo Nordisk A/S,All,"30 Years and older   (Adult, Older Adult)",Phase 3,38,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN1998-1617|2006-004731-29,15-May-07,5-Mar-08,5-Mar-08,14-May-07,null,1-Mar-17,"Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Ciudad de Buenos Aires, Argentina|Novo Nordisk Investigational Site, Chandigarh, Punjab, India|Novo Nordisk Investigational Site, Vellore, Tamil Nadu, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Hyderabad, India|Novo Nordisk Investigational Site, Mumbai, India|Novo Nordisk Investigational Site, Pune, India|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Kosice, Slovakia|Novo Nordisk Investigational Site, Lubochna, Slovakia|Novo Nordisk Investigational Site, Moldava nad Bodvou, Slovakia|Novo Nordisk Investigational Site, Zilina, Slovakia|Novo Nordisk Investigational Site, Zilina, Slovakia|Novo Nordisk Investigational Site, Changhua, Taiwan|Novo Nordisk Investigational Site, Chiayi City, Taiwan|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Erzurum, Turkey|Novo Nordisk Investigational Site, Gaziantep, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Kocaeli, Turkey",,https://ClinicalTrials.gov/show/NCT00472953
NCT00468754,A Study Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections With Insulin Lispro and Glargine,,Completed,No Results Available,Diabetes Mellitus Type 1,Device: Insulin pumps,Variability of blood glucose characterised by the standard deviation of the mean blood glucose|HbA1c|Mean BG during the last month of the respective treatment period|Frequency of severe hypoglycemia|Daily insulin requirement,Hoffmann-La Roche,All,18 Years to 60 Years   (Adult),Not Applicable,50,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RD000275|RD000000275,Jul-03,May-05,May-05,3-May-07,null,3-Mar-16,"Bergamo, Italy|Brescia, Italy|Padova, Italy|Pisa, Italy",,https://ClinicalTrials.gov/show/NCT00468754
NCT00468117,Efficacy of Islet After Kidney Transplantation,,Completed,No Results Available,Type 1 Diabetes Mellitus,Procedure: Islet transplantation|Biological: Antithymocyte Globulin|Biological: Daclizumab or Basiliximab|Biological: Etanercept|Biological: Allogenic human purified pancreatic islets,"Proportion of patients w/HbA1c </= to 6.5% and an absence of severe hypoglycemic events or a reduction in HbA1c of at least 1 point and an absence of severe hypoglycemic events|Reduction in insulin requirements, HbA1c, MAGE, LI, HYPO score, fasting glucose, beta score, serum creatinine, c-peptide levels, MMTT, Clarke Survey, FSIGT, CGMS, number of hypoglycemic events, renal impact, cardiovascular impact, and quality of life",National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years to 68 Years   (Adult, Older Adult)",Phase 3,24,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAIT CIT-06,Jan-07,Jul-15,5-Jul-17,2-May-07,null,20-Oct-17,"University of California, San Francisco, San Francisco, California, United States|University of Miami, Miami, Florida, United States|Emory Universtiy, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Wisconsin, Madison, Wisconsin, United States|University of Alberta, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT00468117
NCT00468403,LEA29Y (Belatacept) Emory Edmonton Protocol,LEEP,Completed,No Results Available,Type 1 Diabetes Mellitus,Biological: Allogeneic Pancreatic Islet Cells|Biological: Belatacept|Biological: Basiliximab|Drug: Mycophenolate Mofetil|Drug: Tacrolimus|Procedure: Intraportal infusion of islet cells,"Proportion of subjects with insulin independence|Proportion of subjects with an HbA1c <7.0% AND free of severe hypoglycemic events|Percent reduction in insulin requirements, HbA1c, Mean amplitude of glycemic excursions (MAGE), Glycemic lability index (LI), Ryan hypoglycemia severity (HYPO) score|Basal (fasting) and 90-min glucose and C-peptide derived from the mixed-meal tolerance test (MMTT), beta-score, C-peptide: glucose-creatinine ration, acute insulin response to glucose|Insulin sensitivity and disposition index derived from the insulin-modified frequently-sampled intravenous glucose tolerance test (FSIGT) test|Glucose variability and hypoglycemia duration, derived from the continuous glucose monitoring system (CGMS), quality of life (QOL) measures|Percent reduction in insulin requirements, HbA1c, Mean amplitude of glycemic excursions (MAGE), Glycemic lability index (LI), Clarke Score, Ryan hypoglycemia severity (HYPO) score|Basal (fasting) and 90-min glucose and C-peptide derived from the mixed-meal tolerance test (MMTT), beta-score, C-peptide: glucose-creatinine ratio|Proportion of participants receiving a second or third islet transplant|Rate of favorable outcome at each center preparing islets (rate of subjects with an HbA1c < 7.0% and free of severe hypoglycemic events)|Incidence and severity of adverse events related to the islet transplant procedure|Incidence and severity of adverse events related to immunosuppression therapy|Incidence of change in the immunosuppression drug regimen|Incidence of immune sensitization defined by presence of Histocompatibility Antigen (HLA) antibodies absent prior to transplantation|Incidence of worsening retinopathy|Percent reduction in insulin requirements, number of severe hypoglycemic events from 28 days to 2 years, HbA1c, Clarke Score|Basal (fasting) and 90-min glucose and C-peptide derived from the mixed-meal tolerance test (MMTT), beta-score, C-peptide|Safety associated with conventional immunosuppression|Renal function as measured by serum creatinine, glomerular filtration rate (GFR) and other relevant laboratory parameters|Lipid profiles (triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol)",National Institute of Allergy and Infectious Diseases (NIAID)|Clinical Islet Transplantation Consortium,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,10,NIH|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAIT CIT-04,Oct-08,Apr-12,Apr-13,2-May-07,null,7-Apr-16,"Emory University, Atlanta, Georgia, United States|University of Alberta, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT00468403
NCT00468442,B-Lymphocyte Immunotherapy in Islet Transplantation,,Terminated,No Results Available,Type 1 Diabetes Mellitus,Biological: Allogeneic Pancreatic Islet Cells|Biological: Antithymocyte globulin|Biological: Daclizumab|Biological: Rituximab|Drug: Sirolimus,"Insulin independence|reduction in insulin requirements, HbA1c, MAGE, LI, HYPO score, fasting glucose, beta score, quality of life",National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,2,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAIT CIT-05,Nov-06,Sep-11,Sep-11,2-May-07,null,21-Mar-16,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00468442
NCT00467688,Effect of Continuous Glucose Monitoring on Course of Glucose in Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes|Hypoglycemia,Device: Real time access to current glucose values during CGMS,Daily time spent in the hypoglycemic glucose range during continuous glucose measurement with and without real time access to glucose values and glucose alarms|Time spent in euglycemic and hyperglycemic glucose range Satisfaction with CGMS Diabetes related distress Treatment satisfaction Anxiety and depressive symptoms,Forschungsinstitut der Diabetes Akademie Mergentheim,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FIDAM 049-06|Nr.70-005928713-0,Feb-07,null,Jul-07,1-May-07,null,31-Oct-07,"FIDAM, Bad Mergentheim, Germany|Research Institute of the Diabetes Academy Mergentheim, Bad Mergentheim, Germany",,https://ClinicalTrials.gov/show/NCT00467688
NCT00467376,"Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus",,Completed,No Results Available,Diabetes Mellitus,Drug: Insulin Glulisine|Drug: Lispro|Drug: Insulin Glargine,"Hypoglycemic episodes|Change in HbA1c|Adverse events|blood glucose parameters, hypoglycemic episodes and dosage of the mealtime and Lantus.",Sanofi,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,485,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APIDR_L_00348,Jan-07,Jun-08,null,30-Apr-07,null,15-Sep-09,"Sanofi-Aventis, Beijing, China",,https://ClinicalTrials.gov/show/NCT00467376
NCT00465478,Autologous Bone Marrow Mononuclear Cells Transplantation in Treating Diabetes Patients,,Unknown status,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Procedure: Autologous bone marrow mononuclear cell transplantation,"Exogenous insulin requirement; Hemoglobin A1C; Glucose and C-peptide level;|Safety assessment parameter: amylase, hepatic function,renal function,|lipid profile, autoantibody， Quality of life",Shandong University,All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,200,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QL060308,Mar-06,null,Mar-14,25-Apr-07,null,25-Apr-07,"Qilu Hospital of Shandong University, Jinan, Shandong, China",,https://ClinicalTrials.gov/show/NCT00465478
NCT00464555,Strategies to Improve Islet Survival,,Completed,No Results Available,Type 1 Diabetes Mellitus,Procedure: Islet transplant|Drug: Antithymocyte globulin|Drug: Basiliximab|Drug: Lisofylline|Drug: Sirolimus|Drug: Tacrolimus,"Proportion of participants with insulin independence|Reduction in insulin requirements, HbA1c, mean amplitude of glycemic excursions (MAGE), glycemic lability index (LI), Ryan hypoglycemia severity (HYPO) score, fasting glucose, glucose variation, beta score|Quality of life measures",National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,5,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAIT CIT-02,Dec-06,Nov-11,Feb-14,23-Apr-07,null,26-Apr-16,"University of Miami, Miami, Florida, United States|University of Illinois at Chicago, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00464555
NCT00462371,Comparison Between Insulin Pump Treatment and Multiple Daily Insulin Injections in Diabetic Type 1 Children,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Child",Device: Insulin pump (CSII),metabolic control|quality of life|cost effectiveness|surrogate markers for late complications|adverse events|impact of disease,"Erasmus Medical Center|Netherlands: Ministry of Health, Welfare and Sports",All,4 Years to 16 Years   (Child),Phase 4,38,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ASB21004821,Jan-02,null,Feb-04,19-Apr-07,null,19-Apr-07,"ErasmusMC/Sophia´s children´s Hospital, Rotterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT00462371
NCT00461331,Comparison of Insulins Aspart and Lispro in Insulin Pumps,,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Insulin Aspart|Drug: Insulin Lispro,"Number of Participants With Glycemic Control (Glucose Levels Between 180-300 mg/dL) 24 to 100 Hours After Line Change|Daily Serum Glycomark Levels 48 to 100 Hours After Keeping the Same Pump Infusion Line in Place|Oxidative Stress Marker 48, 72 and 96 Hours After Keeping the Same Pump Infusion Line in Place",Tulane University Health Sciences Center|Tulane University,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",F-0215,Oct-04,Jun-07,Aug-08,18-Apr-07,19-May-11,30-Jan-17,"General Clinical Research Center, New Orleans, Louisiana, United States",,https://ClinicalTrials.gov/show/NCT00461331
NCT00460941,A Titration Study of a Glucagon-Like Peptide-1 (GLP-1) Analogue in Patients With Type 2 Diabetes Treated With Metformin.,,Completed,No Results Available,Diabetes Mellitus Type 2,Drug: Placebo|Drug: Taspoglutide 20mg|Drug: Taspoglutide 20mg-30mg|Drug: Taspoglutide 20mg-40mg,"Percentage of patients withdrawn because of gastrointestinal effects|Mean changes in 24h blood glucose Area Under the Curve (AUC), Fasting Plasma Glucose (FPG), fructosamine, Hemoglobin A1c (HbA1c), body weight, Adverse Events (AEs), laboratory parameters.",Hoffmann-La Roche,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,133,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BC20728,Apr-07,Jan-08,Jan-08,17-Apr-07,null,2-Nov-16,"Harrisburg, Arkansas, United States|Hot Springs, Arkansas, United States|Jonesboro, Arkansas, United States|National City, California, United States|Jacksonville, Florida, United States|Madisonville, Kentucky, United States|Hyattsville, Maryland, United States|Winston-salem, North Carolina, United States|Dallas, Texas, United States|Dallas, Texas, United States|Richmond, Virginia, United States|Adelaide, Australia|Camperdown, Australia|Besancon, France|Corbeil Essonnes, France|Narbonne, France|Paris, France|Poitiers, France|Berlin, Germany|München, Germany|Neuss, Germany|Chihuahua, Mexico|Culiacan, Mexico|Monterrey, Mexico|Tampico, Mexico|Lima, Peru|Lima, Peru|Lima, Peru|Ponce, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00460941
NCT00460304,The Effect of Pramlintide on Meal Time Insulin Bolus,,Completed,No Results Available,Type 1 Diabetes,Drug: pramlintide|Procedure: continuous glucose monitoring,The mean ICR from Vist 3a-e and 4a-e will be compared. Percentage reduction of ICR will be calculated. From these the mean ICR will be calculated.|The mean post-meal glucose from the four hour period after beginning a meal will be averaged for each bolus wave form. Then the three wave form mean glucose results will be compared.,"Diabetes Care Center|Amylin Pharmaceuticals, LLC.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,12,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1-Jul,Sep-07,Nov-08,Nov-08,13-Apr-07,null,3-Apr-09,,,https://ClinicalTrials.gov/show/NCT00460304
NCT00456027,Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult),,Completed,No Results Available,Latent Autoimmune Diabetes in Adult (LADA),Drug: rhGAD65 formulated in Alhydrogel® (Diamyd®),"The development over time of safety variables, i.e. injection site discomfort, vital signs, laboratory values and AEs/SAEs as well as development of diabetes status, i.e. HbA1c, C-peptide, blood glucose and insulin requirement.",Diamyd Therapeutics AB,All,"30 Years to 70 Years   (Adult, Older Adult)",Phase 2,160,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D/P2/04/2|EUDRACT 2004-001998-25,Dec-04,Mar-08,Apr-08,4-Apr-07,null,10-Jun-11,"Alingsås Hospital, Alingsås, Sweden|Falu Hospital, Falun, Sweden|Capio Lundby Hospital, Göteborg, Sweden|Helsingborg Hospital, Helsingborg, Sweden|Härnösand Hospital, Härnösand, Sweden|Karlstad Central Hospital, Karlstad, Sweden|Central Hospital, Kristianstad, Kristianstad, Sweden|Sunderby Hospital, Luleå, Sweden|University Hospital MAS, Malmö, Sweden|Vrinnevi Hospital, Norrköping, Sweden|Skellefteå Hospital, Skellefteå, Sweden|S:t Göran Hospital, Stockholm, Sweden|Stockholm South General Hospital, Stockholm, Sweden|Norrlands University Hospital, Umeå, Sweden|Uppsala University Hospital, Uppsala, Sweden|Växjö Central Hospital, Växjö, Sweden|Odensala Health Clinic, Östersund, Sweden",,https://ClinicalTrials.gov/show/NCT00456027
NCT00456300,Role of Exenatide in Type 1 Diabetes,,Completed,Has Results,Type 1 Diabetes,Drug: Exenatide|Drug: Insulin,"Mean Plasma Glucose Area Under the Curve (AUC) for Blood Glucose Concentration in the Exenatide 1.25 mcg or Exenatide 2.5 mcg Treated Groups Along With Insulin, Compared to Insulin Alone",Montefiore Medical Center|National Institutes of Health (NIH),All,"12 Years to 21 Years   (Child, Adult)",Phase 2,11,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",H-16488,Mar-07,Mar-09,Mar-09,4-Apr-07,26-Feb-19,26-Feb-19,"Texas Children's Hospital/ Baylor College of Medicine, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00456300
NCT00453817,Islet of Langerhans Graft Monitoring by Magnetic Resonance Imaging,,Terminated,No Results Available,Type 1 Diabetes Mellitus,Drug: ferucarbotran (iron-based MRI contrast agent)|Procedure: Islet transplantation|Procedure: Magnetic resonance imaging,"Semi-quantitative assessment of intrahepatic MRI signal on T2*-weighted sequences, at 6 days, 6 weeks, 6 months and 1 year after transplantation|Islet graft function assessed by exogenous insulin requirements, HbA1c, mean amplitude of glucose excursions (MAGE) and fasting C-peptide.","University Hospital, Geneva",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,5,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,04-019,Jun-05,Jun-10,Jun-10,29-Mar-07,null,2-Dec-14,"Geneva University Hospitals Department of Surgery, Geneva, Switzerland",,https://ClinicalTrials.gov/show/NCT00453817
NCT00453934,Patient Preference of h-Patch vs. Pen or Needle/Syringe as Insulin Administration Device,,Terminated,No Results Available,Type 1 Diabetes|Type 2 Diabetes,Device: h-Patch,"Mean glucose using CGM.|Glucose SD, MAGE, Proportion of 24 hours in euglycemic range 70-160 mg/dl, using CGM.|End of Study Patient Questions|Hypoglycemia|Proportion of time with glucose < 70 mg/dl, from CGM.|Number and type of adverse events.","Valeritas, Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,11,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,V4001,May-07,null,Sep-07,29-Mar-07,null,6-Dec-07,"Diabetes and Glandular Research, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00453934
NCT00453375,Phase 1 Study of BHT-3021 in Subjects With Type 1 Diabetes Mellitus,,Completed,No Results Available,Diabetes|Hypoglycemia,Drug: BHT-3021|Drug: BHT-Placebo,"The primary endpoint in this study is safety.Safety parameters include: stimulated C-peptide response levels, opthalmologic examination, laboratory assessments, 24-hr urine protein, allergic reactions and adverse events including hypoglycemia.|The secondary endpoints are pharmacodynamic parameters. Parameters include plasmid levels and insulin mRNA levels in blood and urine, Stimulated C-peptide response and Immunological response.",Bayhill Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 1,80,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BHT-3021-01,Oct-06,May-11,May-11,28-Mar-07,null,28-Jun-11,"University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, United States|Valley Research, Fresno, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Private Practice, Denver, Colorado, United States|MedStar Research Institute, Washington, District of Columbia, United States|University of Miami, Miller School of Medicine, Diabetes Research Institute, Miami, Florida, United States|Private Practice, Wellington, Florida, United States|Creighton Diabetes Center, Omaha, Nebraska, United States|Diabetes and Glandular Disease Center, San Antonio, Texas, United States|Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States|Peninsula Clinical Research Centre, Kippa Ring, Queensland, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Eastern Clinical Research Unit, Ringwood East, Victoria, Australia|Fremantle Hospital, Fremantle, Western Australia, Australia|Middlemore Hospital, Otahuhu, Auckland, New Zealand|Christchurch Hospital, Christchurch, Canterbury, New Zealand|Waikato Regional Diabetes Service, Hamilton, Waikato, New Zealand|The Diabetes Centre, Newtown, Wellington, New Zealand",,https://ClinicalTrials.gov/show/NCT00453375
NCT00451321,TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM),TTEDD,Terminated,Has Results,"Diabetes Mellitus, Type 1",Drug: Otelixizumab,"Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Cytokine Release AE|Number of Participants With Abnormal Hematology Values of Potential Clinical Concern (PCC)|Number of Participants With Abnormal Clinical Chemistry Values of PCC|Number of Participants With Abnormal Urinalysis Dipstick Results|Mean Overall Maximum Cytokines Level|Number of Participants With Positive Epstein Barr Virus (EBV) Viral Load|Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUClast) of Otelixizumab|Maximum Plasma Drug Concentration (Cmax) of Otelixizumab|Time of Last Quantifiable Drug Concentration (Tlast) and Time of Occurrence of Maximum Plasma Drug Concentration (Tmax) of Otelixizumab|Mean Lymphocytes Subsets (CD19+ B Cells, CD4+CD25hiFoxP3+ T Cells, CD8+CD25+FoxP3+ T Cells) Count|Mean Lymphocytes Subsets (CD4+ T Cells, CD8+ T Cells) Count|Mean CD4+/CD8+ Ratio|Percent Lymphocytes Subsets (CD25+CD8+Tregs) Count|Amounts of Cell-bound Otelixizumab on CD4+ and CD8+ T Cells|Saturation of CD4+ and CD8+ T Cells With Otelixizumab|CD3/TCR Complexes on CD4+ and CD8+ T Cells|Number of Participants With Detectable Anti-otelixizumab Antiglobulin Response|Number of Participants With Use of Analgesics, Antihistamines and IV Hydration as Concomitant Medication During Dosing Days|Change From Baseline in Percent Glycosylated Hemoglobin (HbA1c)",GlaxoSmithKline|Juvenile Diabetes Research Foundation,All,"12 Years to 45 Years   (Child, Adult)",Phase 2,88,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,115493|TRX4005,31-Jul-06,1-Dec-11,1-Dec-11,23-Mar-07,13-Nov-17,13-Nov-17,"GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Aurora, Colorado, United States|GSK Investigational Site, Washington, D.C., District of Columbia, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Pinellas Park, Florida, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Worcester, Massachusetts, United States|GSK Investigational Site, Kalamazoo, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Gulfport, Mississippi, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Mentor, Ohio, United States|GSK Investigational Site, Rapid City, South Dakota, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00451321
NCT00449605,A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes,ALLEGRO,Terminated,No Results Available,"Diabetes Mellitus, Type 2",Drug: Rimonabant|Drug: Glimepiride|Drug: Metformin,Change from baseline in glycemic measure HbA1c|Absolute change from baseline in body weight|Relative change from baseline in HDL-C,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,508,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFC10007|2006-005385-39,Mar-07,Nov-08,Mar-09,20-Mar-07,null,16-May-16,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Santiago, Chile|Sanofi-aventis adminsitrative office, Santiago, Chile|Sanofi-Aventis Administrative Office, Horsholm, Denmark|Sanofi-Aventis Administrative Office, Helsinki, Finland|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Mumbai, India|Sanofi-Aventis Administrative Office, Milan, Italy|Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of|Sanofi-Aventis Administrative Office, Mexico, Mexico|Sanofi-Aventis Administrative Office, Puerto Rico, Puerto Rico|Sanofi-Aventis Administrative Office, Bucuresti, Romania|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Bromma, Sweden",,https://ClinicalTrials.gov/show/NCT00449605
NCT00447213,A Study for Patients With Type 1 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Insulin glargine|Drug: Human Insulin Inhalation Powder|Drug: Injectable Insulin,"Change in HbA1c from baseline|Proportion of patients who achieve an HbA1c < 7% and <= 6.5%|Insulin (regular human insulin, insulin lispro, human insulin inhalation powder or insulin glargine)doses|8-point self monitoring blood glucose profiles|Two hour glucose excursions for the morning, midday, and evening meals|Inhaler reliability|Patient-reported treatment satisfaction and insulin delivery satisfaction|Preference for the study therapies","Eli Lilly and Company|Alkermes, Inc.",All,"20 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,70,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10299|H7U-JE-IDBB,Apr-07,May-08,May-08,14-Mar-07,null,13-Oct-10,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Changhua, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan",,https://ClinicalTrials.gov/show/NCT00447213
NCT00447382,Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes,,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin detemir|Drug: insulin aspart,Change From Baseline in Insulin Detemir - Human Insulin Cross-reacting Antibodies|Hypoglycaemic Episodes|Glycaemic Control Parameters (Change in HbA1c)|Glycaemic Control Parameters (Change in Fasting Plasma Glucose [FPG])|Glycaemic Control Parameters (9-point Self Measured Plasma Glucose [SMPG])|Change From Baseline in Detemir Specific Antibodies|Change From Baseline in Total Antibodies|Clinical Laboratory Values (Change in Haematology - Basophilis)|Clinical Laboratory Values (Change in Haematology - Eosinophils)|Clinical Laboratory Values (Change in Haematology - Haemoglobin)|Clinical Laboratory Values (Change in Haematology - Lymphocytes)|Clinical Laboratory Values (Change in Haematology - Monocytes)|Clinical Laboratory Values (Change in Haematology - Neutrophils)|Clinical Laboratory Values (Change in Haematology - Thrombocytes)|Clinical Laboratory Values (Change in Haematology - Leucocytes)|Clinical Laboratory Values (Change in Biochemistry - Albumin)|Clinical Laboratory Values (Change in Biochemistry - Alanine Aminotransferase [ALAT])|Clinical Laboratory Values (Change in Biochemistry - Alkaline Phosphatase [ALP])|Clinical Laboratory Values (Change in Biochemistry - Creatinine)|Clinical Laboratory Values (Change in Biochemistry - Lactate Dehydrogenase [LDH])|Clinical Laboratory Values (Change in Biochemistry - Potassium)|Clinical Laboratory Values (Change in Biochemistry - Sodium)|Clinical Laboratory Values (Change in Biochemistry - Total Protein)|Adverse Events,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,330,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EX1729-1778|2006-004733-15,Mar-07,Jul-08,Jul-08,14-Mar-07,12-May-11,9-Oct-14,"Belgrade, Former Serbia and Montenegro|Frankfurt, Germany|Skopje, Macedonia, The Former Yugoslav Republic of|Moscow, Russian Federation|Cape Town, Western Cape, South Africa",,https://ClinicalTrials.gov/show/NCT00447382
NCT00446264,Islet Allotransplantation With Steroid Free Immunosuppression,,Completed,Has Results,Type 1 Diabetes|Hypoglycemia|Metabolic Diseases,Procedure: islet transplantation|Drug: daclizumab - sirolimus - tacrolimus,Composite Criteria: Insulin Independence and Glycosylated Hemoglobin (HbA1c) Under 6.5% at One Year|Hypoglycemic Events|Plasma C-peptide|HbA1c < 6.5%|Percentage of Time Spent in Hypoglycemia (<0.70 mg/L)|Number of Adverse Events,"University Hospital, Lille|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,14,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CP 01/48|PHRC|AFSSAPS 030209,May-03,Oct-07,Feb-09,12-Mar-07,12-May-10,27-Apr-12,"University Hospital of Lille, Lille, France",,https://ClinicalTrials.gov/show/NCT00446264
NCT00445913,Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study,,Completed,No Results Available,Type 1 Diabetes,Biological: Diabetes-suppressive dendritic cell vaccine|Biological: control dendritic cells,The trial is designed to assure that the toxicity rate is acceptably low to warrant further study of the cell vaccine in efficacy trials.,University of Pittsburgh,All,18 Years to 60 Years   (Adult),Phase 1,10,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0509115|NIDDK R33 DK683044,Mar-07,Jan-12,Feb-16,9-Mar-07,null,15-Feb-16,"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00445913
NCT00444899,Clinical and Economic Benefits of Cardiovascular Risk Management by a Dietician in Type 2 Diabetes Patients,GRC,Completed,No Results Available,Type 1 Diabetes|Type 2 Diabetes,Behavioral: Intensive treatment|Other: Normal follow-up,Lipid profile|Blood pressure|HbA1c,Université de Sherbrooke|Pfizer,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,101,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NRA3840020,Mar-07,Dec-13,31-Dec-18,8-Mar-07,null,1-May-19,"Centre de recherche clinique Étienne-Le Bel du CHUS, Sherbrooke, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00444899
NCT00442767,Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus,,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Insulin|Drug: Pramlintide + Insulin,"Assess the Mean Area Under the Curve (AUC) for Blood Glucose Concentration in Subjects Treated With Pramlintide + Insulin, Compared to Insulin Alone|Measure of Glucagon Concentration in Subjects Treated With Pramlintide + Insulin, Compared to Insulin Alone.","Montefiore Medical Center|Amylin Pharmaceuticals, LLC.",All,"12 Years to 21 Years   (Child, Adult)",Phase 4,8,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-18629|GCRC protocol #:0954,Feb-07,Feb-09,Feb-09,2-Mar-07,10-Jul-18,10-Jul-18,"Montefiore Medical Center, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT00442767
NCT00441844,Monocyte Function and Inflammation in Type 1 Diabetes and Its Modulation,,Completed,No Results Available,Type 1 Diabetes,Drug: Simvastatin,HsCRP|Monocyte function|Plasma biomarkers,"University of California, Davis|Juvenile Diabetes Research Foundation|National Institutes of Health (NIH)",All,"20 Years and older   (Adult, Older Adult)",Phase 2,50,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,JDFT1DMSIMVA|UCD IRB # 200210057,Oct-02,null,Jul-05,1-Mar-07,null,1-Mar-07,"UCDavis Medical Center, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT00441844
NCT00441129,Obtain a Good Blood Glucose Control With the Paradigm Real Time System,RTD,Completed,Has Results,Type 1 Diabetes,Device: Minimed paradigm Real Time Sytem|Device: Minimed Paradigm 512/712 Insulin pump,Difference in HbA1C From Baseline and 6 Months|Change From Baseline in Mean Blood Glucose Value Calculated From CGMS Recordings.|Change From Baseline in Total Daily Dose (TDD),Medtronic Diabetes,All,"2 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,115,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,186,Jun-06,May-08,May-08,28-Feb-07,5-Dec-18,5-Dec-18,"CHU Côte de Nacre, Caen, France|Hôpital Universitaire Debrousse, Lyon, France|Hôpital Sainte Marguerite, Marseille, France|CH La Peyronie, Montpellier, France|American Memorial Hospital, Reims, France|Hôpital Jeanne D'Arc, Saint-Mandé, France|Hôpitaux Universitaires de Strasbourg, Strasbourg, France|CHU Rangueil, Toulouse, France",,https://ClinicalTrials.gov/show/NCT00441129
NCT00439985,Improving Metabolic Control in Diabetic Young Children,,Terminated,No Results Available,Type 1 Diabetes Mellitus,Behavioral: Cognitive Behavioral Therapy,adherence|quality of life|optimism|self-efficacy|parent-child collaboration,Icahn School of Medicine at Mount Sinai|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,7 Years to 11 Years   (Child),Not Applicable,23,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DK074580|05-0667,Sep-06,Jul-09,Jul-09,26-Feb-07,null,8-Jun-11,"Mount Sinai School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00439985
NCT00437398,Islet Transplantation for Type 1 Diabetes Mellitus,,Terminated,Has Results,Type 1 Diabetes Mellitus,Biological: Islet Transplant,Mean Number of Hypoglycemic Events After Transplant|Mean Glycated Hemoglobin (HbA1c) Since Transplant,Mayo Clinic|National Center for Research Resources (NCRR),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,2,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,06-003564|UL1RR024150,Jul-06,Jan-12,Jan-12,21-Feb-07,16-Apr-13,25-Apr-13,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00437398
NCT00437554,Phase III Study for Glimepiride + Metformin Hydrochloride (Amaryl M) Slow Release (SR),,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Glimepiride,"Efficacy : Change in HbA1c between baseline and endpoint|Efficacy : Change in HbA1c measured at baseline, week 8 and week 16. Change in FPG and PP2h measured at baseline, week 8 and week 16. Response rates in terms of HbA1c, FPG.Patient compliance|Safety: episodes of hypoglycemia, adverse events, laboratory values including hematology, blood chemistry and urinalysis, vital sign and physical examination, Frequency with hypoglycemic episode","Handok Pharmaceuticals Co., Ltd.",All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 3,188,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,GLIME_L_01019,Aug-06,null,Jul-07,21-Feb-07,null,29-Nov-07,"Handok, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00437554
NCT00435981,Efficacy and Safety of Diamyd® in Children and Adolescents With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Drug: rhGAD65 formulated in Alhydrogel® (Diamyd®),To evaluate the efficacy of Diamyd® 20ug versus placebo with respect to preserving residual insulin secretion as measured by C-peptide levels. The effect of intervention will be evaluated at month 15 (main study period) and at month 30 (Extension phase).|To evaluate the safety of Diamyd® 20ug.,Diamyd Therapeutics AB,All,"10 Years to 18 Years   (Child, Adult)",Phase 2,70,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,D/P2/04/3|EUDRACT 2004-003764-30,Jan-05,Oct-07,Dec-07,16-Feb-07,null,30-Jan-08,"Borås Hospital, Borås, Sweden|The Queen Silvia Children´s Hospital, Göteborg, Sweden|Halmstad Hospital, Halmstad, Sweden|Ryhov Hospital, Jönköping, Sweden|Linköping University, Linköping, Sweden|University Hospital, MAS, Malmö, Sweden|Astrid Lindgren Children´s Hospital, Stockholm, Sweden|Örebro University Hospital, Örebro, Sweden",,https://ClinicalTrials.gov/show/NCT00435981
NCT00435019,Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 Diabetes,,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin detemir|Drug: insulin NPH|Drug: insulin aspart,Glycosylated Haemoglobin A1c (HbA1c)|Number of Subjects Reporting Adverse Events|Observed Insulin Antibody Values,Novo Nordisk A/S,All,2 Years to 16 Years   (Child),Phase 3,348,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN304-1689|2006-000051-18,Feb-07,Sep-08,Sep-08,14-Feb-07,8-Dec-09,10-Mar-17,"Novo Nordisk Investigational Site, Pleven, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Varna, Bulgaria|Novo Nordisk Investigational Site, Olomouc, Czech Republic|Novo Nordisk Investigational Site, Pardubice, Czech Republic|Novo Nordisk Investigational Site, Prague 5, Czech Republic|Novo Nordisk Investigational Site, Glostrup, Denmark|Novo Nordisk Investigational Site, Kolding, Denmark|Novo Nordisk Investigational Site, Odense, Denmark|Novo Nordisk Investigational Site, Viborg, Denmark|Novo Nordisk Investigational Site, Espoo, Finland|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Oulu, Finland|Novo Nordisk Investigational Site, Seinäjoki, Finland|Novo Nordisk Investigational Site, Tampere, Finland|Novo Nordisk Investigational Site, Turku, Finland|Novo Nordisk Investigational Site, ANGERS cedex 09, France|Novo Nordisk Investigational Site, MONTPELLIER cedex 05, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Toulouse, France|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Miskolc, Hungary|Novo Nordisk Investigational Site, Skopje, Macedonia, The Former Yugoslav Republic of|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Kielce, Poland|Novo Nordisk Investigational Site, Siedlce, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Altunizade-Istanbul, Turkey|Novo Nordisk Investigational Site, Antalya, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Izmir, Turkey|Novo Nordisk Investigational Site, Kayseri, Turkey|Novo Nordisk Investigational Site, Aberdeen, United Kingdom|Novo Nordisk Investigational Site, Birmingham, United Kingdom|Novo Nordisk Investigational Site, Cambridge, United Kingdom|Novo Nordisk Investigational Site, Dundee, United Kingdom|Novo Nordisk Investigational Site, Norfolk, United Kingdom",,https://ClinicalTrials.gov/show/NCT00435019
NCT00434811,Islet Transplantation in Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus,Biological: Allogeneic Pancreatic Islet Cells|Biological: Antithymocyte Globulin|Drug: Sirolimus|Drug: Tacrolimus|Biological: Etanercept|Procedure: Islet Transplantation|Biological: Basiliximab,"Proportion of participants with an HbA1c less than 7.0% and free of severe hypoglycemic events|Percent reduction in insulin requirements|HbA1c|Mean amplitude of glycemic excursions (MAGE)|Glycemic liability index (LI)|Ryan hypoglycemia severity score (HYPO)|Basal (fasting) and 90-minute glucose and C-peptide derived from mixed meal tolerance test (MMTT)|β-score|C-peptide:glucose creatinine ratio|Acute insulin response to glucose, insulin sensitivity, and disposition index derived from the insulin-modified frequently sampled intravenous glucose tolerance (FSIGT) test|Glucose variability and hypoglycemia duration derived from the continuous glucose monitoring system (CGMS)|Quality of life|Incidence of worsening retinopathy|Proportion of insulin-independent subjects|MAGE|LI|Clarke score|HYPO score|Basal (fasting) and 90-minute glucose and C-peptide (MTT)|C-peptide: glucose creatinine ratio|Proportion of participants receiving a second islet transplant|Proportion of participants receiving a third islet transplant|Incidence and severity of adverse events related to the islet transplant procedure|Incidence and severity of adverse events related to the immunosuppression therapy|Incidence of a change in the immunosuppression drug regimen|Incidence of immune sensitization defined by detecting anti-HLA antibodies not present prior to transplantation|Proportion of insulin-independent participants|Acute insulin response to glucose insulin sensitivity, and disposition index derived from the FSIGT test",National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,48,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAIT CIT-07,Oct-06,Sep-12,May-14,13-Feb-07,null,31-Aug-16,"University of Callifornia, San Francisco, San Francisco, California, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Illinois, Chicago, Chicago, Illinois, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Alberta, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT00434811
NCT00434850,Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Biological: Allogeneic Pancreatic Islet Cells|Drug: Deoxyspergualin|Biological: Antithymocyte globulin|Biological: Daclizumab or basiliximab|Drug: Sirolimus|Drug: Tacrolimus|Biological: Etanercept,"Proportion of Insulin-independent Subjects|Percent Reduction in Insulin Requirements|Hemoglobin A1c (HbA1c)|Mean Amplitude of Glycemic Excursions (MAGE)|Glycemic Lability Index (LI)|Ryan Hypoglycemia Severity Score (HYPO)|Basal (fasting) and 90-minute Glucose and C-peptide Results|Beta-score|C-peptide: Glucose Creatinine Ratio|Acute Insulin Response to Glucose, Insulin Sensitivity, and Disposition Index|Glucose Variability and Hypoglycemia Duration|Quality of Life (QOL) Measure|Incidence of Worsening Retinopathy|Clarke Score|HYPO Score|Basal (fasting) and 90-minute Glucose and C-peptide|Quality of life (QOL) Measure|Proportion of Subjects Receiving a Second Islet Cell Transplant|Proportion of Subjects Receiving a Third Islet Cell Transplant|Incidence and Severity of Adverse Events Related to the Islet Cell Transplant Procedure|Incidence and Severity of Adverse Events Related to the Immunosuppression Therapy|Incidence of a Change in the Immunosuppression Drug Regimen|Incidence of Immune Sensitization|Acute Insulin Response to Glucose, Insulin Sensitivity, and Disposition Index (DI)",National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,14,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAIT CIT-03,Oct-06,Sep-11,Nov-13,13-Feb-07,null,16-Mar-16,"University of Californinia, San Francisco, San Francisco, California, United States|Northwestern University, Chicago, Illinois, United States|University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00434850
NCT00433758,"Evaluation of the GlucoTrack, Non-Invasive Glucose Monitoring Device",,Unknown status,No Results Available,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus|Gestational Diabetes,Device: GlucoTrack,Clarke Error Grid,Integrity Applications Ltd.,All,"10 Years and older   (Child, Adult, Older Adult)",Not Applicable,142,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IA-A2-2007-01-CTIL,Dec-06,null,Dec-08,12-Feb-07,null,18-Mar-08,"Soroka University Medical Center, Beer-Sheva, Israel",,https://ClinicalTrials.gov/show/NCT00433758
NCT00432029,Correlation of Flicker Induced and Flow Mediated Vasodilatation in Patients With Endothelial Dysfunction and Healthy Volunteers.,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Hypertension|Hypercholesterolemia|Regional Blood Flow","Procedure: Forearm blood flow measurement, Flow mediated dilation (FMD)|Device: Zeiss Retinal Vessel Analyzer (RVA), Stimulation with Flicker-light",Retinal vessel diameters (Retinal vessel analyzer)|Forearm Blood Flow,Medical University of Vienna,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,OPHT-180506,Dec-06,Dec-07,Jan-08,6-Feb-07,null,4-Jul-08,"Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT00432029
NCT00430742,An Investigational Drug Study to Assess Weight Loss in Patients With Type 2 Diabetes Mellitus (0364-011)(TERMINATED),,Terminated,No Results Available,Obesity Type 2 Diabetes Mellitus|Type 2 Diabetes Mellitus,Drug: Taranabant|Drug: Comparator: Placebo,"Body weight at 36 weeks, HbA1c at 36 weeks|Body weight at 24 and 52 weeks, HbA1c at 24 and 52 weeks",Merck Sharp & Dohme Corp.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,600,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0364-011|2006_021,Nov-06,Jan-08,Nov-08,2-Feb-07,null,13-Feb-15,,,https://ClinicalTrials.gov/show/NCT00430742
NCT00428207,Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy,,Terminated,Has Results,Type 1 Diabetes Mellitus,Drug: Insulin Aspart versus Insulin Lispro|Drug: Insulin Lispro versus Insulin Aspart,Glycemic Stability|Frequency of Catheter Change,Joslin Diabetes Center|Novo Nordisk A/S,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,4,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-Jun,Feb-07,Aug-08,Aug-08,29-Jan-07,30-May-17,30-May-17,"Joslin Diabetes Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00428207
NCT00427154,Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes,,Terminated,No Results Available,"Diabetes|Diabetes Mellitus, Type 2",Drug: rosiglitazone|Drug: inhaled human insulin|Drug: metformin|Drug: glimepiride,Change in HbA1c|Fasting plasma glucose|Lipid profiles|Hypoglycaemic episodes|Glucose profiles|Change in body weight,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,227,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN1998-1540,10-Jan-07,11-Mar-08,11-Mar-08,26-Jan-07,null,5-Sep-18,"Novo Nordisk Investigational Site, Hueytown, Alabama, United States|Novo Nordisk Investigational Site, Ozark, Alabama, United States|Novo Nordisk Investigational Site, Tuscaloosa, Alabama, United States|Novo Nordisk Investigational Site, Vestavia Hills, Alabama, United States|Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Escondido, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Huntington Beach, California, United States|Novo Nordisk Investigational Site, La Jolla, California, United States|Novo Nordisk Investigational Site, Orange, California, United States|Novo Nordisk Investigational Site, Poway, California, United States|Novo Nordisk Investigational Site, Roseville, California, United States|Novo Nordisk Investigational Site, Sacramento, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, Santa Barbara, California, United States|Novo Nordisk Investigational Site, Temecula, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Colorado Springs, Colorado, United States|Novo Nordisk Investigational Site, Waterbury, Connecticut, United States|Novo Nordisk Investigational Site, Boca Raton, Florida, United States|Novo Nordisk Investigational Site, Clearwater, Florida, United States|Novo Nordisk Investigational Site, Hialeah, Florida, United States|Novo Nordisk Investigational Site, Hollywood, Florida, United States|Novo Nordisk Investigational Site, Lake Mary, Florida, United States|Novo Nordisk Investigational Site, Marianna, Florida, United States|Novo Nordisk Investigational Site, Melbourne, Florida, United States|Novo Nordisk Investigational Site, Merritt Island, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Palm Harbor, Florida, United States|Novo Nordisk Investigational Site, Pembroke Pines, Florida, United States|Novo Nordisk Investigational Site, Vero Beach, Florida, United States|Novo Nordisk Investigational Site, West Palm Beach, Florida, United States|Novo Nordisk Investigational Site, Athens, Georgia, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Augusta, Georgia, United States|Novo Nordisk Investigational Site, Dunwoody, Georgia, United States|Novo Nordisk Investigational Site, Powder Springs, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Suwanee, Georgia, United States|Novo Nordisk Investigational Site, Tucker, Georgia, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, United States|Novo Nordisk Investigational Site, Boise, Idaho, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Peoria, Illinois, United States|Novo Nordisk Investigational Site, Springfield, Illinois, United States|Novo Nordisk Investigational Site, Lafayette, Indiana, United States|Novo Nordisk Investigational Site, Des Moines, Iowa, United States|Novo Nordisk Investigational Site, Shawnee Mission, Kansas, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Wichita, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Scarborough, Maine, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Marlborough, Massachusetts, United States|Novo Nordisk Investigational Site, Springfield, Massachusetts, United States|Novo Nordisk Investigational Site, Jackson, Mississippi, United States|Novo Nordisk Investigational Site, Chesterfield, Missouri, United States|Novo Nordisk Investigational Site, Jefferson City, Missouri, United States|Novo Nordisk Investigational Site, Kansas City, Missouri, United States|Novo Nordisk Investigational Site, Saint Louis, Missouri, United States|Novo Nordisk Investigational Site, Billings, Montana, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Berlin, New Jersey, United States|Novo Nordisk Investigational Site, Cherry Hill, New Jersey, United States|Novo Nordisk Investigational Site, Lawrenceville, New Jersey, United States|Novo Nordisk Investigational Site, Staten Island, New York, United States|Novo Nordisk Investigational Site, Syracuse, New York, United States|Novo Nordisk Investigational Site, Asheville, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Greenville, North Carolina, United States|Novo Nordisk Investigational Site, High Point, North Carolina, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Cleveland, Ohio, United States|Novo Nordisk Investigational Site, Cleveland, Ohio, United States|Novo Nordisk Investigational Site, Dayton, Ohio, United States|Novo Nordisk Investigational Site, Dayton, Ohio, United States|Novo Nordisk Investigational Site, Clinton, Oklahoma, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, United States|Novo Nordisk Investigational Site, Medford, Oregon, United States|Novo Nordisk Investigational Site, Altoona, Pennsylvania, United States|Novo Nordisk Investigational Site, Beaver, Pennsylvania, United States|Novo Nordisk Investigational Site, Norristown, Pennsylvania, United States|Novo Nordisk Investigational Site, Greer, South Carolina, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Clarksville, Tennessee, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Hurst, Texas, United States|Novo Nordisk Investigational Site, Lewisville, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Arlington, Virginia, United States|Novo Nordisk Investigational Site, Norfolk, Virginia, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Warrenton, Virginia, United States|Novo Nordisk Investigational Site, Renton, Washington, United States|Novo Nordisk Investigational Site, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT00427154
NCT00423501,A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.,,Completed,No Results Available,Diabetes Mellitus Type 2,Drug: Placebo|Drug: taspoglutide,"Absolute change from baseline in HbAlc|Absolute change from baseline in FPG, fructosamine, body weight, fasting insulin, C-peptide, glucagon.|Changes in lipid profile|AEs, laboratory parameters, primary pharmacokinetic parameters",Hoffmann-La Roche,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,306,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BC20688,Feb-07,Nov-07,Nov-07,18-Jan-07,null,2-Nov-16,"Washington, District of Columbia, United States|Woodstock, Georgia, United States|Chicago, Illinois, United States|Springfield, Illinois, United States|Rochester, New York, United States|Portland, Oregon, United States|Dallas, Texas, United States|Midland, Texas, United States|San Antonio, Texas, United States|Richmond, Virginia, United States|Adelaide, Australia|Camperdown, Australia|Dimitrovgrad, Bulgaria|Pleven, Bulgaria|Ruse, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Bad Lauterberg, Germany|Berlin, Germany|Görlitz, Germany|Hannover, Germany|Mainz, Germany|Neuss, Germany|Nürnberg, Germany|Guatemala City, Guatemala|Hong Kong, Hong Kong|Riga, Latvia|Kaunas, Lithuania|Klaipeda, Lithuania|Vilnius, Lithuania|Guadalajara, Mexico|Guadalajara, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Monterrey, Mexico|Pachuca, Mexico|Brasov, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Cluj-napoca, Romania|Jud Covasna, Romania|Mures, Romania|Ploiesti, Romania|Satu Mare, Romania|Sibiu, Romania",,https://ClinicalTrials.gov/show/NCT00423501
NCT00419718,Effect of Exercise on the Absorption of Inhaled Human Insulin in Subjects With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: inhaled human insulin,Area under the plasma insulin profile in the interval|Area under the plasma insulin profile in the interval from 120-240 min after trial product administration|Area under the plasma insulin profile in the interval from 240-360 min after trial product administration|Area under the plasma insulin profile in the interval 0-600 min after trial product administration|Maximum plasma insulin concentration,Novo Nordisk A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,23,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN1998-1562,Oct-05,Nov-05,Nov-05,9-Jan-07,null,24-Jan-17,"Novo Nordisk Investigational Site, Graz, Austria",,https://ClinicalTrials.gov/show/NCT00419718
NCT00420095,A Study for Patients With Diabetes Mellitus (IOPA),IOPA,Completed,Has Results,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Drug: Human insulin 30/70|Drug: Insulin lispro low mix,Glycosylated Hemoglobin (HbA1c) Value at 12 Week Endpoint|Changes in Glycosylated Hemoglobin (HbA1c) From Baseline to 12 Weeks of Treatment|Change in Fasting Blood Glucose Values From Baseline to 12 Weeks of Treatment|Change in Total Daily Insulin Dose Values From Baseline to 12 Weeks of Treatment|Number of Participants Achieving Target Glycosylated Hemoglobin (HbA1c) Values <=7% and <=6.5%|Number of Participants With Laboratory Parameters Significantly Different From Baseline|Hypoglycemia Rate Per Participant Per 30 Days,Eli Lilly and Company,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,117,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11423|F3Z-GH-IOPA,Jan-07,Jan-08,Jan-08,9-Jan-07,5-Jun-09,17-Jun-09,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guang Zhou, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hangzhou, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Harbin, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hefei, China",,https://ClinicalTrials.gov/show/NCT00420095
NCT00419562,Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus,,Unknown status,No Results Available,"Diabetes Mellitus, Type 1",Drug: Oral Insulin,Effect of treatment with oral insulin versus placebo in individuals in the primary stratum ( ICA+ confirmed or GAD65 and ICA512 positive on the same sample with confirmation of at least one of these autoantibodies).|Secondary analyses will be done to assess the effects of oral insulin versus placebo in other categories of subjects defined using different combinations of autoantibodies and metabolic status.,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|National Center for Research Resources (NCRR)|American Diabetes Association|Juvenile Diabetes Research Foundation,All,"3 Years to 45 Years   (Child, Adult)",Phase 3,400,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",Oral Insulin (IND),Feb-07,Dec-16,Jun-17,8-Jan-07,null,28-Mar-17,"University of California-San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|Indiana University-Riley Hospital for Children, Indianapolis, Indiana, United States|University of Minnesota, Minneapolis, Minnesota, United States|Columbia University, New York, New York, United States|Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt Eskind Diabetes Clinic, Nashville, Tennessee, United States|University of Texas, Dallas, Texas, United States|Benaroya Research Institute, Seattle, Washington, United States|Walter and Eliza Hall Institute, Parkville, Victoria, Australia|The Hospital for Sick Children, Toronto, Ontario, Canada|University of Turku, Turku, Finland|San Raffaele Hospital, Milan, Italy|University of Bristol, Bristol, United Kingdom",,https://ClinicalTrials.gov/show/NCT00419562
NCT00418522,This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus,,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Insulin glargine|Drug: Inhaled Insulin (Exubera),"Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the Per Protocol (PP) Population|Percentage of Subjects Achieving Glycemic Control (HbA1c < 6.5%) at Week 26|Percentage of Subjects Achieving Glycemic Control (HbA1c < 7.0%) at Week 26|Percentage of Subjects Achieving Glycemic Control (HbA1c < 8.0%) at Week 26|Change From Baseline in Fasting Plasma Glucose at Week 26|Change From Baseline in Fasting and Postprandial Blood Glucose as Determined by Standardized Meal Tolerance Tests at Week 26|Change From Baseline in Postprandial Blood Glucose as Measured by 8-Point Profiles at Week 26|Change From Baseline in Lipids at Week 26|Change From Baseline in Cardiovascular (CV) Biomarkers High Sensitivity C-reactive Protein (Hs-CRP), Leptin, and Spot Urine Microalbumin at Week 26|Change From Baseline in CV Biomarkers Adiponectin and Apolipoprotein B (ApoB) at Week 26|Change From Baseline in 24-Hour Continuous Glucose Monitoring System (CGMS) Glucose Values at Week 26|Change From Baseline in Mean Standard Deviation (SD) of 24-Hour Glucose Values Measured by CGMS at Week 26|Number of Subjects With Hypoglycemic Events|Number of Total Hypoglycemic Events|Number of Total Subject Months of Treatment|Crude Hypoglycemic Event Rate|Number of Nocturnal Hypoglycemic Events|Change From Baseline in Body Weight at Week 26|Change From Baseline in Body Mass Index (BMI) at Week 26|Change From Baseline in Diabetes Treatment Satisfaction Questionnaire-Status, Diabetes Treatment Satisfaction Questionnaire-Change, Diabetes-39, Mental Health Inventory-17, and SF-36 Vitality Domain Questionnaire",Pfizer,All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 4,413,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A2171095,Mar-07,Aug-08,Aug-08,5-Jan-07,4-Sep-09,28-Sep-18,"Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Tucson, Arizona, United States|Pfizer Investigational Site, Concord, California, United States|Pfizer Investigational Site, Encino, California, United States|Pfizer Investigational Site, Fresno, California, United States|Pfizer Investigational Site, Fullerton, California, United States|Pfizer Investigational Site, Long Beach, California, United States|Pfizer Investigational Site, Mission Viejo, California, United States|Pfizer Investigational Site, Pasadena, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Luis Obispo, California, United States|Pfizer Investigational Site, Spring Valley, California, United States|Pfizer Investigational Site, Stockton, California, United States|Pfizer Investigational Site, Walnut Creek, California, United States|Pfizer Investigational Site, West Hills, California, United States|Pfizer Investigational Site, Golden, Colorado, United States|Pfizer Investigational Site, Waterbury, Connecticut, United States|Pfizer Investigational Site, Newark, Delaware, United States|Pfizer Investigational Site, Chiefland, Florida, United States|Pfizer Investigational Site, Clearwater, Florida, United States|Pfizer Investigational Site, Hollywood, Florida, United States|Pfizer Investigational Site, Kissimmee, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Ocala, Florida, United States|Pfizer Investigational Site, Saint Cloud, Florida, United States|Pfizer Investigational Site, Winter Park, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Lawrenceville, Georgia, United States|Pfizer Investigational Site, Lawrenceville, Georgia, United States|Pfizer Investigational Site, Woodstock, Georgia, United States|Pfizer Investigational Site, Boise, Idaho, United States|Pfizer Investigational Site, Hayden Lake, Idaho, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, Overland Park, Kansas, United States|Pfizer Investigational Site, Topeka, Kansas, United States|Pfizer Investigational Site, Lexington, Kentucky, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Baton Rouge, Louisiana, United States|Pfizer Investigational Site, New Orleans, Louisiana, United States|Pfizer Investigational Site, Haverhill, Massachusetts, United States|Pfizer Investigational Site, Springfield, Missouri, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Staten Island, New York, United States|Pfizer Investigational Site, Charlotte, North Carolina, United States|Pfizer Investigational Site, Statesville, North Carolina, United States|Pfizer Investigational Site, Winston-Salem, North Carolina, United States|Pfizer Investigational Site, Kettering, Ohio, United States|Pfizer Investigational Site, Maumee, Ohio, United States|Pfizer Investigational Site, Toledo, Ohio, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Medford, Oregon, United States|Pfizer Investigational Site, Melrose Park, Pennsylvania, United States|Pfizer Investigational Site, Greenville, South Carolina, United States|Pfizer Investigational Site, Greer, South Carolina, United States|Pfizer Investigational Site, Spartanburg, South Carolina, United States|Pfizer Investigational Site, Milan, Tennessee, United States|Pfizer Investigational Site, Arlington, Texas, United States|Pfizer Investigational Site, Beaumont, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, El Paso, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Bennington, Vermont, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Federal Way, Washington, United States|Pfizer Investigational Site, Menomonee Falls, Wisconsin, United States|Pfizer Investigational Site, Carolina, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00418522
NCT00417924,Eye on Diabetes: A Multidisciplinary Patient Education Intervention,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Behavioral: Patient education,"Patient knowledge (pre-test, post-test, and 3 month post-test)|Patient satisfaction post-examination",Nova Southeastern University,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Educational/Counseling/Training,OPT06170409X,Oct-04,null,Oct-05,4-Jan-07,null,4-Jan-07,"Sanford L. Ziff Health Center, Ft. Lauderdale, Florida, United States",,https://ClinicalTrials.gov/show/NCT00417924
NCT00417989,Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy,STAR3,Completed,Has Results,Type 1 Diabetes,Device: MiniMed Paradigm REAL-Time System,"Change in A1c From Baseline to 52 Weeks|Difference in Frequency of Severe Hypoglycemia From Baseline to Week 52;|Overall Difference in Rate of Severe Hypoglycemia Events Between Study Arms From Baseline to Week 52|Changes in Hypoglycemia Area Under the Curve (AUC) From Baseline to Week 52;|Changes From Baseline in Hyperglycemia Area Under the Curve (AUC) From Baseline to Week 52|Quality of Life - Hypoglycemia Fear Scale (HFS), Overall Score|Health Economic Outcome|Quality of Life - Short Form-36 (SF-36v2™), General Health|Quality of Life - Insulin Delivery System Rating Questionnaire (IDSRQ) for Subject Satisfaction With Type of Insulin Therapy",Medtronic Diabetes,All,"7 Years to 70 Years   (Child, Adult, Older Adult)",Not Applicable,485,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CEP179/Z25,Jan-07,Dec-09,Jun-10,4-Jan-07,10-Mar-11,23-May-18,"Scripps Institute, La Jolla, California, United States|Children's Hospital of Orange County (CHOC), Orange, California, United States|Barbara Davis Center, University of Colorado, Boulder, Colorado, United States|Yale University, New Haven, Connecticut, United States|Diabetes Research Institute (DRI), Miami, Florida, United States|Endocrine Research Solutions, Inc., Roswell, Georgia, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Mid-America Diabetes Associates, Wichita, Kansas, United States|Kentucky Diabetes Endocrinology Center, Lexington, Kentucky, United States|Joslin Clinic, Boston, Massachusetts, United States|DeVos Children's Hospital, Grand Rapids, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Minnesota International Diabetes Center, Saint Louis Park, Minnesota, United States|Children's Hospital of St. Paul, Saint Paul, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|University of Rochester, Rochester, New York, United States|Mountain Diabetes & Endocrine Center, Asheville, North Carolina, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center Diabetes Research Clinic, Durham, North Carolina, United States|Diabetes and Obesity Center, East Carolina University, Greenville, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|Utah Diabetes Center, Salt Lake City, Utah, United States|University of Wisconsin Health West, Madison, Wisconsin, United States|Endocrine Research, Inc., Vancouver, British Columbia, Canada|Health Science Center Memorial Hospital of Newfoundland, St. John's, Newfoundland and Labrador, Canada|Kingston General Hospital, Kingston, Ontario, Canada|Toronto General Hospital - UHN, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00417989
NCT00418288,The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men During Hypoglycemia,,Completed,No Results Available,Type 2 Diabetes|Stroke|Myocardial Infarction,Drug: glucagon-like-peptide-1|Drug: placebo,The acute effect of GLP-1 on glucose uptake in the brain|The acute effect of GLP-1 on glucose uptake in the heart|The acute effect of GLP-1 on glucose metabolic rate in the brain|The acute effect of GLP-1 on intracerebral glucose concentration|The acute effect of GLP-1 on lumped constant in the brain,University of Aarhus,Male,20 Years to 50 Years   (Adult),Not Applicable,10,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2005-0089,Jan-07,Oct-07,Feb-08,4-Jan-07,null,10-Jun-08,"Department of pharmacology, Aarhus university, Aarhus, Denmark",,https://ClinicalTrials.gov/show/NCT00418288
NCT00411892,Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes,,Terminated,No Results Available,"Diabetes|Diabetes Mellitus, Type 2",Drug: pioglitazone|Drug: inhaled human insulin,HbA1c change from baseline|Fasting plasma glucose|Lipid profiles|Frequency of hypoglycaemic episodes|Glucose profiles|Change in body weight,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,196,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN1998-1683,29-Nov-06,18-Mar-08,18-Mar-08,15-Dec-06,null,5-Sep-18,"Novo Nordisk Investigational Site, Ozark, Alabama, United States|Novo Nordisk Investigational Site, Tuscaloosa, Alabama, United States|Novo Nordisk Investigational Site, Vestavia Hills, Alabama, United States|Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Little Rock, Arkansas, United States|Novo Nordisk Investigational Site, Bermuda Dunes, California, United States|Novo Nordisk Investigational Site, Escondido, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Huntington Beach, California, United States|Novo Nordisk Investigational Site, La Jolla, California, United States|Novo Nordisk Investigational Site, Northridge, California, United States|Novo Nordisk Investigational Site, Orange, California, United States|Novo Nordisk Investigational Site, Orange, California, United States|Novo Nordisk Investigational Site, Poway, California, United States|Novo Nordisk Investigational Site, Roseville, California, United States|Novo Nordisk Investigational Site, Sacramento, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, Santa Barbara, California, United States|Novo Nordisk Investigational Site, Temecula, California, United States|Novo Nordisk Investigational Site, Tustin, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Arvada, Colorado, United States|Novo Nordisk Investigational Site, Colorado Springs, Colorado, United States|Novo Nordisk Investigational Site, Beverly Hills, Florida, United States|Novo Nordisk Investigational Site, Boca Raton, Florida, United States|Novo Nordisk Investigational Site, Clearwater, Florida, United States|Novo Nordisk Investigational Site, Hialeah, Florida, United States|Novo Nordisk Investigational Site, Hollywood, Florida, United States|Novo Nordisk Investigational Site, Lake Mary, Florida, United States|Novo Nordisk Investigational Site, Marianna, Florida, United States|Novo Nordisk Investigational Site, Melbourne, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Niceville, Florida, United States|Novo Nordisk Investigational Site, Palm Harbor, Florida, United States|Novo Nordisk Investigational Site, Panama City, Florida, United States|Novo Nordisk Investigational Site, Pembroke Pines, Florida, United States|Novo Nordisk Investigational Site, Saint Petersburg, Florida, United States|Novo Nordisk Investigational Site, Tallahassee, Florida, United States|Novo Nordisk Investigational Site, Vero Beach, Florida, United States|Novo Nordisk Investigational Site, West Palm Beach, Florida, United States|Novo Nordisk Investigational Site, Athens, Georgia, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Blue Ridge, Georgia, United States|Novo Nordisk Investigational Site, Dunwoody, Georgia, United States|Novo Nordisk Investigational Site, Powder Springs, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Sandy Springs, Georgia, United States|Novo Nordisk Investigational Site, Suwanee, Georgia, United States|Novo Nordisk Investigational Site, Tucker, Georgia, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, United States|Novo Nordisk Investigational Site, Boise, Idaho, United States|Novo Nordisk Investigational Site, Avon, Illinois, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Peoria, Illinois, United States|Novo Nordisk Investigational Site, Lafayette, Indiana, United States|Novo Nordisk Investigational Site, Des Moines, Iowa, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Wichita, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Prince Frederick, Maryland, United States|Novo Nordisk Investigational Site, Marlborough, Massachusetts, United States|Novo Nordisk Investigational Site, Waltham, Massachusetts, United States|Novo Nordisk Investigational Site, Bloomington, Minnesota, United States|Novo Nordisk Investigational Site, Jackson, Mississippi, United States|Novo Nordisk Investigational Site, Chesterfield, Missouri, United States|Novo Nordisk Investigational Site, Jefferson City, Missouri, United States|Novo Nordisk Investigational Site, Kansas City, Missouri, United States|Novo Nordisk Investigational Site, Saint Louis, Missouri, United States|Novo Nordisk Investigational Site, Billings, Montana, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Syracuse, New York, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, High Point, North Carolina, United States|Novo Nordisk Investigational Site, Raleigh, North Carolina, United States|Novo Nordisk Investigational Site, Winston-Salem, North Carolina, United States|Novo Nordisk Investigational Site, Bismarck, North Dakota, United States|Novo Nordisk Investigational Site, Canal Fulton, Ohio, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Cleveland, Ohio, United States|Novo Nordisk Investigational Site, Cleveland, Ohio, United States|Novo Nordisk Investigational Site, Dayton, Ohio, United States|Novo Nordisk Investigational Site, Clinton, Oklahoma, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, United States|Novo Nordisk Investigational Site, Medford, Oregon, United States|Novo Nordisk Investigational Site, Altoona, Pennsylvania, United States|Novo Nordisk Investigational Site, Beaver, Pennsylvania, United States|Novo Nordisk Investigational Site, Bensalem, Pennsylvania, United States|Novo Nordisk Investigational Site, Hershey, Pennsylvania, United States|Novo Nordisk Investigational Site, Norristown, Pennsylvania, United States|Novo Nordisk Investigational Site, Greer, South Carolina, United States|Novo Nordisk Investigational Site, Clarksville, Tennessee, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Lewisville, Texas, United States|Novo Nordisk Investigational Site, Plano, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Saint George, Utah, United States|Novo Nordisk Investigational Site, Arlington, Virginia, United States|Novo Nordisk Investigational Site, Norfolk, Virginia, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Warrenton, Virginia, United States|Novo Nordisk Investigational Site, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT00411892
NCT00410436,Resistance Exercise in Already-active Diabetic Individuals (READI) Trial,,Completed,No Results Available,Diabetes,Behavioral: Resistance Exercise,"Change in HbA1c|body composition,LDL particle diameter,apolipoprotein B (Apo-B)|apolipoprotein A1 (Apo-A1,Apo-B/Apo-A1 ratio,urinary albumin excretion|serum C-reactive protein,",Ottawa Hospital Research Institute|Canadian Institutes of Health Research (CIHR),All,"16 Years and older   (Child, Adult, Older Adult)",Phase 4,131,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2005301-01H|2005783,Oct-06,Dec-11,Jun-12,12-Dec-06,null,27-Feb-13,"University of Calgary, Calgary, Alberta, Canada|Ottawa Health Research Institute, Ottawa, Ontario, Canada|University Health Network, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00410436
NCT00406133,Randomized Study of Real-Time Continuous Glucose Monitors (RT-CGM) in the Management of Type 1 Diabetes,,Completed,Has Results,Type 1 Diabetes,Device: Continuous glucose monitor,Change in Glycated Hemoglobin (HbA1c) From Baseline to 26 Weeks in the Continuous Glucose Monitoring (CGM) and Control Groups (for the Cohort With Baseline HbA1c >=7.0% Cohort)|Time With Glucose Level <=70 mg/dL (for the Cohort With Baseline HbA1c <7.0%)|Severe Hypoglycemia (for the Cohort With Baseline HbA1c >=7.0% Cohort)|Minutes Per Day Continuous Glucose Monitoring (CGM) Glucose Values 71-180 mg/dL (for the Cohort With Baseline HbA1c >=7.0% Cohort)|Minutes Per Day Continuous Glucose Monitoring (CGM) Glucose Values >180 mg/dL (for the Cohort With Baseline HbA1c >=7.0% Cohort)|Minutes Per Day Continuous Glucose Monitoring (CGM) Glucose Values >250 mg/dL (for the Cohort With Baseline HbA1c >=7.0% Cohort|Minutes Per Day Continuous Glucose Monitoring (CGM) Glucose Values <=70 mg/dL (for Cohort With Baseline HbA1c >=7.0%)|Minutes Per Day Continuous Glucose Monitoring (CGM) Glucose Values <=50 mg/dL (for Cohort With Baseline HbA1c >=7.0%)|Glucose (mg/dl) at Baseline and 26 Weeks (for Cohort With Baseline HbA1c >=7.0%)|Change in Glycated Hemoglobin (HbA1c) From Baseline to 26 Weeks in the Continuous Glucose Monitoring (CGM) and Control Groups (for the Cohort With Baseline HbA1c <7.0% Cohort)|Minutes Per Day of Continuous Glucose Monitoring (CGM) Glucose Values 71-180 mg/dL (for Cohort With Baseline HbA1c <7.0%)|Minutes Per Day Continuous Glucose Monitoring (CGM) Glucose Values >180 mg/dL (for Cohort With Baseline HbA1c <7.0%)|Minutes Per Day Continuous Glucose Monitoring (CGM) Glucose Values >250 mg/dL (for the Cohort With Baseline HbA1c <7.0% Cohort|Minutes Per Day Continuous Glucose Monitoring (CGM) Glucose Values <=50 mg/dL (for Cohort With Baseline HbA1c <7.0%)|Absolute Rate of Change (mg/dl/Min) at 26 Weeks (for Cohort With Baseline HbA1c <7.0%)|Quality of Life|Cost-effectiveness of CGM.|QALW|Total Costs: Direct and Indirect Costs,Jaeb Center for Health Research|JDRF Artificial Pancreas Project,All,"8 Years and older   (Child, Adult, Older Adult)",Phase 3,451,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2006-2402,Dec-06,Jul-08,Feb-09,4-Dec-06,2-Sep-09,14-Apr-17,"University of Southern California, Beverly Hills, California, United States|Kaiser Permanente, San Diego, California, United States|Stanford University, Stanford, California, United States|University of Colorado, Aurora, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Children's Hospital of Iowa, Iowa City, Iowa, United States|Joslin Diabetes Center - Adults, Boston, Massachusetts, United States|Joslin Diabetes Center - Children, Boston, Massachusetts, United States|University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00406133
NCT00406458,Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Diabetic Polyneuropathy",Drug: SB-509|Other: Normal Saline,"Visual analog scale for pain intensity (VASPI), Nerve Conduction Velocity (NCV), Total Neuropathy Score (TNS), Epidermal Nerve Fiber Density (ENFD) & Epidermal Nerve Fiber Density Regeneration (ENFDR)|Safety",Sangamo Therapeutics|Juvenile Diabetes Research Foundation,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,110,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",SB-509-0601,Nov-06,Dec-08,May-09,4-Dec-06,null,1-Nov-12,"Coordinated Clinical Research, La Jolla, California, United States|Advanced Medical Research, LLC, Lakewood, California, United States|SF Clinical Research Center, San Francisco, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Bradenton Research Center, Bradenton, Florida, United States|University of Miami, Diabetes Research Institute, Miami, Florida, United States|Neurology Clinical Research, Sunrise, Florida, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Creighton Diabetes Center, Omaha, Nebraska, United States|Upstate Clinical Research, Albany, New York, United States|Peripheral Neuropathy Center, Weill Medical College of Cornell University, New York, New York, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Nerve and Muscle Center of Texas, Houston, Texas, United States|DGD Research, San Antonio, Texas, United States|Instituto Mexicano de Investigación Clinica, Mexico City, Col. Roma, Mexico",,https://ClinicalTrials.gov/show/NCT00406458
NCT00406991,Retinal Blood Flow and Microthrombi in Type 1 Diabetes,,Completed,No Results Available,Diabetes|Diabetic Retinopathy,Drug: aspirin|Drug: clopidogrel,Retinal blood flow|Retinal arterial blood speed|Retinal arterial diameter,Schepens Eye Research Institute|Massachusetts Eye and Ear Infirmary,All,18 Years to 45 Years   (Adult),Phase 2,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Diagnostic,2002-015|2003P-000224|EY014812,Jun-03,null,Mar-06,4-Dec-06,null,30-Oct-15,"Schepens Eye Research Institute, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00406991
NCT00397553,"Insulin Glulisine, Diabetes Mellitus Type 1",,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Insulin glulisine,HbA1c|Fasting Blood Glucose|Post-prandial glycemia (2 hour after breakfast),Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,104,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HMR1964A_3517,Jan-05,Dec-07,null,9-Nov-06,null,18-Sep-09,"Sanofi-Aventis, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT00397553
NCT00396227,Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: vildagliptin|Drug: thiazolidinedione (TZD),Change from baseline in HemoglobinA1c (HbA1c)|Change from baseline in body weight|Change from baseline in fasting plasma glucose (FPG)|Incidence of prespecified adverse events while on treatment with study drug,Novartis Pharmaceuticals|Novartis,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,2665,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLAF237A23119,Oct-06,Oct-07,null,6-Nov-06,null,18-Nov-16,"Novartis Pharmaceuticals, East Hanover, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00396227
NCT00396357,Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Vildagliptin|Drug: metformin,Change from baseline in hemoglobin A 1 c (HbA1c) after 24 weeks of treatment|Adverse event profile after 24 weeks of treatment|Gastrointestinal tolerability after 24 weeks of treatment|Patients with endpoint HbA1c <7% and <6.5% after 24 weeks|Patients with reduction in HbA1c >0.7% after 24 weeks|Change from baseline in fasting plasma glucose after 24 weeks,Novartis Pharmaceuticals|Novartis,All,"18 Years to 78 Years   (Adult, Older Adult)",Phase 3,914,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CLAF237A23104,Oct-06,Jun-08,null,6-Nov-06,null,1-Jan-13,"Novartis Pharmaceuticals, East Hanover, New Jersey, United States|Novartis Investigative Site, Investigative Centers, Germany",,https://ClinicalTrials.gov/show/NCT00396357
NCT00390728,"Insulin Glargine in Type I Diabetes Mellitus> Main Study ""AT.LANTUS"": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: ""HALT""(Hypoglycaemia Avoidance With Lantus Trial)",AT-LANTUS,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Insulin Glargine,"Main study: Frequency of severe hypoglycaemia|Sub-study: The fear of hypoglycaemia as measured by the Hypoglycaemia Fear Survey questionnaire (HFS-98) assessed at baseline, 3 months and study end point or upon withdrawal of the subject from the study.|Main study: HbA1c|Incidence of nocturnal, symptomatic and asymptomatic hypoglycaemia|Self monitored blood glucose|Change in subject weight|Changes in doses of insulin|Changes in treatment satisfaction|Safety assessment|Quality of Life (QoL)using the Diabetes Treatment Satisfaction Questionnaire (DTSQ)|Sub-study:Quality of Life tools assessed at baseline, 3 months and at study end point or upon withdrawal of the subject|Quality of Life - EQ-5D|Hospital Anxiety and Depression Scale (HADS)|Adverse events correlating with Quality of Life tools and hypoglycaemic events|Medications for diabetes|HbA1c|Weight and height (BMI)|Proportion of patients reaching HbA1c target as per participation with the Prescription Plan",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 4,2346,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HOE901_3505,Apr-02,Aug-03,Aug-03,20-Oct-06,null,31-Aug-10,,,https://ClinicalTrials.gov/show/NCT00390728
NCT00389415,Long Term Safety of Vildagliptin (100mg qd) In Patients With Type 2 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Vildagliptin,Adverse events profile after 52 weeks of treatment|Change from baseline to endpoint on HbA1c at 52 weeks|Change from baseline to endpoint on fasting plasma glucose at 52 weeks|Change from baseline to endpoint in HOMA B at 52 weeks|Change from baseline to endpoint in HOMA IR at 52 weeks|Change from baseline to endpoint in body weight at 52 weeks,Novartis,All,"20 Years and older   (Adult, Older Adult)",Phase 3,150,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLAF237A1303E1,Oct-06,null,null,18-Oct-06,null,27-Nov-08,"Novartis Pharmaceuticals, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00389415
NCT00385697,The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Teplizumab|Other: Placebo,"The first primary endpoint is a composite endpoint at 52 weeks: the proportion of subjects with both a total daily insulin dose of less than 0.5 U/kg/day and HbA1c level of less than 6.5%.|The second primary endpoint is the mean HbA1c change from baseline at 52 weeks after randomization.|Change from baseline in C-peptide AUC at 52 Weeks and 104 weeks after randomization.|The proportion of subjects at 104 weeks after randomization, that have both a total daily insulin dose of less than 0.5 U/kg/day and HbA1c level of less than 6.5%|The proportion of subjects at 52 weeks after randomization, that have both a total daily insulin dose of less than 0.5 U/kg/day and HbA1c level of less than 7.0%.|Mean HbA1c change from baseline at 104 weeks after randomization.",MacroGenics|Eli Lilly and Company,All,"8 Years to 35 Years   (Child, Adult)",Phase 2|Phase 3,554,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",CP-MGA031-01,Oct-06,Jun-10,Aug-11,11-Oct-06,null,29-Aug-12,"UAB School of Medicine, Birmingham, Alabama, United States|NEA Clinic, Jonesboro, Arkansas, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Diabetes Medical Center of California, Northridge, California, United States|UCSF Medical Center, San Francisco, California, United States|University of Colorado Health Sciences Center, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|Christiana Care Research Institute, Newark, Delaware, United States|Richard Hays, MD, Wellington, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Humphrey Diabetes Center, Boise, Idaho, United States|Rocky Mountain Diabetes & Osteoporosis Center, Idaho Falls, Idaho, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|University of Iowa Children's Hospital, Iowa City, Iowa, United States|Mid-America Diabetes Associates, PA, Wichita, Kansas, United States|Commonwealth Biomedical Research, LLC, Madisonville, Kentucky, United States|St. Agnes Hospital, Baltimore, Maryland, United States|Maryland Diabetes & Endocrine Associates, Rockville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Alzohaili Medical Consultants, Dearborne, Michigan, United States|The Children's Mercy Hospital, Kansas City, Missouri, United States|Creighton Diabetes Center, Omaha, Nebraska, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|University of Medicine & Dentistry of NJ, New Brunswick, New Jersey, United States|Albany Medical Center, Albany, New York, United States|Schneider Children's Hospital, New Hyde Park, New York, United States|Joslin Diabetes Center, Syracuse, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|St. Mary Medical Center, Langhorne, Pennsylvania, United States|Sumter Medical Specialists, Sumter, South Carolina, United States|University Diabetes & Endocrine Consultants, Chattanooga, Tennessee, United States|Methodist Healthcare, Memphis, Tennessee, United States|Research Institute of Dallas, Dallas, Texas, United States|Spectra Research Center, McAllen, Texas, United States|Diabetes and Glandular Disease Research, San Antonio, Texas, United States|Endocrine Research Specialists, Ogden, Utah, United States|Pacific Northwest Research Institute, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Alberta Children's Hospital, Calgary, Alberta, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|University Health Sciences Centre, St. John's, Newfoundland and Labrador, Canada|Capital District Health Authority, Halifax, Nova Scotia, Canada|Oxford AIM Clinic, London, Ontario, Canada|Children's Hospital of Western, London, Ontario, Canada|FN Brno- Detska nemocnice, Brno, Czech Republic|FN Hradec Kralove, Hradec Kralove, Czech Republic|Nemocnice Jihlava, Jihlava, Czech Republic|FN Kralovske Vinohrady, Praha 10, Czech Republic|Fakultni nemocnice v Motole, Praha, Czech Republic|Masarykova nemocnice v Usti nad Labem, Usti nad Labem, Czech Republic|East Tallinn Central Hospital, Ravi, Tallinn, Estonia|Tartu University Hospital, Puusepa, Tartu, Estonia|Universitätsklinikum Heidelberg, Heidelberg, Baden-Wurttemberg, Germany|Medizinische Universitätsklinik Ulm, Ulm, Baden-Wurttemberg, Germany|Herz-und Diabetszentrum Nordrhein-Westfalen, Bad Oeynhausen, North Rhine-Westphalia, Germany|Charité-Hochschulmedizin Berlin, Berlin, Germany|Universitatsklinik Giessen, Giessen, Germany|Nizam's Institute of Medical Sciences, Hyderabad, Andhra Pradesh, India|King George Hospital, Visakhapatnam, Andhra Pradesh, India|Gujarat Endocrine Centre, Ahmedabad, Gujarat, India|DHL Research Centre, Ahmedabad, Gujarat, India|Bharti Research Institute of Diabetes & Endocrinology, Karnal, Haryana, India|Bangalore Diabetes Centre, Bangalore, Karnataka, India|Diabetes Thyroid Hormone Research Institute PVT LTD, Indore, Madhya Pradesh, India|Diabetes Action Centre, Mumbai, Maharashtra, India|Gandhi Endocrinology and Diabetes Centre, Nagpur, Maharashtra, India|Endocrine Clinic, Nasik, Maharashtra, India|Grant Medical Foundation, Pune, Maharashtra, India|Fortis Escorts Hospital, Jaipur, Rajasthan, India|B.P.Poddar Hospital and Medical Research Ltd, Kolkata, West Bengal, India|Medwin Hospitals, Hyderabad, India|Pushpawati Singhania Research Institute, New Delhi, India|Soroka Medical Centre, Beer Sheba, Israel|Hillel Yaffe Medical Center, Hadera, Israel|Rambam Medical Centre, Haifa, Israel|Wolfson Medical Centre, Holon, Israel|National Centre for Childhood and Diabetes, Petach Tikva, Israel|Chaim Sheba Medical Center, Ramat-Gan, Israel|P. Stradins Clinical University Hospital, Riga, Latvia|Hospital CIMA Santa Engracia, San Pedro Garza García, Nuevo Leon, Mexico|Hospital Mexico-Americano, Guadalajara, Mexico|Hospital General de Mexico, Mexico City, Mexico|Hospital Central, San Luis Potosí, Mexico|Diabeter Center for Pediatric and Adolescent Diabetes Care and Research, Rotterdam, Netherlands|Samodzielny Publiczny Szpital Kliniczny Akademi Medycznej w Bialymstoku, Bialystok, Poland|Oddzial Diabetologiczny Klinika Pediatrii, Gdansk, Poland|Wojewodzki Specjalistyczny Szpital Dzieciecy, Kielce, Poland|I. Szpital Miejski im. Dr. E. Sonnenberga w Lodzi, Kodz, Poland|Uniwersytecki Szpital Kliniczny, Lodz, Poland|Powiatowy Zespot Szpitali w Olesnicy, Oddzial Chorob Wewnetrznych, Olesnica, Poland|Klinika Endokrynologii i Diabetologii Wieku Rozwojowego, Wroclaw, Poland|S.C. Minimed S.R.L., Bacau, Romania|Institutul de Diabet, Bucharest, Romania|Centrul Medical ""Sanatatea ta"", Bucuresti, Romania|Spitulul Clinic Judetean de Urgenta Cluj, Cluj-Napoca, Romania|Spitalul Clinic Judetean de Urgenta, Iasi, Romania|Spitalul Judetean Satu Mare, Satu Mare, Romania|Hospital Universitari Dr. Josep Trueta de Girona, Girona, Gerona, Spain|Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Universitetssjukhuset i Linkoping, Linkoping, Sweden|Universitetssjukhuset i Lund, Lund, Sweden|Sodersjukhuset AB, Stockholm, Sweden|Donetsk Regional Children Clinical Hospital, Donetsk, Ukraine|V. Danilevsky Institute of Endocrine Pathology Problems, Kharkiv, Ukraine|Kharkiv Regional Clinical Children's Hospital, Kharkiv, Ukraine|Ukrainian Scientific and Practical Center of Endocrine Surgery, Kyiv, Ukraine|Ukranian Children Specialised Clinical Hospital, Kyiv, Ukraine|Regional Clinical Endocrinological Dispensary, Vinnitsa, Ukraine|Zaporizhzhya Regional Pediatric Hospital, Zaporizhzhya, Ukraine|Addenbrookes Hospital, Cambridge, Cambridgeshire, United Kingdom|Royal Devon and Exeter Hospital, Exeter, Devon, United Kingdom",,https://ClinicalTrials.gov/show/NCT00385697
NCT00383578,Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Vildagliptin 100 mg qd|Drug: Metformin 1500 mg daily,Change from baseline in HbA1c|Adverse event profile|Gastrointestinal tolerability|Patients with endpoint HbA1c <7% and patients with reduction in HbA1c > 0.7%|Change from baseline in fasting plasma glucose|Change from baseline in body weight,Novartis Pharmaceuticals|Novartis,All,65 Years and older   (Older Adult),Phase 3,335,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CLAF237A2398,Sep-06,May-08,null,3-Oct-06,null,4-Jan-13,"Investigative Centers, Nurnberg, Germany|Novartis Pharmaceuticals, Basel, Switzerland",,https://ClinicalTrials.gov/show/NCT00383578
NCT00382096,Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Vildagliptin|Drug: Metformin|Drug: Vildagliptin + Metformin,Change from baseline in HbA1c|Change from baseline in fasting plasma glucose|Percent of patients with endpoint HbA1c <7%|Percent of patients with reduction in HbA1c >/=0.7%|Adverse event profile after treatment|Change from baseline in body weight,Novartis Pharmaceuticals|Novartis,All,"18 Years to 78 Years   (Adult, Older Adult)",Phase 3,1179,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CLMF237A2302,Sep-06,3-Jun-08,3-Jun-08,28-Sep-06,null,17-May-17,"Novartis Pharmaceuticals, East Hanover, New Jersey, United States|Investigative Centers, Germany",,https://ClinicalTrials.gov/show/NCT00382096
NCT00378508,Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes,,Completed,Has Results,Type 1 Diabetes Mellitus,"Drug: mAb hOKT3gamma1(Ala-Ala), Teplizumab|Drug: Placebo Arm",C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT) at 12 Months|C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT) at Baseline|Hemoglobin A1c|Average Insulin Use Over 12 Months|Baseline Insulin Use|Baseline Hemoglobin A1c,Yale University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Juvenile Diabetes Research Foundation,All,"8 Years to 30 Years   (Child, Adult)",Phase 2,63,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Delay-Study 5|R01DK057846,Sep-06,Aug-11,Aug-13,20-Sep-06,31-Oct-12,2-Aug-16,"University of California at San Francisco, San Francisco, California, United States|Barbara Davis Diabetes Center, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00378508
NCT00374270,Improving Blood Pressure Management in Patients With Diabetes,SCRIP-HTN,Completed,No Results Available,"Hypertension|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Behavioral: Lifestyle Counselling; Opinion Leader Influence Statements,difference in change in systolic BP between the intervention and usual care groups|change in antihypertensive therapy by new/additional hypertension medication or dosage increase between groups|proportion of patients achieving goal BP of <130/80 mm Hg between groups|proportion of patients that are prescribed an ACE inhibitor or angiotensin receptor antagonist between groups,"University of Alberta|Canadian Diabetes Association|Heart and Stroke Foundation of Canada|College and Association of Registered Nurses of Alberta|Alberta Health & Wellness|Medicine Shoppe of Canada|Canadian Council of Cardiovascular Nurses|MED Institute, Incorporated|Capital Health, Canada|Alberta Heritage Foundation for Medical Research|Alberta Medical Association|Merck Frosst Canada Ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 4,227,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,EPICORE-GG5130000107,May-05,null,May-07,11-Sep-06,null,11-Dec-07,"University of Alberta, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT00374270
NCT00372814,"Study of Intensive, Home-Based Family Therapy to Improve Illness Management in Youth With Diabetes",,Completed,No Results Available,"Diabetes Mellitus, Insulin Dependent",Behavioral: Intensive Home-Based Family Therapy|Behavioral: Supportive Telephone Calls,"Metabolic Control: Hemoglobin A1c (HbA1c)|BMI percentile|Diabetes-Specific Family Functioning|DKA admissions and emergency room (ER) Visits: hospital information systems data extraction, Service Utilization Questionnaire (SUQ)|Regimen Adherence: Diabetes Management Scale (DMS), Twenty-Four Hour Recall Interview, Glucose Meter Downloads",Wayne State University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,10 Years to 17 Years   (Child),Not Applicable,146,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,DK59067B (completed)|R01DK059067,Mar-07,Jan-11,Jan-11,7-Sep-06,null,2-Jun-17,"Children's Hospital of Michigan, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT00372814
NCT00372086,Rosiglitazone and Insulin in T1DM Adolescents,,Completed,No Results Available,Type 1 Diabetes|Puberty: >Tanner 2 Breast Development or Testis >4ml,Drug: Rosiglitazone,"HbA1c|insulin dose|frequency of severe hypoglycaemia|insulin sensitivity assessed by euglycaemic, hyperinsulinaemic clamp|weight|BMI-SDS|skin fold thickness|cholesterol|adiponectin","The University of New South Wales|Sydney Children's Hospitals Network|National Health and Medical Research Council, Australia|Novo Nordisk A/S",All,"10 Years to 18 Years   (Child, Adult)",Phase 4,32,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,02/315|JHH ethics: 04/02/11/3.04|CHW ethics: 2003/037,Aug-03,null,Sep-05,6-Sep-06,null,6-Sep-06,"Sydney Children's Hospital, Sydney, New South Wales, Australia",,https://ClinicalTrials.gov/show/NCT00372086
NCT00371800,The Effect of Cinnamon on HbA1c Among Adolescents With Type I Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: cinnamon,HbA1c|Total Daily Insulin|Carbohydrate/insulin dose|Hypoglycemic events|Compliance,Dartmouth-Hitchcock Medical Center|Dartmouth College,All,"13 Years to 18 Years   (Child, Adult)",Phase 2|Phase 3,72,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,17648,Oct-05,null,May-06,4-Sep-06,null,4-Sep-06,"Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States",,https://ClinicalTrials.gov/show/NCT00371800
NCT00370084,Itopride Hydrochloride in Diabetes: Effects on Gastric Emptying and Glycemia,,Completed,No Results Available,Gastroparesis,Drug: Itopride|Other: Placebo,"Gastric emptying assessment|Glycemia, relief of upper gastrointestinal symptoms, intragastric meal distribution",Forest Laboratories,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,25,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ITODG04-01|041026,Mar-05,May-06,Jul-06,30-Aug-06,null,9-Feb-17,"University of Adelaide, Department of Medicine, Adelaide, South Australia, Australia",,https://ClinicalTrials.gov/show/NCT00370084
NCT00368134,To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Vildagliptin,Change in HbA1c after 12 weeks|Change in FPG after 12 weeks|Change in Fasting Lipids after 12 weeks|Change in HOMA-IR after 12 weeks|Change in HOMA-B after 12 weeks|Safety Profile after 12 weeks treatment,Novartis,All,"20 Years and older   (Adult, Older Adult)",Phase 3,370,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CLAF237A1301,Aug-06,null,null,24-Aug-06,null,28-Jun-07,"Novartis Pharmaceuticals, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00368134
NCT00368394,Dose-Exposure-Response in Type 1 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Type I",Drug: Insulin glulisine,"Outcome measures: Glucose infusion rate, insulin concentrations.|Outcome:In T1DM, glulisine, like RHI, displays dose proportionality in exposure over the dose range 0.075 to 0.3 U/kg, which partly only translates into dose proportionality in glucodynamics.",Sanofi,Male,18 Years to 55 Years   (Adult),Phase 1,18,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single|Primary Purpose: Treatment,HMR1964/1019|HMR1964,Jan-04,null,null,24-Aug-06,null,24-Aug-06,"Sanofi-Aventis, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT00368394
NCT00367445,A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Inhaled Human Insulin (Exubera)|Drug: Insulin Glargine (Lantus),Variability of blood glucose over a period of 72 hours|Insulin pharmacokinetics,Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 4,30,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A2171094,Sep-06,null,Feb-07,22-Aug-06,null,29-Jan-08,"Pfizer Investigational Site, Chula Vista, California, United States",,https://ClinicalTrials.gov/show/NCT00367445
NCT00365170,Efficacy and Safety of Insulin Aspart vs. Human Insulin During Pregnancy by Women With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: human insulin|Drug: insulin aspart,Relative risk of major maternal hypoglycaemia|Relative risk of major and minor hypoglycaemia|Diabetic complications|Obstetric complications|Other Adverse Events,Novo Nordisk A/S,Female,"18 Years and older   (Adult, Older Adult)",Phase 4,419,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANA-1474,Sep-02,Apr-05,Apr-05,17-Aug-06,null,21-Dec-16,"Novo Nordisk Investigational Site, Ciudad de Buenos Aires, Argentina|Novo Nordisk Investigational Site, Pcia de Cordoba, Argentina|Novo Nordisk Investigational Site, Graz, Austria|Novo Nordisk Investigational Site, Salzburg, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Halifax, Nova Scotia, Canada|Novo Nordisk Investigational Site, Ottawa, Canada|Novo Nordisk Investigational Site, St John's, Canada|Novo Nordisk Investigational Site, Toronto, Canada|Novo Nordisk Investigational Site, Toronto, Canada|Novo Nordisk Investigational Site, Vancouver, Canada|Novo Nordisk Investigational Site, Winnipeg, Canada|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Hvidovre, Denmark|Novo Nordisk Investigational Site, København ø, Denmark|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Kuopio, Finland|Novo Nordisk Investigational Site, Oulu, Finland|Novo Nordisk Investigational Site, ANGERS cedex 09, France|Novo Nordisk Investigational Site, Avignon, France|Novo Nordisk Investigational Site, Bondy, France|Novo Nordisk Investigational Site, Brest, France|Novo Nordisk Investigational Site, Lille, France|Novo Nordisk Investigational Site, MARSEILLE Cédex 05, France|Novo Nordisk Investigational Site, Nantes, France|Novo Nordisk Investigational Site, Nimes, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, PuyRicard, France|Novo Nordisk Investigational Site, Strasbourg, France|Novo Nordisk Investigational Site, Strasbourg, France|Novo Nordisk Investigational Site, TOULOUSE cedex, France|Novo Nordisk Investigational Site, Valenciennes, France|Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Beer Sheva, Israel|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Petah-Tikva, Israel|Novo Nordisk Investigational Site, Apeldoorn, Netherlands|Novo Nordisk Investigational Site, Brunssum, Netherlands|Novo Nordisk Investigational Site, Den Haag, Netherlands|Novo Nordisk Investigational Site, Eindhoven, Netherlands|Novo Nordisk Investigational Site, Roermond, Netherlands|Novo Nordisk Investigational Site, Rotterdam, Netherlands|Novo Nordisk Investigational Site, Utrecht, Netherlands|Novo Nordisk Investigational Site, Oslo, Norway|Novo Nordisk Investigational Site, Tromsø, Norway|Novo Nordisk Investigational Site, Trondheim, Norway|Novo Nordisk Investigational Site, Krakow, Poland|Novo Nordisk Investigational Site, Lodz, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Olsztyn, Poland|Novo Nordisk Investigational Site, Poznan, Poland|Novo Nordisk Investigational Site, Szczecin, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Wroclaw, Poland|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Alicante, Spain|Novo Nordisk Investigational Site, Girona, Spain|Novo Nordisk Investigational Site, Santander, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Ashington, United Kingdom|Novo Nordisk Investigational Site, Bath, United Kingdom|Novo Nordisk Investigational Site, Belfast, United Kingdom|Novo Nordisk Investigational Site, Birmingham, United Kingdom|Novo Nordisk Investigational Site, Bristol, United Kingdom|Novo Nordisk Investigational Site, Cambridge, United Kingdom|Novo Nordisk Investigational Site, Edgbaston, Birmingham, United Kingdom|Novo Nordisk Investigational Site, Edinburgh, United Kingdom|Novo Nordisk Investigational Site, Exeter, United Kingdom|Novo Nordisk Investigational Site, Hull, United Kingdom|Novo Nordisk Investigational Site, Leeds, United Kingdom|Novo Nordisk Investigational Site, Leicester, United Kingdom|Novo Nordisk Investigational Site, Liverpool, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Newcastle, United Kingdom|Novo Nordisk Investigational Site, Norfolk, United Kingdom|Novo Nordisk Investigational Site, Northampton, United Kingdom|Novo Nordisk Investigational Site, Nottingham, United Kingdom|Novo Nordisk Investigational Site, Oxford, United Kingdom|Novo Nordisk Investigational Site, Plymouth, United Kingdom|Novo Nordisk Investigational Site, Reading, United Kingdom|Novo Nordisk Investigational Site, Sheffield, United Kingdom|Novo Nordisk Investigational Site, Sheffield, United Kingdom|Novo Nordisk Investigational Site, Southampton, United Kingdom|Novo Nordisk Investigational Site, Stourbridge, United Kingdom|Novo Nordisk Investigational Site, Worcester, United Kingdom",,https://ClinicalTrials.gov/show/NCT00365170
NCT00365781,Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: ISIS 113715,"Compare the dermatologic responses to 200 mg/1.0 mL and 200 mg/2.0 mL ISIS 113715 administered subcutaneously into separate abdominal sites, with both injections given on the same day.|Evaluate and examine the effect of treatment on laboratory results, vital signs, and adverse events.","Ionis Pharmaceuticals, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,10,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISIS 113715-CS13,Aug-06,null,Sep-06,17-Aug-06,null,17-Oct-07,"Therapeutics Clinical Research, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT00365781
NCT00360984,Prevention of Severe Hypoglycemia in Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: insulin glargine|Device: continuous subcutaneous insulin infusion,prevention of severe hypoglycemia|incidence of mild symptomatic hypoglycemia|HbA1C|Continuous Subcutaneous Glucose Monitoring System profiles|Altered Hypoglycemia Awareness survey|Hypoglycemia Fear Survey|Diabetes Quality Of Life of questionnaires.,Newcastle University|Newcastle-upon-Tyne Hospitals NHS Trust|Newcastle Primary Care Trust|Sanofi|Medtronic,All,"18 Years to 74 Years   (Adult, Older Adult)",Phase 4,21,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4044,May-03,null,Sep-04,7-Aug-06,null,7-Aug-06,"Newcastle Diabetes Centre, Newcastle, Tyne and Wear, United Kingdom",,https://ClinicalTrials.gov/show/NCT00360984
NCT00361023,Effects of Losartan on Insulin Sensitivity and Secretion in Type 2 Diabetes and Nephropathy,,Completed,No Results Available,Type 2 Diabetes|Diabetic Nephropathy,Drug: losartan,,Shanghai Jiao Tong University School of Medicine,All,"17 Years and older   (Child, Adult, Older Adult)",Not Applicable,25,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LISS,Jan-06,null,Jul-06,7-Aug-06,null,7-Aug-06,,,https://ClinicalTrials.gov/show/NCT00361023
NCT00361153,Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Colesevelam hydrochloride|Drug: placebo,"To evaluate the effect of 8 weeks treatment with WelChol on insulin sensitivity,as measured by the hyperinsulinemic-euglycemic clamp method, i.e., placebo-corrected change from baseline in M-value.|To evaluate the effect of 2 weeks treatment with WelChol on insulin sensitivity,as measured by the hyperinsulinemic-euglycemic clamp method.|To evaluate acute and chronic effects of treatment with WelChol on plasma glucose after ingestion of a standard meal replacement.|To evaluate the effect of treatment with WelChol on HbA1C, insulin, fasting plasma glucose, and fructosamine.","Daiichi Sankyo, Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,35,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",WEL-202,May-06,Oct-06,Mar-07,7-Aug-06,null,25-Jun-08,"Diabetes and Glandular Research Associates, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00361153
NCT00360334,A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients,,Completed,Has Results,Type 2 Diabetes,Drug: exenatide|Drug: insulin glargine,Percent of Patients Who Achieved HbA1c ≤ 7.4% With Minimal Weight Gain (≤ 1kg)|Percent of Patients Who Achieved HbA1c ≤ 7.4% and Weight Gain ≤ 0.5kg|Change in Fasting Serum Glucose|Percent of Patients Achieving HbA1c ≤ 7.4%|Percent of Patients Achieving HbA1c < 7%|Percent of Patients Achieving HbA1c < 6.5%|Change in 7 Point Self Monitored Blood Glucose Profile|Change in Body Mass Index (BMI)|Change in Waist Circumference|Change in Waist-to-hip Ratio|Change in Body Weight|Percent Change in Body Weight|Percent of Patients Achieving 5% Weight Loss|Percent of Patients Achieving 10% Weight Loss|Change in Systolic Blood Pressure|Change in Diastolic Blood Pressure|Change in Fasting Serum Total Cholesterol (TC)|Change in High Density Lipoprotein (HDL) Cholesterol|Change in TC to HDL Cholesterol Ratio|Change in Fasting Serum Triglycerides|Change in Low Density Lipoprotein (LDL) Cholesterol|Change in Apolipoprotein-B|Incidence of Hypoglycemic Episodes|Incidence of Nocturnal Hypoglycemic Episodes|Incidence of Severe Hypoglycemic Episodes|Hypoglycemic Rate Per 30 Days|Nocturnal Hypoglycemic Rate Per 30 Days|Severe Hypoglycemic Rate Per 30 Days,AstraZeneca|Eli Lilly and Company,All,"30 Years and older   (Adult, Older Adult)",Phase 3,235,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H8O-BP-GWBG,Jun-06,Apr-08,Apr-08,4-Aug-06,5-Jun-09,7-Apr-15,"Research Site, Aberdeen, United Kingdom|Research Site, Bath, United Kingdom|Research Site, Blackburn, United Kingdom|Research Site, Bolton, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Chippenham, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Haywards Heath, United Kingdom|Research Site, High Wycombe, United Kingdom|Research Site, Hull, United Kingdom|Research Site, Ipswich, United Kingdom|Research Site, Kent, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Livingstone, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Middlesborough, United Kingdom|Research Site, Norwich, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Oldham, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Rochdale, United Kingdom|Research Site, Salford, United Kingdom|Research Site, Swansea, United Kingdom|Research Site, Torquay, United Kingdom|Research Site, Wakefield, United Kingdom|Research Site, Wirral, United Kingdom",,https://ClinicalTrials.gov/show/NCT00360334
NCT00360061,CBT in Adolescents With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus,Behavioral: Cognitive Behaviour Therapy,"HBA1c|Well Being Questionnaire, Children’s Health locus of control,|Diabetes Quality of Life for Youths (modified from DCCT),|Self Efficacy for Diabetes Scale (modified version,),|Diabetes Family Behaviour Scale, Diabetes Readiness to Change Questionnaire,|Modified Health Care Climate Questionnaire (at baseline only).",University of Bristol|Diabetes UK,All,11 Years to 16 Years   (Child),Not Applicable,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ECCRA/2001|DUK grant BDA: RD01/0002114,Sep-01,null,Jun-05,3-Aug-06,null,3-Aug-06,"Bristol Royal Hospital for Children, Bristol, United Kingdom",,https://ClinicalTrials.gov/show/NCT00360061
NCT00359112,AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes,,Completed,No Results Available,Non-Insulin-Dependent Diabetes Mellitus,Drug: metformin|Drug: sulphonylurea|Drug: Avandamet,Change in HbA1c level from baseline following 52 weeks of treatment.|Change in FPG (fasting plasma glucose)|insulin sensitivity|beta cell function|change in PAI-1|CRP|number of hypoglycaemic events|Change in 24 hr ABPM|Diabetes treatment satisfaction.,GlaxoSmithKline,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,544,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,AVM100264,Feb-04,null,null,1-Aug-06,null,18-May-09,"GSK Investigational Site, Brugge, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Heverlee, Belgium|GSK Investigational Site, Landen, Belgium|GSK Investigational Site, Namur (Champion), Belgium|GSK Investigational Site, Oostham, Belgium|GSK Investigational Site, Petit-Rechain, Belgium|GSK Investigational Site, Tessenderlo, Belgium|GSK Investigational Site, Tremelo, Belgium|GSK Investigational Site, Willebroek, Belgium|GSK Investigational Site, Zandhoven (Pulle), Belgium|GSK Investigational Site, Roubaix, Nord-Pas-de-Calais, France|GSK Investigational Site, Anzin, France|GSK Investigational Site, Briollay, France|GSK Investigational Site, Commelle Vernay, France|GSK Investigational Site, Cremeaux, France|GSK Investigational Site, Evron, France|GSK Investigational Site, Laval, France|GSK Investigational Site, Louverne, France|GSK Investigational Site, Lyon, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Roanne, France|GSK Investigational Site, Saint Ouen, France|GSK Investigational Site, Sainte Suzanne, France|GSK Investigational Site, Segré, France|GSK Investigational Site, Venissieux, France|GSK Investigational Site, Gueglingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Kippenheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Koenigsfeld, Baden-Wuerttemberg, Germany|GSK Investigational Site, Waldshut-Tiengen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Weinheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Grafing, Bayern, Germany|GSK Investigational Site, Herzogenaurach, Bayern, Germany|GSK Investigational Site, Immenstadt, Bayern, Germany|GSK Investigational Site, Oberteisendorf, Bayern, Germany|GSK Investigational Site, Saaldorf-Surheim, Bayern, Germany|GSK Investigational Site, Wallerfing, Bayern, Germany|GSK Investigational Site, Wuerzburg, Bayern, Germany|GSK Investigational Site, Grossalmerode, Hessen, Germany|GSK Investigational Site, Einbeck, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Isernhagen, Niedersachsen, Germany|GSK Investigational Site, Papenburg, Niedersachsen, Germany|GSK Investigational Site, Beckum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bergkamen-Rünthe, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dinslaken, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dortmund, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Goch, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Viersen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Mainz, Rheinland-Pfalz, Germany|GSK Investigational Site, Neuwied, Rheinland-Pfalz, Germany|GSK Investigational Site, Rhaunen, Rheinland-Pfalz, Germany|GSK Investigational Site, Speyer, Rheinland-Pfalz, Germany|GSK Investigational Site, Saarlouis, Saarland, Germany|GSK Investigational Site, Wolmirstedt, Sachsen-Anhalt, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Elmshorn, Schleswig-Holstein, Germany|GSK Investigational Site, Blanchardstown, Ireland|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Bologna, Emilia-Romagna, Italy|GSK Investigational Site, Ferrara, Emilia-Romagna, Italy|GSK Investigational Site, Ravenna, Emilia-Romagna, Italy|GSK Investigational Site, Arenzano (GE), Liguria, Italy|GSK Investigational Site, Genova, Liguria, Italy|GSK Investigational Site, Sassari, Sardegna, Italy|GSK Investigational Site, Città di Castello (PG), Umbria, Italy|GSK Investigational Site, Terni, Umbria, Italy|GSK Investigational Site, Kaunas, Lithuania|GSK Investigational Site, Kaunas, Lithuania|GSK Investigational Site, Vilnius, Lithuania|GSK Investigational Site, Vilnius, Lithuania|GSK Investigational Site, Tijuana, Baja California Norte, Mexico|GSK Investigational Site, Pachuca, Hidalgo, Mexico|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Durango, Mexico|GSK Investigational Site, Mexico, D.F., Mexico|GSK Investigational Site, Beek En Donk, Netherlands|GSK Investigational Site, Beerzerveld, Netherlands|GSK Investigational Site, Den Haag, Netherlands|GSK Investigational Site, Heerlen, Netherlands|GSK Investigational Site, Hoogvliet, Netherlands|GSK Investigational Site, Landgraaf, Netherlands|GSK Investigational Site, Musselkanaal, Netherlands|GSK Investigational Site, Oude Pekela, Netherlands|GSK Investigational Site, Spijkenisse, Netherlands|GSK Investigational Site, Woerden, Netherlands|GSK Investigational Site, Zaandam, Netherlands|GSK Investigational Site, Zieuwent, Netherlands|GSK Investigational Site, Alcobendas/Madrid, Spain|GSK Investigational Site, Alcora/Castellón, Spain|GSK Investigational Site, Alicante, Spain|GSK Investigational Site, Alzira, Spain|GSK Investigational Site, Artana/Castellón, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Benicassim (Castellon), Spain|GSK Investigational Site, Cadiz, Spain|GSK Investigational Site, Castellón, Spain|GSK Investigational Site, Cáceres, Spain|GSK Investigational Site, Gerona, Spain|GSK Investigational Site, Granada, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Malaga, Spain|GSK Investigational Site, Merida, Spain|GSK Investigational Site, Móstoles/Madrid, Spain|GSK Investigational Site, Onda (Castellon), Spain|GSK Investigational Site, Pontevedra, Spain|GSK Investigational Site, Sabadell (Barcelona), Spain|GSK Investigational Site, San Juan De Alicante, Spain|GSK Investigational Site, Sta Coloma de Gramanet (Barcelona), Spain|GSK Investigational Site, Tarrasa, Barcelona, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Bern, Switzerland|GSK Investigational Site, Emmenbrücke, Switzerland|GSK Investigational Site, Gettnau, Switzerland|GSK Investigational Site, Jegenstorf, Switzerland|GSK Investigational Site, Lugano, Switzerland|GSK Investigational Site, Luzern, Switzerland|GSK Investigational Site, Pregassona, Switzerland|GSK Investigational Site, Salmsach, Switzerland|GSK Investigational Site, St. Maurice, Switzerland|GSK Investigational Site, Steckborn, Switzerland|GSK Investigational Site, Winterthur, Switzerland|GSK Investigational Site, Winterthur, Switzerland|GSK Investigational Site, Zürich, Switzerland|GSK Investigational Site, Zürich, Switzerland|GSK Investigational Site, Glasgow, Lanarkshire, United Kingdom|GSK Investigational Site, Glasgow, Lanarkshire, United Kingdom|GSK Investigational Site, Blackpool, Lancashire, United Kingdom|GSK Investigational Site, Bath, Somerset, United Kingdom|GSK Investigational Site, Bristol, United Kingdom|GSK Investigational Site, Leeds, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT00359112
NCT00357890,Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D),,Completed,No Results Available,"Diabetes Mellitus, Insulin-Dependent",Device: Pump therapy (CSII)|Drug: Multiple daily injections (MDI) using insulin glargine + rapid acting analog,Hemoglobin A1c (HbA1c or A1c)|insulin sensitivity|beta cell function,Nemours Children's Clinic,All,12 Years to 17 Years   (Child),Not Applicable,12,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16-03890-002,Dec-05,Oct-14,Oct-14,28-Jul-06,null,14-Jun-16,"Nemours Children's Clinic, Jacksonville, Florida, United States",,https://ClinicalTrials.gov/show/NCT00357890
NCT00358059,Behavior Therapy for Families of Diabetic Adolescents,,Completed,No Results Available,Type 1 Diabetes Mellitus,Behavioral: Behavioral Family Systems Therapy for Diabetes,Glycosylated hemoglobin (HbA1c)|Treatment adherence|Parent-adolescent communication|Family problem solving and conflict resolution skills|Diabetes-related quality of life,Nemours Children's Clinic|Washington University School of Medicine,All,12 Years to 16 Years   (Child),Phase 3,120,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01DK043802,Oct-00,null,Jan-06,28-Jul-06,null,28-Jul-06,"Nemours Children's Clinic, Jacksonville, Florida, United States|Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00358059
NCT00356421,A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®,,Terminated,Has Results,"Diabetes Mellitus, Type 1",Drug: Inhaled Human Insulin (Exubera®)|Drug: Insulin lispro (Humalog),"Change From Baseline in Glycosylated Hemoglobin (HbA1c) Percent (%)|Percentage of Subjects Who Attained HbA1c Levels of <8%, <7%, <6.5%, and >=8%|Percentage of Subjects With Absolute Reduction in HbA1c Levels From Baseline of >0.5%, >0.7% and >1.0%|Percentage of Subjects Who Attained Target Fasting Plasma Glucose (FPG) Values (4.0 to 6.5 mmol/l; 72 to 117 mg/dl) From Baseline|Change From Baseline in FPG|Change From Baseline in Fasting Blood Glucose Based on Glucometer Data and In-hospital Assessments|Change From Baseline in Post-prandial Blood Glucose Based on Glucometer Data and In-hospital Assessments|Change From Baseline in Insulin Antibody Levels|Change From Baseline in Body Weight|Change From Baseline in Body Mass Index|Change From Baseline in Basal Insulin Doses|Change From Baseline in Prandial Insulin Doses|Blood Glucose Values From Baseline Determined by Home-monitored Blood Glucose (Subject Recorded Worksheet Values)|Change in Fasting Lipids From Baseline",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 4,58,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A2171035,Nov-06,Jun-08,Jun-08,26-Jul-06,11-Aug-09,2-Sep-09,"Pfizer Investigational Site, Hamilton, New Jersey, United States|Pfizer Investigational Site, New Brunswick, New Jersey, United States|Pfizer Investigational Site, Vienna, Austria|Pfizer Investigational Site, Vienna, Austria|Pfizer Investigational Site, Edegem, Belgium|Pfizer Investigational Site, Genk, Belgium|Pfizer Investigational Site, Leuven, Belgium|Pfizer Investigational Site, Aarhus, Denmark|Pfizer Investigational Site, Kuopio, Finland|Pfizer Investigational Site, Brest CEDEX, France|Pfizer Investigational Site, Corbeil Essonnes Cedex, France|Pfizer Investigational Site, Strasbourg Cedex, France|Pfizer Investigational Site, Waterford, Ireland|Pfizer Investigational Site, Amsterdam, Netherlands|Pfizer Investigational Site, Stavanger, Norway|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Las Palmas, Las Palmas de Gran Canaria, Spain|Pfizer Investigational Site, Valencia, Spain|Pfizer Investigational Site, Stockholm, Sweden|Pfizer Investigational Site, Stockholm, Sweden|Pfizer Investigational Site, Bournemouth, Dorset, United Kingdom|Pfizer Investigational Site, Dundee, Tayside, United Kingdom|Pfizer Investigational Site, Birmingham, West Midlands, United Kingdom",,https://ClinicalTrials.gov/show/NCT00356421
NCT00356109,Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Human Insulin Inhalation Powder|Drug: Injectable insulin|Drug: Insulin Glargine,To test that preprandial AIR Insulin is non-inferior to preprandial injectable insulin (insulin lispro) with respect to mean change in HbA1c from baseline to endpoint.|Insulin dose requirements|Insulin antibody binding levels|To compare HbAlc change|To assess rate and incidence of hypoglycemia,"Eli Lilly and Company|Alkermes, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,494,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9627|H7U-MC-IDAV,Aug-06,May-08,May-08,25-Jul-06,null,9-Mar-18,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aurora, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Idaho Falls, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Springfield, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Grand Rapids, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., El Paso, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ogden, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aalst, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edegem, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gent, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Angers, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poitiers, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tours, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aschaffenburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Münster, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangalore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chennai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cochin, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mumbai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Delhi, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Perugia, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toa Baja, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00356109
NCT00351832,A Study To Compare the Effect of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Vildagliptin,Change from baseline on HbA1c at 12 weeks|Change from baseline on fasting plasma glucose at 12 weeks|Change from baseline on HOMA B at 12 weeks|Change from baseline on HOMA IR at 12 weeks|Change from baseline in body weight at 12 weeks|Change from baseline on fasting lipids at 12 weeks,Novartis,All,"20 Years and older   (Adult, Older Adult)",Phase 3,236,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CLAF237A1303,Jun-06,null,null,13-Jul-06,null,9-May-07,"Novartis Pharmaceuticals, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00351832
NCT00351884,Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in Patients With Type 2 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Vildagliptin AM|Drug: vildagliptin pm|Drug: placebo,Change from baseline in HbA1c at 24 weeks|Safety of vildagliptin in combination with metformin during 24 weeks of treatment|Change from baseline in fasting plasma glucose at 24 weeks|Patients with endpoint HbA1c < 7% after 24 weeks|Patients with reduction in HbA1c greater than or equal to 0.7% after 24 weeks|Change from baseline in body weight at 24 weeks,Novartis Pharmaceuticals|Novartis,All,"18 Years to 78 Years   (Adult, Older Adult)",Phase 3,370,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CLAF237A23103,May-06,Nov-07,null,13-Jul-06,null,18-Nov-16,"Novartis Pharmaceuticals, East Hanover, New Jersey, United States|Novartis Investigative Site, Investigative Centers, Germany",,https://ClinicalTrials.gov/show/NCT00351884
NCT00346996,Insulin Analogues and Severe Hypoglycaemia,,Completed,No Results Available,Type 1 Diabetes,Drug: insulin levemir / aspart|Drug: human insulin /insulin isophane,Severe hypoglycaemia|asymptomatic hypoglycaemia|hypoglycaemia during nighttime|hypoglycaemia during daytime,Lise Tarnow|Novo Nordisk A/S|Steno Diabetes Center Copenhagen,All,"18 Years and older   (Adult, Older Adult)",Phase 4,179,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HypoAna,May-07,Nov-11,Aug-12,4-Jul-06,null,3-Sep-12,"Steno Diabetes Center, Gentofte, Denmark",,https://ClinicalTrials.gov/show/NCT00346996
NCT00348179,"Vascular Function in Adolescent, Diabetic Children",,Completed,No Results Available,Type 1 Diabetes,Procedure: Measurement of vascular function per SphymgnoCor equipment,Vascular abnormalities as measured by the SyphmgnoCor equipment,Children's Mercy Hospital Kansas City,All,12 Years to 14 Years   (Child),Not Applicable,85,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,04 04-036E,Apr-04,Apr-07,Apr-07,4-Jul-06,null,24-Jan-08,"Children's Mercy Hospital, Kansas City, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00348179
NCT00343343,Comparison of NovoFine® Needles (4 mm vs. 6 mm),,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Delivery Systems",Device: NovoFine® needle 6 mm|Device: NovoFine® needle 4 mm,Deposition of sterile air depositions.|Thickness of 1) dermis and 2) distance from skin surface to muscle fascia|Amount of backflow,Novo Nordisk A/S,All,"6 Years to 75 Years   (Child, Adult, Older Adult)",Phase 2,62,Industry,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PDS322-1749|2006-000174-78,Jun-06,Aug-06,Aug-06,22-Jun-06,null,8-Feb-17,"Novo Nordisk Investigational Site, Ålborg, Denmark|Novo Nordisk Investigational Site, Århus C, Denmark",,https://ClinicalTrials.gov/show/NCT00343343
NCT00340613,Lunch Time Insulin Injection by School Nurse for Poorly Controlled Diabetes,,Completed,No Results Available,Type 1 Diabetes,Drug: glargine insulin,Hemoglobin A1c|Urine microalbumin,Baylor College of Medicine,All,"10 Years to 19 Years   (Child, Adult)",Phase 4,36,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-16630,Jun-06,null,Jun-07,21-Jun-06,null,14-Jul-16,"Texas Children's Diabetes Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00340613
NCT00340938,Family Management of Childhood Diabetes Study,,Completed,No Results Available,Diabetes|Type 1 Diabetes,Procedure: Blood testing,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC),All,"9 Years to 70 Years   (Child, Adult, Older Adult)",Phase 1,1298,NIH,Interventional,Primary Purpose: Treatment,999905030|05-CH-N030,8-Nov-04,1-Mar-09,20-Aug-09,21-Jun-06,null,19-Apr-19,"Childrens Memorial Hospital, Chicago, Chicago, Illinois, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Texas Children's Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00340938
NCT00337298,The Effect of Amlodipine and Lisinopril on Retinal Autoregulation in Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes|Diabetic Retinopathy|Eye Diseases|Diabetes Complications,Drug: Amlodipine|Drug: Lisinopril,Vessel diameter changes in arbitrary units as measured with the Retinal Vessel Analyzer|Blood pressure (mmHG)|24 hour ambulatory blood pressure (mmHg),University of Aarhus|Velux Fonden,All,18 Years to 35 Years   (Adult),Not Applicable,25,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",Jmehl01,Jul-06,Feb-09,Feb-09,15-Jun-06,null,23-Jun-09,"Aarhus university hospital, Aarhus, Denmark",,https://ClinicalTrials.gov/show/NCT00337298
NCT00336674,Trial of Intranasal Insulin in Children and Young Adults at Risk of Type 1 Diabetes,INITII,"Active, not recruiting",No Results Available,Type 1 Diabetes,Biological: Intranasal insulin|Other: Placebo,Diagnosis of Diabetes AT 5 years according to American Diabetes Association / World Health Organization (ADA/WHO) criteria.|B cell function|Insulin Action|Immune function,Melbourne Health,All,"4 Years to 30 Years   (Child, Adult)",Phase 2,110,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",INIT II,Dec-06,Dec-19,Dec-19,14-Jun-06,null,30-May-18,"The Children's Hospital at Westmead, Westmead, New South Wales, Australia|Mater Children's Hospital, Brisbane, Queensland, Australia|Womens and Childrens Hospital, North Adelaide, South Australia, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|Princess Margaret Hospital, Subiaco, Western Australia, Australia|University of Auckland, Auckland, New Zealand",,https://ClinicalTrials.gov/show/NCT00336674
NCT00335413,Autoregulation of Glomerular Filtration Rate in Patients With Type 1 Diabetes During Spironolactone Therapy,,Completed,No Results Available,Hypertension,Drug: Spironolactone,Changes in glomerular filtration rate|Changes in blood pressure|Changes in albuminuria|Changes in fractional albumin clearance,Steno Diabetes Center Copenhagen,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,17,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,2006-001453-10|2612-3144|KA-20060055,Jun-06,null,Apr-07,9-Jun-06,null,5-Jun-08,,,https://ClinicalTrials.gov/show/NCT00335413
NCT00333554,Nutritional Intervention to Prevent Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus,Dietary Supplement: DHA Treatment|Dietary Supplement: Placebo for DHA,"20% higher level of plasma and/or red blood cell membrane phospholipid DHA achieved in the treatment group|At least a 20% reduction in the level of the major inflammatory cytokine, IL1-beta, achieved in the plasma of the treatment group|95% of families will continue to attend follow-up visits",National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,up to 5 Months   (Child),Not Applicable,99,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",NIP (IND),Jun-06,Feb-08,Apr-13,5-Jun-06,null,16-May-16,"Childrens Hospital of Los Angeles, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|University of California, San Francisco, San Francisco, California, United States|Indiana University-Riley Hospital for Children, Indianapolis, Indiana, United States|University of Iowa Health Care, Iowa City, Iowa, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|The Children's Mercy Hospital, Kansas City, Missouri, United States|Utah Diabetes Center, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT00333554
NCT00332826,Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma,,Terminated,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Asthma",Drug: Technosphere Insulin,The primary safety outcome will be measurements of post bronchodilator FEV1 throughout the treatment period,Mannkind Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 3,3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MKC-TI-105,Jun-06,Oct-07,Oct-07,2-Jun-06,null,4-May-12,"Arizona Research Center, Phoenix, Arizona, United States|Northwest Medical Center, Phoenix, Arizona, United States|Premiere Pharmaceutical Research LLC, Tempe, Arizona, United States|Canyon Internal Medicine, Tucson, Arizona, United States|Associated Pharmaceutical Research Center Inc, Buena Park, California, United States|Family Medical Center, Foothill Ranch, California, United States|Health Care Partners Medical Group, Long Beach, California, United States|Golden Pine Clinical Research, Long Beach, California, United States|Keck USC School of Medicine, Los Angeles, California, United States|Pinaccle Trials Inc (SMO), Atlanta, Georgia, United States|Executive Health and Research Associates Inc, Atlanta, Georgia, United States|Atlanta Pharmaceutical Research Center, Dunwoody, Georgia, United States|Southeastern Endocrine & Diabetes, Roswell, Georgia, United States|Cedar-Crosse Research Center, Chicago, Illinois, United States|Franklin Square Hospital, Baltimore, Maryland, United States|Healthcare Research, Florissant, Missouri, United States|MedEx Healthcare Research Inc(009), St Louis, Missouri, United States|Billings Clinic Research Division, Billings, Montana, United States|Your Doctors Care, Hillsborough, New Jersey, United States|Hopewell Valley Family Medicine PA, Trenton, New Jersey, United States|Eastside Comprehensive Medical Center, New York, New York, United States|Carolinas Research, Concord, North Carolina, United States|Cleveland Clinic Dept of Endocrinology, Cleveland, Ohio, United States|Diabetes & Glandular Disease Research Assoc PA, San Antonio, Texas, United States|McLennan County Medical Education and Research Foundation, Waco, Texas, United States|DIM (Clinica Privada), Buenos Aires, Argentina|Ins De Inv Cardiovascular La Plata, La Plata, Argentina|Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Hospital Sao Lucas - PUCRS (Fritscher), Porto Alegre, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, Brazil|Ccbr Brasil Centro de Analises e Pesquisas Clinicas Ltda, Rio de Janeiro, Brazil|CPClin-Centro de Pesquisas Clinicas, Sao Paulo, Brazil|Clinica de Endocrinologia, Sao Paulo, Brazil|Finchlea Medical Group, Brampton, Ontario, Canada|Courtice Health Centre, Courtice, Ontario, Canada|Parkwood Hospital, London, Ontario, Canada|The London Road Diagnostic Clinic and Medical Centre, Sarnia, Ontario, Canada|Albany Medical Center, Toronto, Ontario, Canada|Windsor Professional Research, Windsor, Ontario, Canada|Surgery of Diabetology, Melnik, CZE, Czech Republic|Interni oddeleni nemocnice Na Homolce, Praha 5, CZE, Czech Republic|Diabetologicka Outpatient Surgery of Diabetology, Slany, CZE, Czech Republic|InternÃ- a diabetologickÃ¡ Outpatient, Ostrava, Czech Republic|I InternÃ- klinika, Ostrava, Czech Republic|Hospital Angeles Mocel, Mexico City, DF, Mexico|Mexican Institute of Clinical Research, Mexico City, MX, Mexico|Nuevo Sanatorio Durango, Delegacion Cuauhtemoc, Mexico|Hospital Angeles de las Lomas, Huixquilucan, Mexico|Klinika Endocrinologii Diabetologii I, Bialystock, POL, Poland|NZOZ Specjalistyczny Osrodek Internistyczno - Diabetologiczny, Bialystok, POL, Poland|Dzial Badan Klinicznych Malopoiskie, Krakow, POL, Poland|III Oddzial Chorob Wewnetrznych Szpital, Krakow, POL, Poland|Oddzial Chorob Wewnetrznych Wojewodzki, Lodz, Zgierz, Poland|Oddzial Kliniczny Diabetologii (009) Kliniczny nr 1 im Norberta Barlickiego Uniwersytety Meycznego, Lodz, Poland|NHI Kemerovo Regional Clinical Hospital, Kemerovo, RUS, Russian Federation|NI Principal Military Clinical Hospital n a academician N.N. Burdenko, Moscow, RUS, Russian Federation|Moscow State Medico-Stomatological University City Hospital # 23, Moscow, RUS, Russian Federation|Smolensk Medical Academy Smolensk Regional Clinical Hospital, Smolensk, RUS, Russian Federation|Central Medical Sanitary Unit #122, St Petersburg, RUS, Russian Federation|City Hospital # 2 Endocrinology Department, St. Petersburg, RUS, Russian Federation|Yaroslavl Municipal Health Care Institution Clinical Hospital for Emergency Care na NV Soloviev, Yaroslavl, RUS, Russian Federation|Federal State Institution Pulmonology Research Institute of Federal Agency of HC&SD, Moscow, Russian Federation|City Clinical Hospital #64 Center of Applied Clinical Paharmacology Friendship University, Moscow, Russian Federation|Central Clinical Hospital of Russian Science Academy, Moscow, Russian Federation|City Clinical Hospital # 61, Moscow, Russian Federation|Russian Scientific Center of Restoration Medicine & Balneology, Moscow, Russian Federation|St Petersburg Medical Academy (Ilkovich), St Petersburg, Russian Federation|Hospital 2 de Maig, Barcelona, Spain|Donetsk State Medical University, Donetsk, UKR, Ukraine|Donetsk State Medical University, Donetsk, UKR, Ukraine|Railway Clinical Hospital on Donetsk Station, Donetsk, UKR, Ukraine|Chair Family Med of National Med University, Kiev, UKR, Ukraine|Institute of Endocrinology and Metabolism, Kiev, UKR, Ukraine|Clinical Research Centre The Royal London Hospital, London, GBR, United Kingdom|Northern General Hospital, Sheffield, GBR, United Kingdom|Birmingham Heartland Hospital, West Midlands, GBR, United Kingdom|Addenbrooke's Hospital Department of Medicine, Cambridge, United Kingdom",,https://ClinicalTrials.gov/show/NCT00332826
NCT00331162,Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation,,Completed,Has Results,Graft Rejection,Drug: Alemtuzumab|Drug: Anti-Thymocyte Globulin,Patient Survival|Graft Survival|Acute Rejection|Hematologic Adverse Events|Infectious Adverse Events|Other Adverse Events|Cost|Health Status and Quality of Life,Wake Forest University Health Sciences,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,222,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,BG04-498,Feb-05,28-Nov-11,28-Nov-11,29-May-06,5-Jun-18,6-Sep-18,"Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00331162
NCT00330330,"Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment",,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: ISIS 113715,To evaluate the safety and tolerability of ISIS 113715|To evaluate the pharmacokinetic profile of ISIS 113715|To evaluate the pharmacologic activity of ISIS 113715,"Ionis Pharmaceuticals, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,96,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,ISIS 113715-CS7,Feb-03,null,Aug-06,26-May-06,null,6-Feb-08,"NZOZ Specjalistyczny Osrodek Internistyczno Diabetologiczny, Bialystok, Poland|Prywatna Praktyka Lekarska, Radom, Poland|Oddzial Chorob Wewnetrznych ze Stacja Dializ Szpital w Wolominie, Wolomin, Poland|Chair of Endocrinology and Diabetology of the Faculty of Advenced Training for Physicians, Moscow, Russian Federation|Endocrinology Scientific Centre of RAMS, Moscow, Russian Federation|Medical Institution ""Polyclinic OAOA Gazprom"", Moscow, Russian Federation|Close Corporation ""MEDSI"", Moscow, Russian Federation|Chair of Endocrinology and Diabetology Central Clinical Hospital of the Ministry of Communications of RF, Moscow, Russian Federation|Moscow Regional Scientific-Research Clinical Institute named after I.F. Vladimirsky, Moscow, Russian Federation|Clinic of Therapy of Postgraduate Education named after N.S. Molchanov, St. Petersburg, Russian Federation",,https://ClinicalTrials.gov/show/NCT00330330
NCT00328302,"Diabetes Type 1, Treatment Study Atacand/Placebo After Kidney Biopsy",,Unknown status,No Results Available,"Diabetes, Type I",Drug: Candesartan|Drug: Placebo,Basement membrane thickness|Mesangial expansion|Hypertension|Microalbuminuria|Kidney Function|24 hour ambulatory blood pressure,Karolinska University Hospital|AstraZeneca,All,"17 Years to 30 Years   (Child, Adult)",Phase 4,13,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,SH-AHM-0044-01,Sep-00,null,Apr-06,19-May-06,null,19-May-06,"Childrens Hospital, Karolinska University Hospital, Huddinge, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT00328302
NCT00327210,Feasibility and Efficacy of Delivering Blood Glucose Awareness Training Over the Internet,,Completed,No Results Available,Type 1 Diabetes Mellitus,Behavioral: Blood Glucose Awareness Training,Feasibility|Improved blood glucose awareness|Reduced adverse events|Improved psychological functioning|Improved knowledge,University of Virginia|American Diabetes Association,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,35,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,11593,May-05,Jul-09,Jul-09,18-May-06,null,8-Nov-17,"University of Viginia Health System, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00327210
NCT00325559,The Effect of Hyperglycaemia on Local Energy Stores in the Working Muscle in Patients With Type 1 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Exercise",Procedure: Normoinsulinemic eu- or hyperglycemic clamp,"Paired difference in the time to complete a time trial corresponding to 5 km cycling between euglycaemia and hyperglycaemia|Muscle glycogen content during exercise in the working muscle (pre test vs. post test), in euglycaemia and hyperglycaemia respectively (All following endpoints are paired differences (euglycaemia vs. hyperglycaemia) of paired differences (pre|IMCL content during exercise in the working muscle|Rate of appearance of glucose|Rate of disappearance of glucose|Rate of glucose infusion|Total glucose oxidation|Oxidation of endogenous glucose|Oxidation of exogenous glucose|Fat oxidation (calculated via tracer and via RER)|Rate of perceived exertion|Serum lactate levels during the exercise test|Amino acid oxidation|Serum free fatty acid concentration|Serum insulin levels|Serum glucose levels|Time to achieve hyperglycemia during clamp|Pretest diary data","University Hospital Inselspital, Berne",Male,20 Years to 40 Years   (Adult),Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single,1122,Jun-06,Mar-07,null,15-May-06,null,13-Jan-11,"Department of Endocrinology, Diabetes and Clinical Nutrition, University Hospital, Bern, Switzerland",,https://ClinicalTrials.gov/show/NCT00325559
NCT00325117,To Assess the Efficacy and Safety of Vildagliptin as Add-on Therapy to Sulfonylurea in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Vildagliptin,Change from baseline to endpoint on HbA1c at 12 weeks|Change from baseline to endpoint on fasting plasma glucose at 12 weeks|Change from baseline to endpoint in HOMA B at 12 weeks|Change from baseline to endpoint in HOMA IR at 12 weeks|Change from baseline to endpoint on fasting lipids at 12 weeks|Adverse events profile after 12 weeks of treatment,Novartis,All,"20 Years and older   (Adult, Older Adult)",Phase 3,200,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CLAF237A1302,Apr-06,null,null,12-May-06,null,14-May-07,"Novartis Pharmaceuticals, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00325117
NCT00325429,Long-Term Safety Study of Vildagliptin in Patients With Type 2 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Vildagliptin,Adverse events profile after 52 weeks of treatment|Change from baseline to endpoint on HbA1c at 52 weeks|Change from baseline to endpoint on fasting plasma glucose at 52 weeks|Change from baseline to endpoint in HOMA B at 52 weeks|Change from baseline to endpoint in HOMA IR at 52 weeks|Change from baseline to endpoint in body weight at 52 weeks,Novartis,All,"20 Years and older   (Adult, Older Adult)",Phase 3,150,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLAF237A1304,Apr-06,null,null,12-May-06,null,7-Jan-09,"Novartis Pharmaceuticals, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00325429
NCT00324584,Web-Based Follow-Up Using Cellular Phone in Type 1 Diabetic Patients Under Insulin Pump Therapy : The PumpNet Study,,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: Telemonitoring of glucose values using GlucoNet device,Glycated hemoglobin HbA1c|monthly mean capillary blood glucose value|blood glucose variability index (MAGE Index and LBGI index)|quality of life score (DQOL score)|frequency of hypoglycemic episodes (<70 mg/dl),"University Hospital, Grenoble",All,"18 Years and older   (Adult, Older Adult)",Phase 3,40,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCIC 03 01,Apr-03,null,Sep-04,11-May-06,null,7-Jul-06,"University Hospital, Department of Endocrinology, Grenoble, France|University Hospital, Department of Endocrinology, Toulouse, France",,https://ClinicalTrials.gov/show/NCT00324584
NCT00322478,Diabetes Technology Study of Real-Time Glucose Alerts in the Team Management of Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Behavioral: Automated informatics driven education and social networking|Behavioral: Blood Glucose Notifications to Remote Caregivers|Behavioral: Frequency of Pattern Management,Blood Sugar Control|Patient Satisfaction|A1c|Self-Test Frequency of SMBG|Standard Deviation of A1c and SMBG,Diabetech,All,"Child, Adult, Older Adult",Phase 2|Phase 3,432,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,DIRB1-2006-1,Apr-06,Oct-15,Oct-15,8-May-06,null,3-Nov-15,"Diabetech, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00322478
NCT00322257,Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes,,Terminated,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: inhaled human insulin|Drug: insulin detemir|Drug: insulin aspart,HbA1c|Body weight|Antibodies|Hypoglycemia|Insulin doses|Pulmonary Function|Fasting plasma glucose,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,596,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN1998-2076,1-May-06,2-Apr-08,2-Apr-08,5-May-06,null,5-Sep-18,"Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Tuscaloosa, Alabama, United States|Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Encino, California, United States|Novo Nordisk Investigational Site, Escondido, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Inglewood, California, United States|Novo Nordisk Investigational Site, La Jolla, California, United States|Novo Nordisk Investigational Site, Mission Viejo, California, United States|Novo Nordisk Investigational Site, Poway, California, United States|Novo Nordisk Investigational Site, San Mateo, California, United States|Novo Nordisk Investigational Site, Santa Barbara, California, United States|Novo Nordisk Investigational Site, Tustin, California, United States|Novo Nordisk Investigational Site, Vista, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, Colorado Springs, Colorado, United States|Novo Nordisk Investigational Site, New Britain, Connecticut, United States|Novo Nordisk Investigational Site, Norwalk, Connecticut, United States|Novo Nordisk Investigational Site, Waterbury, Connecticut, United States|Novo Nordisk Investigational Site, Boca Raton, Florida, United States|Novo Nordisk Investigational Site, Hollywood, Florida, United States|Novo Nordisk Investigational Site, Lake Mary, Florida, United States|Novo Nordisk Investigational Site, Melbourne, Florida, United States|Novo Nordisk Investigational Site, Merritt Island, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, West Palm Beach, Florida, United States|Novo Nordisk Investigational Site, Athens, Georgia, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Savannah, Georgia, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Peoria, Illinois, United States|Novo Nordisk Investigational Site, Springfield, Illinois, United States|Novo Nordisk Investigational Site, Lafayette, Indiana, United States|Novo Nordisk Investigational Site, New Albany, Indiana, United States|Novo Nordisk Investigational Site, Des Moines, Iowa, United States|Novo Nordisk Investigational Site, Shawnee Mission, Kansas, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Baton Rouge, Louisiana, United States|Novo Nordisk Investigational Site, Scarborough, Maine, United States|Novo Nordisk Investigational Site, Hyattsville, Maryland, United States|Novo Nordisk Investigational Site, Springfield, Massachusetts, United States|Novo Nordisk Investigational Site, Waltham, Massachusetts, United States|Novo Nordisk Investigational Site, Bloomington, Minnesota, United States|Novo Nordisk Investigational Site, Duluth, Minnesota, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, Tupelo, Mississippi, United States|Novo Nordisk Investigational Site, Jefferson City, Missouri, United States|Novo Nordisk Investigational Site, Kansas City, Missouri, United States|Novo Nordisk Investigational Site, Saint Louis, Missouri, United States|Novo Nordisk Investigational Site, Butte, Montana, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Dover, New Hampshire, United States|Novo Nordisk Investigational Site, Hampton, New Hampshire, United States|Novo Nordisk Investigational Site, Lawrenceville, New Jersey, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, New Hyde Park, New York, United States|Novo Nordisk Investigational Site, Rochester, New York, United States|Novo Nordisk Investigational Site, Asheville, North Carolina, United States|Novo Nordisk Investigational Site, Greenville, North Carolina, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Cleveland, Ohio, United States|Novo Nordisk Investigational Site, Dayton, Ohio, United States|Novo Nordisk Investigational Site, Kettering, Ohio, United States|Novo Nordisk Investigational Site, Mentor, Ohio, United States|Novo Nordisk Investigational Site, Medford, Oregon, United States|Novo Nordisk Investigational Site, Hershey, Pennsylvania, United States|Novo Nordisk Investigational Site, Norristown, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Midland, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Ogden, Utah, United States|Novo Nordisk Investigational Site, Olympia, Washington, United States|Novo Nordisk Investigational Site, Renton, Washington, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States|Novo Nordisk Investigational Site, Victoria, British Columbia, Canada|Novo Nordisk Investigational Site, Winnipeg, Manitoba, Canada|Novo Nordisk Investigational Site, Laval, Quebec, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Gatineau, Canada|Novo Nordisk Investigational Site, Mississauga, Canada|Novo Nordisk Investigational Site, Penticton, Canada|Novo Nordisk Investigational Site, Red Deer, Canada|Novo Nordisk Investigational Site, St John's, Canada|Novo Nordisk Investigational Site, Vancouver, Canada",,https://ClinicalTrials.gov/show/NCT00322257
NCT00321256,Human Islet Transplantation in Brittle Type 1 Diabetes Mellitus. The GRAGIL 2 Study.,,Completed,No Results Available,Type 1 Diabetes Mellitus,Procedure: human pancreatic islet transplantation,"The rate of insulin-independence, judged upon the following criteria : HbA1c < 6.1%,|post-prandial blood glucose < 180 mg/dl, mean amplitude of glycemic excursion (MAGE index)|< 60 mg/dl, basal C-peptide > 0.5 ng/ml. This insulin independent rate will be assessed 6 months|and 12 months following transplantation.|The rate of success according to the DiaCell composite score defined by the following 4 items : functional islet graft, defined by a basal C-peptide > 0.5 ng/ml;|good metabolic control, defined by HbA1c ≤ 6.5%; disappearance of hypoglycemic events; reduction in exogenous insulin needs ≥ 30%.|Morbidity and quality of life will also be assessed.","University Hospital, Grenoble|Alfediam",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,22,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,011226/DGS-2001/0195,Jul-03,null,Jul-07,3-May-06,null,2-Mar-12,"University Hospital, Department of Endocrinology, Besancon, France|University Hospital, Department of Endocrinology, Grenoble, France|University Hospital, Department of Endocrinology, Lyon, France|University Hospital, Department of Endocrinology, Montpellier, France|University Hospital, Department of Endocrinology, Strasbourg, France|University Hospital, Department of Surgery, Geneva, Switzerland",,https://ClinicalTrials.gov/show/NCT00321256
NCT00320021,Effect of Pyridorin in Patients With Diabetic Nephropathy,,Completed,No Results Available,Diabetic Nephropathy,Drug: Pyridorin (pyridoxamine dihydrochloride),Change in Serum Creatinine from baseline to week 26,BioStratum,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,80,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,PYR-205/207|PYR-205|PYR-207,Jul-02,null,Sep-03,27-Apr-06,null,27-Apr-06,,,https://ClinicalTrials.gov/show/NCT00320021
NCT00320060,Effect of Pyridorin in Patients With Diabetic Nephropathy,,Completed,No Results Available,Diabetic Nephropathy,Drug: Pyridorin (pyridoxamine dihydrochloride),,BioStratum,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,128,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,PYR-206,Oct-01,null,Jan-03,27-Apr-06,null,27-Apr-06,,,https://ClinicalTrials.gov/show/NCT00320060
NCT00318422,Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes,LEAD-1,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: rosiglitazone|Drug: glimepiride,"HbA1c|body weight|Safety and tolerability|beta-cell function|Glycemic control parameters (fasting plasma glucose, -glucose profiles)",Novo Nordisk A/S,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,1041,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN2211-1436|2005-003414-15,May-06,May-07,May-07,26-Apr-06,null,25-Jan-17,"Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Córdoba, Argentina|Novo Nordisk Investigational Site, Mar del Plata, Argentina|Novo Nordisk Investigational Site, Mendoza, Argentina|Novo Nordisk Investigational Site, Woolloongabba, Queensland, Australia|Novo Nordisk Investigational Site, Melbourne, Victoria, Australia|Novo Nordisk Investigational Site, Caboolture, Australia|Novo Nordisk Investigational Site, Ingleburn, Australia|Novo Nordisk Investigational Site, Kippa Ring, Australia|Novo Nordisk Investigational Site, Miranda, Australia|Novo Nordisk Investigational Site, Randwick, Australia|Novo Nordisk Investigational Site, Southport, Australia|Novo Nordisk Investigational Site, Stones Corner, Australia|Novo Nordisk Investigational Site, Fortaleza, Brazil|Novo Nordisk Investigational Site, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Pleven, Bulgaria|Novo Nordisk Investigational Site, Plovdiv, Bulgaria|Novo Nordisk Investigational Site, Russe, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Varna, Bulgaria|Novo Nordisk Investigational Site, Osijek, Croatia|Novo Nordisk Investigational Site, Slavonski Brod, Croatia|Novo Nordisk Investigational Site, Split, Croatia|Novo Nordisk Investigational Site, Brno, Czech Republic|Novo Nordisk Investigational Site, Hradec Králové, Czech Republic|Novo Nordisk Investigational Site, Ostrava, Czech Republic|Novo Nordisk Investigational Site, Plzen - Lochotin, Czech Republic|Novo Nordisk Investigational Site, Prague 4, Czech Republic|Novo Nordisk Investigational Site, Praha 10, Czech Republic|Novo Nordisk Investigational Site, Praha 5, Czech Republic|Novo Nordisk Investigational Site, Espoo, Finland|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Lahti, Finland|Novo Nordisk Investigational Site, Nurmijärvi, Finland|Novo Nordisk Investigational Site, Oulu, Finland|Novo Nordisk Investigational Site, Pieksämäki, Finland|Novo Nordisk Investigational Site, Rauma, Finland|Novo Nordisk Investigational Site, Rovaniemi, Finland|Novo Nordisk Investigational Site, Tampere, Finland|Novo Nordisk Investigational Site, Tampere, Finland|Novo Nordisk Investigational Site, DAX, France|Novo Nordisk Investigational Site, LA ROCHELLE cedex, France|Novo Nordisk Investigational Site, Montpellier, France|Novo Nordisk Investigational Site, Mougins, France|Novo Nordisk Investigational Site, Narbonne, France|Novo Nordisk Investigational Site, NEVERS cedex, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Rennes, France|Novo Nordisk Investigational Site, Saint Mandé, France|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Chandigarh, Punjab, India|Novo Nordisk Investigational Site, Chennai, India|Novo Nordisk Investigational Site, Mumbai, India|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Tel Hashomer, Israel|Novo Nordisk Investigational Site, Catania, Italy|Novo Nordisk Investigational Site, Lucca, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Napoli, Italy|Novo Nordisk Investigational Site, Perugia, Italy|Novo Nordisk Investigational Site, Ravenna, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Torino, Italy|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Cheras, Malaysia|Novo Nordisk Investigational Site, Kota Bharu, Kelantan, Malaysia|Novo Nordisk Investigational Site, Pulau Pinang, Malaysia|Novo Nordisk Investigational Site, Davao City, Philippines|Novo Nordisk Investigational Site, Makati City, Philippines|Novo Nordisk Investigational Site, Marikina City, Philippines|Novo Nordisk Investigational Site, Quezon City, Philippines|Novo Nordisk Investigational Site, Bytom, Poland|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Gniewkowo, Poland|Novo Nordisk Investigational Site, Kamieniec Zabkowicki, Poland|Novo Nordisk Investigational Site, Krakow, Poland|Novo Nordisk Investigational Site, Lodz, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Mazowieckie, Poland|Novo Nordisk Investigational Site, Nysa, Poland|Novo Nordisk Investigational Site, Rawa Mazowiecka, Poland|Novo Nordisk Investigational Site, Szczecin, Poland|Novo Nordisk Investigational Site, Tychy, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Zabrze, Poland|Novo Nordisk Investigational Site, Ploiesti, Prahova, Romania|Novo Nordisk Investigational Site, Baia Mare, Romania|Novo Nordisk Investigational Site, Brasov, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Timisoara, Romania|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Umhlanga, South Africa|Novo Nordisk Investigational Site, Gijón, Spain|Novo Nordisk Investigational Site, Palma de Mallorca, Spain|Novo Nordisk Investigational Site, Reus, Spain|Novo Nordisk Investigational Site, Bern, Switzerland|Novo Nordisk Investigational Site, Lausanne, Switzerland|Novo Nordisk Investigational Site, St. Gallen, Switzerland|Novo Nordisk Investigational Site, Zürich, Switzerland|Novo Nordisk Investigational Site, Zürich, Switzerland|Novo Nordisk Investigational Site, Changhua, Taiwan|Novo Nordisk Investigational Site, Kaohsiung City, Taiwan|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Antalya, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Izmir, Turkey",,https://ClinicalTrials.gov/show/NCT00318422
NCT00315939,Improving Control and Reducing the Risk of Hypoglycemic Episodes in Type 1 Diabetes,BPK002,Completed,Has Results,"Diabetes Mellitus, Type 1",Device: Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1)|Device: Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2),Hemoglobin A1c|Frequency of Severe Hypoglycemia,"Boris Kovatchev, PhD|University of Virginia",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),12126,Jan-06,Dec-09,Dec-09,19-Apr-06,9-Sep-14,18-Sep-14,"University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00315939
NCT00315952,Study to Estimate the Effects of Inhaled Versus Intravenous (IV) Infusion of Human Insulin in Subjects With Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Exubera,"To perform positron emission tomography (PET) imaging of [18F]-fluoro-deoxy-glucose (FDG) uptake by muscle, following administration of a single dose of inhaled compared to infused insulin in volunteers with type 1 diabetes|To determine overnight rates of glucose production and plasma glucose after a single pre-dinner dose of inhaled compared to IV infused insulin in volunteers with type 1 diabetes",University of Pittsburgh|Pfizer,All,18 Years to 50 Years   (Adult),Phase 4,12,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6020777,Apr-06,null,Dec-06,19-Apr-06,null,18-Feb-08,"University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00315952
NCT00315991,Blood Glucose Awareness Training for Parents,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Behavioral: Blood Glucose Awareness Training for Parents,Accuracy of blood glucose level estimation,University of Virginia|Joslin Diabetes Center,All,6 Years to 11 Years   (Child),Not Applicable,77,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label),12202,Apr-06,Dec-08,Dec-08,19-Apr-06,null,16-Jan-13,"Joslin Diabetes Center, Boston, Massachusetts, United States|University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00315991
NCT00315588,Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Islet Transplantation,"Insulin Independence.|Stimulated C-peptide Greater Than 0.5 ng/ml|Reduction of Insulin Requirements|Reduction in Severe Hypoglycemia, Improvement in Hypoglycemia Awareness",Rodolfo Alejandro|National Institutes of Health (NIH)|Health Resources and Services Administration (HRSA)|Diabetes Research Institute Foundation|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Miami,All,18 Years to 60 Years   (Adult),Phase 2,7,Other|NIH|U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2000/0329|5R01DK055347|5R01DK025802,Dec-00,May-14,May-14,18-Apr-06,12-Apr-17,12-Apr-17,"Diabetes Research Institute, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT00315588
NCT00315614,Islet Cell Transplantation Alone and CD34+ Donor Bone Marrow Cell Infusion in Type 1 Diabetes Mellitus,,Terminated,Has Results,Type 1 Diabetes Mellitus,Biological: Islet Transplantation and Bone Marrow,The Achievement of Persistent Islet Function Following Cessation of Immunosuppression.|A Reduction or Absence of Rejection Episodes|Number of Subjects With Basal C-peptide Greater Than 0.5 ng/ml|Number of Subjects With Reduction of Severe Hypoglycemia and Improvement in Hypoglycemia Awareness,University of Miami|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Diabetes Research Institute Foundation,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,3,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2000/0024|R01DK056953,Dec-00,Dec-10,Dec-10,18-Apr-06,10-Feb-14,4-Apr-17,"Diabetes Research Institute, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT00315614
NCT00315627,Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation,,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Islet transplantation,Measurement of Glycemic Control by HbA1c and Prevention of Severe Hypoglycemia|Islet Allograft Function|Improvement in Metabolic Control as Evidenced by Hemoglobin A1c < 6.5%|Elimination of Severe Hypoglycemia|Restoration of Hypoglycemia Awareness 1 Year After Transplantation,Rodolfo Alejandro|Juvenile Diabetes Research Foundation|University of Miami,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,3,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2004-0205,Jul-05,Jan-14,Jan-14,18-Apr-06,25-May-17,25-May-17,"Diabetes Research Institute, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT00315627
NCT00315133,Safety and Efficacy Study of Autologous Stem Cell Transplantation for Early Onset Type I Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes Mellitus,Procedure: Immunosuppression and autologous stem cell transplantation,C-peptide levels|Transplant-related toxicity|Anti-GAD titres|Exogenous insulin dose|Hemoglobin A1C|Immunologic reconstitution parameters|Quality of Life,"University of Sao Paulo|Northwestern University|Genzyme, a Sanofi Company",All,"12 Years to 35 Years   (Child, Adult)",Phase 1|Phase 2,25,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HCFMRPUSP,Dec-03,Dec-10,Dec-14,17-Apr-06,null,18-Jan-17,"Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto, Brazil",,https://ClinicalTrials.gov/show/NCT00315133
NCT00313183,A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: pramlintide acetate,To evaluate the pharmacokinetics of Symlin in adolescent subjects with type 1 diabetes|To assess the safety and tolerability of Symlin in adolescent subjects with type 1 diabetes|To evaluate the effects of Symlin compared to placebo in adolescent subjects with type 1 diabetes on various pharmacodynamic endpoints,AstraZeneca,All,12 Years to 17 Years   (Child),Phase 2,12,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,137-162,Apr-06,Aug-07,Aug-07,12-Apr-06,null,6-Mar-15,"Research Site, Aurora, Colorado, United States|Research Site, Kansas City, Missouri, United States|Research Site, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00313183
NCT00313742,The Effect of Exercise on Blood Glucose Levels in Patients With Type 1 Diabetes: A Comparison of 3 Long-acting Insulins,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin detemir|Drug: insulin glargine|Drug: insulin NPH,"The difference between plasma glucose concentrations immediately pre-exercise and the minimum plasma glucose concentrations (nadir) in the period 0-150 min following exercise|Plasma glucose pre-exercise & post-exercise|Hypoglycaemia episodes (major and minor episodes) during exercise, afterwards & from end of study until 07:30 the following morning|Plasma glucose profile post-exercise|Incidence of adverse events during the trial",Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 4,51,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN304-1724,Apr-06,Nov-06,Nov-06,12-Apr-06,null,26-Nov-14,"Neuss, Germany|Newcastle upon Tyne, United Kingdom",,https://ClinicalTrials.gov/show/NCT00313742
NCT00313937,"SAM - Skip a Meal - Insulin Glargine, Diabetes Mellitus Type 1",,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Insulin glargine,Difference of change of blood glucose between patients on Insulin glargine and NPH insulin.,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 4,91,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HOE901_4028,Nov-01,Jun-04,null,12-Apr-06,null,7-Dec-09,"Sanofi-Aventis, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT00313937
NCT00312104,Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin detemir|Drug: insulin glargine|Drug: insulin aspart,HbA1c|Adverse events|Body weight|Blood glucose|Hypoglycaemia,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,325,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN304-1372,Apr-02,Mar-03,Mar-03,7-Apr-06,null,27-Jan-17,"Novo Nordisk Investigational Site, Graz, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Bad Kreuznach, Germany|Novo Nordisk Investigational Site, Bad Mergentheim, Germany|Novo Nordisk Investigational Site, Bad Neuenahr-Ahrweiler, Germany|Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Diez, Germany|Novo Nordisk Investigational Site, Erlangen, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Flensburg, Germany|Novo Nordisk Investigational Site, Frankfurt, Germany|Novo Nordisk Investigational Site, Friedrichsthal, Germany|Novo Nordisk Investigational Site, Genthin, Germany|Novo Nordisk Investigational Site, Halle, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Hannover, Germany|Novo Nordisk Investigational Site, Heidelberg, Germany|Novo Nordisk Investigational Site, Hennigsdorf, Germany|Novo Nordisk Investigational Site, Hünxe, Germany|Novo Nordisk Investigational Site, Jena, Germany|Novo Nordisk Investigational Site, Kiel, Germany|Novo Nordisk Investigational Site, Landau, Germany|Novo Nordisk Investigational Site, Ludwigshafen, Germany|Novo Nordisk Investigational Site, Marl, Germany|Novo Nordisk Investigational Site, Mönchengladbach, Germany|Novo Nordisk Investigational Site, Neunkirchen, Germany|Novo Nordisk Investigational Site, Neuss, Germany|Novo Nordisk Investigational Site, Northeim, Germany|Novo Nordisk Investigational Site, Nürnberg, Germany|Novo Nordisk Investigational Site, Rehlingen-Siersburg, Germany|Novo Nordisk Investigational Site, Rheda-Wiedenbrück, Germany|Novo Nordisk Investigational Site, Saarbrücken, Germany|Novo Nordisk Investigational Site, Saarlouis, Germany|Novo Nordisk Investigational Site, Schwabenheim, Germany|Novo Nordisk Investigational Site, Schwerin, Germany|Novo Nordisk Investigational Site, Schönebeck, Germany|Novo Nordisk Investigational Site, Völklingen, Germany|Novo Nordisk Investigational Site, Wiesbaden, Germany|Novo Nordisk Investigational Site, Würzburg, Germany|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa",,https://ClinicalTrials.gov/show/NCT00312104
NCT00312156,Comparison of Efficacy and Safety of Insulin Detemir and NPH Insulin in Children and Adolescents With Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin detemir|Drug: insulin NPH|Drug: insulin aspart,HbA1c|Adverse events|body weight|Antibodies|Blood glucose|Hypoglycaemia,Novo Nordisk A/S,All,6 Years to 17 Years   (Child),Phase 3,347,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN304-1379,Aug-02,Aug-03,Aug-03,7-Apr-06,null,27-Jan-17,"Novo Nordisk Investigational Site, Bree, Belgium|Novo Nordisk Investigational Site, Edegem, Belgium|Novo Nordisk Investigational Site, Rijeka, Croatia|Novo Nordisk Investigational Site, Glostrup, Denmark|Novo Nordisk Investigational Site, Kolding, Denmark|Novo Nordisk Investigational Site, Odense, Denmark|Novo Nordisk Investigational Site, Viborg, Denmark|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Oulu, Finland|Novo Nordisk Investigational Site, Caen, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Rennes, France|Novo Nordisk Investigational Site, TOULOUSE cedex, France|Novo Nordisk Investigational Site, Frankfurt, Germany|Novo Nordisk Investigational Site, Hannover, Germany|Novo Nordisk Investigational Site, Kiel, Germany|Novo Nordisk Investigational Site, Stuttgart, Germany|Novo Nordisk Investigational Site, Dublin 24, Ireland|Novo Nordisk Investigational Site, Petah Tikva, Israel|Novo Nordisk Investigational Site, Skopje, Macedonia, The Former Yugoslav Republic of|Novo Nordisk Investigational Site, Eindhoven, Netherlands|Novo Nordisk Investigational Site, Spijkenisse, Netherlands|Novo Nordisk Investigational Site, Utrecht, Netherlands|Novo Nordisk Investigational Site, Bodø, Norway|Novo Nordisk Investigational Site, Gjøvik, Norway|Novo Nordisk Investigational Site, Sarpsborg, Norway|Novo Nordisk Investigational Site, Tønsberg, Norway|Novo Nordisk Investigational Site, Ljubljana, Slovenia|Novo Nordisk Investigational Site, Leganés, Spain|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Helsingborg, Sweden|Novo Nordisk Investigational Site, Linköping, Sweden|Novo Nordisk Investigational Site, Lund, Sweden|Novo Nordisk Investigational Site, Malmö, Sweden|Novo Nordisk Investigational Site, Stockholm, Sweden|Novo Nordisk Investigational Site, Örebro, Sweden|Novo Nordisk Investigational Site, Zürich, Switzerland|Novo Nordisk Investigational Site, Aberdeen, United Kingdom|Novo Nordisk Investigational Site, Belfast, United Kingdom|Novo Nordisk Investigational Site, Birmingham, United Kingdom|Novo Nordisk Investigational Site, Glasgow, United Kingdom|Novo Nordisk Investigational Site, Stirling, United Kingdom",,https://ClinicalTrials.gov/show/NCT00312156
NCT00309608,Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes,,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Linagliptin|Drug: Placebo|Drug: Glimepiride,HbA1c Change From Baseline at Week 12|Percentage of Patients With HbA1c<=7.0% at Week 12|Fasting Blood Plasma Glucose Level (FPG) Change From Baseline at Week 12,Boehringer Ingelheim,All,"21 Years to 75 Years   (Adult, Older Adult)",Phase 2,333,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,1218.6|2005-004597-24,Apr-06,Aug-07,null,3-Apr-06,15-Jun-11,8-Jul-14,"1218.6.3304A Boehringer Ingelheim Investigational Site, Joue les Tours, France|1218.6.3305A Euraxi Pharma, Joue les Tours, France|1218.6.3302A Boehringer Ingelheim Investigational Site, Joué les Tours, France|1218.6.3303A Boehringer Ingelheim Investigational Site, Joué Les Tours, France|1218.6.3301A Boehringer Ingelheim Investigational Site, Paris cedex 13, France|1218.6.49007 Boehringer Ingelheim Investigational Site, Aschaffenburg, Germany|1218.6.49013 Boehringer Ingelheim Investigational Site, Bosenheim, Germany|1218.6.49008 Boehringer Ingelheim Investigational Site, Dresden, Germany|1218.6.49009 Boehringer Ingelheim Investigational Site, Düsseldorf, Germany|1218.6.49014 Boehringer Ingelheim Investigational Site, Heidelberg, Germany|1218.6.49012 Boehringer Ingelheim Investigational Site, Immenstadt, Germany|1218.6.49001 Boehringer Ingelheim Investigational Site, Mainz, Germany|1218.6.49005 Boehringer Ingelheim Investigational Site, Neuwied, Germany|1218.6.49017 Boehringer Ingelheim Investigational Site, Offenbach a. M., Germany|1218.6.49002 Boehringer Ingelheim Investigational Site, Saarbrücken, Germany|1218.6.49011 Boehringer Ingelheim Investigational Site, Sinsheim, Germany|1218.6.49010 Boehringer Ingelheim Investigational Site, St. Ingbert/Oberwürzbach, Germany|1218.6.49015 Boehringer Ingelheim Investigational Site, Sulzbach-Rosenberg, Germany|1218.6.49016 Boehringer Ingelheim Investigational Site, Wangen, Germany|1218.6.49003 Boehringer Ingelheim Investigational Site, Würzburg, Germany|1218.6.42103 Boehringer Ingelheim Investigational Site, Banska Bystrica, Slovakia|1218.6.42104 Boehringer Ingelheim Investigational Site, Bratislava, Slovakia|1218.6.42105 Boehringer Ingelheim Investigational Site, Bratislava, Slovakia|1218.6.42101 Boehringer Ingelheim Investigational Site, Nove Mesto nad Vahom, Slovakia|1218.6.46003 Boehringer Ingelheim Investigational Site, Göteborg, Sweden|1218.6.46001 Boehringer Ingelheim Investigational Site, Malmö, Sweden|1218.6.46002 Boehringer Ingelheim Investigational Site, Uddevalla, Sweden|1218.6.46004 Boehringer Ingelheim Investigational Site, Uppsala, Sweden|1218.6.38002 Boehringer Ingelheim Investigational Site, Dnyepropetrovsk, Ukraine|1218.6.38001 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|1218.6.38003 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|1218.6.38005 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|1218.6.44012 Boehringer Ingelheim Investigational Site, Ashford, United Kingdom|1218.6.44004 Boehringer Ingelheim Investigational Site, Baillieston, Glasgow, United Kingdom|1218.6.44002 Boehringer Ingelheim Investigational Site, Bath, United Kingdom|1218.6.44003 Boehringer Ingelheim Investigational Site, Birmingham, United Kingdom|1218.6.44013 Boehringer Ingelheim Investigational Site, Camberley, United Kingdom|1218.6.44016 Boehringer Ingelheim Investigational Site, Chorley, United Kingdom|1218.6.44007 Boehringer Ingelheim Investigational Site, Dundee, United Kingdom|1218.6.44006 Boehringer Ingelheim Investigational Site, Exeter, United Kingdom|1218.6.44005 Boehringer Ingelheim Investigational Site, Gillingham, United Kingdom|1218.6.44015 Boehringer Ingelheim Investigational Site, Glasgow, United Kingdom|1218.6.44008 Boehringer Ingelheim Investigational Site, Guildford, United Kingdom|1218.6.44017 Boehringer Ingelheim Investigational Site, Liverpool, United Kingdom|1218.6.44001 Boehringer Ingelheim Investigational Site, London, United Kingdom|1218.6.44018 Boehringer Ingelheim Investigational Site, Manchester, United Kingdom|1218.6.44009 Boehringer Ingelheim Investigational Site, Newcastle upon Tyne, United Kingdom|1218.6.44019 Boehringer Ingelheim Investigational Site, Reading, United Kingdom",,https://ClinicalTrials.gov/show/NCT00309608
NCT00308737,Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes,,Completed,Has Results,"Diabetes, Type 1|Diabetes, Type 2",Drug: Technosphere® Insulin Inhalation Powder|Drug: Usual Care,Change From Baseline to Month 24 in Forced Expiratory Volume in 1 Second (FEV1) by MMRM for TI vs Usual Care|FEV1 Decrease of ≥ 15% From Baseline Value at Last Measurement for TI vs Usual Care|Change From Baseline to Last Measurement in FEV1 for TI vs Usual Care|Change From Baseline to Month 24 in Forced Vital Capacity (FVC) by MMRM|Change From Baseline to Month 24 in Total Lung Capacity (TLC) by MMRM|Change From Baseline to Month 24 in Hemoglobin Corrected DLco by MMRM|Forced Vital Capacity (FVC) Decrease of ≥ 15% From Baseline Value at Last Measurement|Total Lung Capacity (TLC) Decrease of ≥ 15% From Baseline Value at Last Measurement|Hemoglobin-Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLco) Decrease of ≥ 15% From Baseline Value at Last Measurement|Hemoglobin-Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLco) Decrease of >3 ml/Min/mmHg From Baseline Value at Last Measurement|Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Last Measurement for TI vs Usual Care|Change in Weight From Baseline at Month 24,Mannkind Corporation,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,2053,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MKC-TI-030,Jun-05,Sep-08,Oct-08,30-Mar-06,16-Oct-14,16-Oct-14,"Southwest Health Ltd Research Division, Phoenix, Arizona, United States|Lovelace Scientific Resources, Phoenix, Arizona, United States|Northwest Medical Center, Phoenix, Arizona, United States|Arizona Center for Clinical Research, Phoenix, Arizona, United States|Premiere Pharmaceutical Research LLC, Tempe, Arizona, United States|Canyon Clinical Research, Tucson, Arizona, United States|Arizona Research Associates, Tuscon, Arizona, United States|Private Practice, Burlingame, California, United States|Saint Agnes Medical Center, Fresno, California, United States|Valley Research, Fresno, California, United States|(Private Practice), Garden Grove, California, United States|Diabetes/Lipid Management Center, Huntington Beach, California, United States|Interlink Research Institute, Los Alamitos, California, United States|Diabetes Care Center, Salinas, California, United States|San Diego Sports Medicine and Family Health Center, San Diego, California, United States|Dorothy L & James E Frank Diabetes Research Institute, San Mateo, California, United States|Sansum Medical Research Institute, Santa Barbara, California, United States|Encompass Clinical Research, Spring Valley, California, United States|Kaiser Permanente, Denver, Colorado, United States|Denver VA Medical Center, Denver, Colorado, United States|Alliance Medical Group of Greater Waterbury, Middlebury, Connecticut, United States|New Britain General Hosptal c?o Betsy Keller, New Britain, Connecticut, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Perimeter Institute for Clinical Research (PICR), Atlanta, Georgia, United States|Executive Health and Research Associates Inc, Atlanta, Georgia, United States|Rockdale Medical Research Associates, Conyers, Georgia, United States|Private Practice, Decatur, Georgia, United States|Atlanta Pharmaceutical Research Center, Dunwoody, Georgia, United States|North Atlanta Endocrinology & Diabetes PC, Lawrenceville, Georgia, United States|Southeastern Endocrine & Diabetes, Roswell, Georgia, United States|Fox Valley Clinical Research Center LLC, Aurora, Illinois, United States|Cedar-Crosse Research Center, Chicago, Illinois, United States|Deerbrook Medical Associates, Vernon Hills, Illinois, United States|Medical Research of Louisiana, Metairie, Louisiana, United States|Ochsner Clinic and Foundation, New Orleans, Louisiana, United States|Health Trends Research LLC, Baltimore, Maryland, United States|Franklin Square Hospital, Baltimore, Maryland, United States|MODEL Clinical Research, Towson, Maryland, United States|East Coast Clinical Research Inc, Haverhill, Massachusetts, United States|Clinical Research, Waltham, Massachusetts, United States|Michigan Institute of Medicine, Livonia, Michigan, United States|PPS Clinical Research / Southwest Medical Center, Chesterfield, Missouri, United States|Healthcare Research, Florissant, Missouri, United States|MedEx Healthcare Research Inc, St Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Mercy Health Research, St. Louis, Missouri, United States|Billings Clinic Research Division, Billings, Montana, United States|Your Doctors Care, Hillsborough, New Jersey, United States|Hopewell Valley Family Medicine PA, Trenton, New Jersey, United States|Umdnj-Som, Voorhees, New Jersey, United States|New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, United States|Lovelace Scientific Resources (Albuquerque), Albuquerque, New Mexico, United States|Southwest Endocrinology Associates, Albuquerque, New Mexico, United States|Physicians Associates of Park Place, Brooklyn, New York, United States|Diabetes Care & Information Center of New York, Flushing, New York, United States|Eastside Comprehensive Medical Center, New York, New York, United States|M.E.R.I., New York, New York, United States|Physicians Clinical Research Service (PCRS) (SMO), White Plains, New York, United States|Metrolina Medical Research, Charlotte, North Carolina, United States|Endocrine Research - Physician's East PA, Greenville, North Carolina, United States|Rapid Medical Research Inc, Cleveland, Ohio, United States|Your Diabetes Endocrine Nutrition Group, Mentor, Ohio, United States|New Hope Research of Oregon, Portland, Oregon, United States|Buckingham Family Medicine, Doyleston, Pennsylvania, United States|Bucks County Clinical Research, Morrisville, Pennsylvania, United States|Upstate Pharmaceutical Research, Greenville, South Carolina, United States|Texas Familicare Clinical Research, Colleyville, Texas, United States|Dallas Diabetes & Endocrine Center, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Houston Medical Research Associates, Houston, Texas, United States|North Texas Medical Research, Plano, Texas, United States|Diabetes & Glandular Disease Research Assoc PA, San Antonio, Texas, United States|Scott & White Hospital and Clinic, Temple, Texas, United States|McLennan County Medical Education and Research Foundation, Waco, Texas, United States|Magna Center for Family Medicine, Magna, Utah, United States|Davis Family Practice, Salt Lake City, Utah, United States|Radiant Research Salt Lake City, Salt Lake City, Utah, United States|Southeastern PA Med Inst LLC (SMO), Salt Lake City, Utah, United States|Granger Medical Clinic, West Valley City, Utah, United States|Hampton Roads Center for Clinical Research Inc, Norfolk, Virginia, United States|Rainier Clinical Research Center Inc, Renton, Washington, United States|Clinical Research Department Wenatchee Valley Medical Center, Wenatchee, Washington, United States|Finchlea Medical Group, Brampton, Ontario, Canada|Courtice Health Centre, Courtice, Ontario, Ontario, Canada|Parkwood Hospital, London, Ontario, Canada|Quest Clinical Trials, Markham, Ontario, Canada|Sarnia Institute of Clinical Research, Sarnia, Ontario, Canada|The London Road Diagnostic Clinic and Medical Centre, Sarnia, Ontario, Canada|Lifestyle Metabolism Center, Thornhill, Ontario, Canada|Albany Medical Center, Toronto, Ontario, Canada|Lifestyle Metabolism Center (600-118 Eglinton Ave W), Toronto, Ontario, Canada|Manna Research, Toronto, Ontario, Canada|Diabetologicka ambulance, Litomerice, CZE, Czech Republic|Surgery of Diabetology, Melnik, CZE, Czech Republic|Internal Clinic, Ostrava - Poruba, CZE, Czech Republic|Diabetologicka a interni ambulance, Ostrava 1, CZE, Czech Republic|Diabetologicka a interni ambulance, Ostrava-Kuncice, CZE, Czech Republic|Surgery of Diabetology Petrovice, Prague 15, CZE, Czech Republic|FN Motol Interni Klinika, Praha 6, CZE, Czech Republic|Klinika Endocrinologii Diabetologii I, Bialystock, POL, Poland|Oddzial Chorob Wewnetrznych, Bialystock, POL, Poland|Dzial Badan Klinicznych Malopoiskie, Krakow, POL, Poland|Endokrynologiczno Metaboliczne DIAB_ENDO_MET, Krakow, POL, Poland|III Oddzial Chorob Wewnetrznych Szpital, Krakow, POL, Poland|Oddzial Internistyczny Specjalistyczna, Lask, POL, Poland|Oddzial Wewnetrzny B, Lodz, POL, Poland|Klliniczny nr 1 im Norberta Barlickiego Uniwersytetu Medycznego w Lodzi, Lodz, POL, Poland|Oddzial Diabetologiczny Centrum, Lodz, POL, Poland|Spzital Kolejowy imm Wlodzimierza Roeflera, Pruszkow, POL, Poland|Katedra i Klinika Gastroentereologii i, Warsaw, POL, Poland|Oddzial Chorob Wewnetznych i Diabetologii, Warsaw, POL, Poland|ZPZOZ w Otwocku Szpital Miejski, Warsaw, POL, Poland|Klinika Medycyny Rodzinnej i Chorob, Warszawa, POL, Poland|Kemerovo State Medical Academy of Ministry of Health, Kemerovo, RUS, Russian Federation|NHI Kemerovo Regional Clinical Hospital, Kemerovo, RUS, Russian Federation|NI Principal Military Clinical Hospital n a academician N.N. Burdenko of the Ministry of Defense, Moscow, RUS, Russian Federation|Russian State Medical University City Hospital # 4, Moscow, RUS, Russian Federation|NI Endrocrinological Research Centre of RAMS In patient replacing technologies department, Moscow, RUS, Russian Federation|Russian Academy of Medical Sciences National Research Ctr for Endocrinology Institute of Diabetes, Moscow, RUS, Russian Federation|Russian State Medical University Central Clinical Hospital Russian Science Academy, Moscow, RUS, Russian Federation|RAAMS Endocrinology and Diabetology Department, Moscow, RUS, Russian Federation|SIH of Moscow City Clinical Hopsital #81 Endocrinology and Diabetology, Moscow, RUS, Russian Federation|NI Moscow Regional Scientific Research Clinical Institute na MF Vladimirsky, Moscow, RUS, Russian Federation|Municipal Clinical Hospital #13, Moscow, RUS, Russian Federation|Moscow State Medical-Stomatological University City Clinical Hospital # 23, Moscow, RUS, Russian Federation|Ryazan State Medical University na academician IP Pavlov, Ryazan, RUS, Russian Federation|NEI HPE Smolensk State Medical Academy of FAHSD RNHI Smolensk Regional Clinical Hospital, Smolensk, RUS, Russian Federation|Krestovsky Island Medical Institute, St Petersburg, RUS, Russian Federation|St Petersburg NHI City Polytclinic #77 City Diabetological Center #4, St Petersburg, RUS, Russian Federation|Central Medical Sanitary Unit #122, St Petersburg, RUS, Russian Federation|St Petersburg Medical Academy St Elizabeth Hospital, St Petersburg, RUS, Russian Federation|Pavlov State Medical Univ of St Petersburg, St Petersburg, RUS, Russian Federation|St Petersburg NHI Municipal Multi-Speciality Hospital # 2, St. Petersburg, RUS, Russian Federation|Clinical Pharm Dept of Yaroslavl Clin Hospital, Yaroslavl, RUS, Russian Federation|MHI Clinical Hospital for Emergency Care na NV Soloviev, Yaroslavl, RUS, Russian Federation|NHI Yaroslavl Regional Clinical Hospital, Yaroslavl, RUS, Russian Federation|Yaroslavl Regional Clinical Hospital, Yaroslavl, RUS, Russian Federation|Federal State Institution Pulmonology Research Institute of Federal Agency of HC&SD, Moscow, Russian Federation|Fundacio Sarda Farriol, Barcelona, ESP, Spain|Fundacion Jimenez Diaz Servicio Endocrinologia y Nutricion, Madrid, ESP, Spain|Hospital 12 de Octubre Consultas Extremas - Endocrinologia, Madrid, ESP, Spain|Hospital Universitario de la Paz, Madrid, ESP, Spain|Sevilla, ESP, Spain|Hospital Univ Virgen del Rocío Scio Endocrinología Centro de Diagnosticos Pl Baja, Sevilla, ESP, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Bukovinian State Medical University Dept of Clinical Immun, Chernivtcy, UKR, Ukraine|Dniepropetrovsh State Medical Academy, Dniepropetrovsk, UKR, Ukraine|Donetsk State Medical University, Donetsk, UKR, Ukraine|Donetsk State Medical University, Donetsk, UKR, Ukraine|Railway Clinical Hospital on Donetsk Station, Donetsk, UKR, Ukraine|V Danilevsky Inst of Endocrinology Pathology, Kharkiv, UKR, Ukraine|Medical University at Kiev Center of Endocrinology and Metab, Kiev, UKR, Ukraine|Chair Family Med of National Med University, Kiev, UKR, Ukraine|Ukr Scientifically Practical Centre of Endocrine Surgery, Kiev, UKR, Ukraine|Lugansk State Medical University Chair of Hosp Therapy #2, Lugansk, UKR, Ukraine|Lugansk State Medical University Chair of Therapy #1, Lugansk, UKR, Ukraine|Chair of Endocrin & Clinical Pharmacology of Lvov State Medical University, Lvov, UKR, Ukraine|Odessa State Medical University Dept of Gen Practice and Med Rehab, Odessa, UKR, Ukraine|Odessa Reg. Clinical Hosp Outpatient Department, Odessa, UKR, Ukraine|Odessa State Med Dept of Family Med and Gen Practice, Odessa, UKR, Ukraine|Crimean State Medical University Dept of Therapy #1, Simferopol, UKR, Ukraine|Vinnitsa State Medical University, Vinnitsa, UKR, Ukraine|Outpatient Clinic of Family Physician ""Rusanovka"", Kiev, Ukraine|Public Institution City Policlinic #20 Odessa, Odessa, Ukraine|Barnsley Hospital, Barnsley, GBR, United Kingdom|Kingthorne Group Practice, Doncaster, GBR, United Kingdom|Manny Cussins Centre, Leeds, GBR, United Kingdom|Royal liverpool University Hospital, Liverpool, GBR, United Kingdom|Clinical Research Centre The Royal London Hospital, London, GBR, United Kingdom|Medinova Research Mount Vernon Hospital, Middlesex, GBR, United Kingdom|Edith Cavel Hospital Diabetes Centre, Petersborough, GBR, United Kingdom|Northern General Hospital, Sheffield, GBR, United Kingdom|Woolpit Medical Practice, Suffolk, GBR, United Kingdom|West Suffolk Hospital, Suffolk, GBR, United Kingdom|Birmingham Heartland Hospital, West Midlands, GBR, United Kingdom|Bradford Hospital Dept of Diabetes & Endocrinology, West Yorkshire, GBR, United Kingdom",,https://ClinicalTrials.gov/show/NCT00308737
NCT00308139,Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1),,Completed,Has Results,Type 2 Diabetes Mellitus,"Drug: exenatide, long acting release|Drug: exenatide",Change in HbA1c From Baseline to Week 30|Sub-study Relative Bioavailability of Exenatide When Administered Using the Exenatide Once Weekly Dual Chambered Pen and the Exenatide Once Weekly Single Dose Tray (Single Dose Tray-11 Weekly Doses Switch to Dual Chamber Pen-11 Weekly Dose)|Change in HbA1c From Baseline to Week 364|Percentage of Subjects Achieving HbA1c Target of <7%|Percentage of Subjects Achieving HbA1c Target of <=6.5%|Percentage of Subjects Achieving HbA1c Target of <=6.0%|Exenatide LAR Steady State Concentration From Week 29 to Week 30|Change in 2 Hours (2h) Postprandial Glucose From Baseline to Week 14|Sub-study Safety and Tolerability of Exenatide When Administered Using the Once Weekly Single Dose Tray and the Once Weekly Dual (Single Dose Tray-11 Weekly Doses Switch to Dual Chamber Pen-11 Weekly Dose)|Change in Body Weight From Baseline to Week 30|Change in Body Weight From Baseline to Week 364|Change in Fasting Plasma Glucose From Baseline to Week 30|Change in Fasting Plasma Glucose From Baseline to Week 364|Change in Blood Pressure From Baseline to Week 30|Change in Blood Pressure From Baseline to Week 364|Change in Total Cholesterol From Baseline to Week 30|Change in Total Cholesterol From Baseline to Week 364|Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 30|Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 364|Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 364|Ratio of Triglycerides at Week 30 to Baseline|Ratio of Triglycerides at Week 364 to Baseline|Assessment on Event Rate of Treatment-emergent Hypoglycemic Events With SU Use at Screening|Assessment on Event Rate of Treatment-emergent Hypoglycemic Events With Non-SU Use at Screening,AstraZeneca,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 3,303,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2993LAR-105 (DURATION - 1)|MB001-010,Apr-06,Jul-08,Aug-14,29-Mar-06,17-Aug-12,26-Aug-15,"Research Site 182, Encino, California, United States|Research Site 171, La Jolla, California, United States|Research Site 518, San Diego, California, United States|Research Site 024, Walnut Creek, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site 057, Miami, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site 149, Indianapolis, Indiana, United States|Research Site 099, Lexington, Kentucky, United States|Research Site 017, Detroit, Michigan, United States|Research Site 224, Minneapolis, Minnesota, United States|Research Site 312, St. Louis, Missouri, United States|Research Site 023, Butte, Montana, United States|Research Site 053, Rochester, New York, United States|Research Site 002, Durham, North Carolina, United States|Research Site 123, Winston-Salem, North Carolina, United States|Research Site 405, Cincinnati, Ohio, United States|Research Site 557, Marion, Ohio, United States|Research Site 231, Portland, Oregon, United States|Research Site 152, Philadelphia, Pennsylvania, United States|Research Site 587, Greer, South Carolina, United States|Research Site 015, Dallas, Texas, United States|Research Site 009, San Antonio, Texas, United States|Research Site 108, Olympia, Washington, United States|Research Site, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00308139
NCT00308256,Effects of Nurse-counselling in the Improvement of the type1 Diabetes Control in Adolescents,,Completed,No Results Available,Type 1 Diabetes,Behavioral: nurse-counselling,"Patient's acceptance of the disease evaluated by an analogical visual scale rating|Glycaemic equilibrium by measuring the rate of glycosylated haemoglobin|Number of diabetic acidosis having required hospitalization,|Episodes number of severe hypoglycaemia having required an intervention of a third party or a hospitalization.",Hospices Civils de Lyon,All,"13 Years to 18 Years   (Child, Adult)",Not Applicable,77,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),2005.395,Mar-06,Aug-11,Aug-11,29-Mar-06,null,30-Dec-11,"Marc Nicolino, Lyon, France",,https://ClinicalTrials.gov/show/NCT00308256
NCT00308308,Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes,,Completed,Has Results,"Diabetes, Type I",Drug: Technosphere Insulin|Drug: Active comparator,Compare the Mean Change From Baseline to Week 52 in HbA1c|Change From Baseline in Weight to Week 52|Change From Baseline in Fasting Plasma Glucose to Week 52|Number of Subjects Achieving Week 52 HbA1c Levels Less Than or Equal to 7.0%|Incidence of Total Hypoglycemia|Incidence of Severe Hypoglycemia|Total Hypoglycemia Event Rate|Severe Hypoglycemia Event Rate,Mannkind Corporation,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,589,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MKC-TI-009,Feb-06,Jul-08,Aug-08,29-Mar-06,16-Oct-14,16-Oct-14,"Coastal Clinical Research Inc, Mobile, Alabama, United States|Radiant Research (Phoenix), Chandler, Arizona, United States|International Clinical Research Network, Chula Vista, California, United States|Family Medical Center, Foothill Ranch, California, United States|Diabetes/Lipid Management and Research Center, Huntington Beach, California, United States|South Bay Clinical Research, Inglewood, California, United States|Radiant Research, San Diego, California, United States|Coastal Biomedical Research Inc, Santa Monica, California, United States|Diabetes Research Center, Tustin, California, United States|International Research Associates LLC, Miami, Florida, United States|Laureate Clinical Research Group, Atlanta, Georgia, United States|Atlanta Pharmaceutical Research Center, Dunwoody, Georgia, United States|North Atlanta Endocrinology & Diabetes PC, Lawrenceville, Georgia, United States|Endocrine Research Solutions, Inc., Roswell, Georgia, United States|John H Stoger Jr Hospital of Cook County, Chicago, Illinois, United States|Clintell Inc, Skokie, Illinois, United States|Medical Research of Louisiana, Metairie, Louisiana, United States|Oschner Clinic Foundation, New Orleans, Louisiana, United States|James A Dicke MDPA, Towson, Maryland, United States|Wayne State University, Detroit, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Michigan Institute of Medicine, Livonia, Michigan, United States|KMED Research, St Clair Shores, Michigan, United States|Radiant Research Inc (Minneapolis), Edina, Minnesota, United States|International Diabetes Center, Minneapolis, Minnesota, United States|Center for Urologic Clinical Trials University of Minnesota, Minneapolis, Minnesota, United States|Healthcare Research, Florissant, Missouri, United States|MedEx Healthcare Research Inc(009), St Louis, Missouri, United States|Amin Radparvar's Private Practice, St Peters, Missouri, United States|Billings Clinic Research Division, Billings, Montana, United States|Creighton Diabetes Center, Omaha, Nebraska, United States|University of New Mexico HCS, Albuquerque, New Mexico, United States|Winthrop University Hospital, Mineola, New York, United States|North Shore Diabetes and Endocrine Associates, New Hyde Park, New York, United States|University of Physicians Group Endocrine Division, Staten Island, New York, United States|Endocrine Research - Physician's East PA, Greenville, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Providence Health Partners - Center of Clinical Research, Dayton, Ohio, United States|Portland Diabetes & Endocrinology Center, Portland, Oregon, United States|Legacy Clinical Research, Portland, Oregon, United States|Covance CRU Inc., Portland, Oregon, United States|Pennsylvania Research Institute, Bensalem, Pennsylvania, United States|Southeastern Research Associates Inc, Williamston, South Carolina, United States|AM Diabetes and Endocrinology Center, Bartlett, Tennessee, United States|The Endocrine Clinic, Memphis, Tennessee, United States|Israel Hartman MD, Arlington, Texas, United States|Dallas Diabetes & Endocrine Center, Dallas, Texas, United States|Radiant Research Dallas-North, Dallas, Texas, United States|Baylor Endocrine Center, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Spuhler Medical Associates, Friendswood, Texas, United States|Quality Assurance Research Center (900), San Antonio, Texas, United States|Diabetes & Glandular Disease Research Assoc PA, San Antonio, Texas, United States|SAM Clinical Research Center, San Antonio, Texas, United States|Edward Bali MD PA, Seguin, Texas, United States|Radiant Research Salt Lake City, Salt Lake City, Utah, United States|Salt Lake Research, Salt Lake City, Utah, United States|Sentara Medical Group, Virginia Beach, Virginia, United States|Larry D Stonesifer MD Inc PS, Federal Way, Washington, United States|Cedar Research, Tacoma, Washington, United States|Liberty Research Center, Tacoma, Washington, United States|Hospital Interzonal de Agudos Pedro Fiorito, Avellaneda, Buenos Aires, Argentina|Centro Endocrinologic Tiempo, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Buenos Aires, Argentina|Hospital Durand /Buenos Aires, Buenos Aires, Argentina|Hospital Gral De Agudos Dr. Teodoro Alvarez, Buenos Aires, Argentina|Cons Asoc de Endocrinologia, Buenos Aires, Argentina|Centro Medico Dra De Salvo, Buenos Aires, Argentina|CIMeL, Buenos Aires, Argentina|Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil|Hospital Sao Lucas da PUCRS, Porto Alegre, Rio Grande do Sul, Brazil|Universidade Estabual de Maringa, Maringa Parana, Brazil|Nucleo de Medicina Integrada, Mogi das Cruzes, Brazil|Instituto Estadual De Diabetes e Endocrinologia Luis Capriglione, Rio de Janeiro, Brazil|Ccbr Brasil Centro de Analises e Pesquisas Clinicas Ltda, Rio de Janeiro, Brazil|Hospital Guilherme Alvaro, Santos, Brazil|CPClin-Centro de Pesquisas Clinicas, Sao Paulo, Brazil|Centro de Diabetes/UNIFESP-EPM, Sao Paulo, Brazil|Blumenau Servicos Medicos S/C Ltda, Sao Paulo, Brazil|Instituto de Pesquisa Clinica e Medicina Avancada, Sao Paulo, Brazil|Lifestyle Metabolism Center, Oakville, Ontario, Canada|Lifestyle Metabolism Center, Thornhill, Ontario, Canada|Lifestyle Metabolism Center, Toronto, Ontario, Canada|Windsor Professional Research, Windsor, Ontario, Canada|Hospital del Salvador, Santiago, Region Metropolitana, Chile|Hospital San Jose, Santiago, Chile|Hospital Clinico Pontificia Universidad (009)Catolica de Chile, Santiago, Chile|Hospital Padre Alberto Hurtado, Santiago, Chile|Hospital San Borja ArriaranUniversidad de Chile, Santiago, Chile|Instituto de Informacion de Tramiento y Educacion en Salud, Santiago, Chile|Instituto Mexicano de Investigacion, Mexico City, Durango, Mexico|Hospital Santa Engracia-CIMA, Garza Garcia, Mexico|Centro de Estudios en Diabetes, Mexico City, Mexico|Hospital General de Mexico Servicio EndocrinologiaJefe Del Servicio, Mexico City, Mexico|Hospital OCA-MIRC (009), Monterrey, Mexico|NZOZ Specjalistyczny Osrodek Internistyczno - Diabetologiczny, Bialystok, POL, Poland|Katedra I Klinika Chorob Metabolicznych Collegium Medicum Uniwersytety Jagiellonskiego, Krakow, POL, Poland|Instytut Centrum Zdrowia (009) Matki Polki, Lodz, POL, Poland|Szpital Kolejowy im Dr w Roeflera(009) Oddzial Gastorenterologii, Pruszkow, POL, Poland|Oddzial Chorob Wewnetrznych (009 Endokrynologii I Diabetologii Szpitala Wojewodzkiego, Bialystok, Poland|Oddzial Kliniczny Diabetologii (009) Kliniczny nr 1 im Norberta Barlickiego Uniwersytety Meycznego, Lodz, Poland|NZOZ Diabetologiczna Poradnia Specjalistyczna, Warszawa, Poland|NHI Kemerovo Regional Clinical Hospital, Kemerovo, RUS, Russian Federation|NI Principal Military Clinical Hospital n a academician N.N. Burdenko of the Ministry of Defense, Moscow, RUS, Russian Federation|NEI HPE Moscow State University of Medicine and Dentistry of FAHSD City Clinical Hospital #70, Moscow, RUS, Russian Federation|Moscow City Clinical Hospital # 13, Moscow, RUS, Russian Federation|SEI HPE Moscow Medical Academy IM Sechenov of Roszdrav Clinic of Endocrinology, Moscow, RUS, Russian Federation|SI Internal Affairs of Moscow- Clinical Hospital, Moscow, RUS, Russian Federation|RAAMS Endocrinology and Diabetology Department, Moscow, RUS, Russian Federation|SIH of Moscow City Clinical Hopsital #81Endocrinology and Diabetology, Moscow, RUS, Russian Federation|St Petersburg NHI City Polytclinic #77 City Diabetological Center #4, St Petersburg, RUS, Russian Federation|Central Medical Sanitary Unit #122, St Petersburg, RUS, Russian Federation|Pavlov State Medical Univ of St Petersburg, St Petersburg, RUS, Russian Federation|St Petersburg NHI Municipal Multi-Speciality Hospital # 2, St. Petersburg, RUS, Russian Federation|MHI Clinical Hospital for Emergency Care na NV Soloviev, Yaroslavl, RUS, Russian Federation|MCHI Medical Sanitary Unit of Novo-Yaroslavsky Oil Refining Plant, Yaroslavl, RUS, Russian Federation|NHI Yaroslavl Regional Clinical Hospital, Yaroslavl, RUS, Russian Federation|City Clinical Hospital # 61, Moscow, Russian Federation|Russian Scientific Center of Restoration Medicine & Balneology, Moscow, Russian Federation|Complejo Hospitalario Nuestra Senora de Valme, Sevilla, Andalucia, Spain|Hospital del Mar, Barcelona, Spain|Hospital Ramon y Cajal, Madrid, Spain|Complejo Hospitalario Virgen del Rocio, Sevilla, Spain|Hospital Virgen Macarena (policlinico) 2ª planta Servicio de Endocrinologia y Nutricion, Sevilla, Spain|Birchwood Surgery, Letchworth, Herts, United Kingdom|Lister Hospital, Stevenage, Herts, United Kingdom|Sandwell General Hospital, Lyndon, West Bromwich, United Kingdom|Guy's & St Thomas Hospital, London, United Kingdom|Yaxley Group Practice, Peterborough, United Kingdom",,https://ClinicalTrials.gov/show/NCT00308308
NCT00306098,Islet Cell Transplantation Alone in Patients With Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression,,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type I",Drug: islets,"a1c less than 6.5 without severe hypoglycemia|Secondary end-points will include: partial graft function, as evidenced by baseline C-peptide greater than 0.5 ng/ml|evidence for reduction in insulin requirements in those patients who do not achieve insulin independence|improvement in metabolic control as evidenced by improvement in: HbA1C (should be < 7), mean amplitude of glycemic excursions (MAGE), mean glucose meter readings, continuous glucose monitoring, OGTT, and acute C-peptide response to arginine challenge|elimination or reduction in the incidence of hypoglycemic coma or unawareness|improvement in or decreased progression of microvascular, macrovascular and neuropathic complications of diabetes|assessment of efficacy of infliximab in preventing early rejection - number of subjects achieving insulin independence with a single infusion|assessment of efficacy of etanercept in preventing early rejection - number of subjects achieving insulin independence with a single infusion|assessment of EXN to re-establish insulin independence or increase insulin secretion - reduction in insulin requirements with restoration of satisfactory glycemic control|assessment of EXN to improve islet survival at time of islet transplantation - number of subjects achieving insulin independence with a single infusion",Rodolfo Alejandro|National Institutes of Health (NIH)|Health Resources and Services Administration (HRSA)|Diabetes Research Institute Foundation|University of Miami,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,40,Other|NIH|U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20000196|NIH #1U42 RR016603-01|HRSA # 1 R38OT01367-01-00,Dec-00,May-20,May-21,22-Mar-06,null,11-Dec-18,"University of Miami, Diabetes Research Institute, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT00306098
NCT00305344,Umbilical Cord Blood Infusion to Treat Type 1 Diabetes,,Completed,Has Results,Type 1 Diabetes Mellitus,Procedure: Autologous Umbilical Cord Blood Transfusion|Biological: Cord blood,Children With T1D Underwent a Single Autologous UCB Transfusion,University of Florida|Juvenile Diabetes Research Foundation|National Institutes of Health (NIH),All,"1 Year and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,23,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1-2005-362|GCRC 593|UF IRB-01 125-2004,Apr-05,May-11,May-11,21-Mar-06,10-Jul-12,10-Jul-12,"University of Florida, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT00305344
NCT00304538,"A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Very Low Dose-Glucagon in Subjects With Type 1 Diabetes Mellitus",,Completed,No Results Available,Type 1 Diabetes,Drug: very low dose (VLD) glucagon,"1) Evaluate the safety and tolerability of VLD-glucagon in doses of 2, 4 and 8 ng/kg/minute when infused overnight 2) Evaluate the PK profile in plasma of VLD-glucagon 3) Evaluate the pharmacodynamic activity of these doses by measuring glucose levels|Compare the number of times and amount of time subjects have glucose levels < 70 mg/dL when treated with VLD-glucagon vs. the control infusion",DiObex,All,18 Years to 55 Years   (Adult),Phase 1,10,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,DIO-103,Mar-06,null,Jul-06,20-Mar-06,null,23-Aug-06,"University Of California, San Diego, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT00304538
NCT00303394,Treatment of Patients With Type 2 Diabetes With an Interleukin-1 Antagonist,,Completed,No Results Available,Type 2 Diabetes,Drug: IL-1Ra,"HbA1c|Insulin requirement|Stimulated C peptide and insulin|Fasting plasma glucose (FPG)|Serum cytokine levels, CRP|Insulin secretion and Insulin-sensitivity index derived from an OGTT with insulin and glucose measurements.|In a subgroup of patients, insulin-sensitivity assessed by clamp techniques|Insulin signaling- and cytokine- gene expression profiles derived from muscle and fat biopsy samples.",University of Zurich|Steno Diabetes Center Copenhagen,All,"20 Years and older   (Adult, Older Adult)",Phase 2,72,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment,EK-1000-ZH,Apr-04,null,Mar-06,16-Mar-06,null,5-Mar-07,"Steno Diabetes Center, Gentofte, Copenhagen, Denmark|University Hospital of Zurich, Division of Endocrinology and Diabetes, Zurich, Switzerland",,https://ClinicalTrials.gov/show/NCT00303394
NCT00303134,Islet Cell Transplants for Diabetes,,Suspended,No Results Available,"Diabetes Mellitus, Type 1",Procedure: Islet Cell Transplantation,Insulin independence 12 months after final islet infusion|Basal c-peptide level|Hemoglobin A1c level|Glucose tolerance|C-peptide response to arginine|Mean Amplitude of Glucose Excursion (MAGE)|Mixed meal test,Weill Medical College of Cornell University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,8,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,105004956,Aug-03,null,null,15-Mar-06,null,5-Dec-08,"New York Presbyterian Hospital - Weill Cornell Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00303134
NCT00302224,"A Phase 1/2a Study of the 2S,4R Enantiomer of Ketoconazole in Subjects With Type 2 Diabetes Mellitus",,Completed,No Results Available,Type 2 Diabetes,"Drug: 2S, 4R Ketoconazole (DIO-902)","To evaluate the safety and tolerability of 14 daily doses; To determine the pharmacokinetic (PK) profile in plasma of DIO-902 after a single dose, and after fourteen daily doses; To evaluate the pharmacodynamic effects of fourteen daily doses|To explore the impact of treatment with the enantiomer of ketoconazole on markers of inflammation and coagulation as well as on lipomic profiles, pre- and post-treatment",DiObex,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,50,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,DIO-501,Feb-05,null,Aug-06,14-Mar-06,null,22-Feb-08,"Asha Thomas, MD - Medstar, Washington DC, District of Columbia, United States|Marc Rendell, MD - Creighton University, Omaha, Nebraska, United States|Dr. Andrew Ahmann, MD - Radiant Research, Portland, Oregon, United States|Carlos Arauz-Pacheco, MD - Radiant Research, Dallas, Texas, United States|Sherwin Schwartz, MD - Diabetes and Glandular Disease Clinic, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00302224
NCT00299871,Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus,,Completed,No Results Available,Type 2 Diabetes,Drug: LIXISENATIDE (AVE0010),"HbA1c levels at baseline and endpoint (at 13 weeks).|Fructosamine, fasting plasma glucose, fasting serum insulin, proinsulin, C-peptide, glucagon.",Sanofi,All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 2,542,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DRI6012,Feb-06,Aug-07,Aug-07,7-Mar-06,null,28-Jan-14,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Sao Paulo, Brazil|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Warszawa, Poland|Sanofi-Aventis Administrative Office, Bucuresti, Romania|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Kiev, Ukraine",,https://ClinicalTrials.gov/show/NCT00299871
NCT00298740,Medtronic MiniMed Implantable Insulin Pump,,Completed,Has Results,Type 1 Diabetes,Device: Aventis U-400 Insulin,Glucose Control as Assessed by Mean Glucose Levels,Johns Hopkins University|National Institutes of Health (NIH)|Medtronic,All,"Child, Adult, Older Adult",Not Applicable,12,Other|NIH|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,03-05-01-08|RR00052,Feb-03,24-Sep-09,24-Sep-09,3-Mar-06,12-Sep-17,12-Sep-17,"Johns Hopkins University, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00298740
NCT00297401,Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: ruboxistaurin|Drug: placebo,"Primary outcomes will be the change in proteinuria, pre- and post-treatment with ruboxistaurin.|Change in the renal and peripheral pressor response to hyperglycemia pre and post treatment with ruboxistaurin|Change in the renal and peripheral pressor response to Angiotensin II pre and post-treatment with ruboxistaurin.|Secondary analyses will consist of the change in endothelial function and vascular compliance pre- and post-treatment with ruboxistaurin.","Chromaderm, Inc.|Heart and Stroke Foundation of Canada",All,"18 Years and older   (Adult, Older Adult)",Phase 3,20,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",8023|B7A-CA-S003,Mar-06,Nov-07,Nov-07,28-Feb-06,null,29-Aug-16,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physcian., Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00297401
NCT00297583,Insulin Glulisine in Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Insulin Glulisine,serum insulin concentrations|glucose infusion rates|blood glucose concentrations|Adverse events and hypoglycemic episodes collection,Sanofi,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,null,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,HMR1964A_1501,Apr-04,May-04,null,28-Feb-06,null,7-Dec-09,,,https://ClinicalTrials.gov/show/NCT00297583
NCT00297635,Telemetric Glucose Data Acquisition During Initiation of Insulin Pump Therapy,,Withdrawn,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Insulin-Dependent",Device: GlucoDYNAMIX™ intervention system|Device: GlucoMON™ telemetry device,"Regulation of blood glucose excursions, measured by hemoglobin A1c at the end of the 3 month study period and again after an additional 3 month follow-up period|Magnitude of glucose excursions and fluctuations as indicated by the standard deviation between glucose tests to indicate relative glucose control and the mean daily glucose value over the 3 month period following the initiation of pump therapy|Frequency of severe hypoglycemia and extended hyperglycemia.|Saving of staff time in support of data collection, analysis and patient feedback including delivery and follow-up to monitor effects on glucose control from patient implementation of prescribed changes.|Whether use of the technology results in perceived improvement in the quality of care and improved satisfaction for all involved",Thomas Jefferson University|LifeScan|Diabetech,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,06C.07,Mar-06,null,Dec-07,28-Feb-06,null,12-Jan-17,,,https://ClinicalTrials.gov/show/NCT00297635
NCT00294723,To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c,LEAD-3,Terminated,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: glimepiride|Drug: placebo,Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 52|Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 104|Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 156|Change in Body Weight at Week 52|Change in Body Weight at Week 104|Change in Body Weight at Week 156|Change in Fasting Plasma Glucose at Week 52|Change in Fasting Plasma Glucose at Week 104|Change in Fasting Plasma Glucose at Week 156|Change in Mean Postprandial Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 52|Change in Mean Postprandial Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 104|Change in Mean Postprandial Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 156|Change in Prandial Increments of Plasma Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 52|Change in Prandial Increments of Plasma Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 104|Change in Prandial Increments of Plasma Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 156|Hypoglycaemic Episodes,Novo Nordisk A/S,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,746,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN2211-1573,Feb-06,Nov-08,Nov-08,22-Feb-06,12-Mar-10,7-Mar-17,"Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Escondido, California, United States|Novo Nordisk Investigational Site, Fullerton, California, United States|Novo Nordisk Investigational Site, Inglewood, California, United States|Novo Nordisk Investigational Site, Mission Viejo, California, United States|Novo Nordisk Investigational Site, Orange, California, United States|Novo Nordisk Investigational Site, Santa Barbara, California, United States|Novo Nordisk Investigational Site, Spring Valley, California, United States|Novo Nordisk Investigational Site, Vista, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Daytona Beach, Florida, United States|Novo Nordisk Investigational Site, Delray Beach, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Longwood, Florida, United States|Novo Nordisk Investigational Site, Ocala, Florida, United States|Novo Nordisk Investigational Site, St. Cloud, Florida, United States|Novo Nordisk Investigational Site, Athens, Georgia, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Blue Ridge, Georgia, United States|Novo Nordisk Investigational Site, Columbus, Georgia, United States|Novo Nordisk Investigational Site, Marietta, Georgia, United States|Novo Nordisk Investigational Site, Powder Springs, Georgia, United States|Novo Nordisk Investigational Site, Tucker, Georgia, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Maywood, Illinois, United States|Novo Nordisk Investigational Site, Indianapolis, Indiana, United States|Novo Nordisk Investigational Site, Des Moines, Iowa, United States|Novo Nordisk Investigational Site, Shawnee Mission, Kansas, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, New Orleans, Louisiana, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Hyattsville, Maryland, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, St. Paul, Minnesota, United States|Novo Nordisk Investigational Site, Jackson, Mississippi, United States|Novo Nordisk Investigational Site, Tupelo, Mississippi, United States|Novo Nordisk Investigational Site, Chesterfield, Missouri, United States|Novo Nordisk Investigational Site, St. Louis, Missouri, United States|Novo Nordisk Investigational Site, St. Louis, Missouri, United States|Novo Nordisk Investigational Site, St. Peters, Missouri, United States|Novo Nordisk Investigational Site, Butte, Montana, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Reno, Nevada, United States|Novo Nordisk Investigational Site, Berlin, New Jersey, United States|Novo Nordisk Investigational Site, Lawrenceville, New Jersey, United States|Novo Nordisk Investigational Site, Plainsboro, New Jersey, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, Lewiston, New York, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, Northport, New York, United States|Novo Nordisk Investigational Site, Staten Island, New York, United States|Novo Nordisk Investigational Site, Syracuse, New York, United States|Novo Nordisk Investigational Site, West Seneca, New York, United States|Novo Nordisk Investigational Site, Asheville, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Durham, North Carolina, United States|Novo Nordisk Investigational Site, Greensboro, North Carolina, United States|Novo Nordisk Investigational Site, Cleveland, Ohio, United States|Novo Nordisk Investigational Site, Dayton, Ohio, United States|Novo Nordisk Investigational Site, Mentor, Ohio, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, United States|Novo Nordisk Investigational Site, Tulsa, Oklahoma, United States|Novo Nordisk Investigational Site, Bend, Oregon, United States|Novo Nordisk Investigational Site, Eugene, Oregon, United States|Novo Nordisk Investigational Site, Medford, Oregon, United States|Novo Nordisk Investigational Site, Medford, Oregon, United States|Novo Nordisk Investigational Site, Lancaster, Pennsylvania, United States|Novo Nordisk Investigational Site, Norristown, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, East Providence, Rhode Island, United States|Novo Nordisk Investigational Site, Greer, South Carolina, United States|Novo Nordisk Investigational Site, Spartanburg, South Carolina, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Corpus Christi, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Midland, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Salt Lake City, Utah, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Edmonds, Washington, United States|Novo Nordisk Investigational Site, Olympia, Washington, United States|Novo Nordisk Investigational Site, Renton, Washington, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Tacoma, Washington, United States|Novo Nordisk Investigational Site, Guadalajara, Jalisco, Mexico|Novo Nordisk Investigational Site, Cuernavaca, Morelos, Mexico|Novo Nordisk Investigational Site, Monterrey, Nuevo León, Mexico|Novo Nordisk Investigational Site, Chihuahua, Chih, Mexico|Novo Nordisk Investigational Site, Ciudad de México, D.F., Mexico|Novo Nordisk Investigational Site, Ciudad de México, D.F., Mexico|Novo Nordisk Investigational Site, Guadalajara, Mexico|Novo Nordisk Investigational Site, Hermosillo, Son., Mexico|Novo Nordisk Investigational Site, Mexico D.F., Mexico|Novo Nordisk Investigational Site, Mexico, D.F., Mexico|Novo Nordisk Investigational Site, Monterrey, N.L., Mexico|Novo Nordisk Investigational Site, Monterrey, NL, Mexico|Novo Nordisk Investigational Site, Santiago de Querétaro, Qro., Mexico|Novo Nordisk Investigational Site, Tampico, Mexico|Novo Nordisk Investigational Site, Rio Piedras, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00294723
NCT00291772,Continuous Subcutaneous Infusion of Pramlintide and Insulin,,Completed,No Results Available,Type 1 Diabetes,Drug: Pramlintide,Area under the curve for glucose|glucagon and gastric emptying,Baylor College of Medicine,All,"13 Years to 22 Years   (Child, Adult)",Phase 4,13,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-17339,Jan-06,Nov-07,Nov-07,15-Feb-06,null,14-Jul-16,"Texas Children's Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00291772
NCT00290979,Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: insulin glulisine,Non-inferiority in the efficacy and safety of HMR1964 as compared with Insulin lispro|6-month safety data,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,250,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EFC6167,Dec-04,null,null,13-Feb-06,null,26-Aug-09,"Sanofi-Aventis, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00290979
NCT00290043,Glulisine Pre- and Postmeal,,Completed,No Results Available,Diabetes Mellitus Type 1,Drug: Insulin glulisine,"Outcome measures: Post-prandial glucose and insulin concentrations. Outcome: In T1DM, insulin glulisine provides a better mimic of the physiological postprandial glucose disposal than RHI.",Sanofi,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HMR1964A/1008|HMR1964,Dec-01,null,Mar-02,10-Feb-06,null,6-Dec-10,,,https://ClinicalTrials.gov/show/NCT00290043
NCT00288977,Islet Transplantation in Type 1 Diabetic Recipients of Kidney Transplants,,Completed,No Results Available,Diabetes|Kidney Transplantation,Procedure: Islet Infusion,independence from insulin injections with adequate control of blood glucose in subjects with Type 1 diabetes at one year post final transplant,Beth Israel Deaconess Medical Center|Joslin Diabetes Center,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,8,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2001P001702,Sep-00,Jun-08,Jun-08,9-Feb-06,null,16-Mar-17,,,https://ClinicalTrials.gov/show/NCT00288977
NCT00287651,Effects of Pulsatile IV Insulin Delivery on Diabetic Retinopathy in Patients With Types 1 and 2 Diabetes Mellitus,,Terminated,No Results Available,"Diabetes Mellitus, With Complications",Procedure: Pulsatile IV Insulin|Procedure: Effects of Pulsatile IV Insulin on Diabetic Retinopathy,Serial fundus photography,Florida Atlantic University|Advanced Diabetes Treatment Centers|Global Infusions,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,150,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,H09-06|MH42900 and MH01386,Nov-05,Aug-09,Aug-09,7-Feb-06,null,10-Aug-16,"Florida Atlantic University Center for Complex Systems and Brain Sciences, Boca Raton, Florida, United States",,https://ClinicalTrials.gov/show/NCT00287651
NCT00286962,Study to Compare Intraperitoneal Insulin to Subcutaneous Insulin Administration in Type 1 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Device: MIP 2007C implantable insulin pump|Device: continuous subcutaneous insulin infusion (CSII) or MDI,"incidence of hypoglycemia; data taken from patient diaries during either study arm.|glycemic control; glycosylated hemoglobin (HbA1c) measurement at baseline, end of entry phase, start of both study arms, halfway through study arms, end of study arms.|average daily insulin usage; as taken from patient diaries for both study arms|frequency of adverse events; as taken from patient diaries for both study arms|frequency of clinically significant abnormal laboratory values and device complications; as taken from patient diaries for both study arms|Quality of life; score on a quality of life scale at baseline and end of either study arm|Treatment satisfaction; score on treatment satisfaction scale at baseline and end of either study arm|daily glucose excursions; measured with continuous glucose monitoring system (CGMS) at baseline, halfway through and at the end of both study arms","Medical Research Foundation, The Netherlands|Medtronic",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,24,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IC-06-01-SL|04.0211p,Feb-06,Apr-08,Apr-08,6-Feb-06,null,11-Apr-08,"Isala Klinieken, Zwolle, Netherlands",,https://ClinicalTrials.gov/show/NCT00286962
NCT00287066,A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition,,Terminated,No Results Available,Diabetes Mellitus,Drug: Inhaled Human Insulin|Drug: Regular Human Insulin,18F-labeled glucose uptake in muscle|Glucose turnover overnight Insulin pharmacokinetics,Pfizer,All,18 Years to 50 Years   (Adult),Phase 3,22,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A2171060,Feb-06,null,Mar-07,6-Feb-06,null,21-Feb-08,"Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00287066
NCT00287456,Use of the Insulin Pump in Cystic Fibrosis Patients With Impaired Glucose Tolerance or CFRD and in Type 1 Diabetes Patients.,,Withdrawn,No Results Available,Cystic Fibrosis Related Diabetes,Device: Insulin Pump|Drug: Insulin|Procedure: Oral Glucose Tolerance Test|Procedure: Whole body Protein Turnover,,University of Texas Southwestern Medical Center,All,"12 Years to 32 Years   (Child, Adult)",Not Applicable,0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0901-466,2-Feb-06,2-Feb-06,2-Feb-06,6-Feb-06,null,10-Jan-19,"Children's Medical Center of Dallas, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00287456
NCT00286624,"Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation",NITA,Completed,No Results Available,Type 1 Diabetes Mellitus|Hypoglycemia,Biological: Allogeneic Islets of Langerhans|Drug: Everolimus|Drug: anti-thymocyte globulin|Drug: Cyclosporine,"• The incidence, timing, and severity of adverse events during one year after the first and any subsequent islet transplants.|• Incidence and severity of hypoglycemia during the first year after the first and any subsequent islet transplants.|• The proportion of recipients who develop alloantibodies directed at islet donor alloantigens during the first year after the first and any subsequent islet transplants.|• The proportion of subjects who achieve insulin independence in the first year after single-donor or sequential transplantation.|• The proportion of islet allograft recipients with full and partial islet graft function at one year after the most recent islet transplant.|• Glycemic control and insulin secretory responses during the first year after the first and any subsequent transplants.|• The effect of donor age, pretransplant islet insulin secretory response in vitro, number of transplanted islet equivalents (IEQ), number of transplanted beta cells, pretransplant recipient insulin requirements and action, recipient body mass index (BM|• The impact of islet transplantation on the quality of life of transplant recipients.",University of Minnesota - Clinical and Translational Science Institute|Juvenile Diabetes Research Foundation|National Institutes of Health (NIH)|Novartis,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,6,Other|NIH|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0207M29841,Mar-03,Aug-06,Aug-06,3-Feb-06,null,8-May-08,"University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00286624
NCT00285194,hOKT3γ1 (Ala-Ala) Combined With Sirolimus and Delayed Tacrolimus in Type 1 Diabetic Islet Allograft Recipients,,Completed,No Results Available,Type 1 Diabetes|Hypoglycemia,Drug: Allogeneic Islets of Langerhans|Drug: hOKT3γ1 (Ala-Ala),"Safety, tolerability, immune activity, and pharmacokinetics of hOKT3γ1 (Ala-Ala) antibody induction therapy for the prevention of autoimmune destruction and rejection of allogeneic islet transplants as measured by:|-Physical examination|-Vital signs|-Body weight|-Adverse events|-Laboratory and diagnostic safety assessments included complete blood counts with differential and platelets, circulating T cell phenotypes, and serum chemistry.|-Immune activity and pharmacokinetic assessments included hOKT3γ1 (Ala-Ala) level and half-life, monoclonal antibody coating and modulation of CD3 on peripheral blood T cells, and anti-hOKT3γ1 (Ala-Ala) antibody responses.|Efficacy of hOKT3γ1 (Ala-Ala) antibody induction therapy for the prevention of autoimmune destruction and rejection of islet transplants as defined by:|-Proportion of subjects with full islet graft function (insulin independence and HbA1c <7%);|-Proportion of subjects with partial islet graft function (insulin dependence, basal or arginine-stimulated C-peptide levels of greater or equal to 0.5 ng/ml and HbA1c <7%);|-Proportion of subjects with slet graft loss will be defined as a return to insulin therapy for >30 days, absence of basal and arginine-stimulated C-peptide, re-transplantation, or patient death;",University of Minnesota - Clinical and Translational Science Institute|Juvenile Diabetes Research Foundation,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,6,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0003M44181,Apr-00,Jan-04,Jan-04,1-Feb-06,null,2-Aug-12,"Universtiy of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00285194
NCT00285233,Delayed Mycophenolate Mofetil in Single-Donor Islet Allotransplantation in Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes|Hypoglycemia,Biological: Allogeneic islets of Langerhans transplant,"Assess the incidence and severity of hypoglycemia in type 1 diabetic subjects receiving an islet allotransplant and immunotherapy during the first year posttransplant.|Assess liver laboratory tests during the first year following intraportal islet allotransplantation.|Assess the incidence, type, and severity of islet transplant-related infectious complications during the first year posttransplant.|Assess the proportion of recipients who develop alloantibodies directed at donor alloantigens during the first year posttransplant.|Monitor the incidence, timing, and severity of adverse events as well as their relationship to the islet transplant procedure and additional protocol-regulated treatment products during the first year after islet transplantation.|Assess the proportion of type 1 diabetic subjects receiving delayed mycophenolate mofetil instead of tacrolimus who achieve insulin independence in the first year after transplantation of allogeneic islets.|Assess the proportion of type 1 diabetic islet allograft recipients with full and partial alloislet function at one year post transplant.|Assess the glycemic control, insulin secretory responses, and the glucose disposal rate during the first year posttransplant.|Effect of donor age, pretransplant islet insulin secretory response, # of transplanted islet equivalents, # of transplanted beta cells, pretransplant insulin action, recipient BMI and immunosuppressive therapy on safety and efficacy.|Assess, in a selected group of islet allotransplant recipients, the autoimmune and alloimmune responses to transplanted islets at intervals during the first year posttransplant.",University of Minnesota - Clinical and Translational Science Institute|Roche Pharma AG|Juvenile Diabetes Research Foundation,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,8,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0006M55241,Sep-00,Sep-04,Mar-05,1-Feb-06,null,2-Aug-12,"University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00285233
NCT00284232,Metabolic Effects of Accurate Blood Sugar Results and Education in Type 1 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Behavioral: Use and interpretation of blood glucose results|Drug: Insulin dosing based on SMBG chart and education,HbA1c %|Hypoclycemic events|Measurement quality of blood glucose instrument|Frequency of SMBG|Satisfaction|New learning points for patients|Confidence in new instrument quality,Helse Stavanger HF,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,140,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),Measure 2004,Oct-04,Aug-06,Dec-06,31-Jan-06,null,28-Jul-15,"Stavanger University Hospital, Stavanger, Norway",,https://ClinicalTrials.gov/show/NCT00284232
NCT00283218,"A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 30, 50 and 70.",,Completed,No Results Available,Type 1 Diabetes,"Drug: NovoRapid, NovoMix 30, Bifasisk Insulin Aspart 50, BIAsp70","Primary endpoint:|• Cmaxglu: Peak plasma glucose following test meal (breakfast). A comparison will be made between BIAsp 50 vs BIAsp 70, BIAsp 30 vs BIAsp 70, BIAsp 30 vs BIAsp 50 and IAsp vs BIAsp 30, 50 and 70.|Secondary endpoints:|AUCglu: The area under the plasma glucose concentration (0-12, 0-6, 6-12, 0-4, 4-8, 8-12 hours after test meal) after a single injection of one of the four insulin aspart preparation: IAsp (NovoRapid®), Biphasic insulin aspart 30, 50 and 70.|AUCins: The area under insulin aspart concentration (0-12, 0-6, 6-12, 0-4, 4-8, 8-12 hours after test meal) after a single injection of one of the four insulin aspart preparation: IAsp (NovoRapid®), Biphasic insulin aspart 30, 50 and 70.",University of Aarhus|Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,24,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Asp-BIAsp-2005/0109,Jan-06,null,Aug-06,27-Jan-06,null,8-Aug-06,"Dept of Medicine M, Aarhus University Hospital, Nørrebrogade 44, Aarhus, C, Denmark",,https://ClinicalTrials.gov/show/NCT00283218
NCT00278980,Effect of C-Peptide on Diabetic Peripheral Neuropathy,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Diabetic Polyneuropathy",Drug: C-peptide,Change in sensory nerve conduction velocity from baseline to 6 mo of treatment|- Change in quantitative sensory tests and|neurological impairment assessment from baseline to 6 mo of treatment|- Safety and tolerability of C-peptide,Creative Peptides Sweden Inc.,All,18 Years to 55 Years   (Adult),Phase 2,180,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CPSp201,Oct-03,null,Dec-04,19-Jan-06,null,19-Jan-06,"Karolinska University Hospital Solna, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT00278980
NCT00279305,Rituximab in New Onset Type 1 Diabetes,,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Anti-CD20 (rituximab)|Drug: Placebo Comparator,Area Under the Stimulated C-peptide Curve Over the First 2 Hours of a 4-hour Mixed Meal Tolerance Test (MMTT) Administered at 1 Year,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|American Diabetes Association|Juvenile Diabetes Research Foundation,All,"8 Years to 45 Years   (Child, Adult)",Phase 2,87,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Ritux (IND) (completed),Aug-05,Apr-09,Nov-09,19-Jan-06,18-Aug-16,2-Nov-16,"Childrens Hospital of Los Angeles, Los Angeles, California, United States|University of California-San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|Indiana University-Riley Hospital for Children, Indianapolis, Indiana, United States|Joslin, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Columbia University, New York, New York, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Texas, Dallas, Texas, United States|Benaroya Research Institute, Seattle, Washington, United States|Walter and Eliza Hall Institute of Medical Research, Victoria, Australia|The Hospital for Sick Children, Toronto, Ontario, Canada|San Raffaele Hospital, Milan, Italy",,https://ClinicalTrials.gov/show/NCT00279305
NCT00276250,Islet Transplantation Using Abatacept,,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Efalizumab|Drug: Abatacept|Drug: Belatacept,"The Number of Insulin-independent Subjects at Day 75 (± 5 Days) Following the First Islet Cell Transplantation|Number of Insulin-independent Subjects Following Islet Transplantation|Number of Subjects With HbA1C Less Than 6.5%|Number of Subjects With HbA1C Levels < 6.5%|Number of Subjects With HbA1C < 6.5%|Number of Participants With Endogenous Insulin Production Post-transplant, Assessed by Fasting C-peptide Levels|The Number of Study Participants Exhibiting a Successful Response to a Standard Mixed Meal Test, Measured by Stimulated C-peptide Levels After Islet Transplant.|Number of Subjects With Normal Renal Function, as Measured by Serum Creatinine Levels",Emory University|Juvenile Diabetes Research Foundation,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,5,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB00021852|1136-2005,Dec-05,Dec-14,Dec-14,13-Jan-06,27-Jul-16,27-Jul-16,"Emory University, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT00276250
NCT00276393,Treatment Trial Evaluating Long Acting Insulin in Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Drug: Basal insulin,HbA1c|Hypoglycemic events|Nocturnal hypoglycemia|Mean glucose|Mean fasting glucose|Days of titration of basal insulin|Fear of hypoglycemia|Continuos glucose monitoring,Mayo Clinic,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,22,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single|Primary Purpose: Treatment,70-02|1A4372,Jul-02,Dec-03,Dec-03,13-Jan-06,null,23-May-11,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00276393
NCT00273286,Family Management of Type 1 Diabetes in Children,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Behavioral: family diabetes management intervention,glycemic control|treatment adherence|quality of life,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),All,108 Months to 174 Months   (Child),Phase 2,422,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,FMOD,Jan-06,Mar-09,Mar-09,9-Jan-06,null,13-May-11,"Nemours Children's Clinic, Jacksonville, Florida, United States|Children's Memorial Hospital, Chicago, Illinois, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Texas Children's Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00273286
NCT00272090,Insulin Glargine in Type 1 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Insulin glargine,severe nocturnal hypoglycemias will be measured throughout the study period.|HbA1c will be measured at basal and 8/16 weeks after start of treatment|8 point glucose profile will be measured during last 2 weeks before each scheduled visit|severe hypoglycemias and nocturnal hypoglycemias will be measured throughout the study period.,Sanofi,All,18 Years to 60 Years   (Adult),Phase 3,489,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HOE901_3507,Nov-02,Dec-05,Dec-05,4-Jan-06,null,8-Jun-11,,,https://ClinicalTrials.gov/show/NCT00272090
NCT00271284,Efficacy Study on the Control of Blood Glucose Concentration in Type 1 Diabetic Patients,VARIABILITE,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: insulin glulisine / insulin glargine|Drug: insulin glulisin / insulin detemir,Efficacy data : fasting blood glucose concentration|Tolerance data : undesirable events including episodes of hypoglycaemia,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,88,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HMR1964A_3516|EudraCT #: 2005-002771-32,Oct-05,Sep-08,Sep-08,30-Dec-05,null,7-Dec-09,"Sanofi-Aventis Administrative Office, Paris, France",,https://ClinicalTrials.gov/show/NCT00271284
NCT00268645,Insulin Glargine in Type 2 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Insulin Glargine,"For efficacy: FBG (Fasting Blood Glucose), HbA1c|For safety: ICA (Insulin Cell Antibody)",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 4,534,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HOE901_5036,Sep-04,null,null,22-Dec-05,null,11-Jan-11,"Sanofi-Aventis, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT00268645
NCT00266240,A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus,,Completed,No Results Available,Diabetes Mellitus Type 2,Drug: GK Activator (2)|Drug: Placebo,"HbA1c mean change from baseline, compared to placebo.|Additional parameters of glycemic and lipid control.|AEs, laboratory parameters.|Pharmacokinetic and exposure-response relationship",Hoffmann-La Roche,All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 2,267,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BM18248,Nov-05,May-07,May-07,16-Dec-05,null,2-Nov-16,"Tucson, Arizona, United States|Pine Bluff, Arkansas, United States|Chula Vista, California, United States|Spring Valley, California, United States|West Hills, California, United States|Hollywood, Florida, United States|Atlanta, Georgia, United States|Binghamton, New York, United States|Fayetteville, North Carolina, United States|Statesville, North Carolina, United States|Winston-salem, North Carolina, United States|Springdale, Ohio, United States|Oklahoma City, Oklahoma, United States|Medford, Oregon, United States|Beaver, Pennsylvania, United States|Tipton, Pennsylvania, United States|Mount Pleasant, South Carolina, United States|Plano, Texas, United States|Renton, Washington, United States|Dimitrovgrad, Bulgaria|Pleven, Bulgaria|Ruse, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Zagreb, Croatia|Guatemala City, Guatemala|Budapest, Hungary|Budapest, Hungary|Gyor, Hungary|Kecskemet, Hungary|Chihuahua, Mexico|Cuernavaca, Mexico|Durango, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico-city, Mexico|Bialystok, Poland|Gdansk, Poland|Gorzow, Poland|Krakow, Poland|Wroclaw, Poland",,https://ClinicalTrials.gov/show/NCT00266240
NCT00266253,A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin,,Completed,No Results Available,Diabetes Mellitus Type 2,Drug: GK Activator (2)|Drug: Metformin,"HbA1c mean change from baseline compared with placebo.|Additional parameters of glycemic and lipid control.|AEs, laboratory parameters.|Pharmacokinetic and exposure-response relationship",Hoffmann-La Roche,All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 2,220,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BM18249,Nov-05,Mar-07,Mar-07,16-Dec-05,null,2-Nov-16,"Phoenix, Arizona, United States|Chula Vista, California, United States|Los Angeles, California, United States|Kissimmee, Florida, United States|Tampa, Florida, United States|Lawrenceville, Georgia, United States|Arkansas City, Kansas, United States|Benzonia, Michigan, United States|Springfield, Missouri, United States|Butte, Montana, United States|Kettering, Ohio, United States|Tulsa, Oklahoma, United States|Medford, Oregon, United States|Morrisville, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Memphis, Tennessee, United States|Bellevue, Washington, United States|Federal Way, Washington, United States|Adelaide, Australia|Heidelberg, Australia|Sydney, Australia|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|London, Ontario, Canada|Montreal, Quebec, Canada|Sherbrooke, Quebec, Canada|Bammental, Germany|Berlin, Germany|Essen, Germany|Giessen, Germany|Görlitz, Germany|Hamburg, Germany|Kuenzing, Germany|Mannheim, Germany|Nürnberg, Germany|Tann, Germany|Alzira, Spain|Bacarot Alicant, Spain|Baracaldo, Spain|Barcelona, Spain|Dundee, United Kingdom|Frome, United Kingdom|Glasgow, United Kingdom|Liverpool, United Kingdom|Motherwell, United Kingdom|Northwood, United Kingdom|Plymouth, United Kingdom",,https://ClinicalTrials.gov/show/NCT00266253
NCT00265473,"MGA031, Sirolimus and Tacrolimus in Islet Transplantation",,Completed,Has Results,Type 1 Diabetes Mellitus|Hypoglycemia,Biological: Allogeneic Islets of Langerhans,Subjects With Full Islet Function.|Serious Adverse Events Related to Immunosuppressive Therapy.|Subjects With Partial Islet Function and no Episodes of Severe Hypoglycemia;|Insulin Independent Single-donor Subjects.|Insulin Independent Multiple-donor Subjects.,University of Minnesota - Clinical and Translational Science Institute|National Institutes of Health (NIH)|Juvenile Diabetes Research Foundation,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,5,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0407M62505,Nov-05,May-10,Jun-10,14-Dec-05,21-Sep-11,9-Mar-17,"University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00265473
NCT00260234,Safety and Efficacy of PEG-Encapsulated Islet Allografts Implanted in Type I Diabetic Recipients,,Terminated,No Results Available,"Diabetes Mellitus, Type 1",Biological: Allogeneic Cultured Islet Cells (human); Encapsulated,"Safety - will be evaluated by the incidence, grade, and type of adverse events, changes in laboratory parameters, evaluation of the implant site and physical exams.|Efficacy - will be assessed by:|Blood glucose levels|Daily glycemic excursions|Pre-prandial glucose levels|Post-prandial glucose levels|Glucose responses from OGTT (mg/dL and AUC:glucose|Stimulated C-peptide levels from OGTT (ng/mL and|AUC:C-Peptide|HbA1c (%)|Insulin requirements (units/day)|Arginine stimulation tests|Numbers of hypoglycemic and hyperglycemic episodes|Functional duration - will be determined by stimulated C-peptide from OGTT.","Novocell|Diabetes & Glandular Disease Research Associates, P.A., San Antonio, TX|CHRISTUS Health",All,"20 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,12,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NC-PCIA-04-001|WIRB #20041068,Nov-05,Dec-07,Dec-07,1-Dec-05,null,9-Sep-14,"CHRISTUS Santa Rosa Transplant Institute, San Antonio, Texas, United States|Diabetes & Glandular Disease Research Associates, P.A., San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00260234
NCT00256867,A Study In Patients With Type 2 Diabetes Mellitus,,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: GSK523338,"Median Percent Change From Baseline to Week 6 in LDL-c in FDC and RSG Monotherapy|Mean Change From Baseline to Week 16 in Glycosylated Hemoglobin A1c (HbA1c) in FDC and SIMV Monotherapy|Median Percent Change From Baseline to Week 6 in LDL-c|Mean Change From Baseline to Week 16 in HbA1c|Mean Change From Baseline to Week 16 in Fasting Plasma Glucose (FPG)|Number of Participant With LDL<100 mg/dL (2.59 mmol/L) at Week 6|Number of Participants With HbA1c < 7.0% or Reduction of HbA1c ≥ 0.7% at Week 16|Number of Participants With FPG< 126 mg/dL (7.0 mmol/L) or Reduction of FPG ≥ 30 mg/dL (1.67 mmol/L) at Week 16|On-Therapy Vital Signs of Potential Clinical Concern Including Systolic, Diastolic Blood Pressure and Heart Rate|On-Therapy Change From Baseline in Body Weight|Number of Participants With Specified Ranges of Red and White Blood Cell Counts Detected in Urine|Number of Participants With Any Adverse Event (AE) and Serious Adverse Event (SAE)|Number of of Participants With Laboratory Evaluations of Potential Clinical Concern at Any Time Post-baseline",GlaxoSmithKline,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,369,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,AVS101946,18-Aug-05,31-Oct-06,31-Oct-06,22-Nov-05,23-Mar-18,2-Jul-18,"GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Wheat Ridge, Colorado, United States|GSK Investigational Site, Waterbury, Connecticut, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Saint Cloud, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Melrose Park, Illinois, United States|GSK Investigational Site, Springfield, Illinois, United States|GSK Investigational Site, Avon, Indiana, United States|GSK Investigational Site, Elkhart, Indiana, United States|GSK Investigational Site, Sunset, Louisiana, United States|GSK Investigational Site, Waltham, Massachusetts, United States|GSK Investigational Site, Saint Peters, Missouri, United States|GSK Investigational Site, Billings, Montana, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Jamaica, New York, United States|GSK Investigational Site, Rochester, New York, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Bend, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Tualatin, Oregon, United States|GSK Investigational Site, Beaver, Pennsylvania, United States|GSK Investigational Site, Fleetwood, Pennsylvania, United States|GSK Investigational Site, Jefferson Hills, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Clinton, South Carolina, United States|GSK Investigational Site, Columbia, South Carolina, United States|GSK Investigational Site, Kingsport, Tennessee, United States|GSK Investigational Site, Bryan, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Georgetown, Texas, United States|GSK Investigational Site, Midland, Texas, United States|GSK Investigational Site, Plano, Texas, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Burke, Virginia, United States|GSK Investigational Site, Manassas, Virginia, United States|GSK Investigational Site, Bellevue, Washington, United States|GSK Investigational Site, Spokane, Washington, United States|GSK Investigational Site, Vancouver, Washington, United States|GSK Investigational Site, Wollongong, New South Wales, Australia|GSK Investigational Site, Kippa Ring, Queensland, Australia|GSK Investigational Site, Adelaide, South Australia, Australia|GSK Investigational Site, Keswick, South Australia, Australia|GSK Investigational Site, Port Lincoln, South Australia, Australia|GSK Investigational Site, Box Hill, Victoria, Australia|GSK Investigational Site, Heidelberg West, Victoria, Australia|GSK Investigational Site, Ringwood East, Victoria, Australia|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Coquitlam, British Columbia, Canada|GSK Investigational Site, Moncton, New Brunswick, Canada|GSK Investigational Site, Mount Pearl, Newfoundland and Labrador, Canada|GSK Investigational Site, Halifax, Nova Scotia, Canada|GSK Investigational Site, Truro, Nova Scotia, Canada|GSK Investigational Site, Brampton, Ontario, Canada|GSK Investigational Site, Hamilton, Ontario, Canada|GSK Investigational Site, North Bay, Ontario, Canada|GSK Investigational Site, Sudbury, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Woodstock, Ontario, Canada|GSK Investigational Site, Bonaventure, Quebec, Canada|GSK Investigational Site, Gatineau, Quebec, Canada|GSK Investigational Site, Granby, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Plessisville, Quebec, Canada|GSK Investigational Site, Pointe-Claire, Quebec, Canada|GSK Investigational Site, Saint Marc Des Carrieres, Quebec, Canada|GSK Investigational Site, Sainte-Foy, Quebec, Canada|GSK Investigational Site, Sainte-Foy, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Saskatoon, Saskatchewan, Canada|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Cuernavaca, Morelos, Mexico|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, Mexico, Mexico|GSK Investigational Site, Manila, Philippines|GSK Investigational Site, Quezon City, Philippines|GSK Investigational Site, Quezon City, Philippines|GSK Investigational Site, Carolina, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00256867
NCT00256256,The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men,,Completed,No Results Available,Type 2 Diabetes|Stroke|Myocardial Infarction,Drug: glucagon-like-peptide-1,FDG-uptake in the brain and heart visualized by Positron emission tomography with and without GLP-1|Laboratory values (insulin secretion and counter-regulatory hormones),University of Aarhus,Male,20 Years to 50 Years   (Adult),Not Applicable,10,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",2005-0079,Nov-05,null,Jan-07,21-Nov-05,null,30-Oct-07,"Department of pharmacology, Aarhus university, Aarhus, Denmark",,https://ClinicalTrials.gov/show/NCT00256256
NCT00254501,Empowering Patients to Better Manage Diabetes Through Self-Care,,Completed,Has Results,Type I or Type II Diabetes (Excludes Gestational Diabetes),Behavioral: Pharmacist Counseling|Behavioral: Educational materials,"Change in Hemoglobin A-1C From Baseline|Changes From Baseline in LDL, HDL, Total Cholesterol, Triglycerides|Changes in Economic Outcomes (Total Cost of Care, Cost of Diabetes Medications, Cost of Diabetes Supplies) From Baseline to 12 Months|Change in Diabetes Knowledge and Empowerment (Patient Self-efficacy) From Baseline to 12 Months",Oregon State University|Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,69,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,OSU_COP_PP_0105|IRB Application 2979,Nov-05,Jun-11,Jun-11,16-Nov-05,22-Jul-16,22-Jul-16,,,https://ClinicalTrials.gov/show/NCT00254501
NCT00252720,DIabetic Retinopathy Candesartan Trials.,DIRECT,Completed,Has Results,Type 1 Diabetes,Drug: candesartan,Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale|Number of Participants With a Regression of Diabetic Retinopathy.|Number of Participants With Incident Clinically Significant Macular Edema (CSME) and/or Proliferative Diabetic Retinopathy (PDR).|Rate of Change in Urinary Albumin Excretion Rate (UAER).,AstraZeneca|Takeda,All,18 Years to 55 Years   (Adult),Phase 3,1850,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D2453C00046|DIRECT|SH-AHM-0046,Aug-01,Feb-08,Apr-08,15-Nov-05,3-Jun-14,3-Jun-14,,,https://ClinicalTrials.gov/show/NCT00252720
NCT00252733,Diabetic Retinopathy Candesartan Trials,DIRECT,Completed,Has Results,Type 1 Diabetes,Drug: candesartan cilexetil,Number of Participants With a 2-step or Greater Increase in Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Scale.|Rate of Change in Urinary Albumin Excretion Rate (UAER).,AstraZeneca|Takeda,All,18 Years to 50 Years   (Adult),Phase 3,5238,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D2453C00045|DIRECT|SH-AHM-0045,Jun-01,Apr-08,Apr-08,15-Nov-05,13-Apr-12,14-May-14,"Research Site, Herston, Australia|Research Site, Perth, Australia|Research Site, Odense, Denmark",,https://ClinicalTrials.gov/show/NCT00252733
NCT00252876,GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes,,Terminated,No Results Available,Type 2 Diabetes,Drug: tesaglitazar,"Adverse events, laboratory variables, physical examination, cardiac evaluation, hypoglycemic events, electrocardiogram, vital signs (blood pressure and pulse), body weight|Pharmacodynamic: fasting plasma glucose, glycosylated hemoglobin A1c, lipid variables (triglyceride, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and non-high-density lipoprotein cholesterol)|Responder rates and proportion of patients on tesaglitazar who reach pre-specified target levels for triglyceride, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and non-high-density lipoprotein cholesterol|C-reactive protein|Central obesity (waist circumference, hip circumference, waist/hip ratio)",AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2000,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D6160C00038|GALLEX 1,Mar-05,null,Jan-07,15-Nov-05,null,17-Mar-08,"Research Site, Birmingham, Alabama, United States|Research Site, Columbiana, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Carlisle, Arkansas, United States|Research Site, Sherwood, Arkansas, United States|Research Site, Chula Vista, California, United States|Research Site, Escondido, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Mission Viejo, California, United States|Research Site, Orange, California, United States|Research Site, Pasadena, California, United States|Research Site, Redondo Beach, California, United States|Research Site, Sacramento, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Wheat Ridge, Colorado, United States|Research Site, Clearwater, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Brunswick, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Boise, Idaho, United States|Research Site, Evansville, Indiana, United States|Research Site, Witchita, Kansas, United States|Research Site, Bossier City, Louisiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Pahrump, Nevada, United States|Research Site, Hamilton, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Bronx, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, White Plains, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Kettering, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Medford, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Simpsonville, South Carolina, United States|Research Site, Morristown, Tennessee, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Burke, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Tacoma, Washington, United States|Research Site, Menomonee Falls, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Moron, Buenos Aires, Argentina|Research Site, Quilmes, Buenos Aires, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Córdoba, Argentina|Research Site, Rosario, Argentina|Research Site, Salta - Salta, Argentina|Research Site, Adelaide, Australia|Research Site, Brisbane, Australia|Research Site, Cairns, Australia|Research Site, Geelong, Australia|Research Site, Melbourne, Australia|Research Site, Perth, Australia|Research Site, Sydney, Australia|Research Site, Tasmania, Australia|Research Site, Curitiba, Brazil|Research Site, Fortaleza, Brazil|Research Site, Goiânia, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Coquitlam, British Columbia, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Bay Roberts, Newfoundland and Labrador, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Bolton, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Hastings, Ontario, Canada|Research Site, Kingston, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Napanee, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Smith Falls, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chomedey-Laval, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montréal, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Brno, Czech Republic|Research Site, Hodonin, Czech Republic|Research Site, Hradec Kralove, Czech Republic|Research Site, Plzen, Czech Republic|Research Site, Praha 5, Czech Republic|Research Site, Pribram, Czech Republic|Research Site, Semily, Czech Republic|Research Site, Tabor, Czech Republic|Research Site, Usti nad Labem, Czech Republic|Research Site, Paide, Estonia|Research Site, Pärnu, Estonia|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Viljandi, Estonia|Research Site, Helsinki, Finland|Research Site, Hämeenlinna, Finland|Research Site, Imatra, Finland|Research Site, Joensuu, Finland|Research Site, Kokkola, Finland|Research Site, Kouvola, Finland|Research Site, Kuopio, Finland|Research Site, Lahti, Finland|Research Site, Mikkeli, Finland|Research Site, Oulu, Finland|Research Site, Pietarsaari, Finland|Research Site, Salo, Finland|Research Site, Seinajoki, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, Vaasa, Finland|Research Site, Vantaa, Finland|Research Site, Belgrade, Former Serbia and Montenegro|Research Site, Athens, Greece|Research Site, Piraeus, Greece|Research Site, Hong Kong, Hong Kong|Research Site, Balatonfüred, Hungary|Research Site, Budapest, Hungary|Research Site, Győr, Hungary|Research Site, Kaposvár, Hungary|Research Site, Kecskemét, Hungary|Research Site, Miskolc, Hungary|Research Site, Siófok, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Bangalore, India|Research Site, Hyderabad, India|Research Site, Mumbai, India|Research Site, New Delhi, India|Research Site, Jakarta, Indonesia|Research Site, Malang, Indonesia|Research Site, Ashkelon, Israel|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Jerusalem, Israel|Research Site, Rishon-Lezion, Israel|Research Site, Tel Aviv, Israel|Research Site, Tel Hashomer, Israel|Research Site, Zefat, Israel|Research Site, Arenzano, Italy|Research Site, Chiavari (GE), Italy|Research Site, Chieri, Italy|Research Site, Firenze, Italy|Research Site, Messina, Italy|Research Site, Milano, Italy|Research Site, Monteccio Emilia, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Pescara, Italy|Research Site, Piacenza, Italy|Research Site, Pistoia, Italy|Research Site, Reggio Calabria, Italy|Research Site, Reggio Emilia, Italy|Research Site, Roma, Italy|Research Site, Scandiano, Italy|Research Site, Udine, Italy|Research Site, Seoul, Korea, Republic of|Research Site, Suwon, Korea, Republic of|Research Site, Daugavpils, Latvia|Research Site, Jekabpils, Latvia|Research Site, Madona, Latvia|Research Site, Riga, Latvia|Research Site, SIgulda, Latvia|Research Site, Talsi, Latvia|Research Site, Valmiera, Latvia|Research Site, Vilnius, Lithuania|Research Site, Kubang Kerian, Kota Bharu, Malaysia|Research Site, Kuala Lumpur, Malaysia|Research Site, Penang, Malaysia|Research Site, Beek en Donk, Netherlands|Research Site, Bennebroek, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Deurne, Netherlands|Research Site, Huizen, Netherlands|Research Site, Losser, Netherlands|Research Site, Nijverdal, Netherlands|Research Site, Rijswijk, Netherlands|Research Site, Roelofarendsveen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Cebu City, Philippines|Research Site, Makati, Philippines|Research Site, Manila, Philippines|Research Site, Marikina City, Philippines|Research Site, Pasig City, Philippines|Research Site, Quezon City, Philippines|Research Site, Katowice, Ochojec, Poland|Research Site, Bialystok, Poland|Research Site, Bydgoszcz, Poland|Research Site, Gdansk, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Olsztyn, Poland|Research Site, Poznan, Poland|Research Site, Radom, Poland|Research Site, Rzeszow, Poland|Research Site, Sopot, Poland|Research Site, Szczecin, Poland|Research Site, Toruñ, Poland|Research Site, Tychy, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Zielona Gora, Poland|Research Site, Almada, Portugal|Research Site, Amadora, Portugal|Research Site, Elvas, Portugal|Research Site, Lisbon, Portugal|Research Site, Portalegre, Portugal|Research Site, Moscow, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Singapore, Singapore|Research Site, Dolny Kubin, Slovakia|Research Site, Levice, Slovakia|Research Site, Lubochna, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Povazska Bystrica, Slovakia|Research Site, Sahy, Slovakia|Research Site, Trencin, Slovakia|Research Site, Velky Meder, Slovakia|Research Site, Zilina, Slovakia|Research Site, Cape Town, South Africa|Research Site, Chatsworth, South Africa|Research Site, Durban, South Africa|Research Site, Gauteng, South Africa|Research Site, Johannesburg, South Africa|Research Site, Pretoria, South Africa|Research Site, Bern, Switzerland|Research Site, Ilanz, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Monthey, Switzerland|Research Site, Zürich, Switzerland|Research Site, Aberdeen, United Kingdom|Research Site, Atherstone, United Kingdom|Research Site, Ayr, United Kingdom|Research Site, Bath, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Berks, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Bolton, United Kingdom|Research Site, Bucks, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Northampton, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Radstock, United Kingdom|Research Site, Shrewsbury, United Kingdom|Research Site, Surrey, United Kingdom|Research Site, West Bromwich, United Kingdom|Research Site, Wiltshire, United Kingdom|Research Site, Wrexham, United Kingdom|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam",,https://ClinicalTrials.gov/show/NCT00252876
NCT00239148,A Study in Type 1 Diabetic Patients With Repeated Doses of E1 in Combination With G1,,Completed,No Results Available,Type 1 Diabetes,Drug: E1 and G1,To evaluate the safety and tolerability of repeated subcutaneous doses of E1 in combination with G1 in patients with type 1 diabetes|To evaluate the pharmacokinetic (PK) profile and clinical effects of repeated subcutaneous doses of E1 in combination with G1 in patients with type 1 diabetes,Transition Therapeutics,All,18 Years to 40 Years   (Adult),Phase 1,20,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,INT-201,Jun-05,null,Dec-06,14-Oct-05,null,27-May-09,"Pinnacle Research Group, Anniston, Alabama, United States|Diablo Clinical Research, Walnut Creek, California, United States|Diabetes - Endocrinology Center of West New York, Buffalo, New York, United States|Highgate Specialty Center, Durham, North Carolina, United States|Diabetes and Glandular Disease Research Associates, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00239148
NCT00239187,A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1,,Completed,No Results Available,Type 2 Diabetes,Drug: E1 and G1,To assess the safety and tolerability of repeated subcutaneous doses of E1 in combination with G1 in patients with type 2 diabetes|To evaluate the pharmacokinetics (PK) profile and clinical effects of repeated subcutaneous doses of E1 in combination with G1 in patients with type 2 diabetes,Transition Therapeutics,All,30 Years to 60 Years   (Adult),Phase 1,30,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,INT-202,Sep-05,null,Jan-07,14-Oct-05,null,21-Jul-08,"Profil Institute for Clinical Research Inc., Chula Vista, California, United States|Clinical Research of West Florida, Clearwater, Florida, United States|Diabetes and Glandular Disease Research Associates, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00239187
NCT00238498,A Clinical Study to Assess the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: vildagliptin,Change from baseline in HbA1c at 12 weeks|Change from baseline for postprandial glucose at 12 weeks|Change from baseline on fasting plasma glucose at 12 weeks|Change from baseline on postprandial glucose AUC at 12 weeks|Change from baseline in HOMA B at 12 weeks|Change from baseline in HOMA IR at 12 weeks,Novartis,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 2,291,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CLAF237A1202,Jul-04,Jun-05,Jun-05,13-Oct-05,null,2-May-12,,,https://ClinicalTrials.gov/show/NCT00238498
NCT00228878,Effect Pulsatile IV Insulin Therapy on the Quality of Life in Patients With Types 1 and 2 Diabetes,,Terminated,No Results Available,Diabetes Mellitus,Procedure: Effects of Pulsatile IV insulin on Diabetic Quality of Life,Researchers will assess whether pulsatile IV insulin therapy can successfully reverse the abnormal underlying metabolism in diabetic patients to the point of improving their quality of life.,Florida Atlantic University|Advanced Diabetes Treatment Centers,All,"21 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,152,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H09-66-QOL,Mar-03,Aug-09,Aug-09,29-Sep-05,null,10-Aug-16,"Florida Atlantic University, Boca Raton, Florida, United States",,https://ClinicalTrials.gov/show/NCT00228878
NCT00228891,Effects of Pulsatile Insulin Delivery on Diabetic Neuropathy in Patients With Types 1 and 2 Diabetes Mellitus,,Terminated,No Results Available,"Diabetes Mellitus, With Complications",Procedure: Effect of Pulsatile IV insulin on diabetic neuropathy|Procedure: Effect of Pulsatile IV Insulin on diabetic neuropathy,Measure the stabilization or reduction of the decline of diabetic neuropathy by pt questionnaires and diagnostic tests,Florida Atlantic University|Advanced Diabetes Treatment Centers|Global Infusions,All,"20 Years to 90 Years   (Adult, Older Adult)",Phase 2|Phase 3,152,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,H09-66 NEU1|MH42900 and MH01386,Feb-04,Aug-09,Aug-09,29-Sep-05,null,10-Aug-16,"Florida Atlantic University Center for Complex Systems and Brain Sciences, Boca Raton, Florida, United States",,https://ClinicalTrials.gov/show/NCT00228891
NCT00228904,Effects of Pulsatile Intravenous Insulin Delivery on Diabetic Neuropathy in pATIENTS (Pts) With Type 1 and Type 2 Diabetes,,Withdrawn,No Results Available,Diabetic Neuropathy,"Procedure: Placebo|Procedure: Pulsatile IV insulin delivery (humalog, humulin, novolog)","To evaluate objective testing performed including nerve conduction velocity in diabetic patients treated with pulsatile intravenous insulin therapy|To obtain patient questionnaires and perform objective testing to analyze, compare and measure progress",Florida Atlantic University|Advanced Diabetes Treatment Centers|Global Infusions,All,"20 Years to 90 Years   (Adult, Older Adult)",Phase 2|Phase 3,0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,H09-66 NEU2|MH42900 and MH01386,Feb-05,May-11,Oct-11,29-Sep-05,null,10-Aug-16,"Florida Atlantic University Center for Complex Systems and Brain Sciences, Boca Raton, Florida, United States",,https://ClinicalTrials.gov/show/NCT00228904
NCT00226330,GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus,,Terminated,No Results Available,"Diabetes Mellitus, Type 2",Drug: Tesaglitazar|Drug: Pioglitazone,"Adverse events|Laboratory variables|Physical examination|Cardiac evaluation|Hypoglycemic events|Electrocardiogram|Vital signs (blood pressure and pulse)|Body weight|Pharmacodynamic: fasting plasma glucose, glycosylated hemoglobin A1c|Lipid variables (triglyceride, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol [HDL-C], and non-HDL-C)|Responder rates and proportion of patients on tesaglitazar who reach pre-specified target levels for triglyceride, total cholesterol, low-density lipoprotein cholesterol, HDL-C and non-HDL-C|C-reactive protein (CRP)|Central obesity (waist circumference, hip circumference, waist/hip ratio)|Patient reported outcomes using the Medical Outcomes Study Short Form-36 (SF-36)",AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,D6160C00048,Mar-05,Dec-06,Dec-06,27-Sep-05,null,19-Nov-10,"Research Site, Birmingham, Alabama, United States|Research Site, Columbiana, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Chandler, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Sierra Vista, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Jonesboro, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Searcy, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Carmichael, California, United States|Research Site, Dinuba, California, United States|Research Site, Elk Grove, California, United States|Research Site, Encinitas, California, United States|Research Site, Encino, California, United States|Research Site, Fresno, California, United States|Research Site, Greenbrae, California, United States|Research Site, Loma Linda, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Mission Viejo, California, United States|Research Site, Northridge, California, United States|Research Site, Pasadena, California, United States|Research Site, Redondo Beach, California, United States|Research Site, Riverside, California, United States|Research Site, Sacramento, California, United States|Research Site, Santa Ana, California, United States|Research Site, Santa Monica, California, United States|Research Site, Spring Valley, California, United States|Research Site, Tustin, California, United States|Research Site, Walnut Creek, California, United States|Research Site, West Hills, California, United States|Research Site, Newark, Delaware, United States|Research Site, Washington, District of Columbia, United States|Research Site, Brandon, Florida, United States|Research Site, Cooper City, Florida, United States|Research Site, Delray Beach, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ocoee, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Plantation, Florida, United States|Research Site, W. Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Dunwoody, Georgia, United States|Research Site, Berwyn, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Elk Grove Village, Illinois, United States|Research Site, Gurnee, Illinois, United States|Research Site, Melrose Park, Illinois, United States|Research Site, North Chicago, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Sterling, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Des Moines, Iowa, United States|Research Site, Waterloo, Iowa, United States|Research Site, Topeka, Kansas, United States|Research Site, Witchita, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, Petoskey, Michigan, United States|Research Site, Excelsior Springs, Missouri, United States|Research Site, Richmond Heights, Missouri, United States|Research Site, Rolla, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, North Las Vegas, Nevada, United States|Research Site, Pahrump, Nevada, United States|Research Site, Reno, Nevada, United States|Research Site, Pleasantville, New Jersey, United States|Research Site, Manlius, New York, United States|Research Site, New York, New York, United States|Research Site, Olean, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Lakewood, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Medford, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Altoona, Pennsylvania, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Reading, Pennsylvania, United States|Research Site, Warminster, Pennsylvania, United States|Research Site, West Chester, Pennsylvania, United States|Research Site, Columbia, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Carrollton, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, North Richland Hills, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Norfolk, Virginia, United States|Research Site, Virginia Beach, Virginia, United States|Research Site, Gig Harbor, Washington, United States|Research Site, Huntington, West Virginia, United States|Research Site, Moron, Buenos Aires, Argentina|Research Site, Quilmes, Buenos Aires, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Córdoba - Córdoba, Argentina|Research Site, Rosario, Argentina|Research Site, Salta - Salta, Argentina|Research Site, Curitiba, Brazil|Research Site, Fortaleza, Brazil|Research Site, Goiânia, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, Edmonton, Alberta, Canada|Research Site, Abbotsford, British Columbia, Canada|Research Site, Chilliwack, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Dartmouth, Nova Scotia, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Truro, Nova Scotia, Canada|Research Site, Windsor, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Etobicoke, Ontario, Canada|Research Site, Kingston, Ontario, Canada|Research Site, Niagara Falls, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, St. Catharines, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Longueuil, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Trois-Rivières, Quebec, Canada|Research Site, Helsinki, Finland|Research Site, Kauniainen, Finland|Research Site, Kuopio, Finland|Research Site, Pietarsaari, Finland|Research Site, Pori, Finland|Research Site, Tampere, Finland|Research Site, Guadalajara, Jalisco., Mexico|Research Site, México, D.F., Mexico|Research Site, Nuevo León, Monterrey, Mexico|Research Site, Puebla, Mexico, Mexico|Research Site, Torreon, Mexico|Research Site, Zapopan, Mexico|Research Site, Belfast, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Co Antrim N Ireland, United Kingdom|Research Site, Co. Wexford, Ireland, United Kingdom|Research Site, Dublin, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Kent, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, Mid Glamorgan, United Kingdom|Research Site, Pembrokeshire, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Reading, United Kingdom|Research Site, Surrey, United Kingdom|Research Site, Wiltshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT00226330
NCT00226902,Vascular Reactivity in Kidney Disease Patients,,Completed,No Results Available,"Kidney Failure, Chronic|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Procedure: Changing hemoglobin concentration,Change in pulse wave velocity at the three different haemoglobin levels,Melbourne Health,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Interactedd,Sep-06,Aug-13,Sep-13,27-Sep-05,null,5-May-15,"The Royal Melbourne Hospital, Melbourne, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT00226902
NCT00214786,Pancreatic Islet Cell Transplantation,,Completed,Has Results,Type 1 Diabetes,Biological: Islet cell transplantation,Achievement of Insulin Independence at 12-month Post Transplant|Presence or Absence of Hypoglycemic Unawareness|Incidence of Hypoglycemic Episodes|Change of Insulin Requirements in Patients Who Did Not Become Insulin Independent|Islet Cell Mass Obtained After Remote Site Processing|The Number of Islet Cell Infusions Needed to Achieve Insulin Independence|Renal Function|Morbidity Related to the Immunosuppression Regimen|Morbidity Related to the Islet Cell Infusion|The Quality of Life of the Recipients Measured With the RAND 36-item Short Form Health Survey,Baylor Research Institute|Baylor Health Care System|University of Miami,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,4,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,003-040,Apr-05,Jul-07,Jul-07,22-Sep-05,6-Jun-14,14-Jun-17,"Baylor Regional Transplant Institute - Baylor University Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00214786
NCT00206258,The Role of Amylin and Glucagon in T1DM,,Completed,No Results Available,Type 1 Diabetes,Drug: Pramlintide and glucagon,Area under the curve for glucose|Glucagon and gastric emptying,Baylor College of Medicine,All,"12 Years to 21 Years   (Child, Adult)",Phase 3,30,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-11741,Jul-02,null,Aug-05,21-Sep-05,null,14-Jul-16,"Baylor College of Medicine, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00206258
NCT00206297,The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes,,Completed,No Results Available,Type 1 Diabetes,Drug: Pramlintide,Area under the curve for glucose|glucagon and gastric emptying,Baylor College of Medicine,All,"12 Years to 21 Years   (Child, Adult)",Phase 3,20,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-14358,Oct-03,null,Feb-06,21-Sep-05,null,14-Jul-16,"Baylor College of Medicine, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00206297
NCT00206401,Lantus in the Treatment of Type 1 Diabetes Children,,Completed,No Results Available,Type 1 Diabetes,Drug: Lantus and short acting analogs Vs NPH and short acting analogs,HbA1C|Glucose excursions,Baylor College of Medicine,All,"6 Years to 25 Years   (Child, Adult)",Phase 4,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16559,Nov-04,null,Oct-06,21-Sep-05,null,14-Jul-16,"Texas Children's Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00206401
NCT00211510,Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes,STAR1,Completed,Has Results,Type 1 Diabetes,Device: Paradigm 722 sensor augmented pump|Device: Paradigm 715 insulin pump,Change in A1c From Baseline to 26 Weeks|Difference in Frequency of Severe Hypoglycemia From Baseline to Week 26|Changes in Hypoglycemia Area Under the Curve (AUC) From Baseline to Week 26|Changes in Hyperglycemia Area Under the Curve (AUC) From Baseline to Week 26|Glucose Sensor Accuracy as Measured in the 722 Group|Problem Areas in Diabetes (PAID) Questionnaire Assessed and Compared Between Groups,Medtronic Diabetes,All,"12 Years to 80 Years   (Child, Adult, Older Adult)",Not Applicable,146,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CEP 178/Z25/A2,Jun-05,Aug-06,Feb-07,21-Sep-05,29-Apr-11,12-Jun-17,"Children's Hospital of Los Angeles, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|The Endocrine Group, Albany, New York, United States|Diabetes and Glandular Diabetes Research Associates, San Antonio, Texas, United States|University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00211510
NCT00211536,Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration,MIP310,Completed,Has Results,Type 1 Diabetes,Drug: Medtronic MiniMed Implantable Pump Human Recombinant Insulin|Device: Medtronic MiniMed Implantable Pump System|Drug: Aventis HOE21PH U400,Change in HbA1c and Compared Between Groups|Incidence of Severe Hypoglycemia Events|Average Daily Blood Glucose|Mean Amplitude of Glycemic Excursions (MAGE)|Low Blood Glucose Index (LBGI);,Medtronic Diabetes,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,107,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CE-025A6,Jun-02,Aug-04,Sep-08,21-Sep-05,23-Jun-11,21-Sep-11,"Sansum Medical Research Institute, Santa Barbara, California, United States|University of Colorado Health Sciences Center, Aurora, Colorado, United States|Hellman & Rosen Endocrine Associates, North Kansas City, Missouri, United States|Cleveland Clinic, Wooser, Ohio, United States|Diabetes & Glandular Disease Clinic, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00211536
NCT00214214,A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody) Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus,,Withdrawn,No Results Available,New Onset Type 1 Diabetes Mellitus,Drug: Campath 1H® (Alemtuzumab),to determine if Campath-1H can be used in patients recently diagnosed with type I DM|to determine if Campath-1H can eliminate or lower insulin requirements,"University of Wisconsin, Madison",All,18 Years to 35 Years   (Adult),Phase 1,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),H-2003-0405,Oct-05,null,null,21-Sep-05,null,8-Oct-15,"University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00214214
NCT00214253,Islet Transplantation in Type 1 Diabetic Patients,,Completed,No Results Available,Type 1 Diabetes,Drug: Thiazolidinedione,number of islets necessary to achieve adequate metabolic control|post-transplant islet function|Suitability of cadaver donor pancreases for islet transplantation,"University of Wisconsin, Madison",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,14,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2001-529,Feb-02,Oct-11,Oct-11,21-Sep-05,null,31-Mar-17,"University of Wisconsin, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00214253
NCT00198146,Prevention of Diabetes Progression Trial (PDPT),,Completed,No Results Available,Newly Diagnosed With Type 1 Diabetes,Drug: Zenapax,"Area under the curve, Glucagon Stimulation Testing for c-peptide measurements at 0, +6min and +10min intervals over 2 years|HbA1c|Insulin requirements (units/kg/day)","Indiana University School of Medicine|Pescovitz, Mark D., M.D.|Hoffmann-La Roche|Facet Biotech|Indiana University",All,"2 Years to 40 Years   (Child, Adult)",Phase 2,40,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9910-34,Jul-00,null,null,20-Sep-05,null,26-Oct-05,"Indiana University - Riley Hospital for Children, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT00198146
NCT00190502,Polyclonal Anti-T-Lymphocyte Globulin (ATG) in Type 1 Diabetes,,Unknown status,No Results Available,"Diabetes Mellitus, Type 1",Drug: Polyclonal anti-T-cell antibodies,C-peptide production|Diabetes remission rate|Insulin dose,"Institute for Clinical and Experimental Medicine|Ministry of Health, Czech Republic",All,"15 Years to 35 Years   (Child, Adult)",Not Applicable,28,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Educational/Counseling/Training,KD CD IKEM 1|NB/6541-3 IGA MZCR,Nov-00,null,Dec-07,19-Sep-05,null,9-Jan-07,"Institute for Clinical and Experimental Medicine, Department of Diabetes, Prague, Czech Republic",,https://ClinicalTrials.gov/show/NCT00190502
NCT00191581,Local Registration Trial in China Humalog Mix 50,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Drug: Humalog Mix 50|Drug: Human Insulin Mix 50:50,"The primary objective of this study is to compare the 2-hour PPBG excursion following a standard test meal in IDDM patients treated BID with human insulin mix 50/50, vs the 2-hour PPBG excursion in patients treated BID with insulin lispro mix 50/50|The secondary objectives of the study are:|Assess hemoglobin A1c (HbA1c) values at baseline and after treatment with insulin lispro mix 50/50.|Assess HbA1c values at baseline and after treatment with human insulin mix 50/50.|To compare human insulin mix 50/50 with insulin lispro mix 50/50 with regard to|Effects on HbA1c values obtained at the end of each treatment period;|Effects on fasting blood glucose values obtained throughout the study;",Eli Lilly and Company,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,120,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9537|F3Z-MC-IOOR,Mar-05,null,Apr-06,19-Sep-05,null,31-Jul-06,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Guangzhou, China",,https://ClinicalTrials.gov/show/NCT00191581
NCT00194558,Outcomes and Cost Consequences of Using an Internet Co-Management Module to Improve the Quality of Type 1 Diabetes Care,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Behavioral: Internet co-management module,Hemoglobin A1c|Utilization|Satisfaction with care,University of Washington|Aventis Pharmaceuticals,All,18 Years to 39 Years   (Adult),Not Applicable,82,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),04-3892-G-01,Feb-05,null,null,19-Sep-05,null,2-Oct-08,"University of Washington, Diabetes Care Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00194558
NCT00179777,TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk,,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 1",Dietary Supplement: hydrolysed infant formula|Dietary Supplement: nonhydrolysed infant formula,"Type 1 diabetes mellitus assessed by (1) blood glucose and HbA1c at 12 and 18 months of age, and annually from age 2 to 10 years, and (2) oral glucose tolerance test at 6 and 10 years of age.|Diabetes associated islet antibodies (ICA, IAA, GADA, IA-2A) at 3, 6, 9, 12 and 18 months of age, and annually from age 2 to 10 years","Children's Hospital of Eastern Ontario|US Congress|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Canadian Institutes of Health Research (CIHR)|Juvenile Diabetes Research Foundation|European Foundation for the Study of Diabetes|European Community (EC)|Mead Johnson Nutrition|Diabetes Research Foundation, Finland|Academy of Finland|Dutch Diabetes Research Foundation",All,up to 7 Days   (Child),Not Applicable,2032,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",MCT-49395|U01HD040364|U01HD042444,Mar-02,Mar-17,Sep-17,16-Sep-05,null,14-Jul-17,"University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Children's Hospital at Westmead, Westmead, New South Wales, Australia|Robarts Research Institute, London, Canada|3rd Faculty of Medicine, Charles University, University Hospital Vinohrady, Prague, Czechia|Tartu University Children's Hospital, Tartu, Estonia|University of Helsinki, Helsinki, Finland|Kinderkrankenhaus auf der Bult, Hannover, Germany|Semmelweis Medical University, Budapest, Hungary|St. Michele Hospital, Cagliari, Sardinia, Italy|University Campus Bio-Medico of Rome, Rome, Italy|Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg|Sophia Children's Hospital, Rotterdam, Netherlands|Medical University of Wroclaw, Wroclaw, Poland|Hospital de Cruces, Barakaldo, Vizcaya, Spain|Hospital Clinico San Carlos, Madrid, Spain|University of Linkoping, Linkoping, Sweden|University Children's Hospital, Zurich, Switzerland",,https://ClinicalTrials.gov/show/NCT00179777
NCT00184561,Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 2",Drug: biphasic insulin aspart,Change in HbA1c|Adverse events|Weight change|Fasting blood glucose|Hypoglycaemic episodes|2-hour postprandial blood glucose|after 24 weeks of treatment.,Novo Nordisk A/S,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,321,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BIASP-1707,Jul-05,Jul-06,Jul-06,16-Sep-05,null,6-Jan-17,"Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Guangzhou, Guangdong, China|Novo Nordisk Investigational Site, Wuhan, Hubei, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Xi'an, Shaanxi, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Tianjin, Tianjin, China",,https://ClinicalTrials.gov/show/NCT00184561
NCT00184639,Comparison of Insulin Detemir and Insulin Semilente®MC in Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin detemir,Fasting plasma glucose|Adverse events|HbA1c results at the end of each treatment period|Blood glucose|Standard Laboratory Safety Parameters|Hypoglycaemia,Novo Nordisk A/S,All,"12 Years to 18 Years   (Child, Adult)",Phase 3,71,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN304-1630,16-Aug-04,22-Nov-05,22-Nov-05,16-Sep-05,null,24-Feb-17,"Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Hannover, Germany",,https://ClinicalTrials.gov/show/NCT00184639
NCT00184665,Comparison of Insulin Detemir With NPH Insulin in Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin detemir|Drug: insulin NPH|Drug: insulin aspart,HbA1c|Adverse events|Body weight|Antibodies|Body composition|Blood glucose|Hypoglycaemia,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,501,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN304-1595,Jun-04,Sep-06,Sep-06,16-Sep-05,null,27-Jan-17,"Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Ciudad Autonoma de Bs As, Argentina|Novo Nordisk Investigational Site, Ciudad Autónoma de BsAs, Argentina|Novo Nordisk Investigational Site, Mar del Plata, Argentina|Novo Nordisk Investigational Site, St Leonards, New South Wales, Australia|Novo Nordisk Investigational Site, Hobart, Tasmania, Australia|Novo Nordisk Investigational Site, Melbourne, Victoria, Australia|Novo Nordisk Investigational Site, Darlinghurst, Australia|Novo Nordisk Investigational Site, Melbourne, Australia|Novo Nordisk Investigational Site, Stones Corner, Australia|Novo Nordisk Investigational Site, Woodville, Australia|Novo Nordisk Investigational Site, Plovdiv, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Vellore, Tamil Nadu, India|Novo Nordisk Investigational Site, Chennai, India|Novo Nordisk Investigational Site, Hyderabad, India|Novo Nordisk Investigational Site, Mumbai, India|Novo Nordisk Investigational Site, Skopje, Macedonia, The Former Yugoslav Republic of|Novo Nordisk Investigational Site, Cheras, Malaysia|Novo Nordisk Investigational Site, Kota Bharu, Kelantan, Malaysia|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Bloemfontein, South Africa|Novo Nordisk Investigational Site, Bornova-IZMIR, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT00184665
NCT00187564,Pilot Study on the Effect of Oral Controlled-Release Alpha-Lipoic Acid on Oxidative Stress in Adolescents With Type 1 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: controlled-release oral alpha-lipoic acid,1. protein carbonyl (measurement of oxidized protein)|2. Thiobarbituric Acid Reactive Substances (TBARS) (measurement of oxidized lipid)|3. 8-Oxo-dG/8-Oxo-dA (measurement of oxidized DNA)|4. Trolox equivalent antioxidant capacity (TEAC) (measurement of total antioxidant status)|1. Hb A1c|2. Urine albumin/creatinine ratio,"University of California, San Francisco",All,"8 Years to 21 Years   (Child, Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,H7023-25421,Aug-04,null,Oct-05,16-Sep-05,null,6-May-08,"UCSF Division of Pediatric Endocrinology, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT00187564
NCT00175253,Alemtuzumab Induction in Islet Transplantation,,Completed,No Results Available,Type 1 Diabetes,Drug: alemtuzumab|Procedure: islet transplant,,University of Alberta|Juvenile Diabetes Research Foundation,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,12,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,5369,Nov-05,null,Apr-12,15-Sep-05,null,12-Jul-12,"University of Alberta - Clinical Islet Transplant Program, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT00175253
NCT00166673,Pilot Study of the Navigator Continuous Glucose Monitor,,Completed,No Results Available,"Diabetes Mellitus, Insulin-Dependent",Device: FreeStyle Navigator Continuous Glucose Monitoring System,"Feasibility of using the Navigator sensor on a daily basis (Average number of sensors used per week, Average number of hours of use per sensor, Number of sensors per week that fail to calibrate)|Navigator Accuracy|Psychosocial Questionnaires|Exploratory assessment of impact of Navigator on HbA1c",Jaeb Center for Health Research|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,3 Years to 17 Years   (Child),Phase 2|Phase 3,60,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),DirecNet 006|HD041890|HD041919|HD041908|HD041906|HD041918|HD041915,Aug-05,null,Aug-07,14-Sep-05,null,5-Sep-16,"Division of Pediatric Endocrinology and Diabetes, Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, University of Colorado, Aurora, Colorado, United States|Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Jaeb Center for Health Research, Tampa, Florida, United States|Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, Iowa, United States",,https://ClinicalTrials.gov/show/NCT00166673
NCT00157729,MATCHED (MC-1 and ACE Therapeutic Combination for Hypertensive Diabetics),,Completed,No Results Available,Diabetes Mellitus Type 2|Hypertension|Metabolic Syndrome,Drug: pyridoxal-5'-phosphate with and without ACE inhibitor,"Effects on blood pressure:|Determine the efficacy of MC-1 and of the combination of MC-1/ACE inhibitor on blood pressure as measured by mean daytime ambulatory systolic blood pressure.|Effects on metabolic function:|Determine the efficacy of MC-1 and of the combination of MC-1/ACE inhibitor on metabolic function as measured by insulinemia, fasting serum glucose, glycated hemoglobin, and triglycerides.|To compare the effects of the different treatment regimens as measured by:|mean change from baseline in mean daytime ambulatory diastolic BP|mean change from baseline in mean 24 hour and mean night-time ambulatory systolic BP|mean changes from baseline in mean 24 hour, mean daytime and mean night-time pulse pressure|mean changes from baseline in clinic trough sitting systolic BP (SiSBP)|mean changes from baseline in mean 24 hour, and mean night-time ambulatory diastolic BP|mean changes from baseline in clinic trough sitting diastolic BP (SiDBP)|mean change in endothelial function as measured by mean changes in different markers such as ICAM-1, VCAM-1, E-selectin and albuminuria|mean changes in C-reactive protein (CRP)|mean changes in homocysteine|mean changes in creatinine",Medicure,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,160,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,MC6021-CL-04001,Aug-04,null,Jul-05,12-Sep-05,null,31-Oct-06,"Centre Hospitalier Université Laval, Sainte-Foy, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00157729
NCT00160732,Allogenic Islet Cell Transplantation,,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 1","Drug: Allogenic islet cells (human, U. Chicago)|Procedure: Intraportal infusion of islet cells",decrease in insulin requirement - Subjects able to maintain fasting blood glucose concentrations below 126 mg/dL and 2-hour post prandial levels below 180 mg/dL will be considered to be insulin independent.|decrease in incidence of hypoglycemic events|absence of complications from the procedure and side effects of the medication,University of Chicago,All,18 Years to 58 Years   (Adult),Phase 1|Phase 2,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12176A|BB-IND 11228,Oct-03,Oct-22,Oct-25,12-Sep-05,null,6-Dec-18,"The University of Chicago Hospitals, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00160732
NCT00148538,Type 1 Diabetes Aerobic and Resistance Exercise (T1-DARE),,Completed,No Results Available,"Diabetes Mellitus, Type 1",Behavioral: Resistance and/or Aerobic Exercise,HbA1c at the end of the 6-month exercise period|frequency of hypoglycemia|fructosamine|blood pressure|lipid concentrations|apolipoproteins A1 and B|C-reactive protein|FFA|body composition (CT & DEXA)|compliance with the exercise|quality of life,Ottawa Hospital Research Institute,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 2|Phase 3,66,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,GA-3-05-1903-RS,Jul-05,Dec-10,Apr-12,8-Sep-05,null,27-Feb-13,"Ottawa Health Research Institute, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00148538
NCT00144144,A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 Diabetes,,Unknown status,No Results Available,"Hypertension|Diabetes Mellitus, Type 2","Drug: Angiotensin II receptor antagonists, Calcium channel blocker","Changes in blood pressure level at home after getting up.|The rate of the blood pressure levels at home after getting up, which effected the target levels (systolic blood pressure < 125 mm Hg, diastolic blood pressure < 80 mm Hg).|Adverse events, adverse drug reactions|Clinical laboratory data|Changes in blood pressure levels measured on an outpatient basis.|The rate of the blood pressure levels measured on an outpatient basis, which effected the standard levels (systolic blood pressure level <130 mm Hg, diastolic blood pressure level < 80 mm Hg).|Changes in blood pressure levels measured at home before going to bed· Changes in IMT of the cervical artery|Changes in PWV· Changes in echocardiographic findings|Changes in urinary albumin level|Changes in BNP· Changes in hs-CRP· Medical cost-effectiveness",Advanced-J|Japan Heart Foundation,All,"20 Years and older   (Adult, Older Adult)",Phase 4,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ADVANCED-J01|UMIN-C000000017,Sep-04,null,Sep-08,5-Sep-05,null,14-Jul-06,"Dept. of Clinical Immunology, Clinical Bioinformatics Research Unit, Graduate School of Medicine, the University of Tokyo, Hongo, Bunkyo-ku, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00144144
NCT00145353,Insulin NovoRapid Versus Actrapid in Treatment of Type 1 Diabetic Patients During Daily Adjustment of Insulin Dose,,Unknown status,No Results Available,Type 1 Diabetes Mellitus,Drug: Insulin NovoRapid versus Actrapid,Meal-regulated insulin time two peaks after the two intervention periods,Odense University Hospital,All,18 Years to 60 Years   (Adult),Phase 4,16,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,7,Nov-04,null,Jun-06,5-Sep-05,null,11-Oct-06,"Diabetes Research Center, Odense, Funen, Denmark",,https://ClinicalTrials.gov/show/NCT00145353
NCT00145379,The Effect of Metformin in Overweight Patients With Dysregulated Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Tablet Metformin 500 mg|Drug: Placebo,"HbA1c after the two intervention periods|Insulin need, hypoglycaemia frequence, body weight, lipid profile, blood pressure after the two intervention periods",Odense University Hospital,All,18 Years to 60 Years   (Adult),Phase 4,42,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Prevention,6,Mar-03,null,Jun-06,5-Sep-05,null,20-May-13,"Diabetes Research Center, Odense, Funen, Denmark",,https://ClinicalTrials.gov/show/NCT00145379
NCT00141986,Feasibility Study of 2000 IU Per Day of Vitamin D for the Primary Prevention of Type 1 Diabetes,,Completed,No Results Available,Type 1 Diabetes,Dietary Supplement: vitamin D3,change in 25(OH)D from baseline|renal ultrasound|bone densitometry|diabetes autoantibody levels|recruitment and retention rates|Change from baseline in serum calcium levels|changes in urine calcium:creatinine ratio,Canadian Diabetes Association|Manitoba Medical Service Foundation|Manitoba Institute of Child Health|The Health Sciences Centre Medical Staff Council,All,up to 4 Weeks   (Child),Phase 1,9,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,1622,Nov-03,Mar-07,Mar-07,2-Sep-05,null,26-Apr-11,"Manitoba Institute of Child Health, Winnipeg, Manitoba, Canada",,https://ClinicalTrials.gov/show/NCT00141986
NCT00142922,Breaking Down Barriers to Diabetes Self-Care,,Completed,No Results Available,Type 1 Diabetes|Type 2 Diabetes,Behavioral: Breaking Down Barriers,Self-Care Behaviors|Glycemic control (HbA1c)|fitness|Quality of life|Diabetes Related emaitonal distress,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,222,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),DK 60115 (completed)|DK 60115|CHS00-34,Oct-02,null,Oct-07,2-Sep-05,null,2-Mar-10,"Joslin Diabetes Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00142922
NCT00143104,"To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.",,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Inhaled insulin,"To assess in patients with type 1 diabetes mellitus the effects, if any, on lung lining, fluid cell count and differential within subjects after 12 weeks of inhaled insulin therapy compared to 12 weeks of subcutaneous short-acting therapy.|(1) Albumin and fibrinogen concentrations, and airway appearance in the above subjects. (2) routine safety, tolerance, and efficacy in the above subjects.",Pfizer|Sanofi,All,18 Years to 55 Years   (Adult),Phase 2,20,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A2171052,Dec-04,null,Oct-06,2-Sep-05,null,11-Mar-08,"Pfizer Investigational Site, Glendale, Arizona, United States|Pfizer Investigational Site, Fresno, California, United States|Pfizer Investigational Site, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00143104
NCT00143247,Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus,,Terminated,Has Results,Diabetes Mellitus,Drug: Exubera® (inhaled insulin),"Change in Forced Expiratory Volume in 1 Second (L) by Time on Exubera Treatment|Change in Carbon Monoxide Diffusing Capacity (mL/Min/mm Hg) by Time on Exubera Treatment|Change in Glycosylated Hemoglobin by Duration of Exubera Treatment|Hypoglycemic Event Rates by Interval of Exubera Treatment|Severe Hypoglycemic Event Rates by Interval of Exubera Treatment|Insulin Antibodies (Percent Binding) by Time on Exubera Treatment - Subjects With Type 1 Diabetes|Insulin Antibodies (Percent Binding) by Time on Exubera Treatment - Subjects With Type 2 Diabetes (Using Insulin at Study Entry)|Insulin Antibodies (Percent Binding) by Time on Exubera Treatment - Subjects With Type 2 Diabetes (Not Using Insulin at Study Entry)|Number of Decliners in Either Forced Expiratory Volume in 1 Second (L) or Carbon Monoxide Diffusing Capacity (ml/Min/mm Hg), by Duration of Exubera Treatment|Number of Decliners in Forced Expiratory Volume in 1 Second (L) by Duration of Exubera Treatment|Number of Decliners in Carbon Monoxide Diffusing Capacity (ml/Min/mm Hg) by Duration of Exubera Treatment",Pfizer,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,173,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A2171036,Mar-03,Jan-08,Jan-08,2-Sep-05,9-Nov-09,15-Apr-10,"Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Albuquerque, New Mexico, United States|Pfizer Investigational Site, Durham, North Carolina, United States|Pfizer Investigational Site, Winston Salem, North Carolina, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00143247
NCT00140543,European Trial of Immunosuppression in SPK Tx,,Unknown status,No Results Available,"Diabetes Mellitus, Type 1|Diabetic Nephropathy",Drug: sirolimus versus mycophenolate mofetil,"At 1 year:Incidence of biopsy-proven (kidney) rejection episodes.|SECONDARY ENDPOINTS: At 6 months and 1 year|* Kidney/Pancreas function (at 6 months and 1 year):|- Kidney function will be measured by:|- S- creatinine|- Creatinine clearance|- Pancreas function will be measured by:|- Fasting Glucose level (< 123 mg/dl)|- HbA1C|- Need for insulin therapy|- Need for oral drugs|* At 6 months and 1 year:|- Patient and graft survival|- Lipid profile|- Infections|- Side effects|- Blood Pressure|- Treatment failure for any reason, such as permanent discontinuation of a drug, graft loss or death.|* % of steroid free patients: at 6 months and 1 year.","EUROSPK Study Group|Fujisawa GmbH|Hoffmann-La Roche|Wyeth is now a wholly owned subsidiary of Pfizer|Neovii Biotech|Genzyme, a Sanofi Company",All,18 Years to 55 Years   (Adult),Phase 3,228,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EUROSPK002,Feb-02,null,Apr-08,1-Sep-05,null,18-Nov-05,"Universitätsklinik, Innsbruck, Austria|Cliniques Universitaires Saint Luc, Brussels, Belgium|UZ Gent, Gent, Belgium|UZ Gasthuisberg, Leuven, Belgium|Institute for clinical and experimental medicine-IKEM, Prague, Czech Republic|Charite Campus Virchow Klinikum, Berlin, Germany|Knappschaftskrankenhaus, Bochum-Langendreer, Germany|Goethe University, Frankfurt am Main, Germany|Chirurgische Universitätsklinik, Freiburg, Germany|Klinikum Grosshadern-University of Munich, Munich, Germany|Klinikum Innenstadt der Universität München, Munich, Germany|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Hospital Clinico, Barcelona, Spain|Hôpital Cantonal de Geneve, Geneva, Switzerland",,https://ClinicalTrials.gov/show/NCT00140543
NCT00139659,A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma,,Completed,Has Results,Asthma|Diabetes Mellitus,Drug: Inhaled Insulin|Drug: Subcutaneous Insulin,Annualized Rate of Change for Forced Expiratory Volume in 1 Second (FEV1)|Annualized Rate of Change for Hemoglobin-adjusted Carbon Monoxide Diffusion Capacity (DLco)|Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in One Second (FEV1)|Change From Baseline in Post-Bronchodilator Carbon Monoxide Diffusing Capacity (DLco)|Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1)|Change From Baseline in Pre-Bronchodilator Carbon Monoxide Diffusing Capacity (DLco)|Change From Baseline in Pre-Insulin Forced Expiratory Volume in One Second (FEV1)|Change From Baseline in Pre-Insulin Carbon Monoxide Diffusing Capacity (DLco)|Change From Baseline in Post-bronchodilator Forced Vital Capacity (FVC)|Bronchodilator Responsiveness as Determined by the Change in Forced Expiratory Volume in 1 Second (FEV1) Pre-albuterol and 30 Minutes Post-albuterol|Percent Predicted and Percent Change From Baseline in Post-Bronchdilator Forced Expiratory Volume in One Second (FEV1)|Change From Baseline in Insulin Dose Responsiveness for Forced Expiratory Volume in One Second (FEV1) Measured 10 and 60 Minutes After the First Daily Dose of Insulin|Percent Predicted and Percent Change From Baseline in 10 Minute and 60 Minute Post-Insulin Forced Expiratory Volume in One Second (FEV1)|Change From Baseline in Insulin Dose Responsiveness for Carbon Monoxide Diffusing Capacity (DLco) Measured 10 and 60 Minutes After the First Daily Dose of Insulin|Methacholine Challenge|Mean Weekly Morning and Evening Peak Expiratory Flow Rate (PEFR) and Forced Expiratory Volume in 1 Second (FEV1)|Mean Weekly Number of Puffs of Albuterol Used (Rescue Medication)|Number of Subjects With Step-up and Step-down Changes in Classification of Asthma Severity by Medication Usage|Step Classification of Asthma Severity by Medication Usage|Mean Weekly Asthma Symptom Scores|Incidence of Non-severe Asthma Exacerbations|Incidence of Severe Asthma Exacerbations|Number of Systemic Corticosteroid Rescues|Asthma Control as Measured by the Asthma Control Questionnaire©|Baseline Dyspnea Index (BDI)|Transition Dyspnea Index (TDI): Change in Total Score|Glycosylated Hemoglobin (HbA1c)|Fasting Plasma Glucose|Body Weight: Mean Baseline and Change From Baseline|Total Daily Long-Acting Insulin Dose (Unadjusted for Body Weight)|Total Daily Long-Acting Insulin Dose Adjusted for Body Weight|Total Daily Short-Acting Insulin Dose (Unadjusted for Body Weight)|Total Daily Short-Acting Insulin Dose Adjusted for Body Weight|Lipids: Median Change From Baseline to Last Observation|Hypoglycemic Event Rates|Severe Hypoglycemic Event Rates,Pfizer,All,"18 Years to 77 Years   (Adult, Older Adult)",Phase 3,288,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A2171028,Jan-03,Oct-08,Oct-08,31-Aug-05,12-May-10,2-Jun-10,"Pfizer Investigational Site, Glendale, Arizona, United States|Pfizer Investigational Site, Peoria, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Tucson, Arizona, United States|Pfizer Investigational Site, Jonesboro, Arkansas, United States|Pfizer Investigational Site, Searcy, Arkansas, United States|Pfizer Investigational Site, Berkeley, California, United States|Pfizer Investigational Site, Beverly Hills, California, United States|Pfizer Investigational Site, Fresno, California, United States|Pfizer Investigational Site, Greenbrae, California, United States|Pfizer Investigational Site, Huntington Beach, California, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Riverside, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Tustin, California, United States|Pfizer Investigational Site, Boulder, Colorado, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Waterbury, Connecticut, United States|Pfizer Investigational Site, Newark, Delaware, United States|Pfizer Investigational Site, Chiefland, Florida, United States|Pfizer Investigational Site, Clearwater, Florida, United States|Pfizer Investigational Site, Clearwater, Florida, United States|Pfizer Investigational Site, Melbourne, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, Augusta, Georgia, United States|Pfizer Investigational Site, Honolulu, Hawaii, United States|Pfizer Investigational Site, Honululu, Hawaii, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Normal, Illinois, United States|Pfizer Investigational Site, Evansville, Indiana, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, Des Moines, Iowa, United States|Pfizer Investigational Site, Dubuque, Iowa, United States|Pfizer Investigational Site, Dubuque, Iowa, United States|Pfizer Investigational Site, Wichita, Kansas, United States|Pfizer Investigational Site, Bossier City, Louisiana, United States|Pfizer Investigational Site, North Dartmouth, Massachusetts, United States|Pfizer Investigational Site, Springfield, Massachusetts, United States|Pfizer Investigational Site, Springfield, Massachusetts, United States|Pfizer Investigational Site, Waltham, Massachusetts, United States|Pfizer Investigational Site, Brooklyn Center, Minnesota, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, Butte, Montana, United States|Pfizer Investigational Site, Henderson, Nevada, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, North Las Vegas, Nevada, United States|Pfizer Investigational Site, Albuquerque, New Mexico, United States|Pfizer Investigational Site, Buffalo, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Dayton, Ohio, United States|Pfizer Investigational Site, Toledo, Ohio, United States|Pfizer Investigational Site, Toledo, Ohio, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Medford, Oregon, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Lansdale, Pennsylvania, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Spartanburg, South Carolina, United States|Pfizer Investigational Site, Spartanburg, South Carolina, United States|Pfizer Investigational Site, Bartlett, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Beaumont, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Houstan, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Norfolk, Virginia, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Spokane, Washington, United States|Pfizer Investigational Site, Spokane, Washington, United States|Pfizer Investigational Site, Porto Alegre, RS, Brazil|Pfizer Investigational Site, SP, Sao Paulo, Brazil|Pfizer Investigational Site, Campinas, SP, Brazil|Pfizer Investigational Site, Sao Paulo, SP, Brazil|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Red Deer, Alberta, Canada|Pfizer Investigational Site, Victoria, British Columbia, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Burlington, Ontario, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Laval, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, San Jose, Costa Rica|Pfizer Investigational Site, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT00139659
NCT00138593,Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With Hemoglobin A1c (HbA1c) 9-11%,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: vildagliptin,Safety in combination with pioglitizone after 52 weeks of treatment|Change from baseline in HbA1c at 52 weeks|Change from baseline in fasting plasma glucose at 52 weeks|Change from baseline in fasting lipids at 52 weeks|Change from baseline in body weight at 52 weeks|Change from baseline in HOMA B at 52 weeks|Change from baseline in HOMA IR at 52 weeks,Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,180,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLAF237A2329E1,Jul-04,Jul-06,Jul-06,30-Aug-05,null,1-Mar-17,"Novartis Pharmaceuticals, Basel, Switzerland",,https://ClinicalTrials.gov/show/NCT00138593
NCT00138671,A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD,,Terminated,Has Results,Diabetes Mellitus|Chronic Obstructive Pulmonary Disease,Drug: Subcutaneous Insulin|Drug: Inhaled Insulin,"Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)|Change From Baseline in Post-Bronchodilator Carbon Monoxide Diffusion Capacity (DLco)|Full Pulmonary Function Tests (PFTs) (Spirometry, Pre-Ipratropium and Pre-Insulin PFTs)|Full PFTs (DLco, Pre-Ipratropium and Pre- Insulin PFTs)|Other PFTs (Besides FEV1 and DLco)|Bronchodilator Responsiveness as Determined by the Change in FEV1|Insulin Dose Responsiveness for FEV1|Insulin Dose Responsiveness for DLco|Methacholine PC20|Mean Weekly Number of Puffs of Short-Acting Bronchodilator Used|Incidence of Non-Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations|Incidence of Severe COPD Exacerbations|Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) Questionnaires|Change From Baseline in Glycosylated Hemoglobin (HbA1c)|Change From Baseline in Fasting Plasma Glucose|Change From Baseline in Body Weight|Mean Total Daily Intermediate-/Long-Acting Insulin Dose (Unadjusted for Body Weight)|Mean Total Daily Short-Acting Insulin Dose (Unadjusted for Body Weight)|Mean Total Daily Intermediate-/Long-Acting Insulin Dose (Adjusted for Body Weight)|Mean Total Daily Short-Acting Insulin Dose (Adjusted for Body Weight)|Lipids|Hypoglycemic Event Rates|Severe Hypoglcyemic Event Rates",Pfizer,All,"30 Years to 77 Years   (Adult, Older Adult)",Phase 3,105,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A2171030,Jan-03,Sep-08,Sep-08,30-Aug-05,13-Nov-09,2-Feb-10,"Pfizer Investigational Site, Glendale, Arizona, United States|Pfizer Investigational Site, Peoria, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Tucson, Arizona, United States|Pfizer Investigational Site, Jonesboro, Arkansas, United States|Pfizer Investigational Site, Searcy, Arkansas, United States|Pfizer Investigational Site, Berkeley, California, United States|Pfizer Investigational Site, Fresno, California, United States|Pfizer Investigational Site, Greenbrae, California, United States|Pfizer Investigational Site, Huntington Beach, California, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Riverside, California, United States|Pfizer Investigational Site, Tustin, California, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Waterbury, Connecticut, United States|Pfizer Investigational Site, Chiefland, Florida, United States|Pfizer Investigational Site, Clearwater, Florida, United States|Pfizer Investigational Site, Clearwater, Florida, United States|Pfizer Investigational Site, DeLand, Florida, United States|Pfizer Investigational Site, Gainesville, Florida, United States|Pfizer Investigational Site, Lake City, Florida, United States|Pfizer Investigational Site, Melbourne, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, Winter Park, Florida, United States|Pfizer Investigational Site, Decatur, Georgia, United States|Pfizer Investigational Site, Honolulu, Hawaii, United States|Pfizer Investigational Site, Honululu, Hawaii, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Normal, Illinois, United States|Pfizer Investigational Site, Evansville, Indiana, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, Des Moines, Iowa, United States|Pfizer Investigational Site, Wichita, Kansas, United States|Pfizer Investigational Site, Madisonville, Kentucky, United States|Pfizer Investigational Site, New Orleans, Louisiana, United States|Pfizer Investigational Site, Springfield, Massachusetts, United States|Pfizer Investigational Site, Springfield, Massachusetts, United States|Pfizer Investigational Site, Waltham, Massachusetts, United States|Pfizer Investigational Site, Kansas City, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, Butte, Montana, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Henderson, Nevada, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Albany, New York, United States|Pfizer Investigational Site, Albany, New York, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Toledo, Ohio, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Medford, Oregon, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Spartanburg, South Carolina, United States|Pfizer Investigational Site, Spartanburg, South Carolina, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Beaumont, Texas, United States|Pfizer Investigational Site, Beaumont, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Fredericksburg, Virginia, United States|Pfizer Investigational Site, Fredericksburg, Virginia, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Spokane, Washington, United States|Pfizer Investigational Site, Spokane, Washington, United States|Pfizer Investigational Site, Huntington, West Virginia, United States|Pfizer Investigational Site, Madison, Wisconsin, United States|Pfizer Investigational Site, Porto Alegre, RS, Brazil|Pfizer Investigational Site, Campinas, SP, Brazil|Pfizer Investigational Site, Sao Paulo, SP, Brazil|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Red Deer, Alberta, Canada|Pfizer Investigational Site, Burlington, Ontario, Canada|Pfizer Investigational Site, Laval, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, San Jose, Costa Rica|Pfizer Investigational Site, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT00138671
NCT00137046,Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes,,Terminated,Has Results,"Diabetes Mellitus, Type 1",Drug: Subcutaneous Insulin|Drug: Inhaled Insulin,Change From Baseline in Forced Expiratory Volume in One Second (FEV1)|Summary of ≥ 15% Decliners in Forced Expiratory Volume in One Second (FEV1)|Change From Baseline in Carbon Monoxide Diffusion Capacity (DLco)|Summary of ≥ 20% Decliners in Carbon Monoxide Diffusing Capacity (DLco).|Annual Rate of Change in Forced Expiratory Volume in 1 Second (FEV1)|Annual Rate of Change in Carbon Monoxide Diffusion Capacity (DLco)|Change From Baseline in Glycosylated Hemoglobin (HbA1c)|Hypoglycemic Event Rates|Severe Hypoglycemic Event Rates|Change From Baseline in Fasting Plasma Glucose|Change From Baseline Body Weight|Total Daily Long-Acting Insulin Dose (Unadjusted for Body Weight)|Total Daily Long-Acting Insulin Dose Adjusted for Body Weight|Total Daily Short-Acting Insulin Dose (Unadjusted for Body Weight)|Total Daily Short-Acting Insulin Dose Adjusted for Body Weight|Baseline Dyspnea Index (BDI)|Transition Dyspnea Index (TDI)|Lipids|Cough Questionnaire|Forced Vital Capacity (FVC)|Total Lung Capacity (TLC)|Insulin Antibodies,Pfizer,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,582,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A2171022,May-02,Dec-08,Dec-08,29-Aug-05,26-Jan-10,18-Feb-10,"Pfizer Investigational Site, Fullerton, California, United States|Pfizer Investigational Site, Long Beach, California, United States|Pfizer Investigational Site, Sacramento, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Santa Barbara, California, United States|Pfizer Investigational Site, Santa Rosa, California, United States|Pfizer Investigational Site, Tustin, California, United States|Pfizer Investigational Site, Walnut Creek, California, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Longmont, Colorado, United States|Pfizer Investigational Site, Hamden, Connecticut, United States|Pfizer Investigational Site, Madison, Connecticut, United States|Pfizer Investigational Site, Newark, Delaware, United States|Pfizer Investigational Site, Coral Gables, Florida, United States|Pfizer Investigational Site, Hollywood, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Tallahassee, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, Winter Park, Florida, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Wilmette, Illinois, United States|Pfizer Investigational Site, Bethesda, Maryland, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, Butte, Montana, United States|Pfizer Investigational Site, New Hyde Park, New York, United States|Pfizer Investigational Site, Durham, North Carolina, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Lansdale, Pennsylvania, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Burlington, Vermont, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Renton, Washington, United States|Pfizer Investigational Site, Milwaukee, Wisconsin, United States|Pfizer Investigational Site, Capital Federal, Buenos Aires, Argentina|Pfizer Investigational Site, Capital Federal, Buenos Aires, Argentina|Pfizer Investigational Site, Capital Federal, Buenos Aires, Argentina|Pfizer Investigational Site, Capital Federal, Buenos Aires, Argentina|Pfizer Investigational Site, Belo Horizonte, MG, Brazil|Pfizer Investigational Site, Curitiba, PR, Brazil|Pfizer Investigational Site, Porto Alegre, RS, Brazil|Pfizer Investigational Site, Porto Alegre, RS, Brazil|Pfizer Investigational Site, Campinas, SP, Brazil|Pfizer Investigational Site, Sao Paulo, SP, Brazil|Pfizer Investigational Site, Sao Paulo, SP, Brazil|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Victoria, British Columbia, Canada|Pfizer Investigational Site, Winnepeg, Manitoba, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Kingston, Ontario, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Mississauga, Ontario, Canada|Pfizer Investigational Site, Oakville, Ontario, Canada|Pfizer Investigational Site, Ottawa, Ontario, Canada|Pfizer Investigational Site, Thornhill, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Laval, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada|Pfizer Investigational Site, Mexico Df, Col Las Americas, Mexico|Pfizer Investigational Site, Mexico, DF, Mexico|Pfizer Investigational Site, Mexico, DF, Mexico|Pfizer Investigational Site, Monterrey, Nuevo Leon, Mexico",,https://ClinicalTrials.gov/show/NCT00137046
NCT00135941,Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2),,Completed,No Results Available,Diabetes Mellitus,Drug: insulin glargine|Drug: insulin glulisine,"To compare improvements from baseline in patient reported outcomes (quality of life, treatment satisfaction) when aggressively treated with insulin glargine plus rapid acting insulin glulisine vs treatment with Premix insulin|change in A1c (baseline to week 24), reported hypo events (throughout the trials), correlation between patient reported outcomes and glucose variability as measured by CGMS (baseline, week 8 and week 20).",Sanofi,All,"21 Years to 70 Years   (Adult, Older Adult)",Phase 3,582,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HMR1964A_3508,Aug-05,null,Sep-07,26-Aug-05,null,4-Jun-09,"Advanced Healthcare, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00135941
NCT00135083,Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: insulin glulisine,"To show non-inferiority between treatment groups (insulin glargine plus insulin glulisine administered once a day, twice a day, or 3 times a day) in the change in glycemic control as measured by hemoglobin A1C.",Sanofi,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 3,347,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HMR1964A_3511,Aug-04,null,Nov-07,25-Aug-05,null,11-Jan-11,,,https://ClinicalTrials.gov/show/NCT00135083
NCT00135226,ASCEND: A Study of Cardiovascular Events iN Diabetes,,"Active, not recruiting",Has Results,Diabetes Mellitus,Drug: Aspirin|Drug: Omega-3 Ethyl Esters|Drug: Placebo Aspirin|Drug: Placebo Omega-3 Ethyl Esters,Number of Participants With First Occurrence of Any Serious Vascular Event (SVE)|Number of Participants With First Occurrence of Any Major Bleed (Aspirin Comparison Only)|Number of Participants With Combined End-point of Serious Vascular Events (SVEs) or Revascularizations|Number of Participants With Any Incident Gastrointestinal (GI) Tract Cancer (Aspirin Comparison Only),University of Oxford|British Heart Foundation|Bayer|EPD Research Ltd.|Medical Research Council,All,"40 Years and older   (Adult, Older Adult)",Phase 4,15480,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",CTSUASCEND1|60635500,Mar-05,12-Mar-18,31-Jul-37,25-Aug-05,26-Apr-19,26-Apr-19,"Clinical Trial Service Unit, University of Oxford, Oxford, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT00135226/SAP_000.pdf|""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT00135226/Prot_ICF_001.pdf",https://ClinicalTrials.gov/show/NCT00135226
NCT00133809,Islet Transplantation in Type 1 Diabetics Using the Edmonton Protocol of Steroid Free Immunosuppression,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Transplantation of Human Islets,The Number of Insulin-Independent Subjects at One Year Following Islet Cell Transplantation|Number of Insulin-independent Subjects Following Islet Transplantation|Number of Subjects With HbA1C ≤ 6.5%|The Number of Subjects Exhibiting Fasting C-peptide Levels ≥ 0.5 ng/mL,Emory University|Juvenile Diabetes Research Foundation,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,8,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB00041120|10402,Jul-02,Dec-14,Dec-14,24-Aug-05,1-Jun-16,18-Jul-16,"The Emory Transplant Center, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT00133809
NCT00131755,Efficacy of Diazoxide in Type 1 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: diazoxide,Insulin secretion (measured by fasting and stimulated c-peptide)|Glycemic control (measured by blood glucose)|Autoimmune activity (measured by islet antibodies)|Side effects,"Grill, Valdemar, M.D.",All,18 Years to 40 Years   (Adult),Phase 4,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",DIAZ 1|Eudract 2004-004103-38,Feb-05,Aug-08,Aug-08,19-Aug-05,null,18-Jul-11,"University Hospital of Trondheim, Trondheim, Norway",,https://ClinicalTrials.gov/show/NCT00131755
NCT00130481,Pediatric Atorvastatin in Diabetes Intervention Trial (PADIT),,Completed,No Results Available,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Drug: Atorvastatin 20 mg daily for 3 months,Augmentation Index (arterial stiffness)|ENDO-PAT (Peripheral Arterial Tone) score (endothelial function)|Low density lipoprotein|Urine microalbumin|Pubertal stage|Body mass index (BMI)|Blood pressure|Glycated hemoglobin (HbA1c),University of Florida,All,"10 Years to 18 Years   (Child, Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Prevention,576-2004|GCRC M-01 RR 000082|Pfizer 2004-0926|DARE 187,Apr-05,Apr-07,Apr-07,15-Aug-05,null,7-Mar-12,"University of Florida, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT00130481
NCT00129259,Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes,AbATE,Completed,Has Results,"Diabetes Mellitus, Type 1",Biological: Anti-CD3 mAb|Other: Diabetes Standard of Care Treatment|Dietary Supplement: Iron supplementation,Change in Mean C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT)|Change in HbA1c|Change in Average Total Insulin Dose Per Body Weight,National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN),All,"8 Years to 30 Years   (Child, Adult)",Phase 2,83,NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,DAIT ITN027AI,Sep-05,Mar-11,Mar-11,11-Aug-05,16-Sep-13,22-May-17,"The Diabetes Center at UCSF, San Francisco, California, United States|Barbara Davis Center for Childhood Diabetes, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|Medical College of Georgia, Augusta, Georgia, United States|Dept. of Medicine, Division of Endocrinology and the Naomi Berrie Diabetes Center/Columbia University, New York, New York, United States|Benaroya Research Institute, Seattle, Washington, United States|Pacific Northwest Research Institute/University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00129259
NCT00128089,Trial of New Dietary Treatment of Diabetes,,Terminated,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: Dietary treatment,Glycated hemoglobin (A1C) changes|Weight (body mass index [BMI]) loss|Diabetes medication reduction|Hypoglycemia|Other medication reduction|Patient satisfaction,Manassas Internal Medicine,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2005-1,Aug-05,null,Dec-05,9-Aug-05,null,21-Dec-05,"Manassas Internal Medicine, Manassas, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00128089
NCT00127634,Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Human Insulin Inhalation Powder|Drug: Injectable Insulin|Drug: Insulin Glargine,"To assess change in baseline to endpoint in HbA1c in type 1 diabetic patients.|To compare preprandial Human Insulin Inhalation Powder with preprandial injectable insulin in patients with type 1 diabetes with respect to FEV1, FVC, and total lung capacity (TLC), and diffusing capacity of the lung for carbon monoxide (DLCO).|To compare preprandial Human Insulin Inhalation Powder with preprandial injectable insulin in patients with type 1 diabetes with respect to safety as assessed by insulin antibody binding levels, adverse events, and episodes of hypoglycemia|To compare preprandial Human Insulin Inhalation Powder with preprandial injectable insulin in patients with type 1 diabetes with respect to safety using serial HRCT scans of the chest|To compare preprandial Human Insulin Inhalation Powder with preprandial injectable insulin in patients with type 1 diabetes with respect to safety as assessed by Six-Minute Walk Test with the Borg CR10 scale to access perceived exertion.|To compare preprandial Human Insulin Inhalation Powder with preprandial injectable insulin in patients with type 1 diabetes with respect to proportion of patients who achieve or maintain an HbA1c < 7.0 %.|To compare preprandial Human Insulin Inhalation Powder with preprandial injectable insulin in patients with type 1 diabetes with respect to insulin dose requirements ( total, preprandial, and basal insulin)|To compare preprandial Human Insulin Inhalation Powder with preprandial injectable insulin in patients with type 1 diabetes with respect to Patient reported questionnaires.|To compare preprandial Human Insulin Inhalation Powder with preprandial injectable insulin in patients with type 1 diabetes with respect to resource utilization|To assess inhaler reliability in patients randomized to treatment with Human Insulin Inhalation Powder.|To explore differences in cough and other pulmonary symptoms in patients treated with Human Insulin Inhalation Powder or preprandial injectable insulin using the Pulmonary Symptom Questionnaire.|To compare preprandial Human Insulin Inhalation Powder with preprandial injectable insulin in patients with type 1 diabetes with respect to glycemic control as assessed by the 8-point self-monitored blood glucose profiles","Eli Lilly and Company|Alkermes, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,385,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6120|H7U-MC-IDAH,Jul-05,May-08,May-08,8-Aug-05,null,9-Mar-18,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sacramento, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Walnut Creek, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aurora, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denver, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newark, Delaware, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hollywood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jacksonville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Largo, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Port Richey, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Palm Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Idaho Falls, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Springfield, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Louisville, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., North Plainfield, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Flushing, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lake Success, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Hyde Park, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Staten Island, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Morehead City, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Raleigh, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Medford, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Downingtown, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sellersville, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sioux Falls, South Dakota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Renton, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milwaukee, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aalst, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arlon, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edegem, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liege, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winnipeg, Manitoba, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Corunna, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Niagara Falls, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Peterborough, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sarnia, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montreal, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zagreb, Croatia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hrs, EST), or speak with your personal physician., Debrecen, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eger, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gyula, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kecskemet, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nyiregyhaza, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hrs, EST), or speak with your personal physician., Szeged, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szolnok, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangalore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kochin, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mumbai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Dehli, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Noida, India",,https://ClinicalTrials.gov/show/NCT00127634
NCT00118937,Effect of Metformin in Patients With Type-1 Diabetes With Inadequate Glycaemic Control by Insulin and Diet,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Metformin|Drug: Placebo.,"HbA1c - difference between final visit and baseline.|Absolute HbA1c|Number of mild and severe hypoglycaemia with or without measurements of blood-glucose.|Insulin-dose|The following parameters are measured at baseline and at the final visit after 12 months of intervention:|Plasma-PAI-antigen and -activity, t-PA-antigen- and activity.|Plasma-fibrinogen|Serum-albumin|Markers of endothelial dysfunction: Von Willebrand Factor, ICAM, VCAM, Amadori-protein, selectin and endothelin.|Plasma-homocysteine|Asymmetric DiMethylArginine - ADMA|Urine-albumin-excretion in three 24 hour urine-collections|Blood-pressure in the sitting position after 10 minutes of rest.|Fasting lipid-profile (total-cholesterol, LDL-cholesterol, HDL-cholesterol, VLDL-cholesterol and triglycerides), small-dense-LDL, Lp(a) and Apo-B100.|Weight, BMI and Waist-hip-ratio|White blood-cell-count, hs-CRP, Interleukin-6 and TNF-alfa.|Serum-creatinine, sodium, potassium, ASAT, alkaline phosphatase, Factor 2, 7, 10, Cobalamin, Erythrocyte-folate and Haemoglobin-concentration.|Extra blood- and urine-samples will be stored at -80 degrees Celsius for potential extra analyses after closure of the study. DNA will be stored for later pharmaco-genetic analysis.",Steno Diabetes Center Copenhagen,All,"18 Years and older   (Adult, Older Adult)",Phase 4,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Type-1-Metformin,Dec-03,Aug-06,Aug-06,12-Jul-05,null,8-Dec-08,,,https://ClinicalTrials.gov/show/NCT00118937
NCT00118976,Maximal Dose of Angiotensin Converting Enzyme (ACE) Inhibitor for Treatment of Diabetic Kidney Disease,,Completed,No Results Available,"Diabetes Mellitus, Type I|Diabetic Nephropathy",Drug: Lisinopril,albuminuria|blood pressure (24 hour ambulatory) and GFR.|Tertiary: differences in response to treatment in patients with different ACE/ID and other renin angiotensin system genotypes.,Steno Diabetes Center Copenhagen,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Prevention,mace,Mar-05,null,Sep-06,12-Jul-05,null,23-Nov-06,"Steno Diabetes Center, Gentofte, Denmark",,https://ClinicalTrials.gov/show/NCT00118976
NCT00119041,Diabetes Telemedicine Consultation: A Systems Improvement Intervention,,Completed,Has Results,"Diabetes Mellitus Type 2|Diabetes Mellitus, Type 1|Primary Care Provider",Behavioral: The Diabetes Treatment Satisfaction Questionnaire|Behavioral: Diabetes Empowerment Scale|Behavioral: CBOC's undergo half-day joint-clinics via teleconference,A1c|Patient Satisfaction,US Department of Veterans Affairs|VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,304,U.S. Fed,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,IIR 03-254,Sep-05,Dec-07,Dec-08,12-Jul-05,12-May-15,15-Jun-15,"VA Ann Arbor Healthcare System, Ann Arbor, Michigan, United States|Louis Stokes VA Medical Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00119041
NCT00117780,Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes,ADAPT,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin detemir|Drug: insulin aspart,Mean HbA1c|HbA1c|Adverse events|Insulin dose requirements during initial 4 months of treatment and during 3 months extension|Weight|Blood glucose|Hypoglycaemia,Novo Nordisk A/S,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,520,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN304-1708|2005-001522-88,Jun-05,Oct-06,Oct-06,8-Jul-05,null,2-Jun-17,"Novo Nordisk Investigational Site, Aalst, Belgium|Novo Nordisk Investigational Site, Lille, France|Novo Nordisk Investigational Site, Luxembourg, Luxembourg",,https://ClinicalTrials.gov/show/NCT00117780
NCT00117026,Effects of Vitamin B1 in Type 1 Diabetic Patients,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Placebo|Drug: Benfotiamine,"Lower-limb nerve conduction velocity|Serum advanced glycation end products (AGEs) and markers of inflammation (CRP, IL-6, VCAM-1)","University Hospital, Aker|The Research Council of Norway|Oslo University Hospital",All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,67,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",AkerU,Aug-05,Jun-10,Feb-11,4-Jul-05,null,10-May-13,"Aker University Hospital, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT00117026
NCT00116207,An Intervention Trial for Cardiac Neuropathy in Type 1 Diabetes,,Completed,Has Results,Diabetic Autonomic Neuropathy,Drug: ORAL ANTIOXIDANT,Global [11C]HED Retention Index (RI)|Global Coronary Flow Reserve as a Measure of Endothelial Function|Systemic Oxidative Stress|Inflammation,University of Michigan|Juvenile Diabetes Research Foundation,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,44,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB:2002-0460,Jan-00,Sep-09,Dec-09,28-Jun-05,5-Jan-16,29-Jul-16,"University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT00116207
NCT00115570,Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents,,Completed,No Results Available,"Diabetes Mellitus, Insulin-Dependent",Drug: Insulin glulisine|Drug: insulin lispro|Drug: insulin glargine|Drug: NPH insulin,Change in total glycated hemoglobin measured as HbA1c equivalents (GHb )from baseline to endpoint|Change from Baseline in GHb at weeks 12 and 26|Change from Baseline in Self-monitored glucose parameters|Incidence of Symptomatic hypoglycemia|Change from Baseline in basal insulin dose,Sanofi,All,4 Years to 17 Years   (Child),Phase 3,572,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EFC6096|HMR 1964,Apr-05,Nov-06,Nov-06,24-Jun-05,null,20-May-16,"Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00115570
NCT00111631,A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes,,Completed,No Results Available,Diabetes Mellitus Type 2,Drug: DPP-IV Inhibitor|Drug: Metformin|Drug: Placebo,"Absolute change from baseline in HbAlc\n|Absolute change in FPG and absolute/relative change in insulin sensitivity, beta-cell-function, and lipid profile, response rate\n|AEs, vital signs, laboratory tests, body weight, waist/hip ratio, ECG\n",Hoffmann-La Roche,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,218,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BM18106,May-05,Oct-06,Oct-06,25-May-05,null,2-Nov-16,"Concord, California, United States|Salinas, California, United States|San Diego, California, United States|Boulder, Colorado, United States|Newark, Delaware, United States|Wilmington, Delaware, United States|Clearwater, Florida, United States|Miami, Florida, United States|Chicago, Illinois, United States|Detroit, Michigan, United States|Buffalo, New York, United States|Rochester, New York, United States|Durham, North Carolina, United States|Mogadore, Ohio, United States|Portland, Oregon, United States|Connellsville, Pennsylvania, United States|Warminster, Pennsylvania, United States|Dallas, Texas, United States|Midland, Texas, United States|San Antonio, Texas, United States|Adelaide, Australia|Sydney, Australia|Winnipeg, Manitoba, Canada|Halifax, Nova Scotia, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Bad Lauterberg, Germany|Berlin, Germany|Dresden, Germany|Görlitz, Germany|Mainz, Germany|Neuss, Germany|Ancona, Italy|Firenze, Italy|Napoli, Italy|Udine, Italy|Ponce, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00111631
NCT00111670,A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes,,Completed,No Results Available,Diabetes Mellitus Type 2,Drug: DPP-IV Inhibitor|Drug: Placebo,"Absolute change from baseline in HbAlc\n\n|Absolute change in FPG and absolute/relative change in insulin sensitivity, beta-cell-function, lipid profile, response rate|AEs, vital signs, laboratory tests, body weight, waist/hip ratio, ECG\n",Hoffmann-La Roche,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,291,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BM18102,Jun-05,Jul-06,Jul-06,25-May-05,null,2-Nov-16,"Salinas, California, United States|Clearwater, Florida, United States|Hialeah, Florida, United States|Pembroke Pines, Florida, United States|Blue Ridge, Georgia, United States|Aurora, Illinois, United States|Elkton, Maryland, United States|Oxon Hill, Maryland, United States|Troy, Michigan, United States|Pahrump, Nevada, United States|Cincinnati, Ohio, United States|Portland, Oregon, United States|Warminster, Pennsylvania, United States|Dallas, Texas, United States|Midland, Texas, United States|San Antonio, Texas, United States|Richmond, Virginia, United States|Virginia Beach, Virginia, United States|Ruse, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|San Jose, Costa Rica|Tartu, Estonia|Tartu, Estonia|Ogre, Latvia|Riga, Latvia|Klaipeda, Lithuania|Vilnius, Lithuania|Chihuahua, Mexico|Guadalajara, Mexico|Guadalajara, Mexico|Mexico City, Mexico|Mexico City, Mexico|Monterrey, Mexico|Pachuca, Mexico|Ponce, Puerto Rico|Bucharest, Romania|Cluj-napoca, Romania|Ploiesti, Romania|Tirgu-mures, Romania",,https://ClinicalTrials.gov/show/NCT00111670
NCT00111540,Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: exenatide,Change in HbA1c (glycosylated hemoglobin) from Visit 1 to each protocol visit|Change in body weight from Visit 1 to each protocol visit|Change in fasting plasma glucose from Visit 1 to each protocol visit|Change in lipids from Visit 1 to each protocol visit,AstraZeneca,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,456,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2993-119,Nov-02,Sep-06,Sep-06,24-May-05,null,23-Feb-15,"Research Site, Birmingham, Alabama, United States|Research Site, Anaheim, California, United States|Research Site, Bellflower, California, United States|Research Site, Burlingame, California, United States|Research Site, Chula Vista, California, United States|Research Site, Concord, California, United States|Research Site, Encino, California, United States|Research Site, Fremont, California, United States|Research Site, La Jolla, California, United States|Research Site, Los Gatos, California, United States|Research Site, Moreno Valley, California, United States|Research Site, Redwood City, California, United States|Research Site, San Mateo, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Gainesville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Maitland, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Blairsville, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Lexington, Kentucky, United States|Research Site, Covington, Louisiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Detroit, Michigan, United States|Research Site, Edina, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Gulfport, Mississippi, United States|Research Site, Picayune, Mississippi, United States|Research Site, Chesterfield, Missouri, United States|Research Site, St. Louis, Missouri, United States|Research Site, Butte, Montana, United States|Research Site, Las Vegas, Nevada, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Cary, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Maumee, Ohio, United States|Research Site, Mentor, Ohio, United States|Research Site, Clinton, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Medford, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Midland, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Olympia, Washington, United States|Research Site, Spokane, Washington, United States",,https://ClinicalTrials.gov/show/NCT00111540
NCT00111228,The Guardcontrol Trial: Study to Assess if Type 1 Diabetics Can Improve Using the Real-time Values of Guardian RT,,Completed,Has Results,Diabetes Mellitus,Device: Guardian RT|Device: SMBG only,"Hemoglobin A1c (HbA1c) - Change From Baseline to End of 3 Month Study Period|Average Blood Glucose - Change From Baseline to End of 3 Month Study Period, Calculated as Average Blood Glucose at 3 Month - Average Blood Glucose at Baseline",Medtronic Diabetes,All,"8 Years to 60 Years   (Child, Adult)",Not Applicable,162,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EU 007_022004,Oct-04,May-05,May-05,19-May-05,1-Apr-19,1-Apr-19,"Hôpital Sud Francilien, Corbeil Esssonnes, France|CH Robert Debre, Paris, France|Klinik für Allgemeine Charité, CVK, Berlin, Germany|Schneider Children Centre, Petah Tikva, Israel|Universita Vita-Salute OspedaleS.Raffaele, Milano, Italy|University Children's Hospital, Ljubljana, Slovenia|Huddinge University Hospital, Huddinge, Sweden|Royal Bournemouth Hospital, Bournemouth, United Kingdom",,https://ClinicalTrials.gov/show/NCT00111228
NCT00108225,"Effect of a High Protein Diet on the 24-hour Profile of Ghrelin, GH (Growth Hormone) and IGF-1 (Insulin-like Growth Factor-1)",,Completed,No Results Available,"Diabetes Mellitus, Type 2",Other: LoBag Diet - test phase|Other: LoBAG Diet - control phase,"IGF-1, GH, Body Composition",US Department of Veterans Affairs|VA Office of Research and Development,All,"55 Years to 75 Years   (Adult, Older Adult)",Not Applicable,8,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,03448-A,Jul-04,Dec-08,May-09,15-Apr-05,null,1-Jul-14,"VA Medical Center, Minneapolis, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00108225
NCT00108004,Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Drug: pramlintide acetate,To investigate the clinical utility and safety of pramlintide in subjects with type 1 and type 2 diabetes mellitus|Understand management issues in subjects with type 1 and type 2 diabetes mellitus,AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,400,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,137-155,Apr-03,Jun-05,Jun-05,13-Apr-05,null,21-May-15,"Research Site, Anaheim, California, United States|Research Site, Escondido, California, United States|Research Site, La Jolla, California, United States|Research Site, Los Gatos, California, United States|Research Site, San Francisco, California, United States|Research Site, Torrance, California, United States|Research Site, New Britain, Connecticut, United States|Research Site, Norwalk, Connecticut, United States|Research Site, Norwich, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Clearwater, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Columbus, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Idaho Falls, Idaho, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Vincennes, Indiana, United States|Research Site, Topeka, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bloomfield Hills, Michigan, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Reno, Nevada, United States|Research Site, Moorestown, New Jersey, United States|Research Site, Neptune, New Jersey, United States|Research Site, Roseland, New Jersey, United States|Research Site, New York, New York, United States|Research Site, Williston Park, New York, United States|Research Site, Yonkers, New York, United States|Research Site, Greenville, North Carolina, United States|Research Site, Lakewood, Ohio, United States|Research Site, Westlake, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Wilkes Barre, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Sumter, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Olympia, Washington, United States|Research Site, Madison, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00108004
NCT00107107,Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: pramlintide acetate,To investigate the long term safety profile of pramlintide treatment in subjects with type 1 diabetes completing protocol 137-150.|To examine the long-term effect of subcutaneously (SC) injected pramlintide on body weight|To examine the effects of long term pramlintide treatment on HbA1c in subjects with type 1 diabetes completing protocol 137-150.,AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,190,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,137-150E,Nov-02,Jun-05,Jun-05,6-Apr-05,null,23-Sep-15,"Research Site, Tempe, Arizona, United States|Research Site, Concord, California, United States|Research Site, Fresno, California, United States|Research Site, San Diego, California, United States|Research Site, San Mateo, California, United States|Research Site, Santa Barbara, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Aventura, Florida, United States|Research Site, Fort Myers, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Tallahassee, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Detroit, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, St. Peters, Missouri, United States|Research Site, Butte, Montana, United States|Research Site, Durham, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Irving, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT00107107
NCT00105352,Improving Metabolic Assessments in Type 1 Diabetes Mellitus Clinical Trials,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Procedure: Mixed Meal Tolerance Test|Procedure: Glucagon Stimulation Test,"Stimulated C-peptide response derived from the 2-hour MMTT and the glucagon stimulation test (GST)|Time to peak C-peptide on MMTT, and the peak and AUC values from each test|Co-efficient of reproducibility of the MMTT, and the GST, provided from the duplicate tests within the same individuals",National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Juvenile Diabetes Research Foundation|National Center for Research Resources (NCRR),All,"8 Years to 35 Years   (Child, Adult)",Not Applicable,120,NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,MMTTGST (IND) (completed),Nov-04,null,Nov-05,14-Mar-05,null,2-Jun-16,"Children's Hospital Los Angeles, Los Angeles, California, United States|University of California San Francisco, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver, Colorado, United States|University of Florida, Gainesville,, Florida, United States|University of Miami School of Medicine, Miami, Florida, United States|Riley Hospital for Children, Indiana University, Indianapolis, Indiana, United States|Joslin Diabetes Center/ Children's Hospital Boston, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Naomi Berrie Diabetes Center, Columbia University, New York, New York, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|University of Texas Medical Center at Dallas, Dallas, Texas, United States|Benaroya Research Institute, Seattle, Washington, United States|Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia|University of Toronto, Toronto, Ontario, Canada|University of Turku, Turku, Finland|Vita-Salute San Raffaele University, Milan, Italy|University of Bristol, Bristol, United Kingdom",,https://ClinicalTrials.gov/show/NCT00105352
NCT00102297,Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus,,Completed,No Results Available,Diabetes Mellitus,Drug: FG-3019,Safety|Tolerability|Pharmacokinetics|Bioactivity on urinary and plasma markers,FibroGen,All,"21 Years to 80 Years   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,FGCL-MC3019-003,Jan-05,null,Jun-07,27-Jan-05,null,12-Dec-07,"UCLA - LA BioMed, Los Angeles, California, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Radiant Research, Dallas, Texas, United States|Diabetes & Glandular Disease, San Antonio, Texas, United States|University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00102297
NCT00101673,Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11%,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: vildagliptin,Change from baseline in HbA1c at 12 weeks|Adverse event profile after 12 weeks of treatment|Patients with reduction in HbA1c >/= 0.7% after 12 weeks|Change from baseline in fasting plasma glucose at 12 weeks|Change from baseline in HOMA-B at 12 weeks|Change from baseline in body weight at 12 weeks,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,251,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CLAF237A2329,Mar-04,Jun-05,Jun-05,13-Jan-05,null,7-May-12,"Novartis Pharmaceuticals, Basel, Switzerland",,https://ClinicalTrials.gov/show/NCT00101673
NCT00101751,INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study,INITIATE plus,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 2",Drug: biphasic insulin aspart|Behavioral: dietary regimen,HbA1c and Incidence of hypoglycemia|Postprandial glucose from 8-point SMBG spontaneously reported adverse events; any changes from baseline,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 4,4877,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BIASP-2192,Oct-04,Jun-06,Jun-06,13-Jan-05,null,17-Oct-14,"Novo Nordisk Clinical Trial Call Center, Princeton, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00101751
NCT00100178,New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial,,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Mycophenolate mofeteil (MMF)|Drug: Daclizumab (DZB)|Drug: Placebo control for Mycophenolate mofeteil (MMF)|Drug: Placebo control for Daclizumab (DZB),Mean Stimulated C-peptide Area Under the Curve,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Juvenile Diabetes Research Foundation|National Center for Research Resources (NCRR),All,"8 Years to 45 Years   (Child, Adult)",Phase 2,126,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)",MMFDZB (IND) (completed),May-04,Apr-08,Apr-08,24-Dec-04,16-Aug-16,16-Aug-16,"Childrens Hospital Los Angeles, Los Angeles, California, United States|University of California-San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|Indiana University, Indianapolis, Indiana, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Columbia University, New York, New York, United States|Benaroya Research Institute, Seattle, Washington, United States|Hospital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00100178
NCT00097500,Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes,,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: exenatide|Drug: Insulin glargine|Drug: Metformin,"Beta-cell Function After 52 Weeks of Therapy|Beta-cell Function 4 Weeks After Cessation of Therapy|Change in First Phase C-peptide Release|Change in Second Phase C-peptide Release|Change in Glycosylated Hemoglobin (HbA1c)|Change in Fasting Plasma Glucose|Seven Point Self Monitored Blood Glucose (SMBG) Measurements|Change in Body Weight|M-value at Baseline, Week 52 and Week 56",AstraZeneca|Eli Lilly and Company,All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 3,69,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2993-114,Sep-04,Dec-09,Dec-09,25-Nov-04,10-Jan-11,7-Apr-15,"Research Site, Helsinki, Finland|Research Site, Amsterdam, Netherlands|Research Site, Goteborg, Sweden",,https://ClinicalTrials.gov/show/NCT00097500
NCT00097071,Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin lispro|Drug: insulin aspart,"HbA1c|Measurements of glycaemic control, safety parameters including frequency of hypoglycaemia, laboratory tests, clinical evaluations and adverse events",Novo Nordisk A/S,All,"3 Years to 18 Years   (Child, Adult)",Phase 3,299,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANA-2181,Oct-04,May-06,May-06,18-Nov-04,null,22-Dec-16,"Novo Nordisk Investigational Site, Mobile, Alabama, United States|Novo Nordisk Investigational Site, Montgomery, Alabama, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Little Rock, Arkansas, United States|Novo Nordisk Investigational Site, Loma Linda, California, United States|Novo Nordisk Investigational Site, Sacramento, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, Denver, Colorado, United States|Novo Nordisk Investigational Site, Englewood, Colorado, United States|Novo Nordisk Investigational Site, New Haven, Connecticut, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, St. Petersburg, Florida, United States|Novo Nordisk Investigational Site, Tallahassee, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Indianapolis, Indiana, United States|Novo Nordisk Investigational Site, Iowa City, Iowa, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Wichita, Kansas, United States|Novo Nordisk Investigational Site, Baton Rouge, Louisiana, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Springfield, Massachusetts, United States|Novo Nordisk Investigational Site, Worcester, Massachusetts, United States|Novo Nordisk Investigational Site, Detroit, Michigan, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, Kansas City, Missouri, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Hackensack, New Jersey, United States|Novo Nordisk Investigational Site, Bronx, New York, United States|Novo Nordisk Investigational Site, Brooklyn, New York, United States|Novo Nordisk Investigational Site, Buffalo, New York, United States|Novo Nordisk Investigational Site, Manhasset, New York, United States|Novo Nordisk Investigational Site, Asheville, North Carolina, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Columbus, Ohio, United States|Novo Nordisk Investigational Site, Tulsa, Oklahoma, United States|Novo Nordisk Investigational Site, Portland, Oregon, United States|Novo Nordisk Investigational Site, Hershey, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Charleston, South Carolina, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Norfolk, Virginia, United States|Novo Nordisk Investigational Site, Seattle, Washington, United States|Novo Nordisk Investigational Site, Charleston, West Virginia, United States|Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00097071
NCT00095446,NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Drug: insulin aspart,Treatment satisfaction with insulin pump therapy|body weight|Insulin dose|Overall glycemic control|number and types of infusion sets used.|infusion set in-use times,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 4,513,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,ANA-2190,Jul-04,Mar-05,Mar-05,5-Nov-04,null,4-Jan-17,"Novo Nordisk Investigational Site, Princeton, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00095446
NCT00095082,Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin detemir|Drug: insulin glargine|Drug: insulin aspart,HbA1c|Adverse events|Body weight|Hypoglycemia|Blood glucose|Insulin Treatment Satisfaction,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,447,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN304-1430|2004-000086-35,Sep-04,Dec-05,Dec-05,1-Nov-04,null,27-Jan-17,"Novo Nordisk Investigational Site, Anaheim, California, United States|Novo Nordisk Investigational Site, Huntington Beach, California, United States|Novo Nordisk Investigational Site, Inglewood, California, United States|Novo Nordisk Investigational Site, Irvine, California, United States|Novo Nordisk Investigational Site, La Jolla, California, United States|Novo Nordisk Investigational Site, Hollywood, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Lake Mary, Florida, United States|Novo Nordisk Investigational Site, Melbourne, Florida, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Vero Beach, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Hyattsville, Maryland, United States|Novo Nordisk Investigational Site, Detroit, Michigan, United States|Novo Nordisk Investigational Site, St. Louis, Missouri, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Berlin, New Jersey, United States|Novo Nordisk Investigational Site, Sea Girt, New Jersey, United States|Novo Nordisk Investigational Site, Asheville, North Carolina, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Kuopio, Finland|Novo Nordisk Investigational Site, Oulu, Finland|Novo Nordisk Investigational Site, Pori, Finland|Novo Nordisk Investigational Site, Vantaa, Finland|Novo Nordisk Investigational Site, ANGERS cedex 09, France|Novo Nordisk Investigational Site, Antibes, France|Novo Nordisk Investigational Site, Brest, France|Novo Nordisk Investigational Site, GRENOBLE cedex, France|Novo Nordisk Investigational Site, LA ROCHELLE cedex, France|Novo Nordisk Investigational Site, Mougins, France|Novo Nordisk Investigational Site, TOULOUSE cedex, France|Novo Nordisk Investigational Site, Alsdorf, Germany|Novo Nordisk Investigational Site, Bad Kreuznach, Germany|Novo Nordisk Investigational Site, Dormagen, Germany|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Flensburg, Germany|Novo Nordisk Investigational Site, Friedrichsthal, Germany|Novo Nordisk Investigational Site, Genthin, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Herrenberg, Germany|Novo Nordisk Investigational Site, Kippenheim, Germany|Novo Nordisk Investigational Site, Rehlingen-Siersburg, Germany|Novo Nordisk Investigational Site, Speyer, Germany|Novo Nordisk Investigational Site, St. Ingbert, Germany|Novo Nordisk Investigational Site, Völklingen, Germany|Novo Nordisk Investigational Site, Würzburg, Germany|Novo Nordisk Investigational Site, Almere, Netherlands|Novo Nordisk Investigational Site, Apeldoorn, Netherlands|Novo Nordisk Investigational Site, Capelle a/d IJssel, Netherlands|Novo Nordisk Investigational Site, Dordrecht, Netherlands|Novo Nordisk Investigational Site, Leeuwarden, Netherlands|Novo Nordisk Investigational Site, Zoetermeer, Netherlands|Novo Nordisk Investigational Site, Norrköping, Sweden|Novo Nordisk Investigational Site, Stockholm, Sweden|Novo Nordisk Investigational Site, Stockholm, Sweden|Novo Nordisk Investigational Site, Umeå, Sweden|Novo Nordisk Investigational Site, Växjö, Sweden|Novo Nordisk Investigational Site, Örebro, Sweden|Novo Nordisk Investigational Site, Abergavenny, United Kingdom|Novo Nordisk Investigational Site, Ayr, United Kingdom|Novo Nordisk Investigational Site, Brighton, United Kingdom|Novo Nordisk Investigational Site, Bristol, United Kingdom|Novo Nordisk Investigational Site, Cosham, United Kingdom|Novo Nordisk Investigational Site, Dundee, United Kingdom|Novo Nordisk Investigational Site, Glasgow, United Kingdom|Novo Nordisk Investigational Site, Livingstone, United Kingdom|Novo Nordisk Investigational Site, Plymouth, United Kingdom|Novo Nordisk Investigational Site, Sheffield, United Kingdom|Novo Nordisk Investigational Site, Watford, United Kingdom|Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom",,https://ClinicalTrials.gov/show/NCT00095082
NCT00073255,Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM),,Completed,No Results Available,"Diabetes Mellitus, Insulin-Dependent",Drug: hokt3g1 (ALA-ALA),,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"8 Years to 30 Years   (Child, Adult)",Phase 1,12,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ITNO17AI (completed),Jun-03,null,Dec-05,20-Nov-03,null,15-Jan-10,"Columbia University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00073255
NCT00073281,Islet Transplantation for Patients With Type 1 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Procedure: Islet transplantation,,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,10,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9903 (completed),Aug-03,null,Dec-04,20-Nov-03,null,15-Jan-10,"Columbia Presbyterian Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00073281
NCT00071448,Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin human|Drug: insulin lispro|Drug: insulin aspart,HbA1c (glycosylated haemoglobin A1c)|FPG (fasting plasma glucose),Novo Nordisk A/S,All,"6 Years to 18 Years   (Child, Adult)",Phase 3,378,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANA-2126,Jun-02,Jun-04,Jun-04,24-Oct-03,null,22-Dec-16,"Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Mobile, Alabama, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Loma Linda, California, United States|Novo Nordisk Investigational Site, Long Beach, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Sacramento, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, Englewood, Colorado, United States|Novo Nordisk Investigational Site, Hartford, Connecticut, United States|Novo Nordisk Investigational Site, New Haven, Connecticut, United States|Novo Nordisk Investigational Site, Gainesville, Florida, United States|Novo Nordisk Investigational Site, Gainesville, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Pensacola, Florida, United States|Novo Nordisk Investigational Site, Tallahassee, Florida, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Indianapolis, Indiana, United States|Novo Nordisk Investigational Site, Indianapolis, Indiana, United States|Novo Nordisk Investigational Site, Iowa City, Iowa, United States|Novo Nordisk Investigational Site, Baton Rouge, Louisiana, United States|Novo Nordisk Investigational Site, New Orleans, Louisiana, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Worcester, Massachusetts, United States|Novo Nordisk Investigational Site, Ann Arbor, Michigan, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, Rochester, Minnesota, United States|Novo Nordisk Investigational Site, Kansas City, Missouri, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Hackensack, New Jersey, United States|Novo Nordisk Investigational Site, Morristown, New Jersey, United States|Novo Nordisk Investigational Site, Paterson, New Jersey, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, Brooklyn, New York, United States|Novo Nordisk Investigational Site, Buffalo, New York, United States|Novo Nordisk Investigational Site, Mineola, New York, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, Rochester, New York, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Akron, Ohio, United States|Novo Nordisk Investigational Site, Cleveland, Ohio, United States|Novo Nordisk Investigational Site, Columbus, Ohio, United States|Novo Nordisk Investigational Site, Dayton, Ohio, United States|Novo Nordisk Investigational Site, Portland, Oregon, United States|Novo Nordisk Investigational Site, Danville, Pennsylvania, United States|Novo Nordisk Investigational Site, Erie, Pennsylvania, United States|Novo Nordisk Investigational Site, Hershey, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Charleston, South Carolina, United States|Novo Nordisk Investigational Site, Columbia, South Carolina, United States|Novo Nordisk Investigational Site, Greer, South Carolina, United States|Novo Nordisk Investigational Site, Memphis, Tennessee, United States|Novo Nordisk Investigational Site, Memphis, Tennessee, United States|Novo Nordisk Investigational Site, Corpus Christi, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Lackland, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Temple, Texas, United States|Novo Nordisk Investigational Site, Salt Lake City, Utah, United States|Novo Nordisk Investigational Site, Norfolk, Virginia, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Morgantown, West Virginia, United States|Novo Nordisk Investigational Site, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00071448
NCT00071409,Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Insulin-Dependent",Drug: INGAP-Peptide|Drug: placebo,"assess efficacy and safety based on arginine stimulated C peptide, fasting C peptide, average daily insulin dose, fasting glucose, glycosylated hemoglobin (Hb A1c), and AEs",Exsulin Corporation,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,63,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2003068,Oct-03,May-04,May-04,23-Oct-03,null,11-Jul-14,"Radiant Research, Irvine, California, United States|VA Hospital UCSD, San Diego, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|MedStar Clinical Research Center, Washington, District of Columbia, United States|Springfield Diabetes and Endocrine Center, Springfield, Illinois, United States|Mercury Street Medical, Butte, Montana, United States|UNC Diabetes Care Center, Durham, North Carolina, United States|Clinical Research Institute of Southern Oregon, Medford, Oregon, United States|University of Texas Health Science Center - Texas Diabetes Institute, San Antonio, Texas, United States|DGD Research Associates, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00071409
NCT00069836,Study Of AVANDAMET® With Or Without Insulin In Type II Diabetes Mellitus Patients. AVANDAMET® is a Registered Trademark of the GSK Group of Companies.,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Rosiglitazone/metformin,"Change from baseline in HbA1c|Insulin dose, FPG,glycaemic responders, beta-cell function, hypoglycaemia, treatment satisfaction",GlaxoSmithKline,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,272,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",712753/009,Oct-03,Nov-04,Nov-04,3-Oct-03,null,1-Sep-16,"GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Roubaix, Nord-Pas-de-Calais, France|GSK Investigational Site, Angers, France|GSK Investigational Site, Bondy Cedex, France|GSK Investigational Site, Cholet, France|GSK Investigational Site, Corbeil Essonnes Cedex, France|GSK Investigational Site, Douai Cedex, France|GSK Investigational Site, Epinay sur Orge, France|GSK Investigational Site, La Rochelle Cedex 1, France|GSK Investigational Site, Lorient, France|GSK Investigational Site, Lyon Cedex 03, France|GSK Investigational Site, Montbrison, France|GSK Investigational Site, Nantes Cedex 1, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Pierre Benite Cedex, France|GSK Investigational Site, Reims Cedex, France|GSK Investigational Site, Rennes Cedex 2, France|GSK Investigational Site, Saint Malo Cedex, France|GSK Investigational Site, Toul Cedex, France|GSK Investigational Site, Venissieux, France|GSK Investigational Site, Hermaringen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Kippenheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Mannheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Mannheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Sinsheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Stockach, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ilvesheim, Bayern, Germany|GSK Investigational Site, Kuenzing, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Wallerfing, Bayern, Germany|GSK Investigational Site, Falkensee, Brandenburg, Germany|GSK Investigational Site, Potsdam, Brandenburg, Germany|GSK Investigational Site, Schwedt, Brandenburg, Germany|GSK Investigational Site, Bad Kreuznach, Hessen, Germany|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Schluechtern, Hessen, Germany|GSK Investigational Site, Vellmar, Hessen, Germany|GSK Investigational Site, Hildesheim, Niedersachsen, Germany|GSK Investigational Site, Aachen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bad Oeynhausen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Beckum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dortmund, Nordrhein-Westfalen, Germany|GSK Investigational Site, Goch, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Neuss, Nordrhein-Westfalen, Germany|GSK Investigational Site, Viersen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Altenkirchen, Rheinland-Pfalz, Germany|GSK Investigational Site, Ludwigshafen, Rheinland-Pfalz, Germany|GSK Investigational Site, Rhaunen, Rheinland-Pfalz, Germany|GSK Investigational Site, Simmern, Rheinland-Pfalz, Germany|GSK Investigational Site, Speyer, Rheinland-Pfalz, Germany|GSK Investigational Site, Saarlouis, Saarland, Germany|GSK Investigational Site, Halberstadt, Sachsen-Anhalt, Germany|GSK Investigational Site, Halle, Sachsen-Anhalt, Germany|GSK Investigational Site, Halle, Sachsen-Anhalt, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Freital, Sachsen, Germany|GSK Investigational Site, Pirna, Sachsen, Germany|GSK Investigational Site, Gotha, Thueringen, Germany|GSK Investigational Site, Schleiz, Thueringen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Parma, Emilia-Romagna, Italy|GSK Investigational Site, Pordenone, Friuli-Venezia-Giulia, Italy|GSK Investigational Site, Genova, Liguria, Italy|GSK Investigational Site, Perugia, Umbria, Italy|GSK Investigational Site, Padova, Veneto, Italy|GSK Investigational Site, Treviso, Veneto, Italy|GSK Investigational Site, Alcobendas/Madrid, Spain|GSK Investigational Site, Alicante, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Cadiz, Spain|GSK Investigational Site, Galdakano, Spain|GSK Investigational Site, Granada, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Móstoles/Madrid, Spain|GSK Investigational Site, Pontevedra, Spain|GSK Investigational Site, Sabadell (Barcelona), Spain|GSK Investigational Site, San Juan De Alicante, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Vigo/Pontevedra, Spain",,https://ClinicalTrials.gov/show/NCT00069836
NCT00069537,Continuous Glucose Monitors for Children With Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Insulin-Dependent",Device: The GlucoWatch® G2™ Biographer (GW2B)|Device: The Continuous Glucose Monitoring System (CGMS™),Accuracy of the GlucoWatch G2 Biographer and CGMS,Jaeb Center for Health Research|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,1 Year to 17 Years   (Child),Phase 4,90,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DirecNet 001|HD041890|HD041919-01|HD041908-01|HD041906-01|HD041918-01|HD041915,May-02,null,Nov-02,30-Sep-03,null,5-Sep-16,"Division of Pediatric Endocrinology and Diabetes, Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver, Colorado, United States|Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, United States|Nemours Children's Clinic, Jacksonville,, Florida, United States|Jaeb Center for Health Research, Tampa, Florida, United States|Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, Iowa, United States",,https://ClinicalTrials.gov/show/NCT00069537
NCT00069615,Pilot Study of the GlucoWatch G2 Biographer for the Management of Type 1 Diabetes in Children,,Completed,No Results Available,"Diabetes Mellitus, Insulin-Dependent",Device: GlucoWatch® G2™ Biographer (GW2B)|Device: Continuous Glucose Monitoring System™ (CGMS),Feasibility of using the GlucoWatch G2 Biographer|Feasibility of collecting data from home computers,Jaeb Center for Health Research|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,7 Years to 17 Years   (Child),Phase 4,15,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),DirecNet 003|HD041890|HD041919-01|HD041908-01|HD041906-01|HD041918-01|HD041915,Feb-03,null,Jun-03,30-Sep-03,null,5-Sep-16,"Division of Pediatric Endocrinology and Diabetes, Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver, Colorado, United States|Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, United States|Nemours Children's Clinic, Jacksonville,, Florida, United States|Jaeb Center for Health Research, Tampa, Florida, United States|Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, Iowa, United States",,https://ClinicalTrials.gov/show/NCT00069615
NCT00069628,Randomized Clinical Trial to Assess the Effectiveness of the GlucoWatch Biographer,,Completed,No Results Available,"Diabetes Mellitus, Insulin-Dependent",Device: GlucoWatch® G2™ Biographer (GW2B)|Device: Continuous Glucose Monitoring System (CGMS),HbA1c value obtained 6 months after randomization|Number of hypoglycemic events during 6 months|Diabetes Worry Scale at 6 months|PedsQL Diabetes Module at 6 months|Diabetes Self Management Profile at 6 months,Jaeb Center for Health Research|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,7 Years to 17 Years   (Child),Phase 4,200,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DirecNet 004|HD041890|HD041919-01|HD041908-01|HD041906-01|HD041918-01|HD041915,Jul-03,null,Nov-04,30-Sep-03,null,5-Sep-16,"Division of Pediatric Endocrinology and Diabetes, Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver, Colorado, United States|Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, United States|Nemours Children's Clinic, Jacksonville,, Florida, United States|Jaeb Center for Health Research, Tampa, Florida, United States|Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, Iowa, United States",,https://ClinicalTrials.gov/show/NCT00069628
NCT00067951,A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: rosiglitazone/metformin,"Hemoglobin A1c (HbA1c) reduction after 24 weeks of treatment.|Change in FPG, insulin,C-peptide, insulin sensitivity,beta cell function, free fatty acids, lipids. Change in weight, vital signs, clinical laboratory tests, and adverse experiences.",GlaxoSmithKline,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,190,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,712753/004,17-Oct-03,1-Nov-04,30-Nov-04,5-Sep-03,null,21-Mar-18,"GSK Investigational Site, Anniston, Alabama, United States|GSK Investigational Site, Chandler, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Encinitas, California, United States|GSK Investigational Site, Fullerton, California, United States|GSK Investigational Site, Los Banos, California, United States|GSK Investigational Site, Mission Viejo, California, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Melbourne, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Saint Cloud, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Fayetteville, Georgia, United States|GSK Investigational Site, Woodstock, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Evansville, Indiana, United States|GSK Investigational Site, Newburgh, Indiana, United States|GSK Investigational Site, Slidell, Louisiana, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, Chesterfield, Missouri, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Kingston, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Rochester, New York, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Mogadore, Ohio, United States|GSK Investigational Site, Downingtown, Pennsylvania, United States|GSK Investigational Site, Warminster, Pennsylvania, United States|GSK Investigational Site, West Chester, Pennsylvania, United States|GSK Investigational Site, Johnson City, Tennessee, United States|GSK Investigational Site, Arlington, Texas, United States|GSK Investigational Site, Beaumont, Texas, United States|GSK Investigational Site, Bryan, Texas, United States|GSK Investigational Site, Corpus Christi, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Midland, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Spokane, Washington, United States|GSK Investigational Site, Wenatchee, Washington, United States|GSK Investigational Site, Camperdown, New South Wales, Australia|GSK Investigational Site, St Leonards, New South Wales, Australia|GSK Investigational Site, Wollongong, New South Wales, Australia|GSK Investigational Site, Kippa Ring, Queensland, Australia|GSK Investigational Site, Woolloongabba, Queensland, Australia|GSK Investigational Site, North Adelaide, South Australia, Australia|GSK Investigational Site, Caulfield, Victoria, Australia|GSK Investigational Site, Fremantle, Western Australia, Australia|GSK Investigational Site, Perth, Western Australia, Australia|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Coquitlam, British Columbia, Canada|GSK Investigational Site, Langley, British Columbia, Canada|GSK Investigational Site, Moncton, New Brunswick, Canada|GSK Investigational Site, Halifax, Nova Scotia, Canada|GSK Investigational Site, Brampton, Ontario, Canada|GSK Investigational Site, Burlington, Ontario, Canada|GSK Investigational Site, Courtice, Ontario, Canada|GSK Investigational Site, Kitchener, Ontario, Canada|GSK Investigational Site, North Bay, Ontario, Canada|GSK Investigational Site, Oshawa, Ontario, Canada|GSK Investigational Site, Peterborough, Ontario, Canada|GSK Investigational Site, Peterborough, Ontario, Canada|GSK Investigational Site, Renfrew, Ontario, Canada|GSK Investigational Site, Stoney Creek, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Laval, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Plessisville, Quebec, Canada|GSK Investigational Site, Pointe-Claire, Quebec, Canada|GSK Investigational Site, Saint Insidore De Dorchester, Quebec, Canada|GSK Investigational Site, Saint Marc Des Carrieres, Quebec, Canada|GSK Investigational Site, Sainte Jerome, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Regina, Saskatchewan, Canada|GSK Investigational Site, Saskatoon, Saskatchewan, Canada|GSK Investigational Site, Pusan, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Uijeongbu,, Korea, Republic of|GSK Investigational Site, Auckland, New Zealand|GSK Investigational Site, Auckland, New Zealand|GSK Investigational Site, Christchurch, New Zealand|GSK Investigational Site, Rotorua, New Zealand|GSK Investigational Site, Wellington, New Zealand",,https://ClinicalTrials.gov/show/NCT00067951
NCT00067678,Soy Protein in Early Diabetic Nephropathy,,Completed,No Results Available,Diabetic Nephropathy|Diabetes Mellitus,Drug: soy protein,,National Center for Complementary and Integrative Health (NCCIH),All,18 Years to 40 Years   (Adult),Phase 1|Phase 2,null,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,R21AT000323-01,Jul-01,null,Jun-03,27-Aug-03,null,18-Aug-06,"University of Kentucky, Lexington, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT00067678
NCT00064714,Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes,,Completed,No Results Available,Diabetes Mellitus,Drug: AC2993 (exenatide)|Drug: daclizumab (immunosuppressive),Change in basal C-peptide level,AstraZeneca|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,18 Years to 60 Years   (Adult),Phase 2,47,Industry|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,030245 (2993T1-101)|03-DK-0245,Jul-03,Mar-08,Mar-08,11-Jul-03,null,11-Mar-15,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00064714
NCT00063128,Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus.,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: insulin|Drug: human insulin inhalation powder (HIIP),"test the hypothesis that preprandial HIIP plus insulin glargine is noninferior to preprandial injectable insulin (regular human insulin or insulin lispro) plus insulin glargine with respect to HbA1c|compare the pharmacokinetics of test doses of preprandial HIIP and preprandial injectable insulin (regular human insulin or insulin lispro) administered to a subgroup of patients|compare 7-point self-monitored blood glucose profiles (blood glucose measurements before & 2 hours after start of morning, midday, evening meals, and blood glucose measurement at bedtime) for preprandial HIIP and preprandial inject|assess the safety of HIIP using pulmonary function tests, chest x rays, insulin antibody titers, adverse events (AEs), and episodes of hypoglycemia|assess symptoms of diabetes, patient vitality, and patient satisfaction with the diabetes treatments|compare insulin dose requirements (both preprandial and basal insulin [insulin glargine]) of patients administering preprandial HIIP and preprandial injectable insulin (regular human insulin or insulin lispro|assess insulin inhaler reliability|assess patient compliance with the HIIP delivery system Directions for Use (DFU)|assess the impact of practice inhalations on inspiratory flow parameters (peak inspiratory flow rate [IFR] and total inspired volume [TIV]) achieved by patients using the insulin inhaler following training with the DFU","Eli Lilly and Company|Alkermes, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,119,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6944|H7U-MC-IDAI,Apr-03,null,Apr-04,25-Jun-03,null,21-Dec-07,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denver, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hollywood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Port Richey, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ocala, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pembroke Pines, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Idaho Falls, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Springfield, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jackson, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chesterfield, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamptom, New Hampshire, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Flushing, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Hyde Park, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenville, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salem, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbia, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Federal Way, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Renton, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tacoma, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT00063128
NCT00058981,"Safety, Tolerability, Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in Latent Autoimmune Diabetes in Adults (LADA)",,Terminated,No Results Available,"Diabetes, Autoimmune",Drug: DiaPep277,,"DeveloGen Israel, Ltd.",All,"30 Years to 65 Years   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,702/PO,Oct-02,Mar-07,May-07,24-Apr-03,null,19-Mar-09,"University of Alabama at Birmingham Endocrinology Department, Birmingham, Alabama, United States|University of Colorado Hospital Endocrinology Practice, Aurora, Colorado, United States|University of Kentucky Department of Internal Medicine, Lexington, Kentucky, United States|Washington University School of Medicine Endocrinology/Metabolic Dept, Saint Louis, Missouri, United States|North Shore Diabetes and Endocrine Associates, New Hyde Park, New York, United States|Diabetes & Glandular Disease Research Associates, San Antonio, Texas, United States|DVA Puget Sound Health Care System Endocrinology (III) Department, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00058981
NCT00057499,Evaluation of a Diabetes Vaccine in Newly Diagnosed Diabetics,,Completed,No Results Available,Insulin-dependent Diabetes Mellitus|Diabetes Mellitus,Biological: IBC-VS01|Biological: IBC-VS01 placebo,"Clinical endpoints including adverse events, local reactions, routine physical exams, insulin dose, and laboratory tests|C-peptide levels in response to mixed meal tolerance test|HbA1c, GAD65Ab, IAA, IA2Ab, GAD65Ab isotypes|CD4- and CD8- Va24JaQ+|T cells' secretion of IL-4 and Interferon (IFN)-gamma",National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN),All,18 Years to 35 Years   (Adult),Phase 1,12,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DAIT ITN012AI|DAIT BD012,Mar-03,Mar-07,Mar-07,4-Apr-03,null,8-Feb-17,"Children's Hospital, Boston, Massachusetts, United States|Joslin Diabetes Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00057499
NCT00046501,Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents,,Completed,No Results Available,Diabetes Mellitus,Drug: Lantus (insulin glargine [rDNA origin] injection)|Drug: Humulin N|Drug: Humulin L|Drug: Lispro,"to measure change in glycemic control as measured by hemoglobin A1c (A1c).|Change in A1c|Percentage of subjects achieving an A1c ≤7.0; percent of preteens (12 years and below) achieving 8%; teens (13-18 years) achieving 7.5%|Change in fasting self-monitored blood glucose (SMBG) for weekdays, weekends and weekday/weekend combined|Change in urinary spot random microalbumin-to-creatinine (A/C) ratio|Change in 8-point blood glucose profiles for weekdays, weekends, and weekday/weekend combined|Change in average basal insulin doses|Change in lipids (total cholesterol [TC], high-density lipoprotein cholesterol [HDL], low-density lipoprotein cholesterol [LDL], and triglycerides [TGs])|Change in glucose|Occurrence of hypoglycemia|Adverse events (AEs)|Clinical values: physical examination, vital signs, change in age-adjusted body mass index (BMI)",Sanofi,All,9 Years to 17 Years   (Child),Phase 3,250,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HOE901_4030,Nov-02,Feb-05,null,2-Oct-02,null,11-Jan-11,"Aventis, Bridgewater, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00046501
NCT00046150,"12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes.",,Completed,No Results Available,"Diabetes, Type I",Drug: Insulin glulisine (HMR1964),"Frequency of catheter occlusions|Unexplained hyperglycemia, parameters of glycemic control",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,59,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HMR1964/3006|HMR1964,May-02,null,Dec-02,23-Sep-02,null,19-Jun-08,"Hospital de Rangueil, Toulouse, France|Sanofi-aventis Administrative Office, Berlin, Germany|Sanofi-aventis Administrative Office, Gouda, Netherlands",,https://ClinicalTrials.gov/show/NCT00046150
NCT00044668,"Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination",,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: AC2993,"Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 24, Week 52, and to each intermediate visit|Change in concentrations of fasting plasma glucose and lipids from Baseline Visit 2 (Day 1) to Week 24, to Week 52, and to each intermediate visit",AstraZeneca|Eli Lilly and Company,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 3,155,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2993-117,Aug-02,Sep-05,Sep-05,5-Sep-02,null,20-Feb-15,"Diagnostic Units Hungary Kft., Budapest, Hungary|Peterfy Teaching Hospital, Budapest, Hungary|Uzsoki Street Municipal Hospital, Budapest, Hungary",,https://ClinicalTrials.gov/show/NCT00044668
NCT00044395,Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes,,Completed,No Results Available,"Diabetic Neuropathies|Diabetes Mellitus, Insulin-Dependent|Diabetes Mellitus, Non-Insulin-Dependent",Drug: Ruboxistaurin mesylate,"Reduction in neuropathic symptoms|Vibration sensation;Neurological signs;Electrophysiology of peroneal, tibial and sural nerves;Relief of symptoms as measured by VAS;Composite scores of nerve function;Clinical global impression of change",Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,200,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,2133|B7A-MC-MBBP,Jul-02,null,Oct-05,30-Aug-02,null,6-Nov-07,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Mesa, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Irvine, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tustin, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, New Britain, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Weston, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Henderson, Nevada, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Medford, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Buffalo, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Syracuse, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Burlington, Vermont, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Norfolk, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Morgantown, West Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Camperdown, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Randwick, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, St Leonards, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Caulfield, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Clayton, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Edegem, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Huy, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Willebroeck, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Aarhus C, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Keila, Estonia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tallinn, Estonia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Dresden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Dusseldorf, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Debrecen, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Jerusalem, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Santiago, La Coruna, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Dos Hermanas, Sevilla, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT00044395
NCT00044408,Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes,,Completed,No Results Available,"Diabetic Neuropathies|Diabetes Mellitus, Insulin-Dependent|Diabetes Mellitus, Non-Insulin-Dependent",Drug: Ruboxistaurin mesylate,"Reduction in neuropathic symptoms|Vibration sensation;Neurological signs;Electrophysiology of peroneal, tibial and sural nerves;Relief of symptoms as measured by VAS;Composite scores of nerve function;Clinical global impression of change","Chromaderm, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,200,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,6204|B7A-MC-MBCW,Jul-02,null,Oct-05,30-Aug-02,null,26-Jul-16,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Long Beach, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Norwalk, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Clearwater, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plantation, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Idaho Falls, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., North Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boston, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Minneapolis, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbia, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbia, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vancouver, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winnipeg, Manitoba, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Halifax, Nova Scotia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charlottetown, Prince Edward Island, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Laval, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zagreb, Croatia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Helsinki, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jyvaskyla, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oulu, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gopalapuram, Chennai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mumbai, Maharashtra, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyderabad, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaunas, Lithuania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Klaipeda, Lithuania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vilnus, Lithuania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amersfoort, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poole, Dorset, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salford, Manchester, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shrewsbury, Shropshire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sheffield, South Yorkshire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT00044408
NCT00042601,Evaluation of the Effect of Pramlintide on Satiety and Food Intake,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Drug: Pramlintide acetate|Drug: Placebo,Change in satiety of participants on Pramlintide|Change in food intake of participants on Pramlintide|Effect of pramlintide on postprandial metabolic and hormonal responses,AstraZeneca,Male,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,51,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",137-149,Jul-02,Oct-03,Oct-03,5-Aug-02,null,21-Oct-15,"Royal Adelaide Hospital, Adelaide, South Australia, Australia",,https://ClinicalTrials.gov/show/NCT00042601
NCT00042458,Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Drug: Pramlintide acetate|Drug: Placebo,"- To investigate the safety of pramlintide treatment employing dose titration upon initiation of pramlintide followed by insulin dose optimization in subjects with type 1 diabetes.|- To examine the change in HbA1c, postprandial glucose concentration, and ",AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,296,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",137-150,Apr-02,Mar-03,Mar-03,1-Aug-02,null,23-Sep-15,"Ana Ventures LLC, Mesa, Arizona, United States|Phoenix Endocrinology Clinic, Ltd., Phoenix, Arizona, United States|East Bay Clinical Trial Center, Concord, California, United States|Valley Research, Fresno, California, United States|UCSD Diabetes Research Center, San Diego, California, United States|Diabetes Research Institute, San Mateo, California, United States|Sansum Medical Research Institute, Santa Barbara, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Barbara Davis Center for Childhood Diabetes, Denver, Colorado, United States|MedStar Clinical Research Center, Washington, District of Columbia, United States|Medical Research Unlimited, Aventura, Florida, United States|Medical Research Unlimited, Aventura, Florida, United States|Internal Medicine Associates, Fort Myers, Florida, United States|Suncoast Clinical Research, New Port Richey, Florida, United States|Children's Clinic, Tallahassee, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|St. James Diabetes Center, Chicago Heights, Illinois, United States|St. James Diabetes Center, Chicago Heights, Illinois, United States|Indiana University Outpatient Clinical Research, Indianapolis, Indiana, United States|University of Maryland Joslin Diabetes Center, Baltimore, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|Grand Rapids Associated Interns, Grand Rapids, Michigan, United States|Radiant Research, St. Louis, Missouri, United States|Mercury Street Medical, Butte, Montana, United States|UNC Diabetes Care Center, Durham, North Carolina, United States|Ohio State Univ.-Division of Endocrinology, Diabetes, Columbus, Ohio, United States|Radiant Research, Portland, Oregon, United States|Physicians for Clinical Research, Camp Hill, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|North Texas Clinical Research, Irving, Texas, United States|Private Practice, Lufkin, Texas, United States|Private Practice, Lufkin, Texas, United States|Rainier Clinical Research Center, Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT00042458
NCT00042471,Evaluation of the Bioavailability of Pramlintide,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Drug: Pramlintide acetate,Effect of varying needle length on bioavailability of Pramlintide|Effect of varying needle length on safety and tolerability of Pramlintide,AstraZeneca,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,75,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,137-153,Jun-02,Dec-02,Dec-02,1-Aug-02,null,23-Sep-15,"Orlando Clinical Research Center, Orlando, Florida, United States|New Orleans Center for Clinical Research, New Orleans, Louisiana, United States|DaVita Clinical Research, Minneapolis, Minnesota, United States|CEDRA Clinical Research, LLC, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT00042471
NCT00039013,Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: AC2993|Drug: Placebo,Change in HbA1c (glycosylated hemoglobin) from baseline to study termination (Week 30)|Change in HbA1c from baseline (Day 1) to each of the intermediate visits|The number of subjects achieving HbA1c target values of < 7% and < 8% by Week 30|The number of subjects achieving HbA1c reductions of > 0.5% and > 1.0% by Week 30|The time to achieve specific HbA1c target values of < 7% and < 8%|The time to achieve HbA1c reductions of 0.5% or more and >1.0% or more|Change in body weight from Baseline to each intermediate visit and Week 30,AstraZeneca,All,"16 Years to 75 Years   (Child, Adult, Older Adult)",Phase 3,336,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2993-112,Mar-02,Jun-03,Jun-03,10-Jun-02,null,24-Feb-15,"Pinnacle Research Group, Anniston, Alabama, United States|Parkway Medical Center, Birmingham, Alabama, United States|Alabama Clinical Therapeutics, Birmingham, Alabama, United States|Eclectic Family Care, Eclectic, Alabama, United States|Winston Physician Services, Haleyville, Alabama, United States|Simon Williamson Clinic, Hueytown, Alabama, United States|Extended Arm Physicians/ Southern Drug, Montgomery, Alabama, United States|Southern Drug Research Network, Tallassee, Alabama, United States|Clinic of Physicians and Surgeons, Ltd., Mesa, Arizona, United States|ANA Ventures, LLC, Mesa, Arizona, United States|Lovelace Scientific Resources-Phoenix, Phoenix, Arizona, United States|Physicians at the Peak, Phoenix, Arizona, United States|Advanced Clinical Therapeutics, Tucson, Arizona, United States|CAVHS, Little Rock, Arkansas, United States|Physicians Group Research Clinic, LLC, Little Rock, Arkansas, United States|Advanced Clinical Research Institute, Anaheim, California, United States|Mitchell Research Group, Inc., Bakersfield, California, United States|William Zigrang, M.D., Burlingame, California, United States|International Clinical Research Network, Chula Vista, California, United States|Arrowhead Regional Medical Center, Colton, California, United States|Valley Research, Fresno, California, United States|Elke Jost-Vu, M.D., Rancho Mirage, California, United States|Comprehensive Diabetes-Endocrine Medical Associates, Redwood City, California, United States|nTouch, San Diego, California, United States|Radiant Research-San Diego, San Diego, California, United States|Veterans Medical Research Foundation, San Diego, California, United States|Diabetes Research Institute of Mills Peninsula, San Mateo, California, United States|Advanced Clinical Research Institute, Santa Ana, California, United States|West Coast Clinical Trials, Signal Hill, California, United States|Protocare Trials at Sharp Mission Park, Vista, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Medstar Clinical Research, Washington, District of Columbia, United States|George Washington University, Washington, District of Columbia, United States|Internal Medical Associates, Ft. Myers, Florida, United States|Clin Sci International, Gainesville, Florida, United States|University of FL, Gainesville, Florida, United States|Jupiter Research Institute, Jupiter, Florida, United States|Baptist Diabetes Associates, Miami, Florida, United States|Tampa Medical Group, Tampa, Florida, United States|Metabolic Research Institute, Inc., West Palm Beach, Florida, United States|Radiant Research, West Palm Beach, Florida, United States|nTouch Research Corporation, Decatur, Georgia, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|St. Luke's Family Health, Meridian, Idaho, United States|University Primary Care Center at Belvidere, Belvidere, Illinois, United States|Northwestern Memorial Physicians Group, Chicago, Illinois, United States|Illinois Center for Clinical Trials, Chicago, Illinois, United States|Lake Forest Internal Medicine, Libertyville, Illinois, United States|Winchester Research Group, Libertyville, Illinois, United States|Medical Group of Fort Wayne, Fort Wayne, Indiana, United States|American Health Network, Indianapolis, Indiana, United States|Center for Metabolic and Hormonal Disorders, Indianapolis, Indiana, United States|nTouch Research-South Bend, South Bend, Indiana, United States|Kentucky Diabetes Center, Lexington, Kentucky, United States|University of Kentucky Metabolic Research Group, Lexington, Kentucky, United States|MedResearch, Inc., Louisville, Kentucky, United States|Drug Research Services, Metairie, Louisiana, United States|New Orleans Institute of Clinical Investigation, New Orleans, Louisiana, United States|Ochsner Clinic, New Orleans, Louisiana, United States|St. Agnes Health Care, Baltimore, Maryland, United States|Doctors Research Associates of Maryland, Lanham, Maryland, United States|Grunberger Diabetes Medical Center, Bloomfield Hills, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Grand Rapids Associated Interns, Grand Rapids, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Diabetes and Endocrinology Specialists, Chesterfield, Missouri, United States|Mid Missouri Research Specialists, Inc., Rolla, Missouri, United States|Radiant Research-St. Louis, St. Louis, Missouri, United States|Midwest Pharmaceutical Research, St. Peters, Missouri, United States|Mercury Street Medical, Butte, Montana, United States|Lovelace Scientific Resources-Las Vegas, Las Vegas, Nevada, United States|HIS Clinical Research, Jersey City, New Jersey, United States|Radiant Research-Moorestown, Moorestown, New Jersey, United States|New Jersey Physicians, Passaic, New Jersey, United States|Lovelace Scientific Resources, Albuquerque, New Mexico, United States|Medical Network Services, P.C., Brooklyn, New York, United States|St. Lukes Roosevelt Hospital, New York, New York, United States|Naomi Berrie Diabetes Center at Columbia University, New York, New York, United States|Heights Medical Care, New York, New York, United States|Rochester Clinical Research, Rochester, New York, United States|DOCS at Beth Israel Medical Center, Yonkers, New York, United States|Metrolina Medical Research, Charlotte, North Carolina, United States|Charlotte Clinical Research, Charlotte, North Carolina, United States|UNC Diabetes Care Center, Durham, North Carolina, United States|Unifour Medical Research, Hickory, North Carolina, United States|New Hanover Medical Research Associates, Wilmington, North Carolina, United States|Piedmont Medical Research, Winston-Salem, North Carolina, United States|Rapid Medical Research, Cleveland, Ohio, United States|Ohio State University-Division of Endocrinology, Columbus, Ohio, United States|Radiant Research-Columbus, Columbus, Ohio, United States|University Mednet, Mentor, Ohio, United States|COR Clinical Research, Oklahoma City, Oklahoma, United States|nTouch Research Corporation-Oklahoma City, Oklahoma City, Oklahoma, United States|Utica Park Clinic, Tulsa, Oklahoma, United States|Medford Medical Clinic, Medford, Oregon, United States|Legacy Clinical Research, Portland, Oregon, United States|Radiant Research, Portland, Oregon, United States|Physicians for Clinical Research, Camp Hill, Pennsylvania, United States|Thomas Jefferson University Diabetes Research Center, Philadelphia, Pennsylvania, United States|Philadelphia Health Associates, Philadelphia, Pennsylvania, United States|Tipton Medical and Diagnostic Center, Tipton, Pennsylvania, United States|Safe Harbor Clinical Research, East Providence, Rhode Island, United States|Radiant Research-Charleston, Charleston, South Carolina, United States|CNS Clinical Trials, Chester, South Carolina, United States|Coastal Carolina Research Center, Mt. Pleasant, South Carolina, United States|Integrity Clinical Research, Jackson, Tennessee, United States|Harmony Clinical Research, Johnson City, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|Endocrine Consultants of ET, Knoxville, Tennessee, United States|Central Texas Clinical Research, Austin, Texas, United States|Rafael Canadas M.D., P.A., Dallas, Texas, United States|Texas Tech University Health Sciences-Internal Medicine, El Paso, Texas, United States|Internal Medicine Associates, El Paso, Texas, United States|North Texas Clinical Research, Irving, Texas, United States|Dr. Humberto Bruschetta, Kingsville, Texas, United States|South Texas Applied Research, McAllen, Texas, United States|University of Texas Health Sciences Center-Texas Diabetes Institute, San Antonio, Texas, United States|Diabetes and Glandular Disease Clinic, San Antonio, Texas, United States|SAM Clinical Research Center, San Antonio, Texas, United States|Salt Lake Research, Salt Lake City, Utah, United States|Evergreen Diabetes & Endocrinology, Kirkland, Washington, United States|West Olympia Internal Medicine, Olympia, Washington, United States|Rainier Clinical Research Center, Renton, Washington, United States|Northside Internal Medicine, Spokane, Washington, United States|Rockwood Clinic, Spokane, Washington, United States|Julia M. Hutchinson, M.D., Spokane, Washington, United States|Wenatchee Valley Clinic, Wenatchee, Washington, United States|Hyperion Clinical Research, Charleston, West Virginia, United States|CAMC Clinical Trials Center, Charleston, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT00039013
NCT00039026,Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea,,Completed,No Results Available,"Diabetes Mellitus, Non-Insulin-Dependent",Drug: AC2993|Drug: Placebo,Change in HbA1c from Baseline to Week 30|Change in HbA1c from baseline (Day 1) to each of the intermediate visits|The number of subjects achieving HbA1c target values of < 7% and < 8% by Week 30|The number of subjects achieving HbA1c reductions of > 0.5% and > 1.0% by Week 30|The time to achieve HbA1c reductions of 0.5% or more and >1.0% or more|The time to achieve specific HbA1c target values of < 7% and < 8%|Change in body weight from Baseline to each intermediate visit and Week 30,AstraZeneca,All,"16 Years to 75 Years   (Child, Adult, Older Adult)",Phase 3,377,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2993-113,Feb-02,Aug-03,Aug-03,10-Jun-02,null,24-Feb-15,"Pinnacle Research Group, Anniston, Alabama, United States|Parkway Medical Center, Birmingham, Alabama, United States|Alabama Clinical Therapeutics, Birmingham, Alabama, United States|Eclectic Family Care, Eclectic, Alabama, United States|Winston Physician Services, Haleyville, Alabama, United States|Simon Williamson Clinic, Hueytown, Alabama, United States|Extended Arm Physicians/ Southern Drug, Montgomery, Alabama, United States|Southern Drug Research Network, Tallassee, Alabama, United States|Clinic of Physicians and Surgeons, Ltd., Mesa, Arizona, United States|ANA Ventures, LLC, Mesa, Arizona, United States|Lovelace Scientific Resources-Phoenix, Phoenix, Arizona, United States|Physicians at the Peak, Phoenix, Arizona, United States|Advanced Clinical Therapeutics, Tucson, Arizona, United States|CAVHS, Little Rock, Arkansas, United States|Physicians Group Research Clinic, LLC, Little Rock, Arkansas, United States|Advanced Clinical Research Institute, Anaheim, California, United States|Mitchell Research Group, Inc., Bakersfield, California, United States|William Zigrang, M.D., Burlingame, California, United States|International Clinical Research Network, Chula Vista, California, United States|Arrowhead Regional Medical Center, Colton, California, United States|East Bay Clinical Trial Center, Concord, California, United States|Valley Research, Fresno, California, United States|Tushar Modi, M.D., Modesto, California, United States|Elke Jost-Vu, M.D., Rancho Mirage, California, United States|Comprehensive Diabetes-Endocrine Medical Associates, Redwood City, California, United States|nTouch, San Diego, California, United States|Radiant Research-San Diego, San Diego, California, United States|Veterans Medical Research Foundation, San Diego, California, United States|Diabetes Research Institute of Mills Peninsula, San Mateo, California, United States|Advanced Clinical Research Institute, Santa Ana, California, United States|West Coast Clinical Trials, Signal Hill, California, United States|Protocare Trials at Sharp Mission Park, Vista, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|George Washington University, Washington, District of Columbia, United States|Internal Medicine Associates, Ft. Myers, Florida, United States|Clin Sci International, Gainesville, Florida, United States|University of FL, Gainesville, Florida, United States|Jupiter Research Institute, Jupiter, Florida, United States|Baptist Diabetes Associates, Miami, Florida, United States|Tampa Medical Group, Tampa, Florida, United States|Metabolic Research Institute, Inc., West Palm Beach, Florida, United States|Radiant Research, West Palm Beach, Florida, United States|Clinical Research Atlanta, Atlanta, Georgia, United States|nTouch Research Corporation, Decatur, Georgia, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|St. Luke's Family Health, Meridian, Idaho, United States|University Primary Care Center at Belvidere, Belvidere, Illinois, United States|Northwestern Memorial Physicians Group, Chicago, Illinois, United States|Illinois Center for Clinical Trials, Chicago, Illinois, United States|Medical Group of Fort Wayne, Fort Wayne, Indiana, United States|American Health Network, Indianapolis, Indiana, United States|nTouch Research-South Bend, South Bend, Indiana, United States|Kentucky Diabetes Center, Lexington, Kentucky, United States|University of Kentucky Metabolic Research Group, Lexington, Kentucky, United States|MedResearch, Inc., Louisville, Kentucky, United States|Drug Research Services, Metairie, Louisiana, United States|New Orleans Institute of Clinical Investigation, New Orleans, Louisiana, United States|Ochsner Clinic, New Orleans, Louisiana, United States|St. Agnes Health Care, Baltimore, Maryland, United States|Doctors Research Associates of Maryland, Lanham, Maryland, United States|Grunberger Diabetes Medical Center, Bloomfield Hills, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Grand Rapids Associated Interns, Grand Rapids, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Diabetes and Endocrinology Specialists, Chesterfield, Missouri, United States|Mid Missouri Research Specialists, Inc., Rolla, Missouri, United States|Radiant Research-St. Louis, St. Louis, Missouri, United States|Midwest Pharmaceutical Research, St. Peters, Missouri, United States|Mercury Street Medical, Butte, Montana, United States|Lovelace Scientific Resources-Las Vegas, Las Vegas, Nevada, United States|HIS Clinical Research, Jersey City, New Jersey, United States|Radiant Research-Moorestown, Moorestown, New Jersey, United States|Lovelace Scientific Resources, Albuquerque, New Mexico, United States|Medical Network Services, P.C., Brooklyn, New York, United States|St. Lukes Roosevelt Hospital, New York, New York, United States|Naomi Berrie Diabetes Center at Columbia University, New York, New York, United States|Heights Medical Care, New York, New York, United States|DOCS at Beth Israel Medical Center, Yonkers, New York, United States|Metrolina Medical Research, Charlotte, North Carolina, United States|Charlotte Clinical Research, Charlotte, North Carolina, United States|UNC Diabetes Care Center, Durham, North Carolina, United States|Unifour Medical Research, Hickory, North Carolina, United States|New Hanover Medical Research Associates, Wilmington, North Carolina, United States|Piedmont Medical Research, Winston-Salem, North Carolina, United States|Rapid Medical Research, Cleveland, Ohio, United States|Ohio State University-Division of Endocrinology, Columbus, Ohio, United States|Radiant Research-Columbus, Columbus, Ohio, United States|University Mednet, Mentor, Ohio, United States|Comprehensive Research Services, Inc., Mogadore, Ohio, United States|COR Clinical Research, Oklahoma City, Oklahoma, United States|nTouch Research Corporation-Oklahoma City, Oklahoma City, Oklahoma, United States|Utica Park Clinic, Tulsa, Oklahoma, United States|Medford Medical Clinic, Medford, Oregon, United States|Legacy Clinical Research, Portland, Oregon, United States|Radiant Research, Portland, Oregon, United States|Physicians for Clinical Research, Camp Hill, Pennsylvania, United States|Thomas Jefferson University Diabetes Research Center, Philadelphia, Pennsylvania, United States|Philadelphia Health Associates, Philadelphia, Pennsylvania, United States|Tipton Medical and Diagnostic Center, Tipton, Pennsylvania, United States|Safe Harbor Clinical Research, East Providence, Rhode Island, United States|Radiant Research-Charleston, Charleston, South Carolina, United States|CNS Clinical Trials, Chester, South Carolina, United States|Coastal Carolina Research Center, Mt. Pleasant, South Carolina, United States|Integrity Clinical Research, Jackson, Tennessee, United States|Harmony Clinical Research, Johnson City, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|Endocrine Consultants of ET, Knoxville, Tennessee, United States|Central Texas Clinical Research, Austin, Texas, United States|Texas Tech University Health Sciences-Internal Medicine, El Paso, Texas, United States|Internal Medicine Associates, El Paso, Texas, United States|North Texas Clinical Research, Irving, Texas, United States|Dr. Humberto Bruschetta, Kingsville, Texas, United States|South Texas Applied Research, McAllen, Texas, United States|University of Texas Health Sciences Center-Texas Diabetes Institute, San Antonio, Texas, United States|Diabetes and Glandular Disease Clinic, San Antonio, Texas, United States|SAM Clinical Research Center, San Antonio, Texas, United States|Salt Lake Research, Salt Lake City, Utah, United States|Clinical Research Center-Eastern Virginia Medical School, Norfolk, Virginia, United States|West Olympia Internal Medicine, Olympia, Washington, United States|Rainier Clinical Research Center, Renton, Washington, United States|Northside Internal Medicine, Spokane, Washington, United States|Rockwood Clinic, Spokane, Washington, United States|Julia M. Hutchinson, M.D., Spokane, Washington, United States|Wenatchee Valley Clinic, Wenatchee, Washington, United States|Hyperion Clinical Research, Charleston, West Virginia, United States|CAMC Clinical Trials Center, Charleston, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT00039026
NCT00035984,Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Non-Insulin-Dependent",Drug: AC2993|Drug: Placebo,Change in HbA1c from Baseline to Week 30|Change in HbA1c from baseline (Day 1) to each of the intermediate visits|The number of subjects achieving HbA1c target values of < 7% and < 8% by Week 30|The number of subjects achieving HbA1c reductions of > 0.5% and > 1.0% by Week 30|The time to achieve specific HbA1c target values of < 7% and < 8%|The time to achieve HbA1c reductions of 0.5% or more and >1.0% or more|Change in body weight from Baseline to each intermediate visit and Week 30,AstraZeneca,All,"16 Years to 75 Years   (Child, Adult, Older Adult)",Phase 3,734,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2993-115,May-02,Aug-03,Aug-03,8-May-02,null,24-Feb-15,"Pinnacle Research Group, Anniston, Alabama, United States|Parkway Medical Center, Birmingham, Alabama, United States|Extended Arm Physicians/ Southern Drug, Montgomery, Alabama, United States|Southern Drug Research Network, Tallassee, Alabama, United States|First Care Family Doctors, Fayetteville, Arkansas, United States|Physicians Group Research Clinic, LLC, Little Rock, Arkansas, United States|Advanced Clinical Research Institute, Anaheim, California, United States|East Bay Clinical Trial Center, Concord, California, United States|Medical Group of Encino, Encino, California, United States|Valley Research, Fresno, California, United States|St. Joseph Heritage Healthcare, Fullerton, California, United States|Whittier Institute for Diabetes, La Jolla, California, United States|Richard Cherlin, M.D., Los Gatos, California, United States|Dr. Martinez Medical Clinic, Moreno Valley, California, United States|Comprehensive Diabetes-Endocrine Medical Associates, Redwood City, California, United States|Radiant Research-San Diego, San Diego, California, United States|Veterans Medical Research Foundation, San Diego, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Creekside Endocrine Associates, Denver, Colorado, United States|University of Colorado-Barbara Davis Center for Childhood Diabetes, Denver, Colorado, United States|Medstar Clinical Research, Washington, District of Columbia, United States|George Washington University, Washington, District of Columbia, United States|Medical Research Unlimited, Aventura, Florida, United States|Morton Plant Mease Health Care, Clearwater, Florida, United States|Clinical Research of West Florida, Inc., Clearwater, Florida, United States|Internal Medicine Associates, Ft. Myers, Florida, United States|Clin Sci International, Gainesville, Florida, United States|Northeast Florida Endocrine & Diabetes Research, Jacksonville, Florida, United States|Jupiter Research Institute, Jupiter, Florida, United States|Baptist Diabetes Associates, Miami, Florida, United States|Comprehensive NeuroScience Inc., Sarasota, Florida, United States|Tallahassee Endocrine Associates, Tallahassee, Florida, United States|Metabolic Research Institute, Inc., West Palm Beach, Florida, United States|Columbus Metabolic Foundation, Columbus, Georgia, United States|University of Hawaii-Diabetes Research Group, Ewa Beach, Hawaii, United States|University Primary Care Center at Belvidere, Belvidere, Illinois, United States|Northwestern Memorial Physicians Group, Chicago, Illinois, United States|Illinois Center for Clinical Trials, Chicago, Illinois, United States|Cook County Hospital, Chicago, Illinois, United States|American Health Network, Indianapolis, Indiana, United States|Indiana University Outpatient Clinical Research, Indianapolis, Indiana, United States|Lipid, Atherosclerosis & Metabolic Clinic, Kansas City, Kansas, United States|Kentucky Diabetes Center, Lexington, Kentucky, United States|Central Kentucky Research Associates, Lexington, Kentucky, United States|University of Kentucky Metabolic Research Group, Lexington, Kentucky, United States|MedResearch, Inc., Louisville, Kentucky, United States|New Orleans Center for Clinical Research, New Orleans, Louisiana, United States|Ochsner Clinic, New Orleans, Louisiana, United States|University of Maryland-Joslin Diabetes Center, Baltimore, Maryland, United States|Clinica Research Inc., Waltham, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Grand Rapids Associated Interns, Grand Rapids, Michigan, United States|International Diabetes Center, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Diabetes and Endocrinology Specialists, Chesterfield, Missouri, United States|Medical Arts Research Collaborative, Excelsior Springs, Missouri, United States|St Lukes Lipid and Diabetes Research Center, Kansas City, Missouri, United States|Mid Missouri Research Specialists, Inc., Rolla, Missouri, United States|Radiant Research-St. Louis, St. Louis, Missouri, United States|Midwest Pharmaceutical Research, St. Peters, Missouri, United States|Mercury Street Medical, Butte, Montana, United States|Lovelace Scientific Resources-Las Vegas, Las Vegas, Nevada, United States|Lisa Abbott, MD, Reno, Nevada, United States|SUNY Downstate, Brooklyn, New York, United States|St. Lukes Roosevelt Hospital, New York, New York, United States|Rochester Clinical Research, Rochester, New York, United States|DOCS at Beth Israel Medical Center, Yonkers, New York, United States|Charlotte Clinical Research, Charlotte, North Carolina, United States|UNC Diabetes Care Center, Durham, North Carolina, United States|Unifour Medical Research, Hickory, North Carolina, United States|New Hanover Medical Research Associates, Wilmington, North Carolina, United States|Radiant Research-Columbus, Columbus, Ohio, United States|University Mednet, Mentor, Ohio, United States|OU Health Sciences Center, Oklahoma City, Oklahoma, United States|Medford Medical Clinic, Medford, Oregon, United States|Radiant Research, Portland, Oregon, United States|Physicians for Clinical Research, Camp Hill, Pennsylvania, United States|Thomas Jefferson University Diabetes Research Center, Philadelphia, Pennsylvania, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States|Philadelphia Health Associates, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|CNS Clinical Trials, Chester, South Carolina, United States|Coastal Carolina Research Center, Mt. Pleasant, South Carolina, United States|Holston Medical Group, Kingsport, Tennessee, United States|The Endocrine Clinic, Memphis, Tennessee, United States|Mid State Endocrine Associates, Nashville, Tennessee, United States|Israel A. Hartman, M.D., Arlington, Texas, United States|Dallas Diabetes and Endocrinology Research Center, Dallas, Texas, United States|Texas Tech University Health Sciences-Internal Medicine, El Paso, Texas, United States|North Texas Clinical Research, Irving, Texas, United States|University of Texas Health Sciences Center-Texas Diabetes Institute, San Antonio, Texas, United States|Diabetes and Glandular Disease Clinic, San Antonio, Texas, United States|SAM Clinical Research, San Antonio, Texas, United States|Utah Diabetes Center at the University of Utah, Salt Lake City, Utah, United States|Salt Lake Research, Salt Lake City, Utah, United States|Medical Associates of Northern Virginia, Arlington, Virginia, United States|West Olympia Internal Medicine, Olympia, Washington, United States|Rockwood Clinic, Spokane, Washington, United States|University of Wisconsin West Clinic, Madison, Wisconsin, United States|Midwest Endocrinology Associates, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00035984
NCT00034255,Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients,,Completed,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Drug: INGAP Peptide,,GMP Endotherapeutics,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,62,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,INGAP-01-001,Dec-01,null,null,25-Apr-02,null,24-Jun-05,"VASDHS Medical Center, San Diego, California, United States|MedStar Research Institute - Clinical Research Center, Washington, District of Columbia, United States|UNC Diabetes, Endocrinology, Metabolism Clinic, Durham, North Carolina, United States|Texas Diabetes Institute, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00034255
NCT00027287,Laser and Medical Treatment of Diabetic Macular Edema,,Completed,No Results Available,Diabetes Mellitus|Macular Edema,Drug: Vitamin E,,National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Older Adult",Phase 1,60,NIH,Interventional,Primary Purpose: Treatment,020063|02-EI-0063,Nov-01,null,Dec-02,30-Nov-01,null,4-Mar-08,"National Eye Institute (NEI), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00027287
NCT00024518,Interferon-Alpha for Diabetes Mellitus Type 1,,Completed,No Results Available,Insulin-Dependent Diabetes Mellitus,"Drug: 30,000 units hrINF-alpha|Drug: 5,000 hrINF-alpha|Other: Placebo",C-Peptide Level|Serum glucose|Hemoglobin A1C,"The University of Texas Health Science Center, Houston|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",All,"3 Years to 25 Years   (Child, Adult)",Phase 2,57,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",010249|01-DK-0249,Sep-01,Sep-08,Sep-08,19-Sep-01,null,19-Nov-13,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Children's Hospital - St. Paul, St. Paul, Minnesota, United States|Children's Hospital - Kansas City, Kansas City, Missouri, United States|University of Texas, Dallas, Dallas, Texas, United States|University of Texas, Houston, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00024518
NCT00014911,Islet Transplantation for Type 1 Diabetes,,Completed,Has Results,"Diabetes Mellitus, Insulin-Dependent",Procedure: Islet Transplantation|Drug: Sirolimus|Drug: Tacrolimus|Drug: Daclizumab|Drug: Sulfamethoxazole|Drug: Ganciclovir|Drug: Trimethoprim|Drug: Pentamidine,Percent of Participants That Achieved Insulin Independence With Adequate Control of Blood Glucose Levels at One Year Post Final Islet Transplantation.|Percent of Participants With Partial Islet Function One Year Post Final Islet Transplantation.|Percent of Participants That Achieved Insulin Independence From First Transplant|Percent of Participants With Detectable Fasting Basal C-Peptide Levels,National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,36,NIH|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAIT ITN005CT (DAIT NIS01),Apr-01,Jun-05,Aug-10,31-Aug-01,17-Oct-12,15-Mar-17,"University of Miami, Miami, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University, St. Louis, Missouri, United States|Benaroya Research Institute at Virginia Mason Research Center, Seattle, Washington, United States|University of Alberta, Edmonton, Alberta, Canada|Justus-Leibig University, Giessen, Germany|University of Milan, Milan, Italy|University of Geneva, Geneva, Switzerland",,https://ClinicalTrials.gov/show/NCT00014911
NCT00021788,Islet Cell Transplantation Alone in Patients With Type I Diabetes Mellitus: Steroid-free Immunosuppression,,Completed,No Results Available,"Diabetes Mellitus, Type 1",Procedure: islet cell transplantation,,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,null,NIH,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,DK55347 (completed)|DK55347,Jul-00,null,Dec-01,6-Aug-01,null,9-Jul-10,"University of Miami Diabetes Research Institute, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT00021788
NCT00021801,Islet Cell Transplantation Alone and CD34+ Enriched Bone Marrow Cell Infusion in Patients With Diabetes Mellitus: Steroid-Free Regimen,,Completed,No Results Available,Type 1 Diabetes Mellitus,Procedure: Islet Cell Transplantation,,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,18 Years to 50 Years   (Adult),Phase 2,null,NIH,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,dk56953 (completed)|DK56953-01,Mar-00,null,Sep-00,6-Aug-01,null,2-Mar-10,"University of Miami Diabetes Research Institute, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT00021801
NCT00006505,Solitary Islet Transplantation for Type 1 Diabetes Mellitus Using Steroid Sparing Immunosuppression,,"Active, not recruiting",No Results Available,Diabetes Mellitus Type 1,Other: Islet Surgery,Insulin independence one year following the transplant.|Islet cell survival|Immune mediated beta cell destruction|Glomerular filtration rate|change in lipid profiles,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,6,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,010036|01-DK-0036,16-Nov-00,30-Jun-02,1-Jun-20,20-Nov-00,null,1-May-19,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00006505
